[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fApI_DAJlrLwbYDlfbFYlDmV0qhkIhIb71Ii-kvC0yUY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Sanofi",[4,6],"Sanofi Pasteur, a Sanofi Company",1900,false,173,709,4095594,200,77,[15,18,21,24,27,30,32,35],{"name":16,"count":17},"Influenza",106,{"name":19,"count":20},"Type 2 Diabetes Mellitus",80,{"name":22,"count":23},"Diabetes Mellitus, Type 2",78,{"name":25,"count":26},"Diphtheria",74,{"name":28,"count":29},"Pertussis",68,{"name":31,"count":29},"Tetanus",{"name":33,"count":34},"Hygiene",52,{"name":36,"count":37},"Healthy Volunteers",46,[39,44,48,53,58,63,68,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05011123","Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia","2022-05-23","Yellow fever vaccine",{"nctId":45,"briefTitle":46,"date":47,"intervention":43},"NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","2022-06-24",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04879628","Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis","2022-09-21","SAR441344 IV",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and\u002For 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","2023-03-09","Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05002777","Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)","2024-05-23","rilzabrutinib",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05405166","SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","2024-11-06","Isatuximab IV",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06556147","A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults","2025-02-14","VXB-241 60 mcg",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06444451","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata","2025-09-24","Amlitelimab",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05222906","Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","2025-10-02","Venglustat",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05156710","BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","2025-10-21","BIVV020",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,536,620,708,757,783,809,845,898,941,1097,1115,1133,1387,1547,1660,1740,1817,1908,1984,2027,2073,2125,2167,2205,2239,2269,2359,2431,2465,2506,2532,2558,2584,2610,2735,2878,3003,3041,3067,3093,3131,3163,3185,3207,3229,3251,3273,3295,3474,3544,3590,3641,3674,3696,3718,3811,3898,3942,3964,3986,4008,4030,4059,4077,4095,4113,4131,4149,4167,4185,4203,4228,4246,4273,4291,4313,4331,4349,4367,4385,4403,4427,4445,4463,4481,4499,4517,4535,4569,4605,4666,4744,4785,4813,4835,4870,4905,4938,4976,5058,5115,5175,5205,5318,5379,5431,5467,5509,5541,5576,5598,5623,5641,5665,5683,5701,5719,5737,5755,5780,5798,5827,5845,5863,5881,5899,5923,5941,5959,5977,5995,6021,6039,6057,6075,6100,6118,6136,6154,6172,6190,6208,6226,6244,6262,6280,6298,6323,6341,6359,6377,6395,6419,6444,6544,6581,6617,6641,6672,6690,6708,6726,6744,6768,6786,6804,6822,6840,6876,6894,6912,6930,6948,6966,6984,7002,7020,7038,7056,7074,7092,7272,7470,7553,7657,7708,7733,7756,7779,7802,7820,7845,7868,7893,7919,7937,7960,7982,8000,8023,8495,8809,9079,9303,9454,9665,9812,9948,10050,10142,10235,10307,10406,10464,10524,10592,10672,10758,10835,10918,10989,11063,11141,11216,11264,11313,11372,11410,11448,11508,11569,11607,11659,11719,11756,11790,11834,11881,11915,11964,12006,12044,12103,12133,12163,12211,12250,12292,12334,12376,12406,12440,12487,12513,12539,12578,12618,12655,12698,12728,12764,12811,12848,12874,12908,12944,12966,12996,13018,13053,13075,13102,13131,13153,13182,13204,13238,13270,13297,13325,13354,13382,13408,13433,13455,13488,13519,13547,13569,13594,13612,13630,13648,13670,13688,13706,13724,13745,13766,13791,13815,13833,13857,13875,13893,13911,13929,13947,13968,13992,14015,14033,14051,14073,14095,14113,14131,14152,14175,14193,14211,14229,14252,14270,14291,14314,14332,14353,14375,14399,14417,14443,14461,14479,14501,14523,14541,14566,14584,14602,14626,14644,14662,14680,14702,14725,14748,14766,14784,14802,14824,14842,14860,14878,14900,14923,14944,14966,14984,15008,15026,15052,15070,15088,15111,15129,15154,15172,15194,15212,15234,15252,15270,15288,15306,15324,15342,15360,15383,15401,15424,15442,15464,15482,15500,15518,15540,15558,15579,15602,15625,15649,15667,15689,15715,15733,15751,15769,15787,15811,15829,15850,15871,15889,15907,15925,15947,15965,15988,16011,16029,16047,16065,16086,16104,16122,16140,16163,16181,16199,16221,16239,16260,16282,16303,16321,16342,16364,16382,16403,16425,16443,16466,16484,16502,16526,16544,16568,16592,16610,16628,16646,16668,16686,16704,16727,16745,16768,16786,16808,16831,16849,16867,16890,16908,16930,16953,16971,16989,17010,17031,17054,17072,17094,17116,17138,17161,17183,17204,17225,17246,17269,17291,17313,17336,17357,17375,17393,17415,17437,17459,17477,17499,17520,17538,17556,17574,17595,17851,18000,18118,18193,18310,18392,18465,18550,18610,18667,18740,18811,18866,18918,19001,19070,19129,19178,19222,19281,19336,19374,19415,19449,19483,19532,19574,19625,19671,19715,19750,19794,19834,19875,19931,19963,20003,20053,20087,20117,20154,20180,20206,20247,20276,20310,20336,20362,20388,20414,20459,20494,20524,20550,20586,20620,20662,20688,20714,20753,20779,20815,20849,20875,20901,20935,20971,21011,21044,21076,21116,21153,21175,21200,21227,21249,21271,21293,21323,21353,21375,21405,21435,21457,21479,21501,21523,21552,21574,21604,21626,21648,21675,21708,21730,21752,21774,21808,21830,21852,21874,21896,21918,21940,21969,21996,22021,22043,22065,22087,22117,22144,22175,22197,22219,22241,22263,22285,22307,22336,22358,22380,22410,22432,22467,22489,22511,22536,22563,22585,22607,22629,22654,22688,22710,22732,22759,22788,22813,22835,22865,22887,22909,22931,22962,22990,23016,23038,23066,23084,23102,23120,23143,23161,23179,23200,23222,23240,23262,23280,23298,23316,23339,23357,23383,23401,23419,23443,23461,23479,23497,23515,23538,23556,23574,23592,23616,23634,23652,23673,23691,23709,23727,23749,23767,23788,23810,23828,23851,23869,23887,23905,23923,23941,23959,23983,24001,24019,24037,24055,24076,24094,24112,24130,24152,24176,24194,24212,24233,24256,24282,24300,24318,24336,24358,24376,24398,24421,24439,24461,24486,24504,24522,24540,24558,24576,24594,24612,24630,24648,24666,24684,24702,24720,24738,24760,24778,24801,24819,24837,24855,24873,24891,24909,24927,24945,24963,24981,24999,25017,25035,25053,25071,25089,25107,25125,25143,25161,25179,25201,25226,25244,25262,25280,25301,25319,25344,25362,25380,25398,25416,25434,25452,25475,25493,25516,25534,25556,25574,25592,25616,25634,25652,25674,25692,25710,25728,25746,25764,25782,25804,25826,25844,25867,25885,25903,25925,25948,25966,25990,26013,26031,26055,26079,26097,26119,26142,26163,26181,26199,26217,26235,26257,26281,26299,26317,26335,26359,26382,26400,26418,26436,26454,26472,26490,26512,26530,26554,26572,26590,26608,26626,26644,26662,26680,26698,26722,26740,26758,26776,26798,26816,26834,26852,26870,26888,26906,26924,26942,26960,26981,27003,27021,27045,27066,27087,27109,27133,27156,27174,27192,27214,27232,27250,27268,27294,27312,27330,27348,27366,27384,27402,27425,27443,27461,27483,27501,27523,27547,27565,27583,27606,27624,27647,27665,27691,27709,27727,27745,27768,27786,27808,27826,27844,27868,27886,27908,27926,27949,27967,27985,28006,28024,28042,28060,28082,28105,28132,28150,28168,28189,28212,28230,28248,28266,28284,28302,28328,28346,28364,28386,28409,28427,28445,28468,28486,28520,28538,28556,28574,28592,28610,28628,28646,28664,28682,28700,28718,28741,28759,28777,28795,28813,28831,28855,28879,28897,28915,28938,28956,28978,28996,29018,29036,29058,29080,29103,29121,29139,29160,29178,29196,29218,29239,29262,29280,29301,29319,29337,29355,29378,29400,29418,29441,29459,29477,29495,29513,29535,29553,29577,29595,29613,29631,29649,29672,29690,29708,29726,29752,29770,29788,29811,29834,29852,29870,29888,29910,29933,29951,29975,29993,30014,30038,30056,30078,30096,30119,30137,30158,30179,30204,30222,30240,30264,30286,30304,30327,30348,30366,30384,30407,30425,30443,30464,30489,30507,30525,30549,30567,30590,30608,30631,30649,30667,30685,30703,30767,30805,30862,30913,30962,31001,31052,31096,31144,31200,31241,31287,31328,31367,31408,31438,31475,31505,31531,31565,31603,31645,31676,31702,31732,31771,31797,31827,31849,31874,31902,31930,31958,31989,32011,32038,32069,32099,32134,32161,32189,32211,32247,32273,32303,32333,32358,32390,32415,32448,32482,32510,32544,32566,32592,32623,32654,32682,32711,32741,32773,32795,32817,32844,32866,32896,32918,32936,32954,32972,32990,33008,33026,33044,33062,33080,33098,33116,33142,33160,33178,33196,33218,33242,33260,33282,33303,33325,33343,33361,33382,33400,33423,33441,33466,33484,33502,33523,33541,33563,33581,33599,33621,33639,33663,33681,33699,33717,33735,33757,33775,33799,33817,33835,33853,33874,33896,33914,33938,33956,33974,33998,34016,34034,34052,34070,34088,34112,34130,34148,34171,34189,34207,34225,34243,34270,34288,34306,34329,34347,34368,34392,34410,34433,34451,34469,34491,34516,34539,34562,34584,34602,34624,34645,34663,34681,34699,34723,34741,34759,34777,34795,34813,34831,34849,34876,34894,34912,34930,34948,34966,34984,35002,35020,35038,35056,35074,35096,35114,35141,35159,35177,35195,35213,35231,35249,35267,35291,35309,35327,35348,35369,35391,35409,35431,35454,35472,35494,35512,35537,35555,35577,35595,35613,35635,35653,35676,35694,35712,35730,35748,35766,35784,35802,35824,35842,35863,35884,35910,35928,35946,35964,35982,36007,36025,36043,36061,36079,36102,36120,36141,36159,36177,36195,36216,36234,36252,36270,36292,36310,36328,36346,36364,36382,36404,36431,36449,36467,36485,36509,36530,36552,36574,36592,36610,36628,36652,36670,36688,36706,36730,36748,36766,36784,36802,36820,36843,36861,36886,36904,36922,36940,36963,36981,36999,37017,37035,37057,37078,37096,37117,37142,37160,37181,37209,37227,37245,37263,37281,37302,37320,37338,37360,37381,37404,37422,37444,37462,37480,37498,37524,37542,37560,37578,37596,37618,37636,37657,37675,37693,37711,37733,37757,37775,37793,37811,37829,37847,37865,37883,37905,37927,37945,37963,37981,38002,38023,38044,38067,38089,38107,38125,38146,38175,38193,38211,38229,38247,38265,38286,38304,38326,38347,38365,38383,38401,38423,38444,38462,38484,38506,38540,38579,38605,38634,38656,38678,38700,38738,38760,38782,38804,38828,38850,38875,38903,38938,38960,38982,39014,39036,39062,39080,39103,39121,39142,39166,39184,39207,39225,39262,39280,39298,39316,39334,39352,39370,39388,39406,39424,39442,39460,39478,39501,39519,39537,39555,39573,39594,39617,39635,39653,39671,39689,39707,39728,39749,39767,39788,39806,39830,39848,39866,39884,39906,39924,39942,39960,39978,39996,40014,40032,40050,40085,40103,40121,40139,40157,40175,40193,40211,40229,40259,40277,40295,40313,40331,40354,40376,40398,40416,40440,40465,40483,40501,40519,40537,40559,40583,40601,40623,40641,40659,40684,40705,40723,40741,40759,40784,40802,40823,40841,40859,40877,40901,40919,40941,40959,40983,41001,41019,41037,41060,41078,41096,41114,41132,41150,41172,41190,41212,41230,41248,41270,41293,41317,41335,41353,41371,41393,41415,41433,41455,41477,41495,41520,41538,41556,41574,41595,41616,41639,41663,41687,41717,41735,41753,41771,41789,41807,41825,41843,41861,41879,41897,41920,41942,41964,41982,42004,42027,42053,42071,42089,42107,42125,42143,42166,42184,42208,42226,42249,42267,42285,42312,42330,42348,42366,42384,42413,42431,42449,42467,42485,42503,42521,42546,42564,42586,42604,42622,42647,42665,42689,42707,42725,42743,42761,42779,42797,42815,42836,42854,42872,43408,43644,43754,43886,43995,44061,44128,44205,44247,44289,44323,44357,44394,44432,44461,44483,44514,44543,44567,44585,44607,44628,44646,44668,44693,44711,44735,44758,44781,44803,44825,44848,44872,44895,44913,44931],{"intervention":97,"totalTrials":98,"cells":99},"Dupilumab",40,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":133,"PHASE3":196,"PHASE4":340,"NA":446},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105,115,124],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT05976373","A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.","COMPLETED",[90],"2015-03-30","2015-01-05",38,[36],[97],{"nctId":116,"briefTitle":117,"status":108,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT05976386","Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults",[90],"2021-09-24","2021-06-08",182,[36],[97],{"nctId":125,"briefTitle":126,"status":108,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":112,"conditions":130,"interventions":132},"NCT05976360","A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants",[90],"2015-01-17","2014-11-02",[131],"Healthy Volunteer",[97,97],{"trials":134,"activeCount":195,"soonestReadout":140},[135,146,160,173,183],{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":29,"conditions":143,"interventions":145},"NCT05731128","A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))","ACTIVE_NOT_RECRUITING",[91],"2026-05-15","2027-02-19","2023-01-12",[144],"Colitis Ulcerative",[97],{"nctId":147,"briefTitle":148,"status":108,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT01854047","An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma",[91],"2014-11","2015-04","2013-06",776,[155],"Asthma",[97,157,158,159],"ICS\u002FLABA therapy","Salbutamol\u002Falbuterol","Levosalbutamol\u002Flevalbuterol",{"nctId":161,"briefTitle":162,"status":108,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":168},"NCT01312961","Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma",[91],"2012-10","2011-03",104,[155],[97,169,170,171,172],"Fluticasone\u002FSalmeterol combination therapy","Fluticasone monotherapy","Albuterol","Levalbuterol",{"nctId":174,"briefTitle":175,"status":108,"phases":176,"primaryCompletion":150,"completion":150,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT01920893","An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis",[91],"2013-08",60,[180],"Nasal Polyps",[97,182],"Mometasone furoate nasal spray",{"nctId":184,"briefTitle":185,"status":108,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":192},"NCT03387852","Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants",[91],"2019-03-21","2019-08-07","2018-03-12",296,[155],[193,97,194],"SAR440340","Fluticasone or Fluticasone\u002Fsalmeterol combination",1,{"trials":197,"activeCount":339,"soonestReadout":213},[198,209,220,233,242,253,264,276,288,299,309,316,328],{"nctId":199,"briefTitle":200,"status":108,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT03912259","Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis",[92],"2020-02-14","2018-12-19",165,[206],"Atopic Dermatitis",[97,208],"Emollient",{"nctId":210,"briefTitle":211,"status":138,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT06687980","A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)",[92],"2026-06-08","2026-08-31","2024-11-25",138,[218],"Lichen Simplex Chronicus",[97],{"nctId":221,"briefTitle":222,"status":108,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"NCT02414854","Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)",[92],"2017-07-29","2017-11-23","2015-04-27",1902,[155],[97,230,231,232],"Inhaled corticosteroid (ICS) therapy","Albuterol\u002FSalbutamol","Levalbuterol\u002FLevosalbutamol",{"nctId":234,"briefTitle":235,"status":108,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":241},"NCT02134028","Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)",[92],"2019-10-11","2014-08-05",2282,[155],[97],{"nctId":243,"briefTitle":244,"status":108,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"NCT02528214","Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma",[92],"2017-09-20","2017-11-13","2015-10-15",210,[155],[97,252,230,231,232],"Oral corticosteroid therapy",{"nctId":254,"briefTitle":255,"status":108,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":261},"NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)",[92],"2025-04-01","2018-06-21",378,[155],[97,262,263],"Asthma controller therapies","Asthma reliever therapies",{"nctId":265,"briefTitle":266,"status":108,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT05878093","Dupilumab in Chinese Adult Participants With CRSwNP",[92],"2024-09-06","2024-11-28","2023-05-16",63,[273],"Chronic Rhinosinusitis With Nasal Polyps",[97,275],"Budesonide",{"nctId":277,"briefTitle":278,"status":279,"phases":280,"primaryCompletion":281,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":287},"NCT06293053","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to \u003C18 Years of Age With Prurigo Nodularis","RECRUITING",[92],"2027-10-28","2027-11-03","2024-05-15",18,[286],"Prurigo Nodularis",[97],{"nctId":289,"briefTitle":290,"status":108,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT02948959","Evaluation of Dupilumab in Children With Uncontrolled Asthma",[92],"2020-08-26","2017-04-21",408,[155],[97,297,298],"Asthma Controller Therapies","Asthma Reliever Therapies",{"nctId":300,"briefTitle":301,"status":279,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT06191315","Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma\u002FAsthmatic Wheeze Aged 2 to \u003C6 Years (LIBERTY ASTHMA TREKIDS)",[92],"2028-12-21","2024-01-03",90,[307,155],"Wheezing",[97],{"nctId":310,"briefTitle":311,"status":138,"phases":312,"primaryCompletion":213,"completion":214,"start":269,"enrollment":313,"conditions":314,"interventions":315},"NCT06687967","A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)",[92],142,[218],[97],{"nctId":317,"briefTitle":318,"status":279,"phases":319,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT05263206","Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)",[92],"2027-06-02","2027-08-25","2022-02-15",284,[325],"Pruritus",[97,327],"Fexofenadine",{"nctId":329,"briefTitle":330,"status":108,"phases":331,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT05526521","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to \u003C12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)",[92],"2024-11-11","2025-02-03","2022-08-25",15,[337],"Chronic Spontaneous Urticaria",[97],5,{"trials":341,"activeCount":445,"soonestReadout":366},[342,353,362,373,384,395,405,416,426,435],{"nctId":343,"briefTitle":344,"status":108,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT04823130","Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis",[93],"2022-06-30","2022-08-30","2021-04-22",54,[351],"Dermatitis Atopic",[97],{"nctId":354,"briefTitle":355,"status":108,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT05624112","Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China",[93],"2024-01-25","2022-11-25",44,[206,351],[97],{"nctId":363,"briefTitle":364,"status":138,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},"NCT06101095","A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)",[93],"2025-11-05","2028-02-01","2023-11-29",69,[371],"Eosinophilic Oesophagitis",[97],{"nctId":374,"briefTitle":375,"status":279,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT07053423","A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.",[93],"2028-12-23","2029-02-02","2025-09-22",218,[382],"Chronic Obstructive Pulmonary Disease",[97],{"nctId":385,"briefTitle":386,"status":138,"phases":387,"primaryCompletion":388,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT05983068","A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis",[93],"2027-04-29","2027-05-19","2024-02-22",48,[351],[394],"dupilumab",{"nctId":396,"briefTitle":397,"status":108,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":404},"NCT05680298","Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China",[93],"2023-12-22","2024-03-15","2023-02-22",34,[206],[97],{"nctId":406,"briefTitle":407,"status":108,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":414},"NCT04998604","EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients",[93],"2024-10-16","2024-12-27","2021-09-27",360,[273,155],[97,415],"Omalizumab",{"nctId":417,"briefTitle":418,"status":138,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT05097287","Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma",[93],"2027-03-16","2029-06-08","2021-12-16",1339,[155],[97],{"nctId":427,"briefTitle":428,"status":108,"phases":429,"primaryCompletion":430,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":434},"NCT04033367","SAR231893-LPS15497- \"Dupilumab Effect on Sleep in AD Patients\"",[93],"2021-10-06","2019-08-22",188,[206],[97],{"nctId":436,"briefTitle":437,"status":108,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":444},"NCT04400318","The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma",[93],"2023-06-26","2023-08-21","2020-06-20",109,[155],[97],4,{"trials":447,"activeCount":535,"soonestReadout":452},[448,459,468,478,487,497,507,516,526],{"nctId":449,"briefTitle":450,"status":138,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},"NCT06393946","Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France",[],"2026-04-28","2026-07-31","2023-10-20",150,[457],"Chronic Rhinosinusitis With Nasal Polyposis",[97],{"nctId":460,"briefTitle":461,"status":138,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":467},"NCT05991323","Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study",[],"2026-09-22","2023-12-12",100,[286],[97],{"nctId":469,"briefTitle":470,"status":279,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":474,"conditions":475,"interventions":477},"NCT07052396","Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions",[],"2029-07-01","2025-07-01",350,[476],"Chronic Obstructive Pulmonary Disease (COPD)",[97],{"nctId":479,"briefTitle":480,"status":138,"phases":481,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":486},"NCT06169527","A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab",[],"2028-05-10","2023-11-28",303,[206],[97],{"nctId":488,"briefTitle":489,"status":279,"phases":490,"primaryCompletion":491,"completion":492,"start":493,"enrollment":455,"conditions":494,"interventions":496},"NCT06695897","A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany",[],"2027-06-01","2029-05-29","2024-12-02",[495],"Eosinophilic Esophagitis",[97],{"nctId":498,"briefTitle":499,"status":279,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":506},"NCT07316114","A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria",[],"2027-11-24","2029-11-22","2026-03-18",400,[337],[97],{"nctId":508,"briefTitle":509,"status":279,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":515},"NCT07467564","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis",[],"2027-05-24","2026-02-24",184,[206],[97],{"nctId":517,"briefTitle":518,"status":138,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":525},"NCT06415175","Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain",[],"2026-09-30","2027-11-23","2024-11-14",143,[206],[97],{"nctId":527,"briefTitle":528,"status":529,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":455,"conditions":533,"interventions":534},"NCT06192563","A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score \u003C 16) Respond to Dupilumab Treatment","UNKNOWN",[],"2026-01-31","2023-11-30",[351],[97],8,{"intervention":537,"totalTrials":538,"cells":539},"Teplizumab",7,{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":556,"PHASE4":568,"NA":581},{"trials":541,"activeCount":102},[],{"trials":543,"activeCount":102},[],{"trials":545,"activeCount":195,"soonestReadout":550},[546],{"nctId":547,"briefTitle":548,"status":279,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT06791291","Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes",[91],"2028-03-06","2025-07-25",10,[554],"Type 1 Diabetes Mellitus",[537],{"trials":557,"activeCount":195,"soonestReadout":562},[558],{"nctId":559,"briefTitle":560,"status":279,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT07088068","A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes",[92],"2028-06-06","2028-12-12","2025-08-06",723,[554],[537],{"trials":569,"activeCount":195,"soonestReadout":574},[570],{"nctId":571,"briefTitle":572,"status":138,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},"NCT05757713","Teplizumab in Pediatric Stage 2 Type 1 Diabetes",[93],"2026-08-27","2023-07-25",20,[578],"Diabetes Mellitus, Type 1",[580],"teplizumab",{"trials":582,"activeCount":619,"soonestReadout":615},[583,593,602,611],{"nctId":584,"briefTitle":585,"status":279,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT07360080","Long-Term Outcomes of Teplizumab in Routine Clinical Care",[],"2035-10-29","2026-03-19",1000,[591],"Type 1 Diabetes",[537],{"nctId":594,"briefTitle":595,"status":108,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":601},"NCT06892002","Description of Patients With Type 1 Diabetes Treated With Teplizumab",[],"2025-08-05","2025-02-11",110,[591],[537],{"nctId":603,"briefTitle":604,"status":279,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT07260110","A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States",[],"2030-12-03","2025-10-31",550,[591],[537],{"nctId":612,"briefTitle":613,"status":279,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":178,"conditions":617,"interventions":618},"NCT07457580","Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)",[],"2026-11-30","2026-03-16",[591],[537],3,{"intervention":621,"totalTrials":622,"cells":623},"Belumosudil",6,{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":660,"PHASE4":685,"NA":706},{"trials":625,"activeCount":102},[],{"trials":627,"activeCount":102},[],{"trials":629,"activeCount":659,"soonestReadout":634},[630,648],{"nctId":631,"briefTitle":632,"status":279,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol",[90,91],"2027-09-13","2028-04-20","2021-01-25",258,[639],"Plasma Cell Myeloma Refractory",[641,642,643,644,645,646,621,647],"Isatuximab","Dexamethasone","Pomalidomide","Belantamab mafodotin","Pegenzileukin","SAR439459","Evorpacept",{"nctId":649,"briefTitle":650,"status":279,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":658},"NCT07116031","A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)",[91],"2028-09-25","2031-02-28","2025-12-02",37,[657],"Chronic Graft Versus Host Disease",[621,621],2,{"trials":661,"activeCount":659,"soonestReadout":666},[662,673],{"nctId":663,"briefTitle":664,"status":138,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":670},"NCT06143891","A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.",[92],"2028-09-29","2024-01-23",260,[657],[621,671,672],"Prednisone","Prednisolone",{"nctId":674,"briefTitle":675,"status":279,"phases":676,"primaryCompletion":677,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":683},"NCT06082037","A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction",[92],"2029-01-29","2030-10-01","2023-10-10",180,[682],"Lung Transplant Rejection",[621,684],"Azithromycin",{"trials":686,"activeCount":195,"soonestReadout":700},[687,695],{"nctId":688,"briefTitle":689,"status":108,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":622,"conditions":693,"interventions":694},"NCT06616415","A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies",[93],"2026-05-12","2024-12-04",[657],[621],{"nctId":696,"briefTitle":697,"status":698,"phases":699,"primaryCompletion":700,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":705},"NCT07135973","A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)","NOT_YET_RECRUITING",[93],"2027-08-30","2028-03-17","2026-08-10",26,[657],[621],{"trials":707,"activeCount":102},[],{"intervention":709,"totalTrials":619,"cells":710},"Fitusiran",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":742,"NA":755},{"trials":712,"activeCount":102},[],{"trials":714,"activeCount":102},[],{"trials":716,"activeCount":102},[],{"trials":718,"activeCount":659,"soonestReadout":723},[719,732],{"nctId":720,"briefTitle":721,"status":138,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT05662319","A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia",[92],"2027-03-25","2029-01-25","2023-02-01",91,[728],"Hemophilia",[709,730,731],"Clotting factor concentrates","Antithrombin concentrate",{"nctId":733,"briefTitle":734,"status":279,"phases":735,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT07285460","A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B",[92],"2029-08-04","2031-12-30","2025-12-18",85,[728],[709,730,731],{"trials":743,"activeCount":195,"soonestReadout":748},[744],{"nctId":745,"briefTitle":746,"status":279,"phases":747,"primaryCompletion":748,"completion":749,"start":750,"enrollment":576,"conditions":751,"interventions":753},"NCT06145373","A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab",[93],"2028-05-28","2030-01-30","2024-03-01",[752],"Hemophilia A",[709,730,731,754],"Emicizumab",{"trials":756,"activeCount":102},[],{"intervention":730,"totalTrials":619,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":775,"NA":781},{"trials":760,"activeCount":102},[],{"trials":762,"activeCount":102},[],{"trials":764,"activeCount":102},[],{"trials":766,"activeCount":659,"soonestReadout":723},[767,771],{"nctId":720,"briefTitle":721,"status":138,"phases":768,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":769,"interventions":770},[92],[728],[709,730,731],{"nctId":733,"briefTitle":734,"status":279,"phases":772,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":773,"interventions":774},[92],[728],[709,730,731],{"trials":776,"activeCount":195,"soonestReadout":748},[777],{"nctId":745,"briefTitle":746,"status":279,"phases":778,"primaryCompletion":748,"completion":749,"start":750,"enrollment":576,"conditions":779,"interventions":780},[93],[752],[709,730,731,754],{"trials":782,"activeCount":102},[],{"intervention":731,"totalTrials":619,"cells":784},{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":801,"NA":807},{"trials":786,"activeCount":102},[],{"trials":788,"activeCount":102},[],{"trials":790,"activeCount":102},[],{"trials":792,"activeCount":659,"soonestReadout":723},[793,797],{"nctId":720,"briefTitle":721,"status":138,"phases":794,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":795,"interventions":796},[92],[728],[709,730,731],{"nctId":733,"briefTitle":734,"status":279,"phases":798,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":799,"interventions":800},[92],[728],[709,730,731],{"trials":802,"activeCount":195,"soonestReadout":748},[803],{"nctId":745,"briefTitle":746,"status":279,"phases":804,"primaryCompletion":748,"completion":749,"start":750,"enrollment":576,"conditions":805,"interventions":806},[93],[752],[709,730,731,754],{"trials":808,"activeCount":102},[],{"intervention":810,"totalTrials":659,"cells":811},"iGlarLixi",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":843},{"trials":813,"activeCount":102},[],{"trials":815,"activeCount":102},[],{"trials":817,"activeCount":102},[],{"trials":819,"activeCount":102},[],{"trials":821,"activeCount":659,"soonestReadout":826},[822,832],{"nctId":823,"briefTitle":824,"status":138,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":831},"NCT06716424","A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus",[93],"2026-06-26","2025-01-06",105,[830],"Type 2 Diabetes",[810],{"nctId":833,"briefTitle":834,"status":279,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":841},"NCT06671587","iGlarLixi CGM Study in Chinese T2D Individuals After OADs",[93],"2026-09-18","2024-12-10",678,[840],"Type 2 Diabetes (T2D)",[810,842],"Gla-100",{"trials":844,"activeCount":102},[],{"intervention":846,"totalTrials":445,"cells":847},"Efanesoctocog alfa",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":879},{"trials":849,"activeCount":102},[],{"trials":851,"activeCount":102},[852],{"nctId":853,"briefTitle":854,"status":108,"phases":855,"primaryCompletion":856,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":860},"NCT05042440","Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A",[90],"2021-11-24","2021-08-11",13,[752],[846,861,862],"Octocog alfa","Rurioctocog alfa pegol",{"trials":864,"activeCount":102},[],{"trials":866,"activeCount":102},[],{"trials":868,"activeCount":195,"soonestReadout":873},[869],{"nctId":870,"briefTitle":871,"status":279,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":878},"NCT06941870","Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy",[93],"2027-10-25","2025-09-23",35,[877],"Factor VIII Deficiency",[846],{"trials":880,"activeCount":195,"soonestReadout":895},[881,891],{"nctId":882,"briefTitle":883,"status":884,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":619,"conditions":888,"interventions":889},"NCT06530030","Goal Attainment and Physical Activity in People With Hemophilia A","TERMINATED",[],"2025-09-18","2024-11-26",[752],[890],"efanesoctocog alfa",{"nctId":892,"briefTitle":893,"status":279,"phases":894,"primaryCompletion":895,"completion":895,"start":332,"enrollment":465,"conditions":896,"interventions":897},"NCT06684314","A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan",[],"2031-08-28",[752],[846],{"intervention":899,"totalTrials":619,"cells":900},"Nirsevimab",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":920,"NA":930},{"trials":902,"activeCount":102},[],{"trials":904,"activeCount":102},[],{"trials":906,"activeCount":102},[],{"trials":908,"activeCount":102},[909],{"nctId":910,"briefTitle":911,"status":108,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT05437510","Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life",[92],"2024-03-27","2025-04-09","2022-08-08",8057,[918,131],"RSV Immunization",[899],{"trials":921,"activeCount":195,"soonestReadout":926},[922],{"nctId":923,"briefTitle":924,"status":138,"phases":925,"primaryCompletion":926,"completion":926,"start":927,"enrollment":599,"conditions":928,"interventions":929},"NCT07109297","Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India",[93],"2026-06-30","2025-07-31",[918],[899],{"trials":931,"activeCount":195,"soonestReadout":936},[932],{"nctId":933,"briefTitle":934,"status":279,"phases":935,"primaryCompletion":936,"completion":936,"start":81,"enrollment":937,"conditions":938,"interventions":940},"NCT07200206","A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea",[],"2029-09-26",3000,[939],"Respiratory Syncytial Virus",[899],{"intervention":942,"totalTrials":858,"cells":943},"Sarilumab",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":1005,"PHASE4":1071,"NA":1095},{"trials":945,"activeCount":102},[],{"trials":947,"activeCount":102},[],{"trials":949,"activeCount":102},[950,960,973,982,994],{"nctId":951,"briefTitle":952,"status":108,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":959},"NCT01061723","Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis",[91],"2011-06","2010-02",301,[958],"Ankylosing Spondylitis",[942],{"nctId":961,"briefTitle":962,"status":108,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":970},"NCT01900431","Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis",[91],"2015-07","2016-04","2013-10",58,[969],"Uveitis",[942,671,971,972],"Methotrexate","Folic\u002Ffolinic acid",{"nctId":974,"briefTitle":975,"status":884,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT01118728","Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis",[91],"2011-12","2010-06",223,[958],[942],{"nctId":983,"briefTitle":984,"status":884,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":991},"NCT01217814","Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers",[91],"2011-09","2010-11",16,[990],"Rheumatoid Arthritis",[942,992,993,972],"Golimumab","methotrexate",{"nctId":995,"briefTitle":996,"status":108,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},"NCT02776735","An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)",[91],"2022-04-08","2023-12-27","2016-09-06",102,[1003],"Juvenile Idiopathic Arthritis",[942],{"trials":1006,"activeCount":102},[1007,1018,1027,1037,1050,1061],{"nctId":1008,"briefTitle":1009,"status":108,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":164,"enrollment":1012,"conditions":1013,"interventions":1014},"NCT01709578","To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)",[92],"2015-03",546,[990],[942,1015,993,1016,1017],"hydroxychloroquine","sulfasalazine","leflunomide",{"nctId":1019,"briefTitle":1020,"status":108,"phases":1021,"primaryCompletion":966,"completion":966,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},"NCT01061736","Evaluation of Sarilumab (SAR153191\u002FREGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients",[91,92],"2010-03",1675,[990],[942,971,1026],"Folic Acid",{"nctId":1028,"briefTitle":1029,"status":884,"phases":1030,"primaryCompletion":1031,"completion":1031,"start":1032,"enrollment":153,"conditions":1033,"interventions":1034},"NCT01764997","An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate",[92],"2015-01","2013-04",[990],[942,1035,971,1036],"Etanercept","Adalimumab",{"nctId":1038,"briefTitle":1039,"status":108,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":726,"conditions":1043,"interventions":1044},"NCT02373202","A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)",[92],"2016-11","2015-02",[990],[942,1045,1046,1047,1048,1049],"Sulfasalazine","Leflunomide","Bucillamine","Tacrolimus","Mizoribine",{"nctId":1051,"briefTitle":1052,"status":108,"phases":1053,"primaryCompletion":1042,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT02057250","To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis",[92],"2016-03","2014-03",217,[1058],"RA",[942,971,1045,1046,1060],"Hydroxychloroquine",{"nctId":1062,"briefTitle":1063,"status":108,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1070},"NCT02332590","Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)",[92],"2016-01-20","2020-12-29","2015-01-28",369,[990],[942,1036],{"trials":1072,"activeCount":195,"soonestReadout":1089},[1073,1085],{"nctId":1074,"briefTitle":1075,"status":108,"phases":1076,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1081},"NCT03449758","Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis",[93],"2019-07-31","2018-03-05",84,[990],[1082,1083,1084,1060,1046,971,1045],"SARILUMAB","Azathioprine","Chloroquine",{"nctId":1086,"briefTitle":1087,"status":279,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":691,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT07286214","Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica",[93],"2029-06-04","2029-07-16",300,[1093],"Polymyalgia Rheumatica",[942,942],{"trials":1096,"activeCount":102},[],{"intervention":754,"totalTrials":195,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1113},{"trials":1100,"activeCount":102},[],{"trials":1102,"activeCount":102},[],{"trials":1104,"activeCount":102},[],{"trials":1106,"activeCount":102},[],{"trials":1108,"activeCount":195,"soonestReadout":748},[1109],{"nctId":745,"briefTitle":746,"status":279,"phases":1110,"primaryCompletion":748,"completion":749,"start":750,"enrollment":576,"conditions":1111,"interventions":1112},[93],[752],[709,730,731,754],{"trials":1114,"activeCount":102},[],{"intervention":842,"totalTrials":195,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1131},{"trials":1118,"activeCount":102},[],{"trials":1120,"activeCount":102},[],{"trials":1122,"activeCount":102},[],{"trials":1124,"activeCount":102},[],{"trials":1126,"activeCount":195,"soonestReadout":836},[1127],{"nctId":833,"briefTitle":834,"status":279,"phases":1128,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":1129,"interventions":1130},[93],[840],[810,842],{"trials":1132,"activeCount":102},[],{"intervention":642,"totalTrials":1134,"cells":1135},21,{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1198,"PHASE3":1278,"PHASE4":1349,"NA":1376},{"trials":1137,"activeCount":102},[],{"trials":1139,"activeCount":102},[1140,1153,1163,1176,1185],{"nctId":1141,"briefTitle":1142,"status":108,"phases":1143,"primaryCompletion":913,"completion":913,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1148},"NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[90],"2019-08-06",56,[1147],"Multiple Myeloma",[1149,1150,1151,1152],"isatuximab SAR650984 IV","pomalidomide","dexamethasone","isatuximab SAR650984 SC",{"nctId":1154,"briefTitle":1155,"status":108,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":349,"conditions":1159,"interventions":1161},"NCT02283775","SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients",[90],"2021-05-26","2015-05-15",[1160],"Plasma Cell Myeloma",[1162,643,642],"Isatuximab SAR650984",{"nctId":1164,"briefTitle":1165,"status":108,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":305,"conditions":1170,"interventions":1171},"NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation",[90],"2022-01-28","2024-01-22","2015-09-30",[1160],[1172,1173,1174,1151,1175],"lenalidomide","bortezomib","cyclophosphamide","isatuximab SAR650984",{"nctId":1177,"briefTitle":1178,"status":108,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1184},"NCT01749969","SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients",[90],"2023-06-20","2013-02-06",57,[1160],[1175,1172,1151],{"nctId":1186,"briefTitle":1187,"status":108,"phases":1188,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":402,"conditions":1192,"interventions":1194},"NCT03324113","Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors",[90],"2022-11-18","2022-12-26","2017-10-17",[1193],"Neoplasm Malignant",[1195,1151,1196,1197],"SAR408701","naphazoline","diphenhydramine",{"trials":1199,"activeCount":445,"soonestReadout":1220},[1200,1216,1228,1239,1243,1254,1267],{"nctId":1201,"briefTitle":1202,"status":279,"phases":1203,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1209},"NCT06356571","A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and\u002For Refractory Multiple Myeloma",[91],"2027-01-08","2027-07-15","2025-03-17",64,[639],[1210,1211,642,1212,1213,1214,1215],"Isatuximab SC-OBDS","Montelukast","Acetaminophen","Diphenhydramine","Methylprednisolone","Carfilzomib",{"nctId":1217,"briefTitle":1218,"status":138,"phases":1219,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT05704049","A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and\u002For Refractory Multiple Myeloma",[91],"2025-12-22","2028-05-12","2023-04-05",118,[1225],"Relapsed\u002FRefractory Multiple Myeloma",[641,1215,642,1227,1211,1212,1213,1214],"Dexamethasone IV",{"nctId":1229,"briefTitle":1230,"status":138,"phases":1231,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":1233,"interventions":1234},"NCT05669989","International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab",[91],70,[1160],[1235,1236,642,1237,643,1238,1215],"Isatuximab intravenous","Cemiplimab","Lenalidomide","Isatuximab subcutaneous",{"nctId":631,"briefTitle":632,"status":279,"phases":1240,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":1241,"interventions":1242},[90,91],[639],[641,642,643,644,645,646,621,647],{"nctId":1244,"briefTitle":1245,"status":108,"phases":1246,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1253},"NCT01084252","Phase 1\u002F2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies",[90,91],"2018-12-21","2023-07-13","2010-05-11",351,[1252],"Hematological Malignancy",[1162,642,642],{"nctId":1255,"briefTitle":1256,"status":884,"phases":1257,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1264},"NCT02999633","Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia",[91],"2017-11-14","2017-03-08",14,[1262,1263],"T-cell Type Acute Leukemia-Precursor","T-lymphoblastic Lymphoma\u002FLeukaemia",[1162,1151,1151,1265,1266,1197],"acetaminophen","ranitidine",{"nctId":1268,"briefTitle":1269,"status":108,"phases":1270,"primaryCompletion":964,"completion":1271,"start":1272,"enrollment":875,"conditions":1273,"interventions":1275},"NCT02061631","Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck",[91],"2015-10","2014-05",[1274],"Squamous Cell Carcinoma of Head and Neck",[1276,1277,642,642],"Cisplatin","DOCETAXEL XRP6976",{"trials":1279,"activeCount":619,"soonestReadout":66},[1280,1291,1301,1312,1325,1335],{"nctId":1281,"briefTitle":1282,"status":108,"phases":1283,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1289},"NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And\u002FOr Refractory Multiple Myeloma Patients",[92],"2022-01-14","2025-01-03","2017-10-25",302,[1160],[1175,1290,1151],"carfilzomib",{"nctId":64,"briefTitle":65,"status":138,"phases":1292,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1298},[92],"2027-03-23","2022-06-23",531,[1297],"Plasma Cell Myeloma Recurrent",[67,1299,642,643,642,1211,1300,1213,1214],"Isatuximab SC","Paracetamol \u002F Acetaminophen",{"nctId":1302,"briefTitle":1303,"status":138,"phases":1304,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1310},"NCT03319667","A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant",[92],"2027-04-05","2027-06-30","2017-12-07",475,[1160],[1162,1311,1237,642],"Bortezomib",{"nctId":1313,"briefTitle":1314,"status":138,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT04270409","Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma",[92],"2030-10-14","2033-10-21","2020-06-16",337,[1160],[1162,1237,642,1322,1212,1323,1324],"Montelukast or equivalent","Diphenhydramine or equivalent","Methylprednisolone or equivalent",{"nctId":1326,"briefTitle":1327,"status":108,"phases":1328,"primaryCompletion":1329,"completion":1330,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1334},"NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients",[92],"2018-11-22","2023-11-01","2016-12-22",307,[1160],[641,643,642],{"nctId":1336,"briefTitle":1337,"status":108,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1346},"NCT00532155","A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",[92],"2011-01","2011-10","2007-09",913,[1344,1345],"Carcinoma","Non Small Cell Lung",[1347,1348,642],"Aflibercept","Docetaxel",{"trials":1350,"activeCount":102},[1351,1364],{"nctId":1352,"briefTitle":1353,"status":108,"phases":1354,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":1356,"interventions":1358},"NCT02441894","Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer",[93],"2016-02",[1357],"Prostate Cancer",[1359,1360,672,1361,1362,1363,642],"CABAZITAXEL XRP6258","PEG-G-CSF","Dexchlorpheniramine or Diphenhydramine","Ranitidine","Metoclopramide, Granisetron, or Ondansetron",{"nctId":1365,"briefTitle":1366,"status":108,"phases":1367,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":1370,"interventions":1372},"NCT06019728","A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme",[93],"2024-10-25","2023-11-10",[1371],"Fabry's Disease",[1373,1212,1213,642,1211,1374,1375,327],"AGALSIDASE BETA","Loratadine","Cetirizine",{"trials":1377,"activeCount":195,"soonestReadout":1382},[1378],{"nctId":1379,"briefTitle":1380,"status":138,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT04458831","A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and\u002For Refractory Multiple Myeloma (RRMM)",[],"2026-02-23","2020-08-13",583,[1160],[1175,643,642,1215],{"intervention":77,"totalTrials":1260,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1408,"PHASE3":1478,"PHASE4":1543,"NA":1545},{"trials":1390,"activeCount":102},[],{"trials":1392,"activeCount":102},[1393],{"nctId":1394,"briefTitle":1395,"status":108,"phases":1396,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1402},"NCT06686628","An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates",[90],"2025-11-21","2026-04-02","2024-11-20",23,[351],[77,1403,1404,1405,1406,1407],"Midazolam","Caffeine","Metoprolol","Omeprazole","Warfarin",{"trials":1409,"activeCount":445,"soonestReadout":76},[1410,1422,1431,1440,1448,1460,1469],{"nctId":1411,"briefTitle":1412,"status":138,"phases":1413,"primaryCompletion":1414,"completion":1415,"start":1416,"enrollment":1417,"conditions":1418,"interventions":1421},"NCT06557772","A Phase 2a\u002Fb Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease",[91],"2026-08-05","2029-04-10","2024-08-29",229,[1419,1420],"Coeliac Disease","Celiac Disease",[77],{"nctId":1423,"briefTitle":1424,"status":138,"phases":1425,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1430},"NCT05769777","Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis",[91],"2031-06-11","2023-04-03",999,[351],[77],{"nctId":1432,"briefTitle":1433,"status":884,"phases":1434,"primaryCompletion":1435,"completion":1436,"start":1330,"enrollment":305,"conditions":1437,"interventions":1439},"NCT06118099","Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",[91],"2025-02-06","2025-10-10",[1438],"Hidradenitis",[77],{"nctId":74,"briefTitle":75,"status":138,"phases":1441,"primaryCompletion":76,"completion":1442,"start":1443,"enrollment":1444,"conditions":1445,"interventions":1447},[91],"2028-01-05","2024-06-06",166,[1446],"Alopecia Areata",[77],{"nctId":1449,"briefTitle":1450,"status":108,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1457},"NCT06015308","A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo",[91],"2025-10-01","2026-01-16","2023-10-06",224,[351],[77,1458,1459],"Tdap vaccine","PPS vaccine",{"nctId":1461,"briefTitle":1462,"status":108,"phases":1463,"primaryCompletion":1464,"completion":1465,"start":346,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT05421598","Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma",[91],"2024-10-11","2025-03-20",437,[155],[77],{"nctId":1470,"briefTitle":1471,"status":138,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT06033833","Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study",[91],"2026-09-29","2023-09-05",335,[155],[77],{"trials":1479,"activeCount":619,"soonestReadout":1527},[1480,1490,1502,1512,1523,1533],{"nctId":1481,"briefTitle":1482,"status":108,"phases":1483,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1489},"NCT06181435","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)",[92],"2025-11-25","2026-03-12","2023-12-21",589,[351],[77],{"nctId":1491,"briefTitle":1492,"status":108,"phases":1493,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1499},"NCT06224348","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids",[92],"2025-08-21","2025-11-01","2024-01-18",643,[351],[77,1500,1501],"Topical corticosteroids","Topical calcineurin inhibitors",{"nctId":1503,"briefTitle":1504,"status":279,"phases":1505,"primaryCompletion":1506,"completion":666,"start":1507,"enrollment":1508,"conditions":1509,"interventions":1510},"NCT06241118","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor",[92],"2027-09-30","2024-02-29",636,[351],[77,1500,1511],"Topical tacrolimus or pimecrolimus",{"nctId":1513,"briefTitle":1514,"status":1515,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1521},"NCT05492578","Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials","ENROLLING_BY_INVITATION",[91,92],"2029-01-22","2022-08-22",1663,[351],[77,1500,1501,1522],"Oral corticosteroids",{"nctId":1524,"briefTitle":1525,"status":138,"phases":1526,"primaryCompletion":1527,"completion":1528,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT06407934","A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis",[92],"2026-06-29","2027-03-17","2024-05-08",1541,[351],[77],{"nctId":1534,"briefTitle":1535,"status":108,"phases":1536,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":1540,"conditions":1541,"interventions":1542},"NCT06130566","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis",[92],"2025-07-23","2025-11-13","2023-11-08",601,[351],[77],{"trials":1544,"activeCount":102},[],{"trials":1546,"activeCount":102},[],{"intervention":62,"totalTrials":552,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1605,"PHASE4":1656,"NA":1658},{"trials":1550,"activeCount":102},[],{"trials":1552,"activeCount":102},[],{"trials":1554,"activeCount":659,"soonestReadout":61},[1555,1568,1577,1587,1597],{"nctId":1556,"briefTitle":1557,"status":279,"phases":1558,"primaryCompletion":1559,"completion":1560,"start":1561,"enrollment":1079,"conditions":1562,"interventions":1565},"NCT06500702","A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease",[91],"2026-12-23","2028-02-16","2024-12-19",[1563,1564],"Focal Segmental Glomerulosclerosis","Glomerulonephritis Minimal Lesion",[1566,1567,62],"frexalimab","brivekimig",{"nctId":1569,"briefTitle":1570,"status":108,"phases":1571,"primaryCompletion":1572,"completion":1573,"start":856,"enrollment":1574,"conditions":1575,"interventions":1576},"NCT05107115","Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine",[91],"2023-07-19","2024-04-23",161,[337],[62],{"nctId":1578,"briefTitle":1579,"status":108,"phases":1580,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1585},"NCT05018806","Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis",[91],"2023-06-23","2021-09-09",124,[206],[1586],"Rilzabrutinib",{"nctId":1588,"briefTitle":1589,"status":108,"phases":1590,"primaryCompletion":1591,"completion":1592,"start":1593,"enrollment":1594,"conditions":1595,"interventions":1596},"NCT05104892","Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma",[91],"2024-02-06","2024-02-28","2021-12-12",196,[155],[1586],{"nctId":59,"briefTitle":60,"status":138,"phases":1598,"primaryCompletion":61,"completion":1599,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1604},[91],"2029-12-31","2021-12-07",22,[1603],"Warm Autoimmune Hemolytic Anemia (wAIHA)",[62],{"trials":1606,"activeCount":339,"soonestReadout":615},[1607,1617,1628,1635,1646],{"nctId":1608,"briefTitle":1609,"status":279,"phases":1610,"primaryCompletion":1611,"completion":1612,"start":1613,"enrollment":178,"conditions":1614,"interventions":1616},"NCT07007962","Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment",[92],"2027-11-05","2028-12-30","2025-10-24",[1615],"Immune Thrombocytopenia",[62],{"nctId":1618,"briefTitle":1619,"status":279,"phases":1620,"primaryCompletion":1621,"completion":1622,"start":1623,"enrollment":1583,"conditions":1624,"interventions":1626},"NCT07190196","A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease",[92],"2028-06-28","2030-12-25","2025-09-26",[1625],"Immunoglobulin G4 Related Disease",[1586,1627],"Glucocorticoid",{"nctId":1629,"briefTitle":1630,"status":138,"phases":1631,"primaryCompletion":615,"completion":615,"start":1632,"enrollment":445,"conditions":1633,"interventions":1634},"NCT07216079","Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan",[92],"2025-10-15",[1615],[62],{"nctId":1636,"briefTitle":1637,"status":279,"phases":1638,"primaryCompletion":1639,"completion":1640,"start":1641,"enrollment":1642,"conditions":1643,"interventions":1645},"NCT06975865","The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease",[92],"2027-07-23","2028-12-29","2025-08-12",192,[1644],"Sickle Cell Disease",[1586],{"nctId":1647,"briefTitle":1648,"status":279,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":305,"conditions":1653,"interventions":1655},"NCT07086976","A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia",[92],"2028-05-31","2029-12-26","2025-08-18",[1654],"Autoimmune Haemolytic Anaemia",[62],{"trials":1657,"activeCount":102},[],{"trials":1659,"activeCount":102},[],{"intervention":1661,"totalTrials":538,"cells":1662},"Itepekimab",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1691,"PHASE4":1736,"NA":1738},{"trials":1664,"activeCount":102},[],{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":195,"soonestReadout":1673},[1669,1680],{"nctId":1670,"briefTitle":1671,"status":138,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1679},"NCT06691113","A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps",[91],"2026-03-31","2026-08-18","2024-12-16",66,[1678],"Chronic Rhinosinusitis Without Nasal Polyps",[1661,182],{"nctId":1681,"briefTitle":1682,"status":108,"phases":1683,"primaryCompletion":1684,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1690},"NCT06280391","A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis",[91],"2025-09-16","2026-02-02","2024-02-20",312,[1689],"Bronchiectasis",[1661],{"trials":1692,"activeCount":339,"soonestReadout":1730},[1693,1700,1709,1718,1727],{"nctId":1694,"briefTitle":1695,"status":1515,"phases":1696,"primaryCompletion":563,"completion":563,"start":1485,"enrollment":1697,"conditions":1698,"interventions":1699},"NCT07424144","An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps",[92],380,[273],[1661],{"nctId":1701,"briefTitle":1702,"status":138,"phases":1703,"primaryCompletion":1704,"completion":1705,"start":1435,"enrollment":1706,"conditions":1707,"interventions":1708},"NCT06834360","A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",[92],"2026-11-06","2027-10-11",216,[273],[1661,182],{"nctId":1710,"briefTitle":1711,"status":698,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":576,"conditions":1716,"interventions":1717},"NCT07484230","A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",[92],"2027-10-20","2028-10-10","2026-05-08",[273],[1661],{"nctId":1719,"briefTitle":1720,"status":138,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT06208306","A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD",[92],"2026-12-01","2024-01-11",700,[382],[1661],{"nctId":1728,"briefTitle":1702,"status":138,"phases":1729,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1735},"NCT06834347",[92],"2026-10-14","2027-09-16","2025-02-12",231,[273],[1661,182],{"trials":1737,"activeCount":102},[],{"trials":1739,"activeCount":102},[],{"intervention":1741,"totalTrials":622,"cells":1742},"Frexalimab",{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1763,"PHASE4":1813,"NA":1815},{"trials":1744,"activeCount":102},[],{"trials":1746,"activeCount":102},[],{"trials":1748,"activeCount":659,"soonestReadout":1559},[1749,1753],{"nctId":1556,"briefTitle":1557,"status":279,"phases":1750,"primaryCompletion":1559,"completion":1560,"start":1561,"enrollment":1079,"conditions":1751,"interventions":1752},[91],[1563,1564],[1566,1567,62],{"nctId":1754,"briefTitle":1755,"status":279,"phases":1756,"primaryCompletion":1757,"completion":1758,"start":1759,"enrollment":1642,"conditions":1760,"interventions":1761},"NCT06111586","FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)",[91],"2027-04-28","2030-10-29","2023-12-11",[554],[1741,1762],"Insulin",{"trials":1764,"activeCount":445,"soonestReadout":1795},[1765,1781,1791,1803],{"nctId":1766,"briefTitle":1767,"status":279,"phases":1768,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1775},"NCT07412470","A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation",[91,92],"2029-08-15","2033-08-15","2026-03-13",526,[1774],"Kidney Transplant Rejection",[1741,1741,1048,1776,1777,1778,1779,1780],"rabbit anti-thymocyte globulin","mycophenolate mofetil","mycophenolate sodium","methylprednisolone","prednisone",{"nctId":1782,"briefTitle":1783,"status":138,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":999,"enrollment":1786,"conditions":1787,"interventions":1789},"NCT06141486","Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis",[92],"2028-03-24",943,[1788],"Multiple Sclerosis",[1741,1790],"MRI contrast-enhancing agents",{"nctId":1792,"briefTitle":1793,"status":138,"phases":1794,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":1797,"conditions":1798,"interventions":1799},"NCT06141473","Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis",[92],"2027-05-06","2023-12-13",1655,[1788],[1741,1800,1790,1801,1802],"Teriflunomide","Cholestyramine","Activated charcoal",{"nctId":1804,"briefTitle":1805,"status":279,"phases":1806,"primaryCompletion":1205,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1811},"NCT07325292","Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis",[92],"2028-11-30","2026-01-14",160,[1788],[1741,1741,1812],"MRI contrast-enhancing preparations",{"trials":1814,"activeCount":102},[],{"trials":1816,"activeCount":102},[],{"intervention":1818,"totalTrials":535,"cells":1819},"Lunsekimig",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1886,"PHASE4":1904,"NA":1906},{"trials":1821,"activeCount":102},[],{"trials":1823,"activeCount":102},[],{"trials":1825,"activeCount":619,"soonestReadout":1857},[1826,1835,1844,1853,1867,1877],{"nctId":1827,"briefTitle":1828,"status":1515,"phases":1829,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1207,"conditions":1832,"interventions":1833},"NCT06914908","Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study",[91],"2031-01-29","2025-05-12",[273],[1834,182],"lunsekimig",{"nctId":1836,"briefTitle":1837,"status":108,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":455,"conditions":1842,"interventions":1843},"NCT06790121","A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis",[91],"2026-02-12","2026-04-09","2025-01-30",[351],[1818],{"nctId":1845,"briefTitle":1846,"status":1515,"phases":1847,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":1850,"conditions":1851,"interventions":1852},"NCT06609239","Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma",[91],"2031-01-20","2024-09-30",900,[155],[1818],{"nctId":1854,"briefTitle":1855,"status":279,"phases":1856,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1862},"NCT06676319","Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma",[91],"2027-09-17","2027-10-15","2024-11-07",1147,[155],[1818,1863,1864,1865,1866],"Short-Acting Beta Agonists","Fluticasone\u002FSalmeterol","Budesonide\u002FFormoterol","Budesonide\u002FAlbuterol",{"nctId":1868,"briefTitle":1869,"status":108,"phases":1870,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1876},"NCT06454240","A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps",[91],"2026-01-29","2026-04-23","2024-07-17",79,[273],[1834],{"nctId":1878,"briefTitle":1879,"status":108,"phases":1880,"primaryCompletion":1382,"completion":1881,"start":1882,"enrollment":1883,"conditions":1884,"interventions":1885},"NCT06102005","Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma",[91],"2026-03-11","2023-10-16",685,[155],[1818],{"trials":1887,"activeCount":659,"soonestReadout":1892},[1888,1898],{"nctId":1889,"briefTitle":1890,"status":279,"phases":1891,"primaryCompletion":1892,"completion":1893,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1897},"NCT07190222","Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype",[92],"2029-11-27","2030-01-22","2025-09-17",942,[382],[1818],{"nctId":1899,"briefTitle":1900,"status":279,"phases":1901,"primaryCompletion":1892,"completion":1893,"start":1684,"enrollment":1895,"conditions":1902,"interventions":1903},"NCT07190209","Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype",[92],[382],[1818],{"trials":1905,"activeCount":102},[],{"trials":1907,"activeCount":102},[],{"intervention":1909,"totalTrials":339,"cells":1910},"PCV21 vaccine",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1980,"NA":1982},{"trials":1912,"activeCount":102},[],{"trials":1914,"activeCount":102},[],{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":339,"soonestReadout":1923},[1919,1935,1948,1959,1971],{"nctId":1920,"briefTitle":1921,"status":138,"phases":1922,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":1926,"interventions":1928},"NCT06736041","Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",[92],"2027-05-17","2024-12-18",1714,[1927],"Pneumococcal Immunization",[1909,1929,1930,1931,1932,1933,1934],"Prevnar 20 vaccine","M-M-R II vaccine","RotaTeq","Vaxelis vaccine","Varivax","Hexaxim Vaccine",{"nctId":1936,"briefTitle":1937,"status":138,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":1942,"interventions":1943},"NCT06824194","Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",[92],"2027-10-22","2025-02-18",2360,[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],"Rotarix","Priorix","VAQTA","Havrix",{"nctId":1949,"briefTitle":1950,"status":279,"phases":1951,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":1956,"interventions":1957},"NCT07348692","Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age",[92],"2027-06-07","2028-05-29","2026-01-20",2195,[1927,36],[1909,1958],"20vPCV licensed vaccine",{"nctId":1960,"briefTitle":1961,"status":138,"phases":1962,"primaryCompletion":321,"completion":321,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1966},"NCT06975878","Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",[92],"2025-05-22",1092,[1927,36],[1909,1967,1968,1969,1970],"Vaxneuvance vaccine","Hexyon vaccine","M-M-RvaxPro vaccine","Varivax vaccine",{"nctId":1972,"briefTitle":1973,"status":138,"phases":1974,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":1978,"interventions":1979},"NCT06824181","Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age",[92],"2027-09-10","2025-02-27",580,[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":1981,"activeCount":102},[],{"trials":1983,"activeCount":102},[],{"intervention":1214,"totalTrials":339,"cells":1985},{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":2000,"PHASE4":2010,"NA":2025},{"trials":1987,"activeCount":102},[],{"trials":1989,"activeCount":102},[],{"trials":1991,"activeCount":659,"soonestReadout":1220},[1992,1996],{"nctId":1201,"briefTitle":1202,"status":279,"phases":1993,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":1994,"interventions":1995},[91],[639],[1210,1211,642,1212,1213,1214,1215],{"nctId":1217,"briefTitle":1218,"status":138,"phases":1997,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":1998,"interventions":1999},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"trials":2001,"activeCount":659,"soonestReadout":66},[2002,2006],{"nctId":64,"briefTitle":65,"status":138,"phases":2003,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":2004,"interventions":2005},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"nctId":1766,"briefTitle":1767,"status":279,"phases":2007,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":2008,"interventions":2009},[91,92],[1774],[1741,1741,1048,1776,1777,1778,1779,1780],{"trials":2011,"activeCount":102},[2012],{"nctId":2013,"briefTitle":2014,"status":108,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":2019,"interventions":2021},"NCT03099122","A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant",[93],"2019-11-12","2017-08-16",115,[2020],"End-stage Renal Disease",[2022,1048,1214,2023,2024,1780],"Rabbit Anti-thymocyte Immunoglobulin","Mycophenolate mofetil","Mycophenolate Na",{"trials":2026,"activeCount":102},[],{"intervention":182,"totalTrials":622,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2047,"PHASE4":2069,"NA":2071},{"trials":2030,"activeCount":102},[],{"trials":2032,"activeCount":102},[],{"trials":2034,"activeCount":659,"soonestReadout":1673},[2035,2039,2043],{"nctId":1827,"briefTitle":1828,"status":1515,"phases":2036,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1207,"conditions":2037,"interventions":2038},[91],[273],[1834,182],{"nctId":1670,"briefTitle":1671,"status":138,"phases":2040,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":2041,"interventions":2042},[91],[1678],[1661,182],{"nctId":174,"briefTitle":175,"status":108,"phases":2044,"primaryCompletion":150,"completion":150,"start":177,"enrollment":178,"conditions":2045,"interventions":2046},[91],[180],[97,182],{"trials":2048,"activeCount":659,"soonestReadout":1730},[2049,2053,2065],{"nctId":1701,"briefTitle":1702,"status":138,"phases":2050,"primaryCompletion":1704,"completion":1705,"start":1435,"enrollment":1706,"conditions":2051,"interventions":2052},[92],[273],[1661,182],{"nctId":2054,"briefTitle":2055,"status":108,"phases":2056,"primaryCompletion":2057,"completion":2058,"start":2059,"enrollment":2060,"conditions":2061,"interventions":2063},"NCT02898454","Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps",[92],"2018-08-27","2018-11-16","2016-11-28",448,[2062],"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)",[2064,182],"Dupilumab SAR231893",{"nctId":1728,"briefTitle":1702,"status":138,"phases":2066,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":1733,"conditions":2067,"interventions":2068},[92],[273],[1661,182],{"trials":2070,"activeCount":102},[],{"trials":2072,"activeCount":102},[],{"intervention":2074,"totalTrials":445,"cells":2075},"Duvakitug",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2082,"PHASE4":2121,"NA":2123},{"trials":2077,"activeCount":102},[],{"trials":2079,"activeCount":102},[],{"trials":2081,"activeCount":102},[],{"trials":2083,"activeCount":445,"soonestReadout":2099},[2084,2095,2105,2112],{"nctId":2085,"briefTitle":2086,"status":279,"phases":2087,"primaryCompletion":2088,"completion":2089,"start":2090,"enrollment":2091,"conditions":2092,"interventions":2094},"NCT07184944","A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease",[92],"2029-08-13","2034-03-20","2026-01-22",751,[2093],"Crohn's Disease",[2074],{"nctId":2096,"briefTitle":2097,"status":279,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2104},"NCT07184996","An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis",[92],"2028-05-09","2025-10-08",980,[2103],"Ulcerative Colitis",[2074],{"nctId":2106,"briefTitle":2107,"status":279,"phases":2108,"primaryCompletion":2109,"completion":2109,"start":1452,"enrollment":2101,"conditions":2110,"interventions":2111},"NCT07184931","An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease",[92],"2029-05-14",[2093],[2074],{"nctId":2113,"briefTitle":2114,"status":279,"phases":2115,"primaryCompletion":2116,"completion":2117,"start":1453,"enrollment":2118,"conditions":2119,"interventions":2120},"NCT07185009","A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis",[92],"2028-09-21","2033-04-28",671,[2103],[2074],{"trials":2122,"activeCount":102},[],{"trials":2124,"activeCount":102},[],{"intervention":643,"totalTrials":538,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2139,"PHASE3":2149,"PHASE4":2159,"NA":2161},{"trials":2128,"activeCount":102},[],{"trials":2130,"activeCount":102},[2131,2135],{"nctId":1141,"briefTitle":1142,"status":108,"phases":2132,"primaryCompletion":913,"completion":913,"start":1144,"enrollment":1145,"conditions":2133,"interventions":2134},[90],[1147],[1149,1150,1151,1152],{"nctId":1154,"briefTitle":1155,"status":108,"phases":2136,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":349,"conditions":2137,"interventions":2138},[90],[1160],[1162,643,642],{"trials":2140,"activeCount":659,"soonestReadout":615},[2141,2145],{"nctId":1229,"briefTitle":1230,"status":138,"phases":2142,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":2143,"interventions":2144},[91],[1160],[1235,1236,642,1237,643,1238,1215],{"nctId":631,"briefTitle":632,"status":279,"phases":2146,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":2147,"interventions":2148},[90,91],[639],[641,642,643,644,645,646,621,647],{"trials":2150,"activeCount":195,"soonestReadout":66},[2151,2155],{"nctId":64,"briefTitle":65,"status":138,"phases":2152,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":2153,"interventions":2154},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"nctId":1326,"briefTitle":1327,"status":108,"phases":2156,"primaryCompletion":1329,"completion":1330,"start":1331,"enrollment":1332,"conditions":2157,"interventions":2158},[92],[1160],[641,643,642],{"trials":2160,"activeCount":102},[],{"trials":2162,"activeCount":195,"soonestReadout":1382},[2163],{"nctId":1379,"briefTitle":1380,"status":138,"phases":2164,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":2165,"interventions":2166},[],[1160],[1175,643,642,1215],{"intervention":1213,"totalTrials":622,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2177,"PHASE3":2191,"PHASE4":2197,"NA":2203},{"trials":2170,"activeCount":102},[],{"trials":2172,"activeCount":102},[2173],{"nctId":1186,"briefTitle":1187,"status":108,"phases":2174,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":402,"conditions":2175,"interventions":2176},[90],[1193],[1195,1151,1196,1197],{"trials":2178,"activeCount":659,"soonestReadout":1220},[2179,2183,2187],{"nctId":1201,"briefTitle":1202,"status":279,"phases":2180,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":2181,"interventions":2182},[91],[639],[1210,1211,642,1212,1213,1214,1215],{"nctId":1217,"briefTitle":1218,"status":138,"phases":2184,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":2185,"interventions":2186},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"nctId":1255,"briefTitle":1256,"status":884,"phases":2188,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":2189,"interventions":2190},[91],[1262,1263],[1162,1151,1151,1265,1266,1197],{"trials":2192,"activeCount":195,"soonestReadout":66},[2193],{"nctId":64,"briefTitle":65,"status":138,"phases":2194,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":2195,"interventions":2196},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"trials":2198,"activeCount":102},[2199],{"nctId":1365,"briefTitle":1366,"status":108,"phases":2200,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":2201,"interventions":2202},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"trials":2204,"activeCount":102},[],{"intervention":1212,"totalTrials":339,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2225,"PHASE4":2231,"NA":2237},{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":659,"soonestReadout":1220},[2213,2217,2221],{"nctId":1201,"briefTitle":1202,"status":279,"phases":2214,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":2215,"interventions":2216},[91],[639],[1210,1211,642,1212,1213,1214,1215],{"nctId":1217,"briefTitle":1218,"status":138,"phases":2218,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":2219,"interventions":2220},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"nctId":1255,"briefTitle":1256,"status":884,"phases":2222,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":2223,"interventions":2224},[91],[1262,1263],[1162,1151,1151,1265,1266,1197],{"trials":2226,"activeCount":195,"soonestReadout":1316},[2227],{"nctId":1313,"briefTitle":1314,"status":138,"phases":2228,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":2229,"interventions":2230},[92],[1160],[1162,1237,642,1322,1212,1323,1324],{"trials":2232,"activeCount":102},[2233],{"nctId":1365,"briefTitle":1366,"status":108,"phases":2234,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":2235,"interventions":2236},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"trials":2238,"activeCount":102},[],{"intervention":1211,"totalTrials":445,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2255,"PHASE4":2261,"NA":2267},{"trials":2242,"activeCount":102},[],{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":659,"soonestReadout":1220},[2247,2251],{"nctId":1201,"briefTitle":1202,"status":279,"phases":2248,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":2249,"interventions":2250},[91],[639],[1210,1211,642,1212,1213,1214,1215],{"nctId":1217,"briefTitle":1218,"status":138,"phases":2252,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":2253,"interventions":2254},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"trials":2256,"activeCount":195,"soonestReadout":66},[2257],{"nctId":64,"briefTitle":65,"status":138,"phases":2258,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":2259,"interventions":2260},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"trials":2262,"activeCount":102},[2263],{"nctId":1365,"briefTitle":1366,"status":108,"phases":2264,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":2265,"interventions":2266},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"trials":2268,"activeCount":102},[],{"intervention":43,"totalTrials":538,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2288,"PHASE3":2305,"PHASE4":2355,"NA":2357},{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[2275],{"nctId":2276,"briefTitle":2277,"status":108,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":2281,"conditions":2282,"interventions":2284},"NCT04142086","Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults",[90],"2021-06-24","2020-01-15",73,[2283],"Yellow Fever (Healthy Volunteers)",[2285,2286,2287,43],"Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine","Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine","Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine",{"trials":2289,"activeCount":659,"soonestReadout":42},[2290,2298],{"nctId":45,"briefTitle":46,"status":138,"phases":2291,"primaryCompletion":47,"completion":2292,"start":2293,"enrollment":2294,"conditions":2295,"interventions":2297},[91],"2027-06-29","2021-07-01",568,[2296,36],"Yellow Fever",[43,43],{"nctId":40,"briefTitle":41,"status":138,"phases":2299,"primaryCompletion":42,"completion":2300,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2304},[91],"2027-04-23","2021-10-07",690,[2296],[43,43],{"trials":2306,"activeCount":195,"soonestReadout":2330},[2307,2326,2338,2346],{"nctId":2308,"briefTitle":2309,"status":108,"phases":2310,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2318},"NCT01436396","Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers",[92],"2013-09","2013-09-02","2011-09-07",792,[2316,2317,2296],"Dengue","Dengue Hemorrhagic Fever",[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],"Live, attenuated dengue serotype 1, 2, 3, and 4 virus","Measles, mumps, and rubella (MMR) vaccine","Pneumococcal Conjugated Vaccine","Hepatitis A Pediatric Vaccine","Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine","Yellow Fever Vaccine","Measles, mumps, and rubella vaccine",{"nctId":2327,"briefTitle":2328,"status":279,"phases":2329,"primaryCompletion":2330,"completion":2331,"start":2332,"enrollment":2333,"conditions":2334,"interventions":2336},"NCT07103148","A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population",[92],"2026-08-08","2030-03-04","2025-07-11",2440,[2335],"Yellow Fever Immunization",[43,43,43,2337],"Measles, combinations with mumps and rubella, live attenuated",{"nctId":2339,"briefTitle":2340,"status":108,"phases":2341,"primaryCompletion":1954,"completion":1954,"start":1963,"enrollment":2342,"conditions":2343,"interventions":2344},"NCT07002060","Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults",[92],640,[2335],[43,2345],"YF vaccine",{"nctId":2347,"briefTitle":2348,"status":108,"phases":2349,"primaryCompletion":2350,"completion":2350,"start":2351,"enrollment":2352,"conditions":2353,"interventions":2354},"NCT07222059","Phase 3 Single Arm, Open Study on vYF in Adults",[92],"2025-12-25","2025-10-23",254,[2296],[43],{"trials":2356,"activeCount":102},[],{"trials":2358,"activeCount":102},[],{"intervention":82,"totalTrials":622,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2392,"PHASE3":2394,"PHASE4":2427,"NA":2429},{"trials":2362,"activeCount":102},[],{"trials":2364,"activeCount":102},[2365,2374,2383],{"nctId":2366,"briefTitle":2367,"status":108,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2373},"NCT06418620","A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants",[90],"2020-08-07","2020-06-18",9,[36],[82],{"nctId":2375,"briefTitle":2376,"status":108,"phases":2377,"primaryCompletion":2378,"completion":2378,"start":2379,"enrollment":703,"conditions":2380,"interventions":2382},"NCT05718258","A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function",[90],"2024-01-29","2023-01-18",[2381],"Hepatic Function Abnormal",[82],{"nctId":2384,"briefTitle":2385,"status":108,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":2390,"interventions":2391},"NCT06418607","A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants",[90],"2020-07-13","2020-06-23",65,[36],[82,82],{"trials":2393,"activeCount":102},[],{"trials":2395,"activeCount":619,"soonestReadout":81},[2396,2407,2416],{"nctId":2397,"briefTitle":2398,"status":138,"phases":2399,"primaryCompletion":2400,"completion":2401,"start":2402,"enrollment":2403,"conditions":2404,"interventions":2406},"NCT05206773","A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease",[92],"2025-12-17","2027-01-04","2022-03-11",122,[2405],"Fabry Disease",[82],{"nctId":79,"briefTitle":80,"status":138,"phases":2408,"primaryCompletion":81,"completion":2409,"start":2410,"enrollment":2411,"conditions":2412,"interventions":2414},[92],"2026-10-30","2022-04-18",43,[2413],"Gaucher's Disease Type III",[82,2415],"imiglucerase",{"nctId":2417,"briefTitle":2418,"status":138,"phases":2419,"primaryCompletion":140,"completion":2420,"start":2421,"enrollment":166,"conditions":2422,"interventions":2423},"NCT05280548","A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease",[92],"2027-12-06","2022-05-03",[2405],[82,2424,2425,2426],"Agalsidase alfa","Agalsidase beta","Migalastat",{"trials":2428,"activeCount":102},[],{"trials":2430,"activeCount":102},[],{"intervention":1237,"totalTrials":339,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2445,"PHASE3":2451,"PHASE4":2461,"NA":2463},{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":102},[2437,2441],{"nctId":1164,"briefTitle":1165,"status":108,"phases":2438,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":305,"conditions":2439,"interventions":2440},[90],[1160],[1172,1173,1174,1151,1175],{"nctId":1177,"briefTitle":1178,"status":108,"phases":2442,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":2443,"interventions":2444},[90],[1160],[1175,1172,1151],{"trials":2446,"activeCount":195,"soonestReadout":615},[2447],{"nctId":1229,"briefTitle":1230,"status":138,"phases":2448,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":2449,"interventions":2450},[91],[1160],[1235,1236,642,1237,643,1238,1215],{"trials":2452,"activeCount":659,"soonestReadout":1305},[2453,2457],{"nctId":1302,"briefTitle":1303,"status":138,"phases":2454,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":2455,"interventions":2456},[92],[1160],[1162,1311,1237,642],{"nctId":1313,"briefTitle":1314,"status":138,"phases":2458,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":2459,"interventions":2460},[92],[1160],[1162,1237,642,1322,1212,1323,1324],{"trials":2462,"activeCount":102},[],{"trials":2464,"activeCount":102},[],{"intervention":1931,"totalTrials":445,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2502,"NA":2504},{"trials":2468,"activeCount":102},[],{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":619,"soonestReadout":1923},[2475,2479,2483,2498],{"nctId":1920,"briefTitle":1921,"status":138,"phases":2476,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":2477,"interventions":2478},[92],[1927],[1909,1929,1930,1931,1932,1933,1934],{"nctId":1936,"briefTitle":1937,"status":138,"phases":2480,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":2481,"interventions":2482},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":2484,"briefTitle":2485,"status":108,"phases":2486,"primaryCompletion":2487,"completion":1042,"start":1032,"enrollment":474,"conditions":2488,"interventions":2492},"NCT01839175","Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination",[92],"2014-07",[2489,2490,2491],"Neisseria Meningitidis","Bacterial Infections","Virus Diseases",[2493,2494,2495,1931,2496,2497],"Hexavalent vaccine","NeisVac-C","Prevenar 13","Nimenrix","M-M-RVAXPRO",{"nctId":1972,"briefTitle":1973,"status":138,"phases":2499,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":2500,"interventions":2501},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":2503,"activeCount":102},[],{"trials":2505,"activeCount":102},[],{"intervention":1929,"totalTrials":619,"cells":2507},{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2528,"NA":2530},{"trials":2509,"activeCount":102},[],{"trials":2511,"activeCount":102},[],{"trials":2513,"activeCount":102},[],{"trials":2515,"activeCount":619,"soonestReadout":1923},[2516,2520,2524],{"nctId":1920,"briefTitle":1921,"status":138,"phases":2517,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":2518,"interventions":2519},[92],[1927],[1909,1929,1930,1931,1932,1933,1934],{"nctId":1936,"briefTitle":1937,"status":138,"phases":2521,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":2522,"interventions":2523},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":2525,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":2526,"interventions":2527},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":2529,"activeCount":102},[],{"trials":2531,"activeCount":102},[],{"intervention":1930,"totalTrials":619,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2554,"NA":2556},{"trials":2535,"activeCount":102},[],{"trials":2537,"activeCount":102},[],{"trials":2539,"activeCount":102},[],{"trials":2541,"activeCount":619,"soonestReadout":1923},[2542,2546,2550],{"nctId":1920,"briefTitle":1921,"status":138,"phases":2543,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":2544,"interventions":2545},[92],[1927],[1909,1929,1930,1931,1932,1933,1934],{"nctId":1936,"briefTitle":1937,"status":138,"phases":2547,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":2548,"interventions":2549},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":2551,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":2552,"interventions":2553},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":2555,"activeCount":102},[],{"trials":2557,"activeCount":102},[],{"intervention":1932,"totalTrials":619,"cells":2559},{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2566,"PHASE4":2580,"NA":2582},{"trials":2561,"activeCount":102},[],{"trials":2563,"activeCount":102},[],{"trials":2565,"activeCount":102},[],{"trials":2567,"activeCount":619,"soonestReadout":1923},[2568,2572,2576],{"nctId":1920,"briefTitle":1921,"status":138,"phases":2569,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":2570,"interventions":2571},[92],[1927],[1909,1929,1930,1931,1932,1933,1934],{"nctId":1936,"briefTitle":1937,"status":138,"phases":2573,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":2574,"interventions":2575},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":2577,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":2578,"interventions":2579},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":2581,"activeCount":102},[],{"trials":2583,"activeCount":102},[],{"intervention":1933,"totalTrials":619,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2606,"NA":2608},{"trials":2587,"activeCount":102},[],{"trials":2589,"activeCount":102},[],{"trials":2591,"activeCount":102},[],{"trials":2593,"activeCount":619,"soonestReadout":1923},[2594,2598,2602],{"nctId":1920,"briefTitle":1921,"status":138,"phases":2595,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":2596,"interventions":2597},[92],[1927],[1909,1929,1930,1931,1932,1933,1934],{"nctId":1936,"briefTitle":1937,"status":138,"phases":2599,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":2600,"interventions":2601},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":2603,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":2604,"interventions":2605},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":2607,"activeCount":102},[],{"trials":2609,"activeCount":102},[],{"intervention":1162,"totalTrials":2611,"cells":2612},17,{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2639,"PHASE3":2713,"PHASE4":2727,"NA":2729},{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[2617,2621,2625,2629],{"nctId":1154,"briefTitle":1155,"status":108,"phases":2618,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":349,"conditions":2619,"interventions":2620},[90],[1160],[1162,643,642],{"nctId":1164,"briefTitle":1165,"status":108,"phases":2622,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":305,"conditions":2623,"interventions":2624},[90],[1160],[1172,1173,1174,1151,1175],{"nctId":1177,"briefTitle":1178,"status":108,"phases":2626,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":2627,"interventions":2628},[90],[1160],[1175,1172,1151],{"nctId":2630,"briefTitle":2631,"status":108,"phases":2632,"primaryCompletion":2633,"completion":2634,"start":2635,"enrollment":2636,"conditions":2637,"interventions":2638},"NCT03733717","Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and\u002For Refractory Multiple Myeloma",[90],"2020-09-06","2023-08-25","2018-10-22",25,[1147],[1162],{"trials":2640,"activeCount":102},[2641,2647,2657,2668,2678,2688,2692,2696,2706],{"nctId":2642,"briefTitle":2643,"status":884,"phases":2644,"primaryCompletion":439,"completion":439,"start":1582,"enrollment":535,"conditions":2645,"interventions":2646},"NCT04661033","Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)",[91],[1603],[1162],{"nctId":2648,"briefTitle":2649,"status":884,"phases":2650,"primaryCompletion":2651,"completion":2651,"start":2370,"enrollment":1400,"conditions":2652,"interventions":2654},"NCT04294459","Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation",[90,91],"2022-05-02",[2653],"Immune System Disorder",[1162,2655,2656,1323,1324,1322],"Acetaminophen (paracetamol) or equivalent","Ranitidine or equivalent",{"nctId":2658,"briefTitle":2659,"status":884,"phases":2660,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2666},"NCT03637764","Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",[90,91],"2022-05-11","2018-08-06",107,[2665],"Neoplasm",[1162,2667],"Atezolizumab",{"nctId":2669,"briefTitle":2670,"status":884,"phases":2671,"primaryCompletion":2672,"completion":2672,"start":2673,"enrollment":967,"conditions":2674,"interventions":2676},"NCT03769181","A Study of Isatuximab-based Therapy in Participants With Lymphoma",[90,91],"2022-11-08","2018-12-11",[2675],"Lymphoma",[1175,2677],"cemiplimab REGN2810",{"nctId":2679,"briefTitle":2680,"status":108,"phases":2681,"primaryCompletion":2682,"completion":2683,"start":2684,"enrollment":2685,"conditions":2686,"interventions":2687},"NCT02812706","Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients",[90,91],"2018-07-31","2022-09-28","2016-09-05",36,[1147],[1162],{"nctId":1244,"briefTitle":1245,"status":108,"phases":2689,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":1250,"conditions":2690,"interventions":2691},[90,91],[1252],[1162,642,642],{"nctId":1255,"briefTitle":1256,"status":884,"phases":2693,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":2694,"interventions":2695},[91],[1262,1263],[1162,1151,1151,1265,1266,1197],{"nctId":2697,"briefTitle":2698,"status":884,"phases":2699,"primaryCompletion":2700,"completion":2700,"start":2701,"enrollment":359,"conditions":2702,"interventions":2704},"NCT03367819","Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies",[90,91],"2021-03-10","2018-01-04",[1357,2703],"Non-small Cell Lung Cancer",[1162,2705],"Cemiplimab REGN2810",{"nctId":2707,"briefTitle":2708,"status":108,"phases":2709,"primaryCompletion":1222,"completion":1222,"start":2710,"enrollment":442,"conditions":2711,"interventions":2712},"NCT03194867","Isatuximab in Combination With Cemiplimab in Relapsed\u002FRefractory Multiple Myeloma (RRMM) Patients",[90,91],"2018-02-21",[1160],[1162,2705],{"trials":2714,"activeCount":659,"soonestReadout":1305},[2715,2719,2723],{"nctId":1281,"briefTitle":1282,"status":108,"phases":2716,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":2717,"interventions":2718},[92],[1160],[1175,1290,1151],{"nctId":1302,"briefTitle":1303,"status":138,"phases":2720,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":2721,"interventions":2722},[92],[1160],[1162,1311,1237,642],{"nctId":1313,"briefTitle":1314,"status":138,"phases":2724,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":2725,"interventions":2726},[92],[1160],[1162,1237,642,1322,1212,1323,1324],{"trials":2728,"activeCount":102},[],{"trials":2730,"activeCount":195,"soonestReadout":1382},[2731],{"nctId":1379,"briefTitle":1380,"status":138,"phases":2732,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":2733,"interventions":2734},[],[1160],[1175,643,642,1215],{"intervention":671,"totalTrials":335,"cells":2736},{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2769,"PHASE4":2839,"NA":2876},{"trials":2738,"activeCount":102},[],{"trials":2740,"activeCount":102},[],{"trials":2742,"activeCount":102},[2743,2755,2765],{"nctId":2744,"briefTitle":2745,"status":884,"phases":2746,"primaryCompletion":2747,"completion":2747,"start":2748,"enrollment":535,"conditions":2749,"interventions":2751},"NCT02379390","Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide",[91],"2018-05-10","2015-06-17",[2750],"Prostate Cancer Metastatic",[2752,2753,2754,671],"Cabazitaxel XRP6258","Ezalutamide","Abiraterone acetate",{"nctId":2756,"briefTitle":2757,"status":108,"phases":2758,"primaryCompletion":2759,"completion":2759,"start":2760,"enrollment":271,"conditions":2761,"interventions":2762},"NCT01718353","Early Switch From First-Line Docetaxel\u002FPrednisone to Cabazitaxel\u002FPrednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[91],"2015-08","2013-03",[2750],[2763,2764,671],"DOCETAXEL","CABAZITAXEL",{"nctId":961,"briefTitle":962,"status":108,"phases":2766,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":2767,"interventions":2768},[91],[969],[942,671,971,972],{"trials":2770,"activeCount":659,"soonestReadout":666},[2771,2782,2786,2795,2808,2812,2820,2830],{"nctId":2772,"briefTitle":2773,"status":884,"phases":2774,"primaryCompletion":2775,"completion":2775,"start":2776,"enrollment":2777,"conditions":2778,"interventions":2780},"NCT03600805","Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA",[92],"2020-11-24","2018-11-20",83,[2779],"Giant Cell Arteritis",[2781,671],"Sarilumab SAR153191",{"nctId":663,"briefTitle":664,"status":138,"phases":2783,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":2784,"interventions":2785},[92],[657],[621,671,672],{"nctId":2787,"briefTitle":2788,"status":108,"phases":2789,"primaryCompletion":2759,"completion":2759,"start":2790,"enrollment":2791,"conditions":2792,"interventions":2793},"NCT01308580","Cabazitaxel at 20 mg\u002Fm² Compared to 25 mg\u002Fm² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer",[92],"2011-04",1200,[1357],[2794,671],"Cabazitaxel",{"nctId":2796,"briefTitle":2797,"status":108,"phases":2798,"primaryCompletion":2799,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2805},"NCT00417079","XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer",[92],"2009-09","2007-01",755,[2803,2804],"Neoplasms","Prostatic Neoplasms",[2806,2807,1780],"cabazitaxel","mitoxantrone",{"nctId":1766,"briefTitle":1767,"status":279,"phases":2809,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":2810,"interventions":2811},[91,92],[1774],[1741,1741,1048,1776,1777,1778,1779,1780],{"nctId":2813,"briefTitle":2814,"status":884,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1223,"conditions":2818,"interventions":2819},"NCT03600818","Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica",[92],"2021-05-19","2018-10-09",[1093],[2781,671,671],{"nctId":2821,"briefTitle":2822,"status":108,"phases":2823,"primaryCompletion":2824,"completion":2825,"start":2826,"enrollment":2827,"conditions":2828,"interventions":2829},"NCT01308567","Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer",[92],"2015-09","2018-05","2011-05-05",1168,[1357],[2794,1348,671],{"nctId":2831,"briefTitle":2832,"status":108,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":2800,"enrollment":2835,"conditions":2836,"interventions":2837},"NCT00436839","Taxotere Prostate Cancer New Indication Registration Trial in China",[92],"2012-06",228,[2804],[1348,2838,671],"Mitoxantrone",{"trials":2840,"activeCount":102},[2841,2847,2851,2863],{"nctId":2842,"briefTitle":2843,"status":108,"phases":2844,"primaryCompletion":1054,"completion":1054,"start":2487,"enrollment":552,"conditions":2845,"interventions":2846},"NCT02074137","Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer",[93],[2750],[1359,671,672],{"nctId":2013,"briefTitle":2014,"status":108,"phases":2848,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":2849,"interventions":2850},[93],[2020],[2022,1048,1214,2023,2024,1780],{"nctId":2852,"briefTitle":2853,"status":108,"phases":2854,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":2859,"interventions":2860},"NCT01649635","Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer",[93],"2014-01","2016-06","2012-07",45,[1357],[2764,671,2861,2862],"Ciprofloxacin","G-CSF",{"nctId":2864,"briefTitle":2865,"status":108,"phases":2866,"primaryCompletion":2867,"completion":2868,"start":2869,"enrollment":2870,"conditions":2871,"interventions":2872},"NCT02485691","Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent",[93],"2019-03-27","2021-03-15","2015-11-09",255,[2750],[2873,2874,2875,1780],"cabazitaxel XRP6258","enzalutamide","abiraterone acetate",{"trials":2877,"activeCount":102},[],{"intervention":2879,"totalTrials":2371,"cells":2880},"MenACYW conjugate vaccine",{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2913,"PHASE4":2990,"NA":3001},{"trials":2882,"activeCount":102},[],{"trials":2884,"activeCount":102},[],{"trials":2886,"activeCount":195,"soonestReadout":1923},[2887,2902],{"nctId":2888,"briefTitle":2889,"status":138,"phases":2890,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":2893,"interventions":2895},"NCT06647407","Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants",[90,91],"2024-11-05",750,[2894,36],"Meningococcal Immunization",[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],"Pentavalent Meningococcal ABCYW vaccine","Meningococcal group B vaccine","Paracetamol","DTap-HepB-IPV-Hib vaccine","Rotavirus vaccine","Pneumococcal 13-valent conjugate vaccine",{"nctId":2903,"briefTitle":2904,"status":108,"phases":2905,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":2908,"conditions":2909,"interventions":2911},"NCT06128733","Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents",[90,91],"2025-08-27","2023-10-31",1215,[2910,36],"Meningococcal Immunisation",[2896,2879,2897,2897,2897,2879,2912],"MenABCYW conjugate vaccine",{"trials":2914,"activeCount":195,"soonestReadout":2945},[2915,2924,2941,2953,2967,2981],{"nctId":2916,"briefTitle":2917,"status":108,"phases":2918,"primaryCompletion":2919,"completion":2919,"start":2920,"enrollment":726,"conditions":2921,"interventions":2923},"NCT03476135","Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children",[92],"2018-09-10","2018-02-27",[2922],"Meningococcal Infections",[2879],{"nctId":2925,"briefTitle":2926,"status":108,"phases":2927,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":2931,"interventions":2933},"NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US",[92],"2023-09-22","2018-04-25",2627,[2932],"Healthy Volunteers (Meningococcal Infection)",[2879,2934,2935,2901,2936,2937,2938,2939,2940],"MenACYW-135 conjugate vaccine","DTaP-IPV\u002F\u002FHib vaccine","Pentavalent rotavirus vaccine","Hepatitis B vaccine","Measles, mumps, rubella (MMR) vaccine","Varicella vaccine","Hepatitis A vaccine",{"nctId":2942,"briefTitle":2943,"status":138,"phases":2944,"primaryCompletion":2945,"completion":2946,"start":1623,"enrollment":2947,"conditions":2948,"interventions":2950},"NCT07135986","Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China",[92],"2026-05-01","2026-09-23",1602,[2949,36],"Meningococcal Infection",[2879,2951,2952],"MenACYW135 polysaccharide vaccine","MenAC conjugate vaccine",{"nctId":2954,"briefTitle":2955,"status":108,"phases":2956,"primaryCompletion":2957,"completion":2958,"start":2959,"enrollment":2960,"conditions":2961,"interventions":2962},"NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe",[92],"2023-05-17","2023-05-24","2018-12-14",1660,[2922],[2879,2963,2964,2965,2965,2966],"Meningococcal group A, C, W-135, and Y conjugate vaccine","DTaP-IPV-HB-Hib vaccine","Pneumococcal vaccine","MMR vaccine",{"nctId":2968,"briefTitle":2969,"status":108,"phases":2970,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":2973,"conditions":2974,"interventions":2976},"NCT03205371","Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers",[92],"2018-07-19","2016-11-07",1183,[2975],"Meningitis, Meningococcal",[2879,2977,2978,2979,2980],"MMR","Varicella","DTaP-IPV-HB-Hib","PCV13",{"nctId":2982,"briefTitle":2983,"status":108,"phases":2984,"primaryCompletion":2985,"completion":2985,"start":2986,"enrollment":2987,"conditions":2988,"interventions":2989},"NCT06284915","Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers",[92],"2025-11-14","2024-03-19",840,[2910,36],[2879,2879],{"trials":2991,"activeCount":102},[2992],{"nctId":2993,"briefTitle":2994,"status":108,"phases":2995,"primaryCompletion":2996,"completion":2996,"start":2997,"enrollment":2998,"conditions":2999,"interventions":3000},"NCT05929651","Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy",[93],"2024-09-09","2023-09-07",71,[2910,36],[2879],{"trials":3002,"activeCount":102},[],{"intervention":1048,"totalTrials":445,"cells":3004},{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3023,"PHASE4":3033,"NA":3039},{"trials":3006,"activeCount":102},[],{"trials":3008,"activeCount":102},[],{"trials":3010,"activeCount":195,"soonestReadout":86},[3011],{"nctId":84,"briefTitle":85,"status":138,"phases":3012,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":3015,"interventions":3017},[91],"2026-10-26","2022-06-09",[3016],"Transplant Rejection",[87,3018,3019,3020,1048,3021,3022],"Intravenous immunoglobulin","Rituximab or biosimilar","Antithymocyte globulin","Mycophenolate","Corticosteroids",{"trials":3024,"activeCount":195,"soonestReadout":1769},[3025,3029],{"nctId":1038,"briefTitle":1039,"status":108,"phases":3026,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":726,"conditions":3027,"interventions":3028},[92],[990],[942,1045,1046,1047,1048,1049],{"nctId":1766,"briefTitle":1767,"status":279,"phases":3030,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":3031,"interventions":3032},[91,92],[1774],[1741,1741,1048,1776,1777,1778,1779,1780],{"trials":3034,"activeCount":102},[3035],{"nctId":2013,"briefTitle":2014,"status":108,"phases":3036,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":3037,"interventions":3038},[93],[2020],[2022,1048,1214,2023,2024,1780],{"trials":3040,"activeCount":102},[],{"intervention":1500,"totalTrials":619,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3049,"PHASE4":3063,"NA":3065},{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":102},[],{"trials":3050,"activeCount":659,"soonestReadout":1506},[3051,3055,3059],{"nctId":1491,"briefTitle":1492,"status":108,"phases":3052,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":1497,"conditions":3053,"interventions":3054},[92],[351],[77,1500,1501],{"nctId":1503,"briefTitle":1504,"status":279,"phases":3056,"primaryCompletion":1506,"completion":666,"start":1507,"enrollment":1508,"conditions":3057,"interventions":3058},[92],[351],[77,1500,1511],{"nctId":1513,"briefTitle":1514,"status":1515,"phases":3060,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":3061,"interventions":3062},[91,92],[351],[77,1500,1501,1522],{"trials":3064,"activeCount":102},[],{"trials":3066,"activeCount":102},[],{"intervention":1812,"totalTrials":659,"cells":3068},{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3083,"PHASE4":3089,"NA":3091},{"trials":3070,"activeCount":102},[],{"trials":3072,"activeCount":102},[],{"trials":3074,"activeCount":195,"soonestReadout":51},[3075],{"nctId":49,"briefTitle":50,"status":138,"phases":3076,"primaryCompletion":51,"completion":3077,"start":3078,"enrollment":3079,"conditions":3080,"interventions":3081},[91],"2027-08-23","2021-06-07",129,[1788],[52,3082,1812],"SAR441344 SC",{"trials":3084,"activeCount":195,"soonestReadout":1205},[3085],{"nctId":1804,"briefTitle":1805,"status":279,"phases":3086,"primaryCompletion":1205,"completion":1807,"start":1808,"enrollment":1809,"conditions":3087,"interventions":3088},[92],[1788],[1741,1741,1812],{"trials":3090,"activeCount":102},[],{"trials":3092,"activeCount":102},[],{"intervention":3094,"totalTrials":659,"cells":3095},"riliprubart",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3102,"PHASE4":3127,"NA":3129},{"trials":3097,"activeCount":102},[],{"trials":3099,"activeCount":102},[],{"trials":3101,"activeCount":102},[],{"trials":3103,"activeCount":659,"soonestReadout":1923},[3104,3115],{"nctId":3105,"briefTitle":3106,"status":279,"phases":3107,"primaryCompletion":3108,"completion":3109,"start":3110,"enrollment":1809,"conditions":3111,"interventions":3113},"NCT06290141","A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[92],"2027-07-09","2029-01-12","2024-08-21",[3112],"Chronic Inflammatory Demyelinating Polyneuropathy",[3094,3094,3114],"IVIg",{"nctId":3116,"briefTitle":3117,"status":279,"phases":3118,"primaryCompletion":1923,"completion":3119,"start":3120,"enrollment":3121,"conditions":3122,"interventions":3125},"NCT06290128","A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work",[92],"2028-11-20","2024-07-12",140,[3123,3124],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Polyneuropathy, Inflammatory Demyelinating, Chronic",[3126,3126],"Riliprubart",{"trials":3128,"activeCount":102},[],{"trials":3130,"activeCount":102},[],{"intervention":3132,"totalTrials":659,"cells":3133},"PCV21",{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3140,"PHASE4":3159,"NA":3161},{"trials":3135,"activeCount":102},[],{"trials":3137,"activeCount":102},[],{"trials":3139,"activeCount":102},[],{"trials":3141,"activeCount":659,"soonestReadout":1722},[3142,3152],{"nctId":3143,"briefTitle":3144,"status":138,"phases":3145,"primaryCompletion":1722,"completion":1722,"start":3146,"enrollment":3147,"conditions":3148,"interventions":3150},"NCT06838000","Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents",[92],"2025-02-28",1268,[3149],"Pneumococcal Infections",[3132,3151],"20vPCV",{"nctId":3153,"briefTitle":3154,"status":279,"phases":3155,"primaryCompletion":3156,"completion":3156,"start":1954,"enrollment":465,"conditions":3157,"interventions":3158},"NCT07247188","Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease",[92],"2027-01-07",[1644],[3132,3151],{"trials":3160,"activeCount":102},[],{"trials":3162,"activeCount":102},[],{"intervention":3151,"totalTrials":659,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3171,"PHASE4":3181,"NA":3183},{"trials":3166,"activeCount":102},[],{"trials":3168,"activeCount":102},[],{"trials":3170,"activeCount":102},[],{"trials":3172,"activeCount":659,"soonestReadout":1722},[3173,3177],{"nctId":3143,"briefTitle":3144,"status":138,"phases":3174,"primaryCompletion":1722,"completion":1722,"start":3146,"enrollment":3147,"conditions":3175,"interventions":3176},[92],[3149],[3132,3151],{"nctId":3153,"briefTitle":3154,"status":279,"phases":3178,"primaryCompletion":3156,"completion":3156,"start":1954,"enrollment":465,"conditions":3179,"interventions":3180},[92],[1644],[3132,3151],{"trials":3182,"activeCount":102},[],{"trials":3184,"activeCount":102},[],{"intervention":1944,"totalTrials":659,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3203,"NA":3205},{"trials":3188,"activeCount":102},[],{"trials":3190,"activeCount":102},[],{"trials":3192,"activeCount":102},[],{"trials":3194,"activeCount":659,"soonestReadout":1975},[3195,3199],{"nctId":1936,"briefTitle":1937,"status":138,"phases":3196,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":3197,"interventions":3198},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":3200,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":3201,"interventions":3202},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":3204,"activeCount":102},[],{"trials":3206,"activeCount":102},[],{"intervention":1945,"totalTrials":659,"cells":3208},{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3225,"NA":3227},{"trials":3210,"activeCount":102},[],{"trials":3212,"activeCount":102},[],{"trials":3214,"activeCount":102},[],{"trials":3216,"activeCount":659,"soonestReadout":1975},[3217,3221],{"nctId":1936,"briefTitle":1937,"status":138,"phases":3218,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":3219,"interventions":3220},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":3222,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":3223,"interventions":3224},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":3226,"activeCount":102},[],{"trials":3228,"activeCount":102},[],{"intervention":1946,"totalTrials":659,"cells":3230},{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3237,"PHASE4":3247,"NA":3249},{"trials":3232,"activeCount":102},[],{"trials":3234,"activeCount":102},[],{"trials":3236,"activeCount":102},[],{"trials":3238,"activeCount":659,"soonestReadout":1975},[3239,3243],{"nctId":1936,"briefTitle":1937,"status":138,"phases":3240,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":3241,"interventions":3242},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":3244,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":3245,"interventions":3246},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":3248,"activeCount":102},[],{"trials":3250,"activeCount":102},[],{"intervention":1947,"totalTrials":659,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3255,"PHASE2":3257,"PHASE3":3259,"PHASE4":3269,"NA":3271},{"trials":3254,"activeCount":102},[],{"trials":3256,"activeCount":102},[],{"trials":3258,"activeCount":102},[],{"trials":3260,"activeCount":659,"soonestReadout":1975},[3261,3265],{"nctId":1936,"briefTitle":1937,"status":138,"phases":3262,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":3263,"interventions":3264},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"nctId":1972,"briefTitle":1973,"status":138,"phases":3266,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":3267,"interventions":3268},[92],[1927],[1909,1929,1930,1944,1931,1932,1933,1945,1946,1947],{"trials":3270,"activeCount":102},[],{"trials":3272,"activeCount":102},[],{"intervention":1790,"totalTrials":659,"cells":3274},{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3279,"PHASE3":3281,"PHASE4":3291,"NA":3293},{"trials":3276,"activeCount":102},[],{"trials":3278,"activeCount":102},[],{"trials":3280,"activeCount":102},[],{"trials":3282,"activeCount":659,"soonestReadout":1795},[3283,3287],{"nctId":1782,"briefTitle":1783,"status":138,"phases":3284,"primaryCompletion":1785,"completion":1785,"start":999,"enrollment":1786,"conditions":3285,"interventions":3286},[92],[1788],[1741,1790],{"nctId":1792,"briefTitle":1793,"status":138,"phases":3288,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":1797,"conditions":3289,"interventions":3290},[92],[1788],[1741,1800,1790,1801,1802],{"trials":3292,"activeCount":102},[],{"trials":3294,"activeCount":102},[],{"intervention":1800,"totalTrials":284,"cells":3296},{"EARLY_PHASE1":3297,"PHASE1":3299,"PHASE2":3301,"PHASE3":3360,"PHASE4":3443,"NA":3463},{"trials":3298,"activeCount":102},[],{"trials":3300,"activeCount":102},[],{"trials":3302,"activeCount":102},[3303,3312,3322,3331,3342,3350],{"nctId":3304,"briefTitle":3305,"status":108,"phases":3306,"primaryCompletion":3307,"completion":3307,"start":3308,"enrollment":1223,"conditions":3309,"interventions":3310},"NCT00489489","Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis",[91],"2009-06","2007-05",[1788],[1800,3311],"Interferon-β",{"nctId":3313,"briefTitle":3314,"status":108,"phases":3315,"primaryCompletion":3316,"completion":3316,"start":3317,"enrollment":121,"conditions":3318,"interventions":3319},"NCT00811395","Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis",[91],"2010-04","2007-10",[1788],[1800,3320,3321],"Interferon-β [IFN-β]","Glatiramer Acetate [GA]",{"nctId":3323,"briefTitle":3324,"status":108,"phases":3325,"primaryCompletion":3326,"completion":3326,"start":3327,"enrollment":3328,"conditions":3329,"interventions":3330},"NCT01487096","Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses",[91],"2003-03","2001-04",179,[1788],[1800],{"nctId":3332,"briefTitle":3333,"status":108,"phases":3334,"primaryCompletion":3335,"completion":3335,"start":986,"enrollment":3336,"conditions":3337,"interventions":3338},"NCT01403376","Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide",[91],"2012-01",128,[1788],[3339,3340,3341],"teriflunomide","Interferon-β-1","Influenza vaccine",{"nctId":3343,"briefTitle":3344,"status":108,"phases":3345,"primaryCompletion":1031,"completion":1031,"start":3346,"enrollment":3347,"conditions":3348,"interventions":3349},"NCT00228163","Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses",[91],"2002-01",147,[1788],[3339],{"nctId":3351,"briefTitle":3352,"status":108,"phases":3353,"primaryCompletion":3354,"completion":3354,"start":3355,"enrollment":3356,"conditions":3357,"interventions":3358},"NCT00475865","Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis",[91],"2009-10","2007-04",123,[1788],[1800,3359],"Glatiramer Acetate",{"trials":3361,"activeCount":659,"soonestReadout":1795},[3362,3371,3382,3391,3401,3412,3421,3425,3434],{"nctId":3363,"briefTitle":3364,"status":108,"phases":3365,"primaryCompletion":3366,"completion":3366,"start":3367,"enrollment":3368,"conditions":3369,"interventions":3370},"NCT00134563","Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis",[92],"2010-07","2004-09",1088,[1788],[1800],{"nctId":3372,"briefTitle":3373,"status":108,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":3377,"conditions":3378,"interventions":3380},"NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)",[92],"2024-07-15","2020-06-30",974,[3379],"Relapsing Multiple Sclerosis",[3381,1800],"Tolebrutinib",{"nctId":3383,"briefTitle":3384,"status":884,"phases":3385,"primaryCompletion":1032,"completion":1032,"start":1339,"enrollment":3386,"conditions":3387,"interventions":3389},"NCT01252355","Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta",[92],534,[3388],"Multiple Sclerosis Relapse",[1800,3390],"Interferon-beta",{"nctId":3392,"briefTitle":3393,"status":108,"phases":3394,"primaryCompletion":986,"completion":3395,"start":3396,"enrollment":3397,"conditions":3398,"interventions":3399},"NCT00883337","A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis",[92],"2015-05","2009-04",324,[1788],[3400,1800],"Interferon β-1a",{"nctId":3402,"briefTitle":3403,"status":138,"phases":3404,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":3408,"interventions":3411},"NCT06372145","A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.",[92],"2029-04-30","2024-04-16",2500,[3379,3409,3410],"Secondary Progressive Multiple Sclerosis","Progressive Relapsing Multiple Sclerosis",[3381,1800],{"nctId":3413,"briefTitle":3414,"status":108,"phases":3415,"primaryCompletion":3416,"completion":2759,"start":3417,"enrollment":3418,"conditions":3419,"interventions":3420},"NCT00751881","An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis",[92],"2012-04","2008-08",1169,[1788],[1800],{"nctId":1792,"briefTitle":1793,"status":138,"phases":3422,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":1797,"conditions":3423,"interventions":3424},[92],[1788],[1741,1800,1790,1801,1802],{"nctId":3426,"briefTitle":3427,"status":108,"phases":3428,"primaryCompletion":3429,"completion":3429,"start":3430,"enrollment":3431,"conditions":3432,"interventions":3433},"NCT00803049","Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis",[92],"2015-12","2006-10",742,[1788],[1800],{"nctId":3435,"briefTitle":3436,"status":108,"phases":3437,"primaryCompletion":3438,"completion":1355,"start":3439,"enrollment":3440,"conditions":3441,"interventions":3442},"NCT00622700","Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis",[92],"2012-12","2008-02",618,[1788],[1800],{"trials":3444,"activeCount":102},[3445,3455],{"nctId":3446,"briefTitle":3447,"status":108,"phases":3448,"primaryCompletion":3449,"completion":3449,"start":3450,"enrollment":3451,"conditions":3452,"interventions":3453},"NCT04410965","Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks",[93],"2021-07-12","2020-05-20",82,[1788],[3454],"TERIFLUNOMIDE",{"nctId":3456,"briefTitle":3457,"status":108,"phases":3458,"primaryCompletion":3459,"completion":3459,"start":152,"enrollment":3460,"conditions":3461,"interventions":3462},"NCT01895335","Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients",[93],"2015-11",1001,[1788],[1800],{"trials":3464,"activeCount":102},[3465],{"nctId":3466,"briefTitle":3467,"status":108,"phases":3468,"primaryCompletion":3469,"completion":3469,"start":3470,"enrollment":3471,"conditions":3472,"interventions":3473},"NCT03198351","An Observational Study on Teriflunomide-exposed Pregnancies",[],"2023-06-13","2013-04-25",220,[1788],[1800],{"intervention":327,"totalTrials":535,"cells":3475},{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3480,"PHASE3":3482,"PHASE4":3502,"NA":3542},{"trials":3477,"activeCount":102},[],{"trials":3479,"activeCount":102},[],{"trials":3481,"activeCount":102},[],{"trials":3483,"activeCount":195,"soonestReadout":320},[3484,3492,3498],{"nctId":3485,"briefTitle":3486,"status":108,"phases":3487,"primaryCompletion":3488,"completion":3488,"start":3489,"enrollment":589,"conditions":3490,"interventions":3491},"NCT00044811","Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma",[92],"2003-10","2002-03",[155],[327],{"nctId":3493,"briefTitle":3486,"status":108,"phases":3494,"primaryCompletion":3488,"completion":3488,"start":3495,"enrollment":589,"conditions":3496,"interventions":3497},"NCT00044824",[92],"2002-02",[155],[327],{"nctId":317,"briefTitle":318,"status":279,"phases":3499,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":3500,"interventions":3501},[92],[325],[97,327],{"trials":3503,"activeCount":102},[3504,3514,3523,3531,3535],{"nctId":3505,"briefTitle":3506,"status":108,"phases":3507,"completion":3508,"start":3509,"enrollment":3510,"conditions":3511,"interventions":3513},"NCT00637585","Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine",[93],"2003-07","2002-12",42,[3512],"Allergic Rhinitis",[327],{"nctId":3515,"briefTitle":3516,"status":108,"phases":3517,"primaryCompletion":3518,"start":3489,"enrollment":3519,"conditions":3520,"interventions":3522},"NCT00741897","Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis",[93],"2003-12",264,[3521],"Rhinitis, Allergic, Perennial",[327],{"nctId":3524,"briefTitle":3525,"status":108,"phases":3526,"completion":3527,"start":3528,"enrollment":3471,"conditions":3529,"interventions":3530},"NCT00636870","Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine",[93],"2004-01","2003-02",[3512],[327],{"nctId":1365,"briefTitle":1366,"status":108,"phases":3532,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":3533,"interventions":3534},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"nctId":3536,"briefTitle":3537,"status":108,"phases":3538,"completion":3539,"start":3528,"enrollment":391,"conditions":3540,"interventions":3541},"NCT00638118","Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen",[93],"2003-05",[3512],[327],{"trials":3543,"activeCount":102},[],{"intervention":672,"totalTrials":339,"cells":3545},{"EARLY_PHASE1":3546,"PHASE1":3548,"PHASE2":3557,"PHASE3":3572,"PHASE4":3578,"NA":3588},{"trials":3547,"activeCount":102},[],{"trials":3549,"activeCount":102},[3550],{"nctId":3551,"briefTitle":3552,"status":108,"phases":3553,"primaryCompletion":150,"completion":150,"start":1339,"enrollment":391,"conditions":3554,"interventions":3555},"NCT01324583","Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer",[90],[1357],[2794,3556],"prednisolone",{"trials":3558,"activeCount":102},[3559],{"nctId":3560,"briefTitle":3561,"status":108,"phases":3562,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":3567,"interventions":3570},"NCT00498797","E3-Hormone Refractory Prostrate Cancer Taxotere Combination",[91],"2007-07","2008-09","2005-12",86,[1357,3568,3569],"Metastatic","Hormone Refractory",[3571,1348,672],"Zactima",{"trials":3573,"activeCount":195,"soonestReadout":666},[3574],{"nctId":663,"briefTitle":664,"status":138,"phases":3575,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":3576,"interventions":3577},[92],[657],[621,671,672],{"trials":3579,"activeCount":102},[3580,3584],{"nctId":2842,"briefTitle":2843,"status":108,"phases":3581,"primaryCompletion":1054,"completion":1054,"start":2487,"enrollment":552,"conditions":3582,"interventions":3583},[93],[2750],[1359,671,672],{"nctId":1352,"briefTitle":1353,"status":108,"phases":3585,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":3586,"interventions":3587},[93],[1357],[1359,1360,672,1361,1362,1363,642],{"trials":3589,"activeCount":102},[],{"intervention":684,"totalTrials":445,"cells":3591},{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3596,"PHASE3":3598,"PHASE4":3616,"NA":3639},{"trials":3593,"activeCount":102},[],{"trials":3595,"activeCount":102},[],{"trials":3597,"activeCount":102},[],{"trials":3599,"activeCount":195,"soonestReadout":677},[3600,3604],{"nctId":674,"briefTitle":675,"status":279,"phases":3601,"primaryCompletion":677,"completion":678,"start":679,"enrollment":680,"conditions":3602,"interventions":3603},[92],[682],[621,684],{"nctId":3605,"briefTitle":3606,"status":884,"phases":3607,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":3611,"interventions":3614},"NCT00315003","TELI COM - Telithromycin in Children With Otitis Media",[92],"2006-07","2006-01",1500,[3612,3613],"Otitis Media, Suppurative","Otitis Media, Purulent",[3615,684],"Telithromycin",{"trials":3617,"activeCount":102},[3618,3629],{"nctId":3619,"briefTitle":3620,"status":884,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":599,"conditions":3624,"interventions":3626},"NCT00237445","Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days",[93],"2006-09","2005-11",[3625],"Pneumonia",[3627,3628],"telithromycin","azithromycin",{"nctId":3630,"briefTitle":3631,"status":884,"phases":3632,"primaryCompletion":3622,"completion":3622,"start":3633,"enrollment":3634,"conditions":3635,"interventions":3638},"NCT00132951","KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections",[93],"2004-10",2051,[3636,3637,3625],"Respiratory Tract Infections","Chronic Bronchitis",[3615,684],{"trials":3640,"activeCount":102},[],{"intervention":3642,"totalTrials":619,"cells":3643},"agalsidase beta",{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3648,"PHASE3":3650,"PHASE4":3656,"NA":3672},{"trials":3645,"activeCount":102},[],{"trials":3647,"activeCount":102},[],{"trials":3649,"activeCount":102},[],{"trials":3651,"activeCount":195,"soonestReadout":140},[3652],{"nctId":2417,"briefTitle":2418,"status":138,"phases":3653,"primaryCompletion":140,"completion":2420,"start":2421,"enrollment":166,"conditions":3654,"interventions":3655},[92],[2405],[82,2424,2425,2426],{"trials":3657,"activeCount":102},[3658,3668],{"nctId":3659,"briefTitle":3660,"status":3661,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":102,"conditions":3665,"interventions":3666},"NCT04143958","To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease","WITHDRAWN",[93],"2023-11","2020-09",[2405],[3642,3667],"agalsidase alfa",{"nctId":1365,"briefTitle":1366,"status":108,"phases":3669,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":3670,"interventions":3671},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"trials":3673,"activeCount":102},[],{"intervention":3667,"totalTrials":659,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3688,"NA":3694},{"trials":3677,"activeCount":102},[],{"trials":3679,"activeCount":102},[],{"trials":3681,"activeCount":102},[],{"trials":3683,"activeCount":195,"soonestReadout":140},[3684],{"nctId":2417,"briefTitle":2418,"status":138,"phases":3685,"primaryCompletion":140,"completion":2420,"start":2421,"enrollment":166,"conditions":3686,"interventions":3687},[92],[2405],[82,2424,2425,2426],{"trials":3689,"activeCount":102},[3690],{"nctId":3659,"briefTitle":3660,"status":3661,"phases":3691,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":102,"conditions":3692,"interventions":3693},[93],[2405],[3642,3667],{"trials":3695,"activeCount":102},[],{"intervention":2023,"totalTrials":659,"cells":3697},{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3704,"PHASE4":3710,"NA":3716},{"trials":3699,"activeCount":102},[],{"trials":3701,"activeCount":102},[],{"trials":3703,"activeCount":102},[],{"trials":3705,"activeCount":195,"soonestReadout":1769},[3706],{"nctId":1766,"briefTitle":1767,"status":279,"phases":3707,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":3708,"interventions":3709},[91,92],[1774],[1741,1741,1048,1776,1777,1778,1779,1780],{"trials":3711,"activeCount":102},[3712],{"nctId":2013,"briefTitle":2014,"status":108,"phases":3713,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":3714,"interventions":3715},[93],[2020],[2022,1048,1214,2023,2024,1780],{"trials":3717,"activeCount":102},[],{"intervention":3381,"totalTrials":552,"cells":3719},{"EARLY_PHASE1":3720,"PHASE1":3722,"PHASE2":3760,"PHASE3":3770,"PHASE4":3807,"NA":3809},{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[3724,3734,3745,3753],{"nctId":3725,"briefTitle":3726,"status":108,"phases":3727,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":1601,"conditions":3730,"interventions":3732},"NCT05282030","Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.",[90],"2022-08-02","2022-03-10",[3731],"Renal Impairment",[3733],"tolebrutinib",{"nctId":3735,"briefTitle":3736,"status":108,"phases":3737,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":3740,"conditions":3741,"interventions":3742},"NCT06064539","Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects",[90],"2020-07-08","2020-05-18",30,[1788],[3381,3743,3744],"gemfibrozil","rifampicin",{"nctId":3746,"briefTitle":3747,"status":108,"phases":3748,"primaryCompletion":3749,"completion":3749,"start":3750,"enrollment":552,"conditions":3751,"interventions":3752},"NCT05283915","Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function",[90],"2022-05-24","2022-03-18",[2381],[3733],{"nctId":3754,"briefTitle":3755,"status":108,"phases":3756,"primaryCompletion":42,"completion":42,"start":3757,"enrollment":2998,"conditions":3758,"interventions":3759},"NCT06106074","Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants",[90],"2020-08-10",[1788],[3381],{"trials":3761,"activeCount":102},[3762],{"nctId":3763,"briefTitle":3764,"status":108,"phases":3765,"primaryCompletion":887,"completion":887,"start":3766,"enrollment":3767,"conditions":3768,"interventions":3769},"NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis",[91],"2019-09-23",125,[3379],[3381],{"trials":3771,"activeCount":195,"soonestReadout":3405},[3772,3776,3785,3789,3799],{"nctId":3372,"briefTitle":3373,"status":108,"phases":3773,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":3377,"conditions":3774,"interventions":3775},[92],[3379],[3381,1800],{"nctId":3777,"briefTitle":3778,"status":108,"phases":3779,"primaryCompletion":1416,"completion":1416,"start":3780,"enrollment":3781,"conditions":3782,"interventions":3784},"NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)",[92],"2020-09-24",1131,[3783],"Non-relapsing Secondary Progressive Multiple Sclerosis",[3381],{"nctId":3402,"briefTitle":3403,"status":138,"phases":3786,"primaryCompletion":3405,"completion":3405,"start":3406,"enrollment":3407,"conditions":3787,"interventions":3788},[92],[3379,3409,3410],[3381,1800],{"nctId":3790,"briefTitle":3791,"status":108,"phases":3792,"primaryCompletion":3793,"completion":3793,"start":3794,"enrollment":3795,"conditions":3796,"interventions":3797},"NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)",[92],"2024-07-16","2020-06-11",899,[3379],[3381,3798],"Teriflunomide HMR1726",{"nctId":3800,"briefTitle":3801,"status":108,"phases":3802,"primaryCompletion":2985,"completion":2985,"start":1383,"enrollment":3803,"conditions":3804,"interventions":3806},"NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)",[92],767,[3805],"Primary Progressive Multiple Sclerosis",[3381],{"trials":3808,"activeCount":102},[],{"trials":3810,"activeCount":102},[],{"intervention":1801,"totalTrials":538,"cells":3812},{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3832,"PHASE3":3850,"PHASE4":3894,"NA":3896},{"trials":3814,"activeCount":102},[],{"trials":3816,"activeCount":102},[3817,3824],{"nctId":3818,"briefTitle":3819,"status":108,"phases":3820,"primaryCompletion":3821,"completion":165,"start":987,"enrollment":988,"conditions":3822,"interventions":3823},"NCT01239459","Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment",[90],"2011-02",[3731],[3798,1801],{"nctId":3825,"briefTitle":3826,"status":108,"phases":3827,"primaryCompletion":2487,"completion":2487,"start":1272,"enrollment":3828,"conditions":3829,"interventions":3830},"NCT02046629","A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers",[90],12,[1788],[3798,3831],"cholestyramine",{"trials":3833,"activeCount":102},[3834],{"nctId":3835,"briefTitle":3836,"status":108,"phases":3837,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":3841,"interventions":3843},"NCT02890992","An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia",[91],"2018-09-13","2019-02-22","2016-09-15",[3842],"Hypercholesterolaemia",[3844,3845,3846,3831,3847,3848,3849],"alirocumab SAR236553","statins","ezetimibe","fenofibrate","omega-3 fatty acids","nicotinic acid",{"trials":3851,"activeCount":195,"soonestReadout":1795},[3852,3873,3881,3885],{"nctId":3853,"briefTitle":3854,"status":108,"phases":3855,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":3860,"interventions":3861},"NCT03510884","An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia",[92],"2021-01-14","2022-08-05","2018-05-31",153,[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],"Alirocumab SAR236553","Rosuvastatin","Atorvastatin","Simvastatin","Pravastatin","Lovastatin","Fluvastatin","Ezetimibe","Nicotinic acid","Fenofibrate","Omega-3 fatty acids",{"nctId":3874,"briefTitle":3875,"status":108,"phases":3876,"primaryCompletion":1031,"completion":1031,"start":966,"enrollment":1232,"conditions":3877,"interventions":3878},"NCT01863888","Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis",[92],[1788],[3879,3831,3880],"teriflunomide HMR1726","charcoal",{"nctId":1792,"briefTitle":1793,"status":138,"phases":3882,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":1797,"conditions":3883,"interventions":3884},[92],[1788],[1741,1800,1790,1801,1802],{"nctId":3886,"briefTitle":3887,"status":108,"phases":3888,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":3891,"interventions":3893},"NCT03510715","An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia",[92],"2020-02-17","2018-08-31",[3892],"Hypercholesterolemia",[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[],{"intervention":1501,"totalTrials":445,"cells":3899},{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3906,"PHASE4":3938,"NA":3940},{"trials":3901,"activeCount":102},[],{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[],{"trials":3907,"activeCount":195,"soonestReadout":1517},[3908,3921,3925,3934],{"nctId":3909,"briefTitle":3910,"status":108,"phases":3911,"primaryCompletion":3912,"completion":3913,"start":3914,"enrollment":3915,"conditions":3916,"interventions":3918},"NCT04183335","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)",[92],"2021-11-12","2022-02-03","2019-12-12",151,[3917],"Neurodermatitis",[2064,3919,3920,1501],"Moisturizers","Low to medium potent topical corticosteroids",{"nctId":1491,"briefTitle":1492,"status":108,"phases":3922,"primaryCompletion":1494,"completion":1495,"start":1496,"enrollment":1497,"conditions":3923,"interventions":3924},[92],[351],[77,1500,1501],{"nctId":3926,"briefTitle":3927,"status":108,"phases":3928,"primaryCompletion":3929,"completion":3930,"start":3931,"enrollment":1809,"conditions":3932,"interventions":3933},"NCT04202679","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)",[92],"2021-08-30","2021-11-22","2020-01-16",[3917],[2064,3919,3920,1501],{"nctId":1513,"briefTitle":1514,"status":1515,"phases":3935,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":3936,"interventions":3937},[91,92],[351],[77,1500,1501,1522],{"trials":3939,"activeCount":102},[],{"trials":3941,"activeCount":102},[],{"intervention":1323,"totalTrials":659,"cells":3943},{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3954,"PHASE4":3960,"NA":3962},{"trials":3945,"activeCount":102},[],{"trials":3947,"activeCount":102},[],{"trials":3949,"activeCount":102},[3950],{"nctId":2648,"briefTitle":2649,"status":884,"phases":3951,"primaryCompletion":2651,"completion":2651,"start":2370,"enrollment":1400,"conditions":3952,"interventions":3953},[90,91],[2653],[1162,2655,2656,1323,1324,1322],{"trials":3955,"activeCount":195,"soonestReadout":1316},[3956],{"nctId":1313,"briefTitle":1314,"status":138,"phases":3957,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":3958,"interventions":3959},[92],[1160],[1162,1237,642,1322,1212,1323,1324],{"trials":3961,"activeCount":102},[],{"trials":3963,"activeCount":102},[],{"intervention":1324,"totalTrials":659,"cells":3965},{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":3970,"PHASE3":3976,"PHASE4":3982,"NA":3984},{"trials":3967,"activeCount":102},[],{"trials":3969,"activeCount":102},[],{"trials":3971,"activeCount":102},[3972],{"nctId":2648,"briefTitle":2649,"status":884,"phases":3973,"primaryCompletion":2651,"completion":2651,"start":2370,"enrollment":1400,"conditions":3974,"interventions":3975},[90,91],[2653],[1162,2655,2656,1323,1324,1322],{"trials":3977,"activeCount":195,"soonestReadout":1316},[3978],{"nctId":1313,"briefTitle":1314,"status":138,"phases":3979,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":3980,"interventions":3981},[92],[1160],[1162,1237,642,1322,1212,1323,1324],{"trials":3983,"activeCount":102},[],{"trials":3985,"activeCount":102},[],{"intervention":1322,"totalTrials":659,"cells":3987},{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3992,"PHASE3":3998,"PHASE4":4004,"NA":4006},{"trials":3989,"activeCount":102},[],{"trials":3991,"activeCount":102},[],{"trials":3993,"activeCount":102},[3994],{"nctId":2648,"briefTitle":2649,"status":884,"phases":3995,"primaryCompletion":2651,"completion":2651,"start":2370,"enrollment":1400,"conditions":3996,"interventions":3997},[90,91],[2653],[1162,2655,2656,1323,1324,1322],{"trials":3999,"activeCount":195,"soonestReadout":1316},[4000],{"nctId":1313,"briefTitle":1314,"status":138,"phases":4001,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":4002,"interventions":4003},[92],[1160],[1162,1237,642,1322,1212,1323,1324],{"trials":4005,"activeCount":102},[],{"trials":4007,"activeCount":102},[],{"intervention":1173,"totalTrials":659,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4018,"PHASE3":4020,"PHASE4":4026,"NA":4028},{"trials":4011,"activeCount":102},[],{"trials":4013,"activeCount":102},[4014],{"nctId":1164,"briefTitle":1165,"status":108,"phases":4015,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":305,"conditions":4016,"interventions":4017},[90],[1160],[1172,1173,1174,1151,1175],{"trials":4019,"activeCount":102},[],{"trials":4021,"activeCount":195,"soonestReadout":1305},[4022],{"nctId":1302,"briefTitle":1303,"status":138,"phases":4023,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":4024,"interventions":4025},[92],[1160],[1162,1311,1237,642],{"trials":4027,"activeCount":102},[],{"trials":4029,"activeCount":102},[],{"intervention":57,"totalTrials":659,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4038,"PHASE4":4055,"NA":4057},{"trials":4033,"activeCount":102},[],{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":195,"soonestReadout":56},[4040,4048],{"nctId":4041,"briefTitle":4042,"status":108,"phases":4043,"primaryCompletion":4044,"completion":4044,"start":1496,"enrollment":4045,"conditions":4046,"interventions":4047},"NCT06228586","Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam",[92],"2024-03-31",447,[2949,36],[57],{"nctId":54,"briefTitle":55,"status":138,"phases":4049,"primaryCompletion":56,"completion":4050,"start":4051,"enrollment":4052,"conditions":4053,"interventions":4054},[92],"2027-12-26","2022-08-23",209,[2910,36],[57],{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":102},[],{"intervention":3114,"totalTrials":195,"cells":4060},{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4067,"PHASE4":4073,"NA":4075},{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[],{"trials":4068,"activeCount":195,"soonestReadout":3108},[4069],{"nctId":3105,"briefTitle":3106,"status":279,"phases":4070,"primaryCompletion":3108,"completion":3109,"start":3110,"enrollment":1809,"conditions":4071,"interventions":4072},[92],[3112],[3094,3094,3114],{"trials":4074,"activeCount":102},[],{"trials":4076,"activeCount":102},[],{"intervention":1934,"totalTrials":195,"cells":4078},{"EARLY_PHASE1":4079,"PHASE1":4081,"PHASE2":4083,"PHASE3":4085,"PHASE4":4091,"NA":4093},{"trials":4080,"activeCount":102},[],{"trials":4082,"activeCount":102},[],{"trials":4084,"activeCount":102},[],{"trials":4086,"activeCount":195,"soonestReadout":1923},[4087],{"nctId":1920,"briefTitle":1921,"status":138,"phases":4088,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":1925,"conditions":4089,"interventions":4090},[92],[1927],[1909,1929,1930,1931,1932,1933,1934],{"trials":4092,"activeCount":102},[],{"trials":4094,"activeCount":102},[],{"intervention":2951,"totalTrials":195,"cells":4096},{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4103,"PHASE4":4109,"NA":4111},{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":195,"soonestReadout":2945},[4105],{"nctId":2942,"briefTitle":2943,"status":138,"phases":4106,"primaryCompletion":2945,"completion":2946,"start":1623,"enrollment":2947,"conditions":4107,"interventions":4108},[92],[2949,36],[2879,2951,2952],{"trials":4110,"activeCount":102},[],{"trials":4112,"activeCount":102},[],{"intervention":2952,"totalTrials":195,"cells":4114},{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4121,"PHASE4":4127,"NA":4129},{"trials":4116,"activeCount":102},[],{"trials":4118,"activeCount":102},[],{"trials":4120,"activeCount":102},[],{"trials":4122,"activeCount":195,"soonestReadout":2945},[4123],{"nctId":2942,"briefTitle":2943,"status":138,"phases":4124,"primaryCompletion":2945,"completion":2946,"start":1623,"enrollment":2947,"conditions":4125,"interventions":4126},[92],[2949,36],[2879,2951,2952],{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[],{"intervention":2415,"totalTrials":195,"cells":4132},{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4139,"PHASE4":4145,"NA":4147},{"trials":4134,"activeCount":102},[],{"trials":4136,"activeCount":102},[],{"trials":4138,"activeCount":102},[],{"trials":4140,"activeCount":195,"soonestReadout":81},[4141],{"nctId":79,"briefTitle":80,"status":138,"phases":4142,"primaryCompletion":81,"completion":2409,"start":2410,"enrollment":2411,"conditions":4143,"interventions":4144},[92],[2413],[82,2415],{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"intervention":67,"totalTrials":195,"cells":4150},{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4157,"PHASE4":4163,"NA":4165},{"trials":4152,"activeCount":102},[],{"trials":4154,"activeCount":102},[],{"trials":4156,"activeCount":102},[],{"trials":4158,"activeCount":195,"soonestReadout":66},[4159],{"nctId":64,"briefTitle":65,"status":138,"phases":4160,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":4161,"interventions":4162},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"trials":4164,"activeCount":102},[],{"trials":4166,"activeCount":102},[],{"intervention":1299,"totalTrials":195,"cells":4168},{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4175,"PHASE4":4181,"NA":4183},{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[],{"trials":4174,"activeCount":102},[],{"trials":4176,"activeCount":195,"soonestReadout":66},[4177],{"nctId":64,"briefTitle":65,"status":138,"phases":4178,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":4179,"interventions":4180},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"trials":4182,"activeCount":102},[],{"trials":4184,"activeCount":102},[],{"intervention":1300,"totalTrials":195,"cells":4186},{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4199,"NA":4201},{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[],{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":195,"soonestReadout":66},[4195],{"nctId":64,"briefTitle":65,"status":138,"phases":4196,"primaryCompletion":66,"completion":1293,"start":1294,"enrollment":1295,"conditions":4197,"interventions":4198},[92],[1297],[67,1299,642,643,642,1211,1300,1213,1214],{"trials":4200,"activeCount":102},[],{"trials":4202,"activeCount":102},[],{"intervention":4204,"totalTrials":195,"cells":4205},"avalglucosidase alfa",{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4212,"PHASE4":4224,"NA":4226},{"trials":4207,"activeCount":102},[],{"trials":4209,"activeCount":102},[],{"trials":4211,"activeCount":102},[],{"trials":4213,"activeCount":195,"soonestReadout":4218},[4214],{"nctId":4215,"briefTitle":4216,"status":138,"phases":4217,"primaryCompletion":4218,"completion":4219,"start":4220,"enrollment":2611,"conditions":4221,"interventions":4223},"NCT04910776","Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa",[92],"2026-03-02","2027-08-10","2021-09-01",[4222],"Glycogen Storage Disease Type II",[4204],{"trials":4225,"activeCount":102},[],{"trials":4227,"activeCount":102},[],{"intervention":1958,"totalTrials":195,"cells":4229},{"EARLY_PHASE1":4230,"PHASE1":4232,"PHASE2":4234,"PHASE3":4236,"PHASE4":4242,"NA":4244},{"trials":4231,"activeCount":102},[],{"trials":4233,"activeCount":102},[],{"trials":4235,"activeCount":102},[],{"trials":4237,"activeCount":195,"soonestReadout":1952},[4238],{"nctId":1949,"briefTitle":1950,"status":279,"phases":4239,"primaryCompletion":1952,"completion":1953,"start":1954,"enrollment":1955,"conditions":4240,"interventions":4241},[92],[1927,36],[1909,1958],{"trials":4243,"activeCount":102},[],{"trials":4245,"activeCount":102},[],{"intervention":4247,"totalTrials":195,"cells":4248},"NVX-CoV2705",{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4253,"PHASE3":4255,"PHASE4":4269,"NA":4271},{"trials":4250,"activeCount":102},[],{"trials":4252,"activeCount":102},[],{"trials":4254,"activeCount":102},[],{"trials":4256,"activeCount":195,"soonestReadout":4261},[4257],{"nctId":4258,"briefTitle":4259,"status":138,"phases":4260,"primaryCompletion":4261,"completion":4262,"start":4263,"enrollment":4264,"conditions":4265,"interventions":4268},"NCT07079670","Safety and Immunogenicity of NVX-CoV2705",[92],"2026-04-16","2026-06-16","2025-10-09",676,[4266,4267],"COVID-19","SARS-CoV-2 Infection",[4247],{"trials":4270,"activeCount":102},[],{"trials":4272,"activeCount":102},[],{"intervention":1627,"totalTrials":195,"cells":4274},{"EARLY_PHASE1":4275,"PHASE1":4277,"PHASE2":4279,"PHASE3":4281,"PHASE4":4287,"NA":4289},{"trials":4276,"activeCount":102},[],{"trials":4278,"activeCount":102},[],{"trials":4280,"activeCount":102},[],{"trials":4282,"activeCount":195,"soonestReadout":1621},[4283],{"nctId":1618,"briefTitle":1619,"status":279,"phases":4284,"primaryCompletion":1621,"completion":1622,"start":1623,"enrollment":1583,"conditions":4285,"interventions":4286},[92],[1625],[1586,1627],{"trials":4288,"activeCount":102},[],{"trials":4290,"activeCount":102},[],{"intervention":4292,"totalTrials":195,"cells":4293},"Riliprubart Prefilled Pen",{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4300,"PHASE4":4309,"NA":4311},{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[],{"trials":4299,"activeCount":102},[],{"trials":4301,"activeCount":195,"soonestReadout":4306},[4302],{"nctId":4303,"briefTitle":4304,"status":1515,"phases":4305,"primaryCompletion":4306,"completion":4306,"start":257,"enrollment":1091,"conditions":4307,"interventions":4308},"NCT06859099","Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP",[92],"2029-10-03",[3124],[4292],{"trials":4310,"activeCount":102},[],{"trials":4312,"activeCount":102},[],{"intervention":1511,"totalTrials":195,"cells":4314},{"EARLY_PHASE1":4315,"PHASE1":4317,"PHASE2":4319,"PHASE3":4321,"PHASE4":4327,"NA":4329},{"trials":4316,"activeCount":102},[],{"trials":4318,"activeCount":102},[],{"trials":4320,"activeCount":102},[],{"trials":4322,"activeCount":195,"soonestReadout":1506},[4323],{"nctId":1503,"briefTitle":1504,"status":279,"phases":4324,"primaryCompletion":1506,"completion":666,"start":1507,"enrollment":1508,"conditions":4325,"interventions":4326},[92],[351],[77,1500,1511],{"trials":4328,"activeCount":102},[],{"trials":4330,"activeCount":102},[],{"intervention":1522,"totalTrials":195,"cells":4332},{"EARLY_PHASE1":4333,"PHASE1":4335,"PHASE2":4337,"PHASE3":4339,"PHASE4":4345,"NA":4347},{"trials":4334,"activeCount":102},[],{"trials":4336,"activeCount":102},[],{"trials":4338,"activeCount":102},[],{"trials":4340,"activeCount":195,"soonestReadout":1517},[4341],{"nctId":1513,"briefTitle":1514,"status":1515,"phases":4342,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":4343,"interventions":4344},[91,92],[351],[77,1500,1501,1522],{"trials":4346,"activeCount":102},[],{"trials":4348,"activeCount":102},[],{"intervention":1776,"totalTrials":195,"cells":4350},{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4357,"PHASE4":4363,"NA":4365},{"trials":4352,"activeCount":102},[],{"trials":4354,"activeCount":102},[],{"trials":4356,"activeCount":102},[],{"trials":4358,"activeCount":195,"soonestReadout":1769},[4359],{"nctId":1766,"briefTitle":1767,"status":279,"phases":4360,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":4361,"interventions":4362},[91,92],[1774],[1741,1741,1048,1776,1777,1778,1779,1780],{"trials":4364,"activeCount":102},[],{"trials":4366,"activeCount":102},[],{"intervention":1778,"totalTrials":195,"cells":4368},{"EARLY_PHASE1":4369,"PHASE1":4371,"PHASE2":4373,"PHASE3":4375,"PHASE4":4381,"NA":4383},{"trials":4370,"activeCount":102},[],{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":102},[],{"trials":4376,"activeCount":195,"soonestReadout":1769},[4377],{"nctId":1766,"briefTitle":1767,"status":279,"phases":4378,"primaryCompletion":1769,"completion":1770,"start":1771,"enrollment":1772,"conditions":4379,"interventions":4380},[91,92],[1774],[1741,1741,1048,1776,1777,1778,1779,1780],{"trials":4382,"activeCount":102},[],{"trials":4384,"activeCount":102},[],{"intervention":2426,"totalTrials":195,"cells":4386},{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4393,"PHASE4":4399,"NA":4401},{"trials":4388,"activeCount":102},[],{"trials":4390,"activeCount":102},[],{"trials":4392,"activeCount":102},[],{"trials":4394,"activeCount":195,"soonestReadout":140},[4395],{"nctId":2417,"briefTitle":2418,"status":138,"phases":4396,"primaryCompletion":140,"completion":2420,"start":2421,"enrollment":166,"conditions":4397,"interventions":4398},[92],[2405],[82,2424,2425,2426],{"trials":4400,"activeCount":102},[],{"trials":4402,"activeCount":102},[],{"intervention":4404,"totalTrials":195,"cells":4405},"Tadalafil 5 mg tablets with a digital tool.",{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4412,"PHASE4":4423,"NA":4425},{"trials":4407,"activeCount":102},[],{"trials":4409,"activeCount":102},[],{"trials":4411,"activeCount":102},[],{"trials":4413,"activeCount":195,"soonestReadout":531},[4414],{"nctId":4415,"briefTitle":4416,"status":279,"phases":4417,"primaryCompletion":531,"completion":4418,"start":1841,"enrollment":4419,"conditions":4420,"interventions":4422},"NCT06805513","Actual Use Trial of Tadalafil 5 mg",[92],"2026-02-28",2250,[4421],"Erectile Dysfunction",[4404],{"trials":4424,"activeCount":102},[],{"trials":4426,"activeCount":102},[],{"intervention":1802,"totalTrials":195,"cells":4428},{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4435,"PHASE4":4441,"NA":4443},{"trials":4430,"activeCount":102},[],{"trials":4432,"activeCount":102},[],{"trials":4434,"activeCount":102},[],{"trials":4436,"activeCount":195,"soonestReadout":1795},[4437],{"nctId":1792,"briefTitle":1793,"status":138,"phases":4438,"primaryCompletion":1795,"completion":1795,"start":1796,"enrollment":1797,"conditions":4439,"interventions":4440},[92],[1788],[1741,1800,1790,1801,1802],{"trials":4442,"activeCount":102},[],{"trials":4444,"activeCount":102},[],{"intervention":1967,"totalTrials":195,"cells":4446},{"EARLY_PHASE1":4447,"PHASE1":4449,"PHASE2":4451,"PHASE3":4453,"PHASE4":4459,"NA":4461},{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[],{"trials":4452,"activeCount":102},[],{"trials":4454,"activeCount":195,"soonestReadout":321},[4455],{"nctId":1960,"briefTitle":1961,"status":138,"phases":4456,"primaryCompletion":321,"completion":321,"start":1963,"enrollment":1964,"conditions":4457,"interventions":4458},[92],[1927,36],[1909,1967,1968,1969,1970],{"trials":4460,"activeCount":102},[],{"trials":4462,"activeCount":102},[],{"intervention":1968,"totalTrials":195,"cells":4464},{"EARLY_PHASE1":4465,"PHASE1":4467,"PHASE2":4469,"PHASE3":4471,"PHASE4":4477,"NA":4479},{"trials":4466,"activeCount":102},[],{"trials":4468,"activeCount":102},[],{"trials":4470,"activeCount":102},[],{"trials":4472,"activeCount":195,"soonestReadout":321},[4473],{"nctId":1960,"briefTitle":1961,"status":138,"phases":4474,"primaryCompletion":321,"completion":321,"start":1963,"enrollment":1964,"conditions":4475,"interventions":4476},[92],[1927,36],[1909,1967,1968,1969,1970],{"trials":4478,"activeCount":102},[],{"trials":4480,"activeCount":102},[],{"intervention":1969,"totalTrials":195,"cells":4482},{"EARLY_PHASE1":4483,"PHASE1":4485,"PHASE2":4487,"PHASE3":4489,"PHASE4":4495,"NA":4497},{"trials":4484,"activeCount":102},[],{"trials":4486,"activeCount":102},[],{"trials":4488,"activeCount":102},[],{"trials":4490,"activeCount":195,"soonestReadout":321},[4491],{"nctId":1960,"briefTitle":1961,"status":138,"phases":4492,"primaryCompletion":321,"completion":321,"start":1963,"enrollment":1964,"conditions":4493,"interventions":4494},[92],[1927,36],[1909,1967,1968,1969,1970],{"trials":4496,"activeCount":102},[],{"trials":4498,"activeCount":102},[],{"intervention":1970,"totalTrials":195,"cells":4500},{"EARLY_PHASE1":4501,"PHASE1":4503,"PHASE2":4505,"PHASE3":4507,"PHASE4":4513,"NA":4515},{"trials":4502,"activeCount":102},[],{"trials":4504,"activeCount":102},[],{"trials":4506,"activeCount":102},[],{"trials":4508,"activeCount":195,"soonestReadout":321},[4509],{"nctId":1960,"briefTitle":1961,"status":138,"phases":4510,"primaryCompletion":321,"completion":321,"start":1963,"enrollment":1964,"conditions":4511,"interventions":4512},[92],[1927,36],[1909,1967,1968,1969,1970],{"trials":4514,"activeCount":102},[],{"trials":4516,"activeCount":102},[],{"intervention":2337,"totalTrials":195,"cells":4518},{"EARLY_PHASE1":4519,"PHASE1":4521,"PHASE2":4523,"PHASE3":4525,"PHASE4":4531,"NA":4533},{"trials":4520,"activeCount":102},[],{"trials":4522,"activeCount":102},[],{"trials":4524,"activeCount":102},[],{"trials":4526,"activeCount":195,"soonestReadout":2330},[4527],{"nctId":2327,"briefTitle":2328,"status":279,"phases":4528,"primaryCompletion":2330,"completion":2331,"start":2332,"enrollment":2333,"conditions":4529,"interventions":4530},[92],[2335],[43,43,43,2337],{"trials":4532,"activeCount":102},[],{"trials":4534,"activeCount":102},[],{"intervention":1215,"totalTrials":339,"cells":4536},{"EARLY_PHASE1":4537,"PHASE1":4539,"PHASE2":4541,"PHASE3":4555,"PHASE4":4561,"NA":4563},{"trials":4538,"activeCount":102},[],{"trials":4540,"activeCount":102},[],{"trials":4542,"activeCount":619,"soonestReadout":1220},[4543,4547,4551],{"nctId":1201,"briefTitle":1202,"status":279,"phases":4544,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":4545,"interventions":4546},[91],[639],[1210,1211,642,1212,1213,1214,1215],{"nctId":1217,"briefTitle":1218,"status":138,"phases":4548,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":4549,"interventions":4550},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"nctId":1229,"briefTitle":1230,"status":138,"phases":4552,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":4553,"interventions":4554},[91],[1160],[1235,1236,642,1237,643,1238,1215],{"trials":4556,"activeCount":102},[4557],{"nctId":1281,"briefTitle":1282,"status":108,"phases":4558,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":4559,"interventions":4560},[92],[1160],[1175,1290,1151],{"trials":4562,"activeCount":102},[],{"trials":4564,"activeCount":195,"soonestReadout":1382},[4565],{"nctId":1379,"briefTitle":1380,"status":138,"phases":4566,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":4567,"interventions":4568},[],[1160],[1175,643,642,1215],{"intervention":4570,"totalTrials":619,"cells":4571},"Brivekimig",{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4576,"PHASE3":4599,"PHASE4":4601,"NA":4603},{"trials":4573,"activeCount":102},[],{"trials":4575,"activeCount":102},[],{"trials":4577,"activeCount":619,"soonestReadout":1559},[4578,4582,4593],{"nctId":1556,"briefTitle":1557,"status":279,"phases":4579,"primaryCompletion":1559,"completion":1560,"start":1561,"enrollment":1079,"conditions":4580,"interventions":4581},[91],[1563,1564],[1566,1567,62],{"nctId":4583,"briefTitle":4584,"status":279,"phases":4585,"primaryCompletion":4586,"completion":4587,"start":4588,"enrollment":4589,"conditions":4590,"interventions":4592},"NCT07170917","Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa",[91],"2027-08-01","2028-04-27","2025-11-06",208,[4591],"Hidradenitis Suppurativa",[4570],{"nctId":4594,"briefTitle":4595,"status":138,"phases":4596,"primaryCompletion":388,"completion":388,"start":3146,"enrollment":1079,"conditions":4597,"interventions":4598},"NCT06812988","Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule",[91],[554],[4570],{"trials":4600,"activeCount":102},[],{"trials":4602,"activeCount":102},[],{"trials":4604,"activeCount":102},[],{"intervention":641,"totalTrials":339,"cells":4606},{"EARLY_PHASE1":4607,"PHASE1":4609,"PHASE2":4620,"PHASE3":4656,"PHASE4":4662,"NA":4664},{"trials":4608,"activeCount":102},[],{"trials":4610,"activeCount":102},[4611],{"nctId":4612,"briefTitle":4613,"status":108,"phases":4614,"primaryCompletion":4615,"completion":4615,"start":4616,"enrollment":4617,"conditions":4618,"interventions":4619},"NCT02514668","A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma",[90],"2021-12-02","2015-09-01",55,[1160],[641],{"trials":4621,"activeCount":659,"soonestReadout":1220},[4622,4648,4652],{"nctId":4623,"briefTitle":4624,"status":884,"phases":4625,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":4629,"interventions":4632},"NCT03860844","Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed\u002FRefractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia",[91],"2022-09-12","2023-05-26",67,[4630,4631],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia",[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],"Dexamethasone or equivalent","Fludarabine","Cytarabine","Liposomal daunorubicin","Daunorubicin","Idarubicin","Filgrastim or equivalent","Doxorubicin","Vincristine","Pegaspargase (PEG) Asparaginase","Cyclophosphamide","Etoposide","L - Asparginase","Hydroxyurea","L - Asparaginase",{"nctId":1217,"briefTitle":1218,"status":138,"phases":4649,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":4650,"interventions":4651},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"nctId":631,"briefTitle":632,"status":279,"phases":4653,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":4654,"interventions":4655},[90,91],[639],[641,642,643,644,645,646,621,647],{"trials":4657,"activeCount":102},[4658],{"nctId":1326,"briefTitle":1327,"status":108,"phases":4659,"primaryCompletion":1329,"completion":1330,"start":1331,"enrollment":1332,"conditions":4660,"interventions":4661},[92],[1160],[641,643,642],{"trials":4663,"activeCount":102},[],{"trials":4665,"activeCount":102},[],{"intervention":4667,"totalTrials":538,"cells":4668},"SAR441566",{"EARLY_PHASE1":4669,"PHASE1":4671,"PHASE2":4699,"PHASE3":4738,"PHASE4":4740,"NA":4742},{"trials":4670,"activeCount":102},[],{"trials":4672,"activeCount":102},[4673,4681,4690],{"nctId":4674,"briefTitle":4675,"status":108,"phases":4676,"primaryCompletion":4677,"completion":4677,"start":4678,"enrollment":552,"conditions":4679,"interventions":4680},"NCT05858788","A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.",[90],"2023-07-17","2023-05-15",[990],[4667],{"nctId":4682,"briefTitle":4683,"status":108,"phases":4684,"primaryCompletion":4685,"completion":4685,"start":4686,"enrollment":112,"conditions":4687,"interventions":4689},"NCT05453942","A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis",[90],"2023-02-09","2022-07-12",[4688],"Psoriasis",[4667],{"nctId":4691,"briefTitle":4692,"status":108,"phases":4693,"primaryCompletion":4694,"completion":4695,"start":4696,"enrollment":178,"conditions":4697,"interventions":4698},"NCT05844735","A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566",[90],"2023-10-15","2023-10-23","2023-05-22",[990],[4667,2861],{"trials":4700,"activeCount":659,"soonestReadout":4715},[4701,4711,4719,4729],{"nctId":4702,"briefTitle":4703,"status":108,"phases":4704,"primaryCompletion":4705,"completion":4706,"start":4707,"enrollment":4708,"conditions":4709,"interventions":4710},"NCT06073119","A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis",[91],"2024-11-13","2024-12-11","2023-10-26",221,[4688],[4667],{"nctId":4712,"briefTitle":4713,"status":279,"phases":4714,"primaryCompletion":4715,"completion":4716,"start":837,"enrollment":668,"conditions":4717,"interventions":4718},"NCT06637631","A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.",[91],"2027-07-21","2029-05-23",[2093],[4667],{"nctId":4720,"briefTitle":4721,"status":279,"phases":4722,"primaryCompletion":4723,"completion":4724,"start":4725,"enrollment":4726,"conditions":4727,"interventions":4728},"NCT06867094","A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis",[91],"2027-07-29","2028-05-11","2025-03-28",204,[144],[4667],{"nctId":4730,"briefTitle":4731,"status":108,"phases":4732,"primaryCompletion":4733,"completion":4734,"start":4735,"enrollment":3519,"conditions":4736,"interventions":4737},"NCT06073093","A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis",[91],"2025-06-18","2025-07-02","2023-11-07",[990],[4667],{"trials":4739,"activeCount":102},[],{"trials":4741,"activeCount":102},[],{"trials":4743,"activeCount":102},[],{"intervention":4745,"totalTrials":619,"cells":4746},"SAR442970",{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4748,"activeCount":102},[],{"trials":4750,"activeCount":102},[],{"trials":4752,"activeCount":659,"soonestReadout":4757},[4753,4763,4770],{"nctId":4754,"briefTitle":4755,"status":279,"phases":4756,"primaryCompletion":4757,"completion":4758,"start":4759,"enrollment":4760,"conditions":4761,"interventions":4762},"NCT06958536","A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease",[91],"2026-12-17","2029-10-17","2025-06-03",99,[2093],[4745],{"nctId":4764,"briefTitle":4765,"status":279,"phases":4766,"primaryCompletion":4757,"completion":4758,"start":4767,"enrollment":4760,"conditions":4768,"interventions":4769},"NCT06975722","A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis",[91],"2025-07-07",[2103],[4745],{"nctId":4771,"briefTitle":4772,"status":108,"phases":4773,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":3566,"conditions":4777,"interventions":4778},"NCT05849922","A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa",[91],"2024-08-22","2025-01-09","2023-06-06",[4591],[4745],{"trials":4780,"activeCount":102},[],{"trials":4782,"activeCount":102},[],{"trials":4784,"activeCount":102},[],{"intervention":52,"totalTrials":659,"cells":4786},{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4807,"PHASE4":4809,"NA":4811},{"trials":4788,"activeCount":102},[],{"trials":4790,"activeCount":102},[],{"trials":4792,"activeCount":659,"soonestReadout":51},[4793,4803],{"nctId":4794,"briefTitle":4795,"status":138,"phases":4796,"primaryCompletion":4797,"completion":4798,"start":4799,"enrollment":442,"conditions":4800,"interventions":4802},"NCT05039840","Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus",[91],"2026-07-10","2026-10-02","2021-11-10",[4801],"Systemic Lupus Erythematosus",[52,3082],{"nctId":49,"briefTitle":50,"status":138,"phases":4804,"primaryCompletion":51,"completion":3077,"start":3078,"enrollment":3079,"conditions":4805,"interventions":4806},[91],[1788],[52,3082,1812],{"trials":4808,"activeCount":102},[],{"trials":4810,"activeCount":102},[],{"trials":4812,"activeCount":102},[],{"intervention":3082,"totalTrials":659,"cells":4814},{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4829,"PHASE4":4831,"NA":4833},{"trials":4816,"activeCount":102},[],{"trials":4818,"activeCount":102},[],{"trials":4820,"activeCount":659,"soonestReadout":51},[4821,4825],{"nctId":4794,"briefTitle":4795,"status":138,"phases":4822,"primaryCompletion":4797,"completion":4798,"start":4799,"enrollment":442,"conditions":4823,"interventions":4824},[91],[4801],[52,3082],{"nctId":49,"briefTitle":50,"status":138,"phases":4826,"primaryCompletion":51,"completion":3077,"start":3078,"enrollment":3079,"conditions":4827,"interventions":4828},[91],[1788],[52,3082,1812],{"trials":4830,"activeCount":102},[],{"trials":4832,"activeCount":102},[],{"trials":4834,"activeCount":102},[],{"intervention":4836,"totalTrials":659,"cells":4837},"SAR445399",{"EARLY_PHASE1":4838,"PHASE1":4840,"PHASE2":4842,"PHASE3":4864,"PHASE4":4866,"NA":4868},{"trials":4839,"activeCount":102},[],{"trials":4841,"activeCount":102},[],{"trials":4843,"activeCount":659,"soonestReadout":4848},[4844,4854],{"nctId":4845,"briefTitle":4846,"status":279,"phases":4847,"primaryCompletion":4848,"completion":4849,"start":4850,"enrollment":4851,"conditions":4852,"interventions":4853},"NCT07225569","A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",[91],"2027-09-22","2027-12-01","2025-12-29",144,[4591],[4836],{"nctId":4855,"briefTitle":4856,"status":279,"phases":4857,"primaryCompletion":4858,"completion":4859,"start":4860,"enrollment":1232,"conditions":4861,"interventions":4863},"NCT07547436","A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis",[91],"2027-10-29","2028-08-07","2026-05-04",[4862],"Non-cystic Fibrosis Bronchiectasis",[4836],{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":102},[],{"trials":4869,"activeCount":102},[],{"intervention":4871,"totalTrials":659,"cells":4872},"Balinatunfib",{"EARLY_PHASE1":4873,"PHASE1":4875,"PHASE2":4887,"PHASE3":4899,"PHASE4":4901,"NA":4903},{"trials":4874,"activeCount":102},[],{"trials":4876,"activeCount":195,"soonestReadout":4881},[4877],{"nctId":4878,"briefTitle":4879,"status":138,"phases":4880,"primaryCompletion":4881,"completion":213,"start":4882,"enrollment":391,"conditions":4883,"interventions":4885},"NCT07272629","A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.",[90],"2026-05-28","2025-12-04",[4884,36],"Cardiac Repolarization",[4871,4886],"Moxifloxacin",{"trials":4888,"activeCount":195,"soonestReadout":4893},[4889],{"nctId":4890,"briefTitle":4891,"status":1515,"phases":4892,"primaryCompletion":4893,"completion":4893,"start":4894,"enrollment":4895,"conditions":4896,"interventions":4897},"NCT07222189","A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)",[91],"2030-05-10","2026-05-19",325,[144,2093],[4898],"balinatunfib",{"trials":4900,"activeCount":102},[],{"trials":4902,"activeCount":102},[],{"trials":4904,"activeCount":102},[],{"intervention":4906,"totalTrials":659,"cells":4907},"Acne mRNA vaccine",{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4932,"PHASE4":4934,"NA":4936},{"trials":4909,"activeCount":102},[],{"trials":4911,"activeCount":102},[],{"trials":4913,"activeCount":659,"soonestReadout":1807},[4914,4924],{"nctId":4915,"briefTitle":4916,"status":279,"phases":4917,"primaryCompletion":4918,"completion":4918,"start":4919,"enrollment":4920,"conditions":4921,"interventions":4923},"NCT07013747","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne",[90,91],"2029-06-19","2025-07-03",120,[4922],"Acne",[4906],{"nctId":4925,"briefTitle":4926,"status":279,"phases":4927,"primaryCompletion":1807,"completion":1807,"start":4928,"enrollment":4929,"conditions":4930,"interventions":4931},"NCT06316297","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne",[90,91],"2024-04-05",800,[4922],[4906],{"trials":4933,"activeCount":102},[],{"trials":4935,"activeCount":102},[],{"trials":4937,"activeCount":102},[],{"intervention":4939,"totalTrials":619,"cells":4940},"insulin",{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4953,"PHASE3":4959,"PHASE4":4961,"NA":4974},{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[4945],{"nctId":4946,"briefTitle":4947,"status":3661,"phases":4948,"primaryCompletion":1041,"completion":1041,"start":965,"enrollment":102,"conditions":4949,"interventions":4950},"NCT02635243","A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia",[90],[554],[4951,4952,4939],"SAR438544","r-glucagon",{"trials":4954,"activeCount":195,"soonestReadout":1757},[4955],{"nctId":1754,"briefTitle":1755,"status":279,"phases":4956,"primaryCompletion":1757,"completion":1758,"start":1759,"enrollment":1642,"conditions":4957,"interventions":4958},[91],[554],[1741,1762],{"trials":4960,"activeCount":102},[],{"trials":4962,"activeCount":102},[4963],{"nctId":4964,"briefTitle":4965,"status":108,"phases":4966,"primaryCompletion":4967,"completion":4968,"start":4969,"enrollment":4970,"conditions":4971,"interventions":4972},"NCT02201004","TOFO Insulin Combination Trial",[93],"2016-01","2016-10","2014-06",211,[19],[4973,4939],"TOFOGLIFLOZIN CSG452",{"trials":4975,"activeCount":102},[],{"intervention":4977,"totalTrials":622,"cells":4978},"Pneumococcal 13-valent Conjugate Vaccine",{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4983,"PHASE3":5005,"PHASE4":5054,"NA":5056},{"trials":4980,"activeCount":102},[],{"trials":4982,"activeCount":102},[],{"trials":4984,"activeCount":195,"soonestReadout":1923},[4985,5001],{"nctId":4986,"briefTitle":4987,"status":108,"phases":4988,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":4991,"interventions":4993},"NCT01049035","A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers",[91],"2012-02-13","2009-12-16",[4992,2949],"Meningitis",[4994,4995,4996,4997,4998,4977,4999,5000],"Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate","Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate","M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live","Varicella Virus Vaccine Live","Pneumococcal 7-valent Conjugate Vaccine","Rotavirus Vaccine","Hepatitis B Vaccine",{"nctId":2888,"briefTitle":2889,"status":138,"phases":5002,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":5003,"interventions":5004},[90,91],[2894,36],[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],{"trials":5006,"activeCount":102},[5007,5011,5026,5040],{"nctId":2925,"briefTitle":2926,"status":108,"phases":5008,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":5009,"interventions":5010},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"nctId":5012,"briefTitle":5013,"status":108,"phases":5014,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":5018,"interventions":5019},"NCT03630705","Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico",[92],"2022-02-18","2018-10-17",525,[2932],[5020,5021,5022,4977,5023,5000,5024,5025],"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","Measles, Mumps, and Rubella Virus Vaccine Live","Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine","Rotavirus Vaccine, Live, Pentavalent","Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine",{"nctId":5027,"briefTitle":5028,"status":108,"phases":5029,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":5033,"interventions":5034},"NCT03673462","Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers",[92],"2023-03-16","2018-09-17",2797,[2932],[5035,5036,5037,4977,4999,5000,5038,5039],"Meningococcal polysaccharide","Meningococcal","Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine","Measles, Mumps, and Rubella Virus Vaccine","Varicella Virus Vaccine",{"nctId":5041,"briefTitle":5042,"status":108,"phases":5043,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":5046,"interventions":5047},"NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers",[92],"2018-10-04",950,[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],"Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine","Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine","Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine","Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine","Haemophilus b Conjugate Vaccine","Rotavirus Vaccine, Live, Oral, Pentavalent",{"trials":5055,"activeCount":102},[],{"trials":5057,"activeCount":102},[],{"intervention":2900,"totalTrials":339,"cells":5059},{"EARLY_PHASE1":5060,"PHASE1":5062,"PHASE2":5064,"PHASE3":5074,"PHASE4":5111,"NA":5113},{"trials":5061,"activeCount":102},[],{"trials":5063,"activeCount":102},[],{"trials":5065,"activeCount":195,"soonestReadout":1923},[5066,5070],{"nctId":4986,"briefTitle":4987,"status":108,"phases":5067,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":5068,"interventions":5069},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"nctId":2888,"briefTitle":2889,"status":138,"phases":5071,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":5072,"interventions":5073},[90,91],[2894,36],[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],{"trials":5075,"activeCount":102},[5076,5080,5093],{"nctId":5027,"briefTitle":5028,"status":108,"phases":5077,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":5078,"interventions":5079},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"nctId":5081,"briefTitle":5082,"status":884,"phases":5083,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":5086,"interventions":5087},"NCT06397768","Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[92],"2024-05-13",2226,[918],[5088,5089,5090,2937,5091,2900,2325,5092],"RSVt vaccine","Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine","Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine","Streptococcus pneumoniae vaccine","Varicella virus vaccine",{"nctId":5094,"briefTitle":5095,"status":108,"phases":5096,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":5100,"interventions":5101},"NCT05794230","Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa",[92],"2025-11-15","2023-03-27",1528,[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],"Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","Oral bivalent types 1 and 3; Poliomyelitis Vaccine","Pneumoccocal Vaccine","Measles, Mumps, and Rubella Vaccine live","DTwP-HepB-Hib-IPV vaccine","DTaP-IPV-Hib-HepB vaccine","Typhoid conjugate vaccine","Measles vaccine","Varicella vaccine live",{"trials":5112,"activeCount":102},[],{"trials":5114,"activeCount":102},[],{"intervention":2897,"totalTrials":339,"cells":5116},{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5134,"PHASE3":5144,"PHASE4":5171,"NA":5173},{"trials":5118,"activeCount":102},[],{"trials":5120,"activeCount":102},[5121],{"nctId":5122,"briefTitle":5123,"status":884,"phases":5124,"primaryCompletion":5125,"completion":5125,"start":5126,"enrollment":5127,"conditions":5128,"interventions":5129},"NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants",[90],"2022-07-22","2021-03-29",576,[2910,36],[5130,5131,5132,5133],"Multicomponent Meningococcal B Vaccine","Meningococcal Group B Vaccine MenB","Meningococcal Group B Vaccine","Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine",{"trials":5135,"activeCount":195,"soonestReadout":1923},[5136,5140],{"nctId":2888,"briefTitle":2889,"status":138,"phases":5137,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":5138,"interventions":5139},[90,91],[2894,36],[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],{"nctId":2903,"briefTitle":2904,"status":108,"phases":5141,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":2908,"conditions":5142,"interventions":5143},[90,91],[2910,36],[2896,2879,2897,2897,2897,2879,2912],{"trials":5145,"activeCount":102},[5146,5159],{"nctId":5147,"briefTitle":5148,"status":108,"phases":5149,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":5152,"conditions":5153,"interventions":5154},"NCT03632720","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom",[92],"2022-12-05","2018-10-10",788,[2932],[5155,2897,5156,5157,5158],"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine","Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine","Human rotavirus RIX4414 strain vaccine","Pneumococcal 13-valent polysaccharide conjugate vaccine",{"nctId":5160,"briefTitle":5161,"status":108,"phases":5162,"primaryCompletion":5163,"completion":5163,"start":5164,"enrollment":5165,"conditions":5166,"interventions":5168},"NCT04084769","Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",[92],"2020-09-14","2019-09-03",570,[5167],"Meningococcal Immunisation (Healthy Volunteers)",[5169,5170,2897],"Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine","Meningococcal Group B vaccine",{"trials":5172,"activeCount":102},[],{"trials":5174,"activeCount":102},[],{"intervention":3022,"totalTrials":659,"cells":5176},{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5187,"PHASE4":5201,"NA":5203},{"trials":5178,"activeCount":102},[],{"trials":5180,"activeCount":102},[],{"trials":5182,"activeCount":195,"soonestReadout":86},[5183],{"nctId":84,"briefTitle":85,"status":138,"phases":5184,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":5185,"interventions":5186},[91],[3016],[87,3018,3019,3020,1048,3021,3022],{"trials":5188,"activeCount":102},[5189],{"nctId":5190,"briefTitle":5191,"status":108,"phases":5192,"primaryCompletion":5193,"completion":5193,"start":5194,"enrollment":5195,"conditions":5196,"interventions":5198},"NCT05468320","Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura",[92],"2024-12-26","2022-11-21",51,[5197],"Thrombotic Thrombocytopenic Purpura",[5199,3022,5200],"Caplacizumab","anti-CD20 antibody",{"trials":5202,"activeCount":102},[],{"trials":5204,"activeCount":102},[],{"intervention":5206,"totalTrials":2371,"cells":5207},"Bevacizumab",{"EARLY_PHASE1":5208,"PHASE1":5210,"PHASE2":5224,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5209,"activeCount":102},[],{"trials":5211,"activeCount":102},[5212],{"nctId":5213,"briefTitle":5214,"status":108,"phases":5215,"primaryCompletion":5216,"completion":5216,"start":5217,"enrollment":5218,"conditions":5219,"interventions":5221},"NCT01193595","Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors",[90],"2014-10","2010-09",39,[5220],"Neoplasms, Malignant",[5222,5223],"Ombrabulin","bevacizumab",{"trials":5225,"activeCount":195,"soonestReadout":5291},[5226,5234,5246,5258,5267,5278,5287,5302],{"nctId":5227,"briefTitle":5228,"status":884,"phases":5229,"primaryCompletion":3564,"completion":3564,"start":2800,"enrollment":2611,"conditions":5230,"interventions":5231},"NCT00378573","Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[91],[2703],[5232,5233,5223],"docetaxel","gemcitabine",{"nctId":5235,"briefTitle":5236,"status":3661,"phases":5237,"primaryCompletion":5238,"completion":5238,"start":3354,"enrollment":102,"conditions":5239,"interventions":5241},"NCT00988897","Colorectal Cancer RECHALLENGE",[91],"2012-05",[5240],"Colorectal Neoplasms",[5242,5243,5244,5245],"OXALIPLATIN","5-FLUOROURACIL","LEUCOVORIN","BEVACIZUMAB",{"nctId":5247,"briefTitle":5248,"status":108,"phases":5249,"completion":5250,"start":5251,"enrollment":5252,"conditions":5253,"interventions":5255},"NCT00399750","TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer",[91],"2005-06","2002-11",373,[5254],"Colorectal Cancer",[5256,5257,5223],"oxaliplatin","fluoropyrimidine",{"nctId":5259,"briefTitle":5260,"status":108,"phases":5261,"primaryCompletion":954,"completion":3416,"start":5262,"enrollment":2281,"conditions":5263,"interventions":5265},"NCT00364611","Pilot Study of Docetaxel & Bevacizumab +\u002F- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer",[91],"2006-08",[5264],"Breast Cancer",[5206,1348,5266],"Trastuzumab",{"nctId":5268,"briefTitle":5269,"status":108,"phases":5270,"primaryCompletion":5271,"completion":5271,"start":5272,"enrollment":5273,"conditions":5274,"interventions":5276},"NCT00446030","Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer",[91],"2010-08","2007-03",127,[5275],"Breast Neoplasms",[1348,4640,5277,4643,5266,5206],"Carboplatin",{"nctId":5279,"briefTitle":5280,"status":108,"phases":5281,"primaryCompletion":5271,"completion":5271,"start":3608,"enrollment":5282,"conditions":5283,"interventions":5285},"NCT00356122","Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)",[91],53,[5284],"Non-Small Cell Lung Cancer",[1348,5286,5206],"Oxaliplatin",{"nctId":5288,"briefTitle":5289,"status":279,"phases":5290,"primaryCompletion":5291,"completion":1621,"start":5292,"enrollment":5293,"conditions":5294,"interventions":5296},"NCT05584670","A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors",[90,91],"2027-01-19","2022-11-29",542,[5295],"Solid Tumor",[5297,5298,5299,5206,5300,5301],"SAR445877","Cetuximab","ADG126","Nivolumab","Ipilimumab",{"nctId":5303,"briefTitle":5304,"status":108,"phases":5305,"primaryCompletion":5306,"completion":5306,"start":5307,"enrollment":5308,"conditions":5309,"interventions":5311},"NCT00296816","TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary",[91],"2011-08","2006-03",132,[5310],"Ovarian Cancer",[5206,1348,5286],{"trials":5313,"activeCount":102},[],{"trials":5315,"activeCount":102},[],{"trials":5317,"activeCount":102},[],{"intervention":5319,"totalTrials":445,"cells":5320},"Quadrivalent Influenza Standard Dose Vaccine",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5322,"activeCount":102},[],{"trials":5324,"activeCount":102},[],{"trials":5326,"activeCount":195,"soonestReadout":4261},[5327,5340,5351,5361],{"nctId":5328,"briefTitle":5329,"status":108,"phases":5330,"primaryCompletion":5331,"completion":5331,"start":5332,"enrollment":5333,"conditions":5334,"interventions":5336},"NCT05650554","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older",[90,91],"2024-04-02","2022-12-12",682,[5335],"Influenza Immunization",[5337,5338,5319,5339],"Quadrivalent Influenza mRNA Vaccine MRT5413","Quadrivalent Recombinant Influenza Vaccine","Quadrivalent Influenza High-Dose Vaccine",{"nctId":5341,"briefTitle":5342,"status":138,"phases":5343,"primaryCompletion":4261,"completion":4261,"start":827,"enrollment":5344,"conditions":5345,"interventions":5346},"NCT06744205","A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older",[90,91],1162,[16,36],[5347,5348,5349,5319,5350],"Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1","TIV mRNA-neuraminidase","TIV mRNA-HA Vaccine 2","Quadrivalent Influenza Vaccine High Dose",{"nctId":5352,"briefTitle":5353,"status":108,"phases":5354,"primaryCompletion":5355,"completion":5355,"start":5356,"enrollment":5357,"conditions":5358,"interventions":5359},"NCT05553301","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older",[90,91],"2024-01-19","2022-10-03",560,[5335],[5360,5338,5319,5339],"Quadrivalent Influenza mRNA Vaccine MRT5407",{"nctId":5362,"briefTitle":5363,"status":108,"phases":5364,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":5367,"conditions":5368,"interventions":5369},"NCT06361875","A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above",[90,91],"2025-06-09","2024-04-01",910,[5335],[5370,5371,5372,5319,5339,5338],"Quadrivalent Influenza mRNA Vaccine MRT5421","Quadrivalent Influenza mRNA Vaccine MRT5424","Quadrivalent Influenza mRNA Vaccine MRT5429",{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[],{"trials":5378,"activeCount":102},[],{"intervention":5298,"totalTrials":445,"cells":5380},{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5385,"PHASE3":5425,"PHASE4":5427,"NA":5429},{"trials":5382,"activeCount":102},[],{"trials":5384,"activeCount":102},[],{"trials":5386,"activeCount":195,"soonestReadout":5291},[5387,5401,5411,5415],{"nctId":5388,"briefTitle":5389,"status":108,"phases":5390,"primaryCompletion":5391,"completion":2996,"start":5392,"enrollment":216,"conditions":5393,"interventions":5398},"NCT05104567","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)",[91],"2023-07-26","2021-12-09",[5394,5395,5396,5254,5397],"Oesophageal Squamous Cell Carcinoma","Gastric Cancer","Hepatocellular Carcinoma","Oesophageal Adenocarcinoma",[5399,5400,5298],"THOR-707","Pembrolizumab",{"nctId":5402,"briefTitle":5403,"status":884,"phases":5404,"primaryCompletion":5405,"completion":887,"start":5406,"enrollment":5407,"conditions":5408,"interventions":5409},"NCT05061420","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)",[91],"2023-07-21","2021-10-08",59,[1274],[5400,5410,5298],"SAR444245",{"nctId":5288,"briefTitle":5289,"status":279,"phases":5412,"primaryCompletion":5291,"completion":1621,"start":5292,"enrollment":5293,"conditions":5413,"interventions":5414},[90,91],[5295],[5297,5298,5299,5206,5300,5301],{"nctId":5416,"briefTitle":5417,"status":884,"phases":5418,"primaryCompletion":4734,"completion":4734,"start":5419,"enrollment":3767,"conditions":5420,"interventions":5422},"NCT04717375","Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors",[90,91],"2021-04-11",[5421,2665],"Cancer",[5423,5400,5298,5277,5424],"SAR444881","Pemetrexed",{"trials":5426,"activeCount":102},[],{"trials":5428,"activeCount":102},[],{"trials":5430,"activeCount":102},[],{"intervention":646,"totalTrials":619,"cells":5432},{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5455,"PHASE3":5461,"PHASE4":5463,"NA":5465},{"trials":5434,"activeCount":102},[],{"trials":5436,"activeCount":102},[5437,5447],{"nctId":5438,"briefTitle":5439,"status":108,"phases":5440,"primaryCompletion":5441,"completion":5442,"start":5443,"enrollment":1574,"conditions":5444,"interventions":5446},"NCT03192345","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors",[90],"2021-12-21","2022-01-17","2017-06-09",[5445],"Malignant Solid Tumor",[646,2705],{"nctId":5448,"briefTitle":5449,"status":884,"phases":5450,"primaryCompletion":5451,"completion":5451,"start":334,"enrollment":988,"conditions":5452,"interventions":5454},"NCT05231668","Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)",[90],"2024-11-12",[5453],"Osteogenesis Imperfecta",[646],{"trials":5456,"activeCount":195,"soonestReadout":634},[5457],{"nctId":631,"briefTitle":632,"status":279,"phases":5458,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":5459,"interventions":5460},[90,91],[639],[641,642,643,644,645,646,621,647],{"trials":5462,"activeCount":102},[],{"trials":5464,"activeCount":102},[],{"trials":5466,"activeCount":102},[],{"intervention":5468,"totalTrials":619,"cells":5469},"SAR443122",{"EARLY_PHASE1":5470,"PHASE1":5472,"PHASE2":5483,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5471,"activeCount":102},[],{"trials":5473,"activeCount":102},[5474],{"nctId":5475,"briefTitle":5476,"status":108,"phases":5477,"primaryCompletion":5478,"completion":5478,"start":5479,"enrollment":29,"conditions":5480,"interventions":5482},"NCT04469621","A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19",[90],"2020-10-23","2020-07-17",[5481],"Corona Virus Infection",[5468],{"trials":5484,"activeCount":195,"soonestReadout":5498},[5485,5494],{"nctId":5486,"briefTitle":5487,"status":108,"phases":5488,"primaryCompletion":5489,"completion":439,"start":5490,"enrollment":23,"conditions":5491,"interventions":5493},"NCT04781816","Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus",[91],"2023-05-25","2021-04-01",[5492],"Cutaneous Lupus Erythematosus",[5468],{"nctId":5495,"briefTitle":5496,"status":138,"phases":5497,"primaryCompletion":5498,"completion":5499,"start":358,"enrollment":5500,"conditions":5501,"interventions":5502},"NCT05588843","Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis",[91],"2026-02-10","2026-12-02",187,[144],[5468],{"trials":5504,"activeCount":102},[],{"trials":5506,"activeCount":102},[],{"trials":5508,"activeCount":102},[],{"intervention":5510,"totalTrials":659,"cells":5511},"SAR444336",{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5524,"PHASE3":5535,"PHASE4":5537,"NA":5539},{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[5516],{"nctId":5517,"briefTitle":5518,"status":108,"phases":5519,"primaryCompletion":464,"completion":464,"start":5520,"enrollment":5521,"conditions":5522,"interventions":5523},"NCT05876767","Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants",[90],"2021-10-15",76,[131],[5510],{"trials":5525,"activeCount":195,"soonestReadout":5530},[5526],{"nctId":5527,"briefTitle":5528,"status":279,"phases":5529,"primaryCompletion":5530,"completion":1795,"start":5531,"enrollment":349,"conditions":5532,"interventions":5534},"NCT07156175","A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission",[91],"2027-04-08","2025-10-14",[5533],"Microscopic Colitis",[5510],{"trials":5536,"activeCount":102},[],{"trials":5538,"activeCount":102},[],{"trials":5540,"activeCount":102},[],{"intervention":5542,"totalTrials":659,"cells":5543},"SAR447537",{"EARLY_PHASE1":5544,"PHASE1":5546,"PHASE2":5548,"PHASE3":5570,"PHASE4":5572,"NA":5574},{"trials":5545,"activeCount":102},[],{"trials":5547,"activeCount":102},[],{"trials":5549,"activeCount":195,"soonestReadout":5564},[5550,5560],{"nctId":5551,"briefTitle":5552,"status":108,"phases":5553,"primaryCompletion":564,"completion":564,"start":5554,"enrollment":4760,"conditions":5555,"interventions":5558},"NCT05856331","Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema",[91],"2023-10-12",[5556,5557],"Alpha 1-Antitrypsin Deficiency","Emphysema",[5542,5559],"Zemaira",{"nctId":5561,"briefTitle":5562,"status":138,"phases":5563,"primaryCompletion":5564,"completion":5565,"start":5566,"enrollment":5567,"conditions":5568,"interventions":5569},"NCT05897424","Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema",[91],"2028-06-30","2028-09-30","2024-06-20",185,[5556,5557],[5542],{"trials":5571,"activeCount":102},[],{"trials":5573,"activeCount":102},[],{"trials":5575,"activeCount":102},[],{"intervention":2896,"totalTrials":659,"cells":5577},{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5592,"PHASE4":5594,"NA":5596},{"trials":5579,"activeCount":102},[],{"trials":5581,"activeCount":102},[],{"trials":5583,"activeCount":195,"soonestReadout":1923},[5584,5588],{"nctId":2888,"briefTitle":2889,"status":138,"phases":5585,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":5586,"interventions":5587},[90,91],[2894,36],[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],{"nctId":2903,"briefTitle":2904,"status":108,"phases":5589,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":2908,"conditions":5590,"interventions":5591},[90,91],[2910,36],[2896,2879,2897,2897,2897,2879,2912],{"trials":5593,"activeCount":102},[],{"trials":5595,"activeCount":102},[],{"trials":5597,"activeCount":102},[],{"intervention":5599,"totalTrials":195,"cells":5600},"SAR446597",{"EARLY_PHASE1":5601,"PHASE1":5603,"PHASE2":5605,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5602,"activeCount":102},[],{"trials":5604,"activeCount":102},[],{"trials":5606,"activeCount":195,"soonestReadout":5611},[5607],{"nctId":5608,"briefTitle":5609,"status":279,"phases":5610,"primaryCompletion":5611,"completion":5612,"start":4263,"enrollment":166,"conditions":5613,"interventions":5615},"NCT07215234","A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration",[90,91],"2027-10-13","2032-07-22",[5614],"Geographic Atrophy",[5599,5616],"Sham Comparator",{"trials":5618,"activeCount":102},[],{"trials":5620,"activeCount":102},[],{"trials":5622,"activeCount":102},[],{"intervention":5616,"totalTrials":195,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5626,"activeCount":102},[],{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":195,"soonestReadout":5611},[5631],{"nctId":5608,"briefTitle":5609,"status":279,"phases":5632,"primaryCompletion":5611,"completion":5612,"start":4263,"enrollment":166,"conditions":5633,"interventions":5634},[90,91],[5614],[5599,5616],{"trials":5636,"activeCount":102},[],{"trials":5638,"activeCount":102},[],{"trials":5640,"activeCount":102},[],{"intervention":5642,"totalTrials":195,"cells":5643},"Blood draw for the laboratory assessment",{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5648,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5645,"activeCount":102},[],{"trials":5647,"activeCount":102},[],{"trials":5649,"activeCount":195,"soonestReadout":5654},[5650],{"nctId":5651,"briefTitle":5652,"status":138,"phases":5653,"primaryCompletion":5654,"completion":5654,"start":5655,"enrollment":2371,"conditions":5656,"interventions":5658},"NCT02065011","A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B",[91],"2031-06-13","2013-09-12",[5657],"Usher's Syndrome",[5642],{"trials":5660,"activeCount":102},[],{"trials":5662,"activeCount":102},[],{"trials":5664,"activeCount":102},[],{"intervention":87,"totalTrials":195,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5677,"PHASE4":5679,"NA":5681},{"trials":5668,"activeCount":102},[],{"trials":5670,"activeCount":102},[],{"trials":5672,"activeCount":195,"soonestReadout":86},[5673],{"nctId":84,"briefTitle":85,"status":138,"phases":5674,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":5675,"interventions":5676},[91],[3016],[87,3018,3019,3020,1048,3021,3022],{"trials":5678,"activeCount":102},[],{"trials":5680,"activeCount":102},[],{"trials":5682,"activeCount":102},[],{"intervention":3018,"totalTrials":195,"cells":5684},{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5686,"activeCount":102},[],{"trials":5688,"activeCount":102},[],{"trials":5690,"activeCount":195,"soonestReadout":86},[5691],{"nctId":84,"briefTitle":85,"status":138,"phases":5692,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":5693,"interventions":5694},[91],[3016],[87,3018,3019,3020,1048,3021,3022],{"trials":5696,"activeCount":102},[],{"trials":5698,"activeCount":102},[],{"trials":5700,"activeCount":102},[],{"intervention":3019,"totalTrials":195,"cells":5702},{"EARLY_PHASE1":5703,"PHASE1":5705,"PHASE2":5707,"PHASE3":5713,"PHASE4":5715,"NA":5717},{"trials":5704,"activeCount":102},[],{"trials":5706,"activeCount":102},[],{"trials":5708,"activeCount":195,"soonestReadout":86},[5709],{"nctId":84,"briefTitle":85,"status":138,"phases":5710,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":5711,"interventions":5712},[91],[3016],[87,3018,3019,3020,1048,3021,3022],{"trials":5714,"activeCount":102},[],{"trials":5716,"activeCount":102},[],{"trials":5718,"activeCount":102},[],{"intervention":3020,"totalTrials":195,"cells":5720},{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5725,"PHASE3":5731,"PHASE4":5733,"NA":5735},{"trials":5722,"activeCount":102},[],{"trials":5724,"activeCount":102},[],{"trials":5726,"activeCount":195,"soonestReadout":86},[5727],{"nctId":84,"briefTitle":85,"status":138,"phases":5728,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":5729,"interventions":5730},[91],[3016],[87,3018,3019,3020,1048,3021,3022],{"trials":5732,"activeCount":102},[],{"trials":5734,"activeCount":102},[],{"trials":5736,"activeCount":102},[],{"intervention":3021,"totalTrials":195,"cells":5738},{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5743,"PHASE3":5749,"PHASE4":5751,"NA":5753},{"trials":5740,"activeCount":102},[],{"trials":5742,"activeCount":102},[],{"trials":5744,"activeCount":195,"soonestReadout":86},[5745],{"nctId":84,"briefTitle":85,"status":138,"phases":5746,"primaryCompletion":86,"completion":3013,"start":3014,"enrollment":391,"conditions":5747,"interventions":5748},[91],[3016],[87,3018,3019,3020,1048,3021,3022],{"trials":5750,"activeCount":102},[],{"trials":5752,"activeCount":102},[],{"trials":5754,"activeCount":102},[],{"intervention":5756,"totalTrials":195,"cells":5757},"Rilzabrutinib dose 1",{"EARLY_PHASE1":5758,"PHASE1":5760,"PHASE2":5762,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5759,"activeCount":102},[],{"trials":5761,"activeCount":102},[],{"trials":5763,"activeCount":195,"soonestReadout":5768},[5764],{"nctId":5765,"briefTitle":5766,"status":279,"phases":5767,"primaryCompletion":5768,"completion":2946,"start":5769,"enrollment":3740,"conditions":5770,"interventions":5772},"NCT06984627","A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease",[91],"2026-08-25","2025-09-02",[5771],"Graves' Disease",[5756,5773],"Rilzabrutinib dose 2",{"trials":5775,"activeCount":102},[],{"trials":5777,"activeCount":102},[],{"trials":5779,"activeCount":102},[],{"intervention":5773,"totalTrials":195,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5786,"PHASE3":5792,"PHASE4":5794,"NA":5796},{"trials":5783,"activeCount":102},[],{"trials":5785,"activeCount":102},[],{"trials":5787,"activeCount":195,"soonestReadout":5768},[5788],{"nctId":5765,"briefTitle":5766,"status":279,"phases":5789,"primaryCompletion":5768,"completion":2946,"start":5769,"enrollment":3740,"conditions":5790,"interventions":5791},[91],[5771],[5756,5773],{"trials":5793,"activeCount":102},[],{"trials":5795,"activeCount":102},[],{"trials":5797,"activeCount":102},[],{"intervention":5799,"totalTrials":195,"cells":5800},"Investigational hMPV\u002FRSV vaccine",{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5821,"PHASE4":5823,"NA":5825},{"trials":5802,"activeCount":102},[],{"trials":5804,"activeCount":102},[],{"trials":5806,"activeCount":195,"soonestReadout":5811},[5807],{"nctId":5808,"briefTitle":5809,"status":138,"phases":5810,"primaryCompletion":5811,"completion":5811,"start":332,"enrollment":5812,"conditions":5813,"interventions":5816},"NCT06686654","Study of a Human Metapneumovirus\u002FRespiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older",[90,91],"2027-01-18",1530,[5814,5815],"Human Metapneumovirus Immunization","Respiratory Syncytial Virus Immunization",[5799,5817,5818,5819,5820],"Investigational hMPV vaccine","Investigational RSV vaccine","Licensed RSV Vaccine","Investigational RSV+hMPV vaccine",{"trials":5822,"activeCount":102},[],{"trials":5824,"activeCount":102},[],{"trials":5826,"activeCount":102},[],{"intervention":5817,"totalTrials":195,"cells":5828},{"EARLY_PHASE1":5829,"PHASE1":5831,"PHASE2":5833,"PHASE3":5839,"PHASE4":5841,"NA":5843},{"trials":5830,"activeCount":102},[],{"trials":5832,"activeCount":102},[],{"trials":5834,"activeCount":195,"soonestReadout":5811},[5835],{"nctId":5808,"briefTitle":5809,"status":138,"phases":5836,"primaryCompletion":5811,"completion":5811,"start":332,"enrollment":5812,"conditions":5837,"interventions":5838},[90,91],[5814,5815],[5799,5817,5818,5819,5820],{"trials":5840,"activeCount":102},[],{"trials":5842,"activeCount":102},[],{"trials":5844,"activeCount":102},[],{"intervention":5818,"totalTrials":195,"cells":5846},{"EARLY_PHASE1":5847,"PHASE1":5849,"PHASE2":5851,"PHASE3":5857,"PHASE4":5859,"NA":5861},{"trials":5848,"activeCount":102},[],{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":195,"soonestReadout":5811},[5853],{"nctId":5808,"briefTitle":5809,"status":138,"phases":5854,"primaryCompletion":5811,"completion":5811,"start":332,"enrollment":5812,"conditions":5855,"interventions":5856},[90,91],[5814,5815],[5799,5817,5818,5819,5820],{"trials":5858,"activeCount":102},[],{"trials":5860,"activeCount":102},[],{"trials":5862,"activeCount":102},[],{"intervention":5819,"totalTrials":195,"cells":5864},{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5875,"PHASE4":5877,"NA":5879},{"trials":5866,"activeCount":102},[],{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":195,"soonestReadout":5811},[5871],{"nctId":5808,"briefTitle":5809,"status":138,"phases":5872,"primaryCompletion":5811,"completion":5811,"start":332,"enrollment":5812,"conditions":5873,"interventions":5874},[90,91],[5814,5815],[5799,5817,5818,5819,5820],{"trials":5876,"activeCount":102},[],{"trials":5878,"activeCount":102},[],{"trials":5880,"activeCount":102},[],{"intervention":5820,"totalTrials":195,"cells":5882},{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5887,"PHASE3":5893,"PHASE4":5895,"NA":5897},{"trials":5884,"activeCount":102},[],{"trials":5886,"activeCount":102},[],{"trials":5888,"activeCount":195,"soonestReadout":5811},[5889],{"nctId":5808,"briefTitle":5809,"status":138,"phases":5890,"primaryCompletion":5811,"completion":5811,"start":332,"enrollment":5812,"conditions":5891,"interventions":5892},[90,91],[5814,5815],[5799,5817,5818,5819,5820],{"trials":5894,"activeCount":102},[],{"trials":5896,"activeCount":102},[],{"trials":5898,"activeCount":102},[],{"intervention":5900,"totalTrials":195,"cells":5901},"Pandemic flu H5 HA mRNA SD2 vaccine",{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5917,"PHASE4":5919,"NA":5921},{"trials":5903,"activeCount":102},[],{"trials":5905,"activeCount":102},[],{"trials":5907,"activeCount":195,"soonestReadout":1722},[5908],{"nctId":5909,"briefTitle":5910,"status":138,"phases":5911,"primaryCompletion":1722,"completion":1722,"start":5912,"enrollment":5913,"conditions":5914,"interventions":5916},"NCT06907511","Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older",[90,91],"2025-04-17",720,[5915,36],"Pandemic Influenza Immunization",[5900],{"trials":5918,"activeCount":102},[],{"trials":5920,"activeCount":102},[],{"trials":5922,"activeCount":102},[],{"intervention":5347,"totalTrials":195,"cells":5924},{"EARLY_PHASE1":5925,"PHASE1":5927,"PHASE2":5929,"PHASE3":5935,"PHASE4":5937,"NA":5939},{"trials":5926,"activeCount":102},[],{"trials":5928,"activeCount":102},[],{"trials":5930,"activeCount":195,"soonestReadout":4261},[5931],{"nctId":5341,"briefTitle":5342,"status":138,"phases":5932,"primaryCompletion":4261,"completion":4261,"start":827,"enrollment":5344,"conditions":5933,"interventions":5934},[90,91],[16,36],[5347,5348,5349,5319,5350],{"trials":5936,"activeCount":102},[],{"trials":5938,"activeCount":102},[],{"trials":5940,"activeCount":102},[],{"intervention":5348,"totalTrials":195,"cells":5942},{"EARLY_PHASE1":5943,"PHASE1":5945,"PHASE2":5947,"PHASE3":5953,"PHASE4":5955,"NA":5957},{"trials":5944,"activeCount":102},[],{"trials":5946,"activeCount":102},[],{"trials":5948,"activeCount":195,"soonestReadout":4261},[5949],{"nctId":5341,"briefTitle":5342,"status":138,"phases":5950,"primaryCompletion":4261,"completion":4261,"start":827,"enrollment":5344,"conditions":5951,"interventions":5952},[90,91],[16,36],[5347,5348,5349,5319,5350],{"trials":5954,"activeCount":102},[],{"trials":5956,"activeCount":102},[],{"trials":5958,"activeCount":102},[],{"intervention":5349,"totalTrials":195,"cells":5960},{"EARLY_PHASE1":5961,"PHASE1":5963,"PHASE2":5965,"PHASE3":5971,"PHASE4":5973,"NA":5975},{"trials":5962,"activeCount":102},[],{"trials":5964,"activeCount":102},[],{"trials":5966,"activeCount":195,"soonestReadout":4261},[5967],{"nctId":5341,"briefTitle":5342,"status":138,"phases":5968,"primaryCompletion":4261,"completion":4261,"start":827,"enrollment":5344,"conditions":5969,"interventions":5970},[90,91],[16,36],[5347,5348,5349,5319,5350],{"trials":5972,"activeCount":102},[],{"trials":5974,"activeCount":102},[],{"trials":5976,"activeCount":102},[],{"intervention":5350,"totalTrials":195,"cells":5978},{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5989,"PHASE4":5991,"NA":5993},{"trials":5980,"activeCount":102},[],{"trials":5982,"activeCount":102},[],{"trials":5984,"activeCount":195,"soonestReadout":4261},[5985],{"nctId":5341,"briefTitle":5342,"status":138,"phases":5986,"primaryCompletion":4261,"completion":4261,"start":827,"enrollment":5344,"conditions":5987,"interventions":5988},[90,91],[16,36],[5347,5348,5349,5319,5350],{"trials":5990,"activeCount":102},[],{"trials":5992,"activeCount":102},[],{"trials":5994,"activeCount":102},[],{"intervention":5996,"totalTrials":195,"cells":5997},"SAR402663",{"EARLY_PHASE1":5998,"PHASE1":6000,"PHASE2":6002,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":5999,"activeCount":102},[],{"trials":6001,"activeCount":102},[],{"trials":6003,"activeCount":195,"soonestReadout":6008},[6004],{"nctId":6005,"briefTitle":6006,"status":279,"phases":6007,"primaryCompletion":6008,"completion":6009,"start":6010,"enrollment":1676,"conditions":6011,"interventions":6013},"NCT06660667","A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration",[90,91],"2027-05-18","2031-06-30","2024-11-21",[6012],"Neovascular Age-related Macular Degeneration",[5996,6014],"Diluent",{"trials":6016,"activeCount":102},[],{"trials":6018,"activeCount":102},[],{"trials":6020,"activeCount":102},[],{"intervention":6014,"totalTrials":195,"cells":6022},{"EARLY_PHASE1":6023,"PHASE1":6025,"PHASE2":6027,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6024,"activeCount":102},[],{"trials":6026,"activeCount":102},[],{"trials":6028,"activeCount":195,"soonestReadout":6008},[6029],{"nctId":6005,"briefTitle":6006,"status":279,"phases":6030,"primaryCompletion":6008,"completion":6009,"start":6010,"enrollment":1676,"conditions":6031,"interventions":6032},[90,91],[6012],[5996,6014],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[],{"trials":6038,"activeCount":102},[],{"intervention":1210,"totalTrials":195,"cells":6040},{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6045,"PHASE3":6051,"PHASE4":6053,"NA":6055},{"trials":6042,"activeCount":102},[],{"trials":6044,"activeCount":102},[],{"trials":6046,"activeCount":195,"soonestReadout":1204},[6047],{"nctId":1201,"briefTitle":1202,"status":279,"phases":6048,"primaryCompletion":1204,"completion":1205,"start":1206,"enrollment":1207,"conditions":6049,"interventions":6050},[91],[639],[1210,1211,642,1212,1213,1214,1215],{"trials":6052,"activeCount":102},[],{"trials":6054,"activeCount":102},[],{"trials":6056,"activeCount":102},[],{"intervention":1227,"totalTrials":195,"cells":6058},{"EARLY_PHASE1":6059,"PHASE1":6061,"PHASE2":6063,"PHASE3":6069,"PHASE4":6071,"NA":6073},{"trials":6060,"activeCount":102},[],{"trials":6062,"activeCount":102},[],{"trials":6064,"activeCount":195,"soonestReadout":1220},[6065],{"nctId":1217,"briefTitle":1218,"status":138,"phases":6066,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":6067,"interventions":6068},[91],[1225],[641,1215,642,1227,1211,1212,1213,1214],{"trials":6070,"activeCount":102},[],{"trials":6072,"activeCount":102},[],{"trials":6074,"activeCount":102},[],{"intervention":6076,"totalTrials":195,"cells":6077},"Chlamydia mRNA Vaccine",{"EARLY_PHASE1":6078,"PHASE1":6080,"PHASE2":6082,"PHASE3":6094,"PHASE4":6096,"NA":6098},{"trials":6079,"activeCount":102},[],{"trials":6081,"activeCount":102},[],{"trials":6083,"activeCount":195,"soonestReadout":6088},[6084],{"nctId":6085,"briefTitle":6086,"status":279,"phases":6087,"primaryCompletion":6088,"completion":6088,"start":6089,"enrollment":6090,"conditions":6091,"interventions":6093},"NCT06891417","Phase 1\u002F2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years",[90,91],"2028-01-03","2025-03-27",1560,[6092],"Chlamydia Trachomatis Immunization",[6076],{"trials":6095,"activeCount":102},[],{"trials":6097,"activeCount":102},[],{"trials":6099,"activeCount":102},[],{"intervention":1235,"totalTrials":195,"cells":6101},{"EARLY_PHASE1":6102,"PHASE1":6104,"PHASE2":6106,"PHASE3":6112,"PHASE4":6114,"NA":6116},{"trials":6103,"activeCount":102},[],{"trials":6105,"activeCount":102},[],{"trials":6107,"activeCount":195,"soonestReadout":615},[6108],{"nctId":1229,"briefTitle":1230,"status":138,"phases":6109,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":6110,"interventions":6111},[91],[1160],[1235,1236,642,1237,643,1238,1215],{"trials":6113,"activeCount":102},[],{"trials":6115,"activeCount":102},[],{"trials":6117,"activeCount":102},[],{"intervention":1238,"totalTrials":195,"cells":6119},{"EARLY_PHASE1":6120,"PHASE1":6122,"PHASE2":6124,"PHASE3":6130,"PHASE4":6132,"NA":6134},{"trials":6121,"activeCount":102},[],{"trials":6123,"activeCount":102},[],{"trials":6125,"activeCount":195,"soonestReadout":615},[6126],{"nctId":1229,"briefTitle":1230,"status":138,"phases":6127,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":6128,"interventions":6129},[91],[1160],[1235,1236,642,1237,643,1238,1215],{"trials":6131,"activeCount":102},[],{"trials":6133,"activeCount":102},[],{"trials":6135,"activeCount":102},[],{"intervention":644,"totalTrials":195,"cells":6137},{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6142,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6139,"activeCount":102},[],{"trials":6141,"activeCount":102},[],{"trials":6143,"activeCount":195,"soonestReadout":634},[6144],{"nctId":631,"briefTitle":632,"status":279,"phases":6145,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":6146,"interventions":6147},[90,91],[639],[641,642,643,644,645,646,621,647],{"trials":6149,"activeCount":102},[],{"trials":6151,"activeCount":102},[],{"trials":6153,"activeCount":102},[],{"intervention":645,"totalTrials":195,"cells":6155},{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6166,"PHASE4":6168,"NA":6170},{"trials":6157,"activeCount":102},[],{"trials":6159,"activeCount":102},[],{"trials":6161,"activeCount":195,"soonestReadout":634},[6162],{"nctId":631,"briefTitle":632,"status":279,"phases":6163,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":6164,"interventions":6165},[90,91],[639],[641,642,643,644,645,646,621,647],{"trials":6167,"activeCount":102},[],{"trials":6169,"activeCount":102},[],{"trials":6171,"activeCount":102},[],{"intervention":647,"totalTrials":195,"cells":6173},{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6184,"PHASE4":6186,"NA":6188},{"trials":6175,"activeCount":102},[],{"trials":6177,"activeCount":102},[],{"trials":6179,"activeCount":195,"soonestReadout":634},[6180],{"nctId":631,"briefTitle":632,"status":279,"phases":6181,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":6182,"interventions":6183},[90,91],[639],[641,642,643,644,645,646,621,647],{"trials":6185,"activeCount":102},[],{"trials":6187,"activeCount":102},[],{"trials":6189,"activeCount":102},[],{"intervention":2898,"totalTrials":195,"cells":6191},{"EARLY_PHASE1":6192,"PHASE1":6194,"PHASE2":6196,"PHASE3":6202,"PHASE4":6204,"NA":6206},{"trials":6193,"activeCount":102},[],{"trials":6195,"activeCount":102},[],{"trials":6197,"activeCount":195,"soonestReadout":1923},[6198],{"nctId":2888,"briefTitle":2889,"status":138,"phases":6199,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":6200,"interventions":6201},[90,91],[2894,36],[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],{"trials":6203,"activeCount":102},[],{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"intervention":2899,"totalTrials":195,"cells":6209},{"EARLY_PHASE1":6210,"PHASE1":6212,"PHASE2":6214,"PHASE3":6220,"PHASE4":6222,"NA":6224},{"trials":6211,"activeCount":102},[],{"trials":6213,"activeCount":102},[],{"trials":6215,"activeCount":195,"soonestReadout":1923},[6216],{"nctId":2888,"briefTitle":2889,"status":138,"phases":6217,"primaryCompletion":1923,"completion":1923,"start":2891,"enrollment":2892,"conditions":6218,"interventions":6219},[90,91],[2894,36],[2896,2879,2879,2897,2898,2899,2899,2899,2900,2901],{"trials":6221,"activeCount":102},[],{"trials":6223,"activeCount":102},[],{"trials":6225,"activeCount":102},[],{"intervention":1863,"totalTrials":195,"cells":6227},{"EARLY_PHASE1":6228,"PHASE1":6230,"PHASE2":6232,"PHASE3":6238,"PHASE4":6240,"NA":6242},{"trials":6229,"activeCount":102},[],{"trials":6231,"activeCount":102},[],{"trials":6233,"activeCount":195,"soonestReadout":1857},[6234],{"nctId":1854,"briefTitle":1855,"status":279,"phases":6235,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":6236,"interventions":6237},[91],[155],[1818,1863,1864,1865,1866],{"trials":6239,"activeCount":102},[],{"trials":6241,"activeCount":102},[],{"trials":6243,"activeCount":102},[],{"intervention":1864,"totalTrials":195,"cells":6245},{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6250,"PHASE3":6256,"PHASE4":6258,"NA":6260},{"trials":6247,"activeCount":102},[],{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":195,"soonestReadout":1857},[6252],{"nctId":1854,"briefTitle":1855,"status":279,"phases":6253,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":6254,"interventions":6255},[91],[155],[1818,1863,1864,1865,1866],{"trials":6257,"activeCount":102},[],{"trials":6259,"activeCount":102},[],{"trials":6261,"activeCount":102},[],{"intervention":1865,"totalTrials":195,"cells":6263},{"EARLY_PHASE1":6264,"PHASE1":6266,"PHASE2":6268,"PHASE3":6274,"PHASE4":6276,"NA":6278},{"trials":6265,"activeCount":102},[],{"trials":6267,"activeCount":102},[],{"trials":6269,"activeCount":195,"soonestReadout":1857},[6270],{"nctId":1854,"briefTitle":1855,"status":279,"phases":6271,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":6272,"interventions":6273},[91],[155],[1818,1863,1864,1865,1866],{"trials":6275,"activeCount":102},[],{"trials":6277,"activeCount":102},[],{"trials":6279,"activeCount":102},[],{"intervention":1866,"totalTrials":195,"cells":6281},{"EARLY_PHASE1":6282,"PHASE1":6284,"PHASE2":6286,"PHASE3":6292,"PHASE4":6294,"NA":6296},{"trials":6283,"activeCount":102},[],{"trials":6285,"activeCount":102},[],{"trials":6287,"activeCount":195,"soonestReadout":1857},[6288],{"nctId":1854,"briefTitle":1855,"status":279,"phases":6289,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":6290,"interventions":6291},[91],[155],[1818,1863,1864,1865,1866],{"trials":6293,"activeCount":102},[],{"trials":6295,"activeCount":102},[],{"trials":6297,"activeCount":102},[],{"intervention":6299,"totalTrials":195,"cells":6300},"SAR446268",{"EARLY_PHASE1":6301,"PHASE1":6303,"PHASE2":6305,"PHASE3":6317,"PHASE4":6319,"NA":6321},{"trials":6302,"activeCount":102},[],{"trials":6304,"activeCount":102},[],{"trials":6306,"activeCount":195,"soonestReadout":6311},[6307],{"nctId":6308,"briefTitle":6309,"status":279,"phases":6310,"primaryCompletion":6311,"completion":6312,"start":1537,"enrollment":6313,"conditions":6314,"interventions":6316},"NCT06844214","A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1",[90,91],"2029-02-28","2032-04-27",32,[6315],"Myotonic Dystrophy",[6299],{"trials":6318,"activeCount":102},[],{"trials":6320,"activeCount":102},[],{"trials":6322,"activeCount":102},[],{"intervention":5297,"totalTrials":195,"cells":6324},{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6335,"PHASE4":6337,"NA":6339},{"trials":6326,"activeCount":102},[],{"trials":6328,"activeCount":102},[],{"trials":6330,"activeCount":195,"soonestReadout":5291},[6331],{"nctId":5288,"briefTitle":5289,"status":279,"phases":6332,"primaryCompletion":5291,"completion":1621,"start":5292,"enrollment":5293,"conditions":6333,"interventions":6334},[90,91],[5295],[5297,5298,5299,5206,5300,5301],{"trials":6336,"activeCount":102},[],{"trials":6338,"activeCount":102},[],{"trials":6340,"activeCount":102},[],{"intervention":5299,"totalTrials":195,"cells":6342},{"EARLY_PHASE1":6343,"PHASE1":6345,"PHASE2":6347,"PHASE3":6353,"PHASE4":6355,"NA":6357},{"trials":6344,"activeCount":102},[],{"trials":6346,"activeCount":102},[],{"trials":6348,"activeCount":195,"soonestReadout":5291},[6349],{"nctId":5288,"briefTitle":5289,"status":279,"phases":6350,"primaryCompletion":5291,"completion":1621,"start":5292,"enrollment":5293,"conditions":6351,"interventions":6352},[90,91],[5295],[5297,5298,5299,5206,5300,5301],{"trials":6354,"activeCount":102},[],{"trials":6356,"activeCount":102},[],{"trials":6358,"activeCount":102},[],{"intervention":5300,"totalTrials":195,"cells":6360},{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6365,"PHASE3":6371,"PHASE4":6373,"NA":6375},{"trials":6362,"activeCount":102},[],{"trials":6364,"activeCount":102},[],{"trials":6366,"activeCount":195,"soonestReadout":5291},[6367],{"nctId":5288,"briefTitle":5289,"status":279,"phases":6368,"primaryCompletion":5291,"completion":1621,"start":5292,"enrollment":5293,"conditions":6369,"interventions":6370},[90,91],[5295],[5297,5298,5299,5206,5300,5301],{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[],{"trials":6376,"activeCount":102},[],{"intervention":5301,"totalTrials":195,"cells":6378},{"EARLY_PHASE1":6379,"PHASE1":6381,"PHASE2":6383,"PHASE3":6389,"PHASE4":6391,"NA":6393},{"trials":6380,"activeCount":102},[],{"trials":6382,"activeCount":102},[],{"trials":6384,"activeCount":195,"soonestReadout":5291},[6385],{"nctId":5288,"briefTitle":5289,"status":279,"phases":6386,"primaryCompletion":5291,"completion":1621,"start":5292,"enrollment":5293,"conditions":6387,"interventions":6388},[90,91],[5295],[5297,5298,5299,5206,5300,5301],{"trials":6390,"activeCount":102},[],{"trials":6392,"activeCount":102},[],{"trials":6394,"activeCount":102},[],{"intervention":6396,"totalTrials":195,"cells":6397},"SAR444836",{"EARLY_PHASE1":6398,"PHASE1":6400,"PHASE2":6402,"PHASE3":6413,"PHASE4":6415,"NA":6417},{"trials":6399,"activeCount":102},[],{"trials":6401,"activeCount":102},[],{"trials":6403,"activeCount":195,"soonestReadout":6408},[6404],{"nctId":6405,"briefTitle":6406,"status":138,"phases":6407,"primaryCompletion":6408,"completion":6408,"start":6409,"enrollment":6313,"conditions":6410,"interventions":6412},"NCT05972629","A Phase 1\u002FPhase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria",[90,91],"2030-04-02","2023-08-07",[6411],"Phenylketonuria",[6396],{"trials":6414,"activeCount":102},[],{"trials":6416,"activeCount":102},[],{"trials":6418,"activeCount":102},[],{"intervention":6420,"totalTrials":195,"cells":6421},"Long term follow up in all patients who received SAR422459 in previous study TDU13583",{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6426,"PHASE3":6438,"PHASE4":6440,"NA":6442},{"trials":6423,"activeCount":102},[],{"trials":6425,"activeCount":102},[],{"trials":6427,"activeCount":195,"soonestReadout":6432},[6428],{"nctId":6429,"briefTitle":6430,"status":138,"phases":6431,"primaryCompletion":6432,"completion":6432,"start":6433,"enrollment":6434,"conditions":6435,"interventions":6437},"NCT01736592","Phase I\u002FII Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration",[91],"2033-08-29","2012-12-14",27,[6436],"Stargardt's Disease",[6420],{"trials":6439,"activeCount":102},[],{"trials":6441,"activeCount":102},[],{"trials":6443,"activeCount":102},[],{"intervention":2781,"totalTrials":6445,"cells":6446},11,{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6476,"PHASE3":6487,"PHASE4":6530,"NA":6532},{"trials":6448,"activeCount":102},[],{"trials":6450,"activeCount":102},[6451,6460,6467],{"nctId":6452,"briefTitle":6453,"status":108,"phases":6454,"primaryCompletion":1054,"completion":1054,"start":2855,"enrollment":6455,"conditions":6456,"interventions":6457},"NCT02017639","Sarilumab Effect on the Pharmacokinetics of Simvastatin",[90],19,[990],[6458,6459],"sarilumab SAR153191","simvastatin",{"nctId":6461,"briefTitle":6462,"status":108,"phases":6463,"primaryCompletion":1054,"completion":1054,"start":3395,"enrollment":3740,"conditions":6464,"interventions":6465},"NCT02404558","Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis",[90],[990],[6458,6466],"tocilizumab",{"nctId":6468,"briefTitle":6469,"status":108,"phases":6470,"primaryCompletion":6471,"completion":6471,"start":1032,"enrollment":6472,"conditions":6473,"interventions":6474},"NCT01850680","Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis",[90],"2013-12",61,[990],[6458,993,6475],"folic acid",{"trials":6477,"activeCount":195,"soonestReadout":6482},[6478],{"nctId":6479,"briefTitle":6480,"status":279,"phases":6481,"primaryCompletion":6482,"completion":6483,"start":6484,"enrollment":5195,"conditions":6485,"interventions":6486},"NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)",[91],"2028-03-01","2031-01-17","2018-08-09",[1003],[2781],{"trials":6488,"activeCount":102},[6489,6498,6506,6516,6520,6526],{"nctId":6490,"briefTitle":6491,"status":108,"phases":6492,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":6494,"interventions":6495},"NCT01768572","To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)",[92],202,[990],[6458,6466,1015,993,1016,1017,6496,6497],"subcutaneous placebo","intravenous placebo",{"nctId":6499,"briefTitle":6500,"status":108,"phases":6501,"primaryCompletion":4968,"completion":4968,"start":150,"enrollment":6502,"conditions":6503,"interventions":6504},"NCT02293902","A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)",[92],243,[990],[2781,971,6505],"Folic acid",{"nctId":6507,"briefTitle":6508,"status":108,"phases":6509,"primaryCompletion":6510,"completion":6511,"start":6512,"enrollment":6513,"conditions":6514,"interventions":6515},"NCT04327388","Sarilumab COVID-19",[92],"2020-07-31","2020-09-02","2020-03-28",420,[5481],[2781],{"nctId":2772,"briefTitle":2773,"status":884,"phases":6517,"primaryCompletion":2775,"completion":2775,"start":2776,"enrollment":2777,"conditions":6518,"interventions":6519},[92],[2779],[2781,671],{"nctId":6521,"briefTitle":6522,"status":108,"phases":6523,"primaryCompletion":3395,"completion":3395,"start":4969,"enrollment":5308,"conditions":6524,"interventions":6525},"NCT02121210","To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)",[92],[990],[6458],{"nctId":2813,"briefTitle":2814,"status":884,"phases":6527,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1223,"conditions":6528,"interventions":6529},[92],[1093],[2781,671,671],{"trials":6531,"activeCount":102},[],{"trials":6533,"activeCount":102},[6534],{"nctId":6535,"briefTitle":6536,"status":108,"phases":6537,"primaryCompletion":6538,"completion":6538,"start":6539,"enrollment":6540,"conditions":6541,"interventions":6543},"NCT03378219","An Observational Study on Sarilumab-exposed Pregnancies",[],"2024-12-06","2018-05-18",113,[6542],"Rheumatoid Arthritis -Exposure During Pregnancy",[2781],{"intervention":1236,"totalTrials":619,"cells":6545},{"EARLY_PHASE1":6546,"PHASE1":6548,"PHASE2":6550,"PHASE3":6566,"PHASE4":6568,"NA":6570},{"trials":6547,"activeCount":102},[],{"trials":6549,"activeCount":102},[],{"trials":6551,"activeCount":195,"soonestReadout":615},[6552,6556],{"nctId":1229,"briefTitle":1230,"status":138,"phases":6553,"primaryCompletion":615,"completion":615,"start":1222,"enrollment":1232,"conditions":6554,"interventions":6555},[91],[1160],[1235,1236,642,1237,643,1238,1215],{"nctId":6557,"briefTitle":6558,"status":884,"phases":6559,"primaryCompletion":6560,"completion":1940,"start":6561,"enrollment":37,"conditions":6562,"interventions":6565},"NCT04913220","A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)",[90,91],"2023-08-22","2021-07-15",[6563,6564],"Malignant Melanoma","Squamous Cell Carcinoma of Skin",[5399,1236],{"trials":6567,"activeCount":102},[],{"trials":6569,"activeCount":102},[],{"trials":6571,"activeCount":102},[6572],{"nctId":6573,"briefTitle":6574,"status":108,"phases":6575,"primaryCompletion":6576,"completion":6576,"start":5442,"enrollment":6577,"conditions":6578,"interventions":6580},"NCT05302297","Comparative Efficacy of Cemiplimab to Historical Standard of Care in France",[],"2022-09-30",305,[6579],"Cancer\u002FSquamous Cell Carcinoma of Skin",[1236],{"intervention":6582,"totalTrials":659,"cells":6583},"SAR448501",{"EARLY_PHASE1":6584,"PHASE1":6586,"PHASE2":6609,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6585,"activeCount":102},[],{"trials":6587,"activeCount":659,"soonestReadout":6592},[6588,6599],{"nctId":6589,"briefTitle":6590,"status":279,"phases":6591,"primaryCompletion":6592,"completion":6593,"start":6594,"enrollment":6595,"conditions":6596,"interventions":6598},"NCT06392477","A Study to Evaluate the Safety and Activity of SAR448501\u002FDR-0201 in Patients With Relapsed\u002F Refractory B-Cell Non-Hodgkin Lymphoma",[90],"2028-01-21","2028-02-11","2024-07-08",96,[6597],"B-cell Non Hodgkin Lymphoma",[6582],{"nctId":6600,"briefTitle":6601,"status":279,"phases":6602,"primaryCompletion":6603,"completion":6603,"start":6089,"enrollment":6604,"conditions":6605,"interventions":6608},"NCT06647069","A Study to Evaluate the Safety and Activity of SAR448501\u002FDR-0201 in Patients With Autoimmune Rheumatic Diseases",[90],"2029-06-25",62,[6606,6607],"Systemic Lupus Erythematosus (SLE)","Rheumatoid Arthritis (RA)",[6582],{"trials":6610,"activeCount":102},[],{"trials":6612,"activeCount":102},[],{"trials":6614,"activeCount":102},[],{"trials":6616,"activeCount":102},[],{"intervention":6618,"totalTrials":195,"cells":6619},"SAR446523",{"EARLY_PHASE1":6620,"PHASE1":6622,"PHASE2":6633,"PHASE3":6635,"PHASE4":6637,"NA":6639},{"trials":6621,"activeCount":102},[],{"trials":6623,"activeCount":195,"soonestReadout":6628},[6624],{"nctId":6625,"briefTitle":6626,"status":279,"phases":6627,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":6630,"conditions":6631,"interventions":6632},"NCT06630806","A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed\u002FRefractory Myeloma",[90],"2031-05-16","2024-10-30",87,[639],[6618],{"trials":6634,"activeCount":102},[],{"trials":6636,"activeCount":102},[],{"trials":6638,"activeCount":102},[],{"trials":6640,"activeCount":102},[],{"intervention":6642,"totalTrials":195,"cells":6643},"trivalent (RSV\u002FhMPV\u002FPIV3) vaccine candidate",{"EARLY_PHASE1":6644,"PHASE1":6646,"PHASE2":6664,"PHASE3":6666,"PHASE4":6668,"NA":6670},{"trials":6645,"activeCount":102},[],{"trials":6647,"activeCount":195,"soonestReadout":6652},[6648],{"nctId":6649,"briefTitle":6650,"status":138,"phases":6651,"primaryCompletion":6652,"completion":6653,"start":6654,"enrollment":6655,"conditions":6656,"interventions":6659},"NCT07295028","Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults",[90],"2026-04-21","2027-04-24","2025-11-17",240,[6657,6658],"Lower Respiratory Tract Disease","Healthy Participants",[6642,6642,6642,6660,6661,6662,6663],"bivalent (RSV\u002FhMPV) unlicensed comparator","monovalent (RSV) unlicensed comparator","Biological\u002FVaccine: monovalent (hMPV) unlicensed comparator","monovalent (PIV3) unlicensed comparator",{"trials":6665,"activeCount":102},[],{"trials":6667,"activeCount":102},[],{"trials":6669,"activeCount":102},[],{"trials":6671,"activeCount":102},[],{"intervention":6660,"totalTrials":195,"cells":6673},{"EARLY_PHASE1":6674,"PHASE1":6676,"PHASE2":6682,"PHASE3":6684,"PHASE4":6686,"NA":6688},{"trials":6675,"activeCount":102},[],{"trials":6677,"activeCount":195,"soonestReadout":6652},[6678],{"nctId":6649,"briefTitle":6650,"status":138,"phases":6679,"primaryCompletion":6652,"completion":6653,"start":6654,"enrollment":6655,"conditions":6680,"interventions":6681},[90],[6657,6658],[6642,6642,6642,6660,6661,6662,6663],{"trials":6683,"activeCount":102},[],{"trials":6685,"activeCount":102},[],{"trials":6687,"activeCount":102},[],{"trials":6689,"activeCount":102},[],{"intervention":6661,"totalTrials":195,"cells":6691},{"EARLY_PHASE1":6692,"PHASE1":6694,"PHASE2":6700,"PHASE3":6702,"PHASE4":6704,"NA":6706},{"trials":6693,"activeCount":102},[],{"trials":6695,"activeCount":195,"soonestReadout":6652},[6696],{"nctId":6649,"briefTitle":6650,"status":138,"phases":6697,"primaryCompletion":6652,"completion":6653,"start":6654,"enrollment":6655,"conditions":6698,"interventions":6699},[90],[6657,6658],[6642,6642,6642,6660,6661,6662,6663],{"trials":6701,"activeCount":102},[],{"trials":6703,"activeCount":102},[],{"trials":6705,"activeCount":102},[],{"trials":6707,"activeCount":102},[],{"intervention":6662,"totalTrials":195,"cells":6709},{"EARLY_PHASE1":6710,"PHASE1":6712,"PHASE2":6718,"PHASE3":6720,"PHASE4":6722,"NA":6724},{"trials":6711,"activeCount":102},[],{"trials":6713,"activeCount":195,"soonestReadout":6652},[6714],{"nctId":6649,"briefTitle":6650,"status":138,"phases":6715,"primaryCompletion":6652,"completion":6653,"start":6654,"enrollment":6655,"conditions":6716,"interventions":6717},[90],[6657,6658],[6642,6642,6642,6660,6661,6662,6663],{"trials":6719,"activeCount":102},[],{"trials":6721,"activeCount":102},[],{"trials":6723,"activeCount":102},[],{"trials":6725,"activeCount":102},[],{"intervention":6663,"totalTrials":195,"cells":6727},{"EARLY_PHASE1":6728,"PHASE1":6730,"PHASE2":6736,"PHASE3":6738,"PHASE4":6740,"NA":6742},{"trials":6729,"activeCount":102},[],{"trials":6731,"activeCount":195,"soonestReadout":6652},[6732],{"nctId":6649,"briefTitle":6650,"status":138,"phases":6733,"primaryCompletion":6652,"completion":6653,"start":6654,"enrollment":6655,"conditions":6734,"interventions":6735},[90],[6657,6658],[6642,6642,6642,6660,6661,6662,6663],{"trials":6737,"activeCount":102},[],{"trials":6739,"activeCount":102},[],{"trials":6741,"activeCount":102},[],{"trials":6743,"activeCount":102},[],{"intervention":72,"totalTrials":195,"cells":6745},{"EARLY_PHASE1":6746,"PHASE1":6748,"PHASE2":6760,"PHASE3":6762,"PHASE4":6764,"NA":6766},{"trials":6747,"activeCount":102},[],{"trials":6749,"activeCount":195,"soonestReadout":71},[6750],{"nctId":69,"briefTitle":70,"status":138,"phases":6751,"primaryCompletion":71,"completion":6752,"start":6753,"enrollment":4851,"conditions":6754,"interventions":6755},[90],"2027-05","2024-08-13",[36],[72,6756,6757,6758,6757,6759],"VXB-241 120 mcg","VXB-241 240 mcg","VXB-241 480 mcg","Arexvy 120 mcg",{"trials":6761,"activeCount":102},[],{"trials":6763,"activeCount":102},[],{"trials":6765,"activeCount":102},[],{"trials":6767,"activeCount":102},[],{"intervention":6756,"totalTrials":195,"cells":6769},{"EARLY_PHASE1":6770,"PHASE1":6772,"PHASE2":6778,"PHASE3":6780,"PHASE4":6782,"NA":6784},{"trials":6771,"activeCount":102},[],{"trials":6773,"activeCount":195,"soonestReadout":71},[6774],{"nctId":69,"briefTitle":70,"status":138,"phases":6775,"primaryCompletion":71,"completion":6752,"start":6753,"enrollment":4851,"conditions":6776,"interventions":6777},[90],[36],[72,6756,6757,6758,6757,6759],{"trials":6779,"activeCount":102},[],{"trials":6781,"activeCount":102},[],{"trials":6783,"activeCount":102},[],{"trials":6785,"activeCount":102},[],{"intervention":6757,"totalTrials":195,"cells":6787},{"EARLY_PHASE1":6788,"PHASE1":6790,"PHASE2":6796,"PHASE3":6798,"PHASE4":6800,"NA":6802},{"trials":6789,"activeCount":102},[],{"trials":6791,"activeCount":195,"soonestReadout":71},[6792],{"nctId":69,"briefTitle":70,"status":138,"phases":6793,"primaryCompletion":71,"completion":6752,"start":6753,"enrollment":4851,"conditions":6794,"interventions":6795},[90],[36],[72,6756,6757,6758,6757,6759],{"trials":6797,"activeCount":102},[],{"trials":6799,"activeCount":102},[],{"trials":6801,"activeCount":102},[],{"trials":6803,"activeCount":102},[],{"intervention":6758,"totalTrials":195,"cells":6805},{"EARLY_PHASE1":6806,"PHASE1":6808,"PHASE2":6814,"PHASE3":6816,"PHASE4":6818,"NA":6820},{"trials":6807,"activeCount":102},[],{"trials":6809,"activeCount":195,"soonestReadout":71},[6810],{"nctId":69,"briefTitle":70,"status":138,"phases":6811,"primaryCompletion":71,"completion":6752,"start":6753,"enrollment":4851,"conditions":6812,"interventions":6813},[90],[36],[72,6756,6757,6758,6757,6759],{"trials":6815,"activeCount":102},[],{"trials":6817,"activeCount":102},[],{"trials":6819,"activeCount":102},[],{"trials":6821,"activeCount":102},[],{"intervention":6759,"totalTrials":195,"cells":6823},{"EARLY_PHASE1":6824,"PHASE1":6826,"PHASE2":6832,"PHASE3":6834,"PHASE4":6836,"NA":6838},{"trials":6825,"activeCount":102},[],{"trials":6827,"activeCount":195,"soonestReadout":71},[6828],{"nctId":69,"briefTitle":70,"status":138,"phases":6829,"primaryCompletion":71,"completion":6752,"start":6753,"enrollment":4851,"conditions":6830,"interventions":6831},[90],[36],[72,6756,6757,6758,6757,6759],{"trials":6833,"activeCount":102},[],{"trials":6835,"activeCount":102},[],{"trials":6837,"activeCount":102},[],{"trials":6839,"activeCount":102},[],{"intervention":6841,"totalTrials":195,"cells":6842},"H5 Flu Investigational Medical Product (IMP) 1",{"EARLY_PHASE1":6843,"PHASE1":6845,"PHASE2":6868,"PHASE3":6870,"PHASE4":6872,"NA":6874},{"trials":6844,"activeCount":102},[],{"trials":6846,"activeCount":195,"soonestReadout":6851},[6847],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6850,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6853,"interventions":6856},"NCT07516418","Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age",[90],"2027-04-04","2026-04-15",[6854,6855],"Respiratory Syncytial Virus (RSV)","Influenza A(H5N1)",[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],"H5 Flu IMP 2","H5 Flu IMP 3","RSV IMP 4","RSV IMP 5","RSV IMP 6","H5 Flu IMP 7","H5 Flu IMP 8","H5 Flu IMP 9","H5 Flu IMP 10","H5 Flu IMP 11","H5 Flu IMP 12",{"trials":6869,"activeCount":102},[],{"trials":6871,"activeCount":102},[],{"trials":6873,"activeCount":102},[],{"trials":6875,"activeCount":102},[],{"intervention":6857,"totalTrials":195,"cells":6877},{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6886,"PHASE3":6888,"PHASE4":6890,"NA":6892},{"trials":6879,"activeCount":102},[],{"trials":6881,"activeCount":195,"soonestReadout":6851},[6882],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6883,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6884,"interventions":6885},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6887,"activeCount":102},[],{"trials":6889,"activeCount":102},[],{"trials":6891,"activeCount":102},[],{"trials":6893,"activeCount":102},[],{"intervention":6858,"totalTrials":195,"cells":6895},{"EARLY_PHASE1":6896,"PHASE1":6898,"PHASE2":6904,"PHASE3":6906,"PHASE4":6908,"NA":6910},{"trials":6897,"activeCount":102},[],{"trials":6899,"activeCount":195,"soonestReadout":6851},[6900],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6901,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6902,"interventions":6903},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6905,"activeCount":102},[],{"trials":6907,"activeCount":102},[],{"trials":6909,"activeCount":102},[],{"trials":6911,"activeCount":102},[],{"intervention":6859,"totalTrials":195,"cells":6913},{"EARLY_PHASE1":6914,"PHASE1":6916,"PHASE2":6922,"PHASE3":6924,"PHASE4":6926,"NA":6928},{"trials":6915,"activeCount":102},[],{"trials":6917,"activeCount":195,"soonestReadout":6851},[6918],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6919,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6920,"interventions":6921},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6923,"activeCount":102},[],{"trials":6925,"activeCount":102},[],{"trials":6927,"activeCount":102},[],{"trials":6929,"activeCount":102},[],{"intervention":6860,"totalTrials":195,"cells":6931},{"EARLY_PHASE1":6932,"PHASE1":6934,"PHASE2":6940,"PHASE3":6942,"PHASE4":6944,"NA":6946},{"trials":6933,"activeCount":102},[],{"trials":6935,"activeCount":195,"soonestReadout":6851},[6936],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6937,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6938,"interventions":6939},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6941,"activeCount":102},[],{"trials":6943,"activeCount":102},[],{"trials":6945,"activeCount":102},[],{"trials":6947,"activeCount":102},[],{"intervention":6861,"totalTrials":195,"cells":6949},{"EARLY_PHASE1":6950,"PHASE1":6952,"PHASE2":6958,"PHASE3":6960,"PHASE4":6962,"NA":6964},{"trials":6951,"activeCount":102},[],{"trials":6953,"activeCount":195,"soonestReadout":6851},[6954],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6955,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6956,"interventions":6957},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6959,"activeCount":102},[],{"trials":6961,"activeCount":102},[],{"trials":6963,"activeCount":102},[],{"trials":6965,"activeCount":102},[],{"intervention":6862,"totalTrials":195,"cells":6967},{"EARLY_PHASE1":6968,"PHASE1":6970,"PHASE2":6976,"PHASE3":6978,"PHASE4":6980,"NA":6982},{"trials":6969,"activeCount":102},[],{"trials":6971,"activeCount":195,"soonestReadout":6851},[6972],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6973,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6974,"interventions":6975},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6977,"activeCount":102},[],{"trials":6979,"activeCount":102},[],{"trials":6981,"activeCount":102},[],{"trials":6983,"activeCount":102},[],{"intervention":6863,"totalTrials":195,"cells":6985},{"EARLY_PHASE1":6986,"PHASE1":6988,"PHASE2":6994,"PHASE3":6996,"PHASE4":6998,"NA":7000},{"trials":6987,"activeCount":102},[],{"trials":6989,"activeCount":195,"soonestReadout":6851},[6990],{"nctId":6848,"briefTitle":6849,"status":279,"phases":6991,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":6992,"interventions":6993},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":6995,"activeCount":102},[],{"trials":6997,"activeCount":102},[],{"trials":6999,"activeCount":102},[],{"trials":7001,"activeCount":102},[],{"intervention":6864,"totalTrials":195,"cells":7003},{"EARLY_PHASE1":7004,"PHASE1":7006,"PHASE2":7012,"PHASE3":7014,"PHASE4":7016,"NA":7018},{"trials":7005,"activeCount":102},[],{"trials":7007,"activeCount":195,"soonestReadout":6851},[7008],{"nctId":6848,"briefTitle":6849,"status":279,"phases":7009,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":7010,"interventions":7011},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":7013,"activeCount":102},[],{"trials":7015,"activeCount":102},[],{"trials":7017,"activeCount":102},[],{"trials":7019,"activeCount":102},[],{"intervention":6865,"totalTrials":195,"cells":7021},{"EARLY_PHASE1":7022,"PHASE1":7024,"PHASE2":7030,"PHASE3":7032,"PHASE4":7034,"NA":7036},{"trials":7023,"activeCount":102},[],{"trials":7025,"activeCount":195,"soonestReadout":6851},[7026],{"nctId":6848,"briefTitle":6849,"status":279,"phases":7027,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":7028,"interventions":7029},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":7031,"activeCount":102},[],{"trials":7033,"activeCount":102},[],{"trials":7035,"activeCount":102},[],{"trials":7037,"activeCount":102},[],{"intervention":6866,"totalTrials":195,"cells":7039},{"EARLY_PHASE1":7040,"PHASE1":7042,"PHASE2":7048,"PHASE3":7050,"PHASE4":7052,"NA":7054},{"trials":7041,"activeCount":102},[],{"trials":7043,"activeCount":195,"soonestReadout":6851},[7044],{"nctId":6848,"briefTitle":6849,"status":279,"phases":7045,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":7046,"interventions":7047},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":7049,"activeCount":102},[],{"trials":7051,"activeCount":102},[],{"trials":7053,"activeCount":102},[],{"trials":7055,"activeCount":102},[],{"intervention":6867,"totalTrials":195,"cells":7057},{"EARLY_PHASE1":7058,"PHASE1":7060,"PHASE2":7066,"PHASE3":7068,"PHASE4":7070,"NA":7072},{"trials":7059,"activeCount":102},[],{"trials":7061,"activeCount":195,"soonestReadout":6851},[7062],{"nctId":6848,"briefTitle":6849,"status":279,"phases":7063,"primaryCompletion":6851,"completion":6851,"start":6852,"enrollment":5165,"conditions":7064,"interventions":7065},[90],[6854,6855],[6841,6857,6858,6859,6860,6861,6862,6863,6864,6865,6866,6867],{"trials":7067,"activeCount":102},[],{"trials":7069,"activeCount":102},[],{"trials":7071,"activeCount":102},[],{"trials":7073,"activeCount":102},[],{"intervention":4886,"totalTrials":195,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7084,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7077,"activeCount":102},[],{"trials":7079,"activeCount":195,"soonestReadout":4881},[7080],{"nctId":4878,"briefTitle":4879,"status":138,"phases":7081,"primaryCompletion":4881,"completion":213,"start":4882,"enrollment":391,"conditions":7082,"interventions":7083},[90],[4884,36],[4871,4886],{"trials":7085,"activeCount":102},[],{"trials":7087,"activeCount":102},[],{"trials":7089,"activeCount":102},[],{"trials":7091,"activeCount":102},[],{"intervention":2064,"totalTrials":6455,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7098,"PHASE3":7100,"PHASE4":7215,"NA":7244},{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":102},[],{"trials":7099,"activeCount":102},[],{"trials":7101,"activeCount":102},[7102,7111,7115,7119,7129,7140,7149,7153,7161,7171,7183,7193,7206],{"nctId":7103,"briefTitle":7104,"status":108,"phases":7105,"primaryCompletion":7106,"completion":7107,"start":7108,"enrollment":6604,"conditions":7109,"interventions":7110},"NCT04678882","Dupilumab in Japanese Patients With Atopic Dermatitis",[92],"2021-12-14","2023-10-28","2021-01-15",[206],[2064],{"nctId":2054,"briefTitle":2055,"status":108,"phases":7112,"primaryCompletion":2057,"completion":2058,"start":2059,"enrollment":2060,"conditions":7113,"interventions":7114},[92],[2062],[2064,182],{"nctId":3909,"briefTitle":3910,"status":108,"phases":7116,"primaryCompletion":3912,"completion":3913,"start":3914,"enrollment":3915,"conditions":7117,"interventions":7118},[92],[3917],[2064,3919,3920,1501],{"nctId":7120,"briefTitle":7121,"status":108,"phases":7122,"primaryCompletion":7123,"completion":7123,"start":7124,"enrollment":7125,"conditions":7126,"interventions":7127},"NCT02912468","A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps",[92],"2018-07-05","2016-12-05",276,[2062],[2064,7128],"Mometasone furoate 50 micrograms",{"nctId":7130,"briefTitle":7131,"status":108,"phases":7132,"primaryCompletion":7133,"completion":7134,"start":7135,"enrollment":3451,"conditions":7136,"interventions":7138},"NCT04681729","Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)",[92],"2023-02-02","2023-04-20","2020-12-10",[7137],"Cold Urticaria",[2064,7139],"Non sedating H1-antihistamine",{"nctId":7141,"briefTitle":7142,"status":108,"phases":7143,"primaryCompletion":7144,"completion":7144,"start":7145,"enrollment":7146,"conditions":7147,"interventions":7148},"NCT03782532","Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma",[92],"2022-05-21","2019-01-25",486,[155],[2064,297,298],{"nctId":3926,"briefTitle":3927,"status":108,"phases":7150,"primaryCompletion":3929,"completion":3930,"start":3931,"enrollment":1809,"conditions":7151,"interventions":7152},[92],[3917],[2064,3919,3920,1501],{"nctId":7154,"briefTitle":7155,"status":108,"phases":7156,"primaryCompletion":5015,"completion":5015,"start":7157,"enrollment":7158,"conditions":7159,"interventions":7160},"NCT03620747","Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)",[92],"2018-08-30",393,[155],[2064],{"nctId":7162,"briefTitle":7163,"status":108,"phases":7164,"primaryCompletion":7165,"completion":1368,"start":7166,"enrollment":7167,"conditions":7168,"interventions":7169},"NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)",[92],"2024-08-01","2019-12-11",397,[337],[2064,7170],"non sedating H1-antihistamine",{"nctId":7172,"briefTitle":7173,"status":108,"phases":7174,"primaryCompletion":7175,"completion":2378,"start":7176,"enrollment":2998,"conditions":7177,"interventions":7182},"NCT04678856","Dupilumab in CRSsNP",[92],"2023-11-14","2020-12-02",[1678,7178,7179,7180,7181],"Sinusitis","Chronic Sinusitis","Sinus Disorder","Respiratory Disorder",[2064],{"nctId":7184,"briefTitle":7185,"status":108,"phases":7186,"primaryCompletion":7187,"completion":7188,"start":7189,"enrollment":6604,"conditions":7190,"interventions":7192},"NCT04684524","Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)",[92],"2024-12-14","2025-03-07","2020-12-01",[7191],"Allergic Fungal Rhinosinusitis",[2064],{"nctId":7194,"briefTitle":7195,"status":108,"phases":7196,"primaryCompletion":7197,"completion":7198,"start":7199,"enrollment":7200,"conditions":7201,"interventions":7202},"NCT03930732","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation",[92],"2023-02-08","2023-05-02","2019-04-15",939,[382],[2064,7203,7204,7205],"Inhaled Corticosteroid","Inhaled Long-Acting Beta Agonist","Inhaled Long-Acting Muscarinic Antagonist",{"nctId":7207,"briefTitle":7208,"status":108,"phases":7209,"primaryCompletion":1592,"completion":7210,"start":7211,"enrollment":7212,"conditions":7213,"interventions":7214},"NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation",[92],"2024-05-27","2020-07-06",935,[382],[2064,7203,7204,7205],{"trials":7216,"activeCount":102},[7217,7227,7235],{"nctId":7218,"briefTitle":7219,"status":108,"phases":7220,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7225,"interventions":7226},"NCT04718870","Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis",[93],"2022-09-07","2022-11-30","2021-02-19",41,[351],[2064],{"nctId":7228,"briefTitle":7229,"status":108,"phases":7230,"primaryCompletion":7231,"completion":7231,"start":7232,"enrollment":34,"conditions":7233,"interventions":7234},"NCT04447417","Dupilumab Skin Barrier Function Study in Atopic Dermatitis",[93],"2021-06-17","2020-07-16",[206],[2064],{"nctId":7236,"briefTitle":7237,"status":108,"phases":7238,"primaryCompletion":7239,"completion":7240,"start":7241,"enrollment":2636,"conditions":7242,"interventions":7243},"NCT05049122","Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)",[93],"2022-12-21","2023-07-05","2021-10-22",[273],[2064],{"trials":7245,"activeCount":619,"soonestReadout":7259},[7246,7255,7263],{"nctId":7247,"briefTitle":7248,"status":138,"phases":7249,"primaryCompletion":7250,"completion":7250,"start":7251,"enrollment":7252,"conditions":7253,"interventions":7254},"NCT03992417","Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)",[],"2027-03-31","2019-06-11",955,[351],[2064],{"nctId":7256,"briefTitle":7257,"status":279,"phases":7258,"primaryCompletion":7259,"completion":7260,"start":999,"enrollment":455,"conditions":7261,"interventions":7262},"NCT06087627","A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine",[],"2026-06-06","2026-12-28",[286],[2064],{"nctId":7264,"briefTitle":7265,"status":138,"phases":7266,"primaryCompletion":7267,"completion":7267,"start":7268,"enrollment":7269,"conditions":7270,"interventions":7271},"NCT04550962","Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)",[],"2026-07-01","2020-11-02",376,[155],[2064],{"intervention":7273,"totalTrials":1601,"cells":7274},"Alirocumab",{"EARLY_PHASE1":7275,"PHASE1":7277,"PHASE2":7302,"PHASE3":7324,"PHASE4":7443,"NA":7457},{"trials":7276,"activeCount":102},[],{"trials":7278,"activeCount":102},[7279,7288,7295],{"nctId":7280,"briefTitle":7281,"status":108,"phases":7282,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":1874,"conditions":7285,"interventions":7286},"NCT01723735","Effect of Alirocumab (SAR236553\u002FREGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects",[90],"2013-07","2012-11",[3892],[7273,3869,7287,3871],"Ezetimibe Placebo",{"nctId":7289,"briefTitle":7290,"status":108,"phases":7291,"primaryCompletion":3335,"completion":3335,"start":7292,"enrollment":6313,"conditions":7293,"interventions":7294},"NCT01448317","Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553\u002FREGN727) in Japanese Healthy Volunteers",[90],"2011-05",[3892],[7273,7273],{"nctId":7296,"briefTitle":7297,"status":108,"phases":7298,"primaryCompletion":3395,"completion":3395,"start":6471,"enrollment":576,"conditions":7299,"interventions":7300},"NCT01959971","Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol",[90],[3892],[7301],"alirocumab",{"trials":7303,"activeCount":102},[7304,7311,7317],{"nctId":7305,"briefTitle":7306,"status":108,"phases":7307,"primaryCompletion":986,"completion":986,"start":1339,"enrollment":7308,"conditions":7309,"interventions":7310},"NCT01288469","Efficacy and Safety Evaluation of Alirocumab (SAR236553\u002FREGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia",[91],92,[3892],[7273,3864],{"nctId":7312,"briefTitle":7313,"status":108,"phases":7314,"primaryCompletion":2855,"completion":2855,"start":2760,"enrollment":465,"conditions":7315,"interventions":7316},"NCT01812707","Efficacy and Safety Evaluation of Alirocumab (SAR236553\u002FREGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan",[91],[3892],[7273,3864],{"nctId":7318,"briefTitle":7319,"status":108,"phases":7320,"primaryCompletion":977,"completion":977,"start":1339,"enrollment":7321,"conditions":7322,"interventions":7323},"NCT01288443","Efficacy and Safety Evaluation of Alirocumab (SAR236553\u002FREGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy",[91],183,[3892],[7273,3864],{"trials":7325,"activeCount":102},[7326,7335,7345,7353,7359,7366,7377,7384,7393,7403,7413,7420,7426,7433],{"nctId":7327,"briefTitle":7328,"status":108,"phases":7329,"primaryCompletion":7330,"completion":7330,"start":2857,"enrollment":7331,"conditions":7332,"interventions":7333},"NCT01644175","Efficacy and Safety of Alirocumab (SAR236553\u002FREGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)",[92],"2014-04",316,[3892],[7273,7334],"Lipid-Modifying Therapy",{"nctId":7336,"briefTitle":7337,"status":108,"phases":7338,"primaryCompletion":7339,"completion":7339,"start":164,"enrollment":7340,"conditions":7341,"interventions":7343},"NCT01663402","ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab",[92],"2018-01-23",18924,[7342],"Atherosclerotic Cardiovascular Disease",[7273,7344],"LMT",{"nctId":7346,"briefTitle":7347,"status":108,"phases":7348,"primaryCompletion":1272,"completion":964,"start":7349,"enrollment":5913,"conditions":7350,"interventions":7351},"NCT01644188","Efficacy and Safety of Alirocumab (SAR236553\u002FREGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)",[92],"2012-08",[3892],[7273,3869,7352],"Lipid Modifying Therapy",{"nctId":7354,"briefTitle":7355,"status":108,"phases":7356,"primaryCompletion":1272,"completion":1031,"start":2834,"enrollment":2663,"conditions":7357,"interventions":7358},"NCT01617655","Efficacy and Safety of Alirocumab (SAR236553\u002FREGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)",[92],[3842],[7273,7352],{"nctId":7360,"briefTitle":7361,"status":108,"phases":7362,"primaryCompletion":7283,"completion":7283,"start":2857,"enrollment":7363,"conditions":7364,"interventions":7365},"NCT01644474","Efficacy and Safety of Alirocumab (SAR236553\u002FREGN727) Versus Ezetimibe in Patients With Hypercholesterolemia",[92],103,[3892],[7273,3869],{"nctId":7367,"briefTitle":7368,"status":108,"phases":7369,"primaryCompletion":7370,"completion":7371,"start":7372,"enrollment":7373,"conditions":7374,"interventions":7375},"NCT02584504","Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin",[92],"2017-04-05","2018-01-09","2015-11-30",163,[3892],[7273,3864,7376],"Non-statin Lipid-Modifying Therapy",{"nctId":7378,"briefTitle":7379,"status":108,"phases":7380,"primaryCompletion":150,"completion":150,"start":3335,"enrollment":7381,"conditions":7382,"interventions":7383},"NCT01507831","Long-term Safety and Tolerability of Alirocumab (SAR236553\u002FREGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)",[92],2341,[3892],[7273,7334],{"nctId":7385,"briefTitle":7386,"status":108,"phases":7387,"primaryCompletion":7388,"completion":7388,"start":7389,"enrollment":7390,"conditions":7391,"interventions":7392},"NCT01954394","Open Label Study of Long Term Safety Evaluation of Alirocumab",[92],"2017-06-30","2013-12-17",986,[3892],[7273,7334],{"nctId":7394,"briefTitle":7395,"status":108,"phases":7396,"primaryCompletion":7397,"completion":7388,"start":7398,"enrollment":7399,"conditions":7400,"interventions":7401},"NCT02023879","Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)",[92],"2014-10-27","2013-12-16",233,[3892],[7273,7402],"Non-statin LMT",{"nctId":7404,"briefTitle":7405,"status":108,"phases":7406,"primaryCompletion":7407,"completion":7407,"start":7408,"enrollment":7409,"conditions":7410,"interventions":7411},"NCT02585778","Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)",[92],"2017-04-03","2015-10-23",517,[3842],[7273,7334,7412],"Antihyperglycemic Drug",{"nctId":7414,"briefTitle":7415,"status":108,"phases":7416,"primaryCompletion":965,"completion":965,"start":1031,"enrollment":7417,"conditions":7418,"interventions":7419},"NCT02289963","Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan",[92],199,[3892],[7273,7334],{"nctId":7421,"briefTitle":7422,"status":108,"phases":7423,"primaryCompletion":1031,"completion":2824,"start":1055,"enrollment":1706,"conditions":7424,"interventions":7425},"NCT02107898","Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)",[92],[3892],[7273,7334],{"nctId":7427,"briefTitle":7428,"status":108,"phases":7429,"primaryCompletion":7330,"completion":7430,"start":2857,"enrollment":7146,"conditions":7431,"interventions":7432},"NCT01623115","Efficacy and Safety of Alirocumab (SAR236553\u002FREGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",[92],"2014-12",[3892],[7273,7352],{"nctId":7434,"briefTitle":7435,"status":108,"phases":7436,"primaryCompletion":2662,"completion":2662,"start":7437,"enrollment":7438,"conditions":7439,"interventions":7440},"NCT02715726","Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia",[92],"2016-07-27",615,[3892],[7273,3846,7441,7442,6459],"atorvastatin","rosuvastatin",{"trials":7444,"activeCount":102},[7445],{"nctId":7446,"briefTitle":7447,"status":108,"phases":7448,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":7453,"interventions":7455},"NCT02642159","Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)",[93],"2017-03-22","2017-05-15","2016-03-15",413,[7454],"Dyslipidemia",[7273,7456,3869,3871,3870,3872,7412],"Statins",{"trials":7458,"activeCount":195,"soonestReadout":7463},[7459],{"nctId":7460,"briefTitle":7461,"status":138,"phases":7462,"primaryCompletion":7463,"completion":7463,"start":7464,"enrollment":7465,"conditions":7466,"interventions":7468},"NCT07615179","Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)",[],"2026-05-30","2025-02-17",2214,[7467],"Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events",[7273,7469],"Comparator: No PCSK9i Therapy",{"intervention":1046,"totalTrials":6445,"cells":7471},{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7476,"PHASE3":7487,"PHASE4":7513,"NA":7541},{"trials":7473,"activeCount":102},[],{"trials":7475,"activeCount":102},[],{"trials":7477,"activeCount":102},[7478],{"nctId":7479,"briefTitle":7480,"status":108,"phases":7481,"completion":7482,"start":7483,"enrollment":6434,"conditions":7484,"interventions":7486},"NCT00637819","Leflunomide in Systemic Lupus Erythematosus",[91],"2004-07","2003-01",[7485],"Systemic Lupus Eythematosus (SLE)",[1046],{"trials":7488,"activeCount":102},[7489,7493,7497,7501,7505],{"nctId":1008,"briefTitle":1009,"status":108,"phases":7490,"primaryCompletion":1011,"completion":1011,"start":164,"enrollment":1012,"conditions":7491,"interventions":7492},[92],[990],[942,1015,993,1016,1017],{"nctId":6490,"briefTitle":6491,"status":108,"phases":7494,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":7495,"interventions":7496},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"nctId":1038,"briefTitle":1039,"status":108,"phases":7498,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":726,"conditions":7499,"interventions":7500},[92],[990],[942,1045,1046,1047,1048,1049],{"nctId":1051,"briefTitle":1052,"status":108,"phases":7502,"primaryCompletion":1042,"completion":1054,"start":1055,"enrollment":1056,"conditions":7503,"interventions":7504},[92],[1058],[942,971,1045,1046,1060],{"nctId":7506,"briefTitle":7507,"status":108,"phases":7508,"primaryCompletion":3354,"completion":3354,"start":7509,"enrollment":1583,"conditions":7510,"interventions":7512},"NCT00596206","Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis",[92],"2007-12",[7511],"Arthritis, Rheumatoid",[1017],{"trials":7514,"activeCount":102},[7515,7519,7526,7534],{"nctId":1074,"briefTitle":1075,"status":108,"phases":7516,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":7517,"interventions":7518},[93],[990],[1082,1083,1084,1060,1046,971,1045],{"nctId":7520,"briefTitle":7521,"status":108,"phases":7522,"completion":7523,"start":3539,"enrollment":26,"conditions":7524,"interventions":7525},"NCT00563849","Leflunomide + Methotrexate in Rheumatoid Arthritis",[93],"2004-08",[990],[1046],{"nctId":7527,"briefTitle":7528,"status":108,"phases":7529,"start":3489,"enrollment":7530,"conditions":7531,"interventions":7532},"NCT00451971","Objective Study in Rheumatoid Arthritis",[93],249,[7511],[7533],"LEFLUNOMIDE",{"nctId":7535,"briefTitle":7536,"status":108,"phases":7537,"start":7538,"enrollment":178,"conditions":7539,"interventions":7540},"NCT00280644","Leflunomide in Rheumatoid Arthritis",[93],"2004-04",[7511],[1046],{"trials":7542,"activeCount":195,"soonestReadout":7547},[7543],{"nctId":7544,"briefTitle":7545,"status":138,"phases":7546,"primaryCompletion":7547,"completion":7547,"start":7548,"enrollment":7549,"conditions":7550,"interventions":7552},"NCT06714461","A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia",[],"2026-05-31","2025-05-05",3500,[990,7551],"Psoriatic Arthritis",[1046],{"intervention":5020,"totalTrials":552,"cells":7554},{"EARLY_PHASE1":7555,"PHASE1":7557,"PHASE2":7559,"PHASE3":7571,"PHASE4":7643,"NA":7645},{"trials":7556,"activeCount":102},[],{"trials":7558,"activeCount":102},[],{"trials":7560,"activeCount":102},[7561],{"nctId":7562,"briefTitle":7563,"status":108,"phases":7564,"primaryCompletion":7565,"completion":7565,"start":7566,"enrollment":432,"conditions":7567,"interventions":7569},"NCT03205358","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers",[91],"2015-08-19","2015-03-31",[4992,7568,2922],"Meningococcal Meningitis",[5020,7570],"Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine",{"trials":7572,"activeCount":102},[7573,7585,7589,7601,7611,7621,7625,7634],{"nctId":7574,"briefTitle":7575,"status":108,"phases":7576,"primaryCompletion":7577,"completion":7577,"start":7578,"enrollment":7579,"conditions":7580,"interventions":7581},"NCT03890367","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers",[92],"2020-10-14","2019-09-12",707,[5167],[7582,7583,7584],"Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine","Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine","Meningococcal group C polysaccharide Conjugate vaccine adsorbed",{"nctId":5012,"briefTitle":5013,"status":108,"phases":7586,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":7587,"interventions":7588},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"nctId":7590,"briefTitle":7591,"status":108,"phases":7592,"primaryCompletion":7593,"completion":7594,"start":7595,"enrollment":7596,"conditions":7597,"interventions":7599},"NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49",[92],"2020-04-01","2022-05-25","2019-10-04",471,[7598],"Meningococcal Infection (Healthy Volunteers)",[7600],"Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine",{"nctId":7602,"briefTitle":7603,"status":108,"phases":7604,"primaryCompletion":7605,"completion":7605,"start":7606,"enrollment":7607,"conditions":7608,"interventions":7609},"NCT02842866","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older",[92],"2017-02-13","2016-07-15",907,[4992,7568,2922],[5020,7610],"Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined",{"nctId":7612,"briefTitle":7613,"status":108,"phases":7614,"primaryCompletion":7615,"completion":7615,"start":7616,"enrollment":7617,"conditions":7618,"interventions":7619},"NCT02955797","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers",[92],"2017-10-26","2017-02-24",918,[4992,7568,2922],[5020,7620,5020,7620],"Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine",{"nctId":5094,"briefTitle":5095,"status":108,"phases":7622,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":7623,"interventions":7624},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"nctId":7626,"briefTitle":7627,"status":108,"phases":7628,"primaryCompletion":7629,"completion":7629,"start":7630,"enrollment":7631,"conditions":7632,"interventions":7633},"NCT02752906","Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine",[92],"2016-12-19","2016-04-15",810,[4992,7568,2922],[5020,5102],{"nctId":7635,"briefTitle":7636,"status":108,"phases":7637,"primaryCompletion":7638,"completion":7638,"start":7606,"enrollment":7639,"conditions":7640,"interventions":7641},"NCT02842853","Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine",[92],"2017-02-28",3344,[4992,7568,2922],[5020,7642],"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"trials":7644,"activeCount":102},[],{"trials":7646,"activeCount":195,"soonestReadout":7651},[7647],{"nctId":7648,"briefTitle":7649,"status":279,"phases":7650,"primaryCompletion":7651,"completion":7651,"start":7652,"enrollment":7653,"conditions":7654,"interventions":7655},"NCT04843111","Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)",[],"2028-05-18","2021-03-05",50,[2949],[7656],"Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine",{"intervention":7658,"totalTrials":445,"cells":7659},"Olipudase alfa",{"EARLY_PHASE1":7660,"PHASE1":7662,"PHASE2":7664,"PHASE3":7675,"PHASE4":7677,"NA":7679},{"trials":7661,"activeCount":102},[],{"trials":7663,"activeCount":102},[],{"trials":7665,"activeCount":102},[7666],{"nctId":7667,"briefTitle":7668,"status":108,"phases":7669,"primaryCompletion":7670,"completion":7670,"start":7671,"enrollment":619,"conditions":7672,"interventions":7674},"NCT06949358","A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France",[91],"2025-04-08","2021-11-18",[7673],"Acid Sphingomyelinase Deficiency",[7658],{"trials":7676,"activeCount":102},[],{"trials":7678,"activeCount":102},[],{"trials":7680,"activeCount":195,"soonestReadout":7685},[7681,7690,7699],{"nctId":7682,"briefTitle":7683,"status":279,"phases":7684,"primaryCompletion":7685,"completion":7686,"start":3406,"enrollment":552,"conditions":7687,"interventions":7689},"NCT06192576","A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)",[],"2029-01-02","2029-01-15",[7688,7673],"Niemann-Pick Diseases",[7658],{"nctId":7691,"briefTitle":7692,"status":7693,"phases":7694,"conditions":7695,"interventions":7697},"NCT04877132","Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)","APPROVED_FOR_MARKETING",[],[7696],"Sphingomyelin Lipidosis",[7698],"olipudase alfa",{"nctId":7700,"briefTitle":7701,"status":108,"phases":7702,"primaryCompletion":7703,"completion":7703,"start":7704,"enrollment":98,"conditions":7705,"interventions":7707},"NCT05359276","Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France",[],"2024-12-31","2022-06-10",[7706],"Acid Sphingomyelinase Deficiency (ASMD)",[7658],{"intervention":7709,"totalTrials":195,"cells":7710},"Dengue Tetravalent Vaccine, Live",{"EARLY_PHASE1":7711,"PHASE1":7713,"PHASE2":7715,"PHASE3":7717,"PHASE4":7719,"NA":7721},{"trials":7712,"activeCount":102},[],{"trials":7714,"activeCount":102},[],{"trials":7716,"activeCount":102},[],{"trials":7718,"activeCount":102},[],{"trials":7720,"activeCount":102},[],{"trials":7722,"activeCount":195,"soonestReadout":7727},[7723],{"nctId":7724,"briefTitle":7725,"status":279,"phases":7726,"primaryCompletion":7727,"completion":7727,"start":7728,"enrollment":7729,"conditions":7730,"interventions":7732},"NCT04486638","Dengvaxia US Pregnancy Registry",[],"2029-06-30","2023-01-01",500,[7731],"Dengue Virus Infection",[7709],{"intervention":7734,"totalTrials":195,"cells":7735},"Cohort 1: Dupilumab",{"EARLY_PHASE1":7736,"PHASE1":7738,"PHASE2":7740,"PHASE3":7742,"PHASE4":7744,"NA":7746},{"trials":7737,"activeCount":102},[],{"trials":7739,"activeCount":102},[],{"trials":7741,"activeCount":102},[],{"trials":7743,"activeCount":102},[],{"trials":7745,"activeCount":102},[],{"trials":7747,"activeCount":195,"soonestReadout":7727},[7748],{"nctId":7749,"briefTitle":7750,"status":698,"phases":7751,"primaryCompletion":7727,"completion":7752,"start":453,"enrollment":474,"conditions":7753,"interventions":7755},"NCT07612878","The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry",[],"2029-11-30",[7754],"COPD (Chronic Obstructive Pulmonary Disease)",[7734],{"intervention":7757,"totalTrials":195,"cells":7758},"Efanesoctocog Alfa BIVV001",{"EARLY_PHASE1":7759,"PHASE1":7761,"PHASE2":7763,"PHASE3":7765,"PHASE4":7767,"NA":7769},{"trials":7760,"activeCount":102},[],{"trials":7762,"activeCount":102},[],{"trials":7764,"activeCount":102},[],{"trials":7766,"activeCount":102},[],{"trials":7768,"activeCount":102},[],{"trials":7770,"activeCount":195,"soonestReadout":562},[7771],{"nctId":7772,"briefTitle":7773,"status":138,"phases":7774,"primaryCompletion":562,"completion":7775,"start":7776,"enrollment":12,"conditions":7777,"interventions":7778},"NCT05911763","A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A",[],"2030-09-17","2023-06-30",[752],[7757],{"intervention":7780,"totalTrials":195,"cells":7781},"Alglucosidase alfa GZ419829",{"EARLY_PHASE1":7782,"PHASE1":7784,"PHASE2":7786,"PHASE3":7788,"PHASE4":7790,"NA":7792},{"trials":7783,"activeCount":102},[],{"trials":7785,"activeCount":102},[],{"trials":7787,"activeCount":102},[],{"trials":7789,"activeCount":102},[],{"trials":7791,"activeCount":102},[],{"trials":7793,"activeCount":195,"soonestReadout":7798},[7794],{"nctId":7795,"briefTitle":7796,"status":138,"phases":7797,"primaryCompletion":7798,"completion":7798,"start":7799,"enrollment":988,"conditions":7800,"interventions":7801},"NCT04848779","A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)",[],"2026-10-28","2021-06-10",[4222],[7780],{"intervention":7469,"totalTrials":195,"cells":7803},{"EARLY_PHASE1":7804,"PHASE1":7806,"PHASE2":7808,"PHASE3":7810,"PHASE4":7812,"NA":7814},{"trials":7805,"activeCount":102},[],{"trials":7807,"activeCount":102},[],{"trials":7809,"activeCount":102},[],{"trials":7811,"activeCount":102},[],{"trials":7813,"activeCount":102},[],{"trials":7815,"activeCount":195,"soonestReadout":7463},[7816],{"nctId":7460,"briefTitle":7461,"status":138,"phases":7817,"primaryCompletion":7463,"completion":7463,"start":7464,"enrollment":7465,"conditions":7818,"interventions":7819},[],[7467],[7273,7469],{"intervention":7821,"totalTrials":195,"cells":7822},"Efluelda® Pre-filled syringe",{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7829,"PHASE4":7831,"NA":7833},{"trials":7824,"activeCount":102},[],{"trials":7826,"activeCount":102},[],{"trials":7828,"activeCount":102},[],{"trials":7830,"activeCount":102},[],{"trials":7832,"activeCount":102},[],{"trials":7834,"activeCount":195,"soonestReadout":7839},[7835],{"nctId":7836,"briefTitle":7837,"status":698,"phases":7838,"primaryCompletion":7839,"completion":7840,"start":7841,"enrollment":7842,"conditions":7843,"interventions":7844},"NCT07282795","Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe",[],"2029-02-22","2029-03-20","2026-10-01",670,[5335,36],[7821],{"intervention":7846,"totalTrials":195,"cells":7847},"Nirsevimab Respiratory Syncytial Virus monoclonal antibody",{"EARLY_PHASE1":7848,"PHASE1":7850,"PHASE2":7852,"PHASE3":7854,"PHASE4":7856,"NA":7858},{"trials":7849,"activeCount":102},[],{"trials":7851,"activeCount":102},[],{"trials":7853,"activeCount":102},[],{"trials":7855,"activeCount":102},[],{"trials":7857,"activeCount":102},[],{"trials":7859,"activeCount":195,"soonestReadout":7864},[7860],{"nctId":7861,"briefTitle":7862,"status":698,"phases":7863,"primaryCompletion":7864,"completion":7864,"start":7865,"enrollment":2791,"conditions":7866,"interventions":7867},"NCT07615192","RSV Immunisation Status in Queensland (Australia)",[],"2026-07-20","2026-05-26",[918],[7846],{"intervention":7869,"totalTrials":195,"cells":7870},"Efluelda Tetra Pre-filled syringe",{"EARLY_PHASE1":7871,"PHASE1":7873,"PHASE2":7875,"PHASE3":7877,"PHASE4":7879,"NA":7881},{"trials":7872,"activeCount":102},[],{"trials":7874,"activeCount":102},[],{"trials":7876,"activeCount":102},[],{"trials":7878,"activeCount":102},[],{"trials":7880,"activeCount":102},[],{"trials":7882,"activeCount":195,"soonestReadout":7887},[7883],{"nctId":7884,"briefTitle":7885,"status":698,"phases":7886,"primaryCompletion":7887,"completion":7888,"start":7841,"enrollment":7842,"conditions":7889,"interventions":7892},"NCT06694025","Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.",[],"2027-12-31","2028-01-31",[7890,7891],"Immunization","Influenza (Healthy Volunteers)",[7869],{"intervention":7894,"totalTrials":195,"cells":7895},"avalglucosidase alfa-NGPT (GZ402666) IV",{"EARLY_PHASE1":7896,"PHASE1":7898,"PHASE2":7900,"PHASE3":7902,"PHASE4":7904,"NA":7906},{"trials":7897,"activeCount":102},[],{"trials":7899,"activeCount":102},[],{"trials":7901,"activeCount":102},[],{"trials":7903,"activeCount":102},[],{"trials":7905,"activeCount":102},[],{"trials":7907,"activeCount":195,"soonestReadout":7912},[7908],{"nctId":7909,"briefTitle":7910,"status":279,"phases":7911,"primaryCompletion":7912,"completion":7912,"start":7913,"enrollment":465,"conditions":7914,"interventions":7917},"NCT05734521","Avalglucosidase Alfa Pregnancy Study",[],"2032-10-31","2022-10-26",[7915,7916],"Pompe Disease","Pregnancy",[7894,7918],"avalglucosidase alfa-NGPT",{"intervention":7918,"totalTrials":195,"cells":7920},{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7927,"PHASE4":7929,"NA":7931},{"trials":7922,"activeCount":102},[],{"trials":7924,"activeCount":102},[],{"trials":7926,"activeCount":102},[],{"trials":7928,"activeCount":102},[],{"trials":7930,"activeCount":102},[],{"trials":7932,"activeCount":195,"soonestReadout":7912},[7933],{"nctId":7909,"briefTitle":7910,"status":279,"phases":7934,"primaryCompletion":7912,"completion":7912,"start":7913,"enrollment":465,"conditions":7935,"interventions":7936},[],[7915,7916],[7894,7918],{"intervention":7938,"totalTrials":195,"cells":7939},"Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine",{"EARLY_PHASE1":7940,"PHASE1":7942,"PHASE2":7944,"PHASE3":7946,"PHASE4":7948,"NA":7950},{"trials":7941,"activeCount":102},[],{"trials":7943,"activeCount":102},[],{"trials":7945,"activeCount":102},[],{"trials":7947,"activeCount":102},[],{"trials":7949,"activeCount":102},[],{"trials":7951,"activeCount":195,"soonestReadout":521},[7952],{"nctId":7953,"briefTitle":7954,"status":698,"phases":7955,"primaryCompletion":521,"completion":521,"start":7956,"enrollment":7957,"conditions":7958,"interventions":7959},"NCT07621653","Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea",[],"2026-05-27",706,[2894,36],[7938],{"intervention":7961,"totalTrials":195,"cells":7962},"Alirocumab 150 mg",{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7969,"PHASE4":7971,"NA":7973},{"trials":7964,"activeCount":102},[],{"trials":7966,"activeCount":102},[],{"trials":7968,"activeCount":102},[],{"trials":7970,"activeCount":102},[],{"trials":7972,"activeCount":102},[],{"trials":7974,"activeCount":195,"soonestReadout":926},[7975],{"nctId":7976,"briefTitle":7977,"status":138,"phases":7978,"primaryCompletion":926,"completion":926,"start":1963,"enrollment":1583,"conditions":7979,"interventions":7980},"NCT07615166","Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice",[],[7342],[7961,7981],"Inclisiran",{"intervention":7981,"totalTrials":195,"cells":7983},{"EARLY_PHASE1":7984,"PHASE1":7986,"PHASE2":7988,"PHASE3":7990,"PHASE4":7992,"NA":7994},{"trials":7985,"activeCount":102},[],{"trials":7987,"activeCount":102},[],{"trials":7989,"activeCount":102},[],{"trials":7991,"activeCount":102},[],{"trials":7993,"activeCount":102},[],{"trials":7995,"activeCount":195,"soonestReadout":926},[7996],{"nctId":7976,"briefTitle":7977,"status":138,"phases":7997,"primaryCompletion":926,"completion":926,"start":1963,"enrollment":1583,"conditions":7998,"interventions":7999},[],[7342],[7961,7981],{"intervention":8001,"totalTrials":195,"cells":8002},"TZIELD",{"EARLY_PHASE1":8003,"PHASE1":8005,"PHASE2":8007,"PHASE3":8009,"PHASE4":8011,"NA":8013},{"trials":8004,"activeCount":102},[],{"trials":8006,"activeCount":102},[],{"trials":8008,"activeCount":102},[],{"trials":8010,"activeCount":102},[],{"trials":8012,"activeCount":102},[],{"trials":8014,"activeCount":195,"soonestReadout":8019},[8015],{"nctId":8016,"briefTitle":8017,"status":279,"phases":8018,"primaryCompletion":8019,"completion":8019,"start":8020,"enrollment":12,"conditions":8021,"interventions":8022},"NCT06481904","Registry for Stage 2 Type 1 Diabetes",[],"2037-01-15","2024-09-27",[591],[8001],{"intervention":8024,"totalTrials":5195,"cells":8025},"Metformin",{"EARLY_PHASE1":8026,"PHASE1":8028,"PHASE2":8048,"PHASE3":8091,"PHASE4":8370,"NA":8493},{"trials":8027,"activeCount":102},[],{"trials":8029,"activeCount":102},[8030,8038],{"nctId":8031,"briefTitle":8032,"status":108,"phases":8033,"primaryCompletion":4967,"completion":4967,"start":1011,"enrollment":5521,"conditions":8034,"interventions":8035},"NCT02411825","Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients",[90],[19],[8036,8037],"SAR425899","metformin",{"nctId":8039,"briefTitle":8040,"status":108,"phases":8041,"primaryCompletion":8042,"completion":8042,"start":8043,"enrollment":1400,"conditions":8044,"interventions":8045},"NCT02803918","A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)",[90],"2020-01-27","2017-05-17",[19],[8046,8047,8024],"Lixisenatide","Basal Insulin",{"trials":8049,"activeCount":102},[8050,8058,8068,8075,8083],{"nctId":8051,"briefTitle":8052,"status":108,"phases":8053,"primaryCompletion":7283,"completion":7283,"start":5238,"enrollment":313,"conditions":8054,"interventions":8055},"NCT01596504","Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin",[91],[19],[8046,8056,8057,8024],"Liraglutide","Insulin Glargine",{"nctId":8059,"briefTitle":8060,"status":108,"phases":8061,"primaryCompletion":3438,"completion":3438,"start":8062,"enrollment":8063,"conditions":8064,"interventions":8065},"NCT01476475","Efficacy and Safety of Insulin Glargine\u002FLixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients",[91],"2011-11",323,[19],[8066,8067,8024],"Insulin glargine \u002Flixisenatide Fixed Ratio Combination","Insulin glargine",{"nctId":8069,"briefTitle":8070,"status":108,"phases":8071,"primaryCompletion":987,"completion":987,"start":5271,"enrollment":8072,"conditions":8073,"interventions":8074},"NCT01175473","Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes",[91],148,[19],[8046,8056,8024],{"nctId":8076,"briefTitle":8077,"status":108,"phases":8078,"primaryCompletion":8079,"completion":8079,"start":8080,"enrollment":190,"conditions":8081,"interventions":8082},"NCT02973321","A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus",[91],"2017-12-27","2016-12-02",[19],[8036,8056,8024],{"nctId":8084,"briefTitle":8085,"status":884,"phases":8086,"primaryCompletion":2759,"completion":2759,"start":151,"enrollment":659,"conditions":8087,"interventions":8089},"NCT02274740","Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients",[91],[8088],"Type II Diabetes Mellitus",[8090,8037],"LIXISENATIDE AVE0010",{"trials":8092,"activeCount":102},[8093,8102,8111,8120,8129,8135,8143,8152,8161,8171,8180,8192,8201,8211,8221,8231,8239,8246,8257,8266,8277,8285,8294,8304,8311,8320,8327,8336,8345,8353,8360],{"nctId":8094,"briefTitle":8095,"status":108,"phases":8096,"primaryCompletion":965,"completion":965,"start":7430,"enrollment":8097,"conditions":8098,"interventions":8099},"NCT02343926","Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin",[92],443,[19],[8100,8101,8037],"GEMIGLIPTIN LS15-0444","vildagliptin",{"nctId":8103,"briefTitle":8104,"status":108,"phases":8105,"primaryCompletion":8106,"completion":8106,"start":8107,"enrollment":8108,"conditions":8109,"interventions":8110},"NCT01517412","Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin",[92],"2013-05","2012-02",451,[19],[8046,8024],{"nctId":8112,"briefTitle":8113,"status":108,"phases":8114,"primaryCompletion":954,"completion":954,"start":3564,"enrollment":8115,"conditions":8116,"interventions":8118},"NCT00763815","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",[92],484,[8117],"Diabetes Mellitus Type 2",[8046,8119,8024],"Pioglitazone",{"nctId":8121,"briefTitle":8122,"status":108,"phases":8123,"primaryCompletion":7189,"completion":7189,"start":8124,"enrollment":8125,"conditions":8126,"interventions":8127},"NCT03798080","Comparison of the Efficacy and Safety of Insulin Glargine\u002FLixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin",[92],"2019-02-19",426,[19],[8128,8067,8024],"Insulin glargine\u002FLixisenatide",{"nctId":8130,"briefTitle":8131,"status":108,"phases":8132,"primaryCompletion":1339,"completion":1339,"start":3564,"enrollment":8115,"conditions":8133,"interventions":8134},"NCT00763451","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",[92],[22],[8046,8024],{"nctId":8136,"briefTitle":8137,"status":108,"phases":8138,"primaryCompletion":986,"completion":986,"start":3307,"enrollment":8139,"conditions":8140,"interventions":8141},"NCT00851903","Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial",[92],112,[22],[8057,8142,8024],"Sitagliptin",{"nctId":8144,"briefTitle":8145,"status":108,"phases":8146,"primaryCompletion":5044,"completion":5044,"start":8147,"enrollment":8148,"conditions":8149,"interventions":8150},"NCT02752412","Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs",[92],"2016-05-17",513,[19],[8128,8151,8024],"Insulin glargine U100",{"nctId":8153,"briefTitle":8154,"status":108,"phases":8155,"primaryCompletion":987,"completion":987,"start":8156,"enrollment":8157,"conditions":8158,"interventions":8159},"NCT00707031","GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",[92],"2008-06",639,[22],[8046,8160,8024],"Exenatide",{"nctId":8162,"briefTitle":8163,"status":108,"phases":8164,"primaryCompletion":8165,"completion":8165,"start":8166,"enrollment":8167,"conditions":8168,"interventions":8169},"NCT02058147","Efficacy and Safety of Insulin Glargine\u002F Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM",[92],"2015-06","2014-02",1170,[830],[8170,8067,8046,8024],"Insulin glargine\u002Flixisenatide Fixed Ratio Combination",{"nctId":8172,"briefTitle":8173,"status":108,"phases":8174,"completion":8175,"start":8176,"enrollment":465,"conditions":8177,"interventions":8178},"NCT00353691","Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus",[92],"2004-11","2002-10",[19],[8179,8037],"glimepiride",{"nctId":8181,"briefTitle":8182,"status":108,"phases":8183,"primaryCompletion":8175,"completion":8184,"start":8185,"enrollment":6655,"conditions":8186,"interventions":8188},"NCT00046462","Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment",[92],"2004-12","2001-11",[8187],"Diabetes Mellitus",[8189,8024,8190,8191],"Lantus","Glyburide","Thiazolidinedione",{"nctId":8193,"briefTitle":8194,"status":108,"phases":8195,"primaryCompletion":1339,"completion":1339,"start":8196,"enrollment":8197,"conditions":8198,"interventions":8199},"NCT00713830","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",[92],"2008-07",859,[22],[8046,8200,8024],"Sulfonylurea",{"nctId":8202,"briefTitle":8203,"status":108,"phases":8204,"primaryCompletion":8205,"start":8184,"enrollment":8206,"conditions":8207,"interventions":8208},"NCT00174642","Opposing Step-by-step Insulin Reinforcement to Intensified Strategy",[92],"2008-12",811,[22],[8057,8209,8024,8210],"Insulin Glulisine","insulin secretagogue",{"nctId":8212,"briefTitle":8213,"status":108,"phases":8214,"primaryCompletion":165,"completion":165,"start":8215,"enrollment":8216,"conditions":8217,"interventions":8218},"NCT00976937","24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years",[92],"2009-08",319,[19],[8046,8219,8142,8220,8024],"Lixisenatide Placebo","Sitagliptin Placebo",{"nctId":8222,"briefTitle":8223,"status":108,"phases":8224,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":8228,"interventions":8229},"NCT03798054","Evaluation of Insulin Glargine\u002FLixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)",[92],"2021-03-01","2019-02-15",878,[19],[8128,8067,8046,8024,8230],"SGLT2 inhibitor",{"nctId":8232,"briefTitle":8233,"status":3661,"phases":8234,"primaryCompletion":8235,"completion":8235,"start":3564,"enrollment":102,"conditions":8236,"interventions":8237},"NCT00754689","Study of Rimonabant\u002FMetformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes",[92],"2008-11",[22],[8238,8024],"Rimonabant",{"nctId":8240,"briefTitle":8241,"status":108,"phases":8242,"primaryCompletion":5306,"completion":5306,"start":3354,"enrollment":8243,"conditions":8244,"interventions":8245},"NCT00975286","24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine",[92],446,[19],[8046,8067,8024,8191],{"nctId":8247,"briefTitle":8248,"status":108,"phases":8249,"primaryCompletion":8250,"completion":8250,"start":8251,"enrollment":8252,"conditions":8253,"interventions":8254},"NCT03529123","Efficacy and Safety of the Insulin Glargine\u002FLixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)",[92],"2019-11-25","2018-06-19",247,[19],[8255,8256,8024,8209],"INSULIN GLARGINE\u002FLIXISENATIDE","INSULIN GLARGINE",{"nctId":8258,"briefTitle":8259,"status":108,"phases":8260,"primaryCompletion":1022,"completion":1022,"start":8261,"enrollment":8262,"conditions":8263,"interventions":8264},"NCT00924573","Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride",[92],"2009-05",189,[19],[8024,8265],"Glimepiride",{"nctId":8267,"briefTitle":8268,"status":884,"phases":8269,"primaryCompletion":8270,"completion":8270,"start":8271,"enrollment":8272,"conditions":8273,"interventions":8274},"NCT03761134","Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea",[92],"2020-04-29","2018-11-30",377,[19],[8275,8037,8276],"sotagliflozin","sulfonylurea",{"nctId":8278,"briefTitle":8279,"status":108,"phases":8280,"primaryCompletion":964,"completion":964,"start":2855,"enrollment":8281,"conditions":8282,"interventions":8283},"NCT02058160","Efficacy and Safety of the Insulin Glargine\u002FLixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes",[92],736,[830],[8284,8067,8024],"Insulin glargine\u002Flixisenatide",{"nctId":8286,"briefTitle":8287,"status":108,"phases":8288,"primaryCompletion":454,"completion":454,"start":8289,"enrollment":8290,"conditions":8291,"interventions":8292},"NCT05413369","iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)",[92],"2022-07-07",582,[19],[8128,8293,8024,8230],"IDegAsp",{"nctId":8295,"briefTitle":8296,"status":108,"phases":8297,"primaryCompletion":7430,"completion":7430,"start":8298,"enrollment":8299,"conditions":8300,"interventions":8301},"NCT01768559","Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients",[92],"2013-01",894,[830],[8046,8302,8303,8057,8024],"Insulin glulisine QD","Insulin glulisine TID",{"nctId":8305,"briefTitle":8306,"status":108,"phases":8307,"primaryCompletion":3821,"completion":3821,"start":8196,"enrollment":8308,"conditions":8309,"interventions":8310},"NCT00715624","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",[92],496,[22],[8046,8047,8024],{"nctId":8312,"briefTitle":8313,"status":884,"phases":8314,"primaryCompletion":8315,"completion":8315,"start":8316,"enrollment":8317,"conditions":8318,"interventions":8319},"NCT00690456","Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes",[92],"2009-02","2008-05",403,[22],[8238,8024],{"nctId":8321,"briefTitle":8322,"status":108,"phases":8323,"primaryCompletion":977,"completion":977,"start":3366,"enrollment":8324,"conditions":8325,"interventions":8326},"NCT01169779","Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin",[92],391,[19],[8046,8024,8200],{"nctId":8328,"briefTitle":8329,"status":108,"phases":8330,"primaryCompletion":8316,"completion":8316,"start":8331,"enrollment":8332,"conditions":8333,"interventions":8334},"NCT00272064","ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.",[92],"2005-10",352,[22],[8335,8067,8024],"Insulin glulisine",{"nctId":8337,"briefTitle":8338,"status":108,"phases":8339,"primaryCompletion":2855,"completion":2855,"start":8107,"enrollment":8340,"conditions":8341,"interventions":8342},"NCT01459809","Efficacy and Safety Comparison of Metformin\u002FGlimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients",[92],538,[22],[8343,8344],"GLIMEPIRIDE","METFORMIN",{"nctId":8346,"briefTitle":8347,"status":884,"phases":8348,"primaryCompletion":8235,"completion":8349,"start":5272,"enrollment":8350,"conditions":8351,"interventions":8352},"NCT00449605","A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes",[92],"2009-03",508,[22],[8238,8265,8024],{"nctId":8354,"briefTitle":8355,"status":108,"phases":8356,"primaryCompletion":165,"completion":165,"start":8156,"enrollment":8357,"conditions":8358,"interventions":8359},"NCT00712673","GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",[92],680,[22],[8046,8024],{"nctId":8361,"briefTitle":8362,"status":108,"phases":8363,"primaryCompletion":8364,"start":8365,"enrollment":8366,"conditions":8367,"interventions":8368},"NCT00783744","Insulin Glargine Combination Therapies in Type II Diabetics",[92],"2003-08","2001-12",375,[22],[8057,8265,8024,8369],"Insulin monotherapy with premixed insulin NPH 30\u002F70",{"trials":8371,"activeCount":102},[8372,8384,8391,8402,8410,8416,8426,8440,8449,8457,8467,8478,8485],{"nctId":8373,"briefTitle":8374,"status":108,"phases":8375,"primaryCompletion":8376,"completion":8376,"start":8377,"enrollment":8378,"conditions":8379,"interventions":8380},"NCT03359837","Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy",[93],"2020-06-29","2018-01-20",384,[19],[8256,8209,8381,8382,8383,8024],"Biphasic insulin aspart 30","Repaglinide","Acarbose",{"nctId":8385,"briefTitle":8386,"status":108,"phases":8387,"primaryCompletion":8388,"completion":8388,"start":8316,"enrollment":4760,"conditions":8389,"interventions":8390},"NCT00708578","Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)",[93],"2009-12",[19],[8265,8024,8057],{"nctId":8392,"briefTitle":8393,"status":108,"phases":8394,"primaryCompletion":8316,"start":8395,"enrollment":8396,"conditions":8397,"interventions":8398},"NCT00347100","Insulin Glargine in Type 2 Diabetic Patients",[93],"2006-06",387,[22],[8057,8190,8399,8400,8401,8024],"Glyclazide","Glimiperide","Glipizide",{"nctId":8403,"briefTitle":8404,"status":108,"phases":8405,"primaryCompletion":8406,"completion":8406,"start":8235,"enrollment":8407,"conditions":8408,"interventions":8409},"NCT00751114","Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients",[93],"2011-07",515,[22],[8057,8142,8024],{"nctId":8411,"briefTitle":8412,"status":108,"phases":8413,"primaryCompletion":3417,"completion":3417,"start":3608,"enrollment":17,"conditions":8414,"interventions":8415},"NCT00360698","Insulin Glulisine in Type 2 Diabetic Patients",[93],[22],[8057,8265,8209,8024],{"nctId":8417,"briefTitle":8418,"status":108,"phases":8419,"completion":8420,"start":8421,"enrollment":3471,"conditions":8422,"interventions":8423},"NCT00358124","Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy",[93],"2002-06","2001-01",[19],[8424,8425,8037],"insulin glargine","rosiglitazone",{"nctId":8427,"briefTitle":8428,"status":108,"phases":8429,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":8432,"interventions":8433},"NCT02954692","A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey",[93],"2017-12-22","2016-11-30",[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],"meglitinides","thiazolidinediones","alpha-glucosidase inhibitors","GLP1 Receptor Agonist","Dipeptidyl peptidase-IV (DPP-IV) inhibitors","Sodium-glucose transport-2 (SGLT-2) inhibitors",{"nctId":8441,"briefTitle":8442,"status":108,"phases":8443,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":513,"conditions":8446,"interventions":8447},"NCT02941367","Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan",[93],"2017-08-04","2017-02-23",[22],[8046,8200,8037,8448],"basal insulin",{"nctId":8450,"briefTitle":8451,"status":108,"phases":8452,"primaryCompletion":8453,"completion":8453,"start":1341,"enrollment":8454,"conditions":8455,"interventions":8456},"NCT00562172","Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)",[93],"2010-10",75,[19],[8067,8265,8024],{"nctId":8458,"briefTitle":8459,"status":108,"phases":8460,"primaryCompletion":8461,"completion":8461,"start":8462,"enrollment":8463,"conditions":8464,"interventions":8465},"NCT02836704","Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)",[93],"2018-04-26","2016-09-09",892,[22],[8256,8037,8466],"acarbose",{"nctId":8468,"briefTitle":8469,"status":108,"phases":8470,"primaryCompletion":8471,"completion":8471,"start":8472,"enrollment":8473,"conditions":8474,"interventions":8475},"NCT03794336","Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive",[93],"2020-12-14","2019-06-29",1293,[19],[8476,8383,8024,8477],"Alogliptin","Aspirin",{"nctId":8479,"briefTitle":8480,"status":108,"phases":8481,"primaryCompletion":164,"completion":2760,"start":3366,"enrollment":8482,"conditions":8483,"interventions":8484},"NCT01117350","Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure",[93],978,[22],[8067,8056,8024],{"nctId":8486,"briefTitle":8487,"status":108,"phases":8488,"primaryCompletion":151,"completion":151,"start":6471,"enrollment":442,"conditions":8489,"interventions":8490},"NCT02027753","Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy",[93],[22],[8256,8024,8491,8492],"DPP-4 inhibitor","Sulphonylurea",{"trials":8494,"activeCount":102},[],{"intervention":8209,"totalTrials":3510,"cells":8496},{"EARLY_PHASE1":8497,"PHASE1":8499,"PHASE2":8555,"PHASE3":8557,"PHASE4":8673,"NA":8807},{"trials":8498,"activeCount":102},[],{"trials":8500,"activeCount":102},[8501,8509,8516,8522,8529,8535,8542],{"nctId":8502,"briefTitle":8503,"status":108,"phases":8504,"primaryCompletion":8505,"completion":8505,"start":1341,"enrollment":655,"conditions":8506,"interventions":8507},"NCT01159353","Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart",[90],"2008-04",[19],[8335,8508],"Insulin aspart",{"nctId":8510,"briefTitle":8511,"status":108,"phases":8512,"completion":3489,"start":8365,"enrollment":576,"conditions":8513,"interventions":8515},"NCT00290043","Glulisine Pre- and Postmeal",[90],[8514],"Diabetes Mellitus Type 1",[8335],{"nctId":8517,"briefTitle":8518,"status":108,"phases":8519,"primaryCompletion":8184,"start":8175,"conditions":8520,"interventions":8521},"NCT00310297","Insulin Glulisine in Type 2 Diabetes Mellitus",[90],[19],[8209],{"nctId":8523,"briefTitle":8524,"status":108,"phases":8525,"primaryCompletion":8526,"start":7538,"conditions":8527,"interventions":8528},"NCT00297583","Insulin Glulisine in Type 1 Diabetes Mellitus",[90],"2004-05",[554],[8209],{"nctId":8530,"briefTitle":8531,"status":108,"phases":8532,"primaryCompletion":3633,"start":7538,"conditions":8533,"interventions":8534},"NCT00311077","Insulin Glulisine in Healthy Lean and Obese Subjects",[90],[8187],[8209],{"nctId":8536,"briefTitle":8537,"status":108,"phases":8538,"start":3527,"enrollment":284,"conditions":8539,"interventions":8541},"NCT00368394","Dose-Exposure-Response in Type 1 Diabetes Mellitus",[90],[8540],"Diabetes Mellitus, Type I",[8335],{"nctId":8543,"briefTitle":8544,"status":108,"phases":8545,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":359,"conditions":8548,"interventions":8550},"NCT02910518","A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus",[90],"2017-05-03","2017-02-17",[8549],"Type1 Diabetes Mellitus",[8335,8335,8508,8551,8552,8553,8554],"NPH insulin","Glucagon","Glucose","Heparin",{"trials":8556,"activeCount":102},[],{"trials":8558,"activeCount":102},[8559,8566,8575,8584,8588,8595,8603,8612,8616,8623,8630,8638,8645,8651,8655,8662],{"nctId":8560,"briefTitle":8561,"status":108,"phases":8562,"primaryCompletion":3622,"start":7482,"enrollment":8563,"conditions":8564,"interventions":8565},"NCT00272012","OPAL - Insulin Glulisine, Diabetes Mellitus",[92],396,[8117],[8335],{"nctId":8567,"briefTitle":8568,"status":884,"phases":8569,"primaryCompletion":8570,"completion":8570,"start":8505,"enrollment":402,"conditions":8571,"interventions":8573},"NCT00670228","Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction",[92],"2009-11",[8572],"AMI",[8057,8209,8574],"Standard Therapy",{"nctId":8576,"briefTitle":8577,"status":108,"phases":8578,"completion":8579,"start":7538,"enrollment":8580,"conditions":8581,"interventions":8582},"NCT00135057","Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin",[92],"2005-08",281,[22],[8583,8424],"insulin glulisine",{"nctId":8202,"briefTitle":8203,"status":108,"phases":8585,"primaryCompletion":8205,"start":8184,"enrollment":8206,"conditions":8586,"interventions":8587},[92],[22],[8057,8209,8024,8210],{"nctId":8589,"briefTitle":8590,"status":108,"phases":8591,"completion":3563,"start":7523,"enrollment":8592,"conditions":8593,"interventions":8594},"NCT00135096","Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin",[92],345,[22],[8583,8424],{"nctId":8596,"briefTitle":8597,"status":108,"phases":8598,"completion":3509,"start":8599,"enrollment":5407,"conditions":8600,"interventions":8602},"NCT00046150","12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.",[92],"2002-05",[8601],"Diabetes, Type I",[8335],{"nctId":8604,"briefTitle":8605,"status":108,"phases":8606,"primaryCompletion":8607,"start":8175,"enrollment":8608,"conditions":8609,"interventions":8610},"NCT00174668","Insulin Glulisine in Diabetes Mellitus, Type 2",[92],"2007-11",311,[22],[8209,8611,8057],"Insulin Therapy",{"nctId":8247,"briefTitle":8248,"status":108,"phases":8613,"primaryCompletion":8250,"completion":8250,"start":8251,"enrollment":8252,"conditions":8614,"interventions":8615},[92],[19],[8255,8256,8024,8209],{"nctId":8617,"briefTitle":8618,"status":108,"phases":8619,"start":3518,"enrollment":8620,"conditions":8621,"interventions":8622},"NCT00290927","Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus",[92],390,[22],[8583],{"nctId":8624,"briefTitle":8625,"status":108,"phases":8626,"start":8184,"enrollment":8627,"conditions":8628,"interventions":8629},"NCT00290979","Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus",[92],250,[578],[8583],{"nctId":8631,"briefTitle":8632,"status":108,"phases":8633,"primaryCompletion":8156,"start":2800,"enrollment":8634,"conditions":8635,"interventions":8636},"NCT00467376","Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus",[92],485,[8187],[8209,8637,8057],"Lispro",{"nctId":8639,"briefTitle":8640,"status":108,"phases":8641,"completion":8607,"start":7523,"enrollment":8642,"conditions":8643,"interventions":8644},"NCT00135083","Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus",[92],347,[22],[8583],{"nctId":8646,"briefTitle":8647,"status":108,"phases":8648,"completion":1341,"start":8579,"enrollment":8290,"conditions":8649,"interventions":8650},"NCT00135941","Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)",[92],[8187],[8424,8583],{"nctId":8328,"briefTitle":8329,"status":108,"phases":8652,"primaryCompletion":8316,"completion":8316,"start":8331,"enrollment":8332,"conditions":8653,"interventions":8654},[92],[22],[8335,8067,8024],{"nctId":8656,"briefTitle":8657,"status":108,"phases":8658,"primaryCompletion":7509,"start":8659,"enrollment":166,"conditions":8660,"interventions":8661},"NCT00397553","Insulin Glulisine, Diabetes Mellitus Type 1",[92],"2005-01",[578],[8335],{"nctId":8663,"briefTitle":8664,"status":108,"phases":8665,"primaryCompletion":8666,"completion":8666,"start":8667,"enrollment":8668,"conditions":8669,"interventions":8671},"NCT00115570","Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents",[92],"2006-11","2005-04",572,[8670],"Diabetes Mellitus, Insulin-Dependent",[8335,8672,8424,8551],"insulin lispro",{"trials":8674,"activeCount":102},[8675,8679,8689,8697,8703,8707,8713,8721,8727,8734,8741,8749,8758,8767,8773,8780,8787,8794,8800],{"nctId":8373,"briefTitle":8374,"status":108,"phases":8676,"primaryCompletion":8376,"completion":8376,"start":8377,"enrollment":8378,"conditions":8677,"interventions":8678},[93],[19],[8256,8209,8381,8382,8383,8024],{"nctId":8680,"briefTitle":8681,"status":108,"phases":8682,"primaryCompletion":8683,"completion":8683,"start":955,"enrollment":8684,"conditions":8685,"interventions":8686},"NCT01121835","Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study",[93],"2012-03",934,[22],[8256,8687,8688],"INSULIN GLULISINE","PREMIXED INSULIN",{"nctId":8690,"briefTitle":8691,"status":108,"phases":8692,"primaryCompletion":2857,"completion":2857,"start":8693,"enrollment":8694,"conditions":8695,"interventions":8696},"NCT01203111","Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs",[93],"2010-12",207,[22],[8256,8687],{"nctId":8698,"briefTitle":8699,"status":108,"phases":8700,"primaryCompletion":164,"completion":164,"start":7292,"enrollment":465,"conditions":8701,"interventions":8702},"NCT01202474","Apidra Children & Adolescents Study",[93],[578],[8687,8256],{"nctId":8411,"briefTitle":8412,"status":108,"phases":8704,"primaryCompletion":3417,"completion":3417,"start":3608,"enrollment":17,"conditions":8705,"interventions":8706},[93],[22],[8057,8265,8209,8024],{"nctId":8708,"briefTitle":8709,"status":884,"phases":8710,"primaryCompletion":3821,"completion":3821,"start":955,"enrollment":335,"conditions":8711,"interventions":8712},"NCT01081938","Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition",[93],[22],[8256,8687],{"nctId":8714,"briefTitle":8715,"status":108,"phases":8716,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":8717,"conditions":8718,"interventions":8719},"NCT01122979","Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.",[93],72,[22],[8256,8551,8687,8720],"Regular insulin",{"nctId":8722,"briefTitle":8723,"status":108,"phases":8724,"primaryCompletion":5238,"completion":5238,"start":5271,"enrollment":1574,"conditions":8725,"interventions":8726},"NCT01212913","Comparison of Insulin Glargine\u002FInsulin Glulisine Regimen to Insulin Aspart\u002FInsulin Aspart Protamine 30\u002F70 in Type 2 Diabetes Mellitus Patients (T2DM)",[93],[22],[8256,8687,8508],{"nctId":8728,"briefTitle":8729,"status":108,"phases":8730,"primaryCompletion":3366,"completion":3366,"start":8731,"enrollment":29,"conditions":8732,"interventions":8733},"NCT00964574","Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus",[93],"2009-07",[578],[8687,8256],{"nctId":8735,"briefTitle":8736,"status":108,"phases":8737,"primaryCompletion":3438,"completion":3438,"start":8731,"enrollment":8738,"conditions":8739,"interventions":8740},"NCT00965549","Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients",[93],463,[22],[8256,8508,8209],{"nctId":8742,"briefTitle":8743,"status":884,"phases":8744,"primaryCompletion":2857,"completion":2857,"start":8745,"enrollment":34,"conditions":8746,"interventions":8747},"NCT01079364","Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting",[93],"2010-01",[22],[8335,8067,8748],"Premixed insulin",{"nctId":8750,"briefTitle":8751,"status":108,"phases":8752,"primaryCompletion":1022,"completion":1022,"start":8753,"enrollment":8754,"conditions":8755,"interventions":8756},"NCT00384085","Insulin Glargine \"All to Target\" Trial",[93],"2006-05",588,[22],[8209,8057,8757,8209],"Premixed Insulin",{"nctId":8759,"briefTitle":8760,"status":108,"phases":8761,"primaryCompletion":3307,"completion":3307,"start":8762,"enrollment":8763,"conditions":8764,"interventions":8765},"NCT00607087","Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus",[93],"2008-01",289,[578],[8335,8766,8508],"Insulin lispro",{"nctId":8768,"briefTitle":8769,"status":108,"phases":8770,"start":8579,"enrollment":2858,"conditions":8771,"interventions":8772},"NCT00489190","APIDRA Registration Study",[93],[578],[8209],{"nctId":8774,"briefTitle":8775,"status":884,"phases":8776,"primaryCompletion":8235,"completion":8235,"start":8777,"enrollment":8620,"conditions":8778,"interventions":8779},"NCT00283049","Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control",[93],"2006-02",[22],[8057,8209],{"nctId":8781,"briefTitle":8782,"status":108,"phases":8783,"primaryCompletion":151,"completion":151,"start":3438,"enrollment":8784,"conditions":8785,"interventions":8786},"NCT01234597","Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day",[93],219,[22],[8256,8687],{"nctId":8788,"briefTitle":8789,"status":108,"phases":8790,"primaryCompletion":8298,"completion":8298,"start":987,"enrollment":8791,"conditions":8792,"interventions":8793},"NCT01204593","baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus",[93],206,[578],[8256,8687],{"nctId":8795,"briefTitle":8796,"status":108,"phases":8797,"primaryCompletion":8316,"completion":8316,"start":3563,"enrollment":432,"conditions":8798,"interventions":8799},"NCT00526513","Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus",[93],[8187],[8209],{"nctId":8801,"briefTitle":8802,"status":108,"phases":8803,"primaryCompletion":8205,"completion":8205,"start":3355,"enrollment":8804,"conditions":8805,"interventions":8806},"NCT00539448","Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study",[93],98,[578],[8424,8583],{"trials":8808,"activeCount":102},[],{"intervention":8810,"totalTrials":7224,"cells":8811},"LACTIC ACID",{"EARLY_PHASE1":8812,"PHASE1":8814,"PHASE2":8816,"PHASE3":8826,"PHASE4":9050,"NA":9077},{"trials":8813,"activeCount":102},[],{"trials":8815,"activeCount":102},[],{"trials":8817,"activeCount":102},[8818],{"nctId":8819,"briefTitle":8820,"status":108,"phases":8821,"primaryCompletion":8505,"start":8822,"enrollment":12,"conditions":8823,"interventions":8824},"NCT00679562","Lactacyd Radiance (Lactic Acid) Prophetic Patch Test",[91],"2008-03",[33],[8825],"Lactic Acid",{"trials":8827,"activeCount":102},[8828,8834,8842,8849,8855,8861,8867,8873,8879,8886,8892,8898,8904,8910,8916,8922,8928,8934,8940,8946,8952,8958,8964,8970,8976,8984,8989,8995,9001,9007,9013,9019,9025,9031,9037,9044],{"nctId":8829,"briefTitle":8830,"status":108,"phases":8831,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":4617,"conditions":8832,"interventions":8833},"NCT00933504","Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral",[92],[33],[8810],{"nctId":8835,"briefTitle":8836,"status":108,"phases":8837,"primaryCompletion":8762,"start":7509,"enrollment":2636,"conditions":8838,"interventions":8840},"NCT00668226","Dermacyd Delicata Pocket BR - Photo Evaluation",[92],[8839],"Healthy",[8841],"Lactic acid",{"nctId":8843,"briefTitle":8844,"status":108,"phases":8845,"primaryCompletion":8235,"start":8846,"enrollment":349,"conditions":8847,"interventions":8848},"NCT00784121","Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility",[92],"2008-10",[33],[8825],{"nctId":8850,"briefTitle":8851,"status":108,"phases":8852,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":6434,"conditions":8853,"interventions":8854},"NCT00933075","Dermacyd Silver Frutal (Lactic Acid) - Photo Evaluation.",[92],[33],[8810],{"nctId":8856,"briefTitle":8857,"status":108,"phases":8858,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":3740,"conditions":8859,"interventions":8860},"NCT00933413","Dermacyd Silver Frutal (Lactic Acid) - Acceptability.",[92],[33],[8810],{"nctId":8862,"briefTitle":8863,"status":108,"phases":8864,"primaryCompletion":8762,"start":7509,"enrollment":3740,"conditions":8865,"interventions":8866},"NCT00663273","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower",[92],[33],[8841],{"nctId":8868,"briefTitle":8869,"status":108,"phases":8870,"primaryCompletion":8235,"start":8846,"enrollment":6434,"conditions":8871,"interventions":8872},"NCT00783640","Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation",[92],[33],[8825],{"nctId":8874,"briefTitle":8875,"status":108,"phases":8876,"primaryCompletion":8316,"start":8505,"enrollment":703,"conditions":8877,"interventions":8878},"NCT00705276","Dermacyd Femina Delicata (Lactic Acid)- Photo Dermatological Evaluation of the Irritation and Sensitivity Potential",[92],[33],[8841],{"nctId":8880,"briefTitle":8881,"status":108,"phases":8882,"primaryCompletion":3564,"start":3564,"enrollment":8883,"conditions":8884,"interventions":8885},"NCT00783939","Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.",[92],31,[33],[8825],{"nctId":8887,"briefTitle":8888,"status":108,"phases":8889,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":6313,"conditions":8890,"interventions":8891},"NCT00933699","Dermacyd PH_DESILSTY_FL (Lactic Acid) - Acceptability - Stay on Floral.",[92],[33],[8810],{"nctId":8893,"briefTitle":8894,"status":108,"phases":8895,"primaryCompletion":8762,"start":7509,"enrollment":3740,"conditions":8896,"interventions":8897},"NCT00663390","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR",[92],[33],[8841],{"nctId":8899,"briefTitle":8900,"status":108,"phases":8901,"primaryCompletion":8762,"start":8607,"enrollment":2636,"conditions":8902,"interventions":8903},"NCT00668889","Dermacyd Tina Gel Tangerina Mix - Photo Evaluation",[92],[8839],[8841],{"nctId":8905,"briefTitle":8906,"status":108,"phases":8907,"primaryCompletion":3564,"completion":3564,"start":8196,"enrollment":5282,"conditions":8908,"interventions":8909},"NCT00784160","Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid)- Compatibility",[92],[33],[8825],{"nctId":8911,"briefTitle":8912,"status":108,"phases":8913,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":6434,"conditions":8914,"interventions":8915},"NCT00933842","Dermacyd PH_DESILSTY_FL (Lactic Acid) - Photo Evaluation - Stay on Floral",[92],[33],[8810],{"nctId":8917,"briefTitle":8918,"status":108,"phases":8919,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":4617,"conditions":8920,"interventions":8921},"NCT00933712","Dermacyd Silver Floral (Lactic Acid) - Compatibility.",[92],[33],[8810],{"nctId":8923,"briefTitle":8924,"status":108,"phases":8925,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":8883,"conditions":8926,"interventions":8927},"NCT00933569","Dermacyd Silver Floral (Lactic Acid) - Acceptability.",[92],[33],[8810],{"nctId":8929,"briefTitle":8930,"status":108,"phases":8931,"primaryCompletion":8762,"start":8607,"enrollment":2636,"conditions":8932,"interventions":8933},"NCT00668629","Dermacyd Tina Gel Sweet Flower - Photo Evaluation",[92],[8839],[8841],{"nctId":8935,"briefTitle":8936,"status":108,"phases":8937,"primaryCompletion":8762,"start":8607,"enrollment":34,"conditions":8938,"interventions":8939},"NCT00668460","Dermatological Evaluation of Topic Compatibility-Dermacyd Delicata Pocket BR",[92],[8839],[8841],{"nctId":8941,"briefTitle":8942,"status":108,"phases":8943,"primaryCompletion":8235,"start":8846,"enrollment":6434,"conditions":8944,"interventions":8945},"NCT00784069","Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation",[92],[33],[8825],{"nctId":8947,"briefTitle":8948,"status":108,"phases":8949,"primaryCompletion":3439,"start":8762,"enrollment":6313,"conditions":8950,"interventions":8951},"NCT00664391","Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze",[92],[33],[8841],{"nctId":8953,"briefTitle":8954,"status":108,"phases":8955,"primaryCompletion":8235,"start":8846,"enrollment":349,"conditions":8956,"interventions":8957},"NCT00783861","Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility",[92],[33],[8825],{"nctId":8959,"briefTitle":8960,"status":108,"phases":8961,"primaryCompletion":8762,"start":7509,"enrollment":34,"conditions":8962,"interventions":8963},"NCT00668668","Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Sweet Flower",[92],[33],[8841],{"nctId":8965,"briefTitle":8966,"status":108,"phases":8967,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":6434,"conditions":8968,"interventions":8969},"NCT00933257","Dermacyd PH_DESILSTY_FR (Lactic Acid) - Photo Evaluation - Stay on Frutal",[92],[33],[8810],{"nctId":8971,"briefTitle":8972,"status":108,"phases":8973,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":4617,"conditions":8974,"interventions":8975},"NCT00933946","Dermacyd Silver Frutal (Lactic Acid) - Compatibility.",[92],[33],[8810],{"nctId":8977,"briefTitle":8978,"status":108,"phases":8979,"primaryCompletion":8693,"completion":8693,"start":3366,"enrollment":8980,"conditions":8981,"interventions":8982},"NCT01158365","Dermacyd in Odor Reducing.",[92],230,[33],[8810,8983],"Glycerine Vegetal Soap Granado Traditional",{"nctId":8985,"briefTitle":8863,"status":108,"phases":8986,"primaryCompletion":8762,"start":7509,"enrollment":3740,"conditions":8987,"interventions":8988},"NCT00663325",[92],[33],[8841],{"nctId":8990,"briefTitle":8991,"status":108,"phases":8992,"primaryCompletion":3564,"completion":3564,"start":3417,"enrollment":703,"conditions":8993,"interventions":8994},"NCT00784056","Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation",[92],[33],[8825],{"nctId":8996,"briefTitle":8997,"status":108,"phases":8998,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":6434,"conditions":8999,"interventions":9000},"NCT00932984","Dermacyd Silver Floral (Lactic Acid) - Photo Evaluation",[92],[33],[8810],{"nctId":9002,"briefTitle":9003,"status":108,"phases":9004,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":6313,"conditions":9005,"interventions":9006},"NCT00932945","Dermacyd PH_DESILSTY_FR (Lactic Acid) - Acceptability - Stay on Frutal",[92],[33],[8810],{"nctId":9008,"briefTitle":9009,"status":108,"phases":9010,"primaryCompletion":8316,"start":8505,"enrollment":703,"conditions":9011,"interventions":9012},"NCT00705744","Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluation of the Irritation and Sensitivity Potential.",[92],[33],[8841],{"nctId":9014,"briefTitle":9015,"status":108,"phases":9016,"primaryCompletion":8316,"completion":8316,"start":8316,"enrollment":5195,"conditions":9017,"interventions":9018},"NCT00761800","Dermacyd Teen Care Tangerina Mix - Compatibility",[92],[33],[8841],{"nctId":9020,"briefTitle":9021,"status":108,"phases":9022,"primaryCompletion":8731,"completion":8731,"start":3307,"enrollment":4617,"conditions":9023,"interventions":9024},"NCT00933907","Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal",[92],[33],[8810],{"nctId":9026,"briefTitle":9027,"status":108,"phases":9028,"primaryCompletion":8762,"start":7509,"enrollment":34,"conditions":9029,"interventions":9030},"NCT00669058","Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Tangerina Mix",[92],[8839],[8841],{"nctId":9032,"briefTitle":9033,"status":108,"phases":9034,"primaryCompletion":3564,"completion":3564,"start":3417,"enrollment":703,"conditions":9035,"interventions":9036},"NCT00783666","Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation",[92],[33],[8825],{"nctId":9038,"briefTitle":9039,"status":108,"phases":9040,"primaryCompletion":3439,"start":8762,"enrollment":9041,"conditions":9042,"interventions":9043},"NCT00668486","Dermacyd Delicata Breeze - Photo Evaluation",[92],28,[8839],[8841],{"nctId":9045,"briefTitle":9046,"status":108,"phases":9047,"primaryCompletion":3439,"start":7509,"enrollment":34,"conditions":9048,"interventions":9049},"NCT00668577","Dermatological Evaluation of Topic Compatibility - Dermacyd Breeze",[92],[8839],[8841],{"trials":9051,"activeCount":102},[9052,9058,9065,9071],{"nctId":9053,"briefTitle":9054,"status":108,"phases":9055,"primaryCompletion":8349,"completion":8349,"start":8349,"enrollment":8883,"conditions":9056,"interventions":9057},"NCT00881270","Dermacyd Infantile - Acceptability.",[93],[33],[8810],{"nctId":9059,"briefTitle":9060,"status":108,"phases":9061,"primaryCompletion":3417,"completion":3417,"start":8156,"enrollment":9062,"conditions":9063,"interventions":9064},"NCT00712868","Acceptability of Lactacyd Femina",[93],559,[33],[8841],{"nctId":9066,"briefTitle":9067,"status":108,"phases":9068,"primaryCompletion":8349,"completion":8349,"start":8315,"enrollment":7653,"conditions":9069,"interventions":9070},"NCT00881374","Dermacyd Infantile (Lactic Acid)- Compatibility.",[93],[33],[8810],{"nctId":9072,"briefTitle":9073,"status":108,"phases":9074,"primaryCompletion":8349,"completion":8349,"start":8315,"enrollment":2636,"conditions":9075,"interventions":9076},"NCT00881348","Dermacyd Infantile (Lactic Acid) - Photo Evaluation.",[93],[33],[8810],{"trials":9078,"activeCount":102},[],{"intervention":5286,"totalTrials":9041,"cells":9080},{"EARLY_PHASE1":9081,"PHASE1":9083,"PHASE2":9085,"PHASE3":9213,"PHASE4":9286,"NA":9301},{"trials":9082,"activeCount":102},[],{"trials":9084,"activeCount":102},[],{"trials":9086,"activeCount":102},[9087,9094,9098,9105,9109,9117,9126,9135,9142,9150,9161,9168,9172,9179,9186,9194,9201,9205],{"nctId":9088,"briefTitle":9089,"status":108,"phases":9090,"primaryCompletion":3608,"completion":3608,"start":3488,"enrollment":576,"conditions":9091,"interventions":9093},"NCT00263354","Oxaliplatin in Gastric Cancer",[91],[9092],"Stomach Neoplasms",[5286],{"nctId":5235,"briefTitle":5236,"status":3661,"phases":9095,"primaryCompletion":5238,"completion":5238,"start":3354,"enrollment":102,"conditions":9096,"interventions":9097},[91],[5240],[5242,5243,5244,5245],{"nctId":9099,"briefTitle":9100,"status":108,"phases":9101,"start":8331,"enrollment":391,"conditions":9102,"interventions":9104},"NCT00261092","GEMOX: Oxaliplatin in Pancreatic Cancer",[91],[9103],"Pancreatic Neoplasms",[5286],{"nctId":5247,"briefTitle":5248,"status":108,"phases":9106,"completion":5250,"start":5251,"enrollment":5252,"conditions":9107,"interventions":9108},[91],[5254],[5256,5257,5223],{"nctId":9110,"briefTitle":9111,"status":108,"phases":9112,"primaryCompletion":3622,"completion":3622,"start":9113,"enrollment":4628,"conditions":9114,"interventions":9116},"NCT00174564","EXIBIT: Oxaliplatin in Biliary Tract Cancer",[91],"2003-04",[9115],"Biliary Tract Neoplasms",[5256],{"nctId":9118,"briefTitle":9119,"status":884,"phases":9120,"primaryCompletion":8364,"start":7483,"enrollment":6445,"conditions":9121,"interventions":9123},"NCT00782041","Patients Who Have Failed First Line Treatment for Locally Advanced and\u002For Metastatic Cervical Cancer",[91],[9122],"Uterine Neoplasms",[5286,9124,9125],"5-FluoroUracil","Folinic acid",{"nctId":9127,"briefTitle":9128,"status":108,"phases":9129,"primaryCompletion":8846,"completion":8846,"start":9130,"enrollment":7224,"conditions":9131,"interventions":9133},"NCT00436800","Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma",[91],"2005-03",[9132],"Nasopharyngeal Neoplasms",[9134,5286],"Gemcitabine",{"nctId":9136,"briefTitle":9137,"status":108,"phases":9138,"primaryCompletion":8666,"start":7482,"conditions":9139,"interventions":9141},"NCT00280618","Oxaliplatin in Unresectable Hepatocellular Carcinoma",[91],[9140],"Carcinoma, Hepatocellular",[5286],{"nctId":9143,"briefTitle":9144,"status":108,"phases":9145,"primaryCompletion":8745,"completion":8745,"start":1341,"enrollment":112,"conditions":9146,"interventions":9147},"NCT00559455","Phase II Study of Eloxatin+5-FU\u002FLV in Patients With Unresectable Hepatocellular Carcinoma",[91],[9140],[5286,9148,9149],"Fluorouracil","Leucovorin",{"nctId":9151,"briefTitle":9152,"status":108,"phases":9153,"primaryCompletion":2790,"completion":3335,"start":8315,"enrollment":9154,"conditions":9155,"interventions":9157},"NCT00851084","Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer",[91],268,[5240,9156],"Neoplasm Metastasis",[9158,5256,9159,9160],"aflibercept","5-FU","Folinic Acid",{"nctId":9162,"briefTitle":9163,"status":108,"phases":9164,"primaryCompletion":5238,"completion":5238,"start":8205,"enrollment":7224,"conditions":9165,"interventions":9166},"NCT00816543","Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma",[91],[5395],[2763,9167,5242],"S-1",{"nctId":5279,"briefTitle":5280,"status":108,"phases":9169,"primaryCompletion":5271,"completion":5271,"start":3608,"enrollment":5282,"conditions":9170,"interventions":9171},[91],[5284],[1348,5286,5206],{"nctId":9173,"briefTitle":9174,"status":884,"phases":9175,"primaryCompletion":8395,"start":8176,"enrollment":37,"conditions":9176,"interventions":9178},"NCT00259363","Oxaliplatin in Rectal Cancer",[90,91],[9177],"Rectal Neoplasms",[5286],{"nctId":9180,"briefTitle":9181,"status":108,"phases":9182,"primaryCompletion":3623,"completion":3623,"start":9183,"enrollment":112,"conditions":9184,"interventions":9185},"NCT00403624","Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer",[90,91],"2001-07",[9177],[5242],{"nctId":9187,"briefTitle":9188,"status":108,"phases":9189,"primaryCompletion":9190,"completion":9190,"start":3367,"enrollment":2411,"conditions":9191,"interventions":9193},"NCT00094965","Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function",[91],"2007-08",[9192],"Gastrointestinal Cancer",[5286],{"nctId":9195,"briefTitle":9196,"status":108,"phases":9197,"primaryCompletion":5272,"start":8420,"enrollment":284,"conditions":9198,"interventions":9199},"NCT00263029","Preoperative Radiotherapy\u002F Oxaliplatin\u002F Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer",[91],[9177],[5286,9200],"Capecitabine",{"nctId":5303,"briefTitle":5304,"status":108,"phases":9202,"primaryCompletion":5306,"completion":5306,"start":5307,"enrollment":5308,"conditions":9203,"interventions":9204},[91],[5310],[5206,1348,5286],{"nctId":9206,"briefTitle":9207,"status":884,"phases":9208,"primaryCompletion":1011,"completion":1011,"start":6471,"enrollment":445,"conditions":9209,"interventions":9211},"NCT01955629","Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient",[90,91],[9210],"Colorectal Cancer Metastatic",[9212,5286,9200],"Aflibercept AVE0005",{"trials":9214,"activeCount":102},[9215,9224,9235,9245,9252,9261,9271,9278],{"nctId":9216,"briefTitle":9217,"status":3661,"phases":9218,"primaryCompletion":8166,"completion":2759,"start":8406,"enrollment":102,"conditions":9219,"interventions":9221},"NCT01245582","Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients",[92],[9220],"Hepatic Neoplasm Malignant",[5256,9222,9223],"capecitabine","sorafenib",{"nctId":9225,"briefTitle":9226,"status":108,"phases":9227,"primaryCompletion":3354,"completion":3354,"start":3565,"enrollment":9228,"conditions":9229,"interventions":9232},"NCT00305188","Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin \u002F 5FU\u002FLV Chemotherapy.",[92],879,[9230,5240,9231],"Metastases","Colorectal Carcinoma",[9233,5286,9234,9149],"Xaliproden","5-Fluorouracil",{"nctId":9236,"briefTitle":9237,"status":108,"phases":9238,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":9242,"conditions":9243,"interventions":9244},"NCT01515748","Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer",[92],"2019-01-21","2021-12-13","2011-12-30",530,[5395],[1348,5286,9167],{"nctId":9246,"briefTitle":9247,"status":108,"phases":9248,"primaryCompletion":7284,"completion":7284,"start":8395,"enrollment":9249,"conditions":9250,"interventions":9251},"NCT00411229","Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer",[92],1035,[9092],[9200,5286],{"nctId":9253,"briefTitle":9254,"status":108,"phases":9255,"primaryCompletion":9113,"completion":9113,"start":9256,"enrollment":9257,"conditions":9258,"interventions":9260},"NCT00275210","MOSAIC - Multicenter International Study of Oxaliplatin\u002F 5FU-LV in the Adjuvant Treatment of Colon Cancer",[92],"1998-10",2246,[9259],"Colonic Neoplasms",[5286],{"nctId":9262,"briefTitle":9263,"status":529,"phases":9264,"start":9265,"conditions":9266,"interventions":9267},"NCT00008281","Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer",[92],"2000-10",[5254],[9268,9269,9270,5256],"FOLFOX regimen","fluorouracil","leucovorin calcium",{"nctId":9272,"briefTitle":9273,"status":108,"phases":9274,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":9275,"conditions":9276,"interventions":9277},"NCT01121848","Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer",[92],108,[9103],[9149,5242,9234],{"nctId":9279,"briefTitle":9280,"status":108,"phases":9281,"completion":8846,"start":9282,"conditions":9283,"interventions":9284},"NCT00012389","Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer",[92],"2000-12",[5254],[9285,5256],"irinotecan hydrochloride",{"trials":9287,"activeCount":102},[9288,9295],{"nctId":9289,"briefTitle":9290,"status":884,"phases":9291,"completion":7509,"start":9292,"enrollment":680,"conditions":9293,"interventions":9294},"NCT00129870","CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium\u002FMagnesium in First-Line Metastatic Colorectal Cancer",[93],"2005-02",[5254],[5256],{"nctId":9296,"briefTitle":9297,"status":108,"phases":9298,"primaryCompletion":5250,"start":7523,"conditions":9299,"interventions":9300},"NCT00263055","MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin\u002F5FU-LV",[93],[9259],[5256],{"trials":9302,"activeCount":102},[],{"intervention":8046,"totalTrials":6434,"cells":9304},{"EARLY_PHASE1":9305,"PHASE1":9307,"PHASE2":9326,"PHASE3":9343,"PHASE4":9446,"NA":9452},{"trials":9306,"activeCount":102},[],{"trials":9308,"activeCount":102},[9309,9315,9322],{"nctId":9310,"briefTitle":9311,"status":108,"phases":9312,"primaryCompletion":8215,"completion":8215,"start":3307,"enrollment":1601,"conditions":9313,"interventions":9314},"NCT00931372","Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2",[90],[22],[8046],{"nctId":9316,"briefTitle":9317,"status":108,"phases":9318,"primaryCompletion":1055,"completion":1055,"start":5238,"enrollment":9319,"conditions":9320,"interventions":9321},"NCT01572649","Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes",[90],24,[19],[8046],{"nctId":8039,"briefTitle":8040,"status":108,"phases":9323,"primaryCompletion":8042,"completion":8042,"start":8043,"enrollment":1400,"conditions":9324,"interventions":9325},[90],[19],[8046,8047,8024],{"trials":9327,"activeCount":102},[9328,9332,9339],{"nctId":8051,"briefTitle":8052,"status":108,"phases":9329,"primaryCompletion":7283,"completion":7283,"start":5238,"enrollment":313,"conditions":9330,"interventions":9331},[91],[19],[8046,8056,8057,8024],{"nctId":9333,"briefTitle":9334,"status":108,"phases":9335,"primaryCompletion":9190,"completion":9190,"start":8777,"enrollment":5293,"conditions":9336,"interventions":9337},"NCT00299871","Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus",[91],[830],[9338],"LIXISENATIDE",{"nctId":8069,"briefTitle":8070,"status":108,"phases":9340,"primaryCompletion":987,"completion":987,"start":5271,"enrollment":8072,"conditions":9341,"interventions":9342},[91],[19],[8046,8056,8024],{"trials":9344,"activeCount":102},[9345,9349,9353,9357,9361,9370,9376,9380,9387,9391,9395,9399,9405,9409,9416,9420,9426,9430,9434,9442],{"nctId":8103,"briefTitle":8104,"status":108,"phases":9346,"primaryCompletion":8106,"completion":8106,"start":8107,"enrollment":8108,"conditions":9347,"interventions":9348},[92],[19],[8046,8024],{"nctId":8112,"briefTitle":8113,"status":108,"phases":9350,"primaryCompletion":954,"completion":954,"start":3564,"enrollment":8115,"conditions":9351,"interventions":9352},[92],[8117],[8046,8119,8024],{"nctId":8130,"briefTitle":8131,"status":108,"phases":9354,"primaryCompletion":1339,"completion":1339,"start":3564,"enrollment":8115,"conditions":9355,"interventions":9356},[92],[22],[8046,8024],{"nctId":8153,"briefTitle":8154,"status":108,"phases":9358,"primaryCompletion":987,"completion":987,"start":8156,"enrollment":8157,"conditions":9359,"interventions":9360},[92],[22],[8046,8160,8024],{"nctId":9362,"briefTitle":9363,"status":108,"phases":9364,"primaryCompletion":2825,"completion":2825,"start":9365,"enrollment":9366,"conditions":9367,"interventions":9368},"NCT02749890","Efficacy and Safety of the Insulin Glargine\u002FLixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan",[92],"2016-05-09",321,[19],[8128,8046,9369],"Oral anti-diabetic drugs",{"nctId":9371,"briefTitle":9372,"status":108,"phases":9373,"primaryCompletion":3395,"completion":3395,"start":164,"enrollment":4045,"conditions":9374,"interventions":9375},"NCT01632163","Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +\u002F- Metformin",[92],[19],[8046],{"nctId":8162,"briefTitle":8163,"status":108,"phases":9377,"primaryCompletion":8165,"completion":8165,"start":8166,"enrollment":8167,"conditions":9378,"interventions":9379},[92],[830],[8170,8067,8046,8024],{"nctId":9381,"briefTitle":9382,"status":108,"phases":9383,"primaryCompletion":1042,"completion":1042,"start":152,"enrollment":474,"conditions":9384,"interventions":9385},"NCT01798706","Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and\u002For Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients",[92],[830],[8046,9386],"Antidiabetic background therapy",{"nctId":8193,"briefTitle":8194,"status":108,"phases":9388,"primaryCompletion":1339,"completion":1339,"start":8196,"enrollment":8197,"conditions":9389,"interventions":9390},[92],[22],[8046,8200,8024],{"nctId":8212,"briefTitle":8213,"status":108,"phases":9392,"primaryCompletion":165,"completion":165,"start":8215,"enrollment":8216,"conditions":9393,"interventions":9394},[92],[19],[8046,8219,8142,8220,8024],{"nctId":8222,"briefTitle":8223,"status":108,"phases":9396,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":9397,"interventions":9398},[92],[19],[8128,8067,8046,8024,8230],{"nctId":9400,"briefTitle":9401,"status":108,"phases":9402,"primaryCompletion":1339,"completion":1339,"start":8261,"enrollment":369,"conditions":9403,"interventions":9404},"NCT00905255","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)",[92],[22],[8046],{"nctId":8240,"briefTitle":8241,"status":108,"phases":9406,"primaryCompletion":5306,"completion":5306,"start":3354,"enrollment":8243,"conditions":9407,"interventions":9408},[92],[19],[8046,8067,8024,8191],{"nctId":9410,"briefTitle":9411,"status":108,"phases":9412,"primaryCompletion":8388,"completion":8388,"start":8316,"enrollment":9413,"conditions":9414,"interventions":9415},"NCT00688701","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy",[92],361,[22],[8046],{"nctId":8295,"briefTitle":8296,"status":108,"phases":9417,"primaryCompletion":7430,"completion":7430,"start":8298,"enrollment":8299,"conditions":9418,"interventions":9419},[92],[830],[8046,8302,8303,8057,8024],{"nctId":9421,"briefTitle":9422,"status":108,"phases":9423,"primaryCompletion":978,"completion":978,"start":8349,"enrollment":8608,"conditions":9424,"interventions":9425},"NCT00866658","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +\u002F- Sulfonylurea (GETGOAL-L-ASIA)",[92],[22],[8046,8200,8047],{"nctId":8305,"briefTitle":8306,"status":108,"phases":9427,"primaryCompletion":3821,"completion":3821,"start":8196,"enrollment":8308,"conditions":9428,"interventions":9429},[92],[22],[8046,8047,8024],{"nctId":8321,"briefTitle":8322,"status":108,"phases":9431,"primaryCompletion":977,"completion":977,"start":3366,"enrollment":8324,"conditions":9432,"interventions":9433},[92],[19],[8046,8024,8200],{"nctId":9435,"briefTitle":9436,"status":108,"phases":9437,"primaryCompletion":1042,"completion":1042,"start":978,"enrollment":9438,"conditions":9439,"interventions":9441},"NCT01147250","Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)",[92],6068,[9440],"Acute Coronary Syndrome",[8046],{"nctId":8354,"briefTitle":8355,"status":108,"phases":9443,"primaryCompletion":165,"completion":165,"start":8156,"enrollment":8357,"conditions":9444,"interventions":9445},[92],[22],[8046,8024],{"trials":9447,"activeCount":102},[9448],{"nctId":8441,"briefTitle":8442,"status":108,"phases":9449,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":513,"conditions":9450,"interventions":9451},[93],[22],[8046,8200,8037,8448],{"trials":9453,"activeCount":102},[],{"intervention":9455,"totalTrials":2636,"cells":9456},"Clopidogrel",{"EARLY_PHASE1":9457,"PHASE1":9459,"PHASE2":9507,"PHASE3":9526,"PHASE4":9630,"NA":9663},{"trials":9458,"activeCount":102},[],{"trials":9460,"activeCount":102},[9461,9467,9473,9481,9488,9494,9501],{"nctId":9462,"briefTitle":9463,"status":108,"phases":9464,"primaryCompletion":8261,"completion":8261,"start":8349,"enrollment":6313,"conditions":9465,"interventions":9466},"NCT01129063","Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects",[90],[8839],[9455],{"nctId":9468,"briefTitle":9469,"status":108,"phases":9470,"primaryCompletion":8215,"completion":8215,"start":3307,"enrollment":8717,"conditions":9471,"interventions":9472},"NCT01129414","Interaction Study of Clopidogrel 600\u002F150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects",[90],[8839],[9455,1406],{"nctId":9474,"briefTitle":9475,"status":108,"phases":9476,"primaryCompletion":8261,"completion":8261,"start":8349,"enrollment":8717,"conditions":9477,"interventions":9478},"NCT01129388","Interaction Study of Clopidogrel 300\u002F75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects",[90],[8839],[9479,9480],"clopidogrel","omeprazole",{"nctId":9482,"briefTitle":9483,"status":108,"phases":9484,"primaryCompletion":8570,"completion":8570,"start":8215,"enrollment":1676,"conditions":9485,"interventions":9486},"NCT01129427","Interaction Study of Clopidogrel 300\u002F75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects",[90],[8839],[9455,9487],"Pantoprazole",{"nctId":9489,"briefTitle":9490,"status":108,"phases":9491,"primaryCompletion":3307,"completion":3307,"start":3396,"enrollment":8717,"conditions":9492,"interventions":9493},"NCT01129271","Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300\u002F75 mg in Healthy Subjects",[90],[8839],[9479],{"nctId":9495,"briefTitle":9496,"status":108,"phases":9497,"primaryCompletion":8215,"completion":8215,"start":3396,"enrollment":98,"conditions":9498,"interventions":9499},"NCT01123824","Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects",[90],[8839],[9500],"CLOPIDOGREL",{"nctId":9502,"briefTitle":9503,"status":108,"phases":9504,"primaryCompletion":8261,"completion":8261,"start":8315,"enrollment":8717,"conditions":9505,"interventions":9506},"NCT01129375","Interaction Study of Clopidogrel 300\u002F75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects",[90],[8839],[9479,9480],{"trials":9508,"activeCount":102},[9509,9518],{"nctId":9510,"briefTitle":9511,"status":108,"phases":9512,"completion":9513,"start":3527,"enrollment":7308,"conditions":9514,"interventions":9517},"NCT00115375","Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)",[91],"2006-04",[9515,9516],"Congenital Heart Defects","Blood Platelet Disorders",[9455],{"nctId":9519,"briefTitle":9520,"status":108,"phases":9521,"primaryCompletion":9292,"completion":9292,"start":9522,"enrollment":599,"conditions":9523,"interventions":9525},"NCT00360386","ALBION \"Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis\"",[91],"2004-03",[9524],"Ischemia",[9455],{"trials":9527,"activeCount":102},[9528,9537,9547,9555,9565,9573,9581,9588,9596,9604,9614,9622],{"nctId":9529,"briefTitle":9530,"status":108,"phases":9531,"primaryCompletion":3366,"completion":3366,"start":9532,"enrollment":9533,"conditions":9534,"interventions":9536},"NCT00833703","Long Term Safety of Clopidogrel in Neonates\u002FInfants With Systemic to Pulmonary Artery Shunt Palliation",[92],"2009-01",49,[9535],"Heart Defects, Congenital",[9455],{"nctId":9538,"briefTitle":9539,"status":108,"phases":9540,"primaryCompletion":5271,"completion":5271,"start":8205,"enrollment":9541,"conditions":9542,"interventions":9545},"NCT00821834","Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina\u002FOld Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned",[92],1003,[9543,9544],"Stable Angina","Myocardial Infarction",[9479,9546],"ticlopidine",{"nctId":9548,"briefTitle":9549,"status":108,"phases":9550,"completion":8579,"start":8176,"enrollment":9551,"conditions":9552,"interventions":9554},"NCT00050817","Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)",[92],15603,[9553],"Arteriosclerosis",[9479],{"nctId":9556,"briefTitle":9557,"status":884,"phases":9558,"primaryCompletion":9559,"completion":9559,"start":3508,"enrollment":9560,"conditions":9561,"interventions":9564},"NCT00243178","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)",[92],"2005-09",6706,[9562,9563],"Atrial Fibrillation","Vascular Risk",[9479],{"nctId":9566,"briefTitle":9567,"status":108,"phases":9568,"start":7482,"enrollment":4929,"conditions":9569,"interventions":9572},"NCT00325390","Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation",[92],[9570,9571],"Platelet Aggregation Inhibitors","NSTEACS",[9479],{"nctId":9574,"briefTitle":9575,"status":108,"phases":9576,"primaryCompletion":8659,"completion":8659,"start":3528,"enrollment":9577,"conditions":9578,"interventions":9580},"NCT00714961","Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction",[92],3491,[9579],"Acute Coronary Syndromes",[9455],{"nctId":9582,"briefTitle":9583,"status":108,"phases":9584,"primaryCompletion":955,"completion":955,"start":8666,"enrollment":9585,"conditions":9586,"interventions":9587},"NCT00396877","Efficacy And Safety Of Clopidogrel In Neonates \u002FInfants With Systemic To Pulmonary Artery Shunt Palliation",[92],906,[9535],[9455],{"nctId":9589,"briefTitle":9590,"status":108,"phases":9591,"primaryCompletion":8349,"completion":8349,"start":9592,"enrollment":9593,"conditions":9594,"interventions":9595},"NCT00249873","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)",[92],"2003-06",7554,[9562,9563],[9479],{"nctId":9597,"briefTitle":9598,"status":108,"phases":9599,"primaryCompletion":8777,"start":8526,"enrollment":9600,"conditions":9601,"interventions":9603},"NCT00716924","CASTLE (Clopidogrel And Serum Troponin Level Elevation)",[92],155,[9602],"Thrombosis",[9455,9455],{"nctId":9605,"briefTitle":9606,"status":108,"phases":9607,"primaryCompletion":2799,"completion":2799,"start":8395,"enrollment":9608,"conditions":9609,"interventions":9612},"NCT00335452","Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs\u002FOptimal Antiplatelet Strategy for InterventionS",[92],25086,[9610,9611],"Acute Coronary Disease","Angina Unstable",[9455,9613],"acetylsalicyclic acid",{"nctId":9615,"briefTitle":9616,"status":108,"phases":9617,"primaryCompletion":7292,"completion":7292,"start":8315,"enrollment":9618,"conditions":9619,"interventions":9621},"NCT00862420","Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease",[92],431,[9620],"Peripheral Arterial Disease (PAD)",[9479,9546],{"nctId":9623,"briefTitle":9624,"status":108,"phases":9625,"start":3367,"enrollment":9626,"conditions":9627,"interventions":9629},"NCT00174759","CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease",[92],1460,[9628],"Arterial Occlusive Diseases",[9455],{"trials":9631,"activeCount":102},[9632,9639,9648,9655],{"nctId":9633,"briefTitle":9634,"status":108,"phases":9635,"completion":7538,"start":3509,"enrollment":5218,"conditions":9636,"interventions":9638},"NCT00648453","Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function",[93],[9637],"Peripheral Arterial Disease",[9455],{"nctId":9640,"briefTitle":9641,"status":108,"phases":9642,"primaryCompletion":5238,"completion":5238,"start":8205,"enrollment":9643,"conditions":9644,"interventions":9646},"NCT00814268","COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke",[93],358,[9645],"Stroke",[9455,9647,8477],"Clopidogrel placebo",{"nctId":9649,"briefTitle":9650,"status":108,"phases":9651,"completion":5262,"start":3623,"enrollment":1706,"conditions":9652,"interventions":9654},"NCT00296803","PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome",[93],[9653],"Metabolic Syndrome x",[9479],{"nctId":9656,"briefTitle":9657,"status":108,"phases":9658,"primaryCompletion":8205,"completion":8205,"start":3622,"enrollment":9659,"conditions":9660,"interventions":9662},"NCT00386191","Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment",[93],1110,[9661],"Cerebral Infarction",[9479],{"trials":9664,"activeCount":102},[],{"intervention":9666,"totalTrials":284,"cells":9667},"Irbesartan",{"EARLY_PHASE1":9668,"PHASE1":9670,"PHASE2":9672,"PHASE3":9685,"PHASE4":9727,"NA":9810},{"trials":9669,"activeCount":102},[],{"trials":9671,"activeCount":102},[],{"trials":9673,"activeCount":102},[9674],{"nctId":9675,"briefTitle":9676,"status":108,"phases":9677,"primaryCompletion":8745,"completion":8745,"start":8731,"enrollment":9678,"conditions":9679,"interventions":9681},"NCT00950066","Irbesartan and Amlodipine Combination in Controlling Blood Pressure",[91],270,[9680],"Hypertension",[9682,9683,9684],"IRBESARTAN","Amlodipine","Irbesartan \u002F Amlodipine",{"trials":9686,"activeCount":102},[9687,9694,9702,9710,9718],{"nctId":9688,"briefTitle":9689,"status":108,"phases":9690,"start":5250,"enrollment":98,"conditions":9691,"interventions":9692},"NCT00263003","Irbesartan\u002FHydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension",[92],[9680],[9693,9666],"Irbesartan\u002Fhydrochlorothiazide",{"nctId":9695,"briefTitle":9696,"status":108,"phases":9697,"primaryCompletion":8215,"completion":8215,"start":9592,"enrollment":9698,"conditions":9699,"interventions":9701},"NCT00249795","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)",[92],9016,[9562,9700],"Cardiovascular Disease",[9666],{"nctId":9703,"briefTitle":9704,"status":108,"phases":9705,"completion":9706,"start":3527,"enrollment":9707,"conditions":9708,"interventions":9709},"NCT00561964","Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria",[92],"2005-07",241,[9680],[9666],{"nctId":9711,"briefTitle":9712,"status":108,"phases":9713,"primaryCompletion":5272,"start":8777,"enrollment":9714,"conditions":9715,"interventions":9717},"NCT00296218","ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation",[92],440,[9716,9680],"Myocardial Ischemia",[9666],{"nctId":9719,"briefTitle":9720,"status":108,"phases":9721,"primaryCompletion":5217,"completion":5217,"start":8731,"enrollment":9722,"conditions":9723,"interventions":9724},"NCT00957554","Irbesartan\u002FAmlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy",[92],435,[9680],[9725,9726],"irbesartan\u002Famlodipine","irbesartan",{"trials":9728,"activeCount":102},[9729,9736,9742,9749,9756,9762,9768,9774,9781,9789,9796,9804],{"nctId":9730,"briefTitle":9731,"status":108,"phases":9732,"completion":7523,"start":3508,"enrollment":9733,"conditions":9734,"interventions":9735},"NCT00562809","The Efficacy and Safety of Irbesartan 150\u002F12.5 mg and 300\u002F25 mg in Patients With Mild Hypertension",[93],1005,[9680],[9682],{"nctId":9737,"briefTitle":9738,"status":108,"phases":9739,"completion":8184,"start":3528,"enrollment":2018,"conditions":9740,"interventions":9741},"NCT00564187","Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice",[93],[9680],[9666,9666],{"nctId":9743,"briefTitle":9744,"status":108,"phases":9745,"primaryCompletion":3564,"completion":3564,"start":8777,"enrollment":9746,"conditions":9747,"interventions":9748},"NCT00362258","I PREVENT - Irbesartan In Hypertensive Diabetic Patients",[93],797,[9680],[9666],{"nctId":9750,"briefTitle":9751,"status":108,"phases":9752,"completion":9190,"start":9292,"enrollment":178,"conditions":9753,"interventions":9754},"NCT00350038","Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions",[93],[9680,7454],[9666,9755],"Ciprofibrate",{"nctId":9757,"briefTitle":9758,"status":108,"phases":9759,"completion":8667,"start":3488,"enrollment":359,"conditions":9760,"interventions":9761},"NCT00549133","Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol",[93],[9680,8117],[9666],{"nctId":9763,"briefTitle":9764,"status":108,"phases":9765,"primaryCompletion":8156,"completion":8156,"start":5307,"enrollment":8580,"conditions":9766,"interventions":9767},"NCT00362037","I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy",[93],[9680],[9666],{"nctId":9769,"briefTitle":9770,"status":108,"phases":9771,"primaryCompletion":8156,"completion":8156,"start":8753,"enrollment":1642,"conditions":9772,"interventions":9773},"NCT00334581","Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria",[93],[9680],[9666,9666],{"nctId":9775,"briefTitle":9776,"status":108,"phases":9777,"primaryCompletion":8846,"start":3622,"enrollment":178,"conditions":9778,"interventions":9779},"NCT00443612","Irbesartan\u002FHydrochlorothiazide National Taiwan University Hospital Listing",[93],[9680],[9780,9666],"Irbesartan\u002FHydrochlorothiazide",{"nctId":9782,"briefTitle":9783,"status":108,"phases":9784,"primaryCompletion":9785,"start":9559,"enrollment":9786,"conditions":9787,"interventions":9788},"NCT00265967","Irbesartan in Hypertension",[93],"2007-02",88,[9680],[9666],{"nctId":9790,"briefTitle":9791,"status":108,"phases":9792,"primaryCompletion":8666,"completion":8666,"start":8777,"enrollment":9793,"conditions":9794,"interventions":9795},"NCT00335673","I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients",[93],1630,[9680],[9666],{"nctId":9797,"briefTitle":9798,"status":108,"phases":9799,"primaryCompletion":8659,"completion":8659,"start":9800,"enrollment":9275,"conditions":9801,"interventions":9802},"NCT00529750","Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension",[93],"2002-07",[9680],[9682,9803],"Atenolol",{"nctId":9805,"briefTitle":9806,"status":108,"phases":9807,"start":8667,"enrollment":12,"conditions":9808,"interventions":9809},"NCT00283036","APROVE : Irbesartan in Hypertension",[93],[9680],[9666],{"trials":9811,"activeCount":102},[],{"intervention":3615,"totalTrials":284,"cells":9813},{"EARLY_PHASE1":9814,"PHASE1":9816,"PHASE2":9818,"PHASE3":9820,"PHASE4":9886,"NA":9946},{"trials":9815,"activeCount":102},[],{"trials":9817,"activeCount":102},[],{"trials":9819,"activeCount":102},[],{"trials":9821,"activeCount":102},[9822,9830,9840,9846,9852,9858,9868,9876,9882],{"nctId":9823,"briefTitle":9824,"status":108,"phases":9825,"primaryCompletion":3633,"completion":3633,"start":9826,"enrollment":1145,"conditions":9827,"interventions":9829},"NCT00638534","Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media",[92],"2004-02",[9828],"Otitis Media",[3615],{"nctId":9831,"briefTitle":9832,"status":884,"phases":9833,"primaryCompletion":5262,"completion":5262,"start":5307,"enrollment":9834,"conditions":9835,"interventions":9838},"NCT00315042","TELI TON - Telithromycin in Tonsillitis",[92],314,[9836,9837],"Tonsillitis","Pharyngitis",[3615,9839],"Penicillin",{"nctId":9841,"briefTitle":9842,"status":884,"phases":9843,"primaryCompletion":8395,"completion":8395,"start":5250,"enrollment":8157,"conditions":9844,"interventions":9845},"NCT00174811","Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections",[92],[9828],[3627],{"nctId":9847,"briefTitle":9848,"status":884,"phases":9849,"primaryCompletion":3622,"completion":3622,"start":8777,"enrollment":7399,"conditions":9850,"interventions":9851},"NCT00315549","TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults",[92],[9836,9837],[3615,9839],{"nctId":9853,"briefTitle":9854,"status":108,"phases":9855,"primaryCompletion":7538,"completion":8526,"start":7483,"conditions":9856,"interventions":9857},"NCT00273520","TELICAST : Telithromycin in Acute Exacerbations of Asthma",[92],[155],[3615],{"nctId":9859,"briefTitle":9860,"status":108,"phases":9861,"primaryCompletion":9862,"completion":9862,"start":7523,"enrollment":9863,"conditions":9864,"interventions":9867},"NCT00408135","Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections",[92],"2005-05",111,[9865,9866],"Infections","Child",[3627],{"nctId":9869,"briefTitle":9870,"status":108,"phases":9871,"primaryCompletion":9872,"completion":9872,"start":3509,"enrollment":1250,"conditions":9873,"interventions":9875},"NCT00537563","AMS VS MOXI Ketek vs Avelox in AMS",[92],"2003-09",[9874],"Maxillary Sinusitis",[3615],{"nctId":9877,"briefTitle":9878,"status":108,"phases":9879,"primaryCompletion":3633,"completion":3633,"start":9522,"enrollment":1145,"conditions":9880,"interventions":9881},"NCT00638859","Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia",[92],[3625],[3615],{"nctId":3605,"briefTitle":3606,"status":884,"phases":9883,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":9884,"interventions":9885},[92],[3612,3613],[3615,684],{"trials":9887,"activeCount":102},[9888,9892,9896,9905,9912,9919,9926,9932,9940],{"nctId":3619,"briefTitle":3620,"status":884,"phases":9889,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":599,"conditions":9890,"interventions":9891},[93],[3625],[3627,3628],{"nctId":3630,"briefTitle":3631,"status":884,"phases":9893,"primaryCompletion":3622,"completion":3622,"start":3633,"enrollment":3634,"conditions":9894,"interventions":9895},[93],[3636,3637,3625],[3615,684],{"nctId":9897,"briefTitle":9898,"status":108,"phases":9899,"completion":8184,"start":8526,"enrollment":9900,"conditions":9901,"interventions":9904},"NCT00546676","Ketek in CAP \u002F AECB in Ambulatory Adult Patients",[93],174,[9902,9903],"Community Acquired Pneumonia (CAP)","Acute Exacerbation of Chronic Bronchitis (AECB)",[3615],{"nctId":9906,"briefTitle":9907,"status":108,"phases":9908,"primaryCompletion":9909,"completion":9909,"start":7483,"enrollment":8482,"conditions":9910,"interventions":9911},"NCT00538018","Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas",[93],"2004-06",[3625],[3615],{"nctId":9913,"briefTitle":9914,"status":108,"phases":9915,"primaryCompletion":3565,"start":8175,"enrollment":9916,"conditions":9917,"interventions":9918},"NCT00174694","CHOOSE : Telithromycin, Acute Bacterial Sinusitis",[93],298,[7178],[3615],{"nctId":9920,"briefTitle":9921,"status":108,"phases":9922,"primaryCompletion":8753,"completion":8753,"start":3527,"enrollment":9923,"conditions":9924,"interventions":9925},"NCT00132938","PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis",[93],5660,[3637],[3627],{"nctId":9927,"briefTitle":9928,"status":108,"phases":9929,"primaryCompletion":8331,"completion":3565,"start":9292,"conditions":9930,"interventions":9931},"NCT00261105","Telithromycin in Respiratory Tract Infections",[93],[3636],[3627],{"nctId":9933,"briefTitle":9934,"status":108,"phases":9935,"primaryCompletion":3367,"completion":3367,"start":5251,"enrollment":9936,"conditions":9937,"interventions":9939},"NCT00538148","Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD",[93],668,[9938],"Bronchitis, Chronic",[3615],{"nctId":9941,"briefTitle":9942,"status":884,"phases":9943,"primaryCompletion":2800,"completion":2800,"start":3609,"enrollment":349,"conditions":9944,"interventions":9945},"NCT00288223","Telithromycin in Acute Exacerbation of Chronic Bronchitis",[93],[9938],[3615],{"trials":9947,"activeCount":102},[],{"intervention":2794,"totalTrials":335,"cells":9949},{"EARLY_PHASE1":9950,"PHASE1":9952,"PHASE2":9987,"PHASE3":10021,"PHASE4":10042,"NA":10048},{"trials":9951,"activeCount":102},[],{"trials":9953,"activeCount":102},[9954,9961,9970,9974,9980],{"nctId":9955,"briefTitle":9956,"status":108,"phases":9957,"primaryCompletion":2760,"completion":2760,"start":3307,"enrollment":5521,"conditions":9958,"interventions":9960},"NCT00925743","A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer",[90],[9959],"Solid Cancer",[2806],{"nctId":9962,"briefTitle":9963,"status":108,"phases":9964,"primaryCompletion":9965,"completion":8176,"start":9966,"enrollment":3510,"conditions":9967,"interventions":9969},"NCT01755390","A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors",[90],"2002-08","1999-10",[9968],"Advanced Solid Tumor",[2794],{"nctId":3551,"briefTitle":3552,"status":108,"phases":9971,"primaryCompletion":150,"completion":150,"start":1339,"enrollment":391,"conditions":9972,"interventions":9973},[90],[1357],[2794,3556],{"nctId":9975,"briefTitle":9976,"status":108,"phases":9977,"primaryCompletion":2790,"completion":8062,"start":1022,"enrollment":2858,"conditions":9978,"interventions":9979},"NCT01087021","Effect of Cabazitaxel on the QTc Interval in Cancer Patients",[90],[5220],[2794],{"nctId":9981,"briefTitle":9982,"status":108,"phases":9983,"primaryCompletion":2487,"completion":2487,"start":9984,"enrollment":1145,"conditions":9985,"interventions":9986},"NCT01140607","Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment",[90],"2010-05",[1193],[2794],{"trials":9988,"activeCount":102},[9989,9993,10001,10009,10015],{"nctId":2756,"briefTitle":2757,"status":108,"phases":9990,"primaryCompletion":2759,"completion":2759,"start":2760,"enrollment":271,"conditions":9991,"interventions":9992},[91],[2750],[2763,2764,671],{"nctId":9994,"briefTitle":9995,"status":108,"phases":9996,"primaryCompletion":7330,"completion":7330,"start":8683,"enrollment":3328,"conditions":9997,"interventions":9999},"NCT01500720","Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer",[91],[9998],"Small Cell Lung Cancer",[2794,10000],"Topotecan",{"nctId":10002,"briefTitle":10003,"status":108,"phases":10004,"primaryCompletion":964,"completion":1355,"start":10005,"enrollment":5218,"conditions":10006,"interventions":10008},"NCT01751308","Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors",[90,91],"2013-02",[10007],"Malignant Solid Tumor - Malignant Nervous System Neoplasm",[2794],{"nctId":10010,"briefTitle":10011,"status":884,"phases":10012,"primaryCompletion":1340,"completion":1340,"start":8570,"enrollment":6455,"conditions":10013,"interventions":10014},"NCT01001221","Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor",[90,91],[5220],[2806,5233],{"nctId":10016,"briefTitle":10017,"status":108,"phases":10018,"primaryCompletion":6471,"completion":6471,"start":7349,"enrollment":659,"conditions":10019,"interventions":10020},"NCT01576029","Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer",[91],[2804],[2764,2763],{"trials":10022,"activeCount":102},[10023,10027,10031,10035],{"nctId":2787,"briefTitle":2788,"status":108,"phases":10024,"primaryCompletion":2759,"completion":2759,"start":2790,"enrollment":2791,"conditions":10025,"interventions":10026},[92],[1357],[2794,671],{"nctId":2796,"briefTitle":2797,"status":108,"phases":10028,"primaryCompletion":2799,"completion":2799,"start":2800,"enrollment":2801,"conditions":10029,"interventions":10030},[92],[2803,2804],[2806,2807,1780],{"nctId":2821,"briefTitle":2822,"status":108,"phases":10032,"primaryCompletion":2824,"completion":2825,"start":2826,"enrollment":2827,"conditions":10033,"interventions":10034},[92],[1357],[2794,1348,671],{"nctId":10036,"briefTitle":10037,"status":108,"phases":10038,"primaryCompletion":7430,"completion":7430,"start":8693,"enrollment":10039,"conditions":10040,"interventions":10041},"NCT01254279","Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen",[92],984,[2750],[2764],{"trials":10043,"activeCount":102},[10044],{"nctId":2852,"briefTitle":2853,"status":108,"phases":10045,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":10046,"interventions":10047},[93],[1357],[2764,671,2861,2862],{"trials":10049,"activeCount":102},[],{"intervention":8265,"totalTrials":1260,"cells":10051},{"EARLY_PHASE1":10052,"PHASE1":10054,"PHASE2":10056,"PHASE3":10058,"PHASE4":10098,"NA":10140},{"trials":10053,"activeCount":102},[],{"trials":10055,"activeCount":102},[],{"trials":10057,"activeCount":102},[],{"trials":10059,"activeCount":102},[10060,10064,10068,10078,10082,10086,10094],{"nctId":8172,"briefTitle":8173,"status":108,"phases":10061,"completion":8175,"start":8176,"enrollment":465,"conditions":10062,"interventions":10063},[92],[19],[8179,8037],{"nctId":8258,"briefTitle":8259,"status":108,"phases":10065,"primaryCompletion":1022,"completion":1022,"start":8261,"enrollment":8262,"conditions":10066,"interventions":10067},[92],[19],[8024,8265],{"nctId":10069,"briefTitle":10070,"status":108,"phases":10071,"completion":10072,"start":10073,"enrollment":10074,"conditions":10075,"interventions":10077},"NCT00044447","Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione",[92],"2002-09","2001-05",170,[10076],"Diabetes Mellitus, Non-Insulin-Dependent",[8265],{"nctId":8337,"briefTitle":8338,"status":108,"phases":10079,"primaryCompletion":2855,"completion":2855,"start":8107,"enrollment":8340,"conditions":10080,"interventions":10081},[92],[22],[8343,8344],{"nctId":8346,"briefTitle":8347,"status":884,"phases":10083,"primaryCompletion":8235,"completion":8349,"start":5272,"enrollment":8350,"conditions":10084,"interventions":10085},[92],[22],[8238,8265,8024],{"nctId":10087,"briefTitle":10088,"status":108,"phases":10089,"primaryCompletion":10005,"completion":10005,"start":1340,"enrollment":10090,"conditions":10091,"interventions":10092},"NCT01457911","Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin",[92],244,[19],[10093,8265],"Glimepiride and Metformin hydrochloride combination",{"nctId":8361,"briefTitle":8362,"status":108,"phases":10095,"primaryCompletion":8364,"start":8365,"enrollment":8366,"conditions":10096,"interventions":10097},[92],[22],[8057,8265,8024,8369],{"trials":10099,"activeCount":102},[10100,10104,10111,10115,10121,10125,10134],{"nctId":8385,"briefTitle":8386,"status":108,"phases":10101,"primaryCompletion":8388,"completion":8388,"start":8316,"enrollment":4760,"conditions":10102,"interventions":10103},[93],[19],[8265,8024,8057],{"nctId":10105,"briefTitle":10106,"status":108,"phases":10107,"primaryCompletion":8453,"completion":8453,"start":8731,"enrollment":504,"conditions":10108,"interventions":10109},"NCT00957060","Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients",[93],[22],[8343,10110],"SITAGLIPTIN",{"nctId":8411,"briefTitle":8412,"status":108,"phases":10112,"primaryCompletion":3417,"completion":3417,"start":3608,"enrollment":17,"conditions":10113,"interventions":10114},[93],[22],[8057,8265,8209,8024],{"nctId":10116,"briefTitle":10117,"status":108,"phases":10118,"completion":3488,"start":8176,"enrollment":2411,"conditions":10119,"interventions":10120},"NCT00633425","Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride",[93],[8187],[8343],{"nctId":8450,"briefTitle":8451,"status":108,"phases":10122,"primaryCompletion":8453,"completion":8453,"start":1341,"enrollment":8454,"conditions":10123,"interventions":10124},[93],[19],[8067,8265,8024],{"nctId":10126,"briefTitle":10127,"status":108,"phases":10128,"primaryCompletion":2857,"completion":2857,"start":8731,"enrollment":10129,"conditions":10130,"interventions":10131},"NCT00949442","Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment",[93],708,[22],[10132,8265,10133],"Insulin Glargine (HOE901) [Lantus]","human insulin [NPH]",{"nctId":10135,"briefTitle":10136,"status":108,"phases":10137,"primaryCompletion":5217,"completion":5217,"start":3396,"enrollment":8324,"conditions":10138,"interventions":10139},"NCT00908921","Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)",[93],[22],[8343],{"trials":10141,"activeCount":102},[],{"intervention":3844,"totalTrials":3828,"cells":10143},{"EARLY_PHASE1":10144,"PHASE1":10146,"PHASE2":10187,"PHASE3":10193,"PHASE4":10220,"NA":10233},{"trials":10145,"activeCount":102},[],{"trials":10147,"activeCount":102},[10148,10154,10160,10166,10174,10181],{"nctId":10149,"briefTitle":10150,"status":108,"phases":10151,"primaryCompletion":986,"completion":986,"start":954,"enrollment":9319,"conditions":10152,"interventions":10153},"NCT01448304","Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)",[90],[3892],[3844],{"nctId":10155,"briefTitle":10156,"status":108,"phases":10157,"primaryCompletion":7283,"completion":7283,"start":10005,"enrollment":178,"conditions":10158,"interventions":10159},"NCT01785329","Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects",[90],[3892],[3844],{"nctId":10161,"briefTitle":10162,"status":108,"phases":10163,"primaryCompletion":7292,"completion":7292,"start":3821,"enrollment":9319,"conditions":10164,"interventions":10165},"NCT01448239","Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)",[90],[3892],[3844,3844],{"nctId":10167,"briefTitle":10168,"status":108,"phases":10169,"primaryCompletion":10170,"completion":10170,"start":10171,"enrollment":875,"conditions":10172,"interventions":10173},"NCT02979015","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects",[90],"2017-11-27","2016-11-29",[3892],[3844],{"nctId":10175,"briefTitle":10176,"status":108,"phases":10177,"primaryCompletion":8106,"completion":8106,"start":10178,"enrollment":2636,"conditions":10179,"interventions":10180},"NCT01670734","Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects",[90],"2012-09",[3892],[3844],{"nctId":10182,"briefTitle":10183,"status":108,"phases":10184,"primaryCompletion":8062,"completion":8062,"start":8406,"enrollment":2685,"conditions":10185,"interventions":10186},"NCT01443650","Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects",[90],[3892],[3844],{"trials":10188,"activeCount":102},[10189],{"nctId":3835,"briefTitle":3836,"status":108,"phases":10190,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":10191,"interventions":10192},[91],[3842],[3844,3845,3846,3831,3847,3848,3849],{"trials":10194,"activeCount":102},[10195,10199,10209,10216],{"nctId":3853,"briefTitle":3854,"status":108,"phases":10196,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":10197,"interventions":10198},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":10200,"briefTitle":10201,"status":108,"phases":10202,"primaryCompletion":10203,"completion":10203,"start":10204,"enrollment":10205,"conditions":10206,"interventions":10207},"NCT02476006","Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)",[92],"2019-04-12","2015-06-23",998,[3892],[10208,3846,7441,7442,6459],"ALIROCUMAB SAR236553",{"nctId":10210,"briefTitle":10211,"status":108,"phases":10212,"primaryCompletion":6484,"completion":6484,"start":10213,"enrollment":369,"conditions":10214,"interventions":10215},"NCT03415178","Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",[92],"2018-03-29",[3842],[3862,3864,3863],{"nctId":3886,"briefTitle":3887,"status":108,"phases":10217,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":10218,"interventions":10219},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":10221,"activeCount":102},[10222],{"nctId":10223,"briefTitle":10224,"status":108,"phases":10225,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":10228,"interventions":10229},"NCT02984982","Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia",[93],"2018-07-27","2016-11-15",[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],"Bezafibrate","Antiplatelets","Anticoagulants",{"trials":10234,"activeCount":102},[],{"intervention":3864,"totalTrials":3828,"cells":10236},{"EARLY_PHASE1":10237,"PHASE1":10239,"PHASE2":10241,"PHASE3":10255,"PHASE4":10289,"NA":10305},{"trials":10238,"activeCount":102},[],{"trials":10240,"activeCount":102},[],{"trials":10242,"activeCount":102},[10243,10247,10251],{"nctId":7305,"briefTitle":7306,"status":108,"phases":10244,"primaryCompletion":986,"completion":986,"start":1339,"enrollment":7308,"conditions":10245,"interventions":10246},[91],[3892],[7273,3864],{"nctId":7312,"briefTitle":7313,"status":108,"phases":10248,"primaryCompletion":2855,"completion":2855,"start":2760,"enrollment":465,"conditions":10249,"interventions":10250},[91],[3892],[7273,3864],{"nctId":7318,"briefTitle":7319,"status":108,"phases":10252,"primaryCompletion":977,"completion":977,"start":1339,"enrollment":7321,"conditions":10253,"interventions":10254},[91],[3892],[7273,3864],{"trials":10256,"activeCount":102},[10257,10261,10265,10269,10273,10277,10281],{"nctId":3853,"briefTitle":3854,"status":108,"phases":10258,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":10259,"interventions":10260},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":10200,"briefTitle":10201,"status":108,"phases":10262,"primaryCompletion":10203,"completion":10203,"start":10204,"enrollment":10205,"conditions":10263,"interventions":10264},[92],[3892],[10208,3846,7441,7442,6459],{"nctId":10210,"briefTitle":10211,"status":108,"phases":10266,"primaryCompletion":6484,"completion":6484,"start":10213,"enrollment":369,"conditions":10267,"interventions":10268},[92],[3842],[3862,3864,3863],{"nctId":7367,"briefTitle":7368,"status":108,"phases":10270,"primaryCompletion":7370,"completion":7371,"start":7372,"enrollment":7373,"conditions":10271,"interventions":10272},[92],[3892],[7273,3864,7376],{"nctId":7434,"briefTitle":7435,"status":108,"phases":10274,"primaryCompletion":2662,"completion":2662,"start":7437,"enrollment":7438,"conditions":10275,"interventions":10276},[92],[3892],[7273,3846,7441,7442,6459],{"nctId":3886,"briefTitle":3887,"status":108,"phases":10278,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":10279,"interventions":10280},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"nctId":10282,"briefTitle":10283,"status":884,"phases":10284,"primaryCompletion":8261,"completion":3307,"start":3417,"enrollment":10285,"conditions":10286,"interventions":10287},"NCT00741715","Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia",[92],1736,[3892],[10288,7441],"AVE5530",{"trials":10290,"activeCount":102},[10291,10301],{"nctId":10292,"briefTitle":10293,"status":108,"phases":10294,"primaryCompletion":10295,"completion":10295,"start":10296,"enrollment":6445,"conditions":10297,"interventions":10298},"NCT02842359","Evaluation of the Fixed-dose Combination of Irbesartan\u002FAtorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension",[93],"2018-04-19","2016-08-23",[19],[10299,10300,3864],"Irbesartan\u002Fatorvastatin fixed dose combination","Irbesartan SR47436",{"nctId":10223,"briefTitle":10224,"status":108,"phases":10302,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":10303,"interventions":10304},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":10306,"activeCount":102},[],{"intervention":10308,"totalTrials":6445,"cells":10309},"Enoxaparin sodium",{"EARLY_PHASE1":10310,"PHASE1":10312,"PHASE2":10314,"PHASE3":10326,"PHASE4":10381,"NA":10404},{"trials":10311,"activeCount":102},[],{"trials":10313,"activeCount":102},[],{"trials":10315,"activeCount":102},[10316],{"nctId":10317,"briefTitle":10318,"status":108,"phases":10319,"primaryCompletion":10320,"completion":10320,"start":8753,"enrollment":10321,"conditions":10322,"interventions":10324},"NCT00331838","Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery",[91],"2007-06",705,[10323],"Venous Thromboembolism",[10325,10308],"Semuloparin sodium",{"trials":10327,"activeCount":102},[10328,10335,10344,10352,10360,10367,10373],{"nctId":10329,"briefTitle":10330,"status":884,"phases":10331,"primaryCompletion":8349,"completion":8349,"start":8196,"enrollment":10332,"conditions":10333,"interventions":10334},"NCT00714597","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility",[92],421,[10323],[10325,10308],{"nctId":10336,"briefTitle":10337,"status":108,"phases":10338,"primaryCompletion":10339,"completion":10339,"start":8176,"enrollment":10340,"conditions":10341,"interventions":10343},"NCT00077792","Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)",[92],"2006-12",20506,[9544,10342],"Acute ST-Segment Elevation",[10308],{"nctId":10345,"briefTitle":10346,"status":108,"phases":10347,"start":8395,"enrollment":10348,"conditions":10349,"interventions":10351},"NCT00349180","Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)",[92],156,[10350],"Arthroplasty, Replacement, Hip",[10308],{"nctId":10353,"briefTitle":10354,"status":108,"phases":10355,"primaryCompletion":9559,"completion":9559,"start":3527,"enrollment":10356,"conditions":10357,"interventions":10359},"NCT00077844","Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)",[91,92],3532,[10358],"Percutaneous Coronary Intervention",[10308],{"nctId":10361,"briefTitle":10362,"status":108,"phases":10363,"primaryCompletion":3307,"completion":3307,"start":8156,"enrollment":10364,"conditions":10365,"interventions":10366},"NCT00697099","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery",[92],2326,[10323],[10325,10308],{"nctId":10368,"briefTitle":10369,"status":108,"phases":10370,"primaryCompletion":3354,"completion":3354,"start":8196,"enrollment":9541,"conditions":10371,"interventions":10372},"NCT00721760","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery",[92],[10323],[10308,10325],{"nctId":10374,"briefTitle":10375,"status":108,"phases":10376,"primaryCompletion":5271,"completion":5271,"start":8505,"enrollment":10377,"conditions":10378,"interventions":10379},"NCT00679588","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery",[92],4413,[10323],[10380,10308],"Semuloparin Sodium",{"trials":10382,"activeCount":102},[10383,10389,10396],{"nctId":10384,"briefTitle":10385,"status":108,"phases":10386,"primaryCompletion":9292,"start":8420,"conditions":10387,"interventions":10388},"NCT00077818","Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)",[93],[9440],[10308],{"nctId":10390,"briefTitle":10391,"status":108,"phases":10392,"primaryCompletion":3608,"start":8364,"conditions":10393,"interventions":10395},"NCT00077805","PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)",[93],[10394],"Acute Ischemic Stroke",[10308],{"nctId":10397,"briefTitle":10398,"status":108,"phases":10399,"primaryCompletion":3430,"completion":9785,"start":3495,"enrollment":10400,"conditions":10401,"interventions":10402},"NCT00077753","EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization",[93],4726,[10323],[10403],"enoxaparin sodium",{"trials":10405,"activeCount":102},[],{"intervention":971,"totalTrials":6445,"cells":10407},{"EARLY_PHASE1":10408,"PHASE1":10410,"PHASE2":10416,"PHASE3":10430,"PHASE4":10456,"NA":10462},{"trials":10409,"activeCount":102},[],{"trials":10411,"activeCount":102},[10412],{"nctId":6468,"briefTitle":6469,"status":108,"phases":10413,"primaryCompletion":6471,"completion":6471,"start":1032,"enrollment":6472,"conditions":10414,"interventions":10415},[90],[990],[6458,993,6475],{"trials":10417,"activeCount":102},[10418,10422,10426],{"nctId":4623,"briefTitle":4624,"status":884,"phases":10419,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":10420,"interventions":10421},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"nctId":961,"briefTitle":962,"status":108,"phases":10423,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":10424,"interventions":10425},[91],[969],[942,671,971,972],{"nctId":983,"briefTitle":984,"status":884,"phases":10427,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":10428,"interventions":10429},[91],[990],[942,992,993,972],{"trials":10431,"activeCount":102},[10432,10436,10440,10444,10448,10452],{"nctId":1008,"briefTitle":1009,"status":108,"phases":10433,"primaryCompletion":1011,"completion":1011,"start":164,"enrollment":1012,"conditions":10434,"interventions":10435},[92],[990],[942,1015,993,1016,1017],{"nctId":6490,"briefTitle":6491,"status":108,"phases":10437,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":10438,"interventions":10439},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"nctId":6499,"briefTitle":6500,"status":108,"phases":10441,"primaryCompletion":4968,"completion":4968,"start":150,"enrollment":6502,"conditions":10442,"interventions":10443},[92],[990],[2781,971,6505],{"nctId":1019,"briefTitle":1020,"status":108,"phases":10445,"primaryCompletion":966,"completion":966,"start":1022,"enrollment":1023,"conditions":10446,"interventions":10447},[91,92],[990],[942,971,1026],{"nctId":1028,"briefTitle":1029,"status":884,"phases":10449,"primaryCompletion":1031,"completion":1031,"start":1032,"enrollment":153,"conditions":10450,"interventions":10451},[92],[990],[942,1035,971,1036],{"nctId":1051,"briefTitle":1052,"status":108,"phases":10453,"primaryCompletion":1042,"completion":1054,"start":1055,"enrollment":1056,"conditions":10454,"interventions":10455},[92],[1058],[942,971,1045,1046,1060],{"trials":10457,"activeCount":102},[10458],{"nctId":1074,"briefTitle":1075,"status":108,"phases":10459,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":10460,"interventions":10461},[93],[990],[1082,1083,1084,1060,1046,971,1045],{"trials":10463,"activeCount":102},[],{"intervention":3869,"totalTrials":6445,"cells":10465},{"EARLY_PHASE1":10466,"PHASE1":10468,"PHASE2":10474,"PHASE3":10486,"PHASE4":10512,"NA":10522},{"trials":10467,"activeCount":102},[],{"trials":10469,"activeCount":102},[10470],{"nctId":7280,"briefTitle":7281,"status":108,"phases":10471,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":1874,"conditions":10472,"interventions":10473},[90],[3892],[7273,3869,7287,3871],{"trials":10475,"activeCount":102},[10476,10480],{"nctId":3835,"briefTitle":3836,"status":108,"phases":10477,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":10478,"interventions":10479},[91],[3842],[3844,3845,3846,3831,3847,3848,3849],{"nctId":10481,"briefTitle":10482,"status":108,"phases":10483,"primaryCompletion":3317,"completion":3317,"start":9785,"enrollment":8791,"conditions":10484,"interventions":10485},"NCT00440154","A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia",[91],[3892],[10288,3846],{"trials":10487,"activeCount":102},[10488,10492,10496,10500,10504,10508],{"nctId":3853,"briefTitle":3854,"status":108,"phases":10489,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":10490,"interventions":10491},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":10200,"briefTitle":10201,"status":108,"phases":10493,"primaryCompletion":10203,"completion":10203,"start":10204,"enrollment":10205,"conditions":10494,"interventions":10495},[92],[3892],[10208,3846,7441,7442,6459],{"nctId":7346,"briefTitle":7347,"status":108,"phases":10497,"primaryCompletion":1272,"completion":964,"start":7349,"enrollment":5913,"conditions":10498,"interventions":10499},[92],[3892],[7273,3869,7352],{"nctId":7360,"briefTitle":7361,"status":108,"phases":10501,"primaryCompletion":7283,"completion":7283,"start":2857,"enrollment":7363,"conditions":10502,"interventions":10503},[92],[3892],[7273,3869],{"nctId":7434,"briefTitle":7435,"status":108,"phases":10505,"primaryCompletion":2662,"completion":2662,"start":7437,"enrollment":7438,"conditions":10506,"interventions":10507},[92],[3892],[7273,3846,7441,7442,6459],{"nctId":3886,"briefTitle":3887,"status":108,"phases":10509,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":10510,"interventions":10511},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":10513,"activeCount":102},[10514,10518],{"nctId":7446,"briefTitle":7447,"status":108,"phases":10515,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":10516,"interventions":10517},[93],[7454],[7273,7456,3869,3871,3870,3872,7412],{"nctId":10223,"briefTitle":10224,"status":108,"phases":10519,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":10520,"interventions":10521},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":10523,"activeCount":102},[],{"intervention":8128,"totalTrials":552,"cells":10525},{"EARLY_PHASE1":10526,"PHASE1":10528,"PHASE2":10530,"PHASE3":10532,"PHASE4":10579,"NA":10590},{"trials":10527,"activeCount":102},[],{"trials":10529,"activeCount":102},[],{"trials":10531,"activeCount":102},[],{"trials":10533,"activeCount":102},[10534,10538,10542,10546,10550,10554,10558,10567,10571],{"nctId":8121,"briefTitle":8122,"status":108,"phases":10535,"primaryCompletion":7189,"completion":7189,"start":8124,"enrollment":8125,"conditions":10536,"interventions":10537},[92],[19],[8128,8067,8024],{"nctId":8144,"briefTitle":8145,"status":108,"phases":10539,"primaryCompletion":5044,"completion":5044,"start":8147,"enrollment":8148,"conditions":10540,"interventions":10541},[92],[19],[8128,8151,8024],{"nctId":9362,"briefTitle":9363,"status":108,"phases":10543,"primaryCompletion":2825,"completion":2825,"start":9365,"enrollment":9366,"conditions":10544,"interventions":10545},[92],[19],[8128,8046,9369],{"nctId":8222,"briefTitle":8223,"status":108,"phases":10547,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":10548,"interventions":10549},[92],[19],[8128,8067,8046,8024,8230],{"nctId":8247,"briefTitle":8248,"status":108,"phases":10551,"primaryCompletion":8250,"completion":8250,"start":8251,"enrollment":8252,"conditions":10552,"interventions":10553},[92],[19],[8255,8256,8024,8209],{"nctId":8278,"briefTitle":8279,"status":108,"phases":10555,"primaryCompletion":964,"completion":964,"start":2855,"enrollment":8281,"conditions":10556,"interventions":10557},[92],[830],[8284,8067,8024],{"nctId":10559,"briefTitle":10560,"status":884,"phases":10561,"primaryCompletion":10562,"completion":10562,"start":10563,"enrollment":9707,"conditions":10564,"interventions":10565},"NCT03434119","Efficacy and Safety of Soliqua Versus Lantus in Ethnically\u002FRacially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents",[92],"2019-01-07","2018-02-20",[19],[8128,8067,10566],"Background therapy",{"nctId":8286,"briefTitle":8287,"status":108,"phases":10568,"primaryCompletion":454,"completion":454,"start":8289,"enrollment":8290,"conditions":10569,"interventions":10570},[92],[19],[8128,8293,8024,8230],{"nctId":10572,"briefTitle":10573,"status":108,"phases":10574,"primaryCompletion":189,"completion":189,"start":10575,"enrollment":10576,"conditions":10577,"interventions":10578},"NCT02752828","Efficacy and Safety of the Insulin Glargine\u002FLixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan",[92],"2016-05-23",521,[19],[8284,8067,9369],{"trials":10580,"activeCount":102},[10581],{"nctId":10582,"briefTitle":10583,"status":108,"phases":10584,"primaryCompletion":10585,"completion":10586,"start":10587,"enrollment":1583,"conditions":10588,"interventions":10589},"NCT05114590","Effect of Soliqua 100\u002F33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus",[93],"2023-03-28","2023-04-14","2022-01-27",[19],[8128],{"trials":10591,"activeCount":102},[],{"intervention":8508,"totalTrials":552,"cells":10593},{"EARLY_PHASE1":10594,"PHASE1":10596,"PHASE2":10632,"PHASE3":10634,"PHASE4":10656,"NA":10670},{"trials":10595,"activeCount":102},[],{"trials":10597,"activeCount":102},[10598,10602,10612,10620,10628],{"nctId":8502,"briefTitle":8503,"status":108,"phases":10599,"primaryCompletion":8505,"completion":8505,"start":1341,"enrollment":655,"conditions":10600,"interventions":10601},[90],[19],[8335,8508],{"nctId":10603,"briefTitle":10604,"status":108,"phases":10605,"primaryCompletion":10606,"completion":10606,"start":10607,"enrollment":3740,"conditions":10608,"interventions":10609},"NCT03202875","A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus",[90],"2012-12-28","2012-11-14",[591],[10610,10611,10611],"SAR341402","Insulin Aspart",{"nctId":10613,"briefTitle":10614,"status":108,"phases":10615,"primaryCompletion":10616,"completion":10616,"start":10617,"enrollment":34,"conditions":10618,"interventions":10619},"NCT03916601","Comparison of Exposure and Activity of SAR341402 Mix 70\u002F30 to NovoLog Mix 70\u002F30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus",[90],"2018-03-22","2017-12-13",[591],[10610,10611,10611,10610],{"nctId":10621,"briefTitle":10622,"status":108,"phases":10623,"primaryCompletion":10624,"completion":10624,"start":2747,"enrollment":2858,"conditions":10625,"interventions":10626},"NCT03436498","Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients",[90],"2018-10-06",[554],[10627,8508],"Insulin aspart SAR341402",{"nctId":8543,"briefTitle":8544,"status":108,"phases":10629,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":359,"conditions":10630,"interventions":10631},[90],[8549],[8335,8335,8508,8551,8552,8553,8554],{"trials":10633,"activeCount":102},[],{"trials":10635,"activeCount":102},[10636,10648],{"nctId":10637,"briefTitle":10638,"status":108,"phases":10639,"primaryCompletion":10640,"completion":10641,"start":10642,"enrollment":10643,"conditions":10644,"interventions":10646},"NCT03211858","Comparison of SAR341402 to NovoLog\u002FNovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine",[92],"2018-07-16","2019-01-12","2017-08-02",597,[10645],"Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus",[8508,10647,8067],"NovoLog\u002FNovoRapid",{"nctId":10649,"briefTitle":10650,"status":108,"phases":10651,"primaryCompletion":3738,"completion":3738,"start":10652,"enrollment":249,"conditions":10653,"interventions":10654},"NCT03874715","Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine",[92],"2019-03-11",[554],[10655,10611,8151],"Insulin Aspart SAR341402",{"trials":10657,"activeCount":102},[10658,10662,10666],{"nctId":8722,"briefTitle":8723,"status":108,"phases":10659,"primaryCompletion":5238,"completion":5238,"start":5271,"enrollment":1574,"conditions":10660,"interventions":10661},[93],[22],[8256,8687,8508],{"nctId":8735,"briefTitle":8736,"status":108,"phases":10663,"primaryCompletion":3438,"completion":3438,"start":8731,"enrollment":8738,"conditions":10664,"interventions":10665},[93],[22],[8256,8508,8209],{"nctId":8759,"briefTitle":8760,"status":108,"phases":10667,"primaryCompletion":3307,"completion":3307,"start":8762,"enrollment":8763,"conditions":10668,"interventions":10669},[93],[578],[8335,8766,8508],{"trials":10671,"activeCount":102},[],{"intervention":10673,"totalTrials":552,"cells":10674},"Influenza virus vaccine",{"EARLY_PHASE1":10675,"PHASE1":10677,"PHASE2":10679,"PHASE3":10699,"PHASE4":10721,"NA":10756},{"trials":10676,"activeCount":102},[],{"trials":10678,"activeCount":102},[],{"trials":10680,"activeCount":102},[10681,10688],{"nctId":10682,"briefTitle":10683,"status":108,"phases":10684,"primaryCompletion":8395,"completion":10339,"start":8667,"enrollment":10685,"conditions":10686,"interventions":10687},"NCT00858468","Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age",[90,91],394,[16],[10673,10673],{"nctId":10689,"briefTitle":10690,"status":108,"phases":10691,"primaryCompletion":3417,"completion":8235,"start":3317,"enrollment":10692,"conditions":10693,"interventions":10696},"NCT00845429","Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects",[91],729,[16,10694,10695],"Orthomyxoviruses","Myxovirus Infection",[10697,10698,10673],"Influenza virus vaccine - cell based","Influenza virus vaccine - cell-based",{"trials":10700,"activeCount":102},[10701,10707,10715],{"nctId":10702,"briefTitle":10703,"status":108,"phases":10704,"primaryCompletion":3366,"completion":3366,"start":978,"enrollment":3079,"conditions":10705,"interventions":10706},"NCT01138397","Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)",[92],[16],[10673,10673],{"nctId":10708,"briefTitle":10709,"status":108,"phases":10710,"primaryCompletion":3609,"completion":1341,"start":8331,"enrollment":10711,"conditions":10712,"interventions":10713},"NCT00885105","Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age",[92],242,[16],[10714,10714],"Influenza Virus Vaccine",{"nctId":10716,"briefTitle":10717,"status":108,"phases":10718,"primaryCompletion":978,"completion":978,"start":9984,"enrollment":3079,"conditions":10719,"interventions":10720},"NCT01121822","Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)",[92],[16],[10673,10673],{"trials":10722,"activeCount":102},[10723,10729,10736,10742,10749],{"nctId":10724,"briefTitle":10725,"status":108,"phases":10726,"primaryCompletion":5307,"completion":9190,"start":8331,"enrollment":3740,"conditions":10727,"interventions":10728},"NCT00258817","Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine",[93],[16],[10714,10714],{"nctId":10730,"briefTitle":10731,"status":108,"phases":10732,"primaryCompletion":9872,"completion":9872,"start":3508,"enrollment":10733,"conditions":10734,"interventions":10735},"NCT00835926","A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination",[93],121,[16],[10673,10673],{"nctId":10737,"briefTitle":10738,"status":108,"phases":10739,"primaryCompletion":1341,"completion":8196,"start":3430,"enrollment":8883,"conditions":10740,"interventions":10741},"NCT00389857","Trial to Collect Safety Data and Sera for Immunogenicity Testing",[93],[16],[10714,10714],{"nctId":10743,"briefTitle":10744,"status":108,"phases":10745,"primaryCompletion":8505,"completion":3564,"start":3430,"enrollment":10746,"conditions":10747,"interventions":10748},"NCT00389532","Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine",[93],116,[16],[10714,10714],{"nctId":10750,"briefTitle":10751,"status":108,"phases":10752,"primaryCompletion":3527,"completion":7482,"start":9872,"enrollment":10753,"conditions":10754,"interventions":10755},"NCT00836953","Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®",[93],33,[16],[10673],{"trials":10757,"activeCount":102},[],{"intervention":8189,"totalTrials":2371,"cells":10759},{"EARLY_PHASE1":10760,"PHASE1":10762,"PHASE2":10764,"PHASE3":10773,"PHASE4":10814,"NA":10833},{"trials":10761,"activeCount":102},[],{"trials":10763,"activeCount":102},[],{"trials":10765,"activeCount":102},[10766],{"nctId":10767,"briefTitle":10768,"status":108,"phases":10769,"primaryCompletion":8106,"completion":8106,"start":7349,"enrollment":5407,"conditions":10770,"interventions":10771},"NCT01658579","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin",[91],[554],[10772,8189],"HOE901-U300",{"trials":10774,"activeCount":102},[10775,10783,10790,10794,10801,10807],{"nctId":10776,"briefTitle":10777,"status":108,"phases":10778,"primaryCompletion":9292,"start":5251,"enrollment":8627,"conditions":10779,"interventions":10780},"NCT00046501","Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents",[92],[8187],[8189,10781,10782,8637],"Humulin N","Humulin L",{"nctId":10784,"briefTitle":10785,"status":108,"phases":10786,"primaryCompletion":2311,"completion":1055,"start":10178,"enrollment":10787,"conditions":10788,"interventions":10789},"NCT01683266","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus",[92],549,[554],[10772,8189],{"nctId":8181,"briefTitle":8182,"status":108,"phases":10791,"primaryCompletion":8175,"completion":8184,"start":8185,"enrollment":6655,"conditions":10792,"interventions":10793},[92],[8187],[8189,8024,8190,8191],{"nctId":10795,"briefTitle":10796,"status":108,"phases":10797,"primaryCompletion":8298,"completion":2311,"start":977,"enrollment":10798,"conditions":10799,"interventions":10800},"NCT01499082","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin",[92],807,[19],[10772,8189],{"nctId":10802,"briefTitle":10803,"status":108,"phases":10804,"primaryCompletion":2311,"completion":1055,"start":7349,"enrollment":8227,"conditions":10805,"interventions":10806},"NCT01676220","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy",[92],[19],[10772,8189],{"nctId":10808,"briefTitle":10809,"status":108,"phases":10810,"primaryCompletion":1032,"completion":10811,"start":977,"enrollment":8206,"conditions":10812,"interventions":10813},"NCT01499095","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy",[92],"2013-11",[19],[8189,10772],{"trials":10815,"activeCount":102},[10816,10823],{"nctId":10817,"briefTitle":10818,"status":108,"phases":10819,"primaryCompletion":3367,"completion":8331,"start":9113,"enrollment":10820,"conditions":10821,"interventions":10822},"NCT00653302","Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)",[93],280,[830],[8189],{"nctId":10824,"briefTitle":10825,"status":108,"phases":10826,"primaryCompletion":10827,"completion":10827,"start":10828,"enrollment":10829,"conditions":10830,"interventions":10831},"NCT02688933","A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus",[93],"2017-06-19","2016-05-05",638,[554],[10772,8189,10832],"Mandated back ground therapy",{"trials":10834,"activeCount":102},[],{"intervention":10836,"totalTrials":2371,"cells":10837},"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate",{"EARLY_PHASE1":10838,"PHASE1":10840,"PHASE2":10842,"PHASE3":10879,"PHASE4":10904,"NA":10916},{"trials":10839,"activeCount":102},[],{"trials":10841,"activeCount":102},[],{"trials":10843,"activeCount":102},[10844,10851,10859,10867,10873],{"nctId":10845,"briefTitle":10846,"status":108,"phases":10847,"primaryCompletion":9785,"completion":7509,"start":3565,"enrollment":10848,"conditions":10849,"interventions":10850},"NCT00269477","Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®",[91],145,[4992,2949],[10836,10836,10836,10836],{"nctId":10852,"briefTitle":10853,"status":108,"phases":10854,"primaryCompletion":9522,"completion":8526,"start":8364,"enrollment":7363,"conditions":10855,"interventions":10857},"NCT00771849","Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children",[91],[4992,10856],"Meningococcemia",[10836,10858],"Haemophilus Influenzae Type b (Hib) vaccine",{"nctId":10860,"briefTitle":10861,"status":108,"phases":10862,"primaryCompletion":8315,"completion":8349,"start":8156,"enrollment":10863,"conditions":10864,"interventions":10865},"NCT00700713","Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26",[91],181,[4992,10856],[10866,10866,10866],"Meningococcal polysaccharide diphtheria toxoid conjugate",{"nctId":10868,"briefTitle":10869,"status":108,"phases":10870,"primaryCompletion":7538,"completion":8667,"start":9826,"enrollment":9707,"conditions":10871,"interventions":10872},"NCT00777790","Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents",[91],[4992,10856],[10836,10836,10836],{"nctId":10874,"briefTitle":10875,"status":884,"phases":10876,"primaryCompletion":7538,"completion":7538,"start":3527,"enrollment":284,"conditions":10877,"interventions":10878},"NCT00772629","Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults",[91],[4992,10856],[10836,10836],{"trials":10880,"activeCount":102},[10881,10887,10893],{"nctId":10882,"briefTitle":10883,"status":108,"phases":10884,"primaryCompletion":3821,"completion":954,"start":978,"enrollment":1091,"conditions":10885,"interventions":10886},"NCT01086969","A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India",[92],[2949,4992],[10836],{"nctId":10888,"briefTitle":10889,"status":108,"phases":10890,"primaryCompletion":10178,"completion":3438,"start":3335,"enrollment":12,"conditions":10891,"interventions":10892},"NCT01519713","Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects",[92],[4992,7568,2922],[10866],{"nctId":10894,"briefTitle":10895,"status":108,"phases":10896,"primaryCompletion":3417,"completion":8315,"start":3622,"enrollment":10897,"conditions":10898,"interventions":10902},"NCT00384397","A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",[92],1128,[7568,10899,10900,10901,2978],"Measles","Mumps","Rubella",[10903,10836,10836],"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"trials":10905,"activeCount":102},[10906],{"nctId":10907,"briefTitle":10908,"status":108,"phases":10909,"primaryCompletion":150,"completion":2824,"start":2857,"enrollment":10910,"conditions":10911,"interventions":10913},"NCT01659996","Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age",[93],1394,[4992,2949,25,31,28,10912],"Haemophilus Influenzae Serotype b (Hib)",[10866,10914,10915],"Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed","Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate",{"trials":10917,"activeCount":102},[],{"intervention":10919,"totalTrials":535,"cells":10920},"Rasburicase",{"EARLY_PHASE1":10921,"PHASE1":10923,"PHASE2":10925,"PHASE3":10949,"PHASE4":10965,"NA":10987},{"trials":10922,"activeCount":102},[],{"trials":10924,"activeCount":102},[],{"trials":10926,"activeCount":102},[10927,10935,10943],{"nctId":10928,"briefTitle":10929,"status":108,"phases":10930,"primaryCompletion":9513,"completion":9513,"start":5250,"enrollment":3740,"conditions":10931,"interventions":10933},"NCT00290992","Rasburicase for Hyperuricemia",[91],[10932],"Nutritional and Metabolic Diseases",[10934],"rasburicase",{"nctId":10936,"briefTitle":10937,"status":108,"phases":10938,"primaryCompletion":9909,"completion":9909,"start":9113,"enrollment":7653,"conditions":10939,"interventions":10942},"NCT00631579","Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma",[91],[10940,10941,2675],"Hyperuricemia","Leukemia",[10919],{"nctId":10944,"briefTitle":10945,"status":884,"phases":10946,"primaryCompletion":8659,"completion":8659,"start":9800,"enrollment":10753,"conditions":10947,"interventions":10948},"NCT00664144","Rasburicase for the Treatment\u002FPrevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma",[91],[10940],[10919],{"trials":10950,"activeCount":102},[10951,10958],{"nctId":10952,"briefTitle":10953,"status":884,"phases":10954,"primaryCompletion":9532,"completion":9532,"start":3317,"enrollment":552,"conditions":10955,"interventions":10956},"NCT00607152","Rasburicase (Fasturtec) Registration Trial",[92],[10940],[10919,10957],"Allopurinol",{"nctId":10959,"briefTitle":10960,"status":108,"phases":10961,"primaryCompletion":7509,"completion":7509,"start":7538,"enrollment":10820,"conditions":10962,"interventions":10964},"NCT00230178","Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome",[92],[10963,5421,10940],"Tumor Lysis Syndrome",[10919,10957],{"trials":10966,"activeCount":102},[10967,10975,10981],{"nctId":10968,"briefTitle":10969,"status":108,"phases":10970,"primaryCompletion":3608,"completion":3608,"start":9522,"enrollment":10971,"conditions":10972,"interventions":10974},"NCT00230217","Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy",[93],94,[10973,10940,10963],"Tumors",[10919],{"nctId":10976,"briefTitle":10977,"status":108,"phases":10978,"completion":3527,"start":3326,"enrollment":112,"conditions":10979,"interventions":10980},"NCT00563771","Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome",[93],[10940],[10919],{"nctId":10982,"briefTitle":10983,"status":108,"phases":10984,"primaryCompletion":8666,"start":8777,"enrollment":10753,"conditions":10985,"interventions":10986},"NCT00302653","Rasburicase in Tumor Lysis Syndrome",[93],[10940],[10919],{"trials":10988,"activeCount":102},[],{"intervention":10990,"totalTrials":535,"cells":10991},"Risedronate",{"EARLY_PHASE1":10992,"PHASE1":10994,"PHASE2":10996,"PHASE3":11006,"PHASE4":11040,"NA":11061},{"trials":10993,"activeCount":102},[],{"trials":10995,"activeCount":102},[],{"trials":10997,"activeCount":102},[10998],{"nctId":10999,"briefTitle":11000,"status":108,"phases":11001,"primaryCompletion":9592,"completion":9592,"start":5251,"enrollment":455,"conditions":11002,"interventions":11004},"NCT00351091","Risedronate in Postmenopausal Women With Low Bone Density",[91],[11003],"OSTEOPOROSIS, POSTMENOPAUSAL",[11005],"RISEDRONATE",{"trials":11007,"activeCount":102},[11008,11017,11025,11032],{"nctId":11009,"briefTitle":11010,"status":108,"phases":11011,"primaryCompletion":8667,"completion":8667,"start":3509,"enrollment":11012,"conditions":11013,"interventions":11015},"NCT00353080","Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women",[92],171,[11014],"Osteoporosis, Postmenopausal",[11016],"risedronate",{"nctId":11018,"briefTitle":11019,"status":108,"phases":11020,"primaryCompletion":3495,"start":11021,"conditions":11022,"interventions":11024},"NCT00268632","IMPACT Study (Improving Measurements of Persistence on \"ACtonel\" Treatment)",[92],"1999-08",[11023],"Osteoporosis",[11016],{"nctId":11026,"briefTitle":11027,"status":108,"phases":11028,"primaryCompletion":3307,"completion":3307,"start":5307,"enrollment":10348,"conditions":11029,"interventions":11030},"NCT00345644","Risedronate in Osteopenic Postmenopausal Women",[92],[11023],[11016,11031],"risedronate placebo",{"nctId":11033,"briefTitle":11034,"status":108,"phases":11035,"primaryCompletion":5272,"completion":5272,"start":7482,"enrollment":11036,"conditions":11037,"interventions":11039},"NCT00358176","Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women",[92],1231,[11038],"Osteoporosis Postmenopausal",[10990],{"trials":11041,"activeCount":102},[11042,11048,11054],{"nctId":11043,"briefTitle":11044,"status":108,"phases":11045,"primaryCompletion":9909,"completion":9909,"start":10072,"enrollment":668,"conditions":11046,"interventions":11047},"NCT00402441","Risedronate in the Prevention of Osteoporosis in Postmenopausal Women",[93],[11014],[10990],{"nctId":11049,"briefTitle":11050,"status":884,"phases":11051,"primaryCompletion":3622,"start":9862,"enrollment":538,"conditions":11052,"interventions":11053},"NCT00544180","ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week",[93],[11023],[10990],{"nctId":11055,"briefTitle":11056,"status":884,"phases":11057,"completion":3633,"start":9909,"enrollment":622,"conditions":11058,"interventions":11059},"NCT00790101","Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation",[93],[11014],[10990,11060],"Raloxifene",{"trials":11062,"activeCount":102},[],{"intervention":11064,"totalTrials":535,"cells":11065},"Enoxaparin",{"EARLY_PHASE1":11066,"PHASE1":11068,"PHASE2":11076,"PHASE3":11078,"PHASE4":11121,"NA":11139},{"trials":11067,"activeCount":102},[],{"trials":11069,"activeCount":102},[11070],{"nctId":11071,"briefTitle":11072,"status":108,"phases":11073,"primaryCompletion":8607,"completion":8607,"start":3563,"enrollment":8717,"conditions":11074,"interventions":11075},"NCT00622115","Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)",[90],[9602],[11064],{"trials":11077,"activeCount":102},[],{"trials":11079,"activeCount":102},[11080,11090,11098,11107,11114],{"nctId":11081,"briefTitle":11082,"status":108,"phases":11083,"primaryCompletion":8453,"completion":8453,"start":8395,"enrollment":11084,"conditions":11085,"interventions":11087},"NCT00345618","Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach",[92],3202,[11086,9602],"Embolism",[11088,1407,11089,11064],"Idrabiotaparinux sodium","Avidin",{"nctId":11091,"briefTitle":11092,"status":108,"phases":11093,"primaryCompletion":5272,"completion":5272,"start":3608,"enrollment":349,"conditions":11094,"interventions":11096},"NCT00685958","Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery",[92],[11095],"Hip Fractures",[11097],"enoxaparin",{"nctId":11099,"briefTitle":11100,"status":108,"phases":11101,"primaryCompletion":9292,"start":11102,"enrollment":11103,"conditions":11104,"interventions":11106},"NCT00043784","SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes",[92],"2001-08",8000,[11105,9544,9716],"Unstable Angina",[11097],{"nctId":11108,"briefTitle":11109,"status":108,"phases":11110,"primaryCompletion":8261,"completion":8261,"start":8196,"enrollment":11111,"conditions":11112,"interventions":11113},"NCT00718224","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery",[92],1150,[10323],[10325,11064],{"nctId":11115,"briefTitle":11116,"status":108,"phases":11117,"primaryCompletion":7509,"completion":7509,"start":5272,"enrollment":3915,"conditions":11118,"interventions":11120},"NCT00723216","Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery",[92],[11119],"Abdominal Neoplasms",[11097],{"trials":11122,"activeCount":102},[11123,11131],{"nctId":11124,"briefTitle":11125,"status":108,"phases":11126,"primaryCompletion":8693,"completion":8693,"start":8762,"enrollment":11127,"conditions":11128,"interventions":11130},"NCT00622648","Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin",[93],8329,[11129],"Acute Illness",[11064],{"nctId":11132,"briefTitle":11133,"status":108,"phases":11134,"primaryCompletion":9532,"completion":9532,"start":8184,"enrollment":11135,"conditions":11136,"interventions":11138},"NCT00265993","Enoxaparin in Acute Venous Thromboembolic Disease",[93],251,[11137],"Venous Thrombosis",[11097],{"trials":11140,"activeCount":102},[],{"intervention":11142,"totalTrials":535,"cells":11143},"Insulin glargine HOE901",{"EARLY_PHASE1":11144,"PHASE1":11146,"PHASE2":11175,"PHASE3":11184,"PHASE4":11204,"NA":11214},{"trials":11145,"activeCount":102},[],{"trials":11147,"activeCount":102},[11148,11155,11162,11169],{"nctId":11149,"briefTitle":11150,"status":108,"phases":11151,"primaryCompletion":5217,"completion":1339,"start":978,"enrollment":1601,"conditions":11152,"interventions":11153},"NCT01146678","Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1",[90],[554],[11142,11154],"Lixisenatide AVE0010",{"nctId":11156,"briefTitle":11157,"status":108,"phases":11158,"primaryCompletion":2856,"completion":2856,"start":965,"enrollment":576,"conditions":11159,"interventions":11160},"NCT02713477","Postprandial Glucodynamic Response to Insulin Glargine\u002FLixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus",[90],[19],[11161,11142],"Insulin glargine\u002F lixisenatide fixed-ratio combination HOE901\u002FAVE0010",{"nctId":11163,"briefTitle":11164,"status":108,"phases":11165,"primaryCompletion":3416,"completion":3416,"start":8062,"enrollment":284,"conditions":11166,"interventions":11167},"NCT01493115","Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus",[90],[554],[11142,11168],"Insulin glargine - New formulation HOE901",{"nctId":11170,"briefTitle":11171,"status":108,"phases":11172,"primaryCompletion":7292,"completion":7292,"start":165,"enrollment":3740,"conditions":11173,"interventions":11174},"NCT01349855","Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus",[90],[554],[11142],{"trials":11176,"activeCount":102},[11177],{"nctId":11178,"briefTitle":11179,"status":108,"phases":11180,"primaryCompletion":9984,"completion":987,"start":955,"enrollment":37,"conditions":11181,"interventions":11182},"NCT01053728","Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)",[90,91],[554],[11183,11142],"SAR161271",{"trials":11185,"activeCount":102},[11186,11196],{"nctId":11187,"briefTitle":11188,"status":108,"phases":11189,"primaryCompletion":1355,"completion":1355,"start":1031,"enrollment":11190,"conditions":11191,"interventions":11192},"NCT02294474","Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",[92],505,[19],[11193,11194,11195],"SAR342434","Humalog","insulin glargine HOE901",{"nctId":11197,"briefTitle":11198,"status":108,"phases":11199,"primaryCompletion":3429,"completion":11200,"start":5216,"enrollment":11201,"conditions":11202,"interventions":11203},"NCT02273180","Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine",[92],"2016-07",507,[554],[11193,11194,11142],{"trials":11205,"activeCount":102},[11206],{"nctId":11207,"briefTitle":11208,"status":108,"phases":11209,"primaryCompletion":3459,"completion":3459,"start":11210,"enrollment":11211,"conditions":11212,"interventions":11213},"NCT02200991","Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine",[93],"2014-08",136,[19],[8090,8142,11142],{"trials":11215,"activeCount":102},[],{"intervention":3863,"totalTrials":538,"cells":11217},{"EARLY_PHASE1":11218,"PHASE1":11220,"PHASE2":11222,"PHASE3":11224,"PHASE4":11256,"NA":11262},{"trials":11219,"activeCount":102},[],{"trials":11221,"activeCount":102},[],{"trials":11223,"activeCount":102},[],{"trials":11225,"activeCount":102},[11226,11230,11234,11244,11248,11252],{"nctId":3853,"briefTitle":3854,"status":108,"phases":11227,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":11228,"interventions":11229},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":10200,"briefTitle":10201,"status":108,"phases":11231,"primaryCompletion":10203,"completion":10203,"start":10204,"enrollment":10205,"conditions":11232,"interventions":11233},[92],[3892],[10208,3846,7441,7442,6459],{"nctId":11235,"briefTitle":11236,"status":108,"phases":11237,"primaryCompletion":11238,"completion":11238,"start":11239,"enrollment":6577,"conditions":11240,"interventions":11241},"NCT04669041","A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe\u002FRosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy",[92],"2022-06-15","2020-12-08",[3892],[3863,11242,11243],"SPC ezetimibe\u002Frosuvastatin","Rosuvastatin active",{"nctId":10210,"briefTitle":10211,"status":108,"phases":11245,"primaryCompletion":6484,"completion":6484,"start":10213,"enrollment":369,"conditions":11246,"interventions":11247},[92],[3842],[3862,3864,3863],{"nctId":7434,"briefTitle":7435,"status":108,"phases":11249,"primaryCompletion":2662,"completion":2662,"start":7437,"enrollment":7438,"conditions":11250,"interventions":11251},[92],[3892],[7273,3846,7441,7442,6459],{"nctId":3886,"briefTitle":3887,"status":108,"phases":11253,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":11254,"interventions":11255},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":11257,"activeCount":102},[11258],{"nctId":10223,"briefTitle":10224,"status":108,"phases":11259,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":11260,"interventions":11261},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":11263,"activeCount":102},[],{"intervention":2752,"totalTrials":538,"cells":11265},{"EARLY_PHASE1":11266,"PHASE1":11268,"PHASE2":11276,"PHASE3":11295,"PHASE4":11297,"NA":11311},{"trials":11267,"activeCount":102},[],{"trials":11269,"activeCount":102},[11270],{"nctId":11271,"briefTitle":11272,"status":108,"phases":11273,"primaryCompletion":10811,"completion":10811,"start":3416,"enrollment":2636,"conditions":11274,"interventions":11275},"NCT01527929","Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment",[90],[1193],[2752],{"trials":11277,"activeCount":102},[11278,11282,11289],{"nctId":2744,"briefTitle":2745,"status":884,"phases":11279,"primaryCompletion":2747,"completion":2747,"start":2748,"enrollment":535,"conditions":11280,"interventions":11281},[91],[2750],[2752,2753,2754,671],{"nctId":11283,"briefTitle":11284,"status":108,"phases":11285,"primaryCompletion":2487,"completion":7430,"start":8683,"enrollment":112,"conditions":11286,"interventions":11287},"NCT01511536","Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer",[90,91],[1357],[2752,2754,11288],"Prednisone 5 mg",{"nctId":11290,"briefTitle":11291,"status":108,"phases":11292,"primaryCompletion":8106,"completion":8106,"start":977,"enrollment":988,"conditions":11293,"interventions":11294},"NCT01497964","Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy",[90,91],[5395],[2873],{"trials":11296,"activeCount":102},[],{"trials":11298,"activeCount":102},[11299,11303,11307],{"nctId":2842,"briefTitle":2843,"status":108,"phases":11300,"primaryCompletion":1054,"completion":1054,"start":2487,"enrollment":552,"conditions":11301,"interventions":11302},[93],[2750],[1359,671,672],{"nctId":1352,"briefTitle":1353,"status":108,"phases":11304,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":11305,"interventions":11306},[93],[1357],[1359,1360,672,1361,1362,1363,642],{"nctId":2864,"briefTitle":2865,"status":108,"phases":11308,"primaryCompletion":2867,"completion":2868,"start":2869,"enrollment":2870,"conditions":11309,"interventions":11310},[93],[2750],[2873,2874,2875,1780],{"trials":11312,"activeCount":102},[],{"intervention":11314,"totalTrials":538,"cells":11315},"lactoserum",{"EARLY_PHASE1":11316,"PHASE1":11318,"PHASE2":11320,"PHASE3":11322,"PHASE4":11348,"NA":11370},{"trials":11317,"activeCount":102},[],{"trials":11319,"activeCount":102},[],{"trials":11321,"activeCount":102},[],{"trials":11323,"activeCount":102},[11324,11330,11336,11342],{"nctId":11325,"briefTitle":11326,"status":108,"phases":11327,"start":8753,"enrollment":7653,"conditions":11328,"interventions":11329},"NCT00371852","Topic Compatibility Dermacyd Wipes - Lactoserum - Hygiene",[92],[33],[11314],{"nctId":11331,"briefTitle":11332,"status":108,"phases":11333,"start":3608,"enrollment":3740,"conditions":11334,"interventions":11335},"NCT00397527","Acceptability Dermacyd Wipes - Lactoserum - Hygiene",[92],[33],[11314],{"nctId":11337,"briefTitle":11338,"status":108,"phases":11339,"start":8753,"enrollment":7653,"conditions":11340,"interventions":11341},"NCT00380991","Topic Compatibility Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene",[92],[33],[11314],{"nctId":11343,"briefTitle":11344,"status":108,"phases":11345,"start":8395,"enrollment":3740,"conditions":11346,"interventions":11347},"NCT00370162","Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene",[92],[33],[11314],{"trials":11349,"activeCount":102},[11350,11357,11363],{"nctId":11351,"briefTitle":11352,"status":108,"phases":11353,"start":3308,"enrollment":3740,"conditions":11354,"interventions":11355},"NCT00497783","Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)",[93],[33],[11356],"Lactoserum",{"nctId":11358,"briefTitle":11359,"status":108,"phases":11360,"start":3308,"enrollment":3740,"conditions":11361,"interventions":11362},"NCT00497692","Topic Compatibility Lactoserum (Dermacyd Delicata - New Fragrance)",[93],[33],[11356],{"nctId":11364,"briefTitle":11365,"status":108,"phases":11366,"primaryCompletion":8205,"start":1341,"enrollment":2403,"conditions":11367,"interventions":11369},"NCT00556179","Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis",[93],[11368],"Bacterial Vaginosis",[11356],{"trials":11371,"activeCount":102},[],{"intervention":3871,"totalTrials":622,"cells":11373},{"EARLY_PHASE1":11374,"PHASE1":11376,"PHASE2":11382,"PHASE3":11388,"PHASE4":11398,"NA":11408},{"trials":11375,"activeCount":102},[],{"trials":11377,"activeCount":102},[11378],{"nctId":7280,"briefTitle":7281,"status":108,"phases":11379,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":1874,"conditions":11380,"interventions":11381},[90],[3892],[7273,3869,7287,3871],{"trials":11383,"activeCount":102},[11384],{"nctId":3835,"briefTitle":3836,"status":108,"phases":11385,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":11386,"interventions":11387},[91],[3842],[3844,3845,3846,3831,3847,3848,3849],{"trials":11389,"activeCount":102},[11390,11394],{"nctId":3853,"briefTitle":3854,"status":108,"phases":11391,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":11392,"interventions":11393},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":3886,"briefTitle":3887,"status":108,"phases":11395,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":11396,"interventions":11397},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":11399,"activeCount":102},[11400,11404],{"nctId":7446,"briefTitle":7447,"status":108,"phases":11401,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":11402,"interventions":11403},[93],[7454],[7273,7456,3869,3871,3870,3872,7412],{"nctId":10223,"briefTitle":10224,"status":108,"phases":11405,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":11406,"interventions":11407},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":11409,"activeCount":102},[],{"intervention":10772,"totalTrials":622,"cells":11411},{"EARLY_PHASE1":11412,"PHASE1":11414,"PHASE2":11416,"PHASE3":11422,"PHASE4":11440,"NA":11446},{"trials":11413,"activeCount":102},[],{"trials":11415,"activeCount":102},[],{"trials":11417,"activeCount":102},[11418],{"nctId":10767,"briefTitle":10768,"status":108,"phases":11419,"primaryCompletion":8106,"completion":8106,"start":7349,"enrollment":5407,"conditions":11420,"interventions":11421},[91],[554],[10772,8189],{"trials":11423,"activeCount":102},[11424,11428,11432,11436],{"nctId":10784,"briefTitle":10785,"status":108,"phases":11425,"primaryCompletion":2311,"completion":1055,"start":10178,"enrollment":10787,"conditions":11426,"interventions":11427},[92],[554],[10772,8189],{"nctId":10795,"briefTitle":10796,"status":108,"phases":11429,"primaryCompletion":8298,"completion":2311,"start":977,"enrollment":10798,"conditions":11430,"interventions":11431},[92],[19],[10772,8189],{"nctId":10802,"briefTitle":10803,"status":108,"phases":11433,"primaryCompletion":2311,"completion":1055,"start":7349,"enrollment":8227,"conditions":11434,"interventions":11435},[92],[19],[10772,8189],{"nctId":10808,"briefTitle":10809,"status":108,"phases":11437,"primaryCompletion":1032,"completion":10811,"start":977,"enrollment":8206,"conditions":11438,"interventions":11439},[92],[19],[8189,10772],{"trials":11441,"activeCount":102},[11442],{"nctId":10824,"briefTitle":10825,"status":108,"phases":11443,"primaryCompletion":10827,"completion":10827,"start":10828,"enrollment":10829,"conditions":11444,"interventions":11445},[93],[554],[10772,8189,10832],{"trials":11447,"activeCount":102},[],{"intervention":11449,"totalTrials":622,"cells":11450},"Zolpidem",{"EARLY_PHASE1":11451,"PHASE1":11453,"PHASE2":11455,"PHASE3":11457,"PHASE4":11476,"NA":11506},{"trials":11452,"activeCount":102},[],{"trials":11454,"activeCount":102},[],{"trials":11456,"activeCount":102},[],{"trials":11458,"activeCount":102},[11459,11467],{"nctId":11460,"briefTitle":11461,"status":108,"phases":11462,"primaryCompletion":5262,"completion":5262,"start":9513,"enrollment":11463,"conditions":11464,"interventions":11466},"NCT00318448","Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia",[92],201,[11465],"Attention Deficit Hyperactivity Disorder",[11449],{"nctId":11468,"briefTitle":11469,"status":108,"phases":11470,"primaryCompletion":9826,"completion":9826,"start":9872,"enrollment":6540,"conditions":11471,"interventions":11473},"NCT00630175","Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia",[92],[11472],"Sleep Initiation and Maintenance Disorders",[11474,11475],"zolpidem-MR","zolpidem",{"trials":11477,"activeCount":102},[11478,11485,11492,11500],{"nctId":11479,"briefTitle":11480,"status":108,"phases":11481,"completion":8395,"start":8659,"enrollment":4920,"conditions":11482,"interventions":11484},"NCT00292734","STILDEP: Zolpidem in Depressive and Dysthimic Patients",[93],[11472,11483],"Depression",[11449],{"nctId":11486,"briefTitle":11487,"status":108,"phases":11488,"primaryCompletion":1341,"start":3608,"enrollment":2018,"conditions":11489,"interventions":11491},"NCT00359229","Stilnox Treatment in Elderly Patients With Insomnia",[93],[11490],"Insomnia",[11449],{"nctId":11493,"briefTitle":11494,"status":108,"phases":11495,"primaryCompletion":2790,"completion":2790,"start":1022,"enrollment":3740,"conditions":11496,"interventions":11498},"NCT01097382","Sleep Satisfaction and Psychomotor Performance of Adults",[93],[11497],"Sleep Disorders",[11499],"ZOLPIDEM",{"nctId":11501,"briefTitle":11502,"status":108,"phases":11503,"primaryCompletion":9909,"completion":9909,"start":3326,"enrollment":10074,"conditions":11504,"interventions":11505},"NCT00530556","Insomnia and Daytime Function in Osteoarthritis",[93],[11497],[11475],{"trials":11507,"activeCount":102},[],{"intervention":11509,"totalTrials":622,"cells":11510},"Ramipril",{"EARLY_PHASE1":11511,"PHASE1":11513,"PHASE2":11525,"PHASE3":11527,"PHASE4":11542,"NA":11567},{"trials":11512,"activeCount":102},[],{"trials":11514,"activeCount":102},[11515],{"nctId":11516,"briefTitle":11517,"status":108,"phases":11518,"primaryCompletion":11519,"completion":11519,"start":11520,"enrollment":988,"conditions":11521,"interventions":11523},"NCT03414723","A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril",[90],"2018-03-10","2018-01-15",[8187,11522],"Healthy Subjects",[11524,11509],"Sotagliflozin",{"trials":11526,"activeCount":102},[],{"trials":11528,"activeCount":102},[11529,11535],{"nctId":11530,"briefTitle":11531,"status":108,"phases":11532,"primaryCompletion":9706,"start":9909,"conditions":11533,"interventions":11534},"NCT00268619","FOCUS:Focus On Coronary Unstable Syndromes",[92],[9716],[11509],{"nctId":11536,"briefTitle":11537,"status":108,"phases":11538,"primaryCompletion":5217,"completion":5217,"start":7482,"enrollment":178,"conditions":11539,"interventions":11541},"NCT00437463","Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor",[92],[11540],"Glomerulonephritis",[11509],{"trials":11543,"activeCount":102},[11544,11551,11559],{"nctId":11545,"briefTitle":11546,"status":108,"phases":11547,"primaryCompletion":2799,"completion":2799,"start":9532,"enrollment":9533,"conditions":11548,"interventions":11549},"NCT00841880","China Medical University Hospital (CMUH) Triapin Listing",[93],[9680],[11550,11509,11509],"Ramipril + Felodipine",{"nctId":11552,"briefTitle":11553,"status":108,"phases":11554,"primaryCompletion":8579,"completion":8579,"start":11555,"enrollment":11556,"conditions":11557,"interventions":11558},"NCT00325806","Ramipril - Hypertension",[93],"2000-05",1008,[9680],[11509],{"nctId":11560,"briefTitle":11561,"status":108,"phases":11562,"primaryCompletion":9706,"start":3488,"enrollment":11563,"conditions":11564,"interventions":11566},"NCT01053910","Ramipril 10 mg\u002FDay Prevention",[93],1012,[11565],"Atherosclerosis",[11509],{"trials":11568,"activeCount":102},[],{"intervention":8200,"totalTrials":622,"cells":11570},{"EARLY_PHASE1":11571,"PHASE1":11573,"PHASE2":11575,"PHASE3":11577,"PHASE4":11595,"NA":11605},{"trials":11572,"activeCount":102},[],{"trials":11574,"activeCount":102},[],{"trials":11576,"activeCount":102},[],{"trials":11578,"activeCount":102},[11579,11583,11587,11591],{"nctId":8193,"briefTitle":8194,"status":108,"phases":11580,"primaryCompletion":1339,"completion":1339,"start":8196,"enrollment":8197,"conditions":11581,"interventions":11582},[92],[22],[8046,8200,8024],{"nctId":8267,"briefTitle":8268,"status":884,"phases":11584,"primaryCompletion":8270,"completion":8270,"start":8271,"enrollment":8272,"conditions":11585,"interventions":11586},[92],[19],[8275,8037,8276],{"nctId":9421,"briefTitle":9422,"status":108,"phases":11588,"primaryCompletion":978,"completion":978,"start":8349,"enrollment":8608,"conditions":11589,"interventions":11590},[92],[22],[8046,8200,8047],{"nctId":8321,"briefTitle":8322,"status":108,"phases":11592,"primaryCompletion":977,"completion":977,"start":3366,"enrollment":8324,"conditions":11593,"interventions":11594},[92],[19],[8046,8024,8200],{"trials":11596,"activeCount":102},[11597,11601],{"nctId":8427,"briefTitle":8428,"status":108,"phases":11598,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":11599,"interventions":11600},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"nctId":8441,"briefTitle":8442,"status":108,"phases":11602,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":513,"conditions":11603,"interventions":11604},[93],[22],[8046,8200,8037,8448],{"trials":11606,"activeCount":102},[],{"intervention":8551,"totalTrials":622,"cells":11608},{"EARLY_PHASE1":11609,"PHASE1":11611,"PHASE2":11617,"PHASE3":11619,"PHASE4":11632,"NA":11657},{"trials":11610,"activeCount":102},[],{"trials":11612,"activeCount":102},[11613],{"nctId":8543,"briefTitle":8544,"status":108,"phases":11614,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":359,"conditions":11615,"interventions":11616},[90],[8549],[8335,8335,8508,8551,8552,8553,8554],{"trials":11618,"activeCount":102},[],{"trials":11620,"activeCount":102},[11621,11628],{"nctId":11622,"briefTitle":11623,"status":108,"phases":11624,"primaryCompletion":1055,"completion":1055,"start":3821,"enrollment":11625,"conditions":11626,"interventions":11627},"NCT01223131","Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.",[92],162,[554],[8067,8551],{"nctId":8663,"briefTitle":8664,"status":108,"phases":11629,"primaryCompletion":8666,"completion":8666,"start":8667,"enrollment":8668,"conditions":11630,"interventions":11631},[92],[8670],[8335,8672,8424,8551],{"trials":11633,"activeCount":102},[11634,11638,11648],{"nctId":8714,"briefTitle":8715,"status":108,"phases":11635,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":8717,"conditions":11636,"interventions":11637},[93],[22],[8256,8551,8687,8720],{"nctId":11639,"briefTitle":11640,"status":108,"phases":11641,"primaryCompletion":11642,"completion":11642,"start":11643,"enrollment":10321,"conditions":11644,"interventions":11645},"NCT02967224","A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin",[93],"2017-10-16","2015-11-05",[22],[8424,8424,8551,11646,11647],"insulin detemir","insulin degludec",{"nctId":11649,"briefTitle":11650,"status":108,"phases":11651,"primaryCompletion":11652,"completion":11652,"start":11653,"enrollment":11654,"conditions":11655,"interventions":11656},"NCT02967211","A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin",[93],"2017-10-20","2015-12-21",609,[22],[8424,8424,8551,11646,11647],{"trials":11658,"activeCount":102},[],{"intervention":11660,"totalTrials":622,"cells":11661},"Risedronate Sodium",{"EARLY_PHASE1":11662,"PHASE1":11664,"PHASE2":11666,"PHASE3":11668,"PHASE4":11670,"NA":11717},{"trials":11663,"activeCount":102},[],{"trials":11665,"activeCount":102},[],{"trials":11667,"activeCount":102},[],{"trials":11669,"activeCount":102},[],{"trials":11671,"activeCount":102},[11672,11679,11689,11695,11702,11710],{"nctId":11673,"briefTitle":11674,"status":108,"phases":11675,"completion":8753,"start":8526,"enrollment":11676,"conditions":11677,"interventions":11678},"NCT00632216","A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis",[93],464,[11014],[11660],{"nctId":11680,"briefTitle":11681,"status":108,"phases":11682,"primaryCompletion":986,"completion":986,"start":5272,"enrollment":11683,"conditions":11684,"interventions":11686},"NCT00460733","SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.",[93],141,[11685],"Colles' Fracture",[11687,11688],"Risedronate sodium","Calcium & Vitamine D3",{"nctId":11690,"briefTitle":11691,"status":108,"phases":11692,"start":3488,"enrollment":6493,"conditions":11693,"interventions":11694},"NCT00549965","Satisfaction and Compliance of Risedronate in PMO",[93],[11014],[11660],{"nctId":11696,"briefTitle":11697,"status":108,"phases":11698,"completion":8175,"start":3528,"enrollment":11699,"conditions":11700,"interventions":11701},"NCT00549068","POWER Point of Care Effect on Satisfaction of Treatment",[93],2433,[11014],[11660],{"nctId":11703,"briefTitle":11704,"status":108,"phases":11705,"completion":5272,"start":9522,"enrollment":11706,"conditions":11707,"interventions":11708},"NCT00130403","OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women",[93],290,[11014],[11709],"risedronate sodium",{"nctId":11711,"briefTitle":11712,"status":108,"phases":11713,"start":3527,"enrollment":11714,"conditions":11715,"interventions":11716},"NCT00453492","Risedronate Sodium in Post Menopausal Osteoporosis",[93],246,[11014],[11709],{"trials":11718,"activeCount":102},[],{"intervention":1015,"totalTrials":339,"cells":11720},{"EARLY_PHASE1":11721,"PHASE1":11723,"PHASE2":11725,"PHASE3":11727,"PHASE4":11748,"NA":11754},{"trials":11722,"activeCount":102},[],{"trials":11724,"activeCount":102},[],{"trials":11726,"activeCount":102},[],{"trials":11728,"activeCount":102},[11729,11733,11737,11744],{"nctId":1008,"briefTitle":1009,"status":108,"phases":11730,"primaryCompletion":1011,"completion":1011,"start":164,"enrollment":1012,"conditions":11731,"interventions":11732},[92],[990],[942,1015,993,1016,1017],{"nctId":6490,"briefTitle":6491,"status":108,"phases":11734,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":11735,"interventions":11736},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"nctId":11738,"briefTitle":11739,"status":108,"phases":11740,"primaryCompletion":6471,"completion":7330,"start":8683,"enrollment":7363,"conditions":11741,"interventions":11743},"NCT01551069","Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion",[92],[11742],"Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus",[1015],{"nctId":1051,"briefTitle":1052,"status":108,"phases":11745,"primaryCompletion":1042,"completion":1054,"start":1055,"enrollment":1056,"conditions":11746,"interventions":11747},[92],[1058],[942,971,1045,1046,1060],{"trials":11749,"activeCount":102},[11750],{"nctId":1074,"briefTitle":1075,"status":108,"phases":11751,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":11752,"interventions":11753},[93],[990],[1082,1083,1084,1060,1046,971,1045],{"trials":11755,"activeCount":102},[],{"intervention":1045,"totalTrials":339,"cells":11757},{"EARLY_PHASE1":11758,"PHASE1":11760,"PHASE2":11762,"PHASE3":11764,"PHASE4":11782,"NA":11788},{"trials":11759,"activeCount":102},[],{"trials":11761,"activeCount":102},[],{"trials":11763,"activeCount":102},[],{"trials":11765,"activeCount":102},[11766,11770,11774,11778],{"nctId":1008,"briefTitle":1009,"status":108,"phases":11767,"primaryCompletion":1011,"completion":1011,"start":164,"enrollment":1012,"conditions":11768,"interventions":11769},[92],[990],[942,1015,993,1016,1017],{"nctId":6490,"briefTitle":6491,"status":108,"phases":11771,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":11772,"interventions":11773},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"nctId":1038,"briefTitle":1039,"status":108,"phases":11775,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":726,"conditions":11776,"interventions":11777},[92],[990],[942,1045,1046,1047,1048,1049],{"nctId":1051,"briefTitle":1052,"status":108,"phases":11779,"primaryCompletion":1042,"completion":1054,"start":1055,"enrollment":1056,"conditions":11780,"interventions":11781},[92],[1058],[942,971,1045,1046,1060],{"trials":11783,"activeCount":102},[11784],{"nctId":1074,"briefTitle":1075,"status":108,"phases":11785,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":11786,"interventions":11787},[93],[990],[1082,1083,1084,1060,1046,971,1045],{"trials":11789,"activeCount":102},[],{"intervention":11791,"totalTrials":339,"cells":11792},"lixisenatide AVE0010",{"EARLY_PHASE1":11793,"PHASE1":11795,"PHASE2":11801,"PHASE3":11807,"PHASE4":11826,"NA":11832},{"trials":11794,"activeCount":102},[],{"trials":11796,"activeCount":102},[11797],{"nctId":11149,"briefTitle":11150,"status":108,"phases":11798,"primaryCompletion":5217,"completion":1339,"start":978,"enrollment":1601,"conditions":11799,"interventions":11800},[90],[554],[11142,11154],{"trials":11802,"activeCount":102},[11803],{"nctId":8084,"briefTitle":8085,"status":884,"phases":11804,"primaryCompletion":2759,"completion":2759,"start":151,"enrollment":659,"conditions":11805,"interventions":11806},[91],[8088],[8090,8037],{"trials":11808,"activeCount":102},[11809,11815],{"nctId":11810,"briefTitle":11811,"status":108,"phases":11812,"primaryCompletion":1011,"completion":1011,"start":10811,"enrollment":9413,"conditions":11813,"interventions":11814},"NCT01960179","Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes",[92],[19],[11791],{"nctId":11816,"briefTitle":11817,"status":108,"phases":11818,"primaryCompletion":964,"completion":964,"start":2311,"enrollment":11819,"conditions":11820,"interventions":11821},"NCT01940965","Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes",[92],294,[19],[11791,11822,11823,11824,11825],"biguanide","TZD","alpha-GI","glinide",{"trials":11827,"activeCount":102},[11828],{"nctId":11207,"briefTitle":11208,"status":108,"phases":11829,"primaryCompletion":3459,"completion":3459,"start":11210,"enrollment":11211,"conditions":11830,"interventions":11831},[93],[19],[8090,8142,11142],{"trials":11833,"activeCount":102},[],{"intervention":8056,"totalTrials":339,"cells":11835},{"EARLY_PHASE1":11836,"PHASE1":11838,"PHASE2":11840,"PHASE3":11854,"PHASE4":11873,"NA":11879},{"trials":11837,"activeCount":102},[],{"trials":11839,"activeCount":102},[],{"trials":11841,"activeCount":102},[11842,11846,11850],{"nctId":8051,"briefTitle":8052,"status":108,"phases":11843,"primaryCompletion":7283,"completion":7283,"start":5238,"enrollment":313,"conditions":11844,"interventions":11845},[91],[19],[8046,8056,8057,8024],{"nctId":8069,"briefTitle":8070,"status":108,"phases":11847,"primaryCompletion":987,"completion":987,"start":5271,"enrollment":8072,"conditions":11848,"interventions":11849},[91],[19],[8046,8056,8024],{"nctId":8076,"briefTitle":8077,"status":108,"phases":11851,"primaryCompletion":8079,"completion":8079,"start":8080,"enrollment":190,"conditions":11852,"interventions":11853},[91],[19],[8036,8056,8024],{"trials":11855,"activeCount":102},[11856],{"nctId":11857,"briefTitle":11858,"status":108,"phases":11859,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":11864,"interventions":11865},"NCT02787551","Efficacy and Safety of the Insulin Glargine\u002FLixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",[92],"2018-05-25","2018-11-17","2016-07-06",514,[19],[11866,11867,11868,11869,11870,11871,11872],"Insulin glargine\u002Flixisenatide fixed ratio combination","liraglutide","exenatide","exenatide extended-release","albiglutide","dulaglutide","Background therapy: Oral Anti-diabetic Drug",{"trials":11874,"activeCount":102},[11875],{"nctId":8479,"briefTitle":8480,"status":108,"phases":11876,"primaryCompletion":164,"completion":2760,"start":3366,"enrollment":8482,"conditions":11877,"interventions":11878},[93],[22],[8067,8056,8024],{"trials":11880,"activeCount":102},[],{"intervention":8142,"totalTrials":339,"cells":11882},{"EARLY_PHASE1":11883,"PHASE1":11885,"PHASE2":11887,"PHASE3":11889,"PHASE4":11899,"NA":11913},{"trials":11884,"activeCount":102},[],{"trials":11886,"activeCount":102},[],{"trials":11888,"activeCount":102},[],{"trials":11890,"activeCount":102},[11891,11895],{"nctId":8136,"briefTitle":8137,"status":108,"phases":11892,"primaryCompletion":986,"completion":986,"start":3307,"enrollment":8139,"conditions":11893,"interventions":11894},[92],[22],[8057,8142,8024],{"nctId":8212,"briefTitle":8213,"status":108,"phases":11896,"primaryCompletion":165,"completion":165,"start":8215,"enrollment":8216,"conditions":11897,"interventions":11898},[92],[19],[8046,8219,8142,8220,8024],{"trials":11900,"activeCount":102},[11901,11905,11909],{"nctId":8403,"briefTitle":8404,"status":108,"phases":11902,"primaryCompletion":8406,"completion":8406,"start":8235,"enrollment":8407,"conditions":11903,"interventions":11904},[93],[22],[8057,8142,8024],{"nctId":10105,"briefTitle":10106,"status":108,"phases":11906,"primaryCompletion":8453,"completion":8453,"start":8731,"enrollment":504,"conditions":11907,"interventions":11908},[93],[22],[8343,10110],{"nctId":11207,"briefTitle":11208,"status":108,"phases":11910,"primaryCompletion":3459,"completion":3459,"start":11210,"enrollment":11211,"conditions":11911,"interventions":11912},[93],[19],[8090,8142,11142],{"trials":11914,"activeCount":102},[],{"intervention":11916,"totalTrials":339,"cells":11917},"Amisulpride",{"EARLY_PHASE1":11918,"PHASE1":11920,"PHASE2":11922,"PHASE3":11931,"PHASE4":11933,"NA":11962},{"trials":11919,"activeCount":102},[],{"trials":11921,"activeCount":102},[],{"trials":11923,"activeCount":102},[11924],{"nctId":11925,"briefTitle":11926,"status":108,"phases":11927,"start":8526,"enrollment":4920,"conditions":11928,"interventions":11930},"NCT00126009","SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients",[91],[11929],"Bipolar Disorder",[11916],{"trials":11932,"activeCount":102},[],{"trials":11934,"activeCount":102},[11935,11942,11949,11955],{"nctId":11936,"briefTitle":11937,"status":108,"phases":11938,"start":9826,"enrollment":216,"conditions":11939,"interventions":11941},"NCT00331981","Amisulpride in Schizophrenic Patients",[93],[11940],"Schizophrenia",[11916],{"nctId":11943,"briefTitle":11944,"status":108,"phases":11945,"primaryCompletion":6471,"completion":6471,"start":7284,"enrollment":7331,"conditions":11946,"interventions":11947},"NCT01795183","Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia",[93],[11940],[11948],"AMISULPRIDE",{"nctId":11950,"briefTitle":11951,"status":108,"phases":11952,"primaryCompletion":8666,"start":9862,"enrollment":7653,"conditions":11953,"interventions":11954},"NCT00436371","Amisulpride in Schizophrenic Acute Phase Patients",[93],[11940],[11916],{"nctId":11956,"briefTitle":11957,"status":108,"phases":11958,"start":5250,"enrollment":1091,"conditions":11959,"interventions":11960},"NCT00245674","SOLIACS: Solian Solution in the Acute Setting",[93],[11940],[11961],"amisulpride",{"trials":11963,"activeCount":102},[],{"intervention":8766,"totalTrials":339,"cells":11965},{"EARLY_PHASE1":11966,"PHASE1":11968,"PHASE2":11983,"PHASE3":11985,"PHASE4":11998,"NA":12004},{"trials":11967,"activeCount":102},[],{"trials":11969,"activeCount":102},[11970,11977],{"nctId":11971,"briefTitle":11972,"status":108,"phases":11973,"primaryCompletion":7283,"completion":7283,"start":2760,"enrollment":3740,"conditions":11974,"interventions":11975},"NCT02273258","A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes",[90],[591],[11193,11976,11976],"Insulin Lispro",{"nctId":11978,"briefTitle":11979,"status":108,"phases":11980,"primaryCompletion":965,"completion":965,"start":3459,"enrollment":6434,"conditions":11981,"interventions":11982},"NCT02603510","Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion",[90],[554],[11193,8672],{"trials":11984,"activeCount":102},[],{"trials":11986,"activeCount":102},[11987,11994],{"nctId":11988,"briefTitle":11989,"status":108,"phases":11990,"primaryCompletion":165,"completion":165,"start":3354,"enrollment":3767,"conditions":11991,"interventions":11992},"NCT00993473","6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes",[92],[554],[8067,11993,8766],"Neutral Protamine Hagedorn (NPH) insulin",{"nctId":8663,"briefTitle":8664,"status":108,"phases":11995,"primaryCompletion":8666,"completion":8666,"start":8667,"enrollment":8668,"conditions":11996,"interventions":11997},[92],[8670],[8335,8672,8424,8551],{"trials":11999,"activeCount":102},[12000],{"nctId":8759,"briefTitle":8760,"status":108,"phases":12001,"primaryCompletion":3307,"completion":3307,"start":8762,"enrollment":8763,"conditions":12002,"interventions":12003},[93],[578],[8335,8766,8508],{"trials":12005,"activeCount":102},[],{"intervention":3798,"totalTrials":339,"cells":12007},{"EARLY_PHASE1":12008,"PHASE1":12010,"PHASE2":12020,"PHASE3":12022,"PHASE4":12032,"NA":12042},{"trials":12009,"activeCount":102},[],{"trials":12011,"activeCount":102},[12012,12016],{"nctId":3818,"briefTitle":3819,"status":108,"phases":12013,"primaryCompletion":3821,"completion":165,"start":987,"enrollment":988,"conditions":12014,"interventions":12015},[90],[3731],[3798,1801],{"nctId":3825,"briefTitle":3826,"status":108,"phases":12017,"primaryCompletion":2487,"completion":2487,"start":1272,"enrollment":3828,"conditions":12018,"interventions":12019},[90],[1788],[3798,3831],{"trials":12021,"activeCount":102},[],{"trials":12023,"activeCount":102},[12024,12028],{"nctId":3790,"briefTitle":3791,"status":108,"phases":12025,"primaryCompletion":3793,"completion":3793,"start":3794,"enrollment":3795,"conditions":12026,"interventions":12027},[92],[3379],[3381,3798],{"nctId":3874,"briefTitle":3875,"status":108,"phases":12029,"primaryCompletion":1031,"completion":1031,"start":966,"enrollment":1232,"conditions":12030,"interventions":12031},[92],[1788],[3879,3831,3880],{"trials":12033,"activeCount":102},[12034],{"nctId":12035,"briefTitle":12036,"status":108,"phases":12037,"primaryCompletion":12038,"completion":12038,"start":2867,"enrollment":10733,"conditions":12039,"interventions":12040},"NCT03856619","To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis",[93],"2022-05-13",[3379],[12041],"TERIFLUNOMIDE HMR1726",{"trials":12043,"activeCount":102},[],{"intervention":10566,"totalTrials":339,"cells":12045},{"EARLY_PHASE1":12046,"PHASE1":12048,"PHASE2":12050,"PHASE3":12052,"PHASE4":12086,"NA":12101},{"trials":12047,"activeCount":102},[],{"trials":12049,"activeCount":102},[],{"trials":12051,"activeCount":102},[],{"trials":12053,"activeCount":102},[12054,12063,12071,12075],{"nctId":12055,"briefTitle":12056,"status":108,"phases":12057,"primaryCompletion":3858,"completion":12058,"start":12059,"enrollment":8738,"conditions":12060,"interventions":12061},"NCT02735044","Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus",[92],"2018-12-20","2016-04-14",[554],[12062,8067,10566],"Insulin glargine,300 U\u002FmL",{"nctId":12064,"briefTitle":12065,"status":108,"phases":12066,"primaryCompletion":12067,"completion":12067,"start":1031,"enrollment":12068,"conditions":12069,"interventions":12070},"NCT02320721","Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications",[92],"2016-05",1014,[19],[8057,8057,10566],{"nctId":10559,"briefTitle":10560,"status":884,"phases":12072,"primaryCompletion":10562,"completion":10562,"start":10563,"enrollment":9707,"conditions":12073,"interventions":12074},[92],[19],[8128,8067,10566],{"nctId":12076,"briefTitle":12077,"status":884,"phases":12078,"primaryCompletion":12079,"completion":12080,"start":12081,"enrollment":12082,"conditions":12083,"interventions":12084},"NCT03713684","Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)",[92],"2020-11-20","2021-01-04","2018-11-09",370,[19],[12085,10566],"Efpeglenatide SAR439977",{"trials":12087,"activeCount":102},[12088],{"nctId":12089,"briefTitle":12090,"status":108,"phases":12091,"primaryCompletion":12092,"completion":6484,"start":12093,"enrollment":12094,"conditions":12095,"interventions":12096},"NCT02451137","A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)",[93],"2018-03-02","2015-06-16",3304,[22],[12097,12098,12099,12100],"Insulin glargine, 300 U\u002Fml","Insulin glargine, 100 U\u002Fml","Insulin detemir","Background Therapy",{"trials":12102,"activeCount":102},[],{"intervention":3870,"totalTrials":445,"cells":12104},{"EARLY_PHASE1":12105,"PHASE1":12107,"PHASE2":12109,"PHASE3":12115,"PHASE4":12125,"NA":12131},{"trials":12106,"activeCount":102},[],{"trials":12108,"activeCount":102},[],{"trials":12110,"activeCount":102},[12111],{"nctId":3835,"briefTitle":3836,"status":108,"phases":12112,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":12113,"interventions":12114},[91],[3842],[3844,3845,3846,3831,3847,3848,3849],{"trials":12116,"activeCount":102},[12117,12121],{"nctId":3853,"briefTitle":3854,"status":108,"phases":12118,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":12119,"interventions":12120},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":3886,"briefTitle":3887,"status":108,"phases":12122,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":12123,"interventions":12124},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":12126,"activeCount":102},[12127],{"nctId":7446,"briefTitle":7447,"status":108,"phases":12128,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":12129,"interventions":12130},[93],[7454],[7273,7456,3869,3871,3870,3872,7412],{"trials":12132,"activeCount":102},[],{"intervention":3872,"totalTrials":445,"cells":12134},{"EARLY_PHASE1":12135,"PHASE1":12137,"PHASE2":12139,"PHASE3":12145,"PHASE4":12155,"NA":12161},{"trials":12136,"activeCount":102},[],{"trials":12138,"activeCount":102},[],{"trials":12140,"activeCount":102},[12141],{"nctId":3835,"briefTitle":3836,"status":108,"phases":12142,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":12143,"interventions":12144},[91],[3842],[3844,3845,3846,3831,3847,3848,3849],{"trials":12146,"activeCount":102},[12147,12151],{"nctId":3853,"briefTitle":3854,"status":108,"phases":12148,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":12149,"interventions":12150},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":3886,"briefTitle":3887,"status":108,"phases":12152,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":12153,"interventions":12154},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":12156,"activeCount":102},[12157],{"nctId":7446,"briefTitle":7447,"status":108,"phases":12158,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":12159,"interventions":12160},[93],[7454],[7273,7456,3869,3871,3870,3872,7412],{"trials":12162,"activeCount":102},[],{"intervention":12164,"totalTrials":445,"cells":12165},"Fexofenadine HCl",{"EARLY_PHASE1":12166,"PHASE1":12168,"PHASE2":12170,"PHASE3":12172,"PHASE4":12184,"NA":12209},{"trials":12167,"activeCount":102},[],{"trials":12169,"activeCount":102},[],{"trials":12171,"activeCount":102},[],{"trials":12173,"activeCount":102},[12174],{"nctId":12175,"briefTitle":12176,"status":108,"phases":12177,"primaryCompletion":2790,"completion":2790,"start":3821,"enrollment":12178,"conditions":12179,"interventions":12181},"NCT01306721","Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis",[92],520,[12180],"Rhinitis Seasonal",[12182,12183],"fexofenadine HCL","pseudoephedrine",{"trials":12185,"activeCount":102},[12186,12194,12202],{"nctId":12187,"briefTitle":12188,"status":108,"phases":12189,"completion":9113,"start":3528,"enrollment":12190,"conditions":12191,"interventions":12193},"NCT00637611","Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit",[93],1010,[12192],"Seasonal Allergic Rhinitis",[12164],{"nctId":12195,"briefTitle":12196,"status":108,"phases":12197,"completion":9826,"start":12198,"enrollment":1232,"conditions":12199,"interventions":12201},"NCT00637884","A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms",[93],"2003-11",[12200],"Cat Induced Allergic Rhinitis",[12164],{"nctId":12203,"briefTitle":12204,"status":108,"phases":12205,"completion":8659,"start":9872,"enrollment":8717,"conditions":12206,"interventions":12207},"NCT00637455","Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel",[93],[12192],[12208],"fexofenadine HCl",{"trials":12210,"activeCount":102},[],{"intervention":9693,"totalTrials":445,"cells":12212},{"EARLY_PHASE1":12213,"PHASE1":12215,"PHASE2":12217,"PHASE3":12219,"PHASE4":12225,"NA":12248},{"trials":12214,"activeCount":102},[],{"trials":12216,"activeCount":102},[],{"trials":12218,"activeCount":102},[],{"trials":12220,"activeCount":102},[12221],{"nctId":9688,"briefTitle":9689,"status":108,"phases":12222,"start":5250,"enrollment":98,"conditions":12223,"interventions":12224},[92],[9680],[9693,9666],{"trials":12226,"activeCount":102},[12227,12235,12239],{"nctId":12228,"briefTitle":12229,"status":108,"phases":12230,"primaryCompletion":8349,"start":8505,"enrollment":12231,"conditions":12232,"interventions":12233},"NCT00670566","Irbesartan\u002FHydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients",[93],503,[9680],[12234],"irbesartan\u002Fhydrochlorothiazide",{"nctId":9775,"briefTitle":9776,"status":108,"phases":12236,"primaryCompletion":8846,"start":3622,"enrollment":178,"conditions":12237,"interventions":12238},[93],[9680],[9780,9666],{"nctId":12240,"briefTitle":12241,"status":108,"phases":12242,"primaryCompletion":8745,"completion":8745,"start":3563,"enrollment":12243,"conditions":12244,"interventions":12245},"NCT00500604","Efficacy of Irbesartan\u002FHydrochlorothiazide Versus Valsartan\u002FHydrochlorothiazide in Mild to Moderate Hypertension",[93],1617,[9680],[9693,12246,12247],"Valsartan\u002Fhydrochlorothiazide","Hydrochlorothiazide",{"trials":12249,"activeCount":102},[],{"intervention":12251,"totalTrials":445,"cells":12252},"Artesunate + Amodiaquine",{"EARLY_PHASE1":12253,"PHASE1":12255,"PHASE2":12264,"PHASE3":12266,"PHASE4":12282,"NA":12290},{"trials":12254,"activeCount":102},[],{"trials":12256,"activeCount":102},[12257],{"nctId":12258,"briefTitle":12259,"status":108,"phases":12260,"primaryCompletion":10339,"start":8395,"enrollment":1601,"conditions":12261,"interventions":12263},"NCT00386503","Bioavailability of the Fixed Combination of Amodiaquine and Artesunate Under Fed & Fasted Conditions",[90],[12262],"Malaria",[12251],{"trials":12265,"activeCount":102},[],{"trials":12267,"activeCount":102},[12268,12275],{"nctId":12269,"briefTitle":12270,"status":108,"phases":12271,"primaryCompletion":152,"completion":152,"start":3335,"enrollment":1697,"conditions":12272,"interventions":12273},"NCT01378286","Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria",[92],[12262],[12274,1084],"ARTESUNATE + AMODIAQUINE",{"nctId":12276,"briefTitle":12277,"status":108,"phases":12278,"start":5307,"enrollment":12279,"conditions":12280,"interventions":12281},"NCT00316329","ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria",[92],1032,[12262],[12251],{"trials":12283,"activeCount":102},[12284],{"nctId":12285,"briefTitle":12286,"status":108,"phases":12287,"primaryCompletion":966,"completion":966,"start":8570,"enrollment":1977,"conditions":12288,"interventions":12289},"NCT01023399","Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire",[93],[12262],[12251],{"trials":12291,"activeCount":102},[],{"intervention":12293,"totalTrials":445,"cells":12294},"Split, Inactivated, Trivalent Influenza Vaccine",{"EARLY_PHASE1":12295,"PHASE1":12297,"PHASE2":12299,"PHASE3":12322,"PHASE4":12324,"NA":12332},{"trials":12296,"activeCount":102},[],{"trials":12298,"activeCount":102},[],{"trials":12300,"activeCount":102},[12301,12308,12316],{"nctId":12302,"briefTitle":12303,"status":108,"phases":12304,"primaryCompletion":8156,"completion":8235,"start":3317,"enrollment":12305,"conditions":12306,"interventions":12307},"NCT00551031","Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects",[91],2098,[16,10695],[12293,12293,12293,12293,12293],{"nctId":12309,"briefTitle":12310,"status":108,"phases":12311,"primaryCompletion":10320,"completion":3564,"start":3622,"enrollment":12312,"conditions":12313,"interventions":12315},"NCT00388583","Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects",[91],817,[12314,16,10695],"Orthomyxoviridae Infection",[12293,12293],{"nctId":12317,"briefTitle":12318,"status":108,"phases":12319,"primaryCompletion":5272,"completion":3317,"start":3430,"enrollment":12178,"conditions":12320,"interventions":12321},"NCT00391391","Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children",[91],[12314,16,10695],[12293,12293,12293,12293],{"trials":12323,"activeCount":102},[],{"trials":12325,"activeCount":102},[12326],{"nctId":12327,"briefTitle":10731,"status":108,"phases":12328,"primaryCompletion":8235,"completion":8235,"start":3417,"enrollment":4920,"conditions":12329,"interventions":12330},"NCT00743275",[93],[16],[12331],"Split, Inactivated, Trivalent Influenza vaccine",{"trials":12333,"activeCount":102},[],{"intervention":12335,"totalTrials":445,"cells":12336},"docetaxel and cisplatin",{"EARLY_PHASE1":12337,"PHASE1":12339,"PHASE2":12341,"PHASE3":12364,"PHASE4":12366,"NA":12374},{"trials":12338,"activeCount":102},[],{"trials":12340,"activeCount":102},[],{"trials":12342,"activeCount":102},[12343,12350,12357],{"nctId":12344,"briefTitle":12345,"status":884,"phases":12346,"primaryCompletion":9785,"completion":9785,"start":9862,"enrollment":1260,"conditions":12347,"interventions":12349},"NCT00271323","Safety Study of Docetaxel\u002FCisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel\u002FCisplatin in NSCLC Patients",[91],[12348],"Non-Small-Cell Lung Carcinoma",[12335],{"nctId":12351,"briefTitle":12352,"status":108,"phases":12353,"primaryCompletion":8753,"start":9183,"enrollment":3566,"conditions":12354,"interventions":12356},"NCT00521521","Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer",[91],[12355],"Head and Neck Neoplasms",[12335,5232],{"nctId":12358,"briefTitle":12359,"status":108,"phases":12360,"primaryCompletion":8156,"start":9872,"enrollment":655,"conditions":12361,"interventions":12363},"NCT00772863","Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer",[91],[12362],"Ovarian Neoplasms",[12335],{"trials":12365,"activeCount":102},[],{"trials":12367,"activeCount":102},[12368],{"nctId":12369,"briefTitle":12370,"status":108,"phases":12371,"primaryCompletion":8822,"completion":8822,"start":3633,"enrollment":1182,"conditions":12372,"interventions":12373},"NCT00772681","Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma",[93],[12355],[12335],{"trials":12375,"activeCount":102},[],{"intervention":8047,"totalTrials":445,"cells":12377},{"EARLY_PHASE1":12378,"PHASE1":12380,"PHASE2":12386,"PHASE3":12388,"PHASE4":12398,"NA":12404},{"trials":12379,"activeCount":102},[],{"trials":12381,"activeCount":102},[12382],{"nctId":8039,"briefTitle":8040,"status":108,"phases":12383,"primaryCompletion":8042,"completion":8042,"start":8043,"enrollment":1400,"conditions":12384,"interventions":12385},[90],[19],[8046,8047,8024],{"trials":12387,"activeCount":102},[],{"trials":12389,"activeCount":102},[12390,12394],{"nctId":9421,"briefTitle":9422,"status":108,"phases":12391,"primaryCompletion":978,"completion":978,"start":8349,"enrollment":8608,"conditions":12392,"interventions":12393},[92],[22],[8046,8200,8047],{"nctId":8305,"briefTitle":8306,"status":108,"phases":12395,"primaryCompletion":3821,"completion":3821,"start":8196,"enrollment":8308,"conditions":12396,"interventions":12397},[92],[22],[8046,8047,8024],{"trials":12399,"activeCount":102},[12400],{"nctId":8441,"briefTitle":8442,"status":108,"phases":12401,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":513,"conditions":12402,"interventions":12403},[93],[22],[8046,8200,8037,8448],{"trials":12405,"activeCount":102},[],{"intervention":11646,"totalTrials":445,"cells":12407},{"EARLY_PHASE1":12408,"PHASE1":12410,"PHASE2":12412,"PHASE3":12414,"PHASE4":12416,"NA":12438},{"trials":12409,"activeCount":102},[],{"trials":12411,"activeCount":102},[],{"trials":12413,"activeCount":102},[],{"trials":12415,"activeCount":102},[],{"trials":12417,"activeCount":102},[12418,12422,12426,12430],{"nctId":12089,"briefTitle":12090,"status":108,"phases":12419,"primaryCompletion":12092,"completion":6484,"start":12093,"enrollment":12094,"conditions":12420,"interventions":12421},[93],[22],[12097,12098,12099,12100],{"nctId":11639,"briefTitle":11640,"status":108,"phases":12423,"primaryCompletion":11642,"completion":11642,"start":11643,"enrollment":10321,"conditions":12424,"interventions":12425},[93],[22],[8424,8424,8551,11646,11647],{"nctId":11649,"briefTitle":11650,"status":108,"phases":12427,"primaryCompletion":11652,"completion":11652,"start":11653,"enrollment":11654,"conditions":12428,"interventions":12429},[93],[22],[8424,8424,8551,11646,11647],{"nctId":12431,"briefTitle":12432,"status":108,"phases":12433,"primaryCompletion":8156,"start":8666,"enrollment":12434,"conditions":12435,"interventions":12436},"NCT00405418","Lantus Versus Levemir Treat-To-Target",[93],973,[22],[8067,12437],"Insulin Detemir",{"trials":12439,"activeCount":102},[],{"intervention":12441,"totalTrials":445,"cells":12442},"Bacillus clausii",{"EARLY_PHASE1":12443,"PHASE1":12445,"PHASE2":12447,"PHASE3":12449,"PHASE4":12459,"NA":12485},{"trials":12444,"activeCount":102},[],{"trials":12446,"activeCount":102},[],{"trials":12448,"activeCount":102},[],{"trials":12450,"activeCount":102},[12451],{"nctId":12452,"briefTitle":12453,"status":108,"phases":12454,"primaryCompletion":7509,"start":5272,"enrollment":3519,"conditions":12455,"interventions":12457},"NCT00457353","ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children",[92],[12456],"Gastroenteritis",[12458],"Bacillus Clausii",{"trials":12460,"activeCount":102},[12461,12470,12478],{"nctId":12462,"briefTitle":12463,"status":108,"phases":12464,"primaryCompletion":4967,"completion":4967,"start":2487,"enrollment":12465,"conditions":12466,"interventions":12468},"NCT02169817","Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children",[93],629,[12467],"Acute Gastroenteritis",[12441,12469],"Oral Rehydration Therapy",{"nctId":12471,"briefTitle":12472,"status":108,"phases":12473,"primaryCompletion":8196,"completion":8196,"start":9513,"enrollment":8627,"conditions":12474,"interventions":12476},"NCT00331994","EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth",[93],[12475],"Irritable Bowel Syndrome",[12441,12477],"Metronidazole",{"nctId":12479,"briefTitle":12480,"status":108,"phases":12481,"primaryCompletion":7509,"start":10339,"enrollment":178,"conditions":12482,"interventions":12484},"NCT00424905","DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect",[93],[12483],"Gastrointestinal Diseases",[12441],{"trials":12486,"activeCount":102},[],{"intervention":8383,"totalTrials":619,"cells":12488},{"EARLY_PHASE1":12489,"PHASE1":12491,"PHASE2":12493,"PHASE3":12495,"PHASE4":12497,"NA":12511},{"trials":12490,"activeCount":102},[],{"trials":12492,"activeCount":102},[],{"trials":12494,"activeCount":102},[],{"trials":12496,"activeCount":102},[],{"trials":12498,"activeCount":102},[12499,12503,12507],{"nctId":8373,"briefTitle":8374,"status":108,"phases":12500,"primaryCompletion":8376,"completion":8376,"start":8377,"enrollment":8378,"conditions":12501,"interventions":12502},[93],[19],[8256,8209,8381,8382,8383,8024],{"nctId":8458,"briefTitle":8459,"status":108,"phases":12504,"primaryCompletion":8461,"completion":8461,"start":8462,"enrollment":8463,"conditions":12505,"interventions":12506},[93],[22],[8256,8037,8466],{"nctId":8468,"briefTitle":8469,"status":108,"phases":12508,"primaryCompletion":8471,"completion":8471,"start":8472,"enrollment":8473,"conditions":12509,"interventions":12510},[93],[19],[8476,8383,8024,8477],{"trials":12512,"activeCount":102},[],{"intervention":8688,"totalTrials":619,"cells":12514},{"EARLY_PHASE1":12515,"PHASE1":12517,"PHASE2":12519,"PHASE3":12521,"PHASE4":12523,"NA":12537},{"trials":12516,"activeCount":102},[],{"trials":12518,"activeCount":102},[],{"trials":12520,"activeCount":102},[],{"trials":12522,"activeCount":102},[],{"trials":12524,"activeCount":102},[12525,12529,12533],{"nctId":8680,"briefTitle":8681,"status":108,"phases":12526,"primaryCompletion":8683,"completion":8683,"start":955,"enrollment":8684,"conditions":12527,"interventions":12528},[93],[22],[8256,8687,8688],{"nctId":8742,"briefTitle":8743,"status":884,"phases":12530,"primaryCompletion":2857,"completion":2857,"start":8745,"enrollment":34,"conditions":12531,"interventions":12532},[93],[22],[8335,8067,8748],{"nctId":8750,"briefTitle":8751,"status":108,"phases":12534,"primaryCompletion":1022,"completion":1022,"start":8753,"enrollment":8754,"conditions":12535,"interventions":12536},[93],[22],[8209,8057,8757,8209],{"trials":12538,"activeCount":102},[],{"intervention":12540,"totalTrials":619,"cells":12541},"Trivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":12542,"PHASE1":12544,"PHASE2":12546,"PHASE3":12555,"PHASE4":12566,"NA":12576},{"trials":12543,"activeCount":102},[],{"trials":12545,"activeCount":102},[],{"trials":12547,"activeCount":102},[12548],{"nctId":12549,"briefTitle":12550,"status":108,"phases":12551,"primaryCompletion":165,"completion":2790,"start":987,"enrollment":1091,"conditions":12552,"interventions":12553},"NCT01258595","A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age",[91],[16],[12554,12540],"High-Dose Trivalent Inactivated Influenza Vaccine",{"trials":12556,"activeCount":102},[12557],{"nctId":12558,"briefTitle":12559,"status":884,"phases":12560,"primaryCompletion":7292,"completion":3416,"start":2799,"enrollment":12561,"conditions":12562,"interventions":12563},"NCT00976027","Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older",[92],9172,[16],[12564,12565],"Trivalent inactivated influenza vaccine High Dose","Trivalent inactivated influenza vaccine",{"trials":12567,"activeCount":102},[12568],{"nctId":12569,"briefTitle":12570,"status":108,"phases":12571,"primaryCompletion":8106,"completion":10811,"start":986,"enrollment":12572,"conditions":12573,"interventions":12574},"NCT01427309","A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults",[93],31989,[16],[12575,12540],"High Dose Trivalent Inactivated Influenza Vaccine",{"trials":12577,"activeCount":102},[],{"intervention":12579,"totalTrials":619,"cells":12580},"Artesunate",{"EARLY_PHASE1":12581,"PHASE1":12583,"PHASE2":12585,"PHASE3":12596,"PHASE4":12598,"NA":12616},{"trials":12582,"activeCount":102},[],{"trials":12584,"activeCount":102},[],{"trials":12586,"activeCount":102},[12587],{"nctId":12588,"briefTitle":12589,"status":884,"phases":12590,"primaryCompletion":987,"completion":987,"start":3354,"enrollment":9714,"conditions":12591,"interventions":12593},"NCT00988507","Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria",[91],[12592],"Plasmodium Falciparum Infection",[12594,12595],"Ferroquine","artesunate",{"trials":12597,"activeCount":102},[],{"trials":12599,"activeCount":102},[12600,12607],{"nctId":12601,"briefTitle":12602,"status":108,"phases":12603,"start":5250,"enrollment":1091,"conditions":12604,"interventions":12605},"NCT00445796","Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance",[93],[12262],[12579,12606],"Amodiaquine",{"nctId":12608,"briefTitle":12609,"status":108,"phases":12610,"primaryCompletion":10320,"completion":10320,"start":9706,"enrollment":12611,"conditions":12612,"interventions":12613},"NCT00452907","ACT MALI: Treatment of Malaria Based on Combination Therapies",[93],780,[12262],[12579,12614,12615],"Artesunate + Sulfadoxine-Pyrimethamine","arthemether + lumefantrine",{"trials":12617,"activeCount":102},[],{"intervention":12619,"totalTrials":619,"cells":12620},"Levofloxacin",{"EARLY_PHASE1":12621,"PHASE1":12623,"PHASE2":12625,"PHASE3":12627,"PHASE4":12644,"NA":12653},{"trials":12622,"activeCount":102},[],{"trials":12624,"activeCount":102},[],{"trials":12626,"activeCount":102},[],{"trials":12628,"activeCount":102},[12629,12637],{"nctId":12630,"briefTitle":12631,"status":108,"phases":12632,"primaryCompletion":3308,"completion":8607,"start":9592,"enrollment":12633,"conditions":12634,"interventions":12635},"NCT00253955","Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia",[92],460,[3625],[12619,12636],"Piperacillin\u002FTazobactam",{"nctId":12638,"briefTitle":12639,"status":108,"phases":12640,"start":3326,"enrollment":4920,"conditions":12641,"interventions":12643},"NCT00277511","Levofloxacin, Chronic Bacterial Prostatitis",[92],[12642],"Prostatitis",[12619],{"trials":12645,"activeCount":102},[12646],{"nctId":12647,"briefTitle":12648,"status":108,"phases":12649,"primaryCompletion":8505,"start":10320,"enrollment":465,"conditions":12650,"interventions":12652},"NCT00495339","MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis",[93],[12651],"Tuberculosis, Pulmonary",[12619],{"trials":12654,"activeCount":102},[],{"intervention":12656,"totalTrials":619,"cells":12657},"Amoxicillin",{"EARLY_PHASE1":12658,"PHASE1":12660,"PHASE2":12662,"PHASE3":12664,"PHASE4":12675,"NA":12696},{"trials":12659,"activeCount":102},[],{"trials":12661,"activeCount":102},[],{"trials":12663,"activeCount":102},[],{"trials":12665,"activeCount":102},[12666],{"nctId":12667,"briefTitle":12668,"status":108,"phases":12669,"primaryCompletion":8822,"start":3430,"enrollment":12670,"conditions":12671,"interventions":12672},"NCT00393744","Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children",[92],395,[9836],[12673,12674],"pristinamycin","amoxicillin",{"trials":12676,"activeCount":102},[12677,12688],{"nctId":12678,"briefTitle":12679,"status":884,"phases":12680,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":1574,"conditions":12683,"interventions":12684},"NCT02332577","Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia",[93],"2023-02-20","2015-04-30",[3625],[12685,12656,12686,12687],"PRISTINAMYCIN XRP7263","Amoxicillin Placebo","PRISTINAMYCIN Placebo",{"nctId":12689,"briefTitle":12690,"status":884,"phases":12691,"primaryCompletion":152,"completion":152,"start":8235,"enrollment":17,"conditions":12692,"interventions":12694},"NCT00799838","Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients",[93],[12693],"Pharyngotonsillitis",[12695,12656],"Ketoprofen",{"trials":12697,"activeCount":102},[],{"intervention":1266,"totalTrials":619,"cells":12699},{"EARLY_PHASE1":12700,"PHASE1":12702,"PHASE2":12712,"PHASE3":12718,"PHASE4":12720,"NA":12726},{"trials":12701,"activeCount":102},[],{"trials":12703,"activeCount":102},[12704],{"nctId":12705,"briefTitle":12706,"status":108,"phases":12707,"primaryCompletion":10178,"completion":10178,"start":8107,"enrollment":402,"conditions":12708,"interventions":12710},"NCT01539655","Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib",[90],[12709],"Medullary Thyroid Cancer",[12711,9480,1266],"vandetanib",{"trials":12713,"activeCount":102},[12714],{"nctId":1255,"briefTitle":1256,"status":884,"phases":12715,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":12716,"interventions":12717},[91],[1262,1263],[1162,1151,1151,1265,1266,1197],{"trials":12719,"activeCount":102},[],{"trials":12721,"activeCount":102},[12722],{"nctId":1352,"briefTitle":1353,"status":108,"phases":12723,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":12724,"interventions":12725},[93],[1357],[1359,1360,672,1361,1362,1363,642],{"trials":12727,"activeCount":102},[],{"intervention":12729,"totalTrials":619,"cells":12730},"KETOPROFEN",{"EARLY_PHASE1":12731,"PHASE1":12733,"PHASE2":12735,"PHASE3":12737,"PHASE4":12756,"NA":12762},{"trials":12732,"activeCount":102},[],{"trials":12734,"activeCount":102},[],{"trials":12736,"activeCount":102},[],{"trials":12738,"activeCount":102},[12739,12747],{"nctId":12740,"briefTitle":12741,"status":108,"phases":12742,"primaryCompletion":3316,"completion":3316,"start":3307,"enrollment":12743,"conditions":12744,"interventions":12746},"NCT00929877","KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges",[92],801,[12745],"Pain",[12729,12729],{"nctId":12748,"briefTitle":12749,"status":108,"phases":12750,"primaryCompletion":3307,"completion":3307,"start":8235,"enrollment":12751,"conditions":12752,"interventions":12753},"NCT00810121","Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)",[92],409,[12745],[12754,12755],"ketoprofen 100 mg","ketoprofen",{"trials":12757,"activeCount":102},[12758],{"nctId":12689,"briefTitle":12690,"status":884,"phases":12759,"primaryCompletion":152,"completion":152,"start":8235,"enrollment":17,"conditions":12760,"interventions":12761},[93],[12693],[12695,12656],{"trials":12763,"activeCount":102},[],{"intervention":10915,"totalTrials":619,"cells":12765},{"EARLY_PHASE1":12766,"PHASE1":12768,"PHASE2":12770,"PHASE3":12801,"PHASE4":12803,"NA":12809},{"trials":12767,"activeCount":102},[],{"trials":12769,"activeCount":102},[],{"trials":12771,"activeCount":102},[12772,12776],{"nctId":4986,"briefTitle":4987,"status":108,"phases":12773,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":12774,"interventions":12775},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"nctId":12777,"briefTitle":12778,"status":108,"phases":12779,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":12783,"interventions":12795},"NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants",[91],"2023-08-10","2020-05-22",852,[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],"Pneumococcal Immunisation","Diphtheria Immunisation","Tetanus Immunisation","Pertussis Immunisation","Hepatitis B Immunisation","Haemophilus Influenzae Type b Immunisation","Polio Immunisation","Measles Immunisation","Rubella Immunisation","Varicella Immunisation","Mumps Immunisation",[12796,12797,12798,4997,5022,12799,10915,5053,12800],"Pneumococcal Conjugate Vaccine formulation 1","Pneumococcal Conjugate Vaccine formulation 2","Pneumococcal Conjugate Vaccine formulation 3","Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]","Hepatitis B Vaccine* [Recombinant] *as applicable",{"trials":12802,"activeCount":102},[],{"trials":12804,"activeCount":102},[12805],{"nctId":10907,"briefTitle":10908,"status":108,"phases":12806,"primaryCompletion":150,"completion":2824,"start":2857,"enrollment":10910,"conditions":12807,"interventions":12808},[93],[4992,2949,25,31,28,10912],[10866,10914,10915],{"trials":12810,"activeCount":102},[],{"intervention":12812,"totalTrials":619,"cells":12813},"Thiocolchicoside",{"EARLY_PHASE1":12814,"PHASE1":12816,"PHASE2":12818,"PHASE3":12820,"PHASE4":12831,"NA":12846},{"trials":12815,"activeCount":102},[],{"trials":12817,"activeCount":102},[],{"trials":12819,"activeCount":102},[],{"trials":12821,"activeCount":102},[12822],{"nctId":12823,"briefTitle":12824,"status":108,"phases":12825,"primaryCompletion":3307,"completion":3307,"start":8505,"enrollment":12826,"conditions":12827,"interventions":12829},"NCT00679146","Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain",[92],334,[12828],"Low Back Pain",[12830,12812],"Thiocolchicoside+Ketoprofen",{"trials":12832,"activeCount":102},[12833,12839],{"nctId":12834,"briefTitle":12835,"status":108,"phases":12836,"primaryCompletion":9706,"completion":9706,"start":8184,"enrollment":7321,"conditions":12837,"interventions":12838},"NCT00917436","Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain",[93],[12828],[12812],{"nctId":12840,"briefTitle":12841,"status":108,"phases":12842,"start":8667,"enrollment":2389,"conditions":12843,"interventions":12845},"NCT00272532","EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes",[93],[12844],"Myofascial Pain Syndromes",[12812],{"trials":12847,"activeCount":102},[],{"intervention":2754,"totalTrials":619,"cells":12849},{"EARLY_PHASE1":12850,"PHASE1":12852,"PHASE2":12854,"PHASE3":12864,"PHASE4":12866,"NA":12872},{"trials":12851,"activeCount":102},[],{"trials":12853,"activeCount":102},[],{"trials":12855,"activeCount":102},[12856,12860],{"nctId":2744,"briefTitle":2745,"status":884,"phases":12857,"primaryCompletion":2747,"completion":2747,"start":2748,"enrollment":535,"conditions":12858,"interventions":12859},[91],[2750],[2752,2753,2754,671],{"nctId":11283,"briefTitle":11284,"status":108,"phases":12861,"primaryCompletion":2487,"completion":7430,"start":8683,"enrollment":112,"conditions":12862,"interventions":12863},[90,91],[1357],[2752,2754,11288],{"trials":12865,"activeCount":102},[],{"trials":12867,"activeCount":102},[12868],{"nctId":2864,"briefTitle":2865,"status":108,"phases":12869,"primaryCompletion":2867,"completion":2868,"start":2869,"enrollment":2870,"conditions":12870,"interventions":12871},[93],[2750],[2873,2874,2875,1780],{"trials":12873,"activeCount":102},[],{"intervention":12875,"totalTrials":619,"cells":12876},"zolpidem tartrate",{"EARLY_PHASE1":12877,"PHASE1":12879,"PHASE2":12881,"PHASE3":12883,"PHASE4":12885,"NA":12906},{"trials":12878,"activeCount":102},[],{"trials":12880,"activeCount":102},[],{"trials":12882,"activeCount":102},[],{"trials":12884,"activeCount":102},[],{"trials":12886,"activeCount":102},[12887,12893,12900],{"nctId":12888,"briefTitle":12889,"status":108,"phases":12890,"completion":9513,"start":3609,"enrollment":2685,"conditions":12891,"interventions":12892},"NCT00283790","Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo",[93],[11490],[12875],{"nctId":12894,"briefTitle":12895,"status":108,"phases":12896,"primaryCompletion":10320,"start":8777,"enrollment":12897,"conditions":12898,"interventions":12899},"NCT00296179","Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro",[93],372,[11490],[12875],{"nctId":12901,"briefTitle":12902,"status":108,"phases":12903,"completion":9785,"start":8777,"enrollment":12897,"conditions":12904,"interventions":12905},"NCT00296790","Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)",[93],[11490],[12875],{"trials":12907,"activeCount":102},[],{"intervention":12909,"totalTrials":659,"cells":12910},"IBUPROFEN",{"EARLY_PHASE1":12911,"PHASE1":12913,"PHASE2":12915,"PHASE3":12917,"PHASE4":12926,"NA":12942},{"trials":12912,"activeCount":102},[],{"trials":12914,"activeCount":102},[],{"trials":12916,"activeCount":102},[],{"trials":12918,"activeCount":102},[12919],{"nctId":12920,"briefTitle":12921,"status":3661,"phases":12922,"primaryCompletion":152,"completion":152,"start":3438,"enrollment":102,"conditions":12923,"interventions":12924},"NCT01426971","Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.",[92],[12745],[12925,12909],"IBUPROFEN + CAFFEINE",{"trials":12927,"activeCount":102},[12928],{"nctId":12929,"briefTitle":12930,"status":884,"phases":12931,"primaryCompletion":12932,"completion":12932,"start":12933,"enrollment":12934,"conditions":12935,"interventions":12937},"NCT00292747","Drotaverine in Dysmenorrhoea Treatment",[93],"2006-02-28","2005-05-25",480,[12936],"Dysmenorrhea",[12938,12939,12940,12941],"Drotaverine","Drotaverine Placebo","Ibuprofen","Ibuprofen Placebo",{"trials":12943,"activeCount":102},[],{"intervention":8190,"totalTrials":659,"cells":12945},{"EARLY_PHASE1":12946,"PHASE1":12948,"PHASE2":12950,"PHASE3":12952,"PHASE4":12958,"NA":12964},{"trials":12947,"activeCount":102},[],{"trials":12949,"activeCount":102},[],{"trials":12951,"activeCount":102},[],{"trials":12953,"activeCount":102},[12954],{"nctId":8181,"briefTitle":8182,"status":108,"phases":12955,"primaryCompletion":8175,"completion":8184,"start":8185,"enrollment":6655,"conditions":12956,"interventions":12957},[92],[8187],[8189,8024,8190,8191],{"trials":12959,"activeCount":102},[12960],{"nctId":8392,"briefTitle":8393,"status":108,"phases":12961,"primaryCompletion":8316,"start":8395,"enrollment":8396,"conditions":12962,"interventions":12963},[93],[22],[8057,8190,8399,8400,8401,8024],{"trials":12965,"activeCount":102},[],{"intervention":12967,"totalTrials":659,"cells":12968},"Diphtheria, tetanus, polio and pertussis vaccination",{"EARLY_PHASE1":12969,"PHASE1":12971,"PHASE2":12973,"PHASE3":12975,"PHASE4":12985,"NA":12994},{"trials":12970,"activeCount":102},[],{"trials":12972,"activeCount":102},[],{"trials":12974,"activeCount":102},[],{"trials":12976,"activeCount":102},[12977],{"nctId":12978,"briefTitle":12979,"status":108,"phases":12980,"primaryCompletion":5238,"completion":5238,"start":1339,"enrollment":12981,"conditions":12982,"interventions":12984},"NCT01287949","Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older",[92],342,[25,31,12983,28],"Poliomyelitis",[12967],{"trials":12986,"activeCount":102},[12987],{"nctId":12988,"briefTitle":12989,"status":108,"phases":12990,"primaryCompletion":3438,"completion":3438,"start":8107,"enrollment":12991,"conditions":12992,"interventions":12993},"NCT01546909","Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE",[93],278,[25,31,12983],[12967],{"trials":12995,"activeCount":102},[],{"intervention":8477,"totalTrials":659,"cells":12997},{"EARLY_PHASE1":12998,"PHASE1":13000,"PHASE2":13002,"PHASE3":13004,"PHASE4":13006,"NA":13016},{"trials":12999,"activeCount":102},[],{"trials":13001,"activeCount":102},[],{"trials":13003,"activeCount":102},[],{"trials":13005,"activeCount":102},[],{"trials":13007,"activeCount":102},[13008,13012],{"nctId":9640,"briefTitle":9641,"status":108,"phases":13009,"primaryCompletion":5238,"completion":5238,"start":8205,"enrollment":9643,"conditions":13010,"interventions":13011},[93],[9645],[9455,9647,8477],{"nctId":8468,"briefTitle":8469,"status":108,"phases":13013,"primaryCompletion":8471,"completion":8471,"start":8472,"enrollment":8473,"conditions":13014,"interventions":13015},[93],[19],[8476,8383,8024,8477],{"trials":13017,"activeCount":102},[],{"intervention":13019,"totalTrials":659,"cells":13020},"TEICOPLANIN",{"EARLY_PHASE1":13021,"PHASE1":13023,"PHASE2":13025,"PHASE3":13027,"PHASE4":13029,"NA":13051},{"trials":13022,"activeCount":102},[],{"trials":13024,"activeCount":102},[],{"trials":13026,"activeCount":102},[],{"trials":13028,"activeCount":102},[],{"trials":13030,"activeCount":102},[13031,13040],{"nctId":13032,"briefTitle":13033,"status":884,"phases":13034,"primaryCompletion":13035,"completion":2700,"start":13036,"enrollment":7653,"conditions":13037,"interventions":13039},"NCT04003818","Efficacy and Safety of Teicoplanin in CDAD",[93],"2021-01-21","2020-05-15",[13038],"Clostridium Difficile Infection-associated Diarrhea and Colitis",[13019],{"nctId":13041,"briefTitle":13042,"status":108,"phases":13043,"primaryCompletion":9190,"completion":9190,"start":8659,"enrollment":13044,"conditions":13045,"interventions":13048},"NCT00454272","Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients",[93],197,[13046,13047],"Infection","Febrile Neutropenia",[13049,13050],"Teicoplanin","Vancomycin",{"trials":13052,"activeCount":102},[],{"intervention":3845,"totalTrials":659,"cells":13054},{"EARLY_PHASE1":13055,"PHASE1":13057,"PHASE2":13059,"PHASE3":13065,"PHASE4":13067,"NA":13073},{"trials":13056,"activeCount":102},[],{"trials":13058,"activeCount":102},[],{"trials":13060,"activeCount":102},[13061],{"nctId":3835,"briefTitle":3836,"status":108,"phases":13062,"primaryCompletion":3838,"completion":3839,"start":3840,"enrollment":3510,"conditions":13063,"interventions":13064},[91],[3842],[3844,3845,3846,3831,3847,3848,3849],{"trials":13066,"activeCount":102},[],{"trials":13068,"activeCount":102},[13069],{"nctId":7446,"briefTitle":7447,"status":108,"phases":13070,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":13071,"interventions":13072},[93],[7454],[7273,7456,3869,3871,3870,3872,7412],{"trials":13074,"activeCount":102},[],{"intervention":13076,"totalTrials":659,"cells":13077},"Insuline glargine",{"EARLY_PHASE1":13078,"PHASE1":13080,"PHASE2":13082,"PHASE3":13084,"PHASE4":13086,"NA":13100},{"trials":13079,"activeCount":102},[],{"trials":13081,"activeCount":102},[],{"trials":13083,"activeCount":102},[],{"trials":13085,"activeCount":102},[],{"trials":13087,"activeCount":102},[13088,13094],{"nctId":13089,"briefTitle":13090,"status":108,"phases":13091,"primaryCompletion":8753,"start":8667,"conditions":13092,"interventions":13093},"NCT00272077","Insulin Glargine in Type 2 Diabetes Mellitus",[93],[22],[13076],{"nctId":13095,"briefTitle":13096,"status":884,"phases":13097,"primaryCompletion":10320,"start":3622,"enrollment":445,"conditions":13098,"interventions":13099},"NCT00349986","LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus",[93],[22],[13076],{"trials":13101,"activeCount":102},[],{"intervention":13103,"totalTrials":659,"cells":13104},"Lantus®",{"EARLY_PHASE1":13105,"PHASE1":13107,"PHASE2":13116,"PHASE3":13118,"PHASE4":13120,"NA":13129},{"trials":13106,"activeCount":102},[],{"trials":13108,"activeCount":102},[13109],{"nctId":13110,"briefTitle":13111,"status":108,"phases":13112,"start":3495,"enrollment":576,"conditions":13113,"interventions":13115},"NCT00348972","Lantus in Prediabetes",[90],[13114,8187],"Hyperglycemia",[13103],{"trials":13117,"activeCount":102},[],{"trials":13119,"activeCount":102},[],{"trials":13121,"activeCount":102},[13122],{"nctId":13123,"briefTitle":13124,"status":108,"phases":13125,"primaryCompletion":9130,"completion":9130,"start":3326,"enrollment":13126,"conditions":13127,"interventions":13128},"NCT00552370","Glycemic Optimization Treatment Study",[93],5062,[22],[13103],{"trials":13130,"activeCount":102},[],{"intervention":1084,"totalTrials":659,"cells":13132},{"EARLY_PHASE1":13133,"PHASE1":13135,"PHASE2":13137,"PHASE3":13139,"PHASE4":13145,"NA":13151},{"trials":13134,"activeCount":102},[],{"trials":13136,"activeCount":102},[],{"trials":13138,"activeCount":102},[],{"trials":13140,"activeCount":102},[13141],{"nctId":12269,"briefTitle":12270,"status":108,"phases":13142,"primaryCompletion":152,"completion":152,"start":3335,"enrollment":1697,"conditions":13143,"interventions":13144},[92],[12262],[12274,1084],{"trials":13146,"activeCount":102},[13147],{"nctId":1074,"briefTitle":1075,"status":108,"phases":13148,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":13149,"interventions":13150},[93],[990],[1082,1083,1084,1060,1046,971,1045],{"trials":13152,"activeCount":102},[],{"intervention":13154,"totalTrials":659,"cells":13155},"Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell",{"EARLY_PHASE1":13156,"PHASE1":13158,"PHASE2":13160,"PHASE3":13162,"PHASE4":13172,"NA":13180},{"trials":13157,"activeCount":102},[],{"trials":13159,"activeCount":102},[],{"trials":13161,"activeCount":102},[],{"trials":13163,"activeCount":102},[13164],{"nctId":13165,"briefTitle":13166,"status":108,"phases":13167,"primaryCompletion":2824,"completion":11200,"start":151,"enrollment":13168,"conditions":13169,"interventions":13171},"NCT02434822","A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic",[92],336,[13170],"Cholera",[13154,13154,13154],{"trials":13173,"activeCount":102},[13174],{"nctId":13175,"briefTitle":13176,"status":108,"phases":13177,"primaryCompletion":1042,"completion":2759,"start":1055,"enrollment":13168,"conditions":13178,"interventions":13179},"NCT01949675","A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines",[93],[13170],[13154,13154,13154],{"trials":13181,"activeCount":102},[],{"intervention":2861,"totalTrials":659,"cells":13183},{"EARLY_PHASE1":13184,"PHASE1":13186,"PHASE2":13192,"PHASE3":13194,"PHASE4":13196,"NA":13202},{"trials":13185,"activeCount":102},[],{"trials":13187,"activeCount":102},[13188],{"nctId":4691,"briefTitle":4692,"status":108,"phases":13189,"primaryCompletion":4694,"completion":4695,"start":4696,"enrollment":178,"conditions":13190,"interventions":13191},[90],[990],[4667,2861],{"trials":13193,"activeCount":102},[],{"trials":13195,"activeCount":102},[],{"trials":13197,"activeCount":102},[13198],{"nctId":2852,"briefTitle":2853,"status":108,"phases":13199,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":13200,"interventions":13201},[93],[1357],[2764,671,2861,2862],{"trials":13203,"activeCount":102},[],{"intervention":13205,"totalTrials":659,"cells":13206},"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":13207,"PHASE1":13209,"PHASE2":13211,"PHASE3":13213,"PHASE4":13224,"NA":13236},{"trials":13208,"activeCount":102},[],{"trials":13210,"activeCount":102},[],{"trials":13212,"activeCount":102},[],{"trials":13214,"activeCount":102},[13215],{"nctId":13216,"briefTitle":13217,"status":108,"phases":13218,"primaryCompletion":2661,"completion":2661,"start":13219,"enrollment":8738,"conditions":13220,"interventions":13221},"NCT04490018","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents",[92],"2021-03-16",[2910,36],[13222,2963,13223,13205],"Meningococcal Polysaccharide","Human Papillomavirus 9-valent Vaccine",{"trials":13225,"activeCount":102},[13226],{"nctId":13227,"briefTitle":13228,"status":108,"phases":13229,"primaryCompletion":13230,"completion":13230,"start":13231,"enrollment":13232,"conditions":13233,"interventions":13235},"NCT04300192","Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa",[93],"2023-01-11","2021-01-27",273,[12787,12785,12786,13234],"Poliomyelitis Vaccine",[13205],{"trials":13237,"activeCount":102},[],{"intervention":13239,"totalTrials":659,"cells":13240},"Riluzole",{"EARLY_PHASE1":13241,"PHASE1":13243,"PHASE2":13245,"PHASE3":13247,"PHASE4":13258,"NA":13268},{"trials":13242,"activeCount":102},[],{"trials":13244,"activeCount":102},[],{"trials":13246,"activeCount":102},[],{"trials":13248,"activeCount":102},[13249],{"nctId":13250,"briefTitle":13251,"status":108,"phases":13252,"primaryCompletion":7482,"completion":7482,"start":13253,"enrollment":13254,"conditions":13255,"interventions":13257},"NCT00277602","Riluzole in Huntington's Disease",[92],"1999-11",537,[13256],"Huntington Disease",[13239],{"trials":13259,"activeCount":102},[13260],{"nctId":13261,"briefTitle":13262,"status":108,"phases":13263,"completion":8184,"start":8421,"enrollment":13264,"conditions":13265,"interventions":13267},"NCT00542412","CARE Canadian ALS Riluzole Evaluation",[93],414,[13266],"Amyotrophic Lateral Sclerosis",[13239],{"trials":13269,"activeCount":102},[],{"intervention":13271,"totalTrials":659,"cells":13272},"Fluzone® Quadrivalent Influenza Vaccine, No Preservative",{"EARLY_PHASE1":13273,"PHASE1":13275,"PHASE2":13277,"PHASE3":13279,"PHASE4":13281,"NA":13295},{"trials":13274,"activeCount":102},[],{"trials":13276,"activeCount":102},[],{"trials":13278,"activeCount":102},[],{"trials":13280,"activeCount":102},[],{"trials":13282,"activeCount":102},[13283,13289],{"nctId":13284,"briefTitle":13285,"status":108,"phases":13286,"primaryCompletion":3429,"completion":11200,"start":2759,"enrollment":178,"conditions":13287,"interventions":13288},"NCT02539108","Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children",[93],[16],[13271,13271],{"nctId":13290,"briefTitle":13291,"status":108,"phases":13292,"primaryCompletion":7430,"completion":8165,"start":11210,"enrollment":178,"conditions":13293,"interventions":13294},"NCT02222870","Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine",[93],[16],[13271,13271],{"trials":13296,"activeCount":102},[],{"intervention":13298,"totalTrials":659,"cells":13299},"SAR231893",{"EARLY_PHASE1":13300,"PHASE1":13302,"PHASE2":13310,"PHASE3":13312,"PHASE4":13314,"NA":13323},{"trials":13301,"activeCount":102},[],{"trials":13303,"activeCount":102},[13304],{"nctId":13305,"briefTitle":13306,"status":108,"phases":13307,"primaryCompletion":164,"completion":164,"start":8683,"enrollment":6313,"conditions":13308,"interventions":13309},"NCT01537653","Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects",[90],[8839],[13298],{"trials":13311,"activeCount":102},[],{"trials":13313,"activeCount":102},[],{"trials":13315,"activeCount":102},[13316],{"nctId":13317,"briefTitle":13318,"status":108,"phases":13319,"primaryCompletion":13320,"completion":1369,"start":3757,"enrollment":6493,"conditions":13321,"interventions":13322},"NCT04502862","A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma",[93],"2023-10-03",[155],[13298],{"trials":13324,"activeCount":102},[],{"intervention":12097,"totalTrials":659,"cells":13326},{"EARLY_PHASE1":13327,"PHASE1":13329,"PHASE2":13331,"PHASE3":13333,"PHASE4":13335,"NA":13352},{"trials":13328,"activeCount":102},[],{"trials":13330,"activeCount":102},[],{"trials":13332,"activeCount":102},[],{"trials":13334,"activeCount":102},[],{"trials":13336,"activeCount":102},[13337,13348],{"nctId":13338,"briefTitle":13339,"status":108,"phases":13340,"primaryCompletion":13341,"completion":13341,"start":13342,"enrollment":13343,"conditions":13344,"interventions":13345},"NCT04075513","Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients",[93],"2021-09-16","2019-10-09",343,[554],[12097,13346,13347],"Insulin degludec, 100U\u002Fml","Background therapy: Rapid acting insulin analogs",{"nctId":12089,"briefTitle":12090,"status":108,"phases":13349,"primaryCompletion":12092,"completion":6484,"start":12093,"enrollment":12094,"conditions":13350,"interventions":13351},[93],[22],[12097,12098,12099,12100],{"trials":13353,"activeCount":102},[],{"intervention":13355,"totalTrials":659,"cells":13356},"GLIMEPIRIDE + METFORMIN",{"EARLY_PHASE1":13357,"PHASE1":13359,"PHASE2":13361,"PHASE3":13363,"PHASE4":13365,"NA":13380},{"trials":13358,"activeCount":102},[],{"trials":13360,"activeCount":102},[],{"trials":13362,"activeCount":102},[],{"trials":13364,"activeCount":102},[],{"trials":13366,"activeCount":102},[13367,13373],{"nctId":13368,"briefTitle":13369,"status":108,"phases":13370,"primaryCompletion":8683,"completion":8683,"start":8693,"enrollment":98,"conditions":13371,"interventions":13372},"NCT01204580","ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination",[93],[22],[13355],{"nctId":13374,"briefTitle":13375,"status":108,"phases":13376,"primaryCompletion":8693,"completion":8693,"start":9984,"enrollment":13377,"conditions":13378,"interventions":13379},"NCT01144728","Initiation and Titration of Amaryl",[93],172,[22],[13355],{"trials":13381,"activeCount":102},[],{"intervention":12606,"totalTrials":659,"cells":13383},{"EARLY_PHASE1":13384,"PHASE1":13386,"PHASE2":13388,"PHASE3":13398,"PHASE4":13400,"NA":13406},{"trials":13385,"activeCount":102},[],{"trials":13387,"activeCount":102},[],{"trials":13389,"activeCount":102},[13390],{"nctId":13391,"briefTitle":13392,"status":108,"phases":13393,"primaryCompletion":8235,"completion":8235,"start":3317,"enrollment":8717,"conditions":13394,"interventions":13395},"NCT00563914","A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria",[90,91],[12262],[13396,13397],"ferroquine","amodiaquine",{"trials":13399,"activeCount":102},[],{"trials":13401,"activeCount":102},[13402],{"nctId":12601,"briefTitle":12602,"status":108,"phases":13403,"start":5250,"enrollment":1091,"conditions":13404,"interventions":13405},[93],[12262],[12579,12606],{"trials":13407,"activeCount":102},[],{"intervention":13409,"totalTrials":659,"cells":13410},"Glatiramer acetate",{"EARLY_PHASE1":13411,"PHASE1":13413,"PHASE2":13415,"PHASE3":13421,"PHASE4":13423,"NA":13431},{"trials":13412,"activeCount":102},[],{"trials":13414,"activeCount":102},[],{"trials":13416,"activeCount":102},[13417],{"nctId":3351,"briefTitle":3352,"status":108,"phases":13418,"primaryCompletion":3354,"completion":3354,"start":3355,"enrollment":3356,"conditions":13419,"interventions":13420},[91],[1788],[1800,3359],{"trials":13422,"activeCount":102},[],{"trials":13424,"activeCount":102},[13425],{"nctId":13426,"briefTitle":13427,"status":108,"phases":13428,"primaryCompletion":3430,"start":9592,"enrollment":9863,"conditions":13429,"interventions":13430},"NCT00267319","FOCUS Fatigue Outcome in Copaxone USers",[93],[1788],[13409],{"trials":13432,"activeCount":102},[],{"intervention":7412,"totalTrials":659,"cells":13434},{"EARLY_PHASE1":13435,"PHASE1":13437,"PHASE2":13439,"PHASE3":13441,"PHASE4":13447,"NA":13453},{"trials":13436,"activeCount":102},[],{"trials":13438,"activeCount":102},[],{"trials":13440,"activeCount":102},[],{"trials":13442,"activeCount":102},[13443],{"nctId":7404,"briefTitle":7405,"status":108,"phases":13444,"primaryCompletion":7407,"completion":7407,"start":7408,"enrollment":7409,"conditions":13445,"interventions":13446},[92],[3842],[7273,7334,7412],{"trials":13448,"activeCount":102},[13449],{"nctId":7446,"briefTitle":7447,"status":108,"phases":13450,"primaryCompletion":7449,"completion":7450,"start":7451,"enrollment":7452,"conditions":13451,"interventions":13452},[93],[7454],[7273,7456,3869,3871,3870,3872,7412],{"trials":13454,"activeCount":102},[],{"intervention":13456,"totalTrials":659,"cells":13457},"Insulin glargine 300 U\u002FmL",{"EARLY_PHASE1":13458,"PHASE1":13460,"PHASE2":13462,"PHASE3":13464,"PHASE4":13466,"NA":13486},{"trials":13459,"activeCount":102},[],{"trials":13461,"activeCount":102},[],{"trials":13463,"activeCount":102},[],{"trials":13465,"activeCount":102},[],{"trials":13467,"activeCount":102},[13468,13477],{"nctId":13469,"briefTitle":13470,"status":884,"phases":13471,"primaryCompletion":13472,"completion":13473,"start":5150,"enrollment":6604,"conditions":13474,"interventions":13475},"NCT05552859","Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment",[93],"2023-07-28","2023-08-04",[19,3731],[13456,13476],"Insulin degludec 100 U\u002FmL",{"nctId":13478,"briefTitle":13479,"status":108,"phases":13480,"primaryCompletion":13481,"completion":13481,"start":13482,"enrollment":5165,"conditions":13483,"interventions":13484},"NCT05002933","A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period",[93],"2023-02-24","2021-05-20",[19],[13485],"Insulin glargine 300 U\u002Fml",{"trials":13487,"activeCount":102},[],{"intervention":13489,"totalTrials":659,"cells":13490},"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed",{"EARLY_PHASE1":13491,"PHASE1":13493,"PHASE2":13495,"PHASE3":13497,"PHASE4":13506,"NA":13517},{"trials":13492,"activeCount":102},[],{"trials":13494,"activeCount":102},[],{"trials":13496,"activeCount":102},[],{"trials":13498,"activeCount":102},[13499],{"nctId":13500,"briefTitle":13501,"status":108,"phases":13502,"primaryCompletion":8298,"completion":152,"start":2857,"enrollment":1091,"conditions":13503,"interventions":13505},"NCT01642589","Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea",[92],[4992,13504],"Meningococcal Disease",[5036,13489],{"trials":13507,"activeCount":102},[13508],{"nctId":13509,"briefTitle":13510,"status":108,"phases":13511,"primaryCompletion":2760,"completion":152,"start":2834,"enrollment":13512,"conditions":13513,"interventions":13515},"NCT01629589","Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents",[93],423,[31,25,28,13514],"Whooping Cough",[13489,13516],"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed",{"trials":13518,"activeCount":102},[],{"intervention":13520,"totalTrials":659,"cells":13521},"Hyalgan",{"EARLY_PHASE1":13522,"PHASE1":13524,"PHASE2":13526,"PHASE3":13528,"PHASE4":13530,"NA":13545},{"trials":13523,"activeCount":102},[],{"trials":13525,"activeCount":102},[],{"trials":13527,"activeCount":102},[],{"trials":13529,"activeCount":102},[],{"trials":13531,"activeCount":102},[13532,13539],{"nctId":13533,"briefTitle":13534,"status":108,"phases":13535,"completion":3430,"start":3565,"enrollment":98,"conditions":13536,"interventions":13538},"NCT00830830","TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis",[93],[13537],"Osteoarthritis",[13520],{"nctId":13540,"briefTitle":13541,"status":108,"phases":13542,"completion":8753,"start":8175,"enrollment":455,"conditions":13543,"interventions":13544},"NCT00130468","TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis",[93],[13537],[13520],{"trials":13546,"activeCount":102},[],{"intervention":11647,"totalTrials":659,"cells":13548},{"EARLY_PHASE1":13549,"PHASE1":13551,"PHASE2":13553,"PHASE3":13555,"PHASE4":13557,"NA":13567},{"trials":13550,"activeCount":102},[],{"trials":13552,"activeCount":102},[],{"trials":13554,"activeCount":102},[],{"trials":13556,"activeCount":102},[],{"trials":13558,"activeCount":102},[13559,13563],{"nctId":11639,"briefTitle":11640,"status":108,"phases":13560,"primaryCompletion":11642,"completion":11642,"start":11643,"enrollment":10321,"conditions":13561,"interventions":13562},[93],[22],[8424,8424,8551,11646,11647],{"nctId":11649,"briefTitle":11650,"status":108,"phases":13564,"primaryCompletion":11652,"completion":11652,"start":11653,"enrollment":11654,"conditions":13565,"interventions":13566},[93],[22],[8424,8424,8551,11646,11647],{"trials":13568,"activeCount":102},[],{"intervention":12247,"totalTrials":659,"cells":13570},{"EARLY_PHASE1":13571,"PHASE1":13573,"PHASE2":13582,"PHASE3":13584,"PHASE4":13586,"NA":13592},{"trials":13572,"activeCount":102},[],{"trials":13574,"activeCount":102},[13575],{"nctId":13576,"briefTitle":13577,"status":108,"phases":13578,"primaryCompletion":12092,"completion":12092,"start":13579,"enrollment":988,"conditions":13580,"interventions":13581},"NCT03387657","A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide",[90],"2018-01-03",[19],[11524,12247],{"trials":13583,"activeCount":102},[],{"trials":13585,"activeCount":102},[],{"trials":13587,"activeCount":102},[13588],{"nctId":12240,"briefTitle":12241,"status":108,"phases":13589,"primaryCompletion":8745,"completion":8745,"start":3563,"enrollment":12243,"conditions":13590,"interventions":13591},[93],[9680],[9693,12246,12247],{"trials":13593,"activeCount":102},[],{"intervention":8381,"totalTrials":195,"cells":13595},{"EARLY_PHASE1":13596,"PHASE1":13598,"PHASE2":13600,"PHASE3":13602,"PHASE4":13604,"NA":13610},{"trials":13597,"activeCount":102},[],{"trials":13599,"activeCount":102},[],{"trials":13601,"activeCount":102},[],{"trials":13603,"activeCount":102},[],{"trials":13605,"activeCount":102},[13606],{"nctId":8373,"briefTitle":8374,"status":108,"phases":13607,"primaryCompletion":8376,"completion":8376,"start":8377,"enrollment":8378,"conditions":13608,"interventions":13609},[93],[19],[8256,8209,8381,8382,8383,8024],{"trials":13611,"activeCount":102},[],{"intervention":8382,"totalTrials":195,"cells":13613},{"EARLY_PHASE1":13614,"PHASE1":13616,"PHASE2":13618,"PHASE3":13620,"PHASE4":13622,"NA":13628},{"trials":13615,"activeCount":102},[],{"trials":13617,"activeCount":102},[],{"trials":13619,"activeCount":102},[],{"trials":13621,"activeCount":102},[],{"trials":13623,"activeCount":102},[13624],{"nctId":8373,"briefTitle":8374,"status":108,"phases":13625,"primaryCompletion":8376,"completion":8376,"start":8377,"enrollment":8378,"conditions":13626,"interventions":13627},[93],[19],[8256,8209,8381,8382,8383,8024],{"trials":13629,"activeCount":102},[],{"intervention":12575,"totalTrials":195,"cells":13631},{"EARLY_PHASE1":13632,"PHASE1":13634,"PHASE2":13636,"PHASE3":13638,"PHASE4":13640,"NA":13646},{"trials":13633,"activeCount":102},[],{"trials":13635,"activeCount":102},[],{"trials":13637,"activeCount":102},[],{"trials":13639,"activeCount":102},[],{"trials":13641,"activeCount":102},[13642],{"nctId":12569,"briefTitle":12570,"status":108,"phases":13643,"primaryCompletion":8106,"completion":10811,"start":986,"enrollment":12572,"conditions":13644,"interventions":13645},[93],[16],[12575,12540],{"trials":13647,"activeCount":102},[],{"intervention":13649,"totalTrials":195,"cells":13650},"Fluzone Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":13651,"PHASE1":13653,"PHASE2":13655,"PHASE3":13657,"PHASE4":13659,"NA":13668},{"trials":13652,"activeCount":102},[],{"trials":13654,"activeCount":102},[],{"trials":13656,"activeCount":102},[],{"trials":13658,"activeCount":102},[],{"trials":13660,"activeCount":102},[13661],{"nctId":13662,"briefTitle":13663,"status":108,"phases":13664,"primaryCompletion":13665,"completion":13665,"start":2748,"enrollment":4920,"conditions":13666,"interventions":13667},"NCT03546192","Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)",[93],"2015-07-17",[16],[13649],{"trials":13669,"activeCount":102},[],{"intervention":8399,"totalTrials":195,"cells":13671},{"EARLY_PHASE1":13672,"PHASE1":13674,"PHASE2":13676,"PHASE3":13678,"PHASE4":13680,"NA":13686},{"trials":13673,"activeCount":102},[],{"trials":13675,"activeCount":102},[],{"trials":13677,"activeCount":102},[],{"trials":13679,"activeCount":102},[],{"trials":13681,"activeCount":102},[13682],{"nctId":8392,"briefTitle":8393,"status":108,"phases":13683,"primaryCompletion":8316,"start":8395,"enrollment":8396,"conditions":13684,"interventions":13685},[93],[22],[8057,8190,8399,8400,8401,8024],{"trials":13687,"activeCount":102},[],{"intervention":8400,"totalTrials":195,"cells":13689},{"EARLY_PHASE1":13690,"PHASE1":13692,"PHASE2":13694,"PHASE3":13696,"PHASE4":13698,"NA":13704},{"trials":13691,"activeCount":102},[],{"trials":13693,"activeCount":102},[],{"trials":13695,"activeCount":102},[],{"trials":13697,"activeCount":102},[],{"trials":13699,"activeCount":102},[13700],{"nctId":8392,"briefTitle":8393,"status":108,"phases":13701,"primaryCompletion":8316,"start":8395,"enrollment":8396,"conditions":13702,"interventions":13703},[93],[22],[8057,8190,8399,8400,8401,8024],{"trials":13705,"activeCount":102},[],{"intervention":8401,"totalTrials":195,"cells":13707},{"EARLY_PHASE1":13708,"PHASE1":13710,"PHASE2":13712,"PHASE3":13714,"PHASE4":13716,"NA":13722},{"trials":13709,"activeCount":102},[],{"trials":13711,"activeCount":102},[],{"trials":13713,"activeCount":102},[],{"trials":13715,"activeCount":102},[],{"trials":13717,"activeCount":102},[13718],{"nctId":8392,"briefTitle":8393,"status":108,"phases":13719,"primaryCompletion":8316,"start":8395,"enrollment":8396,"conditions":13720,"interventions":13721},[93],[22],[8057,8190,8399,8400,8401,8024],{"trials":13723,"activeCount":102},[],{"intervention":13725,"totalTrials":195,"cells":13726},"DTacP-IPV combined vaccine",{"EARLY_PHASE1":13727,"PHASE1":13729,"PHASE2":13731,"PHASE3":13733,"PHASE4":13735,"NA":13743},{"trials":13728,"activeCount":102},[],{"trials":13730,"activeCount":102},[],{"trials":13732,"activeCount":102},[],{"trials":13734,"activeCount":102},[],{"trials":13736,"activeCount":102},[13737],{"nctId":13738,"briefTitle":13739,"status":108,"phases":13740,"primaryCompletion":5217,"completion":1339,"start":8388,"enrollment":3356,"conditions":13741,"interventions":13742},"NCT01031303","Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age",[93],[25,31,28,12983],[13725],{"trials":13744,"activeCount":102},[],{"intervention":13746,"totalTrials":195,"cells":13747},"Insulin Glargine (HOE901)\u002FNPH Insulin",{"EARLY_PHASE1":13748,"PHASE1":13750,"PHASE2":13752,"PHASE3":13754,"PHASE4":13756,"NA":13764},{"trials":13749,"activeCount":102},[],{"trials":13751,"activeCount":102},[],{"trials":13753,"activeCount":102},[],{"trials":13755,"activeCount":102},[],{"trials":13757,"activeCount":102},[13758],{"nctId":13759,"briefTitle":13760,"status":108,"phases":13761,"primaryCompletion":164,"completion":164,"start":3307,"enrollment":8592,"conditions":13762,"interventions":13763},"NCT00941369","Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients",[93],[22],[13746],{"trials":13765,"activeCount":102},[],{"intervention":13767,"totalTrials":195,"cells":13768},"Fexofenadine HCL and pseudoephedrine HCL",{"EARLY_PHASE1":13769,"PHASE1":13771,"PHASE2":13773,"PHASE3":13775,"PHASE4":13777,"NA":13789},{"trials":13770,"activeCount":102},[],{"trials":13772,"activeCount":102},[],{"trials":13774,"activeCount":102},[],{"trials":13776,"activeCount":102},[],{"trials":13778,"activeCount":102},[13779],{"nctId":13780,"briefTitle":13781,"status":108,"phases":13782,"primaryCompletion":13783,"completion":13783,"start":13784,"enrollment":13785,"conditions":13786,"interventions":13788},"NCT05720455","Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above",[93],"2025-12-05","2025-06-15",203,[13787],"Rhinitis Allergic",[13767],{"trials":13790,"activeCount":102},[],{"intervention":13792,"totalTrials":195,"cells":13793},"Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio",{"EARLY_PHASE1":13794,"PHASE1":13796,"PHASE2":13798,"PHASE3":13800,"PHASE4":13802,"NA":13813},{"trials":13795,"activeCount":102},[],{"trials":13797,"activeCount":102},[],{"trials":13799,"activeCount":102},[],{"trials":13801,"activeCount":102},[],{"trials":13803,"activeCount":102},[13804],{"nctId":13805,"briefTitle":13806,"status":108,"phases":13807,"primaryCompletion":8106,"completion":10811,"start":8062,"enrollment":13808,"conditions":13809,"interventions":13811},"NCT01475539","Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine",[93],456,[13810,12983],"Polio",[13792,13792,13812],"Live oral poliovirus type 1, 2 and 3",{"trials":13814,"activeCount":102},[],{"intervention":13812,"totalTrials":195,"cells":13816},{"EARLY_PHASE1":13817,"PHASE1":13819,"PHASE2":13821,"PHASE3":13823,"PHASE4":13825,"NA":13831},{"trials":13818,"activeCount":102},[],{"trials":13820,"activeCount":102},[],{"trials":13822,"activeCount":102},[],{"trials":13824,"activeCount":102},[],{"trials":13826,"activeCount":102},[13827],{"nctId":13805,"briefTitle":13806,"status":108,"phases":13828,"primaryCompletion":8106,"completion":10811,"start":8062,"enrollment":13808,"conditions":13829,"interventions":13830},[93],[13810,12983],[13792,13792,13812],{"trials":13832,"activeCount":102},[],{"intervention":13834,"totalTrials":195,"cells":13835},"T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.",{"EARLY_PHASE1":13836,"PHASE1":13838,"PHASE2":13840,"PHASE3":13842,"PHASE4":13844,"NA":13855},{"trials":13837,"activeCount":102},[],{"trials":13839,"activeCount":102},[],{"trials":13841,"activeCount":102},[],{"trials":13843,"activeCount":102},[],{"trials":13845,"activeCount":102},[13846],{"nctId":13847,"briefTitle":13848,"status":108,"phases":13849,"primaryCompletion":5272,"completion":1341,"start":8667,"enrollment":13850,"conditions":13851,"interventions":13852},"NCT00777257","Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine",[93],1345,[4992,10856,28,31,25],[13834,13853,13854],"Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.","Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap",{"trials":13856,"activeCount":102},[],{"intervention":13853,"totalTrials":195,"cells":13858},{"EARLY_PHASE1":13859,"PHASE1":13861,"PHASE2":13863,"PHASE3":13865,"PHASE4":13867,"NA":13873},{"trials":13860,"activeCount":102},[],{"trials":13862,"activeCount":102},[],{"trials":13864,"activeCount":102},[],{"trials":13866,"activeCount":102},[],{"trials":13868,"activeCount":102},[13869],{"nctId":13847,"briefTitle":13848,"status":108,"phases":13870,"primaryCompletion":5272,"completion":1341,"start":8667,"enrollment":13850,"conditions":13871,"interventions":13872},[93],[4992,10856,28,31,25],[13834,13853,13854],{"trials":13874,"activeCount":102},[],{"intervention":13854,"totalTrials":195,"cells":13876},{"EARLY_PHASE1":13877,"PHASE1":13879,"PHASE2":13881,"PHASE3":13883,"PHASE4":13885,"NA":13891},{"trials":13878,"activeCount":102},[],{"trials":13880,"activeCount":102},[],{"trials":13882,"activeCount":102},[],{"trials":13884,"activeCount":102},[],{"trials":13886,"activeCount":102},[13887],{"nctId":13847,"briefTitle":13848,"status":108,"phases":13888,"primaryCompletion":5272,"completion":1341,"start":8667,"enrollment":13850,"conditions":13889,"interventions":13890},[93],[4992,10856,28,31,25],[13834,13853,13854],{"trials":13892,"activeCount":102},[],{"intervention":12685,"totalTrials":195,"cells":13894},{"EARLY_PHASE1":13895,"PHASE1":13897,"PHASE2":13899,"PHASE3":13901,"PHASE4":13903,"NA":13909},{"trials":13896,"activeCount":102},[],{"trials":13898,"activeCount":102},[],{"trials":13900,"activeCount":102},[],{"trials":13902,"activeCount":102},[],{"trials":13904,"activeCount":102},[13905],{"nctId":12678,"briefTitle":12679,"status":884,"phases":13906,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":1574,"conditions":13907,"interventions":13908},[93],[3625],[12685,12656,12686,12687],{"trials":13910,"activeCount":102},[],{"intervention":12686,"totalTrials":195,"cells":13912},{"EARLY_PHASE1":13913,"PHASE1":13915,"PHASE2":13917,"PHASE3":13919,"PHASE4":13921,"NA":13927},{"trials":13914,"activeCount":102},[],{"trials":13916,"activeCount":102},[],{"trials":13918,"activeCount":102},[],{"trials":13920,"activeCount":102},[],{"trials":13922,"activeCount":102},[13923],{"nctId":12678,"briefTitle":12679,"status":884,"phases":13924,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":1574,"conditions":13925,"interventions":13926},[93],[3625],[12685,12656,12686,12687],{"trials":13928,"activeCount":102},[],{"intervention":12687,"totalTrials":195,"cells":13930},{"EARLY_PHASE1":13931,"PHASE1":13933,"PHASE2":13935,"PHASE3":13937,"PHASE4":13939,"NA":13945},{"trials":13932,"activeCount":102},[],{"trials":13934,"activeCount":102},[],{"trials":13936,"activeCount":102},[],{"trials":13938,"activeCount":102},[],{"trials":13940,"activeCount":102},[13941],{"nctId":12678,"briefTitle":12679,"status":884,"phases":13942,"primaryCompletion":12681,"completion":12681,"start":12682,"enrollment":1574,"conditions":13943,"interventions":13944},[93],[3625],[12685,12656,12686,12687],{"trials":13946,"activeCount":102},[],{"intervention":13948,"totalTrials":195,"cells":13949},"IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine",{"EARLY_PHASE1":13950,"PHASE1":13952,"PHASE2":13954,"PHASE3":13956,"PHASE4":13958,"NA":13966},{"trials":13951,"activeCount":102},[],{"trials":13953,"activeCount":102},[],{"trials":13955,"activeCount":102},[],{"trials":13957,"activeCount":102},[],{"trials":13959,"activeCount":102},[13960],{"nctId":13961,"briefTitle":13962,"status":108,"phases":13963,"primaryCompletion":954,"completion":977,"start":987,"enrollment":4929,"conditions":13964,"interventions":13965},"NCT01244464","A Study of the Safety of IMOVAX Polio™ in China",[93],[12983,13810],[13948],{"trials":13967,"activeCount":102},[],{"intervention":13969,"totalTrials":195,"cells":13970},"plerixafor + G-CSF",{"EARLY_PHASE1":13971,"PHASE1":13973,"PHASE2":13975,"PHASE3":13977,"PHASE4":13979,"NA":13990},{"trials":13972,"activeCount":102},[],{"trials":13974,"activeCount":102},[],{"trials":13976,"activeCount":102},[],{"trials":13978,"activeCount":102},[],{"trials":13980,"activeCount":102},[13981],{"nctId":13982,"briefTitle":13983,"status":108,"phases":13984,"primaryCompletion":13985,"completion":13986,"start":7241,"enrollment":5282,"conditions":13987,"interventions":13989},"NCT05087212","Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients",[93],"2022-12-06","2022-12-30",[13988],"Autologous Haematopoietic Stem Cell Transplant",[13969],{"trials":13991,"activeCount":102},[],{"intervention":13993,"totalTrials":195,"cells":13994},"Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),",{"EARLY_PHASE1":13995,"PHASE1":13997,"PHASE2":13999,"PHASE3":14001,"PHASE4":14003,"NA":14013},{"trials":13996,"activeCount":102},[],{"trials":13998,"activeCount":102},[],{"trials":14000,"activeCount":102},[],{"trials":14002,"activeCount":102},[],{"trials":14004,"activeCount":102},[14005],{"nctId":14006,"briefTitle":14007,"status":108,"phases":14008,"primaryCompletion":6471,"completion":2487,"start":2311,"enrollment":4589,"conditions":14009,"interventions":14010},"NCT01946438","Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults",[93],[16],[13993,14011,13993,14012],"Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),","Fluzone® High-Dose, Influenza Virus Vaccine",{"trials":14014,"activeCount":102},[],{"intervention":14011,"totalTrials":195,"cells":14016},{"EARLY_PHASE1":14017,"PHASE1":14019,"PHASE2":14021,"PHASE3":14023,"PHASE4":14025,"NA":14031},{"trials":14018,"activeCount":102},[],{"trials":14020,"activeCount":102},[],{"trials":14022,"activeCount":102},[],{"trials":14024,"activeCount":102},[],{"trials":14026,"activeCount":102},[14027],{"nctId":14006,"briefTitle":14007,"status":108,"phases":14028,"primaryCompletion":6471,"completion":2487,"start":2311,"enrollment":4589,"conditions":14029,"interventions":14030},[93],[16],[13993,14011,13993,14012],{"trials":14032,"activeCount":102},[],{"intervention":14012,"totalTrials":195,"cells":14034},{"EARLY_PHASE1":14035,"PHASE1":14037,"PHASE2":14039,"PHASE3":14041,"PHASE4":14043,"NA":14049},{"trials":14036,"activeCount":102},[],{"trials":14038,"activeCount":102},[],{"trials":14040,"activeCount":102},[],{"trials":14042,"activeCount":102},[],{"trials":14044,"activeCount":102},[14045],{"nctId":14006,"briefTitle":14007,"status":108,"phases":14046,"primaryCompletion":6471,"completion":2487,"start":2311,"enrollment":4589,"conditions":14047,"interventions":14048},[93],[16],[13993,14011,13993,14012],{"trials":14050,"activeCount":102},[],{"intervention":14052,"totalTrials":195,"cells":14053},"Apidra",{"EARLY_PHASE1":14054,"PHASE1":14056,"PHASE2":14058,"PHASE3":14060,"PHASE4":14062,"NA":14071},{"trials":14055,"activeCount":102},[],{"trials":14057,"activeCount":102},[],{"trials":14059,"activeCount":102},[],{"trials":14061,"activeCount":102},[],{"trials":14063,"activeCount":102},[14064],{"nctId":14065,"briefTitle":14066,"status":108,"phases":14067,"primaryCompletion":3335,"completion":3335,"start":3354,"enrollment":14068,"conditions":14069,"interventions":14070},"NCT01013571","Self Titration With Apidra to Reach Target Study (START)",[93],493,[22],[8424,14052],{"trials":14072,"activeCount":102},[],{"intervention":14074,"totalTrials":195,"cells":14075},"Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed",{"EARLY_PHASE1":14076,"PHASE1":14078,"PHASE2":14080,"PHASE3":14082,"PHASE4":14084,"NA":14093},{"trials":14077,"activeCount":102},[],{"trials":14079,"activeCount":102},[],{"trials":14081,"activeCount":102},[],{"trials":14083,"activeCount":102},[],{"trials":14085,"activeCount":102},[14086],{"nctId":14087,"briefTitle":14088,"status":108,"phases":14089,"primaryCompletion":8062,"completion":3335,"start":165,"enrollment":14090,"conditions":14091,"interventions":14092},"NCT01311557","Study of Adacel® Vaccine Administered to Persons 10 Years of Age",[93],1302,[31,25,28],[14074,14074],{"trials":14094,"activeCount":102},[],{"intervention":2022,"totalTrials":195,"cells":14096},{"EARLY_PHASE1":14097,"PHASE1":14099,"PHASE2":14101,"PHASE3":14103,"PHASE4":14105,"NA":14111},{"trials":14098,"activeCount":102},[],{"trials":14100,"activeCount":102},[],{"trials":14102,"activeCount":102},[],{"trials":14104,"activeCount":102},[],{"trials":14106,"activeCount":102},[14107],{"nctId":2013,"briefTitle":2014,"status":108,"phases":14108,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":14109,"interventions":14110},[93],[2020],[2022,1048,1214,2023,2024,1780],{"trials":14112,"activeCount":102},[],{"intervention":2024,"totalTrials":195,"cells":14114},{"EARLY_PHASE1":14115,"PHASE1":14117,"PHASE2":14119,"PHASE3":14121,"PHASE4":14123,"NA":14129},{"trials":14116,"activeCount":102},[],{"trials":14118,"activeCount":102},[],{"trials":14120,"activeCount":102},[],{"trials":14122,"activeCount":102},[],{"trials":14124,"activeCount":102},[14125],{"nctId":2013,"briefTitle":2014,"status":108,"phases":14126,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":14127,"interventions":14128},[93],[2020],[2022,1048,1214,2023,2024,1780],{"trials":14130,"activeCount":102},[],{"intervention":14132,"totalTrials":195,"cells":14133},"Meningococcal Polysaccharide Groups A\\C\\Y\\W-135 Combined",{"EARLY_PHASE1":14134,"PHASE1":14136,"PHASE2":14138,"PHASE3":14140,"PHASE4":14142,"NA":14150},{"trials":14135,"activeCount":102},[],{"trials":14137,"activeCount":102},[],{"trials":14139,"activeCount":102},[],{"trials":14141,"activeCount":102},[],{"trials":14143,"activeCount":102},[14144],{"nctId":14145,"briefTitle":14146,"status":108,"phases":14147,"primaryCompletion":3539,"completion":8175,"start":8176,"enrollment":10074,"conditions":14148,"interventions":14149},"NCT00850603","Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®",[93],[2922,4992],[14132,14132,14132,14132,14132],{"trials":14151,"activeCount":102},[],{"intervention":14153,"totalTrials":195,"cells":14154},"Purified Verocell Rabies Vaccine",{"EARLY_PHASE1":14155,"PHASE1":14157,"PHASE2":14159,"PHASE3":14161,"PHASE4":14163,"NA":14173},{"trials":14156,"activeCount":102},[],{"trials":14158,"activeCount":102},[],{"trials":14160,"activeCount":102},[],{"trials":14162,"activeCount":102},[],{"trials":14164,"activeCount":102},[14165],{"nctId":14166,"briefTitle":14167,"status":108,"phases":14168,"primaryCompletion":3417,"completion":8846,"start":8184,"enrollment":14169,"conditions":14170,"interventions":14172},"NCT00260351","Immunogenicity and Safety of Verorab™ in Indian Population",[93],405,[14171],"Rabies",[14153,14153,14153],{"trials":14174,"activeCount":102},[],{"intervention":1360,"totalTrials":195,"cells":14176},{"EARLY_PHASE1":14177,"PHASE1":14179,"PHASE2":14181,"PHASE3":14183,"PHASE4":14185,"NA":14191},{"trials":14178,"activeCount":102},[],{"trials":14180,"activeCount":102},[],{"trials":14182,"activeCount":102},[],{"trials":14184,"activeCount":102},[],{"trials":14186,"activeCount":102},[14187],{"nctId":1352,"briefTitle":1353,"status":108,"phases":14188,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":14189,"interventions":14190},[93],[1357],[1359,1360,672,1361,1362,1363,642],{"trials":14192,"activeCount":102},[],{"intervention":1361,"totalTrials":195,"cells":14194},{"EARLY_PHASE1":14195,"PHASE1":14197,"PHASE2":14199,"PHASE3":14201,"PHASE4":14203,"NA":14209},{"trials":14196,"activeCount":102},[],{"trials":14198,"activeCount":102},[],{"trials":14200,"activeCount":102},[],{"trials":14202,"activeCount":102},[],{"trials":14204,"activeCount":102},[14205],{"nctId":1352,"briefTitle":1353,"status":108,"phases":14206,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":14207,"interventions":14208},[93],[1357],[1359,1360,672,1361,1362,1363,642],{"trials":14210,"activeCount":102},[],{"intervention":1363,"totalTrials":195,"cells":14212},{"EARLY_PHASE1":14213,"PHASE1":14215,"PHASE2":14217,"PHASE3":14219,"PHASE4":14221,"NA":14227},{"trials":14214,"activeCount":102},[],{"trials":14216,"activeCount":102},[],{"trials":14218,"activeCount":102},[],{"trials":14220,"activeCount":102},[],{"trials":14222,"activeCount":102},[14223],{"nctId":1352,"briefTitle":1353,"status":108,"phases":14224,"primaryCompletion":1355,"completion":1041,"start":151,"enrollment":1134,"conditions":14225,"interventions":14226},[93],[1357],[1359,1360,672,1361,1362,1363,642],{"trials":14228,"activeCount":102},[],{"intervention":14230,"totalTrials":195,"cells":14231},"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate",{"EARLY_PHASE1":14232,"PHASE1":14234,"PHASE2":14236,"PHASE3":14238,"PHASE4":14240,"NA":14250},{"trials":14233,"activeCount":102},[],{"trials":14235,"activeCount":102},[],{"trials":14237,"activeCount":102},[],{"trials":14239,"activeCount":102},[],{"trials":14241,"activeCount":102},[14242],{"nctId":14243,"briefTitle":14244,"status":108,"phases":14245,"primaryCompletion":14246,"completion":14246,"start":14247,"enrollment":178,"conditions":14248,"interventions":14249},"NCT02591290","Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects",[93],"2016-03-16","2015-10-20",[4992,7568,2922],[14230],{"trials":14251,"activeCount":102},[],{"intervention":9647,"totalTrials":195,"cells":14253},{"EARLY_PHASE1":14254,"PHASE1":14256,"PHASE2":14258,"PHASE3":14260,"PHASE4":14262,"NA":14268},{"trials":14255,"activeCount":102},[],{"trials":14257,"activeCount":102},[],{"trials":14259,"activeCount":102},[],{"trials":14261,"activeCount":102},[],{"trials":14263,"activeCount":102},[14264],{"nctId":9640,"briefTitle":9641,"status":108,"phases":14265,"primaryCompletion":5238,"completion":5238,"start":8205,"enrollment":9643,"conditions":14266,"interventions":14267},[93],[9645],[9455,9647,8477],{"trials":14269,"activeCount":102},[],{"intervention":14271,"totalTrials":195,"cells":14272},"Fluzone®: Influenza Virus Vaccine",{"EARLY_PHASE1":14273,"PHASE1":14275,"PHASE2":14277,"PHASE3":14279,"PHASE4":14281,"NA":14289},{"trials":14274,"activeCount":102},[],{"trials":14276,"activeCount":102},[],{"trials":14278,"activeCount":102},[],{"trials":14280,"activeCount":102},[],{"trials":14282,"activeCount":102},[14283],{"nctId":14284,"briefTitle":14285,"status":108,"phases":14286,"primaryCompletion":8777,"completion":5272,"start":9559,"enrollment":4920,"conditions":14287,"interventions":14288},"NCT00258830","Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine",[93],[16],[14271,14271],{"trials":14290,"activeCount":102},[],{"intervention":14292,"totalTrials":195,"cells":14293},"Coarsucam®",{"EARLY_PHASE1":14294,"PHASE1":14296,"PHASE2":14298,"PHASE3":14300,"PHASE4":14302,"NA":14312},{"trials":14295,"activeCount":102},[],{"trials":14297,"activeCount":102},[],{"trials":14299,"activeCount":102},[],{"trials":14301,"activeCount":102},[],{"trials":14303,"activeCount":102},[14304],{"nctId":14305,"briefTitle":14306,"status":108,"phases":14307,"primaryCompletion":8315,"completion":8315,"start":1341,"enrollment":14308,"conditions":14309,"interventions":14310},"NCT00540410","Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks",[93],366,[12262],[14292,14311],"Coartem®",{"trials":14313,"activeCount":102},[],{"intervention":14311,"totalTrials":195,"cells":14315},{"EARLY_PHASE1":14316,"PHASE1":14318,"PHASE2":14320,"PHASE3":14322,"PHASE4":14324,"NA":14330},{"trials":14317,"activeCount":102},[],{"trials":14319,"activeCount":102},[],{"trials":14321,"activeCount":102},[],{"trials":14323,"activeCount":102},[],{"trials":14325,"activeCount":102},[14326],{"nctId":14305,"briefTitle":14306,"status":108,"phases":14327,"primaryCompletion":8315,"completion":8315,"start":1341,"enrollment":14308,"conditions":14328,"interventions":14329},[93],[12262],[14292,14311],{"trials":14331,"activeCount":102},[],{"intervention":14333,"totalTrials":195,"cells":14334},"Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"EARLY_PHASE1":14335,"PHASE1":14337,"PHASE2":14339,"PHASE3":14341,"PHASE4":14343,"NA":14351},{"trials":14336,"activeCount":102},[],{"trials":14338,"activeCount":102},[],{"trials":14340,"activeCount":102},[],{"trials":14342,"activeCount":102},[],{"trials":14344,"activeCount":102},[14345],{"nctId":14346,"briefTitle":14347,"status":108,"phases":14348,"primaryCompletion":1355,"completion":1054,"start":3429,"enrollment":599,"conditions":14349,"interventions":14350},"NCT02633787","Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier",[93],[4992,7568,2922],[14333],{"trials":14352,"activeCount":102},[],{"intervention":14354,"totalTrials":195,"cells":14355},"IMOVAX POLIO®: Inactive Poliovirus Vaccine",{"EARLY_PHASE1":14356,"PHASE1":14358,"PHASE2":14360,"PHASE3":14362,"PHASE4":14364,"NA":14373},{"trials":14357,"activeCount":102},[],{"trials":14359,"activeCount":102},[],{"trials":14361,"activeCount":102},[],{"trials":14363,"activeCount":102},[],{"trials":14365,"activeCount":102},[14366],{"nctId":14367,"briefTitle":14368,"status":108,"phases":14369,"primaryCompletion":14370,"completion":5216,"start":6471,"enrollment":178,"conditions":14371,"interventions":14372},"NCT02005536","Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan",[93],"2014-09",[12983,13810],[14354],{"trials":14374,"activeCount":102},[],{"intervention":14376,"totalTrials":195,"cells":14377},"Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella",{"EARLY_PHASE1":14378,"PHASE1":14380,"PHASE2":14382,"PHASE3":14384,"PHASE4":14386,"NA":14397},{"trials":14379,"activeCount":102},[],{"trials":14381,"activeCount":102},[],{"trials":14383,"activeCount":102},[],{"trials":14385,"activeCount":102},[],{"trials":14387,"activeCount":102},[14388],{"nctId":14389,"briefTitle":14390,"status":108,"phases":14391,"primaryCompletion":8388,"completion":3316,"start":3622,"enrollment":14392,"conditions":14393,"interventions":14395},"NCT00313950","Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine",[93],470,[10899,10900,10901,14394],"Hepatitis A",[14376,14396,14376],"Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine",{"trials":14398,"activeCount":102},[],{"intervention":14396,"totalTrials":195,"cells":14400},{"EARLY_PHASE1":14401,"PHASE1":14403,"PHASE2":14405,"PHASE3":14407,"PHASE4":14409,"NA":14415},{"trials":14402,"activeCount":102},[],{"trials":14404,"activeCount":102},[],{"trials":14406,"activeCount":102},[],{"trials":14408,"activeCount":102},[],{"trials":14410,"activeCount":102},[14411],{"nctId":14389,"briefTitle":14390,"status":108,"phases":14412,"primaryCompletion":8388,"completion":3316,"start":3622,"enrollment":14392,"conditions":14413,"interventions":14414},[93],[10899,10900,10901,14394],[14376,14396,14376],{"trials":14416,"activeCount":102},[],{"intervention":14418,"totalTrials":195,"cells":14419},"Insulin glargine, 300U\u002FmL",{"EARLY_PHASE1":14420,"PHASE1":14422,"PHASE2":14424,"PHASE3":14426,"PHASE4":14428,"NA":14441},{"trials":14421,"activeCount":102},[],{"trials":14423,"activeCount":102},[],{"trials":14425,"activeCount":102},[],{"trials":14427,"activeCount":102},[],{"trials":14429,"activeCount":102},[14430],{"nctId":14431,"briefTitle":14432,"status":108,"phases":14433,"primaryCompletion":14434,"completion":14434,"start":14435,"enrollment":14436,"conditions":14437,"interventions":14438},"NCT02738151","Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist",[93],"2017-08-15","2016-05-19",929,[22],[14418,14439,14440],"Insulin degludec, 100 U\u002FmL","Non-insulin anti-diabetic treatment",{"trials":14442,"activeCount":102},[],{"intervention":14439,"totalTrials":195,"cells":14444},{"EARLY_PHASE1":14445,"PHASE1":14447,"PHASE2":14449,"PHASE3":14451,"PHASE4":14453,"NA":14459},{"trials":14446,"activeCount":102},[],{"trials":14448,"activeCount":102},[],{"trials":14450,"activeCount":102},[],{"trials":14452,"activeCount":102},[],{"trials":14454,"activeCount":102},[14455],{"nctId":14431,"briefTitle":14432,"status":108,"phases":14456,"primaryCompletion":14434,"completion":14434,"start":14435,"enrollment":14436,"conditions":14457,"interventions":14458},[93],[22],[14418,14439,14440],{"trials":14460,"activeCount":102},[],{"intervention":14440,"totalTrials":195,"cells":14462},{"EARLY_PHASE1":14463,"PHASE1":14465,"PHASE2":14467,"PHASE3":14469,"PHASE4":14471,"NA":14477},{"trials":14464,"activeCount":102},[],{"trials":14466,"activeCount":102},[],{"trials":14468,"activeCount":102},[],{"trials":14470,"activeCount":102},[],{"trials":14472,"activeCount":102},[14473],{"nctId":14431,"briefTitle":14432,"status":108,"phases":14474,"primaryCompletion":14434,"completion":14434,"start":14435,"enrollment":14436,"conditions":14475,"interventions":14476},[93],[22],[14418,14439,14440],{"trials":14478,"activeCount":102},[],{"intervention":14480,"totalTrials":195,"cells":14481},"irbesartan and irbesartan-hydrochlorothiazide",{"EARLY_PHASE1":14482,"PHASE1":14484,"PHASE2":14486,"PHASE3":14488,"PHASE4":14490,"NA":14499},{"trials":14483,"activeCount":102},[],{"trials":14485,"activeCount":102},[],{"trials":14487,"activeCount":102},[],{"trials":14489,"activeCount":102},[],{"trials":14491,"activeCount":102},[14492],{"nctId":14493,"briefTitle":14494,"status":108,"phases":14495,"start":7523,"enrollment":14496,"conditions":14497,"interventions":14498},"NCT00264212","AMISH : Aprovel for Management of Isolated Systolic Hypertension",[93],436,[9680],[14480],{"trials":14500,"activeCount":102},[],{"intervention":14502,"totalTrials":195,"cells":14503},"IMOVAX Polio™: Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":14504,"PHASE1":14506,"PHASE2":14508,"PHASE3":14510,"PHASE4":14512,"NA":14521},{"trials":14505,"activeCount":102},[],{"trials":14507,"activeCount":102},[],{"trials":14509,"activeCount":102},[],{"trials":14511,"activeCount":102},[],{"trials":14513,"activeCount":102},[14514],{"nctId":14515,"briefTitle":14516,"status":108,"phases":14517,"primaryCompletion":977,"completion":2834,"start":8693,"enrollment":14518,"conditions":14519,"interventions":14520},"NCT01278433","A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China",[93],5007,[13810,12983],[14502],{"trials":14522,"activeCount":102},[],{"intervention":9755,"totalTrials":195,"cells":14524},{"EARLY_PHASE1":14525,"PHASE1":14527,"PHASE2":14529,"PHASE3":14531,"PHASE4":14533,"NA":14539},{"trials":14526,"activeCount":102},[],{"trials":14528,"activeCount":102},[],{"trials":14530,"activeCount":102},[],{"trials":14532,"activeCount":102},[],{"trials":14534,"activeCount":102},[14535],{"nctId":9750,"briefTitle":9751,"status":108,"phases":14536,"completion":9190,"start":9292,"enrollment":178,"conditions":14537,"interventions":14538},[93],[9680,7454],[9666,9755],{"trials":14540,"activeCount":102},[],{"intervention":14542,"totalTrials":195,"cells":14543},"Levothyroxin-Na",{"EARLY_PHASE1":14544,"PHASE1":14546,"PHASE2":14548,"PHASE3":14550,"PHASE4":14552,"NA":14564},{"trials":14545,"activeCount":102},[],{"trials":14547,"activeCount":102},[],{"trials":14549,"activeCount":102},[],{"trials":14551,"activeCount":102},[],{"trials":14553,"activeCount":102},[14554],{"nctId":14555,"briefTitle":14556,"status":108,"phases":14557,"primaryCompletion":8205,"completion":8205,"start":8526,"enrollment":14558,"conditions":14559,"interventions":14561},"NCT00277589","LISA-study : Levothyroxin in Nodular Goiter",[93],1024,[14560],"Goiter, Nodular",[14542,14562,14563],"Levothyroxine-Na + iodide","Iodide",{"trials":14565,"activeCount":102},[],{"intervention":14562,"totalTrials":195,"cells":14567},{"EARLY_PHASE1":14568,"PHASE1":14570,"PHASE2":14572,"PHASE3":14574,"PHASE4":14576,"NA":14582},{"trials":14569,"activeCount":102},[],{"trials":14571,"activeCount":102},[],{"trials":14573,"activeCount":102},[],{"trials":14575,"activeCount":102},[],{"trials":14577,"activeCount":102},[14578],{"nctId":14555,"briefTitle":14556,"status":108,"phases":14579,"primaryCompletion":8205,"completion":8205,"start":8526,"enrollment":14558,"conditions":14580,"interventions":14581},[93],[14560],[14542,14562,14563],{"trials":14583,"activeCount":102},[],{"intervention":14563,"totalTrials":195,"cells":14585},{"EARLY_PHASE1":14586,"PHASE1":14588,"PHASE2":14590,"PHASE3":14592,"PHASE4":14594,"NA":14600},{"trials":14587,"activeCount":102},[],{"trials":14589,"activeCount":102},[],{"trials":14591,"activeCount":102},[],{"trials":14593,"activeCount":102},[],{"trials":14595,"activeCount":102},[14596],{"nctId":14555,"briefTitle":14556,"status":108,"phases":14597,"primaryCompletion":8205,"completion":8205,"start":8526,"enrollment":14558,"conditions":14598,"interventions":14599},[93],[14560],[14542,14562,14563],{"trials":14601,"activeCount":102},[],{"intervention":14603,"totalTrials":195,"cells":14604},"Fluzone Quadrivalent vaccine, 2018-2019 formulation",{"EARLY_PHASE1":14605,"PHASE1":14607,"PHASE2":14609,"PHASE3":14611,"PHASE4":14613,"NA":14624},{"trials":14606,"activeCount":102},[],{"trials":14608,"activeCount":102},[],{"trials":14610,"activeCount":102},[],{"trials":14612,"activeCount":102},[],{"trials":14614,"activeCount":102},[14615],{"nctId":14616,"briefTitle":14617,"status":108,"phases":14618,"primaryCompletion":14619,"completion":14619,"start":2919,"enrollment":6655,"conditions":14620,"interventions":14621},"NCT03617523","Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations",[93],"2018-11-12",[16],[14603,14622,14623],"Flublok Quadrivalent vaccine, 2018-2019 formulation","Fluzone High-Dose vaccine, 2018-2019 formulation",{"trials":14625,"activeCount":102},[],{"intervention":14622,"totalTrials":195,"cells":14627},{"EARLY_PHASE1":14628,"PHASE1":14630,"PHASE2":14632,"PHASE3":14634,"PHASE4":14636,"NA":14642},{"trials":14629,"activeCount":102},[],{"trials":14631,"activeCount":102},[],{"trials":14633,"activeCount":102},[],{"trials":14635,"activeCount":102},[],{"trials":14637,"activeCount":102},[14638],{"nctId":14616,"briefTitle":14617,"status":108,"phases":14639,"primaryCompletion":14619,"completion":14619,"start":2919,"enrollment":6655,"conditions":14640,"interventions":14641},[93],[16],[14603,14622,14623],{"trials":14643,"activeCount":102},[],{"intervention":14623,"totalTrials":195,"cells":14645},{"EARLY_PHASE1":14646,"PHASE1":14648,"PHASE2":14650,"PHASE3":14652,"PHASE4":14654,"NA":14660},{"trials":14647,"activeCount":102},[],{"trials":14649,"activeCount":102},[],{"trials":14651,"activeCount":102},[],{"trials":14653,"activeCount":102},[],{"trials":14655,"activeCount":102},[14656],{"nctId":14616,"briefTitle":14617,"status":108,"phases":14657,"primaryCompletion":14619,"completion":14619,"start":2919,"enrollment":6655,"conditions":14658,"interventions":14659},[93],[16],[14603,14622,14623],{"trials":14661,"activeCount":102},[],{"intervention":1083,"totalTrials":195,"cells":14663},{"EARLY_PHASE1":14664,"PHASE1":14666,"PHASE2":14668,"PHASE3":14670,"PHASE4":14672,"NA":14678},{"trials":14665,"activeCount":102},[],{"trials":14667,"activeCount":102},[],{"trials":14669,"activeCount":102},[],{"trials":14671,"activeCount":102},[],{"trials":14673,"activeCount":102},[14674],{"nctId":1074,"briefTitle":1075,"status":108,"phases":14675,"primaryCompletion":1077,"completion":1077,"start":1078,"enrollment":1079,"conditions":14676,"interventions":14677},[93],[990],[1082,1083,1084,1060,1046,971,1045],{"trials":14679,"activeCount":102},[],{"intervention":14681,"totalTrials":195,"cells":14682},"COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine",{"EARLY_PHASE1":14683,"PHASE1":14685,"PHASE2":14687,"PHASE3":14689,"PHASE4":14691,"NA":14700},{"trials":14684,"activeCount":102},[],{"trials":14686,"activeCount":102},[],{"trials":14688,"activeCount":102},[],{"trials":14690,"activeCount":102},[],{"trials":14692,"activeCount":102},[14693],{"nctId":14694,"briefTitle":14695,"status":108,"phases":14696,"primaryCompletion":3430,"completion":3317,"start":5307,"enrollment":14697,"conditions":14698,"interventions":14699},"NCT00304265","Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine",[93],215,[28,25,31,12983],[14681],{"trials":14701,"activeCount":102},[],{"intervention":14703,"totalTrials":195,"cells":14704},"RASBURICASE SR29142",{"EARLY_PHASE1":14705,"PHASE1":14707,"PHASE2":14709,"PHASE3":14711,"PHASE4":14713,"NA":14723},{"trials":14706,"activeCount":102},[],{"trials":14708,"activeCount":102},[],{"trials":14710,"activeCount":102},[],{"trials":14712,"activeCount":102},[],{"trials":14714,"activeCount":102},[14715],{"nctId":14716,"briefTitle":14717,"status":108,"phases":14718,"primaryCompletion":14719,"completion":14719,"start":14720,"enrollment":7653,"conditions":14721,"interventions":14722},"NCT04349306","Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia",[93],"2021-03-12","2020-05-14",[2675],[14703],{"trials":14724,"activeCount":102},[],{"intervention":14726,"totalTrials":195,"cells":14727},"Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation",{"EARLY_PHASE1":14728,"PHASE1":14730,"PHASE2":14732,"PHASE3":14734,"PHASE4":14736,"NA":14746},{"trials":14729,"activeCount":102},[],{"trials":14731,"activeCount":102},[],{"trials":14733,"activeCount":102},[],{"trials":14735,"activeCount":102},[],{"trials":14737,"activeCount":102},[14738],{"nctId":14739,"briefTitle":14740,"status":108,"phases":14741,"primaryCompletion":7284,"completion":10005,"start":10178,"enrollment":12,"conditions":14742,"interventions":14743},"NCT01691339","Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.",[93],[16],[14726,14744,14726,14745],"Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation","Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation",{"trials":14747,"activeCount":102},[],{"intervention":14744,"totalTrials":195,"cells":14749},{"EARLY_PHASE1":14750,"PHASE1":14752,"PHASE2":14754,"PHASE3":14756,"PHASE4":14758,"NA":14764},{"trials":14751,"activeCount":102},[],{"trials":14753,"activeCount":102},[],{"trials":14755,"activeCount":102},[],{"trials":14757,"activeCount":102},[],{"trials":14759,"activeCount":102},[14760],{"nctId":14739,"briefTitle":14740,"status":108,"phases":14761,"primaryCompletion":7284,"completion":10005,"start":10178,"enrollment":12,"conditions":14762,"interventions":14763},[93],[16],[14726,14744,14726,14745],{"trials":14765,"activeCount":102},[],{"intervention":14745,"totalTrials":195,"cells":14767},{"EARLY_PHASE1":14768,"PHASE1":14770,"PHASE2":14772,"PHASE3":14774,"PHASE4":14776,"NA":14782},{"trials":14769,"activeCount":102},[],{"trials":14771,"activeCount":102},[],{"trials":14773,"activeCount":102},[],{"trials":14775,"activeCount":102},[],{"trials":14777,"activeCount":102},[14778],{"nctId":14739,"briefTitle":14740,"status":108,"phases":14779,"primaryCompletion":7284,"completion":10005,"start":10178,"enrollment":12,"conditions":14780,"interventions":14781},[93],[16],[14726,14744,14726,14745],{"trials":14783,"activeCount":102},[],{"intervention":2862,"totalTrials":195,"cells":14785},{"EARLY_PHASE1":14786,"PHASE1":14788,"PHASE2":14790,"PHASE3":14792,"PHASE4":14794,"NA":14800},{"trials":14787,"activeCount":102},[],{"trials":14789,"activeCount":102},[],{"trials":14791,"activeCount":102},[],{"trials":14793,"activeCount":102},[],{"trials":14795,"activeCount":102},[14796],{"nctId":2852,"briefTitle":2853,"status":108,"phases":14797,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":14798,"interventions":14799},[93],[1357],[2764,671,2861,2862],{"trials":14801,"activeCount":102},[],{"intervention":14803,"totalTrials":195,"cells":14804},"Coarsucam",{"EARLY_PHASE1":14805,"PHASE1":14807,"PHASE2":14809,"PHASE3":14811,"PHASE4":14813,"NA":14822},{"trials":14806,"activeCount":102},[],{"trials":14808,"activeCount":102},[],{"trials":14810,"activeCount":102},[],{"trials":14812,"activeCount":102},[],{"trials":14814,"activeCount":102},[14815],{"nctId":14816,"briefTitle":14817,"status":108,"phases":14818,"primaryCompletion":978,"completion":978,"start":8156,"enrollment":7452,"conditions":14819,"interventions":14820},"NCT00699920","Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks",[93],[12262],[14803,14821],"Coartem",{"trials":14823,"activeCount":102},[],{"intervention":14821,"totalTrials":195,"cells":14825},{"EARLY_PHASE1":14826,"PHASE1":14828,"PHASE2":14830,"PHASE3":14832,"PHASE4":14834,"NA":14840},{"trials":14827,"activeCount":102},[],{"trials":14829,"activeCount":102},[],{"trials":14831,"activeCount":102},[],{"trials":14833,"activeCount":102},[],{"trials":14835,"activeCount":102},[14836],{"nctId":14816,"briefTitle":14817,"status":108,"phases":14837,"primaryCompletion":978,"completion":978,"start":8156,"enrollment":7452,"conditions":14838,"interventions":14839},[93],[12262],[14803,14821],{"trials":14841,"activeCount":102},[],{"intervention":11550,"totalTrials":195,"cells":14843},{"EARLY_PHASE1":14844,"PHASE1":14846,"PHASE2":14848,"PHASE3":14850,"PHASE4":14852,"NA":14858},{"trials":14845,"activeCount":102},[],{"trials":14847,"activeCount":102},[],{"trials":14849,"activeCount":102},[],{"trials":14851,"activeCount":102},[],{"trials":14853,"activeCount":102},[14854],{"nctId":11545,"briefTitle":11546,"status":108,"phases":14855,"primaryCompletion":2799,"completion":2799,"start":9532,"enrollment":9533,"conditions":14856,"interventions":14857},[93],[9680],[11550,11509,11509],{"trials":14859,"activeCount":102},[],{"intervention":10914,"totalTrials":195,"cells":14861},{"EARLY_PHASE1":14862,"PHASE1":14864,"PHASE2":14866,"PHASE3":14868,"PHASE4":14870,"NA":14876},{"trials":14863,"activeCount":102},[],{"trials":14865,"activeCount":102},[],{"trials":14867,"activeCount":102},[],{"trials":14869,"activeCount":102},[],{"trials":14871,"activeCount":102},[14872],{"nctId":10907,"briefTitle":10908,"status":108,"phases":14873,"primaryCompletion":150,"completion":2824,"start":2857,"enrollment":10910,"conditions":14874,"interventions":14875},[93],[4992,2949,25,31,28,10912],[10866,10914,10915],{"trials":14877,"activeCount":102},[],{"intervention":14879,"totalTrials":195,"cells":14880},"Hylan G-F 20",{"EARLY_PHASE1":14881,"PHASE1":14883,"PHASE2":14885,"PHASE3":14887,"PHASE4":14889,"NA":14898},{"trials":14882,"activeCount":102},[],{"trials":14884,"activeCount":102},[],{"trials":14886,"activeCount":102},[],{"trials":14888,"activeCount":102},[],{"trials":14890,"activeCount":102},[14891],{"nctId":14892,"briefTitle":14893,"status":108,"phases":14894,"primaryCompletion":2311,"completion":2311,"start":8683,"enrollment":14895,"conditions":14896,"interventions":14897},"NCT01586338","A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)",[93],237,[13537],[14879],{"trials":14899,"activeCount":102},[],{"intervention":14901,"totalTrials":195,"cells":14902},"Blood draw for insulin auto-anti body tests*",{"EARLY_PHASE1":14903,"PHASE1":14905,"PHASE2":14907,"PHASE3":14909,"PHASE4":14911,"NA":14921},{"trials":14904,"activeCount":102},[],{"trials":14906,"activeCount":102},[],{"trials":14908,"activeCount":102},[],{"trials":14910,"activeCount":102},[],{"trials":14912,"activeCount":102},[14913],{"nctId":14914,"briefTitle":14915,"status":108,"phases":14916,"primaryCompletion":14917,"completion":14917,"start":14918,"enrollment":8366,"conditions":14919,"interventions":14920},"NCT03312478","Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes",[93],"2018-08-19","2017-10-13",[591],[14901],{"trials":14922,"activeCount":102},[],{"intervention":14924,"totalTrials":195,"cells":14925},"Fluzone®: Influenza virus vaccine 2004-2005 formulation",{"EARLY_PHASE1":14926,"PHASE1":14928,"PHASE2":14930,"PHASE3":14932,"PHASE4":14934,"NA":14942},{"trials":14927,"activeCount":102},[],{"trials":14929,"activeCount":102},[],{"trials":14931,"activeCount":102},[],{"trials":14933,"activeCount":102},[],{"trials":14935,"activeCount":102},[14936],{"nctId":14937,"briefTitle":14938,"status":108,"phases":14939,"primaryCompletion":8777,"completion":8777,"start":7523,"enrollment":4920,"conditions":14940,"interventions":14941},"NCT00831987","Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine",[93],[16],[14924,14924],{"trials":14943,"activeCount":102},[],{"intervention":14945,"totalTrials":195,"cells":14946},"IDflu™: Split virion inactivated influenza vaccine",{"EARLY_PHASE1":14947,"PHASE1":14949,"PHASE2":14951,"PHASE3":14953,"PHASE4":14955,"NA":14964},{"trials":14948,"activeCount":102},[],{"trials":14950,"activeCount":102},[],{"trials":14952,"activeCount":102},[],{"trials":14954,"activeCount":102},[],{"trials":14956,"activeCount":102},[14957],{"nctId":14958,"briefTitle":14959,"status":108,"phases":14960,"primaryCompletion":3821,"completion":2790,"start":8453,"enrollment":6655,"conditions":14961,"interventions":14962},"NCT01215669","Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea",[93],[16],[14945,14963,14945,14963],"Vaxigrip®: Split virion inactivated influenza vaccine",{"trials":14965,"activeCount":102},[],{"intervention":14963,"totalTrials":195,"cells":14967},{"EARLY_PHASE1":14968,"PHASE1":14970,"PHASE2":14972,"PHASE3":14974,"PHASE4":14976,"NA":14982},{"trials":14969,"activeCount":102},[],{"trials":14971,"activeCount":102},[],{"trials":14973,"activeCount":102},[],{"trials":14975,"activeCount":102},[],{"trials":14977,"activeCount":102},[14978],{"nctId":14958,"briefTitle":14959,"status":108,"phases":14979,"primaryCompletion":3821,"completion":2790,"start":8453,"enrollment":6655,"conditions":14980,"interventions":14981},[93],[16],[14945,14963,14945,14963],{"trials":14983,"activeCount":102},[],{"intervention":14985,"totalTrials":195,"cells":14986},"Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation",{"EARLY_PHASE1":14987,"PHASE1":14989,"PHASE2":14991,"PHASE3":14993,"PHASE4":14995,"NA":15006},{"trials":14988,"activeCount":102},[],{"trials":14990,"activeCount":102},[],{"trials":14992,"activeCount":102},[],{"trials":14994,"activeCount":102},[],{"trials":14996,"activeCount":102},[14997],{"nctId":14998,"briefTitle":14999,"status":108,"phases":15000,"primaryCompletion":15001,"completion":15001,"start":15002,"enrollment":305,"conditions":15003,"interventions":15004},"NCT04551677","Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",[93],"2020-12-18","2020-09-16",[5335,36],[14985,15005],"Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation",{"trials":15007,"activeCount":102},[],{"intervention":15005,"totalTrials":195,"cells":15009},{"EARLY_PHASE1":15010,"PHASE1":15012,"PHASE2":15014,"PHASE3":15016,"PHASE4":15018,"NA":15024},{"trials":15011,"activeCount":102},[],{"trials":15013,"activeCount":102},[],{"trials":15015,"activeCount":102},[],{"trials":15017,"activeCount":102},[],{"trials":15019,"activeCount":102},[15020],{"nctId":14998,"briefTitle":14999,"status":108,"phases":15021,"primaryCompletion":15001,"completion":15001,"start":15002,"enrollment":305,"conditions":15022,"interventions":15023},[93],[5335,36],[14985,15005],{"trials":15025,"activeCount":102},[],{"intervention":15027,"totalTrials":195,"cells":15028},"SP Shz TIV",{"EARLY_PHASE1":15029,"PHASE1":15031,"PHASE2":15033,"PHASE3":15035,"PHASE4":15037,"NA":15050},{"trials":15030,"activeCount":102},[],{"trials":15032,"activeCount":102},[],{"trials":15034,"activeCount":102},[],{"trials":15036,"activeCount":102},[],{"trials":15038,"activeCount":102},[15039],{"nctId":15040,"briefTitle":15041,"status":108,"phases":15042,"primaryCompletion":15043,"completion":15043,"start":15044,"enrollment":15045,"conditions":15046,"interventions":15048},"NCT03344029","Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years",[93],"2018-05-22","2017-11-03",1600,[16,15047],"Flu",[15027,15049],"Hualan TIV",{"trials":15051,"activeCount":102},[],{"intervention":15049,"totalTrials":195,"cells":15053},{"EARLY_PHASE1":15054,"PHASE1":15056,"PHASE2":15058,"PHASE3":15060,"PHASE4":15062,"NA":15068},{"trials":15055,"activeCount":102},[],{"trials":15057,"activeCount":102},[],{"trials":15059,"activeCount":102},[],{"trials":15061,"activeCount":102},[],{"trials":15063,"activeCount":102},[15064],{"nctId":15040,"briefTitle":15041,"status":108,"phases":15065,"primaryCompletion":15043,"completion":15043,"start":15044,"enrollment":15045,"conditions":15066,"interventions":15067},[93],[16,15047],[15027,15049],{"trials":15069,"activeCount":102},[],{"intervention":8720,"totalTrials":195,"cells":15071},{"EARLY_PHASE1":15072,"PHASE1":15074,"PHASE2":15076,"PHASE3":15078,"PHASE4":15080,"NA":15086},{"trials":15073,"activeCount":102},[],{"trials":15075,"activeCount":102},[],{"trials":15077,"activeCount":102},[],{"trials":15079,"activeCount":102},[],{"trials":15081,"activeCount":102},[15082],{"nctId":8714,"briefTitle":8715,"status":108,"phases":15083,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":8717,"conditions":15084,"interventions":15085},[93],[22],[8256,8551,8687,8720],{"trials":15087,"activeCount":102},[],{"intervention":15089,"totalTrials":195,"cells":15090},"Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation",{"EARLY_PHASE1":15091,"PHASE1":15093,"PHASE2":15095,"PHASE3":15097,"PHASE4":15099,"NA":15109},{"trials":15092,"activeCount":102},[],{"trials":15094,"activeCount":102},[],{"trials":15096,"activeCount":102},[],{"trials":15098,"activeCount":102},[],{"trials":15100,"activeCount":102},[15101],{"nctId":15102,"briefTitle":15103,"status":108,"phases":15104,"primaryCompletion":4799,"completion":4799,"start":15105,"enrollment":305,"conditions":15106,"interventions":15107},"NCT05050318","Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively",[93],"2021-09-08",[5335,36],[15089,15108],"Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation",{"trials":15110,"activeCount":102},[],{"intervention":15108,"totalTrials":195,"cells":15112},{"EARLY_PHASE1":15113,"PHASE1":15115,"PHASE2":15117,"PHASE3":15119,"PHASE4":15121,"NA":15127},{"trials":15114,"activeCount":102},[],{"trials":15116,"activeCount":102},[],{"trials":15118,"activeCount":102},[],{"trials":15120,"activeCount":102},[],{"trials":15122,"activeCount":102},[15123],{"nctId":15102,"briefTitle":15103,"status":108,"phases":15124,"primaryCompletion":4799,"completion":4799,"start":15105,"enrollment":305,"conditions":15125,"interventions":15126},[93],[5335,36],[15089,15108],{"trials":15128,"activeCount":102},[],{"intervention":15130,"totalTrials":195,"cells":15131},"Oral Iron",{"EARLY_PHASE1":15132,"PHASE1":15134,"PHASE2":15136,"PHASE3":15138,"PHASE4":15140,"NA":15152},{"trials":15133,"activeCount":102},[],{"trials":15135,"activeCount":102},[],{"trials":15137,"activeCount":102},[],{"trials":15139,"activeCount":102},[],{"trials":15141,"activeCount":102},[15142],{"nctId":15143,"briefTitle":15144,"status":884,"phases":15145,"primaryCompletion":15146,"completion":15146,"start":15147,"enrollment":8139,"conditions":15148,"interventions":15150},"NCT00223938","Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.",[93],"2007-04-27","2003-12-30",[15149],"Anemia",[15130,15151,15151],"sodium ferric gluconate",{"trials":15153,"activeCount":102},[],{"intervention":15151,"totalTrials":195,"cells":15155},{"EARLY_PHASE1":15156,"PHASE1":15158,"PHASE2":15160,"PHASE3":15162,"PHASE4":15164,"NA":15170},{"trials":15157,"activeCount":102},[],{"trials":15159,"activeCount":102},[],{"trials":15161,"activeCount":102},[],{"trials":15163,"activeCount":102},[],{"trials":15165,"activeCount":102},[15166],{"nctId":15143,"briefTitle":15144,"status":884,"phases":15167,"primaryCompletion":15146,"completion":15146,"start":15147,"enrollment":8139,"conditions":15168,"interventions":15169},[93],[15149],[15130,15151,15151],{"trials":15171,"activeCount":102},[],{"intervention":15173,"totalTrials":195,"cells":15174},"Bacillus Clausii Multi ATB Resist",{"EARLY_PHASE1":15175,"PHASE1":15177,"PHASE2":15179,"PHASE3":15181,"PHASE4":15183,"NA":15192},{"trials":15176,"activeCount":102},[],{"trials":15178,"activeCount":102},[],{"trials":15180,"activeCount":102},[],{"trials":15182,"activeCount":102},[],{"trials":15184,"activeCount":102},[15185],{"nctId":15186,"briefTitle":15187,"status":108,"phases":15188,"primaryCompletion":3317,"start":3608,"enrollment":8063,"conditions":15189,"interventions":15191},"NCT00447161","Preventing Antibiotic-Associated DiarRhea Using Erceflora",[93],[15190],"Diarrhea, Infantile",[15173],{"trials":15193,"activeCount":102},[],{"intervention":11688,"totalTrials":195,"cells":15195},{"EARLY_PHASE1":15196,"PHASE1":15198,"PHASE2":15200,"PHASE3":15202,"PHASE4":15204,"NA":15210},{"trials":15197,"activeCount":102},[],{"trials":15199,"activeCount":102},[],{"trials":15201,"activeCount":102},[],{"trials":15203,"activeCount":102},[],{"trials":15205,"activeCount":102},[15206],{"nctId":11680,"briefTitle":11681,"status":108,"phases":15207,"primaryCompletion":986,"completion":986,"start":5272,"enrollment":11683,"conditions":15208,"interventions":15209},[93],[11685],[11687,11688],{"trials":15211,"activeCount":102},[],{"intervention":15213,"totalTrials":195,"cells":15214},"Influenza Virus Vaccine No Preservative: Pediatric Dose",{"EARLY_PHASE1":15215,"PHASE1":15217,"PHASE2":15219,"PHASE3":15221,"PHASE4":15223,"NA":15232},{"trials":15216,"activeCount":102},[],{"trials":15218,"activeCount":102},[],{"trials":15220,"activeCount":102},[],{"trials":15222,"activeCount":102},[],{"trials":15224,"activeCount":102},[15225],{"nctId":15226,"briefTitle":15227,"status":108,"phases":15228,"primaryCompletion":9532,"completion":9532,"start":3564,"enrollment":6313,"conditions":15229,"interventions":15231},"NCT00755274","Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®",[93],[16,15230],"Orthomyxoviridae Infections",[15213,15213],{"trials":15233,"activeCount":102},[],{"intervention":8425,"totalTrials":195,"cells":15235},{"EARLY_PHASE1":15236,"PHASE1":15238,"PHASE2":15240,"PHASE3":15242,"PHASE4":15244,"NA":15250},{"trials":15237,"activeCount":102},[],{"trials":15239,"activeCount":102},[],{"trials":15241,"activeCount":102},[],{"trials":15243,"activeCount":102},[],{"trials":15245,"activeCount":102},[15246],{"nctId":8417,"briefTitle":8418,"status":108,"phases":15247,"completion":8420,"start":8421,"enrollment":3471,"conditions":15248,"interventions":15249},[93],[19],[8424,8425,8037],{"trials":15251,"activeCount":102},[],{"intervention":8434,"totalTrials":195,"cells":15253},{"EARLY_PHASE1":15254,"PHASE1":15256,"PHASE2":15258,"PHASE3":15260,"PHASE4":15262,"NA":15268},{"trials":15255,"activeCount":102},[],{"trials":15257,"activeCount":102},[],{"trials":15259,"activeCount":102},[],{"trials":15261,"activeCount":102},[],{"trials":15263,"activeCount":102},[15264],{"nctId":8427,"briefTitle":8428,"status":108,"phases":15265,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":15266,"interventions":15267},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"trials":15269,"activeCount":102},[],{"intervention":8435,"totalTrials":195,"cells":15271},{"EARLY_PHASE1":15272,"PHASE1":15274,"PHASE2":15276,"PHASE3":15278,"PHASE4":15280,"NA":15286},{"trials":15273,"activeCount":102},[],{"trials":15275,"activeCount":102},[],{"trials":15277,"activeCount":102},[],{"trials":15279,"activeCount":102},[],{"trials":15281,"activeCount":102},[15282],{"nctId":8427,"briefTitle":8428,"status":108,"phases":15283,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":15284,"interventions":15285},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"trials":15287,"activeCount":102},[],{"intervention":8436,"totalTrials":195,"cells":15289},{"EARLY_PHASE1":15290,"PHASE1":15292,"PHASE2":15294,"PHASE3":15296,"PHASE4":15298,"NA":15304},{"trials":15291,"activeCount":102},[],{"trials":15293,"activeCount":102},[],{"trials":15295,"activeCount":102},[],{"trials":15297,"activeCount":102},[],{"trials":15299,"activeCount":102},[15300],{"nctId":8427,"briefTitle":8428,"status":108,"phases":15301,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":15302,"interventions":15303},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"trials":15305,"activeCount":102},[],{"intervention":8437,"totalTrials":195,"cells":15307},{"EARLY_PHASE1":15308,"PHASE1":15310,"PHASE2":15312,"PHASE3":15314,"PHASE4":15316,"NA":15322},{"trials":15309,"activeCount":102},[],{"trials":15311,"activeCount":102},[],{"trials":15313,"activeCount":102},[],{"trials":15315,"activeCount":102},[],{"trials":15317,"activeCount":102},[15318],{"nctId":8427,"briefTitle":8428,"status":108,"phases":15319,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":15320,"interventions":15321},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"trials":15323,"activeCount":102},[],{"intervention":8438,"totalTrials":195,"cells":15325},{"EARLY_PHASE1":15326,"PHASE1":15328,"PHASE2":15330,"PHASE3":15332,"PHASE4":15334,"NA":15340},{"trials":15327,"activeCount":102},[],{"trials":15329,"activeCount":102},[],{"trials":15331,"activeCount":102},[],{"trials":15333,"activeCount":102},[],{"trials":15335,"activeCount":102},[15336],{"nctId":8427,"briefTitle":8428,"status":108,"phases":15337,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":15338,"interventions":15339},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"trials":15341,"activeCount":102},[],{"intervention":8439,"totalTrials":195,"cells":15343},{"EARLY_PHASE1":15344,"PHASE1":15346,"PHASE2":15348,"PHASE3":15350,"PHASE4":15352,"NA":15358},{"trials":15345,"activeCount":102},[],{"trials":15347,"activeCount":102},[],{"trials":15349,"activeCount":102},[],{"trials":15351,"activeCount":102},[],{"trials":15353,"activeCount":102},[15354],{"nctId":8427,"briefTitle":8428,"status":108,"phases":15355,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":15356,"interventions":15357},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"trials":15359,"activeCount":102},[],{"intervention":15361,"totalTrials":195,"cells":15362},"Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative",{"EARLY_PHASE1":15363,"PHASE1":15365,"PHASE2":15367,"PHASE3":15369,"PHASE4":15371,"NA":15381},{"trials":15364,"activeCount":102},[],{"trials":15366,"activeCount":102},[],{"trials":15368,"activeCount":102},[],{"trials":15370,"activeCount":102},[],{"trials":15372,"activeCount":102},[15373],{"nctId":15374,"briefTitle":15375,"status":108,"phases":15376,"primaryCompletion":15377,"completion":15377,"start":3840,"enrollment":680,"conditions":15378,"interventions":15379},"NCT02908269","Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations",[93],"2016-12-09",[16],[15361,15361,15380],"Fluzone High-Dose, vaccine, 2016-2017 formulation",{"trials":15382,"activeCount":102},[],{"intervention":15380,"totalTrials":195,"cells":15384},{"EARLY_PHASE1":15385,"PHASE1":15387,"PHASE2":15389,"PHASE3":15391,"PHASE4":15393,"NA":15399},{"trials":15386,"activeCount":102},[],{"trials":15388,"activeCount":102},[],{"trials":15390,"activeCount":102},[],{"trials":15392,"activeCount":102},[],{"trials":15394,"activeCount":102},[15395],{"nctId":15374,"briefTitle":15375,"status":108,"phases":15396,"primaryCompletion":15377,"completion":15377,"start":3840,"enrollment":680,"conditions":15397,"interventions":15398},[93],[16],[15361,15361,15380],{"trials":15400,"activeCount":102},[],{"intervention":15402,"totalTrials":195,"cells":15403},"Irbesartan 150mg \u002F Hydrochlorothiazide 12.5mg",{"EARLY_PHASE1":15404,"PHASE1":15406,"PHASE2":15408,"PHASE3":15410,"PHASE4":15412,"NA":15422},{"trials":15405,"activeCount":102},[],{"trials":15407,"activeCount":102},[],{"trials":15409,"activeCount":102},[],{"trials":15411,"activeCount":102},[],{"trials":15413,"activeCount":102},[15414],{"nctId":15415,"briefTitle":15416,"status":108,"phases":15417,"primaryCompletion":9909,"start":3518,"enrollment":15418,"conditions":15419,"interventions":15420},"NCT00847834","Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population",[93],968,[9680],[15402,15421],"Irbesartan 150mg",{"trials":15423,"activeCount":102},[],{"intervention":15421,"totalTrials":195,"cells":15425},{"EARLY_PHASE1":15426,"PHASE1":15428,"PHASE2":15430,"PHASE3":15432,"PHASE4":15434,"NA":15440},{"trials":15427,"activeCount":102},[],{"trials":15429,"activeCount":102},[],{"trials":15431,"activeCount":102},[],{"trials":15433,"activeCount":102},[],{"trials":15435,"activeCount":102},[15436],{"nctId":15415,"briefTitle":15416,"status":108,"phases":15437,"primaryCompletion":9909,"start":3518,"enrollment":15418,"conditions":15438,"interventions":15439},[93],[9680],[15402,15421],{"trials":15441,"activeCount":102},[],{"intervention":15443,"totalTrials":195,"cells":15444},"Irbesartan - Hydrochlorothiazide",{"EARLY_PHASE1":15445,"PHASE1":15447,"PHASE2":15449,"PHASE3":15451,"PHASE4":15453,"NA":15462},{"trials":15446,"activeCount":102},[],{"trials":15448,"activeCount":102},[],{"trials":15450,"activeCount":102},[],{"trials":15452,"activeCount":102},[],{"trials":15454,"activeCount":102},[15455],{"nctId":15456,"briefTitle":15457,"status":108,"phases":15458,"primaryCompletion":8731,"completion":8731,"start":8156,"enrollment":15459,"conditions":15460,"interventions":15461},"NCT00708344","ACTUAL: Efficacy and Safety of Irbesartan\u002FHydrochlorothiazide Combination",[93],832,[9680],[15443,15443],{"trials":15463,"activeCount":102},[],{"intervention":13346,"totalTrials":195,"cells":15465},{"EARLY_PHASE1":15466,"PHASE1":15468,"PHASE2":15470,"PHASE3":15472,"PHASE4":15474,"NA":15480},{"trials":15467,"activeCount":102},[],{"trials":15469,"activeCount":102},[],{"trials":15471,"activeCount":102},[],{"trials":15473,"activeCount":102},[],{"trials":15475,"activeCount":102},[15476],{"nctId":13338,"briefTitle":13339,"status":108,"phases":15477,"primaryCompletion":13341,"completion":13341,"start":13342,"enrollment":13343,"conditions":15478,"interventions":15479},[93],[554],[12097,13346,13347],{"trials":15481,"activeCount":102},[],{"intervention":13347,"totalTrials":195,"cells":15483},{"EARLY_PHASE1":15484,"PHASE1":15486,"PHASE2":15488,"PHASE3":15490,"PHASE4":15492,"NA":15498},{"trials":15485,"activeCount":102},[],{"trials":15487,"activeCount":102},[],{"trials":15489,"activeCount":102},[],{"trials":15491,"activeCount":102},[],{"trials":15493,"activeCount":102},[15494],{"nctId":13338,"briefTitle":13339,"status":108,"phases":15495,"primaryCompletion":13341,"completion":13341,"start":13342,"enrollment":13343,"conditions":15496,"interventions":15497},[93],[554],[12097,13346,13347],{"trials":15499,"activeCount":102},[],{"intervention":2874,"totalTrials":195,"cells":15501},{"EARLY_PHASE1":15502,"PHASE1":15504,"PHASE2":15506,"PHASE3":15508,"PHASE4":15510,"NA":15516},{"trials":15503,"activeCount":102},[],{"trials":15505,"activeCount":102},[],{"trials":15507,"activeCount":102},[],{"trials":15509,"activeCount":102},[],{"trials":15511,"activeCount":102},[15512],{"nctId":2864,"briefTitle":2865,"status":108,"phases":15513,"primaryCompletion":2867,"completion":2868,"start":2869,"enrollment":2870,"conditions":15514,"interventions":15515},[93],[2750],[2873,2874,2875,1780],{"trials":15517,"activeCount":102},[],{"intervention":15519,"totalTrials":195,"cells":15520},"Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation",{"EARLY_PHASE1":15521,"PHASE1":15523,"PHASE2":15525,"PHASE3":15527,"PHASE4":15529,"NA":15538},{"trials":15522,"activeCount":102},[],{"trials":15524,"activeCount":102},[],{"trials":15526,"activeCount":102},[],{"trials":15528,"activeCount":102},[],{"trials":15530,"activeCount":102},[15531],{"nctId":15532,"briefTitle":15533,"status":108,"phases":15534,"primaryCompletion":8107,"completion":8107,"start":986,"enrollment":1091,"conditions":15535,"interventions":15536},"NCT01430819","Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults",[93],[16],[15519,15537],"Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation",{"trials":15539,"activeCount":102},[],{"intervention":15537,"totalTrials":195,"cells":15541},{"EARLY_PHASE1":15542,"PHASE1":15544,"PHASE2":15546,"PHASE3":15548,"PHASE4":15550,"NA":15556},{"trials":15543,"activeCount":102},[],{"trials":15545,"activeCount":102},[],{"trials":15547,"activeCount":102},[],{"trials":15549,"activeCount":102},[],{"trials":15551,"activeCount":102},[15552],{"nctId":15532,"briefTitle":15533,"status":108,"phases":15553,"primaryCompletion":8107,"completion":8107,"start":986,"enrollment":1091,"conditions":15554,"interventions":15555},[93],[16],[15519,15537],{"trials":15557,"activeCount":102},[],{"intervention":15559,"totalTrials":195,"cells":15560},"Valproic acid, sodium salt",{"EARLY_PHASE1":15561,"PHASE1":15563,"PHASE2":15565,"PHASE3":15567,"PHASE4":15569,"NA":15577},{"trials":15562,"activeCount":102},[],{"trials":15564,"activeCount":102},[],{"trials":15566,"activeCount":102},[],{"trials":15568,"activeCount":102},[],{"trials":15570,"activeCount":102},[15571],{"nctId":15572,"briefTitle":15573,"status":108,"phases":15574,"primaryCompletion":3430,"completion":3430,"start":8184,"enrollment":967,"conditions":15575,"interventions":15576},"NCT00431522","Valproic Acid Sodium Salt in Bipolar Disorder",[93],[11929],[15559],{"trials":15578,"activeCount":102},[],{"intervention":15580,"totalTrials":195,"cells":15581},"valproate microgranules",{"EARLY_PHASE1":15582,"PHASE1":15584,"PHASE2":15586,"PHASE3":15588,"PHASE4":15590,"NA":15600},{"trials":15583,"activeCount":102},[],{"trials":15585,"activeCount":102},[],{"trials":15587,"activeCount":102},[],{"trials":15589,"activeCount":102},[],{"trials":15591,"activeCount":102},[15592],{"nctId":15593,"briefTitle":15594,"status":108,"phases":15595,"primaryCompletion":8846,"completion":8846,"start":5307,"enrollment":15596,"conditions":15597,"interventions":15599},"NCT00385411","Study of Valproate in Young Patients Suffering From Epilepsy",[93],81,[15598],"Epilepsy",[15580],{"trials":15601,"activeCount":102},[],{"intervention":15603,"totalTrials":195,"cells":15604},"Avaxim 80U Pediatric: Inactivated Hepatitis A Virus",{"EARLY_PHASE1":15605,"PHASE1":15607,"PHASE2":15609,"PHASE3":15611,"PHASE4":15613,"NA":15623},{"trials":15606,"activeCount":102},[],{"trials":15608,"activeCount":102},[],{"trials":15610,"activeCount":102},[],{"trials":15612,"activeCount":102},[],{"trials":15614,"activeCount":102},[15615],{"nctId":15616,"briefTitle":15617,"status":108,"phases":15618,"primaryCompletion":14370,"completion":2759,"start":6471,"enrollment":15619,"conditions":15620,"interventions":15622},"NCT02011763","Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents",[93],355,[14394,15621],"Hepatitis A Virus",[15603],{"trials":15624,"activeCount":102},[],{"intervention":15626,"totalTrials":195,"cells":15627},"Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine",{"EARLY_PHASE1":15628,"PHASE1":15630,"PHASE2":15632,"PHASE3":15634,"PHASE4":15636,"NA":15647},{"trials":15629,"activeCount":102},[],{"trials":15631,"activeCount":102},[],{"trials":15633,"activeCount":102},[],{"trials":15635,"activeCount":102},[],{"trials":15637,"activeCount":102},[15638],{"nctId":15639,"briefTitle":15640,"status":108,"phases":15641,"primaryCompletion":3429,"completion":15642,"start":8062,"enrollment":15643,"conditions":15644,"interventions":15645},"NCT01439165","Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose",[93],"2017-02",1330,[31,25,28,13514],[15626,15646],"Tetanus and Diphtheria Toxoids Adsorbed For Adult Use",{"trials":15648,"activeCount":102},[],{"intervention":15646,"totalTrials":195,"cells":15650},{"EARLY_PHASE1":15651,"PHASE1":15653,"PHASE2":15655,"PHASE3":15657,"PHASE4":15659,"NA":15665},{"trials":15652,"activeCount":102},[],{"trials":15654,"activeCount":102},[],{"trials":15656,"activeCount":102},[],{"trials":15658,"activeCount":102},[],{"trials":15660,"activeCount":102},[15661],{"nctId":15639,"briefTitle":15640,"status":108,"phases":15662,"primaryCompletion":3429,"completion":15642,"start":8062,"enrollment":15643,"conditions":15663,"interventions":15664},[93],[31,25,28,13514],[15626,15646],{"trials":15666,"activeCount":102},[],{"intervention":15668,"totalTrials":195,"cells":15669},"LENOGRASTIM",{"EARLY_PHASE1":15670,"PHASE1":15672,"PHASE2":15674,"PHASE3":15676,"PHASE4":15678,"NA":15687},{"trials":15671,"activeCount":102},[],{"trials":15673,"activeCount":102},[],{"trials":15675,"activeCount":102},[],{"trials":15677,"activeCount":102},[],{"trials":15679,"activeCount":102},[15680],{"nctId":15681,"briefTitle":15682,"status":108,"phases":15683,"primaryCompletion":2857,"completion":2857,"start":1022,"enrollment":8317,"conditions":15684,"interventions":15686},"NCT01107756","A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen",[93],[15685],"Neoplasms (no Otherwise Specified)",[15668],{"trials":15688,"activeCount":102},[],{"intervention":15690,"totalTrials":195,"cells":15691},"300mg vandetanib",{"EARLY_PHASE1":15692,"PHASE1":15694,"PHASE2":15696,"PHASE3":15698,"PHASE4":15700,"NA":15713},{"trials":15693,"activeCount":102},[],{"trials":15695,"activeCount":102},[],{"trials":15697,"activeCount":102},[],{"trials":15699,"activeCount":102},[],{"trials":15701,"activeCount":102},[15702],{"nctId":15703,"briefTitle":15704,"status":108,"phases":15705,"primaryCompletion":15706,"completion":15707,"start":15708,"enrollment":15596,"conditions":15709,"interventions":15711},"NCT01496313","To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",[93],"2014-04-02","2024-07-11","2012-06-08",[15710],"Thyroid Cancer",[15690,15712],"150mg vandetanib",{"trials":15714,"activeCount":102},[],{"intervention":15712,"totalTrials":195,"cells":15716},{"EARLY_PHASE1":15717,"PHASE1":15719,"PHASE2":15721,"PHASE3":15723,"PHASE4":15725,"NA":15731},{"trials":15718,"activeCount":102},[],{"trials":15720,"activeCount":102},[],{"trials":15722,"activeCount":102},[],{"trials":15724,"activeCount":102},[],{"trials":15726,"activeCount":102},[15727],{"nctId":15703,"briefTitle":15704,"status":108,"phases":15728,"primaryCompletion":15706,"completion":15707,"start":15708,"enrollment":15596,"conditions":15729,"interventions":15730},[93],[15710],[15690,15712],{"trials":15732,"activeCount":102},[],{"intervention":10299,"totalTrials":195,"cells":15734},{"EARLY_PHASE1":15735,"PHASE1":15737,"PHASE2":15739,"PHASE3":15741,"PHASE4":15743,"NA":15749},{"trials":15736,"activeCount":102},[],{"trials":15738,"activeCount":102},[],{"trials":15740,"activeCount":102},[],{"trials":15742,"activeCount":102},[],{"trials":15744,"activeCount":102},[15745],{"nctId":10292,"briefTitle":10293,"status":108,"phases":15746,"primaryCompletion":10295,"completion":10295,"start":10296,"enrollment":6445,"conditions":15747,"interventions":15748},[93],[19],[10299,10300,3864],{"trials":15750,"activeCount":102},[],{"intervention":10300,"totalTrials":195,"cells":15752},{"EARLY_PHASE1":15753,"PHASE1":15755,"PHASE2":15757,"PHASE3":15759,"PHASE4":15761,"NA":15767},{"trials":15754,"activeCount":102},[],{"trials":15756,"activeCount":102},[],{"trials":15758,"activeCount":102},[],{"trials":15760,"activeCount":102},[],{"trials":15762,"activeCount":102},[15763],{"nctId":10292,"briefTitle":10293,"status":108,"phases":15764,"primaryCompletion":10295,"completion":10295,"start":10296,"enrollment":6445,"conditions":15765,"interventions":15766},[93],[19],[10299,10300,3864],{"trials":15768,"activeCount":102},[],{"intervention":12098,"totalTrials":195,"cells":15770},{"EARLY_PHASE1":15771,"PHASE1":15773,"PHASE2":15775,"PHASE3":15777,"PHASE4":15779,"NA":15785},{"trials":15772,"activeCount":102},[],{"trials":15774,"activeCount":102},[],{"trials":15776,"activeCount":102},[],{"trials":15778,"activeCount":102},[],{"trials":15780,"activeCount":102},[15781],{"nctId":12089,"briefTitle":12090,"status":108,"phases":15782,"primaryCompletion":12092,"completion":6484,"start":12093,"enrollment":12094,"conditions":15783,"interventions":15784},[93],[22],[12097,12098,12099,12100],{"trials":15786,"activeCount":102},[],{"intervention":15788,"totalTrials":195,"cells":15789},"RAMIPRIL HOE498",{"EARLY_PHASE1":15790,"PHASE1":15792,"PHASE2":15794,"PHASE3":15796,"PHASE4":15798,"NA":15809},{"trials":15791,"activeCount":102},[],{"trials":15793,"activeCount":102},[],{"trials":15795,"activeCount":102},[],{"trials":15797,"activeCount":102},[],{"trials":15799,"activeCount":102},[15800],{"nctId":15801,"briefTitle":15802,"status":108,"phases":15803,"primaryCompletion":15804,"completion":15804,"start":15805,"enrollment":3328,"conditions":15806,"interventions":15808},"NCT03099213","An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event",[93],"2010-04-23","2008-11-01",[15807],"Coronary Artery Disease",[15788],{"trials":15810,"activeCount":102},[],{"intervention":13476,"totalTrials":195,"cells":15812},{"EARLY_PHASE1":15813,"PHASE1":15815,"PHASE2":15817,"PHASE3":15819,"PHASE4":15821,"NA":15827},{"trials":15814,"activeCount":102},[],{"trials":15816,"activeCount":102},[],{"trials":15818,"activeCount":102},[],{"trials":15820,"activeCount":102},[],{"trials":15822,"activeCount":102},[15823],{"nctId":13469,"briefTitle":13470,"status":884,"phases":15824,"primaryCompletion":13472,"completion":13473,"start":5150,"enrollment":6604,"conditions":15825,"interventions":15826},[93],[19,3731],[13456,13476],{"trials":15828,"activeCount":102},[],{"intervention":15830,"totalTrials":195,"cells":15831},"DTacP IPV\u002F\u002FPRP~T combined vaccine: PENTAXIM®",{"EARLY_PHASE1":15832,"PHASE1":15834,"PHASE2":15836,"PHASE3":15838,"PHASE4":15840,"NA":15848},{"trials":15833,"activeCount":102},[],{"trials":15835,"activeCount":102},[],{"trials":15837,"activeCount":102},[],{"trials":15839,"activeCount":102},[],{"trials":15841,"activeCount":102},[15842],{"nctId":15843,"briefTitle":15844,"status":108,"phases":15845,"primaryCompletion":2857,"completion":3438,"start":977,"enrollment":1850,"conditions":15846,"interventions":15847},"NCT01491087","Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China",[93],[25,31,28,13810],[15830],{"trials":15849,"activeCount":102},[],{"intervention":15851,"totalTrials":195,"cells":15852},"Live Attenuated Varicella Virus Vaccine",{"EARLY_PHASE1":15853,"PHASE1":15855,"PHASE2":15857,"PHASE3":15859,"PHASE4":15861,"NA":15869},{"trials":15854,"activeCount":102},[],{"trials":15856,"activeCount":102},[],{"trials":15858,"activeCount":102},[],{"trials":15860,"activeCount":102},[],{"trials":15862,"activeCount":102},[15863],{"nctId":15864,"briefTitle":15865,"status":108,"phases":15866,"primaryCompletion":3354,"completion":8388,"start":9532,"enrollment":2403,"conditions":15867,"interventions":15868},"NCT00830648","Safety of a Second Dose of Biken's Varicella Vaccine",[93],[2978],[15851],{"trials":15870,"activeCount":102},[],{"intervention":10230,"totalTrials":195,"cells":15872},{"EARLY_PHASE1":15873,"PHASE1":15875,"PHASE2":15877,"PHASE3":15879,"PHASE4":15881,"NA":15887},{"trials":15874,"activeCount":102},[],{"trials":15876,"activeCount":102},[],{"trials":15878,"activeCount":102},[],{"trials":15880,"activeCount":102},[],{"trials":15882,"activeCount":102},[15883],{"nctId":10223,"briefTitle":10224,"status":108,"phases":15884,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":15885,"interventions":15886},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":15888,"activeCount":102},[],{"intervention":10231,"totalTrials":195,"cells":15890},{"EARLY_PHASE1":15891,"PHASE1":15893,"PHASE2":15895,"PHASE3":15897,"PHASE4":15899,"NA":15905},{"trials":15892,"activeCount":102},[],{"trials":15894,"activeCount":102},[],{"trials":15896,"activeCount":102},[],{"trials":15898,"activeCount":102},[],{"trials":15900,"activeCount":102},[15901],{"nctId":10223,"briefTitle":10224,"status":108,"phases":15902,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":15903,"interventions":15904},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":15906,"activeCount":102},[],{"intervention":10232,"totalTrials":195,"cells":15908},{"EARLY_PHASE1":15909,"PHASE1":15911,"PHASE2":15913,"PHASE3":15915,"PHASE4":15917,"NA":15923},{"trials":15910,"activeCount":102},[],{"trials":15912,"activeCount":102},[],{"trials":15914,"activeCount":102},[],{"trials":15916,"activeCount":102},[],{"trials":15918,"activeCount":102},[15919],{"nctId":10223,"briefTitle":10224,"status":108,"phases":15920,"primaryCompletion":10226,"completion":10226,"start":10227,"enrollment":8791,"conditions":15921,"interventions":15922},[93],[3892,9440],[3862,3864,3863,3871,10230,3869,10231,10232],{"trials":15924,"activeCount":102},[],{"intervention":15926,"totalTrials":195,"cells":15927},"Tetanus-diphtheria-acellular pertussis (Tdap) vaccine",{"EARLY_PHASE1":15928,"PHASE1":15930,"PHASE2":15932,"PHASE3":15934,"PHASE4":15936,"NA":15945},{"trials":15929,"activeCount":102},[],{"trials":15931,"activeCount":102},[],{"trials":15933,"activeCount":102},[],{"trials":15935,"activeCount":102},[],{"trials":15937,"activeCount":102},[15938],{"nctId":15939,"briefTitle":15940,"status":108,"phases":15941,"primaryCompletion":3439,"completion":8846,"start":5262,"enrollment":15942,"conditions":15943,"interventions":15944},"NCT00347958","Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine",[93],545,[31,25,28],[15926],{"trials":15946,"activeCount":102},[],{"intervention":13516,"totalTrials":195,"cells":15948},{"EARLY_PHASE1":15949,"PHASE1":15951,"PHASE2":15953,"PHASE3":15955,"PHASE4":15957,"NA":15963},{"trials":15950,"activeCount":102},[],{"trials":15952,"activeCount":102},[],{"trials":15954,"activeCount":102},[],{"trials":15956,"activeCount":102},[],{"trials":15958,"activeCount":102},[15959],{"nctId":13509,"briefTitle":13510,"status":108,"phases":15960,"primaryCompletion":2760,"completion":152,"start":2834,"enrollment":13512,"conditions":15961,"interventions":15962},[93],[31,25,28,13514],[13489,13516],{"trials":15964,"activeCount":102},[],{"intervention":15966,"totalTrials":195,"cells":15967},"ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined",{"EARLY_PHASE1":15968,"PHASE1":15970,"PHASE2":15972,"PHASE3":15974,"PHASE4":15976,"NA":15986},{"trials":15969,"activeCount":102},[],{"trials":15971,"activeCount":102},[],{"trials":15973,"activeCount":102},[],{"trials":15975,"activeCount":102},[],{"trials":15977,"activeCount":102},[15978],{"nctId":15979,"briefTitle":15980,"status":108,"phases":15981,"primaryCompletion":1054,"completion":15982,"start":978,"enrollment":15983,"conditions":15984,"interventions":15985},"NCT01137435","Post Marketing Surveillance for ADACEL™ in South Korea",[93],"2016-09",659,[25,31,28],[15966],{"trials":15987,"activeCount":102},[],{"intervention":15989,"totalTrials":195,"cells":15990},"TAA-AQ, Nasacort® AQ",{"EARLY_PHASE1":15991,"PHASE1":15993,"PHASE2":15995,"PHASE3":15997,"PHASE4":15999,"NA":16009},{"trials":15992,"activeCount":102},[],{"trials":15994,"activeCount":102},[],{"trials":15996,"activeCount":102},[],{"trials":15998,"activeCount":102},[],{"trials":16000,"activeCount":102},[16001],{"nctId":16002,"briefTitle":16003,"status":108,"phases":16004,"primaryCompletion":1340,"completion":1340,"start":5272,"enrollment":16005,"conditions":16006,"interventions":16007},"NCT00449072","Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)",[93],299,[3521],[15989,16008],"Claritin®",{"trials":16010,"activeCount":102},[],{"intervention":16008,"totalTrials":195,"cells":16012},{"EARLY_PHASE1":16013,"PHASE1":16015,"PHASE2":16017,"PHASE3":16019,"PHASE4":16021,"NA":16027},{"trials":16014,"activeCount":102},[],{"trials":16016,"activeCount":102},[],{"trials":16018,"activeCount":102},[],{"trials":16020,"activeCount":102},[],{"trials":16022,"activeCount":102},[16023],{"nctId":16002,"briefTitle":16003,"status":108,"phases":16024,"primaryCompletion":1340,"completion":1340,"start":5272,"enrollment":16005,"conditions":16025,"interventions":16026},[93],[3521],[15989,16008],{"trials":16028,"activeCount":102},[],{"intervention":8476,"totalTrials":195,"cells":16030},{"EARLY_PHASE1":16031,"PHASE1":16033,"PHASE2":16035,"PHASE3":16037,"PHASE4":16039,"NA":16045},{"trials":16032,"activeCount":102},[],{"trials":16034,"activeCount":102},[],{"trials":16036,"activeCount":102},[],{"trials":16038,"activeCount":102},[],{"trials":16040,"activeCount":102},[16041],{"nctId":8468,"briefTitle":8469,"status":108,"phases":16042,"primaryCompletion":8471,"completion":8471,"start":8472,"enrollment":8473,"conditions":16043,"interventions":16044},[93],[19],[8476,8383,8024,8477],{"trials":16046,"activeCount":102},[],{"intervention":4973,"totalTrials":195,"cells":16048},{"EARLY_PHASE1":16049,"PHASE1":16051,"PHASE2":16053,"PHASE3":16055,"PHASE4":16057,"NA":16063},{"trials":16050,"activeCount":102},[],{"trials":16052,"activeCount":102},[],{"trials":16054,"activeCount":102},[],{"trials":16056,"activeCount":102},[],{"trials":16058,"activeCount":102},[16059],{"nctId":4964,"briefTitle":4965,"status":108,"phases":16060,"primaryCompletion":4967,"completion":4968,"start":4969,"enrollment":4970,"conditions":16061,"interventions":16062},[93],[19],[4973,4939],{"trials":16064,"activeCount":102},[],{"intervention":16066,"totalTrials":195,"cells":16067},"Influenza Virus Vaccine, Fluzone®",{"EARLY_PHASE1":16068,"PHASE1":16070,"PHASE2":16072,"PHASE3":16074,"PHASE4":16076,"NA":16084},{"trials":16069,"activeCount":102},[],{"trials":16071,"activeCount":102},[],{"trials":16073,"activeCount":102},[],{"trials":16075,"activeCount":102},[],{"trials":16077,"activeCount":102},[16078],{"nctId":16079,"briefTitle":16080,"status":108,"phases":16081,"primaryCompletion":10320,"completion":3564,"start":3430,"enrollment":9,"conditions":16082,"interventions":16083},"NCT00390884","Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.",[93],[16],[16066,16066],{"trials":16085,"activeCount":102},[],{"intervention":12938,"totalTrials":195,"cells":16087},{"EARLY_PHASE1":16088,"PHASE1":16090,"PHASE2":16092,"PHASE3":16094,"PHASE4":16096,"NA":16102},{"trials":16089,"activeCount":102},[],{"trials":16091,"activeCount":102},[],{"trials":16093,"activeCount":102},[],{"trials":16095,"activeCount":102},[],{"trials":16097,"activeCount":102},[16098],{"nctId":12929,"briefTitle":12930,"status":884,"phases":16099,"primaryCompletion":12932,"completion":12932,"start":12933,"enrollment":12934,"conditions":16100,"interventions":16101},[93],[12936],[12938,12939,12940,12941],{"trials":16103,"activeCount":102},[],{"intervention":12939,"totalTrials":195,"cells":16105},{"EARLY_PHASE1":16106,"PHASE1":16108,"PHASE2":16110,"PHASE3":16112,"PHASE4":16114,"NA":16120},{"trials":16107,"activeCount":102},[],{"trials":16109,"activeCount":102},[],{"trials":16111,"activeCount":102},[],{"trials":16113,"activeCount":102},[],{"trials":16115,"activeCount":102},[16116],{"nctId":12929,"briefTitle":12930,"status":884,"phases":16117,"primaryCompletion":12932,"completion":12932,"start":12933,"enrollment":12934,"conditions":16118,"interventions":16119},[93],[12936],[12938,12939,12940,12941],{"trials":16121,"activeCount":102},[],{"intervention":12941,"totalTrials":195,"cells":16123},{"EARLY_PHASE1":16124,"PHASE1":16126,"PHASE2":16128,"PHASE3":16130,"PHASE4":16132,"NA":16138},{"trials":16125,"activeCount":102},[],{"trials":16127,"activeCount":102},[],{"trials":16129,"activeCount":102},[],{"trials":16131,"activeCount":102},[],{"trials":16133,"activeCount":102},[16134],{"nctId":12929,"briefTitle":12930,"status":884,"phases":16135,"primaryCompletion":12932,"completion":12932,"start":12933,"enrollment":12934,"conditions":16136,"interventions":16137},[93],[12936],[12938,12939,12940,12941],{"trials":16139,"activeCount":102},[],{"intervention":16141,"totalTrials":195,"cells":16142},"Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative",{"EARLY_PHASE1":16143,"PHASE1":16145,"PHASE2":16147,"PHASE3":16149,"PHASE4":16151,"NA":16161},{"trials":16144,"activeCount":102},[],{"trials":16146,"activeCount":102},[],{"trials":16148,"activeCount":102},[],{"trials":16150,"activeCount":102},[],{"trials":16152,"activeCount":102},[16153],{"nctId":16154,"briefTitle":16155,"status":108,"phases":16156,"primaryCompletion":3429,"completion":11200,"start":2824,"enrollment":4589,"conditions":16157,"interventions":16158},"NCT02563093","Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults",[93],[16],[16141,16159,16141,16160],"Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation","Fluzone High-Dose vaccine, 2015-2016 formulation",{"trials":16162,"activeCount":102},[],{"intervention":16159,"totalTrials":195,"cells":16164},{"EARLY_PHASE1":16165,"PHASE1":16167,"PHASE2":16169,"PHASE3":16171,"PHASE4":16173,"NA":16179},{"trials":16166,"activeCount":102},[],{"trials":16168,"activeCount":102},[],{"trials":16170,"activeCount":102},[],{"trials":16172,"activeCount":102},[],{"trials":16174,"activeCount":102},[16175],{"nctId":16154,"briefTitle":16155,"status":108,"phases":16176,"primaryCompletion":3429,"completion":11200,"start":2824,"enrollment":4589,"conditions":16177,"interventions":16178},[93],[16],[16141,16159,16141,16160],{"trials":16180,"activeCount":102},[],{"intervention":16160,"totalTrials":195,"cells":16182},{"EARLY_PHASE1":16183,"PHASE1":16185,"PHASE2":16187,"PHASE3":16189,"PHASE4":16191,"NA":16197},{"trials":16184,"activeCount":102},[],{"trials":16186,"activeCount":102},[],{"trials":16188,"activeCount":102},[],{"trials":16190,"activeCount":102},[],{"trials":16192,"activeCount":102},[16193],{"nctId":16154,"briefTitle":16155,"status":108,"phases":16194,"primaryCompletion":3429,"completion":11200,"start":2824,"enrollment":4589,"conditions":16195,"interventions":16196},[93],[16],[16141,16159,16141,16160],{"trials":16198,"activeCount":102},[],{"intervention":16200,"totalTrials":195,"cells":16201},"Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose",{"EARLY_PHASE1":16202,"PHASE1":16204,"PHASE2":16206,"PHASE3":16208,"PHASE4":16210,"NA":16219},{"trials":16203,"activeCount":102},[],{"trials":16205,"activeCount":102},[],{"trials":16207,"activeCount":102},[],{"trials":16209,"activeCount":102},[],{"trials":16211,"activeCount":102},[16212],{"nctId":16213,"briefTitle":16214,"status":108,"phases":16215,"primaryCompletion":3438,"completion":10005,"start":10178,"enrollment":178,"conditions":16216,"interventions":16217},"NCT01691326","Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)",[93],[16],[16200,16218],"Fluzone®; Influenza Virus Vaccine, No Preservative",{"trials":16220,"activeCount":102},[],{"intervention":16218,"totalTrials":195,"cells":16222},{"EARLY_PHASE1":16223,"PHASE1":16225,"PHASE2":16227,"PHASE3":16229,"PHASE4":16231,"NA":16237},{"trials":16224,"activeCount":102},[],{"trials":16226,"activeCount":102},[],{"trials":16228,"activeCount":102},[],{"trials":16230,"activeCount":102},[],{"trials":16232,"activeCount":102},[16233],{"nctId":16213,"briefTitle":16214,"status":108,"phases":16234,"primaryCompletion":3438,"completion":10005,"start":10178,"enrollment":178,"conditions":16235,"interventions":16236},[93],[16],[16200,16218],{"trials":16238,"activeCount":102},[],{"intervention":16240,"totalTrials":195,"cells":16241},"amisulpride and risperidone",{"EARLY_PHASE1":16242,"PHASE1":16244,"PHASE2":16246,"PHASE3":16248,"PHASE4":16250,"NA":16258},{"trials":16243,"activeCount":102},[],{"trials":16245,"activeCount":102},[],{"trials":16247,"activeCount":102},[],{"trials":16249,"activeCount":102},[],{"trials":16251,"activeCount":102},[16252],{"nctId":16253,"briefTitle":16254,"status":108,"phases":16255,"primaryCompletion":8745,"completion":8745,"start":3564,"enrollment":655,"conditions":16256,"interventions":16257},"NCT00761670","Efficacy Study on Cognitive Functions in Schizophrenic Patients",[93],[11940],[16240],{"trials":16259,"activeCount":102},[],{"intervention":16261,"totalTrials":195,"cells":16262},"Beta blocker or calcium antagonist or digoxin",{"EARLY_PHASE1":16263,"PHASE1":16265,"PHASE2":16267,"PHASE3":16269,"PHASE4":16271,"NA":16280},{"trials":16264,"activeCount":102},[],{"trials":16266,"activeCount":102},[],{"trials":16268,"activeCount":102},[],{"trials":16270,"activeCount":102},[],{"trials":16272,"activeCount":102},[16273],{"nctId":16274,"briefTitle":16275,"status":108,"phases":16276,"primaryCompletion":986,"completion":986,"start":3316,"enrollment":7321,"conditions":16277,"interventions":16278},"NCT01047566","Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)",[93],[9562],[16279,16261],"Dronedarone",{"trials":16281,"activeCount":102},[],{"intervention":16283,"totalTrials":195,"cells":16284},"Lantus, Amaryl",{"EARLY_PHASE1":16285,"PHASE1":16287,"PHASE2":16289,"PHASE3":16291,"PHASE4":16293,"NA":16301},{"trials":16286,"activeCount":102},[],{"trials":16288,"activeCount":102},[],{"trials":16290,"activeCount":102},[],{"trials":16292,"activeCount":102},[],{"trials":16294,"activeCount":102},[16295],{"nctId":16296,"briefTitle":16297,"status":108,"phases":16298,"completion":7482,"start":9592,"enrollment":465,"conditions":16299,"interventions":16300},"NCT00642915","Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)",[93],[8187],[16283],{"trials":16302,"activeCount":102},[],{"intervention":415,"totalTrials":195,"cells":16304},{"EARLY_PHASE1":16305,"PHASE1":16307,"PHASE2":16309,"PHASE3":16311,"PHASE4":16313,"NA":16319},{"trials":16306,"activeCount":102},[],{"trials":16308,"activeCount":102},[],{"trials":16310,"activeCount":102},[],{"trials":16312,"activeCount":102},[],{"trials":16314,"activeCount":102},[16315],{"nctId":406,"briefTitle":407,"status":108,"phases":16316,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":16317,"interventions":16318},[93],[273,155],[97,415],{"trials":16320,"activeCount":102},[],{"intervention":16322,"totalTrials":195,"cells":16323},"2007-2008 Influenza Virus Vaccine",{"EARLY_PHASE1":16324,"PHASE1":16326,"PHASE2":16328,"PHASE3":16330,"PHASE4":16332,"NA":16340},{"trials":16325,"activeCount":102},[],{"trials":16327,"activeCount":102},[],{"trials":16329,"activeCount":102},[],{"trials":16331,"activeCount":102},[],{"trials":16333,"activeCount":102},[16334],{"nctId":16335,"briefTitle":16336,"status":108,"phases":16337,"primaryCompletion":8316,"completion":8156,"start":3317,"enrollment":402,"conditions":16338,"interventions":16339},"NCT00561002","Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine",[93],[16],[16322,16322],{"trials":16341,"activeCount":102},[],{"intervention":16343,"totalTrials":195,"cells":16344},"TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio",{"EARLY_PHASE1":16345,"PHASE1":16347,"PHASE2":16349,"PHASE3":16351,"PHASE4":16353,"NA":16362},{"trials":16346,"activeCount":102},[],{"trials":16348,"activeCount":102},[],{"trials":16350,"activeCount":102},[],{"trials":16352,"activeCount":102},[],{"trials":16354,"activeCount":102},[16355],{"nctId":16356,"briefTitle":16357,"status":108,"phases":16358,"primaryCompletion":3459,"completion":3459,"start":954,"enrollment":16359,"conditions":16360,"interventions":16361},"NCT01437423","Regulatory Post-Marketing Surveillance Study for TETRAXIM™",[93],600,[25,31,28,12983],[16343],{"trials":16363,"activeCount":102},[],{"intervention":12469,"totalTrials":195,"cells":16365},{"EARLY_PHASE1":16366,"PHASE1":16368,"PHASE2":16370,"PHASE3":16372,"PHASE4":16374,"NA":16380},{"trials":16367,"activeCount":102},[],{"trials":16369,"activeCount":102},[],{"trials":16371,"activeCount":102},[],{"trials":16373,"activeCount":102},[],{"trials":16375,"activeCount":102},[16376],{"nctId":12462,"briefTitle":12463,"status":108,"phases":16377,"primaryCompletion":4967,"completion":4967,"start":2487,"enrollment":12465,"conditions":16378,"interventions":16379},[93],[12467],[12441,12469],{"trials":16381,"activeCount":102},[],{"intervention":16383,"totalTrials":195,"cells":16384},"Valproate sodium",{"EARLY_PHASE1":16385,"PHASE1":16387,"PHASE2":16389,"PHASE3":16391,"PHASE4":16393,"NA":16401},{"trials":16386,"activeCount":102},[],{"trials":16388,"activeCount":102},[],{"trials":16390,"activeCount":102},[],{"trials":16392,"activeCount":102},[],{"trials":16394,"activeCount":102},[16395],{"nctId":16396,"briefTitle":16397,"status":108,"phases":16398,"completion":3622,"start":9826,"enrollment":9678,"conditions":16399,"interventions":16400},"NCT00264173","VALID : VAlproate Versus LIthium in Bipolar Disorders",[93],[11929],[16383],{"trials":16402,"activeCount":102},[],{"intervention":16404,"totalTrials":195,"cells":16405},"fluorouracil cream 0.5%",{"EARLY_PHASE1":16406,"PHASE1":16408,"PHASE2":16410,"PHASE3":16412,"PHASE4":16414,"NA":16423},{"trials":16407,"activeCount":102},[],{"trials":16409,"activeCount":102},[],{"trials":16411,"activeCount":102},[],{"trials":16413,"activeCount":102},[],{"trials":16415,"activeCount":102},[16416],{"nctId":16417,"briefTitle":16418,"status":108,"phases":16419,"completion":8331,"start":12198,"enrollment":8627,"conditions":16420,"interventions":16422},"NCT00377273","An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses",[93],[16421],"Actinic Keratoses",[16404],{"trials":16424,"activeCount":102},[],{"intervention":13050,"totalTrials":195,"cells":16426},{"EARLY_PHASE1":16427,"PHASE1":16429,"PHASE2":16431,"PHASE3":16433,"PHASE4":16435,"NA":16441},{"trials":16428,"activeCount":102},[],{"trials":16430,"activeCount":102},[],{"trials":16432,"activeCount":102},[],{"trials":16434,"activeCount":102},[],{"trials":16436,"activeCount":102},[16437],{"nctId":13041,"briefTitle":13042,"status":108,"phases":16438,"primaryCompletion":9190,"completion":9190,"start":8659,"enrollment":13044,"conditions":16439,"interventions":16440},[93],[13046,13047],[13049,13050],{"trials":16442,"activeCount":102},[],{"intervention":16444,"totalTrials":195,"cells":16445},"Triamcinolone acetonide aqueous",{"EARLY_PHASE1":16446,"PHASE1":16448,"PHASE2":16450,"PHASE3":16452,"PHASE4":16454,"NA":16464},{"trials":16447,"activeCount":102},[],{"trials":16449,"activeCount":102},[],{"trials":16451,"activeCount":102},[],{"trials":16453,"activeCount":102},[],{"trials":16455,"activeCount":102},[16456],{"nctId":16457,"briefTitle":16458,"status":108,"phases":16459,"primaryCompletion":8453,"completion":8453,"start":978,"enrollment":3121,"conditions":16460,"interventions":16462},"NCT01154153","Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis",[93],[16461],"Rhinitis, Allergic, Perennial and\u002For Seasonal",[16444,16463],"Claritin® Syrup",{"trials":16465,"activeCount":102},[],{"intervention":16463,"totalTrials":195,"cells":16467},{"EARLY_PHASE1":16468,"PHASE1":16470,"PHASE2":16472,"PHASE3":16474,"PHASE4":16476,"NA":16482},{"trials":16469,"activeCount":102},[],{"trials":16471,"activeCount":102},[],{"trials":16473,"activeCount":102},[],{"trials":16475,"activeCount":102},[],{"trials":16477,"activeCount":102},[16478],{"nctId":16457,"briefTitle":16458,"status":108,"phases":16479,"primaryCompletion":8453,"completion":8453,"start":978,"enrollment":3121,"conditions":16480,"interventions":16481},[93],[16461],[16444,16463],{"trials":16483,"activeCount":102},[],{"intervention":11060,"totalTrials":195,"cells":16485},{"EARLY_PHASE1":16486,"PHASE1":16488,"PHASE2":16490,"PHASE3":16492,"PHASE4":16494,"NA":16500},{"trials":16487,"activeCount":102},[],{"trials":16489,"activeCount":102},[],{"trials":16491,"activeCount":102},[],{"trials":16493,"activeCount":102},[],{"trials":16495,"activeCount":102},[16496],{"nctId":11055,"briefTitle":11056,"status":884,"phases":16497,"completion":3633,"start":9909,"enrollment":622,"conditions":16498,"interventions":16499},[93],[11014],[10990,11060],{"trials":16501,"activeCount":102},[],{"intervention":16503,"totalTrials":195,"cells":16504},"Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation",{"EARLY_PHASE1":16505,"PHASE1":16507,"PHASE2":16509,"PHASE3":16511,"PHASE4":16513,"NA":16524},{"trials":16506,"activeCount":102},[],{"trials":16508,"activeCount":102},[],{"trials":16510,"activeCount":102},[],{"trials":16512,"activeCount":102},[],{"trials":16514,"activeCount":102},[16515],{"nctId":16516,"briefTitle":16517,"status":108,"phases":16518,"primaryCompletion":16519,"completion":16519,"start":16520,"enrollment":305,"conditions":16521,"interventions":16522},"NCT04109222","Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively",[93],"2019-12-10","2019-09-30",[16],[16503,16523],"Fluzone High-Dose vaccine, 2019-2020 formulation",{"trials":16525,"activeCount":102},[],{"intervention":16523,"totalTrials":195,"cells":16527},{"EARLY_PHASE1":16528,"PHASE1":16530,"PHASE2":16532,"PHASE3":16534,"PHASE4":16536,"NA":16542},{"trials":16529,"activeCount":102},[],{"trials":16531,"activeCount":102},[],{"trials":16533,"activeCount":102},[],{"trials":16535,"activeCount":102},[],{"trials":16537,"activeCount":102},[16538],{"nctId":16516,"briefTitle":16517,"status":108,"phases":16539,"primaryCompletion":16519,"completion":16519,"start":16520,"enrollment":305,"conditions":16540,"interventions":16541},[93],[16],[16503,16523],{"trials":16543,"activeCount":102},[],{"intervention":16545,"totalTrials":195,"cells":16546},"Fluzone Quadrivalent vaccine, No Preservative",{"EARLY_PHASE1":16547,"PHASE1":16549,"PHASE2":16551,"PHASE3":16553,"PHASE4":16555,"NA":16566},{"trials":16548,"activeCount":102},[],{"trials":16550,"activeCount":102},[],{"trials":16552,"activeCount":102},[],{"trials":16554,"activeCount":102},[],{"trials":16556,"activeCount":102},[16557],{"nctId":16558,"briefTitle":16559,"status":108,"phases":16560,"primaryCompletion":16561,"completion":16561,"start":16562,"enrollment":16563,"conditions":16564,"interventions":16565},"NCT02915302","Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children",[93],"2017-03-06","2016-09-23",1950,[16],[16545,16545],{"trials":16567,"activeCount":102},[],{"intervention":16569,"totalTrials":195,"cells":16570},"Fluzone Quadrivalent vaccine",{"EARLY_PHASE1":16571,"PHASE1":16573,"PHASE2":16575,"PHASE3":16577,"PHASE4":16579,"NA":16590},{"trials":16572,"activeCount":102},[],{"trials":16574,"activeCount":102},[],{"trials":16576,"activeCount":102},[],{"trials":16578,"activeCount":102},[],{"trials":16580,"activeCount":102},[16581],{"nctId":16582,"briefTitle":16583,"status":108,"phases":16584,"primaryCompletion":16585,"completion":16585,"start":16586,"enrollment":6655,"conditions":16587,"interventions":16588},"NCT03308825","Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines",[93],"2017-11-22","2017-09-11",[16,15047],[16569,16569,16589],"Fluzone High-Dose vaccine",{"trials":16591,"activeCount":102},[],{"intervention":16589,"totalTrials":195,"cells":16593},{"EARLY_PHASE1":16594,"PHASE1":16596,"PHASE2":16598,"PHASE3":16600,"PHASE4":16602,"NA":16608},{"trials":16595,"activeCount":102},[],{"trials":16597,"activeCount":102},[],{"trials":16599,"activeCount":102},[],{"trials":16601,"activeCount":102},[],{"trials":16603,"activeCount":102},[16604],{"nctId":16582,"briefTitle":16583,"status":108,"phases":16605,"primaryCompletion":16585,"completion":16585,"start":16586,"enrollment":6655,"conditions":16606,"interventions":16607},[93],[16,15047],[16569,16569,16589],{"trials":16609,"activeCount":102},[],{"intervention":10132,"totalTrials":195,"cells":16611},{"EARLY_PHASE1":16612,"PHASE1":16614,"PHASE2":16616,"PHASE3":16618,"PHASE4":16620,"NA":16626},{"trials":16613,"activeCount":102},[],{"trials":16615,"activeCount":102},[],{"trials":16617,"activeCount":102},[],{"trials":16619,"activeCount":102},[],{"trials":16621,"activeCount":102},[16622],{"nctId":10126,"briefTitle":10127,"status":108,"phases":16623,"primaryCompletion":2857,"completion":2857,"start":8731,"enrollment":10129,"conditions":16624,"interventions":16625},[93],[22],[10132,8265,10133],{"trials":16627,"activeCount":102},[],{"intervention":10133,"totalTrials":195,"cells":16629},{"EARLY_PHASE1":16630,"PHASE1":16632,"PHASE2":16634,"PHASE3":16636,"PHASE4":16638,"NA":16644},{"trials":16631,"activeCount":102},[],{"trials":16633,"activeCount":102},[],{"trials":16635,"activeCount":102},[],{"trials":16637,"activeCount":102},[],{"trials":16639,"activeCount":102},[16640],{"nctId":10126,"briefTitle":10127,"status":108,"phases":16641,"primaryCompletion":2857,"completion":2857,"start":8731,"enrollment":10129,"conditions":16642,"interventions":16643},[93],[22],[10132,8265,10133],{"trials":16645,"activeCount":102},[],{"intervention":16647,"totalTrials":195,"cells":16648},"Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation",{"EARLY_PHASE1":16649,"PHASE1":16651,"PHASE2":16653,"PHASE3":16655,"PHASE4":16657,"NA":16666},{"trials":16650,"activeCount":102},[],{"trials":16652,"activeCount":102},[],{"trials":16654,"activeCount":102},[],{"trials":16656,"activeCount":102},[],{"trials":16658,"activeCount":102},[16659],{"nctId":16660,"briefTitle":16661,"status":108,"phases":16662,"primaryCompletion":7430,"completion":1271,"start":14370,"enrollment":16663,"conditions":16664,"interventions":16665},"NCT02228980","Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China",[93],602,[16],[16647,16647,16647,16647],{"trials":16667,"activeCount":102},[],{"intervention":1374,"totalTrials":195,"cells":16669},{"EARLY_PHASE1":16670,"PHASE1":16672,"PHASE2":16674,"PHASE3":16676,"PHASE4":16678,"NA":16684},{"trials":16671,"activeCount":102},[],{"trials":16673,"activeCount":102},[],{"trials":16675,"activeCount":102},[],{"trials":16677,"activeCount":102},[],{"trials":16679,"activeCount":102},[16680],{"nctId":1365,"briefTitle":1366,"status":108,"phases":16681,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":16682,"interventions":16683},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"trials":16685,"activeCount":102},[],{"intervention":1375,"totalTrials":195,"cells":16687},{"EARLY_PHASE1":16688,"PHASE1":16690,"PHASE2":16692,"PHASE3":16694,"PHASE4":16696,"NA":16702},{"trials":16689,"activeCount":102},[],{"trials":16691,"activeCount":102},[],{"trials":16693,"activeCount":102},[],{"trials":16695,"activeCount":102},[],{"trials":16697,"activeCount":102},[16698],{"nctId":1365,"briefTitle":1366,"status":108,"phases":16699,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":535,"conditions":16700,"interventions":16701},[93],[1371],[1373,1212,1213,642,1211,1374,1375,327],{"trials":16703,"activeCount":102},[],{"intervention":16705,"totalTrials":195,"cells":16706},"ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed",{"EARLY_PHASE1":16707,"PHASE1":16709,"PHASE2":16711,"PHASE3":16713,"PHASE4":16715,"NA":16725},{"trials":16708,"activeCount":102},[],{"trials":16710,"activeCount":102},[],{"trials":16712,"activeCount":102},[],{"trials":16714,"activeCount":102},[],{"trials":16716,"activeCount":102},[16717],{"nctId":16718,"briefTitle":16719,"status":108,"phases":16720,"primaryCompletion":8846,"completion":8205,"start":8753,"enrollment":16721,"conditions":16722,"interventions":16723},"NCT00319553","Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®",[93],647,[28,31,25],[16705,16724],"BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed",{"trials":16726,"activeCount":102},[],{"intervention":16724,"totalTrials":195,"cells":16728},{"EARLY_PHASE1":16729,"PHASE1":16731,"PHASE2":16733,"PHASE3":16735,"PHASE4":16737,"NA":16743},{"trials":16730,"activeCount":102},[],{"trials":16732,"activeCount":102},[],{"trials":16734,"activeCount":102},[],{"trials":16736,"activeCount":102},[],{"trials":16738,"activeCount":102},[16739],{"nctId":16718,"briefTitle":16719,"status":108,"phases":16740,"primaryCompletion":8846,"completion":8205,"start":8753,"enrollment":16721,"conditions":16741,"interventions":16742},[93],[28,31,25],[16705,16724],{"trials":16744,"activeCount":102},[],{"intervention":16746,"totalTrials":195,"cells":16747},"Diphtheria and Tetanus Toxoids and Acellular Pertussis",{"EARLY_PHASE1":16748,"PHASE1":16750,"PHASE2":16752,"PHASE3":16754,"PHASE4":16756,"NA":16766},{"trials":16749,"activeCount":102},[],{"trials":16751,"activeCount":102},[],{"trials":16753,"activeCount":102},[],{"trials":16755,"activeCount":102},[],{"trials":16757,"activeCount":102},[16758],{"nctId":16759,"briefTitle":16760,"status":108,"phases":16761,"primaryCompletion":5250,"completion":9559,"start":9826,"enrollment":16762,"conditions":16763,"interventions":16765},"NCT00802867","Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™",[93],989,[25,31,28,13810,16764],"Haemophilus Infection",[16746],{"trials":16767,"activeCount":102},[],{"intervention":12477,"totalTrials":195,"cells":16769},{"EARLY_PHASE1":16770,"PHASE1":16772,"PHASE2":16774,"PHASE3":16776,"PHASE4":16778,"NA":16784},{"trials":16771,"activeCount":102},[],{"trials":16773,"activeCount":102},[],{"trials":16775,"activeCount":102},[],{"trials":16777,"activeCount":102},[],{"trials":16779,"activeCount":102},[16780],{"nctId":12471,"briefTitle":12472,"status":108,"phases":16781,"primaryCompletion":8196,"completion":8196,"start":9513,"enrollment":8627,"conditions":16782,"interventions":16783},[93],[12475],[12441,12477],{"trials":16785,"activeCount":102},[],{"intervention":16787,"totalTrials":195,"cells":16788},"Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine",{"EARLY_PHASE1":16789,"PHASE1":16791,"PHASE2":16793,"PHASE3":16795,"PHASE4":16797,"NA":16806},{"trials":16790,"activeCount":102},[],{"trials":16792,"activeCount":102},[],{"trials":16794,"activeCount":102},[],{"trials":16796,"activeCount":102},[],{"trials":16798,"activeCount":102},[16799],{"nctId":16800,"briefTitle":16801,"status":108,"phases":16802,"primaryCompletion":9706,"completion":9706,"start":8526,"enrollment":16803,"conditions":16804,"interventions":16805},"NCT00601835","Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td",[93],3651,[25,31],[16787,16787],{"trials":16807,"activeCount":102},[],{"intervention":16809,"totalTrials":195,"cells":16810},"Fluzone® Quadrivalent vaccine, 2014-2015 formulation",{"EARLY_PHASE1":16811,"PHASE1":16813,"PHASE2":16815,"PHASE3":16817,"PHASE4":16819,"NA":16829},{"trials":16812,"activeCount":102},[],{"trials":16814,"activeCount":102},[],{"trials":16816,"activeCount":102},[],{"trials":16818,"activeCount":102},[],{"trials":16820,"activeCount":102},[16821],{"nctId":16822,"briefTitle":16823,"status":108,"phases":16824,"primaryCompletion":150,"completion":7430,"start":5216,"enrollment":4589,"conditions":16825,"interventions":16826},"NCT02258334","Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults",[93],[16],[16809,16827,16809,16828],"Fluzone I®ntradermal vaccine, 2014-2015 formulation","Fluzone High Dose vaccine, 2014-2015 formulation",{"trials":16830,"activeCount":102},[],{"intervention":16827,"totalTrials":195,"cells":16832},{"EARLY_PHASE1":16833,"PHASE1":16835,"PHASE2":16837,"PHASE3":16839,"PHASE4":16841,"NA":16847},{"trials":16834,"activeCount":102},[],{"trials":16836,"activeCount":102},[],{"trials":16838,"activeCount":102},[],{"trials":16840,"activeCount":102},[],{"trials":16842,"activeCount":102},[16843],{"nctId":16822,"briefTitle":16823,"status":108,"phases":16844,"primaryCompletion":150,"completion":7430,"start":5216,"enrollment":4589,"conditions":16845,"interventions":16846},[93],[16],[16809,16827,16809,16828],{"trials":16848,"activeCount":102},[],{"intervention":16828,"totalTrials":195,"cells":16850},{"EARLY_PHASE1":16851,"PHASE1":16853,"PHASE2":16855,"PHASE3":16857,"PHASE4":16859,"NA":16865},{"trials":16852,"activeCount":102},[],{"trials":16854,"activeCount":102},[],{"trials":16856,"activeCount":102},[],{"trials":16858,"activeCount":102},[],{"trials":16860,"activeCount":102},[16861],{"nctId":16822,"briefTitle":16823,"status":108,"phases":16862,"primaryCompletion":150,"completion":7430,"start":5216,"enrollment":4589,"conditions":16863,"interventions":16864},[93],[16],[16809,16827,16809,16828],{"trials":16866,"activeCount":102},[],{"intervention":16868,"totalTrials":195,"cells":16869},"clindamycin 1% \u002F benzoyl peroxide 5% gel pump",{"EARLY_PHASE1":16870,"PHASE1":16872,"PHASE2":16874,"PHASE3":16876,"PHASE4":16878,"NA":16888},{"trials":16871,"activeCount":102},[],{"trials":16873,"activeCount":102},[],{"trials":16875,"activeCount":102},[],{"trials":16877,"activeCount":102},[],{"trials":16879,"activeCount":102},[16880],{"nctId":16881,"briefTitle":16882,"status":108,"phases":16883,"completion":5307,"start":3623,"enrollment":178,"conditions":16884,"interventions":16886},"NCT00377000","A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin\u002FBenzoyl Peroxide Gels.",[93],[16885],"Acne Vulgaris",[16868,16887],"clindamycin 1% \u002F benzoyl peroxide 5% tube",{"trials":16889,"activeCount":102},[],{"intervention":16887,"totalTrials":195,"cells":16891},{"EARLY_PHASE1":16892,"PHASE1":16894,"PHASE2":16896,"PHASE3":16898,"PHASE4":16900,"NA":16906},{"trials":16893,"activeCount":102},[],{"trials":16895,"activeCount":102},[],{"trials":16897,"activeCount":102},[],{"trials":16899,"activeCount":102},[],{"trials":16901,"activeCount":102},[16902],{"nctId":16881,"briefTitle":16882,"status":108,"phases":16903,"completion":5307,"start":3623,"enrollment":178,"conditions":16904,"interventions":16905},[93],[16885],[16868,16887],{"trials":16907,"activeCount":102},[],{"intervention":16909,"totalTrials":195,"cells":16910},"Ramipril-Felodipine",{"EARLY_PHASE1":16911,"PHASE1":16913,"PHASE2":16915,"PHASE3":16917,"PHASE4":16919,"NA":16928},{"trials":16912,"activeCount":102},[],{"trials":16914,"activeCount":102},[],{"trials":16916,"activeCount":102},[],{"trials":16918,"activeCount":102},[],{"trials":16920,"activeCount":102},[16921],{"nctId":16922,"briefTitle":16923,"status":108,"phases":16924,"primaryCompletion":8505,"start":10320,"enrollment":16925,"conditions":16926,"interventions":16927},"NCT00507845","Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina",[93],271,[9680],[16909],{"trials":16929,"activeCount":102},[],{"intervention":16931,"totalTrials":195,"cells":16932},"Insulin glargine, 300 units per milliliter",{"EARLY_PHASE1":16933,"PHASE1":16935,"PHASE2":16937,"PHASE3":16939,"PHASE4":16941,"NA":16951},{"trials":16934,"activeCount":102},[],{"trials":16936,"activeCount":102},[],{"trials":16938,"activeCount":102},[],{"trials":16940,"activeCount":102},[],{"trials":16942,"activeCount":102},[16943],{"nctId":16944,"briefTitle":16945,"status":884,"phases":16946,"primaryCompletion":1329,"completion":1329,"start":16947,"enrollment":335,"conditions":16948,"interventions":16949},"NCT03260868","Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)",[93],"2017-09-19",[554],[16931,16950],"Background therapy: Rapid Acting meal time insulin analogs",{"trials":16952,"activeCount":102},[],{"intervention":16950,"totalTrials":195,"cells":16954},{"EARLY_PHASE1":16955,"PHASE1":16957,"PHASE2":16959,"PHASE3":16961,"PHASE4":16963,"NA":16969},{"trials":16956,"activeCount":102},[],{"trials":16958,"activeCount":102},[],{"trials":16960,"activeCount":102},[],{"trials":16962,"activeCount":102},[],{"trials":16964,"activeCount":102},[16965],{"nctId":16944,"briefTitle":16945,"status":884,"phases":16966,"primaryCompletion":1329,"completion":1329,"start":16947,"enrollment":335,"conditions":16967,"interventions":16968},[93],[554],[16931,16950],{"trials":16970,"activeCount":102},[],{"intervention":12246,"totalTrials":195,"cells":16972},{"EARLY_PHASE1":16973,"PHASE1":16975,"PHASE2":16977,"PHASE3":16979,"PHASE4":16981,"NA":16987},{"trials":16974,"activeCount":102},[],{"trials":16976,"activeCount":102},[],{"trials":16978,"activeCount":102},[],{"trials":16980,"activeCount":102},[],{"trials":16982,"activeCount":102},[16983],{"nctId":12240,"briefTitle":12241,"status":108,"phases":16984,"primaryCompletion":8745,"completion":8745,"start":3563,"enrollment":12243,"conditions":16985,"interventions":16986},[93],[9680],[9693,12246,12247],{"trials":16988,"activeCount":102},[],{"intervention":16990,"totalTrials":195,"cells":16991},"insulin glargine [rDNA origin]",{"EARLY_PHASE1":16992,"PHASE1":16994,"PHASE2":16996,"PHASE3":16998,"PHASE4":17000,"NA":17008},{"trials":16993,"activeCount":102},[],{"trials":16995,"activeCount":102},[],{"trials":16997,"activeCount":102},[],{"trials":16999,"activeCount":102},[],{"trials":17001,"activeCount":102},[17002],{"nctId":17003,"briefTitle":17004,"status":108,"phases":17005,"completion":9292,"start":8365,"enrollment":8332,"conditions":17006,"interventions":17007},"NCT00384215","Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin",[93],[22],[16990],{"trials":17009,"activeCount":102},[],{"intervention":17011,"totalTrials":195,"cells":17012},"Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg",{"EARLY_PHASE1":17013,"PHASE1":17015,"PHASE2":17017,"PHASE3":17019,"PHASE4":17021,"NA":17029},{"trials":17014,"activeCount":102},[],{"trials":17016,"activeCount":102},[],{"trials":17018,"activeCount":102},[],{"trials":17020,"activeCount":102},[],{"trials":17022,"activeCount":102},[17023],{"nctId":17024,"briefTitle":17025,"status":108,"phases":17026,"primaryCompletion":4969,"completion":4969,"start":4969,"enrollment":9319,"conditions":17027,"interventions":17028},"NCT02175485","Evaluation of Efficacy of Dellegra in Exposure Unit",[93],[13787],[17011],{"trials":17030,"activeCount":102},[],{"intervention":17032,"totalTrials":195,"cells":17033},"ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed",{"EARLY_PHASE1":17034,"PHASE1":17036,"PHASE2":17038,"PHASE3":17040,"PHASE4":17042,"NA":17052},{"trials":17035,"activeCount":102},[],{"trials":17037,"activeCount":102},[],{"trials":17039,"activeCount":102},[],{"trials":17041,"activeCount":102},[],{"trials":17043,"activeCount":102},[17044],{"nctId":17045,"briefTitle":17046,"status":108,"phases":17047,"primaryCompletion":3564,"completion":8235,"start":5272,"enrollment":17048,"conditions":17049,"interventions":17050},"NCT00457249","A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older",[93],1564,[28,31,25],[17032,17051],"DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed",{"trials":17053,"activeCount":102},[],{"intervention":17051,"totalTrials":195,"cells":17055},{"EARLY_PHASE1":17056,"PHASE1":17058,"PHASE2":17060,"PHASE3":17062,"PHASE4":17064,"NA":17070},{"trials":17057,"activeCount":102},[],{"trials":17059,"activeCount":102},[],{"trials":17061,"activeCount":102},[],{"trials":17063,"activeCount":102},[],{"trials":17065,"activeCount":102},[17066],{"nctId":17045,"briefTitle":17046,"status":108,"phases":17067,"primaryCompletion":3564,"completion":8235,"start":5272,"enrollment":17048,"conditions":17068,"interventions":17069},[93],[28,31,25],[17032,17051],{"trials":17071,"activeCount":102},[],{"intervention":17073,"totalTrials":195,"cells":17074},"L-arginine aspartate",{"EARLY_PHASE1":17075,"PHASE1":17077,"PHASE2":17079,"PHASE3":17081,"PHASE4":17083,"NA":17092},{"trials":17076,"activeCount":102},[],{"trials":17078,"activeCount":102},[],{"trials":17080,"activeCount":102},[],{"trials":17082,"activeCount":102},[],{"trials":17084,"activeCount":102},[17085],{"nctId":17086,"briefTitle":17087,"status":884,"phases":17088,"primaryCompletion":8205,"completion":8205,"start":8846,"enrollment":2685,"conditions":17089,"interventions":17091},"NCT00785811","Effect of Chronic Supplementation of L-arginine in the Muscular Performance",[93],[17090],"Muscular Fatigue",[17073],{"trials":17093,"activeCount":102},[],{"intervention":17095,"totalTrials":195,"cells":17096},"ZOLPIDEM SL800750",{"EARLY_PHASE1":17097,"PHASE1":17099,"PHASE2":17101,"PHASE3":17103,"PHASE4":17105,"NA":17114},{"trials":17098,"activeCount":102},[],{"trials":17100,"activeCount":102},[],{"trials":17102,"activeCount":102},[],{"trials":17104,"activeCount":102},[],{"trials":17106,"activeCount":102},[17107],{"nctId":17108,"briefTitle":17109,"status":108,"phases":17110,"primaryCompletion":3366,"completion":3366,"start":8570,"enrollment":17111,"conditions":17112,"interventions":17113},"NCT01024192","Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA",[93],135,[11497],[17095],{"trials":17115,"activeCount":102},[],{"intervention":17117,"totalTrials":195,"cells":17118},"Enoxaparine",{"EARLY_PHASE1":17119,"PHASE1":17121,"PHASE2":17123,"PHASE3":17125,"PHASE4":17127,"NA":17136},{"trials":17120,"activeCount":102},[],{"trials":17122,"activeCount":102},[],{"trials":17124,"activeCount":102},[],{"trials":17126,"activeCount":102},[],{"trials":17128,"activeCount":102},[17129],{"nctId":17130,"briefTitle":17131,"status":108,"phases":17132,"primaryCompletion":3355,"completion":10320,"start":8753,"enrollment":465,"conditions":17133,"interventions":17135},"NCT00347490","HENOX: Enoxaparine in Hemodialysis",[93],[17134],"Hemodialysis",[17117],{"trials":17137,"activeCount":102},[],{"intervention":17139,"totalTrials":195,"cells":17140},"Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac",{"EARLY_PHASE1":17141,"PHASE1":17143,"PHASE2":17145,"PHASE3":17147,"PHASE4":17149,"NA":17159},{"trials":17142,"activeCount":102},[],{"trials":17144,"activeCount":102},[],{"trials":17146,"activeCount":102},[],{"trials":17148,"activeCount":102},[],{"trials":17150,"activeCount":102},[17151],{"nctId":17152,"briefTitle":17153,"status":108,"phases":17154,"primaryCompletion":1341,"completion":9532,"start":3565,"enrollment":17155,"conditions":17156,"interventions":17158},"NCT00255021","Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand",[93],186,[25,31,12983,17157,28],"Haemophilus Infections",[17139],{"trials":17160,"activeCount":102},[],{"intervention":17162,"totalTrials":195,"cells":17163},"Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine",{"EARLY_PHASE1":17164,"PHASE1":17166,"PHASE2":17168,"PHASE3":17170,"PHASE4":17172,"NA":17181},{"trials":17165,"activeCount":102},[],{"trials":17167,"activeCount":102},[],{"trials":17169,"activeCount":102},[],{"trials":17171,"activeCount":102},[],{"trials":17173,"activeCount":102},[17174],{"nctId":17175,"briefTitle":17176,"status":108,"phases":17177,"primaryCompletion":8777,"completion":8777,"start":3488,"enrollment":8396,"conditions":17178,"interventions":17180},"NCT00254917","Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines",[93],[25,31,13810,28,17179],"Haemophilus Influenzae Type B",[17162,17162],{"trials":17182,"activeCount":102},[],{"intervention":17184,"totalTrials":195,"cells":17185},"urate oxidase",{"EARLY_PHASE1":17186,"PHASE1":17188,"PHASE2":17190,"PHASE3":17192,"PHASE4":17194,"NA":17202},{"trials":17187,"activeCount":102},[],{"trials":17189,"activeCount":102},[],{"trials":17191,"activeCount":102},[],{"trials":17193,"activeCount":102},[],{"trials":17195,"activeCount":102},[17196],{"nctId":17197,"briefTitle":17198,"status":108,"phases":17199,"completion":7482,"start":3508,"enrollment":2858,"conditions":17200,"interventions":17201},"NCT00651911","Fasturtec TLS Treatment \u002F Prophylysis",[93],[10963],[17184],{"trials":17203,"activeCount":102},[],{"intervention":17205,"totalTrials":195,"cells":17206},"Oral Anti Diabetics",{"EARLY_PHASE1":17207,"PHASE1":17209,"PHASE2":17211,"PHASE3":17213,"PHASE4":17215,"NA":17223},{"trials":17208,"activeCount":102},[],{"trials":17210,"activeCount":102},[],{"trials":17212,"activeCount":102},[],{"trials":17214,"activeCount":102},[],{"trials":17216,"activeCount":102},[17217],{"nctId":17218,"briefTitle":17219,"status":884,"phases":17220,"primaryCompletion":5271,"completion":5271,"start":8731,"enrollment":2636,"conditions":17221,"interventions":17222},"NCT00950534","Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care",[93],[22],[8256,17205],{"trials":17224,"activeCount":102},[],{"intervention":17226,"totalTrials":195,"cells":17227},"Bacterial Lysates",{"EARLY_PHASE1":17228,"PHASE1":17230,"PHASE2":17232,"PHASE3":17234,"PHASE4":17236,"NA":17244},{"trials":17229,"activeCount":102},[],{"trials":17231,"activeCount":102},[],{"trials":17233,"activeCount":102},[],{"trials":17235,"activeCount":102},[],{"trials":17237,"activeCount":102},[17238],{"nctId":17239,"briefTitle":17240,"status":108,"phases":17241,"primaryCompletion":3564,"completion":3564,"start":7509,"enrollment":20,"conditions":17242,"interventions":17243},"NCT00599417","PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections",[93],[3636],[17226],{"trials":17245,"activeCount":102},[],{"intervention":17247,"totalTrials":195,"cells":17248},"IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine",{"EARLY_PHASE1":17249,"PHASE1":17251,"PHASE2":17253,"PHASE3":17255,"PHASE4":17257,"NA":17267},{"trials":17250,"activeCount":102},[],{"trials":17252,"activeCount":102},[],{"trials":17254,"activeCount":102},[],{"trials":17256,"activeCount":102},[],{"trials":17258,"activeCount":102},[17259],{"nctId":17260,"briefTitle":17261,"status":108,"phases":17262,"primaryCompletion":151,"completion":1271,"start":10811,"enrollment":17263,"conditions":17264,"interventions":17266},"NCT01981967","Post-licensure Safety Study of IMOJEV® in Thailand",[93],10000,[17265],"Japanese Encephalitis",[17247,17247],{"trials":17268,"activeCount":102},[],{"intervention":17270,"totalTrials":195,"cells":17271},"Meningococcal (Groups A and C) Polysaccharide Vaccine",{"EARLY_PHASE1":17272,"PHASE1":17274,"PHASE2":17276,"PHASE3":17278,"PHASE4":17280,"NA":17289},{"trials":17273,"activeCount":102},[],{"trials":17275,"activeCount":102},[],{"trials":17277,"activeCount":102},[],{"trials":17279,"activeCount":102},[],{"trials":17281,"activeCount":102},[17282],{"nctId":17283,"briefTitle":17284,"status":108,"phases":17285,"primaryCompletion":7349,"completion":7284,"start":5306,"enrollment":17286,"conditions":17287,"interventions":17288},"NCT01430611","Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children",[93],666,[13504,4992],[17270,17270],{"trials":17290,"activeCount":102},[],{"intervention":17292,"totalTrials":195,"cells":17293},"INSULIN GLARGINE HOE 901",{"EARLY_PHASE1":17294,"PHASE1":17296,"PHASE2":17298,"PHASE3":17300,"PHASE4":17302,"NA":17311},{"trials":17295,"activeCount":102},[],{"trials":17297,"activeCount":102},[],{"trials":17299,"activeCount":102},[],{"trials":17301,"activeCount":102},[],{"trials":17303,"activeCount":102},[17304],{"nctId":17305,"briefTitle":17306,"status":108,"phases":17307,"primaryCompletion":3438,"completion":3438,"start":8062,"enrollment":17308,"conditions":17309,"interventions":17310},"NCT01461577","Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure",[93],89,[19],[17292],{"trials":17312,"activeCount":102},[],{"intervention":17314,"totalTrials":195,"cells":17315},"Cerezyme® \u002F Imiglucerase",{"EARLY_PHASE1":17316,"PHASE1":17318,"PHASE2":17320,"PHASE3":17322,"PHASE4":17324,"NA":17334},{"trials":17317,"activeCount":102},[],{"trials":17319,"activeCount":102},[],{"trials":17321,"activeCount":102},[],{"trials":17323,"activeCount":102},[],{"trials":17325,"activeCount":102},[17326],{"nctId":17327,"briefTitle":17328,"status":108,"phases":17329,"primaryCompletion":5554,"completion":5554,"start":17330,"enrollment":3828,"conditions":17331,"interventions":17333},"NCT04656600","Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ",[93],"2021-03-02",[17332],"Gaucher's Disease",[17314],{"trials":17335,"activeCount":102},[],{"intervention":17337,"totalTrials":195,"cells":17338},"depakine chrono",{"EARLY_PHASE1":17339,"PHASE1":17341,"PHASE2":17343,"PHASE3":17345,"PHASE4":17347,"NA":17355},{"trials":17340,"activeCount":102},[],{"trials":17342,"activeCount":102},[],{"trials":17344,"activeCount":102},[],{"trials":17346,"activeCount":102},[],{"trials":17348,"activeCount":102},[17349],{"nctId":17350,"briefTitle":17351,"status":108,"phases":17352,"primaryCompletion":7509,"start":10339,"enrollment":1232,"conditions":17353,"interventions":17354},"NCT00477373","Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study",[93],[11929],[17337],{"trials":17356,"activeCount":102},[],{"intervention":8491,"totalTrials":195,"cells":17358},{"EARLY_PHASE1":17359,"PHASE1":17361,"PHASE2":17363,"PHASE3":17365,"PHASE4":17367,"NA":17373},{"trials":17360,"activeCount":102},[],{"trials":17362,"activeCount":102},[],{"trials":17364,"activeCount":102},[],{"trials":17366,"activeCount":102},[],{"trials":17368,"activeCount":102},[17369],{"nctId":8486,"briefTitle":8487,"status":108,"phases":17370,"primaryCompletion":151,"completion":151,"start":6471,"enrollment":442,"conditions":17371,"interventions":17372},[93],[22],[8256,8024,8491,8492],{"trials":17374,"activeCount":102},[],{"intervention":8492,"totalTrials":195,"cells":17376},{"EARLY_PHASE1":17377,"PHASE1":17379,"PHASE2":17381,"PHASE3":17383,"PHASE4":17385,"NA":17391},{"trials":17378,"activeCount":102},[],{"trials":17380,"activeCount":102},[],{"trials":17382,"activeCount":102},[],{"trials":17384,"activeCount":102},[],{"trials":17386,"activeCount":102},[17387],{"nctId":8486,"briefTitle":8487,"status":108,"phases":17388,"primaryCompletion":151,"completion":151,"start":6471,"enrollment":442,"conditions":17389,"interventions":17390},[93],[22],[8256,8024,8491,8492],{"trials":17392,"activeCount":102},[],{"intervention":17394,"totalTrials":195,"cells":17395},"insulin human",{"EARLY_PHASE1":17396,"PHASE1":17398,"PHASE2":17400,"PHASE3":17402,"PHASE4":17404,"NA":17413},{"trials":17397,"activeCount":102},[],{"trials":17399,"activeCount":102},[],{"trials":17401,"activeCount":102},[],{"trials":17403,"activeCount":102},[],{"trials":17405,"activeCount":102},[17406],{"nctId":17407,"briefTitle":17408,"status":108,"phases":17409,"primaryCompletion":8106,"completion":8106,"start":8107,"enrollment":17410,"conditions":17411,"interventions":17412},"NCT01630369","Efficacy and Safety of Insuman Basal\u002FComb\u002FRapid in Patients With Type 2 Diabetes",[93],552,[19],[17394],{"trials":17414,"activeCount":102},[],{"intervention":17416,"totalTrials":195,"cells":17417},"Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis",{"EARLY_PHASE1":17418,"PHASE1":17420,"PHASE2":17422,"PHASE3":17424,"PHASE4":17426,"NA":17435},{"trials":17419,"activeCount":102},[],{"trials":17421,"activeCount":102},[],{"trials":17423,"activeCount":102},[],{"trials":17425,"activeCount":102},[],{"trials":17427,"activeCount":102},[17428],{"nctId":17429,"briefTitle":17430,"status":108,"phases":17431,"primaryCompletion":2799,"completion":8388,"start":8156,"enrollment":17432,"conditions":17433,"interventions":17434},"NCT00712959","Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose",[93],769,[28,31,25],[17416,17416],{"trials":17436,"activeCount":102},[],{"intervention":17438,"totalTrials":195,"cells":17439},"Fexofenadine HCI",{"EARLY_PHASE1":17440,"PHASE1":17442,"PHASE2":17444,"PHASE3":17446,"PHASE4":17448,"NA":17457},{"trials":17441,"activeCount":102},[],{"trials":17443,"activeCount":102},[],{"trials":17445,"activeCount":102},[],{"trials":17447,"activeCount":102},[],{"trials":17449,"activeCount":102},[17450],{"nctId":17451,"briefTitle":17452,"status":108,"phases":17453,"completion":3509,"start":5251,"enrollment":2685,"conditions":17454,"interventions":17456},"NCT00547768","Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.",[93],[17455],"Allergy",[17438],{"trials":17458,"activeCount":102},[],{"intervention":9803,"totalTrials":195,"cells":17460},{"EARLY_PHASE1":17461,"PHASE1":17463,"PHASE2":17465,"PHASE3":17467,"PHASE4":17469,"NA":17475},{"trials":17462,"activeCount":102},[],{"trials":17464,"activeCount":102},[],{"trials":17466,"activeCount":102},[],{"trials":17468,"activeCount":102},[],{"trials":17470,"activeCount":102},[17471],{"nctId":9797,"briefTitle":9798,"status":108,"phases":17472,"primaryCompletion":8659,"completion":8659,"start":9800,"enrollment":9275,"conditions":17473,"interventions":17474},[93],[9680],[9682,9803],{"trials":17476,"activeCount":102},[],{"intervention":17478,"totalTrials":195,"cells":17479},"Actonel",{"EARLY_PHASE1":17480,"PHASE1":17482,"PHASE2":17484,"PHASE3":17486,"PHASE4":17488,"NA":17497},{"trials":17481,"activeCount":102},[],{"trials":17483,"activeCount":102},[],{"trials":17485,"activeCount":102},[],{"trials":17487,"activeCount":102},[],{"trials":17489,"activeCount":102},[17490],{"nctId":17491,"briefTitle":17492,"status":108,"phases":17493,"completion":8184,"start":9800,"enrollment":17494,"conditions":17495,"interventions":17496},"NCT00616694","Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy",[93],248,[11023],[17478],{"trials":17498,"activeCount":102},[],{"intervention":17500,"totalTrials":195,"cells":17501},"Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative",{"EARLY_PHASE1":17502,"PHASE1":17504,"PHASE2":17506,"PHASE3":17508,"PHASE4":17510,"NA":17518},{"trials":17503,"activeCount":102},[],{"trials":17505,"activeCount":102},[],{"trials":17507,"activeCount":102},[],{"trials":17509,"activeCount":102},[],{"trials":17511,"activeCount":102},[17512],{"nctId":17513,"briefTitle":17514,"status":108,"phases":17515,"primaryCompletion":6471,"completion":2487,"start":2311,"enrollment":178,"conditions":17516,"interventions":17517},"NCT01946425","Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine",[93],[16],[17500,17500],{"trials":17519,"activeCount":102},[],{"intervention":12614,"totalTrials":195,"cells":17521},{"EARLY_PHASE1":17522,"PHASE1":17524,"PHASE2":17526,"PHASE3":17528,"PHASE4":17530,"NA":17536},{"trials":17523,"activeCount":102},[],{"trials":17525,"activeCount":102},[],{"trials":17527,"activeCount":102},[],{"trials":17529,"activeCount":102},[],{"trials":17531,"activeCount":102},[17532],{"nctId":12608,"briefTitle":12609,"status":108,"phases":17533,"primaryCompletion":10320,"completion":10320,"start":9706,"enrollment":12611,"conditions":17534,"interventions":17535},[93],[12262],[12579,12614,12615],{"trials":17537,"activeCount":102},[],{"intervention":12615,"totalTrials":195,"cells":17539},{"EARLY_PHASE1":17540,"PHASE1":17542,"PHASE2":17544,"PHASE3":17546,"PHASE4":17548,"NA":17554},{"trials":17541,"activeCount":102},[],{"trials":17543,"activeCount":102},[],{"trials":17545,"activeCount":102},[],{"trials":17547,"activeCount":102},[],{"trials":17549,"activeCount":102},[17550],{"nctId":12608,"briefTitle":12609,"status":108,"phases":17551,"primaryCompletion":10320,"completion":10320,"start":9706,"enrollment":12611,"conditions":17552,"interventions":17553},[93],[12262],[12579,12614,12615],{"trials":17555,"activeCount":102},[],{"intervention":10832,"totalTrials":195,"cells":17557},{"EARLY_PHASE1":17558,"PHASE1":17560,"PHASE2":17562,"PHASE3":17564,"PHASE4":17566,"NA":17572},{"trials":17559,"activeCount":102},[],{"trials":17561,"activeCount":102},[],{"trials":17563,"activeCount":102},[],{"trials":17565,"activeCount":102},[],{"trials":17567,"activeCount":102},[17568],{"nctId":10824,"briefTitle":10825,"status":108,"phases":17569,"primaryCompletion":10827,"completion":10827,"start":10828,"enrollment":10829,"conditions":17570,"interventions":17571},[93],[554],[10772,8189,10832],{"trials":17573,"activeCount":102},[],{"intervention":17575,"totalTrials":195,"cells":17576},"Influenza Vaccine 2004-2005 Paediatric Formulation",{"EARLY_PHASE1":17577,"PHASE1":17579,"PHASE2":17581,"PHASE3":17583,"PHASE4":17585,"NA":17593},{"trials":17578,"activeCount":102},[],{"trials":17580,"activeCount":102},[],{"trials":17582,"activeCount":102},[],{"trials":17584,"activeCount":102},[],{"trials":17586,"activeCount":102},[17587],{"nctId":17588,"briefTitle":17589,"status":108,"phases":17590,"primaryCompletion":9513,"completion":9513,"start":3367,"enrollment":3740,"conditions":17591,"interventions":17592},"NCT00831675","Study of Safety and Immunogenicity of Fluzone® in Healthy Children",[93],[16],[17575,17575],{"trials":17594,"activeCount":102},[],{"intervention":8238,"totalTrials":875,"cells":17596},{"EARLY_PHASE1":17597,"PHASE1":17599,"PHASE2":17601,"PHASE3":17612,"PHASE4":17847,"NA":17849},{"trials":17598,"activeCount":102},[],{"trials":17600,"activeCount":102},[],{"trials":17602,"activeCount":102},[17603],{"nctId":17604,"briefTitle":17605,"status":108,"phases":17606,"primaryCompletion":9513,"completion":9513,"start":3633,"enrollment":17607,"conditions":17608,"interventions":17610},"NCT00459004","Japanese Dose-Response Study of Rimonabant in Obese Patients",[91],527,[17609],"Obesity",[17611],"rimonabant",{"trials":17613,"activeCount":102},[17614,17622,17628,17635,17641,17649,17655,17663,17670,17678,17685,17691,17697,17704,17708,17716,17724,17732,17739,17747,17754,17763,17771,17777,17785,17792,17798,17805,17812,17816,17823,17829,17833,17840],{"nctId":17615,"briefTitle":17616,"status":108,"phases":17617,"primaryCompletion":12198,"completion":12198,"start":17618,"enrollment":17619,"conditions":17620,"interventions":17621},"NCT00029835","Obese Patients With Untreated Dyslipidemias",[92],"2001-09",1033,[17609,7454],[8238],{"nctId":17623,"briefTitle":17624,"status":884,"phases":17625,"primaryCompletion":9532,"completion":9532,"start":3355,"enrollment":9366,"conditions":17626,"interventions":17627},"NCT00478972","Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise",[92],[17609,8117],[8238],{"nctId":17629,"briefTitle":17630,"status":884,"phases":17631,"primaryCompletion":8235,"completion":8315,"start":9785,"enrollment":17632,"conditions":17633,"interventions":17634},"NCT00434096","Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)",[92],915,[17609],[17611],{"nctId":17636,"briefTitle":17637,"status":108,"phases":17638,"primaryCompletion":8315,"completion":8315,"start":3317,"enrollment":9643,"conditions":17639,"interventions":17640},"NCT00546325","REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents",[92],[22],[8238],{"nctId":17642,"briefTitle":17643,"status":884,"phases":17644,"primaryCompletion":8349,"completion":8349,"start":8753,"enrollment":17645,"conditions":17646,"interventions":17648},"NCT00325650","Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes",[92],2420,[17647],"Prediabetic State",[8238],{"nctId":17650,"briefTitle":17651,"status":108,"phases":17652,"primaryCompletion":3355,"completion":3355,"start":9513,"enrollment":1497,"conditions":17653,"interventions":17654},"NCT00325546","Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)",[92],[17609],[8238],{"nctId":17656,"briefTitle":17657,"status":108,"phases":17658,"primaryCompletion":7538,"completion":7538,"start":11102,"enrollment":17659,"conditions":17660,"interventions":17662},"NCT00029861","Obese Patients With or Without Comorbidities (RIO-North America)",[92],3045,[17609,17661],"Weight Loss",[8238],{"nctId":17664,"briefTitle":17665,"status":108,"phases":17666,"primaryCompletion":3563,"completion":3563,"start":3609,"enrollment":17667,"conditions":17668,"interventions":17669},"NCT00288236","Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)",[92],368,[19],[8238],{"nctId":17671,"briefTitle":17672,"status":108,"phases":17673,"primaryCompletion":3317,"completion":3317,"start":8659,"enrollment":17674,"conditions":17675,"interventions":17677},"NCT00124332","STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)",[92],839,[17676],"Coronary Atherosclerosis",[8238],{"nctId":17679,"briefTitle":17680,"status":884,"phases":17681,"primaryCompletion":3396,"completion":3396,"start":3565,"enrollment":17682,"conditions":17683,"interventions":17684},"NCT00263042","Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes",[92],18695,[9700],[8238],{"nctId":17686,"briefTitle":17687,"status":108,"phases":17688,"primaryCompletion":8395,"completion":8395,"start":9130,"enrollment":8580,"conditions":17689,"interventions":17690},"NCT00257257","Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients",[92],[19],[8238],{"nctId":17692,"briefTitle":17693,"status":884,"phases":17694,"primaryCompletion":8205,"completion":8205,"start":3430,"enrollment":1207,"conditions":17695,"interventions":17696},"NCT00408148","High Density Lipoprotein Turnover",[92],[17609],[8238],{"nctId":17698,"briefTitle":17699,"status":108,"phases":17700,"primaryCompletion":8196,"completion":8196,"start":8777,"enrollment":2352,"conditions":17701,"interventions":17703},"NCT00299325","VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt",[92],[17702],"Metabolic Syndrome",[8238],{"nctId":8232,"briefTitle":8233,"status":3661,"phases":17705,"primaryCompletion":8235,"completion":8235,"start":3564,"enrollment":102,"conditions":17706,"interventions":17707},[92],[22],[8238,8024],{"nctId":17709,"briefTitle":17710,"status":108,"phases":17711,"primaryCompletion":9559,"completion":9559,"start":5251,"enrollment":17712,"conditions":17713,"interventions":17715},"NCT00459173","Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation",[92],4850,[17714],"Maintenance of Smoking Cessation",[17611],{"nctId":17717,"briefTitle":17718,"status":884,"phases":17719,"primaryCompletion":8315,"completion":8315,"start":3355,"enrollment":17720,"conditions":17721,"interventions":17722},"NCT00478595","Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug",[92],458,[17609,8117],[8238,17723],"Anti-diabetic monotherapy",{"nctId":17725,"briefTitle":17726,"status":884,"phases":17727,"primaryCompletion":9532,"completion":9532,"start":10339,"enrollment":17728,"conditions":17729,"interventions":17731},"NCT00412698","European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia",[92],645,[17609,17730],"Dyslipidemias",[17611],{"nctId":17733,"briefTitle":17734,"status":884,"phases":17735,"primaryCompletion":8315,"completion":8315,"start":3439,"enrollment":17308,"conditions":17736,"interventions":17738},"NCT00577148","An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes",[92],[17737],"Fatty Liver",[8238],{"nctId":17740,"briefTitle":17741,"status":108,"phases":17742,"primaryCompletion":8364,"completion":8364,"start":10072,"enrollment":17743,"conditions":17744,"interventions":17746},"NCT00358228","Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg\u002FDay or 20 mg\u002FDay, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)",[92],787,[17745],"Smoking Cessation",[8238],{"nctId":17748,"briefTitle":17749,"status":884,"phases":17750,"primaryCompletion":8315,"completion":8315,"start":10339,"enrollment":17751,"conditions":17752,"interventions":17753},"NCT00405808","Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose",[92],2666,[17609],[8238],{"nctId":17755,"briefTitle":17756,"status":884,"phases":17757,"primaryCompletion":3396,"completion":3396,"start":8579,"enrollment":17758,"conditions":17759,"interventions":17762},"NCT00228176","Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant",[92],661,[17760,9553,17609,17761],"Carotid Artery Plaque","Metabolic Syndrome X",[8238],{"nctId":17764,"briefTitle":17765,"status":108,"phases":17766,"primaryCompletion":9909,"completion":9909,"start":17767,"enrollment":17768,"conditions":17769,"interventions":17770},"NCT00386061","Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)",[92],"2001-10",1507,[17609],[17611],{"nctId":17772,"briefTitle":17773,"status":884,"phases":17774,"primaryCompletion":8315,"completion":8315,"start":8762,"enrollment":204,"conditions":17775,"interventions":17776},"NCT00576667","An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes",[92],[17737],[8238],{"nctId":17778,"briefTitle":17779,"status":108,"phases":17780,"primaryCompletion":8526,"completion":8526,"start":17767,"enrollment":17781,"conditions":17782,"interventions":17784},"NCT00029848","Obese Patients With Type 2 Diabetes",[92],1045,[17609,10076,17783],"Obesity in Diabetes",[8238],{"nctId":17786,"briefTitle":17787,"status":884,"phases":17788,"primaryCompletion":9532,"completion":9532,"start":5272,"enrollment":9900,"conditions":17789,"interventions":17791},"NCT00458081","Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors",[92],[17609,17790,22,7454],"Microalbuminuria",[8238],{"nctId":17793,"briefTitle":17794,"status":108,"phases":17795,"primaryCompletion":9706,"completion":9706,"start":3367,"enrollment":2801,"conditions":17796,"interventions":17797},"NCT00458718","Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch",[92],[17745],[17611],{"nctId":17799,"briefTitle":17800,"status":884,"phases":17801,"primaryCompletion":8235,"completion":8315,"start":8505,"enrollment":17802,"conditions":17803,"interventions":17804},"NCT00678483","Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients",[92],331,[17609,17661],[17611],{"nctId":17806,"briefTitle":17807,"status":108,"phases":17808,"primaryCompletion":8175,"completion":8175,"start":7538,"enrollment":17809,"conditions":17810,"interventions":17811},"NCT00464256","Comparison of Efficacy and Safety of Rimonabant 20mg\u002FDay Versus Placebo in Smoking Cessation",[92],533,[17745],[17611],{"nctId":8312,"briefTitle":8313,"status":884,"phases":17813,"primaryCompletion":8315,"completion":8315,"start":8316,"enrollment":8317,"conditions":17814,"interventions":17815},[92],[22],[8238,8024],{"nctId":17817,"briefTitle":17818,"status":108,"phases":17819,"primaryCompletion":8579,"completion":8579,"start":7523,"enrollment":8763,"conditions":17820,"interventions":17822},"NCT00481975","Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients",[92],[17609,17821],"Eating Disorders",[17611],{"nctId":17824,"briefTitle":17825,"status":108,"phases":17826,"primaryCompletion":8667,"completion":8667,"start":8526,"enrollment":10348,"conditions":17827,"interventions":17828},"NCT00481923","Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients",[92],[17609],[17611],{"nctId":8346,"briefTitle":8347,"status":884,"phases":17830,"primaryCompletion":8235,"completion":8349,"start":5272,"enrollment":8350,"conditions":17831,"interventions":17832},[92],[22],[8238,8265,8024],{"nctId":17834,"briefTitle":17835,"status":108,"phases":17836,"primaryCompletion":9785,"completion":9785,"start":9862,"enrollment":17837,"conditions":17838,"interventions":17839},"NCT00239967","An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients",[92],803,[7454,17609],[8238],{"nctId":17841,"briefTitle":17842,"status":108,"phases":17843,"primaryCompletion":3488,"completion":3488,"start":5251,"enrollment":17844,"conditions":17845,"interventions":17846},"NCT00464165","Comparison of Efficacy and Safety of Rimonabant 5mg\u002FDay or 20mg\u002FDay Versus Placebo in Smoking Cessation",[92],789,[17745],[17611],{"trials":17848,"activeCount":102},[],{"trials":17850,"activeCount":102},[],{"intervention":1276,"totalTrials":284,"cells":17852},{"EARLY_PHASE1":17853,"PHASE1":17855,"PHASE2":17880,"PHASE3":17932,"PHASE4":17996,"NA":17998},{"trials":17854,"activeCount":102},[],{"trials":17856,"activeCount":102},[17857,17865,17872],{"nctId":17858,"briefTitle":17859,"status":108,"phases":17860,"primaryCompletion":977,"completion":977,"start":9984,"enrollment":6445,"conditions":17861,"interventions":17862},"NCT01095302","Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors",[90],[5220],[17863,17864,5232],"OMBRABULIN","cisplatin",{"nctId":17866,"briefTitle":17867,"status":108,"phases":17868,"primaryCompletion":7292,"completion":7292,"start":1022,"enrollment":3828,"conditions":17869,"interventions":17870},"NCT01021150","Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors",[90],[5220],[17871,17864],"ombrabulin",{"nctId":17873,"briefTitle":17874,"status":108,"phases":17875,"primaryCompletion":8570,"completion":8062,"start":10339,"enrollment":391,"conditions":17876,"interventions":17878},"NCT00450138","Open Label, Phase I ZD6474 Head and Neck Cancer Study",[90],[17877],"Head and Neck Cancer",[17879,1276],"ZD6474",{"trials":17881,"activeCount":102},[17882,17888,17894,17902,17912,17916,17923],{"nctId":17883,"briefTitle":17884,"status":108,"phases":17885,"primaryCompletion":8683,"completion":8683,"start":8395,"enrollment":5407,"conditions":17886,"interventions":17887},"NCT00343239","Docetaxel in Locally Advanced Gastric Adenocarcinoma",[91],[9092],[1348,1276,9148],{"nctId":17889,"briefTitle":17890,"status":108,"phases":17891,"primaryCompletion":1022,"completion":1022,"start":3509,"enrollment":6472,"conditions":17892,"interventions":17893},"NCT00436293","Taxotere + Cisplatin in Nasopharyngeal Carcinoma",[91],[9132],[1348,1276],{"nctId":17895,"briefTitle":17896,"status":108,"phases":17897,"primaryCompletion":1055,"completion":1055,"start":1339,"enrollment":402,"conditions":17898,"interventions":17900},"NCT01266512","Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer",[91],[17899],"Lung Neoplasms",[2763,17901],"CISPLATIN",{"nctId":17903,"briefTitle":17904,"status":884,"phases":17905,"primaryCompletion":17906,"completion":17907,"start":17908,"enrollment":1182,"conditions":17909,"interventions":17911},"NCT04524689","Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC",[91],"2024-03-12","2024-12-24","2020-10-26",[17910],"Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)",[1195,5400,1276,5277,5424],{"nctId":1268,"briefTitle":1269,"status":108,"phases":17913,"primaryCompletion":964,"completion":1271,"start":1272,"enrollment":875,"conditions":17914,"interventions":17915},[91],[1274],[1276,1277,642,642],{"nctId":17917,"briefTitle":17918,"status":108,"phases":17919,"primaryCompletion":8349,"completion":3335,"start":8607,"enrollment":8454,"conditions":17920,"interventions":17921},"NCT00565448","Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents",[91],[9132,1344],[5232,17864,17922],"5-fluorouracil",{"nctId":17924,"briefTitle":17925,"status":108,"phases":17926,"primaryCompletion":977,"completion":977,"start":9984,"enrollment":17927,"conditions":17928,"interventions":17930},"NCT01086254","SAR240550 in Combination With Gemcitabine\u002FCisplatin in Non-small Cell Lung Cancer",[91],119,[17929],"Non-small Cell Lung Cancer Stage IV",[17931,5233,17864],"Iniparib",{"trials":17933,"activeCount":102},[17934,17943,17951,17957,17963,17971,17979,17987],{"nctId":17935,"briefTitle":17936,"status":108,"phases":17937,"primaryCompletion":8762,"completion":8762,"start":8667,"enrollment":17938,"conditions":17939,"interventions":17941},"NCT00174837","TRACE: Tirapazamine-Radiation And Cisplatin Evaluation",[92],317,[17940],"Head and Neck Squamous Cell Carcinoma",[17942,1276],"Tirapazamine",{"nctId":17944,"briefTitle":17945,"status":108,"phases":17946,"primaryCompletion":17947,"completion":17947,"start":17948,"enrollment":6655,"conditions":17949,"interventions":17950},"NCT00995293","Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial",[92],"2018-01-26","2009-08-27",[12355],[2763,17901,5243],{"nctId":17952,"briefTitle":17953,"status":108,"phases":17954,"primaryCompletion":2834,"completion":2834,"start":8235,"enrollment":6502,"conditions":17955,"interventions":17956},"NCT00811447","Taxotere New Indication - Gastric Cancer Treatment Registration Trial",[92],[9092],[17922,1276,1348],{"nctId":17958,"briefTitle":17959,"status":108,"phases":17960,"primaryCompletion":7349,"completion":7349,"start":8570,"enrollment":8366,"conditions":17961,"interventions":17962},"NCT01038661","Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy",[92],[17899],[1348,1276],{"nctId":17964,"briefTitle":17965,"status":108,"phases":17966,"primaryCompletion":3821,"completion":3821,"start":3439,"enrollment":1319,"conditions":17967,"interventions":17969},"NCT00625664","Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced\u002FMetastatic Urothelial Tract or Bladder Cancer",[92],[17968],"Urinary Bladder Neoplasms",[17970,5233,17864],"larotaxel",{"nctId":17972,"briefTitle":17973,"status":108,"phases":17974,"primaryCompletion":9592,"completion":9592,"start":17975,"enrollment":2294,"conditions":17976,"interventions":17978},"NCT00401323","Taxotere (Docetaxel) in 1st Line Treatment of Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[91,92],"1998-01",[12355,17977,9156],"Neoplasm Recurrence, Local",[5232,17864,17922],{"nctId":17980,"briefTitle":17981,"status":108,"phases":17982,"primaryCompletion":3622,"completion":3622,"start":8176,"enrollment":17983,"conditions":17984,"interventions":17985},"NCT00094081","Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer",[92],861,[12355],[17986,17864],"tirapazamine",{"nctId":17988,"briefTitle":17989,"status":108,"phases":17990,"completion":9826,"start":17991,"conditions":17992,"interventions":17994},"NCT00017459","Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[92],"2000-07",[17993],"Lung Cancer",[17864,17986,17995],"vinorelbine tartrate",{"trials":17997,"activeCount":102},[],{"trials":17999,"activeCount":102},[],{"intervention":11524,"totalTrials":1260,"cells":18001},{"EARLY_PHASE1":18002,"PHASE1":18004,"PHASE2":18090,"PHASE3":18100,"PHASE4":18114,"NA":18116},{"trials":18003,"activeCount":102},[],{"trials":18005,"activeCount":102},[18006,18014,18023,18033,18042,18050,18057,18065,18074,18078,18082],{"nctId":18007,"briefTitle":18008,"status":108,"phases":18009,"primaryCompletion":18010,"completion":18010,"start":18011,"enrollment":5521,"conditions":18012,"interventions":18013},"NCT03211195","Sotagliflozin Bioequivalence Study",[90],"2017-08-22","2017-06-29",[19],[11524],{"nctId":18015,"briefTitle":18016,"status":108,"phases":18017,"primaryCompletion":18018,"completion":18018,"start":18019,"enrollment":988,"conditions":18020,"interventions":18021},"NCT03070678","Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects",[90],"2017-04-18","2017-03-14",[8187],[11524,18022],"Mefenamic acid",{"nctId":18024,"briefTitle":18025,"status":108,"phases":18026,"primaryCompletion":18027,"completion":18027,"start":18028,"enrollment":622,"conditions":18029,"interventions":18030},"NCT03802487","Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects",[90],"2019-03-28","2019-01-14",[19,11522],[11524,18031,18032],"14C-microtracer","Charcoal",{"nctId":18034,"briefTitle":18035,"status":108,"phases":18036,"primaryCompletion":18037,"completion":18037,"start":18038,"enrollment":988,"conditions":18039,"interventions":18040},"NCT03063580","Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin",[90],"2017-05-12","2017-02-27",[8187],[11524,18041],"Rifampicin",{"nctId":18043,"briefTitle":18044,"status":108,"phases":18045,"primaryCompletion":18046,"completion":18046,"start":18047,"enrollment":9319,"conditions":18048,"interventions":18049},"NCT03909451","Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects",[90],"2019-08-19","2019-04-28",[8187],[11524],{"nctId":18051,"briefTitle":18052,"status":108,"phases":18053,"primaryCompletion":18054,"completion":18054,"start":7145,"enrollment":1676,"conditions":18055,"interventions":18056},"NCT03776227","A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions",[90],"2019-04-22",[19,11522],[8275],{"nctId":18058,"briefTitle":18059,"status":108,"phases":18060,"primaryCompletion":18061,"completion":18061,"start":18062,"enrollment":3828,"conditions":18063,"interventions":18064},"NCT03310944","Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects",[90],"2017-12-08","2017-10-18",[554,19],[8275],{"nctId":18066,"briefTitle":18067,"status":108,"phases":18068,"primaryCompletion":18069,"completion":18069,"start":4968,"enrollment":9319,"conditions":18070,"interventions":18071},"NCT02940379","A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol",[90],"2016-12",[19],[8275,18072,18073],"midazolam","metoprolol",{"nctId":11516,"briefTitle":11517,"status":108,"phases":18075,"primaryCompletion":11519,"completion":11519,"start":11520,"enrollment":988,"conditions":18076,"interventions":18077},[90],[8187,11522],[11524,11509],{"nctId":13576,"briefTitle":13577,"status":108,"phases":18079,"primaryCompletion":12092,"completion":12092,"start":13579,"enrollment":988,"conditions":18080,"interventions":18081},[90],[19],[11524,12247],{"nctId":18083,"briefTitle":18084,"status":108,"phases":18085,"primaryCompletion":18086,"completion":18086,"start":18087,"enrollment":1260,"conditions":18088,"interventions":18089},"NCT03174548","A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects",[90],"2017-09-15","2017-06-12",[8187],[11524,11524],{"trials":18091,"activeCount":102},[18092],{"nctId":18093,"briefTitle":18094,"status":108,"phases":18095,"primaryCompletion":18096,"completion":18096,"start":189,"enrollment":7224,"conditions":18097,"interventions":18098},"NCT03462069","Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension",[91],"2019-04-18",[8187],[11524,18099],"Empagliflozin",{"trials":18101,"activeCount":102},[18102,18110],{"nctId":18103,"briefTitle":18104,"status":884,"phases":18105,"primaryCompletion":18106,"completion":18106,"start":18107,"enrollment":7125,"conditions":18108,"interventions":18109},"NCT03760965","Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise",[92],"2020-04-24","2018-11-27",[19],[8275],{"nctId":8267,"briefTitle":8268,"status":884,"phases":18111,"primaryCompletion":8270,"completion":8270,"start":8271,"enrollment":8272,"conditions":18112,"interventions":18113},[92],[19],[8275,8037,8276],{"trials":18115,"activeCount":102},[],{"trials":18117,"activeCount":102},[],{"intervention":9234,"totalTrials":3828,"cells":18119},{"EARLY_PHASE1":18120,"PHASE1":18122,"PHASE2":18131,"PHASE3":18145,"PHASE4":18189,"NA":18191},{"trials":18121,"activeCount":102},[],{"trials":18123,"activeCount":102},[18124],{"nctId":18125,"briefTitle":18126,"status":108,"phases":18127,"primaryCompletion":7430,"completion":7430,"start":2311,"enrollment":576,"conditions":18128,"interventions":18129},"NCT01930552","A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies",[90],[1193],[9212,9149,18130,9234],"Irinotecan",{"trials":18132,"activeCount":102},[18133,18137,18141],{"nctId":5235,"briefTitle":5236,"status":3661,"phases":18134,"primaryCompletion":5238,"completion":5238,"start":3354,"enrollment":102,"conditions":18135,"interventions":18136},[91],[5240],[5242,5243,5244,5245],{"nctId":9118,"briefTitle":9119,"status":884,"phases":18138,"primaryCompletion":8364,"start":7483,"enrollment":6445,"conditions":18139,"interventions":18140},[91],[9122],[5286,9124,9125],{"nctId":17917,"briefTitle":17918,"status":108,"phases":18142,"primaryCompletion":8349,"completion":3335,"start":8607,"enrollment":8454,"conditions":18143,"interventions":18144},[91],[9132,1344],[5232,17864,17922],{"trials":18146,"activeCount":102},[18147,18151,18155,18162,18166,18173,18181,18185],{"nctId":17944,"briefTitle":17945,"status":108,"phases":18148,"primaryCompletion":17947,"completion":17947,"start":17948,"enrollment":6655,"conditions":18149,"interventions":18150},[92],[12355],[2763,17901,5243],{"nctId":17952,"briefTitle":17953,"status":108,"phases":18152,"primaryCompletion":2834,"completion":2834,"start":8235,"enrollment":6502,"conditions":18153,"interventions":18154},[92],[9092],[17922,1276,1348],{"nctId":18156,"briefTitle":18157,"status":884,"phases":18158,"primaryCompletion":1022,"completion":1022,"start":3439,"enrollment":6472,"conditions":18159,"interventions":18161},"NCT00602745","S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen",[92],[18160,9156],"Pancreatic Neoplasm",[9167,9234],{"nctId":9225,"briefTitle":9226,"status":108,"phases":18163,"primaryCompletion":3354,"completion":3354,"start":3565,"enrollment":9228,"conditions":18164,"interventions":18165},[92],[9230,5240,9231],[9233,5286,9234,9149],{"nctId":18167,"briefTitle":18168,"status":108,"phases":18169,"primaryCompletion":8731,"completion":8570,"start":10339,"enrollment":294,"conditions":18170,"interventions":18171},"NCT00417209","Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen",[92],[9103],[18172,9234,9200],"Larotaxel",{"nctId":18174,"briefTitle":18175,"status":108,"phases":18176,"primaryCompletion":8745,"completion":8745,"start":18177,"enrollment":18178,"conditions":18179,"interventions":18180},"NCT00688740","Docetaxel in Node Positive Adjuvant Breast Cancer",[92],"1997-06",1491,[5264],[1348,17922,4640,4643],{"nctId":17972,"briefTitle":17973,"status":108,"phases":18182,"primaryCompletion":9592,"completion":9592,"start":17975,"enrollment":2294,"conditions":18183,"interventions":18184},[91,92],[12355,17977,9156],[5232,17864,17922],{"nctId":9272,"briefTitle":9273,"status":108,"phases":18186,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":9275,"conditions":18187,"interventions":18188},[92],[9103],[9149,5242,9234],{"trials":18190,"activeCount":102},[],{"trials":18192,"activeCount":102},[],{"intervention":18194,"totalTrials":6445,"cells":18195},"CYD Dengue Vaccine",{"EARLY_PHASE1":18196,"PHASE1":18198,"PHASE2":18200,"PHASE3":18275,"PHASE4":18306,"NA":18308},{"trials":18197,"activeCount":102},[],{"trials":18199,"activeCount":102},[],{"trials":18201,"activeCount":102},[18202,18216,18223,18232,18242,18250,18259,18267],{"nctId":18203,"briefTitle":18204,"status":108,"phases":18205,"primaryCompletion":5216,"completion":18206,"start":18207,"enrollment":18208,"conditions":18209,"interventions":18213},"NCT00880893","Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore",[91],"2014-10-14","2009-04-07",1198,[18210,2317,18211,18212],"Dengue Fever","Dengue Virus","Dengue Diseases",[18214,18215],"CYD Dengue vaccine","NaCl + influenza virus or hepatitis A vaccine",{"nctId":18217,"briefTitle":18218,"status":108,"phases":18219,"primaryCompletion":986,"completion":8683,"start":3354,"enrollment":16359,"conditions":18220,"interventions":18221},"NCT00993447","Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America",[91],[2316,2317,18211,18210],[18194,18222],"Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis",{"nctId":18224,"briefTitle":18225,"status":108,"phases":18226,"primaryCompletion":18227,"completion":18227,"start":18228,"enrollment":305,"conditions":18229,"interventions":18230},"NCT01943825","Immunologic Mechanisms of Immune Interference and\u002For Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine",[91],"2015-11-25","2013-11-05",[2316,18210,2317],[18194,18194,18231,18231],"Japanese Encephalitis Vaccine",{"nctId":18233,"briefTitle":18234,"status":108,"phases":18235,"primaryCompletion":18236,"completion":18236,"start":18237,"enrollment":18238,"conditions":18239,"interventions":18241},"NCT02741128","Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults",[91],"2023-01-19","2019-11-06",133,[18210,2317,18240],"Human Immunodeficiency Virus",[18194],{"nctId":18243,"briefTitle":18244,"status":108,"phases":18245,"primaryCompletion":18246,"completion":18247,"start":12059,"enrollment":11135,"conditions":18248,"interventions":18249},"NCT02623725","Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule",[91],"2016-11-23","2018-10-28",[18210,2317],[18194],{"nctId":18251,"briefTitle":18252,"status":108,"phases":18253,"primaryCompletion":18254,"completion":18255,"start":18256,"enrollment":1223,"conditions":18257,"interventions":18258},"NCT02824198","Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule",[91],"2017-03-18","2019-01-18","2016-07-01",[18210,2317],[18194],{"nctId":18260,"briefTitle":18261,"status":108,"phases":18262,"primaryCompletion":8270,"completion":8270,"start":18263,"enrollment":18264,"conditions":18265,"interventions":18266},"NCT02628444","Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age",[91],"2016-05-02",1050,[18210,2317],[18194],{"nctId":18268,"briefTitle":18269,"status":108,"phases":18270,"primaryCompletion":2311,"completion":8166,"start":8315,"enrollment":18271,"conditions":18272,"interventions":18273},"NCT00842530","Efficacy and Safety of Dengue Vaccine in Healthy Children",[91],4002,[18211,18210,2317,18212],[18194,18274],"Inactivated rabies virus vaccine",{"trials":18276,"activeCount":102},[18277,18288,18297],{"nctId":18278,"briefTitle":18279,"status":108,"phases":18280,"primaryCompletion":18281,"completion":18281,"start":18282,"enrollment":18283,"conditions":18284,"interventions":18286},"NCT02993757","Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®",[92],"2019-05-27","2016-12-01",528,[18210,2317,18285],"Human Papillomavirus Disease",[18194,18194,18287],"Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.",{"nctId":18289,"briefTitle":18290,"status":884,"phases":18291,"primaryCompletion":16519,"completion":16519,"start":7629,"enrollment":18292,"conditions":18293,"interventions":18294},"NCT02992418","Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects",[92],688,[18210,2317],[18194,18295,18296],"Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed","Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed",{"nctId":18298,"briefTitle":18299,"status":108,"phases":18300,"primaryCompletion":18301,"completion":18301,"start":18302,"enrollment":12934,"conditions":18303,"interventions":18304},"NCT02979535","Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®",[92],"2019-03-25","2016-11-16",[18210,2317,18285],[18194,18194,18305,18305],"Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant",{"trials":18307,"activeCount":102},[],{"trials":18309,"activeCount":102},[],{"intervention":9134,"totalTrials":6445,"cells":18311},{"EARLY_PHASE1":18312,"PHASE1":18314,"PHASE2":18331,"PHASE3":18367,"PHASE4":18388,"NA":18390},{"trials":18313,"activeCount":102},[],{"trials":18315,"activeCount":102},[18316,18323],{"nctId":18317,"briefTitle":18318,"status":108,"phases":18319,"primaryCompletion":10005,"completion":10005,"start":5217,"enrollment":284,"conditions":18320,"interventions":18322},"NCT01213381","Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors",[90],[18321],"Advance Solid Tumors",[17931,9134,5277],{"nctId":18324,"briefTitle":18325,"status":108,"phases":18326,"primaryCompletion":8106,"completion":7330,"start":8062,"enrollment":5407,"conditions":18327,"interventions":18328},"NCT01455532","A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors",[90],[1193],[17931,9134,5277,18329,18330],"Placlitaxel","Pegylated liposomal doxorubicin",{"trials":18332,"activeCount":102},[18333,18344,18348,18355,18359,18363],{"nctId":18334,"briefTitle":18335,"status":884,"phases":18336,"primaryCompletion":18337,"completion":18338,"start":5126,"enrollment":7653,"conditions":18339,"interventions":18342},"NCT04659603","Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",[91],"2024-02-16","2025-01-19",[18340,18341],"Breast Cancer Metastatic","Pancreatic Carcinoma Metastatic",[18343,9134],"tusamitamab ravtansine",{"nctId":5227,"briefTitle":5228,"status":884,"phases":18345,"primaryCompletion":3564,"completion":3564,"start":2800,"enrollment":2611,"conditions":18346,"interventions":18347},[91],[2703],[5232,5233,5223],{"nctId":18349,"briefTitle":18350,"status":108,"phases":18351,"primaryCompletion":165,"completion":7284,"start":955,"enrollment":7373,"conditions":18352,"interventions":18354},"NCT01045304","Study of SAR240550 (BSI-201) in Combination With Gemcitabine\u002FCarboplatin, in Patients With Metastatic Triple Negative Breast Cancer",[91],[18353],"Breast Cancer, Metastatic",[17931,9134,5277],{"nctId":9127,"briefTitle":9128,"status":108,"phases":18356,"primaryCompletion":8846,"completion":8846,"start":9130,"enrollment":7224,"conditions":18357,"interventions":18358},[91],[9132],[9134,5286],{"nctId":10010,"briefTitle":10011,"status":884,"phases":18360,"primaryCompletion":1340,"completion":1340,"start":8570,"enrollment":6455,"conditions":18361,"interventions":18362},[90,91],[5220],[2806,5233],{"nctId":17924,"briefTitle":17925,"status":108,"phases":18364,"primaryCompletion":977,"completion":977,"start":9984,"enrollment":17927,"conditions":18365,"interventions":18366},[91],[17929],[17931,5233,17864],{"trials":18368,"activeCount":102},[18369,18373,18382],{"nctId":17964,"briefTitle":17965,"status":108,"phases":18370,"primaryCompletion":3821,"completion":3821,"start":3439,"enrollment":1319,"conditions":18371,"interventions":18372},[92],[17968],[17970,5233,17864],{"nctId":18374,"briefTitle":18375,"status":108,"phases":18376,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":18377,"interventions":18379},"NCT01593228","Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial",[92],[18378],"Solid Tumors",[17931,5277,18380,9134,18130,18381,10000],"Doxorubicin HCL liposome","Paclitaxel",{"nctId":18383,"briefTitle":18384,"status":884,"phases":18385,"primaryCompletion":3354,"completion":987,"start":7509,"enrollment":1012,"conditions":18386,"interventions":18387},"NCT00574275","Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer",[92],[18160],[1347,9134],{"trials":18389,"activeCount":102},[],{"trials":18391,"activeCount":102},[],{"intervention":5222,"totalTrials":552,"cells":18393},{"EARLY_PHASE1":18394,"PHASE1":18396,"PHASE2":18435,"PHASE3":18452,"PHASE4":18461,"NA":18463},{"trials":18395,"activeCount":102},[],{"trials":18397,"activeCount":102},[18398,18402,18406,18412,18418,18422,18429],{"nctId":17858,"briefTitle":17859,"status":108,"phases":18399,"primaryCompletion":977,"completion":977,"start":9984,"enrollment":6445,"conditions":18400,"interventions":18401},[90],[5220],[17863,17864,5232],{"nctId":5213,"briefTitle":5214,"status":108,"phases":18403,"primaryCompletion":5216,"completion":5216,"start":5217,"enrollment":5218,"conditions":18404,"interventions":18405},[90],[5220],[5222,5223],{"nctId":18407,"briefTitle":18408,"status":108,"phases":18409,"primaryCompletion":5306,"completion":5306,"start":2799,"enrollment":335,"conditions":18410,"interventions":18411},"NCT00968916","Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors",[90],[5295],[17871],{"nctId":18413,"briefTitle":18414,"status":108,"phases":18415,"primaryCompletion":165,"completion":986,"start":8745,"enrollment":619,"conditions":18416,"interventions":18417},"NCT01063946","A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor",[90],[5220],[5222],{"nctId":17866,"briefTitle":17867,"status":108,"phases":18419,"primaryCompletion":7292,"completion":7292,"start":1022,"enrollment":3828,"conditions":18420,"interventions":18421},[90],[5220],[17871,17864],{"nctId":18423,"briefTitle":18424,"status":108,"phases":18425,"primaryCompletion":966,"completion":966,"start":1339,"enrollment":284,"conditions":18426,"interventions":18428},"NCT01293630","A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors",[90],[18427],"Advanced Solid Tumors",[5222,18381,5277],{"nctId":18430,"briefTitle":18431,"status":108,"phases":18432,"primaryCompletion":10005,"completion":10005,"start":8196,"enrollment":2998,"conditions":18433,"interventions":18434},"NCT00719524","AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor",[90],[2803],[17863],{"trials":18436,"activeCount":102},[18437,18444],{"nctId":18438,"briefTitle":18439,"status":108,"phases":18440,"primaryCompletion":8683,"completion":164,"start":3821,"enrollment":18441,"conditions":18442,"interventions":18443},"NCT01263886","Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer",[91],176,[2703],[17871],{"nctId":18445,"briefTitle":18446,"status":108,"phases":18447,"primaryCompletion":2487,"completion":2487,"start":7292,"enrollment":18448,"conditions":18449,"interventions":18451},"NCT01332656","Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin\u002FPaclitaxel",[91],154,[18450],"Ovarian Cancer Recurrent",[5222,18381,5277],{"trials":18453,"activeCount":102},[18454],{"nctId":18455,"briefTitle":18456,"status":108,"phases":18457,"primaryCompletion":1032,"completion":1032,"start":8156,"enrollment":15619,"conditions":18458,"interventions":18460},"NCT00699517","A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies",[92],[18459],"Sarcoma",[17863],{"trials":18462,"activeCount":102},[],{"trials":18464,"activeCount":102},[],{"intervention":18466,"totalTrials":552,"cells":18467},"SR58611A",{"EARLY_PHASE1":18468,"PHASE1":18470,"PHASE2":18472,"PHASE3":18474,"PHASE4":18546,"NA":18548},{"trials":18469,"activeCount":102},[],{"trials":18471,"activeCount":102},[],{"trials":18473,"activeCount":102},[],{"trials":18475,"activeCount":102},[18476,18483,18491,18498,18507,18515,18520,18527,18534,18540],{"nctId":18477,"briefTitle":18478,"status":108,"phases":18479,"primaryCompletion":2800,"completion":2800,"start":3565,"enrollment":14308,"conditions":18480,"interventions":18482},"NCT00266747","An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder",[92],[18481],"Anxiety Disorders",[18466],{"nctId":18484,"briefTitle":18485,"status":108,"phases":18486,"primaryCompletion":3355,"completion":9190,"start":9513,"enrollment":18487,"conditions":18488,"interventions":18490},"NCT00319709","An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression",[92],288,[18489],"Depressive Disorder",[18466],{"nctId":18492,"briefTitle":18493,"status":108,"phases":18494,"primaryCompletion":9785,"completion":9785,"start":9559,"enrollment":412,"conditions":18495,"interventions":18497},"NCT00252343","Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder",[92],[18496],"Anxiety Disorder",[18466],{"nctId":18499,"briefTitle":18500,"status":108,"phases":18501,"primaryCompletion":3439,"completion":3439,"start":2800,"enrollment":18502,"conditions":18503,"interventions":18505},"NCT00432614","Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder",[92],510,[18504],"Major Depressive Disorder",[18466,18506],"escitalopram",{"nctId":18508,"briefTitle":18509,"status":108,"phases":18510,"primaryCompletion":3439,"completion":3439,"start":8753,"enrollment":18511,"conditions":18512,"interventions":18514},"NCT00345098","A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder",[92],704,[18489,18513],"Major Depression",[18466],{"nctId":18516,"briefTitle":18478,"status":108,"phases":18517,"primaryCompletion":3355,"completion":3355,"start":5307,"enrollment":8350,"conditions":18518,"interventions":18519},"NCT00332891",[92],[18481],[18466],{"nctId":18521,"briefTitle":18522,"status":108,"phases":18523,"primaryCompletion":2800,"completion":2800,"start":9559,"enrollment":18524,"conditions":18525,"interventions":18526},"NCT00252330","Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder",[92],476,[18504],[18466],{"nctId":18528,"briefTitle":18529,"status":884,"phases":18530,"primaryCompletion":1341,"completion":1341,"start":8666,"enrollment":18531,"conditions":18532,"interventions":18533},"NCT00397098","Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder",[92],257,[18481],[18466],{"nctId":18535,"briefTitle":18536,"status":884,"phases":18537,"primaryCompletion":9190,"completion":9190,"start":5272,"enrollment":4617,"conditions":18538,"interventions":18539},"NCT00535340","An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder",[92],[18481],[18466],{"nctId":18541,"briefTitle":18522,"status":108,"phases":18542,"primaryCompletion":2800,"completion":3308,"start":9559,"enrollment":18543,"conditions":18544,"interventions":18545},"NCT00252356",[92],468,[18504],[18466],{"trials":18547,"activeCount":102},[],{"trials":18549,"activeCount":102},[],{"intervention":10325,"totalTrials":2371,"cells":18551},{"EARLY_PHASE1":18552,"PHASE1":18554,"PHASE2":18556,"PHASE3":18569,"PHASE4":18606,"NA":18608},{"trials":18553,"activeCount":102},[],{"trials":18555,"activeCount":102},[],{"trials":18557,"activeCount":102},[18558,18562],{"nctId":10317,"briefTitle":10318,"status":108,"phases":18559,"primaryCompletion":10320,"completion":10320,"start":8753,"enrollment":10321,"conditions":18560,"interventions":18561},[91],[10323],[10325,10308],{"nctId":18563,"briefTitle":18564,"status":884,"phases":18565,"primaryCompletion":2857,"completion":2857,"start":5238,"enrollment":659,"conditions":18566,"interventions":18568},"NCT01567904","Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line",[91],[18567],"Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)",[10325],{"trials":18570,"activeCount":102},[18571,18575,18582,18590,18594,18598,18602],{"nctId":10329,"briefTitle":10330,"status":884,"phases":18572,"primaryCompletion":8349,"completion":8349,"start":8196,"enrollment":10332,"conditions":18573,"interventions":18574},[92],[10323],[10325,10308],{"nctId":18576,"briefTitle":18577,"status":108,"phases":18578,"primaryCompletion":987,"completion":987,"start":8156,"enrollment":18579,"conditions":18580,"interventions":18581},"NCT00694382","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy",[92],3212,[10323,5421],[10325],{"nctId":18583,"briefTitle":18584,"status":108,"phases":18585,"primaryCompletion":8745,"completion":8745,"start":8156,"enrollment":18586,"conditions":18587,"interventions":18588},"NCT00709904","Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery",[92],469,[10323],[18589,10325],"Open-label Semuloparin sodium",{"nctId":10361,"briefTitle":10362,"status":108,"phases":18591,"primaryCompletion":3307,"completion":3307,"start":8156,"enrollment":10364,"conditions":18592,"interventions":18593},[92],[10323],[10325,10308],{"nctId":11108,"briefTitle":11109,"status":108,"phases":18595,"primaryCompletion":8261,"completion":8261,"start":8196,"enrollment":11111,"conditions":18596,"interventions":18597},[92],[10323],[10325,11064],{"nctId":10368,"briefTitle":10369,"status":108,"phases":18599,"primaryCompletion":3354,"completion":3354,"start":8196,"enrollment":9541,"conditions":18600,"interventions":18601},[92],[10323],[10308,10325],{"nctId":10374,"briefTitle":10375,"status":108,"phases":18603,"primaryCompletion":5271,"completion":5271,"start":8505,"enrollment":10377,"conditions":18604,"interventions":18605},[92],[10323],[10380,10308],{"trials":18607,"activeCount":102},[],{"trials":18609,"activeCount":102},[],{"intervention":2937,"totalTrials":535,"cells":18611},{"EARLY_PHASE1":18612,"PHASE1":18614,"PHASE2":18616,"PHASE3":18632,"PHASE4":18663,"NA":18665},{"trials":18613,"activeCount":102},[],{"trials":18615,"activeCount":102},[],{"trials":18617,"activeCount":102},[18618,18628],{"nctId":18619,"briefTitle":18620,"status":108,"phases":18621,"primaryCompletion":11555,"completion":11555,"start":18622,"enrollment":18623,"conditions":18624,"interventions":18626},"NCT02040636","Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis",[91],"1999-01",277,[28,31,25,12983,18625],"Hepatitis B",[18627,2937],"Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV",{"nctId":4986,"briefTitle":4987,"status":108,"phases":18629,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":18630,"interventions":18631},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"trials":18633,"activeCount":102},[18634,18638,18642,18646,18650,18659],{"nctId":2925,"briefTitle":2926,"status":108,"phases":18635,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":18636,"interventions":18637},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"nctId":5012,"briefTitle":5013,"status":108,"phases":18639,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":18640,"interventions":18641},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"nctId":5027,"briefTitle":5028,"status":108,"phases":18643,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":18644,"interventions":18645},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"nctId":5081,"briefTitle":5082,"status":884,"phases":18647,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":18648,"interventions":18649},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"nctId":18651,"briefTitle":18652,"status":108,"phases":18653,"primaryCompletion":3563,"completion":3439,"start":3608,"enrollment":18654,"conditions":18655,"interventions":18656},"NCT00315055","Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule",[92],310,[18625,13810,25,28],[18657,18658,2937],"DTaP-IPV-HB-PRP~T vaccine","DTaP-IPV\u002F\u002FPRP~T combined",{"nctId":5041,"briefTitle":5042,"status":108,"phases":18660,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":18661,"interventions":18662},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":18664,"activeCount":102},[],{"trials":18666,"activeCount":102},[],{"intervention":18668,"totalTrials":535,"cells":18669},"Saredutant",{"EARLY_PHASE1":18670,"PHASE1":18672,"PHASE2":18674,"PHASE3":18676,"PHASE4":18736,"NA":18738},{"trials":18671,"activeCount":102},[],{"trials":18673,"activeCount":102},[],{"trials":18675,"activeCount":102},[],{"trials":18677,"activeCount":102},[18678,18687,18694,18704,18711,18717,18724,18730],{"nctId":18679,"briefTitle":18680,"status":108,"phases":18681,"primaryCompletion":8505,"completion":8505,"start":10339,"enrollment":18682,"conditions":18683,"interventions":18685},"NCT00417118","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder",[92],365,[18684],"Generalized Anxiety",[18668,18686],"Escitalopram",{"nctId":18688,"briefTitle":18689,"status":108,"phases":18690,"primaryCompletion":8607,"completion":8607,"start":3430,"enrollment":14308,"conditions":18691,"interventions":18693},"NCT00390650","A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder",[92],[18692],"Anxiety",[18668],{"nctId":18695,"briefTitle":18696,"status":108,"phases":18697,"primaryCompletion":8315,"completion":8315,"start":3439,"enrollment":18698,"conditions":18699,"interventions":18701},"NCT00629551","An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder",[92],825,[18700],"Depressive Disorder, Major",[18702,18703],"saredutant","paroxetine",{"nctId":18705,"briefTitle":18706,"status":108,"phases":18707,"primaryCompletion":3439,"completion":3439,"start":3622,"enrollment":18708,"conditions":18709,"interventions":18710},"NCT00390533","An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder",[92],428,[18684],[18668],{"nctId":18712,"briefTitle":18713,"status":108,"phases":18714,"primaryCompletion":10320,"completion":10320,"start":2800,"enrollment":3767,"conditions":18715,"interventions":18716},"NCT00429260","A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression",[92],[18489],[18668],{"nctId":18718,"briefTitle":18719,"status":108,"phases":18720,"primaryCompletion":8505,"completion":8505,"start":8753,"enrollment":18721,"conditions":18722,"interventions":18723},"NCT00336713","A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)",[92],430,[18489],[18668],{"nctId":18725,"briefTitle":18726,"status":108,"phases":18727,"primaryCompletion":9532,"completion":9532,"start":1341,"enrollment":1497,"conditions":18728,"interventions":18729},"NCT00531622","An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder",[92],[18504],[18702,18506],{"nctId":18731,"briefTitle":18732,"status":108,"phases":18733,"primaryCompletion":3439,"completion":3439,"start":10339,"enrollment":7158,"conditions":18734,"interventions":18735},"NCT00415142","An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder",[92],[18489],[18702,18506],{"trials":18737,"activeCount":102},[],{"trials":18739,"activeCount":102},[],{"intervention":18741,"totalTrials":535,"cells":18742},"satavaptan",{"EARLY_PHASE1":18743,"PHASE1":18745,"PHASE2":18747,"PHASE3":18778,"PHASE4":18807,"NA":18809},{"trials":18744,"activeCount":102},[],{"trials":18746,"activeCount":102},[],{"trials":18748,"activeCount":102},[18749,18757,18763,18769],{"nctId":18750,"briefTitle":18751,"status":108,"phases":18752,"completion":8659,"start":7538,"enrollment":8072,"conditions":18753,"interventions":18756},"NCT00501566","Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites",[91],[18754,18755],"Ascites","Liver Cirrhosis",[18741],{"nctId":18758,"briefTitle":18759,"status":108,"phases":18760,"primaryCompletion":9862,"completion":9862,"start":7538,"enrollment":3915,"conditions":18761,"interventions":18762},"NCT00501384","Satavaptan Dose-Ranging Study in the Prevention of Ascites",[91],[18754,18755],[18741],{"nctId":18764,"briefTitle":18765,"status":108,"phases":18766,"primaryCompletion":9130,"completion":9130,"start":7538,"enrollment":599,"conditions":18767,"interventions":18768},"NCT00501722","Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites",[91],[18754,18755],[18741],{"nctId":18770,"briefTitle":18771,"status":108,"phases":18772,"completion":3508,"start":18773,"enrollment":875,"conditions":18774,"interventions":18777},"NCT00032734","Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion",[91],"2001-06",[18775,18776],"Syndrome of Inappropriate ADH (SIADH) Secretion","Hyponatremia",[18741],{"trials":18779,"activeCount":102},[18780,18787,18794,18801],{"nctId":18781,"briefTitle":18782,"status":884,"phases":18783,"primaryCompletion":8205,"completion":8205,"start":5262,"enrollment":9707,"conditions":18784,"interventions":18785},"NCT00366795","Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver",[92],[18754,18755],[18786],"Satavaptan",{"nctId":18788,"briefTitle":18789,"status":884,"phases":18790,"primaryCompletion":8846,"completion":8846,"start":3608,"enrollment":18791,"conditions":18792,"interventions":18793},"NCT00359437","Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver",[92],501,[18754,18755],[18786],{"nctId":18795,"briefTitle":18796,"status":884,"phases":18797,"primaryCompletion":8205,"completion":8205,"start":8196,"enrollment":659,"conditions":18798,"interventions":18800},"NCT00728091","A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia",[92],[18776,18799],"Inappropriate ADH Syndrome",[18786],{"nctId":18802,"briefTitle":18803,"status":108,"phases":18804,"primaryCompletion":8205,"completion":8205,"start":3608,"enrollment":8738,"conditions":18805,"interventions":18806},"NCT00358878","Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)",[92],[18754,18755],[18786],{"trials":18808,"activeCount":102},[],{"trials":18810,"activeCount":102},[],{"intervention":9200,"totalTrials":535,"cells":18812},{"EARLY_PHASE1":18813,"PHASE1":18815,"PHASE2":18817,"PHASE3":18841,"PHASE4":18862,"NA":18864},{"trials":18814,"activeCount":102},[],{"trials":18816,"activeCount":102},[],{"trials":18818,"activeCount":102},[18819,18825,18833,18837],{"nctId":18820,"briefTitle":18821,"status":108,"phases":18822,"primaryCompletion":8349,"completion":8349,"start":5262,"enrollment":402,"conditions":18823,"interventions":18824},"NCT00327743","Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer",[90,91],[5264,5421],[17970,9222],{"nctId":18826,"briefTitle":18827,"status":3661,"phases":18828,"primaryCompletion":18829,"completion":18829,"start":1055,"enrollment":102,"conditions":18830,"interventions":18831},"NCT02085005","Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer",[91],"2016-08",[9210],[9200,9212,18832],"Oxaliplatin SR96669",{"nctId":9195,"briefTitle":9196,"status":108,"phases":18834,"primaryCompletion":5272,"start":8420,"enrollment":284,"conditions":18835,"interventions":18836},[91],[9177],[5286,9200],{"nctId":9206,"briefTitle":9207,"status":884,"phases":18838,"primaryCompletion":1011,"completion":1011,"start":6471,"enrollment":445,"conditions":18839,"interventions":18840},[90,91],[9210],[9212,5286,9200],{"trials":18842,"activeCount":102},[18843,18847,18851,18855],{"nctId":9216,"briefTitle":9217,"status":3661,"phases":18844,"primaryCompletion":8166,"completion":2759,"start":8406,"enrollment":102,"conditions":18845,"interventions":18846},[92],[9220],[5256,9222,9223],{"nctId":9246,"briefTitle":9247,"status":108,"phases":18848,"primaryCompletion":7284,"completion":7284,"start":8395,"enrollment":9249,"conditions":18849,"interventions":18850},[92],[9092],[9200,5286],{"nctId":18167,"briefTitle":18168,"status":108,"phases":18852,"primaryCompletion":8731,"completion":8570,"start":10339,"enrollment":294,"conditions":18853,"interventions":18854},[92],[9103],[18172,9234,9200],{"nctId":18856,"briefTitle":18857,"status":108,"phases":18858,"primaryCompletion":3622,"completion":3622,"start":7538,"enrollment":18859,"conditions":18860,"interventions":18861},"NCT00081796","Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer",[92],438,[5264,9230],[17970,9222],{"trials":18863,"activeCount":102},[],{"trials":18865,"activeCount":102},[],{"intervention":17970,"totalTrials":538,"cells":18867},{"EARLY_PHASE1":18868,"PHASE1":18870,"PHASE2":18872,"PHASE3":18900,"PHASE4":18914,"NA":18916},{"trials":18869,"activeCount":102},[],{"trials":18871,"activeCount":102},[],{"trials":18873,"activeCount":102},[18874,18881,18888,18892],{"nctId":18875,"briefTitle":18876,"status":108,"phases":18877,"primaryCompletion":8846,"completion":1339,"start":3608,"enrollment":5195,"conditions":18878,"interventions":18879},"NCT00386685","XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer",[91],[5275],[17970,18880],"trastuzumab",{"nctId":18882,"briefTitle":18883,"status":108,"phases":18884,"primaryCompletion":5271,"completion":5271,"start":10320,"enrollment":18885,"conditions":18886,"interventions":18887},"NCT00485979","Treatment of Larotaxel\u002FDocetaxel, +\u002F- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients",[91],330,[5275],[17970,5232,18880],{"nctId":18820,"briefTitle":18821,"status":108,"phases":18889,"primaryCompletion":8349,"completion":8349,"start":5262,"enrollment":402,"conditions":18890,"interventions":18891},[90,91],[5264,5421],[17970,9222],{"nctId":18893,"briefTitle":18894,"status":108,"phases":18895,"primaryCompletion":8822,"completion":8822,"start":3430,"enrollment":622,"conditions":18896,"interventions":18899},"NCT00387907","Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer",[91],[18897,5264,18898],"Advanced Breast Cancer","Metastatic Breast Cancer",[17970,18880],{"trials":18901,"activeCount":102},[18902,18906,18910],{"nctId":17964,"briefTitle":17965,"status":108,"phases":18903,"primaryCompletion":3821,"completion":3821,"start":3439,"enrollment":1319,"conditions":18904,"interventions":18905},[92],[17968],[17970,5233,17864],{"nctId":18167,"briefTitle":18168,"status":108,"phases":18907,"primaryCompletion":8731,"completion":8570,"start":10339,"enrollment":294,"conditions":18908,"interventions":18909},[92],[9103],[18172,9234,9200],{"nctId":18856,"briefTitle":18857,"status":108,"phases":18911,"primaryCompletion":3622,"completion":3622,"start":7538,"enrollment":18859,"conditions":18912,"interventions":18913},[92],[5264,9230],[17970,9222],{"trials":18915,"activeCount":102},[],{"trials":18917,"activeCount":102},[],{"intervention":18919,"totalTrials":538,"cells":18920},"Amcenestrant",{"EARLY_PHASE1":18921,"PHASE1":18923,"PHASE2":18951,"PHASE3":18987,"PHASE4":18997,"NA":18999},{"trials":18922,"activeCount":102},[],{"trials":18924,"activeCount":102},[18925,18934,18944],{"nctId":18926,"briefTitle":18927,"status":884,"phases":18928,"primaryCompletion":18929,"completion":18929,"start":18930,"enrollment":858,"conditions":18931,"interventions":18932},"NCT05126329","Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function",[90],"2022-05-16","2021-11-15",[2381],[18933],"amcenestrant",{"nctId":18935,"briefTitle":18936,"status":108,"phases":18937,"primaryCompletion":18938,"completion":18938,"start":18939,"enrollment":622,"conditions":18940,"interventions":18941},"NCT04940026","Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women",[90],"2021-08-19","2021-06-15",[5264,36],[18933,18942,18943],"[14C]-SAR439859 microtracer","[14C]-SAR439859",{"nctId":18945,"briefTitle":18946,"status":884,"phases":18947,"primaryCompletion":18948,"completion":5193,"start":18301,"enrollment":552,"conditions":18949,"interventions":18950},"NCT03816839","Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)",[90],"2020-10-27",[5264],[18919],{"trials":18952,"activeCount":102},[18953,18967,18976],{"nctId":18954,"briefTitle":18955,"status":884,"phases":18956,"primaryCompletion":322,"completion":18957,"start":18958,"enrollment":18959,"conditions":18960,"interventions":18961},"NCT04059484","Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer",[91],"2025-01-02","2019-10-22",367,[18340],[18919,18962,18963,18964,18965,18966],"Fulvestrant","Anastrozole","Letrozole","Exemestane","Tamoxifen",{"nctId":18968,"briefTitle":18969,"status":884,"phases":18970,"primaryCompletion":18971,"completion":18972,"start":18973,"enrollment":828,"conditions":18974,"interventions":18975},"NCT04191382","Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer",[91],"2021-04-30","2021-05-28","2020-02-04",[5264],[18919,18964],{"nctId":18977,"briefTitle":18978,"status":884,"phases":18979,"primaryCompletion":18980,"completion":18980,"start":246,"enrollment":11211,"conditions":18981,"interventions":18982},"NCT03284957","Phase 1\u002F2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer",[90,91],"2024-11-08",[5264],[18919,18983,18984,18985,18986],"Palbociclib","Alpelisib","Everolimus","Abemaciclib",{"trials":18988,"activeCount":102},[18989],{"nctId":18990,"briefTitle":18991,"status":884,"phases":18992,"primaryCompletion":18993,"completion":18993,"start":18994,"enrollment":619,"conditions":18995,"interventions":18996},"NCT05128773","Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity",[92],"2022-10-13","2022-02-17",[5264],[18919,18966],{"trials":18998,"activeCount":102},[],{"trials":19000,"activeCount":102},[],{"intervention":19002,"totalTrials":538,"cells":19003},"eplivanserin",{"EARLY_PHASE1":19004,"PHASE1":19006,"PHASE2":19015,"PHASE3":19027,"PHASE4":19066,"NA":19068},{"trials":19005,"activeCount":102},[],{"trials":19007,"activeCount":102},[19008],{"nctId":19009,"briefTitle":19010,"status":108,"phases":19011,"primaryCompletion":8388,"completion":8388,"start":3307,"enrollment":7224,"conditions":19012,"interventions":19013},"NCT00913614","Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia",[90],[11472],[19014],"Eplivanserin",{"trials":19016,"activeCount":102},[19017],{"nctId":19018,"briefTitle":19019,"status":108,"phases":19020,"primaryCompletion":5250,"completion":5250,"start":7538,"enrollment":19021,"conditions":19022,"interventions":19026},"NCT00313885","Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia",[91],205,[19023,19024,19025],"Fibromyalgia","Sleep","Chronic Pain",[19002],{"trials":19028,"activeCount":102},[19029,19036,19044,19052,19059],{"nctId":19030,"briefTitle":19031,"status":108,"phases":19032,"primaryCompletion":8607,"completion":3564,"start":3623,"enrollment":19033,"conditions":19034,"interventions":19035},"NCT00253903","Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year",[92],1155,[11472,11490],[19002],{"nctId":19037,"briefTitle":19038,"status":108,"phases":19039,"primaryCompletion":3307,"completion":3307,"start":8205,"enrollment":19040,"conditions":19041,"interventions":19043},"NCT00805350","Efficacy and Safety of Eplivanserin 5mg\u002FDay in Insomnia Characterized by Sleep Maintenance Difficulties",[92],637,[19042],"Primary Insomnia",[19014],{"nctId":19045,"briefTitle":19046,"status":108,"phases":19047,"primaryCompletion":8349,"completion":8349,"start":8505,"enrollment":19048,"conditions":19049,"interventions":19050},"NCT00679900","Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties",[92],283,[11472],[19002,19051],"lormetazepam",{"nctId":19053,"briefTitle":19054,"status":108,"phases":19055,"primaryCompletion":9190,"completion":9190,"start":8777,"enrollment":19056,"conditions":19057,"interventions":19058},"NCT00308503","Efficacy and Safety of Eplivanserin 5mg\u002FDay on Sleep Maintenance Insomnia",[92],608,[11472,11490],[19002],{"nctId":19060,"briefTitle":19061,"status":108,"phases":19062,"primaryCompletion":8762,"completion":8762,"start":3623,"enrollment":19063,"conditions":19064,"interventions":19065},"NCT00253968","Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia",[92],967,[11472,11490],[19014],{"trials":19067,"activeCount":102},[],{"trials":19069,"activeCount":102},[],{"intervention":19071,"totalTrials":538,"cells":19072},"paclitaxel",{"EARLY_PHASE1":19073,"PHASE1":19075,"PHASE2":19091,"PHASE3":19119,"PHASE4":19125,"NA":19127},{"trials":19074,"activeCount":102},[],{"trials":19076,"activeCount":102},[19077,19087],{"nctId":19078,"briefTitle":19079,"status":108,"phases":19080,"primaryCompletion":5238,"completion":164,"start":3564,"enrollment":34,"conditions":19081,"interventions":19084},"NCT00756847","Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors",[90],[5421,5284,19082,19083],"Endometrial Carcinoma","Ovarian Carcinoma",[19085,19071,19086],"XL147 (SAR245408),","carboplatin",{"nctId":18423,"briefTitle":18424,"status":108,"phases":19088,"primaryCompletion":966,"completion":966,"start":1339,"enrollment":284,"conditions":19089,"interventions":19090},[90],[18427],[5222,18381,5277],{"trials":19092,"activeCount":102},[19093,19100,19107,19115],{"nctId":19094,"briefTitle":19095,"status":108,"phases":19096,"primaryCompletion":3438,"completion":3438,"start":955,"enrollment":3510,"conditions":19097,"interventions":19098},"NCT01042925","Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen",[90,91],[5264,5275],[19099,18880,19071],"XL147",{"nctId":19101,"briefTitle":19102,"status":108,"phases":19103,"primaryCompletion":164,"completion":15642,"start":5217,"enrollment":11683,"conditions":19104,"interventions":19106},"NCT01204125","Two Regimens of SAR240550\u002FWeekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients",[91],[19105],"Breast Cancer Female",[19071,17931],{"nctId":19108,"briefTitle":19109,"status":108,"phases":19110,"primaryCompletion":1022,"completion":977,"start":8316,"enrollment":1601,"conditions":19111,"interventions":19113},"NCT00687687","Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma",[91],[19112],"Uterine Carcinosarcoma",[19071,19086,19114],"BSI-201",{"nctId":18445,"briefTitle":18446,"status":108,"phases":19116,"primaryCompletion":2487,"completion":2487,"start":7292,"enrollment":18448,"conditions":19117,"interventions":19118},[91],[18450],[5222,18381,5277],{"trials":19120,"activeCount":102},[19121],{"nctId":18374,"briefTitle":18375,"status":108,"phases":19122,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":19123,"interventions":19124},[92],[18378],[17931,5277,18380,9134,18130,18381,10000],{"trials":19126,"activeCount":102},[],{"trials":19128,"activeCount":102},[],{"intervention":4640,"totalTrials":622,"cells":19130},{"EARLY_PHASE1":19131,"PHASE1":19133,"PHASE2":19135,"PHASE3":19152,"PHASE4":19174,"NA":19176},{"trials":19132,"activeCount":102},[],{"trials":19134,"activeCount":102},[],{"trials":19136,"activeCount":102},[19137,19141,19145],{"nctId":4623,"briefTitle":4624,"status":884,"phases":19138,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":19139,"interventions":19140},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"nctId":5268,"briefTitle":5269,"status":108,"phases":19142,"primaryCompletion":5271,"completion":5271,"start":5272,"enrollment":5273,"conditions":19143,"interventions":19144},[91],[5275],[1348,4640,5277,4643,5266,5206],{"nctId":19146,"briefTitle":19147,"status":884,"phases":19148,"primaryCompletion":5250,"completion":9190,"start":7482,"enrollment":576,"conditions":19149,"interventions":19151},"NCT00461344","Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer",[91],[19150],"Ductal Carcinoma",[1348,4640],{"trials":19153,"activeCount":102},[19154,19162,19166],{"nctId":19155,"briefTitle":19156,"status":108,"phases":19157,"primaryCompletion":1022,"completion":1022,"start":5272,"enrollment":19158,"conditions":19159,"interventions":19160},"NCT00471965","Oxaliplatin + 5-FluoroUracil\u002FLeucoVorin (5-FU\u002FLV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients",[92],371,[9140],[19161,4640],"Oxaliplatin + 5-Fluorouracil\u002FLeucovorin",{"nctId":18174,"briefTitle":18175,"status":108,"phases":19163,"primaryCompletion":8745,"completion":8745,"start":18177,"enrollment":18178,"conditions":19164,"interventions":19165},[92],[5264],[1348,17922,4640,4643],{"nctId":19167,"briefTitle":19168,"status":108,"phases":19169,"primaryCompletion":7430,"completion":7430,"start":3327,"enrollment":19170,"conditions":19171,"interventions":19172},"NCT00021255","Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer",[92],3222,[5275],[4640,4643,1348,19173,5277],"Herceptin",{"trials":19175,"activeCount":102},[],{"trials":19177,"activeCount":102},[],{"intervention":18506,"totalTrials":622,"cells":19179},{"EARLY_PHASE1":19180,"PHASE1":19182,"PHASE2":19184,"PHASE3":19200,"PHASE4":19218,"NA":19220},{"trials":19181,"activeCount":102},[],{"trials":19183,"activeCount":102},[],{"trials":19185,"activeCount":102},[19186,19193],{"nctId":19187,"briefTitle":19188,"status":108,"phases":19189,"primaryCompletion":955,"completion":955,"start":8205,"enrollment":17607,"conditions":19190,"interventions":19191},"NCT00822744","An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients",[91],[18504],[19192,18686],"SSR411298",{"nctId":19194,"briefTitle":19195,"status":108,"phases":19196,"primaryCompletion":165,"completion":165,"start":955,"enrollment":1977,"conditions":19197,"interventions":19198},"NCT01034995","A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder",[91],[18513],[19199,18506],"SSR125543",{"trials":19201,"activeCount":102},[19202,19206,19210,19214],{"nctId":18679,"briefTitle":18680,"status":108,"phases":19203,"primaryCompletion":8505,"completion":8505,"start":10339,"enrollment":18682,"conditions":19204,"interventions":19205},[92],[18684],[18668,18686],{"nctId":18499,"briefTitle":18500,"status":108,"phases":19207,"primaryCompletion":3439,"completion":3439,"start":2800,"enrollment":18502,"conditions":19208,"interventions":19209},[92],[18504],[18466,18506],{"nctId":18725,"briefTitle":18726,"status":108,"phases":19211,"primaryCompletion":9532,"completion":9532,"start":1341,"enrollment":1497,"conditions":19212,"interventions":19213},[92],[18504],[18702,18506],{"nctId":18731,"briefTitle":18732,"status":108,"phases":19215,"primaryCompletion":3439,"completion":3439,"start":10339,"enrollment":7158,"conditions":19216,"interventions":19217},[92],[18489],[18702,18506],{"trials":19219,"activeCount":102},[],{"trials":19221,"activeCount":102},[],{"intervention":19223,"totalTrials":622,"cells":19224},"Inactivated, split-virion influenza vaccine",{"EARLY_PHASE1":19225,"PHASE1":19227,"PHASE2":19229,"PHASE3":19259,"PHASE4":19277,"NA":19279},{"trials":19226,"activeCount":102},[],{"trials":19228,"activeCount":102},[],{"trials":19230,"activeCount":102},[19231,19238,19246,19253],{"nctId":19232,"briefTitle":19233,"status":108,"phases":19234,"primaryCompletion":8156,"completion":3564,"start":9559,"enrollment":8482,"conditions":19235,"interventions":19236},"NCT00258934","Immunogenicity Study of the Influenza Vaccine in Adults",[91],[15230,16],[19223,19237],"Inactivated, split-virion, influenza virus",{"nctId":19239,"briefTitle":19240,"status":108,"phases":19241,"primaryCompletion":8315,"completion":3396,"start":1341,"enrollment":1809,"conditions":19242,"interventions":19244},"NCT00776438","Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines",[91],[16,19243,10695],"Orthomyxovirus Infections",[19245,19245,19223,19223],"Inactivated, split-virion, influenza vaccine",{"nctId":19247,"briefTitle":19248,"status":108,"phases":19249,"primaryCompletion":9785,"completion":9785,"start":3609,"enrollment":19250,"conditions":19251,"interventions":19252},"NCT00296829","Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly",[91],1080,[12314,16,10695],[19223],{"nctId":19254,"briefTitle":19255,"status":108,"phases":19256,"primaryCompletion":8753,"completion":3608,"start":9872,"enrollment":11111,"conditions":19257,"interventions":19258},"NCT00703651","Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults",[91],[16,12314,10695],[19223,19223,19223],{"trials":19260,"activeCount":102},[19261,19270],{"nctId":19262,"briefTitle":19263,"status":108,"phases":19264,"primaryCompletion":3563,"completion":3439,"start":3430,"enrollment":19265,"conditions":19266,"interventions":19267},"NCT00391053","Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",[92],3851,[12314,16,10695],[19268,19268,19268,19269],"High-Dose Inactivated, Split-Virion Influenza Vaccine","Inactivated, Split-Virion Influenza Vaccine",{"nctId":19271,"briefTitle":19272,"status":108,"phases":19273,"primaryCompletion":3307,"completion":2799,"start":3622,"enrollment":19274,"conditions":19275,"interventions":19276},"NCT00383526","Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly",[92],3707,[12314,16,10695],[19223,19223],{"trials":19278,"activeCount":102},[],{"trials":19280,"activeCount":102},[],{"intervention":5338,"totalTrials":622,"cells":19282},{"EARLY_PHASE1":19283,"PHASE1":19285,"PHASE2":19308,"PHASE3":19322,"PHASE4":19332,"NA":19334},{"trials":19284,"activeCount":102},[],{"trials":19286,"activeCount":102},[19287,19298],{"nctId":19288,"briefTitle":19289,"status":108,"phases":19290,"primaryCompletion":19291,"completion":19291,"start":19292,"enrollment":19293,"conditions":19294,"interventions":19295},"NCT05829356","Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above",[90],"2024-03-14","2023-04-12",159,[5335],[19296,19297],"H3 mRNA \u002F LNP Vaccine","Quadrivalent recombinant influenza Vaccine",{"nctId":19299,"briefTitle":19300,"status":108,"phases":19301,"primaryCompletion":19302,"completion":19302,"start":19303,"enrollment":19304,"conditions":19305,"interventions":19306},"NCT06118151","Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older",[90],"2023-02-17","2022-04-11",388,[16,5335],[19307,5338],"Influenza Hemagglutinin mRNA vaccine",{"trials":19309,"activeCount":102},[19310,19314,19318],{"nctId":5328,"briefTitle":5329,"status":108,"phases":19311,"primaryCompletion":5331,"completion":5331,"start":5332,"enrollment":5333,"conditions":19312,"interventions":19313},[90,91],[5335],[5337,5338,5319,5339],{"nctId":5352,"briefTitle":5353,"status":108,"phases":19315,"primaryCompletion":5355,"completion":5355,"start":5356,"enrollment":5357,"conditions":19316,"interventions":19317},[90,91],[5335],[5360,5338,5319,5339],{"nctId":5362,"briefTitle":5363,"status":108,"phases":19319,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":5367,"conditions":19320,"interventions":19321},[90,91],[5335],[5370,5371,5372,5319,5339,5338],{"trials":19323,"activeCount":102},[19324],{"nctId":19325,"briefTitle":19326,"status":108,"phases":19327,"primaryCompletion":19328,"completion":19328,"start":1600,"enrollment":956,"conditions":19329,"interventions":19330},"NCT05144945","Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea",[92],"2022-09-01",[7891],[5338,19331],"Quadrivalent inactivated influenza vaccine",{"trials":19333,"activeCount":102},[],{"trials":19335,"activeCount":102},[],{"intervention":7334,"totalTrials":622,"cells":19337},{"EARLY_PHASE1":19338,"PHASE1":19340,"PHASE2":19342,"PHASE3":19344,"PHASE4":19370,"NA":19372},{"trials":19339,"activeCount":102},[],{"trials":19341,"activeCount":102},[],{"trials":19343,"activeCount":102},[],{"trials":19345,"activeCount":102},[19346,19350,19354,19358,19362,19366],{"nctId":7327,"briefTitle":7328,"status":108,"phases":19347,"primaryCompletion":7330,"completion":7330,"start":2857,"enrollment":7331,"conditions":19348,"interventions":19349},[92],[3892],[7273,7334],{"nctId":7378,"briefTitle":7379,"status":108,"phases":19351,"primaryCompletion":150,"completion":150,"start":3335,"enrollment":7381,"conditions":19352,"interventions":19353},[92],[3892],[7273,7334],{"nctId":7385,"briefTitle":7386,"status":108,"phases":19355,"primaryCompletion":7388,"completion":7388,"start":7389,"enrollment":7390,"conditions":19356,"interventions":19357},[92],[3892],[7273,7334],{"nctId":7404,"briefTitle":7405,"status":108,"phases":19359,"primaryCompletion":7407,"completion":7407,"start":7408,"enrollment":7409,"conditions":19360,"interventions":19361},[92],[3842],[7273,7334,7412],{"nctId":7414,"briefTitle":7415,"status":108,"phases":19363,"primaryCompletion":965,"completion":965,"start":1031,"enrollment":7417,"conditions":19364,"interventions":19365},[92],[3892],[7273,7334],{"nctId":7421,"briefTitle":7422,"status":108,"phases":19367,"primaryCompletion":1031,"completion":2824,"start":1055,"enrollment":1706,"conditions":19368,"interventions":19369},[92],[3892],[7273,7334],{"trials":19371,"activeCount":102},[],{"trials":19373,"activeCount":102},[],{"intervention":9149,"totalTrials":622,"cells":19375},{"EARLY_PHASE1":19376,"PHASE1":19378,"PHASE2":19384,"PHASE3":19394,"PHASE4":19411,"NA":19413},{"trials":19377,"activeCount":102},[],{"trials":19379,"activeCount":102},[19380],{"nctId":18125,"briefTitle":18126,"status":108,"phases":19381,"primaryCompletion":7430,"completion":7430,"start":2311,"enrollment":576,"conditions":19382,"interventions":19383},[90],[1193],[9212,9149,18130,9234],{"trials":19385,"activeCount":102},[19386,19390],{"nctId":5235,"briefTitle":5236,"status":3661,"phases":19387,"primaryCompletion":5238,"completion":5238,"start":3354,"enrollment":102,"conditions":19388,"interventions":19389},[91],[5240],[5242,5243,5244,5245],{"nctId":9143,"briefTitle":9144,"status":108,"phases":19391,"primaryCompletion":8745,"completion":8745,"start":1341,"enrollment":112,"conditions":19392,"interventions":19393},[91],[9140],[5286,9148,9149],{"trials":19395,"activeCount":102},[19396,19400,19407],{"nctId":9225,"briefTitle":9226,"status":108,"phases":19397,"primaryCompletion":3354,"completion":3354,"start":3565,"enrollment":9228,"conditions":19398,"interventions":19399},[92],[9230,5240,9231],[9233,5286,9234,9149],{"nctId":19401,"briefTitle":9210,"status":108,"phases":19402,"primaryCompletion":8165,"completion":8165,"start":7349,"enrollment":19403,"conditions":19404,"interventions":19405},"NCT01670721",[92],175,[9210],[19406,18130,9148,9149],"AFLIBERCEPT",{"nctId":9272,"briefTitle":9273,"status":108,"phases":19408,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":9275,"conditions":19409,"interventions":19410},[92],[9103],[9149,5242,9234],{"trials":19412,"activeCount":102},[],{"trials":19414,"activeCount":102},[],{"intervention":4643,"totalTrials":339,"cells":19416},{"EARLY_PHASE1":19417,"PHASE1":19419,"PHASE2":19425,"PHASE3":19435,"PHASE4":19445,"NA":19447},{"trials":19418,"activeCount":102},[],{"trials":19420,"activeCount":102},[19421],{"nctId":1164,"briefTitle":1165,"status":108,"phases":19422,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":305,"conditions":19423,"interventions":19424},[90],[1160],[1172,1173,1174,1151,1175],{"trials":19426,"activeCount":102},[19427,19431],{"nctId":4623,"briefTitle":4624,"status":884,"phases":19428,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":19429,"interventions":19430},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"nctId":5268,"briefTitle":5269,"status":108,"phases":19432,"primaryCompletion":5271,"completion":5271,"start":5272,"enrollment":5273,"conditions":19433,"interventions":19434},[91],[5275],[1348,4640,5277,4643,5266,5206],{"trials":19436,"activeCount":102},[19437,19441],{"nctId":18174,"briefTitle":18175,"status":108,"phases":19438,"primaryCompletion":8745,"completion":8745,"start":18177,"enrollment":18178,"conditions":19439,"interventions":19440},[92],[5264],[1348,17922,4640,4643],{"nctId":19167,"briefTitle":19168,"status":108,"phases":19442,"primaryCompletion":7430,"completion":7430,"start":3327,"enrollment":19170,"conditions":19443,"interventions":19444},[92],[5275],[4640,4643,1348,19173,5277],{"trials":19446,"activeCount":102},[],{"trials":19448,"activeCount":102},[],{"intervention":6459,"totalTrials":339,"cells":19450},{"EARLY_PHASE1":19451,"PHASE1":19453,"PHASE2":19459,"PHASE3":19461,"PHASE4":19479,"NA":19481},{"trials":19452,"activeCount":102},[],{"trials":19454,"activeCount":102},[19455],{"nctId":6452,"briefTitle":6453,"status":108,"phases":19456,"primaryCompletion":1054,"completion":1054,"start":2855,"enrollment":6455,"conditions":19457,"interventions":19458},[90],[990],[6458,6459],{"trials":19460,"activeCount":102},[],{"trials":19462,"activeCount":102},[19463,19467,19471,19475],{"nctId":3853,"briefTitle":3854,"status":108,"phases":19464,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":19465,"interventions":19466},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":10200,"briefTitle":10201,"status":108,"phases":19468,"primaryCompletion":10203,"completion":10203,"start":10204,"enrollment":10205,"conditions":19469,"interventions":19470},[92],[3892],[10208,3846,7441,7442,6459],{"nctId":7434,"briefTitle":7435,"status":108,"phases":19472,"primaryCompletion":2662,"completion":2662,"start":7437,"enrollment":7438,"conditions":19473,"interventions":19474},[92],[3892],[7273,3846,7441,7442,6459],{"nctId":3886,"briefTitle":3887,"status":108,"phases":19476,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":19477,"interventions":19478},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":19480,"activeCount":102},[],{"trials":19482,"activeCount":102},[],{"intervention":19484,"totalTrials":339,"cells":19485},"Vandetanib",{"EARLY_PHASE1":19486,"PHASE1":19488,"PHASE2":19514,"PHASE3":19516,"PHASE4":19528,"NA":19530},{"trials":19487,"activeCount":102},[],{"trials":19489,"activeCount":102},[19490,19497,19503,19507],{"nctId":19491,"briefTitle":19492,"status":108,"phases":19493,"primaryCompletion":2857,"completion":2857,"start":8683,"enrollment":1260,"conditions":19494,"interventions":19495},"NCT01561781","Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib",[90],[36],[19496,19484],"Digoxin",{"nctId":19498,"briefTitle":19499,"status":108,"phases":19500,"primaryCompletion":2857,"completion":2857,"start":3416,"enrollment":988,"conditions":19501,"interventions":19502},"NCT01544140","Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib",[90],[36],[1403,12711],{"nctId":12705,"briefTitle":12706,"status":108,"phases":19504,"primaryCompletion":10178,"completion":10178,"start":8107,"enrollment":402,"conditions":19505,"interventions":19506},[90],[12709],[12711,9480,1266],{"nctId":19508,"briefTitle":19509,"status":108,"phases":19510,"primaryCompletion":3307,"completion":3307,"start":3608,"enrollment":535,"conditions":19511,"interventions":19513},"NCT00681798","Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma",[90],[19512],"Pancreatic Cancer",[19484],{"trials":19515,"activeCount":102},[],{"trials":19517,"activeCount":102},[19518],{"nctId":19519,"briefTitle":19520,"status":108,"phases":19521,"primaryCompletion":19522,"completion":19523,"start":19524,"enrollment":19021,"conditions":19525,"interventions":19527},"NCT01298323","Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment",[92],"2013-04-26","2025-03-13","2011-02-25",[19526,12709],"Locally Advanced or Metastatic Medullary Thyroid Cancer",[19484],{"trials":19529,"activeCount":102},[],{"trials":19531,"activeCount":102},[],{"intervention":2940,"totalTrials":339,"cells":19533},{"EARLY_PHASE1":19534,"PHASE1":19536,"PHASE2":19538,"PHASE3":19547,"PHASE4":19570,"NA":19572},{"trials":19535,"activeCount":102},[],{"trials":19537,"activeCount":102},[],{"trials":19539,"activeCount":102},[19540],{"nctId":19541,"briefTitle":19542,"status":108,"phases":19543,"primaryCompletion":8388,"completion":8106,"start":8822,"enrollment":1091,"conditions":19544,"interventions":19545},"NCT00621764","Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children",[91],[17265,14394],[19546,2940,19546,2940],"Japanese encephalitis vaccine",{"trials":19548,"activeCount":102},[19549,19555,19559,19563],{"nctId":19550,"briefTitle":19551,"status":108,"phases":19552,"primaryCompletion":8261,"completion":8215,"start":3417,"enrollment":2791,"conditions":19553,"interventions":19554},"NCT00735644","Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines",[92],[17265,14394],[19546,19546,19546,19546,2940],{"nctId":2925,"briefTitle":2926,"status":108,"phases":19556,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":19557,"interventions":19558},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"nctId":5094,"briefTitle":5095,"status":108,"phases":19560,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":19561,"interventions":19562},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"nctId":19564,"briefTitle":19565,"status":108,"phases":19566,"primaryCompletion":8316,"completion":3417,"start":10320,"enrollment":5913,"conditions":19567,"interventions":19568},"NCT00483470","Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose",[92],[14394],[19569,2940],"Hepatitis A vaccine AVAXIM 80U",{"trials":19571,"activeCount":102},[],{"trials":19573,"activeCount":102},[],{"intervention":1195,"totalTrials":339,"cells":19575},{"EARLY_PHASE1":19576,"PHASE1":19578,"PHASE2":19593,"PHASE3":19611,"PHASE4":19621,"NA":19623},{"trials":19577,"activeCount":102},[],{"trials":19579,"activeCount":102},[19580,19584],{"nctId":1186,"briefTitle":1187,"status":108,"phases":19581,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":402,"conditions":19582,"interventions":19583},[90],[1193],[1195,1151,1196,1197],{"nctId":19585,"briefTitle":19586,"status":884,"phases":19587,"primaryCompletion":19588,"completion":19589,"start":19590,"enrollment":2352,"conditions":19591,"interventions":19592},"NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors",[90],"2020-11-10","2024-11-19","2014-07-23",[1193],[1195],{"trials":19594,"activeCount":102},[19595,19607],{"nctId":19596,"briefTitle":19597,"status":884,"phases":19598,"primaryCompletion":19599,"completion":19600,"start":19601,"enrollment":8883,"conditions":19602,"interventions":19604},"NCT04394624","Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)",[91],"2023-03-06","2024-10-24","2020-08-31",[19603],"Non-small Cell Lung Cancer Metastatic",[1195,19605,19606],"ramucirumab","pembrolizumab",{"nctId":17903,"briefTitle":17904,"status":884,"phases":19608,"primaryCompletion":17906,"completion":17907,"start":17908,"enrollment":1182,"conditions":19609,"interventions":19610},[91],[17910],[1195,5400,1276,5277,5424],{"trials":19612,"activeCount":102},[19613],{"nctId":19614,"briefTitle":19615,"status":884,"phases":19616,"primaryCompletion":2928,"completion":4261,"start":19617,"enrollment":19618,"conditions":19619,"interventions":19620},"NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients",[92],"2020-02-06",389,[19603],[1195,1348],{"trials":19622,"activeCount":102},[],{"trials":19624,"activeCount":102},[],{"intervention":19626,"totalTrials":339,"cells":19627},"Saredutant succinate",{"EARLY_PHASE1":19628,"PHASE1":19630,"PHASE2":19632,"PHASE3":19634,"PHASE4":19667,"NA":19669},{"trials":19629,"activeCount":102},[],{"trials":19631,"activeCount":102},[],{"trials":19633,"activeCount":102},[],{"trials":19635,"activeCount":102},[19636,19643,19650,19656,19661],{"nctId":19637,"briefTitle":19638,"status":108,"phases":19639,"primaryCompletion":10339,"completion":10339,"start":8184,"enrollment":19640,"conditions":19641,"interventions":19642},"NCT00250627","An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression",[92],465,[18489],[19626],{"nctId":19644,"briefTitle":19645,"status":108,"phases":19646,"primaryCompletion":10339,"completion":10339,"start":8184,"enrollment":19647,"conditions":19648,"interventions":19649},"NCT00256113","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression",[92],467,[18489],[19626],{"nctId":19651,"briefTitle":19652,"status":108,"phases":19653,"primaryCompletion":3355,"completion":3355,"start":9862,"enrollment":18682,"conditions":19654,"interventions":19655},"NCT00250653","A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression",[92],[18489],[19626],{"nctId":19657,"briefTitle":19645,"status":108,"phases":19658,"primaryCompletion":3563,"completion":3563,"start":8667,"enrollment":12633,"conditions":19659,"interventions":19660},"NCT00250601",[92],[18489],[19626],{"nctId":19662,"briefTitle":19645,"status":108,"phases":19663,"primaryCompletion":3430,"completion":3430,"start":8667,"enrollment":19664,"conditions":19665,"interventions":19666},"NCT00250614",[92],452,[18489],[19626],{"trials":19668,"activeCount":102},[],{"trials":19670,"activeCount":102},[],{"intervention":19672,"totalTrials":445,"cells":19673},"volinanserin",{"EARLY_PHASE1":19674,"PHASE1":19676,"PHASE2":19678,"PHASE3":19680,"PHASE4":19711,"NA":19713},{"trials":19675,"activeCount":102},[],{"trials":19677,"activeCount":102},[],{"trials":19679,"activeCount":102},[],{"trials":19681,"activeCount":102},[19682,19689,19697,19704],{"nctId":19683,"briefTitle":19684,"status":108,"phases":19685,"primaryCompletion":8846,"completion":8846,"start":10320,"enrollment":19686,"conditions":19687,"interventions":19688},"NCT00495885","Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus",[92],848,[11472],[19672],{"nctId":19690,"briefTitle":19691,"status":884,"phases":19692,"primaryCompletion":8349,"completion":8349,"start":3355,"enrollment":19693,"conditions":19694,"interventions":19695},"NCT00464061","Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus",[92],1847,[11472],[19696],"Volinanserin",{"nctId":19698,"briefTitle":19699,"status":884,"phases":19700,"primaryCompletion":9532,"completion":9532,"start":8235,"enrollment":10753,"conditions":19701,"interventions":19702},"NCT00788515","Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties",[92],[11472],[19696,19703],"Lormetazepam",{"nctId":19705,"briefTitle":19706,"status":108,"phases":19707,"primaryCompletion":8762,"completion":8762,"start":3355,"enrollment":19708,"conditions":19709,"interventions":19710},"NCT00464243","Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study",[92],604,[11472],[19672],{"trials":19712,"activeCount":102},[],{"trials":19714,"activeCount":102},[],{"intervention":10288,"totalTrials":445,"cells":19716},{"EARLY_PHASE1":19717,"PHASE1":19719,"PHASE2":19721,"PHASE3":19727,"PHASE4":19746,"NA":19748},{"trials":19718,"activeCount":102},[],{"trials":19720,"activeCount":102},[],{"trials":19722,"activeCount":102},[19723],{"nctId":10481,"briefTitle":10482,"status":108,"phases":19724,"primaryCompletion":3317,"completion":3317,"start":9785,"enrollment":8791,"conditions":19725,"interventions":19726},[91],[3892],[10288,3846],{"trials":19728,"activeCount":102},[19729,19736,19742],{"nctId":19730,"briefTitle":19731,"status":884,"phases":19732,"primaryCompletion":8235,"completion":3307,"start":8196,"enrollment":19733,"conditions":19734,"interventions":19735},"NCT00718965","Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia",[92],826,[3892],[10288],{"nctId":19737,"briefTitle":19738,"status":884,"phases":19739,"primaryCompletion":3396,"completion":3307,"start":8846,"enrollment":1497,"conditions":19740,"interventions":19741},"NCT00766688","Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia",[92],[3892],[10288],{"nctId":10282,"briefTitle":10283,"status":884,"phases":19743,"primaryCompletion":8261,"completion":3307,"start":3417,"enrollment":10285,"conditions":19744,"interventions":19745},[92],[3892],[10288,7441],{"trials":19747,"activeCount":102},[],{"trials":19749,"activeCount":102},[],{"intervention":19751,"totalTrials":445,"cells":19752},"Ciclesonide",{"EARLY_PHASE1":19753,"PHASE1":19755,"PHASE2":19757,"PHASE3":19759,"PHASE4":19790,"NA":19792},{"trials":19754,"activeCount":102},[],{"trials":19756,"activeCount":102},[],{"trials":19758,"activeCount":102},[],{"trials":19760,"activeCount":102},[19761,19767,19777,19784],{"nctId":19762,"briefTitle":19763,"status":108,"phases":19764,"primaryCompletion":9785,"completion":9785,"start":9559,"enrollment":10129,"conditions":19765,"interventions":19766},"NCT00174720","Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.",[92],[155],[19751],{"nctId":19768,"briefTitle":19769,"status":108,"phases":19770,"primaryCompletion":5250,"completion":5250,"start":3527,"enrollment":19771,"conditions":19772,"interventions":19775},"NCT00254956","Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma",[92],1568,[19773,19774,155],"Respiratory Tract Diseases","Respiratory Hypersensitivity",[19776],"ciclesonide",{"nctId":19778,"briefTitle":19779,"status":108,"phases":19780,"completion":3367,"start":9282,"enrollment":19781,"conditions":19782,"interventions":19783},"NCT00270348","Effects of Ciclesonide MDI 50mg\u002FDay and 200mg\u002FDay (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma",[92],450,[155],[19776],{"nctId":19785,"briefTitle":19786,"status":108,"phases":19787,"primaryCompletion":8777,"completion":8777,"start":9706,"enrollment":13808,"conditions":19788,"interventions":19789},"NCT00174733","Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid",[92],[155],[19751],{"trials":19791,"activeCount":102},[],{"trials":19793,"activeCount":102},[],{"intervention":18964,"totalTrials":445,"cells":19795},{"EARLY_PHASE1":19796,"PHASE1":19798,"PHASE2":19800,"PHASE3":19818,"PHASE4":19830,"NA":19832},{"trials":19797,"activeCount":102},[],{"trials":19799,"activeCount":102},[],{"trials":19801,"activeCount":102},[19802,19806,19810],{"nctId":18954,"briefTitle":18955,"status":884,"phases":19803,"primaryCompletion":322,"completion":18957,"start":18958,"enrollment":18959,"conditions":19804,"interventions":19805},[91],[18340],[18919,18962,18963,18964,18965,18966],{"nctId":18968,"briefTitle":18969,"status":884,"phases":19807,"primaryCompletion":18971,"completion":18972,"start":18973,"enrollment":828,"conditions":19808,"interventions":19809},[91],[5264],[18919,18964],{"nctId":19811,"briefTitle":19812,"status":108,"phases":19813,"primaryCompletion":1032,"completion":1032,"start":978,"enrollment":8717,"conditions":19814,"interventions":19815},"NCT01082068","Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer",[90,91],[5264],[19099,19816,19817],"XL765","letrozole",{"trials":19819,"activeCount":102},[19820],{"nctId":19821,"briefTitle":19822,"status":884,"phases":19823,"primaryCompletion":19824,"completion":4627,"start":7577,"enrollment":19825,"conditions":19826,"interventions":19827},"NCT04478266","Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer",[92],"2022-06-28",1068,[5264],[19828,18983,18964,19829],"SAR439859","Goserelin",{"trials":19831,"activeCount":102},[],{"trials":19833,"activeCount":102},[],{"intervention":19835,"totalTrials":445,"cells":19836},"amibegron",{"EARLY_PHASE1":19837,"PHASE1":19839,"PHASE2":19841,"PHASE3":19843,"PHASE4":19871,"NA":19873},{"trials":19838,"activeCount":102},[],{"trials":19840,"activeCount":102},[],{"trials":19842,"activeCount":102},[],{"trials":19844,"activeCount":102},[19845,19851,19858,19865],{"nctId":19846,"briefTitle":19847,"status":108,"phases":19848,"primaryCompletion":8607,"completion":8607,"start":3622,"enrollment":8357,"conditions":19849,"interventions":19850},"NCT00385307","Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)",[92],[18504],[19835],{"nctId":19852,"briefTitle":19853,"status":108,"phases":19854,"primaryCompletion":3563,"completion":3563,"start":9559,"enrollment":17607,"conditions":19855,"interventions":19857},"NCT00855530","Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder",[92],[19856],"Major Depressive Disorders",[19835],{"nctId":19859,"briefTitle":19860,"status":108,"phases":19861,"primaryCompletion":3633,"completion":8184,"start":9872,"enrollment":19862,"conditions":19863,"interventions":19864},"NCT00825019","Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine",[92],306,[19856],[19835,18703],{"nctId":19866,"briefTitle":19867,"status":108,"phases":19868,"primaryCompletion":8526,"completion":3633,"start":12198,"enrollment":17938,"conditions":19869,"interventions":19870},"NCT00825058","Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine",[92],[19856],[19835,18703],{"trials":19872,"activeCount":102},[],{"trials":19874,"activeCount":102},[],{"intervention":19876,"totalTrials":445,"cells":19877},"Purified inactivated rabies vaccine",{"EARLY_PHASE1":19878,"PHASE1":19880,"PHASE2":19882,"PHASE3":19891,"PHASE4":19927,"NA":19929},{"trials":19879,"activeCount":102},[],{"trials":19881,"activeCount":102},[],{"trials":19883,"activeCount":102},[19884],{"nctId":19885,"briefTitle":19886,"status":108,"phases":19887,"primaryCompletion":3821,"completion":5306,"start":8731,"enrollment":8378,"conditions":19888,"interventions":19889},"NCT00948272","Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults",[91],[14171],[19890,19876],"Purified Vero Rabies Vaccine - Serum Free",{"trials":19892,"activeCount":102},[19893,19904,19916],{"nctId":19894,"briefTitle":19895,"status":108,"phases":19896,"primaryCompletion":19897,"completion":19897,"start":19898,"enrollment":11463,"conditions":19899,"interventions":19901},"NCT04594551","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland",[92],"2021-06-23","2020-10-11",[19900],"Rabies (Healthy Volunteers)",[19902,19876,19903],"Purified vero rabies vaccine - serum free","Human rabies immunoglobulins",{"nctId":19905,"briefTitle":19906,"status":108,"phases":19907,"primaryCompletion":19908,"completion":2293,"start":19909,"enrollment":2342,"conditions":19910,"interventions":19911},"NCT03965962","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults",[92],"2020-12-22","2019-07-01",[19900],[19912,19913,19914,19915],"VRVg-2","Purified Inactivated Rabies Vaccine","Human Diploid Cell Vaccine","Rabies immune globulin",{"nctId":19917,"briefTitle":19918,"status":108,"phases":19919,"primaryCompletion":19920,"completion":19921,"start":19922,"enrollment":8317,"conditions":19923,"interventions":19924},"NCT04478084","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland",[92],"2022-03-19","2022-07-21","2020-08-04",[19900],[19925,19876,19926,19903],"Purified vero rabies vaccine - serum free VRVg-2","Equine rabies immunoglobulins",{"trials":19928,"activeCount":102},[],{"trials":19930,"activeCount":102},[],{"intervention":9167,"totalTrials":445,"cells":19932},{"EARLY_PHASE1":19933,"PHASE1":19935,"PHASE2":19943,"PHASE3":19949,"PHASE4":19959,"NA":19961},{"trials":19934,"activeCount":102},[],{"trials":19936,"activeCount":102},[19937],{"nctId":19938,"briefTitle":19939,"status":108,"phases":19940,"primaryCompletion":1339,"completion":1339,"start":5272,"enrollment":1601,"conditions":19941,"interventions":19942},"NCT00479076","A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients",[90],[2803],[9158,9167],{"trials":19944,"activeCount":102},[19945],{"nctId":9162,"briefTitle":9163,"status":108,"phases":19946,"primaryCompletion":5238,"completion":5238,"start":8205,"enrollment":7224,"conditions":19947,"interventions":19948},[91],[5395],[2763,9167,5242],{"trials":19950,"activeCount":102},[19951,19955],{"nctId":18156,"briefTitle":18157,"status":884,"phases":19952,"primaryCompletion":1022,"completion":1022,"start":3439,"enrollment":6472,"conditions":19953,"interventions":19954},[92],[18160,9156],[9167,9234],{"nctId":9236,"briefTitle":9237,"status":108,"phases":19956,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":9242,"conditions":19957,"interventions":19958},[92],[5395],[1348,5286,9167],{"trials":19960,"activeCount":102},[],{"trials":19962,"activeCount":102},[],{"intervention":9233,"totalTrials":445,"cells":19964},{"EARLY_PHASE1":19965,"PHASE1":19967,"PHASE2":19969,"PHASE3":19971,"PHASE4":19999,"NA":20001},{"trials":19966,"activeCount":102},[],{"trials":19968,"activeCount":102},[],{"trials":19970,"activeCount":102},[],{"trials":19972,"activeCount":102},[19973,19979,19988,19992],{"nctId":19974,"briefTitle":19975,"status":884,"phases":19976,"primaryCompletion":8570,"completion":8570,"start":8762,"enrollment":1001,"conditions":19977,"interventions":19978},"NCT00603577","Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens",[92],[5240],[9233],{"nctId":19980,"briefTitle":19981,"status":108,"phases":19982,"primaryCompletion":3317,"completion":3317,"start":12198,"enrollment":19983,"conditions":19984,"interventions":19986},"NCT00103649","18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",[92],1306,[19985],"Alzheimer Disease",[19987],"xaliproden",{"nctId":9225,"briefTitle":9226,"status":108,"phases":19989,"primaryCompletion":3354,"completion":3354,"start":3565,"enrollment":9228,"conditions":19990,"interventions":19991},[92],[9230,5240,9231],[9233,5286,9234,9149],{"nctId":19993,"briefTitle":19994,"status":108,"phases":19995,"primaryCompletion":8607,"completion":8607,"start":12198,"enrollment":19996,"conditions":19997,"interventions":19998},"NCT00104013","Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",[92],1455,[19985],[19987],{"trials":20000,"activeCount":102},[],{"trials":20002,"activeCount":102},[],{"intervention":20004,"totalTrials":445,"cells":20005},"Otamixaban",{"EARLY_PHASE1":20006,"PHASE1":20008,"PHASE2":20017,"PHASE3":20038,"PHASE4":20049,"NA":20051},{"trials":20007,"activeCount":102},[],{"trials":20009,"activeCount":102},[20010],{"nctId":20011,"briefTitle":20012,"status":108,"phases":20013,"primaryCompletion":8406,"completion":8406,"start":3316,"enrollment":391,"conditions":20014,"interventions":20015},"NCT01120314","Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment",[90],[3731],[20016],"OTAMIXABAN",{"trials":20018,"activeCount":102},[20019,20028],{"nctId":20020,"briefTitle":20021,"status":108,"phases":20022,"completion":8331,"start":3367,"enrollment":20023,"conditions":20024,"interventions":20026},"NCT00133731","The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention",[91],947,[20025],"Angioplasty, Transluminal, Percutaneous Coronary",[20004,20027],"Unfractionated Heparin",{"nctId":20029,"briefTitle":20030,"status":108,"phases":20031,"primaryCompletion":8846,"completion":8349,"start":8395,"enrollment":20032,"conditions":20033,"interventions":20035},"NCT00317395","Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome",[91],3241,[20034],"Coronary Disease",[20004,20036,20037],"unfractionated heparin","eptifibatide",{"trials":20039,"activeCount":102},[20040],{"nctId":20041,"briefTitle":20042,"status":108,"phases":20043,"primaryCompletion":8106,"completion":8106,"start":3316,"enrollment":20044,"conditions":20045,"interventions":20046},"NCT01076764","Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina\u002FNon ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy",[92],13220,[9440],[20004,20047,20048],"UFH","Eptifibatide",{"trials":20050,"activeCount":102},[],{"trials":20052,"activeCount":102},[],{"intervention":18703,"totalTrials":445,"cells":20054},{"EARLY_PHASE1":20055,"PHASE1":20057,"PHASE2":20059,"PHASE3":20069,"PHASE4":20083,"NA":20085},{"trials":20056,"activeCount":102},[],{"trials":20058,"activeCount":102},[],{"trials":20060,"activeCount":102},[20061],{"nctId":20062,"briefTitle":20063,"status":108,"phases":20064,"primaryCompletion":3439,"completion":3439,"start":5262,"enrollment":4895,"conditions":20065,"interventions":20066},"NCT00374166","An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder",[91],[18481],[20067,20068],"SSR149415","Paroxetine",{"trials":20070,"activeCount":102},[20071,20075,20079],{"nctId":18695,"briefTitle":18696,"status":108,"phases":20072,"primaryCompletion":8315,"completion":8315,"start":3439,"enrollment":18698,"conditions":20073,"interventions":20074},[92],[18700],[18702,18703],{"nctId":19859,"briefTitle":19860,"status":108,"phases":20076,"primaryCompletion":3633,"completion":8184,"start":9872,"enrollment":19862,"conditions":20077,"interventions":20078},[92],[19856],[19835,18703],{"nctId":19866,"briefTitle":19867,"status":108,"phases":20080,"primaryCompletion":8526,"completion":3633,"start":12198,"enrollment":17938,"conditions":20081,"interventions":20082},[92],[19856],[19835,18703],{"trials":20084,"activeCount":102},[],{"trials":20086,"activeCount":102},[],{"intervention":11193,"totalTrials":445,"cells":20088},{"EARLY_PHASE1":20089,"PHASE1":20091,"PHASE2":20101,"PHASE3":20103,"PHASE4":20113,"NA":20115},{"trials":20090,"activeCount":102},[],{"trials":20092,"activeCount":102},[20093,20097],{"nctId":11971,"briefTitle":11972,"status":108,"phases":20094,"primaryCompletion":7283,"completion":7283,"start":2760,"enrollment":3740,"conditions":20095,"interventions":20096},[90],[591],[11193,11976,11976],{"nctId":11978,"briefTitle":11979,"status":108,"phases":20098,"primaryCompletion":965,"completion":965,"start":3459,"enrollment":6434,"conditions":20099,"interventions":20100},[90],[554],[11193,8672],{"trials":20102,"activeCount":102},[],{"trials":20104,"activeCount":102},[20105,20109],{"nctId":11187,"briefTitle":11188,"status":108,"phases":20106,"primaryCompletion":1355,"completion":1355,"start":1031,"enrollment":11190,"conditions":20107,"interventions":20108},[92],[19],[11193,11194,11195],{"nctId":11197,"briefTitle":11198,"status":108,"phases":20110,"primaryCompletion":3429,"completion":11200,"start":5216,"enrollment":11201,"conditions":20111,"interventions":20112},[92],[554],[11193,11194,11142],{"trials":20114,"activeCount":102},[],{"trials":20116,"activeCount":102},[],{"intervention":9212,"totalTrials":445,"cells":20118},{"EARLY_PHASE1":20119,"PHASE1":20121,"PHASE2":20127,"PHASE3":20137,"PHASE4":20150,"NA":20152},{"trials":20120,"activeCount":102},[],{"trials":20122,"activeCount":102},[20123],{"nctId":18125,"briefTitle":18126,"status":108,"phases":20124,"primaryCompletion":7430,"completion":7430,"start":2311,"enrollment":576,"conditions":20125,"interventions":20126},[90],[1193],[9212,9149,18130,9234],{"trials":20128,"activeCount":102},[20129,20133],{"nctId":18826,"briefTitle":18827,"status":3661,"phases":20130,"primaryCompletion":18829,"completion":18829,"start":1055,"enrollment":102,"conditions":20131,"interventions":20132},[91],[9210],[9200,9212,18832],{"nctId":9206,"briefTitle":9207,"status":884,"phases":20134,"primaryCompletion":1011,"completion":1011,"start":6471,"enrollment":445,"conditions":20135,"interventions":20136},[90,91],[9210],[9212,5286,9200],{"trials":20138,"activeCount":102},[20139],{"nctId":20140,"briefTitle":20141,"status":108,"phases":20142,"primaryCompletion":20143,"completion":20143,"start":20144,"enrollment":20145,"conditions":20146,"interventions":20147},"NCT01571284","Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen",[92],"2017-01-31","2012-05-30",781,[9210],[20148,20149],"AFLIBERCEPT AVE0005","FOLFIRI",{"trials":20151,"activeCount":102},[],{"trials":20153,"activeCount":102},[],{"intervention":17986,"totalTrials":619,"cells":20155},{"EARLY_PHASE1":20156,"PHASE1":20158,"PHASE2":20160,"PHASE3":20162,"PHASE4":20176,"NA":20178},{"trials":20157,"activeCount":102},[],{"trials":20159,"activeCount":102},[],{"trials":20161,"activeCount":102},[],{"trials":20163,"activeCount":102},[20164,20168,20172],{"nctId":17935,"briefTitle":17936,"status":108,"phases":20165,"primaryCompletion":8762,"completion":8762,"start":8667,"enrollment":17938,"conditions":20166,"interventions":20167},[92],[17940],[17942,1276],{"nctId":17980,"briefTitle":17981,"status":108,"phases":20169,"primaryCompletion":3622,"completion":3622,"start":8176,"enrollment":17983,"conditions":20170,"interventions":20171},[92],[12355],[17986,17864],{"nctId":17988,"briefTitle":17989,"status":108,"phases":20173,"completion":9826,"start":17991,"conditions":20174,"interventions":20175},[92],[17993],[17864,17986,17995],{"trials":20177,"activeCount":102},[],{"trials":20179,"activeCount":102},[],{"intervention":2838,"totalTrials":619,"cells":20181},{"EARLY_PHASE1":20182,"PHASE1":20184,"PHASE2":20186,"PHASE3":20192,"PHASE4":20202,"NA":20204},{"trials":20183,"activeCount":102},[],{"trials":20185,"activeCount":102},[],{"trials":20187,"activeCount":102},[20188],{"nctId":4623,"briefTitle":4624,"status":884,"phases":20189,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":20190,"interventions":20191},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":20193,"activeCount":102},[20194,20198],{"nctId":2796,"briefTitle":2797,"status":108,"phases":20195,"primaryCompletion":2799,"completion":2799,"start":2800,"enrollment":2801,"conditions":20196,"interventions":20197},[92],[2803,2804],[2806,2807,1780],{"nctId":2831,"briefTitle":2832,"status":108,"phases":20199,"primaryCompletion":2834,"completion":2834,"start":2800,"enrollment":2835,"conditions":20200,"interventions":20201},[92],[2804],[1348,2838,671],{"trials":20203,"activeCount":102},[],{"trials":20205,"activeCount":102},[],{"intervention":20207,"totalTrials":619,"cells":20208},"Itepekimab SAR440340",{"EARLY_PHASE1":20209,"PHASE1":20211,"PHASE2":20213,"PHASE3":20223,"PHASE4":20243,"NA":20245},{"trials":20210,"activeCount":102},[],{"trials":20212,"activeCount":102},[],{"trials":20214,"activeCount":102},[20215],{"nctId":20216,"briefTitle":20217,"status":108,"phases":20218,"primaryCompletion":20219,"completion":551,"start":20220,"enrollment":9533,"conditions":20221,"interventions":20222},"NCT05326412","Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD",[91],"2025-03-05","2022-05-19",[382],[20207],{"trials":20224,"activeCount":102},[20225,20235],{"nctId":20226,"briefTitle":20227,"status":108,"phases":20228,"primaryCompletion":20229,"completion":20230,"start":20231,"enrollment":20232,"conditions":20233,"interventions":20234},"NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340\u002FREGN3500\u002FItepekimab in Chronic Obstructive Pulmonary Disease (COPD)",[92],"2025-04-21","2025-08-28","2021-02-12",1239,[382],[20207],{"nctId":20236,"briefTitle":20227,"status":108,"phases":20237,"primaryCompletion":20238,"completion":2906,"start":20239,"enrollment":20240,"conditions":20241,"interventions":20242},"NCT04701983",[92],"2025-04-11","2020-12-16",1127,[382],[20207],{"trials":20244,"activeCount":102},[],{"trials":20246,"activeCount":102},[],{"intervention":13222,"totalTrials":619,"cells":20248},{"EARLY_PHASE1":20249,"PHASE1":20251,"PHASE2":20253,"PHASE3":20255,"PHASE4":20272,"NA":20274},{"trials":20250,"activeCount":102},[],{"trials":20252,"activeCount":102},[],{"trials":20254,"activeCount":102},[],{"trials":20256,"activeCount":102},[20257,20264,20268],{"nctId":20258,"briefTitle":20259,"status":108,"phases":20260,"primaryCompletion":20261,"completion":20261,"start":12781,"enrollment":412,"conditions":20262,"interventions":20263},"NCT04368429","Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age",[92],"2020-11-07",[5167],[13222,5102],{"nctId":5027,"briefTitle":5028,"status":108,"phases":20265,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":20266,"interventions":20267},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"nctId":13216,"briefTitle":13217,"status":108,"phases":20269,"primaryCompletion":2661,"completion":2661,"start":13219,"enrollment":8738,"conditions":20270,"interventions":20271},[92],[2910,36],[13222,2963,13223,13205],{"trials":20273,"activeCount":102},[],{"trials":20275,"activeCount":102},[],{"intervention":11088,"totalTrials":619,"cells":20277},{"EARLY_PHASE1":20278,"PHASE1":20280,"PHASE2":20282,"PHASE3":20284,"PHASE4":20306,"NA":20308},{"trials":20279,"activeCount":102},[],{"trials":20281,"activeCount":102},[],{"trials":20283,"activeCount":102},[],{"trials":20285,"activeCount":102},[20286,20290,20299],{"nctId":11081,"briefTitle":11082,"status":108,"phases":20287,"primaryCompletion":8453,"completion":8453,"start":8395,"enrollment":11084,"conditions":20288,"interventions":20289},[92],[11086,9602],[11088,1407,11089,11064],{"nctId":20291,"briefTitle":20292,"status":108,"phases":20293,"primaryCompletion":8762,"completion":8762,"start":9513,"enrollment":20294,"conditions":20295,"interventions":20297},"NCT00311090","Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs",[92],757,[20296],"Deep Venous Thrombosis",[11088,20298,11089],"Idraparinux sodium",{"nctId":20300,"briefTitle":20301,"status":884,"phases":20302,"primaryCompletion":8453,"completion":8453,"start":7509,"enrollment":20303,"conditions":20304,"interventions":20305},"NCT00580216","Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation",[92],3773,[9562],[11088,1407,11089],{"trials":20307,"activeCount":102},[],{"trials":20309,"activeCount":102},[],{"intervention":1407,"totalTrials":619,"cells":20311},{"EARLY_PHASE1":20312,"PHASE1":20314,"PHASE2":20320,"PHASE3":20322,"PHASE4":20332,"NA":20334},{"trials":20313,"activeCount":102},[],{"trials":20315,"activeCount":102},[20316],{"nctId":1394,"briefTitle":1395,"status":108,"phases":20317,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":20318,"interventions":20319},[90],[351],[77,1403,1404,1405,1406,1407],{"trials":20321,"activeCount":102},[],{"trials":20323,"activeCount":102},[20324,20328],{"nctId":11081,"briefTitle":11082,"status":108,"phases":20325,"primaryCompletion":8453,"completion":8453,"start":8395,"enrollment":11084,"conditions":20326,"interventions":20327},[92],[11086,9602],[11088,1407,11089,11064],{"nctId":20300,"briefTitle":20301,"status":884,"phases":20329,"primaryCompletion":8453,"completion":8453,"start":7509,"enrollment":20303,"conditions":20330,"interventions":20331},[92],[9562],[11088,1407,11089],{"trials":20333,"activeCount":102},[],{"trials":20335,"activeCount":102},[],{"intervention":11089,"totalTrials":619,"cells":20337},{"EARLY_PHASE1":20338,"PHASE1":20340,"PHASE2":20342,"PHASE3":20344,"PHASE4":20358,"NA":20360},{"trials":20339,"activeCount":102},[],{"trials":20341,"activeCount":102},[],{"trials":20343,"activeCount":102},[],{"trials":20345,"activeCount":102},[20346,20350,20354],{"nctId":11081,"briefTitle":11082,"status":108,"phases":20347,"primaryCompletion":8453,"completion":8453,"start":8395,"enrollment":11084,"conditions":20348,"interventions":20349},[92],[11086,9602],[11088,1407,11089,11064],{"nctId":20291,"briefTitle":20292,"status":108,"phases":20351,"primaryCompletion":8762,"completion":8762,"start":9513,"enrollment":20294,"conditions":20352,"interventions":20353},[92],[20296],[11088,20298,11089],{"nctId":20300,"briefTitle":20301,"status":884,"phases":20355,"primaryCompletion":8453,"completion":8453,"start":7509,"enrollment":20303,"conditions":20356,"interventions":20357},[92],[9562],[11088,1407,11089],{"trials":20359,"activeCount":102},[],{"trials":20361,"activeCount":102},[],{"intervention":19546,"totalTrials":619,"cells":20363},{"EARLY_PHASE1":20364,"PHASE1":20366,"PHASE2":20368,"PHASE3":20378,"PHASE4":20384,"NA":20386},{"trials":20365,"activeCount":102},[],{"trials":20367,"activeCount":102},[],{"trials":20369,"activeCount":102},[20370,20374],{"nctId":19541,"briefTitle":19542,"status":108,"phases":20371,"primaryCompletion":8388,"completion":8106,"start":8822,"enrollment":1091,"conditions":20372,"interventions":20373},[91],[17265,14394],[19546,2940,19546,2940],{"nctId":18224,"briefTitle":18225,"status":108,"phases":20375,"primaryCompletion":18227,"completion":18227,"start":18228,"enrollment":305,"conditions":20376,"interventions":20377},[91],[2316,18210,2317],[18194,18194,18231,18231],{"trials":20379,"activeCount":102},[20380],{"nctId":19550,"briefTitle":19551,"status":108,"phases":20381,"primaryCompletion":8261,"completion":8215,"start":3417,"enrollment":2791,"conditions":20382,"interventions":20383},[92],[17265,14394],[19546,19546,19546,19546,2940],{"trials":20385,"activeCount":102},[],{"trials":20387,"activeCount":102},[],{"intervention":6505,"totalTrials":619,"cells":20389},{"EARLY_PHASE1":20390,"PHASE1":20392,"PHASE2":20398,"PHASE3":20400,"PHASE4":20410,"NA":20412},{"trials":20391,"activeCount":102},[],{"trials":20393,"activeCount":102},[20394],{"nctId":6468,"briefTitle":6469,"status":108,"phases":20395,"primaryCompletion":6471,"completion":6471,"start":1032,"enrollment":6472,"conditions":20396,"interventions":20397},[90],[990],[6458,993,6475],{"trials":20399,"activeCount":102},[],{"trials":20401,"activeCount":102},[20402,20406],{"nctId":6499,"briefTitle":6500,"status":108,"phases":20403,"primaryCompletion":4968,"completion":4968,"start":150,"enrollment":6502,"conditions":20404,"interventions":20405},[92],[990],[2781,971,6505],{"nctId":1019,"briefTitle":1020,"status":108,"phases":20407,"primaryCompletion":966,"completion":966,"start":1022,"enrollment":1023,"conditions":20408,"interventions":20409},[91,92],[990],[942,971,1026],{"trials":20411,"activeCount":102},[],{"trials":20413,"activeCount":102},[],{"intervention":20415,"totalTrials":619,"cells":20416},"Inactivated Poliomyelitis vaccine",{"EARLY_PHASE1":20417,"PHASE1":20419,"PHASE2":20421,"PHASE3":20430,"PHASE4":20455,"NA":20457},{"trials":20418,"activeCount":102},[],{"trials":20420,"activeCount":102},[],{"trials":20422,"activeCount":102},[20423],{"nctId":20424,"briefTitle":20425,"status":108,"phases":20426,"primaryCompletion":3564,"completion":8205,"start":8762,"enrollment":20427,"conditions":20428,"interventions":20429},"NCT00604058","Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly",[91],236,[12983],[20415,20415],{"trials":20431,"activeCount":102},[20432,20449],{"nctId":20433,"briefTitle":20434,"status":108,"phases":20435,"primaryCompletion":20436,"completion":20437,"start":20438,"enrollment":12633,"conditions":20439,"interventions":20442},"NCT04429295","Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand",[92],"2021-02-26","2021-11-20","2020-06-28",[12787,12785,12790,12788,20440,12786,20441,12784],"Haemophilus Influenzae Type B Immunisation","Rotavirus Immunisation",[20443,20444,20445,20446,20447,20448],"DTwP-HepB-Hib-IPV hexavalent vaccine","DTwP-HepB-Hib pentavalent vaccine","Inactivated Poliomyelitis Vaccine","Poliomyelitis Vaccine bivalent types 1 and 3","Human Rotavirus, live attenuated","Pneumococcal polysaccharide conjugate vaccine",{"nctId":20450,"briefTitle":20451,"status":108,"phases":20452,"primaryCompletion":8777,"completion":9513,"start":3623,"enrollment":98,"conditions":20453,"interventions":20454},"NCT00258843","Safety of Imovax Polio in Chinese Infants and Children",[92],[12983],[20415,20415],{"trials":20456,"activeCount":102},[],{"trials":20458,"activeCount":102},[],{"intervention":20460,"totalTrials":619,"cells":20461},"RSVt Vaccine",{"EARLY_PHASE1":20462,"PHASE1":20464,"PHASE2":20466,"PHASE3":20476,"PHASE4":20490,"NA":20492},{"trials":20463,"activeCount":102},[],{"trials":20465,"activeCount":102},[],{"trials":20467,"activeCount":102},[20468],{"nctId":20469,"briefTitle":20470,"status":108,"phases":20471,"primaryCompletion":410,"completion":410,"start":20472,"enrollment":20,"conditions":20473,"interventions":20475},"NCT05687279","Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to \u003C 24 Months of Age in Puerto Rico (USA)",[90,91],"2023-02-06",[20474],"Respiratory Syncytial Virus Infection",[20460],{"trials":20477,"activeCount":102},[20478,20486],{"nctId":20479,"briefTitle":20480,"status":884,"phases":20481,"primaryCompletion":4882,"completion":4882,"start":1591,"enrollment":20482,"conditions":20483,"interventions":20485},"NCT06252285","Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[92],6300,[20484],"RSV Immunisation",[20460],{"nctId":5081,"briefTitle":5082,"status":884,"phases":20487,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":20488,"interventions":20489},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"trials":20491,"activeCount":102},[],{"trials":20493,"activeCount":102},[],{"intervention":5021,"totalTrials":619,"cells":20495},{"EARLY_PHASE1":20496,"PHASE1":20498,"PHASE2":20500,"PHASE3":20502,"PHASE4":20520,"NA":20522},{"trials":20497,"activeCount":102},[],{"trials":20499,"activeCount":102},[],{"trials":20501,"activeCount":102},[],{"trials":20503,"activeCount":102},[20504,20508,20516],{"nctId":5012,"briefTitle":5013,"status":108,"phases":20505,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":20506,"interventions":20507},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"nctId":20509,"briefTitle":20510,"status":108,"phases":20511,"primaryCompletion":20512,"completion":20512,"start":8547,"enrollment":589,"conditions":20513,"interventions":20514},"NCT03077438","Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years",[92],"2017-10-10",[4992,7568,2922],[20515,5021],"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate",{"nctId":5041,"briefTitle":5042,"status":108,"phases":20517,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":20518,"interventions":20519},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":20521,"activeCount":102},[],{"trials":20523,"activeCount":102},[],{"intervention":5022,"totalTrials":619,"cells":20525},{"EARLY_PHASE1":20526,"PHASE1":20528,"PHASE2":20530,"PHASE3":20536,"PHASE4":20546,"NA":20548},{"trials":20527,"activeCount":102},[],{"trials":20529,"activeCount":102},[],{"trials":20531,"activeCount":102},[20532],{"nctId":12777,"briefTitle":12778,"status":108,"phases":20533,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":20534,"interventions":20535},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":20537,"activeCount":102},[20538,20542],{"nctId":5012,"briefTitle":5013,"status":108,"phases":20539,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":20540,"interventions":20541},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"nctId":5041,"briefTitle":5042,"status":108,"phases":20543,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":20544,"interventions":20545},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":20547,"activeCount":102},[],{"trials":20549,"activeCount":102},[],{"intervention":19903,"totalTrials":619,"cells":20551},{"EARLY_PHASE1":20552,"PHASE1":20554,"PHASE2":20556,"PHASE3":20572,"PHASE4":20582,"NA":20584},{"trials":20553,"activeCount":102},[],{"trials":20555,"activeCount":102},[],{"trials":20557,"activeCount":102},[20558],{"nctId":20559,"briefTitle":20560,"status":108,"phases":20561,"primaryCompletion":20562,"completion":20562,"start":20563,"enrollment":20564,"conditions":20565,"interventions":20567},"NCT03145766","Immunogenicity and Safety of a Purified Vero Rabies Vaccine",[91],"2018-01-08","2017-04-17",320,[20566],"Rabies Virus",[20568,20569,20570,20568,20568,20571],"VRVg 2","VRVg 1","Imovax Rabies","Human Rabies Immunoglobulins",{"trials":20573,"activeCount":102},[20574,20578],{"nctId":19894,"briefTitle":19895,"status":108,"phases":20575,"primaryCompletion":19897,"completion":19897,"start":19898,"enrollment":11463,"conditions":20576,"interventions":20577},[92],[19900],[19902,19876,19903],{"nctId":19917,"briefTitle":19918,"status":108,"phases":20579,"primaryCompletion":19920,"completion":19921,"start":19922,"enrollment":8317,"conditions":20580,"interventions":20581},[92],[19900],[19925,19876,19926,19903],{"trials":20583,"activeCount":102},[],{"trials":20585,"activeCount":102},[],{"intervention":20587,"totalTrials":619,"cells":20588},"SR121463B",{"EARLY_PHASE1":20589,"PHASE1":20591,"PHASE2":20593,"PHASE3":20595,"PHASE4":20616,"NA":20618},{"trials":20590,"activeCount":102},[],{"trials":20592,"activeCount":102},[],{"trials":20594,"activeCount":102},[],{"trials":20596,"activeCount":102},[20597,20603,20609],{"nctId":20598,"briefTitle":20599,"status":108,"phases":20600,"primaryCompletion":1341,"completion":1341,"start":8526,"enrollment":13,"conditions":20601,"interventions":20602},"NCT00264927","Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion",[92],[18799,18776],[20587],{"nctId":20604,"briefTitle":20605,"status":108,"phases":20606,"primaryCompletion":9190,"completion":9190,"start":9706,"enrollment":1182,"conditions":20607,"interventions":20608},"NCT00264914","Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion",[92],[18799,18776],[20587],{"nctId":20610,"briefTitle":20611,"status":108,"phases":20612,"primaryCompletion":3563,"completion":3563,"start":9862,"enrollment":455,"conditions":20613,"interventions":20615},"NCT00274326","DILIPO (DILutIonal HyPOnatremia)",[92],[20614],"Congestive Heart Failure",[20587],{"trials":20617,"activeCount":102},[],{"trials":20619,"activeCount":102},[],{"intervention":20621,"totalTrials":619,"cells":20622},"Oral Polio Vaccine",{"EARLY_PHASE1":20623,"PHASE1":20625,"PHASE2":20627,"PHASE3":20629,"PHASE4":20658,"NA":20660},{"trials":20624,"activeCount":102},[],{"trials":20626,"activeCount":102},[],{"trials":20628,"activeCount":102},[],{"trials":20630,"activeCount":102},[20631,20640,20649],{"nctId":20632,"briefTitle":20633,"status":108,"phases":20634,"primaryCompletion":8205,"completion":3396,"start":1341,"enrollment":20635,"conditions":20636,"interventions":20637},"NCT00514709","Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants",[92],1843,[25,31,28,18625,16],[20638,20639,20621],"DTaP-HB PRP~T Combined Vaccine","DTaP-HB-PRP~T vaccine",{"nctId":20641,"briefTitle":20642,"status":108,"phases":20643,"primaryCompletion":8607,"completion":8505,"start":5262,"enrollment":20644,"conditions":20645,"interventions":20646},"NCT00343889","Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB\u002FHib™, Both Given Concomitantly With Oral Polio Vaccine",[92],379,[25,31,28,18625,17157],[20647,20648,20621],"DTaP-HB-PRP~T vaccine + OPV","Tritanrix-HepB\u002FHib™ + OPV vaccine",{"nctId":20650,"briefTitle":20651,"status":108,"phases":20652,"primaryCompletion":3564,"completion":8349,"start":1341,"enrollment":20653,"conditions":20654,"interventions":20656},"NCT00534833","Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB\u002FHib™",[92],362,[25,31,28,18625,20655],"Haemophilus Influenzae Type b",[20639,20657,20621],"Tritanrix-HepB\u002FHib™",{"trials":20659,"activeCount":102},[],{"trials":20661,"activeCount":102},[],{"intervention":297,"totalTrials":619,"cells":20663},{"EARLY_PHASE1":20664,"PHASE1":20666,"PHASE2":20668,"PHASE3":20670,"PHASE4":20684,"NA":20686},{"trials":20665,"activeCount":102},[],{"trials":20667,"activeCount":102},[],{"trials":20669,"activeCount":102},[],{"trials":20671,"activeCount":102},[20672,20676,20680],{"nctId":254,"briefTitle":255,"status":108,"phases":20673,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":20674,"interventions":20675},[92],[155],[97,262,263],{"nctId":7141,"briefTitle":7142,"status":108,"phases":20677,"primaryCompletion":7144,"completion":7144,"start":7145,"enrollment":7146,"conditions":20678,"interventions":20679},[92],[155],[2064,297,298],{"nctId":289,"briefTitle":290,"status":108,"phases":20681,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":20682,"interventions":20683},[92],[155],[97,297,298],{"trials":20685,"activeCount":102},[],{"trials":20687,"activeCount":102},[],{"intervention":298,"totalTrials":619,"cells":20689},{"EARLY_PHASE1":20690,"PHASE1":20692,"PHASE2":20694,"PHASE3":20696,"PHASE4":20710,"NA":20712},{"trials":20691,"activeCount":102},[],{"trials":20693,"activeCount":102},[],{"trials":20695,"activeCount":102},[],{"trials":20697,"activeCount":102},[20698,20702,20706],{"nctId":254,"briefTitle":255,"status":108,"phases":20699,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":20700,"interventions":20701},[92],[155],[97,262,263],{"nctId":7141,"briefTitle":7142,"status":108,"phases":20703,"primaryCompletion":7144,"completion":7144,"start":7145,"enrollment":7146,"conditions":20704,"interventions":20705},[92],[155],[2064,297,298],{"nctId":289,"briefTitle":290,"status":108,"phases":20707,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":20708,"interventions":20709},[92],[155],[97,297,298],{"trials":20711,"activeCount":102},[],{"trials":20713,"activeCount":102},[],{"intervention":20715,"totalTrials":619,"cells":20716},"CELIVARONE",{"EARLY_PHASE1":20717,"PHASE1":20719,"PHASE2":20721,"PHASE3":20740,"PHASE4":20749,"NA":20751},{"trials":20718,"activeCount":102},[],{"trials":20720,"activeCount":102},[],{"trials":20722,"activeCount":102},[20723,20733],{"nctId":20724,"briefTitle":20725,"status":108,"phases":20726,"primaryCompletion":7292,"completion":7292,"start":2799,"enrollment":7146,"conditions":20727,"interventions":20730},"NCT00993382","Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death",[91],[20728,20729],"Arrhythmia Prophylaxis","Ventricular Arrhythmia",[20731,20732],"Celivarone","Amiodarone",{"nctId":20734,"briefTitle":20735,"status":108,"phases":20736,"primaryCompletion":9513,"completion":9513,"start":8331,"enrollment":455,"conditions":20737,"interventions":20739},"NCT00232310","Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation \u002F fluttEr",[91],[9562,20738],"Atrial Flutter",[20715],{"trials":20741,"activeCount":102},[20742],{"nctId":20743,"briefTitle":20744,"status":108,"phases":20745,"primaryCompletion":8753,"completion":8753,"start":8184,"enrollment":20746,"conditions":20747,"interventions":20748},"NCT00233441","Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation\u002FFlutter",[91,92],673,[9562,20738],[20715],{"trials":20750,"activeCount":102},[],{"trials":20752,"activeCount":102},[],{"intervention":7352,"totalTrials":619,"cells":20754},{"EARLY_PHASE1":20755,"PHASE1":20757,"PHASE2":20759,"PHASE3":20761,"PHASE4":20775,"NA":20777},{"trials":20756,"activeCount":102},[],{"trials":20758,"activeCount":102},[],{"trials":20760,"activeCount":102},[],{"trials":20762,"activeCount":102},[20763,20767,20771],{"nctId":7346,"briefTitle":7347,"status":108,"phases":20764,"primaryCompletion":1272,"completion":964,"start":7349,"enrollment":5913,"conditions":20765,"interventions":20766},[92],[3892],[7273,3869,7352],{"nctId":7354,"briefTitle":7355,"status":108,"phases":20768,"primaryCompletion":1272,"completion":1031,"start":2834,"enrollment":2663,"conditions":20769,"interventions":20770},[92],[3842],[7273,7352],{"nctId":7427,"briefTitle":7428,"status":108,"phases":20772,"primaryCompletion":7330,"completion":7430,"start":2857,"enrollment":7146,"conditions":20773,"interventions":20774},[92],[3892],[7273,7352],{"trials":20776,"activeCount":102},[],{"trials":20778,"activeCount":102},[],{"intervention":2965,"totalTrials":619,"cells":20780},{"EARLY_PHASE1":20781,"PHASE1":20783,"PHASE2":20793,"PHASE3":20795,"PHASE4":20811,"NA":20813},{"trials":20782,"activeCount":102},[],{"trials":20784,"activeCount":102},[20785],{"nctId":20786,"briefTitle":20787,"status":108,"phases":20788,"primaryCompletion":9190,"completion":9190,"start":9785,"enrollment":271,"conditions":20789,"interventions":20791},"NCT01444001","Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers",[90],[3149,20790],"Pneumococcal Pneumonia",[20792,20792,20792],"Pneumococcal Vaccine",{"trials":20794,"activeCount":102},[],{"trials":20796,"activeCount":102},[20797,20801],{"nctId":2954,"briefTitle":2955,"status":108,"phases":20798,"primaryCompletion":2957,"completion":2958,"start":2959,"enrollment":2960,"conditions":20799,"interventions":20800},[92],[2922],[2879,2963,2964,2965,2965,2966],{"nctId":20802,"briefTitle":20803,"status":108,"phases":20804,"primaryCompletion":20805,"completion":7330,"start":20806,"enrollment":5913,"conditions":20807,"interventions":20808},"NCT01411241","Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers",[92],"2014-02-04","2011-07-18",[2316,2317],[20809,20810,2325,2965,20809,20810,2325,2965],"Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus","DTaP IPV\u002F\u002FHib vaccine",{"trials":20812,"activeCount":102},[],{"trials":20814,"activeCount":102},[],{"intervention":20027,"totalTrials":619,"cells":20816},{"EARLY_PHASE1":20817,"PHASE1":20819,"PHASE2":20821,"PHASE3":20831,"PHASE4":20845,"NA":20847},{"trials":20818,"activeCount":102},[],{"trials":20820,"activeCount":102},[],{"trials":20822,"activeCount":102},[20823,20827],{"nctId":20020,"briefTitle":20021,"status":108,"phases":20824,"completion":8331,"start":3367,"enrollment":20023,"conditions":20825,"interventions":20826},[91],[20025],[20004,20027],{"nctId":20029,"briefTitle":20030,"status":108,"phases":20828,"primaryCompletion":8846,"completion":8349,"start":8395,"enrollment":20032,"conditions":20829,"interventions":20830},[91],[20034],[20004,20036,20037],{"trials":20832,"activeCount":102},[20833],{"nctId":20834,"briefTitle":20835,"status":108,"phases":20836,"primaryCompletion":9559,"completion":9559,"start":3539,"enrollment":20837,"conditions":20838,"interventions":20840},"NCT00067093","Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)",[92],1452,[20839],"Deep Vein Thrombosis",[20841,20842,20843,20844],"SanOrg34006","LMW heparin","Unfractionated heparin","Vitamin K antagonist",{"trials":20846,"activeCount":102},[],{"trials":20848,"activeCount":102},[],{"intervention":2325,"totalTrials":619,"cells":20850},{"EARLY_PHASE1":20851,"PHASE1":20853,"PHASE2":20855,"PHASE3":20857,"PHASE4":20871,"NA":20873},{"trials":20852,"activeCount":102},[],{"trials":20854,"activeCount":102},[],{"trials":20856,"activeCount":102},[],{"trials":20858,"activeCount":102},[20859,20863,20867],{"nctId":5081,"briefTitle":5082,"status":884,"phases":20860,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":20861,"interventions":20862},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"nctId":2308,"briefTitle":2309,"status":108,"phases":20864,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":20865,"interventions":20866},[92],[2316,2317,2296],[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],{"nctId":20802,"briefTitle":20803,"status":108,"phases":20868,"primaryCompletion":20805,"completion":7330,"start":20806,"enrollment":5913,"conditions":20869,"interventions":20870},[92],[2316,2317],[20809,20810,2325,2965,20809,20810,2325,2965],{"trials":20872,"activeCount":102},[],{"trials":20874,"activeCount":102},[],{"intervention":4997,"totalTrials":619,"cells":20876},{"EARLY_PHASE1":20877,"PHASE1":20879,"PHASE2":20881,"PHASE3":20891,"PHASE4":20897,"NA":20899},{"trials":20878,"activeCount":102},[],{"trials":20880,"activeCount":102},[],{"trials":20882,"activeCount":102},[20883,20887],{"nctId":4986,"briefTitle":4987,"status":108,"phases":20884,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":20885,"interventions":20886},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"nctId":12777,"briefTitle":12778,"status":108,"phases":20888,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":20889,"interventions":20890},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":20892,"activeCount":102},[20893],{"nctId":5041,"briefTitle":5042,"status":108,"phases":20894,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":20895,"interventions":20896},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":20898,"activeCount":102},[],{"trials":20900,"activeCount":102},[],{"intervention":9725,"totalTrials":619,"cells":20902},{"EARLY_PHASE1":20903,"PHASE1":20905,"PHASE2":20907,"PHASE3":20909,"PHASE4":20931,"NA":20933},{"trials":20904,"activeCount":102},[],{"trials":20906,"activeCount":102},[],{"trials":20908,"activeCount":102},[],{"trials":20910,"activeCount":102},[20911,20919,20923],{"nctId":20912,"briefTitle":20913,"status":108,"phases":20914,"primaryCompletion":5271,"completion":5271,"start":8731,"enrollment":20915,"conditions":20916,"interventions":20917},"NCT00956644","Irbesartan\u002FAmlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy",[92],406,[9680],[9725,20918],"amlodipine",{"nctId":9719,"briefTitle":9720,"status":108,"phases":20920,"primaryCompletion":5217,"completion":5217,"start":8731,"enrollment":9722,"conditions":20921,"interventions":20922},[92],[9680],[9725,9726],{"nctId":20924,"briefTitle":20925,"status":108,"phases":20926,"primaryCompletion":8298,"completion":8298,"start":5238,"enrollment":20927,"conditions":20928,"interventions":20929},"NCT01625494","Study of Efficacy and Safety of Irbesartan\u002FAmlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy",[92],158,[9680],[20930,20930,20930,20930],"Irbesartan\u002FAmlodipine",{"trials":20932,"activeCount":102},[],{"trials":20934,"activeCount":102},[],{"intervention":20936,"totalTrials":619,"cells":20937},"Influenza Virus Vaccine USP Trivalent Types A and B",{"EARLY_PHASE1":20938,"PHASE1":20940,"PHASE2":20942,"PHASE3":20958,"PHASE4":20967,"NA":20969},{"trials":20939,"activeCount":102},[],{"trials":20941,"activeCount":102},[],{"trials":20943,"activeCount":102},[20944,20951],{"nctId":20945,"briefTitle":20946,"status":108,"phases":20947,"primaryCompletion":3307,"completion":8731,"start":8846,"enrollment":10798,"conditions":20948,"interventions":20950},"NCT00775450","Influenza Vaccine Revaccination in Ambulatory Elderly Subjects",[91],[16,20949,10695],"Orthomyxovirus Infection",[20936,20936,20936,20936,20936],{"nctId":20952,"briefTitle":20953,"status":108,"phases":20954,"primaryCompletion":9984,"completion":8453,"start":2799,"enrollment":20955,"conditions":20956,"interventions":20957},"NCT01011049","Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM",[91],1250,[16],[20936,20936,20936,20936],{"trials":20959,"activeCount":102},[20960],{"nctId":20961,"briefTitle":20962,"status":108,"phases":20963,"primaryCompletion":8261,"completion":8731,"start":8846,"enrollment":20964,"conditions":20965,"interventions":20966},"NCT00772109","Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults",[92],4292,[12314,16,10695],[20936,20936,20936,20936],{"trials":20968,"activeCount":102},[],{"trials":20970,"activeCount":102},[],{"intervention":20972,"totalTrials":619,"cells":20973},"SR34006 (idraparinux sodium)",{"EARLY_PHASE1":20974,"PHASE1":20976,"PHASE2":20978,"PHASE3":20980,"PHASE4":21007,"NA":21009},{"trials":20975,"activeCount":102},[],{"trials":20977,"activeCount":102},[],{"trials":20979,"activeCount":102},[],{"trials":20981,"activeCount":102},[20982,20990,21001],{"nctId":20983,"briefTitle":20984,"status":108,"phases":20985,"primaryCompletion":5307,"completion":5307,"start":9872,"enrollment":20986,"conditions":20987,"interventions":20988},"NCT00070655","Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)",[92],4673,[9562],[20972,20989],"vitamin K antagonist (warfarin or acenocoumarol)",{"nctId":20991,"briefTitle":20992,"status":108,"phases":20993,"primaryCompletion":8331,"completion":8331,"start":9592,"conditions":20994,"interventions":20996},"NCT00062803","SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism",[92],[20995],"Pulmonary Embolism",[20997,20998,20999,21000],"SR34006","(LMW)heparin","Warfarin VKA","Acenocoumarol VKA",{"nctId":21002,"briefTitle":21003,"status":108,"phases":21004,"primaryCompletion":3565,"completion":3565,"start":12198,"enrollment":2908,"conditions":21005,"interventions":21006},"NCT00071279","SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis",[92],[20995,20839],[20972],{"trials":21008,"activeCount":102},[],{"trials":21010,"activeCount":102},[],{"intervention":21012,"totalTrials":619,"cells":21013},"Dermacyd PH_DETINLYN",{"EARLY_PHASE1":21014,"PHASE1":21016,"PHASE2":21018,"PHASE3":21020,"PHASE4":21040,"NA":21042},{"trials":21015,"activeCount":102},[],{"trials":21017,"activeCount":102},[],{"trials":21019,"activeCount":102},[],{"trials":21021,"activeCount":102},[21022,21028,21034],{"nctId":21023,"briefTitle":21024,"status":108,"phases":21025,"primaryCompletion":3564,"completion":3564,"start":3417,"enrollment":703,"conditions":21026,"interventions":21027},"NCT00785590","Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.",[92],[33],[21012],{"nctId":21029,"briefTitle":21030,"status":108,"phases":21031,"primaryCompletion":3564,"completion":3564,"start":8196,"enrollment":5282,"conditions":21032,"interventions":21033},"NCT00785655","Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility",[92],[33],[21012],{"nctId":21035,"briefTitle":21036,"status":108,"phases":21037,"primaryCompletion":3564,"completion":3564,"start":8196,"enrollment":5282,"conditions":21038,"interventions":21039},"NCT00786097","Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibility",[92],[33],[21012],{"trials":21041,"activeCount":102},[],{"trials":21043,"activeCount":102},[],{"intervention":18657,"totalTrials":619,"cells":21045},{"EARLY_PHASE1":21046,"PHASE1":21048,"PHASE2":21050,"PHASE3":21052,"PHASE4":21072,"NA":21074},{"trials":21047,"activeCount":102},[],{"trials":21049,"activeCount":102},[],{"trials":21051,"activeCount":102},[],{"trials":21053,"activeCount":102},[21054,21058,21066],{"nctId":18651,"briefTitle":18652,"status":108,"phases":21055,"primaryCompletion":3563,"completion":3439,"start":3608,"enrollment":18654,"conditions":21056,"interventions":21057},[92],[18625,13810,25,28],[18657,18658,2937],{"nctId":21059,"briefTitle":21060,"status":108,"phases":21061,"primaryCompletion":8505,"completion":8196,"start":8666,"enrollment":21062,"conditions":21063,"interventions":21064},"NCT00404651","Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants",[92],1189,[25,31,28,18625,12983],[18657,18657,18657,21065],"DTaP-HBV-IPV vaccine",{"nctId":21067,"briefTitle":21068,"status":108,"phases":21069,"primaryCompletion":8196,"completion":8196,"start":7509,"enrollment":2352,"conditions":21070,"interventions":21071},"NCT00619502","Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants",[92],[25,13810,28,18625],[18657],{"trials":21073,"activeCount":102},[],{"trials":21075,"activeCount":102},[],{"intervention":21077,"totalTrials":619,"cells":21078},"DTaP-IPV-HB-PRP~T",{"EARLY_PHASE1":21079,"PHASE1":21081,"PHASE2":21083,"PHASE3":21093,"PHASE4":21112,"NA":21114},{"trials":21080,"activeCount":102},[],{"trials":21082,"activeCount":102},[],{"trials":21084,"activeCount":102},[21085],{"nctId":21086,"briefTitle":21087,"status":108,"phases":21088,"primaryCompletion":3623,"completion":5272,"start":3633,"enrollment":21089,"conditions":21090,"interventions":21091},"NCT00831311","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants",[91],624,[25,31,28,20655,12983],[21077,21092],"DTaP-IPV\u002F\u002FPRP~T combined vaccine & Recombinant hep B vaccine",{"trials":21094,"activeCount":102},[21095,21104],{"nctId":21096,"briefTitle":21097,"status":108,"phases":21098,"primaryCompletion":8316,"completion":8215,"start":5262,"enrollment":21099,"conditions":21100,"interventions":21101},"NCT00362336","Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV",[92],622,[18625,13810,25,28,20655],[21077,21102,21103],"CombAct-HIB®","Engerix B® Pediatric",{"nctId":21105,"briefTitle":21106,"status":108,"phases":21107,"primaryCompletion":8762,"completion":3439,"start":3608,"enrollment":21108,"conditions":21109,"interventions":21110},"NCT00313911","Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB\u002FHib™ and OPV Given at Age 2, 4, and 6 Months.",[92],2133,[25,31,28,20655,18625],[21077,21111],"Tritanrix-HepB\u002FHib",{"trials":21113,"activeCount":102},[],{"trials":21115,"activeCount":102},[],{"intervention":21117,"totalTrials":619,"cells":21118},"gemcitabine\u002Fcarboplatin",{"EARLY_PHASE1":21119,"PHASE1":21121,"PHASE2":21123,"PHASE3":21132,"PHASE4":21149,"NA":21151},{"trials":21120,"activeCount":102},[],{"trials":21122,"activeCount":102},[],{"trials":21124,"activeCount":102},[21125],{"nctId":21126,"briefTitle":21127,"status":108,"phases":21128,"primaryCompletion":8570,"completion":978,"start":3317,"enrollment":3356,"conditions":21129,"interventions":21130},"NCT00540358","A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer",[91],[5264],[21117,21131],"iniparib",{"trials":21133,"activeCount":102},[21134,21142],{"nctId":21135,"briefTitle":21136,"status":108,"phases":21137,"primaryCompletion":1032,"completion":1032,"start":1022,"enrollment":12611,"conditions":21138,"interventions":21140},"NCT01082549","Trial of Gemcitabine\u002FCarboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)",[92],[21139],"Squamous Cell Lung Cancer",[21117,21141],"gemcitabine\u002Fcarboplatin plus Iniparib",{"nctId":21143,"briefTitle":21144,"status":108,"phases":21145,"primaryCompletion":1339,"completion":8107,"start":8731,"enrollment":21146,"conditions":21147,"interventions":21148},"NCT00938652","A Phase 3, Multi-Center Study of Gemcitabine\u002FCarboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer",[92],519,[5264],[21117,17931],{"trials":21150,"activeCount":102},[],{"trials":21152,"activeCount":102},[],{"intervention":8637,"totalTrials":659,"cells":21154},{"EARLY_PHASE1":21155,"PHASE1":21157,"PHASE2":21159,"PHASE3":21161,"PHASE4":21171,"NA":21173},{"trials":21156,"activeCount":102},[],{"trials":21158,"activeCount":102},[],{"trials":21160,"activeCount":102},[],{"trials":21162,"activeCount":102},[21163,21167],{"nctId":10776,"briefTitle":10777,"status":108,"phases":21164,"primaryCompletion":9292,"start":5251,"enrollment":8627,"conditions":21165,"interventions":21166},[92],[8187],[8189,10781,10782,8637],{"nctId":8631,"briefTitle":8632,"status":108,"phases":21168,"primaryCompletion":8156,"start":2800,"enrollment":8634,"conditions":21169,"interventions":21170},[92],[8187],[8209,8637,8057],{"trials":21172,"activeCount":102},[],{"trials":21174,"activeCount":102},[],{"intervention":11474,"totalTrials":659,"cells":21176},{"EARLY_PHASE1":21177,"PHASE1":21179,"PHASE2":21181,"PHASE3":21183,"PHASE4":21196,"NA":21198},{"trials":21178,"activeCount":102},[],{"trials":21180,"activeCount":102},[],{"trials":21182,"activeCount":102},[],{"trials":21184,"activeCount":102},[21185,21192],{"nctId":21186,"briefTitle":21187,"status":108,"phases":21188,"primaryCompletion":3609,"completion":3609,"start":7523,"enrollment":21189,"conditions":21190,"interventions":21191},"NCT00425243","Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)",[92],1025,[11472],[11474],{"nctId":11468,"briefTitle":11469,"status":108,"phases":21193,"primaryCompletion":9826,"completion":9826,"start":9872,"enrollment":6540,"conditions":21194,"interventions":21195},[92],[11472],[11474,11475],{"trials":21197,"activeCount":102},[],{"trials":21199,"activeCount":102},[],{"intervention":21201,"totalTrials":659,"cells":21202},"Cetylpyridinium chloride",{"EARLY_PHASE1":21203,"PHASE1":21205,"PHASE2":21207,"PHASE3":21209,"PHASE4":21223,"NA":21225},{"trials":21204,"activeCount":102},[],{"trials":21206,"activeCount":102},[],{"trials":21208,"activeCount":102},[],{"trials":21210,"activeCount":102},[21211,21217],{"nctId":21212,"briefTitle":21213,"status":108,"phases":21214,"primaryCompletion":3417,"start":8196,"enrollment":8883,"conditions":21215,"interventions":21216},"NCT00729599","Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.",[92],[33],[21201],{"nctId":21218,"briefTitle":21219,"status":108,"phases":21220,"primaryCompletion":3439,"start":8762,"enrollment":3740,"conditions":21221,"interventions":21222},"NCT00687037","Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power",[92],[8839],[21201],{"trials":21224,"activeCount":102},[],{"trials":21226,"activeCount":102},[],{"intervention":3866,"totalTrials":659,"cells":21228},{"EARLY_PHASE1":21229,"PHASE1":21231,"PHASE2":21233,"PHASE3":21235,"PHASE4":21245,"NA":21247},{"trials":21230,"activeCount":102},[],{"trials":21232,"activeCount":102},[],{"trials":21234,"activeCount":102},[],{"trials":21236,"activeCount":102},[21237,21241],{"nctId":3853,"briefTitle":3854,"status":108,"phases":21238,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":21239,"interventions":21240},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":3886,"briefTitle":3887,"status":108,"phases":21242,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":21243,"interventions":21244},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":21246,"activeCount":102},[],{"trials":21248,"activeCount":102},[],{"intervention":3867,"totalTrials":659,"cells":21250},{"EARLY_PHASE1":21251,"PHASE1":21253,"PHASE2":21255,"PHASE3":21257,"PHASE4":21267,"NA":21269},{"trials":21252,"activeCount":102},[],{"trials":21254,"activeCount":102},[],{"trials":21256,"activeCount":102},[],{"trials":21258,"activeCount":102},[21259,21263],{"nctId":3853,"briefTitle":3854,"status":108,"phases":21260,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":21261,"interventions":21262},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":3886,"briefTitle":3887,"status":108,"phases":21264,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":21265,"interventions":21266},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":21268,"activeCount":102},[],{"trials":21270,"activeCount":102},[],{"intervention":3868,"totalTrials":659,"cells":21272},{"EARLY_PHASE1":21273,"PHASE1":21275,"PHASE2":21277,"PHASE3":21279,"PHASE4":21289,"NA":21291},{"trials":21274,"activeCount":102},[],{"trials":21276,"activeCount":102},[],{"trials":21278,"activeCount":102},[],{"trials":21280,"activeCount":102},[21281,21285],{"nctId":3853,"briefTitle":3854,"status":108,"phases":21282,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":21283,"interventions":21284},[92],[3842],[3862,3863,3864,3865,3866,3867,3868,3869,1801,3870,3871,3872],{"nctId":3886,"briefTitle":3887,"status":108,"phases":21286,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":284,"conditions":21287,"interventions":21288},[92],[3892],[3862,3864,3865,3868,3866,3867,3863,3869,1801,3870,3871,3872],{"trials":21290,"activeCount":102},[],{"trials":21292,"activeCount":102},[],{"intervention":21294,"totalTrials":659,"cells":21295},"ChimeriVax™-JE",{"EARLY_PHASE1":21296,"PHASE1":21298,"PHASE2":21300,"PHASE3":21309,"PHASE4":21319,"NA":21321},{"trials":21297,"activeCount":102},[],{"trials":21299,"activeCount":102},[],{"trials":21301,"activeCount":102},[21302],{"nctId":21303,"briefTitle":21304,"status":108,"phases":21305,"primaryCompletion":3821,"completion":977,"start":2800,"enrollment":6595,"conditions":21306,"interventions":21307},"NCT00441259","Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age",[91],[17265],[21294,21308],"Japanese Encephalitis Inactivated Mouse Brain Vaccine",{"trials":21310,"activeCount":102},[21311],{"nctId":21312,"briefTitle":21313,"status":108,"phases":21314,"primaryCompletion":8395,"completion":8666,"start":3623,"enrollment":21315,"conditions":21316,"interventions":21317},"NCT00314145","A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX",[92],820,[17265],[21294,21318],"JE-VAX®",{"trials":21320,"activeCount":102},[],{"trials":21322,"activeCount":102},[],{"intervention":21324,"totalTrials":659,"cells":21325},"Purified Vero Rabies Vaccine",{"EARLY_PHASE1":21326,"PHASE1":21328,"PHASE2":21330,"PHASE3":21339,"PHASE4":21349,"NA":21351},{"trials":21327,"activeCount":102},[],{"trials":21329,"activeCount":102},[],{"trials":21331,"activeCount":102},[21332],{"nctId":21333,"briefTitle":21334,"status":108,"phases":21335,"primaryCompletion":1272,"completion":14370,"start":152,"enrollment":12981,"conditions":21336,"interventions":21337},"NCT01877395","Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen",[91],[14171],[21324,21338],"Imovax® Rabies: inactivated rabies vaccine",{"trials":21340,"activeCount":102},[21341],{"nctId":21342,"briefTitle":21343,"status":108,"phases":21344,"primaryCompletion":8683,"completion":10178,"start":2790,"enrollment":21345,"conditions":21346,"interventions":21347},"NCT01339312","Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine",[92],816,[14171,20566],[21348,21348,21324,21324],"Purified inactivated rabies vaccine, serum free",{"trials":21350,"activeCount":102},[],{"trials":21352,"activeCount":102},[],{"intervention":10957,"totalTrials":659,"cells":21354},{"EARLY_PHASE1":21355,"PHASE1":21357,"PHASE2":21359,"PHASE3":21361,"PHASE4":21371,"NA":21373},{"trials":21356,"activeCount":102},[],{"trials":21358,"activeCount":102},[],{"trials":21360,"activeCount":102},[],{"trials":21362,"activeCount":102},[21363,21367],{"nctId":10952,"briefTitle":10953,"status":884,"phases":21364,"primaryCompletion":9532,"completion":9532,"start":3317,"enrollment":552,"conditions":21365,"interventions":21366},[92],[10940],[10919,10957],{"nctId":10959,"briefTitle":10960,"status":108,"phases":21368,"primaryCompletion":7509,"completion":7509,"start":7538,"enrollment":10820,"conditions":21369,"interventions":21370},[92],[10963,5421,10940],[10919,10957],{"trials":21372,"activeCount":102},[],{"trials":21374,"activeCount":102},[],{"intervention":21376,"totalTrials":659,"cells":21377},"XRP6976",{"EARLY_PHASE1":21378,"PHASE1":21380,"PHASE2":21382,"PHASE3":21384,"PHASE4":21401,"NA":21403},{"trials":21379,"activeCount":102},[],{"trials":21381,"activeCount":102},[],{"trials":21383,"activeCount":102},[],{"trials":21385,"activeCount":102},[21386,21393],{"nctId":21387,"briefTitle":21388,"status":108,"phases":21389,"primaryCompletion":8777,"completion":8777,"start":21390,"enrollment":7729,"conditions":21391,"interventions":21392},"NCT00273546","Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer",[92],"1999-05",[5421],[21376],{"nctId":21394,"briefTitle":21395,"status":108,"phases":21396,"completion":3539,"start":9256,"enrollment":21397,"conditions":21398,"interventions":21400},"NCT00290966","Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer",[91,92],610,[21399],"Stomach Neoplasm",[21376],{"trials":21402,"activeCount":102},[],{"trials":21404,"activeCount":102},[],{"intervention":21406,"totalTrials":659,"cells":21407},"SAR153191",{"EARLY_PHASE1":21408,"PHASE1":21410,"PHASE2":21418,"PHASE3":21420,"PHASE4":21431,"NA":21433},{"trials":21409,"activeCount":102},[],{"trials":21411,"activeCount":102},[21412],{"nctId":21413,"briefTitle":21414,"status":108,"phases":21415,"primaryCompletion":986,"completion":986,"start":7292,"enrollment":6313,"conditions":21416,"interventions":21417},"NCT01328522","Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients",[90],[990],[21406],{"trials":21419,"activeCount":102},[],{"trials":21421,"activeCount":102},[21422],{"nctId":21423,"briefTitle":21424,"status":108,"phases":21425,"primaryCompletion":21426,"completion":21426,"start":21427,"enrollment":21428,"conditions":21429,"interventions":21430},"NCT01146652","Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)",[92],"2020-12-31","2010-06-21",2023,[990],[21406],{"trials":21432,"activeCount":102},[],{"trials":21434,"activeCount":102},[],{"intervention":6466,"totalTrials":659,"cells":21436},{"EARLY_PHASE1":21437,"PHASE1":21439,"PHASE2":21445,"PHASE3":21447,"PHASE4":21453,"NA":21455},{"trials":21438,"activeCount":102},[],{"trials":21440,"activeCount":102},[21441],{"nctId":6461,"briefTitle":6462,"status":108,"phases":21442,"primaryCompletion":1054,"completion":1054,"start":3395,"enrollment":3740,"conditions":21443,"interventions":21444},[90],[990],[6458,6466],{"trials":21446,"activeCount":102},[],{"trials":21448,"activeCount":102},[21449],{"nctId":6490,"briefTitle":6491,"status":108,"phases":21450,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":21451,"interventions":21452},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"trials":21454,"activeCount":102},[],{"trials":21456,"activeCount":102},[],{"intervention":230,"totalTrials":659,"cells":21458},{"EARLY_PHASE1":21459,"PHASE1":21461,"PHASE2":21463,"PHASE3":21465,"PHASE4":21475,"NA":21477},{"trials":21460,"activeCount":102},[],{"trials":21462,"activeCount":102},[],{"trials":21464,"activeCount":102},[],{"trials":21466,"activeCount":102},[21467,21471],{"nctId":221,"briefTitle":222,"status":108,"phases":21468,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":21469,"interventions":21470},[92],[155],[97,230,231,232],{"nctId":243,"briefTitle":244,"status":108,"phases":21472,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":21473,"interventions":21474},[92],[155],[97,252,230,231,232],{"trials":21476,"activeCount":102},[],{"trials":21478,"activeCount":102},[],{"intervention":231,"totalTrials":659,"cells":21480},{"EARLY_PHASE1":21481,"PHASE1":21483,"PHASE2":21485,"PHASE3":21487,"PHASE4":21497,"NA":21499},{"trials":21482,"activeCount":102},[],{"trials":21484,"activeCount":102},[],{"trials":21486,"activeCount":102},[],{"trials":21488,"activeCount":102},[21489,21493],{"nctId":221,"briefTitle":222,"status":108,"phases":21490,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":21491,"interventions":21492},[92],[155],[97,230,231,232],{"nctId":243,"briefTitle":244,"status":108,"phases":21494,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":21495,"interventions":21496},[92],[155],[97,252,230,231,232],{"trials":21498,"activeCount":102},[],{"trials":21500,"activeCount":102},[],{"intervention":232,"totalTrials":659,"cells":21502},{"EARLY_PHASE1":21503,"PHASE1":21505,"PHASE2":21507,"PHASE3":21509,"PHASE4":21519,"NA":21521},{"trials":21504,"activeCount":102},[],{"trials":21506,"activeCount":102},[],{"trials":21508,"activeCount":102},[],{"trials":21510,"activeCount":102},[21511,21515],{"nctId":221,"briefTitle":222,"status":108,"phases":21512,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":21513,"interventions":21514},[92],[155],[97,230,231,232],{"nctId":243,"briefTitle":244,"status":108,"phases":21516,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":21517,"interventions":21518},[92],[155],[97,252,230,231,232],{"trials":21520,"activeCount":102},[],{"trials":21522,"activeCount":102},[],{"intervention":21524,"totalTrials":659,"cells":21525},"Granulocyte-colony stimulating factor",{"EARLY_PHASE1":21526,"PHASE1":21528,"PHASE2":21530,"PHASE3":21539,"PHASE4":21548,"NA":21550},{"trials":21527,"activeCount":102},[],{"trials":21529,"activeCount":102},[],{"trials":21531,"activeCount":102},[21532],{"nctId":21533,"briefTitle":21534,"status":108,"phases":21535,"primaryCompletion":15982,"completion":15982,"start":152,"enrollment":1400,"conditions":21536,"interventions":21537},"NCT01753453","An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells",[91],[1147],[21538,21524],"Plerixafor",{"trials":21540,"activeCount":102},[21541],{"nctId":21542,"briefTitle":21543,"status":108,"phases":21544,"primaryCompletion":150,"completion":150,"start":1032,"enrollment":465,"conditions":21545,"interventions":21547},"NCT01767714","Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells\u002Fkg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation",[92],[21546],"Non-Hodgkin's Lymphoma",[21524,21538],{"trials":21549,"activeCount":102},[],{"trials":21551,"activeCount":102},[],{"intervention":21538,"totalTrials":659,"cells":21553},{"EARLY_PHASE1":21554,"PHASE1":21556,"PHASE2":21558,"PHASE3":21564,"PHASE4":21570,"NA":21572},{"trials":21555,"activeCount":102},[],{"trials":21557,"activeCount":102},[],{"trials":21559,"activeCount":102},[21560],{"nctId":21533,"briefTitle":21534,"status":108,"phases":21561,"primaryCompletion":15982,"completion":15982,"start":152,"enrollment":1400,"conditions":21562,"interventions":21563},[91],[1147],[21538,21524],{"trials":21565,"activeCount":102},[21566],{"nctId":21542,"briefTitle":21543,"status":108,"phases":21567,"primaryCompletion":150,"completion":150,"start":1032,"enrollment":465,"conditions":21568,"interventions":21569},[92],[21546],[21524,21538],{"trials":21571,"activeCount":102},[],{"trials":21573,"activeCount":102},[],{"intervention":2939,"totalTrials":659,"cells":21575},{"EARLY_PHASE1":21576,"PHASE1":21578,"PHASE2":21580,"PHASE3":21582,"PHASE4":21600,"NA":21602},{"trials":21577,"activeCount":102},[],{"trials":21579,"activeCount":102},[],{"trials":21581,"activeCount":102},[],{"trials":21583,"activeCount":102},[21584,21588],{"nctId":2925,"briefTitle":2926,"status":108,"phases":21585,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":21586,"interventions":21587},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"nctId":21589,"briefTitle":21590,"status":108,"phases":21591,"primaryCompletion":21592,"completion":21593,"start":21594,"enrollment":21595,"conditions":21596,"interventions":21597},"NCT01190228","Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV",[92],"2010-10-29","2015-10-12","2010-08-25",454,[17265,2978],[21598,21599],"JE-CV Vaccine","Varicella Vaccine",{"trials":21601,"activeCount":102},[],{"trials":21603,"activeCount":102},[],{"intervention":9546,"totalTrials":659,"cells":21605},{"EARLY_PHASE1":21606,"PHASE1":21608,"PHASE2":21610,"PHASE3":21612,"PHASE4":21622,"NA":21624},{"trials":21607,"activeCount":102},[],{"trials":21609,"activeCount":102},[],{"trials":21611,"activeCount":102},[],{"trials":21613,"activeCount":102},[21614,21618],{"nctId":9538,"briefTitle":9539,"status":108,"phases":21615,"primaryCompletion":5271,"completion":5271,"start":8205,"enrollment":9541,"conditions":21616,"interventions":21617},[92],[9543,9544],[9479,9546],{"nctId":9615,"briefTitle":9616,"status":108,"phases":21619,"primaryCompletion":7292,"completion":7292,"start":8315,"enrollment":9618,"conditions":21620,"interventions":21621},[92],[9620],[9479,9546],{"trials":21623,"activeCount":102},[],{"trials":21625,"activeCount":102},[],{"intervention":18966,"totalTrials":659,"cells":21627},{"EARLY_PHASE1":21628,"PHASE1":21630,"PHASE2":21632,"PHASE3":21638,"PHASE4":21644,"NA":21646},{"trials":21629,"activeCount":102},[],{"trials":21631,"activeCount":102},[],{"trials":21633,"activeCount":102},[21634],{"nctId":18954,"briefTitle":18955,"status":884,"phases":21635,"primaryCompletion":322,"completion":18957,"start":18958,"enrollment":18959,"conditions":21636,"interventions":21637},[91],[18340],[18919,18962,18963,18964,18965,18966],{"trials":21639,"activeCount":102},[21640],{"nctId":18990,"briefTitle":18991,"status":884,"phases":21641,"primaryCompletion":18993,"completion":18993,"start":18994,"enrollment":619,"conditions":21642,"interventions":21643},[92],[5264],[18919,18966],{"trials":21645,"activeCount":102},[],{"trials":21647,"activeCount":102},[],{"intervention":21649,"totalTrials":659,"cells":21650},"Dermacyd PH_DETINBACK",{"EARLY_PHASE1":21651,"PHASE1":21653,"PHASE2":21655,"PHASE3":21657,"PHASE4":21671,"NA":21673},{"trials":21652,"activeCount":102},[],{"trials":21654,"activeCount":102},[],{"trials":21656,"activeCount":102},[],{"trials":21658,"activeCount":102},[21659,21665],{"nctId":21660,"briefTitle":21661,"status":108,"phases":21662,"primaryCompletion":3564,"completion":3564,"start":8196,"enrollment":5282,"conditions":21663,"interventions":21664},"NCT00785681","Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Compatibility",[92],[33],[21649],{"nctId":21666,"briefTitle":21667,"status":108,"phases":21668,"primaryCompletion":3564,"completion":3564,"start":3417,"enrollment":703,"conditions":21669,"interventions":21670},"NCT00785720","Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Photo Avaluation",[92],[33],[21649],{"trials":21672,"activeCount":102},[],{"trials":21674,"activeCount":102},[],{"intervention":21676,"totalTrials":659,"cells":21677},"Live, attenuated, dengue serotype 1, 2, 3, 4 virus",{"EARLY_PHASE1":21678,"PHASE1":21680,"PHASE2":21682,"PHASE3":21684,"PHASE4":21704,"NA":21706},{"trials":21679,"activeCount":102},[],{"trials":21681,"activeCount":102},[],{"trials":21683,"activeCount":102},[],{"trials":21685,"activeCount":102},[21686,21696],{"nctId":21687,"briefTitle":21688,"status":108,"phases":21689,"primaryCompletion":21690,"completion":21691,"start":21692,"enrollment":21693,"conditions":21694,"interventions":21695},"NCT01373281","Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia",[92],"2014-08-01","2017-11-21","2011-06-03",10275,[2316,18210,2317],[21676],{"nctId":21697,"briefTitle":21698,"status":108,"phases":21699,"primaryCompletion":150,"completion":1078,"start":21700,"enrollment":21701,"conditions":21702,"interventions":21703},"NCT01374516","Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America",[92],"2011-06-08",20869,[18210,2317,2316],[21676],{"trials":21705,"activeCount":102},[],{"trials":21707,"activeCount":102},[],{"intervention":8151,"totalTrials":659,"cells":21709},{"EARLY_PHASE1":21710,"PHASE1":21712,"PHASE2":21714,"PHASE3":21716,"PHASE4":21726,"NA":21728},{"trials":21711,"activeCount":102},[],{"trials":21713,"activeCount":102},[],{"trials":21715,"activeCount":102},[],{"trials":21717,"activeCount":102},[21718,21722],{"nctId":8144,"briefTitle":8145,"status":108,"phases":21719,"primaryCompletion":5044,"completion":5044,"start":8147,"enrollment":8148,"conditions":21720,"interventions":21721},[92],[19],[8128,8151,8024],{"nctId":10649,"briefTitle":10650,"status":108,"phases":21723,"primaryCompletion":3738,"completion":3738,"start":10652,"enrollment":249,"conditions":21724,"interventions":21725},[92],[554],[10655,10611,8151],{"trials":21727,"activeCount":102},[],{"trials":21729,"activeCount":102},[],{"intervention":5036,"totalTrials":659,"cells":21731},{"EARLY_PHASE1":21732,"PHASE1":21734,"PHASE2":21736,"PHASE3":21738,"PHASE4":21748,"NA":21750},{"trials":21733,"activeCount":102},[],{"trials":21735,"activeCount":102},[],{"trials":21737,"activeCount":102},[],{"trials":21739,"activeCount":102},[21740,21744],{"nctId":5027,"briefTitle":5028,"status":108,"phases":21741,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":21742,"interventions":21743},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"nctId":13500,"briefTitle":13501,"status":108,"phases":21745,"primaryCompletion":8298,"completion":152,"start":2857,"enrollment":1091,"conditions":21746,"interventions":21747},[92],[4992,13504],[5036,13489],{"trials":21749,"activeCount":102},[],{"trials":21751,"activeCount":102},[],{"intervention":5039,"totalTrials":659,"cells":21753},{"EARLY_PHASE1":21754,"PHASE1":21756,"PHASE2":21758,"PHASE3":21760,"PHASE4":21770,"NA":21772},{"trials":21755,"activeCount":102},[],{"trials":21757,"activeCount":102},[],{"trials":21759,"activeCount":102},[],{"trials":21761,"activeCount":102},[21762,21766],{"nctId":5027,"briefTitle":5028,"status":108,"phases":21763,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":21764,"interventions":21765},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"nctId":5081,"briefTitle":5082,"status":884,"phases":21767,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":21768,"interventions":21769},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"trials":21771,"activeCount":102},[],{"trials":21773,"activeCount":102},[],{"intervention":21775,"totalTrials":659,"cells":21776},"C. difficile toxoid vaccine",{"EARLY_PHASE1":21777,"PHASE1":21779,"PHASE2":21789,"PHASE3":21791,"PHASE4":21804,"NA":21806},{"trials":21778,"activeCount":102},[],{"trials":21780,"activeCount":102},[21781],{"nctId":21782,"briefTitle":21783,"status":108,"phases":21784,"primaryCompletion":8777,"completion":8777,"start":3623,"enrollment":391,"conditions":21785,"interventions":21787},"NCT00214461","Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers",[90],[21786],"Clostridium Infections",[21788,21775,21775,21775],"Vaccine diluent buffer",{"trials":21790,"activeCount":102},[],{"trials":21792,"activeCount":102},[21793],{"nctId":21794,"briefTitle":21795,"status":884,"phases":21796,"primaryCompletion":21797,"completion":21797,"start":21798,"enrollment":21799,"conditions":21800,"interventions":21802},"NCT01887912","Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",[92],"2018-06-12","2013-07-30",9302,[21801],"Clostridium Difficile Infection",[21803],"C. difficile Toxoid Vaccine",{"trials":21805,"activeCount":102},[],{"trials":21807,"activeCount":102},[],{"intervention":19902,"totalTrials":659,"cells":21809},{"EARLY_PHASE1":21810,"PHASE1":21812,"PHASE2":21814,"PHASE3":21820,"PHASE4":21826,"NA":21828},{"trials":21811,"activeCount":102},[],{"trials":21813,"activeCount":102},[],{"trials":21815,"activeCount":102},[21816],{"nctId":19885,"briefTitle":19886,"status":108,"phases":21817,"primaryCompletion":3821,"completion":5306,"start":8731,"enrollment":8378,"conditions":21818,"interventions":21819},[91],[14171],[19890,19876],{"trials":21821,"activeCount":102},[21822],{"nctId":19894,"briefTitle":19895,"status":108,"phases":21823,"primaryCompletion":19897,"completion":19897,"start":19898,"enrollment":11463,"conditions":21824,"interventions":21825},[92],[19900],[19902,19876,19903],{"trials":21827,"activeCount":102},[],{"trials":21829,"activeCount":102},[],{"intervention":8160,"totalTrials":659,"cells":21831},{"EARLY_PHASE1":21832,"PHASE1":21834,"PHASE2":21836,"PHASE3":21838,"PHASE4":21848,"NA":21850},{"trials":21833,"activeCount":102},[],{"trials":21835,"activeCount":102},[],{"trials":21837,"activeCount":102},[],{"trials":21839,"activeCount":102},[21840,21844],{"nctId":8153,"briefTitle":8154,"status":108,"phases":21841,"primaryCompletion":987,"completion":987,"start":8156,"enrollment":8157,"conditions":21842,"interventions":21843},[92],[22],[8046,8160,8024],{"nctId":11857,"briefTitle":11858,"status":108,"phases":21845,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":21846,"interventions":21847},[92],[19],[11866,11867,11868,11869,11870,11871,11872],{"trials":21849,"activeCount":102},[],{"trials":21851,"activeCount":102},[],{"intervention":20639,"totalTrials":659,"cells":21853},{"EARLY_PHASE1":21854,"PHASE1":21856,"PHASE2":21858,"PHASE3":21860,"PHASE4":21870,"NA":21872},{"trials":21855,"activeCount":102},[],{"trials":21857,"activeCount":102},[],{"trials":21859,"activeCount":102},[],{"trials":21861,"activeCount":102},[21862,21866],{"nctId":20632,"briefTitle":20633,"status":108,"phases":21863,"primaryCompletion":8205,"completion":3396,"start":1341,"enrollment":20635,"conditions":21864,"interventions":21865},[92],[25,31,28,18625,16],[20638,20639,20621],{"nctId":20650,"briefTitle":20651,"status":108,"phases":21867,"primaryCompletion":3564,"completion":8349,"start":1341,"enrollment":20653,"conditions":21868,"interventions":21869},[92],[25,31,28,18625,20655],[20639,20657,20621],{"trials":21871,"activeCount":102},[],{"trials":21873,"activeCount":102},[],{"intervention":3919,"totalTrials":659,"cells":21875},{"EARLY_PHASE1":21876,"PHASE1":21878,"PHASE2":21880,"PHASE3":21882,"PHASE4":21892,"NA":21894},{"trials":21877,"activeCount":102},[],{"trials":21879,"activeCount":102},[],{"trials":21881,"activeCount":102},[],{"trials":21883,"activeCount":102},[21884,21888],{"nctId":3909,"briefTitle":3910,"status":108,"phases":21885,"primaryCompletion":3912,"completion":3913,"start":3914,"enrollment":3915,"conditions":21886,"interventions":21887},[92],[3917],[2064,3919,3920,1501],{"nctId":3926,"briefTitle":3927,"status":108,"phases":21889,"primaryCompletion":3929,"completion":3930,"start":3931,"enrollment":1809,"conditions":21890,"interventions":21891},[92],[3917],[2064,3919,3920,1501],{"trials":21893,"activeCount":102},[],{"trials":21895,"activeCount":102},[],{"intervention":3920,"totalTrials":659,"cells":21897},{"EARLY_PHASE1":21898,"PHASE1":21900,"PHASE2":21902,"PHASE3":21904,"PHASE4":21914,"NA":21916},{"trials":21899,"activeCount":102},[],{"trials":21901,"activeCount":102},[],{"trials":21903,"activeCount":102},[],{"trials":21905,"activeCount":102},[21906,21910],{"nctId":3909,"briefTitle":3910,"status":108,"phases":21907,"primaryCompletion":3912,"completion":3913,"start":3914,"enrollment":3915,"conditions":21908,"interventions":21909},[92],[3917],[2064,3919,3920,1501],{"nctId":3926,"briefTitle":3927,"status":108,"phases":21911,"primaryCompletion":3929,"completion":3930,"start":3931,"enrollment":1809,"conditions":21912,"interventions":21913},[92],[3917],[2064,3919,3920,1501],{"trials":21915,"activeCount":102},[],{"trials":21917,"activeCount":102},[],{"intervention":9839,"totalTrials":659,"cells":21919},{"EARLY_PHASE1":21920,"PHASE1":21922,"PHASE2":21924,"PHASE3":21926,"PHASE4":21936,"NA":21938},{"trials":21921,"activeCount":102},[],{"trials":21923,"activeCount":102},[],{"trials":21925,"activeCount":102},[],{"trials":21927,"activeCount":102},[21928,21932],{"nctId":9831,"briefTitle":9832,"status":884,"phases":21929,"primaryCompletion":5262,"completion":5262,"start":5307,"enrollment":9834,"conditions":21930,"interventions":21931},[92],[9836,9837],[3615,9839],{"nctId":9847,"briefTitle":9848,"status":884,"phases":21933,"primaryCompletion":3622,"completion":3622,"start":8777,"enrollment":7399,"conditions":21934,"interventions":21935},[92],[9836,9837],[3615,9839],{"trials":21937,"activeCount":102},[],{"trials":21939,"activeCount":102},[],{"intervention":21941,"totalTrials":659,"cells":21942},"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®",{"EARLY_PHASE1":21943,"PHASE1":21945,"PHASE2":21947,"PHASE3":21956,"PHASE4":21965,"NA":21967},{"trials":21944,"activeCount":102},[],{"trials":21946,"activeCount":102},[],{"trials":21948,"activeCount":102},[21949],{"nctId":21950,"briefTitle":21951,"status":108,"phases":21952,"primaryCompletion":2834,"completion":3438,"start":986,"enrollment":21953,"conditions":21954,"interventions":21955},"NCT01442675","Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine",[91],834,[4992,2949],[21941],{"trials":21957,"activeCount":102},[21958],{"nctId":21959,"briefTitle":21960,"status":108,"phases":21961,"primaryCompletion":2857,"completion":7284,"start":7292,"enrollment":3356,"conditions":21962,"interventions":21963},"NCT01359449","Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations",[92],[4992,2949],[21941,21964],"Meningococcal Group C Conjugate vaccine: MenC",{"trials":21966,"activeCount":102},[],{"trials":21968,"activeCount":102},[],{"intervention":20732,"totalTrials":659,"cells":21970},{"EARLY_PHASE1":21971,"PHASE1":21973,"PHASE2":21975,"PHASE3":21981,"PHASE4":21992,"NA":21994},{"trials":21972,"activeCount":102},[],{"trials":21974,"activeCount":102},[],{"trials":21976,"activeCount":102},[21977],{"nctId":20724,"briefTitle":20725,"status":108,"phases":21978,"primaryCompletion":7292,"completion":7292,"start":2799,"enrollment":7146,"conditions":21979,"interventions":21980},[91],[20728,20729],[20731,20732],{"trials":21982,"activeCount":102},[21983],{"nctId":21984,"briefTitle":21985,"status":108,"phases":21986,"primaryCompletion":8846,"completion":8846,"start":10320,"enrollment":21987,"conditions":21988,"interventions":21989},"NCT00489736","Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation",[92],504,[9562],[21990,21991],"dronedarone","amiodarone",{"trials":21993,"activeCount":102},[],{"trials":21995,"activeCount":102},[],{"intervention":18295,"totalTrials":659,"cells":21997},{"EARLY_PHASE1":21998,"PHASE1":22000,"PHASE2":22002,"PHASE3":22004,"PHASE4":22017,"NA":22019},{"trials":21999,"activeCount":102},[],{"trials":22001,"activeCount":102},[],{"trials":22003,"activeCount":102},[],{"trials":22005,"activeCount":102},[22006,22010],{"nctId":18289,"briefTitle":18290,"status":884,"phases":22007,"primaryCompletion":16519,"completion":16519,"start":7629,"enrollment":18292,"conditions":22008,"interventions":22009},[92],[18210,2317],[18194,18295,18296],{"nctId":22011,"briefTitle":22012,"status":108,"phases":22013,"primaryCompletion":14370,"completion":1011,"start":1055,"enrollment":3386,"conditions":22014,"interventions":22015},"NCT02089347","Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old",[92],[31,25,28],[18296,22016],"Diphtheria and Tetanus toxoids adsorbed",{"trials":22018,"activeCount":102},[],{"trials":22020,"activeCount":102},[],{"intervention":9369,"totalTrials":659,"cells":22022},{"EARLY_PHASE1":22023,"PHASE1":22025,"PHASE2":22027,"PHASE3":22029,"PHASE4":22039,"NA":22041},{"trials":22024,"activeCount":102},[],{"trials":22026,"activeCount":102},[],{"trials":22028,"activeCount":102},[],{"trials":22030,"activeCount":102},[22031,22035],{"nctId":9362,"briefTitle":9363,"status":108,"phases":22032,"primaryCompletion":2825,"completion":2825,"start":9365,"enrollment":9366,"conditions":22033,"interventions":22034},[92],[19],[8128,8046,9369],{"nctId":10572,"briefTitle":10573,"status":108,"phases":22036,"primaryCompletion":189,"completion":189,"start":10575,"enrollment":10576,"conditions":22037,"interventions":22038},[92],[19],[8284,8067,9369],{"trials":22040,"activeCount":102},[],{"trials":22042,"activeCount":102},[],{"intervention":2963,"totalTrials":659,"cells":22044},{"EARLY_PHASE1":22045,"PHASE1":22047,"PHASE2":22049,"PHASE3":22051,"PHASE4":22061,"NA":22063},{"trials":22046,"activeCount":102},[],{"trials":22048,"activeCount":102},[],{"trials":22050,"activeCount":102},[],{"trials":22052,"activeCount":102},[22053,22057],{"nctId":2954,"briefTitle":2955,"status":108,"phases":22054,"primaryCompletion":2957,"completion":2958,"start":2959,"enrollment":2960,"conditions":22055,"interventions":22056},[92],[2922],[2879,2963,2964,2965,2965,2966],{"nctId":13216,"briefTitle":13217,"status":108,"phases":22058,"primaryCompletion":2661,"completion":2661,"start":13219,"enrollment":8738,"conditions":22059,"interventions":22060},[92],[2910,36],[13222,2963,13223,13205],{"trials":22062,"activeCount":102},[],{"trials":22064,"activeCount":102},[],{"intervention":7139,"totalTrials":659,"cells":22066},{"EARLY_PHASE1":22067,"PHASE1":22069,"PHASE2":22071,"PHASE3":22073,"PHASE4":22083,"NA":22085},{"trials":22068,"activeCount":102},[],{"trials":22070,"activeCount":102},[],{"trials":22072,"activeCount":102},[],{"trials":22074,"activeCount":102},[22075,22079],{"nctId":7130,"briefTitle":7131,"status":108,"phases":22076,"primaryCompletion":7133,"completion":7134,"start":7135,"enrollment":3451,"conditions":22077,"interventions":22078},[92],[7137],[2064,7139],{"nctId":7162,"briefTitle":7163,"status":108,"phases":22080,"primaryCompletion":7165,"completion":1368,"start":7166,"enrollment":7167,"conditions":22081,"interventions":22082},[92],[337],[2064,7170],{"trials":22084,"activeCount":102},[],{"trials":22086,"activeCount":102},[],{"intervention":5155,"totalTrials":659,"cells":22088},{"EARLY_PHASE1":22089,"PHASE1":22091,"PHASE2":22093,"PHASE3":22095,"PHASE4":22113,"NA":22115},{"trials":22090,"activeCount":102},[],{"trials":22092,"activeCount":102},[],{"trials":22094,"activeCount":102},[],{"trials":22096,"activeCount":102},[22097,22101],{"nctId":5147,"briefTitle":5148,"status":108,"phases":22098,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":5152,"conditions":22099,"interventions":22100},[92],[2932],[5155,2897,5156,5157,5158],{"nctId":22102,"briefTitle":22103,"status":108,"phases":22104,"primaryCompletion":22105,"completion":22105,"start":22106,"enrollment":22107,"conditions":22108,"interventions":22109},"NCT04143061","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa",[92],"2023-01-28","2019-12-30",1328,[2894,36],[22110,22111,22112],"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine","Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine","Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine",{"trials":22114,"activeCount":102},[],{"trials":22116,"activeCount":102},[],{"intervention":9223,"totalTrials":659,"cells":22118},{"EARLY_PHASE1":22119,"PHASE1":22121,"PHASE2":22123,"PHASE3":22134,"PHASE4":22140,"NA":22142},{"trials":22120,"activeCount":102},[],{"trials":22122,"activeCount":102},[],{"trials":22124,"activeCount":102},[22125],{"nctId":22126,"briefTitle":22127,"status":884,"phases":22128,"primaryCompletion":8570,"completion":8570,"start":8235,"enrollment":858,"conditions":22129,"interventions":22131},"NCT00791544","Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma",[90,91],[22130],"Liver Carcinoma",[22132,9223,22133],"AVE1642","erlotinib",{"trials":22135,"activeCount":102},[22136],{"nctId":9216,"briefTitle":9217,"status":3661,"phases":22137,"primaryCompletion":8166,"completion":2759,"start":8406,"enrollment":102,"conditions":22138,"interventions":22139},[92],[9220],[5256,9222,9223],{"trials":22141,"activeCount":102},[],{"trials":22143,"activeCount":102},[],{"intervention":22145,"totalTrials":659,"cells":22146},"Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus",{"EARLY_PHASE1":22147,"PHASE1":22149,"PHASE2":22151,"PHASE3":22161,"PHASE4":22171,"NA":22173},{"trials":22148,"activeCount":102},[],{"trials":22150,"activeCount":102},[],{"trials":22152,"activeCount":102},[22153],{"nctId":22154,"briefTitle":22155,"status":108,"phases":22156,"primaryCompletion":22157,"completion":22157,"start":22158,"enrollment":8620,"conditions":22159,"interventions":22160},"NCT01488890","Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine",[91],"2013-09-27","2011-12-06",[2316,18210,2317,2296],[22145,22145,22145,2296],{"trials":22162,"activeCount":102},[22163],{"nctId":22164,"briefTitle":22165,"status":108,"phases":22166,"primaryCompletion":22167,"completion":8298,"start":22168,"enrollment":8627,"conditions":22169,"interventions":22170},"NCT01254422","Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia",[92],"2012-09-28","2010-12-02",[18210,2317],[22145],{"trials":22172,"activeCount":102},[],{"trials":22174,"activeCount":102},[],{"intervention":8170,"totalTrials":659,"cells":22176},{"EARLY_PHASE1":22177,"PHASE1":22179,"PHASE2":22181,"PHASE3":22183,"PHASE4":22193,"NA":22195},{"trials":22178,"activeCount":102},[],{"trials":22180,"activeCount":102},[],{"trials":22182,"activeCount":102},[],{"trials":22184,"activeCount":102},[22185,22189],{"nctId":8162,"briefTitle":8163,"status":108,"phases":22186,"primaryCompletion":8165,"completion":8165,"start":8166,"enrollment":8167,"conditions":22187,"interventions":22188},[92],[830],[8170,8067,8046,8024],{"nctId":11857,"briefTitle":11858,"status":108,"phases":22190,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":22191,"interventions":22192},[92],[19],[11866,11867,11868,11869,11870,11871,11872],{"trials":22194,"activeCount":102},[],{"trials":22196,"activeCount":102},[],{"intervention":8191,"totalTrials":659,"cells":22198},{"EARLY_PHASE1":22199,"PHASE1":22201,"PHASE2":22203,"PHASE3":22205,"PHASE4":22215,"NA":22217},{"trials":22200,"activeCount":102},[],{"trials":22202,"activeCount":102},[],{"trials":22204,"activeCount":102},[],{"trials":22206,"activeCount":102},[22207,22211],{"nctId":8181,"briefTitle":8182,"status":108,"phases":22208,"primaryCompletion":8175,"completion":8184,"start":8185,"enrollment":6655,"conditions":22209,"interventions":22210},[92],[8187],[8189,8024,8190,8191],{"nctId":8240,"briefTitle":8241,"status":108,"phases":22212,"primaryCompletion":5306,"completion":5306,"start":3354,"enrollment":8243,"conditions":22213,"interventions":22214},[92],[19],[8046,8067,8024,8191],{"trials":22216,"activeCount":102},[],{"trials":22218,"activeCount":102},[],{"intervention":20918,"totalTrials":659,"cells":22220},{"EARLY_PHASE1":22221,"PHASE1":22223,"PHASE2":22225,"PHASE3":22231,"PHASE4":22237,"NA":22239},{"trials":22222,"activeCount":102},[],{"trials":22224,"activeCount":102},[],{"trials":22226,"activeCount":102},[22227],{"nctId":9675,"briefTitle":9676,"status":108,"phases":22228,"primaryCompletion":8745,"completion":8745,"start":8731,"enrollment":9678,"conditions":22229,"interventions":22230},[91],[9680],[9682,9683,9684],{"trials":22232,"activeCount":102},[22233],{"nctId":20912,"briefTitle":20913,"status":108,"phases":22234,"primaryCompletion":5271,"completion":5271,"start":8731,"enrollment":20915,"conditions":22235,"interventions":22236},[92],[9680],[9725,20918],{"trials":22238,"activeCount":102},[],{"trials":22240,"activeCount":102},[],{"intervention":5053,"totalTrials":659,"cells":22242},{"EARLY_PHASE1":22243,"PHASE1":22245,"PHASE2":22247,"PHASE3":22253,"PHASE4":22259,"NA":22261},{"trials":22244,"activeCount":102},[],{"trials":22246,"activeCount":102},[],{"trials":22248,"activeCount":102},[22249],{"nctId":12777,"briefTitle":12778,"status":108,"phases":22250,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":22251,"interventions":22252},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":22254,"activeCount":102},[22255],{"nctId":5041,"briefTitle":5042,"status":108,"phases":22256,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":22257,"interventions":22258},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":22260,"activeCount":102},[],{"trials":22262,"activeCount":102},[],{"intervention":20048,"totalTrials":659,"cells":22264},{"EARLY_PHASE1":22265,"PHASE1":22267,"PHASE2":22269,"PHASE3":22275,"PHASE4":22281,"NA":22283},{"trials":22266,"activeCount":102},[],{"trials":22268,"activeCount":102},[],{"trials":22270,"activeCount":102},[22271],{"nctId":20029,"briefTitle":20030,"status":108,"phases":22272,"primaryCompletion":8846,"completion":8349,"start":8395,"enrollment":20032,"conditions":22273,"interventions":22274},[91],[20034],[20004,20036,20037],{"trials":22276,"activeCount":102},[22277],{"nctId":20041,"briefTitle":20042,"status":108,"phases":22278,"primaryCompletion":8106,"completion":8106,"start":3316,"enrollment":20044,"conditions":22279,"interventions":22280},[92],[9440],[20004,20047,20048],{"trials":22282,"activeCount":102},[],{"trials":22284,"activeCount":102},[],{"intervention":20989,"totalTrials":659,"cells":22286},{"EARLY_PHASE1":22287,"PHASE1":22289,"PHASE2":22291,"PHASE3":22293,"PHASE4":22303,"NA":22305},{"trials":22288,"activeCount":102},[],{"trials":22290,"activeCount":102},[],{"trials":22292,"activeCount":102},[],{"trials":22294,"activeCount":102},[22295,22299],{"nctId":20983,"briefTitle":20984,"status":108,"phases":22296,"primaryCompletion":5307,"completion":5307,"start":9872,"enrollment":20986,"conditions":22297,"interventions":22298},[92],[9562],[20972,20989],{"nctId":20834,"briefTitle":20835,"status":108,"phases":22300,"primaryCompletion":9559,"completion":9559,"start":3539,"enrollment":20837,"conditions":22301,"interventions":22302},[92],[20839],[20841,20842,20843,20844],{"trials":22304,"activeCount":102},[],{"trials":22306,"activeCount":102},[],{"intervention":22308,"totalTrials":659,"cells":22309},"Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib",{"EARLY_PHASE1":22310,"PHASE1":22312,"PHASE2":22314,"PHASE3":22316,"PHASE4":22332,"NA":22334},{"trials":22311,"activeCount":102},[],{"trials":22313,"activeCount":102},[],{"trials":22315,"activeCount":102},[],{"trials":22317,"activeCount":102},[22318,22325],{"nctId":22319,"briefTitle":22320,"status":108,"phases":22321,"primaryCompletion":8205,"completion":9532,"start":5272,"enrollment":2314,"conditions":22322,"interventions":22323},"NCT00453570","Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months",[92],[25,31,20655,28,12983],[22308,22308,22324],"Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed",{"nctId":22326,"briefTitle":22327,"status":108,"phases":22328,"primaryCompletion":8316,"completion":8745,"start":8331,"enrollment":22329,"conditions":22330,"interventions":22331},"NCT00254969","Immunogenicity and Safety of Pentaxim in South African Infants",[92],212,[25,31,17157,28,12983],[22308],{"trials":22333,"activeCount":102},[],{"trials":22335,"activeCount":102},[],{"intervention":5169,"totalTrials":659,"cells":22337},{"EARLY_PHASE1":22338,"PHASE1":22340,"PHASE2":22346,"PHASE3":22348,"PHASE4":22354,"NA":22356},{"trials":22339,"activeCount":102},[],{"trials":22341,"activeCount":102},[22342],{"nctId":5122,"briefTitle":5123,"status":884,"phases":22343,"primaryCompletion":5125,"completion":5125,"start":5126,"enrollment":5127,"conditions":22344,"interventions":22345},[90],[2910,36],[5130,5131,5132,5133],{"trials":22347,"activeCount":102},[],{"trials":22349,"activeCount":102},[22350],{"nctId":5160,"briefTitle":5161,"status":108,"phases":22351,"primaryCompletion":5163,"completion":5163,"start":5164,"enrollment":5165,"conditions":22352,"interventions":22353},[92],[5167],[5169,5170,2897],{"trials":22355,"activeCount":102},[],{"trials":22357,"activeCount":102},[],{"intervention":22111,"totalTrials":659,"cells":22359},{"EARLY_PHASE1":22360,"PHASE1":22362,"PHASE2":22364,"PHASE3":22366,"PHASE4":22376,"NA":22378},{"trials":22361,"activeCount":102},[],{"trials":22363,"activeCount":102},[],{"trials":22365,"activeCount":102},[],{"trials":22367,"activeCount":102},[22368,22372],{"nctId":22102,"briefTitle":22103,"status":108,"phases":22369,"primaryCompletion":22105,"completion":22105,"start":22106,"enrollment":22107,"conditions":22370,"interventions":22371},[92],[2894,36],[22110,22111,22112],{"nctId":5041,"briefTitle":5042,"status":108,"phases":22373,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":22374,"interventions":22375},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":22377,"activeCount":102},[],{"trials":22379,"activeCount":102},[],{"intervention":22381,"totalTrials":659,"cells":22382},"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap",{"EARLY_PHASE1":22383,"PHASE1":22385,"PHASE2":22393,"PHASE3":22395,"PHASE4":22406,"NA":22408},{"trials":22384,"activeCount":102},[],{"trials":22386,"activeCount":102},[22387],{"nctId":22388,"briefTitle":22389,"status":108,"phases":22390,"primaryCompletion":10811,"completion":2855,"start":177,"enrollment":98,"conditions":22391,"interventions":22392},"NCT01933776","Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China",[90],[25,31,28],[22381,22381],{"trials":22394,"activeCount":102},[],{"trials":22396,"activeCount":102},[22397],{"nctId":22398,"briefTitle":22399,"status":108,"phases":22400,"primaryCompletion":8166,"completion":151,"start":10811,"enrollment":22401,"conditions":22402,"interventions":22403},"NCT01993173","Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.",[92],1440,[25,31,28],[22381,22404,22405],"DT vaccine","Td vaccine",{"trials":22407,"activeCount":102},[],{"trials":22409,"activeCount":102},[],{"intervention":8230,"totalTrials":659,"cells":22411},{"EARLY_PHASE1":22412,"PHASE1":22414,"PHASE2":22416,"PHASE3":22418,"PHASE4":22428,"NA":22430},{"trials":22413,"activeCount":102},[],{"trials":22415,"activeCount":102},[],{"trials":22417,"activeCount":102},[],{"trials":22419,"activeCount":102},[22420,22424],{"nctId":8222,"briefTitle":8223,"status":108,"phases":22421,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":22422,"interventions":22423},[92],[19],[8128,8067,8046,8024,8230],{"nctId":8286,"briefTitle":8287,"status":108,"phases":22425,"primaryCompletion":454,"completion":454,"start":8289,"enrollment":8290,"conditions":22426,"interventions":22427},[92],[19],[8128,8293,8024,8230],{"trials":22429,"activeCount":102},[],{"trials":22431,"activeCount":102},[],{"intervention":22433,"totalTrials":659,"cells":22434},"PVRV",{"EARLY_PHASE1":22435,"PHASE1":22437,"PHASE2":22439,"PHASE3":22441,"PHASE4":22463,"NA":22465},{"trials":22436,"activeCount":102},[],{"trials":22438,"activeCount":102},[],{"trials":22440,"activeCount":102},[],{"trials":22442,"activeCount":102},[22443,22452],{"nctId":22444,"briefTitle":22445,"status":108,"phases":22446,"primaryCompletion":22447,"completion":22447,"start":22448,"enrollment":16359,"conditions":22449,"interventions":22450},"NCT01622062","Immunogenicity and Safety of Verorab® in a \"One-week\" Intradermal Post-exposure Prophylaxis Regimen",[92],"2018-11-14","2012-06-29",[14171],[22433,22451,22451],"PVRV and pERIG Favirab®",{"nctId":22453,"briefTitle":22454,"status":108,"phases":22455,"primaryCompletion":22456,"completion":22457,"start":22458,"enrollment":5165,"conditions":22459,"interventions":22461},"NCT03700242","Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year",[92],"2019-01-19","2020-04-08","2018-09-26",[22460],"Healthy Volunteers (Rabies Immunization)",[22462,22462,22433,22433],"HDCV",{"trials":22464,"activeCount":102},[],{"trials":22466,"activeCount":102},[],{"intervention":7620,"totalTrials":659,"cells":22468},{"EARLY_PHASE1":22469,"PHASE1":22471,"PHASE2":22473,"PHASE3":22479,"PHASE4":22485,"NA":22487},{"trials":22470,"activeCount":102},[],{"trials":22472,"activeCount":102},[],{"trials":22474,"activeCount":102},[22475],{"nctId":7562,"briefTitle":7563,"status":108,"phases":22476,"primaryCompletion":7565,"completion":7565,"start":7566,"enrollment":432,"conditions":22477,"interventions":22478},[91],[4992,7568,2922],[5020,7570],{"trials":22480,"activeCount":102},[22481],{"nctId":7612,"briefTitle":7613,"status":108,"phases":22482,"primaryCompletion":7615,"completion":7615,"start":7616,"enrollment":7617,"conditions":22483,"interventions":22484},[92],[4992,7568,2922],[5020,7620,5020,7620],{"trials":22486,"activeCount":102},[],{"trials":22488,"activeCount":102},[],{"intervention":11194,"totalTrials":659,"cells":22490},{"EARLY_PHASE1":22491,"PHASE1":22493,"PHASE2":22495,"PHASE3":22497,"PHASE4":22507,"NA":22509},{"trials":22492,"activeCount":102},[],{"trials":22494,"activeCount":102},[],{"trials":22496,"activeCount":102},[],{"trials":22498,"activeCount":102},[22499,22503],{"nctId":11187,"briefTitle":11188,"status":108,"phases":22500,"primaryCompletion":1355,"completion":1355,"start":1031,"enrollment":11190,"conditions":22501,"interventions":22502},[92],[19],[11193,11194,11195],{"nctId":11197,"briefTitle":11198,"status":108,"phases":22504,"primaryCompletion":3429,"completion":11200,"start":5216,"enrollment":11201,"conditions":22505,"interventions":22506},[92],[554],[11193,11194,11142],{"trials":22508,"activeCount":102},[],{"trials":22510,"activeCount":102},[],{"intervention":7642,"totalTrials":659,"cells":22512},{"EARLY_PHASE1":22513,"PHASE1":22515,"PHASE2":22517,"PHASE3":22526,"PHASE4":22532,"NA":22534},{"trials":22514,"activeCount":102},[],{"trials":22516,"activeCount":102},[],{"trials":22518,"activeCount":102},[22519],{"nctId":22520,"briefTitle":22521,"status":108,"phases":22522,"primaryCompletion":7124,"completion":7124,"start":22523,"enrollment":1455,"conditions":22524,"interventions":22525},"NCT02640404","Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam",[91],"2016-06-06",[4992,7568,2922],[7642,7642],{"trials":22527,"activeCount":102},[22528],{"nctId":7635,"briefTitle":7636,"status":108,"phases":22529,"primaryCompletion":7638,"completion":7638,"start":7606,"enrollment":7639,"conditions":22530,"interventions":22531},[92],[4992,7568,2922],[5020,7642],{"trials":22533,"activeCount":102},[],{"trials":22535,"activeCount":102},[],{"intervention":22537,"totalTrials":659,"cells":22538},"Insulin glargine new formulation",{"EARLY_PHASE1":22539,"PHASE1":22541,"PHASE2":22543,"PHASE3":22545,"PHASE4":22559,"NA":22561},{"trials":22540,"activeCount":102},[],{"trials":22542,"activeCount":102},[],{"trials":22544,"activeCount":102},[],{"trials":22546,"activeCount":102},[22547,22553],{"nctId":22548,"briefTitle":22549,"status":108,"phases":22550,"primaryCompletion":10811,"completion":4969,"start":10178,"enrollment":6655,"conditions":22551,"interventions":22552},"NCT01689142","Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus",[92],[19],[22537,8067],{"nctId":22554,"briefTitle":22555,"status":108,"phases":22556,"primaryCompletion":966,"completion":7330,"start":10178,"enrollment":6502,"conditions":22557,"interventions":22558},"NCT01689129","Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus",[92],[554],[22537,8067],{"trials":22560,"activeCount":102},[],{"trials":22562,"activeCount":102},[],{"intervention":18032,"totalTrials":659,"cells":22564},{"EARLY_PHASE1":22565,"PHASE1":22567,"PHASE2":22573,"PHASE3":22575,"PHASE4":22581,"NA":22583},{"trials":22566,"activeCount":102},[],{"trials":22568,"activeCount":102},[22569],{"nctId":18024,"briefTitle":18025,"status":108,"phases":22570,"primaryCompletion":18027,"completion":18027,"start":18028,"enrollment":622,"conditions":22571,"interventions":22572},[90],[19,11522],[11524,18031,18032],{"trials":22574,"activeCount":102},[],{"trials":22576,"activeCount":102},[22577],{"nctId":3874,"briefTitle":3875,"status":108,"phases":22578,"primaryCompletion":1031,"completion":1031,"start":966,"enrollment":1232,"conditions":22579,"interventions":22580},[92],[1788],[3879,3831,3880],{"trials":22582,"activeCount":102},[],{"trials":22584,"activeCount":102},[],{"intervention":10000,"totalTrials":659,"cells":22586},{"EARLY_PHASE1":22587,"PHASE1":22589,"PHASE2":22591,"PHASE3":22597,"PHASE4":22603,"NA":22605},{"trials":22588,"activeCount":102},[],{"trials":22590,"activeCount":102},[],{"trials":22592,"activeCount":102},[22593],{"nctId":9994,"briefTitle":9995,"status":108,"phases":22594,"primaryCompletion":7330,"completion":7330,"start":8683,"enrollment":3328,"conditions":22595,"interventions":22596},[91],[9998],[2794,10000],{"trials":22598,"activeCount":102},[22599],{"nctId":18374,"briefTitle":18375,"status":108,"phases":22600,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":22601,"interventions":22602},[92],[18378],[17931,5277,18380,9134,18130,18381,10000],{"trials":22604,"activeCount":102},[],{"trials":22606,"activeCount":102},[],{"intervention":1036,"totalTrials":659,"cells":22608},{"EARLY_PHASE1":22609,"PHASE1":22611,"PHASE2":22613,"PHASE3":22615,"PHASE4":22625,"NA":22627},{"trials":22610,"activeCount":102},[],{"trials":22612,"activeCount":102},[],{"trials":22614,"activeCount":102},[],{"trials":22616,"activeCount":102},[22617,22621],{"nctId":1028,"briefTitle":1029,"status":884,"phases":22618,"primaryCompletion":1031,"completion":1031,"start":1032,"enrollment":153,"conditions":22619,"interventions":22620},[92],[990],[942,1035,971,1036],{"nctId":1062,"briefTitle":1063,"status":108,"phases":22622,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":22623,"interventions":22624},[92],[990],[942,1036],{"trials":22626,"activeCount":102},[],{"trials":22628,"activeCount":102},[],{"intervention":20149,"totalTrials":659,"cells":22630},{"EARLY_PHASE1":22631,"PHASE1":22633,"PHASE2":22635,"PHASE3":22637,"PHASE4":22650,"NA":22652},{"trials":22632,"activeCount":102},[],{"trials":22634,"activeCount":102},[],{"trials":22636,"activeCount":102},[],{"trials":22638,"activeCount":102},[22639,22643],{"nctId":20140,"briefTitle":20141,"status":108,"phases":22640,"primaryCompletion":20143,"completion":20143,"start":20144,"enrollment":20145,"conditions":22641,"interventions":22642},[92],[9210],[20148,20149],{"nctId":22644,"briefTitle":22645,"status":108,"phases":22646,"primaryCompletion":3821,"completion":2834,"start":8607,"enrollment":22647,"conditions":22648,"interventions":22649},"NCT00561470","Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen",[92],1226,[5240,9156],[1347,20149,20149],{"trials":22651,"activeCount":102},[],{"trials":22653,"activeCount":102},[],{"intervention":22655,"totalTrials":659,"cells":22656},"Efpeglenatide",{"EARLY_PHASE1":22657,"PHASE1":22659,"PHASE2":22661,"PHASE3":22663,"PHASE4":22684,"NA":22686},{"trials":22658,"activeCount":102},[],{"trials":22660,"activeCount":102},[],{"trials":22662,"activeCount":102},[],{"trials":22664,"activeCount":102},[22665,22676],{"nctId":22666,"briefTitle":22667,"status":884,"phases":22668,"primaryCompletion":22669,"completion":22670,"start":22458,"enrollment":22671,"conditions":22672,"interventions":22673},"NCT03684642","Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin",[92],"2020-10-13","2020-11-17",908,[19],[22655,22674,22675],"Dulaglutide","Background therapy Metformin",{"nctId":22677,"briefTitle":22678,"status":884,"phases":22679,"primaryCompletion":7135,"completion":7135,"start":22680,"enrollment":22681,"conditions":22682,"interventions":22683},"NCT03496298","Effect of Efpeglenatide on Cardiovascular Outcomes",[92],"2018-04-27",4076,[19],[22655],{"trials":22685,"activeCount":102},[],{"trials":22687,"activeCount":102},[],{"intervention":22674,"totalTrials":659,"cells":22689},{"EARLY_PHASE1":22690,"PHASE1":22692,"PHASE2":22694,"PHASE3":22696,"PHASE4":22706,"NA":22708},{"trials":22691,"activeCount":102},[],{"trials":22693,"activeCount":102},[],{"trials":22695,"activeCount":102},[],{"trials":22697,"activeCount":102},[22698,22702],{"nctId":22666,"briefTitle":22667,"status":884,"phases":22699,"primaryCompletion":22669,"completion":22670,"start":22458,"enrollment":22671,"conditions":22700,"interventions":22701},[92],[19],[22655,22674,22675],{"nctId":11857,"briefTitle":11858,"status":108,"phases":22703,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":22704,"interventions":22705},[92],[19],[11866,11867,11868,11869,11870,11871,11872],{"trials":22707,"activeCount":102},[],{"trials":22709,"activeCount":102},[],{"intervention":19051,"totalTrials":659,"cells":22711},{"EARLY_PHASE1":22712,"PHASE1":22714,"PHASE2":22716,"PHASE3":22718,"PHASE4":22728,"NA":22730},{"trials":22713,"activeCount":102},[],{"trials":22715,"activeCount":102},[],{"trials":22717,"activeCount":102},[],{"trials":22719,"activeCount":102},[22720,22724],{"nctId":19045,"briefTitle":19046,"status":108,"phases":22721,"primaryCompletion":8349,"completion":8349,"start":8505,"enrollment":19048,"conditions":22722,"interventions":22723},[92],[11472],[19002,19051],{"nctId":19698,"briefTitle":19699,"status":884,"phases":22725,"primaryCompletion":9532,"completion":9532,"start":8235,"enrollment":10753,"conditions":22726,"interventions":22727},[92],[11472],[19696,19703],{"trials":22729,"activeCount":102},[],{"trials":22731,"activeCount":102},[],{"intervention":22733,"totalTrials":659,"cells":22734},"Insuline glulisine",{"EARLY_PHASE1":22735,"PHASE1":22737,"PHASE2":22739,"PHASE3":22741,"PHASE4":22755,"NA":22757},{"trials":22736,"activeCount":102},[],{"trials":22738,"activeCount":102},[],{"trials":22740,"activeCount":102},[],{"trials":22742,"activeCount":102},[22743,22749],{"nctId":22744,"briefTitle":22745,"status":108,"phases":22746,"primaryCompletion":5250,"completion":5250,"start":3367,"enrollment":178,"conditions":22747,"interventions":22748},"NCT00545337","Glulisine + Lantus in Type I Patients",[92],[578],[22733],{"nctId":22750,"briefTitle":22745,"status":108,"phases":22751,"primaryCompletion":9292,"completion":9292,"start":3367,"enrollment":313,"conditions":22752,"interventions":22753},"NCT00546702",[92],[578],[22754],"Insuline Glulisine",{"trials":22756,"activeCount":102},[],{"trials":22758,"activeCount":102},[],{"intervention":22760,"totalTrials":659,"cells":22761},"SENNA+CASSIA",{"EARLY_PHASE1":22762,"PHASE1":22764,"PHASE2":22766,"PHASE3":22768,"PHASE4":22784,"NA":22786},{"trials":22763,"activeCount":102},[],{"trials":22765,"activeCount":102},[],{"trials":22767,"activeCount":102},[],{"trials":22769,"activeCount":102},[22770,22778],{"nctId":22771,"briefTitle":22772,"status":108,"phases":22773,"primaryCompletion":977,"completion":977,"start":5217,"enrollment":22774,"conditions":22775,"interventions":22777},"NCT00931853","Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).",[92],117,[22776],"Constipation",[22760],{"nctId":22779,"briefTitle":22780,"status":108,"phases":22781,"primaryCompletion":7349,"completion":7349,"start":2799,"enrollment":6595,"conditions":22782,"interventions":22783},"NCT00994851","Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.",[92],[22776],[22760],{"trials":22785,"activeCount":102},[],{"trials":22787,"activeCount":102},[],{"intervention":8983,"totalTrials":659,"cells":22789},{"EARLY_PHASE1":22790,"PHASE1":22792,"PHASE2":22794,"PHASE3":22796,"PHASE4":22809,"NA":22811},{"trials":22791,"activeCount":102},[],{"trials":22793,"activeCount":102},[],{"trials":22795,"activeCount":102},[],{"trials":22797,"activeCount":102},[22798,22805],{"nctId":22799,"briefTitle":22800,"status":108,"phases":22801,"primaryCompletion":987,"completion":987,"start":5271,"enrollment":1232,"conditions":22802,"interventions":22803},"NCT01126606","Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional",[92],[33],[22804,8983],"Dermacid Silver",{"nctId":8977,"briefTitle":8978,"status":108,"phases":22806,"primaryCompletion":8693,"completion":8693,"start":3366,"enrollment":8980,"conditions":22807,"interventions":22808},[92],[33],[8810,8983],{"trials":22810,"activeCount":102},[],{"trials":22812,"activeCount":102},[],{"intervention":18983,"totalTrials":659,"cells":22814},{"EARLY_PHASE1":22815,"PHASE1":22817,"PHASE2":22819,"PHASE3":22825,"PHASE4":22831,"NA":22833},{"trials":22816,"activeCount":102},[],{"trials":22818,"activeCount":102},[],{"trials":22820,"activeCount":102},[22821],{"nctId":18977,"briefTitle":18978,"status":884,"phases":22822,"primaryCompletion":18980,"completion":18980,"start":246,"enrollment":11211,"conditions":22823,"interventions":22824},[90,91],[5264],[18919,18983,18984,18985,18986],{"trials":22826,"activeCount":102},[22827],{"nctId":19821,"briefTitle":19822,"status":884,"phases":22828,"primaryCompletion":19824,"completion":4627,"start":7577,"enrollment":19825,"conditions":22829,"interventions":22830},[92],[5264],[19828,18983,18964,19829],{"trials":22832,"activeCount":102},[],{"trials":22834,"activeCount":102},[],{"intervention":22836,"totalTrials":659,"cells":22837},"Live attenuated Japanese encephalitis chimeric virus vaccine",{"EARLY_PHASE1":22838,"PHASE1":22840,"PHASE2":22842,"PHASE3":22844,"PHASE4":22861,"NA":22863},{"trials":22839,"activeCount":102},[],{"trials":22841,"activeCount":102},[],{"trials":22843,"activeCount":102},[],{"trials":22845,"activeCount":102},[22846,22855],{"nctId":22847,"briefTitle":22848,"status":108,"phases":22849,"primaryCompletion":2760,"completion":152,"start":8406,"enrollment":22850,"conditions":22851,"interventions":22853},"NCT01396512","Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers",[92],274,[17265,22852],"Japanese Encephalitis Virus Disease",[22836,22854],"Japanese encephalitis live attenuated vaccine",{"nctId":22856,"briefTitle":22857,"status":108,"phases":22858,"primaryCompletion":1054,"completion":2856,"start":8165,"enrollment":8627,"conditions":22859,"interventions":22860},"NCT02492165","Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects",[92],[17265],[22836,22836,22836,22836],{"trials":22862,"activeCount":102},[],{"trials":22864,"activeCount":102},[],{"intervention":7203,"totalTrials":659,"cells":22866},{"EARLY_PHASE1":22867,"PHASE1":22869,"PHASE2":22871,"PHASE3":22873,"PHASE4":22883,"NA":22885},{"trials":22868,"activeCount":102},[],{"trials":22870,"activeCount":102},[],{"trials":22872,"activeCount":102},[],{"trials":22874,"activeCount":102},[22875,22879],{"nctId":7194,"briefTitle":7195,"status":108,"phases":22876,"primaryCompletion":7197,"completion":7198,"start":7199,"enrollment":7200,"conditions":22877,"interventions":22878},[92],[382],[2064,7203,7204,7205],{"nctId":7207,"briefTitle":7208,"status":108,"phases":22880,"primaryCompletion":1592,"completion":7210,"start":7211,"enrollment":7212,"conditions":22881,"interventions":22882},[92],[382],[2064,7203,7204,7205],{"trials":22884,"activeCount":102},[],{"trials":22886,"activeCount":102},[],{"intervention":7204,"totalTrials":659,"cells":22888},{"EARLY_PHASE1":22889,"PHASE1":22891,"PHASE2":22893,"PHASE3":22895,"PHASE4":22905,"NA":22907},{"trials":22890,"activeCount":102},[],{"trials":22892,"activeCount":102},[],{"trials":22894,"activeCount":102},[],{"trials":22896,"activeCount":102},[22897,22901],{"nctId":7194,"briefTitle":7195,"status":108,"phases":22898,"primaryCompletion":7197,"completion":7198,"start":7199,"enrollment":7200,"conditions":22899,"interventions":22900},[92],[382],[2064,7203,7204,7205],{"nctId":7207,"briefTitle":7208,"status":108,"phases":22902,"primaryCompletion":1592,"completion":7210,"start":7211,"enrollment":7212,"conditions":22903,"interventions":22904},[92],[382],[2064,7203,7204,7205],{"trials":22906,"activeCount":102},[],{"trials":22908,"activeCount":102},[],{"intervention":7205,"totalTrials":659,"cells":22910},{"EARLY_PHASE1":22911,"PHASE1":22913,"PHASE2":22915,"PHASE3":22917,"PHASE4":22927,"NA":22929},{"trials":22912,"activeCount":102},[],{"trials":22914,"activeCount":102},[],{"trials":22916,"activeCount":102},[],{"trials":22918,"activeCount":102},[22919,22923],{"nctId":7194,"briefTitle":7195,"status":108,"phases":22920,"primaryCompletion":7197,"completion":7198,"start":7199,"enrollment":7200,"conditions":22921,"interventions":22922},[92],[382],[2064,7203,7204,7205],{"nctId":7207,"briefTitle":7208,"status":108,"phases":22924,"primaryCompletion":1592,"completion":7210,"start":7211,"enrollment":7212,"conditions":22925,"interventions":22926},[92],[382],[2064,7203,7204,7205],{"trials":22928,"activeCount":102},[],{"trials":22930,"activeCount":102},[],{"intervention":22932,"totalTrials":659,"cells":22933},"DT5aP-IPV-Hib 5-component Pertussis vaccine",{"EARLY_PHASE1":22934,"PHASE1":22936,"PHASE2":22938,"PHASE3":22940,"PHASE4":22958,"NA":22960},{"trials":22935,"activeCount":102},[],{"trials":22937,"activeCount":102},[],{"trials":22939,"activeCount":102},[],{"trials":22941,"activeCount":102},[22942,22951],{"nctId":22943,"briefTitle":22944,"status":108,"phases":22945,"primaryCompletion":1341,"completion":8196,"start":3622,"enrollment":22946,"conditions":22947,"interventions":22949},"NCT00355654","Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®",[92],847,[22948,8839],"Infant",[22932,22950],"DT3aP-HBs-IPV",{"nctId":22952,"briefTitle":22953,"status":108,"phases":22954,"primaryCompletion":3308,"completion":3564,"start":8777,"enrollment":10798,"conditions":22955,"interventions":22956},"NCT00287092","Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants",[92],[28,25,31,12983,20655],[22932,22957],"Infanrix® -IPV+Hib",{"trials":22959,"activeCount":102},[],{"trials":22961,"activeCount":102},[],{"intervention":12085,"totalTrials":659,"cells":22963},{"EARLY_PHASE1":22964,"PHASE1":22966,"PHASE2":22968,"PHASE3":22970,"PHASE4":22986,"NA":22988},{"trials":22965,"activeCount":102},[],{"trials":22967,"activeCount":102},[],{"trials":22969,"activeCount":102},[],{"trials":22971,"activeCount":102},[22972,22982],{"nctId":22973,"briefTitle":22974,"status":884,"phases":22975,"primaryCompletion":22976,"completion":22977,"start":22978,"enrollment":1687,"conditions":22979,"interventions":22980},"NCT03770728","Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea",[92],"2020-11-28","2020-12-27","2019-08-01",[19],[12085,22981],"Background therapy: Metformin alone or in combination with SU",{"nctId":12076,"briefTitle":12077,"status":884,"phases":22983,"primaryCompletion":12079,"completion":12080,"start":12081,"enrollment":12082,"conditions":22984,"interventions":22985},[92],[19],[12085,10566],{"trials":22987,"activeCount":102},[],{"trials":22989,"activeCount":102},[],{"intervention":5048,"totalTrials":659,"cells":22991},{"EARLY_PHASE1":22992,"PHASE1":22994,"PHASE2":22996,"PHASE3":22998,"PHASE4":23012,"NA":23014},{"trials":22993,"activeCount":102},[],{"trials":22995,"activeCount":102},[],{"trials":22997,"activeCount":102},[],{"trials":22999,"activeCount":102},[23000,23004],{"nctId":5041,"briefTitle":5042,"status":108,"phases":23001,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":23002,"interventions":23003},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"nctId":23005,"briefTitle":23006,"status":108,"phases":23007,"primaryCompletion":3750,"completion":3750,"start":23008,"enrollment":11706,"conditions":23009,"interventions":23010},"NCT03869866","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon",[92],"2019-04-09",[2932],[23011],"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine",{"trials":23013,"activeCount":102},[],{"trials":23015,"activeCount":102},[],{"intervention":10627,"totalTrials":659,"cells":23017},{"EARLY_PHASE1":23018,"PHASE1":23020,"PHASE2":23026,"PHASE3":23028,"PHASE4":23034,"NA":23036},{"trials":23019,"activeCount":102},[],{"trials":23021,"activeCount":102},[23022],{"nctId":10621,"briefTitle":10622,"status":108,"phases":23023,"primaryCompletion":10624,"completion":10624,"start":2747,"enrollment":2858,"conditions":23024,"interventions":23025},[90],[554],[10627,8508],{"trials":23027,"activeCount":102},[],{"trials":23029,"activeCount":102},[23030],{"nctId":10649,"briefTitle":10650,"status":108,"phases":23031,"primaryCompletion":3738,"completion":3738,"start":10652,"enrollment":249,"conditions":23032,"interventions":23033},[92],[554],[10655,10611,8151],{"trials":23035,"activeCount":102},[],{"trials":23037,"activeCount":102},[],{"intervention":23039,"totalTrials":659,"cells":23040},"fexofenadine\u002FAllegra",{"EARLY_PHASE1":23041,"PHASE1":23043,"PHASE2":23045,"PHASE3":23047,"PHASE4":23062,"NA":23064},{"trials":23042,"activeCount":102},[],{"trials":23044,"activeCount":102},[],{"trials":23046,"activeCount":102},[],{"trials":23048,"activeCount":102},[23049,23056],{"nctId":23050,"briefTitle":23051,"status":108,"phases":23052,"primaryCompletion":8406,"completion":5306,"start":8453,"enrollment":465,"conditions":23053,"interventions":23055},"NCT01244217","Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)",[91,92],[23054],"Rhinitis Perennial",[23039],{"nctId":23057,"briefTitle":23058,"status":108,"phases":23059,"primaryCompletion":8406,"completion":5306,"start":987,"enrollment":465,"conditions":23060,"interventions":23061},"NCT01244230","Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)",[91,92],[206],[23039],{"trials":23063,"activeCount":102},[],{"trials":23065,"activeCount":102},[],{"intervention":18287,"totalTrials":195,"cells":23067},{"EARLY_PHASE1":23068,"PHASE1":23070,"PHASE2":23072,"PHASE3":23074,"PHASE4":23080,"NA":23082},{"trials":23069,"activeCount":102},[],{"trials":23071,"activeCount":102},[],{"trials":23073,"activeCount":102},[],{"trials":23075,"activeCount":102},[23076],{"nctId":18278,"briefTitle":18279,"status":108,"phases":23077,"primaryCompletion":18281,"completion":18281,"start":18282,"enrollment":18283,"conditions":23078,"interventions":23079},[92],[18210,2317,18285],[18194,18194,18287],{"trials":23081,"activeCount":102},[],{"trials":23083,"activeCount":102},[],{"intervention":10781,"totalTrials":195,"cells":23085},{"EARLY_PHASE1":23086,"PHASE1":23088,"PHASE2":23090,"PHASE3":23092,"PHASE4":23098,"NA":23100},{"trials":23087,"activeCount":102},[],{"trials":23089,"activeCount":102},[],{"trials":23091,"activeCount":102},[],{"trials":23093,"activeCount":102},[23094],{"nctId":10776,"briefTitle":10777,"status":108,"phases":23095,"primaryCompletion":9292,"start":5251,"enrollment":8627,"conditions":23096,"interventions":23097},[92],[8187],[8189,10781,10782,8637],{"trials":23099,"activeCount":102},[],{"trials":23101,"activeCount":102},[],{"intervention":10782,"totalTrials":195,"cells":23103},{"EARLY_PHASE1":23104,"PHASE1":23106,"PHASE2":23108,"PHASE3":23110,"PHASE4":23116,"NA":23118},{"trials":23105,"activeCount":102},[],{"trials":23107,"activeCount":102},[],{"trials":23109,"activeCount":102},[],{"trials":23111,"activeCount":102},[23112],{"nctId":10776,"briefTitle":10777,"status":108,"phases":23113,"primaryCompletion":9292,"start":5251,"enrollment":8627,"conditions":23114,"interventions":23115},[92],[8187],[8189,10781,10782,8637],{"trials":23117,"activeCount":102},[],{"trials":23119,"activeCount":102},[],{"intervention":23121,"totalTrials":195,"cells":23122},"MAXOMAT ®, biosynthetic growth hormone",{"EARLY_PHASE1":23123,"PHASE1":23125,"PHASE2":23127,"PHASE3":23129,"PHASE4":23139,"NA":23141},{"trials":23124,"activeCount":102},[],{"trials":23126,"activeCount":102},[],{"trials":23128,"activeCount":102},[],{"trials":23130,"activeCount":102},[23131],{"nctId":23132,"briefTitle":23133,"status":108,"phases":23134,"primaryCompletion":3366,"completion":3366,"start":23135,"enrollment":2685,"conditions":23136,"interventions":23138},"NCT00452725","Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome",[92],"1997-10",[23137],"Noonan Syndrome",[23121],{"trials":23140,"activeCount":102},[],{"trials":23142,"activeCount":102},[],{"intervention":8100,"totalTrials":195,"cells":23144},{"EARLY_PHASE1":23145,"PHASE1":23147,"PHASE2":23149,"PHASE3":23151,"PHASE4":23157,"NA":23159},{"trials":23146,"activeCount":102},[],{"trials":23148,"activeCount":102},[],{"trials":23150,"activeCount":102},[],{"trials":23152,"activeCount":102},[23153],{"nctId":8094,"briefTitle":8095,"status":108,"phases":23154,"primaryCompletion":965,"completion":965,"start":7430,"enrollment":8097,"conditions":23155,"interventions":23156},[92],[19],[8100,8101,8037],{"trials":23158,"activeCount":102},[],{"trials":23160,"activeCount":102},[],{"intervention":8101,"totalTrials":195,"cells":23162},{"EARLY_PHASE1":23163,"PHASE1":23165,"PHASE2":23167,"PHASE3":23169,"PHASE4":23175,"NA":23177},{"trials":23164,"activeCount":102},[],{"trials":23166,"activeCount":102},[],{"trials":23168,"activeCount":102},[],{"trials":23170,"activeCount":102},[23171],{"nctId":8094,"briefTitle":8095,"status":108,"phases":23172,"primaryCompletion":965,"completion":965,"start":7430,"enrollment":8097,"conditions":23173,"interventions":23174},[92],[19],[8100,8101,8037],{"trials":23176,"activeCount":102},[],{"trials":23178,"activeCount":102},[],{"intervention":23180,"totalTrials":195,"cells":23181},"Dermacyd Femina Pocket BR",{"EARLY_PHASE1":23182,"PHASE1":23184,"PHASE2":23186,"PHASE3":23188,"PHASE4":23196,"NA":23198},{"trials":23183,"activeCount":102},[],{"trials":23185,"activeCount":102},[],{"trials":23187,"activeCount":102},[],{"trials":23189,"activeCount":102},[23190],{"nctId":23191,"briefTitle":23192,"status":108,"phases":23193,"primaryCompletion":8235,"start":8235,"enrollment":3740,"conditions":23194,"interventions":23195},"NCT00794612","Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.",[92],[33],[23180],{"trials":23197,"activeCount":102},[],{"trials":23199,"activeCount":102},[],{"intervention":23201,"totalTrials":195,"cells":23202},"dianicline",{"EARLY_PHASE1":23203,"PHASE1":23205,"PHASE2":23207,"PHASE3":23209,"PHASE4":23218,"NA":23220},{"trials":23204,"activeCount":102},[],{"trials":23206,"activeCount":102},[],{"trials":23208,"activeCount":102},[],{"trials":23210,"activeCount":102},[23211],{"nctId":23212,"briefTitle":23213,"status":108,"phases":23214,"primaryCompletion":10320,"completion":10320,"start":8395,"enrollment":16663,"conditions":23215,"interventions":23217},"NCT00356967","Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation",[92],[23216],"Smoking",[23201],{"trials":23219,"activeCount":102},[],{"trials":23221,"activeCount":102},[],{"intervention":21318,"totalTrials":195,"cells":23223},{"EARLY_PHASE1":23224,"PHASE1":23226,"PHASE2":23228,"PHASE3":23230,"PHASE4":23236,"NA":23238},{"trials":23225,"activeCount":102},[],{"trials":23227,"activeCount":102},[],{"trials":23229,"activeCount":102},[],{"trials":23231,"activeCount":102},[23232],{"nctId":21312,"briefTitle":21313,"status":108,"phases":23233,"primaryCompletion":8395,"completion":8666,"start":3623,"enrollment":21315,"conditions":23234,"interventions":23235},[92],[17265],[21294,21318],{"trials":23237,"activeCount":102},[],{"trials":23239,"activeCount":102},[],{"intervention":23241,"totalTrials":195,"cells":23242},"Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine",{"EARLY_PHASE1":23243,"PHASE1":23245,"PHASE2":23247,"PHASE3":23249,"PHASE4":23258,"NA":23260},{"trials":23244,"activeCount":102},[],{"trials":23246,"activeCount":102},[],{"trials":23248,"activeCount":102},[],{"trials":23250,"activeCount":102},[23251],{"nctId":23252,"briefTitle":23253,"status":108,"phases":23254,"primaryCompletion":3439,"completion":8315,"start":9785,"enrollment":19781,"conditions":23255,"interventions":23256},"NCT00444951","Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia",[92],[2489,2922],[23241,23257,23241],"Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine",{"trials":23259,"activeCount":102},[],{"trials":23261,"activeCount":102},[],{"intervention":23257,"totalTrials":195,"cells":23263},{"EARLY_PHASE1":23264,"PHASE1":23266,"PHASE2":23268,"PHASE3":23270,"PHASE4":23276,"NA":23278},{"trials":23265,"activeCount":102},[],{"trials":23267,"activeCount":102},[],{"trials":23269,"activeCount":102},[],{"trials":23271,"activeCount":102},[23272],{"nctId":23252,"briefTitle":23253,"status":108,"phases":23273,"primaryCompletion":3439,"completion":8315,"start":9785,"enrollment":19781,"conditions":23274,"interventions":23275},[92],[2489,2922],[23241,23257,23241],{"trials":23277,"activeCount":102},[],{"trials":23279,"activeCount":102},[],{"intervention":12183,"totalTrials":195,"cells":23281},{"EARLY_PHASE1":23282,"PHASE1":23284,"PHASE2":23286,"PHASE3":23288,"PHASE4":23294,"NA":23296},{"trials":23283,"activeCount":102},[],{"trials":23285,"activeCount":102},[],{"trials":23287,"activeCount":102},[],{"trials":23289,"activeCount":102},[23290],{"nctId":12175,"briefTitle":12176,"status":108,"phases":23291,"primaryCompletion":2790,"completion":2790,"start":3821,"enrollment":12178,"conditions":23292,"interventions":23293},[92],[12180],[12182,12183],{"trials":23295,"activeCount":102},[],{"trials":23297,"activeCount":102},[],{"intervention":12925,"totalTrials":195,"cells":23299},{"EARLY_PHASE1":23300,"PHASE1":23302,"PHASE2":23304,"PHASE3":23306,"PHASE4":23312,"NA":23314},{"trials":23301,"activeCount":102},[],{"trials":23303,"activeCount":102},[],{"trials":23305,"activeCount":102},[],{"trials":23307,"activeCount":102},[23308],{"nctId":12920,"briefTitle":12921,"status":3661,"phases":23309,"primaryCompletion":152,"completion":152,"start":3438,"enrollment":102,"conditions":23310,"interventions":23311},[92],[12745],[12925,12909],{"trials":23313,"activeCount":102},[],{"trials":23315,"activeCount":102},[],{"intervention":23317,"totalTrials":195,"cells":23318},"REPEVAX® after REVAXIS®",{"EARLY_PHASE1":23319,"PHASE1":23321,"PHASE2":23323,"PHASE3":23325,"PHASE4":23335,"NA":23337},{"trials":23320,"activeCount":102},[],{"trials":23322,"activeCount":102},[],{"trials":23324,"activeCount":102},[],{"trials":23326,"activeCount":102},[23327],{"nctId":23328,"briefTitle":23329,"status":108,"phases":23330,"primaryCompletion":9785,"completion":9785,"start":8395,"enrollment":7729,"conditions":23331,"interventions":23333},"NCT00400309","Safety of REPEVAX® Given One Month After REVAXIS®",[92],[23332],"Healthy Adult",[23317,23334],"REPEVAX® after Placebo",{"trials":23336,"activeCount":102},[],{"trials":23338,"activeCount":102},[],{"intervention":23334,"totalTrials":195,"cells":23340},{"EARLY_PHASE1":23341,"PHASE1":23343,"PHASE2":23345,"PHASE3":23347,"PHASE4":23353,"NA":23355},{"trials":23342,"activeCount":102},[],{"trials":23344,"activeCount":102},[],{"trials":23346,"activeCount":102},[],{"trials":23348,"activeCount":102},[23349],{"nctId":23328,"briefTitle":23329,"status":108,"phases":23350,"primaryCompletion":9785,"completion":9785,"start":8395,"enrollment":7729,"conditions":23351,"interventions":23352},[92],[23332],[23317,23334],{"trials":23354,"activeCount":102},[],{"trials":23356,"activeCount":102},[],{"intervention":23358,"totalTrials":195,"cells":23359},"SARS-CoV-2 adjuvanted recombinant protein vaccine",{"EARLY_PHASE1":23360,"PHASE1":23362,"PHASE2":23364,"PHASE3":23366,"PHASE4":23379,"NA":23381},{"trials":23361,"activeCount":102},[],{"trials":23363,"activeCount":102},[],{"trials":23365,"activeCount":102},[],{"trials":23367,"activeCount":102},[23368],{"nctId":23369,"briefTitle":23370,"status":108,"phases":23371,"primaryCompletion":23372,"completion":23372,"start":23373,"enrollment":23374,"conditions":23375,"interventions":23376},"NCT04904549","Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older",[92],"2024-08-31","2020-08-20",23726,[4266],[23358,23358,23377,23378],"SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination","SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination",{"trials":23380,"activeCount":102},[],{"trials":23382,"activeCount":102},[],{"intervention":23377,"totalTrials":195,"cells":23384},{"EARLY_PHASE1":23385,"PHASE1":23387,"PHASE2":23389,"PHASE3":23391,"PHASE4":23397,"NA":23399},{"trials":23386,"activeCount":102},[],{"trials":23388,"activeCount":102},[],{"trials":23390,"activeCount":102},[],{"trials":23392,"activeCount":102},[23393],{"nctId":23369,"briefTitle":23370,"status":108,"phases":23394,"primaryCompletion":23372,"completion":23372,"start":23373,"enrollment":23374,"conditions":23395,"interventions":23396},[92],[4266],[23358,23358,23377,23378],{"trials":23398,"activeCount":102},[],{"trials":23400,"activeCount":102},[],{"intervention":23378,"totalTrials":195,"cells":23402},{"EARLY_PHASE1":23403,"PHASE1":23405,"PHASE2":23407,"PHASE3":23409,"PHASE4":23415,"NA":23417},{"trials":23404,"activeCount":102},[],{"trials":23406,"activeCount":102},[],{"trials":23408,"activeCount":102},[],{"trials":23410,"activeCount":102},[23411],{"nctId":23369,"briefTitle":23370,"status":108,"phases":23412,"primaryCompletion":23372,"completion":23372,"start":23373,"enrollment":23374,"conditions":23413,"interventions":23414},[92],[4266],[23358,23358,23377,23378],{"trials":23416,"activeCount":102},[],{"trials":23418,"activeCount":102},[],{"intervention":23420,"totalTrials":195,"cells":23421},"epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile",{"EARLY_PHASE1":23422,"PHASE1":23424,"PHASE2":23426,"PHASE3":23428,"PHASE4":23439,"NA":23441},{"trials":23423,"activeCount":102},[],{"trials":23425,"activeCount":102},[],{"trials":23427,"activeCount":102},[],{"trials":23429,"activeCount":102},[23430],{"nctId":23431,"briefTitle":23432,"status":108,"phases":23433,"primaryCompletion":7509,"completion":7509,"start":23434,"enrollment":10205,"conditions":23435,"interventions":23436},"NCT00174707","Study of Docetaxel in Breast Cancer Patients",[92],"1997-12",[5275],[23420,23437,23438],"epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile","epidoxorubicine, docetaxel, cyclophosphamide",{"trials":23440,"activeCount":102},[],{"trials":23442,"activeCount":102},[],{"intervention":23437,"totalTrials":195,"cells":23444},{"EARLY_PHASE1":23445,"PHASE1":23447,"PHASE2":23449,"PHASE3":23451,"PHASE4":23457,"NA":23459},{"trials":23446,"activeCount":102},[],{"trials":23448,"activeCount":102},[],{"trials":23450,"activeCount":102},[],{"trials":23452,"activeCount":102},[23453],{"nctId":23431,"briefTitle":23432,"status":108,"phases":23454,"primaryCompletion":7509,"completion":7509,"start":23434,"enrollment":10205,"conditions":23455,"interventions":23456},[92],[5275],[23420,23437,23438],{"trials":23458,"activeCount":102},[],{"trials":23460,"activeCount":102},[],{"intervention":23438,"totalTrials":195,"cells":23462},{"EARLY_PHASE1":23463,"PHASE1":23465,"PHASE2":23467,"PHASE3":23469,"PHASE4":23475,"NA":23477},{"trials":23464,"activeCount":102},[],{"trials":23466,"activeCount":102},[],{"trials":23468,"activeCount":102},[],{"trials":23470,"activeCount":102},[23471],{"nctId":23431,"briefTitle":23432,"status":108,"phases":23472,"primaryCompletion":7509,"completion":7509,"start":23434,"enrollment":10205,"conditions":23473,"interventions":23474},[92],[5275],[23420,23437,23438],{"trials":23476,"activeCount":102},[],{"trials":23478,"activeCount":102},[],{"intervention":7583,"totalTrials":195,"cells":23480},{"EARLY_PHASE1":23481,"PHASE1":23483,"PHASE2":23485,"PHASE3":23487,"PHASE4":23493,"NA":23495},{"trials":23482,"activeCount":102},[],{"trials":23484,"activeCount":102},[],{"trials":23486,"activeCount":102},[],{"trials":23488,"activeCount":102},[23489],{"nctId":7574,"briefTitle":7575,"status":108,"phases":23490,"primaryCompletion":7577,"completion":7577,"start":7578,"enrollment":7579,"conditions":23491,"interventions":23492},[92],[5167],[7582,7583,7584],{"trials":23494,"activeCount":102},[],{"trials":23496,"activeCount":102},[],{"intervention":7584,"totalTrials":195,"cells":23498},{"EARLY_PHASE1":23499,"PHASE1":23501,"PHASE2":23503,"PHASE3":23505,"PHASE4":23511,"NA":23513},{"trials":23500,"activeCount":102},[],{"trials":23502,"activeCount":102},[],{"trials":23504,"activeCount":102},[],{"trials":23506,"activeCount":102},[23507],{"nctId":7574,"briefTitle":7575,"status":108,"phases":23508,"primaryCompletion":7577,"completion":7577,"start":7578,"enrollment":7579,"conditions":23509,"interventions":23510},[92],[5167],[7582,7583,7584],{"trials":23512,"activeCount":102},[],{"trials":23514,"activeCount":102},[],{"intervention":23516,"totalTrials":195,"cells":23517},"DAPTACEL®",{"EARLY_PHASE1":23518,"PHASE1":23520,"PHASE2":23522,"PHASE3":23524,"PHASE4":23534,"NA":23536},{"trials":23519,"activeCount":102},[],{"trials":23521,"activeCount":102},[],{"trials":23523,"activeCount":102},[],{"trials":23525,"activeCount":102},[23526],{"nctId":23527,"briefTitle":23528,"status":108,"phases":23529,"primaryCompletion":3527,"completion":3527,"start":10073,"enrollment":23530,"conditions":23531,"interventions":23532},"NCT00662870","Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine",[92],1941,[25,31,13514,13810,20655],[23516,23533],"Pentacel: DTaP-IPV\u002FHib",{"trials":23535,"activeCount":102},[],{"trials":23537,"activeCount":102},[],{"intervention":23533,"totalTrials":195,"cells":23539},{"EARLY_PHASE1":23540,"PHASE1":23542,"PHASE2":23544,"PHASE3":23546,"PHASE4":23552,"NA":23554},{"trials":23541,"activeCount":102},[],{"trials":23543,"activeCount":102},[],{"trials":23545,"activeCount":102},[],{"trials":23547,"activeCount":102},[23548],{"nctId":23527,"briefTitle":23528,"status":108,"phases":23549,"primaryCompletion":3527,"completion":3527,"start":10073,"enrollment":23530,"conditions":23550,"interventions":23551},[92],[25,31,13514,13810,20655],[23516,23533],{"trials":23553,"activeCount":102},[],{"trials":23555,"activeCount":102},[],{"intervention":8119,"totalTrials":195,"cells":23557},{"EARLY_PHASE1":23558,"PHASE1":23560,"PHASE2":23562,"PHASE3":23564,"PHASE4":23570,"NA":23572},{"trials":23559,"activeCount":102},[],{"trials":23561,"activeCount":102},[],{"trials":23563,"activeCount":102},[],{"trials":23565,"activeCount":102},[23566],{"nctId":8112,"briefTitle":8113,"status":108,"phases":23567,"primaryCompletion":954,"completion":954,"start":3564,"enrollment":8115,"conditions":23568,"interventions":23569},[92],[8117],[8046,8119,8024],{"trials":23571,"activeCount":102},[],{"trials":23573,"activeCount":102},[],{"intervention":208,"totalTrials":195,"cells":23575},{"EARLY_PHASE1":23576,"PHASE1":23578,"PHASE2":23580,"PHASE3":23582,"PHASE4":23588,"NA":23590},{"trials":23577,"activeCount":102},[],{"trials":23579,"activeCount":102},[],{"trials":23581,"activeCount":102},[],{"trials":23583,"activeCount":102},[23584],{"nctId":199,"briefTitle":200,"status":108,"phases":23585,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":23586,"interventions":23587},[92],[206],[97,208],{"trials":23589,"activeCount":102},[],{"trials":23591,"activeCount":102},[],{"intervention":23593,"totalTrials":195,"cells":23594},"Low Dose (LD) RSVt vaccine",{"EARLY_PHASE1":23595,"PHASE1":23597,"PHASE2":23599,"PHASE3":23601,"PHASE4":23612,"NA":23614},{"trials":23596,"activeCount":102},[],{"trials":23598,"activeCount":102},[],{"trials":23600,"activeCount":102},[],{"trials":23602,"activeCount":102},[23603],{"nctId":23604,"briefTitle":23605,"status":884,"phases":23606,"primaryCompletion":23607,"completion":23607,"start":215,"enrollment":20023,"conditions":23608,"interventions":23609},"NCT06705140","A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[92],"2025-06-11",[20484],[23593,23610,23611],"Standard Dose (SD) RSVt vaccine","High Dose (HD) RSVt vaccine",{"trials":23613,"activeCount":102},[],{"trials":23615,"activeCount":102},[],{"intervention":23610,"totalTrials":195,"cells":23617},{"EARLY_PHASE1":23618,"PHASE1":23620,"PHASE2":23622,"PHASE3":23624,"PHASE4":23630,"NA":23632},{"trials":23619,"activeCount":102},[],{"trials":23621,"activeCount":102},[],{"trials":23623,"activeCount":102},[],{"trials":23625,"activeCount":102},[23626],{"nctId":23604,"briefTitle":23605,"status":884,"phases":23627,"primaryCompletion":23607,"completion":23607,"start":215,"enrollment":20023,"conditions":23628,"interventions":23629},[92],[20484],[23593,23610,23611],{"trials":23631,"activeCount":102},[],{"trials":23633,"activeCount":102},[],{"intervention":23611,"totalTrials":195,"cells":23635},{"EARLY_PHASE1":23636,"PHASE1":23638,"PHASE2":23640,"PHASE3":23642,"PHASE4":23648,"NA":23650},{"trials":23637,"activeCount":102},[],{"trials":23639,"activeCount":102},[],{"trials":23641,"activeCount":102},[],{"trials":23643,"activeCount":102},[23644],{"nctId":23604,"briefTitle":23605,"status":884,"phases":23645,"primaryCompletion":23607,"completion":23607,"start":215,"enrollment":20023,"conditions":23646,"interventions":23647},[92],[20484],[23593,23610,23611],{"trials":23649,"activeCount":102},[],{"trials":23651,"activeCount":102},[],{"intervention":23653,"totalTrials":195,"cells":23654},"Insulin glargine U300 (new formulation of insulin glargine) HOE901",{"EARLY_PHASE1":23655,"PHASE1":23657,"PHASE2":23659,"PHASE3":23661,"PHASE4":23669,"NA":23671},{"trials":23656,"activeCount":102},[],{"trials":23658,"activeCount":102},[],{"trials":23660,"activeCount":102},[],{"trials":23662,"activeCount":102},[23663],{"nctId":23664,"briefTitle":23665,"status":108,"phases":23666,"primaryCompletion":150,"completion":150,"start":11210,"enrollment":98,"conditions":23667,"interventions":23668},"NCT02227212","Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM",[92],[8117],[23653],{"trials":23670,"activeCount":102},[],{"trials":23672,"activeCount":102},[],{"intervention":12636,"totalTrials":195,"cells":23674},{"EARLY_PHASE1":23675,"PHASE1":23677,"PHASE2":23679,"PHASE3":23681,"PHASE4":23687,"NA":23689},{"trials":23676,"activeCount":102},[],{"trials":23678,"activeCount":102},[],{"trials":23680,"activeCount":102},[],{"trials":23682,"activeCount":102},[23683],{"nctId":12630,"briefTitle":12631,"status":108,"phases":23684,"primaryCompletion":3308,"completion":8607,"start":9592,"enrollment":12633,"conditions":23685,"interventions":23686},[92],[3625],[12619,12636],{"trials":23688,"activeCount":102},[],{"trials":23690,"activeCount":102},[],{"intervention":6496,"totalTrials":195,"cells":23692},{"EARLY_PHASE1":23693,"PHASE1":23695,"PHASE2":23697,"PHASE3":23699,"PHASE4":23705,"NA":23707},{"trials":23694,"activeCount":102},[],{"trials":23696,"activeCount":102},[],{"trials":23698,"activeCount":102},[],{"trials":23700,"activeCount":102},[23701],{"nctId":6490,"briefTitle":6491,"status":108,"phases":23702,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":23703,"interventions":23704},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"trials":23706,"activeCount":102},[],{"trials":23708,"activeCount":102},[],{"intervention":6497,"totalTrials":195,"cells":23710},{"EARLY_PHASE1":23711,"PHASE1":23713,"PHASE2":23715,"PHASE3":23717,"PHASE4":23723,"NA":23725},{"trials":23712,"activeCount":102},[],{"trials":23714,"activeCount":102},[],{"trials":23716,"activeCount":102},[],{"trials":23718,"activeCount":102},[23719],{"nctId":6490,"briefTitle":6491,"status":108,"phases":23720,"primaryCompletion":5216,"completion":5216,"start":2760,"enrollment":6493,"conditions":23721,"interventions":23722},[92],[990],[6458,6466,1015,993,1016,1017,6496,6497],{"trials":23724,"activeCount":102},[],{"trials":23726,"activeCount":102},[],{"intervention":23728,"totalTrials":195,"cells":23729},"Docetaxel + Estramustine + Hydrocortisone",{"EARLY_PHASE1":23730,"PHASE1":23732,"PHASE2":23734,"PHASE3":23736,"PHASE4":23745,"NA":23747},{"trials":23731,"activeCount":102},[],{"trials":23733,"activeCount":102},[],{"trials":23735,"activeCount":102},[],{"trials":23737,"activeCount":102},[23738],{"nctId":23739,"briefTitle":23740,"status":884,"phases":23741,"primaryCompletion":8731,"completion":8731,"start":5262,"enrollment":349,"conditions":23742,"interventions":23743},"NCT00705822","Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer",[92],[2804],[23728,23744],"Docetaxel + Prednisone",{"trials":23746,"activeCount":102},[],{"trials":23748,"activeCount":102},[],{"intervention":23744,"totalTrials":195,"cells":23750},{"EARLY_PHASE1":23751,"PHASE1":23753,"PHASE2":23755,"PHASE3":23757,"PHASE4":23763,"NA":23765},{"trials":23752,"activeCount":102},[],{"trials":23754,"activeCount":102},[],{"trials":23756,"activeCount":102},[],{"trials":23758,"activeCount":102},[23759],{"nctId":23739,"briefTitle":23740,"status":884,"phases":23760,"primaryCompletion":8731,"completion":8731,"start":5262,"enrollment":349,"conditions":23761,"interventions":23762},[92],[2804],[23728,23744],{"trials":23764,"activeCount":102},[],{"trials":23766,"activeCount":102},[],{"intervention":23768,"totalTrials":195,"cells":23769},"Levofloxacin (HR355) and Rifampicin Therapy",{"EARLY_PHASE1":23770,"PHASE1":23772,"PHASE2":23774,"PHASE3":23776,"PHASE4":23784,"NA":23786},{"trials":23771,"activeCount":102},[],{"trials":23773,"activeCount":102},[],{"trials":23775,"activeCount":102},[],{"trials":23777,"activeCount":102},[23778],{"nctId":23779,"briefTitle":23780,"status":884,"phases":23781,"primaryCompletion":3316,"completion":3316,"start":3396,"enrollment":552,"conditions":23782,"interventions":23783},"NCT00906048","LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection",[92],[13046],[23768],{"trials":23785,"activeCount":102},[],{"trials":23787,"activeCount":102},[],{"intervention":23789,"totalTrials":195,"cells":23790},"REPEVAX",{"EARLY_PHASE1":23791,"PHASE1":23793,"PHASE2":23795,"PHASE3":23797,"PHASE4":23806,"NA":23808},{"trials":23792,"activeCount":102},[],{"trials":23794,"activeCount":102},[],{"trials":23796,"activeCount":102},[],{"trials":23798,"activeCount":102},[23799],{"nctId":23800,"briefTitle":23801,"status":108,"phases":23802,"primaryCompletion":8388,"completion":8388,"start":8731,"enrollment":34,"conditions":23803,"interventions":23804},"NCT00928785","Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults",[92],[8839],[23789,23805],"Monovalent Tetanus vaccine",{"trials":23807,"activeCount":102},[],{"trials":23809,"activeCount":102},[],{"intervention":23805,"totalTrials":195,"cells":23811},{"EARLY_PHASE1":23812,"PHASE1":23814,"PHASE2":23816,"PHASE3":23818,"PHASE4":23824,"NA":23826},{"trials":23813,"activeCount":102},[],{"trials":23815,"activeCount":102},[],{"trials":23817,"activeCount":102},[],{"trials":23819,"activeCount":102},[23820],{"nctId":23800,"briefTitle":23801,"status":108,"phases":23821,"primaryCompletion":8388,"completion":8388,"start":8731,"enrollment":34,"conditions":23822,"interventions":23823},[92],[8839],[23789,23805],{"trials":23825,"activeCount":102},[],{"trials":23827,"activeCount":102},[],{"intervention":23829,"totalTrials":195,"cells":23830},"docetaxel, doxorubicin, cyclophosphamide",{"EARLY_PHASE1":23831,"PHASE1":23833,"PHASE2":23835,"PHASE3":23837,"PHASE4":23847,"NA":23849},{"trials":23832,"activeCount":102},[],{"trials":23834,"activeCount":102},[],{"trials":23836,"activeCount":102},[],{"trials":23838,"activeCount":102},[23839],{"nctId":23840,"briefTitle":23841,"status":108,"phases":23842,"primaryCompletion":8846,"completion":966,"start":8185,"enrollment":23843,"conditions":23844,"interventions":23845},"NCT00312208","Docetaxel in Breast Cancer",[92],3299,[5264],[23829,23846],"Docetaxel,doxorubicin, cyclophosphamide",{"trials":23848,"activeCount":102},[],{"trials":23850,"activeCount":102},[],{"intervention":23846,"totalTrials":195,"cells":23852},{"EARLY_PHASE1":23853,"PHASE1":23855,"PHASE2":23857,"PHASE3":23859,"PHASE4":23865,"NA":23867},{"trials":23854,"activeCount":102},[],{"trials":23856,"activeCount":102},[],{"trials":23858,"activeCount":102},[],{"trials":23860,"activeCount":102},[23861],{"nctId":23840,"briefTitle":23841,"status":108,"phases":23862,"primaryCompletion":8846,"completion":966,"start":8185,"enrollment":23843,"conditions":23863,"interventions":23864},[92],[5264],[23829,23846],{"trials":23866,"activeCount":102},[],{"trials":23868,"activeCount":102},[],{"intervention":10647,"totalTrials":195,"cells":23870},{"EARLY_PHASE1":23871,"PHASE1":23873,"PHASE2":23875,"PHASE3":23877,"PHASE4":23883,"NA":23885},{"trials":23872,"activeCount":102},[],{"trials":23874,"activeCount":102},[],{"trials":23876,"activeCount":102},[],{"trials":23878,"activeCount":102},[23879],{"nctId":10637,"briefTitle":10638,"status":108,"phases":23880,"primaryCompletion":10640,"completion":10641,"start":10642,"enrollment":10643,"conditions":23881,"interventions":23882},[92],[10645],[8508,10647,8067],{"trials":23884,"activeCount":102},[],{"trials":23886,"activeCount":102},[],{"intervention":2934,"totalTrials":195,"cells":23888},{"EARLY_PHASE1":23889,"PHASE1":23891,"PHASE2":23893,"PHASE3":23895,"PHASE4":23901,"NA":23903},{"trials":23890,"activeCount":102},[],{"trials":23892,"activeCount":102},[],{"trials":23894,"activeCount":102},[],{"trials":23896,"activeCount":102},[23897],{"nctId":2925,"briefTitle":2926,"status":108,"phases":23898,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":23899,"interventions":23900},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"trials":23902,"activeCount":102},[],{"trials":23904,"activeCount":102},[],{"intervention":2935,"totalTrials":195,"cells":23906},{"EARLY_PHASE1":23907,"PHASE1":23909,"PHASE2":23911,"PHASE3":23913,"PHASE4":23919,"NA":23921},{"trials":23908,"activeCount":102},[],{"trials":23910,"activeCount":102},[],{"trials":23912,"activeCount":102},[],{"trials":23914,"activeCount":102},[23915],{"nctId":2925,"briefTitle":2926,"status":108,"phases":23916,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":23917,"interventions":23918},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"trials":23920,"activeCount":102},[],{"trials":23922,"activeCount":102},[],{"intervention":2936,"totalTrials":195,"cells":23924},{"EARLY_PHASE1":23925,"PHASE1":23927,"PHASE2":23929,"PHASE3":23931,"PHASE4":23937,"NA":23939},{"trials":23926,"activeCount":102},[],{"trials":23928,"activeCount":102},[],{"trials":23930,"activeCount":102},[],{"trials":23932,"activeCount":102},[23933],{"nctId":2925,"briefTitle":2926,"status":108,"phases":23934,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":23935,"interventions":23936},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"trials":23938,"activeCount":102},[],{"trials":23940,"activeCount":102},[],{"intervention":2938,"totalTrials":195,"cells":23942},{"EARLY_PHASE1":23943,"PHASE1":23945,"PHASE2":23947,"PHASE3":23949,"PHASE4":23955,"NA":23957},{"trials":23944,"activeCount":102},[],{"trials":23946,"activeCount":102},[],{"trials":23948,"activeCount":102},[],{"trials":23950,"activeCount":102},[23951],{"nctId":2925,"briefTitle":2926,"status":108,"phases":23952,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":2930,"conditions":23953,"interventions":23954},[92],[2932],[2879,2934,2935,2901,2936,2937,2938,2939,2940],{"trials":23956,"activeCount":102},[],{"trials":23958,"activeCount":102},[],{"intervention":23960,"totalTrials":195,"cells":23961},"DTaP-IPV-Hep B-PRP~T vaccine",{"EARLY_PHASE1":23962,"PHASE1":23964,"PHASE2":23966,"PHASE3":23968,"PHASE4":23979,"NA":23981},{"trials":23963,"activeCount":102},[],{"trials":23965,"activeCount":102},[],{"trials":23967,"activeCount":102},[],{"trials":23969,"activeCount":102},[23970],{"nctId":23971,"briefTitle":23972,"status":108,"phases":23973,"primaryCompletion":8261,"completion":8731,"start":8822,"enrollment":23974,"conditions":23975,"interventions":23977},"NCT00654901","Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™",[92],881,[25,31,28,18625,12983,23976],"Haemophilus Influenzae Type B Infection",[23960,23960,23960,23978],"Infanrix Hexa™",{"trials":23980,"activeCount":102},[],{"trials":23982,"activeCount":102},[],{"intervention":23978,"totalTrials":195,"cells":23984},{"EARLY_PHASE1":23985,"PHASE1":23987,"PHASE2":23989,"PHASE3":23991,"PHASE4":23997,"NA":23999},{"trials":23986,"activeCount":102},[],{"trials":23988,"activeCount":102},[],{"trials":23990,"activeCount":102},[],{"trials":23992,"activeCount":102},[23993],{"nctId":23971,"briefTitle":23972,"status":108,"phases":23994,"primaryCompletion":8261,"completion":8731,"start":8822,"enrollment":23974,"conditions":23995,"interventions":23996},[92],[25,31,28,18625,12983,23976],[23960,23960,23960,23978],{"trials":23998,"activeCount":102},[],{"trials":24000,"activeCount":102},[],{"intervention":5023,"totalTrials":195,"cells":24002},{"EARLY_PHASE1":24003,"PHASE1":24005,"PHASE2":24007,"PHASE3":24009,"PHASE4":24015,"NA":24017},{"trials":24004,"activeCount":102},[],{"trials":24006,"activeCount":102},[],{"trials":24008,"activeCount":102},[],{"trials":24010,"activeCount":102},[24011],{"nctId":5012,"briefTitle":5013,"status":108,"phases":24012,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":24013,"interventions":24014},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"trials":24016,"activeCount":102},[],{"trials":24018,"activeCount":102},[],{"intervention":5024,"totalTrials":195,"cells":24020},{"EARLY_PHASE1":24021,"PHASE1":24023,"PHASE2":24025,"PHASE3":24027,"PHASE4":24033,"NA":24035},{"trials":24022,"activeCount":102},[],{"trials":24024,"activeCount":102},[],{"trials":24026,"activeCount":102},[],{"trials":24028,"activeCount":102},[24029],{"nctId":5012,"briefTitle":5013,"status":108,"phases":24030,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":24031,"interventions":24032},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"trials":24034,"activeCount":102},[],{"trials":24036,"activeCount":102},[],{"intervention":5025,"totalTrials":195,"cells":24038},{"EARLY_PHASE1":24039,"PHASE1":24041,"PHASE2":24043,"PHASE3":24045,"PHASE4":24051,"NA":24053},{"trials":24040,"activeCount":102},[],{"trials":24042,"activeCount":102},[],{"trials":24044,"activeCount":102},[],{"trials":24046,"activeCount":102},[24047],{"nctId":5012,"briefTitle":5013,"status":108,"phases":24048,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":5017,"conditions":24049,"interventions":24050},[92],[2932],[5020,5021,5022,4977,5023,5000,5024,5025],{"trials":24052,"activeCount":102},[],{"trials":24054,"activeCount":102},[],{"intervention":24056,"totalTrials":195,"cells":24057},"HBVAXPRO 5µg",{"EARLY_PHASE1":24058,"PHASE1":24060,"PHASE2":24062,"PHASE3":24064,"PHASE4":24072,"NA":24074},{"trials":24059,"activeCount":102},[],{"trials":24061,"activeCount":102},[],{"trials":24063,"activeCount":102},[],{"trials":24065,"activeCount":102},[24066],{"nctId":24067,"briefTitle":24068,"status":108,"phases":24069,"primaryCompletion":1042,"completion":1042,"start":2855,"enrollment":2091,"conditions":24070,"interventions":24071},"NCT02012998","Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA",[92],[2491,18625],[24056],{"trials":24073,"activeCount":102},[],{"trials":24075,"activeCount":102},[],{"intervention":21598,"totalTrials":195,"cells":24077},{"EARLY_PHASE1":24078,"PHASE1":24080,"PHASE2":24082,"PHASE3":24084,"PHASE4":24090,"NA":24092},{"trials":24079,"activeCount":102},[],{"trials":24081,"activeCount":102},[],{"trials":24083,"activeCount":102},[],{"trials":24085,"activeCount":102},[24086],{"nctId":21589,"briefTitle":21590,"status":108,"phases":24087,"primaryCompletion":21592,"completion":21593,"start":21594,"enrollment":21595,"conditions":24088,"interventions":24089},[92],[17265,2978],[21598,21599],{"trials":24091,"activeCount":102},[],{"trials":24093,"activeCount":102},[],{"intervention":5037,"totalTrials":195,"cells":24095},{"EARLY_PHASE1":24096,"PHASE1":24098,"PHASE2":24100,"PHASE3":24102,"PHASE4":24108,"NA":24110},{"trials":24097,"activeCount":102},[],{"trials":24099,"activeCount":102},[],{"trials":24101,"activeCount":102},[],{"trials":24103,"activeCount":102},[24104],{"nctId":5027,"briefTitle":5028,"status":108,"phases":24105,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":24106,"interventions":24107},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"trials":24109,"activeCount":102},[],{"trials":24111,"activeCount":102},[],{"intervention":5038,"totalTrials":195,"cells":24113},{"EARLY_PHASE1":24114,"PHASE1":24116,"PHASE2":24118,"PHASE3":24120,"PHASE4":24126,"NA":24128},{"trials":24115,"activeCount":102},[],{"trials":24117,"activeCount":102},[],{"trials":24119,"activeCount":102},[],{"trials":24121,"activeCount":102},[24122],{"nctId":5027,"briefTitle":5028,"status":108,"phases":24123,"primaryCompletion":5030,"completion":5030,"start":5031,"enrollment":5032,"conditions":24124,"interventions":24125},[92],[2932],[5035,5036,5037,4977,4999,5000,5038,5039],{"trials":24127,"activeCount":102},[],{"trials":24129,"activeCount":102},[],{"intervention":24131,"totalTrials":195,"cells":24132},"Inactivated Split-virion influenza vaccine",{"EARLY_PHASE1":24133,"PHASE1":24135,"PHASE2":24137,"PHASE3":24139,"PHASE4":24148,"NA":24150},{"trials":24134,"activeCount":102},[],{"trials":24136,"activeCount":102},[],{"trials":24138,"activeCount":102},[],{"trials":24140,"activeCount":102},[24141],{"nctId":24142,"briefTitle":24143,"status":108,"phases":24144,"primaryCompletion":3563,"completion":7509,"start":3622,"enrollment":24145,"conditions":24146,"interventions":24147},"NCT00383539","Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults",[92],2256,[12314,16,10695],[24131,24131,24131,24131],{"trials":24149,"activeCount":102},[],{"trials":24151,"activeCount":102},[],{"intervention":24153,"totalTrials":195,"cells":24154},"Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative",{"EARLY_PHASE1":24155,"PHASE1":24157,"PHASE2":24159,"PHASE3":24161,"PHASE4":24172,"NA":24174},{"trials":24156,"activeCount":102},[],{"trials":24158,"activeCount":102},[],{"trials":24160,"activeCount":102},[],{"trials":24162,"activeCount":102},[24163],{"nctId":24164,"briefTitle":24165,"status":108,"phases":24166,"primaryCompletion":165,"completion":2790,"start":8453,"enrollment":24167,"conditions":24168,"interventions":24169},"NCT01218646","Study of Quadrivalent Influenza Vaccine Among Adults",[92],739,[16],[24153,24170,24171,24171],"Investigational Trivalent Inactivated Influenza Vaccine, No Preservative","Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative",{"trials":24173,"activeCount":102},[],{"trials":24175,"activeCount":102},[],{"intervention":24170,"totalTrials":195,"cells":24177},{"EARLY_PHASE1":24178,"PHASE1":24180,"PHASE2":24182,"PHASE3":24184,"PHASE4":24190,"NA":24192},{"trials":24179,"activeCount":102},[],{"trials":24181,"activeCount":102},[],{"trials":24183,"activeCount":102},[],{"trials":24185,"activeCount":102},[24186],{"nctId":24164,"briefTitle":24165,"status":108,"phases":24187,"primaryCompletion":165,"completion":2790,"start":8453,"enrollment":24167,"conditions":24188,"interventions":24189},[92],[16],[24153,24170,24171,24171],{"trials":24191,"activeCount":102},[],{"trials":24193,"activeCount":102},[],{"intervention":24171,"totalTrials":195,"cells":24195},{"EARLY_PHASE1":24196,"PHASE1":24198,"PHASE2":24200,"PHASE3":24202,"PHASE4":24208,"NA":24210},{"trials":24197,"activeCount":102},[],{"trials":24199,"activeCount":102},[],{"trials":24201,"activeCount":102},[],{"trials":24203,"activeCount":102},[24204],{"nctId":24164,"briefTitle":24165,"status":108,"phases":24205,"primaryCompletion":165,"completion":2790,"start":8453,"enrollment":24167,"conditions":24206,"interventions":24207},[92],[16],[24153,24170,24171,24171],{"trials":24209,"activeCount":102},[],{"trials":24211,"activeCount":102},[],{"intervention":24213,"totalTrials":195,"cells":24214},"FDC KETOPROFEN+OMEPRAZOLE",{"EARLY_PHASE1":24215,"PHASE1":24217,"PHASE2":24219,"PHASE3":24221,"PHASE4":24229,"NA":24231},{"trials":24216,"activeCount":102},[],{"trials":24218,"activeCount":102},[],{"trials":24220,"activeCount":102},[],{"trials":24222,"activeCount":102},[24223],{"nctId":24224,"briefTitle":24225,"status":108,"phases":24226,"primaryCompletion":9984,"completion":9984,"start":8215,"enrollment":34,"conditions":24227,"interventions":24228},"NCT00971581","Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole",[92],[12745],[24213],{"trials":24230,"activeCount":102},[],{"trials":24232,"activeCount":102},[],{"intervention":24234,"totalTrials":195,"cells":24235},"A\u002FH1N1 pandemic influenza vaccine",{"EARLY_PHASE1":24236,"PHASE1":24238,"PHASE2":24240,"PHASE3":24242,"PHASE4":24252,"NA":24254},{"trials":24237,"activeCount":102},[],{"trials":24239,"activeCount":102},[],{"trials":24241,"activeCount":102},[],{"trials":24243,"activeCount":102},[24244],{"nctId":24245,"briefTitle":24246,"status":108,"phases":24247,"primaryCompletion":5271,"completion":5217,"start":8745,"enrollment":465,"conditions":24248,"interventions":24251},"NCT01053143","Study of Swine-Origin A\u002FH1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India",[92],[16,24249,24250],"Pandemic Influenza","Influenza A Virus, H1N1 Subtype",[24234],{"trials":24253,"activeCount":102},[],{"trials":24255,"activeCount":102},[],{"intervention":24257,"totalTrials":195,"cells":24258},"Standard-Dose influenza virus surface antigens",{"EARLY_PHASE1":24259,"PHASE1":24261,"PHASE2":24263,"PHASE3":24265,"PHASE4":24278,"NA":24280},{"trials":24260,"activeCount":102},[],{"trials":24262,"activeCount":102},[],{"trials":24264,"activeCount":102},[],{"trials":24266,"activeCount":102},[24267],{"nctId":24268,"briefTitle":24269,"status":108,"phases":24270,"primaryCompletion":24271,"completion":24272,"start":24273,"enrollment":24274,"conditions":24275,"interventions":24276},"NCT04024228","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older",[92],"2020-01-09","2020-06-05","2019-10-28",1539,[5335,36],[24257,24277],"High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation",{"trials":24279,"activeCount":102},[],{"trials":24281,"activeCount":102},[],{"intervention":24277,"totalTrials":195,"cells":24283},{"EARLY_PHASE1":24284,"PHASE1":24286,"PHASE2":24288,"PHASE3":24290,"PHASE4":24296,"NA":24298},{"trials":24285,"activeCount":102},[],{"trials":24287,"activeCount":102},[],{"trials":24289,"activeCount":102},[],{"trials":24291,"activeCount":102},[24292],{"nctId":24268,"briefTitle":24269,"status":108,"phases":24293,"primaryCompletion":24271,"completion":24272,"start":24273,"enrollment":24274,"conditions":24294,"interventions":24295},[92],[5335,36],[24257,24277],{"trials":24297,"activeCount":102},[],{"trials":24299,"activeCount":102},[],{"intervention":20638,"totalTrials":195,"cells":24301},{"EARLY_PHASE1":24302,"PHASE1":24304,"PHASE2":24306,"PHASE3":24308,"PHASE4":24314,"NA":24316},{"trials":24303,"activeCount":102},[],{"trials":24305,"activeCount":102},[],{"trials":24307,"activeCount":102},[],{"trials":24309,"activeCount":102},[24310],{"nctId":20632,"briefTitle":20633,"status":108,"phases":24311,"primaryCompletion":8205,"completion":3396,"start":1341,"enrollment":20635,"conditions":24312,"interventions":24313},[92],[25,31,28,18625,16],[20638,20639,20621],{"trials":24315,"activeCount":102},[],{"trials":24317,"activeCount":102},[],{"intervention":252,"totalTrials":195,"cells":24319},{"EARLY_PHASE1":24320,"PHASE1":24322,"PHASE2":24324,"PHASE3":24326,"PHASE4":24332,"NA":24334},{"trials":24321,"activeCount":102},[],{"trials":24323,"activeCount":102},[],{"trials":24325,"activeCount":102},[],{"trials":24327,"activeCount":102},[24328],{"nctId":243,"briefTitle":244,"status":108,"phases":24329,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":24330,"interventions":24331},[92],[155],[97,252,230,231,232],{"trials":24333,"activeCount":102},[],{"trials":24335,"activeCount":102},[],{"intervention":24337,"totalTrials":195,"cells":24338},"Leuprolide",{"EARLY_PHASE1":24339,"PHASE1":24341,"PHASE2":24343,"PHASE3":24345,"PHASE4":24354,"NA":24356},{"trials":24340,"activeCount":102},[],{"trials":24342,"activeCount":102},[],{"trials":24344,"activeCount":102},[],{"trials":24346,"activeCount":102},[24347],{"nctId":24348,"briefTitle":24349,"status":884,"phases":24350,"primaryCompletion":10178,"completion":10178,"start":3563,"enrollment":7452,"conditions":24351,"interventions":24352},"NCT00514917","A Study of Androgen Deprivation With Leuprolide, +\u002F- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)",[92],[2804],[1348,24337,24353],"Bicalutamide",{"trials":24355,"activeCount":102},[],{"trials":24357,"activeCount":102},[],{"intervention":24353,"totalTrials":195,"cells":24359},{"EARLY_PHASE1":24360,"PHASE1":24362,"PHASE2":24364,"PHASE3":24366,"PHASE4":24372,"NA":24374},{"trials":24361,"activeCount":102},[],{"trials":24363,"activeCount":102},[],{"trials":24365,"activeCount":102},[],{"trials":24367,"activeCount":102},[24368],{"nctId":24348,"briefTitle":24349,"status":884,"phases":24369,"primaryCompletion":10178,"completion":10178,"start":3563,"enrollment":7452,"conditions":24370,"interventions":24371},[92],[2804],[1348,24337,24353],{"trials":24373,"activeCount":102},[],{"trials":24375,"activeCount":102},[],{"intervention":24377,"totalTrials":195,"cells":24378},"DAPTACEL®: DTaP",{"EARLY_PHASE1":24379,"PHASE1":24381,"PHASE2":24383,"PHASE3":24385,"PHASE4":24394,"NA":24396},{"trials":24380,"activeCount":102},[],{"trials":24382,"activeCount":102},[],{"trials":24384,"activeCount":102},[],{"trials":24386,"activeCount":102},[24387],{"nctId":24388,"briefTitle":24389,"status":108,"phases":24390,"primaryCompletion":10339,"completion":3355,"start":9130,"enrollment":24391,"conditions":24392,"interventions":24393},"NCT00258895","Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®",[92],649,[25,31,28],[24377,24377],{"trials":24395,"activeCount":102},[],{"trials":24397,"activeCount":102},[],{"intervention":24399,"totalTrials":195,"cells":24400},"HBVaxPRO® 5 µg \u002F 0.5 mL",{"EARLY_PHASE1":24401,"PHASE1":24403,"PHASE2":24405,"PHASE3":24407,"PHASE4":24417,"NA":24419},{"trials":24402,"activeCount":102},[],{"trials":24404,"activeCount":102},[],{"trials":24406,"activeCount":102},[],{"trials":24408,"activeCount":102},[24409],{"nctId":24410,"briefTitle":24411,"status":108,"phases":24412,"primaryCompletion":8388,"completion":1022,"start":8846,"enrollment":24413,"conditions":24414,"interventions":24415},"NCT00693186","A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA",[92],410,[18625],[24399,24416],"Engerix B® 10 µg \u002F 0.5 mL",{"trials":24418,"activeCount":102},[],{"trials":24420,"activeCount":102},[],{"intervention":24416,"totalTrials":195,"cells":24422},{"EARLY_PHASE1":24423,"PHASE1":24425,"PHASE2":24427,"PHASE3":24429,"PHASE4":24435,"NA":24437},{"trials":24424,"activeCount":102},[],{"trials":24426,"activeCount":102},[],{"trials":24428,"activeCount":102},[],{"trials":24430,"activeCount":102},[24431],{"nctId":24410,"briefTitle":24411,"status":108,"phases":24432,"primaryCompletion":8388,"completion":1022,"start":8846,"enrollment":24413,"conditions":24433,"interventions":24434},[92],[18625],[24399,24416],{"trials":24436,"activeCount":102},[],{"trials":24438,"activeCount":102},[],{"intervention":24440,"totalTrials":195,"cells":24441},"AVANAFIL",{"EARLY_PHASE1":24442,"PHASE1":24444,"PHASE2":24446,"PHASE3":24448,"PHASE4":24457,"NA":24459},{"trials":24443,"activeCount":102},[],{"trials":24445,"activeCount":102},[],{"trials":24447,"activeCount":102},[],{"trials":24449,"activeCount":102},[24450],{"nctId":24451,"briefTitle":24452,"status":108,"phases":24453,"primaryCompletion":1054,"completion":1054,"start":964,"enrollment":8262,"conditions":24454,"interventions":24456},"NCT02503306","Efficacy and Tolerability Study of Avanafil in Russia",[92],[24455],"Sexual Function and Fertility Disorders NEC-Erectile Dysfunction",[24440],{"trials":24458,"activeCount":102},[],{"trials":24460,"activeCount":102},[],{"intervention":24462,"totalTrials":195,"cells":24463},"Measles-mumps-rubella-varicella vaccine",{"EARLY_PHASE1":24464,"PHASE1":24466,"PHASE2":24468,"PHASE3":24470,"PHASE4":24482,"NA":24484},{"trials":24465,"activeCount":102},[],{"trials":24467,"activeCount":102},[],{"trials":24469,"activeCount":102},[],{"trials":24471,"activeCount":102},[24472],{"nctId":24473,"briefTitle":24474,"status":108,"phases":24475,"primaryCompletion":9532,"completion":3396,"start":3308,"enrollment":24476,"conditions":24477,"interventions":24478},"NCT00483574","Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers",[92],1378,[7568,10899,10900,10901,2978],[24479,24462,24480,24481],"Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate","Routine paediatric vaccine - Pneumococcal conjugate","Routine paediatric vaccine - Hepatitis A",{"trials":24483,"activeCount":102},[],{"trials":24485,"activeCount":102},[],{"intervention":24480,"totalTrials":195,"cells":24487},{"EARLY_PHASE1":24488,"PHASE1":24490,"PHASE2":24492,"PHASE3":24494,"PHASE4":24500,"NA":24502},{"trials":24489,"activeCount":102},[],{"trials":24491,"activeCount":102},[],{"trials":24493,"activeCount":102},[],{"trials":24495,"activeCount":102},[24496],{"nctId":24473,"briefTitle":24474,"status":108,"phases":24497,"primaryCompletion":9532,"completion":3396,"start":3308,"enrollment":24476,"conditions":24498,"interventions":24499},[92],[7568,10899,10900,10901,2978],[24479,24462,24480,24481],{"trials":24501,"activeCount":102},[],{"trials":24503,"activeCount":102},[],{"intervention":24481,"totalTrials":195,"cells":24505},{"EARLY_PHASE1":24506,"PHASE1":24508,"PHASE2":24510,"PHASE3":24512,"PHASE4":24518,"NA":24520},{"trials":24507,"activeCount":102},[],{"trials":24509,"activeCount":102},[],{"trials":24511,"activeCount":102},[],{"trials":24513,"activeCount":102},[24514],{"nctId":24473,"briefTitle":24474,"status":108,"phases":24515,"primaryCompletion":9532,"completion":3396,"start":3308,"enrollment":24476,"conditions":24516,"interventions":24517},[92],[7568,10899,10900,10901,2978],[24479,24462,24480,24481],{"trials":24519,"activeCount":102},[],{"trials":24521,"activeCount":102},[],{"intervention":21964,"totalTrials":195,"cells":24523},{"EARLY_PHASE1":24524,"PHASE1":24526,"PHASE2":24528,"PHASE3":24530,"PHASE4":24536,"NA":24538},{"trials":24525,"activeCount":102},[],{"trials":24527,"activeCount":102},[],{"trials":24529,"activeCount":102},[],{"trials":24531,"activeCount":102},[24532],{"nctId":21959,"briefTitle":21960,"status":108,"phases":24533,"primaryCompletion":2857,"completion":7284,"start":7292,"enrollment":3356,"conditions":24534,"interventions":24535},[92],[4992,2949],[21941,21964],{"trials":24537,"activeCount":102},[],{"trials":24539,"activeCount":102},[],{"intervention":7610,"totalTrials":195,"cells":24541},{"EARLY_PHASE1":24542,"PHASE1":24544,"PHASE2":24546,"PHASE3":24548,"PHASE4":24554,"NA":24556},{"trials":24543,"activeCount":102},[],{"trials":24545,"activeCount":102},[],{"trials":24547,"activeCount":102},[],{"trials":24549,"activeCount":102},[24550],{"nctId":7602,"briefTitle":7603,"status":108,"phases":24551,"primaryCompletion":7605,"completion":7605,"start":7606,"enrollment":7607,"conditions":24552,"interventions":24553},[92],[4992,7568,2922],[5020,7610],{"trials":24555,"activeCount":102},[],{"trials":24557,"activeCount":102},[],{"intervention":11822,"totalTrials":195,"cells":24559},{"EARLY_PHASE1":24560,"PHASE1":24562,"PHASE2":24564,"PHASE3":24566,"PHASE4":24572,"NA":24574},{"trials":24561,"activeCount":102},[],{"trials":24563,"activeCount":102},[],{"trials":24565,"activeCount":102},[],{"trials":24567,"activeCount":102},[24568],{"nctId":11816,"briefTitle":11817,"status":108,"phases":24569,"primaryCompletion":964,"completion":964,"start":2311,"enrollment":11819,"conditions":24570,"interventions":24571},[92],[19],[11791,11822,11823,11824,11825],{"trials":24573,"activeCount":102},[],{"trials":24575,"activeCount":102},[],{"intervention":11823,"totalTrials":195,"cells":24577},{"EARLY_PHASE1":24578,"PHASE1":24580,"PHASE2":24582,"PHASE3":24584,"PHASE4":24590,"NA":24592},{"trials":24579,"activeCount":102},[],{"trials":24581,"activeCount":102},[],{"trials":24583,"activeCount":102},[],{"trials":24585,"activeCount":102},[24586],{"nctId":11816,"briefTitle":11817,"status":108,"phases":24587,"primaryCompletion":964,"completion":964,"start":2311,"enrollment":11819,"conditions":24588,"interventions":24589},[92],[19],[11791,11822,11823,11824,11825],{"trials":24591,"activeCount":102},[],{"trials":24593,"activeCount":102},[],{"intervention":11824,"totalTrials":195,"cells":24595},{"EARLY_PHASE1":24596,"PHASE1":24598,"PHASE2":24600,"PHASE3":24602,"PHASE4":24608,"NA":24610},{"trials":24597,"activeCount":102},[],{"trials":24599,"activeCount":102},[],{"trials":24601,"activeCount":102},[],{"trials":24603,"activeCount":102},[24604],{"nctId":11816,"briefTitle":11817,"status":108,"phases":24605,"primaryCompletion":964,"completion":964,"start":2311,"enrollment":11819,"conditions":24606,"interventions":24607},[92],[19],[11791,11822,11823,11824,11825],{"trials":24609,"activeCount":102},[],{"trials":24611,"activeCount":102},[],{"intervention":11825,"totalTrials":195,"cells":24613},{"EARLY_PHASE1":24614,"PHASE1":24616,"PHASE2":24618,"PHASE3":24620,"PHASE4":24626,"NA":24628},{"trials":24615,"activeCount":102},[],{"trials":24617,"activeCount":102},[],{"trials":24619,"activeCount":102},[],{"trials":24621,"activeCount":102},[24622],{"nctId":11816,"briefTitle":11817,"status":108,"phases":24623,"primaryCompletion":964,"completion":964,"start":2311,"enrollment":11819,"conditions":24624,"interventions":24625},[92],[19],[11791,11822,11823,11824,11825],{"trials":24627,"activeCount":102},[],{"trials":24629,"activeCount":102},[],{"intervention":8574,"totalTrials":195,"cells":24631},{"EARLY_PHASE1":24632,"PHASE1":24634,"PHASE2":24636,"PHASE3":24638,"PHASE4":24644,"NA":24646},{"trials":24633,"activeCount":102},[],{"trials":24635,"activeCount":102},[],{"trials":24637,"activeCount":102},[],{"trials":24639,"activeCount":102},[24640],{"nctId":8567,"briefTitle":8568,"status":884,"phases":24641,"primaryCompletion":8570,"completion":8570,"start":8505,"enrollment":402,"conditions":24642,"interventions":24643},[92],[8572],[8057,8209,8574],{"trials":24645,"activeCount":102},[],{"trials":24647,"activeCount":102},[],{"intervention":7344,"totalTrials":195,"cells":24649},{"EARLY_PHASE1":24650,"PHASE1":24652,"PHASE2":24654,"PHASE3":24656,"PHASE4":24662,"NA":24664},{"trials":24651,"activeCount":102},[],{"trials":24653,"activeCount":102},[],{"trials":24655,"activeCount":102},[],{"trials":24657,"activeCount":102},[24658],{"nctId":7336,"briefTitle":7337,"status":108,"phases":24659,"primaryCompletion":7339,"completion":7339,"start":164,"enrollment":7340,"conditions":24660,"interventions":24661},[92],[7342],[7273,7344],{"trials":24663,"activeCount":102},[],{"trials":24665,"activeCount":102},[],{"intervention":19331,"totalTrials":195,"cells":24667},{"EARLY_PHASE1":24668,"PHASE1":24670,"PHASE2":24672,"PHASE3":24674,"PHASE4":24680,"NA":24682},{"trials":24669,"activeCount":102},[],{"trials":24671,"activeCount":102},[],{"trials":24673,"activeCount":102},[],{"trials":24675,"activeCount":102},[24676],{"nctId":19325,"briefTitle":19326,"status":108,"phases":24677,"primaryCompletion":19328,"completion":19328,"start":1600,"enrollment":956,"conditions":24678,"interventions":24679},[92],[7891],[5338,19331],{"trials":24681,"activeCount":102},[],{"trials":24683,"activeCount":102},[],{"intervention":11242,"totalTrials":195,"cells":24685},{"EARLY_PHASE1":24686,"PHASE1":24688,"PHASE2":24690,"PHASE3":24692,"PHASE4":24698,"NA":24700},{"trials":24687,"activeCount":102},[],{"trials":24689,"activeCount":102},[],{"trials":24691,"activeCount":102},[],{"trials":24693,"activeCount":102},[24694],{"nctId":11235,"briefTitle":11236,"status":108,"phases":24695,"primaryCompletion":11238,"completion":11238,"start":11239,"enrollment":6577,"conditions":24696,"interventions":24697},[92],[3892],[3863,11242,11243],{"trials":24699,"activeCount":102},[],{"trials":24701,"activeCount":102},[],{"intervention":11243,"totalTrials":195,"cells":24703},{"EARLY_PHASE1":24704,"PHASE1":24706,"PHASE2":24708,"PHASE3":24710,"PHASE4":24716,"NA":24718},{"trials":24705,"activeCount":102},[],{"trials":24707,"activeCount":102},[],{"trials":24709,"activeCount":102},[],{"trials":24711,"activeCount":102},[24712],{"nctId":11235,"briefTitle":11236,"status":108,"phases":24713,"primaryCompletion":11238,"completion":11238,"start":11239,"enrollment":6577,"conditions":24714,"interventions":24715},[92],[3892],[3863,11242,11243],{"trials":24717,"activeCount":102},[],{"trials":24719,"activeCount":102},[],{"intervention":275,"totalTrials":195,"cells":24721},{"EARLY_PHASE1":24722,"PHASE1":24724,"PHASE2":24726,"PHASE3":24728,"PHASE4":24734,"NA":24736},{"trials":24723,"activeCount":102},[],{"trials":24725,"activeCount":102},[],{"trials":24727,"activeCount":102},[],{"trials":24729,"activeCount":102},[24730],{"nctId":265,"briefTitle":266,"status":108,"phases":24731,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":24732,"interventions":24733},[92],[273],[97,275],{"trials":24735,"activeCount":102},[],{"trials":24737,"activeCount":102},[],{"intervention":24739,"totalTrials":195,"cells":24740},"PENTAXIM™: DTacP IPV\u002F\u002FPRP~T combined vaccine",{"EARLY_PHASE1":24741,"PHASE1":24743,"PHASE2":24745,"PHASE3":24747,"PHASE4":24756,"NA":24758},{"trials":24742,"activeCount":102},[],{"trials":24744,"activeCount":102},[],{"trials":24746,"activeCount":102},[],{"trials":24748,"activeCount":102},[24749],{"nctId":24750,"briefTitle":24751,"status":108,"phases":24752,"primaryCompletion":8062,"completion":977,"start":5217,"enrollment":12082,"conditions":24753,"interventions":24754},"NCT01214889","Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.",[92],[25,31,28,12983,17179],[24739,24755],"TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine",{"trials":24757,"activeCount":102},[],{"trials":24759,"activeCount":102},[],{"intervention":24755,"totalTrials":195,"cells":24761},{"EARLY_PHASE1":24762,"PHASE1":24764,"PHASE2":24766,"PHASE3":24768,"PHASE4":24774,"NA":24776},{"trials":24763,"activeCount":102},[],{"trials":24765,"activeCount":102},[],{"trials":24767,"activeCount":102},[],{"trials":24769,"activeCount":102},[24770],{"nctId":24750,"briefTitle":24751,"status":108,"phases":24771,"primaryCompletion":8062,"completion":977,"start":5217,"enrollment":12082,"conditions":24772,"interventions":24773},[92],[25,31,28,12983,17179],[24739,24755],{"trials":24775,"activeCount":102},[],{"trials":24777,"activeCount":102},[],{"intervention":24779,"totalTrials":195,"cells":24780},"DTaP IPV HB PRP~T vaccine",{"EARLY_PHASE1":24781,"PHASE1":24783,"PHASE2":24785,"PHASE3":24787,"PHASE4":24797,"NA":24799},{"trials":24782,"activeCount":102},[],{"trials":24784,"activeCount":102},[],{"trials":24786,"activeCount":102},[],{"trials":24788,"activeCount":102},[24789],{"nctId":24790,"briefTitle":24791,"status":108,"phases":24792,"primaryCompletion":8261,"completion":8570,"start":8316,"enrollment":24793,"conditions":24794,"interventions":24795},"NCT00831753","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants",[92],263,[25,31,28,20655,18625],[24779,24796],"DTaP-HB-IPV and Haemophilus influenzae type b",{"trials":24798,"activeCount":102},[],{"trials":24800,"activeCount":102},[],{"intervention":24796,"totalTrials":195,"cells":24802},{"EARLY_PHASE1":24803,"PHASE1":24805,"PHASE2":24807,"PHASE3":24809,"PHASE4":24815,"NA":24817},{"trials":24804,"activeCount":102},[],{"trials":24806,"activeCount":102},[],{"trials":24808,"activeCount":102},[],{"trials":24810,"activeCount":102},[24811],{"nctId":24790,"briefTitle":24791,"status":108,"phases":24812,"primaryCompletion":8261,"completion":8570,"start":8316,"enrollment":24793,"conditions":24813,"interventions":24814},[92],[25,31,28,20655,18625],[24779,24796],{"trials":24816,"activeCount":102},[],{"trials":24818,"activeCount":102},[],{"intervention":11993,"totalTrials":195,"cells":24820},{"EARLY_PHASE1":24821,"PHASE1":24823,"PHASE2":24825,"PHASE3":24827,"PHASE4":24833,"NA":24835},{"trials":24822,"activeCount":102},[],{"trials":24824,"activeCount":102},[],{"trials":24826,"activeCount":102},[],{"trials":24828,"activeCount":102},[24829],{"nctId":11988,"briefTitle":11989,"status":108,"phases":24830,"primaryCompletion":165,"completion":165,"start":3354,"enrollment":3767,"conditions":24831,"interventions":24832},[92],[554],[8067,11993,8766],{"trials":24834,"activeCount":102},[],{"trials":24836,"activeCount":102},[],{"intervention":2493,"totalTrials":195,"cells":24838},{"EARLY_PHASE1":24839,"PHASE1":24841,"PHASE2":24843,"PHASE3":24845,"PHASE4":24851,"NA":24853},{"trials":24840,"activeCount":102},[],{"trials":24842,"activeCount":102},[],{"trials":24844,"activeCount":102},[],{"trials":24846,"activeCount":102},[24847],{"nctId":2484,"briefTitle":2485,"status":108,"phases":24848,"primaryCompletion":2487,"completion":1042,"start":1032,"enrollment":474,"conditions":24849,"interventions":24850},[92],[2489,2490,2491],[2493,2494,2495,1931,2496,2497],{"trials":24852,"activeCount":102},[],{"trials":24854,"activeCount":102},[],{"intervention":2494,"totalTrials":195,"cells":24856},{"EARLY_PHASE1":24857,"PHASE1":24859,"PHASE2":24861,"PHASE3":24863,"PHASE4":24869,"NA":24871},{"trials":24858,"activeCount":102},[],{"trials":24860,"activeCount":102},[],{"trials":24862,"activeCount":102},[],{"trials":24864,"activeCount":102},[24865],{"nctId":2484,"briefTitle":2485,"status":108,"phases":24866,"primaryCompletion":2487,"completion":1042,"start":1032,"enrollment":474,"conditions":24867,"interventions":24868},[92],[2489,2490,2491],[2493,2494,2495,1931,2496,2497],{"trials":24870,"activeCount":102},[],{"trials":24872,"activeCount":102},[],{"intervention":2495,"totalTrials":195,"cells":24874},{"EARLY_PHASE1":24875,"PHASE1":24877,"PHASE2":24879,"PHASE3":24881,"PHASE4":24887,"NA":24889},{"trials":24876,"activeCount":102},[],{"trials":24878,"activeCount":102},[],{"trials":24880,"activeCount":102},[],{"trials":24882,"activeCount":102},[24883],{"nctId":2484,"briefTitle":2485,"status":108,"phases":24884,"primaryCompletion":2487,"completion":1042,"start":1032,"enrollment":474,"conditions":24885,"interventions":24886},[92],[2489,2490,2491],[2493,2494,2495,1931,2496,2497],{"trials":24888,"activeCount":102},[],{"trials":24890,"activeCount":102},[],{"intervention":2496,"totalTrials":195,"cells":24892},{"EARLY_PHASE1":24893,"PHASE1":24895,"PHASE2":24897,"PHASE3":24899,"PHASE4":24905,"NA":24907},{"trials":24894,"activeCount":102},[],{"trials":24896,"activeCount":102},[],{"trials":24898,"activeCount":102},[],{"trials":24900,"activeCount":102},[24901],{"nctId":2484,"briefTitle":2485,"status":108,"phases":24902,"primaryCompletion":2487,"completion":1042,"start":1032,"enrollment":474,"conditions":24903,"interventions":24904},[92],[2489,2490,2491],[2493,2494,2495,1931,2496,2497],{"trials":24906,"activeCount":102},[],{"trials":24908,"activeCount":102},[],{"intervention":2497,"totalTrials":195,"cells":24910},{"EARLY_PHASE1":24911,"PHASE1":24913,"PHASE2":24915,"PHASE3":24917,"PHASE4":24923,"NA":24925},{"trials":24912,"activeCount":102},[],{"trials":24914,"activeCount":102},[],{"trials":24916,"activeCount":102},[],{"trials":24918,"activeCount":102},[24919],{"nctId":2484,"briefTitle":2485,"status":108,"phases":24920,"primaryCompletion":2487,"completion":1042,"start":1032,"enrollment":474,"conditions":24921,"interventions":24922},[92],[2489,2490,2491],[2493,2494,2495,1931,2496,2497],{"trials":24924,"activeCount":102},[],{"trials":24926,"activeCount":102},[],{"intervention":7128,"totalTrials":195,"cells":24928},{"EARLY_PHASE1":24929,"PHASE1":24931,"PHASE2":24933,"PHASE3":24935,"PHASE4":24941,"NA":24943},{"trials":24930,"activeCount":102},[],{"trials":24932,"activeCount":102},[],{"trials":24934,"activeCount":102},[],{"trials":24936,"activeCount":102},[24937],{"nctId":7120,"briefTitle":7121,"status":108,"phases":24938,"primaryCompletion":7123,"completion":7123,"start":7124,"enrollment":7125,"conditions":24939,"interventions":24940},[92],[2062],[2064,7128],{"trials":24942,"activeCount":102},[],{"trials":24944,"activeCount":102},[],{"intervention":2964,"totalTrials":195,"cells":24946},{"EARLY_PHASE1":24947,"PHASE1":24949,"PHASE2":24951,"PHASE3":24953,"PHASE4":24959,"NA":24961},{"trials":24948,"activeCount":102},[],{"trials":24950,"activeCount":102},[],{"trials":24952,"activeCount":102},[],{"trials":24954,"activeCount":102},[24955],{"nctId":2954,"briefTitle":2955,"status":108,"phases":24956,"primaryCompletion":2957,"completion":2958,"start":2959,"enrollment":2960,"conditions":24957,"interventions":24958},[92],[2922],[2879,2963,2964,2965,2965,2966],{"trials":24960,"activeCount":102},[],{"trials":24962,"activeCount":102},[],{"intervention":2966,"totalTrials":195,"cells":24964},{"EARLY_PHASE1":24965,"PHASE1":24967,"PHASE2":24969,"PHASE3":24971,"PHASE4":24977,"NA":24979},{"trials":24966,"activeCount":102},[],{"trials":24968,"activeCount":102},[],{"trials":24970,"activeCount":102},[],{"trials":24972,"activeCount":102},[24973],{"nctId":2954,"briefTitle":2955,"status":108,"phases":24974,"primaryCompletion":2957,"completion":2958,"start":2959,"enrollment":2960,"conditions":24975,"interventions":24976},[92],[2922],[2879,2963,2964,2965,2965,2966],{"trials":24978,"activeCount":102},[],{"trials":24980,"activeCount":102},[],{"intervention":5156,"totalTrials":195,"cells":24982},{"EARLY_PHASE1":24983,"PHASE1":24985,"PHASE2":24987,"PHASE3":24989,"PHASE4":24995,"NA":24997},{"trials":24984,"activeCount":102},[],{"trials":24986,"activeCount":102},[],{"trials":24988,"activeCount":102},[],{"trials":24990,"activeCount":102},[24991],{"nctId":5147,"briefTitle":5148,"status":108,"phases":24992,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":5152,"conditions":24993,"interventions":24994},[92],[2932],[5155,2897,5156,5157,5158],{"trials":24996,"activeCount":102},[],{"trials":24998,"activeCount":102},[],{"intervention":5157,"totalTrials":195,"cells":25000},{"EARLY_PHASE1":25001,"PHASE1":25003,"PHASE2":25005,"PHASE3":25007,"PHASE4":25013,"NA":25015},{"trials":25002,"activeCount":102},[],{"trials":25004,"activeCount":102},[],{"trials":25006,"activeCount":102},[],{"trials":25008,"activeCount":102},[25009],{"nctId":5147,"briefTitle":5148,"status":108,"phases":25010,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":5152,"conditions":25011,"interventions":25012},[92],[2932],[5155,2897,5156,5157,5158],{"trials":25014,"activeCount":102},[],{"trials":25016,"activeCount":102},[],{"intervention":5158,"totalTrials":195,"cells":25018},{"EARLY_PHASE1":25019,"PHASE1":25021,"PHASE2":25023,"PHASE3":25025,"PHASE4":25031,"NA":25033},{"trials":25020,"activeCount":102},[],{"trials":25022,"activeCount":102},[],{"trials":25024,"activeCount":102},[],{"trials":25026,"activeCount":102},[25027],{"nctId":5147,"briefTitle":5148,"status":108,"phases":25028,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":5152,"conditions":25029,"interventions":25030},[92],[2932],[5155,2897,5156,5157,5158],{"trials":25032,"activeCount":102},[],{"trials":25034,"activeCount":102},[],{"intervention":20443,"totalTrials":195,"cells":25036},{"EARLY_PHASE1":25037,"PHASE1":25039,"PHASE2":25041,"PHASE3":25043,"PHASE4":25049,"NA":25051},{"trials":25038,"activeCount":102},[],{"trials":25040,"activeCount":102},[],{"trials":25042,"activeCount":102},[],{"trials":25044,"activeCount":102},[25045],{"nctId":20433,"briefTitle":20434,"status":108,"phases":25046,"primaryCompletion":20436,"completion":20437,"start":20438,"enrollment":12633,"conditions":25047,"interventions":25048},[92],[12787,12785,12790,12788,20440,12786,20441,12784],[20443,20444,20445,20446,20447,20448],{"trials":25050,"activeCount":102},[],{"trials":25052,"activeCount":102},[],{"intervention":20444,"totalTrials":195,"cells":25054},{"EARLY_PHASE1":25055,"PHASE1":25057,"PHASE2":25059,"PHASE3":25061,"PHASE4":25067,"NA":25069},{"trials":25056,"activeCount":102},[],{"trials":25058,"activeCount":102},[],{"trials":25060,"activeCount":102},[],{"trials":25062,"activeCount":102},[25063],{"nctId":20433,"briefTitle":20434,"status":108,"phases":25064,"primaryCompletion":20436,"completion":20437,"start":20438,"enrollment":12633,"conditions":25065,"interventions":25066},[92],[12787,12785,12790,12788,20440,12786,20441,12784],[20443,20444,20445,20446,20447,20448],{"trials":25068,"activeCount":102},[],{"trials":25070,"activeCount":102},[],{"intervention":20446,"totalTrials":195,"cells":25072},{"EARLY_PHASE1":25073,"PHASE1":25075,"PHASE2":25077,"PHASE3":25079,"PHASE4":25085,"NA":25087},{"trials":25074,"activeCount":102},[],{"trials":25076,"activeCount":102},[],{"trials":25078,"activeCount":102},[],{"trials":25080,"activeCount":102},[25081],{"nctId":20433,"briefTitle":20434,"status":108,"phases":25082,"primaryCompletion":20436,"completion":20437,"start":20438,"enrollment":12633,"conditions":25083,"interventions":25084},[92],[12787,12785,12790,12788,20440,12786,20441,12784],[20443,20444,20445,20446,20447,20448],{"trials":25086,"activeCount":102},[],{"trials":25088,"activeCount":102},[],{"intervention":20447,"totalTrials":195,"cells":25090},{"EARLY_PHASE1":25091,"PHASE1":25093,"PHASE2":25095,"PHASE3":25097,"PHASE4":25103,"NA":25105},{"trials":25092,"activeCount":102},[],{"trials":25094,"activeCount":102},[],{"trials":25096,"activeCount":102},[],{"trials":25098,"activeCount":102},[25099],{"nctId":20433,"briefTitle":20434,"status":108,"phases":25100,"primaryCompletion":20436,"completion":20437,"start":20438,"enrollment":12633,"conditions":25101,"interventions":25102},[92],[12787,12785,12790,12788,20440,12786,20441,12784],[20443,20444,20445,20446,20447,20448],{"trials":25104,"activeCount":102},[],{"trials":25106,"activeCount":102},[],{"intervention":20448,"totalTrials":195,"cells":25108},{"EARLY_PHASE1":25109,"PHASE1":25111,"PHASE2":25113,"PHASE3":25115,"PHASE4":25121,"NA":25123},{"trials":25110,"activeCount":102},[],{"trials":25112,"activeCount":102},[],{"trials":25114,"activeCount":102},[],{"trials":25116,"activeCount":102},[25117],{"nctId":20433,"briefTitle":20434,"status":108,"phases":25118,"primaryCompletion":20436,"completion":20437,"start":20438,"enrollment":12633,"conditions":25119,"interventions":25120},[92],[12787,12785,12790,12788,20440,12786,20441,12784],[20443,20444,20445,20446,20447,20448],{"trials":25122,"activeCount":102},[],{"trials":25124,"activeCount":102},[],{"intervention":5089,"totalTrials":195,"cells":25126},{"EARLY_PHASE1":25127,"PHASE1":25129,"PHASE2":25131,"PHASE3":25133,"PHASE4":25139,"NA":25141},{"trials":25128,"activeCount":102},[],{"trials":25130,"activeCount":102},[],{"trials":25132,"activeCount":102},[],{"trials":25134,"activeCount":102},[25135],{"nctId":5081,"briefTitle":5082,"status":884,"phases":25136,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":25137,"interventions":25138},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"trials":25140,"activeCount":102},[],{"trials":25142,"activeCount":102},[],{"intervention":5090,"totalTrials":195,"cells":25144},{"EARLY_PHASE1":25145,"PHASE1":25147,"PHASE2":25149,"PHASE3":25151,"PHASE4":25157,"NA":25159},{"trials":25146,"activeCount":102},[],{"trials":25148,"activeCount":102},[],{"trials":25150,"activeCount":102},[],{"trials":25152,"activeCount":102},[25153],{"nctId":5081,"briefTitle":5082,"status":884,"phases":25154,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":25155,"interventions":25156},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"trials":25158,"activeCount":102},[],{"trials":25160,"activeCount":102},[],{"intervention":5091,"totalTrials":195,"cells":25162},{"EARLY_PHASE1":25163,"PHASE1":25165,"PHASE2":25167,"PHASE3":25169,"PHASE4":25175,"NA":25177},{"trials":25164,"activeCount":102},[],{"trials":25166,"activeCount":102},[],{"trials":25168,"activeCount":102},[],{"trials":25170,"activeCount":102},[25171],{"nctId":5081,"briefTitle":5082,"status":884,"phases":25172,"primaryCompletion":886,"completion":886,"start":5084,"enrollment":5085,"conditions":25173,"interventions":25174},[92],[918],[5088,5089,5090,2937,5091,2900,2325,5092],{"trials":25176,"activeCount":102},[],{"trials":25178,"activeCount":102},[],{"intervention":25180,"totalTrials":195,"cells":25181},"Fexofenadine M016455",{"EARLY_PHASE1":25182,"PHASE1":25184,"PHASE2":25186,"PHASE3":25188,"PHASE4":25197,"NA":25199},{"trials":25183,"activeCount":102},[],{"trials":25185,"activeCount":102},[],{"trials":25187,"activeCount":102},[],{"trials":25189,"activeCount":102},[25190],{"nctId":25191,"briefTitle":25192,"status":108,"phases":25193,"primaryCompletion":25194,"completion":25194,"start":5031,"enrollment":6655,"conditions":25195,"interventions":25196},"NCT03664882","Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants",[92],"2019-01-03",[12180],[25180],{"trials":25198,"activeCount":102},[],{"trials":25200,"activeCount":102},[],{"intervention":25202,"totalTrials":195,"cells":25203},"HUMAN INSULIN",{"EARLY_PHASE1":25204,"PHASE1":25206,"PHASE2":25208,"PHASE3":25210,"PHASE4":25222,"NA":25224},{"trials":25205,"activeCount":102},[],{"trials":25207,"activeCount":102},[],{"trials":25209,"activeCount":102},[],{"trials":25211,"activeCount":102},[25212],{"nctId":25213,"briefTitle":25214,"status":108,"phases":25215,"primaryCompletion":25216,"completion":25216,"start":25217,"enrollment":25218,"conditions":25219,"interventions":25220},"NCT01194882","Benefit\u002FRisk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes",[92],"2018-02-01","2010-11-16",479,[578],[25202,25221],"Insuplant",{"trials":25223,"activeCount":102},[],{"trials":25225,"activeCount":102},[],{"intervention":25221,"totalTrials":195,"cells":25227},{"EARLY_PHASE1":25228,"PHASE1":25230,"PHASE2":25232,"PHASE3":25234,"PHASE4":25240,"NA":25242},{"trials":25229,"activeCount":102},[],{"trials":25231,"activeCount":102},[],{"trials":25233,"activeCount":102},[],{"trials":25235,"activeCount":102},[25236],{"nctId":25213,"briefTitle":25214,"status":108,"phases":25237,"primaryCompletion":25216,"completion":25216,"start":25217,"enrollment":25218,"conditions":25238,"interventions":25239},[92],[578],[25202,25221],{"trials":25241,"activeCount":102},[],{"trials":25243,"activeCount":102},[],{"intervention":20298,"totalTrials":195,"cells":25245},{"EARLY_PHASE1":25246,"PHASE1":25248,"PHASE2":25250,"PHASE3":25252,"PHASE4":25258,"NA":25260},{"trials":25247,"activeCount":102},[],{"trials":25249,"activeCount":102},[],{"trials":25251,"activeCount":102},[],{"trials":25253,"activeCount":102},[25254],{"nctId":20291,"briefTitle":20292,"status":108,"phases":25255,"primaryCompletion":8762,"completion":8762,"start":9513,"enrollment":20294,"conditions":25256,"interventions":25257},[92],[20296],[11088,20298,11089],{"trials":25259,"activeCount":102},[],{"trials":25261,"activeCount":102},[],{"intervention":9386,"totalTrials":195,"cells":25263},{"EARLY_PHASE1":25264,"PHASE1":25266,"PHASE2":25268,"PHASE3":25270,"PHASE4":25276,"NA":25278},{"trials":25265,"activeCount":102},[],{"trials":25267,"activeCount":102},[],{"trials":25269,"activeCount":102},[],{"trials":25271,"activeCount":102},[25272],{"nctId":9381,"briefTitle":9382,"status":108,"phases":25273,"primaryCompletion":1042,"completion":1042,"start":152,"enrollment":474,"conditions":25274,"interventions":25275},[92],[830],[8046,9386],{"trials":25277,"activeCount":102},[],{"trials":25279,"activeCount":102},[],{"intervention":25281,"totalTrials":195,"cells":25282},"SODIUM DIVALPROATE",{"EARLY_PHASE1":25283,"PHASE1":25285,"PHASE2":25287,"PHASE3":25289,"PHASE4":25297,"NA":25299},{"trials":25284,"activeCount":102},[],{"trials":25286,"activeCount":102},[],{"trials":25288,"activeCount":102},[],{"trials":25290,"activeCount":102},[25291],{"nctId":25292,"briefTitle":25293,"status":108,"phases":25294,"completion":2800,"start":8659,"enrollment":12,"conditions":25295,"interventions":25296},"NCT00271258","Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents",[92],[11929],[25281],{"trials":25298,"activeCount":102},[],{"trials":25300,"activeCount":102},[],{"intervention":3390,"totalTrials":195,"cells":25302},{"EARLY_PHASE1":25303,"PHASE1":25305,"PHASE2":25307,"PHASE3":25309,"PHASE4":25315,"NA":25317},{"trials":25304,"activeCount":102},[],{"trials":25306,"activeCount":102},[],{"trials":25308,"activeCount":102},[],{"trials":25310,"activeCount":102},[25311],{"nctId":3383,"briefTitle":3384,"status":884,"phases":25312,"primaryCompletion":1032,"completion":1032,"start":1339,"enrollment":3386,"conditions":25313,"interventions":25314},[92],[3388],[1800,3390],{"trials":25316,"activeCount":102},[],{"trials":25318,"activeCount":102},[],{"intervention":25320,"totalTrials":195,"cells":25321},"DTaP-IPV\u002FHib Combined vaccine",{"EARLY_PHASE1":25322,"PHASE1":25324,"PHASE2":25326,"PHASE3":25328,"PHASE4":25340,"NA":25342},{"trials":25323,"activeCount":102},[],{"trials":25325,"activeCount":102},[],{"trials":25327,"activeCount":102},[],{"trials":25329,"activeCount":102},[25330],{"nctId":25331,"briefTitle":25332,"status":108,"phases":25333,"primaryCompletion":25334,"completion":25334,"start":5216,"enrollment":25335,"conditions":25336,"interventions":25338},"NCT02274285","DTaP-IPV\u002FHib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants",[92],"2016-05-28",424,[31,25,28,12983,25337],"Bacterial Meningitis",[25320,25339,25320],"DTaP-IPV vaccine and Hib vaccine",{"trials":25341,"activeCount":102},[],{"trials":25343,"activeCount":102},[],{"intervention":25339,"totalTrials":195,"cells":25345},{"EARLY_PHASE1":25346,"PHASE1":25348,"PHASE2":25350,"PHASE3":25352,"PHASE4":25358,"NA":25360},{"trials":25347,"activeCount":102},[],{"trials":25349,"activeCount":102},[],{"trials":25351,"activeCount":102},[],{"trials":25353,"activeCount":102},[25354],{"nctId":25331,"briefTitle":25332,"status":108,"phases":25355,"primaryCompletion":25334,"completion":25334,"start":5216,"enrollment":25335,"conditions":25356,"interventions":25357},[92],[31,25,28,12983,25337],[25320,25339,25320],{"trials":25359,"activeCount":102},[],{"trials":25361,"activeCount":102},[],{"intervention":2977,"totalTrials":195,"cells":25363},{"EARLY_PHASE1":25364,"PHASE1":25366,"PHASE2":25368,"PHASE3":25370,"PHASE4":25376,"NA":25378},{"trials":25365,"activeCount":102},[],{"trials":25367,"activeCount":102},[],{"trials":25369,"activeCount":102},[],{"trials":25371,"activeCount":102},[25372],{"nctId":2968,"briefTitle":2969,"status":108,"phases":25373,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":2973,"conditions":25374,"interventions":25375},[92],[2975],[2879,2977,2978,2979,2980],{"trials":25377,"activeCount":102},[],{"trials":25379,"activeCount":102},[],{"intervention":2978,"totalTrials":195,"cells":25381},{"EARLY_PHASE1":25382,"PHASE1":25384,"PHASE2":25386,"PHASE3":25388,"PHASE4":25394,"NA":25396},{"trials":25383,"activeCount":102},[],{"trials":25385,"activeCount":102},[],{"trials":25387,"activeCount":102},[],{"trials":25389,"activeCount":102},[25390],{"nctId":2968,"briefTitle":2969,"status":108,"phases":25391,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":2973,"conditions":25392,"interventions":25393},[92],[2975],[2879,2977,2978,2979,2980],{"trials":25395,"activeCount":102},[],{"trials":25397,"activeCount":102},[],{"intervention":2979,"totalTrials":195,"cells":25399},{"EARLY_PHASE1":25400,"PHASE1":25402,"PHASE2":25404,"PHASE3":25406,"PHASE4":25412,"NA":25414},{"trials":25401,"activeCount":102},[],{"trials":25403,"activeCount":102},[],{"trials":25405,"activeCount":102},[],{"trials":25407,"activeCount":102},[25408],{"nctId":2968,"briefTitle":2969,"status":108,"phases":25409,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":2973,"conditions":25410,"interventions":25411},[92],[2975],[2879,2977,2978,2979,2980],{"trials":25413,"activeCount":102},[],{"trials":25415,"activeCount":102},[],{"intervention":2980,"totalTrials":195,"cells":25417},{"EARLY_PHASE1":25418,"PHASE1":25420,"PHASE2":25422,"PHASE3":25424,"PHASE4":25430,"NA":25432},{"trials":25419,"activeCount":102},[],{"trials":25421,"activeCount":102},[],{"trials":25423,"activeCount":102},[],{"trials":25425,"activeCount":102},[25426],{"nctId":2968,"briefTitle":2969,"status":108,"phases":25427,"primaryCompletion":2971,"completion":2971,"start":2972,"enrollment":2973,"conditions":25428,"interventions":25429},[92],[2975],[2879,2977,2978,2979,2980],{"trials":25431,"activeCount":102},[],{"trials":25433,"activeCount":102},[],{"intervention":3400,"totalTrials":195,"cells":25435},{"EARLY_PHASE1":25436,"PHASE1":25438,"PHASE2":25440,"PHASE3":25442,"PHASE4":25448,"NA":25450},{"trials":25437,"activeCount":102},[],{"trials":25439,"activeCount":102},[],{"trials":25441,"activeCount":102},[],{"trials":25443,"activeCount":102},[25444],{"nctId":3392,"briefTitle":3393,"status":108,"phases":25445,"primaryCompletion":986,"completion":3395,"start":3396,"enrollment":3397,"conditions":25446,"interventions":25447},[92],[1788],[3400,1800],{"trials":25449,"activeCount":102},[],{"trials":25451,"activeCount":102},[],{"intervention":25453,"totalTrials":195,"cells":25454},"IMOJEV",{"EARLY_PHASE1":25455,"PHASE1":25457,"PHASE2":25459,"PHASE3":25461,"PHASE4":25471,"NA":25473},{"trials":25456,"activeCount":102},[],{"trials":25458,"activeCount":102},[],{"trials":25460,"activeCount":102},[],{"trials":25462,"activeCount":102},[25463],{"nctId":25464,"briefTitle":25465,"status":108,"phases":25466,"primaryCompletion":25467,"completion":25467,"start":25468,"enrollment":17927,"conditions":25469,"interventions":25470},"NCT01900444","Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea",[92],"2014-03-11","2013-07-11",[17265],[25453],{"trials":25472,"activeCount":102},[],{"trials":25474,"activeCount":102},[],{"intervention":20047,"totalTrials":195,"cells":25476},{"EARLY_PHASE1":25477,"PHASE1":25479,"PHASE2":25481,"PHASE3":25483,"PHASE4":25489,"NA":25491},{"trials":25478,"activeCount":102},[],{"trials":25480,"activeCount":102},[],{"trials":25482,"activeCount":102},[],{"trials":25484,"activeCount":102},[25485],{"nctId":20041,"briefTitle":20042,"status":108,"phases":25486,"primaryCompletion":8106,"completion":8106,"start":3316,"enrollment":20044,"conditions":25487,"interventions":25488},[92],[9440],[20004,20047,20048],{"trials":25490,"activeCount":102},[],{"trials":25492,"activeCount":102},[],{"intervention":25494,"totalTrials":195,"cells":25495},"2011 to 2012 Trivalent Influenza Vaccine",{"EARLY_PHASE1":25496,"PHASE1":25498,"PHASE2":25500,"PHASE3":25502,"PHASE4":25512,"NA":25514},{"trials":25497,"activeCount":102},[],{"trials":25499,"activeCount":102},[],{"trials":25501,"activeCount":102},[],{"trials":25503,"activeCount":102},[25504],{"nctId":25505,"briefTitle":25506,"status":108,"phases":25507,"primaryCompletion":164,"completion":3438,"start":8683,"enrollment":25508,"conditions":25509,"interventions":25510},"NCT01481454","Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children\u002FAdolescents and Adults",[92],1701,[16],[25511,25511,25511,25494],"Quadrivalent Influenza Vaccine",{"trials":25513,"activeCount":102},[],{"trials":25515,"activeCount":102},[],{"intervention":11031,"totalTrials":195,"cells":25517},{"EARLY_PHASE1":25518,"PHASE1":25520,"PHASE2":25522,"PHASE3":25524,"PHASE4":25530,"NA":25532},{"trials":25519,"activeCount":102},[],{"trials":25521,"activeCount":102},[],{"trials":25523,"activeCount":102},[],{"trials":25525,"activeCount":102},[25526],{"nctId":11026,"briefTitle":11027,"status":108,"phases":25527,"primaryCompletion":3307,"completion":3307,"start":5307,"enrollment":10348,"conditions":25528,"interventions":25529},[92],[11023],[11016,11031],{"trials":25531,"activeCount":102},[],{"trials":25533,"activeCount":102},[],{"intervention":25535,"totalTrials":195,"cells":25536},"DOCETAXEL(XRP6976) + MODAFINIL",{"EARLY_PHASE1":25537,"PHASE1":25539,"PHASE2":25541,"PHASE3":25543,"PHASE4":25552,"NA":25554},{"trials":25538,"activeCount":102},[],{"trials":25540,"activeCount":102},[],{"trials":25542,"activeCount":102},[],{"trials":25544,"activeCount":102},[25545],{"nctId":25546,"briefTitle":25547,"status":108,"phases":25548,"primaryCompletion":165,"completion":165,"start":3307,"enrollment":1079,"conditions":25549,"interventions":25550},"NCT00917748","Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)",[92],[2804,5264],[25535,25551],"Modafinil",{"trials":25553,"activeCount":102},[],{"trials":25555,"activeCount":102},[],{"intervention":25551,"totalTrials":195,"cells":25557},{"EARLY_PHASE1":25558,"PHASE1":25560,"PHASE2":25562,"PHASE3":25564,"PHASE4":25570,"NA":25572},{"trials":25559,"activeCount":102},[],{"trials":25561,"activeCount":102},[],{"trials":25563,"activeCount":102},[],{"trials":25565,"activeCount":102},[25566],{"nctId":25546,"briefTitle":25547,"status":108,"phases":25567,"primaryCompletion":165,"completion":165,"start":3307,"enrollment":1079,"conditions":25568,"interventions":25569},[92],[2804,5264],[25535,25551],{"trials":25571,"activeCount":102},[],{"trials":25573,"activeCount":102},[],{"intervention":22324,"totalTrials":195,"cells":25575},{"EARLY_PHASE1":25576,"PHASE1":25578,"PHASE2":25580,"PHASE3":25582,"PHASE4":25588,"NA":25590},{"trials":25577,"activeCount":102},[],{"trials":25579,"activeCount":102},[],{"trials":25581,"activeCount":102},[],{"trials":25583,"activeCount":102},[25584],{"nctId":22319,"briefTitle":22320,"status":108,"phases":25585,"primaryCompletion":8205,"completion":9532,"start":5272,"enrollment":2314,"conditions":25586,"interventions":25587},[92],[25,31,20655,28,12983],[22308,22308,22324],{"trials":25589,"activeCount":102},[],{"trials":25591,"activeCount":102},[],{"intervention":25593,"totalTrials":195,"cells":25594},"Quadrivalent Recombinant influenza vaccine (RIV4) season\u002F2022-2023\u002FNH",{"EARLY_PHASE1":25595,"PHASE1":25597,"PHASE2":25599,"PHASE3":25601,"PHASE4":25612,"NA":25614},{"trials":25596,"activeCount":102},[],{"trials":25598,"activeCount":102},[],{"trials":25600,"activeCount":102},[],{"trials":25602,"activeCount":102},[25603],{"nctId":25604,"briefTitle":25605,"status":108,"phases":25606,"primaryCompletion":25607,"completion":25607,"start":25608,"enrollment":25609,"conditions":25610,"interventions":25611},"NCT05513053","Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.",[92],"2023-10-27","2022-10-27",1308,[5335],[25593],{"trials":25613,"activeCount":102},[],{"trials":25615,"activeCount":102},[],{"intervention":22112,"totalTrials":195,"cells":25617},{"EARLY_PHASE1":25618,"PHASE1":25620,"PHASE2":25622,"PHASE3":25624,"PHASE4":25630,"NA":25632},{"trials":25619,"activeCount":102},[],{"trials":25621,"activeCount":102},[],{"trials":25623,"activeCount":102},[],{"trials":25625,"activeCount":102},[25626],{"nctId":22102,"briefTitle":22103,"status":108,"phases":25627,"primaryCompletion":22105,"completion":22105,"start":22106,"enrollment":22107,"conditions":25628,"interventions":25629},[92],[2894,36],[22110,22111,22112],{"trials":25631,"activeCount":102},[],{"trials":25633,"activeCount":102},[],{"intervention":8210,"totalTrials":195,"cells":25635},{"EARLY_PHASE1":25636,"PHASE1":25638,"PHASE2":25640,"PHASE3":25642,"PHASE4":25648,"NA":25650},{"trials":25637,"activeCount":102},[],{"trials":25639,"activeCount":102},[],{"trials":25641,"activeCount":102},[],{"trials":25643,"activeCount":102},[25644],{"nctId":8202,"briefTitle":8203,"status":108,"phases":25645,"primaryCompletion":8205,"start":8184,"enrollment":8206,"conditions":25646,"interventions":25647},[92],[22],[8057,8209,8024,8210],{"trials":25649,"activeCount":102},[],{"trials":25651,"activeCount":102},[],{"intervention":25653,"totalTrials":195,"cells":25654},"Insulin human\u002FInsuman Comb 25",{"EARLY_PHASE1":25655,"PHASE1":25657,"PHASE2":25659,"PHASE3":25661,"PHASE4":25670,"NA":25672},{"trials":25656,"activeCount":102},[],{"trials":25658,"activeCount":102},[],{"trials":25660,"activeCount":102},[],{"trials":25662,"activeCount":102},[25663],{"nctId":25664,"briefTitle":25665,"status":108,"phases":25666,"primaryCompletion":7284,"completion":7284,"start":7292,"enrollment":8634,"conditions":25667,"interventions":25668},"NCT01353469","Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy",[92],[19],[25653,25669],"Insulin human\u002FNovolin® 30R",{"trials":25671,"activeCount":102},[],{"trials":25673,"activeCount":102},[],{"intervention":25669,"totalTrials":195,"cells":25675},{"EARLY_PHASE1":25676,"PHASE1":25678,"PHASE2":25680,"PHASE3":25682,"PHASE4":25688,"NA":25690},{"trials":25677,"activeCount":102},[],{"trials":25679,"activeCount":102},[],{"trials":25681,"activeCount":102},[],{"trials":25683,"activeCount":102},[25684],{"nctId":25664,"briefTitle":25665,"status":108,"phases":25685,"primaryCompletion":7284,"completion":7284,"start":7292,"enrollment":8634,"conditions":25686,"interventions":25687},[92],[19],[25653,25669],{"trials":25689,"activeCount":102},[],{"trials":25691,"activeCount":102},[],{"intervention":19161,"totalTrials":195,"cells":25693},{"EARLY_PHASE1":25694,"PHASE1":25696,"PHASE2":25698,"PHASE3":25700,"PHASE4":25706,"NA":25708},{"trials":25695,"activeCount":102},[],{"trials":25697,"activeCount":102},[],{"trials":25699,"activeCount":102},[],{"trials":25701,"activeCount":102},[25702],{"nctId":19155,"briefTitle":19156,"status":108,"phases":25703,"primaryCompletion":1022,"completion":1022,"start":5272,"enrollment":19158,"conditions":25704,"interventions":25705},[92],[9140],[19161,4640],{"trials":25707,"activeCount":102},[],{"trials":25709,"activeCount":102},[],{"intervention":8219,"totalTrials":195,"cells":25711},{"EARLY_PHASE1":25712,"PHASE1":25714,"PHASE2":25716,"PHASE3":25718,"PHASE4":25724,"NA":25726},{"trials":25713,"activeCount":102},[],{"trials":25715,"activeCount":102},[],{"trials":25717,"activeCount":102},[],{"trials":25719,"activeCount":102},[25720],{"nctId":8212,"briefTitle":8213,"status":108,"phases":25721,"primaryCompletion":165,"completion":165,"start":8215,"enrollment":8216,"conditions":25722,"interventions":25723},[92],[19],[8046,8219,8142,8220,8024],{"trials":25725,"activeCount":102},[],{"trials":25727,"activeCount":102},[],{"intervention":8220,"totalTrials":195,"cells":25729},{"EARLY_PHASE1":25730,"PHASE1":25732,"PHASE2":25734,"PHASE3":25736,"PHASE4":25742,"NA":25744},{"trials":25731,"activeCount":102},[],{"trials":25733,"activeCount":102},[],{"trials":25735,"activeCount":102},[],{"trials":25737,"activeCount":102},[25738],{"nctId":8212,"briefTitle":8213,"status":108,"phases":25739,"primaryCompletion":165,"completion":165,"start":8215,"enrollment":8216,"conditions":25740,"interventions":25741},[92],[19],[8046,8219,8142,8220,8024],{"trials":25743,"activeCount":102},[],{"trials":25745,"activeCount":102},[],{"intervention":22451,"totalTrials":195,"cells":25747},{"EARLY_PHASE1":25748,"PHASE1":25750,"PHASE2":25752,"PHASE3":25754,"PHASE4":25760,"NA":25762},{"trials":25749,"activeCount":102},[],{"trials":25751,"activeCount":102},[],{"trials":25753,"activeCount":102},[],{"trials":25755,"activeCount":102},[25756],{"nctId":22444,"briefTitle":22445,"status":108,"phases":25757,"primaryCompletion":22447,"completion":22447,"start":22448,"enrollment":16359,"conditions":25758,"interventions":25759},[92],[14171],[22433,22451,22451],{"trials":25761,"activeCount":102},[],{"trials":25763,"activeCount":102},[],{"intervention":13223,"totalTrials":195,"cells":25765},{"EARLY_PHASE1":25766,"PHASE1":25768,"PHASE2":25770,"PHASE3":25772,"PHASE4":25778,"NA":25780},{"trials":25767,"activeCount":102},[],{"trials":25769,"activeCount":102},[],{"trials":25771,"activeCount":102},[],{"trials":25773,"activeCount":102},[25774],{"nctId":13216,"briefTitle":13217,"status":108,"phases":25775,"primaryCompletion":2661,"completion":2661,"start":13219,"enrollment":8738,"conditions":25776,"interventions":25777},[92],[2910,36],[13222,2963,13223,13205],{"trials":25779,"activeCount":102},[],{"trials":25781,"activeCount":102},[],{"intervention":25783,"totalTrials":195,"cells":25784},"INSULIN GLARGINE\u002FLIXISENATIDE HOE901\u002FAVE0010",{"EARLY_PHASE1":25785,"PHASE1":25787,"PHASE2":25789,"PHASE3":25791,"PHASE4":25800,"NA":25802},{"trials":25786,"activeCount":102},[],{"trials":25788,"activeCount":102},[],{"trials":25790,"activeCount":102},[],{"trials":25792,"activeCount":102},[25793],{"nctId":25794,"briefTitle":25795,"status":108,"phases":25796,"primaryCompletion":5478,"completion":5478,"start":10652,"enrollment":25797,"conditions":25798,"interventions":25799},"NCT03767543","Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)\u002FLixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)",[92],265,[19],[25783],{"trials":25801,"activeCount":102},[],{"trials":25803,"activeCount":102},[],{"intervention":25805,"totalTrials":195,"cells":25806},"Docetaxel (TAXOTERE®) Chemotherapy",{"EARLY_PHASE1":25807,"PHASE1":25809,"PHASE2":25811,"PHASE3":25813,"PHASE4":25822,"NA":25824},{"trials":25808,"activeCount":102},[],{"trials":25810,"activeCount":102},[],{"trials":25812,"activeCount":102},[],{"trials":25814,"activeCount":102},[25815],{"nctId":25816,"briefTitle":25817,"status":108,"phases":25818,"primaryCompletion":8693,"completion":8693,"start":3565,"enrollment":2835,"conditions":25819,"interventions":25820},"NCT00283062","Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy",[92],[2804],[25805,25821,25805,25821,25821],"Leuprolide acetate ( ELIGARD®) Hormonal Therapy",{"trials":25823,"activeCount":102},[],{"trials":25825,"activeCount":102},[],{"intervention":25821,"totalTrials":195,"cells":25827},{"EARLY_PHASE1":25828,"PHASE1":25830,"PHASE2":25832,"PHASE3":25834,"PHASE4":25840,"NA":25842},{"trials":25829,"activeCount":102},[],{"trials":25831,"activeCount":102},[],{"trials":25833,"activeCount":102},[],{"trials":25835,"activeCount":102},[25836],{"nctId":25816,"briefTitle":25817,"status":108,"phases":25837,"primaryCompletion":8693,"completion":8693,"start":3565,"enrollment":2835,"conditions":25838,"interventions":25839},[92],[2804],[25805,25821,25805,25821,25821],{"trials":25841,"activeCount":102},[],{"trials":25843,"activeCount":102},[],{"intervention":25845,"totalTrials":195,"cells":25846},"Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy",{"EARLY_PHASE1":25847,"PHASE1":25849,"PHASE2":25851,"PHASE3":25853,"PHASE4":25863,"NA":25865},{"trials":25848,"activeCount":102},[],{"trials":25850,"activeCount":102},[],{"trials":25852,"activeCount":102},[],{"trials":25854,"activeCount":102},[25855],{"nctId":25856,"briefTitle":25857,"status":108,"phases":25858,"primaryCompletion":3366,"completion":3366,"start":3509,"enrollment":25859,"conditions":25860,"interventions":25861},"NCT00261703","Docetaxel in Head and Neck Cancer",[91,92],439,[12355],[25845,25862],"Cisplatin, 5-fluorouracil (5-FU), radiotherapy",{"trials":25864,"activeCount":102},[],{"trials":25866,"activeCount":102},[],{"intervention":25862,"totalTrials":195,"cells":25868},{"EARLY_PHASE1":25869,"PHASE1":25871,"PHASE2":25873,"PHASE3":25875,"PHASE4":25881,"NA":25883},{"trials":25870,"activeCount":102},[],{"trials":25872,"activeCount":102},[],{"trials":25874,"activeCount":102},[],{"trials":25876,"activeCount":102},[25877],{"nctId":25856,"briefTitle":25857,"status":108,"phases":25878,"primaryCompletion":3366,"completion":3366,"start":3509,"enrollment":25859,"conditions":25879,"interventions":25880},[91,92],[12355],[25845,25862],{"trials":25882,"activeCount":102},[],{"trials":25884,"activeCount":102},[],{"intervention":18658,"totalTrials":195,"cells":25886},{"EARLY_PHASE1":25887,"PHASE1":25889,"PHASE2":25891,"PHASE3":25893,"PHASE4":25899,"NA":25901},{"trials":25888,"activeCount":102},[],{"trials":25890,"activeCount":102},[],{"trials":25892,"activeCount":102},[],{"trials":25894,"activeCount":102},[25895],{"nctId":18651,"briefTitle":18652,"status":108,"phases":25896,"primaryCompletion":3563,"completion":3439,"start":3608,"enrollment":18654,"conditions":25897,"interventions":25898},[92],[18625,13810,25,28],[18657,18658,2937],{"trials":25900,"activeCount":102},[],{"trials":25902,"activeCount":102},[],{"intervention":25904,"totalTrials":195,"cells":25905},"sodium hyaluronate",{"EARLY_PHASE1":25906,"PHASE1":25908,"PHASE2":25910,"PHASE3":25912,"PHASE4":25921,"NA":25923},{"trials":25907,"activeCount":102},[],{"trials":25909,"activeCount":102},[],{"trials":25911,"activeCount":102},[],{"trials":25913,"activeCount":102},[25914],{"nctId":25915,"briefTitle":25916,"status":108,"phases":25917,"completion":3367,"start":3346,"enrollment":16663,"conditions":25918,"interventions":25920},"NCT00377624","HUPS: Hyalgan Use in Painful Shoulder",[92],[25919],"Osteoarthritis of Shoulder",[25904],{"trials":25922,"activeCount":102},[],{"trials":25924,"activeCount":102},[],{"intervention":25926,"totalTrials":195,"cells":25927},"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus",{"EARLY_PHASE1":25928,"PHASE1":25930,"PHASE2":25932,"PHASE3":25934,"PHASE4":25944,"NA":25946},{"trials":25929,"activeCount":102},[],{"trials":25931,"activeCount":102},[],{"trials":25933,"activeCount":102},[],{"trials":25935,"activeCount":102},[25936],{"nctId":25937,"briefTitle":25938,"status":108,"phases":25939,"primaryCompletion":8106,"completion":2311,"start":2790,"enrollment":25940,"conditions":25941,"interventions":25942},"NCT01346293","Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age",[92],3372,[31,25,28,10899,13810],[25926,25943,25926,25943],"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus",{"trials":25945,"activeCount":102},[],{"trials":25947,"activeCount":102},[],{"intervention":25943,"totalTrials":195,"cells":25949},{"EARLY_PHASE1":25950,"PHASE1":25952,"PHASE2":25954,"PHASE3":25956,"PHASE4":25962,"NA":25964},{"trials":25951,"activeCount":102},[],{"trials":25953,"activeCount":102},[],{"trials":25955,"activeCount":102},[],{"trials":25957,"activeCount":102},[25958],{"nctId":25937,"briefTitle":25938,"status":108,"phases":25959,"primaryCompletion":8106,"completion":2311,"start":2790,"enrollment":25940,"conditions":25960,"interventions":25961},[92],[31,25,28,10899,13810],[25926,25943,25926,25943],{"trials":25963,"activeCount":102},[],{"trials":25965,"activeCount":102},[],{"intervention":25967,"totalTrials":195,"cells":25968},"Hexaxim®",{"EARLY_PHASE1":25969,"PHASE1":25971,"PHASE2":25973,"PHASE3":25975,"PHASE4":25986,"NA":25988},{"trials":25970,"activeCount":102},[],{"trials":25972,"activeCount":102},[],{"trials":25974,"activeCount":102},[],{"trials":25976,"activeCount":102},[25977],{"nctId":25978,"briefTitle":25979,"status":108,"phases":25980,"primaryCompletion":25981,"completion":25981,"start":25982,"enrollment":25983,"conditions":25984,"interventions":25985},"NCT02428491","Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth",[92],"2017-01-11","2015-04-20",354,[25,31,28,12983,18625,20655],[25967],{"trials":25987,"activeCount":102},[],{"trials":25989,"activeCount":102},[],{"intervention":25991,"totalTrials":195,"cells":25992},"Concomitant administration",{"EARLY_PHASE1":25993,"PHASE1":25995,"PHASE2":25997,"PHASE3":25999,"PHASE4":26009,"NA":26011},{"trials":25994,"activeCount":102},[],{"trials":25996,"activeCount":102},[],{"trials":25998,"activeCount":102},[],{"trials":26000,"activeCount":102},[26001],{"nctId":26002,"briefTitle":26003,"status":108,"phases":26004,"primaryCompletion":986,"completion":986,"start":8453,"enrollment":26005,"conditions":26006,"interventions":26007},"NCT01249183","Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old",[92],954,[25,31,28,12983],[25991,26008],"Separate administration",{"trials":26010,"activeCount":102},[],{"trials":26012,"activeCount":102},[],{"intervention":26008,"totalTrials":195,"cells":26014},{"EARLY_PHASE1":26015,"PHASE1":26017,"PHASE2":26019,"PHASE3":26021,"PHASE4":26027,"NA":26029},{"trials":26016,"activeCount":102},[],{"trials":26018,"activeCount":102},[],{"trials":26020,"activeCount":102},[],{"trials":26022,"activeCount":102},[26023],{"nctId":26002,"briefTitle":26003,"status":108,"phases":26024,"primaryCompletion":986,"completion":986,"start":8453,"enrollment":26005,"conditions":26025,"interventions":26026},[92],[25,31,28,12983],[25991,26008],{"trials":26028,"activeCount":102},[],{"trials":26030,"activeCount":102},[],{"intervention":26032,"totalTrials":195,"cells":26033},"Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains",{"EARLY_PHASE1":26034,"PHASE1":26036,"PHASE2":26038,"PHASE3":26040,"PHASE4":26051,"NA":26053},{"trials":26035,"activeCount":102},[],{"trials":26037,"activeCount":102},[],{"trials":26039,"activeCount":102},[],{"trials":26041,"activeCount":102},[26042],{"nctId":26043,"briefTitle":26044,"status":884,"phases":26045,"primaryCompletion":26046,"completion":26046,"start":26047,"enrollment":26048,"conditions":26049,"interventions":26050},"NCT04137887","Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older",[92],"2020-05-31","2019-11-04",33096,[7891],[25511,26032],{"trials":26052,"activeCount":102},[],{"trials":26054,"activeCount":102},[],{"intervention":26056,"totalTrials":195,"cells":26057},"Quadrivalent influenza vaccine, high-dose",{"EARLY_PHASE1":26058,"PHASE1":26060,"PHASE2":26062,"PHASE3":26064,"PHASE4":26075,"NA":26077},{"trials":26059,"activeCount":102},[],{"trials":26061,"activeCount":102},[],{"trials":26063,"activeCount":102},[],{"trials":26065,"activeCount":102},[26066],{"nctId":26067,"briefTitle":26068,"status":884,"phases":26069,"primaryCompletion":26070,"completion":26070,"start":26071,"enrollment":465,"conditions":26072,"interventions":26073},"NCT04544267","Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age",[92],"2021-06-02","2020-09-15",[16],[26056,26074],"Quadrivalent influenza vaccine, standard dose",{"trials":26076,"activeCount":102},[],{"trials":26078,"activeCount":102},[],{"intervention":26074,"totalTrials":195,"cells":26080},{"EARLY_PHASE1":26081,"PHASE1":26083,"PHASE2":26085,"PHASE3":26087,"PHASE4":26093,"NA":26095},{"trials":26082,"activeCount":102},[],{"trials":26084,"activeCount":102},[],{"trials":26086,"activeCount":102},[],{"trials":26088,"activeCount":102},[26089],{"nctId":26067,"briefTitle":26068,"status":884,"phases":26090,"primaryCompletion":26070,"completion":26070,"start":26071,"enrollment":465,"conditions":26091,"interventions":26092},[92],[16],[26056,26074],{"trials":26094,"activeCount":102},[],{"trials":26096,"activeCount":102},[],{"intervention":26098,"totalTrials":195,"cells":26099},"omega-3 polyunsaturated fatty acids",{"EARLY_PHASE1":26100,"PHASE1":26102,"PHASE2":26104,"PHASE3":26106,"PHASE4":26115,"NA":26117},{"trials":26101,"activeCount":102},[],{"trials":26103,"activeCount":102},[],{"trials":26105,"activeCount":102},[],{"trials":26107,"activeCount":102},[26108],{"nctId":26109,"briefTitle":26110,"status":108,"phases":26111,"primaryCompletion":977,"completion":977,"start":8364,"enrollment":26112,"conditions":26113,"interventions":26114},"NCT00069784","The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)",[92],12537,[10076],[8424,26098],{"trials":26116,"activeCount":102},[],{"trials":26118,"activeCount":102},[],{"intervention":26120,"totalTrials":195,"cells":26121},"SSR591813L",{"EARLY_PHASE1":26122,"PHASE1":26124,"PHASE2":26126,"PHASE3":26128,"PHASE4":26138,"NA":26140},{"trials":26123,"activeCount":102},[],{"trials":26125,"activeCount":102},[],{"trials":26127,"activeCount":102},[],{"trials":26129,"activeCount":102},[26130],{"nctId":26131,"briefTitle":26132,"status":108,"phases":26133,"primaryCompletion":1341,"completion":1341,"start":3622,"enrollment":26134,"conditions":26135,"interventions":26137},"NCT00387946","Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)",[92],630,[17745,26136],"Tobacco Use Cessation",[26120],{"trials":26139,"activeCount":102},[],{"trials":26141,"activeCount":102},[],{"intervention":26143,"totalTrials":195,"cells":26144},"Dermacyd PH_DETINLYN Tangerine Mix",{"EARLY_PHASE1":26145,"PHASE1":26147,"PHASE2":26149,"PHASE3":26151,"PHASE4":26159,"NA":26161},{"trials":26146,"activeCount":102},[],{"trials":26148,"activeCount":102},[],{"trials":26150,"activeCount":102},[],{"trials":26152,"activeCount":102},[26153],{"nctId":26154,"briefTitle":26155,"status":108,"phases":26156,"primaryCompletion":3564,"start":3417,"enrollment":3740,"conditions":26157,"interventions":26158},"NCT00785642","Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.",[92],[33],[26143],{"trials":26160,"activeCount":102},[],{"trials":26162,"activeCount":102},[],{"intervention":20998,"totalTrials":195,"cells":26164},{"EARLY_PHASE1":26165,"PHASE1":26167,"PHASE2":26169,"PHASE3":26171,"PHASE4":26177,"NA":26179},{"trials":26166,"activeCount":102},[],{"trials":26168,"activeCount":102},[],{"trials":26170,"activeCount":102},[],{"trials":26172,"activeCount":102},[26173],{"nctId":20991,"briefTitle":20992,"status":108,"phases":26174,"primaryCompletion":8331,"completion":8331,"start":9592,"conditions":26175,"interventions":26176},[92],[20995],[20997,20998,20999,21000],{"trials":26178,"activeCount":102},[],{"trials":26180,"activeCount":102},[],{"intervention":20999,"totalTrials":195,"cells":26182},{"EARLY_PHASE1":26183,"PHASE1":26185,"PHASE2":26187,"PHASE3":26189,"PHASE4":26195,"NA":26197},{"trials":26184,"activeCount":102},[],{"trials":26186,"activeCount":102},[],{"trials":26188,"activeCount":102},[],{"trials":26190,"activeCount":102},[26191],{"nctId":20991,"briefTitle":20992,"status":108,"phases":26192,"primaryCompletion":8331,"completion":8331,"start":9592,"conditions":26193,"interventions":26194},[92],[20995],[20997,20998,20999,21000],{"trials":26196,"activeCount":102},[],{"trials":26198,"activeCount":102},[],{"intervention":21000,"totalTrials":195,"cells":26200},{"EARLY_PHASE1":26201,"PHASE1":26203,"PHASE2":26205,"PHASE3":26207,"PHASE4":26213,"NA":26215},{"trials":26202,"activeCount":102},[],{"trials":26204,"activeCount":102},[],{"trials":26206,"activeCount":102},[],{"trials":26208,"activeCount":102},[26209],{"nctId":20991,"briefTitle":20992,"status":108,"phases":26210,"primaryCompletion":8331,"completion":8331,"start":9592,"conditions":26211,"interventions":26212},[92],[20995],[20997,20998,20999,21000],{"trials":26214,"activeCount":102},[],{"trials":26216,"activeCount":102},[],{"intervention":21065,"totalTrials":195,"cells":26218},{"EARLY_PHASE1":26219,"PHASE1":26221,"PHASE2":26223,"PHASE3":26225,"PHASE4":26231,"NA":26233},{"trials":26220,"activeCount":102},[],{"trials":26222,"activeCount":102},[],{"trials":26224,"activeCount":102},[],{"trials":26226,"activeCount":102},[26227],{"nctId":21059,"briefTitle":21060,"status":108,"phases":26228,"primaryCompletion":8505,"completion":8196,"start":8666,"enrollment":21062,"conditions":26229,"interventions":26230},[92],[25,31,28,18625,12983],[18657,18657,18657,21065],{"trials":26232,"activeCount":102},[],{"trials":26234,"activeCount":102},[],{"intervention":26236,"totalTrials":195,"cells":26237},"Spores of Bacillus Clausii Probiotic Strain",{"EARLY_PHASE1":26238,"PHASE1":26240,"PHASE2":26242,"PHASE3":26244,"PHASE4":26253,"NA":26255},{"trials":26239,"activeCount":102},[],{"trials":26241,"activeCount":102},[],{"trials":26243,"activeCount":102},[],{"trials":26245,"activeCount":102},[26246],{"nctId":26247,"briefTitle":26248,"status":108,"phases":26249,"start":8526,"enrollment":6513,"conditions":26250,"interventions":26252},"NCT00265369","TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children",[92],[26251],"Diarrhea",[26236],{"trials":26254,"activeCount":102},[],{"trials":26256,"activeCount":102},[],{"intervention":26258,"totalTrials":195,"cells":26259},"DAPTACEL®. (DTaP), IPOL®., and ActHIB®.",{"EARLY_PHASE1":26260,"PHASE1":26262,"PHASE2":26264,"PHASE3":26266,"PHASE4":26277,"NA":26279},{"trials":26261,"activeCount":102},[],{"trials":26263,"activeCount":102},[],{"trials":26265,"activeCount":102},[],{"trials":26267,"activeCount":102},[26268],{"nctId":26269,"briefTitle":26270,"status":108,"phases":26271,"primaryCompletion":8196,"completion":8315,"start":3623,"enrollment":26272,"conditions":26273,"interventions":26274},"NCT00255047","Safety and Immune Response of Different Pediatric Combination Vaccines.",[92],2167,[25,13810,28],[26258,26275,26276,26275],"Pentacel®: DTaP-IPV\u002FHib combined","DTaP-IPV and ActHIB®",{"trials":26278,"activeCount":102},[],{"trials":26280,"activeCount":102},[],{"intervention":26275,"totalTrials":195,"cells":26282},{"EARLY_PHASE1":26283,"PHASE1":26285,"PHASE2":26287,"PHASE3":26289,"PHASE4":26295,"NA":26297},{"trials":26284,"activeCount":102},[],{"trials":26286,"activeCount":102},[],{"trials":26288,"activeCount":102},[],{"trials":26290,"activeCount":102},[26291],{"nctId":26269,"briefTitle":26270,"status":108,"phases":26292,"primaryCompletion":8196,"completion":8315,"start":3623,"enrollment":26272,"conditions":26293,"interventions":26294},[92],[25,13810,28],[26258,26275,26276,26275],{"trials":26296,"activeCount":102},[],{"trials":26298,"activeCount":102},[],{"intervention":26276,"totalTrials":195,"cells":26300},{"EARLY_PHASE1":26301,"PHASE1":26303,"PHASE2":26305,"PHASE3":26307,"PHASE4":26313,"NA":26315},{"trials":26302,"activeCount":102},[],{"trials":26304,"activeCount":102},[],{"trials":26306,"activeCount":102},[],{"trials":26308,"activeCount":102},[26309],{"nctId":26269,"briefTitle":26270,"status":108,"phases":26310,"primaryCompletion":8196,"completion":8315,"start":3623,"enrollment":26272,"conditions":26311,"interventions":26312},[92],[25,13810,28],[26258,26275,26276,26275],{"trials":26314,"activeCount":102},[],{"trials":26316,"activeCount":102},[],{"intervention":7376,"totalTrials":195,"cells":26318},{"EARLY_PHASE1":26319,"PHASE1":26321,"PHASE2":26323,"PHASE3":26325,"PHASE4":26331,"NA":26333},{"trials":26320,"activeCount":102},[],{"trials":26322,"activeCount":102},[],{"trials":26324,"activeCount":102},[],{"trials":26326,"activeCount":102},[26327],{"nctId":7367,"briefTitle":7368,"status":108,"phases":26328,"primaryCompletion":7370,"completion":7371,"start":7372,"enrollment":7373,"conditions":26329,"interventions":26330},[92],[3892],[7273,3864,7376],{"trials":26332,"activeCount":102},[],{"trials":26334,"activeCount":102},[],{"intervention":26336,"totalTrials":195,"cells":26337},"Tolebrutininb",{"EARLY_PHASE1":26338,"PHASE1":26340,"PHASE2":26342,"PHASE3":26344,"PHASE4":26355,"NA":26357},{"trials":26339,"activeCount":102},[],{"trials":26341,"activeCount":102},[],{"trials":26343,"activeCount":102},[],{"trials":26345,"activeCount":102},[26346],{"nctId":26347,"briefTitle":26348,"status":884,"phases":26349,"primaryCompletion":26350,"completion":26350,"start":26351,"enrollment":622,"conditions":26352,"interventions":26354},"NCT05132569","Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis",[92],"2023-02-21","2021-12-03",[26353],"Myasthenia Gravis",[26336],{"trials":26356,"activeCount":102},[],{"trials":26358,"activeCount":102},[],{"intervention":26360,"totalTrials":195,"cells":26361},"25 mg\u002Fday AVE5530",{"EARLY_PHASE1":26362,"PHASE1":26364,"PHASE2":26366,"PHASE3":26368,"PHASE4":26378,"NA":26380},{"trials":26363,"activeCount":102},[],{"trials":26365,"activeCount":102},[],{"trials":26367,"activeCount":102},[],{"trials":26369,"activeCount":102},[26370],{"nctId":26371,"briefTitle":26372,"status":884,"phases":26373,"primaryCompletion":3307,"completion":3307,"start":8196,"enrollment":26374,"conditions":26375,"interventions":26376},"NCT00729027","Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia",[92],1015,[3892],[26360,26377],"50 mg\u002Fday AVE5530",{"trials":26379,"activeCount":102},[],{"trials":26381,"activeCount":102},[],{"intervention":26377,"totalTrials":195,"cells":26383},{"EARLY_PHASE1":26384,"PHASE1":26386,"PHASE2":26388,"PHASE3":26390,"PHASE4":26396,"NA":26398},{"trials":26385,"activeCount":102},[],{"trials":26387,"activeCount":102},[],{"trials":26389,"activeCount":102},[],{"trials":26391,"activeCount":102},[26392],{"nctId":26371,"briefTitle":26372,"status":884,"phases":26393,"primaryCompletion":3307,"completion":3307,"start":8196,"enrollment":26374,"conditions":26394,"interventions":26395},[92],[3892],[26360,26377],{"trials":26397,"activeCount":102},[],{"trials":26399,"activeCount":102},[],{"intervention":12830,"totalTrials":195,"cells":26401},{"EARLY_PHASE1":26402,"PHASE1":26404,"PHASE2":26406,"PHASE3":26408,"PHASE4":26414,"NA":26416},{"trials":26403,"activeCount":102},[],{"trials":26405,"activeCount":102},[],{"trials":26407,"activeCount":102},[],{"trials":26409,"activeCount":102},[26410],{"nctId":12823,"briefTitle":12824,"status":108,"phases":26411,"primaryCompletion":3307,"completion":3307,"start":8505,"enrollment":12826,"conditions":26412,"interventions":26413},[92],[12828],[12830,12812],{"trials":26415,"activeCount":102},[],{"trials":26417,"activeCount":102},[],{"intervention":1035,"totalTrials":195,"cells":26419},{"EARLY_PHASE1":26420,"PHASE1":26422,"PHASE2":26424,"PHASE3":26426,"PHASE4":26432,"NA":26434},{"trials":26421,"activeCount":102},[],{"trials":26423,"activeCount":102},[],{"trials":26425,"activeCount":102},[],{"trials":26427,"activeCount":102},[26428],{"nctId":1028,"briefTitle":1029,"status":884,"phases":26429,"primaryCompletion":1031,"completion":1031,"start":1032,"enrollment":153,"conditions":26430,"interventions":26431},[92],[990],[942,1035,971,1036],{"trials":26433,"activeCount":102},[],{"trials":26435,"activeCount":102},[],{"intervention":19912,"totalTrials":195,"cells":26437},{"EARLY_PHASE1":26438,"PHASE1":26440,"PHASE2":26442,"PHASE3":26444,"PHASE4":26450,"NA":26452},{"trials":26439,"activeCount":102},[],{"trials":26441,"activeCount":102},[],{"trials":26443,"activeCount":102},[],{"trials":26445,"activeCount":102},[26446],{"nctId":19905,"briefTitle":19906,"status":108,"phases":26447,"primaryCompletion":19908,"completion":2293,"start":19909,"enrollment":2342,"conditions":26448,"interventions":26449},[92],[19900],[19912,19913,19914,19915],{"trials":26451,"activeCount":102},[],{"trials":26453,"activeCount":102},[],{"intervention":19914,"totalTrials":195,"cells":26455},{"EARLY_PHASE1":26456,"PHASE1":26458,"PHASE2":26460,"PHASE3":26462,"PHASE4":26468,"NA":26470},{"trials":26457,"activeCount":102},[],{"trials":26459,"activeCount":102},[],{"trials":26461,"activeCount":102},[],{"trials":26463,"activeCount":102},[26464],{"nctId":19905,"briefTitle":19906,"status":108,"phases":26465,"primaryCompletion":19908,"completion":2293,"start":19909,"enrollment":2342,"conditions":26466,"interventions":26467},[92],[19900],[19912,19913,19914,19915],{"trials":26469,"activeCount":102},[],{"trials":26471,"activeCount":102},[],{"intervention":19915,"totalTrials":195,"cells":26473},{"EARLY_PHASE1":26474,"PHASE1":26476,"PHASE2":26478,"PHASE3":26480,"PHASE4":26486,"NA":26488},{"trials":26475,"activeCount":102},[],{"trials":26477,"activeCount":102},[],{"trials":26479,"activeCount":102},[],{"trials":26481,"activeCount":102},[26482],{"nctId":19905,"briefTitle":19906,"status":108,"phases":26483,"primaryCompletion":19908,"completion":2293,"start":19909,"enrollment":2342,"conditions":26484,"interventions":26485},[92],[19900],[19912,19913,19914,19915],{"trials":26487,"activeCount":102},[],{"trials":26489,"activeCount":102},[],{"intervention":26491,"totalTrials":195,"cells":26492},"SR57746A",{"EARLY_PHASE1":26493,"PHASE1":26495,"PHASE2":26497,"PHASE3":26499,"PHASE4":26508,"NA":26510},{"trials":26494,"activeCount":102},[],{"trials":26496,"activeCount":102},[],{"trials":26498,"activeCount":102},[],{"trials":26500,"activeCount":102},[26501],{"nctId":26502,"briefTitle":26503,"status":108,"phases":26504,"completion":8526,"start":9800,"enrollment":26505,"conditions":26506,"interventions":26507},"NCT00272051","XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU\u002FLV Chemotherapy",[92],620,[9230,5240,9231],[26491],{"trials":26509,"activeCount":102},[],{"trials":26511,"activeCount":102},[],{"intervention":17723,"totalTrials":195,"cells":26513},{"EARLY_PHASE1":26514,"PHASE1":26516,"PHASE2":26518,"PHASE3":26520,"PHASE4":26526,"NA":26528},{"trials":26515,"activeCount":102},[],{"trials":26517,"activeCount":102},[],{"trials":26519,"activeCount":102},[],{"trials":26521,"activeCount":102},[26522],{"nctId":17717,"briefTitle":17718,"status":884,"phases":26523,"primaryCompletion":8315,"completion":8315,"start":3355,"enrollment":17720,"conditions":26524,"interventions":26525},[92],[17609,8117],[8238,17723],{"trials":26527,"activeCount":102},[],{"trials":26529,"activeCount":102},[],{"intervention":26531,"totalTrials":195,"cells":26532},"FluBlok®",{"EARLY_PHASE1":26533,"PHASE1":26535,"PHASE2":26537,"PHASE3":26539,"PHASE4":26550,"NA":26552},{"trials":26534,"activeCount":102},[],{"trials":26536,"activeCount":102},[],{"trials":26538,"activeCount":102},[],{"trials":26540,"activeCount":102},[26541],{"nctId":26542,"briefTitle":26543,"status":108,"phases":26544,"primaryCompletion":26545,"completion":26545,"start":26546,"enrollment":26547,"conditions":26548,"interventions":26549},"NCT00539981","Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok",[92],"2008-05-28","2007-09-15",4648,[16],[26531],{"trials":26551,"activeCount":102},[],{"trials":26553,"activeCount":102},[],{"intervention":2319,"totalTrials":195,"cells":26555},{"EARLY_PHASE1":26556,"PHASE1":26558,"PHASE2":26560,"PHASE3":26562,"PHASE4":26568,"NA":26570},{"trials":26557,"activeCount":102},[],{"trials":26559,"activeCount":102},[],{"trials":26561,"activeCount":102},[],{"trials":26563,"activeCount":102},[26564],{"nctId":2308,"briefTitle":2309,"status":108,"phases":26565,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":26566,"interventions":26567},[92],[2316,2317,2296],[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],{"trials":26569,"activeCount":102},[],{"trials":26571,"activeCount":102},[],{"intervention":2320,"totalTrials":195,"cells":26573},{"EARLY_PHASE1":26574,"PHASE1":26576,"PHASE2":26578,"PHASE3":26580,"PHASE4":26586,"NA":26588},{"trials":26575,"activeCount":102},[],{"trials":26577,"activeCount":102},[],{"trials":26579,"activeCount":102},[],{"trials":26581,"activeCount":102},[26582],{"nctId":2308,"briefTitle":2309,"status":108,"phases":26583,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":26584,"interventions":26585},[92],[2316,2317,2296],[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],{"trials":26587,"activeCount":102},[],{"trials":26589,"activeCount":102},[],{"intervention":2321,"totalTrials":195,"cells":26591},{"EARLY_PHASE1":26592,"PHASE1":26594,"PHASE2":26596,"PHASE3":26598,"PHASE4":26604,"NA":26606},{"trials":26593,"activeCount":102},[],{"trials":26595,"activeCount":102},[],{"trials":26597,"activeCount":102},[],{"trials":26599,"activeCount":102},[26600],{"nctId":2308,"briefTitle":2309,"status":108,"phases":26601,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":26602,"interventions":26603},[92],[2316,2317,2296],[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],{"trials":26605,"activeCount":102},[],{"trials":26607,"activeCount":102},[],{"intervention":2322,"totalTrials":195,"cells":26609},{"EARLY_PHASE1":26610,"PHASE1":26612,"PHASE2":26614,"PHASE3":26616,"PHASE4":26622,"NA":26624},{"trials":26611,"activeCount":102},[],{"trials":26613,"activeCount":102},[],{"trials":26615,"activeCount":102},[],{"trials":26617,"activeCount":102},[26618],{"nctId":2308,"briefTitle":2309,"status":108,"phases":26619,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":26620,"interventions":26621},[92],[2316,2317,2296],[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],{"trials":26623,"activeCount":102},[],{"trials":26625,"activeCount":102},[],{"intervention":2323,"totalTrials":195,"cells":26627},{"EARLY_PHASE1":26628,"PHASE1":26630,"PHASE2":26632,"PHASE3":26634,"PHASE4":26640,"NA":26642},{"trials":26629,"activeCount":102},[],{"trials":26631,"activeCount":102},[],{"trials":26633,"activeCount":102},[],{"trials":26635,"activeCount":102},[26636],{"nctId":2308,"briefTitle":2309,"status":108,"phases":26637,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":26638,"interventions":26639},[92],[2316,2317,2296],[2319,43,2320,2321,2322,2323,2319,2324,2325,2321,2323,2322],{"trials":26641,"activeCount":102},[],{"trials":26643,"activeCount":102},[],{"intervention":19268,"totalTrials":195,"cells":26645},{"EARLY_PHASE1":26646,"PHASE1":26648,"PHASE2":26650,"PHASE3":26652,"PHASE4":26658,"NA":26660},{"trials":26647,"activeCount":102},[],{"trials":26649,"activeCount":102},[],{"trials":26651,"activeCount":102},[],{"trials":26653,"activeCount":102},[26654],{"nctId":19262,"briefTitle":19263,"status":108,"phases":26655,"primaryCompletion":3563,"completion":3439,"start":3430,"enrollment":19265,"conditions":26656,"interventions":26657},[92],[12314,16,10695],[19268,19268,19268,19269],{"trials":26659,"activeCount":102},[],{"trials":26661,"activeCount":102},[],{"intervention":1047,"totalTrials":195,"cells":26663},{"EARLY_PHASE1":26664,"PHASE1":26666,"PHASE2":26668,"PHASE3":26670,"PHASE4":26676,"NA":26678},{"trials":26665,"activeCount":102},[],{"trials":26667,"activeCount":102},[],{"trials":26669,"activeCount":102},[],{"trials":26671,"activeCount":102},[26672],{"nctId":1038,"briefTitle":1039,"status":108,"phases":26673,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":726,"conditions":26674,"interventions":26675},[92],[990],[942,1045,1046,1047,1048,1049],{"trials":26677,"activeCount":102},[],{"trials":26679,"activeCount":102},[],{"intervention":1049,"totalTrials":195,"cells":26681},{"EARLY_PHASE1":26682,"PHASE1":26684,"PHASE2":26686,"PHASE3":26688,"PHASE4":26694,"NA":26696},{"trials":26683,"activeCount":102},[],{"trials":26685,"activeCount":102},[],{"trials":26687,"activeCount":102},[],{"trials":26689,"activeCount":102},[26690],{"nctId":1038,"briefTitle":1039,"status":108,"phases":26691,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":726,"conditions":26692,"interventions":26693},[92],[990],[942,1045,1046,1047,1048,1049],{"trials":26695,"activeCount":102},[],{"trials":26697,"activeCount":102},[],{"intervention":26699,"totalTrials":195,"cells":26700},"DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine",{"EARLY_PHASE1":26701,"PHASE1":26703,"PHASE2":26705,"PHASE3":26707,"PHASE4":26718,"NA":26720},{"trials":26702,"activeCount":102},[],{"trials":26704,"activeCount":102},[],{"trials":26706,"activeCount":102},[],{"trials":26708,"activeCount":102},[26709],{"nctId":26710,"briefTitle":26711,"status":108,"phases":26712,"primaryCompletion":8165,"completion":3429,"start":966,"enrollment":26713,"conditions":26714,"interventions":26715},"NCT01983540","Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination",[92],558,[25,31,13514,18625,12983,20655],[26699,26716,26717],"DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine","Infanrix hexa + Prevenar + Rotarix vaccine",{"trials":26719,"activeCount":102},[],{"trials":26721,"activeCount":102},[],{"intervention":26716,"totalTrials":195,"cells":26723},{"EARLY_PHASE1":26724,"PHASE1":26726,"PHASE2":26728,"PHASE3":26730,"PHASE4":26736,"NA":26738},{"trials":26725,"activeCount":102},[],{"trials":26727,"activeCount":102},[],{"trials":26729,"activeCount":102},[],{"trials":26731,"activeCount":102},[26732],{"nctId":26710,"briefTitle":26711,"status":108,"phases":26733,"primaryCompletion":8165,"completion":3429,"start":966,"enrollment":26713,"conditions":26734,"interventions":26735},[92],[25,31,13514,18625,12983,20655],[26699,26716,26717],{"trials":26737,"activeCount":102},[],{"trials":26739,"activeCount":102},[],{"intervention":26717,"totalTrials":195,"cells":26741},{"EARLY_PHASE1":26742,"PHASE1":26744,"PHASE2":26746,"PHASE3":26748,"PHASE4":26754,"NA":26756},{"trials":26743,"activeCount":102},[],{"trials":26745,"activeCount":102},[],{"trials":26747,"activeCount":102},[],{"trials":26749,"activeCount":102},[26750],{"nctId":26710,"briefTitle":26711,"status":108,"phases":26751,"primaryCompletion":8165,"completion":3429,"start":966,"enrollment":26713,"conditions":26752,"interventions":26753},[92],[25,31,13514,18625,12983,20655],[26699,26716,26717],{"trials":26755,"activeCount":102},[],{"trials":26757,"activeCount":102},[],{"intervention":8611,"totalTrials":195,"cells":26759},{"EARLY_PHASE1":26760,"PHASE1":26762,"PHASE2":26764,"PHASE3":26766,"PHASE4":26772,"NA":26774},{"trials":26761,"activeCount":102},[],{"trials":26763,"activeCount":102},[],{"trials":26765,"activeCount":102},[],{"trials":26767,"activeCount":102},[26768],{"nctId":8604,"briefTitle":8605,"status":108,"phases":26769,"primaryCompletion":8607,"start":8175,"enrollment":8608,"conditions":26770,"interventions":26771},[92],[22],[8209,8611,8057],{"trials":26773,"activeCount":102},[],{"trials":26775,"activeCount":102},[],{"intervention":26777,"totalTrials":195,"cells":26778},"Euvax B®: Hepatitis B vaccine",{"EARLY_PHASE1":26779,"PHASE1":26781,"PHASE2":26783,"PHASE3":26785,"PHASE4":26794,"NA":26796},{"trials":26780,"activeCount":102},[],{"trials":26782,"activeCount":102},[],{"trials":26784,"activeCount":102},[],{"trials":26786,"activeCount":102},[26787],{"nctId":26788,"briefTitle":26789,"status":108,"phases":26790,"primaryCompletion":2856,"completion":26791,"start":1355,"enrollment":455,"conditions":26792,"interventions":26793},"NCT02697474","Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.",[92],"2017-01",[18625],[26777,26777],{"trials":26795,"activeCount":102},[],{"trials":26797,"activeCount":102},[],{"intervention":5103,"totalTrials":195,"cells":26799},{"EARLY_PHASE1":26800,"PHASE1":26802,"PHASE2":26804,"PHASE3":26806,"PHASE4":26812,"NA":26814},{"trials":26801,"activeCount":102},[],{"trials":26803,"activeCount":102},[],{"trials":26805,"activeCount":102},[],{"trials":26807,"activeCount":102},[26808],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26809,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26810,"interventions":26811},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26813,"activeCount":102},[],{"trials":26815,"activeCount":102},[],{"intervention":5104,"totalTrials":195,"cells":26817},{"EARLY_PHASE1":26818,"PHASE1":26820,"PHASE2":26822,"PHASE3":26824,"PHASE4":26830,"NA":26832},{"trials":26819,"activeCount":102},[],{"trials":26821,"activeCount":102},[],{"trials":26823,"activeCount":102},[],{"trials":26825,"activeCount":102},[26826],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26827,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26828,"interventions":26829},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26831,"activeCount":102},[],{"trials":26833,"activeCount":102},[],{"intervention":5105,"totalTrials":195,"cells":26835},{"EARLY_PHASE1":26836,"PHASE1":26838,"PHASE2":26840,"PHASE3":26842,"PHASE4":26848,"NA":26850},{"trials":26837,"activeCount":102},[],{"trials":26839,"activeCount":102},[],{"trials":26841,"activeCount":102},[],{"trials":26843,"activeCount":102},[26844],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26845,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26846,"interventions":26847},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26849,"activeCount":102},[],{"trials":26851,"activeCount":102},[],{"intervention":5106,"totalTrials":195,"cells":26853},{"EARLY_PHASE1":26854,"PHASE1":26856,"PHASE2":26858,"PHASE3":26860,"PHASE4":26866,"NA":26868},{"trials":26855,"activeCount":102},[],{"trials":26857,"activeCount":102},[],{"trials":26859,"activeCount":102},[],{"trials":26861,"activeCount":102},[26862],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26863,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26864,"interventions":26865},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26867,"activeCount":102},[],{"trials":26869,"activeCount":102},[],{"intervention":5107,"totalTrials":195,"cells":26871},{"EARLY_PHASE1":26872,"PHASE1":26874,"PHASE2":26876,"PHASE3":26878,"PHASE4":26884,"NA":26886},{"trials":26873,"activeCount":102},[],{"trials":26875,"activeCount":102},[],{"trials":26877,"activeCount":102},[],{"trials":26879,"activeCount":102},[26880],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26881,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26882,"interventions":26883},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26885,"activeCount":102},[],{"trials":26887,"activeCount":102},[],{"intervention":5108,"totalTrials":195,"cells":26889},{"EARLY_PHASE1":26890,"PHASE1":26892,"PHASE2":26894,"PHASE3":26896,"PHASE4":26902,"NA":26904},{"trials":26891,"activeCount":102},[],{"trials":26893,"activeCount":102},[],{"trials":26895,"activeCount":102},[],{"trials":26897,"activeCount":102},[26898],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26899,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26900,"interventions":26901},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26903,"activeCount":102},[],{"trials":26905,"activeCount":102},[],{"intervention":5109,"totalTrials":195,"cells":26907},{"EARLY_PHASE1":26908,"PHASE1":26910,"PHASE2":26912,"PHASE3":26914,"PHASE4":26920,"NA":26922},{"trials":26909,"activeCount":102},[],{"trials":26911,"activeCount":102},[],{"trials":26913,"activeCount":102},[],{"trials":26915,"activeCount":102},[26916],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26917,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26918,"interventions":26919},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26921,"activeCount":102},[],{"trials":26923,"activeCount":102},[],{"intervention":5110,"totalTrials":195,"cells":26925},{"EARLY_PHASE1":26926,"PHASE1":26928,"PHASE2":26930,"PHASE3":26932,"PHASE4":26938,"NA":26940},{"trials":26927,"activeCount":102},[],{"trials":26929,"activeCount":102},[],{"trials":26931,"activeCount":102},[],{"trials":26933,"activeCount":102},[26934],{"nctId":5094,"briefTitle":5095,"status":108,"phases":26935,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":26936,"interventions":26937},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"trials":26939,"activeCount":102},[],{"trials":26941,"activeCount":102},[],{"intervention":18305,"totalTrials":195,"cells":26943},{"EARLY_PHASE1":26944,"PHASE1":26946,"PHASE2":26948,"PHASE3":26950,"PHASE4":26956,"NA":26958},{"trials":26945,"activeCount":102},[],{"trials":26947,"activeCount":102},[],{"trials":26949,"activeCount":102},[],{"trials":26951,"activeCount":102},[26952],{"nctId":18298,"briefTitle":18299,"status":108,"phases":26953,"primaryCompletion":18301,"completion":18301,"start":18302,"enrollment":12934,"conditions":26954,"interventions":26955},[92],[18210,2317,18285],[18194,18194,18305,18305],{"trials":26957,"activeCount":102},[],{"trials":26959,"activeCount":102},[],{"intervention":26961,"totalTrials":195,"cells":26962},"Dermacyd PH_DETINLYN Sweet Flower",{"EARLY_PHASE1":26963,"PHASE1":26965,"PHASE2":26967,"PHASE3":26969,"PHASE4":26977,"NA":26979},{"trials":26964,"activeCount":102},[],{"trials":26966,"activeCount":102},[],{"trials":26968,"activeCount":102},[],{"trials":26970,"activeCount":102},[26971],{"nctId":26972,"briefTitle":26973,"status":108,"phases":26974,"primaryCompletion":3564,"start":3417,"enrollment":8883,"conditions":26975,"interventions":26976},"NCT00785148","Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety",[92],[33],[26961],{"trials":26978,"activeCount":102},[],{"trials":26980,"activeCount":102},[],{"intervention":26982,"totalTrials":195,"cells":26983},"Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016",{"EARLY_PHASE1":26984,"PHASE1":26986,"PHASE2":26988,"PHASE3":26990,"PHASE4":26999,"NA":27001},{"trials":26985,"activeCount":102},[],{"trials":26987,"activeCount":102},[],{"trials":26989,"activeCount":102},[],{"trials":26991,"activeCount":102},[26992],{"nctId":26993,"briefTitle":26994,"status":108,"phases":26995,"primaryCompletion":965,"completion":11200,"start":2824,"enrollment":1091,"conditions":26996,"interventions":26997},"NCT02550197","Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years",[92],[16],[26982,26998],"Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation",{"trials":27000,"activeCount":102},[],{"trials":27002,"activeCount":102},[],{"intervention":26998,"totalTrials":195,"cells":27004},{"EARLY_PHASE1":27005,"PHASE1":27007,"PHASE2":27009,"PHASE3":27011,"PHASE4":27017,"NA":27019},{"trials":27006,"activeCount":102},[],{"trials":27008,"activeCount":102},[],{"trials":27010,"activeCount":102},[],{"trials":27012,"activeCount":102},[27013],{"nctId":26993,"briefTitle":26994,"status":108,"phases":27014,"primaryCompletion":965,"completion":11200,"start":2824,"enrollment":1091,"conditions":27015,"interventions":27016},[92],[16],[26982,26998],{"trials":27018,"activeCount":102},[],{"trials":27020,"activeCount":102},[],{"intervention":27022,"totalTrials":195,"cells":27023},"sutimlimab",{"EARLY_PHASE1":27024,"PHASE1":27026,"PHASE2":27028,"PHASE3":27030,"PHASE4":27041,"NA":27043},{"trials":27025,"activeCount":102},[],{"trials":27027,"activeCount":102},[],{"trials":27029,"activeCount":102},[],{"trials":27031,"activeCount":102},[27032],{"nctId":27033,"briefTitle":27034,"status":108,"phases":27035,"primaryCompletion":27036,"completion":27036,"start":27037,"enrollment":538,"conditions":27038,"interventions":27040},"NCT05132127","Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan",[92],"2022-11-15","2021-11-11",[27039],"Cold Agglutinin Disease",[27022],{"trials":27042,"activeCount":102},[],{"trials":27044,"activeCount":102},[],{"intervention":27046,"totalTrials":195,"cells":27047},"Fexofenadine, Comparator = Montelukast",{"EARLY_PHASE1":27048,"PHASE1":27050,"PHASE2":27052,"PHASE3":27054,"PHASE4":27062,"NA":27064},{"trials":27049,"activeCount":102},[],{"trials":27051,"activeCount":102},[],{"trials":27053,"activeCount":102},[],{"trials":27055,"activeCount":102},[27056],{"nctId":27057,"briefTitle":27058,"status":108,"phases":27059,"primaryCompletion":12198,"completion":12198,"start":3495,"enrollment":2791,"conditions":27060,"interventions":27061},"NCT00045955","Long-Term Safety Performance of Fexofenadine in Asthma",[92],[155],[27046],{"trials":27063,"activeCount":102},[],{"trials":27065,"activeCount":102},[],{"intervention":27067,"totalTrials":195,"cells":27068},"Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower",{"EARLY_PHASE1":27069,"PHASE1":27071,"PHASE2":27073,"PHASE3":27075,"PHASE4":27083,"NA":27085},{"trials":27070,"activeCount":102},[],{"trials":27072,"activeCount":102},[],{"trials":27074,"activeCount":102},[],{"trials":27076,"activeCount":102},[27077],{"nctId":27078,"briefTitle":27079,"status":108,"phases":27080,"primaryCompletion":3564,"start":3417,"enrollment":8883,"conditions":27081,"interventions":27082},"NCT00785850","Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety.",[92],[33],[27067],{"trials":27084,"activeCount":102},[],{"trials":27086,"activeCount":102},[],{"intervention":27088,"totalTrials":195,"cells":27089},"Non-insulin antihyperglycemic drugs",{"EARLY_PHASE1":27090,"PHASE1":27092,"PHASE2":27094,"PHASE3":27096,"PHASE4":27105,"NA":27107},{"trials":27091,"activeCount":102},[],{"trials":27093,"activeCount":102},[],{"trials":27095,"activeCount":102},[],{"trials":27097,"activeCount":102},[27098],{"nctId":27099,"briefTitle":27100,"status":108,"phases":27101,"primaryCompletion":2662,"completion":2662,"start":27102,"enrollment":19708,"conditions":27103,"interventions":27104},"NCT02855684","Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy",[92],"2016-08-24",[19],[8067,8067,27088],{"trials":27106,"activeCount":102},[],{"trials":27108,"activeCount":102},[],{"intervention":27110,"totalTrials":195,"cells":27111},"Venglustat GZ402671",{"EARLY_PHASE1":27112,"PHASE1":27114,"PHASE2":27116,"PHASE3":27118,"PHASE4":27129,"NA":27131},{"trials":27113,"activeCount":102},[],{"trials":27115,"activeCount":102},[],{"trials":27117,"activeCount":102},[],{"trials":27119,"activeCount":102},[27120],{"nctId":27121,"briefTitle":27122,"status":884,"phases":27123,"primaryCompletion":27124,"completion":27124,"start":27125,"enrollment":9319,"conditions":27126,"interventions":27128},"NCT04705051","Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat",[92],"2021-07-13","2021-02-09",[27127],"Congenital Cystic Kidney Disease",[27110],{"trials":27130,"activeCount":102},[],{"trials":27132,"activeCount":102},[],{"intervention":27134,"totalTrials":195,"cells":27135},"DTaP-HB-PRP~T combined vaccine",{"EARLY_PHASE1":27136,"PHASE1":27138,"PHASE2":27140,"PHASE3":27142,"PHASE4":27152,"NA":27154},{"trials":27137,"activeCount":102},[],{"trials":27139,"activeCount":102},[],{"trials":27141,"activeCount":102},[],{"trials":27143,"activeCount":102},[27144],{"nctId":27145,"briefTitle":27146,"status":108,"phases":27147,"primaryCompletion":3317,"completion":8156,"start":8395,"enrollment":21108,"conditions":27148,"interventions":27149},"NCT00348881","Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB\u002FHib™, Concomitantly With OPV in Healthy Infants",[92],[25,31,28,18625,16],[27134,27150,27151],"Tritanrix-HepB\u002FHib™ vaccine","Oral poliomyelitis vaccine",{"trials":27153,"activeCount":102},[],{"trials":27155,"activeCount":102},[],{"intervention":27150,"totalTrials":195,"cells":27157},{"EARLY_PHASE1":27158,"PHASE1":27160,"PHASE2":27162,"PHASE3":27164,"PHASE4":27170,"NA":27172},{"trials":27159,"activeCount":102},[],{"trials":27161,"activeCount":102},[],{"trials":27163,"activeCount":102},[],{"trials":27165,"activeCount":102},[27166],{"nctId":27145,"briefTitle":27146,"status":108,"phases":27167,"primaryCompletion":3317,"completion":8156,"start":8395,"enrollment":21108,"conditions":27168,"interventions":27169},[92],[25,31,28,18625,16],[27134,27150,27151],{"trials":27171,"activeCount":102},[],{"trials":27173,"activeCount":102},[],{"intervention":27151,"totalTrials":195,"cells":27175},{"EARLY_PHASE1":27176,"PHASE1":27178,"PHASE2":27180,"PHASE3":27182,"PHASE4":27188,"NA":27190},{"trials":27177,"activeCount":102},[],{"trials":27179,"activeCount":102},[],{"trials":27181,"activeCount":102},[],{"trials":27183,"activeCount":102},[27184],{"nctId":27145,"briefTitle":27146,"status":108,"phases":27185,"primaryCompletion":3317,"completion":8156,"start":8395,"enrollment":21108,"conditions":27186,"interventions":27187},[92],[25,31,28,18625,16],[27134,27150,27151],{"trials":27189,"activeCount":102},[],{"trials":27191,"activeCount":102},[],{"intervention":27193,"totalTrials":195,"cells":27194},"Diphteria\u002FTetanus\u002FPolio\u002FAcellular Pertussis\u002FHib vaccine",{"EARLY_PHASE1":27195,"PHASE1":27197,"PHASE2":27199,"PHASE3":27201,"PHASE4":27210,"NA":27212},{"trials":27196,"activeCount":102},[],{"trials":27198,"activeCount":102},[],{"trials":27200,"activeCount":102},[],{"trials":27202,"activeCount":102},[27203],{"nctId":27204,"briefTitle":27205,"status":108,"phases":27206,"primaryCompletion":8505,"completion":8205,"start":8777,"enrollment":27207,"conditions":27208,"interventions":27209},"NCT00259337","Immunogenicity and Safety of Pentaxim™ in an Indian Population",[92],226,[25,31,13810,28,17157],[27193],{"trials":27211,"activeCount":102},[],{"trials":27213,"activeCount":102},[],{"intervention":22675,"totalTrials":195,"cells":27215},{"EARLY_PHASE1":27216,"PHASE1":27218,"PHASE2":27220,"PHASE3":27222,"PHASE4":27228,"NA":27230},{"trials":27217,"activeCount":102},[],{"trials":27219,"activeCount":102},[],{"trials":27221,"activeCount":102},[],{"trials":27223,"activeCount":102},[27224],{"nctId":22666,"briefTitle":22667,"status":884,"phases":27225,"primaryCompletion":22669,"completion":22670,"start":22458,"enrollment":22671,"conditions":27226,"interventions":27227},[92],[19],[22655,22674,22675],{"trials":27229,"activeCount":102},[],{"trials":27231,"activeCount":102},[],{"intervention":20809,"totalTrials":195,"cells":27233},{"EARLY_PHASE1":27234,"PHASE1":27236,"PHASE2":27238,"PHASE3":27240,"PHASE4":27246,"NA":27248},{"trials":27235,"activeCount":102},[],{"trials":27237,"activeCount":102},[],{"trials":27239,"activeCount":102},[],{"trials":27241,"activeCount":102},[27242],{"nctId":20802,"briefTitle":20803,"status":108,"phases":27243,"primaryCompletion":20805,"completion":7330,"start":20806,"enrollment":5913,"conditions":27244,"interventions":27245},[92],[2316,2317],[20809,20810,2325,2965,20809,20810,2325,2965],{"trials":27247,"activeCount":102},[],{"trials":27249,"activeCount":102},[],{"intervention":20810,"totalTrials":195,"cells":27251},{"EARLY_PHASE1":27252,"PHASE1":27254,"PHASE2":27256,"PHASE3":27258,"PHASE4":27264,"NA":27266},{"trials":27253,"activeCount":102},[],{"trials":27255,"activeCount":102},[],{"trials":27257,"activeCount":102},[],{"trials":27259,"activeCount":102},[27260],{"nctId":20802,"briefTitle":20803,"status":108,"phases":27261,"primaryCompletion":20805,"completion":7330,"start":20806,"enrollment":5913,"conditions":27262,"interventions":27263},[92],[2316,2317],[20809,20810,2325,2965,20809,20810,2325,2965],{"trials":27265,"activeCount":102},[],{"trials":27267,"activeCount":102},[],{"intervention":27269,"totalTrials":195,"cells":27270},"Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative",{"EARLY_PHASE1":27271,"PHASE1":27273,"PHASE2":27275,"PHASE3":27277,"PHASE4":27290,"NA":27292},{"trials":27272,"activeCount":102},[],{"trials":27274,"activeCount":102},[],{"trials":27276,"activeCount":102},[],{"trials":27278,"activeCount":102},[27279],{"nctId":27280,"briefTitle":27281,"status":108,"phases":27282,"primaryCompletion":27283,"completion":27283,"start":27284,"enrollment":504,"conditions":27285,"interventions":27286},"NCT02451358","Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India",[92],"2017-01-28","2015-07-27",[16],[27269,27287,27288,27289],"Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative","Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative","Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative",{"trials":27291,"activeCount":102},[],{"trials":27293,"activeCount":102},[],{"intervention":27287,"totalTrials":195,"cells":27295},{"EARLY_PHASE1":27296,"PHASE1":27298,"PHASE2":27300,"PHASE3":27302,"PHASE4":27308,"NA":27310},{"trials":27297,"activeCount":102},[],{"trials":27299,"activeCount":102},[],{"trials":27301,"activeCount":102},[],{"trials":27303,"activeCount":102},[27304],{"nctId":27280,"briefTitle":27281,"status":108,"phases":27305,"primaryCompletion":27283,"completion":27283,"start":27284,"enrollment":504,"conditions":27306,"interventions":27307},[92],[16],[27269,27287,27288,27289],{"trials":27309,"activeCount":102},[],{"trials":27311,"activeCount":102},[],{"intervention":27288,"totalTrials":195,"cells":27313},{"EARLY_PHASE1":27314,"PHASE1":27316,"PHASE2":27318,"PHASE3":27320,"PHASE4":27326,"NA":27328},{"trials":27315,"activeCount":102},[],{"trials":27317,"activeCount":102},[],{"trials":27319,"activeCount":102},[],{"trials":27321,"activeCount":102},[27322],{"nctId":27280,"briefTitle":27281,"status":108,"phases":27323,"primaryCompletion":27283,"completion":27283,"start":27284,"enrollment":504,"conditions":27324,"interventions":27325},[92],[16],[27269,27287,27288,27289],{"trials":27327,"activeCount":102},[],{"trials":27329,"activeCount":102},[],{"intervention":27289,"totalTrials":195,"cells":27331},{"EARLY_PHASE1":27332,"PHASE1":27334,"PHASE2":27336,"PHASE3":27338,"PHASE4":27344,"NA":27346},{"trials":27333,"activeCount":102},[],{"trials":27335,"activeCount":102},[],{"trials":27337,"activeCount":102},[],{"trials":27339,"activeCount":102},[27340],{"nctId":27280,"briefTitle":27281,"status":108,"phases":27341,"primaryCompletion":27283,"completion":27283,"start":27284,"enrollment":504,"conditions":27342,"interventions":27343},[92],[16],[27269,27287,27288,27289],{"trials":27345,"activeCount":102},[],{"trials":27347,"activeCount":102},[],{"intervention":7402,"totalTrials":195,"cells":27349},{"EARLY_PHASE1":27350,"PHASE1":27352,"PHASE2":27354,"PHASE3":27356,"PHASE4":27362,"NA":27364},{"trials":27351,"activeCount":102},[],{"trials":27353,"activeCount":102},[],{"trials":27355,"activeCount":102},[],{"trials":27357,"activeCount":102},[27358],{"nctId":7394,"briefTitle":7395,"status":108,"phases":27359,"primaryCompletion":7397,"completion":7388,"start":7398,"enrollment":7399,"conditions":27360,"interventions":27361},[92],[3892],[7273,7402],{"trials":27363,"activeCount":102},[],{"trials":27365,"activeCount":102},[],{"intervention":12754,"totalTrials":195,"cells":27367},{"EARLY_PHASE1":27368,"PHASE1":27370,"PHASE2":27372,"PHASE3":27374,"PHASE4":27380,"NA":27382},{"trials":27369,"activeCount":102},[],{"trials":27371,"activeCount":102},[],{"trials":27373,"activeCount":102},[],{"trials":27375,"activeCount":102},[27376],{"nctId":12748,"briefTitle":12749,"status":108,"phases":27377,"primaryCompletion":3307,"completion":3307,"start":8235,"enrollment":12751,"conditions":27378,"interventions":27379},[92],[12745],[12754,12755],{"trials":27381,"activeCount":102},[],{"trials":27383,"activeCount":102},[],{"intervention":18589,"totalTrials":195,"cells":27385},{"EARLY_PHASE1":27386,"PHASE1":27388,"PHASE2":27390,"PHASE3":27392,"PHASE4":27398,"NA":27400},{"trials":27387,"activeCount":102},[],{"trials":27389,"activeCount":102},[],{"trials":27391,"activeCount":102},[],{"trials":27393,"activeCount":102},[27394],{"nctId":18583,"briefTitle":18584,"status":108,"phases":27395,"primaryCompletion":8745,"completion":8745,"start":8156,"enrollment":18586,"conditions":27396,"interventions":27397},[92],[10323],[18589,10325],{"trials":27399,"activeCount":102},[],{"trials":27401,"activeCount":102},[],{"intervention":27403,"totalTrials":195,"cells":27404},"REVAXIS®",{"EARLY_PHASE1":27405,"PHASE1":27407,"PHASE2":27409,"PHASE3":27411,"PHASE4":27421,"NA":27423},{"trials":27406,"activeCount":102},[],{"trials":27408,"activeCount":102},[],{"trials":27410,"activeCount":102},[],{"trials":27412,"activeCount":102},[27413],{"nctId":27414,"briefTitle":27415,"status":108,"phases":27416,"primaryCompletion":8762,"completion":8762,"start":9785,"enrollment":27417,"conditions":27418,"interventions":27419},"NCT00447525","REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children",[92],760,[25,31,12983],[27403,27420],"DT-Polio®",{"trials":27422,"activeCount":102},[],{"trials":27424,"activeCount":102},[],{"intervention":27420,"totalTrials":195,"cells":27426},{"EARLY_PHASE1":27427,"PHASE1":27429,"PHASE2":27431,"PHASE3":27433,"PHASE4":27439,"NA":27441},{"trials":27428,"activeCount":102},[],{"trials":27430,"activeCount":102},[],{"trials":27432,"activeCount":102},[],{"trials":27434,"activeCount":102},[27435],{"nctId":27414,"briefTitle":27415,"status":108,"phases":27436,"primaryCompletion":8762,"completion":8762,"start":9785,"enrollment":27417,"conditions":27437,"interventions":27438},[92],[25,31,12983],[27403,27420],{"trials":27440,"activeCount":102},[],{"trials":27442,"activeCount":102},[],{"intervention":12062,"totalTrials":195,"cells":27444},{"EARLY_PHASE1":27445,"PHASE1":27447,"PHASE2":27449,"PHASE3":27451,"PHASE4":27457,"NA":27459},{"trials":27446,"activeCount":102},[],{"trials":27448,"activeCount":102},[],{"trials":27450,"activeCount":102},[],{"trials":27452,"activeCount":102},[27453],{"nctId":12055,"briefTitle":12056,"status":108,"phases":27454,"primaryCompletion":3858,"completion":12058,"start":12059,"enrollment":8738,"conditions":27455,"interventions":27456},[92],[554],[12062,8067,10566],{"trials":27458,"activeCount":102},[],{"trials":27460,"activeCount":102},[],{"intervention":27462,"totalTrials":195,"cells":27463},"PEDIACEL® and Prevenar®",{"EARLY_PHASE1":27464,"PHASE1":27466,"PHASE2":27468,"PHASE3":27470,"PHASE4":27479,"NA":27481},{"trials":27465,"activeCount":102},[],{"trials":27467,"activeCount":102},[],{"trials":27469,"activeCount":102},[],{"trials":27471,"activeCount":102},[27472],{"nctId":27473,"briefTitle":27474,"status":108,"phases":27475,"primaryCompletion":8156,"completion":3307,"start":3608,"enrollment":8754,"conditions":27476,"interventions":27477},"NCT00343421","Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers",[92],[25,31,28,12983,20655],[27462,27478],"Infanrix®-IPV+Hib and Prevenar®",{"trials":27480,"activeCount":102},[],{"trials":27482,"activeCount":102},[],{"intervention":27478,"totalTrials":195,"cells":27484},{"EARLY_PHASE1":27485,"PHASE1":27487,"PHASE2":27489,"PHASE3":27491,"PHASE4":27497,"NA":27499},{"trials":27486,"activeCount":102},[],{"trials":27488,"activeCount":102},[],{"trials":27490,"activeCount":102},[],{"trials":27492,"activeCount":102},[27493],{"nctId":27473,"briefTitle":27474,"status":108,"phases":27494,"primaryCompletion":8156,"completion":3307,"start":3608,"enrollment":8754,"conditions":27495,"interventions":27496},[92],[25,31,28,12983,20655],[27462,27478],{"trials":27498,"activeCount":102},[],{"trials":27500,"activeCount":102},[],{"intervention":27502,"totalTrials":195,"cells":27503},"riferminogene pecaplasmid",{"EARLY_PHASE1":27504,"PHASE1":27506,"PHASE2":27508,"PHASE3":27510,"PHASE4":27519,"NA":27521},{"trials":27505,"activeCount":102},[],{"trials":27507,"activeCount":102},[],{"trials":27509,"activeCount":102},[],{"trials":27511,"activeCount":102},[27512],{"nctId":27513,"briefTitle":27514,"status":108,"phases":27515,"primaryCompletion":5271,"completion":7349,"start":8607,"enrollment":5017,"conditions":27516,"interventions":27518},"NCT00566657","Efficacy and Safety of XRP0038\u002FNV1FGF in Critical Limb Ischemia Patients With Skin Lesions",[92],[27517],"Peripheral Vascular Diseases",[27502],{"trials":27520,"activeCount":102},[],{"trials":27522,"activeCount":102},[],{"intervention":27524,"totalTrials":195,"cells":27525},"DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide",{"EARLY_PHASE1":27526,"PHASE1":27528,"PHASE2":27530,"PHASE3":27532,"PHASE4":27543,"NA":27545},{"trials":27527,"activeCount":102},[],{"trials":27529,"activeCount":102},[],{"trials":27531,"activeCount":102},[],{"trials":27533,"activeCount":102},[27534],{"nctId":27535,"briefTitle":27536,"status":108,"phases":27537,"primaryCompletion":1032,"completion":966,"start":986,"enrollment":27538,"conditions":27539,"interventions":27540},"NCT01444781","Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants",[92],1106,[25,31,13514,18625,12983],[27524,27541,27542],"DTaP-Hep B-IPV \u002F\u002F Hib Vaccine + Pneumococcal polysaccharide","DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine",{"trials":27544,"activeCount":102},[],{"trials":27546,"activeCount":102},[],{"intervention":27541,"totalTrials":195,"cells":27548},{"EARLY_PHASE1":27549,"PHASE1":27551,"PHASE2":27553,"PHASE3":27555,"PHASE4":27561,"NA":27563},{"trials":27550,"activeCount":102},[],{"trials":27552,"activeCount":102},[],{"trials":27554,"activeCount":102},[],{"trials":27556,"activeCount":102},[27557],{"nctId":27535,"briefTitle":27536,"status":108,"phases":27558,"primaryCompletion":1032,"completion":966,"start":986,"enrollment":27538,"conditions":27559,"interventions":27560},[92],[25,31,13514,18625,12983],[27524,27541,27542],{"trials":27562,"activeCount":102},[],{"trials":27564,"activeCount":102},[],{"intervention":27542,"totalTrials":195,"cells":27566},{"EARLY_PHASE1":27567,"PHASE1":27569,"PHASE2":27571,"PHASE3":27573,"PHASE4":27579,"NA":27581},{"trials":27568,"activeCount":102},[],{"trials":27570,"activeCount":102},[],{"trials":27572,"activeCount":102},[],{"trials":27574,"activeCount":102},[27575],{"nctId":27535,"briefTitle":27536,"status":108,"phases":27576,"primaryCompletion":1032,"completion":966,"start":986,"enrollment":27538,"conditions":27577,"interventions":27578},[92],[25,31,13514,18625,12983],[27524,27541,27542],{"trials":27580,"activeCount":102},[],{"trials":27582,"activeCount":102},[],{"intervention":27584,"totalTrials":195,"cells":27585},"DTaP\u002F\u002FPRP-T Combined Vaccine",{"EARLY_PHASE1":27586,"PHASE1":27588,"PHASE2":27590,"PHASE3":27592,"PHASE4":27602,"NA":27604},{"trials":27587,"activeCount":102},[],{"trials":27589,"activeCount":102},[],{"trials":27591,"activeCount":102},[],{"trials":27593,"activeCount":102},[27594],{"nctId":27595,"briefTitle":27596,"status":108,"phases":27597,"primaryCompletion":986,"completion":977,"start":8745,"enrollment":27598,"conditions":27599,"interventions":27600},"NCT01062477","A Study of DTaP\u002F\u002FPRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants",[92],1056,[25,31,28,17179],[27584,27584,27601],"DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine",{"trials":27603,"activeCount":102},[],{"trials":27605,"activeCount":102},[],{"intervention":27601,"totalTrials":195,"cells":27607},{"EARLY_PHASE1":27608,"PHASE1":27610,"PHASE2":27612,"PHASE3":27614,"PHASE4":27620,"NA":27622},{"trials":27609,"activeCount":102},[],{"trials":27611,"activeCount":102},[],{"trials":27613,"activeCount":102},[],{"trials":27615,"activeCount":102},[27616],{"nctId":27595,"briefTitle":27596,"status":108,"phases":27617,"primaryCompletion":986,"completion":977,"start":8745,"enrollment":27598,"conditions":27618,"interventions":27619},[92],[25,31,28,17179],[27584,27584,27601],{"trials":27621,"activeCount":102},[],{"trials":27623,"activeCount":102},[],{"intervention":27625,"totalTrials":195,"cells":27626},"Trivalent Influenza Vaccine 1 SP Shz TIV1",{"EARLY_PHASE1":27627,"PHASE1":27629,"PHASE2":27631,"PHASE3":27633,"PHASE4":27643,"NA":27645},{"trials":27628,"activeCount":102},[],{"trials":27630,"activeCount":102},[],{"trials":27632,"activeCount":102},[],{"trials":27634,"activeCount":102},[27635],{"nctId":27636,"briefTitle":27637,"status":108,"phases":27638,"primaryCompletion":7189,"completion":7189,"start":24271,"enrollment":27639,"conditions":27640,"interventions":27641},"NCT04210349","Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age",[92],7106,[16],[25511,27625,27642],"Trivalent Influenza Vaccine 2 SP Shz TIV2",{"trials":27644,"activeCount":102},[],{"trials":27646,"activeCount":102},[],{"intervention":27642,"totalTrials":195,"cells":27648},{"EARLY_PHASE1":27649,"PHASE1":27651,"PHASE2":27653,"PHASE3":27655,"PHASE4":27661,"NA":27663},{"trials":27650,"activeCount":102},[],{"trials":27652,"activeCount":102},[],{"trials":27654,"activeCount":102},[],{"trials":27656,"activeCount":102},[27657],{"nctId":27636,"briefTitle":27637,"status":108,"phases":27658,"primaryCompletion":7189,"completion":7189,"start":24271,"enrollment":27639,"conditions":27659,"interventions":27660},[92],[16],[25511,27625,27642],{"trials":27662,"activeCount":102},[],{"trials":27664,"activeCount":102},[],{"intervention":27666,"totalTrials":195,"cells":27667},"Doxorubicine + docetaxel sequential",{"EARLY_PHASE1":27668,"PHASE1":27670,"PHASE2":27672,"PHASE3":27674,"PHASE4":27687,"NA":27689},{"trials":27669,"activeCount":102},[],{"trials":27671,"activeCount":102},[],{"trials":27673,"activeCount":102},[],{"trials":27675,"activeCount":102},[27676],{"nctId":27677,"briefTitle":27678,"status":108,"phases":27679,"primaryCompletion":986,"completion":986,"start":27680,"enrollment":27681,"conditions":27682,"interventions":27683},"NCT00174655","BIG 02\u002F98 Docetaxel - Breast Cancer",[92],"1998-06",2887,[5275],[27666,27684,27685,27686],"doxorubicine + cyclophosphamide sequential","doxorubicine + cyclophosphamide combined","doxorubicine + docetaxel combined",{"trials":27688,"activeCount":102},[],{"trials":27690,"activeCount":102},[],{"intervention":27684,"totalTrials":195,"cells":27692},{"EARLY_PHASE1":27693,"PHASE1":27695,"PHASE2":27697,"PHASE3":27699,"PHASE4":27705,"NA":27707},{"trials":27694,"activeCount":102},[],{"trials":27696,"activeCount":102},[],{"trials":27698,"activeCount":102},[],{"trials":27700,"activeCount":102},[27701],{"nctId":27677,"briefTitle":27678,"status":108,"phases":27702,"primaryCompletion":986,"completion":986,"start":27680,"enrollment":27681,"conditions":27703,"interventions":27704},[92],[5275],[27666,27684,27685,27686],{"trials":27706,"activeCount":102},[],{"trials":27708,"activeCount":102},[],{"intervention":27685,"totalTrials":195,"cells":27710},{"EARLY_PHASE1":27711,"PHASE1":27713,"PHASE2":27715,"PHASE3":27717,"PHASE4":27723,"NA":27725},{"trials":27712,"activeCount":102},[],{"trials":27714,"activeCount":102},[],{"trials":27716,"activeCount":102},[],{"trials":27718,"activeCount":102},[27719],{"nctId":27677,"briefTitle":27678,"status":108,"phases":27720,"primaryCompletion":986,"completion":986,"start":27680,"enrollment":27681,"conditions":27721,"interventions":27722},[92],[5275],[27666,27684,27685,27686],{"trials":27724,"activeCount":102},[],{"trials":27726,"activeCount":102},[],{"intervention":27686,"totalTrials":195,"cells":27728},{"EARLY_PHASE1":27729,"PHASE1":27731,"PHASE2":27733,"PHASE3":27735,"PHASE4":27741,"NA":27743},{"trials":27730,"activeCount":102},[],{"trials":27732,"activeCount":102},[],{"trials":27734,"activeCount":102},[],{"trials":27736,"activeCount":102},[27737],{"nctId":27677,"briefTitle":27678,"status":108,"phases":27738,"primaryCompletion":986,"completion":986,"start":27680,"enrollment":27681,"conditions":27739,"interventions":27740},[92],[5275],[27666,27684,27685,27686],{"trials":27742,"activeCount":102},[],{"trials":27744,"activeCount":102},[],{"intervention":27746,"totalTrials":195,"cells":27747},"DTaP-IPV-Hep B-PRP~T combined vaccine",{"EARLY_PHASE1":27748,"PHASE1":27750,"PHASE2":27752,"PHASE3":27754,"PHASE4":27764,"NA":27766},{"trials":27749,"activeCount":102},[],{"trials":27751,"activeCount":102},[],{"trials":27753,"activeCount":102},[],{"trials":27755,"activeCount":102},[27756],{"nctId":27757,"briefTitle":27758,"status":108,"phases":27759,"primaryCompletion":965,"completion":1041,"start":1055,"enrollment":18654,"conditions":27760,"interventions":27762},"NCT02094833","DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV\u002F\u002FPRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants",[92],[25,31,28,27761,12983,18625],"Haemophilus Influenzae Type b Infection",[27746,27763],"DTaP-IPV\u002F\u002FPRP~T and Hepatitis B vaccine",{"trials":27765,"activeCount":102},[],{"trials":27767,"activeCount":102},[],{"intervention":27763,"totalTrials":195,"cells":27769},{"EARLY_PHASE1":27770,"PHASE1":27772,"PHASE2":27774,"PHASE3":27776,"PHASE4":27782,"NA":27784},{"trials":27771,"activeCount":102},[],{"trials":27773,"activeCount":102},[],{"trials":27775,"activeCount":102},[],{"trials":27777,"activeCount":102},[27778],{"nctId":27757,"briefTitle":27758,"status":108,"phases":27779,"primaryCompletion":965,"completion":1041,"start":1055,"enrollment":18654,"conditions":27780,"interventions":27781},[92],[25,31,28,27761,12983,18625],[27746,27763],{"trials":27783,"activeCount":102},[],{"trials":27785,"activeCount":102},[],{"intervention":27787,"totalTrials":195,"cells":27788},"Prednisone or Prednisolone",{"EARLY_PHASE1":27789,"PHASE1":27791,"PHASE2":27793,"PHASE3":27795,"PHASE4":27804,"NA":27806},{"trials":27790,"activeCount":102},[],{"trials":27792,"activeCount":102},[],{"trials":27794,"activeCount":102},[],{"trials":27796,"activeCount":102},[27797],{"nctId":27798,"briefTitle":27799,"status":108,"phases":27800,"primaryCompletion":3416,"completion":3416,"start":9190,"enrollment":27801,"conditions":27802,"interventions":27803},"NCT00519285","Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer",[92],1224,[2804,9156],[1347,1348,27787],{"trials":27805,"activeCount":102},[],{"trials":27807,"activeCount":102},[],{"intervention":19173,"totalTrials":195,"cells":27809},{"EARLY_PHASE1":27810,"PHASE1":27812,"PHASE2":27814,"PHASE3":27816,"PHASE4":27822,"NA":27824},{"trials":27811,"activeCount":102},[],{"trials":27813,"activeCount":102},[],{"trials":27815,"activeCount":102},[],{"trials":27817,"activeCount":102},[27818],{"nctId":19167,"briefTitle":19168,"status":108,"phases":27819,"primaryCompletion":7430,"completion":7430,"start":3327,"enrollment":19170,"conditions":27820,"interventions":27821},[92],[5275],[4640,4643,1348,19173,5277],{"trials":27823,"activeCount":102},[],{"trials":27825,"activeCount":102},[],{"intervention":22804,"totalTrials":195,"cells":27827},{"EARLY_PHASE1":27828,"PHASE1":27830,"PHASE2":27832,"PHASE3":27834,"PHASE4":27840,"NA":27842},{"trials":27829,"activeCount":102},[],{"trials":27831,"activeCount":102},[],{"trials":27833,"activeCount":102},[],{"trials":27835,"activeCount":102},[27836],{"nctId":22799,"briefTitle":22800,"status":108,"phases":27837,"primaryCompletion":987,"completion":987,"start":5271,"enrollment":1232,"conditions":27838,"interventions":27839},[92],[33],[22804,8983],{"trials":27841,"activeCount":102},[],{"trials":27843,"activeCount":102},[],{"intervention":27845,"totalTrials":195,"cells":27846},"Doxercalciferol",{"EARLY_PHASE1":27847,"PHASE1":27849,"PHASE2":27851,"PHASE3":27853,"PHASE4":27864,"NA":27866},{"trials":27848,"activeCount":102},[],{"trials":27850,"activeCount":102},[],{"trials":27852,"activeCount":102},[],{"trials":27854,"activeCount":102},[27855],{"nctId":27856,"briefTitle":27857,"status":884,"phases":27858,"primaryCompletion":23607,"completion":23607,"start":27859,"enrollment":1134,"conditions":27860,"interventions":27862},"NCT02859896","Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis",[92],"2017-01-19",[27861],"Secondary Hyperparathyroidism-Chronic Kidney Disease",[27845,27863],"Calcitriol",{"trials":27865,"activeCount":102},[],{"trials":27867,"activeCount":102},[],{"intervention":27863,"totalTrials":195,"cells":27869},{"EARLY_PHASE1":27870,"PHASE1":27872,"PHASE2":27874,"PHASE3":27876,"PHASE4":27882,"NA":27884},{"trials":27871,"activeCount":102},[],{"trials":27873,"activeCount":102},[],{"trials":27875,"activeCount":102},[],{"trials":27877,"activeCount":102},[27878],{"nctId":27856,"briefTitle":27857,"status":884,"phases":27879,"primaryCompletion":23607,"completion":23607,"start":27859,"enrollment":1134,"conditions":27880,"interventions":27881},[92],[27861],[27845,27863],{"trials":27883,"activeCount":102},[],{"trials":27885,"activeCount":102},[],{"intervention":27887,"totalTrials":195,"cells":27888},"Poliomyelitis Vaccine inactivated",{"EARLY_PHASE1":27889,"PHASE1":27891,"PHASE2":27893,"PHASE3":27895,"PHASE4":27904,"NA":27906},{"trials":27890,"activeCount":102},[],{"trials":27892,"activeCount":102},[],{"trials":27894,"activeCount":102},[],{"trials":27896,"activeCount":102},[27897],{"nctId":27898,"briefTitle":27899,"status":108,"phases":27900,"primaryCompletion":3564,"completion":8205,"start":8395,"enrollment":16359,"conditions":27901,"interventions":27902},"NCT00348387","Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV",[92],[12983,13810],[27887,27903],"Poliomyelitis Vaccine in Dragee Candy",{"trials":27905,"activeCount":102},[],{"trials":27907,"activeCount":102},[],{"intervention":27903,"totalTrials":195,"cells":27909},{"EARLY_PHASE1":27910,"PHASE1":27912,"PHASE2":27914,"PHASE3":27916,"PHASE4":27922,"NA":27924},{"trials":27911,"activeCount":102},[],{"trials":27913,"activeCount":102},[],{"trials":27915,"activeCount":102},[],{"trials":27917,"activeCount":102},[27918],{"nctId":27898,"briefTitle":27899,"status":108,"phases":27919,"primaryCompletion":3564,"completion":8205,"start":8395,"enrollment":16359,"conditions":27920,"interventions":27921},[92],[12983,13810],[27887,27903],{"trials":27923,"activeCount":102},[],{"trials":27925,"activeCount":102},[],{"intervention":27927,"totalTrials":195,"cells":27928},"Typhoid Vi polysaccharide",{"EARLY_PHASE1":27929,"PHASE1":27931,"PHASE2":27933,"PHASE3":27935,"PHASE4":27945,"NA":27947},{"trials":27930,"activeCount":102},[],{"trials":27932,"activeCount":102},[],{"trials":27934,"activeCount":102},[],{"trials":27936,"activeCount":102},[27937],{"nctId":27938,"briefTitle":27939,"status":108,"phases":27940,"primaryCompletion":10178,"completion":3438,"start":5238,"enrollment":12,"conditions":27941,"interventions":27944},"NCT01608815","Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects",[92],[27942,27943,2490],"Salmonella Infections","Typhoid Fever",[27927],{"trials":27946,"activeCount":102},[],{"trials":27948,"activeCount":102},[],{"intervention":20515,"totalTrials":195,"cells":27950},{"EARLY_PHASE1":27951,"PHASE1":27953,"PHASE2":27955,"PHASE3":27957,"PHASE4":27963,"NA":27965},{"trials":27952,"activeCount":102},[],{"trials":27954,"activeCount":102},[],{"trials":27956,"activeCount":102},[],{"trials":27958,"activeCount":102},[27959],{"nctId":20509,"briefTitle":20510,"status":108,"phases":27960,"primaryCompletion":20512,"completion":20512,"start":8547,"enrollment":589,"conditions":27961,"interventions":27962},[92],[4992,7568,2922],[20515,5021],{"trials":27964,"activeCount":102},[],{"trials":27966,"activeCount":102},[],{"intervention":22016,"totalTrials":195,"cells":27968},{"EARLY_PHASE1":27969,"PHASE1":27971,"PHASE2":27973,"PHASE3":27975,"PHASE4":27981,"NA":27983},{"trials":27970,"activeCount":102},[],{"trials":27972,"activeCount":102},[],{"trials":27974,"activeCount":102},[],{"trials":27976,"activeCount":102},[27977],{"nctId":22011,"briefTitle":22012,"status":108,"phases":27978,"primaryCompletion":14370,"completion":1011,"start":1055,"enrollment":3386,"conditions":27979,"interventions":27980},[92],[31,25,28],[18296,22016],{"trials":27982,"activeCount":102},[],{"trials":27984,"activeCount":102},[],{"intervention":27986,"totalTrials":195,"cells":27987},"Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus",{"EARLY_PHASE1":27988,"PHASE1":27990,"PHASE2":27992,"PHASE3":27994,"PHASE4":28002,"NA":28004},{"trials":27989,"activeCount":102},[],{"trials":27991,"activeCount":102},[],{"trials":27993,"activeCount":102},[],{"trials":27995,"activeCount":102},[27996],{"nctId":27997,"briefTitle":27998,"status":108,"phases":27999,"primaryCompletion":2857,"completion":3438,"start":5271,"enrollment":5293,"conditions":28000,"interventions":28001},"NCT01188343","Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers",[92],[17265,10899,10900,10901],[27986,27986,27986],{"trials":28003,"activeCount":102},[],{"trials":28005,"activeCount":102},[],{"intervention":19828,"totalTrials":195,"cells":28007},{"EARLY_PHASE1":28008,"PHASE1":28010,"PHASE2":28012,"PHASE3":28014,"PHASE4":28020,"NA":28022},{"trials":28009,"activeCount":102},[],{"trials":28011,"activeCount":102},[],{"trials":28013,"activeCount":102},[],{"trials":28015,"activeCount":102},[28016],{"nctId":19821,"briefTitle":19822,"status":884,"phases":28017,"primaryCompletion":19824,"completion":4627,"start":7577,"enrollment":19825,"conditions":28018,"interventions":28019},[92],[5264],[19828,18983,18964,19829],{"trials":28021,"activeCount":102},[],{"trials":28023,"activeCount":102},[],{"intervention":19829,"totalTrials":195,"cells":28025},{"EARLY_PHASE1":28026,"PHASE1":28028,"PHASE2":28030,"PHASE3":28032,"PHASE4":28038,"NA":28040},{"trials":28027,"activeCount":102},[],{"trials":28029,"activeCount":102},[],{"trials":28031,"activeCount":102},[],{"trials":28033,"activeCount":102},[28034],{"nctId":19821,"briefTitle":19822,"status":884,"phases":28035,"primaryCompletion":19824,"completion":4627,"start":7577,"enrollment":19825,"conditions":28036,"interventions":28037},[92],[5264],[19828,18983,18964,19829],{"trials":28039,"activeCount":102},[],{"trials":28041,"activeCount":102},[],{"intervention":17995,"totalTrials":195,"cells":28043},{"EARLY_PHASE1":28044,"PHASE1":28046,"PHASE2":28048,"PHASE3":28050,"PHASE4":28056,"NA":28058},{"trials":28045,"activeCount":102},[],{"trials":28047,"activeCount":102},[],{"trials":28049,"activeCount":102},[],{"trials":28051,"activeCount":102},[28052],{"nctId":17988,"briefTitle":17989,"status":108,"phases":28053,"completion":9826,"start":17991,"conditions":28054,"interventions":28055},[92],[17993],[17864,17986,17995],{"trials":28057,"activeCount":102},[],{"trials":28059,"activeCount":102},[],{"intervention":28061,"totalTrials":195,"cells":28062},"afuzosin",{"EARLY_PHASE1":28063,"PHASE1":28065,"PHASE2":28067,"PHASE3":28069,"PHASE4":28078,"NA":28080},{"trials":28064,"activeCount":102},[],{"trials":28066,"activeCount":102},[],{"trials":28068,"activeCount":102},[],{"trials":28070,"activeCount":102},[28071],{"nctId":28072,"briefTitle":28073,"status":108,"phases":28074,"primaryCompletion":3317,"completion":3317,"start":8753,"enrollment":8072,"conditions":28075,"interventions":28077},"NCT00347061","Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH",[92],[28076],"Benign Prostatic Hyperplasia",[28061],{"trials":28079,"activeCount":102},[],{"trials":28081,"activeCount":102},[],{"intervention":28083,"totalTrials":195,"cells":28084},"Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine",{"EARLY_PHASE1":28085,"PHASE1":28087,"PHASE2":28089,"PHASE3":28091,"PHASE4":28101,"NA":28103},{"trials":28086,"activeCount":102},[],{"trials":28088,"activeCount":102},[],{"trials":28090,"activeCount":102},[],{"trials":28092,"activeCount":102},[28093],{"nctId":28094,"briefTitle":28095,"status":108,"phases":28096,"primaryCompletion":3839,"completion":3839,"start":28097,"enrollment":5282,"conditions":28098,"interventions":28100},"NCT02817451","DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants",[92],"2016-07-14",[25,31,28,18625,13810,28099],"Human Immunodeficiency Virus Infection",[28083,28083],{"trials":28102,"activeCount":102},[],{"trials":28104,"activeCount":102},[],{"intervention":28106,"totalTrials":195,"cells":28107},"Purified vero rabies vaccine - serum free - VRVg-2",{"EARLY_PHASE1":28108,"PHASE1":28110,"PHASE2":28112,"PHASE3":28114,"PHASE4":28128,"NA":28130},{"trials":28109,"activeCount":102},[],{"trials":28111,"activeCount":102},[],{"trials":28113,"activeCount":102},[],{"trials":28115,"activeCount":102},[28116],{"nctId":28117,"briefTitle":28118,"status":108,"phases":28119,"primaryCompletion":28120,"completion":28121,"start":28122,"enrollment":28123,"conditions":28124,"interventions":28125},"NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults",[92],"2020-03-25","2025-04-24","2019-10-21",1708,[14171,36],[28106,28126,28127],"Purified inactivated rabies vaccine - Verorab®","Purified inactivated rabies vaccine - Imovax® Rabies",{"trials":28129,"activeCount":102},[],{"trials":28131,"activeCount":102},[],{"intervention":28126,"totalTrials":195,"cells":28133},{"EARLY_PHASE1":28134,"PHASE1":28136,"PHASE2":28138,"PHASE3":28140,"PHASE4":28146,"NA":28148},{"trials":28135,"activeCount":102},[],{"trials":28137,"activeCount":102},[],{"trials":28139,"activeCount":102},[],{"trials":28141,"activeCount":102},[28142],{"nctId":28117,"briefTitle":28118,"status":108,"phases":28143,"primaryCompletion":28120,"completion":28121,"start":28122,"enrollment":28123,"conditions":28144,"interventions":28145},[92],[14171,36],[28106,28126,28127],{"trials":28147,"activeCount":102},[],{"trials":28149,"activeCount":102},[],{"intervention":28127,"totalTrials":195,"cells":28151},{"EARLY_PHASE1":28152,"PHASE1":28154,"PHASE2":28156,"PHASE3":28158,"PHASE4":28164,"NA":28166},{"trials":28153,"activeCount":102},[],{"trials":28155,"activeCount":102},[],{"trials":28157,"activeCount":102},[],{"trials":28159,"activeCount":102},[28160],{"nctId":28117,"briefTitle":28118,"status":108,"phases":28161,"primaryCompletion":28120,"completion":28121,"start":28122,"enrollment":28123,"conditions":28162,"interventions":28163},[92],[14171,36],[28106,28126,28127],{"trials":28165,"activeCount":102},[],{"trials":28167,"activeCount":102},[],{"intervention":28169,"totalTrials":195,"cells":28170},"75% insulin lispro protamine suspension and 25 % insulin lispro",{"EARLY_PHASE1":28171,"PHASE1":28173,"PHASE2":28175,"PHASE3":28177,"PHASE4":28185,"NA":28187},{"trials":28172,"activeCount":102},[],{"trials":28174,"activeCount":102},[],{"trials":28176,"activeCount":102},[],{"trials":28178,"activeCount":102},[28179],{"nctId":28180,"briefTitle":28181,"status":108,"phases":28182,"primaryCompletion":3509,"completion":3509,"start":9183,"enrollment":22329,"conditions":28183,"interventions":28184},"NCT01336751","Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment",[92],[22],[8067,28169],{"trials":28186,"activeCount":102},[],{"trials":28188,"activeCount":102},[],{"intervention":28190,"totalTrials":195,"cells":28191},"Japanese encephalitis chimeric virus vaccine",{"EARLY_PHASE1":28192,"PHASE1":28194,"PHASE2":28196,"PHASE3":28198,"PHASE4":28208,"NA":28210},{"trials":28193,"activeCount":102},[],{"trials":28195,"activeCount":102},[],{"trials":28197,"activeCount":102},[],{"trials":28199,"activeCount":102},[28200],{"nctId":28201,"briefTitle":28202,"status":108,"phases":28203,"primaryCompletion":986,"completion":1340,"start":1022,"enrollment":1091,"conditions":28204,"interventions":28206},"NCT01092507","A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers",[92],[28205,17265],"Encephalitis",[28190,28207],"Japanese encephalitis live vaccine",{"trials":28209,"activeCount":102},[],{"trials":28211,"activeCount":102},[],{"intervention":28207,"totalTrials":195,"cells":28213},{"EARLY_PHASE1":28214,"PHASE1":28216,"PHASE2":28218,"PHASE3":28220,"PHASE4":28226,"NA":28228},{"trials":28215,"activeCount":102},[],{"trials":28217,"activeCount":102},[],{"trials":28219,"activeCount":102},[],{"trials":28221,"activeCount":102},[28222],{"nctId":28201,"briefTitle":28202,"status":108,"phases":28223,"primaryCompletion":986,"completion":1340,"start":1022,"enrollment":1091,"conditions":28224,"interventions":28225},[92],[28205,17265],[28190,28207],{"trials":28227,"activeCount":102},[],{"trials":28229,"activeCount":102},[],{"intervention":18380,"totalTrials":195,"cells":28231},{"EARLY_PHASE1":28232,"PHASE1":28234,"PHASE2":28236,"PHASE3":28238,"PHASE4":28244,"NA":28246},{"trials":28233,"activeCount":102},[],{"trials":28235,"activeCount":102},[],{"trials":28237,"activeCount":102},[],{"trials":28239,"activeCount":102},[28240],{"nctId":18374,"briefTitle":18375,"status":108,"phases":28241,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":28242,"interventions":28243},[92],[18378],[17931,5277,18380,9134,18130,18381,10000],{"trials":28245,"activeCount":102},[],{"trials":28247,"activeCount":102},[],{"intervention":11869,"totalTrials":195,"cells":28249},{"EARLY_PHASE1":28250,"PHASE1":28252,"PHASE2":28254,"PHASE3":28256,"PHASE4":28262,"NA":28264},{"trials":28251,"activeCount":102},[],{"trials":28253,"activeCount":102},[],{"trials":28255,"activeCount":102},[],{"trials":28257,"activeCount":102},[28258],{"nctId":11857,"briefTitle":11858,"status":108,"phases":28259,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":28260,"interventions":28261},[92],[19],[11866,11867,11868,11869,11870,11871,11872],{"trials":28263,"activeCount":102},[],{"trials":28265,"activeCount":102},[],{"intervention":11870,"totalTrials":195,"cells":28267},{"EARLY_PHASE1":28268,"PHASE1":28270,"PHASE2":28272,"PHASE3":28274,"PHASE4":28280,"NA":28282},{"trials":28269,"activeCount":102},[],{"trials":28271,"activeCount":102},[],{"trials":28273,"activeCount":102},[],{"trials":28275,"activeCount":102},[28276],{"nctId":11857,"briefTitle":11858,"status":108,"phases":28277,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":28278,"interventions":28279},[92],[19],[11866,11867,11868,11869,11870,11871,11872],{"trials":28281,"activeCount":102},[],{"trials":28283,"activeCount":102},[],{"intervention":11872,"totalTrials":195,"cells":28285},{"EARLY_PHASE1":28286,"PHASE1":28288,"PHASE2":28290,"PHASE3":28292,"PHASE4":28298,"NA":28300},{"trials":28287,"activeCount":102},[],{"trials":28289,"activeCount":102},[],{"trials":28291,"activeCount":102},[],{"trials":28293,"activeCount":102},[28294],{"nctId":11857,"briefTitle":11858,"status":108,"phases":28295,"primaryCompletion":11860,"completion":11861,"start":11862,"enrollment":11863,"conditions":28296,"interventions":28297},[92],[19],[11866,11867,11868,11869,11870,11871,11872],{"trials":28299,"activeCount":102},[],{"trials":28301,"activeCount":102},[],{"intervention":28303,"totalTrials":195,"cells":28304},"High-Dose trivalent influenza vaccine",{"EARLY_PHASE1":28305,"PHASE1":28307,"PHASE2":28309,"PHASE3":28311,"PHASE4":28324,"NA":28326},{"trials":28306,"activeCount":102},[],{"trials":28308,"activeCount":102},[],{"trials":28310,"activeCount":102},[],{"trials":28312,"activeCount":102},[28313],{"nctId":28314,"briefTitle":28315,"status":108,"phases":28316,"primaryCompletion":28317,"completion":28318,"start":28319,"enrollment":28320,"conditions":28321,"interventions":28322},"NCT06641180","Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age",[92],"2025-01-28","2025-06-24","2024-11-04",1180,[16],[28303,28323],"Standard-dose trivalent influenza vaccine",{"trials":28325,"activeCount":102},[],{"trials":28327,"activeCount":102},[],{"intervention":28323,"totalTrials":195,"cells":28329},{"EARLY_PHASE1":28330,"PHASE1":28332,"PHASE2":28334,"PHASE3":28336,"PHASE4":28342,"NA":28344},{"trials":28331,"activeCount":102},[],{"trials":28333,"activeCount":102},[],{"trials":28335,"activeCount":102},[],{"trials":28337,"activeCount":102},[28338],{"nctId":28314,"briefTitle":28315,"status":108,"phases":28339,"primaryCompletion":28317,"completion":28318,"start":28319,"enrollment":28320,"conditions":28340,"interventions":28341},[92],[16],[28303,28323],{"trials":28343,"activeCount":102},[],{"trials":28345,"activeCount":102},[],{"intervention":8293,"totalTrials":195,"cells":28347},{"EARLY_PHASE1":28348,"PHASE1":28350,"PHASE2":28352,"PHASE3":28354,"PHASE4":28360,"NA":28362},{"trials":28349,"activeCount":102},[],{"trials":28351,"activeCount":102},[],{"trials":28353,"activeCount":102},[],{"trials":28355,"activeCount":102},[28356],{"nctId":8286,"briefTitle":8287,"status":108,"phases":28357,"primaryCompletion":454,"completion":454,"start":8289,"enrollment":8290,"conditions":28358,"interventions":28359},[92],[19],[8128,8293,8024,8230],{"trials":28361,"activeCount":102},[],{"trials":28363,"activeCount":102},[],{"intervention":28365,"totalTrials":195,"cells":28366},"Standard-Dose Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":28367,"PHASE1":28369,"PHASE2":28371,"PHASE3":28373,"PHASE4":28382,"NA":28384},{"trials":28368,"activeCount":102},[],{"trials":28370,"activeCount":102},[],{"trials":28372,"activeCount":102},[],{"trials":28374,"activeCount":102},[28375],{"nctId":28376,"briefTitle":28377,"status":108,"phases":28378,"primaryCompletion":27125,"completion":27125,"start":19588,"enrollment":204,"conditions":28379,"interventions":28380},"NCT04537234","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older",[92],[7891],[28381,28365],"High-Dose Quadrivalent Influenza Vaccine",{"trials":28383,"activeCount":102},[],{"trials":28385,"activeCount":102},[],{"intervention":28387,"totalTrials":195,"cells":28388},"Plasma exchange",{"EARLY_PHASE1":28389,"PHASE1":28391,"PHASE2":28393,"PHASE3":28395,"PHASE4":28405,"NA":28407},{"trials":28390,"activeCount":102},[],{"trials":28392,"activeCount":102},[],{"trials":28394,"activeCount":102},[],{"trials":28396,"activeCount":102},[28397],{"nctId":28398,"briefTitle":28399,"status":108,"phases":28400,"primaryCompletion":2816,"completion":2816,"start":28122,"enrollment":1134,"conditions":28401,"interventions":28402},"NCT04074187","A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",[91,92],[5197],[5199,28387,28403,28404],"Corticosteroid treatment","Immunosuppressive treatment",{"trials":28406,"activeCount":102},[],{"trials":28408,"activeCount":102},[],{"intervention":28403,"totalTrials":195,"cells":28410},{"EARLY_PHASE1":28411,"PHASE1":28413,"PHASE2":28415,"PHASE3":28417,"PHASE4":28423,"NA":28425},{"trials":28412,"activeCount":102},[],{"trials":28414,"activeCount":102},[],{"trials":28416,"activeCount":102},[],{"trials":28418,"activeCount":102},[28419],{"nctId":28398,"briefTitle":28399,"status":108,"phases":28420,"primaryCompletion":2816,"completion":2816,"start":28122,"enrollment":1134,"conditions":28421,"interventions":28422},[91,92],[5197],[5199,28387,28403,28404],{"trials":28424,"activeCount":102},[],{"trials":28426,"activeCount":102},[],{"intervention":28404,"totalTrials":195,"cells":28428},{"EARLY_PHASE1":28429,"PHASE1":28431,"PHASE2":28433,"PHASE3":28435,"PHASE4":28441,"NA":28443},{"trials":28430,"activeCount":102},[],{"trials":28432,"activeCount":102},[],{"trials":28434,"activeCount":102},[],{"trials":28436,"activeCount":102},[28437],{"nctId":28398,"briefTitle":28399,"status":108,"phases":28438,"primaryCompletion":2816,"completion":2816,"start":28122,"enrollment":1134,"conditions":28439,"interventions":28440},[91,92],[5197],[5199,28387,28403,28404],{"trials":28442,"activeCount":102},[],{"trials":28444,"activeCount":102},[],{"intervention":28446,"totalTrials":195,"cells":28447},"Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine",{"EARLY_PHASE1":28448,"PHASE1":28450,"PHASE2":28452,"PHASE3":28454,"PHASE4":28464,"NA":28466},{"trials":28449,"activeCount":102},[],{"trials":28451,"activeCount":102},[],{"trials":28453,"activeCount":102},[],{"trials":28455,"activeCount":102},[28456],{"nctId":28457,"briefTitle":28458,"status":108,"phases":28459,"primaryCompletion":7430,"completion":8165,"start":8166,"enrollment":28460,"conditions":28461,"interventions":28463},"NCT01948193","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth",[92],177,[25,31,13514,18625,12983,28462],"Invasive Hib Infections",[28446],{"trials":28465,"activeCount":102},[],{"trials":28467,"activeCount":102},[],{"intervention":12564,"totalTrials":195,"cells":28469},{"EARLY_PHASE1":28470,"PHASE1":28472,"PHASE2":28474,"PHASE3":28476,"PHASE4":28482,"NA":28484},{"trials":28471,"activeCount":102},[],{"trials":28473,"activeCount":102},[],{"trials":28475,"activeCount":102},[],{"trials":28477,"activeCount":102},[28478],{"nctId":12558,"briefTitle":12559,"status":884,"phases":28479,"primaryCompletion":7292,"completion":3416,"start":2799,"enrollment":12561,"conditions":28480,"interventions":28481},[92],[16],[12564,12565],{"trials":28483,"activeCount":102},[],{"trials":28485,"activeCount":102},[],{"intervention":28487,"totalTrials":195,"cells":28488},"SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1",{"EARLY_PHASE1":28489,"PHASE1":28491,"PHASE2":28493,"PHASE3":28495,"PHASE4":28516,"NA":28518},{"trials":28490,"activeCount":102},[],{"trials":28492,"activeCount":102},[],{"trials":28494,"activeCount":102},[],{"trials":28496,"activeCount":102},[28497],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28500,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28504,"interventions":28505},"NCT04762680","Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older",[91,92],"2023-06-29","2021-02-24",3159,[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],"SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2","SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3","SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4","SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03",{"trials":28517,"activeCount":102},[],{"trials":28519,"activeCount":102},[],{"intervention":28506,"totalTrials":195,"cells":28521},{"EARLY_PHASE1":28522,"PHASE1":28524,"PHASE2":28526,"PHASE3":28528,"PHASE4":28534,"NA":28536},{"trials":28523,"activeCount":102},[],{"trials":28525,"activeCount":102},[],{"trials":28527,"activeCount":102},[],{"trials":28529,"activeCount":102},[28530],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28531,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28532,"interventions":28533},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28535,"activeCount":102},[],{"trials":28537,"activeCount":102},[],{"intervention":28507,"totalTrials":195,"cells":28539},{"EARLY_PHASE1":28540,"PHASE1":28542,"PHASE2":28544,"PHASE3":28546,"PHASE4":28552,"NA":28554},{"trials":28541,"activeCount":102},[],{"trials":28543,"activeCount":102},[],{"trials":28545,"activeCount":102},[],{"trials":28547,"activeCount":102},[28548],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28549,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28550,"interventions":28551},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28553,"activeCount":102},[],{"trials":28555,"activeCount":102},[],{"intervention":28508,"totalTrials":195,"cells":28557},{"EARLY_PHASE1":28558,"PHASE1":28560,"PHASE2":28562,"PHASE3":28564,"PHASE4":28570,"NA":28572},{"trials":28559,"activeCount":102},[],{"trials":28561,"activeCount":102},[],{"trials":28563,"activeCount":102},[],{"trials":28565,"activeCount":102},[28566],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28567,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28568,"interventions":28569},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28571,"activeCount":102},[],{"trials":28573,"activeCount":102},[],{"intervention":28509,"totalTrials":195,"cells":28575},{"EARLY_PHASE1":28576,"PHASE1":28578,"PHASE2":28580,"PHASE3":28582,"PHASE4":28588,"NA":28590},{"trials":28577,"activeCount":102},[],{"trials":28579,"activeCount":102},[],{"trials":28581,"activeCount":102},[],{"trials":28583,"activeCount":102},[28584],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28585,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28586,"interventions":28587},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28589,"activeCount":102},[],{"trials":28591,"activeCount":102},[],{"intervention":28510,"totalTrials":195,"cells":28593},{"EARLY_PHASE1":28594,"PHASE1":28596,"PHASE2":28598,"PHASE3":28600,"PHASE4":28606,"NA":28608},{"trials":28595,"activeCount":102},[],{"trials":28597,"activeCount":102},[],{"trials":28599,"activeCount":102},[],{"trials":28601,"activeCount":102},[28602],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28603,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28604,"interventions":28605},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28607,"activeCount":102},[],{"trials":28609,"activeCount":102},[],{"intervention":28511,"totalTrials":195,"cells":28611},{"EARLY_PHASE1":28612,"PHASE1":28614,"PHASE2":28616,"PHASE3":28618,"PHASE4":28624,"NA":28626},{"trials":28613,"activeCount":102},[],{"trials":28615,"activeCount":102},[],{"trials":28617,"activeCount":102},[],{"trials":28619,"activeCount":102},[28620],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28621,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28622,"interventions":28623},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28625,"activeCount":102},[],{"trials":28627,"activeCount":102},[],{"intervention":28512,"totalTrials":195,"cells":28629},{"EARLY_PHASE1":28630,"PHASE1":28632,"PHASE2":28634,"PHASE3":28636,"PHASE4":28642,"NA":28644},{"trials":28631,"activeCount":102},[],{"trials":28633,"activeCount":102},[],{"trials":28635,"activeCount":102},[],{"trials":28637,"activeCount":102},[28638],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28639,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28640,"interventions":28641},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28643,"activeCount":102},[],{"trials":28645,"activeCount":102},[],{"intervention":28513,"totalTrials":195,"cells":28647},{"EARLY_PHASE1":28648,"PHASE1":28650,"PHASE2":28652,"PHASE3":28654,"PHASE4":28660,"NA":28662},{"trials":28649,"activeCount":102},[],{"trials":28651,"activeCount":102},[],{"trials":28653,"activeCount":102},[],{"trials":28655,"activeCount":102},[28656],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28657,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28658,"interventions":28659},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28661,"activeCount":102},[],{"trials":28663,"activeCount":102},[],{"intervention":28514,"totalTrials":195,"cells":28665},{"EARLY_PHASE1":28666,"PHASE1":28668,"PHASE2":28670,"PHASE3":28672,"PHASE4":28678,"NA":28680},{"trials":28667,"activeCount":102},[],{"trials":28669,"activeCount":102},[],{"trials":28671,"activeCount":102},[],{"trials":28673,"activeCount":102},[28674],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28675,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28676,"interventions":28677},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28679,"activeCount":102},[],{"trials":28681,"activeCount":102},[],{"intervention":28515,"totalTrials":195,"cells":28683},{"EARLY_PHASE1":28684,"PHASE1":28686,"PHASE2":28688,"PHASE3":28690,"PHASE4":28696,"NA":28698},{"trials":28685,"activeCount":102},[],{"trials":28687,"activeCount":102},[],{"trials":28689,"activeCount":102},[],{"trials":28691,"activeCount":102},[28692],{"nctId":28498,"briefTitle":28499,"status":108,"phases":28693,"primaryCompletion":28501,"completion":28501,"start":28502,"enrollment":28503,"conditions":28694,"interventions":28695},[91,92],[4266],[28487,28506,28507,28508,28509,28510,28511,28512,28513,28514,28515],{"trials":28697,"activeCount":102},[],{"trials":28699,"activeCount":102},[],{"intervention":12673,"totalTrials":195,"cells":28701},{"EARLY_PHASE1":28702,"PHASE1":28704,"PHASE2":28706,"PHASE3":28708,"PHASE4":28714,"NA":28716},{"trials":28703,"activeCount":102},[],{"trials":28705,"activeCount":102},[],{"trials":28707,"activeCount":102},[],{"trials":28709,"activeCount":102},[28710],{"nctId":12667,"briefTitle":12668,"status":108,"phases":28711,"primaryCompletion":8822,"start":3430,"enrollment":12670,"conditions":28712,"interventions":28713},[92],[9836],[12673,12674],{"trials":28715,"activeCount":102},[],{"trials":28717,"activeCount":102},[],{"intervention":28719,"totalTrials":195,"cells":28720},"Recombinant influenza vaccine",{"EARLY_PHASE1":28721,"PHASE1":28723,"PHASE2":28725,"PHASE3":28727,"PHASE4":28737,"NA":28739},{"trials":28722,"activeCount":102},[],{"trials":28724,"activeCount":102},[],{"trials":28726,"activeCount":102},[],{"trials":28728,"activeCount":102},[28729],{"nctId":28730,"briefTitle":28731,"status":884,"phases":28732,"primaryCompletion":13320,"completion":13320,"start":28733,"enrollment":14308,"conditions":28734,"interventions":28735},"NCT05513391","Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years",[92],"2022-11-10",[5335],[28719,28736],"Quadrivalent influenza vaccine",{"trials":28738,"activeCount":102},[],{"trials":28740,"activeCount":102},[],{"intervention":20647,"totalTrials":195,"cells":28742},{"EARLY_PHASE1":28743,"PHASE1":28745,"PHASE2":28747,"PHASE3":28749,"PHASE4":28755,"NA":28757},{"trials":28744,"activeCount":102},[],{"trials":28746,"activeCount":102},[],{"trials":28748,"activeCount":102},[],{"trials":28750,"activeCount":102},[28751],{"nctId":20641,"briefTitle":20642,"status":108,"phases":28752,"primaryCompletion":8607,"completion":8505,"start":5262,"enrollment":20644,"conditions":28753,"interventions":28754},[92],[25,31,28,18625,17157],[20647,20648,20621],{"trials":28756,"activeCount":102},[],{"trials":28758,"activeCount":102},[],{"intervention":20648,"totalTrials":195,"cells":28760},{"EARLY_PHASE1":28761,"PHASE1":28763,"PHASE2":28765,"PHASE3":28767,"PHASE4":28773,"NA":28775},{"trials":28762,"activeCount":102},[],{"trials":28764,"activeCount":102},[],{"trials":28766,"activeCount":102},[],{"trials":28768,"activeCount":102},[28769],{"nctId":20641,"briefTitle":20642,"status":108,"phases":28770,"primaryCompletion":8607,"completion":8505,"start":5262,"enrollment":20644,"conditions":28771,"interventions":28772},[92],[25,31,28,18625,17157],[20647,20648,20621],{"trials":28774,"activeCount":102},[],{"trials":28776,"activeCount":102},[],{"intervention":21102,"totalTrials":195,"cells":28778},{"EARLY_PHASE1":28779,"PHASE1":28781,"PHASE2":28783,"PHASE3":28785,"PHASE4":28791,"NA":28793},{"trials":28780,"activeCount":102},[],{"trials":28782,"activeCount":102},[],{"trials":28784,"activeCount":102},[],{"trials":28786,"activeCount":102},[28787],{"nctId":21096,"briefTitle":21097,"status":108,"phases":28788,"primaryCompletion":8316,"completion":8215,"start":5262,"enrollment":21099,"conditions":28789,"interventions":28790},[92],[18625,13810,25,28,20655],[21077,21102,21103],{"trials":28792,"activeCount":102},[],{"trials":28794,"activeCount":102},[],{"intervention":21103,"totalTrials":195,"cells":28796},{"EARLY_PHASE1":28797,"PHASE1":28799,"PHASE2":28801,"PHASE3":28803,"PHASE4":28809,"NA":28811},{"trials":28798,"activeCount":102},[],{"trials":28800,"activeCount":102},[],{"trials":28802,"activeCount":102},[],{"trials":28804,"activeCount":102},[28805],{"nctId":21096,"briefTitle":21097,"status":108,"phases":28806,"primaryCompletion":8316,"completion":8215,"start":5262,"enrollment":21099,"conditions":28807,"interventions":28808},[92],[18625,13810,25,28,20655],[21077,21102,21103],{"trials":28810,"activeCount":102},[],{"trials":28812,"activeCount":102},[],{"intervention":21111,"totalTrials":195,"cells":28814},{"EARLY_PHASE1":28815,"PHASE1":28817,"PHASE2":28819,"PHASE3":28821,"PHASE4":28827,"NA":28829},{"trials":28816,"activeCount":102},[],{"trials":28818,"activeCount":102},[],{"trials":28820,"activeCount":102},[],{"trials":28822,"activeCount":102},[28823],{"nctId":21105,"briefTitle":21106,"status":108,"phases":28824,"primaryCompletion":8762,"completion":3439,"start":3608,"enrollment":21108,"conditions":28825,"interventions":28826},[92],[25,31,28,20655,18625],[21077,21111],{"trials":28828,"activeCount":102},[],{"trials":28830,"activeCount":102},[],{"intervention":28832,"totalTrials":195,"cells":28833},"Sevelamer Carbonate",{"EARLY_PHASE1":28834,"PHASE1":28836,"PHASE2":28838,"PHASE3":28840,"PHASE4":28851,"NA":28853},{"trials":28835,"activeCount":102},[],{"trials":28837,"activeCount":102},[],{"trials":28839,"activeCount":102},[],{"trials":28841,"activeCount":102},[28842],{"nctId":28843,"briefTitle":28844,"status":108,"phases":28845,"primaryCompletion":28846,"completion":28846,"start":28847,"enrollment":6493,"conditions":28848,"interventions":28850},"NCT03001011","Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China",[92],"2019-08-16","2017-06-07",[28849],"Hyperphosphatemia",[28832],{"trials":28852,"activeCount":102},[],{"trials":28854,"activeCount":102},[],{"intervention":28856,"totalTrials":195,"cells":28857},"Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation",{"EARLY_PHASE1":28858,"PHASE1":28860,"PHASE2":28862,"PHASE3":28864,"PHASE4":28875,"NA":28877},{"trials":28859,"activeCount":102},[],{"trials":28861,"activeCount":102},[],{"trials":28863,"activeCount":102},[],{"trials":28865,"activeCount":102},[28866],{"nctId":28867,"briefTitle":28868,"status":108,"phases":28869,"primaryCompletion":152,"completion":966,"start":164,"enrollment":28870,"conditions":28871,"interventions":28872},"NCT01712984","Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years",[92],3360,[16],[28856,28873,28874],"Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal","Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal",{"trials":28876,"activeCount":102},[],{"trials":28878,"activeCount":102},[],{"intervention":28873,"totalTrials":195,"cells":28880},{"EARLY_PHASE1":28881,"PHASE1":28883,"PHASE2":28885,"PHASE3":28887,"PHASE4":28893,"NA":28895},{"trials":28882,"activeCount":102},[],{"trials":28884,"activeCount":102},[],{"trials":28886,"activeCount":102},[],{"trials":28888,"activeCount":102},[28889],{"nctId":28867,"briefTitle":28868,"status":108,"phases":28890,"primaryCompletion":152,"completion":966,"start":164,"enrollment":28870,"conditions":28891,"interventions":28892},[92],[16],[28856,28873,28874],{"trials":28894,"activeCount":102},[],{"trials":28896,"activeCount":102},[],{"intervention":28874,"totalTrials":195,"cells":28898},{"EARLY_PHASE1":28899,"PHASE1":28901,"PHASE2":28903,"PHASE3":28905,"PHASE4":28911,"NA":28913},{"trials":28900,"activeCount":102},[],{"trials":28902,"activeCount":102},[],{"trials":28904,"activeCount":102},[],{"trials":28906,"activeCount":102},[28907],{"nctId":28867,"briefTitle":28868,"status":108,"phases":28908,"primaryCompletion":152,"completion":966,"start":164,"enrollment":28870,"conditions":28909,"interventions":28910},[92],[16],[28856,28873,28874],{"trials":28912,"activeCount":102},[],{"trials":28914,"activeCount":102},[],{"intervention":28916,"totalTrials":195,"cells":28917},"Flu-ID 15μg",{"EARLY_PHASE1":28918,"PHASE1":28920,"PHASE2":28922,"PHASE3":28924,"PHASE4":28934,"NA":28936},{"trials":28919,"activeCount":102},[],{"trials":28921,"activeCount":102},[],{"trials":28923,"activeCount":102},[],{"trials":28925,"activeCount":102},[28926],{"nctId":28927,"briefTitle":28928,"status":108,"phases":28929,"primaryCompletion":7509,"completion":7509,"start":3317,"enrollment":28930,"conditions":28931,"interventions":28932},"NCT00554333","Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine",[92],795,[16],[28916,28933],"Inactivated adjuvanted Influenza Vaccine",{"trials":28935,"activeCount":102},[],{"trials":28937,"activeCount":102},[],{"intervention":28933,"totalTrials":195,"cells":28939},{"EARLY_PHASE1":28940,"PHASE1":28942,"PHASE2":28944,"PHASE3":28946,"PHASE4":28952,"NA":28954},{"trials":28941,"activeCount":102},[],{"trials":28943,"activeCount":102},[],{"trials":28945,"activeCount":102},[],{"trials":28947,"activeCount":102},[28948],{"nctId":28927,"briefTitle":28928,"status":108,"phases":28949,"primaryCompletion":7509,"completion":7509,"start":3317,"enrollment":28930,"conditions":28950,"interventions":28951},[92],[16],[28916,28933],{"trials":28953,"activeCount":102},[],{"trials":28955,"activeCount":102},[],{"intervention":28957,"totalTrials":195,"cells":28958},"Glutamine",{"EARLY_PHASE1":28959,"PHASE1":28961,"PHASE2":28963,"PHASE3":28965,"PHASE4":28974,"NA":28976},{"trials":28960,"activeCount":102},[],{"trials":28962,"activeCount":102},[],{"trials":28964,"activeCount":102},[],{"trials":28966,"activeCount":102},[28967],{"nctId":28968,"briefTitle":28969,"status":108,"phases":28970,"primaryCompletion":2760,"completion":2760,"start":955,"enrollment":12,"conditions":28971,"interventions":28972},"NCT01087658","Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity",[92],[5240],[28957,28973],"Calcium and Magnesium",{"trials":28975,"activeCount":102},[],{"trials":28977,"activeCount":102},[],{"intervention":28973,"totalTrials":195,"cells":28979},{"EARLY_PHASE1":28980,"PHASE1":28982,"PHASE2":28984,"PHASE3":28986,"PHASE4":28992,"NA":28994},{"trials":28981,"activeCount":102},[],{"trials":28983,"activeCount":102},[],{"trials":28985,"activeCount":102},[],{"trials":28987,"activeCount":102},[28988],{"nctId":28968,"briefTitle":28969,"status":108,"phases":28989,"primaryCompletion":2760,"completion":2760,"start":955,"enrollment":12,"conditions":28990,"interventions":28991},[92],[5240],[28957,28973],{"trials":28993,"activeCount":102},[],{"trials":28995,"activeCount":102},[],{"intervention":28997,"totalTrials":195,"cells":28998},"insulin glulisine \u002F insulin glargine",{"EARLY_PHASE1":28999,"PHASE1":29001,"PHASE2":29003,"PHASE3":29005,"PHASE4":29014,"NA":29016},{"trials":29000,"activeCount":102},[],{"trials":29002,"activeCount":102},[],{"trials":29004,"activeCount":102},[],{"trials":29006,"activeCount":102},[29007],{"nctId":29008,"briefTitle":29009,"status":108,"phases":29010,"primaryCompletion":3564,"completion":3564,"start":8331,"enrollment":9786,"conditions":29011,"interventions":29012},"NCT00271284","Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients",[92],[578],[28997,29013],"insulin glulisin \u002F insulin detemir",{"trials":29015,"activeCount":102},[],{"trials":29017,"activeCount":102},[],{"intervention":29013,"totalTrials":195,"cells":29019},{"EARLY_PHASE1":29020,"PHASE1":29022,"PHASE2":29024,"PHASE3":29026,"PHASE4":29032,"NA":29034},{"trials":29021,"activeCount":102},[],{"trials":29023,"activeCount":102},[],{"trials":29025,"activeCount":102},[],{"trials":29027,"activeCount":102},[29028],{"nctId":29008,"briefTitle":29009,"status":108,"phases":29029,"primaryCompletion":3564,"completion":3564,"start":8331,"enrollment":9786,"conditions":29030,"interventions":29031},[92],[578],[28997,29013],{"trials":29033,"activeCount":102},[],{"trials":29035,"activeCount":102},[],{"intervention":29037,"totalTrials":195,"cells":29038},"Phosphatidylcholine",{"EARLY_PHASE1":29039,"PHASE1":29041,"PHASE2":29043,"PHASE3":29045,"PHASE4":29054,"NA":29056},{"trials":29040,"activeCount":102},[],{"trials":29042,"activeCount":102},[],{"trials":29044,"activeCount":102},[],{"trials":29046,"activeCount":102},[29047],{"nctId":29048,"briefTitle":29049,"status":108,"phases":29050,"primaryCompletion":2856,"completion":2856,"start":2759,"enrollment":3347,"conditions":29051,"interventions":29053},"NCT02517385","Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases",[92],[29052],"Hepatic and Hepatobiliary Disorders",[29037],{"trials":29055,"activeCount":102},[],{"trials":29057,"activeCount":102},[],{"intervention":29059,"totalTrials":195,"cells":29060},"somatropine",{"EARLY_PHASE1":29061,"PHASE1":29063,"PHASE2":29065,"PHASE3":29067,"PHASE4":29076,"NA":29078},{"trials":29062,"activeCount":102},[],{"trials":29064,"activeCount":102},[],{"trials":29066,"activeCount":102},[],{"trials":29068,"activeCount":102},[29069],{"nctId":29070,"briefTitle":29071,"status":108,"phases":29072,"primaryCompletion":3565,"start":9592,"enrollment":3828,"conditions":29073,"interventions":29075},"NCT00476385","Practicability and Acceptability of Stylomax® in Children",[92],[29074],"Growth Hormone Deficiency",[29059],{"trials":29077,"activeCount":102},[],{"trials":29079,"activeCount":102},[],{"intervention":29081,"totalTrials":195,"cells":29082},"ChimeriVax-JE, Japanese Encephalitis vaccine",{"EARLY_PHASE1":29083,"PHASE1":29085,"PHASE2":29087,"PHASE3":29089,"PHASE4":29099,"NA":29101},{"trials":29084,"activeCount":102},[],{"trials":29086,"activeCount":102},[],{"trials":29088,"activeCount":102},[],{"trials":29090,"activeCount":102},[29091],{"nctId":29092,"briefTitle":29093,"status":108,"phases":29094,"primaryCompletion":8666,"completion":8666,"start":8331,"enrollment":29095,"conditions":29096,"interventions":29097},"NCT00314132","Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.",[92],2004,[28205,17265],[29081,29098],"0.9% Saline",{"trials":29100,"activeCount":102},[],{"trials":29102,"activeCount":102},[],{"intervention":29098,"totalTrials":195,"cells":29104},{"EARLY_PHASE1":29105,"PHASE1":29107,"PHASE2":29109,"PHASE3":29111,"PHASE4":29117,"NA":29119},{"trials":29106,"activeCount":102},[],{"trials":29108,"activeCount":102},[],{"trials":29110,"activeCount":102},[],{"trials":29112,"activeCount":102},[29113],{"nctId":29092,"briefTitle":29093,"status":108,"phases":29114,"primaryCompletion":8666,"completion":8666,"start":8331,"enrollment":29095,"conditions":29115,"interventions":29116},[92],[28205,17265],[29081,29098],{"trials":29118,"activeCount":102},[],{"trials":29120,"activeCount":102},[],{"intervention":22854,"totalTrials":195,"cells":29122},{"EARLY_PHASE1":29123,"PHASE1":29125,"PHASE2":29127,"PHASE3":29129,"PHASE4":29135,"NA":29137},{"trials":29124,"activeCount":102},[],{"trials":29126,"activeCount":102},[],{"trials":29128,"activeCount":102},[],{"trials":29130,"activeCount":102},[29131],{"nctId":22847,"briefTitle":22848,"status":108,"phases":29132,"primaryCompletion":2760,"completion":152,"start":8406,"enrollment":22850,"conditions":29133,"interventions":29134},[92],[17265,22852],[22836,22854],{"trials":29136,"activeCount":102},[],{"trials":29138,"activeCount":102},[],{"intervention":29140,"totalTrials":195,"cells":29141},"TdcP-IPV vaccine",{"EARLY_PHASE1":29142,"PHASE1":29144,"PHASE2":29146,"PHASE3":29148,"PHASE4":29156,"NA":29158},{"trials":29143,"activeCount":102},[],{"trials":29145,"activeCount":102},[],{"trials":29147,"activeCount":102},[],{"trials":29149,"activeCount":102},[29150],{"nctId":29151,"briefTitle":29152,"status":108,"phases":29153,"primaryCompletion":3396,"completion":8731,"start":8235,"enrollment":5308,"conditions":29154,"interventions":29155},"NCT00797511","Immunogenicity and Safety of Adacel Polio Vaccine",[92],[25,31,28,12983],[29140],{"trials":29157,"activeCount":102},[],{"trials":29159,"activeCount":102},[],{"intervention":19925,"totalTrials":195,"cells":29161},{"EARLY_PHASE1":29162,"PHASE1":29164,"PHASE2":29166,"PHASE3":29168,"PHASE4":29174,"NA":29176},{"trials":29163,"activeCount":102},[],{"trials":29165,"activeCount":102},[],{"trials":29167,"activeCount":102},[],{"trials":29169,"activeCount":102},[29170],{"nctId":19917,"briefTitle":19918,"status":108,"phases":29171,"primaryCompletion":19920,"completion":19921,"start":19922,"enrollment":8317,"conditions":29172,"interventions":29173},[92],[19900],[19925,19876,19926,19903],{"trials":29175,"activeCount":102},[],{"trials":29177,"activeCount":102},[],{"intervention":19926,"totalTrials":195,"cells":29179},{"EARLY_PHASE1":29180,"PHASE1":29182,"PHASE2":29184,"PHASE3":29186,"PHASE4":29192,"NA":29194},{"trials":29181,"activeCount":102},[],{"trials":29183,"activeCount":102},[],{"trials":29185,"activeCount":102},[],{"trials":29187,"activeCount":102},[29188],{"nctId":19917,"briefTitle":19918,"status":108,"phases":29189,"primaryCompletion":19920,"completion":19921,"start":19922,"enrollment":8317,"conditions":29190,"interventions":29191},[92],[19900],[19925,19876,19926,19903],{"trials":29193,"activeCount":102},[],{"trials":29195,"activeCount":102},[],{"intervention":29197,"totalTrials":195,"cells":29198},"paracetamol 4.8% paediatric oral suspension",{"EARLY_PHASE1":29199,"PHASE1":29201,"PHASE2":29203,"PHASE3":29205,"PHASE4":29214,"NA":29216},{"trials":29200,"activeCount":102},[],{"trials":29202,"activeCount":102},[],{"trials":29204,"activeCount":102},[],{"trials":29206,"activeCount":102},[29207],{"nctId":29208,"briefTitle":29209,"status":108,"phases":29210,"completion":3355,"start":3430,"enrollment":391,"conditions":29211,"interventions":29213},"NCT00434681","Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.",[92],[29212,12745],"Fever",[29197],{"trials":29215,"activeCount":102},[],{"trials":29217,"activeCount":102},[],{"intervention":29219,"totalTrials":195,"cells":29220},"DTaP-IPV\u002F\u002FPRP~T combined vaccine",{"EARLY_PHASE1":29221,"PHASE1":29223,"PHASE2":29225,"PHASE3":29227,"PHASE4":29235,"NA":29237},{"trials":29222,"activeCount":102},[],{"trials":29224,"activeCount":102},[],{"trials":29226,"activeCount":102},[],{"trials":29228,"activeCount":102},[29229],{"nctId":29230,"briefTitle":29231,"status":108,"phases":29232,"primaryCompletion":3355,"completion":1341,"start":8777,"enrollment":17720,"conditions":29233,"interventions":29234},"NCT00303316","Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants",[92],[25,31,28,12983,18625],[29219,29219],{"trials":29236,"activeCount":102},[],{"trials":29238,"activeCount":102},[],{"intervention":29240,"totalTrials":195,"cells":29241},"triamcinolone XRG5029",{"EARLY_PHASE1":29242,"PHASE1":29244,"PHASE2":29246,"PHASE3":29248,"PHASE4":29258,"NA":29260},{"trials":29243,"activeCount":102},[],{"trials":29245,"activeCount":102},[],{"trials":29247,"activeCount":102},[],{"trials":29249,"activeCount":102},[29250],{"nctId":29251,"briefTitle":29252,"status":108,"phases":29253,"primaryCompletion":29254,"completion":29254,"start":8431,"enrollment":668,"conditions":29255,"interventions":29256},"NCT03317015","A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)",[92],"2017-07-10",[13787],[29240,29257],"fluticasone",{"trials":29259,"activeCount":102},[],{"trials":29261,"activeCount":102},[],{"intervention":29257,"totalTrials":195,"cells":29263},{"EARLY_PHASE1":29264,"PHASE1":29266,"PHASE2":29268,"PHASE3":29270,"PHASE4":29276,"NA":29278},{"trials":29265,"activeCount":102},[],{"trials":29267,"activeCount":102},[],{"trials":29269,"activeCount":102},[],{"trials":29271,"activeCount":102},[29272],{"nctId":29251,"briefTitle":29252,"status":108,"phases":29273,"primaryCompletion":29254,"completion":29254,"start":8431,"enrollment":668,"conditions":29274,"interventions":29275},[92],[13787],[29240,29257],{"trials":29277,"activeCount":102},[],{"trials":29279,"activeCount":102},[],{"intervention":29281,"totalTrials":195,"cells":29282},"Adacel®",{"EARLY_PHASE1":29283,"PHASE1":29285,"PHASE2":29287,"PHASE3":29289,"PHASE4":29297,"NA":29299},{"trials":29284,"activeCount":102},[],{"trials":29286,"activeCount":102},[],{"trials":29288,"activeCount":102},[],{"trials":29290,"activeCount":102},[29291],{"nctId":29292,"briefTitle":29293,"status":108,"phases":29294,"primaryCompletion":955,"completion":3316,"start":8388,"enrollment":3740,"conditions":29295,"interventions":29296},"NCT01040052","A Study to Assess the Safety of Adacel® Vaccine",[92],[25,31,28],[29281],{"trials":29298,"activeCount":102},[],{"trials":29300,"activeCount":102},[],{"intervention":8302,"totalTrials":195,"cells":29302},{"EARLY_PHASE1":29303,"PHASE1":29305,"PHASE2":29307,"PHASE3":29309,"PHASE4":29315,"NA":29317},{"trials":29304,"activeCount":102},[],{"trials":29306,"activeCount":102},[],{"trials":29308,"activeCount":102},[],{"trials":29310,"activeCount":102},[29311],{"nctId":8295,"briefTitle":8296,"status":108,"phases":29312,"primaryCompletion":7430,"completion":7430,"start":8298,"enrollment":8299,"conditions":29313,"interventions":29314},[92],[830],[8046,8302,8303,8057,8024],{"trials":29316,"activeCount":102},[],{"trials":29318,"activeCount":102},[],{"intervention":8303,"totalTrials":195,"cells":29320},{"EARLY_PHASE1":29321,"PHASE1":29323,"PHASE2":29325,"PHASE3":29327,"PHASE4":29333,"NA":29335},{"trials":29322,"activeCount":102},[],{"trials":29324,"activeCount":102},[],{"trials":29326,"activeCount":102},[],{"trials":29328,"activeCount":102},[29329],{"nctId":8295,"briefTitle":8296,"status":108,"phases":29330,"primaryCompletion":7430,"completion":7430,"start":8298,"enrollment":8299,"conditions":29331,"interventions":29332},[92],[830],[8046,8302,8303,8057,8024],{"trials":29334,"activeCount":102},[],{"trials":29336,"activeCount":102},[],{"intervention":22462,"totalTrials":195,"cells":29338},{"EARLY_PHASE1":29339,"PHASE1":29341,"PHASE2":29343,"PHASE3":29345,"PHASE4":29351,"NA":29353},{"trials":29340,"activeCount":102},[],{"trials":29342,"activeCount":102},[],{"trials":29344,"activeCount":102},[],{"trials":29346,"activeCount":102},[29347],{"nctId":22453,"briefTitle":22454,"status":108,"phases":29348,"primaryCompletion":22456,"completion":22457,"start":22458,"enrollment":5165,"conditions":29349,"interventions":29350},[92],[22460],[22462,22462,22433,22433],{"trials":29352,"activeCount":102},[],{"trials":29354,"activeCount":102},[],{"intervention":29356,"totalTrials":195,"cells":29357},"somatropin",{"EARLY_PHASE1":29358,"PHASE1":29360,"PHASE2":29362,"PHASE3":29364,"PHASE4":29374,"NA":29376},{"trials":29359,"activeCount":102},[],{"trials":29361,"activeCount":102},[],{"trials":29363,"activeCount":102},[],{"trials":29365,"activeCount":102},[29366],{"nctId":29367,"briefTitle":29368,"status":108,"phases":29369,"primaryCompletion":3316,"completion":3316,"start":29370,"enrollment":19862,"conditions":29371,"interventions":29373},"NCT00452491","MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children",[92],"1993-05",[29372],"Fetal Growth Retardation",[29356,29356],{"trials":29375,"activeCount":102},[],{"trials":29377,"activeCount":102},[],{"intervention":29379,"totalTrials":195,"cells":29380},"SR123781A",{"EARLY_PHASE1":29381,"PHASE1":29383,"PHASE2":29385,"PHASE3":29387,"PHASE4":29396,"NA":29398},{"trials":29382,"activeCount":102},[],{"trials":29384,"activeCount":102},[],{"trials":29386,"activeCount":102},[],{"trials":29388,"activeCount":102},[29389],{"nctId":29390,"briefTitle":29391,"status":108,"phases":29392,"primaryCompletion":3308,"completion":3308,"start":8753,"enrollment":29393,"conditions":29394,"interventions":29395},"NCT00338897","Dose Ranging Study in Elective Total Hip Replacement Surgery",[91,92],1090,[10323],[29379],{"trials":29397,"activeCount":102},[],{"trials":29399,"activeCount":102},[],{"intervention":2345,"totalTrials":195,"cells":29401},{"EARLY_PHASE1":29402,"PHASE1":29404,"PHASE2":29406,"PHASE3":29408,"PHASE4":29414,"NA":29416},{"trials":29403,"activeCount":102},[],{"trials":29405,"activeCount":102},[],{"trials":29407,"activeCount":102},[],{"trials":29409,"activeCount":102},[29410],{"nctId":2339,"briefTitle":2340,"status":108,"phases":29411,"primaryCompletion":1954,"completion":1954,"start":1963,"enrollment":2342,"conditions":29412,"interventions":29413},[92],[2335],[43,2345],{"trials":29415,"activeCount":102},[],{"trials":29417,"activeCount":102},[],{"intervention":29419,"totalTrials":195,"cells":29420},"DTaP-IPV combined vaccine",{"EARLY_PHASE1":29421,"PHASE1":29423,"PHASE2":29425,"PHASE3":29427,"PHASE4":29437,"NA":29439},{"trials":29422,"activeCount":102},[],{"trials":29424,"activeCount":102},[],{"trials":29426,"activeCount":102},[],{"trials":29428,"activeCount":102},[29429],{"nctId":29430,"briefTitle":29431,"status":108,"phases":29432,"primaryCompletion":8505,"completion":8196,"start":9513,"enrollment":29433,"conditions":29434,"interventions":29435},"NCT00319852","Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV",[92],442,[28,25,12983,31],[29419,29436],"DTaP vaccine",{"trials":29438,"activeCount":102},[],{"trials":29440,"activeCount":102},[],{"intervention":29436,"totalTrials":195,"cells":29442},{"EARLY_PHASE1":29443,"PHASE1":29445,"PHASE2":29447,"PHASE3":29449,"PHASE4":29455,"NA":29457},{"trials":29444,"activeCount":102},[],{"trials":29446,"activeCount":102},[],{"trials":29448,"activeCount":102},[],{"trials":29450,"activeCount":102},[29451],{"nctId":29430,"briefTitle":29431,"status":108,"phases":29452,"primaryCompletion":8505,"completion":8196,"start":9513,"enrollment":29433,"conditions":29453,"interventions":29454},[92],[28,25,12983,31],[29419,29436],{"trials":29456,"activeCount":102},[],{"trials":29458,"activeCount":102},[],{"intervention":20841,"totalTrials":195,"cells":29460},{"EARLY_PHASE1":29461,"PHASE1":29463,"PHASE2":29465,"PHASE3":29467,"PHASE4":29473,"NA":29475},{"trials":29462,"activeCount":102},[],{"trials":29464,"activeCount":102},[],{"trials":29466,"activeCount":102},[],{"trials":29468,"activeCount":102},[29469],{"nctId":20834,"briefTitle":20835,"status":108,"phases":29470,"primaryCompletion":9559,"completion":9559,"start":3539,"enrollment":20837,"conditions":29471,"interventions":29472},[92],[20839],[20841,20842,20843,20844],{"trials":29474,"activeCount":102},[],{"trials":29476,"activeCount":102},[],{"intervention":20842,"totalTrials":195,"cells":29478},{"EARLY_PHASE1":29479,"PHASE1":29481,"PHASE2":29483,"PHASE3":29485,"PHASE4":29491,"NA":29493},{"trials":29480,"activeCount":102},[],{"trials":29482,"activeCount":102},[],{"trials":29484,"activeCount":102},[],{"trials":29486,"activeCount":102},[29487],{"nctId":20834,"briefTitle":20835,"status":108,"phases":29488,"primaryCompletion":9559,"completion":9559,"start":3539,"enrollment":20837,"conditions":29489,"interventions":29490},[92],[20839],[20841,20842,20843,20844],{"trials":29492,"activeCount":102},[],{"trials":29494,"activeCount":102},[],{"intervention":21348,"totalTrials":195,"cells":29496},{"EARLY_PHASE1":29497,"PHASE1":29499,"PHASE2":29501,"PHASE3":29503,"PHASE4":29509,"NA":29511},{"trials":29498,"activeCount":102},[],{"trials":29500,"activeCount":102},[],{"trials":29502,"activeCount":102},[],{"trials":29504,"activeCount":102},[29505],{"nctId":21342,"briefTitle":21343,"status":108,"phases":29506,"primaryCompletion":8683,"completion":10178,"start":2790,"enrollment":21345,"conditions":29507,"interventions":29508},[92],[14171,20566],[21348,21348,21324,21324],{"trials":29510,"activeCount":102},[],{"trials":29512,"activeCount":102},[],{"intervention":29514,"totalTrials":195,"cells":29515},"Glimepiride+metformin (Amaryl M®) - HOE4900",{"EARLY_PHASE1":29516,"PHASE1":29518,"PHASE2":29520,"PHASE3":29522,"PHASE4":29531,"NA":29533},{"trials":29517,"activeCount":102},[],{"trials":29519,"activeCount":102},[],{"trials":29521,"activeCount":102},[],{"trials":29523,"activeCount":102},[29524],{"nctId":29525,"briefTitle":29526,"status":108,"phases":29527,"primaryCompletion":7330,"completion":7330,"start":10178,"enrollment":29528,"conditions":29529,"interventions":29530},"NCT01699932","Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled",[92],167,[19],[29514],{"trials":29532,"activeCount":102},[],{"trials":29534,"activeCount":102},[],{"intervention":9613,"totalTrials":195,"cells":29536},{"EARLY_PHASE1":29537,"PHASE1":29539,"PHASE2":29541,"PHASE3":29543,"PHASE4":29549,"NA":29551},{"trials":29538,"activeCount":102},[],{"trials":29540,"activeCount":102},[],{"trials":29542,"activeCount":102},[],{"trials":29544,"activeCount":102},[29545],{"nctId":9605,"briefTitle":9606,"status":108,"phases":29546,"primaryCompletion":2799,"completion":2799,"start":8395,"enrollment":9608,"conditions":29547,"interventions":29548},[92],[9610,9611],[9455,9613],{"trials":29550,"activeCount":102},[],{"trials":29552,"activeCount":102},[],{"intervention":29554,"totalTrials":195,"cells":29555},"Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative",{"EARLY_PHASE1":29556,"PHASE1":29558,"PHASE2":29560,"PHASE3":29562,"PHASE4":29573,"NA":29575},{"trials":29557,"activeCount":102},[],{"trials":29559,"activeCount":102},[],{"trials":29561,"activeCount":102},[],{"trials":29563,"activeCount":102},[29564],{"nctId":29565,"briefTitle":29566,"status":108,"phases":29567,"primaryCompletion":977,"completion":8107,"start":987,"enrollment":29568,"conditions":29569,"interventions":29570},"NCT01240746","Study of Quadrivalent Influenza Vaccine Among Children",[92],4363,[16],[29554,29571,29572],"Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative","Quadrivalent Influenza Vaccine, No Preservative",{"trials":29574,"activeCount":102},[],{"trials":29576,"activeCount":102},[],{"intervention":29571,"totalTrials":195,"cells":29578},{"EARLY_PHASE1":29579,"PHASE1":29581,"PHASE2":29583,"PHASE3":29585,"PHASE4":29591,"NA":29593},{"trials":29580,"activeCount":102},[],{"trials":29582,"activeCount":102},[],{"trials":29584,"activeCount":102},[],{"trials":29586,"activeCount":102},[29587],{"nctId":29565,"briefTitle":29566,"status":108,"phases":29588,"primaryCompletion":977,"completion":8107,"start":987,"enrollment":29568,"conditions":29589,"interventions":29590},[92],[16],[29554,29571,29572],{"trials":29592,"activeCount":102},[],{"trials":29594,"activeCount":102},[],{"intervention":29572,"totalTrials":195,"cells":29596},{"EARLY_PHASE1":29597,"PHASE1":29599,"PHASE2":29601,"PHASE3":29603,"PHASE4":29609,"NA":29611},{"trials":29598,"activeCount":102},[],{"trials":29600,"activeCount":102},[],{"trials":29602,"activeCount":102},[],{"trials":29604,"activeCount":102},[29605],{"nctId":29565,"briefTitle":29566,"status":108,"phases":29606,"primaryCompletion":977,"completion":8107,"start":987,"enrollment":29568,"conditions":29607,"interventions":29608},[92],[16],[29554,29571,29572],{"trials":29610,"activeCount":102},[],{"trials":29612,"activeCount":102},[],{"intervention":22950,"totalTrials":195,"cells":29614},{"EARLY_PHASE1":29615,"PHASE1":29617,"PHASE2":29619,"PHASE3":29621,"PHASE4":29627,"NA":29629},{"trials":29616,"activeCount":102},[],{"trials":29618,"activeCount":102},[],{"trials":29620,"activeCount":102},[],{"trials":29622,"activeCount":102},[29623],{"nctId":22943,"briefTitle":22944,"status":108,"phases":29624,"primaryCompletion":1341,"completion":8196,"start":3622,"enrollment":22946,"conditions":29625,"interventions":29626},[92],[22948,8839],[22932,22950],{"trials":29628,"activeCount":102},[],{"trials":29630,"activeCount":102},[],{"intervention":22981,"totalTrials":195,"cells":29632},{"EARLY_PHASE1":29633,"PHASE1":29635,"PHASE2":29637,"PHASE3":29639,"PHASE4":29645,"NA":29647},{"trials":29634,"activeCount":102},[],{"trials":29636,"activeCount":102},[],{"trials":29638,"activeCount":102},[],{"trials":29640,"activeCount":102},[29641],{"nctId":22973,"briefTitle":22974,"status":884,"phases":29642,"primaryCompletion":22976,"completion":22977,"start":22978,"enrollment":1687,"conditions":29643,"interventions":29644},[92],[19],[12085,22981],{"trials":29646,"activeCount":102},[],{"trials":29648,"activeCount":102},[],{"intervention":29650,"totalTrials":195,"cells":29651},"NPH human insulin",{"EARLY_PHASE1":29652,"PHASE1":29654,"PHASE2":29656,"PHASE3":29658,"PHASE4":29668,"NA":29670},{"trials":29653,"activeCount":102},[],{"trials":29655,"activeCount":102},[],{"trials":29657,"activeCount":102},[],{"trials":29659,"activeCount":102},[29660],{"nctId":29661,"briefTitle":29662,"status":108,"phases":29663,"primaryCompletion":17767,"completion":17767,"start":29664,"enrollment":29665,"conditions":29666,"interventions":29667},"NCT00653341","Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)",[92],"2000-01",764,[22],[8424,29650],{"trials":29669,"activeCount":102},[],{"trials":29671,"activeCount":102},[],{"intervention":5050,"totalTrials":195,"cells":29673},{"EARLY_PHASE1":29674,"PHASE1":29676,"PHASE2":29678,"PHASE3":29680,"PHASE4":29686,"NA":29688},{"trials":29675,"activeCount":102},[],{"trials":29677,"activeCount":102},[],{"trials":29679,"activeCount":102},[],{"trials":29681,"activeCount":102},[29682],{"nctId":5041,"briefTitle":5042,"status":108,"phases":29683,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":29684,"interventions":29685},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":29687,"activeCount":102},[],{"trials":29689,"activeCount":102},[],{"intervention":5051,"totalTrials":195,"cells":29691},{"EARLY_PHASE1":29692,"PHASE1":29694,"PHASE2":29696,"PHASE3":29698,"PHASE4":29704,"NA":29706},{"trials":29693,"activeCount":102},[],{"trials":29695,"activeCount":102},[],{"trials":29697,"activeCount":102},[],{"trials":29699,"activeCount":102},[29700],{"nctId":5041,"briefTitle":5042,"status":108,"phases":29701,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":29702,"interventions":29703},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":29705,"activeCount":102},[],{"trials":29707,"activeCount":102},[],{"intervention":5052,"totalTrials":195,"cells":29709},{"EARLY_PHASE1":29710,"PHASE1":29712,"PHASE2":29714,"PHASE3":29716,"PHASE4":29722,"NA":29724},{"trials":29711,"activeCount":102},[],{"trials":29713,"activeCount":102},[],{"trials":29715,"activeCount":102},[],{"trials":29717,"activeCount":102},[29718],{"nctId":5041,"briefTitle":5042,"status":108,"phases":29719,"primaryCompletion":454,"completion":454,"start":5044,"enrollment":5045,"conditions":29720,"interventions":29721},[92],[2932],[5048,5021,5049,5050,5051,5052,4977,5053,5000,5022,4997],{"trials":29723,"activeCount":102},[],{"trials":29725,"activeCount":102},[],{"intervention":29727,"totalTrials":195,"cells":29728},"QIV-HD",{"EARLY_PHASE1":29729,"PHASE1":29731,"PHASE2":29733,"PHASE3":29735,"PHASE4":29748,"NA":29750},{"trials":29730,"activeCount":102},[],{"trials":29732,"activeCount":102},[],{"trials":29734,"activeCount":102},[],{"trials":29736,"activeCount":102},[29737],{"nctId":29738,"briefTitle":29739,"status":108,"phases":29740,"primaryCompletion":29741,"completion":10295,"start":29742,"enrollment":29743,"conditions":29744,"interventions":29745},"NCT03282240","Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US",[92],"2017-11-02","2017-09-08",2670,[16],[29727,29746,29747],"Licensed TIV-HD1","Investigational TIV-HD2",{"trials":29749,"activeCount":102},[],{"trials":29751,"activeCount":102},[],{"intervention":29746,"totalTrials":195,"cells":29753},{"EARLY_PHASE1":29754,"PHASE1":29756,"PHASE2":29758,"PHASE3":29760,"PHASE4":29766,"NA":29768},{"trials":29755,"activeCount":102},[],{"trials":29757,"activeCount":102},[],{"trials":29759,"activeCount":102},[],{"trials":29761,"activeCount":102},[29762],{"nctId":29738,"briefTitle":29739,"status":108,"phases":29763,"primaryCompletion":29741,"completion":10295,"start":29742,"enrollment":29743,"conditions":29764,"interventions":29765},[92],[16],[29727,29746,29747],{"trials":29767,"activeCount":102},[],{"trials":29769,"activeCount":102},[],{"intervention":29747,"totalTrials":195,"cells":29771},{"EARLY_PHASE1":29772,"PHASE1":29774,"PHASE2":29776,"PHASE3":29778,"PHASE4":29784,"NA":29786},{"trials":29773,"activeCount":102},[],{"trials":29775,"activeCount":102},[],{"trials":29777,"activeCount":102},[],{"trials":29779,"activeCount":102},[29780],{"nctId":29738,"briefTitle":29739,"status":108,"phases":29781,"primaryCompletion":29741,"completion":10295,"start":29742,"enrollment":29743,"conditions":29782,"interventions":29783},[92],[16],[29727,29746,29747],{"trials":29785,"activeCount":102},[],{"trials":29787,"activeCount":102},[],{"intervention":29789,"totalTrials":195,"cells":29790},"ambroxol BIH1526",{"EARLY_PHASE1":29791,"PHASE1":29793,"PHASE2":29795,"PHASE3":29797,"PHASE4":29807,"NA":29809},{"trials":29792,"activeCount":102},[],{"trials":29794,"activeCount":102},[],{"trials":29796,"activeCount":102},[],{"trials":29798,"activeCount":102},[29799],{"nctId":29800,"briefTitle":29801,"status":108,"phases":29802,"primaryCompletion":29803,"completion":29803,"start":29804,"enrollment":8620,"conditions":29805,"interventions":29806},"NCT03583658","Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis",[92],"2018-09-02","2018-06-30",[9837],[29789],{"trials":29808,"activeCount":102},[],{"trials":29810,"activeCount":102},[],{"intervention":29812,"totalTrials":195,"cells":29813},"DTaP-IPV-Hep B-PRP-T Vaccine",{"EARLY_PHASE1":29814,"PHASE1":29816,"PHASE2":29818,"PHASE3":29820,"PHASE4":29830,"NA":29832},{"trials":29815,"activeCount":102},[],{"trials":29817,"activeCount":102},[],{"trials":29819,"activeCount":102},[],{"trials":29821,"activeCount":102},[29822],{"nctId":29823,"briefTitle":29824,"status":108,"phases":29825,"primaryCompletion":1340,"completion":977,"start":5271,"enrollment":29826,"conditions":29827,"interventions":29828},"NCT01177722","A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants",[92],1375,[25,31,13514,18625,12983],[29812,29812,29812,29829],"DTaP-Hep B-IPV vaccine",{"trials":29831,"activeCount":102},[],{"trials":29833,"activeCount":102},[],{"intervention":29829,"totalTrials":195,"cells":29835},{"EARLY_PHASE1":29836,"PHASE1":29838,"PHASE2":29840,"PHASE3":29842,"PHASE4":29848,"NA":29850},{"trials":29837,"activeCount":102},[],{"trials":29839,"activeCount":102},[],{"trials":29841,"activeCount":102},[],{"trials":29843,"activeCount":102},[29844],{"nctId":29823,"briefTitle":29824,"status":108,"phases":29845,"primaryCompletion":1340,"completion":977,"start":5271,"enrollment":29826,"conditions":29846,"interventions":29847},[92],[25,31,13514,18625,12983],[29812,29812,29812,29829],{"trials":29849,"activeCount":102},[],{"trials":29851,"activeCount":102},[],{"intervention":9268,"totalTrials":195,"cells":29853},{"EARLY_PHASE1":29854,"PHASE1":29856,"PHASE2":29858,"PHASE3":29860,"PHASE4":29866,"NA":29868},{"trials":29855,"activeCount":102},[],{"trials":29857,"activeCount":102},[],{"trials":29859,"activeCount":102},[],{"trials":29861,"activeCount":102},[29862],{"nctId":9262,"briefTitle":9263,"status":529,"phases":29863,"start":9265,"conditions":29864,"interventions":29865},[92],[5254],[9268,9269,9270,5256],{"trials":29867,"activeCount":102},[],{"trials":29869,"activeCount":102},[],{"intervention":9270,"totalTrials":195,"cells":29871},{"EARLY_PHASE1":29872,"PHASE1":29874,"PHASE2":29876,"PHASE3":29878,"PHASE4":29884,"NA":29886},{"trials":29873,"activeCount":102},[],{"trials":29875,"activeCount":102},[],{"trials":29877,"activeCount":102},[],{"trials":29879,"activeCount":102},[29880],{"nctId":9262,"briefTitle":9263,"status":529,"phases":29881,"start":9265,"conditions":29882,"interventions":29883},[92],[5254],[9268,9269,9270,5256],{"trials":29885,"activeCount":102},[],{"trials":29887,"activeCount":102},[],{"intervention":29889,"totalTrials":195,"cells":29890},"Pentacel™: HCPDT-IPV\u002F\u002FPRP-T Vaccine and Prevnar®",{"EARLY_PHASE1":29891,"PHASE1":29893,"PHASE2":29895,"PHASE3":29897,"PHASE4":29906,"NA":29908},{"trials":29892,"activeCount":102},[],{"trials":29894,"activeCount":102},[],{"trials":29896,"activeCount":102},[],{"trials":29898,"activeCount":102},[29899],{"nctId":29900,"briefTitle":29901,"status":108,"phases":29902,"primaryCompletion":8753,"completion":8666,"start":3488,"enrollment":29903,"conditions":29904,"interventions":29905},"NCT00772928","Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™",[92],1167,[25,31,16764,28,13810],[29889,29889],{"trials":29907,"activeCount":102},[],{"trials":29909,"activeCount":102},[],{"intervention":29911,"totalTrials":195,"cells":29912},"Docetaxel\u002FDDP",{"EARLY_PHASE1":29913,"PHASE1":29915,"PHASE2":29917,"PHASE3":29919,"PHASE4":29929,"NA":29931},{"trials":29914,"activeCount":102},[],{"trials":29916,"activeCount":102},[],{"trials":29918,"activeCount":102},[],{"trials":29920,"activeCount":102},[29921],{"nctId":29922,"briefTitle":29923,"status":108,"phases":29924,"primaryCompletion":2800,"start":18773,"enrollment":29925,"conditions":29926,"interventions":29927},"NCT00174629","GILT Docetaxel - Non-Small Cell Lung Cancer",[92],449,[17899],[29911,29928],"docetaxel\u002Fgemcitabine",{"trials":29930,"activeCount":102},[],{"trials":29932,"activeCount":102},[],{"intervention":29928,"totalTrials":195,"cells":29934},{"EARLY_PHASE1":29935,"PHASE1":29937,"PHASE2":29939,"PHASE3":29941,"PHASE4":29947,"NA":29949},{"trials":29936,"activeCount":102},[],{"trials":29938,"activeCount":102},[],{"trials":29940,"activeCount":102},[],{"trials":29942,"activeCount":102},[29943],{"nctId":29922,"briefTitle":29923,"status":108,"phases":29944,"primaryCompletion":2800,"start":18773,"enrollment":29925,"conditions":29945,"interventions":29946},[92],[17899],[29911,29928],{"trials":29948,"activeCount":102},[],{"trials":29950,"activeCount":102},[],{"intervention":29952,"totalTrials":195,"cells":29953},"Pneumo 23",{"EARLY_PHASE1":29954,"PHASE1":29956,"PHASE2":29958,"PHASE3":29960,"PHASE4":29971,"NA":29973},{"trials":29955,"activeCount":102},[],{"trials":29957,"activeCount":102},[],{"trials":29959,"activeCount":102},[],{"trials":29961,"activeCount":102},[29962],{"nctId":29963,"briefTitle":29964,"status":108,"phases":29965,"primaryCompletion":8822,"completion":3396,"start":8607,"enrollment":29966,"conditions":29967,"interventions":29969},"NCT00594347","Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar",[92],339,[29968],"Streptococcus Pneumoniae",[29952,29970],"Prevnar",{"trials":29972,"activeCount":102},[],{"trials":29974,"activeCount":102},[],{"intervention":29970,"totalTrials":195,"cells":29976},{"EARLY_PHASE1":29977,"PHASE1":29979,"PHASE2":29981,"PHASE3":29983,"PHASE4":29989,"NA":29991},{"trials":29978,"activeCount":102},[],{"trials":29980,"activeCount":102},[],{"trials":29982,"activeCount":102},[],{"trials":29984,"activeCount":102},[29985],{"nctId":29963,"briefTitle":29964,"status":108,"phases":29986,"primaryCompletion":8822,"completion":3396,"start":8607,"enrollment":29966,"conditions":29987,"interventions":29988},[92],[29968],[29952,29970],{"trials":29990,"activeCount":102},[],{"trials":29992,"activeCount":102},[],{"intervention":29994,"totalTrials":195,"cells":29995},"Diphteria, tetanus, and Acellular Pertussis vaccine",{"EARLY_PHASE1":29996,"PHASE1":29998,"PHASE2":30000,"PHASE3":30002,"PHASE4":30010,"NA":30012},{"trials":29997,"activeCount":102},[],{"trials":29999,"activeCount":102},[],{"trials":30001,"activeCount":102},[],{"trials":30003,"activeCount":102},[30004],{"nctId":30005,"briefTitle":30006,"status":108,"phases":30007,"primaryCompletion":5262,"completion":5262,"start":3623,"enrollment":2018,"conditions":30008,"interventions":30009},"NCT00258908","Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan",[92],[25,31,28],[29994],{"trials":30011,"activeCount":102},[],{"trials":30013,"activeCount":102},[],{"intervention":30015,"totalTrials":195,"cells":30016},"gemcitabine\u002FEloxatin",{"EARLY_PHASE1":30017,"PHASE1":30019,"PHASE2":30021,"PHASE3":30023,"PHASE4":30034,"NA":30036},{"trials":30018,"activeCount":102},[],{"trials":30020,"activeCount":102},[],{"trials":30022,"activeCount":102},[],{"trials":30024,"activeCount":102},[30025],{"nctId":30026,"briefTitle":30027,"status":108,"phases":30028,"primaryCompletion":3308,"start":9522,"enrollment":30029,"conditions":30030,"interventions":30032},"NCT00087802","Gemcitabine\u002FOxaliplatin (GEMOX) vs Carboplatin\u002FPaclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)",[92],383,[30031],"Carcinoma, Non-Small-Cell Lung",[30015,30033],"carboplatin\u002Fpaclitaxel",{"trials":30035,"activeCount":102},[],{"trials":30037,"activeCount":102},[],{"intervention":30033,"totalTrials":195,"cells":30039},{"EARLY_PHASE1":30040,"PHASE1":30042,"PHASE2":30044,"PHASE3":30046,"PHASE4":30052,"NA":30054},{"trials":30041,"activeCount":102},[],{"trials":30043,"activeCount":102},[],{"trials":30045,"activeCount":102},[],{"trials":30047,"activeCount":102},[30048],{"nctId":30026,"briefTitle":30027,"status":108,"phases":30049,"primaryCompletion":3308,"start":9522,"enrollment":30029,"conditions":30050,"interventions":30051},[92],[30031],[30015,30033],{"trials":30053,"activeCount":102},[],{"trials":30055,"activeCount":102},[],{"intervention":30057,"totalTrials":195,"cells":30058},"Tdap",{"EARLY_PHASE1":30059,"PHASE1":30061,"PHASE2":30063,"PHASE3":30065,"PHASE4":30074,"NA":30076},{"trials":30060,"activeCount":102},[],{"trials":30062,"activeCount":102},[],{"trials":30064,"activeCount":102},[],{"trials":30066,"activeCount":102},[30067],{"nctId":30068,"briefTitle":30069,"status":108,"phases":30070,"primaryCompletion":8570,"completion":8388,"start":3355,"enrollment":17781,"conditions":30071,"interventions":30072},"NCT00467519","Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age",[92],[31,25,28],[30057,30073],"DTaP",{"trials":30075,"activeCount":102},[],{"trials":30077,"activeCount":102},[],{"intervention":30073,"totalTrials":195,"cells":30079},{"EARLY_PHASE1":30080,"PHASE1":30082,"PHASE2":30084,"PHASE3":30086,"PHASE4":30092,"NA":30094},{"trials":30081,"activeCount":102},[],{"trials":30083,"activeCount":102},[],{"trials":30085,"activeCount":102},[],{"trials":30087,"activeCount":102},[30088],{"nctId":30068,"briefTitle":30069,"status":108,"phases":30089,"primaryCompletion":8570,"completion":8388,"start":3355,"enrollment":17781,"conditions":30090,"interventions":30091},[92],[31,25,28],[30057,30073],{"trials":30093,"activeCount":102},[],{"trials":30095,"activeCount":102},[],{"intervention":30097,"totalTrials":195,"cells":30098},"AVE7688",{"EARLY_PHASE1":30099,"PHASE1":30101,"PHASE2":30103,"PHASE3":30105,"PHASE4":30115,"NA":30117},{"trials":30100,"activeCount":102},[],{"trials":30102,"activeCount":102},[],{"trials":30104,"activeCount":102},[],{"trials":30106,"activeCount":102},[30107],{"nctId":30108,"briefTitle":30109,"status":108,"phases":30110,"primaryCompletion":8822,"completion":8822,"start":3565,"enrollment":30111,"conditions":30112,"interventions":30113},"NCT00284128","AVE7688 in Patients With Mild to Moderate Blood Pressure",[91,92],1940,[9680],[30097,30114],"Losartan-potassium",{"trials":30116,"activeCount":102},[],{"trials":30118,"activeCount":102},[],{"intervention":30114,"totalTrials":195,"cells":30120},{"EARLY_PHASE1":30121,"PHASE1":30123,"PHASE2":30125,"PHASE3":30127,"PHASE4":30133,"NA":30135},{"trials":30122,"activeCount":102},[],{"trials":30124,"activeCount":102},[],{"trials":30126,"activeCount":102},[],{"trials":30128,"activeCount":102},[30129],{"nctId":30108,"briefTitle":30109,"status":108,"phases":30130,"primaryCompletion":8822,"completion":8822,"start":3565,"enrollment":30111,"conditions":30131,"interventions":30132},[91,92],[9680],[30097,30114],{"trials":30134,"activeCount":102},[],{"trials":30136,"activeCount":102},[],{"intervention":30138,"totalTrials":195,"cells":30139},"Triamcinolone",{"EARLY_PHASE1":30140,"PHASE1":30142,"PHASE2":30144,"PHASE3":30146,"PHASE4":30154,"NA":30156},{"trials":30141,"activeCount":102},[],{"trials":30143,"activeCount":102},[],{"trials":30145,"activeCount":102},[],{"trials":30147,"activeCount":102},[30148],{"nctId":30149,"briefTitle":30150,"status":108,"phases":30151,"completion":8777,"start":12198,"enrollment":12633,"conditions":30152,"interventions":30153},"NCT00132925","An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis",[92],[3521],[30138],{"trials":30155,"activeCount":102},[],{"trials":30157,"activeCount":102},[],{"intervention":30159,"totalTrials":195,"cells":30160},"Dermacyd Breeze Pocket BR",{"EARLY_PHASE1":30161,"PHASE1":30163,"PHASE2":30165,"PHASE3":30167,"PHASE4":30175,"NA":30177},{"trials":30162,"activeCount":102},[],{"trials":30164,"activeCount":102},[],{"trials":30166,"activeCount":102},[],{"trials":30168,"activeCount":102},[30169],{"nctId":30170,"briefTitle":30171,"status":108,"phases":30172,"primaryCompletion":8235,"start":8235,"enrollment":3740,"conditions":30173,"interventions":30174},"NCT00793026","Dermacyd Breeze Pocket BR (Lactic Acid) - Acceptability",[92],[33],[30159],{"trials":30176,"activeCount":102},[],{"trials":30178,"activeCount":102},[],{"intervention":30180,"totalTrials":195,"cells":30181},"Eliglustat GZ385660",{"EARLY_PHASE1":30182,"PHASE1":30184,"PHASE2":30186,"PHASE3":30188,"PHASE4":30200,"NA":30202},{"trials":30183,"activeCount":102},[],{"trials":30185,"activeCount":102},[],{"trials":30187,"activeCount":102},[],{"trials":30189,"activeCount":102},[30190],{"nctId":30191,"briefTitle":30192,"status":108,"phases":30193,"primaryCompletion":30194,"completion":30194,"start":30195,"enrollment":1182,"conditions":30196,"interventions":30198},"NCT03485677","Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3",[92],"2025-12-12","2018-04-11",[30197,2413],"Gaucher's Disease Type I",[30180,30199],"Imiglucerase GZ437843",{"trials":30201,"activeCount":102},[],{"trials":30203,"activeCount":102},[],{"intervention":30199,"totalTrials":195,"cells":30205},{"EARLY_PHASE1":30206,"PHASE1":30208,"PHASE2":30210,"PHASE3":30212,"PHASE4":30218,"NA":30220},{"trials":30207,"activeCount":102},[],{"trials":30209,"activeCount":102},[],{"trials":30211,"activeCount":102},[],{"trials":30213,"activeCount":102},[30214],{"nctId":30191,"briefTitle":30192,"status":108,"phases":30215,"primaryCompletion":30194,"completion":30194,"start":30195,"enrollment":1182,"conditions":30216,"interventions":30217},[92],[30197,2413],[30180,30199],{"trials":30219,"activeCount":102},[],{"trials":30221,"activeCount":102},[],{"intervention":5200,"totalTrials":195,"cells":30223},{"EARLY_PHASE1":30224,"PHASE1":30226,"PHASE2":30228,"PHASE3":30230,"PHASE4":30236,"NA":30238},{"trials":30225,"activeCount":102},[],{"trials":30227,"activeCount":102},[],{"trials":30229,"activeCount":102},[],{"trials":30231,"activeCount":102},[30232],{"nctId":5190,"briefTitle":5191,"status":108,"phases":30233,"primaryCompletion":5193,"completion":5193,"start":5194,"enrollment":5195,"conditions":30234,"interventions":30235},[92],[5197],[5199,3022,5200],{"trials":30237,"activeCount":102},[],{"trials":30239,"activeCount":102},[],{"intervention":30241,"totalTrials":195,"cells":30242},"JE-CV administered in Study JEC02",{"EARLY_PHASE1":30243,"PHASE1":30245,"PHASE2":30247,"PHASE3":30249,"PHASE4":30260,"NA":30262},{"trials":30244,"activeCount":102},[],{"trials":30246,"activeCount":102},[],{"trials":30248,"activeCount":102},[],{"trials":30250,"activeCount":102},[30251],{"nctId":30252,"briefTitle":30253,"status":108,"phases":30254,"primaryCompletion":30255,"completion":30255,"start":30256,"enrollment":30257,"conditions":30258,"interventions":30259},"NCT01001988","Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers",[92],"2013-10-16","2009-08-07",596,[28205,17265],[30241],{"trials":30261,"activeCount":102},[],{"trials":30263,"activeCount":102},[],{"intervention":30265,"totalTrials":195,"cells":30266},"triamcinolone acetonide",{"EARLY_PHASE1":30267,"PHASE1":30269,"PHASE2":30271,"PHASE3":30273,"PHASE4":30282,"NA":30284},{"trials":30268,"activeCount":102},[],{"trials":30270,"activeCount":102},[],{"trials":30272,"activeCount":102},[],{"trials":30274,"activeCount":102},[30275],{"nctId":30276,"briefTitle":30277,"status":884,"phases":30278,"primaryCompletion":3355,"start":9513,"enrollment":13,"conditions":30279,"interventions":30281},"NCT00344942","Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults",[92],[30280],"Rhinitis",[30265],{"trials":30283,"activeCount":102},[],{"trials":30285,"activeCount":102},[],{"intervention":19569,"totalTrials":195,"cells":30287},{"EARLY_PHASE1":30288,"PHASE1":30290,"PHASE2":30292,"PHASE3":30294,"PHASE4":30300,"NA":30302},{"trials":30289,"activeCount":102},[],{"trials":30291,"activeCount":102},[],{"trials":30293,"activeCount":102},[],{"trials":30295,"activeCount":102},[30296],{"nctId":19564,"briefTitle":19565,"status":108,"phases":30297,"primaryCompletion":8316,"completion":3417,"start":10320,"enrollment":5913,"conditions":30298,"interventions":30299},[92],[14394],[19569,2940],{"trials":30301,"activeCount":102},[],{"trials":30303,"activeCount":102},[],{"intervention":30305,"totalTrials":195,"cells":30306},"Meningococcal Diphtheria Toxoid Vaccine",{"EARLY_PHASE1":30307,"PHASE1":30309,"PHASE2":30311,"PHASE3":30313,"PHASE4":30323,"NA":30325},{"trials":30308,"activeCount":102},[],{"trials":30310,"activeCount":102},[],{"trials":30312,"activeCount":102},[],{"trials":30314,"activeCount":102},[30315],{"nctId":30316,"briefTitle":30317,"status":108,"phases":30318,"primaryCompletion":30319,"completion":30319,"start":30320,"enrollment":1091,"conditions":30321,"interventions":30322},"NCT01890759","Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation",[92],"2016-04-12","2013-06-25",[4992,2949],[30305],{"trials":30324,"activeCount":102},[],{"trials":30326,"activeCount":102},[],{"intervention":30328,"totalTrials":195,"cells":30329},"FEX60\u002FPE10",{"EARLY_PHASE1":30330,"PHASE1":30332,"PHASE2":30334,"PHASE3":30336,"PHASE4":30344,"NA":30346},{"trials":30331,"activeCount":102},[],{"trials":30333,"activeCount":102},[],{"trials":30335,"activeCount":102},[],{"trials":30337,"activeCount":102},[30338],{"nctId":30339,"briefTitle":30340,"status":108,"phases":30341,"primaryCompletion":964,"completion":964,"start":1011,"enrollment":828,"conditions":30342,"interventions":30343},"NCT02401191","A Study Assessing the Safety and Effectiveness of FEX60\u002FPE10 Fixed Combination Tablet in Patients With Allergic Rhinitis",[92],[13787],[30328],{"trials":30345,"activeCount":102},[],{"trials":30347,"activeCount":102},[],{"intervention":22404,"totalTrials":195,"cells":30349},{"EARLY_PHASE1":30350,"PHASE1":30352,"PHASE2":30354,"PHASE3":30356,"PHASE4":30362,"NA":30364},{"trials":30351,"activeCount":102},[],{"trials":30353,"activeCount":102},[],{"trials":30355,"activeCount":102},[],{"trials":30357,"activeCount":102},[30358],{"nctId":22398,"briefTitle":22399,"status":108,"phases":30359,"primaryCompletion":8166,"completion":151,"start":10811,"enrollment":22401,"conditions":30360,"interventions":30361},[92],[25,31,28],[22381,22404,22405],{"trials":30363,"activeCount":102},[],{"trials":30365,"activeCount":102},[],{"intervention":22405,"totalTrials":195,"cells":30367},{"EARLY_PHASE1":30368,"PHASE1":30370,"PHASE2":30372,"PHASE3":30374,"PHASE4":30380,"NA":30382},{"trials":30369,"activeCount":102},[],{"trials":30371,"activeCount":102},[],{"trials":30373,"activeCount":102},[],{"trials":30375,"activeCount":102},[30376],{"nctId":22398,"briefTitle":22399,"status":108,"phases":30377,"primaryCompletion":8166,"completion":151,"start":10811,"enrollment":22401,"conditions":30378,"interventions":30379},[92],[25,31,28],[22381,22404,22405],{"trials":30381,"activeCount":102},[],{"trials":30383,"activeCount":102},[],{"intervention":30385,"totalTrials":195,"cells":30386},"Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus",{"EARLY_PHASE1":30387,"PHASE1":30389,"PHASE2":30391,"PHASE3":30393,"PHASE4":30403,"NA":30405},{"trials":30388,"activeCount":102},[],{"trials":30390,"activeCount":102},[],{"trials":30392,"activeCount":102},[],{"trials":30394,"activeCount":102},[30395],{"nctId":30396,"briefTitle":30397,"status":108,"phases":30398,"primaryCompletion":7284,"completion":10005,"start":30399,"enrollment":30400,"conditions":30401,"interventions":30402},"NCT01134263","Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia",[92],"2010-10-05",715,[18210,2317],[30385,30385,30385,30385],{"trials":30404,"activeCount":102},[],{"trials":30406,"activeCount":102},[],{"intervention":10903,"totalTrials":195,"cells":30408},{"EARLY_PHASE1":30409,"PHASE1":30411,"PHASE2":30413,"PHASE3":30415,"PHASE4":30421,"NA":30423},{"trials":30410,"activeCount":102},[],{"trials":30412,"activeCount":102},[],{"trials":30414,"activeCount":102},[],{"trials":30416,"activeCount":102},[30417],{"nctId":10894,"briefTitle":10895,"status":108,"phases":30418,"primaryCompletion":3417,"completion":8315,"start":3622,"enrollment":10897,"conditions":30419,"interventions":30420},[92],[7568,10899,10900,10901,2978],[10903,10836,10836],{"trials":30422,"activeCount":102},[],{"trials":30424,"activeCount":102},[],{"intervention":22957,"totalTrials":195,"cells":30426},{"EARLY_PHASE1":30427,"PHASE1":30429,"PHASE2":30431,"PHASE3":30433,"PHASE4":30439,"NA":30441},{"trials":30428,"activeCount":102},[],{"trials":30430,"activeCount":102},[],{"trials":30432,"activeCount":102},[],{"trials":30434,"activeCount":102},[30435],{"nctId":22952,"briefTitle":22953,"status":108,"phases":30436,"primaryCompletion":3308,"completion":3564,"start":8777,"enrollment":10798,"conditions":30437,"interventions":30438},[92],[28,25,31,12983,20655],[22932,22957],{"trials":30440,"activeCount":102},[],{"trials":30442,"activeCount":102},[],{"intervention":30444,"totalTrials":195,"cells":30445},"Inactive Poliovirus Vaccine",{"EARLY_PHASE1":30446,"PHASE1":30448,"PHASE2":30450,"PHASE3":30452,"PHASE4":30460,"NA":30462},{"trials":30447,"activeCount":102},[],{"trials":30449,"activeCount":102},[],{"trials":30451,"activeCount":102},[],{"trials":30453,"activeCount":102},[30454],{"nctId":30455,"briefTitle":30456,"status":108,"phases":30457,"primaryCompletion":3335,"completion":3335,"start":8406,"enrollment":26,"conditions":30458,"interventions":30459},"NCT01389687","Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan",[92],[12983,13810],[30444],{"trials":30461,"activeCount":102},[],{"trials":30463,"activeCount":102},[],{"intervention":30465,"totalTrials":195,"cells":30466},"Multi-dose Quadrivalent Influenza Vaccine",{"EARLY_PHASE1":30467,"PHASE1":30469,"PHASE2":30471,"PHASE3":30473,"PHASE4":30485,"NA":30487},{"trials":30468,"activeCount":102},[],{"trials":30470,"activeCount":102},[],{"trials":30472,"activeCount":102},[],{"trials":30474,"activeCount":102},[30475],{"nctId":30476,"briefTitle":30477,"status":108,"phases":30478,"primaryCompletion":30479,"completion":30480,"start":30481,"enrollment":956,"conditions":30482,"interventions":30483},"NCT03391193","Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine",[92],"2018-03-28","2018-08-25","2017-12-19",[16],[30465,30484],"Single-dose Quadrivalent Influenza Vaccine",{"trials":30486,"activeCount":102},[],{"trials":30488,"activeCount":102},[],{"intervention":30484,"totalTrials":195,"cells":30490},{"EARLY_PHASE1":30491,"PHASE1":30493,"PHASE2":30495,"PHASE3":30497,"PHASE4":30503,"NA":30505},{"trials":30492,"activeCount":102},[],{"trials":30494,"activeCount":102},[],{"trials":30496,"activeCount":102},[],{"trials":30498,"activeCount":102},[30499],{"nctId":30476,"briefTitle":30477,"status":108,"phases":30500,"primaryCompletion":30479,"completion":30480,"start":30481,"enrollment":956,"conditions":30501,"interventions":30502},[92],[16],[30465,30484],{"trials":30504,"activeCount":102},[],{"trials":30506,"activeCount":102},[],{"intervention":9285,"totalTrials":195,"cells":30508},{"EARLY_PHASE1":30509,"PHASE1":30511,"PHASE2":30513,"PHASE3":30515,"PHASE4":30521,"NA":30523},{"trials":30510,"activeCount":102},[],{"trials":30512,"activeCount":102},[],{"trials":30514,"activeCount":102},[],{"trials":30516,"activeCount":102},[30517],{"nctId":9279,"briefTitle":9280,"status":108,"phases":30518,"completion":8846,"start":9282,"conditions":30519,"interventions":30520},[92],[5254],[9285,5256],{"trials":30522,"activeCount":102},[],{"trials":30524,"activeCount":102},[],{"intervention":30526,"totalTrials":195,"cells":30527},"High-Dose Quadrivalent Influenza Vaccine,",{"EARLY_PHASE1":30528,"PHASE1":30530,"PHASE2":30532,"PHASE3":30534,"PHASE4":30545,"NA":30547},{"trials":30529,"activeCount":102},[],{"trials":30531,"activeCount":102},[],{"trials":30533,"activeCount":102},[],{"trials":30535,"activeCount":102},[30536],{"nctId":30537,"briefTitle":30538,"status":108,"phases":30539,"primaryCompletion":3856,"completion":3856,"start":30540,"enrollment":30541,"conditions":30542,"interventions":30543},"NCT04498832","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older",[92],"2020-10-21",2100,[5335,36],[30526,30544],"Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains",{"trials":30546,"activeCount":102},[],{"trials":30548,"activeCount":102},[],{"intervention":30544,"totalTrials":195,"cells":30550},{"EARLY_PHASE1":30551,"PHASE1":30553,"PHASE2":30555,"PHASE3":30557,"PHASE4":30563,"NA":30565},{"trials":30552,"activeCount":102},[],{"trials":30554,"activeCount":102},[],{"trials":30556,"activeCount":102},[],{"trials":30558,"activeCount":102},[30559],{"nctId":30537,"briefTitle":30538,"status":108,"phases":30560,"primaryCompletion":3856,"completion":3856,"start":30540,"enrollment":30541,"conditions":30561,"interventions":30562},[92],[5335,36],[30526,30544],{"trials":30564,"activeCount":102},[],{"trials":30566,"activeCount":102},[],{"intervention":30568,"totalTrials":195,"cells":30569},"Meningococcal Polysaccharide Diphtheria Conjugate Vaccine",{"EARLY_PHASE1":30570,"PHASE1":30572,"PHASE2":30574,"PHASE3":30576,"PHASE4":30586,"NA":30588},{"trials":30571,"activeCount":102},[],{"trials":30573,"activeCount":102},[],{"trials":30575,"activeCount":102},[],{"trials":30577,"activeCount":102},[30578],{"nctId":30579,"briefTitle":30580,"status":108,"phases":30581,"primaryCompletion":9532,"completion":3396,"start":10339,"enrollment":30582,"conditions":30583,"interventions":30584},"NCT00422292","Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers",[92],1664,[7568,10899,10900,10901,2978],[30568,30568,30568,30585],"Measles, Mumps, Rubella and Varicella",{"trials":30587,"activeCount":102},[],{"trials":30589,"activeCount":102},[],{"intervention":30585,"totalTrials":195,"cells":30591},{"EARLY_PHASE1":30592,"PHASE1":30594,"PHASE2":30596,"PHASE3":30598,"PHASE4":30604,"NA":30606},{"trials":30593,"activeCount":102},[],{"trials":30595,"activeCount":102},[],{"trials":30597,"activeCount":102},[],{"trials":30599,"activeCount":102},[30600],{"nctId":30579,"briefTitle":30580,"status":108,"phases":30601,"primaryCompletion":9532,"completion":3396,"start":10339,"enrollment":30582,"conditions":30602,"interventions":30603},[92],[7568,10899,10900,10901,2978],[30568,30568,30568,30585],{"trials":30605,"activeCount":102},[],{"trials":30607,"activeCount":102},[],{"intervention":30609,"totalTrials":195,"cells":30610},"SR48692",{"EARLY_PHASE1":30611,"PHASE1":30613,"PHASE2":30615,"PHASE3":30617,"PHASE4":30627,"NA":30629},{"trials":30612,"activeCount":102},[],{"trials":30614,"activeCount":102},[],{"trials":30616,"activeCount":102},[],{"trials":30618,"activeCount":102},[30619],{"nctId":30620,"briefTitle":30621,"status":108,"phases":30622,"primaryCompletion":5307,"completion":5307,"start":8176,"enrollment":30623,"conditions":30624,"interventions":30626},"NCT00290953","Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide",[91,92],432,[17993,30625,9998],"Pulmonary Neoplasms",[30609],{"trials":30628,"activeCount":102},[],{"trials":30630,"activeCount":102},[],{"intervention":21141,"totalTrials":195,"cells":30632},{"EARLY_PHASE1":30633,"PHASE1":30635,"PHASE2":30637,"PHASE3":30639,"PHASE4":30645,"NA":30647},{"trials":30634,"activeCount":102},[],{"trials":30636,"activeCount":102},[],{"trials":30638,"activeCount":102},[],{"trials":30640,"activeCount":102},[30641],{"nctId":21135,"briefTitle":21136,"status":108,"phases":30642,"primaryCompletion":1032,"completion":1032,"start":1022,"enrollment":12611,"conditions":30643,"interventions":30644},[92],[21139],[21117,21141],{"trials":30646,"activeCount":102},[],{"trials":30648,"activeCount":102},[],{"intervention":10093,"totalTrials":195,"cells":30650},{"EARLY_PHASE1":30651,"PHASE1":30653,"PHASE2":30655,"PHASE3":30657,"PHASE4":30663,"NA":30665},{"trials":30652,"activeCount":102},[],{"trials":30654,"activeCount":102},[],{"trials":30656,"activeCount":102},[],{"trials":30658,"activeCount":102},[30659],{"nctId":10087,"briefTitle":10088,"status":108,"phases":30660,"primaryCompletion":10005,"completion":10005,"start":1340,"enrollment":10090,"conditions":30661,"interventions":30662},[92],[19],[10093,8265],{"trials":30664,"activeCount":102},[],{"trials":30666,"activeCount":102},[],{"intervention":20657,"totalTrials":195,"cells":30668},{"EARLY_PHASE1":30669,"PHASE1":30671,"PHASE2":30673,"PHASE3":30675,"PHASE4":30681,"NA":30683},{"trials":30670,"activeCount":102},[],{"trials":30672,"activeCount":102},[],{"trials":30674,"activeCount":102},[],{"trials":30676,"activeCount":102},[30677],{"nctId":20650,"briefTitle":20651,"status":108,"phases":30678,"primaryCompletion":3564,"completion":8349,"start":1341,"enrollment":20653,"conditions":30679,"interventions":30680},[92],[25,31,28,18625,20655],[20639,20657,20621],{"trials":30682,"activeCount":102},[],{"trials":30684,"activeCount":102},[],{"intervention":8369,"totalTrials":195,"cells":30686},{"EARLY_PHASE1":30687,"PHASE1":30689,"PHASE2":30691,"PHASE3":30693,"PHASE4":30699,"NA":30701},{"trials":30688,"activeCount":102},[],{"trials":30690,"activeCount":102},[],{"trials":30692,"activeCount":102},[],{"trials":30694,"activeCount":102},[30695],{"nctId":8361,"briefTitle":8362,"status":108,"phases":30696,"primaryCompletion":8364,"start":8365,"enrollment":8366,"conditions":30697,"interventions":30698},[92],[22],[8057,8265,8024,8369],{"trials":30700,"activeCount":102},[],{"trials":30702,"activeCount":102},[],{"intervention":5400,"totalTrials":535,"cells":30704},{"EARLY_PHASE1":30705,"PHASE1":30707,"PHASE2":30709,"PHASE3":30761,"PHASE4":30763,"NA":30765},{"trials":30706,"activeCount":102},[],{"trials":30708,"activeCount":102},[],{"trials":30710,"activeCount":102},[30711,30715,30725,30734,30738,30742,30746,30750],{"nctId":5388,"briefTitle":5389,"status":108,"phases":30712,"primaryCompletion":5391,"completion":2996,"start":5392,"enrollment":216,"conditions":30713,"interventions":30714},[91],[5394,5395,5396,5254,5397],[5399,5400,5298],{"nctId":30716,"briefTitle":30717,"status":884,"phases":30718,"primaryCompletion":30719,"completion":30720,"start":30721,"enrollment":17,"conditions":30722,"interventions":30724},"NCT04914897","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)",[91],"2023-07-18","2024-10-17","2021-09-23",[30723,2703],"Pleural Mesothelioma",[5399,5400],{"nctId":30726,"briefTitle":30727,"status":884,"phases":30728,"primaryCompletion":30729,"completion":268,"start":1600,"enrollment":1260,"conditions":30730,"interventions":30733},"NCT05179603","A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]",[91],"2023-09-14",[30731,30732],"Classic Hodgkin Lymphoma","Diffuse Large B-cell Lymphoma",[5399,5400],{"nctId":5402,"briefTitle":5403,"status":884,"phases":30735,"primaryCompletion":5405,"completion":887,"start":5406,"enrollment":5407,"conditions":30736,"interventions":30737},[91],[1274],[5400,5410,5298],{"nctId":19596,"briefTitle":19597,"status":884,"phases":30739,"primaryCompletion":19599,"completion":19600,"start":19601,"enrollment":8883,"conditions":30740,"interventions":30741},[91],[19603],[1195,19605,19606],{"nctId":17903,"briefTitle":17904,"status":884,"phases":30743,"primaryCompletion":17906,"completion":17907,"start":17908,"enrollment":1182,"conditions":30744,"interventions":30745},[91],[17910],[1195,5400,1276,5277,5424],{"nctId":5416,"briefTitle":5417,"status":884,"phases":30747,"primaryCompletion":4734,"completion":4734,"start":5419,"enrollment":3767,"conditions":30748,"interventions":30749},[90,91],[5421,2665],[5423,5400,5298,5277,5424],{"nctId":30751,"briefTitle":30752,"status":884,"phases":30753,"primaryCompletion":30754,"completion":30754,"start":30755,"enrollment":2389,"conditions":30756,"interventions":30758},"NCT04418661","Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies",[90,91],"2024-04-04","2020-06-09",[30757],"Metastatic Neoplasm",[30759,5400,30760],"Vociprotafib","Adagrasib",{"trials":30762,"activeCount":102},[],{"trials":30764,"activeCount":102},[],{"trials":30766,"activeCount":102},[],{"intervention":18880,"totalTrials":622,"cells":30768},{"EARLY_PHASE1":30769,"PHASE1":30771,"PHASE2":30773,"PHASE3":30799,"PHASE4":30801,"NA":30803},{"trials":30770,"activeCount":102},[],{"trials":30772,"activeCount":102},[],{"trials":30774,"activeCount":102},[30775,30779,30783,30787,30791,30795],{"nctId":18875,"briefTitle":18876,"status":108,"phases":30776,"primaryCompletion":8846,"completion":1339,"start":3608,"enrollment":5195,"conditions":30777,"interventions":30778},[91],[5275],[17970,18880],{"nctId":19094,"briefTitle":19095,"status":108,"phases":30780,"primaryCompletion":3438,"completion":3438,"start":955,"enrollment":3510,"conditions":30781,"interventions":30782},[90,91],[5264,5275],[19099,18880,19071],{"nctId":18882,"briefTitle":18883,"status":108,"phases":30784,"primaryCompletion":5271,"completion":5271,"start":10320,"enrollment":18885,"conditions":30785,"interventions":30786},[91],[5275],[17970,5232,18880],{"nctId":5259,"briefTitle":5260,"status":108,"phases":30788,"primaryCompletion":954,"completion":3416,"start":5262,"enrollment":2281,"conditions":30789,"interventions":30790},[91],[5264],[5206,1348,5266],{"nctId":5268,"briefTitle":5269,"status":108,"phases":30792,"primaryCompletion":5271,"completion":5271,"start":5272,"enrollment":5273,"conditions":30793,"interventions":30794},[91],[5275],[1348,4640,5277,4643,5266,5206],{"nctId":18893,"briefTitle":18894,"status":108,"phases":30796,"primaryCompletion":8822,"completion":8822,"start":3430,"enrollment":622,"conditions":30797,"interventions":30798},[91],[18897,5264,18898],[17970,18880],{"trials":30800,"activeCount":102},[],{"trials":30802,"activeCount":102},[],{"trials":30804,"activeCount":102},[],{"intervention":8036,"totalTrials":622,"cells":30806},{"EARLY_PHASE1":30807,"PHASE1":30809,"PHASE2":30841,"PHASE3":30856,"PHASE4":30858,"NA":30860},{"trials":30808,"activeCount":102},[],{"trials":30810,"activeCount":102},[30811,30819,30827,30837],{"nctId":30812,"briefTitle":30813,"status":108,"phases":30814,"primaryCompletion":30815,"completion":30815,"start":30816,"enrollment":178,"conditions":30817,"interventions":30818},"NCT03414736","A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period",[90],"2018-10-05","2018-01-19",[19],[8036],{"nctId":30820,"briefTitle":30821,"status":108,"phases":30822,"primaryCompletion":30823,"completion":30823,"start":30824,"enrollment":9319,"conditions":30825,"interventions":30826},"NCT03376802","A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects",[90],"2018-12-27","2018-04-18",[19],[8036],{"nctId":30828,"briefTitle":30829,"status":108,"phases":30830,"primaryCompletion":30831,"completion":30831,"start":30832,"enrollment":858,"conditions":30833,"interventions":30834},"NCT03350191","A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients",[90],"2018-06-07","2017-12-20",[19],[8036,30835,30836],"[68Ga] Ga-DO3A-VS-Cys40-Tuna-2","[68Ga] Ga-DO3A-VS-Cys40-Exendin-4",{"nctId":8031,"briefTitle":8032,"status":108,"phases":30838,"primaryCompletion":4967,"completion":4967,"start":1011,"enrollment":5521,"conditions":30839,"interventions":30840},[90],[19],[8036,8037],{"trials":30842,"activeCount":102},[30843,30852],{"nctId":30844,"briefTitle":30845,"status":3661,"phases":30846,"primaryCompletion":30847,"completion":30847,"start":30848,"enrollment":102,"conditions":30849,"interventions":30851},"NCT03437720","Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease",[91],"2021-08-25","2019-05-23",[30850,19],"Non-alcoholic Steatohepatitis",[8036],{"nctId":8076,"briefTitle":8077,"status":108,"phases":30853,"primaryCompletion":8079,"completion":8079,"start":8080,"enrollment":190,"conditions":30854,"interventions":30855},[91],[19],[8036,8056,8024],{"trials":30857,"activeCount":102},[],{"trials":30859,"activeCount":102},[],{"trials":30861,"activeCount":102},[],{"intervention":19099,"totalTrials":622,"cells":30863},{"EARLY_PHASE1":30864,"PHASE1":30866,"PHASE2":30889,"PHASE3":30907,"PHASE4":30909,"NA":30911},{"trials":30865,"activeCount":102},[],{"trials":30867,"activeCount":102},[30868,30874,30881],{"nctId":30869,"briefTitle":30870,"status":108,"phases":30871,"primaryCompletion":164,"completion":164,"start":10320,"enrollment":1223,"conditions":30872,"interventions":30873},"NCT00486135","Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma",[90],[5421,2675],[19099,19099],{"nctId":30875,"briefTitle":30876,"status":108,"phases":30877,"primaryCompletion":8062,"completion":8062,"start":8316,"enrollment":875,"conditions":30878,"interventions":30879},"NCT00692640","Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors",[90],[5421,2703],[19099,30880],"Erlotinib",{"nctId":30882,"briefTitle":30883,"status":108,"phases":30884,"primaryCompletion":2834,"completion":2834,"start":1339,"enrollment":98,"conditions":30885,"interventions":30888},"NCT01240460","Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection",[90],[30886,30887],"Glioblastoma","Astrocytoma, Grade IV",[19816,19099],{"trials":30890,"activeCount":102},[30891,30895,30899],{"nctId":19094,"briefTitle":19095,"status":108,"phases":30892,"primaryCompletion":3438,"completion":3438,"start":955,"enrollment":3510,"conditions":30893,"interventions":30894},[90,91],[5264,5275],[19099,18880,19071],{"nctId":19811,"briefTitle":19812,"status":108,"phases":30896,"primaryCompletion":1032,"completion":1032,"start":978,"enrollment":8717,"conditions":30897,"interventions":30898},[90,91],[5264],[19099,19816,19817],{"nctId":30900,"briefTitle":30901,"status":108,"phases":30902,"primaryCompletion":2760,"completion":2760,"start":8745,"enrollment":4628,"conditions":30903,"interventions":30906},"NCT01013324","Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma",[91],[30904,30905],"Endometrial Cancer","Endometrial Neoplasms",[19099],{"trials":30908,"activeCount":102},[],{"trials":30910,"activeCount":102},[],{"trials":30912,"activeCount":102},[],{"intervention":30914,"totalTrials":339,"cells":30915},"SAR3419",{"EARLY_PHASE1":30916,"PHASE1":30918,"PHASE2":30933,"PHASE3":30956,"PHASE4":30958,"NA":30960},{"trials":30917,"activeCount":102},[],{"trials":30919,"activeCount":102},[30920,30927],{"nctId":30921,"briefTitle":30922,"status":108,"phases":30923,"primaryCompletion":2834,"completion":2834,"start":8846,"enrollment":13,"conditions":30924,"interventions":30926},"NCT00796731","SAR3419 Administered Weekly in Patients With Relapsed\u002FRefractory CD19-positive B-cell Non-Hodgkin's Lymphoma",[90],[2675,30925],"Non-Hodgkin",[30914],{"nctId":30928,"briefTitle":30929,"status":108,"phases":30930,"primaryCompletion":3335,"completion":3335,"start":3317,"enrollment":5218,"conditions":30931,"interventions":30932},"NCT00549185","Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed\u002FRefractory B-cell Non Hodgkin's Lymphoma",[90],[2675,30925],[30914],{"trials":30934,"activeCount":102},[30935,30943,30950],{"nctId":30936,"briefTitle":30937,"status":108,"phases":30938,"primaryCompletion":7283,"completion":14370,"start":8062,"enrollment":7653,"conditions":30939,"interventions":30941},"NCT01470456","Combination of SAR3419 and Rituximab in Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[91],[30940],"Diffuse Large B-Cell Lymphoma",[30914,30942],"rituximab",{"nctId":30944,"briefTitle":30945,"status":884,"phases":30946,"primaryCompletion":1272,"completion":1272,"start":1340,"enrollment":465,"conditions":30947,"interventions":30949},"NCT01440179","SAR3419 in Acute Lymphoblastic Leukemia",[91],[30948],"Acute Lymphocytic Leukaemia",[30914],{"nctId":30951,"briefTitle":30952,"status":108,"phases":30953,"primaryCompletion":15982,"completion":15982,"start":3335,"enrollment":6472,"conditions":30954,"interventions":30955},"NCT01472887","SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients",[91],[30732],[30914],{"trials":30957,"activeCount":102},[],{"trials":30959,"activeCount":102},[],{"trials":30961,"activeCount":102},[],{"intervention":2705,"totalTrials":339,"cells":30963},{"EARLY_PHASE1":30964,"PHASE1":30966,"PHASE2":30981,"PHASE3":30995,"PHASE4":30997,"NA":30999},{"trials":30965,"activeCount":102},[],{"trials":30967,"activeCount":102},[30968,30972],{"nctId":5438,"briefTitle":5439,"status":108,"phases":30969,"primaryCompletion":5441,"completion":5442,"start":5443,"enrollment":1574,"conditions":30970,"interventions":30971},[90],[5445],[646,2705],{"nctId":30973,"briefTitle":30974,"status":884,"phases":30975,"primaryCompletion":30976,"completion":30977,"start":25194,"enrollment":13,"conditions":30978,"interventions":30979},"NCT03871348","A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",[90],"2022-07-25","2024-02-21",[30757],[30980,2705],"SAR441000",{"trials":30982,"activeCount":102},[30983,30987,30991],{"nctId":2669,"briefTitle":2670,"status":884,"phases":30984,"primaryCompletion":2672,"completion":2672,"start":2673,"enrollment":967,"conditions":30985,"interventions":30986},[90,91],[2675],[1175,2677],{"nctId":2697,"briefTitle":2698,"status":884,"phases":30988,"primaryCompletion":2700,"completion":2700,"start":2701,"enrollment":359,"conditions":30989,"interventions":30990},[90,91],[1357,2703],[1162,2705],{"nctId":2707,"briefTitle":2708,"status":108,"phases":30992,"primaryCompletion":1222,"completion":1222,"start":2710,"enrollment":442,"conditions":30993,"interventions":30994},[90,91],[1160],[1162,2705],{"trials":30996,"activeCount":102},[],{"trials":30998,"activeCount":102},[],{"trials":31000,"activeCount":102},[],{"intervention":31002,"totalTrials":339,"cells":31003},"SAR245408",{"EARLY_PHASE1":31004,"PHASE1":31006,"PHASE2":31035,"PHASE3":31046,"PHASE4":31048,"NA":31050},{"trials":31005,"activeCount":102},[],{"trials":31007,"activeCount":102},[31008,31016,31023,31029],{"nctId":31009,"briefTitle":31010,"status":108,"phases":31011,"primaryCompletion":1272,"completion":1272,"start":8062,"enrollment":703,"conditions":31012,"interventions":31014},"NCT01436565","A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers",[90],[31013],"Solid Tumor Cancers",[31015,31002],"MM-121",{"nctId":31017,"briefTitle":31018,"status":108,"phases":31019,"primaryCompletion":2834,"completion":2834,"start":7292,"enrollment":284,"conditions":31020,"interventions":31021},"NCT01357330","Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors",[90],[18378],[31002,31022],"MSC1936369B",{"nctId":31024,"briefTitle":31025,"status":108,"phases":31026,"primaryCompletion":1042,"completion":1042,"start":966,"enrollment":284,"conditions":31027,"interventions":31028},"NCT01943838","A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma",[90],[1193],[31002],{"nctId":31030,"briefTitle":31031,"status":108,"phases":31032,"primaryCompletion":8107,"completion":150,"start":5306,"enrollment":552,"conditions":31033,"interventions":31034},"NCT01392924","Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors",[90],[1193],[31002],{"trials":31036,"activeCount":102},[31037],{"nctId":31038,"briefTitle":31039,"status":108,"phases":31040,"primaryCompletion":31041,"completion":31041,"start":31042,"enrollment":6472,"conditions":31043,"interventions":31044},"NCT01587040","Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen",[90,91],"2018-05-23","2012-07-20",[1193],[31002,31045],"SAR245409",{"trials":31047,"activeCount":102},[],{"trials":31049,"activeCount":102},[],{"trials":31051,"activeCount":102},[],{"intervention":19816,"totalTrials":339,"cells":31053},{"EARLY_PHASE1":31054,"PHASE1":31056,"PHASE2":31084,"PHASE3":31090,"PHASE4":31092,"NA":31094},{"trials":31055,"activeCount":102},[],{"trials":31057,"activeCount":102},[31058,31064,31070,31080],{"nctId":31059,"briefTitle":31060,"status":108,"phases":31061,"primaryCompletion":10178,"completion":10178,"start":10320,"enrollment":2777,"conditions":31062,"interventions":31063},"NCT00485719","Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors",[90],[5421],[19816],{"nctId":31065,"briefTitle":31066,"status":108,"phases":31067,"primaryCompletion":3821,"completion":3821,"start":3417,"enrollment":20,"conditions":31068,"interventions":31069},"NCT00777699","Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors",[90],[5421,5284],[19816,22133],{"nctId":31071,"briefTitle":31072,"status":108,"phases":31073,"primaryCompletion":8107,"completion":10005,"start":3417,"enrollment":349,"conditions":31074,"interventions":31078},"NCT00704080","A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas",[90],[31075,31076,31077],"Mixed Gliomas","Malignant Gliomas","Glioblastoma Multiforme",[19816,31079],"Temozolomide",{"nctId":30882,"briefTitle":30883,"status":108,"phases":31081,"primaryCompletion":2834,"completion":2834,"start":1339,"enrollment":98,"conditions":31082,"interventions":31083},[90],[30886,30887],[19816,19099],{"trials":31085,"activeCount":102},[31086],{"nctId":19811,"briefTitle":19812,"status":108,"phases":31087,"primaryCompletion":1032,"completion":1032,"start":978,"enrollment":8717,"conditions":31088,"interventions":31089},[90,91],[5264],[19099,19816,19817],{"trials":31091,"activeCount":102},[],{"trials":31093,"activeCount":102},[],{"trials":31095,"activeCount":102},[],{"intervention":31097,"totalTrials":339,"cells":31098},"XRP0038",{"EARLY_PHASE1":31099,"PHASE1":31101,"PHASE2":31117,"PHASE3":31138,"PHASE4":31140,"NA":31142},{"trials":31100,"activeCount":102},[],{"trials":31102,"activeCount":102},[31103,31111],{"nctId":31104,"briefTitle":31105,"status":108,"phases":31106,"primaryCompletion":17618,"completion":17618,"start":31107,"enrollment":5195,"conditions":31108,"interventions":31110},"NCT01157156","Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease",[90],"1999-06",[31109],"Peripheral Arterial Occlusive Disease",[31097],{"nctId":31112,"briefTitle":31113,"status":108,"phases":31114,"primaryCompletion":3488,"completion":3488,"start":3346,"enrollment":622,"conditions":31115,"interventions":31116},"NCT01157143","Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation",[90],[31109],[31097],{"trials":31118,"activeCount":102},[31119,31125,31131],{"nctId":31120,"briefTitle":31121,"status":108,"phases":31122,"primaryCompletion":8579,"completion":8579,"start":9909,"enrollment":2685,"conditions":31123,"interventions":31124},"NCT01157871","Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication",[91],[31109],[31097],{"nctId":31126,"briefTitle":31127,"status":108,"phases":31128,"primaryCompletion":8667,"completion":8667,"start":3489,"enrollment":3767,"conditions":31129,"interventions":31130},"NCT00368797","Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease",[91],[9637],[31097],{"nctId":31132,"briefTitle":31133,"status":108,"phases":31134,"primaryCompletion":9706,"completion":9706,"start":8420,"enrollment":2998,"conditions":31135,"interventions":31137},"NCT00798005","Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.",[91],[31136],"Severe Peripheral Artery Occlusive Disease",[31097],{"trials":31139,"activeCount":102},[],{"trials":31141,"activeCount":102},[],{"trials":31143,"activeCount":102},[],{"intervention":31145,"totalTrials":339,"cells":31146},"SAR443820",{"EARLY_PHASE1":31147,"PHASE1":31149,"PHASE2":31177,"PHASE3":31194,"PHASE4":31196,"NA":31198},{"trials":31148,"activeCount":102},[],{"trials":31150,"activeCount":102},[31151,31160,31168],{"nctId":31152,"briefTitle":31153,"status":108,"phases":31154,"primaryCompletion":31155,"completion":31155,"start":31156,"enrollment":1079,"conditions":31157,"interventions":31159},"NCT05795907","Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants",[90],"2021-07-20","2020-11-30",[31158],"Amyotrophic Lateral Sclerosis (Healthy Volunteers)",[31145],{"nctId":31161,"briefTitle":31162,"status":108,"phases":31163,"primaryCompletion":31164,"completion":31164,"start":31165,"enrollment":284,"conditions":31166,"interventions":31167},"NCT05797701","A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)",[90],"2021-09-06","2021-07-28",[31158],[31145,31145],{"nctId":31169,"briefTitle":31170,"status":108,"phases":31171,"primaryCompletion":31172,"completion":31172,"start":5015,"enrollment":988,"conditions":31173,"interventions":31174},"NCT05797753","A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)",[90],"2022-07-01",[13266,131],[31145,31145,31175,31176],"Erythromycin ethyl succinate","Itraconazole",{"trials":31178,"activeCount":102},[31179,31186],{"nctId":31180,"briefTitle":31181,"status":884,"phases":31182,"primaryCompletion":6010,"completion":6010,"start":31183,"enrollment":9900,"conditions":31184,"interventions":31185},"NCT05630547","A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis",[91],"2022-12-19",[1788],[31145],{"nctId":31187,"briefTitle":31188,"status":884,"phases":31189,"primaryCompletion":31190,"completion":31190,"start":31191,"enrollment":6577,"conditions":31192,"interventions":31193},"NCT05237284","Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)",[91],"2024-03-07","2022-04-13",[13266],[31145],{"trials":31195,"activeCount":102},[],{"trials":31197,"activeCount":102},[],{"trials":31199,"activeCount":102},[],{"intervention":31201,"totalTrials":445,"cells":31202},"SAR113945",{"EARLY_PHASE1":31203,"PHASE1":31205,"PHASE2":31226,"PHASE3":31235,"PHASE4":31237,"NA":31239},{"trials":31204,"activeCount":102},[],{"trials":31206,"activeCount":102},[31207,31214,31220],{"nctId":31208,"briefTitle":31209,"status":108,"phases":31210,"primaryCompletion":7349,"completion":7349,"start":8062,"enrollment":9319,"conditions":31211,"interventions":31213},"NCT01463488","Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients \u002F Part I",[90],[31212],"Knee Osteoarthritis",[31201],{"nctId":31215,"briefTitle":31216,"status":108,"phases":31217,"primaryCompletion":3821,"completion":3821,"start":3316,"enrollment":98,"conditions":31218,"interventions":31219},"NCT01113333","Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis",[90],[13537],[31201],{"nctId":31221,"briefTitle":31222,"status":108,"phases":31223,"primaryCompletion":10178,"completion":10178,"start":3335,"enrollment":9319,"conditions":31224,"interventions":31225},"NCT01511549","Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis",[90],[31212],[31201],{"trials":31227,"activeCount":102},[31228],{"nctId":31229,"briefTitle":31230,"status":108,"phases":31231,"primaryCompletion":10005,"completion":10005,"start":3416,"enrollment":31232,"conditions":31233,"interventions":31234},"NCT01598415","Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients \u002F Part II",[91],130,[31212],[31201],{"trials":31236,"activeCount":102},[],{"trials":31238,"activeCount":102},[],{"trials":31240,"activeCount":102},[],{"intervention":31242,"totalTrials":445,"cells":31243},"Tusamitamab ravtansine",{"EARLY_PHASE1":31244,"PHASE1":31246,"PHASE2":31256,"PHASE3":31281,"PHASE4":31283,"NA":31285},{"trials":31245,"activeCount":102},[],{"trials":31247,"activeCount":102},[31248],{"nctId":31249,"briefTitle":31250,"status":884,"phases":31251,"primaryCompletion":31252,"completion":31253,"start":5356,"enrollment":1145,"conditions":31254,"interventions":31255},"NCT05429762","Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors",[90],"2023-08-01","2024-04-10",[2665],[31242],{"trials":31257,"activeCount":102},[31258,31262,31272],{"nctId":18334,"briefTitle":18335,"status":884,"phases":31259,"primaryCompletion":18337,"completion":18338,"start":5126,"enrollment":7653,"conditions":31260,"interventions":31261},[91],[18340,18341],[18343,9134],{"nctId":31263,"briefTitle":31264,"status":884,"phases":31265,"primaryCompletion":1581,"completion":2891,"start":31266,"enrollment":875,"conditions":31267,"interventions":31270},"NCT05071053","Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer",[91],"2021-11-16",[31268,31269],"Adenocarcinoma Gastric","Gastrooesophageal Cancer",[31271,31242],"Ramucirumab",{"nctId":31273,"briefTitle":31274,"status":884,"phases":31275,"primaryCompletion":31276,"completion":1399,"start":31277,"enrollment":1601,"conditions":31278,"interventions":31280},"NCT05245071","Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA",[91],"2024-03-06","2022-06-01",[31279],"Non-squamous Non-small Cell Lung Cancer",[31242],{"trials":31282,"activeCount":102},[],{"trials":31284,"activeCount":102},[],{"trials":31286,"activeCount":102},[],{"intervention":31288,"totalTrials":445,"cells":31289},"SR57667B",{"EARLY_PHASE1":31290,"PHASE1":31292,"PHASE2":31294,"PHASE3":31322,"PHASE4":31324,"NA":31326},{"trials":31291,"activeCount":102},[],{"trials":31293,"activeCount":102},[],{"trials":31295,"activeCount":102},[31296,31302,31308,31316],{"nctId":31297,"briefTitle":31298,"status":108,"phases":31299,"completion":9559,"start":9130,"enrollment":7729,"conditions":31300,"interventions":31301},"NCT00285025","Study of the Effect of SR57667B in Patients With Alzheimer's Disease",[91],[19985],[31288],{"nctId":31303,"briefTitle":31304,"status":108,"phases":31305,"primaryCompletion":8666,"completion":8666,"start":9522,"enrollment":8620,"conditions":31306,"interventions":31307},"NCT00285077","Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease",[91],[19985],[31288],{"nctId":31309,"briefTitle":31310,"status":108,"phases":31311,"primaryCompletion":9513,"completion":9513,"start":3508,"enrollment":31312,"conditions":31313,"interventions":31315},"NCT00228150","Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease",[91],564,[31314],"Parkinson Disease",[31288],{"nctId":31317,"briefTitle":31318,"status":108,"phases":31319,"primaryCompletion":5272,"completion":5272,"start":3527,"enrollment":7321,"conditions":31320,"interventions":31321},"NCT00220272","Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease",[91],[31314],[31288],{"trials":31323,"activeCount":102},[],{"trials":31325,"activeCount":102},[],{"trials":31327,"activeCount":102},[],{"intervention":31045,"totalTrials":445,"cells":31329},{"EARLY_PHASE1":31330,"PHASE1":31332,"PHASE2":31349,"PHASE3":31361,"PHASE4":31363,"NA":31365},{"trials":31331,"activeCount":102},[],{"trials":31333,"activeCount":102},[31334,31343],{"nctId":31335,"briefTitle":31336,"status":108,"phases":31337,"primaryCompletion":1272,"completion":1272,"start":977,"enrollment":655,"conditions":31338,"interventions":31342},"NCT01410513","Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia",[90],[31339,31340,31341],"Indolent Non-Hodgkin Lymphoma","Mantle Cell Lymphoma","Chronic Lymphocytic Leukemia",[31045],{"nctId":31344,"briefTitle":31345,"status":108,"phases":31346,"primaryCompletion":5216,"completion":5216,"start":2834,"enrollment":9533,"conditions":31347,"interventions":31348},"NCT01596270","A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma",[90],[1193],[31045],{"trials":31350,"activeCount":102},[31351,31355],{"nctId":31038,"briefTitle":31039,"status":108,"phases":31352,"primaryCompletion":31041,"completion":31041,"start":31042,"enrollment":6472,"conditions":31353,"interventions":31354},[90,91],[1193],[31002,31045],{"nctId":31356,"briefTitle":31357,"status":108,"phases":31358,"primaryCompletion":14370,"completion":14370,"start":1340,"enrollment":29528,"conditions":31359,"interventions":31360},"NCT01403636","A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia",[91],[2675],[31045],{"trials":31362,"activeCount":102},[],{"trials":31364,"activeCount":102},[],{"trials":31366,"activeCount":102},[],{"intervention":31368,"totalTrials":445,"cells":31369},"Swine A\u002FH1N1 influenza vaccine",{"EARLY_PHASE1":31370,"PHASE1":31372,"PHASE2":31374,"PHASE3":31402,"PHASE4":31404,"NA":31406},{"trials":31371,"activeCount":102},[],{"trials":31373,"activeCount":102},[],{"trials":31375,"activeCount":102},[31376,31383,31390,31396],{"nctId":31377,"briefTitle":31378,"status":108,"phases":31379,"primaryCompletion":5217,"completion":987,"start":8215,"enrollment":484,"conditions":31380,"interventions":31382},"NCT00956202","A Study of Inactivated Swine-Origin A\u002FH1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years",[91],[16,31381],"Swine-origin A\u002FH1N1 Influenza",[31368,31368,31368],{"nctId":31384,"briefTitle":31385,"status":108,"phases":31386,"primaryCompletion":1339,"completion":954,"start":2799,"enrollment":31387,"conditions":31388,"interventions":31389},"NCT00956046","A Study of Swine-origin A\u002FH1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months",[91],401,[16,31381],[31368,31368,31368],{"nctId":31391,"briefTitle":31392,"status":108,"phases":31393,"primaryCompletion":5217,"completion":8693,"start":1022,"enrollment":6493,"conditions":31394,"interventions":31395},"NCT01089660","A Study of the Immunogenicity of Swine-origin A\u002FH1N1 Influenza Vaccine in Healthy Adults",[91],[16,31381],[31368,31368],{"nctId":31397,"briefTitle":31398,"status":108,"phases":31399,"primaryCompletion":8693,"completion":165,"start":8215,"enrollment":19781,"conditions":31400,"interventions":31401},"NCT00954798","A Study of Swine-origin A\u002FH1N1 Influenza Vaccines in Healthy European Adults and the Elderly",[91],[16,31381],[31368,31368,31368],{"trials":31403,"activeCount":102},[],{"trials":31405,"activeCount":102},[],{"trials":31407,"activeCount":102},[],{"intervention":5399,"totalTrials":445,"cells":31409},{"EARLY_PHASE1":31410,"PHASE1":31412,"PHASE2":31414,"PHASE3":31432,"PHASE4":31434,"NA":31436},{"trials":31411,"activeCount":102},[],{"trials":31413,"activeCount":102},[],{"trials":31415,"activeCount":102},[31416,31420,31424,31428],{"nctId":5388,"briefTitle":5389,"status":108,"phases":31417,"primaryCompletion":5391,"completion":2996,"start":5392,"enrollment":216,"conditions":31418,"interventions":31419},[91],[5394,5395,5396,5254,5397],[5399,5400,5298],{"nctId":30716,"briefTitle":30717,"status":884,"phases":31421,"primaryCompletion":30719,"completion":30720,"start":30721,"enrollment":17,"conditions":31422,"interventions":31423},[91],[30723,2703],[5399,5400],{"nctId":30726,"briefTitle":30727,"status":884,"phases":31425,"primaryCompletion":30729,"completion":268,"start":1600,"enrollment":1260,"conditions":31426,"interventions":31427},[91],[30731,30732],[5399,5400],{"nctId":6557,"briefTitle":6558,"status":884,"phases":31429,"primaryCompletion":6560,"completion":1940,"start":6561,"enrollment":37,"conditions":31430,"interventions":31431},[90,91],[6563,6564],[5399,1236],{"trials":31433,"activeCount":102},[],{"trials":31435,"activeCount":102},[],{"trials":31437,"activeCount":102},[],{"intervention":19114,"totalTrials":445,"cells":31439},{"EARLY_PHASE1":31440,"PHASE1":31442,"PHASE2":31451,"PHASE3":31469,"PHASE4":31471,"NA":31473},{"trials":31441,"activeCount":102},[],{"trials":31443,"activeCount":102},[31444],{"nctId":31445,"briefTitle":31446,"status":108,"phases":31447,"primaryCompletion":3366,"completion":7292,"start":5307,"enrollment":5407,"conditions":31448,"interventions":31449},"NCT00298675","Phase 1\u002F1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors",[90],[10973],[19114,31450],"irinotecan",{"trials":31452,"activeCount":102},[31453,31459,31463],{"nctId":31454,"briefTitle":31455,"status":108,"phases":31456,"primaryCompletion":8107,"completion":8107,"start":8388,"enrollment":7224,"conditions":31457,"interventions":31458},"NCT01033123","A Single-Arm Study Evaluating Carboplatin\u002FGemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer",[91],[5310],[19114],{"nctId":19108,"briefTitle":19109,"status":108,"phases":31460,"primaryCompletion":1022,"completion":977,"start":8316,"enrollment":1601,"conditions":31461,"interventions":31462},[91],[19112],[19071,19086,19114],{"nctId":31464,"briefTitle":31465,"status":108,"phases":31466,"primaryCompletion":3438,"completion":3438,"start":8388,"enrollment":2411,"conditions":31467,"interventions":31468},"NCT01033292","A Single-Arm Study Evaluating Carboplatin\u002FGemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer",[91],[5310],[19114],{"trials":31470,"activeCount":102},[],{"trials":31472,"activeCount":102},[],{"trials":31474,"activeCount":102},[],{"intervention":12594,"totalTrials":619,"cells":31476},{"EARLY_PHASE1":31477,"PHASE1":31479,"PHASE2":31481,"PHASE3":31499,"PHASE4":31501,"NA":31503},{"trials":31478,"activeCount":102},[],{"trials":31480,"activeCount":102},[],{"trials":31482,"activeCount":102},[31483,31487,31495],{"nctId":12588,"briefTitle":12589,"status":884,"phases":31484,"primaryCompletion":987,"completion":987,"start":3354,"enrollment":9714,"conditions":31485,"interventions":31486},[91],[12592],[12594,12595],{"nctId":31488,"briefTitle":31489,"status":108,"phases":31490,"primaryCompletion":18237,"completion":18237,"start":31491,"enrollment":3121,"conditions":31492,"interventions":31493},"NCT03660839","Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria",[91],"2018-09-11",[12592],[31494,12594],"Artefenomel",{"nctId":13391,"briefTitle":13392,"status":108,"phases":31496,"primaryCompletion":8235,"completion":8235,"start":3317,"enrollment":8717,"conditions":31497,"interventions":31498},[90,91],[12262],[13396,13397],{"trials":31500,"activeCount":102},[],{"trials":31502,"activeCount":102},[],{"trials":31504,"activeCount":102},[],{"intervention":5339,"totalTrials":619,"cells":31506},{"EARLY_PHASE1":31507,"PHASE1":31509,"PHASE2":31511,"PHASE3":31525,"PHASE4":31527,"NA":31529},{"trials":31508,"activeCount":102},[],{"trials":31510,"activeCount":102},[],{"trials":31512,"activeCount":102},[31513,31517,31521],{"nctId":5328,"briefTitle":5329,"status":108,"phases":31514,"primaryCompletion":5331,"completion":5331,"start":5332,"enrollment":5333,"conditions":31515,"interventions":31516},[90,91],[5335],[5337,5338,5319,5339],{"nctId":5352,"briefTitle":5353,"status":108,"phases":31518,"primaryCompletion":5355,"completion":5355,"start":5356,"enrollment":5357,"conditions":31519,"interventions":31520},[90,91],[5335],[5360,5338,5319,5339],{"nctId":5362,"briefTitle":5363,"status":108,"phases":31522,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":5367,"conditions":31523,"interventions":31524},[90,91],[5335],[5370,5371,5372,5319,5339,5338],{"trials":31526,"activeCount":102},[],{"trials":31528,"activeCount":102},[],{"trials":31530,"activeCount":102},[],{"intervention":31532,"totalTrials":619,"cells":31533},"SAR125844",{"EARLY_PHASE1":31534,"PHASE1":31536,"PHASE2":31551,"PHASE3":31559,"PHASE4":31561,"NA":31563},{"trials":31535,"activeCount":102},[],{"trials":31537,"activeCount":102},[31538,31545],{"nctId":31539,"briefTitle":31540,"status":108,"phases":31541,"primaryCompletion":965,"completion":965,"start":8406,"enrollment":8717,"conditions":31542,"interventions":31544},"NCT01391533","Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors",[90],[31543],"Malignant Solid Tumors",[31532],{"nctId":31546,"briefTitle":31547,"status":108,"phases":31548,"primaryCompletion":4967,"completion":4967,"start":10178,"enrollment":1232,"conditions":31549,"interventions":31550},"NCT01657214","Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients",[90],[1193],[31532],{"trials":31552,"activeCount":102},[31553],{"nctId":31554,"briefTitle":31555,"status":108,"phases":31556,"primaryCompletion":4967,"completion":4967,"start":3459,"enrollment":195,"conditions":31557,"interventions":31558},"NCT02435121","A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification",[91],[1193],[31532],{"trials":31560,"activeCount":102},[],{"trials":31562,"activeCount":102},[],{"trials":31564,"activeCount":102},[],{"intervention":31566,"totalTrials":619,"cells":31567},"Clostridium difficile toxoid vaccine",{"EARLY_PHASE1":31568,"PHASE1":31570,"PHASE2":31579,"PHASE3":31597,"PHASE4":31599,"NA":31601},{"trials":31569,"activeCount":102},[],{"trials":31571,"activeCount":102},[31572],{"nctId":31573,"briefTitle":31574,"status":884,"phases":31575,"primaryCompletion":8395,"completion":8395,"start":5307,"enrollment":2685,"conditions":31576,"interventions":31578},"NCT00772954","Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity",[90],[21801,31577],"Clostridium Difficile Diarrhea",[21788,31566,31566],{"trials":31580,"activeCount":102},[31581,31589],{"nctId":31582,"briefTitle":31583,"status":108,"phases":31584,"primaryCompletion":8406,"completion":2834,"start":8315,"enrollment":10746,"conditions":31585,"interventions":31586},"NCT00772343","Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection",[91],[26251,21801],[31587,31566,31588,31566],"0.9% Normal Saline","Clostridium difficile toxoid vaccine with adjuvant",{"nctId":31590,"briefTitle":31591,"status":108,"phases":31592,"primaryCompletion":966,"completion":4969,"start":7283,"enrollment":1001,"conditions":31593,"interventions":31594},"NCT01896830","Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan",[90,91],[21801],[31595,31596],"Clostridium difficile Toxoid Vaccine","0.9% normal saline",{"trials":31598,"activeCount":102},[],{"trials":31600,"activeCount":102},[],{"trials":31602,"activeCount":102},[],{"intervention":31604,"totalTrials":619,"cells":31605},"SAR156597",{"EARLY_PHASE1":31606,"PHASE1":31608,"PHASE2":31610,"PHASE3":31639,"PHASE4":31641,"NA":31643},{"trials":31607,"activeCount":102},[],{"trials":31609,"activeCount":102},[],{"trials":31611,"activeCount":102},[31612,31623,31629],{"nctId":31613,"briefTitle":31614,"status":108,"phases":31615,"primaryCompletion":31616,"completion":31617,"start":31618,"enrollment":31619,"conditions":31620,"interventions":31622},"NCT02345070","Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis",[91],"2017-05-22","2017-08-14","2015-05-01",327,[31621],"Idiopathic Pulmonary Fibrosis",[31604],{"nctId":31624,"briefTitle":31625,"status":108,"phases":31626,"primaryCompletion":966,"completion":966,"start":3335,"enrollment":9319,"conditions":31627,"interventions":31628},"NCT01529853","To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)",[90,91],[31621],[31604],{"nctId":31630,"briefTitle":31631,"status":108,"phases":31632,"primaryCompletion":18028,"completion":31633,"start":31634,"enrollment":31635,"conditions":31636,"interventions":31638},"NCT02921971","Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis",[91],"2019-04-01","2016-12-21",97,[31637],"Systemic Sclerosis",[31604],{"trials":31640,"activeCount":102},[],{"trials":31642,"activeCount":102},[],{"trials":31644,"activeCount":102},[],{"intervention":22132,"totalTrials":619,"cells":31646},{"EARLY_PHASE1":31647,"PHASE1":31649,"PHASE2":31658,"PHASE3":31670,"PHASE4":31672,"NA":31674},{"trials":31648,"activeCount":102},[],{"trials":31650,"activeCount":102},[31651],{"nctId":31652,"briefTitle":31653,"status":108,"phases":31654,"primaryCompletion":3564,"completion":3564,"start":3622,"enrollment":703,"conditions":31655,"interventions":31656},"NCT01233895","Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma",[90],[1147],[22132,31657],"Velcade",{"trials":31659,"activeCount":102},[31660,31664],{"nctId":22126,"briefTitle":22127,"status":884,"phases":31661,"primaryCompletion":8570,"completion":8570,"start":8235,"enrollment":858,"conditions":31662,"interventions":31663},[90,91],[22130],[22132,9223,22133],{"nctId":31665,"briefTitle":31666,"status":884,"phases":31667,"primaryCompletion":987,"completion":987,"start":8846,"enrollment":284,"conditions":31668,"interventions":31669},"NCT00774878","Study of AVE1642 (IGF-1R\u002FCD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer",[91],[5275],[22132,18962],{"trials":31671,"activeCount":102},[],{"trials":31673,"activeCount":102},[],{"trials":31675,"activeCount":102},[],{"intervention":22133,"totalTrials":619,"cells":31677},{"EARLY_PHASE1":31678,"PHASE1":31680,"PHASE2":31690,"PHASE3":31696,"PHASE4":31698,"NA":31700},{"trials":31679,"activeCount":102},[],{"trials":31681,"activeCount":102},[31682,31686],{"nctId":30875,"briefTitle":30876,"status":108,"phases":31683,"primaryCompletion":8062,"completion":8062,"start":8316,"enrollment":875,"conditions":31684,"interventions":31685},[90],[5421,2703],[19099,30880],{"nctId":31065,"briefTitle":31066,"status":108,"phases":31687,"primaryCompletion":3821,"completion":3821,"start":3417,"enrollment":20,"conditions":31688,"interventions":31689},[90],[5421,5284],[19816,22133],{"trials":31691,"activeCount":102},[31692],{"nctId":22126,"briefTitle":22127,"status":884,"phases":31693,"primaryCompletion":8570,"completion":8570,"start":8235,"enrollment":858,"conditions":31694,"interventions":31695},[90,91],[22130],[22132,9223,22133],{"trials":31697,"activeCount":102},[],{"trials":31699,"activeCount":102},[],{"trials":31701,"activeCount":102},[],{"intervention":20067,"totalTrials":619,"cells":31703},{"EARLY_PHASE1":31704,"PHASE1":31706,"PHASE2":31708,"PHASE3":31726,"PHASE4":31728,"NA":31730},{"trials":31705,"activeCount":102},[],{"trials":31707,"activeCount":102},[],{"trials":31709,"activeCount":102},[31710,31714,31720],{"nctId":20062,"briefTitle":20063,"status":108,"phases":31711,"primaryCompletion":3439,"completion":3439,"start":5262,"enrollment":4895,"conditions":31712,"interventions":31713},[91],[18481],[20067,20068],{"nctId":31715,"briefTitle":31716,"status":108,"phases":31717,"primaryCompletion":1341,"completion":1341,"start":5262,"enrollment":3397,"conditions":31718,"interventions":31719},"NCT00361491","An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder",[91],[18489],[20067],{"nctId":31721,"briefTitle":31722,"status":108,"phases":31723,"primaryCompletion":7509,"completion":7509,"start":3608,"enrollment":8216,"conditions":31724,"interventions":31725},"NCT00358631","An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder",[91],[18489],[20067],{"trials":31727,"activeCount":102},[],{"trials":31729,"activeCount":102},[],{"trials":31731,"activeCount":102},[],{"intervention":31733,"totalTrials":619,"cells":31734},"Monovalent Subvirion A\u002FH1N1 Influenza vaccine",{"EARLY_PHASE1":31735,"PHASE1":31737,"PHASE2":31739,"PHASE3":31765,"PHASE4":31767,"NA":31769},{"trials":31736,"activeCount":102},[],{"trials":31738,"activeCount":102},[],{"trials":31740,"activeCount":102},[31741,31751,31758],{"nctId":31742,"briefTitle":31743,"status":108,"phases":31744,"primaryCompletion":8693,"completion":165,"start":3354,"enrollment":31745,"conditions":31746,"interventions":31747},"NCT00952276","A Study of Different Formulations of an Adjuvanted A\u002FH1N1 Pandemic Vaccine in Healthy Adults and the Elderly",[91],548,[16,31381],[31748,31748,31749,31749,31750],"Monovalent Subvirion A\u002FH1N1 influenza vaccine with adjuvant","Monovalent Subvirion A\u002FH1N1 influenza vaccine","Normal saline solution",{"nctId":31752,"briefTitle":31753,"status":108,"phases":31754,"primaryCompletion":1022,"completion":8693,"start":8215,"enrollment":31755,"conditions":31756,"interventions":31757},"NCT00953524","A Study of Different Formulations of an A\u002FH1N1 Pandemic Vaccine in Healthy Adults and the Elderly",[91],849,[16,31381],[31733,31733,31733,31750],{"nctId":31759,"briefTitle":31760,"status":108,"phases":31761,"primaryCompletion":1022,"completion":978,"start":8215,"enrollment":31762,"conditions":31763,"interventions":31764},"NCT00952419","A Study of Different Formulations of an A\u002FH1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years",[91],474,[16,31381],[31733,31733,31750],{"trials":31766,"activeCount":102},[],{"trials":31768,"activeCount":102},[],{"trials":31770,"activeCount":102},[],{"intervention":31750,"totalTrials":619,"cells":31772},{"EARLY_PHASE1":31773,"PHASE1":31775,"PHASE2":31777,"PHASE3":31791,"PHASE4":31793,"NA":31795},{"trials":31774,"activeCount":102},[],{"trials":31776,"activeCount":102},[],{"trials":31778,"activeCount":102},[31779,31783,31787],{"nctId":31742,"briefTitle":31743,"status":108,"phases":31780,"primaryCompletion":8693,"completion":165,"start":3354,"enrollment":31745,"conditions":31781,"interventions":31782},[91],[16,31381],[31748,31748,31749,31749,31750],{"nctId":31752,"briefTitle":31753,"status":108,"phases":31784,"primaryCompletion":1022,"completion":8693,"start":8215,"enrollment":31755,"conditions":31785,"interventions":31786},[91],[16,31381],[31733,31733,31733,31750],{"nctId":31759,"briefTitle":31760,"status":108,"phases":31788,"primaryCompletion":1022,"completion":978,"start":8215,"enrollment":31762,"conditions":31789,"interventions":31790},[91],[16,31381],[31733,31733,31750],{"trials":31792,"activeCount":102},[],{"trials":31794,"activeCount":102},[],{"trials":31796,"activeCount":102},[],{"intervention":4634,"totalTrials":659,"cells":31798},{"EARLY_PHASE1":31799,"PHASE1":31801,"PHASE2":31815,"PHASE3":31821,"PHASE4":31823,"NA":31825},{"trials":31800,"activeCount":102},[],{"trials":31802,"activeCount":102},[31803],{"nctId":31804,"briefTitle":31805,"status":884,"phases":31806,"primaryCompletion":31807,"completion":17906,"start":31808,"enrollment":538,"conditions":31809,"interventions":31811},"NCT05712278","A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed\u002FRefractory Acute Myeloid Leukemia",[90],"2024-02-23","2023-06-16",[31810],"Acute Myeloid Leukaemia",[31812,31813,31814],"SAR445419","fludarabine","cytarabine",{"trials":31816,"activeCount":102},[31817],{"nctId":4623,"briefTitle":4624,"status":884,"phases":31818,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":31819,"interventions":31820},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":31822,"activeCount":102},[],{"trials":31824,"activeCount":102},[],{"trials":31826,"activeCount":102},[],{"intervention":4635,"totalTrials":659,"cells":31828},{"EARLY_PHASE1":31829,"PHASE1":31831,"PHASE2":31837,"PHASE3":31843,"PHASE4":31845,"NA":31847},{"trials":31830,"activeCount":102},[],{"trials":31832,"activeCount":102},[31833],{"nctId":31804,"briefTitle":31805,"status":884,"phases":31834,"primaryCompletion":31807,"completion":17906,"start":31808,"enrollment":538,"conditions":31835,"interventions":31836},[90],[31810],[31812,31813,31814],{"trials":31838,"activeCount":102},[31839],{"nctId":4623,"briefTitle":4624,"status":884,"phases":31840,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":31841,"interventions":31842},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":31844,"activeCount":102},[],{"trials":31846,"activeCount":102},[],{"trials":31848,"activeCount":102},[],{"intervention":21338,"totalTrials":659,"cells":31850},{"EARLY_PHASE1":31851,"PHASE1":31853,"PHASE2":31855,"PHASE3":31868,"PHASE4":31870,"NA":31872},{"trials":31852,"activeCount":102},[],{"trials":31854,"activeCount":102},[],{"trials":31856,"activeCount":102},[31857,31861],{"nctId":21333,"briefTitle":21334,"status":108,"phases":31858,"primaryCompletion":1272,"completion":14370,"start":152,"enrollment":12981,"conditions":31859,"interventions":31860},[91],[14171],[21324,21338],{"nctId":31862,"briefTitle":31863,"status":108,"phases":31864,"primaryCompletion":7330,"completion":3429,"start":10005,"enrollment":294,"conditions":31865,"interventions":31866},"NCT01784874","Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use",[91],[14171],[31867,21338],"Purified Vero Rabies Vaccine (VRVg) - Serum Free",{"trials":31869,"activeCount":102},[],{"trials":31871,"activeCount":102},[],{"trials":31873,"activeCount":102},[],{"intervention":31875,"totalTrials":659,"cells":31876},"AVE1625",{"EARLY_PHASE1":31877,"PHASE1":31879,"PHASE2":31881,"PHASE3":31896,"PHASE4":31898,"NA":31900},{"trials":31878,"activeCount":102},[],{"trials":31880,"activeCount":102},[],{"trials":31882,"activeCount":102},[31883,31890],{"nctId":31884,"briefTitle":31885,"status":884,"phases":31886,"primaryCompletion":2799,"completion":2799,"start":9785,"enrollment":31887,"conditions":31888,"interventions":31889},"NCT00439634","Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia",[91],873,[11940],[31875],{"nctId":31891,"briefTitle":31892,"status":108,"phases":31893,"primaryCompletion":3563,"completion":3563,"start":3622,"enrollment":11625,"conditions":31894,"interventions":31895},"NCT00380302","Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.",[90,91],[19985],[31875],{"trials":31897,"activeCount":102},[],{"trials":31899,"activeCount":102},[],{"trials":31901,"activeCount":102},[],{"intervention":31903,"totalTrials":659,"cells":31904},"SAR97276A",{"EARLY_PHASE1":31905,"PHASE1":31907,"PHASE2":31909,"PHASE3":31924,"PHASE4":31926,"NA":31928},{"trials":31906,"activeCount":102},[],{"trials":31908,"activeCount":102},[],{"trials":31910,"activeCount":102},[31911,31917],{"nctId":31912,"briefTitle":31913,"status":884,"phases":31914,"primaryCompletion":3307,"completion":3307,"start":3417,"enrollment":6540,"conditions":31915,"interventions":31916},"NCT00739206","Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.",[91],[12262],[31903],{"nctId":31918,"briefTitle":31919,"status":884,"phases":31920,"primaryCompletion":3335,"completion":3335,"start":1340,"enrollment":576,"conditions":31921,"interventions":31922},"NCT01445938","Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria",[91],[12262],[31903,31923],"arthemeter + lumefantrine",{"trials":31925,"activeCount":102},[],{"trials":31927,"activeCount":102},[],{"trials":31929,"activeCount":102},[],{"intervention":31931,"totalTrials":659,"cells":31932},"A\u002FC\u002FY\u002FW-135, Meningococcal Polysaccharide Vaccine",{"EARLY_PHASE1":31933,"PHASE1":31935,"PHASE2":31937,"PHASE3":31952,"PHASE4":31954,"NA":31956},{"trials":31934,"activeCount":102},[],{"trials":31936,"activeCount":102},[],{"trials":31938,"activeCount":102},[31939,31945],{"nctId":31940,"briefTitle":31941,"status":108,"phases":31942,"primaryCompletion":8364,"completion":8526,"start":3326,"enrollment":9,"conditions":31943,"interventions":31944},"NCT00772070","Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine",[91],[4992,10856,2489],[31931,31931],{"nctId":31946,"briefTitle":31947,"status":108,"phases":31948,"primaryCompletion":5307,"completion":3317,"start":8184,"enrollment":259,"conditions":31949,"interventions":31950},"NCT00643916","Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age",[91],[4992,2949],[31951,31951,31951,31951,31951,31931],"Meningococcal Polysaccharide Diphtheria Protein Conjugate",{"trials":31953,"activeCount":102},[],{"trials":31955,"activeCount":102},[],{"trials":31957,"activeCount":102},[],{"intervention":31959,"totalTrials":659,"cells":31960},"SAR442168",{"EARLY_PHASE1":31961,"PHASE1":31963,"PHASE2":31972,"PHASE3":31983,"PHASE4":31985,"NA":31987},{"trials":31962,"activeCount":102},[],{"trials":31964,"activeCount":102},[31965],{"nctId":31966,"briefTitle":31967,"status":108,"phases":31968,"primaryCompletion":22106,"completion":22106,"start":31969,"enrollment":622,"conditions":31970,"interventions":31971},"NCT04171310","Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects",[90],"2019-11-13",[1788],[31959],{"trials":31973,"activeCount":102},[31974],{"nctId":31975,"briefTitle":31976,"status":108,"phases":31977,"primaryCompletion":31978,"completion":31978,"start":31979,"enrollment":31232,"conditions":31980,"interventions":31981},"NCT03889639","Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis",[91],"2020-01-02","2019-03-29",[3379],[31959,31982],"Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging",{"trials":31984,"activeCount":102},[],{"trials":31986,"activeCount":102},[],{"trials":31988,"activeCount":102},[],{"intervention":18962,"totalTrials":659,"cells":31990},{"EARLY_PHASE1":31991,"PHASE1":31993,"PHASE2":31995,"PHASE3":32005,"PHASE4":32007,"NA":32009},{"trials":31992,"activeCount":102},[],{"trials":31994,"activeCount":102},[],{"trials":31996,"activeCount":102},[31997,32001],{"nctId":18954,"briefTitle":18955,"status":884,"phases":31998,"primaryCompletion":322,"completion":18957,"start":18958,"enrollment":18959,"conditions":31999,"interventions":32000},[91],[18340],[18919,18962,18963,18964,18965,18966],{"nctId":31665,"briefTitle":31666,"status":884,"phases":32002,"primaryCompletion":987,"completion":987,"start":8846,"enrollment":284,"conditions":32003,"interventions":32004},[91],[5275],[22132,18962],{"trials":32006,"activeCount":102},[],{"trials":32008,"activeCount":102},[],{"trials":32010,"activeCount":102},[],{"intervention":31812,"totalTrials":659,"cells":32012},{"EARLY_PHASE1":32013,"PHASE1":32015,"PHASE2":32021,"PHASE3":32032,"PHASE4":32034,"NA":32036},{"trials":32014,"activeCount":102},[],{"trials":32016,"activeCount":102},[32017],{"nctId":31804,"briefTitle":31805,"status":884,"phases":32018,"primaryCompletion":31807,"completion":17906,"start":31808,"enrollment":538,"conditions":32019,"interventions":32020},[90],[31810],[31812,31813,31814],{"trials":32022,"activeCount":102},[32023],{"nctId":32024,"briefTitle":32025,"status":3661,"phases":32026,"primaryCompletion":32027,"completion":1705,"start":32028,"enrollment":102,"conditions":32029,"interventions":32031},"NCT05726682","A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[91],"2027-02-12","2024-10-08",[32030],"Allogenic Stem Cell Transplantation",[31812],{"trials":32033,"activeCount":102},[],{"trials":32035,"activeCount":102},[],{"trials":32037,"activeCount":102},[],{"intervention":32039,"totalTrials":659,"cells":32040},"SAR444656",{"EARLY_PHASE1":32041,"PHASE1":32043,"PHASE2":32045,"PHASE3":32063,"PHASE4":32065,"NA":32067},{"trials":32042,"activeCount":102},[],{"trials":32044,"activeCount":102},[],{"trials":32046,"activeCount":102},[32047,32055],{"nctId":32048,"briefTitle":32049,"status":884,"phases":32050,"primaryCompletion":4263,"completion":32051,"start":32052,"enrollment":1232,"conditions":32053,"interventions":32054},"NCT06028230","A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",[91],"2025-11-12","2023-09-29",[4591],[32039],{"nctId":32056,"briefTitle":32057,"status":884,"phases":32058,"primaryCompletion":2351,"completion":32059,"start":32060,"enrollment":1232,"conditions":32061,"interventions":32062},"NCT06058156","Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis",[91],"2025-11-20","2023-11-09",[206],[32039],{"trials":32064,"activeCount":102},[],{"trials":32066,"activeCount":102},[],{"trials":32068,"activeCount":102},[],{"intervention":32070,"totalTrials":659,"cells":32071},"A\u002FH5N1 Inactivated, Split Virion Pandemic Influenza Vaccine",{"EARLY_PHASE1":32072,"PHASE1":32074,"PHASE2":32076,"PHASE3":32093,"PHASE4":32095,"NA":32097},{"trials":32073,"activeCount":102},[],{"trials":32075,"activeCount":102},[],{"trials":32077,"activeCount":102},[32078,32084],{"nctId":32079,"briefTitle":32080,"status":108,"phases":32081,"primaryCompletion":1022,"completion":978,"start":3396,"enrollment":474,"conditions":32082,"interventions":32083},"NCT00884182","Safety and Immunogenicity of an Intramuscular A\u002FH5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children",[91],[16,15230,19243],[32070],{"nctId":32085,"briefTitle":32086,"status":108,"phases":32087,"primaryCompletion":8388,"completion":978,"start":10320,"enrollment":6655,"conditions":32088,"interventions":32090},"NCT00491985","Safety and Immunogenicity of 2 Formulations of an Intramuscular A\u002FH5N1 Pandemic Influenza Vaccine in Children",[91],[16,15230,32089],"Influenza A Virus Infection",[32091,32092,32092],"A\u002FH5N1 Inactivated, split-virion pandemic influenza vaccine","A\u002FH5N1 Inactivated, split virion pandemic influenza vaccine",{"trials":32094,"activeCount":102},[],{"trials":32096,"activeCount":102},[],{"trials":32098,"activeCount":102},[],{"intervention":32100,"totalTrials":659,"cells":32101},"SAR407899",{"EARLY_PHASE1":32102,"PHASE1":32104,"PHASE2":32106,"PHASE3":32128,"PHASE4":32130,"NA":32132},{"trials":32103,"activeCount":102},[],{"trials":32105,"activeCount":102},[],{"trials":32107,"activeCount":102},[32108,32121],{"nctId":32109,"briefTitle":32110,"status":884,"phases":32111,"primaryCompletion":32112,"completion":32112,"start":32113,"enrollment":552,"conditions":32114,"interventions":32116},"NCT03236311","A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and\u002For Persistent Stable Angina Despite Angiographically Successful PCI",[91],"2018-07-23","2017-10-12",[32115],"Microvascular Coronary Artery Disease",[32100,32117,32118,32119,32120],"Adenosine","Regadenoson","13N-ammonia","82Rubidium",{"nctId":32122,"briefTitle":32123,"status":108,"phases":32124,"primaryCompletion":2799,"completion":3354,"start":8261,"enrollment":9319,"conditions":32125,"interventions":32126},"NCT00914277","SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction",[91],[4421],[32100,32127],"Sildenafil",{"trials":32129,"activeCount":102},[],{"trials":32131,"activeCount":102},[],{"trials":32133,"activeCount":102},[],{"intervention":32135,"totalTrials":659,"cells":32136},"SAR339658",{"EARLY_PHASE1":32137,"PHASE1":32139,"PHASE2":32141,"PHASE3":32155,"PHASE4":32157,"NA":32159},{"trials":32138,"activeCount":102},[],{"trials":32140,"activeCount":102},[],{"trials":32142,"activeCount":102},[32143,32149],{"nctId":32144,"briefTitle":32145,"status":884,"phases":32146,"primaryCompletion":4969,"completion":965,"start":7349,"enrollment":9041,"conditions":32147,"interventions":32148},"NCT01659138","Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis",[91],[2103],[32135],{"nctId":32150,"briefTitle":32151,"status":884,"phases":32152,"primaryCompletion":1272,"completion":965,"start":7283,"enrollment":622,"conditions":32153,"interventions":32154},"NCT01861249","Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)",[91],[2103],[32135],{"trials":32156,"activeCount":102},[],{"trials":32158,"activeCount":102},[],{"trials":32160,"activeCount":102},[],{"intervention":32127,"totalTrials":659,"cells":32162},{"EARLY_PHASE1":32163,"PHASE1":32165,"PHASE2":32177,"PHASE3":32183,"PHASE4":32185,"NA":32187},{"trials":32164,"activeCount":102},[],{"trials":32166,"activeCount":102},[32167],{"nctId":32168,"briefTitle":32169,"status":108,"phases":32170,"primaryCompletion":32171,"completion":32171,"start":32172,"enrollment":349,"conditions":32173,"interventions":32174},"NCT03462017","Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus",[90],"2018-12-22","2018-03-07",[32115],[32175,32127,32176],"SAR247799","Acetylcholine",{"trials":32178,"activeCount":102},[32179],{"nctId":32122,"briefTitle":32123,"status":108,"phases":32180,"primaryCompletion":2799,"completion":3354,"start":8261,"enrollment":9319,"conditions":32181,"interventions":32182},[91],[4421],[32100,32127],{"trials":32184,"activeCount":102},[],{"trials":32186,"activeCount":102},[],{"trials":32188,"activeCount":102},[],{"intervention":31271,"totalTrials":659,"cells":32190},{"EARLY_PHASE1":32191,"PHASE1":32193,"PHASE2":32195,"PHASE3":32205,"PHASE4":32207,"NA":32209},{"trials":32192,"activeCount":102},[],{"trials":32194,"activeCount":102},[],{"trials":32196,"activeCount":102},[32197,32201],{"nctId":31263,"briefTitle":31264,"status":884,"phases":32198,"primaryCompletion":1581,"completion":2891,"start":31266,"enrollment":875,"conditions":32199,"interventions":32200},[91],[31268,31269],[31271,31242],{"nctId":19596,"briefTitle":19597,"status":884,"phases":32202,"primaryCompletion":19599,"completion":19600,"start":19601,"enrollment":8883,"conditions":32203,"interventions":32204},[91],[19603],[1195,19605,19606],{"trials":32206,"activeCount":102},[],{"trials":32208,"activeCount":102},[],{"trials":32210,"activeCount":102},[],{"intervention":32212,"totalTrials":659,"cells":32213},"SAR443579",{"EARLY_PHASE1":32214,"PHASE1":32216,"PHASE2":32218,"PHASE3":32241,"PHASE4":32243,"NA":32245},{"trials":32215,"activeCount":102},[],{"trials":32217,"activeCount":102},[],{"trials":32219,"activeCount":102},[32220,32232],{"nctId":32221,"briefTitle":32222,"status":884,"phases":32223,"primaryCompletion":32224,"completion":32224,"start":32225,"enrollment":32226,"conditions":32227,"interventions":32231},"NCT05086315","First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R\u002FR AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",[90,91],"2025-06-13","2021-12-08",101,[30948,32228,32229,32230],"Acute Myeloid Leukaemia Refractory","Myelodysplastic Syndromes","Blastic Plasmacytoid Dendritic Cell Neoplasia",[32212],{"nctId":32233,"briefTitle":32234,"status":884,"phases":32235,"primaryCompletion":32236,"completion":32236,"start":6753,"enrollment":538,"conditions":32237,"interventions":32238},"NCT06508489","A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies",[90,91],"2025-08-08",[4631],[32212,32239,32240],"venetoclax","azacitidine",{"trials":32242,"activeCount":102},[],{"trials":32244,"activeCount":102},[],{"trials":32246,"activeCount":102},[],{"intervention":2667,"totalTrials":659,"cells":32248},{"EARLY_PHASE1":32249,"PHASE1":32251,"PHASE2":32253,"PHASE3":32267,"PHASE4":32269,"NA":32271},{"trials":32250,"activeCount":102},[],{"trials":32252,"activeCount":102},[],{"trials":32254,"activeCount":102},[32255,32259],{"nctId":2658,"briefTitle":2659,"status":884,"phases":32256,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":2663,"conditions":32257,"interventions":32258},[90,91],[2665],[1162,2667],{"nctId":32260,"briefTitle":32261,"status":884,"phases":32262,"primaryCompletion":1220,"completion":1220,"start":32263,"enrollment":10753,"conditions":32264,"interventions":32265},"NCT05450562","Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors",[90,91],"2022-09-20",[2665],[32266,2667],"SAR444200",{"trials":32268,"activeCount":102},[],{"trials":32270,"activeCount":102},[],{"trials":32272,"activeCount":102},[],{"intervention":32274,"totalTrials":659,"cells":32275},"SAR442501",{"EARLY_PHASE1":32276,"PHASE1":32278,"PHASE2":32289,"PHASE3":32297,"PHASE4":32299,"NA":32301},{"trials":32277,"activeCount":102},[],{"trials":32279,"activeCount":102},[32280],{"nctId":32281,"briefTitle":32282,"status":108,"phases":32283,"primaryCompletion":32284,"completion":32284,"start":32285,"enrollment":5521,"conditions":32286,"interventions":32288},"NCT05846009","A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects",[90],"2022-01-12","2020-11-18",[32287],"Osteochondrodysplasia",[32274],{"trials":32290,"activeCount":102},[32291],{"nctId":32292,"briefTitle":32293,"status":884,"phases":32294,"primaryCompletion":1732,"completion":1732,"start":679,"enrollment":988,"conditions":32295,"interventions":32296},"NCT06067425","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia",[91],[32287],[32274],{"trials":32298,"activeCount":102},[],{"trials":32300,"activeCount":102},[],{"trials":32302,"activeCount":102},[],{"intervention":193,"totalTrials":659,"cells":32304},{"EARLY_PHASE1":32305,"PHASE1":32307,"PHASE2":32309,"PHASE3":32327,"PHASE4":32329,"NA":32331},{"trials":32306,"activeCount":102},[],{"trials":32308,"activeCount":102},[],{"trials":32310,"activeCount":102},[32311,32323],{"nctId":32312,"briefTitle":32313,"status":108,"phases":32314,"primaryCompletion":32315,"completion":32316,"start":10640,"enrollment":13343,"conditions":32317,"interventions":32318},"NCT03546907","Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",[91],"2019-10-03","2020-02-21",[382],[193,32319,32320,32321,32322],"Any Inhaled Corticosteroids as prescribed by treating physician as standard of care","Any Long Acting Beta Agonist as prescribed by treating physician as standard of care","Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care","Any short-acting β agonist as prescribed by treating physician as standard of care",{"nctId":184,"briefTitle":185,"status":108,"phases":32324,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":32325,"interventions":32326},[91],[155],[193,97,194],{"trials":32328,"activeCount":102},[],{"trials":32330,"activeCount":102},[],{"trials":32332,"activeCount":102},[],{"intervention":9159,"totalTrials":659,"cells":32334},{"EARLY_PHASE1":32335,"PHASE1":32337,"PHASE2":32339,"PHASE3":32352,"PHASE4":32354,"NA":32356},{"trials":32336,"activeCount":102},[],{"trials":32338,"activeCount":102},[],{"trials":32340,"activeCount":102},[32341,32348],{"nctId":32342,"briefTitle":32343,"status":108,"phases":32344,"primaryCompletion":2759,"completion":2759,"start":7283,"enrollment":6604,"conditions":32345,"interventions":32346},"NCT01882868","A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan",[91],[9210],[1347,32347,18130,9159],"Levofolinate",{"nctId":9151,"briefTitle":9152,"status":108,"phases":32349,"primaryCompletion":2790,"completion":3335,"start":8315,"enrollment":9154,"conditions":32350,"interventions":32351},[91],[5240,9156],[9158,5256,9159,9160],{"trials":32353,"activeCount":102},[],{"trials":32355,"activeCount":102},[],{"trials":32357,"activeCount":102},[],{"intervention":32359,"totalTrials":659,"cells":32360},"sargramostim GZ402664",{"EARLY_PHASE1":32361,"PHASE1":32363,"PHASE2":32365,"PHASE3":32384,"PHASE4":32386,"NA":32388},{"trials":32362,"activeCount":102},[],{"trials":32364,"activeCount":102},[],{"trials":32366,"activeCount":102},[32367,32374],{"nctId":32368,"briefTitle":32369,"status":3661,"phases":32370,"primaryCompletion":7638,"completion":7638,"start":15642,"enrollment":102,"conditions":32371,"interventions":32373},"NCT02520102","Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia",[91],[32372],"Acute Myeloid Leukemia NOS",[32359],{"nctId":32375,"briefTitle":32376,"status":3661,"phases":32377,"primaryCompletion":32378,"completion":32378,"start":1041,"enrollment":102,"conditions":32379,"interventions":32381},"NCT02667496","Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease",[91],"2017-03-31",[32380],"Dementia Alzheimer's Type",[32382,32383],"Sargramostim GZ402664","Florbetapir F18",{"trials":32385,"activeCount":102},[],{"trials":32387,"activeCount":102},[],{"trials":32389,"activeCount":102},[],{"intervention":19192,"totalTrials":659,"cells":32391},{"EARLY_PHASE1":32392,"PHASE1":32394,"PHASE2":32396,"PHASE3":32409,"PHASE4":32411,"NA":32413},{"trials":32393,"activeCount":102},[],{"trials":32395,"activeCount":102},[],{"trials":32397,"activeCount":102},[32398,32402],{"nctId":19187,"briefTitle":19188,"status":108,"phases":32399,"primaryCompletion":955,"completion":955,"start":8205,"enrollment":17607,"conditions":32400,"interventions":32401},[91],[18504],[19192,18686],{"nctId":32403,"briefTitle":32404,"status":884,"phases":32405,"primaryCompletion":8107,"completion":8107,"start":3335,"enrollment":339,"conditions":32406,"interventions":32408},"NCT01439919","A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain",[91],[12745,32407],"Breakthrough Cancer Pain",[19192],{"trials":32410,"activeCount":102},[],{"trials":32412,"activeCount":102},[],{"trials":32414,"activeCount":102},[],{"intervention":32416,"totalTrials":659,"cells":32417},"SAR566658",{"EARLY_PHASE1":32418,"PHASE1":32420,"PHASE2":32431,"PHASE3":32442,"PHASE4":32444,"NA":32446},{"trials":32419,"activeCount":102},[],{"trials":32421,"activeCount":102},[32422],{"nctId":32423,"briefTitle":32424,"status":108,"phases":32425,"primaryCompletion":32426,"completion":32426,"start":32427,"enrollment":32428,"conditions":32429,"interventions":32430},"NCT01156870","First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor",[90],"2017-04-07","2010-09-08",114,[1193],[32416],{"trials":32432,"activeCount":102},[32433],{"nctId":32434,"briefTitle":32435,"status":884,"phases":32436,"primaryCompletion":32437,"completion":32437,"start":32438,"enrollment":1400,"conditions":32439,"interventions":32441},"NCT02984683","Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer",[91],"2018-09-07","2017-03-23",[32440],"Triple Negative Breast Cancer",[32416],{"trials":32443,"activeCount":102},[],{"trials":32445,"activeCount":102},[],{"trials":32447,"activeCount":102},[],{"intervention":32449,"totalTrials":659,"cells":32450},"rC19",{"EARLY_PHASE1":32451,"PHASE1":32453,"PHASE2":32455,"PHASE3":32476,"PHASE4":32478,"NA":32480},{"trials":32452,"activeCount":102},[],{"trials":32454,"activeCount":102},[],{"trials":32456,"activeCount":102},[32457,32466],{"nctId":32458,"briefTitle":32459,"status":108,"phases":32460,"primaryCompletion":4261,"completion":4261,"start":19589,"enrollment":2101,"conditions":32461,"interventions":32463},"NCT06695117","Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older",[90,91],[32462,5335],"COVID-19 Immunization",[32464,32449,32465,32465,32465,32465],"IIV-HD","IIV-HD + rC19",{"nctId":32467,"briefTitle":32468,"status":108,"phases":32469,"primaryCompletion":32470,"completion":32470,"start":32471,"enrollment":2101,"conditions":32472,"interventions":32473},"NCT06695130","Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older",[90,91],"2026-04-03","2024-11-18",[32462,5335],[32474,32449,32475,32475,32475,32475],"RIV","RIV + rC19",{"trials":32477,"activeCount":102},[],{"trials":32479,"activeCount":102},[],{"trials":32481,"activeCount":102},[],{"intervention":32483,"totalTrials":659,"cells":32484},"Inactivated, split-virion influenza virus",{"EARLY_PHASE1":32485,"PHASE1":32487,"PHASE2":32489,"PHASE3":32504,"PHASE4":32506,"NA":32508},{"trials":32486,"activeCount":102},[],{"trials":32488,"activeCount":102},[],{"trials":32490,"activeCount":102},[32491,32497],{"nctId":32492,"briefTitle":32493,"status":108,"phases":32494,"primaryCompletion":3439,"completion":8156,"start":8607,"enrollment":6604,"conditions":32495,"interventions":32496},"NCT00606359","Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects",[91],[16,15230],[32483,32483],{"nctId":32498,"briefTitle":32499,"status":108,"phases":32500,"primaryCompletion":1341,"completion":7509,"start":9190,"enrollment":1583,"conditions":32501,"interventions":32502},"NCT00524940","Trial to Describe the Safety and Immunogenicity of Fluzone®",[91],[16],[32503],"Inactivated, Split-Virion Influenza Virus",{"trials":32505,"activeCount":102},[],{"trials":32507,"activeCount":102},[],{"trials":32509,"activeCount":102},[],{"intervention":32511,"totalTrials":659,"cells":32512},"SAR441344",{"EARLY_PHASE1":32513,"PHASE1":32515,"PHASE2":32526,"PHASE3":32538,"PHASE4":32540,"NA":32542},{"trials":32514,"activeCount":102},[],{"trials":32516,"activeCount":102},[32517],{"nctId":32518,"briefTitle":32519,"status":108,"phases":32520,"primaryCompletion":32521,"completion":32521,"start":32522,"enrollment":1145,"conditions":32523,"interventions":32524},"NCT05845996","Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects",[90],"2020-04-10","2018-11-08",[36],[32511,32525],"Keyhole limpet hemocyanin",{"trials":32527,"activeCount":102},[32528],{"nctId":32529,"briefTitle":32530,"status":108,"phases":32531,"primaryCompletion":1539,"completion":32532,"start":32533,"enrollment":1079,"conditions":32534,"interventions":32537},"NCT04572841","Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)",[91],"2024-02-09","2020-11-12",[32535,32536],"Sjögren's Syndrome","Sjogren's Syndrome",[32511],{"trials":32539,"activeCount":102},[],{"trials":32541,"activeCount":102},[],{"trials":32543,"activeCount":102},[],{"intervention":9125,"totalTrials":659,"cells":32545},{"EARLY_PHASE1":32546,"PHASE1":32548,"PHASE2":32550,"PHASE3":32560,"PHASE4":32562,"NA":32564},{"trials":32547,"activeCount":102},[],{"trials":32549,"activeCount":102},[],{"trials":32551,"activeCount":102},[32552,32556],{"nctId":9118,"briefTitle":9119,"status":884,"phases":32553,"primaryCompletion":8364,"start":7483,"enrollment":6445,"conditions":32554,"interventions":32555},[91],[9122],[5286,9124,9125],{"nctId":9151,"briefTitle":9152,"status":108,"phases":32557,"primaryCompletion":2790,"completion":3335,"start":8315,"enrollment":9154,"conditions":32558,"interventions":32559},[91],[5240,9156],[9158,5256,9159,9160],{"trials":32561,"activeCount":102},[],{"trials":32563,"activeCount":102},[],{"trials":32565,"activeCount":102},[],{"intervention":31494,"totalTrials":659,"cells":32567},{"EARLY_PHASE1":32568,"PHASE1":32570,"PHASE2":32572,"PHASE3":32586,"PHASE4":32588,"NA":32590},{"trials":32569,"activeCount":102},[],{"trials":32571,"activeCount":102},[],{"trials":32573,"activeCount":102},[32574,32578],{"nctId":31488,"briefTitle":31489,"status":108,"phases":32575,"primaryCompletion":18237,"completion":18237,"start":31491,"enrollment":3121,"conditions":32576,"interventions":32577},[91],[12592],[31494,12594],{"nctId":32579,"briefTitle":32580,"status":884,"phases":32581,"primaryCompletion":3766,"completion":3766,"start":32582,"enrollment":8272,"conditions":32583,"interventions":32584},"NCT02497612","To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria",[91],"2015-07-25",[12592],[32585,31494],"Ferroquine SSR97193",{"trials":32587,"activeCount":102},[],{"trials":32589,"activeCount":102},[],{"trials":32591,"activeCount":102},[],{"intervention":32593,"totalTrials":659,"cells":32594},"MVA Smallpox vaccine",{"EARLY_PHASE1":32595,"PHASE1":32597,"PHASE2":32608,"PHASE3":32617,"PHASE4":32619,"NA":32621},{"trials":32596,"activeCount":102},[],{"trials":32598,"activeCount":102},[32599],{"nctId":32600,"briefTitle":32601,"status":884,"phases":32602,"primaryCompletion":3563,"completion":3563,"start":3430,"enrollment":659,"conditions":32603,"interventions":32606},"NCT00282581","Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive",[90],[32604,32605],"HIV Infections","Smallpox",[32607],"MVA Smallpox Vaccine",{"trials":32609,"activeCount":102},[32610],{"nctId":32611,"briefTitle":32612,"status":108,"phases":32613,"primaryCompletion":8395,"completion":8395,"start":9706,"enrollment":32614,"conditions":32615,"interventions":32616},"NCT00466245","Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine",[91],590,[32605],[32593],{"trials":32618,"activeCount":102},[],{"trials":32620,"activeCount":102},[],{"trials":32622,"activeCount":102},[],{"intervention":32624,"totalTrials":659,"cells":32625},"AVE0657",{"EARLY_PHASE1":32626,"PHASE1":32628,"PHASE2":32630,"PHASE3":32648,"PHASE4":32650,"NA":32652},{"trials":32627,"activeCount":102},[],{"trials":32629,"activeCount":102},[],{"trials":32631,"activeCount":102},[32632,32641],{"nctId":32633,"briefTitle":32634,"status":884,"phases":32635,"primaryCompletion":8349,"completion":8349,"start":8156,"enrollment":535,"conditions":32636,"interventions":32640},"NCT00694720","Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients",[91],[32637,32638,32639],"Heart Failure","Sleep Apnea Syndromes","Cheyne-Stokes Respiration",[32624],{"nctId":32642,"briefTitle":32643,"status":108,"phases":32644,"primaryCompletion":9532,"completion":9532,"start":8762,"enrollment":112,"conditions":32645,"interventions":32647},"NCT00614250","Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea",[91],[32646],"Sleep Apnea, Obstructive",[32624],{"trials":32649,"activeCount":102},[],{"trials":32651,"activeCount":102},[],{"trials":32653,"activeCount":102},[],{"intervention":12554,"totalTrials":659,"cells":32655},{"EARLY_PHASE1":32656,"PHASE1":32658,"PHASE2":32660,"PHASE3":32676,"PHASE4":32678,"NA":32680},{"trials":32657,"activeCount":102},[],{"trials":32659,"activeCount":102},[],{"trials":32661,"activeCount":102},[32662,32666],{"nctId":12549,"briefTitle":12550,"status":108,"phases":32663,"primaryCompletion":165,"completion":2790,"start":987,"enrollment":1091,"conditions":32664,"interventions":32665},[91],[16],[12554,12540],{"nctId":32667,"briefTitle":32668,"status":108,"phases":32669,"primaryCompletion":32670,"completion":32670,"start":2824,"enrollment":2314,"conditions":32671,"interventions":32672},"NCT02553343","A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older",[91],"2016-04-04",[16],[32673,32674,32675,32675],"High-dose quadrivalent influenza virus vaccine","High-dose influenza virus vaccine","High-dose trivalent inactivated influenza vaccine",{"trials":32677,"activeCount":102},[],{"trials":32679,"activeCount":102},[],{"trials":32681,"activeCount":102},[],{"intervention":32683,"totalTrials":659,"cells":32684},"Nerispirdine",{"EARLY_PHASE1":32685,"PHASE1":32687,"PHASE2":32689,"PHASE3":32705,"PHASE4":32707,"NA":32709},{"trials":32686,"activeCount":102},[],{"trials":32688,"activeCount":102},[],{"trials":32690,"activeCount":102},[32691,32699],{"nctId":32692,"briefTitle":32693,"status":108,"phases":32694,"primaryCompletion":3307,"completion":3307,"start":3564,"enrollment":8883,"conditions":32695,"interventions":32698},"NCT00772525","Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis",[91],[1788,32696,32697],"Optic Nerve","Neuritis",[32683],{"nctId":32700,"briefTitle":32701,"status":108,"phases":32702,"primaryCompletion":1022,"completion":1022,"start":8205,"enrollment":14169,"conditions":32703,"interventions":32704},"NCT00811902","Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis",[91],[1788],[32683],{"trials":32706,"activeCount":102},[],{"trials":32708,"activeCount":102},[],{"trials":32710,"activeCount":102},[],{"intervention":32712,"totalTrials":659,"cells":32713},"ataciguat",{"EARLY_PHASE1":32714,"PHASE1":32716,"PHASE2":32718,"PHASE3":32735,"PHASE4":32737,"NA":32739},{"trials":32715,"activeCount":102},[],{"trials":32717,"activeCount":102},[],{"trials":32719,"activeCount":102},[32720,32729],{"nctId":32721,"briefTitle":32722,"status":108,"phases":32723,"primaryCompletion":8846,"completion":8846,"start":9785,"enrollment":32724,"conditions":32725,"interventions":32727},"NCT00443287","Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease",[91],553,[32726],"Intermittent Claudication",[32712,32728],"cilostazol",{"nctId":32730,"briefTitle":32731,"status":108,"phases":32732,"primaryCompletion":3307,"completion":2799,"start":8235,"enrollment":6604,"conditions":32733,"interventions":32734},"NCT00799656","Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain",[91],[12745],[32712],{"trials":32736,"activeCount":102},[],{"trials":32738,"activeCount":102},[],{"trials":32740,"activeCount":102},[],{"intervention":32742,"totalTrials":659,"cells":32743},"Donepezil",{"EARLY_PHASE1":32744,"PHASE1":32746,"PHASE2":32748,"PHASE3":32767,"PHASE4":32769,"NA":32771},{"trials":32745,"activeCount":102},[],{"trials":32747,"activeCount":102},[],{"trials":32749,"activeCount":102},[32750,32758],{"nctId":32751,"briefTitle":32752,"status":108,"phases":32753,"primaryCompletion":8298,"completion":8298,"start":3821,"enrollment":32754,"conditions":32755,"interventions":32756},"NCT01266525","Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil",[91],291,[32380],[32757,32742],"SAR110894",{"nctId":32759,"briefTitle":32760,"status":884,"phases":32761,"primaryCompletion":8196,"completion":8196,"start":8762,"enrollment":195,"conditions":32762,"interventions":32764},"NCT00602680","Effect on Cognitive Performance and Safety\u002FTolerability of SSR180711C in Mild Alzheimer's Disease",[91],[32763],"Alzheimer's Disease",[32765,32766],"SSR180711C","donepezil",{"trials":32768,"activeCount":102},[],{"trials":32770,"activeCount":102},[],{"trials":32772,"activeCount":102},[],{"intervention":31587,"totalTrials":659,"cells":32774},{"EARLY_PHASE1":32775,"PHASE1":32777,"PHASE2":32779,"PHASE3":32789,"PHASE4":32791,"NA":32793},{"trials":32776,"activeCount":102},[],{"trials":32778,"activeCount":102},[],{"trials":32780,"activeCount":102},[32781,32785],{"nctId":31582,"briefTitle":31583,"status":108,"phases":32782,"primaryCompletion":8406,"completion":2834,"start":8315,"enrollment":10746,"conditions":32783,"interventions":32784},[91],[26251,21801],[31587,31566,31588,31566],{"nctId":31590,"briefTitle":31591,"status":108,"phases":32786,"primaryCompletion":966,"completion":4969,"start":7283,"enrollment":1001,"conditions":32787,"interventions":32788},[90,91],[21801],[31595,31596],{"trials":32790,"activeCount":102},[],{"trials":32792,"activeCount":102},[],{"trials":32794,"activeCount":102},[],{"intervention":972,"totalTrials":659,"cells":32796},{"EARLY_PHASE1":32797,"PHASE1":32799,"PHASE2":32801,"PHASE3":32811,"PHASE4":32813,"NA":32815},{"trials":32798,"activeCount":102},[],{"trials":32800,"activeCount":102},[],{"trials":32802,"activeCount":102},[32803,32807],{"nctId":961,"briefTitle":962,"status":108,"phases":32804,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":32805,"interventions":32806},[91],[969],[942,671,971,972],{"nctId":983,"briefTitle":984,"status":884,"phases":32808,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":32809,"interventions":32810},[91],[990],[942,992,993,972],{"trials":32812,"activeCount":102},[],{"trials":32814,"activeCount":102},[],{"trials":32816,"activeCount":102},[],{"intervention":32818,"totalTrials":659,"cells":32819},"A\u002FH5N1 inactivated, split-virion influenza virus",{"EARLY_PHASE1":32820,"PHASE1":32822,"PHASE2":32824,"PHASE3":32838,"PHASE4":32840,"NA":32842},{"trials":32821,"activeCount":102},[],{"trials":32823,"activeCount":102},[],{"trials":32825,"activeCount":102},[32826,32832],{"nctId":32827,"briefTitle":32828,"status":108,"phases":32829,"primaryCompletion":8205,"completion":8349,"start":8395,"enrollment":16359,"conditions":32830,"interventions":32831},"NCT00415129","Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly",[91],[16,15230],[32818,32818],{"nctId":32833,"briefTitle":32834,"status":108,"phases":32835,"primaryCompletion":8156,"completion":3564,"start":3317,"enrollment":465,"conditions":32836,"interventions":32837},"NCT00545701","Immunogenicity and Safety of an Intramuscular A\u002FH5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults",[91],[16,15230],[32818],{"trials":32839,"activeCount":102},[],{"trials":32841,"activeCount":102},[],{"trials":32843,"activeCount":102},[],{"intervention":5424,"totalTrials":659,"cells":32845},{"EARLY_PHASE1":32846,"PHASE1":32848,"PHASE2":32850,"PHASE3":32860,"PHASE4":32862,"NA":32864},{"trials":32847,"activeCount":102},[],{"trials":32849,"activeCount":102},[],{"trials":32851,"activeCount":102},[32852,32856],{"nctId":17903,"briefTitle":17904,"status":884,"phases":32853,"primaryCompletion":17906,"completion":17907,"start":17908,"enrollment":1182,"conditions":32854,"interventions":32855},[91],[17910],[1195,5400,1276,5277,5424],{"nctId":5416,"briefTitle":5417,"status":884,"phases":32857,"primaryCompletion":4734,"completion":4734,"start":5419,"enrollment":3767,"conditions":32858,"interventions":32859},[90,91],[5421,2665],[5423,5400,5298,5277,5424],{"trials":32861,"activeCount":102},[],{"trials":32863,"activeCount":102},[],{"trials":32865,"activeCount":102},[],{"intervention":32867,"totalTrials":659,"cells":32868},"SSR240600C",{"EARLY_PHASE1":32869,"PHASE1":32871,"PHASE2":32873,"PHASE3":32890,"PHASE4":32892,"NA":32894},{"trials":32870,"activeCount":102},[],{"trials":32872,"activeCount":102},[],{"trials":32874,"activeCount":102},[32875,32883],{"nctId":32876,"briefTitle":32877,"status":108,"phases":32878,"primaryCompletion":8753,"completion":8753,"start":9862,"enrollment":1223,"conditions":32879,"interventions":32881},"NCT00174798","MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.",[91],[32880],"Overactive Bladder",[32867,32882],"Tolterodine",{"nctId":32884,"briefTitle":32885,"status":108,"phases":32886,"primaryCompletion":8315,"completion":8315,"start":8607,"enrollment":8592,"conditions":32887,"interventions":32888},"NCT00564226","SSR240600C Treatment in Women With Overactive Bladder",[91],[32880],[32867,32889],"tolterodine",{"trials":32891,"activeCount":102},[],{"trials":32893,"activeCount":102},[],{"trials":32895,"activeCount":102},[],{"intervention":32882,"totalTrials":659,"cells":32897},{"EARLY_PHASE1":32898,"PHASE1":32900,"PHASE2":32902,"PHASE3":32912,"PHASE4":32914,"NA":32916},{"trials":32899,"activeCount":102},[],{"trials":32901,"activeCount":102},[],{"trials":32903,"activeCount":102},[32904,32908],{"nctId":32876,"briefTitle":32877,"status":108,"phases":32905,"primaryCompletion":8753,"completion":8753,"start":9862,"enrollment":1223,"conditions":32906,"interventions":32907},[91],[32880],[32867,32882],{"nctId":32884,"briefTitle":32885,"status":108,"phases":32909,"primaryCompletion":8315,"completion":8315,"start":8607,"enrollment":8592,"conditions":32910,"interventions":32911},[91],[32880],[32867,32889],{"trials":32913,"activeCount":102},[],{"trials":32915,"activeCount":102},[],{"trials":32917,"activeCount":102},[],{"intervention":4633,"totalTrials":195,"cells":32919},{"EARLY_PHASE1":32920,"PHASE1":32922,"PHASE2":32924,"PHASE3":32930,"PHASE4":32932,"NA":32934},{"trials":32921,"activeCount":102},[],{"trials":32923,"activeCount":102},[],{"trials":32925,"activeCount":102},[32926],{"nctId":4623,"briefTitle":4624,"status":884,"phases":32927,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":32928,"interventions":32929},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":32931,"activeCount":102},[],{"trials":32933,"activeCount":102},[],{"trials":32935,"activeCount":102},[],{"intervention":4636,"totalTrials":195,"cells":32937},{"EARLY_PHASE1":32938,"PHASE1":32940,"PHASE2":32942,"PHASE3":32948,"PHASE4":32950,"NA":32952},{"trials":32939,"activeCount":102},[],{"trials":32941,"activeCount":102},[],{"trials":32943,"activeCount":102},[32944],{"nctId":4623,"briefTitle":4624,"status":884,"phases":32945,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":32946,"interventions":32947},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":32949,"activeCount":102},[],{"trials":32951,"activeCount":102},[],{"trials":32953,"activeCount":102},[],{"intervention":4637,"totalTrials":195,"cells":32955},{"EARLY_PHASE1":32956,"PHASE1":32958,"PHASE2":32960,"PHASE3":32966,"PHASE4":32968,"NA":32970},{"trials":32957,"activeCount":102},[],{"trials":32959,"activeCount":102},[],{"trials":32961,"activeCount":102},[32962],{"nctId":4623,"briefTitle":4624,"status":884,"phases":32963,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":32964,"interventions":32965},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":32967,"activeCount":102},[],{"trials":32969,"activeCount":102},[],{"trials":32971,"activeCount":102},[],{"intervention":4638,"totalTrials":195,"cells":32973},{"EARLY_PHASE1":32974,"PHASE1":32976,"PHASE2":32978,"PHASE3":32984,"PHASE4":32986,"NA":32988},{"trials":32975,"activeCount":102},[],{"trials":32977,"activeCount":102},[],{"trials":32979,"activeCount":102},[32980],{"nctId":4623,"briefTitle":4624,"status":884,"phases":32981,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":32982,"interventions":32983},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":32985,"activeCount":102},[],{"trials":32987,"activeCount":102},[],{"trials":32989,"activeCount":102},[],{"intervention":4639,"totalTrials":195,"cells":32991},{"EARLY_PHASE1":32992,"PHASE1":32994,"PHASE2":32996,"PHASE3":33002,"PHASE4":33004,"NA":33006},{"trials":32993,"activeCount":102},[],{"trials":32995,"activeCount":102},[],{"trials":32997,"activeCount":102},[32998],{"nctId":4623,"briefTitle":4624,"status":884,"phases":32999,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33000,"interventions":33001},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33003,"activeCount":102},[],{"trials":33005,"activeCount":102},[],{"trials":33007,"activeCount":102},[],{"intervention":4641,"totalTrials":195,"cells":33009},{"EARLY_PHASE1":33010,"PHASE1":33012,"PHASE2":33014,"PHASE3":33020,"PHASE4":33022,"NA":33024},{"trials":33011,"activeCount":102},[],{"trials":33013,"activeCount":102},[],{"trials":33015,"activeCount":102},[33016],{"nctId":4623,"briefTitle":4624,"status":884,"phases":33017,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33018,"interventions":33019},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33021,"activeCount":102},[],{"trials":33023,"activeCount":102},[],{"trials":33025,"activeCount":102},[],{"intervention":4642,"totalTrials":195,"cells":33027},{"EARLY_PHASE1":33028,"PHASE1":33030,"PHASE2":33032,"PHASE3":33038,"PHASE4":33040,"NA":33042},{"trials":33029,"activeCount":102},[],{"trials":33031,"activeCount":102},[],{"trials":33033,"activeCount":102},[33034],{"nctId":4623,"briefTitle":4624,"status":884,"phases":33035,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33036,"interventions":33037},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33039,"activeCount":102},[],{"trials":33041,"activeCount":102},[],{"trials":33043,"activeCount":102},[],{"intervention":4644,"totalTrials":195,"cells":33045},{"EARLY_PHASE1":33046,"PHASE1":33048,"PHASE2":33050,"PHASE3":33056,"PHASE4":33058,"NA":33060},{"trials":33047,"activeCount":102},[],{"trials":33049,"activeCount":102},[],{"trials":33051,"activeCount":102},[33052],{"nctId":4623,"briefTitle":4624,"status":884,"phases":33053,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33054,"interventions":33055},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33057,"activeCount":102},[],{"trials":33059,"activeCount":102},[],{"trials":33061,"activeCount":102},[],{"intervention":4645,"totalTrials":195,"cells":33063},{"EARLY_PHASE1":33064,"PHASE1":33066,"PHASE2":33068,"PHASE3":33074,"PHASE4":33076,"NA":33078},{"trials":33065,"activeCount":102},[],{"trials":33067,"activeCount":102},[],{"trials":33069,"activeCount":102},[33070],{"nctId":4623,"briefTitle":4624,"status":884,"phases":33071,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33072,"interventions":33073},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33075,"activeCount":102},[],{"trials":33077,"activeCount":102},[],{"trials":33079,"activeCount":102},[],{"intervention":4646,"totalTrials":195,"cells":33081},{"EARLY_PHASE1":33082,"PHASE1":33084,"PHASE2":33086,"PHASE3":33092,"PHASE4":33094,"NA":33096},{"trials":33083,"activeCount":102},[],{"trials":33085,"activeCount":102},[],{"trials":33087,"activeCount":102},[33088],{"nctId":4623,"briefTitle":4624,"status":884,"phases":33089,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33090,"interventions":33091},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33093,"activeCount":102},[],{"trials":33095,"activeCount":102},[],{"trials":33097,"activeCount":102},[],{"intervention":4647,"totalTrials":195,"cells":33099},{"EARLY_PHASE1":33100,"PHASE1":33102,"PHASE2":33104,"PHASE3":33110,"PHASE4":33112,"NA":33114},{"trials":33101,"activeCount":102},[],{"trials":33103,"activeCount":102},[],{"trials":33105,"activeCount":102},[33106],{"nctId":4623,"briefTitle":4624,"status":884,"phases":33107,"primaryCompletion":4626,"completion":4627,"start":1144,"enrollment":4628,"conditions":33108,"interventions":33109},[91],[4630,4631],[641,4633,4634,4635,4636,4637,4638,4639,2838,4640,4641,4642,4643,4644,971,4645,4646,4647],{"trials":33111,"activeCount":102},[],{"trials":33113,"activeCount":102},[],{"trials":33115,"activeCount":102},[],{"intervention":33117,"totalTrials":195,"cells":33118},"RSV\u002FhMPV vaccine candidate Dose L",{"EARLY_PHASE1":33119,"PHASE1":33121,"PHASE2":33123,"PHASE3":33136,"PHASE4":33138,"NA":33140},{"trials":33120,"activeCount":102},[],{"trials":33122,"activeCount":102},[],{"trials":33124,"activeCount":102},[33125],{"nctId":33126,"briefTitle":33127,"status":108,"phases":33128,"primaryCompletion":33129,"completion":33129,"start":1330,"enrollment":33130,"conditions":33131,"interventions":33133},"NCT06134648","Study of a Respiratory Syncytial Virus\u002FHuman Metapneumovirus Vaccine Candidate",[90,91],"2026-02-27",646,[20474,36,33132],"Human Metapneumovirus",[33117,33134,33135],"RSV\u002FhMPV vaccine candidate Dose A","RSV\u002FhMPV vaccine candidate Dose B",{"trials":33137,"activeCount":102},[],{"trials":33139,"activeCount":102},[],{"trials":33141,"activeCount":102},[],{"intervention":33134,"totalTrials":195,"cells":33143},{"EARLY_PHASE1":33144,"PHASE1":33146,"PHASE2":33148,"PHASE3":33154,"PHASE4":33156,"NA":33158},{"trials":33145,"activeCount":102},[],{"trials":33147,"activeCount":102},[],{"trials":33149,"activeCount":102},[33150],{"nctId":33126,"briefTitle":33127,"status":108,"phases":33151,"primaryCompletion":33129,"completion":33129,"start":1330,"enrollment":33130,"conditions":33152,"interventions":33153},[90,91],[20474,36,33132],[33117,33134,33135],{"trials":33155,"activeCount":102},[],{"trials":33157,"activeCount":102},[],{"trials":33159,"activeCount":102},[],{"intervention":33135,"totalTrials":195,"cells":33161},{"EARLY_PHASE1":33162,"PHASE1":33164,"PHASE2":33166,"PHASE3":33172,"PHASE4":33174,"NA":33176},{"trials":33163,"activeCount":102},[],{"trials":33165,"activeCount":102},[],{"trials":33167,"activeCount":102},[33168],{"nctId":33126,"briefTitle":33127,"status":108,"phases":33169,"primaryCompletion":33129,"completion":33129,"start":1330,"enrollment":33130,"conditions":33170,"interventions":33171},[90,91],[20474,36,33132],[33117,33134,33135],{"trials":33173,"activeCount":102},[],{"trials":33175,"activeCount":102},[],{"trials":33177,"activeCount":102},[],{"intervention":18627,"totalTrials":195,"cells":33179},{"EARLY_PHASE1":33180,"PHASE1":33182,"PHASE2":33184,"PHASE3":33190,"PHASE4":33192,"NA":33194},{"trials":33181,"activeCount":102},[],{"trials":33183,"activeCount":102},[],{"trials":33185,"activeCount":102},[33186],{"nctId":18619,"briefTitle":18620,"status":108,"phases":33187,"primaryCompletion":11555,"completion":11555,"start":18622,"enrollment":18623,"conditions":33188,"interventions":33189},[91],[28,31,25,12983,18625],[18627,2937],{"trials":33191,"activeCount":102},[],{"trials":33193,"activeCount":102},[],{"trials":33195,"activeCount":102},[],{"intervention":33197,"totalTrials":195,"cells":33198},"SAR279356",{"EARLY_PHASE1":33199,"PHASE1":33201,"PHASE2":33203,"PHASE3":33212,"PHASE4":33214,"NA":33216},{"trials":33200,"activeCount":102},[],{"trials":33202,"activeCount":102},[],{"trials":33204,"activeCount":102},[33205],{"nctId":33206,"briefTitle":33207,"status":884,"phases":33208,"primaryCompletion":3438,"completion":3438,"start":1340,"enrollment":538,"conditions":33209,"interventions":33211},"NCT01389700","Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients",[91],[33210],"Infection Prophylaxis",[33197],{"trials":33213,"activeCount":102},[],{"trials":33215,"activeCount":102},[],{"trials":33217,"activeCount":102},[],{"intervention":33219,"totalTrials":195,"cells":33220},"SSR149744C",{"EARLY_PHASE1":33221,"PHASE1":33223,"PHASE2":33225,"PHASE3":33236,"PHASE4":33238,"NA":33240},{"trials":33222,"activeCount":102},[],{"trials":33224,"activeCount":102},[],{"trials":33226,"activeCount":102},[33227],{"nctId":33228,"briefTitle":33229,"status":108,"phases":33230,"primaryCompletion":9785,"completion":9785,"start":5250,"enrollment":3859,"conditions":33231,"interventions":33235},"NCT00232297","Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS",[91],[33232,33233,33234],"Arrhythmia","Tachycardia, Ventricular","Ventricular Fibrillation",[33219],{"trials":33237,"activeCount":102},[],{"trials":33239,"activeCount":102},[],{"trials":33241,"activeCount":102},[],{"intervention":18215,"totalTrials":195,"cells":33243},{"EARLY_PHASE1":33244,"PHASE1":33246,"PHASE2":33248,"PHASE3":33254,"PHASE4":33256,"NA":33258},{"trials":33245,"activeCount":102},[],{"trials":33247,"activeCount":102},[],{"trials":33249,"activeCount":102},[33250],{"nctId":18203,"briefTitle":18204,"status":108,"phases":33251,"primaryCompletion":5216,"completion":18206,"start":18207,"enrollment":18208,"conditions":33252,"interventions":33253},[91],[18210,2317,18211,18212],[18214,18215],{"trials":33255,"activeCount":102},[],{"trials":33257,"activeCount":102},[],{"trials":33259,"activeCount":102},[],{"intervention":33261,"totalTrials":195,"cells":33262},"oxaliplatine \u002F gemcitabine \u002F Vinorelbine",{"EARLY_PHASE1":33263,"PHASE1":33265,"PHASE2":33267,"PHASE3":33276,"PHASE4":33278,"NA":33280},{"trials":33264,"activeCount":102},[],{"trials":33266,"activeCount":102},[],{"trials":33268,"activeCount":102},[33269],{"nctId":33270,"briefTitle":33271,"status":108,"phases":33272,"completion":3430,"start":9592,"enrollment":98,"conditions":33273,"interventions":33275},"NCT00271271","Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients",[91],[33274],"Non Small Cell Lung Cancer",[33261],{"trials":33277,"activeCount":102},[],{"trials":33279,"activeCount":102},[],{"trials":33281,"activeCount":102},[],{"intervention":33283,"totalTrials":195,"cells":33284},"Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC",{"EARLY_PHASE1":33285,"PHASE1":33287,"PHASE2":33289,"PHASE3":33297,"PHASE4":33299,"NA":33301},{"trials":33286,"activeCount":102},[],{"trials":33288,"activeCount":102},[],{"trials":33290,"activeCount":102},[33291],{"nctId":33292,"briefTitle":33293,"status":108,"phases":33294,"primaryCompletion":8315,"completion":8349,"start":5262,"enrollment":12633,"conditions":33295,"interventions":33296},"NCT00362427","Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®",[91],[25,28,13810,18625,31],[33283,33283,33283],{"trials":33298,"activeCount":102},[],{"trials":33300,"activeCount":102},[],{"trials":33302,"activeCount":102},[],{"intervention":33304,"totalTrials":195,"cells":33305},"AVE2635A",{"EARLY_PHASE1":33306,"PHASE1":33308,"PHASE2":33310,"PHASE3":33319,"PHASE4":33321,"NA":33323},{"trials":33307,"activeCount":102},[],{"trials":33309,"activeCount":102},[],{"trials":33311,"activeCount":102},[33312],{"nctId":33313,"briefTitle":33314,"status":108,"phases":33315,"primaryCompletion":3623,"completion":3623,"start":9130,"enrollment":33316,"conditions":33317,"interventions":33318},"NCT00174746","Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma",[91],1145,[155],[33304],{"trials":33320,"activeCount":102},[],{"trials":33322,"activeCount":102},[],{"trials":33324,"activeCount":102},[],{"intervention":2655,"totalTrials":195,"cells":33326},{"EARLY_PHASE1":33327,"PHASE1":33329,"PHASE2":33331,"PHASE3":33337,"PHASE4":33339,"NA":33341},{"trials":33328,"activeCount":102},[],{"trials":33330,"activeCount":102},[],{"trials":33332,"activeCount":102},[33333],{"nctId":2648,"briefTitle":2649,"status":884,"phases":33334,"primaryCompletion":2651,"completion":2651,"start":2370,"enrollment":1400,"conditions":33335,"interventions":33336},[90,91],[2653],[1162,2655,2656,1323,1324,1322],{"trials":33338,"activeCount":102},[],{"trials":33340,"activeCount":102},[],{"trials":33342,"activeCount":102},[],{"intervention":2656,"totalTrials":195,"cells":33344},{"EARLY_PHASE1":33345,"PHASE1":33347,"PHASE2":33349,"PHASE3":33355,"PHASE4":33357,"NA":33359},{"trials":33346,"activeCount":102},[],{"trials":33348,"activeCount":102},[],{"trials":33350,"activeCount":102},[33351],{"nctId":2648,"briefTitle":2649,"status":884,"phases":33352,"primaryCompletion":2651,"completion":2651,"start":2370,"enrollment":1400,"conditions":33353,"interventions":33354},[90,91],[2653],[1162,2655,2656,1323,1324,1322],{"trials":33356,"activeCount":102},[],{"trials":33358,"activeCount":102},[],{"trials":33360,"activeCount":102},[],{"intervention":33362,"totalTrials":195,"cells":33363},"Split virion, inactivated Influenza vaccine",{"EARLY_PHASE1":33364,"PHASE1":33366,"PHASE2":33368,"PHASE3":33376,"PHASE4":33378,"NA":33380},{"trials":33365,"activeCount":102},[],{"trials":33367,"activeCount":102},[],{"trials":33369,"activeCount":102},[33370],{"nctId":33371,"briefTitle":33372,"status":108,"phases":33373,"primaryCompletion":3417,"completion":3564,"start":8156,"enrollment":31232,"conditions":33374,"interventions":33375},"NCT00718146","Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation",[91],[16,15230],[33362,33362],{"trials":33377,"activeCount":102},[],{"trials":33379,"activeCount":102},[],{"trials":33381,"activeCount":102},[],{"intervention":19237,"totalTrials":195,"cells":33383},{"EARLY_PHASE1":33384,"PHASE1":33386,"PHASE2":33388,"PHASE3":33394,"PHASE4":33396,"NA":33398},{"trials":33385,"activeCount":102},[],{"trials":33387,"activeCount":102},[],{"trials":33389,"activeCount":102},[33390],{"nctId":19232,"briefTitle":19233,"status":108,"phases":33391,"primaryCompletion":8156,"completion":3564,"start":9559,"enrollment":8482,"conditions":33392,"interventions":33393},[91],[15230,16],[19223,19237],{"trials":33395,"activeCount":102},[],{"trials":33397,"activeCount":102},[],{"trials":33399,"activeCount":102},[],{"intervention":33401,"totalTrials":195,"cells":33402},"ALVAC(2) Melanoma multi-antigen therapeutic vaccine",{"EARLY_PHASE1":33403,"PHASE1":33405,"PHASE2":33407,"PHASE3":33417,"PHASE4":33419,"NA":33421},{"trials":33404,"activeCount":102},[],{"trials":33406,"activeCount":102},[],{"trials":33408,"activeCount":102},[33409],{"nctId":33410,"briefTitle":33411,"status":884,"phases":33412,"primaryCompletion":3316,"completion":978,"start":8156,"enrollment":1400,"conditions":33413,"interventions":33415},"NCT00613509","Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma",[91],[33414,5421],"Melanoma",[33401,33416],"Intron A, Interferon alpha -2b",{"trials":33418,"activeCount":102},[],{"trials":33420,"activeCount":102},[],{"trials":33422,"activeCount":102},[],{"intervention":33416,"totalTrials":195,"cells":33424},{"EARLY_PHASE1":33425,"PHASE1":33427,"PHASE2":33429,"PHASE3":33435,"PHASE4":33437,"NA":33439},{"trials":33426,"activeCount":102},[],{"trials":33428,"activeCount":102},[],{"trials":33430,"activeCount":102},[33431],{"nctId":33410,"briefTitle":33411,"status":884,"phases":33432,"primaryCompletion":3316,"completion":978,"start":8156,"enrollment":1400,"conditions":33433,"interventions":33434},[91],[33414,5421],[33401,33416],{"trials":33436,"activeCount":102},[],{"trials":33438,"activeCount":102},[],{"trials":33440,"activeCount":102},[],{"intervention":33442,"totalTrials":195,"cells":33443},"CYD Dengue Vaccine Serotypes 1, 2, 3, and 4",{"EARLY_PHASE1":33444,"PHASE1":33446,"PHASE2":33448,"PHASE3":33460,"PHASE4":33462,"NA":33464},{"trials":33445,"activeCount":102},[],{"trials":33447,"activeCount":102},[],{"trials":33449,"activeCount":102},[33450],{"nctId":33451,"briefTitle":33452,"status":108,"phases":33453,"primaryCompletion":33454,"completion":33455,"start":33456,"enrollment":1091,"conditions":33457,"interventions":33458},"NCT00788151","Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years",[91],"2010-02-16","2010-08-16","2008-09-26",[18211,18210,2317,18212],[33442,33459],"Pneumococcal polysaccharide vaccine",{"trials":33461,"activeCount":102},[],{"trials":33463,"activeCount":102},[],{"trials":33465,"activeCount":102},[],{"intervention":33459,"totalTrials":195,"cells":33467},{"EARLY_PHASE1":33468,"PHASE1":33470,"PHASE2":33472,"PHASE3":33478,"PHASE4":33480,"NA":33482},{"trials":33469,"activeCount":102},[],{"trials":33471,"activeCount":102},[],{"trials":33473,"activeCount":102},[33474],{"nctId":33451,"briefTitle":33452,"status":108,"phases":33475,"primaryCompletion":33454,"completion":33455,"start":33456,"enrollment":1091,"conditions":33476,"interventions":33477},[91],[18211,18210,2317,18212],[33442,33459],{"trials":33479,"activeCount":102},[],{"trials":33481,"activeCount":102},[],{"trials":33483,"activeCount":102},[],{"intervention":31982,"totalTrials":195,"cells":33485},{"EARLY_PHASE1":33486,"PHASE1":33488,"PHASE2":33490,"PHASE3":33496,"PHASE4":33498,"NA":33500},{"trials":33487,"activeCount":102},[],{"trials":33489,"activeCount":102},[],{"trials":33491,"activeCount":102},[33492],{"nctId":31975,"briefTitle":31976,"status":108,"phases":33493,"primaryCompletion":31978,"completion":31978,"start":31979,"enrollment":31232,"conditions":33494,"interventions":33495},[91],[3379],[31959,31982],{"trials":33497,"activeCount":102},[],{"trials":33499,"activeCount":102},[],{"trials":33501,"activeCount":102},[],{"intervention":33503,"totalTrials":195,"cells":33504},"Inactivated influenza vaccine (split virion) NH 2007-2008 formulation",{"EARLY_PHASE1":33505,"PHASE1":33507,"PHASE2":33509,"PHASE3":33517,"PHASE4":33519,"NA":33521},{"trials":33506,"activeCount":102},[],{"trials":33508,"activeCount":102},[],{"trials":33510,"activeCount":102},[33511],{"nctId":33512,"briefTitle":33513,"status":108,"phases":33514,"primaryCompletion":3563,"completion":3563,"start":10320,"enrollment":31232,"conditions":33515,"interventions":33516},"NCT00491257","A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine",[91],[16,15230],[33503],{"trials":33518,"activeCount":102},[],{"trials":33520,"activeCount":102},[],{"trials":33522,"activeCount":102},[],{"intervention":5337,"totalTrials":195,"cells":33524},{"EARLY_PHASE1":33525,"PHASE1":33527,"PHASE2":33529,"PHASE3":33535,"PHASE4":33537,"NA":33539},{"trials":33526,"activeCount":102},[],{"trials":33528,"activeCount":102},[],{"trials":33530,"activeCount":102},[33531],{"nctId":5328,"briefTitle":5329,"status":108,"phases":33532,"primaryCompletion":5331,"completion":5331,"start":5332,"enrollment":5333,"conditions":33533,"interventions":33534},[90,91],[5335],[5337,5338,5319,5339],{"trials":33536,"activeCount":102},[],{"trials":33538,"activeCount":102},[],{"trials":33540,"activeCount":102},[],{"intervention":33542,"totalTrials":195,"cells":33543},"Influenza virus vaccine 2009-2010 formulation",{"EARLY_PHASE1":33544,"PHASE1":33546,"PHASE2":33548,"PHASE3":33557,"PHASE4":33559,"NA":33561},{"trials":33545,"activeCount":102},[],{"trials":33547,"activeCount":102},[],{"trials":33549,"activeCount":102},[33550],{"nctId":33551,"briefTitle":33552,"status":108,"phases":33553,"primaryCompletion":3307,"completion":8731,"start":8261,"enrollment":33554,"conditions":33555,"interventions":33556},"NCT00945438","Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)",[91],131,[16],[33542,33542],{"trials":33558,"activeCount":102},[],{"trials":33560,"activeCount":102},[],{"trials":33562,"activeCount":102},[],{"intervention":18963,"totalTrials":195,"cells":33564},{"EARLY_PHASE1":33565,"PHASE1":33567,"PHASE2":33569,"PHASE3":33575,"PHASE4":33577,"NA":33579},{"trials":33566,"activeCount":102},[],{"trials":33568,"activeCount":102},[],{"trials":33570,"activeCount":102},[33571],{"nctId":18954,"briefTitle":18955,"status":884,"phases":33572,"primaryCompletion":322,"completion":18957,"start":18958,"enrollment":18959,"conditions":33573,"interventions":33574},[91],[18340],[18919,18962,18963,18964,18965,18966],{"trials":33576,"activeCount":102},[],{"trials":33578,"activeCount":102},[],{"trials":33580,"activeCount":102},[],{"intervention":18965,"totalTrials":195,"cells":33582},{"EARLY_PHASE1":33583,"PHASE1":33585,"PHASE2":33587,"PHASE3":33593,"PHASE4":33595,"NA":33597},{"trials":33584,"activeCount":102},[],{"trials":33586,"activeCount":102},[],{"trials":33588,"activeCount":102},[33589],{"nctId":18954,"briefTitle":18955,"status":884,"phases":33590,"primaryCompletion":322,"completion":18957,"start":18958,"enrollment":18959,"conditions":33591,"interventions":33592},[91],[18340],[18919,18962,18963,18964,18965,18966],{"trials":33594,"activeCount":102},[],{"trials":33596,"activeCount":102},[],{"trials":33598,"activeCount":102},[],{"intervention":33600,"totalTrials":195,"cells":33601},"SSR150106",{"EARLY_PHASE1":33602,"PHASE1":33604,"PHASE2":33606,"PHASE3":33615,"PHASE4":33617,"NA":33619},{"trials":33603,"activeCount":102},[],{"trials":33605,"activeCount":102},[],{"trials":33607,"activeCount":102},[33608],{"nctId":33609,"briefTitle":33610,"status":108,"phases":33611,"primaryCompletion":8156,"completion":8156,"start":3317,"enrollment":1874,"conditions":33612,"interventions":33613},"NCT00545454","Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis",[91],[990],[33600,33614],"Placebos",{"trials":33616,"activeCount":102},[],{"trials":33618,"activeCount":102},[],{"trials":33620,"activeCount":102},[],{"intervention":33614,"totalTrials":195,"cells":33622},{"EARLY_PHASE1":33623,"PHASE1":33625,"PHASE2":33627,"PHASE3":33633,"PHASE4":33635,"NA":33637},{"trials":33624,"activeCount":102},[],{"trials":33626,"activeCount":102},[],{"trials":33628,"activeCount":102},[33629],{"nctId":33609,"briefTitle":33610,"status":108,"phases":33630,"primaryCompletion":8156,"completion":8156,"start":3317,"enrollment":1874,"conditions":33631,"interventions":33632},[91],[990],[33600,33614],{"trials":33634,"activeCount":102},[],{"trials":33636,"activeCount":102},[],{"trials":33638,"activeCount":102},[],{"intervention":33640,"totalTrials":195,"cells":33641},"Bivalent CYD-1,3 Dengue",{"EARLY_PHASE1":33642,"PHASE1":33644,"PHASE2":33646,"PHASE3":33657,"PHASE4":33659,"NA":33661},{"trials":33643,"activeCount":102},[],{"trials":33645,"activeCount":102},[],{"trials":33647,"activeCount":102},[33648],{"nctId":33649,"briefTitle":33650,"status":108,"phases":33651,"primaryCompletion":3354,"completion":8745,"start":3417,"enrollment":18448,"conditions":33652,"interventions":33653},"NCT00740155","Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults",[91],[18211,18210,2317,18212],[33640,33640,33654,33655,33656],"Tetravalent blending VDV-2\u002FCYD-1,3,4 Dengue","Tetravalent CYD-1,2,3,4 Dengue","JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue",{"trials":33658,"activeCount":102},[],{"trials":33660,"activeCount":102},[],{"trials":33662,"activeCount":102},[],{"intervention":33654,"totalTrials":195,"cells":33664},{"EARLY_PHASE1":33665,"PHASE1":33667,"PHASE2":33669,"PHASE3":33675,"PHASE4":33677,"NA":33679},{"trials":33666,"activeCount":102},[],{"trials":33668,"activeCount":102},[],{"trials":33670,"activeCount":102},[33671],{"nctId":33649,"briefTitle":33650,"status":108,"phases":33672,"primaryCompletion":3354,"completion":8745,"start":3417,"enrollment":18448,"conditions":33673,"interventions":33674},[91],[18211,18210,2317,18212],[33640,33640,33654,33655,33656],{"trials":33676,"activeCount":102},[],{"trials":33678,"activeCount":102},[],{"trials":33680,"activeCount":102},[],{"intervention":33655,"totalTrials":195,"cells":33682},{"EARLY_PHASE1":33683,"PHASE1":33685,"PHASE2":33687,"PHASE3":33693,"PHASE4":33695,"NA":33697},{"trials":33684,"activeCount":102},[],{"trials":33686,"activeCount":102},[],{"trials":33688,"activeCount":102},[33689],{"nctId":33649,"briefTitle":33650,"status":108,"phases":33690,"primaryCompletion":3354,"completion":8745,"start":3417,"enrollment":18448,"conditions":33691,"interventions":33692},[91],[18211,18210,2317,18212],[33640,33640,33654,33655,33656],{"trials":33694,"activeCount":102},[],{"trials":33696,"activeCount":102},[],{"trials":33698,"activeCount":102},[],{"intervention":33656,"totalTrials":195,"cells":33700},{"EARLY_PHASE1":33701,"PHASE1":33703,"PHASE2":33705,"PHASE3":33711,"PHASE4":33713,"NA":33715},{"trials":33702,"activeCount":102},[],{"trials":33704,"activeCount":102},[],{"trials":33706,"activeCount":102},[33707],{"nctId":33649,"briefTitle":33650,"status":108,"phases":33708,"primaryCompletion":3354,"completion":8745,"start":3417,"enrollment":18448,"conditions":33709,"interventions":33710},[91],[18211,18210,2317,18212],[33640,33640,33654,33655,33656],{"trials":33712,"activeCount":102},[],{"trials":33714,"activeCount":102},[],{"trials":33716,"activeCount":102},[],{"intervention":3311,"totalTrials":195,"cells":33718},{"EARLY_PHASE1":33719,"PHASE1":33721,"PHASE2":33723,"PHASE3":33729,"PHASE4":33731,"NA":33733},{"trials":33720,"activeCount":102},[],{"trials":33722,"activeCount":102},[],{"trials":33724,"activeCount":102},[33725],{"nctId":3304,"briefTitle":3305,"status":108,"phases":33726,"primaryCompletion":3307,"completion":3307,"start":3308,"enrollment":1223,"conditions":33727,"interventions":33728},[91],[1788],[1800,3311],{"trials":33730,"activeCount":102},[],{"trials":33732,"activeCount":102},[],{"trials":33734,"activeCount":102},[],{"intervention":33736,"totalTrials":195,"cells":33737},"Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide",{"EARLY_PHASE1":33738,"PHASE1":33740,"PHASE2":33742,"PHASE3":33751,"PHASE4":33753,"NA":33755},{"trials":33739,"activeCount":102},[],{"trials":33741,"activeCount":102},[],{"trials":33743,"activeCount":102},[33744],{"nctId":33745,"briefTitle":33746,"status":108,"phases":33747,"primaryCompletion":8762,"completion":8846,"start":3317,"enrollment":1706,"conditions":33748,"interventions":33749},"NCT00874549","Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years",[90,91],[2922,7568],[33736,33750,33750,33750],"Menactra®: Polysaccharide Diphtheria Toxoid Conjugate",{"trials":33752,"activeCount":102},[],{"trials":33754,"activeCount":102},[],{"trials":33756,"activeCount":102},[],{"intervention":33750,"totalTrials":195,"cells":33758},{"EARLY_PHASE1":33759,"PHASE1":33761,"PHASE2":33763,"PHASE3":33769,"PHASE4":33771,"NA":33773},{"trials":33760,"activeCount":102},[],{"trials":33762,"activeCount":102},[],{"trials":33764,"activeCount":102},[33765],{"nctId":33745,"briefTitle":33746,"status":108,"phases":33766,"primaryCompletion":8762,"completion":8846,"start":3317,"enrollment":1706,"conditions":33767,"interventions":33768},[90,91],[2922,7568],[33736,33750,33750,33750],{"trials":33770,"activeCount":102},[],{"trials":33772,"activeCount":102},[],{"trials":33774,"activeCount":102},[],{"intervention":33776,"totalTrials":195,"cells":33777},"Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus",{"EARLY_PHASE1":33778,"PHASE1":33780,"PHASE2":33782,"PHASE3":33793,"PHASE4":33795,"NA":33797},{"trials":33779,"activeCount":102},[],{"trials":33781,"activeCount":102},[],{"trials":33783,"activeCount":102},[33784],{"nctId":33785,"briefTitle":33786,"status":108,"phases":33787,"primaryCompletion":164,"completion":3438,"start":5271,"enrollment":455,"conditions":33788,"interventions":33789},"NCT01187433","Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America",[91],[2316,2317],[33776,33790,33791,33792],"NaCl 0.9%","Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed","Meningococcal A+C vaccine",{"trials":33794,"activeCount":102},[],{"trials":33796,"activeCount":102},[],{"trials":33798,"activeCount":102},[],{"intervention":33790,"totalTrials":195,"cells":33800},{"EARLY_PHASE1":33801,"PHASE1":33803,"PHASE2":33805,"PHASE3":33811,"PHASE4":33813,"NA":33815},{"trials":33802,"activeCount":102},[],{"trials":33804,"activeCount":102},[],{"trials":33806,"activeCount":102},[33807],{"nctId":33785,"briefTitle":33786,"status":108,"phases":33808,"primaryCompletion":164,"completion":3438,"start":5271,"enrollment":455,"conditions":33809,"interventions":33810},[91],[2316,2317],[33776,33790,33791,33792],{"trials":33812,"activeCount":102},[],{"trials":33814,"activeCount":102},[],{"trials":33816,"activeCount":102},[],{"intervention":33791,"totalTrials":195,"cells":33818},{"EARLY_PHASE1":33819,"PHASE1":33821,"PHASE2":33823,"PHASE3":33829,"PHASE4":33831,"NA":33833},{"trials":33820,"activeCount":102},[],{"trials":33822,"activeCount":102},[],{"trials":33824,"activeCount":102},[33825],{"nctId":33785,"briefTitle":33786,"status":108,"phases":33826,"primaryCompletion":164,"completion":3438,"start":5271,"enrollment":455,"conditions":33827,"interventions":33828},[91],[2316,2317],[33776,33790,33791,33792],{"trials":33830,"activeCount":102},[],{"trials":33832,"activeCount":102},[],{"trials":33834,"activeCount":102},[],{"intervention":33792,"totalTrials":195,"cells":33836},{"EARLY_PHASE1":33837,"PHASE1":33839,"PHASE2":33841,"PHASE3":33847,"PHASE4":33849,"NA":33851},{"trials":33838,"activeCount":102},[],{"trials":33840,"activeCount":102},[],{"trials":33842,"activeCount":102},[33843],{"nctId":33785,"briefTitle":33786,"status":108,"phases":33844,"primaryCompletion":164,"completion":3438,"start":5271,"enrollment":455,"conditions":33845,"interventions":33846},[91],[2316,2317],[33776,33790,33791,33792],{"trials":33848,"activeCount":102},[],{"trials":33850,"activeCount":102},[],{"trials":33852,"activeCount":102},[],{"intervention":33854,"totalTrials":195,"cells":33855},"surinabant",{"EARLY_PHASE1":33856,"PHASE1":33858,"PHASE2":33860,"PHASE3":33868,"PHASE4":33870,"NA":33872},{"trials":33857,"activeCount":102},[],{"trials":33859,"activeCount":102},[],{"trials":33861,"activeCount":102},[33862],{"nctId":33863,"briefTitle":33864,"status":108,"phases":33865,"primaryCompletion":8505,"completion":8505,"start":2800,"enrollment":7631,"conditions":33866,"interventions":33867},"NCT00432575","Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)",[91],[17745],[33854],{"trials":33869,"activeCount":102},[],{"trials":33871,"activeCount":102},[],{"trials":33873,"activeCount":102},[],{"intervention":33875,"totalTrials":195,"cells":33876},"Live attenuated Japanese encephalitis virus",{"EARLY_PHASE1":33877,"PHASE1":33879,"PHASE2":33881,"PHASE3":33890,"PHASE4":33892,"NA":33894},{"trials":33878,"activeCount":102},[],{"trials":33880,"activeCount":102},[],{"trials":33882,"activeCount":102},[33883],{"nctId":33884,"briefTitle":33885,"status":108,"phases":33886,"primaryCompletion":8777,"completion":8607,"start":8175,"enrollment":3336,"conditions":33887,"interventions":33888},"NCT00981630","Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine",[91],[17265],[33875,33875,33875,33889],"ChimeriVax™ diluent",{"trials":33891,"activeCount":102},[],{"trials":33893,"activeCount":102},[],{"trials":33895,"activeCount":102},[],{"intervention":33889,"totalTrials":195,"cells":33897},{"EARLY_PHASE1":33898,"PHASE1":33900,"PHASE2":33902,"PHASE3":33908,"PHASE4":33910,"NA":33912},{"trials":33899,"activeCount":102},[],{"trials":33901,"activeCount":102},[],{"trials":33903,"activeCount":102},[33904],{"nctId":33884,"briefTitle":33885,"status":108,"phases":33905,"primaryCompletion":8777,"completion":8607,"start":8175,"enrollment":3336,"conditions":33906,"interventions":33907},[91],[17265],[33875,33875,33875,33889],{"trials":33909,"activeCount":102},[],{"trials":33911,"activeCount":102},[],{"trials":33913,"activeCount":102},[],{"intervention":33915,"totalTrials":195,"cells":33916},"QIV-HD by IM",{"EARLY_PHASE1":33917,"PHASE1":33919,"PHASE2":33921,"PHASE3":33932,"PHASE4":33934,"NA":33936},{"trials":33918,"activeCount":102},[],{"trials":33920,"activeCount":102},[],{"trials":33922,"activeCount":102},[33923],{"nctId":33924,"briefTitle":33925,"status":108,"phases":33926,"primaryCompletion":33927,"completion":33927,"start":18086,"enrollment":19403,"conditions":33928,"interventions":33929},"NCT03233217","Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years",[90,91],"2017-11-28",[16],[33915,33930,33931],"QIV-SD by SC","QIV-HD by SC",{"trials":33933,"activeCount":102},[],{"trials":33935,"activeCount":102},[],{"trials":33937,"activeCount":102},[],{"intervention":33930,"totalTrials":195,"cells":33939},{"EARLY_PHASE1":33940,"PHASE1":33942,"PHASE2":33944,"PHASE3":33950,"PHASE4":33952,"NA":33954},{"trials":33941,"activeCount":102},[],{"trials":33943,"activeCount":102},[],{"trials":33945,"activeCount":102},[33946],{"nctId":33924,"briefTitle":33925,"status":108,"phases":33947,"primaryCompletion":33927,"completion":33927,"start":18086,"enrollment":19403,"conditions":33948,"interventions":33949},[90,91],[16],[33915,33930,33931],{"trials":33951,"activeCount":102},[],{"trials":33953,"activeCount":102},[],{"trials":33955,"activeCount":102},[],{"intervention":33931,"totalTrials":195,"cells":33957},{"EARLY_PHASE1":33958,"PHASE1":33960,"PHASE2":33962,"PHASE3":33968,"PHASE4":33970,"NA":33972},{"trials":33959,"activeCount":102},[],{"trials":33961,"activeCount":102},[],{"trials":33963,"activeCount":102},[33964],{"nctId":33924,"briefTitle":33925,"status":108,"phases":33965,"primaryCompletion":33927,"completion":33927,"start":18086,"enrollment":19403,"conditions":33966,"interventions":33967},[90,91],[16],[33915,33930,33931],{"trials":33969,"activeCount":102},[],{"trials":33971,"activeCount":102},[],{"trials":33973,"activeCount":102},[],{"intervention":33975,"totalTrials":195,"cells":33976},"Tetravalent CYD Dengue Vaccine , 5555 formulation",{"EARLY_PHASE1":33977,"PHASE1":33979,"PHASE2":33981,"PHASE3":33992,"PHASE4":33994,"NA":33996},{"trials":33978,"activeCount":102},[],{"trials":33980,"activeCount":102},[],{"trials":33982,"activeCount":102},[33983],{"nctId":33984,"briefTitle":33985,"status":108,"phases":33986,"primaryCompletion":8388,"completion":955,"start":33987,"enrollment":668,"conditions":33988,"interventions":33989},"NCT00617344","Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US",[91],"2008-04-17",[18210,2317,18211],[33975,33990,33991],"Tetravalent CYD Dengue Vaccine , 5553 formulation","Tetravalent CYD Dengue Vaccine, 4444 formulation",{"trials":33993,"activeCount":102},[],{"trials":33995,"activeCount":102},[],{"trials":33997,"activeCount":102},[],{"intervention":33990,"totalTrials":195,"cells":33999},{"EARLY_PHASE1":34000,"PHASE1":34002,"PHASE2":34004,"PHASE3":34010,"PHASE4":34012,"NA":34014},{"trials":34001,"activeCount":102},[],{"trials":34003,"activeCount":102},[],{"trials":34005,"activeCount":102},[34006],{"nctId":33984,"briefTitle":33985,"status":108,"phases":34007,"primaryCompletion":8388,"completion":955,"start":33987,"enrollment":668,"conditions":34008,"interventions":34009},[91],[18210,2317,18211],[33975,33990,33991],{"trials":34011,"activeCount":102},[],{"trials":34013,"activeCount":102},[],{"trials":34015,"activeCount":102},[],{"intervention":33991,"totalTrials":195,"cells":34017},{"EARLY_PHASE1":34018,"PHASE1":34020,"PHASE2":34022,"PHASE3":34028,"PHASE4":34030,"NA":34032},{"trials":34019,"activeCount":102},[],{"trials":34021,"activeCount":102},[],{"trials":34023,"activeCount":102},[34024],{"nctId":33984,"briefTitle":33985,"status":108,"phases":34025,"primaryCompletion":8388,"completion":955,"start":33987,"enrollment":668,"conditions":34026,"interventions":34027},[91],[18210,2317,18211],[33975,33990,33991],{"trials":34029,"activeCount":102},[],{"trials":34031,"activeCount":102},[],{"trials":34033,"activeCount":102},[],{"intervention":18222,"totalTrials":195,"cells":34035},{"EARLY_PHASE1":34036,"PHASE1":34038,"PHASE2":34040,"PHASE3":34046,"PHASE4":34048,"NA":34050},{"trials":34037,"activeCount":102},[],{"trials":34039,"activeCount":102},[],{"trials":34041,"activeCount":102},[34042],{"nctId":18217,"briefTitle":18218,"status":108,"phases":34043,"primaryCompletion":986,"completion":8683,"start":3354,"enrollment":16359,"conditions":34044,"interventions":34045},[91],[2316,2317,18211,18210],[18194,18222],{"trials":34047,"activeCount":102},[],{"trials":34049,"activeCount":102},[],{"trials":34051,"activeCount":102},[],{"intervention":30942,"totalTrials":195,"cells":34053},{"EARLY_PHASE1":34054,"PHASE1":34056,"PHASE2":34058,"PHASE3":34064,"PHASE4":34066,"NA":34068},{"trials":34055,"activeCount":102},[],{"trials":34057,"activeCount":102},[],{"trials":34059,"activeCount":102},[34060],{"nctId":30936,"briefTitle":30937,"status":108,"phases":34061,"primaryCompletion":7283,"completion":14370,"start":8062,"enrollment":7653,"conditions":34062,"interventions":34063},[91],[30940],[30914,30942],{"trials":34065,"activeCount":102},[],{"trials":34067,"activeCount":102},[],{"trials":34069,"activeCount":102},[],{"intervention":21308,"totalTrials":195,"cells":34071},{"EARLY_PHASE1":34072,"PHASE1":34074,"PHASE2":34076,"PHASE3":34082,"PHASE4":34084,"NA":34086},{"trials":34073,"activeCount":102},[],{"trials":34075,"activeCount":102},[],{"trials":34077,"activeCount":102},[34078],{"nctId":21303,"briefTitle":21304,"status":108,"phases":34079,"primaryCompletion":3821,"completion":977,"start":2800,"enrollment":6595,"conditions":34080,"interventions":34081},[91],[17265],[21294,21308],{"trials":34083,"activeCount":102},[],{"trials":34085,"activeCount":102},[],{"trials":34087,"activeCount":102},[],{"intervention":34089,"totalTrials":195,"cells":34090},"Docetaxel + Oxaliplatin",{"EARLY_PHASE1":34091,"PHASE1":34093,"PHASE2":34095,"PHASE3":34106,"PHASE4":34108,"NA":34110},{"trials":34092,"activeCount":102},[],{"trials":34094,"activeCount":102},[],{"trials":34096,"activeCount":102},[34097],{"nctId":34098,"briefTitle":34099,"status":108,"phases":34100,"primaryCompletion":3316,"completion":3316,"start":3622,"enrollment":34101,"conditions":34102,"interventions":34103},"NCT00382720","Docetaxel and Oxaliplatin in Gastric Cancer",[91],275,[9092],[34089,34104,34105],"Docetaxel + Oxaliplatin + 5-FU","Docetaxel + Oxaliplatin + Capecitabine",{"trials":34107,"activeCount":102},[],{"trials":34109,"activeCount":102},[],{"trials":34111,"activeCount":102},[],{"intervention":34104,"totalTrials":195,"cells":34113},{"EARLY_PHASE1":34114,"PHASE1":34116,"PHASE2":34118,"PHASE3":34124,"PHASE4":34126,"NA":34128},{"trials":34115,"activeCount":102},[],{"trials":34117,"activeCount":102},[],{"trials":34119,"activeCount":102},[34120],{"nctId":34098,"briefTitle":34099,"status":108,"phases":34121,"primaryCompletion":3316,"completion":3316,"start":3622,"enrollment":34101,"conditions":34122,"interventions":34123},[91],[9092],[34089,34104,34105],{"trials":34125,"activeCount":102},[],{"trials":34127,"activeCount":102},[],{"trials":34129,"activeCount":102},[],{"intervention":34105,"totalTrials":195,"cells":34131},{"EARLY_PHASE1":34132,"PHASE1":34134,"PHASE2":34136,"PHASE3":34142,"PHASE4":34144,"NA":34146},{"trials":34133,"activeCount":102},[],{"trials":34135,"activeCount":102},[],{"trials":34137,"activeCount":102},[34138],{"nctId":34098,"briefTitle":34099,"status":108,"phases":34139,"primaryCompletion":3316,"completion":3316,"start":3622,"enrollment":34101,"conditions":34140,"interventions":34141},[91],[9092],[34089,34104,34105],{"trials":34143,"activeCount":102},[],{"trials":34145,"activeCount":102},[],{"trials":34147,"activeCount":102},[],{"intervention":34149,"totalTrials":195,"cells":34150},"HP184",{"EARLY_PHASE1":34151,"PHASE1":34153,"PHASE2":34155,"PHASE3":34165,"PHASE4":34167,"NA":34169},{"trials":34152,"activeCount":102},[],{"trials":34154,"activeCount":102},[],{"trials":34156,"activeCount":102},[34157],{"nctId":34158,"briefTitle":34159,"status":108,"phases":34160,"primaryCompletion":3565,"completion":3565,"start":3633,"enrollment":34161,"conditions":34162,"interventions":34164},"NCT00093275","HP184 in Chronic Spinal Cord Injury Subjects",[91],262,[34163],"Spinal Cord Injury",[34149],{"trials":34166,"activeCount":102},[],{"trials":34168,"activeCount":102},[],{"trials":34170,"activeCount":102},[],{"intervention":32117,"totalTrials":195,"cells":34172},{"EARLY_PHASE1":34173,"PHASE1":34175,"PHASE2":34177,"PHASE3":34183,"PHASE4":34185,"NA":34187},{"trials":34174,"activeCount":102},[],{"trials":34176,"activeCount":102},[],{"trials":34178,"activeCount":102},[34179],{"nctId":32109,"briefTitle":32110,"status":884,"phases":34180,"primaryCompletion":32112,"completion":32112,"start":32113,"enrollment":552,"conditions":34181,"interventions":34182},[91],[32115],[32100,32117,32118,32119,32120],{"trials":34184,"activeCount":102},[],{"trials":34186,"activeCount":102},[],{"trials":34188,"activeCount":102},[],{"intervention":32118,"totalTrials":195,"cells":34190},{"EARLY_PHASE1":34191,"PHASE1":34193,"PHASE2":34195,"PHASE3":34201,"PHASE4":34203,"NA":34205},{"trials":34192,"activeCount":102},[],{"trials":34194,"activeCount":102},[],{"trials":34196,"activeCount":102},[34197],{"nctId":32109,"briefTitle":32110,"status":884,"phases":34198,"primaryCompletion":32112,"completion":32112,"start":32113,"enrollment":552,"conditions":34199,"interventions":34200},[91],[32115],[32100,32117,32118,32119,32120],{"trials":34202,"activeCount":102},[],{"trials":34204,"activeCount":102},[],{"trials":34206,"activeCount":102},[],{"intervention":32119,"totalTrials":195,"cells":34208},{"EARLY_PHASE1":34209,"PHASE1":34211,"PHASE2":34213,"PHASE3":34219,"PHASE4":34221,"NA":34223},{"trials":34210,"activeCount":102},[],{"trials":34212,"activeCount":102},[],{"trials":34214,"activeCount":102},[34215],{"nctId":32109,"briefTitle":32110,"status":884,"phases":34216,"primaryCompletion":32112,"completion":32112,"start":32113,"enrollment":552,"conditions":34217,"interventions":34218},[91],[32115],[32100,32117,32118,32119,32120],{"trials":34220,"activeCount":102},[],{"trials":34222,"activeCount":102},[],{"trials":34224,"activeCount":102},[],{"intervention":32120,"totalTrials":195,"cells":34226},{"EARLY_PHASE1":34227,"PHASE1":34229,"PHASE2":34231,"PHASE3":34237,"PHASE4":34239,"NA":34241},{"trials":34228,"activeCount":102},[],{"trials":34230,"activeCount":102},[],{"trials":34232,"activeCount":102},[34233],{"nctId":32109,"briefTitle":32110,"status":884,"phases":34234,"primaryCompletion":32112,"completion":32112,"start":32113,"enrollment":552,"conditions":34235,"interventions":34236},[91],[32115],[32100,32117,32118,32119,32120],{"trials":34238,"activeCount":102},[],{"trials":34240,"activeCount":102},[],{"trials":34242,"activeCount":102},[],{"intervention":34244,"totalTrials":195,"cells":34245},"Panblok + MF59 Dose 1",{"EARLY_PHASE1":34246,"PHASE1":34248,"PHASE2":34250,"PHASE3":34264,"PHASE4":34266,"NA":34268},{"trials":34247,"activeCount":102},[],{"trials":34249,"activeCount":102},[],{"trials":34251,"activeCount":102},[34252],{"nctId":34253,"briefTitle":34254,"status":108,"phases":34255,"primaryCompletion":34256,"completion":34257,"start":34258,"enrollment":34259,"conditions":34260,"interventions":34261},"NCT05608005","Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older",[90,91],"2023-02-18","2024-02-13","2022-11-03",581,[16,36],[34244,34262,34263],"Panblok + MF59 Dose 2","Unadjuvanted Panblok Dose 3",{"trials":34265,"activeCount":102},[],{"trials":34267,"activeCount":102},[],{"trials":34269,"activeCount":102},[],{"intervention":34262,"totalTrials":195,"cells":34271},{"EARLY_PHASE1":34272,"PHASE1":34274,"PHASE2":34276,"PHASE3":34282,"PHASE4":34284,"NA":34286},{"trials":34273,"activeCount":102},[],{"trials":34275,"activeCount":102},[],{"trials":34277,"activeCount":102},[34278],{"nctId":34253,"briefTitle":34254,"status":108,"phases":34279,"primaryCompletion":34256,"completion":34257,"start":34258,"enrollment":34259,"conditions":34280,"interventions":34281},[90,91],[16,36],[34244,34262,34263],{"trials":34283,"activeCount":102},[],{"trials":34285,"activeCount":102},[],{"trials":34287,"activeCount":102},[],{"intervention":34263,"totalTrials":195,"cells":34289},{"EARLY_PHASE1":34290,"PHASE1":34292,"PHASE2":34294,"PHASE3":34300,"PHASE4":34302,"NA":34304},{"trials":34291,"activeCount":102},[],{"trials":34293,"activeCount":102},[],{"trials":34295,"activeCount":102},[34296],{"nctId":34253,"briefTitle":34254,"status":108,"phases":34297,"primaryCompletion":34256,"completion":34257,"start":34258,"enrollment":34259,"conditions":34298,"interventions":34299},[90,91],[16,36],[34244,34262,34263],{"trials":34301,"activeCount":102},[],{"trials":34303,"activeCount":102},[],{"trials":34305,"activeCount":102},[],{"intervention":34307,"totalTrials":195,"cells":34308},"SR31747A",{"EARLY_PHASE1":34309,"PHASE1":34311,"PHASE2":34313,"PHASE3":34323,"PHASE4":34325,"NA":34327},{"trials":34310,"activeCount":102},[],{"trials":34312,"activeCount":102},[],{"trials":34314,"activeCount":102},[34315],{"nctId":34316,"briefTitle":34317,"status":108,"phases":34318,"primaryCompletion":5262,"completion":5262,"start":3488,"enrollment":34319,"conditions":34320,"interventions":34322},"NCT00174863","Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer",[91],232,[34321],"Prostatic Neoplasm",[34307],{"trials":34324,"activeCount":102},[],{"trials":34326,"activeCount":102},[],{"trials":34328,"activeCount":102},[],{"intervention":11183,"totalTrials":195,"cells":34330},{"EARLY_PHASE1":34331,"PHASE1":34333,"PHASE2":34335,"PHASE3":34341,"PHASE4":34343,"NA":34345},{"trials":34332,"activeCount":102},[],{"trials":34334,"activeCount":102},[],{"trials":34336,"activeCount":102},[34337],{"nctId":11178,"briefTitle":11179,"status":108,"phases":34338,"primaryCompletion":9984,"completion":987,"start":955,"enrollment":37,"conditions":34339,"interventions":34340},[90,91],[554],[11183,11142],{"trials":34342,"activeCount":102},[],{"trials":34344,"activeCount":102},[],{"trials":34346,"activeCount":102},[],{"intervention":34348,"totalTrials":195,"cells":34349},"oxaliplatin, 5 FU",{"EARLY_PHASE1":34350,"PHASE1":34352,"PHASE2":34354,"PHASE3":34362,"PHASE4":34364,"NA":34366},{"trials":34351,"activeCount":102},[],{"trials":34353,"activeCount":102},[],{"trials":34355,"activeCount":102},[34356],{"nctId":34357,"briefTitle":34358,"status":108,"phases":34359,"completion":9130,"start":8421,"enrollment":8883,"conditions":34360,"interventions":34361},"NCT00612495","Endometrial Cancer - LOHP Alone and With 5FU",[91],[30904],[34348],{"trials":34363,"activeCount":102},[],{"trials":34365,"activeCount":102},[],{"trials":34367,"activeCount":102},[],{"intervention":34369,"totalTrials":195,"cells":34370},"Quadrivalent Inactivated Influenza High Dose",{"EARLY_PHASE1":34371,"PHASE1":34373,"PHASE2":34375,"PHASE3":34386,"PHASE4":34388,"NA":34390},{"trials":34372,"activeCount":102},[],{"trials":34374,"activeCount":102},[],{"trials":34376,"activeCount":102},[34377],{"nctId":34378,"briefTitle":34379,"status":108,"phases":34380,"primaryCompletion":34381,"completion":34381,"start":34382,"enrollment":19862,"conditions":34383,"interventions":34384},"NCT04969276","Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",[91],"2022-02-08","2021-07-16",[5335,36],[34369,34385],"COVID-19 mRNA Vaccine",{"trials":34387,"activeCount":102},[],{"trials":34389,"activeCount":102},[],{"trials":34391,"activeCount":102},[],{"intervention":34385,"totalTrials":195,"cells":34393},{"EARLY_PHASE1":34394,"PHASE1":34396,"PHASE2":34398,"PHASE3":34404,"PHASE4":34406,"NA":34408},{"trials":34395,"activeCount":102},[],{"trials":34397,"activeCount":102},[],{"trials":34399,"activeCount":102},[34400],{"nctId":34378,"briefTitle":34379,"status":108,"phases":34401,"primaryCompletion":34381,"completion":34381,"start":34382,"enrollment":19862,"conditions":34402,"interventions":34403},[91],[5335,36],[34369,34385],{"trials":34405,"activeCount":102},[],{"trials":34407,"activeCount":102},[],{"trials":34409,"activeCount":102},[],{"intervention":34411,"totalTrials":195,"cells":34412},"SAR292833",{"EARLY_PHASE1":34413,"PHASE1":34415,"PHASE2":34417,"PHASE3":34427,"PHASE4":34429,"NA":34431},{"trials":34414,"activeCount":102},[],{"trials":34416,"activeCount":102},[],{"trials":34418,"activeCount":102},[34419],{"nctId":34420,"briefTitle":34421,"status":108,"phases":34422,"primaryCompletion":8106,"completion":8106,"start":8683,"enrollment":34423,"conditions":34424,"interventions":34426},"NCT01463397","Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain",[91],191,[34425],"Neuropathic Pain",[34411],{"trials":34428,"activeCount":102},[],{"trials":34430,"activeCount":102},[],{"trials":34432,"activeCount":102},[],{"intervention":3320,"totalTrials":195,"cells":34434},{"EARLY_PHASE1":34435,"PHASE1":34437,"PHASE2":34439,"PHASE3":34445,"PHASE4":34447,"NA":34449},{"trials":34436,"activeCount":102},[],{"trials":34438,"activeCount":102},[],{"trials":34440,"activeCount":102},[34441],{"nctId":3313,"briefTitle":3314,"status":108,"phases":34442,"primaryCompletion":3316,"completion":3316,"start":3317,"enrollment":121,"conditions":34443,"interventions":34444},[91],[1788],[1800,3320,3321],{"trials":34446,"activeCount":102},[],{"trials":34448,"activeCount":102},[],{"trials":34450,"activeCount":102},[],{"intervention":3321,"totalTrials":195,"cells":34452},{"EARLY_PHASE1":34453,"PHASE1":34455,"PHASE2":34457,"PHASE3":34463,"PHASE4":34465,"NA":34467},{"trials":34454,"activeCount":102},[],{"trials":34456,"activeCount":102},[],{"trials":34458,"activeCount":102},[34459],{"nctId":3313,"briefTitle":3314,"status":108,"phases":34460,"primaryCompletion":3316,"completion":3316,"start":3317,"enrollment":121,"conditions":34461,"interventions":34462},[91],[1788],[1800,3320,3321],{"trials":34464,"activeCount":102},[],{"trials":34466,"activeCount":102},[],{"trials":34468,"activeCount":102},[],{"intervention":34470,"totalTrials":195,"cells":34471},"bsi-201 plus temozolomide",{"EARLY_PHASE1":34472,"PHASE1":34474,"PHASE2":34476,"PHASE3":34485,"PHASE4":34487,"NA":34489},{"trials":34473,"activeCount":102},[],{"trials":34475,"activeCount":102},[],{"trials":34477,"activeCount":102},[34478],{"nctId":34479,"briefTitle":34480,"status":108,"phases":34481,"primaryCompletion":8165,"completion":8165,"start":8196,"enrollment":34482,"conditions":34483,"interventions":34484},"NCT00687765","Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma",[90,91],126,[30886],[34470],{"trials":34486,"activeCount":102},[],{"trials":34488,"activeCount":102},[],{"trials":34490,"activeCount":102},[],{"intervention":34492,"totalTrials":195,"cells":34493},"INIPARIB + irinotecan",{"EARLY_PHASE1":34494,"PHASE1":34496,"PHASE2":34498,"PHASE3":34510,"PHASE4":34512,"NA":34514},{"trials":34495,"activeCount":102},[],{"trials":34497,"activeCount":102},[],{"trials":34499,"activeCount":102},[34500],{"nctId":34501,"briefTitle":34502,"status":108,"phases":34503,"primaryCompletion":164,"completion":7283,"start":3366,"enrollment":359,"conditions":34504,"interventions":34509},"NCT01173497","A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis",[91],[34505,34506,34507,34508],"Estrogen Receptor Negative (ER-Negative) Breast Cancer","Progesterone Receptor Negative (PR-Negative) Breast Cancer","Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer","Brain Metastases",[34492],{"trials":34511,"activeCount":102},[],{"trials":34513,"activeCount":102},[],{"trials":34515,"activeCount":102},[],{"intervention":34517,"totalTrials":195,"cells":34518},"Fixed-dose combination of capecitabine and cyclophosphamide SAR439281",{"EARLY_PHASE1":34519,"PHASE1":34521,"PHASE2":34523,"PHASE3":34533,"PHASE4":34535,"NA":34537},{"trials":34520,"activeCount":102},[],{"trials":34522,"activeCount":102},[],{"trials":34524,"activeCount":102},[34525],{"nctId":34526,"briefTitle":34527,"status":108,"phases":34528,"primaryCompletion":34529,"completion":34529,"start":34530,"enrollment":659,"conditions":34531,"interventions":34532},"NCT02664103","Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer",[91],"2017-11-06","2016-01-23",[18340],[34517],{"trials":34534,"activeCount":102},[],{"trials":34536,"activeCount":102},[],{"trials":34538,"activeCount":102},[],{"intervention":34540,"totalTrials":195,"cells":34541},"Vasopressin V2 Receptor Antagonist",{"EARLY_PHASE1":34542,"PHASE1":34544,"PHASE2":34546,"PHASE3":34556,"PHASE4":34558,"NA":34560},{"trials":34543,"activeCount":102},[],{"trials":34545,"activeCount":102},[],{"trials":34547,"activeCount":102},[34548],{"nctId":34549,"briefTitle":34550,"status":108,"phases":34551,"completion":3528,"start":11102,"enrollment":34552,"conditions":34553,"interventions":34555},"NCT00032747","Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).",[91],338,[34554],"Chronic Heart Failure",[34540],{"trials":34557,"activeCount":102},[],{"trials":34559,"activeCount":102},[],{"trials":34561,"activeCount":102},[],{"intervention":34563,"totalTrials":195,"cells":34564},"Smallpox vaccine, LISTER strain, from chick embryo cells",{"EARLY_PHASE1":34565,"PHASE1":34567,"PHASE2":34569,"PHASE3":34578,"PHASE4":34580,"NA":34582},{"trials":34566,"activeCount":102},[],{"trials":34568,"activeCount":102},[],{"trials":34570,"activeCount":102},[34571],{"nctId":34572,"briefTitle":34573,"status":108,"phases":34574,"primaryCompletion":10339,"completion":2800,"start":9559,"enrollment":8980,"conditions":34575,"interventions":34577},"NCT00258947","Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults",[91],[32605,34576],"Poxvirus Infection",[34563],{"trials":34579,"activeCount":102},[],{"trials":34581,"activeCount":102},[],{"trials":34583,"activeCount":102},[],{"intervention":10858,"totalTrials":195,"cells":34585},{"EARLY_PHASE1":34586,"PHASE1":34588,"PHASE2":34590,"PHASE3":34596,"PHASE4":34598,"NA":34600},{"trials":34587,"activeCount":102},[],{"trials":34589,"activeCount":102},[],{"trials":34591,"activeCount":102},[34592],{"nctId":10852,"briefTitle":10853,"status":108,"phases":34593,"primaryCompletion":9522,"completion":8526,"start":8364,"enrollment":7363,"conditions":34594,"interventions":34595},[91],[4992,10856],[10836,10858],{"trials":34597,"activeCount":102},[],{"trials":34599,"activeCount":102},[],{"trials":34601,"activeCount":102},[],{"intervention":34603,"totalTrials":195,"cells":34604},"Inactivated types 1, 2, and 3 poliovirus, D antigens",{"EARLY_PHASE1":34605,"PHASE1":34607,"PHASE2":34609,"PHASE3":34618,"PHASE4":34620,"NA":34622},{"trials":34606,"activeCount":102},[],{"trials":34608,"activeCount":102},[],{"trials":34610,"activeCount":102},[34611],{"nctId":34612,"briefTitle":34613,"status":108,"phases":34614,"primaryCompletion":3354,"completion":8388,"start":3396,"enrollment":34615,"conditions":34616,"interventions":34617},"NCT00885157","Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly",[91],225,[12983],[34603,34603],{"trials":34619,"activeCount":102},[],{"trials":34621,"activeCount":102},[],{"trials":34623,"activeCount":102},[],{"intervention":34625,"totalTrials":195,"cells":34626},"Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine",{"EARLY_PHASE1":34627,"PHASE1":34629,"PHASE2":34631,"PHASE3":34639,"PHASE4":34641,"NA":34643},{"trials":34628,"activeCount":102},[],{"trials":34630,"activeCount":102},[],{"trials":34632,"activeCount":102},[34633],{"nctId":34634,"briefTitle":34635,"status":108,"phases":34636,"primaryCompletion":1341,"start":17767,"enrollment":3121,"conditions":34637,"interventions":34638},"NCT00258739","Docetaxel in Non Small Cell Lung Cancer (NSCLC)",[91],[17899],[34625],{"trials":34640,"activeCount":102},[],{"trials":34642,"activeCount":102},[],{"trials":34644,"activeCount":102},[],{"intervention":20568,"totalTrials":195,"cells":34646},{"EARLY_PHASE1":34647,"PHASE1":34649,"PHASE2":34651,"PHASE3":34657,"PHASE4":34659,"NA":34661},{"trials":34648,"activeCount":102},[],{"trials":34650,"activeCount":102},[],{"trials":34652,"activeCount":102},[34653],{"nctId":20559,"briefTitle":20560,"status":108,"phases":34654,"primaryCompletion":20562,"completion":20562,"start":20563,"enrollment":20564,"conditions":34655,"interventions":34656},[91],[20566],[20568,20569,20570,20568,20568,20571],{"trials":34658,"activeCount":102},[],{"trials":34660,"activeCount":102},[],{"trials":34662,"activeCount":102},[],{"intervention":20569,"totalTrials":195,"cells":34664},{"EARLY_PHASE1":34665,"PHASE1":34667,"PHASE2":34669,"PHASE3":34675,"PHASE4":34677,"NA":34679},{"trials":34666,"activeCount":102},[],{"trials":34668,"activeCount":102},[],{"trials":34670,"activeCount":102},[34671],{"nctId":20559,"briefTitle":20560,"status":108,"phases":34672,"primaryCompletion":20562,"completion":20562,"start":20563,"enrollment":20564,"conditions":34673,"interventions":34674},[91],[20566],[20568,20569,20570,20568,20568,20571],{"trials":34676,"activeCount":102},[],{"trials":34678,"activeCount":102},[],{"trials":34680,"activeCount":102},[],{"intervention":20570,"totalTrials":195,"cells":34682},{"EARLY_PHASE1":34683,"PHASE1":34685,"PHASE2":34687,"PHASE3":34693,"PHASE4":34695,"NA":34697},{"trials":34684,"activeCount":102},[],{"trials":34686,"activeCount":102},[],{"trials":34688,"activeCount":102},[34689],{"nctId":20559,"briefTitle":20560,"status":108,"phases":34690,"primaryCompletion":20562,"completion":20562,"start":20563,"enrollment":20564,"conditions":34691,"interventions":34692},[91],[20566],[20568,20569,20570,20568,20568,20571],{"trials":34694,"activeCount":102},[],{"trials":34696,"activeCount":102},[],{"trials":34698,"activeCount":102},[],{"intervention":34700,"totalTrials":195,"cells":34701},"Fluarix Quadrivalent Influenza vaccine",{"EARLY_PHASE1":34702,"PHASE1":34704,"PHASE2":34706,"PHASE3":34717,"PHASE4":34719,"NA":34721},{"trials":34703,"activeCount":102},[],{"trials":34705,"activeCount":102},[],{"trials":34707,"activeCount":102},[34708],{"nctId":34709,"briefTitle":34710,"status":108,"phases":34711,"primaryCompletion":34712,"completion":34712,"start":2817,"enrollment":34713,"conditions":34714,"interventions":34715},"NCT03698279","Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age",[91],"2019-10-16",665,[16],[28381,28381,28381,34700,34716],"FLUAD Pediatric",{"trials":34718,"activeCount":102},[],{"trials":34720,"activeCount":102},[],{"trials":34722,"activeCount":102},[],{"intervention":34716,"totalTrials":195,"cells":34724},{"EARLY_PHASE1":34725,"PHASE1":34727,"PHASE2":34729,"PHASE3":34735,"PHASE4":34737,"NA":34739},{"trials":34726,"activeCount":102},[],{"trials":34728,"activeCount":102},[],{"trials":34730,"activeCount":102},[34731],{"nctId":34709,"briefTitle":34710,"status":108,"phases":34732,"primaryCompletion":34712,"completion":34712,"start":2817,"enrollment":34713,"conditions":34733,"interventions":34734},[91],[16],[28381,28381,28381,34700,34716],{"trials":34736,"activeCount":102},[],{"trials":34738,"activeCount":102},[],{"trials":34740,"activeCount":102},[],{"intervention":2296,"totalTrials":195,"cells":34742},{"EARLY_PHASE1":34743,"PHASE1":34745,"PHASE2":34747,"PHASE3":34753,"PHASE4":34755,"NA":34757},{"trials":34744,"activeCount":102},[],{"trials":34746,"activeCount":102},[],{"trials":34748,"activeCount":102},[34749],{"nctId":22154,"briefTitle":22155,"status":108,"phases":34750,"primaryCompletion":22157,"completion":22157,"start":22158,"enrollment":8620,"conditions":34751,"interventions":34752},[91],[2316,18210,2317,2296],[22145,22145,22145,2296],{"trials":34754,"activeCount":102},[],{"trials":34756,"activeCount":102},[],{"trials":34758,"activeCount":102},[],{"intervention":5257,"totalTrials":195,"cells":34760},{"EARLY_PHASE1":34761,"PHASE1":34763,"PHASE2":34765,"PHASE3":34771,"PHASE4":34773,"NA":34775},{"trials":34762,"activeCount":102},[],{"trials":34764,"activeCount":102},[],{"trials":34766,"activeCount":102},[34767],{"nctId":5247,"briefTitle":5248,"status":108,"phases":34768,"completion":5250,"start":5251,"enrollment":5252,"conditions":34769,"interventions":34770},[91],[5254],[5256,5257,5223],{"trials":34772,"activeCount":102},[],{"trials":34774,"activeCount":102},[],{"trials":34776,"activeCount":102},[],{"intervention":4994,"totalTrials":195,"cells":34778},{"EARLY_PHASE1":34779,"PHASE1":34781,"PHASE2":34783,"PHASE3":34789,"PHASE4":34791,"NA":34793},{"trials":34780,"activeCount":102},[],{"trials":34782,"activeCount":102},[],{"trials":34784,"activeCount":102},[34785],{"nctId":4986,"briefTitle":4987,"status":108,"phases":34786,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":34787,"interventions":34788},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"trials":34790,"activeCount":102},[],{"trials":34792,"activeCount":102},[],{"trials":34794,"activeCount":102},[],{"intervention":4996,"totalTrials":195,"cells":34796},{"EARLY_PHASE1":34797,"PHASE1":34799,"PHASE2":34801,"PHASE3":34807,"PHASE4":34809,"NA":34811},{"trials":34798,"activeCount":102},[],{"trials":34800,"activeCount":102},[],{"trials":34802,"activeCount":102},[34803],{"nctId":4986,"briefTitle":4987,"status":108,"phases":34804,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":34805,"interventions":34806},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"trials":34808,"activeCount":102},[],{"trials":34810,"activeCount":102},[],{"trials":34812,"activeCount":102},[],{"intervention":4998,"totalTrials":195,"cells":34814},{"EARLY_PHASE1":34815,"PHASE1":34817,"PHASE2":34819,"PHASE3":34825,"PHASE4":34827,"NA":34829},{"trials":34816,"activeCount":102},[],{"trials":34818,"activeCount":102},[],{"trials":34820,"activeCount":102},[34821],{"nctId":4986,"briefTitle":4987,"status":108,"phases":34822,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":1977,"conditions":34823,"interventions":34824},[91],[4992,2949],[4994,4995,4996,4997,4998,4977,4999,5000],{"trials":34826,"activeCount":102},[],{"trials":34828,"activeCount":102},[],{"trials":34830,"activeCount":102},[],{"intervention":19245,"totalTrials":195,"cells":34832},{"EARLY_PHASE1":34833,"PHASE1":34835,"PHASE2":34837,"PHASE3":34843,"PHASE4":34845,"NA":34847},{"trials":34834,"activeCount":102},[],{"trials":34836,"activeCount":102},[],{"trials":34838,"activeCount":102},[34839],{"nctId":19239,"briefTitle":19240,"status":108,"phases":34840,"primaryCompletion":8315,"completion":3396,"start":1341,"enrollment":1809,"conditions":34841,"interventions":34842},[91],[16,19243,10695],[19245,19245,19223,19223],{"trials":34844,"activeCount":102},[],{"trials":34846,"activeCount":102},[],{"trials":34848,"activeCount":102},[],{"intervention":34850,"totalTrials":195,"cells":34851},"Doxorubicin and cyclophosphamide (AC) + bevacizumab",{"EARLY_PHASE1":34852,"PHASE1":34854,"PHASE2":34856,"PHASE3":34870,"PHASE4":34872,"NA":34874},{"trials":34853,"activeCount":102},[],{"trials":34855,"activeCount":102},[],{"trials":34857,"activeCount":102},[34858],{"nctId":34859,"briefTitle":34860,"status":108,"phases":34861,"primaryCompletion":1340,"completion":1340,"start":5262,"enrollment":34862,"conditions":34863,"interventions":34864},"NCT00365365","Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer",[91],214,[5264],[34850,34865,34866,34867,34868,34869],"Docetaxel (T) + bevacizumab","Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab","Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab","Bevacizumab and trastuzumab maintenance therapy","Bevacizumab maintenance therapy",{"trials":34871,"activeCount":102},[],{"trials":34873,"activeCount":102},[],{"trials":34875,"activeCount":102},[],{"intervention":34865,"totalTrials":195,"cells":34877},{"EARLY_PHASE1":34878,"PHASE1":34880,"PHASE2":34882,"PHASE3":34888,"PHASE4":34890,"NA":34892},{"trials":34879,"activeCount":102},[],{"trials":34881,"activeCount":102},[],{"trials":34883,"activeCount":102},[34884],{"nctId":34859,"briefTitle":34860,"status":108,"phases":34885,"primaryCompletion":1340,"completion":1340,"start":5262,"enrollment":34862,"conditions":34886,"interventions":34887},[91],[5264],[34850,34865,34866,34867,34868,34869],{"trials":34889,"activeCount":102},[],{"trials":34891,"activeCount":102},[],{"trials":34893,"activeCount":102},[],{"intervention":34866,"totalTrials":195,"cells":34895},{"EARLY_PHASE1":34896,"PHASE1":34898,"PHASE2":34900,"PHASE3":34906,"PHASE4":34908,"NA":34910},{"trials":34897,"activeCount":102},[],{"trials":34899,"activeCount":102},[],{"trials":34901,"activeCount":102},[34902],{"nctId":34859,"briefTitle":34860,"status":108,"phases":34903,"primaryCompletion":1340,"completion":1340,"start":5262,"enrollment":34862,"conditions":34904,"interventions":34905},[91],[5264],[34850,34865,34866,34867,34868,34869],{"trials":34907,"activeCount":102},[],{"trials":34909,"activeCount":102},[],{"trials":34911,"activeCount":102},[],{"intervention":34867,"totalTrials":195,"cells":34913},{"EARLY_PHASE1":34914,"PHASE1":34916,"PHASE2":34918,"PHASE3":34924,"PHASE4":34926,"NA":34928},{"trials":34915,"activeCount":102},[],{"trials":34917,"activeCount":102},[],{"trials":34919,"activeCount":102},[34920],{"nctId":34859,"briefTitle":34860,"status":108,"phases":34921,"primaryCompletion":1340,"completion":1340,"start":5262,"enrollment":34862,"conditions":34922,"interventions":34923},[91],[5264],[34850,34865,34866,34867,34868,34869],{"trials":34925,"activeCount":102},[],{"trials":34927,"activeCount":102},[],{"trials":34929,"activeCount":102},[],{"intervention":34868,"totalTrials":195,"cells":34931},{"EARLY_PHASE1":34932,"PHASE1":34934,"PHASE2":34936,"PHASE3":34942,"PHASE4":34944,"NA":34946},{"trials":34933,"activeCount":102},[],{"trials":34935,"activeCount":102},[],{"trials":34937,"activeCount":102},[34938],{"nctId":34859,"briefTitle":34860,"status":108,"phases":34939,"primaryCompletion":1340,"completion":1340,"start":5262,"enrollment":34862,"conditions":34940,"interventions":34941},[91],[5264],[34850,34865,34866,34867,34868,34869],{"trials":34943,"activeCount":102},[],{"trials":34945,"activeCount":102},[],{"trials":34947,"activeCount":102},[],{"intervention":34869,"totalTrials":195,"cells":34949},{"EARLY_PHASE1":34950,"PHASE1":34952,"PHASE2":34954,"PHASE3":34960,"PHASE4":34962,"NA":34964},{"trials":34951,"activeCount":102},[],{"trials":34953,"activeCount":102},[],{"trials":34955,"activeCount":102},[34956],{"nctId":34859,"briefTitle":34860,"status":108,"phases":34957,"primaryCompletion":1340,"completion":1340,"start":5262,"enrollment":34862,"conditions":34958,"interventions":34959},[91],[5264],[34850,34865,34866,34867,34868,34869],{"trials":34961,"activeCount":102},[],{"trials":34963,"activeCount":102},[],{"trials":34965,"activeCount":102},[],{"intervention":31951,"totalTrials":195,"cells":34967},{"EARLY_PHASE1":34968,"PHASE1":34970,"PHASE2":34972,"PHASE3":34978,"PHASE4":34980,"NA":34982},{"trials":34969,"activeCount":102},[],{"trials":34971,"activeCount":102},[],{"trials":34973,"activeCount":102},[34974],{"nctId":31946,"briefTitle":31947,"status":108,"phases":34975,"primaryCompletion":5307,"completion":3317,"start":8184,"enrollment":259,"conditions":34976,"interventions":34977},[91],[4992,2949],[31951,31951,31951,31951,31951,31931],{"trials":34979,"activeCount":102},[],{"trials":34981,"activeCount":102},[],{"trials":34983,"activeCount":102},[],{"intervention":12796,"totalTrials":195,"cells":34985},{"EARLY_PHASE1":34986,"PHASE1":34988,"PHASE2":34990,"PHASE3":34996,"PHASE4":34998,"NA":35000},{"trials":34987,"activeCount":102},[],{"trials":34989,"activeCount":102},[],{"trials":34991,"activeCount":102},[34992],{"nctId":12777,"briefTitle":12778,"status":108,"phases":34993,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":34994,"interventions":34995},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":34997,"activeCount":102},[],{"trials":34999,"activeCount":102},[],{"trials":35001,"activeCount":102},[],{"intervention":12797,"totalTrials":195,"cells":35003},{"EARLY_PHASE1":35004,"PHASE1":35006,"PHASE2":35008,"PHASE3":35014,"PHASE4":35016,"NA":35018},{"trials":35005,"activeCount":102},[],{"trials":35007,"activeCount":102},[],{"trials":35009,"activeCount":102},[35010],{"nctId":12777,"briefTitle":12778,"status":108,"phases":35011,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":35012,"interventions":35013},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":35015,"activeCount":102},[],{"trials":35017,"activeCount":102},[],{"trials":35019,"activeCount":102},[],{"intervention":12798,"totalTrials":195,"cells":35021},{"EARLY_PHASE1":35022,"PHASE1":35024,"PHASE2":35026,"PHASE3":35032,"PHASE4":35034,"NA":35036},{"trials":35023,"activeCount":102},[],{"trials":35025,"activeCount":102},[],{"trials":35027,"activeCount":102},[35028],{"nctId":12777,"briefTitle":12778,"status":108,"phases":35029,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":35030,"interventions":35031},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":35033,"activeCount":102},[],{"trials":35035,"activeCount":102},[],{"trials":35037,"activeCount":102},[],{"intervention":12799,"totalTrials":195,"cells":35039},{"EARLY_PHASE1":35040,"PHASE1":35042,"PHASE2":35044,"PHASE3":35050,"PHASE4":35052,"NA":35054},{"trials":35041,"activeCount":102},[],{"trials":35043,"activeCount":102},[],{"trials":35045,"activeCount":102},[35046],{"nctId":12777,"briefTitle":12778,"status":108,"phases":35047,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":35048,"interventions":35049},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":35051,"activeCount":102},[],{"trials":35053,"activeCount":102},[],{"trials":35055,"activeCount":102},[],{"intervention":12800,"totalTrials":195,"cells":35057},{"EARLY_PHASE1":35058,"PHASE1":35060,"PHASE2":35062,"PHASE3":35068,"PHASE4":35070,"NA":35072},{"trials":35059,"activeCount":102},[],{"trials":35061,"activeCount":102},[],{"trials":35063,"activeCount":102},[35064],{"nctId":12777,"briefTitle":12778,"status":108,"phases":35065,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":12782,"conditions":35066,"interventions":35067},[91],[12784,12785,12786,12787,12788,12789,12790,12791,12792,12793,12794],[12796,12797,12798,4997,5022,12799,10915,5053,12800],{"trials":35069,"activeCount":102},[],{"trials":35071,"activeCount":102},[],{"trials":35073,"activeCount":102},[],{"intervention":35075,"totalTrials":195,"cells":35076},"Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy",{"EARLY_PHASE1":35077,"PHASE1":35079,"PHASE2":35081,"PHASE3":35090,"PHASE4":35092,"NA":35094},{"trials":35078,"activeCount":102},[],{"trials":35080,"activeCount":102},[],{"trials":35082,"activeCount":102},[35083],{"nctId":35084,"briefTitle":35085,"status":108,"phases":35086,"primaryCompletion":3439,"start":7483,"enrollment":32226,"conditions":35087,"interventions":35088},"NCT00357149","Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)",[91],[12355],[35075,35089],"Concomitant cisplatin, 5-FU and radiotherapy",{"trials":35091,"activeCount":102},[],{"trials":35093,"activeCount":102},[],{"trials":35095,"activeCount":102},[],{"intervention":35089,"totalTrials":195,"cells":35097},{"EARLY_PHASE1":35098,"PHASE1":35100,"PHASE2":35102,"PHASE3":35108,"PHASE4":35110,"NA":35112},{"trials":35099,"activeCount":102},[],{"trials":35101,"activeCount":102},[],{"trials":35103,"activeCount":102},[35104],{"nctId":35084,"briefTitle":35085,"status":108,"phases":35105,"primaryCompletion":3439,"start":7483,"enrollment":32226,"conditions":35106,"interventions":35107},[91],[12355],[35075,35089],{"trials":35109,"activeCount":102},[],{"trials":35111,"activeCount":102},[],{"trials":35113,"activeCount":102},[],{"intervention":35115,"totalTrials":195,"cells":35116},"CoV2 preS dTM-AF03",{"EARLY_PHASE1":35117,"PHASE1":35119,"PHASE2":35121,"PHASE3":35135,"PHASE4":35137,"NA":35139},{"trials":35118,"activeCount":102},[],{"trials":35120,"activeCount":102},[],{"trials":35122,"activeCount":102},[35123],{"nctId":35124,"briefTitle":35125,"status":108,"phases":35126,"primaryCompletion":35127,"completion":35127,"start":35128,"enrollment":35129,"conditions":35130,"interventions":35132},"NCT04537208","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older",[90,91],"2021-11-19","2020-09-03",441,[35131],"COVID-19 (Healthy Volunteers)",[35115,35115,35133,35133,35134],"CoV2 preS dTM-AS03","CoV2 preS dTM (high-dose) without adjuvant",{"trials":35136,"activeCount":102},[],{"trials":35138,"activeCount":102},[],{"trials":35140,"activeCount":102},[],{"intervention":35133,"totalTrials":195,"cells":35142},{"EARLY_PHASE1":35143,"PHASE1":35145,"PHASE2":35147,"PHASE3":35153,"PHASE4":35155,"NA":35157},{"trials":35144,"activeCount":102},[],{"trials":35146,"activeCount":102},[],{"trials":35148,"activeCount":102},[35149],{"nctId":35124,"briefTitle":35125,"status":108,"phases":35150,"primaryCompletion":35127,"completion":35127,"start":35128,"enrollment":35129,"conditions":35151,"interventions":35152},[90,91],[35131],[35115,35115,35133,35133,35134],{"trials":35154,"activeCount":102},[],{"trials":35156,"activeCount":102},[],{"trials":35158,"activeCount":102},[],{"intervention":35134,"totalTrials":195,"cells":35160},{"EARLY_PHASE1":35161,"PHASE1":35163,"PHASE2":35165,"PHASE3":35171,"PHASE4":35173,"NA":35175},{"trials":35162,"activeCount":102},[],{"trials":35164,"activeCount":102},[],{"trials":35166,"activeCount":102},[35167],{"nctId":35124,"briefTitle":35125,"status":108,"phases":35168,"primaryCompletion":35127,"completion":35127,"start":35128,"enrollment":35129,"conditions":35169,"interventions":35170},[90,91],[35131],[35115,35115,35133,35133,35134],{"trials":35172,"activeCount":102},[],{"trials":35174,"activeCount":102},[],{"trials":35176,"activeCount":102},[],{"intervention":32319,"totalTrials":195,"cells":35178},{"EARLY_PHASE1":35179,"PHASE1":35181,"PHASE2":35183,"PHASE3":35189,"PHASE4":35191,"NA":35193},{"trials":35180,"activeCount":102},[],{"trials":35182,"activeCount":102},[],{"trials":35184,"activeCount":102},[35185],{"nctId":32312,"briefTitle":32313,"status":108,"phases":35186,"primaryCompletion":32315,"completion":32316,"start":10640,"enrollment":13343,"conditions":35187,"interventions":35188},[91],[382],[193,32319,32320,32321,32322],{"trials":35190,"activeCount":102},[],{"trials":35192,"activeCount":102},[],{"trials":35194,"activeCount":102},[],{"intervention":32320,"totalTrials":195,"cells":35196},{"EARLY_PHASE1":35197,"PHASE1":35199,"PHASE2":35201,"PHASE3":35207,"PHASE4":35209,"NA":35211},{"trials":35198,"activeCount":102},[],{"trials":35200,"activeCount":102},[],{"trials":35202,"activeCount":102},[35203],{"nctId":32312,"briefTitle":32313,"status":108,"phases":35204,"primaryCompletion":32315,"completion":32316,"start":10640,"enrollment":13343,"conditions":35205,"interventions":35206},[91],[382],[193,32319,32320,32321,32322],{"trials":35208,"activeCount":102},[],{"trials":35210,"activeCount":102},[],{"trials":35212,"activeCount":102},[],{"intervention":32321,"totalTrials":195,"cells":35214},{"EARLY_PHASE1":35215,"PHASE1":35217,"PHASE2":35219,"PHASE3":35225,"PHASE4":35227,"NA":35229},{"trials":35216,"activeCount":102},[],{"trials":35218,"activeCount":102},[],{"trials":35220,"activeCount":102},[35221],{"nctId":32312,"briefTitle":32313,"status":108,"phases":35222,"primaryCompletion":32315,"completion":32316,"start":10640,"enrollment":13343,"conditions":35223,"interventions":35224},[91],[382],[193,32319,32320,32321,32322],{"trials":35226,"activeCount":102},[],{"trials":35228,"activeCount":102},[],{"trials":35230,"activeCount":102},[],{"intervention":32322,"totalTrials":195,"cells":35232},{"EARLY_PHASE1":35233,"PHASE1":35235,"PHASE2":35237,"PHASE3":35243,"PHASE4":35245,"NA":35247},{"trials":35234,"activeCount":102},[],{"trials":35236,"activeCount":102},[],{"trials":35238,"activeCount":102},[35239],{"nctId":32312,"briefTitle":32313,"status":108,"phases":35240,"primaryCompletion":32315,"completion":32316,"start":10640,"enrollment":13343,"conditions":35241,"interventions":35242},[91],[382],[193,32319,32320,32321,32322],{"trials":35244,"activeCount":102},[],{"trials":35246,"activeCount":102},[],{"trials":35248,"activeCount":102},[],{"intervention":32347,"totalTrials":195,"cells":35250},{"EARLY_PHASE1":35251,"PHASE1":35253,"PHASE2":35255,"PHASE3":35261,"PHASE4":35263,"NA":35265},{"trials":35252,"activeCount":102},[],{"trials":35254,"activeCount":102},[],{"trials":35256,"activeCount":102},[35257],{"nctId":32342,"briefTitle":32343,"status":108,"phases":35258,"primaryCompletion":2759,"completion":2759,"start":7283,"enrollment":6604,"conditions":35259,"interventions":35260},[91],[9210],[1347,32347,18130,9159],{"trials":35262,"activeCount":102},[],{"trials":35264,"activeCount":102},[],{"trials":35266,"activeCount":102},[],{"intervention":35268,"totalTrials":195,"cells":35269},"MRT5005",{"EARLY_PHASE1":35270,"PHASE1":35272,"PHASE2":35274,"PHASE3":35285,"PHASE4":35287,"NA":35289},{"trials":35271,"activeCount":102},[],{"trials":35273,"activeCount":102},[],{"trials":35275,"activeCount":102},[35276],{"nctId":35277,"briefTitle":35278,"status":108,"phases":35279,"primaryCompletion":35280,"completion":35280,"start":2747,"enrollment":3510,"conditions":35281,"interventions":35283},"NCT03375047","Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis",[90,91],"2022-03-15",[35282],"Cystic Fibrosis",[35268,35284],"Normal saline",{"trials":35286,"activeCount":102},[],{"trials":35288,"activeCount":102},[],{"trials":35290,"activeCount":102},[],{"intervention":35284,"totalTrials":195,"cells":35292},{"EARLY_PHASE1":35293,"PHASE1":35295,"PHASE2":35297,"PHASE3":35303,"PHASE4":35305,"NA":35307},{"trials":35294,"activeCount":102},[],{"trials":35296,"activeCount":102},[],{"trials":35298,"activeCount":102},[35299],{"nctId":35277,"briefTitle":35278,"status":108,"phases":35300,"primaryCompletion":35280,"completion":35280,"start":2747,"enrollment":3510,"conditions":35301,"interventions":35302},[90,91],[35282],[35268,35284],{"trials":35304,"activeCount":102},[],{"trials":35306,"activeCount":102},[],{"trials":35308,"activeCount":102},[],{"intervention":18099,"totalTrials":195,"cells":35310},{"EARLY_PHASE1":35311,"PHASE1":35313,"PHASE2":35315,"PHASE3":35321,"PHASE4":35323,"NA":35325},{"trials":35312,"activeCount":102},[],{"trials":35314,"activeCount":102},[],{"trials":35316,"activeCount":102},[35317],{"nctId":18093,"briefTitle":18094,"status":108,"phases":35318,"primaryCompletion":18096,"completion":18096,"start":189,"enrollment":7224,"conditions":35319,"interventions":35320},[91],[8187],[11524,18099],{"trials":35322,"activeCount":102},[],{"trials":35324,"activeCount":102},[],{"trials":35326,"activeCount":102},[],{"intervention":35328,"totalTrials":195,"cells":35329},"gemcitabine plus carboplatin plus BSI-201",{"EARLY_PHASE1":35330,"PHASE1":35332,"PHASE2":35334,"PHASE3":35342,"PHASE4":35344,"NA":35346},{"trials":35331,"activeCount":102},[],{"trials":35333,"activeCount":102},[],{"trials":35335,"activeCount":102},[35336],{"nctId":35337,"briefTitle":35338,"status":108,"phases":35339,"primaryCompletion":164,"completion":164,"start":8205,"enrollment":20,"conditions":35340,"interventions":35341},"NCT00813956","A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer",[91],[32440],[35328],{"trials":35343,"activeCount":102},[],{"trials":35345,"activeCount":102},[],{"trials":35347,"activeCount":102},[],{"intervention":35349,"totalTrials":195,"cells":35350},"Oxaliplatin, 5-FU",{"EARLY_PHASE1":35351,"PHASE1":35353,"PHASE2":35355,"PHASE3":35363,"PHASE4":35365,"NA":35367},{"trials":35352,"activeCount":102},[],{"trials":35354,"activeCount":102},[],{"trials":35356,"activeCount":102},[35357],{"nctId":35358,"briefTitle":35359,"status":108,"phases":35360,"completion":3528,"start":11555,"enrollment":335,"conditions":35361,"interventions":35362},"NCT00611754","Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck",[91],[17877],[35349],{"trials":35364,"activeCount":102},[],{"trials":35366,"activeCount":102},[],{"trials":35368,"activeCount":102},[],{"intervention":35370,"totalTrials":195,"cells":35371},"Docetaxel and cisplatin followed by gemcitabine",{"EARLY_PHASE1":35372,"PHASE1":35374,"PHASE2":35376,"PHASE3":35385,"PHASE4":35387,"NA":35389},{"trials":35373,"activeCount":102},[],{"trials":35375,"activeCount":102},[],{"trials":35377,"activeCount":102},[35378],{"nctId":35379,"briefTitle":35380,"status":108,"phases":35381,"primaryCompletion":3417,"completion":3417,"start":9862,"enrollment":9786,"conditions":35382,"interventions":35383},"NCT00424853","ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)",[91],[30031],[35370,35384],"docetaxel and cisplatin followed by gemcitabine",{"trials":35386,"activeCount":102},[],{"trials":35388,"activeCount":102},[],{"trials":35390,"activeCount":102},[],{"intervention":8066,"totalTrials":195,"cells":35392},{"EARLY_PHASE1":35393,"PHASE1":35395,"PHASE2":35397,"PHASE3":35403,"PHASE4":35405,"NA":35407},{"trials":35394,"activeCount":102},[],{"trials":35396,"activeCount":102},[],{"trials":35398,"activeCount":102},[35399],{"nctId":8059,"briefTitle":8060,"status":108,"phases":35400,"primaryCompletion":3438,"completion":3438,"start":8062,"enrollment":8063,"conditions":35401,"interventions":35402},[91],[19],[8066,8067,8024],{"trials":35404,"activeCount":102},[],{"trials":35406,"activeCount":102},[],{"trials":35408,"activeCount":102},[],{"intervention":35410,"totalTrials":195,"cells":35411},"alvocidib",{"EARLY_PHASE1":35412,"PHASE1":35414,"PHASE2":35416,"PHASE3":35425,"PHASE4":35427,"NA":35429},{"trials":35413,"activeCount":102},[],{"trials":35415,"activeCount":102},[],{"trials":35417,"activeCount":102},[35418],{"nctId":35419,"briefTitle":35420,"status":108,"phases":35421,"primaryCompletion":977,"completion":977,"start":5272,"enrollment":204,"conditions":35422,"interventions":35424},"NCT00464633","Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)",[91],[35423],"Leukemia, Lymphocytic, Chronic",[35410],{"trials":35426,"activeCount":102},[],{"trials":35428,"activeCount":102},[],{"trials":35430,"activeCount":102},[],{"intervention":35432,"totalTrials":195,"cells":35433},"Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide",{"EARLY_PHASE1":35434,"PHASE1":35436,"PHASE2":35438,"PHASE3":35448,"PHASE4":35450,"NA":35452},{"trials":35435,"activeCount":102},[],{"trials":35437,"activeCount":102},[],{"trials":35439,"activeCount":102},[35440],{"nctId":35441,"briefTitle":35442,"status":108,"phases":35443,"primaryCompletion":2790,"completion":8107,"start":987,"enrollment":35444,"conditions":35445,"interventions":35446},"NCT01239043","Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination",[91],139,[4992,7568,2922],[35432,35447],"Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate",{"trials":35449,"activeCount":102},[],{"trials":35451,"activeCount":102},[],{"trials":35453,"activeCount":102},[],{"intervention":35447,"totalTrials":195,"cells":35455},{"EARLY_PHASE1":35456,"PHASE1":35458,"PHASE2":35460,"PHASE3":35466,"PHASE4":35468,"NA":35470},{"trials":35457,"activeCount":102},[],{"trials":35459,"activeCount":102},[],{"trials":35461,"activeCount":102},[35462],{"nctId":35441,"briefTitle":35442,"status":108,"phases":35463,"primaryCompletion":2790,"completion":8107,"start":987,"enrollment":35444,"conditions":35464,"interventions":35465},[91],[4992,7568,2922],[35432,35447],{"trials":35467,"activeCount":102},[],{"trials":35469,"activeCount":102},[],{"trials":35471,"activeCount":102},[],{"intervention":35473,"totalTrials":195,"cells":35474},"Docetaxel and Gemcitabine",{"EARLY_PHASE1":35475,"PHASE1":35477,"PHASE2":35479,"PHASE3":35488,"PHASE4":35490,"NA":35492},{"trials":35476,"activeCount":102},[],{"trials":35478,"activeCount":102},[],{"trials":35480,"activeCount":102},[35481],{"nctId":35482,"briefTitle":35483,"status":108,"phases":35484,"primaryCompletion":8667,"start":9800,"enrollment":204,"conditions":35485,"interventions":35486},"NCT00425191","Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.",[91],[2703],[35473,35473,35487],"Gemcitabine cisplatin followed by docetaxel",{"trials":35489,"activeCount":102},[],{"trials":35491,"activeCount":102},[],{"trials":35493,"activeCount":102},[],{"intervention":35487,"totalTrials":195,"cells":35495},{"EARLY_PHASE1":35496,"PHASE1":35498,"PHASE2":35500,"PHASE3":35506,"PHASE4":35508,"NA":35510},{"trials":35497,"activeCount":102},[],{"trials":35499,"activeCount":102},[],{"trials":35501,"activeCount":102},[35502],{"nctId":35482,"briefTitle":35483,"status":108,"phases":35503,"primaryCompletion":8667,"start":9800,"enrollment":204,"conditions":35504,"interventions":35505},[91],[2703],[35473,35473,35487],{"trials":35507,"activeCount":102},[],{"trials":35509,"activeCount":102},[],{"trials":35511,"activeCount":102},[],{"intervention":35513,"totalTrials":195,"cells":35514},"RSV vaccine candiate formulation 1",{"EARLY_PHASE1":35515,"PHASE1":35517,"PHASE2":35519,"PHASE3":35531,"PHASE4":35533,"NA":35535},{"trials":35516,"activeCount":102},[],{"trials":35518,"activeCount":102},[],{"trials":35520,"activeCount":102},[35521],{"nctId":35522,"briefTitle":35523,"status":108,"phases":35524,"primaryCompletion":35525,"completion":35525,"start":35526,"enrollment":35527,"conditions":35528,"interventions":35529},"NCT05639894","Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older",[90,91],"2025-05-02","2022-11-17",865,[5815],[35513,35530],"RSV vaccine candidate formulation 2",{"trials":35532,"activeCount":102},[],{"trials":35534,"activeCount":102},[],{"trials":35536,"activeCount":102},[],{"intervention":35530,"totalTrials":195,"cells":35538},{"EARLY_PHASE1":35539,"PHASE1":35541,"PHASE2":35543,"PHASE3":35549,"PHASE4":35551,"NA":35553},{"trials":35540,"activeCount":102},[],{"trials":35542,"activeCount":102},[],{"trials":35544,"activeCount":102},[35545],{"nctId":35522,"briefTitle":35523,"status":108,"phases":35546,"primaryCompletion":35525,"completion":35525,"start":35526,"enrollment":35527,"conditions":35547,"interventions":35548},[90,91],[5815],[35513,35530],{"trials":35550,"activeCount":102},[],{"trials":35552,"activeCount":102},[],{"trials":35554,"activeCount":102},[],{"intervention":35556,"totalTrials":195,"cells":35557},"ACAM1000",{"EARLY_PHASE1":35558,"PHASE1":35560,"PHASE2":35562,"PHASE3":35571,"PHASE4":35573,"NA":35575},{"trials":35559,"activeCount":102},[],{"trials":35561,"activeCount":102},[],{"trials":35563,"activeCount":102},[35564],{"nctId":35565,"briefTitle":35566,"status":884,"phases":35567,"primaryCompletion":3326,"completion":9872,"start":10072,"enrollment":22850,"conditions":35568,"interventions":35569},"NCT00053508","Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination",[91],[32605],[35556,35570],"vaccinia virus (calf lymph) smallpox vaccine: Dryvax",{"trials":35572,"activeCount":102},[],{"trials":35574,"activeCount":102},[],{"trials":35576,"activeCount":102},[],{"intervention":35570,"totalTrials":195,"cells":35578},{"EARLY_PHASE1":35579,"PHASE1":35581,"PHASE2":35583,"PHASE3":35589,"PHASE4":35591,"NA":35593},{"trials":35580,"activeCount":102},[],{"trials":35582,"activeCount":102},[],{"trials":35584,"activeCount":102},[35585],{"nctId":35565,"briefTitle":35566,"status":884,"phases":35586,"primaryCompletion":3326,"completion":9872,"start":10072,"enrollment":22850,"conditions":35587,"interventions":35588},[91],[32605],[35556,35570],{"trials":35590,"activeCount":102},[],{"trials":35592,"activeCount":102},[],{"trials":35594,"activeCount":102},[],{"intervention":32091,"totalTrials":195,"cells":35596},{"EARLY_PHASE1":35597,"PHASE1":35599,"PHASE2":35601,"PHASE3":35607,"PHASE4":35609,"NA":35611},{"trials":35598,"activeCount":102},[],{"trials":35600,"activeCount":102},[],{"trials":35602,"activeCount":102},[35603],{"nctId":32085,"briefTitle":32086,"status":108,"phases":35604,"primaryCompletion":8388,"completion":978,"start":10320,"enrollment":6655,"conditions":35605,"interventions":35606},[91],[16,15230,32089],[32091,32092,32092],{"trials":35608,"activeCount":102},[],{"trials":35610,"activeCount":102},[],{"trials":35612,"activeCount":102},[],{"intervention":35614,"totalTrials":195,"cells":35615},"Purified Vero Rabies Vaccine Serum Free",{"EARLY_PHASE1":35616,"PHASE1":35618,"PHASE2":35620,"PHASE3":35629,"PHASE4":35631,"NA":35633},{"trials":35617,"activeCount":102},[],{"trials":35619,"activeCount":102},[],{"trials":35621,"activeCount":102},[35622],{"nctId":35623,"briefTitle":35624,"status":108,"phases":35625,"primaryCompletion":11210,"completion":8165,"start":2311,"enrollment":12981,"conditions":35626,"interventions":35627},"NCT01930357","Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen",[91],[14171],[35614,35628],"Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),",{"trials":35630,"activeCount":102},[],{"trials":35632,"activeCount":102},[],{"trials":35634,"activeCount":102},[],{"intervention":35628,"totalTrials":195,"cells":35636},{"EARLY_PHASE1":35637,"PHASE1":35639,"PHASE2":35641,"PHASE3":35647,"PHASE4":35649,"NA":35651},{"trials":35638,"activeCount":102},[],{"trials":35640,"activeCount":102},[],{"trials":35642,"activeCount":102},[35643],{"nctId":35623,"briefTitle":35624,"status":108,"phases":35644,"primaryCompletion":11210,"completion":8165,"start":2311,"enrollment":12981,"conditions":35645,"interventions":35646},[91],[14171],[35614,35628],{"trials":35648,"activeCount":102},[],{"trials":35650,"activeCount":102},[],{"trials":35652,"activeCount":102},[],{"intervention":35654,"totalTrials":195,"cells":35655},"2009-2010 Trivalent Influenza Virus Vaccine",{"EARLY_PHASE1":35656,"PHASE1":35658,"PHASE2":35660,"PHASE3":35670,"PHASE4":35672,"NA":35674},{"trials":35657,"activeCount":102},[],{"trials":35659,"activeCount":102},[],{"trials":35661,"activeCount":102},[35662],{"nctId":35663,"briefTitle":35664,"status":108,"phases":35665,"primaryCompletion":8388,"completion":1022,"start":3354,"enrollment":16359,"conditions":35666,"interventions":35667},"NCT00988143","A Study of Influenza Virus Vaccines in Children and Adults",[91],[16],[35654,35668,35669],"2008-2009 Trivalent Influenza Virus Vaccine","Quadrivalent Influenza Virus Vaccine",{"trials":35671,"activeCount":102},[],{"trials":35673,"activeCount":102},[],{"trials":35675,"activeCount":102},[],{"intervention":35668,"totalTrials":195,"cells":35677},{"EARLY_PHASE1":35678,"PHASE1":35680,"PHASE2":35682,"PHASE3":35688,"PHASE4":35690,"NA":35692},{"trials":35679,"activeCount":102},[],{"trials":35681,"activeCount":102},[],{"trials":35683,"activeCount":102},[35684],{"nctId":35663,"briefTitle":35664,"status":108,"phases":35685,"primaryCompletion":8388,"completion":1022,"start":3354,"enrollment":16359,"conditions":35686,"interventions":35687},[91],[16],[35654,35668,35669],{"trials":35689,"activeCount":102},[],{"trials":35691,"activeCount":102},[],{"trials":35693,"activeCount":102},[],{"intervention":35669,"totalTrials":195,"cells":35695},{"EARLY_PHASE1":35696,"PHASE1":35698,"PHASE2":35700,"PHASE3":35706,"PHASE4":35708,"NA":35710},{"trials":35697,"activeCount":102},[],{"trials":35699,"activeCount":102},[],{"trials":35701,"activeCount":102},[35702],{"nctId":35663,"briefTitle":35664,"status":108,"phases":35703,"primaryCompletion":8388,"completion":1022,"start":3354,"enrollment":16359,"conditions":35704,"interventions":35705},[91],[16],[35654,35668,35669],{"trials":35707,"activeCount":102},[],{"trials":35709,"activeCount":102},[],{"trials":35711,"activeCount":102},[],{"intervention":32464,"totalTrials":195,"cells":35713},{"EARLY_PHASE1":35714,"PHASE1":35716,"PHASE2":35718,"PHASE3":35724,"PHASE4":35726,"NA":35728},{"trials":35715,"activeCount":102},[],{"trials":35717,"activeCount":102},[],{"trials":35719,"activeCount":102},[35720],{"nctId":32458,"briefTitle":32459,"status":108,"phases":35721,"primaryCompletion":4261,"completion":4261,"start":19589,"enrollment":2101,"conditions":35722,"interventions":35723},[90,91],[32462,5335],[32464,32449,32465,32465,32465,32465],{"trials":35725,"activeCount":102},[],{"trials":35727,"activeCount":102},[],{"trials":35729,"activeCount":102},[],{"intervention":32465,"totalTrials":195,"cells":35731},{"EARLY_PHASE1":35732,"PHASE1":35734,"PHASE2":35736,"PHASE3":35742,"PHASE4":35744,"NA":35746},{"trials":35733,"activeCount":102},[],{"trials":35735,"activeCount":102},[],{"trials":35737,"activeCount":102},[35738],{"nctId":32458,"briefTitle":32459,"status":108,"phases":35739,"primaryCompletion":4261,"completion":4261,"start":19589,"enrollment":2101,"conditions":35740,"interventions":35741},[90,91],[32462,5335],[32464,32449,32465,32465,32465,32465],{"trials":35743,"activeCount":102},[],{"trials":35745,"activeCount":102},[],{"trials":35747,"activeCount":102},[],{"intervention":157,"totalTrials":195,"cells":35749},{"EARLY_PHASE1":35750,"PHASE1":35752,"PHASE2":35754,"PHASE3":35760,"PHASE4":35762,"NA":35764},{"trials":35751,"activeCount":102},[],{"trials":35753,"activeCount":102},[],{"trials":35755,"activeCount":102},[35756],{"nctId":147,"briefTitle":148,"status":108,"phases":35757,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":35758,"interventions":35759},[91],[155],[97,157,158,159],{"trials":35761,"activeCount":102},[],{"trials":35763,"activeCount":102},[],{"trials":35765,"activeCount":102},[],{"intervention":158,"totalTrials":195,"cells":35767},{"EARLY_PHASE1":35768,"PHASE1":35770,"PHASE2":35772,"PHASE3":35778,"PHASE4":35780,"NA":35782},{"trials":35769,"activeCount":102},[],{"trials":35771,"activeCount":102},[],{"trials":35773,"activeCount":102},[35774],{"nctId":147,"briefTitle":148,"status":108,"phases":35775,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":35776,"interventions":35777},[91],[155],[97,157,158,159],{"trials":35779,"activeCount":102},[],{"trials":35781,"activeCount":102},[],{"trials":35783,"activeCount":102},[],{"intervention":159,"totalTrials":195,"cells":35785},{"EARLY_PHASE1":35786,"PHASE1":35788,"PHASE2":35790,"PHASE3":35796,"PHASE4":35798,"NA":35800},{"trials":35787,"activeCount":102},[],{"trials":35789,"activeCount":102},[],{"trials":35791,"activeCount":102},[35792],{"nctId":147,"briefTitle":148,"status":108,"phases":35793,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":35794,"interventions":35795},[91],[155],[97,157,158,159],{"trials":35797,"activeCount":102},[],{"trials":35799,"activeCount":102},[],{"trials":35801,"activeCount":102},[],{"intervention":35803,"totalTrials":195,"cells":35804},"Live attenuated Japanese encephalitis virus, then ChimeriVax diluent",{"EARLY_PHASE1":35805,"PHASE1":35807,"PHASE2":35809,"PHASE3":35818,"PHASE4":35820,"NA":35822},{"trials":35806,"activeCount":102},[],{"trials":35808,"activeCount":102},[],{"trials":35810,"activeCount":102},[35811],{"nctId":35812,"briefTitle":35813,"status":108,"phases":35814,"primaryCompletion":9909,"completion":3439,"start":9113,"enrollment":6493,"conditions":35815,"interventions":35816},"NCT00981175","A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults",[91],[28205,17265],[35803,35817],"ChimeriVax diluent, then Live attenuated Japanese encephalitis virus",{"trials":35819,"activeCount":102},[],{"trials":35821,"activeCount":102},[],{"trials":35823,"activeCount":102},[],{"intervention":35817,"totalTrials":195,"cells":35825},{"EARLY_PHASE1":35826,"PHASE1":35828,"PHASE2":35830,"PHASE3":35836,"PHASE4":35838,"NA":35840},{"trials":35827,"activeCount":102},[],{"trials":35829,"activeCount":102},[],{"trials":35831,"activeCount":102},[35832],{"nctId":35812,"briefTitle":35813,"status":108,"phases":35833,"primaryCompletion":9909,"completion":3439,"start":9113,"enrollment":6493,"conditions":35834,"interventions":35835},[91],[28205,17265],[35803,35817],{"trials":35837,"activeCount":102},[],{"trials":35839,"activeCount":102},[],{"trials":35841,"activeCount":102},[],{"intervention":35843,"totalTrials":195,"cells":35844},"docetaxel and carboplatin",{"EARLY_PHASE1":35845,"PHASE1":35847,"PHASE2":35849,"PHASE3":35857,"PHASE4":35859,"NA":35861},{"trials":35846,"activeCount":102},[],{"trials":35848,"activeCount":102},[],{"trials":35850,"activeCount":102},[35851],{"nctId":35852,"briefTitle":35853,"status":108,"phases":35854,"primaryCompletion":8731,"completion":8731,"start":3488,"enrollment":9533,"conditions":35855,"interventions":35856},"NCT00826852","Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax",[91],[17899],[35843],{"trials":35858,"activeCount":102},[],{"trials":35860,"activeCount":102},[],{"trials":35862,"activeCount":102},[],{"intervention":35864,"totalTrials":195,"cells":35865},"SR147778",{"EARLY_PHASE1":35866,"PHASE1":35868,"PHASE2":35870,"PHASE3":35878,"PHASE4":35880,"NA":35882},{"trials":35867,"activeCount":102},[],{"trials":35869,"activeCount":102},[],{"trials":35871,"activeCount":102},[35872],{"nctId":35873,"briefTitle":35874,"status":108,"phases":35875,"primaryCompletion":3623,"completion":3623,"start":8175,"enrollment":10685,"conditions":35876,"interventions":35877},"NCT00239174","A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients",[91],[17609],[35864],{"trials":35879,"activeCount":102},[],{"trials":35881,"activeCount":102},[],{"trials":35883,"activeCount":102},[],{"intervention":35885,"totalTrials":195,"cells":35886},"ChimeriVax-WN02 Low Dose",{"EARLY_PHASE1":35887,"PHASE1":35889,"PHASE2":35891,"PHASE3":35904,"PHASE4":35906,"NA":35908},{"trials":35888,"activeCount":102},[],{"trials":35890,"activeCount":102},[],{"trials":35892,"activeCount":102},[35893],{"nctId":35894,"briefTitle":35895,"status":108,"phases":35896,"primaryCompletion":8156,"completion":3396,"start":3565,"enrollment":4589,"conditions":35897,"interventions":35899},"NCT00442169","Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults",[91],[35898],"West Nile Fever",[35885,35900,35901,35902,35901,35903],"ChimeriVax-WN02 Medium Dose","ChimeriVax-WN02 High Dose","0.9% Saline solution","0.9 % NaCl solution",{"trials":35905,"activeCount":102},[],{"trials":35907,"activeCount":102},[],{"trials":35909,"activeCount":102},[],{"intervention":35900,"totalTrials":195,"cells":35911},{"EARLY_PHASE1":35912,"PHASE1":35914,"PHASE2":35916,"PHASE3":35922,"PHASE4":35924,"NA":35926},{"trials":35913,"activeCount":102},[],{"trials":35915,"activeCount":102},[],{"trials":35917,"activeCount":102},[35918],{"nctId":35894,"briefTitle":35895,"status":108,"phases":35919,"primaryCompletion":8156,"completion":3396,"start":3565,"enrollment":4589,"conditions":35920,"interventions":35921},[91],[35898],[35885,35900,35901,35902,35901,35903],{"trials":35923,"activeCount":102},[],{"trials":35925,"activeCount":102},[],{"trials":35927,"activeCount":102},[],{"intervention":35901,"totalTrials":195,"cells":35929},{"EARLY_PHASE1":35930,"PHASE1":35932,"PHASE2":35934,"PHASE3":35940,"PHASE4":35942,"NA":35944},{"trials":35931,"activeCount":102},[],{"trials":35933,"activeCount":102},[],{"trials":35935,"activeCount":102},[35936],{"nctId":35894,"briefTitle":35895,"status":108,"phases":35937,"primaryCompletion":8156,"completion":3396,"start":3565,"enrollment":4589,"conditions":35938,"interventions":35939},[91],[35898],[35885,35900,35901,35902,35901,35903],{"trials":35941,"activeCount":102},[],{"trials":35943,"activeCount":102},[],{"trials":35945,"activeCount":102},[],{"intervention":35902,"totalTrials":195,"cells":35947},{"EARLY_PHASE1":35948,"PHASE1":35950,"PHASE2":35952,"PHASE3":35958,"PHASE4":35960,"NA":35962},{"trials":35949,"activeCount":102},[],{"trials":35951,"activeCount":102},[],{"trials":35953,"activeCount":102},[35954],{"nctId":35894,"briefTitle":35895,"status":108,"phases":35955,"primaryCompletion":8156,"completion":3396,"start":3565,"enrollment":4589,"conditions":35956,"interventions":35957},[91],[35898],[35885,35900,35901,35902,35901,35903],{"trials":35959,"activeCount":102},[],{"trials":35961,"activeCount":102},[],{"trials":35963,"activeCount":102},[],{"intervention":35903,"totalTrials":195,"cells":35965},{"EARLY_PHASE1":35966,"PHASE1":35968,"PHASE2":35970,"PHASE3":35976,"PHASE4":35978,"NA":35980},{"trials":35967,"activeCount":102},[],{"trials":35969,"activeCount":102},[],{"trials":35971,"activeCount":102},[35972],{"nctId":35894,"briefTitle":35895,"status":108,"phases":35973,"primaryCompletion":8156,"completion":3396,"start":3565,"enrollment":4589,"conditions":35974,"interventions":35975},[91],[35898],[35885,35900,35901,35902,35901,35903],{"trials":35977,"activeCount":102},[],{"trials":35979,"activeCount":102},[],{"trials":35981,"activeCount":102},[],{"intervention":35983,"totalTrials":195,"cells":35984},"Dupilumab SAR231893\u002FREGN668",{"EARLY_PHASE1":35985,"PHASE1":35987,"PHASE2":35989,"PHASE3":36001,"PHASE4":36003,"NA":36005},{"trials":35986,"activeCount":102},[],{"trials":35988,"activeCount":102},[],{"trials":35990,"activeCount":102},[35991],{"nctId":35992,"briefTitle":35993,"status":108,"phases":35994,"primaryCompletion":13579,"completion":13579,"start":35995,"enrollment":3510,"conditions":35996,"interventions":35997},"NCT02573233","Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma",[91],"2016-01-27",[155],[35983,35998,35999,36000],"fluticasone propionate and salmeterol","budesonide and formoterol","mometasone furoate and formoterol",{"trials":36002,"activeCount":102},[],{"trials":36004,"activeCount":102},[],{"trials":36006,"activeCount":102},[],{"intervention":35998,"totalTrials":195,"cells":36008},{"EARLY_PHASE1":36009,"PHASE1":36011,"PHASE2":36013,"PHASE3":36019,"PHASE4":36021,"NA":36023},{"trials":36010,"activeCount":102},[],{"trials":36012,"activeCount":102},[],{"trials":36014,"activeCount":102},[36015],{"nctId":35992,"briefTitle":35993,"status":108,"phases":36016,"primaryCompletion":13579,"completion":13579,"start":35995,"enrollment":3510,"conditions":36017,"interventions":36018},[91],[155],[35983,35998,35999,36000],{"trials":36020,"activeCount":102},[],{"trials":36022,"activeCount":102},[],{"trials":36024,"activeCount":102},[],{"intervention":35999,"totalTrials":195,"cells":36026},{"EARLY_PHASE1":36027,"PHASE1":36029,"PHASE2":36031,"PHASE3":36037,"PHASE4":36039,"NA":36041},{"trials":36028,"activeCount":102},[],{"trials":36030,"activeCount":102},[],{"trials":36032,"activeCount":102},[36033],{"nctId":35992,"briefTitle":35993,"status":108,"phases":36034,"primaryCompletion":13579,"completion":13579,"start":35995,"enrollment":3510,"conditions":36035,"interventions":36036},[91],[155],[35983,35998,35999,36000],{"trials":36038,"activeCount":102},[],{"trials":36040,"activeCount":102},[],{"trials":36042,"activeCount":102},[],{"intervention":36000,"totalTrials":195,"cells":36044},{"EARLY_PHASE1":36045,"PHASE1":36047,"PHASE2":36049,"PHASE3":36055,"PHASE4":36057,"NA":36059},{"trials":36046,"activeCount":102},[],{"trials":36048,"activeCount":102},[],{"trials":36050,"activeCount":102},[36051],{"nctId":35992,"briefTitle":35993,"status":108,"phases":36052,"primaryCompletion":13579,"completion":13579,"start":35995,"enrollment":3510,"conditions":36053,"interventions":36054},[91],[155],[35983,35998,35999,36000],{"trials":36056,"activeCount":102},[],{"trials":36058,"activeCount":102},[],{"trials":36060,"activeCount":102},[],{"intervention":31748,"totalTrials":195,"cells":36062},{"EARLY_PHASE1":36063,"PHASE1":36065,"PHASE2":36067,"PHASE3":36073,"PHASE4":36075,"NA":36077},{"trials":36064,"activeCount":102},[],{"trials":36066,"activeCount":102},[],{"trials":36068,"activeCount":102},[36069],{"nctId":31742,"briefTitle":31743,"status":108,"phases":36070,"primaryCompletion":8693,"completion":165,"start":3354,"enrollment":31745,"conditions":36071,"interventions":36072},[91],[16,31381],[31748,31748,31749,31749,31750],{"trials":36074,"activeCount":102},[],{"trials":36076,"activeCount":102},[],{"trials":36078,"activeCount":102},[],{"intervention":36080,"totalTrials":195,"cells":36081},"Pandemic flu H5 mRNA vaccine",{"EARLY_PHASE1":36082,"PHASE1":36084,"PHASE2":36086,"PHASE3":36096,"PHASE4":36098,"NA":36100},{"trials":36083,"activeCount":102},[],{"trials":36085,"activeCount":102},[],{"trials":36087,"activeCount":102},[36088],{"nctId":36089,"briefTitle":36090,"status":108,"phases":36091,"primaryCompletion":36092,"completion":36092,"start":36093,"enrollment":7125,"conditions":36094,"interventions":36095},"NCT06727058","Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older",[90,91],"2026-03-24","2024-12-09",[5335],[36080],{"trials":36097,"activeCount":102},[],{"trials":36099,"activeCount":102},[],{"trials":36101,"activeCount":102},[],{"intervention":3571,"totalTrials":195,"cells":36103},{"EARLY_PHASE1":36104,"PHASE1":36106,"PHASE2":36108,"PHASE3":36114,"PHASE4":36116,"NA":36118},{"trials":36105,"activeCount":102},[],{"trials":36107,"activeCount":102},[],{"trials":36109,"activeCount":102},[36110],{"nctId":3560,"briefTitle":3561,"status":108,"phases":36111,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":36112,"interventions":36113},[91],[1357,3568,3569],[3571,1348,672],{"trials":36115,"activeCount":102},[],{"trials":36117,"activeCount":102},[],{"trials":36119,"activeCount":102},[],{"intervention":36121,"totalTrials":195,"cells":36122},"Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus",{"EARLY_PHASE1":36123,"PHASE1":36125,"PHASE2":36127,"PHASE3":36135,"PHASE4":36137,"NA":36139},{"trials":36124,"activeCount":102},[],{"trials":36126,"activeCount":102},[],{"trials":36128,"activeCount":102},[36129],{"nctId":36130,"briefTitle":36131,"status":108,"phases":36132,"primaryCompletion":6471,"completion":8166,"start":8683,"enrollment":8262,"conditions":36133,"interventions":36134},"NCT01550289","Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India",[91],[2316,18210,2317],[36121],{"trials":36136,"activeCount":102},[],{"trials":36138,"activeCount":102},[],{"trials":36140,"activeCount":102},[],{"intervention":32239,"totalTrials":195,"cells":36142},{"EARLY_PHASE1":36143,"PHASE1":36145,"PHASE2":36147,"PHASE3":36153,"PHASE4":36155,"NA":36157},{"trials":36144,"activeCount":102},[],{"trials":36146,"activeCount":102},[],{"trials":36148,"activeCount":102},[36149],{"nctId":32233,"briefTitle":32234,"status":884,"phases":36150,"primaryCompletion":32236,"completion":32236,"start":6753,"enrollment":538,"conditions":36151,"interventions":36152},[90,91],[4631],[32212,32239,32240],{"trials":36154,"activeCount":102},[],{"trials":36156,"activeCount":102},[],{"trials":36158,"activeCount":102},[],{"intervention":32240,"totalTrials":195,"cells":36160},{"EARLY_PHASE1":36161,"PHASE1":36163,"PHASE2":36165,"PHASE3":36171,"PHASE4":36173,"NA":36175},{"trials":36162,"activeCount":102},[],{"trials":36164,"activeCount":102},[],{"trials":36166,"activeCount":102},[36167],{"nctId":32233,"briefTitle":32234,"status":884,"phases":36168,"primaryCompletion":32236,"completion":32236,"start":6753,"enrollment":538,"conditions":36169,"interventions":36170},[90,91],[4631],[32212,32239,32240],{"trials":36172,"activeCount":102},[],{"trials":36174,"activeCount":102},[],{"trials":36176,"activeCount":102},[],{"intervention":2753,"totalTrials":195,"cells":36178},{"EARLY_PHASE1":36179,"PHASE1":36181,"PHASE2":36183,"PHASE3":36189,"PHASE4":36191,"NA":36193},{"trials":36180,"activeCount":102},[],{"trials":36182,"activeCount":102},[],{"trials":36184,"activeCount":102},[36185],{"nctId":2744,"briefTitle":2745,"status":884,"phases":36186,"primaryCompletion":2747,"completion":2747,"start":2748,"enrollment":535,"conditions":36187,"interventions":36188},[91],[2750],[2752,2753,2754,671],{"trials":36190,"activeCount":102},[],{"trials":36192,"activeCount":102},[],{"trials":36194,"activeCount":102},[],{"intervention":36196,"totalTrials":195,"cells":36197},"Influenza virus (split virion, inactivated) vaccine",{"EARLY_PHASE1":36198,"PHASE1":36200,"PHASE2":36202,"PHASE3":36210,"PHASE4":36212,"NA":36214},{"trials":36199,"activeCount":102},[],{"trials":36201,"activeCount":102},[],{"trials":36203,"activeCount":102},[36204],{"nctId":36205,"briefTitle":36206,"status":108,"phases":36207,"primaryCompletion":3307,"completion":8731,"start":8261,"enrollment":31232,"conditions":36208,"interventions":36209},"NCT00946179","Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation",[91],[16],[36196],{"trials":36211,"activeCount":102},[],{"trials":36213,"activeCount":102},[],{"trials":36215,"activeCount":102},[],{"intervention":5410,"totalTrials":195,"cells":36217},{"EARLY_PHASE1":36218,"PHASE1":36220,"PHASE2":36222,"PHASE3":36228,"PHASE4":36230,"NA":36232},{"trials":36219,"activeCount":102},[],{"trials":36221,"activeCount":102},[],{"trials":36223,"activeCount":102},[36224],{"nctId":5402,"briefTitle":5403,"status":884,"phases":36225,"primaryCompletion":5405,"completion":887,"start":5406,"enrollment":5407,"conditions":36226,"interventions":36227},[91],[1274],[5400,5410,5298],{"trials":36229,"activeCount":102},[],{"trials":36231,"activeCount":102},[],{"trials":36233,"activeCount":102},[],{"intervention":5559,"totalTrials":195,"cells":36235},{"EARLY_PHASE1":36236,"PHASE1":36238,"PHASE2":36240,"PHASE3":36246,"PHASE4":36248,"NA":36250},{"trials":36237,"activeCount":102},[],{"trials":36239,"activeCount":102},[],{"trials":36241,"activeCount":102},[36242],{"nctId":5551,"briefTitle":5552,"status":108,"phases":36243,"primaryCompletion":564,"completion":564,"start":5554,"enrollment":4760,"conditions":36244,"interventions":36245},[91],[5556,5557],[5542,5559],{"trials":36247,"activeCount":102},[],{"trials":36249,"activeCount":102},[],{"trials":36251,"activeCount":102},[],{"intervention":5360,"totalTrials":195,"cells":36253},{"EARLY_PHASE1":36254,"PHASE1":36256,"PHASE2":36258,"PHASE3":36264,"PHASE4":36266,"NA":36268},{"trials":36255,"activeCount":102},[],{"trials":36257,"activeCount":102},[],{"trials":36259,"activeCount":102},[36260],{"nctId":5352,"briefTitle":5353,"status":108,"phases":36261,"primaryCompletion":5355,"completion":5355,"start":5356,"enrollment":5357,"conditions":36262,"interventions":36263},[90,91],[5335],[5360,5338,5319,5339],{"trials":36265,"activeCount":102},[],{"trials":36267,"activeCount":102},[],{"trials":36269,"activeCount":102},[],{"intervention":36271,"totalTrials":195,"cells":36272},"Polysaccharide Diphtheria Conjugate Vaccine",{"EARLY_PHASE1":36273,"PHASE1":36275,"PHASE2":36277,"PHASE3":36286,"PHASE4":36288,"NA":36290},{"trials":36274,"activeCount":102},[],{"trials":36276,"activeCount":102},[],{"trials":36278,"activeCount":102},[36279],{"nctId":36280,"briefTitle":36281,"status":108,"phases":36282,"primaryCompletion":5272,"completion":8607,"start":3609,"enrollment":36283,"conditions":36284,"interventions":36285},"NCT00258856","Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®",[91],234,[4992,2949],[36271,36271,36271,36271],{"trials":36287,"activeCount":102},[],{"trials":36289,"activeCount":102},[],{"trials":36291,"activeCount":102},[],{"intervention":32383,"totalTrials":195,"cells":36293},{"EARLY_PHASE1":36294,"PHASE1":36296,"PHASE2":36298,"PHASE3":36304,"PHASE4":36306,"NA":36308},{"trials":36295,"activeCount":102},[],{"trials":36297,"activeCount":102},[],{"trials":36299,"activeCount":102},[36300],{"nctId":32375,"briefTitle":32376,"status":3661,"phases":36301,"primaryCompletion":32378,"completion":32378,"start":1041,"enrollment":102,"conditions":36302,"interventions":36303},[91],[32380],[32382,32383],{"trials":36305,"activeCount":102},[],{"trials":36307,"activeCount":102},[],{"trials":36309,"activeCount":102},[],{"intervention":169,"totalTrials":195,"cells":36311},{"EARLY_PHASE1":36312,"PHASE1":36314,"PHASE2":36316,"PHASE3":36322,"PHASE4":36324,"NA":36326},{"trials":36313,"activeCount":102},[],{"trials":36315,"activeCount":102},[],{"trials":36317,"activeCount":102},[36318],{"nctId":161,"briefTitle":162,"status":108,"phases":36319,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":36320,"interventions":36321},[91],[155],[97,169,170,171,172],{"trials":36323,"activeCount":102},[],{"trials":36325,"activeCount":102},[],{"trials":36327,"activeCount":102},[],{"intervention":170,"totalTrials":195,"cells":36329},{"EARLY_PHASE1":36330,"PHASE1":36332,"PHASE2":36334,"PHASE3":36340,"PHASE4":36342,"NA":36344},{"trials":36331,"activeCount":102},[],{"trials":36333,"activeCount":102},[],{"trials":36335,"activeCount":102},[36336],{"nctId":161,"briefTitle":162,"status":108,"phases":36337,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":36338,"interventions":36339},[91],[155],[97,169,170,171,172],{"trials":36341,"activeCount":102},[],{"trials":36343,"activeCount":102},[],{"trials":36345,"activeCount":102},[],{"intervention":171,"totalTrials":195,"cells":36347},{"EARLY_PHASE1":36348,"PHASE1":36350,"PHASE2":36352,"PHASE3":36358,"PHASE4":36360,"NA":36362},{"trials":36349,"activeCount":102},[],{"trials":36351,"activeCount":102},[],{"trials":36353,"activeCount":102},[36354],{"nctId":161,"briefTitle":162,"status":108,"phases":36355,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":36356,"interventions":36357},[91],[155],[97,169,170,171,172],{"trials":36359,"activeCount":102},[],{"trials":36361,"activeCount":102},[],{"trials":36363,"activeCount":102},[],{"intervention":172,"totalTrials":195,"cells":36365},{"EARLY_PHASE1":36366,"PHASE1":36368,"PHASE2":36370,"PHASE3":36376,"PHASE4":36378,"NA":36380},{"trials":36367,"activeCount":102},[],{"trials":36369,"activeCount":102},[],{"trials":36371,"activeCount":102},[36372],{"nctId":161,"briefTitle":162,"status":108,"phases":36373,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":36374,"interventions":36375},[91],[155],[97,169,170,171,172],{"trials":36377,"activeCount":102},[],{"trials":36379,"activeCount":102},[],{"trials":36381,"activeCount":102},[],{"intervention":36383,"totalTrials":195,"cells":36384},"HOE140 Icatibant",{"EARLY_PHASE1":36385,"PHASE1":36387,"PHASE2":36389,"PHASE3":36398,"PHASE4":36400,"NA":36402},{"trials":36386,"activeCount":102},[],{"trials":36388,"activeCount":102},[],{"trials":36390,"activeCount":102},[36391],{"nctId":36392,"briefTitle":36393,"status":108,"phases":36394,"primaryCompletion":3563,"completion":3563,"start":8777,"enrollment":32614,"conditions":36395,"interventions":36397},"NCT00303056","Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis",[91],[36396],"Joint Disease",[36383],{"trials":36399,"activeCount":102},[],{"trials":36401,"activeCount":102},[],{"trials":36403,"activeCount":102},[],{"intervention":36405,"totalTrials":195,"cells":36406},"Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine",{"EARLY_PHASE1":36407,"PHASE1":36409,"PHASE2":36411,"PHASE3":36425,"PHASE4":36427,"NA":36429},{"trials":36408,"activeCount":102},[],{"trials":36410,"activeCount":102},[],{"trials":36412,"activeCount":102},[36413],{"nctId":36414,"briefTitle":36415,"status":108,"phases":36416,"primaryCompletion":36417,"completion":36417,"start":36418,"enrollment":36419,"conditions":36420,"interventions":36421},"NCT02199691","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents",[91],"2015-10-02","2014-07-22",1715,[4992,7568,2922],[36405,36422,36423,36424,36405,36423,36424],"Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed","GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant",{"trials":36426,"activeCount":102},[],{"trials":36428,"activeCount":102},[],{"trials":36430,"activeCount":102},[],{"intervention":36422,"totalTrials":195,"cells":36432},{"EARLY_PHASE1":36433,"PHASE1":36435,"PHASE2":36437,"PHASE3":36443,"PHASE4":36445,"NA":36447},{"trials":36434,"activeCount":102},[],{"trials":36436,"activeCount":102},[],{"trials":36438,"activeCount":102},[36439],{"nctId":36414,"briefTitle":36415,"status":108,"phases":36440,"primaryCompletion":36417,"completion":36417,"start":36418,"enrollment":36419,"conditions":36441,"interventions":36442},[91],[4992,7568,2922],[36405,36422,36423,36424,36405,36423,36424],{"trials":36444,"activeCount":102},[],{"trials":36446,"activeCount":102},[],{"trials":36448,"activeCount":102},[],{"intervention":36423,"totalTrials":195,"cells":36450},{"EARLY_PHASE1":36451,"PHASE1":36453,"PHASE2":36455,"PHASE3":36461,"PHASE4":36463,"NA":36465},{"trials":36452,"activeCount":102},[],{"trials":36454,"activeCount":102},[],{"trials":36456,"activeCount":102},[36457],{"nctId":36414,"briefTitle":36415,"status":108,"phases":36458,"primaryCompletion":36417,"completion":36417,"start":36418,"enrollment":36419,"conditions":36459,"interventions":36460},[91],[4992,7568,2922],[36405,36422,36423,36424,36405,36423,36424],{"trials":36462,"activeCount":102},[],{"trials":36464,"activeCount":102},[],{"trials":36466,"activeCount":102},[],{"intervention":36424,"totalTrials":195,"cells":36468},{"EARLY_PHASE1":36469,"PHASE1":36471,"PHASE2":36473,"PHASE3":36479,"PHASE4":36481,"NA":36483},{"trials":36470,"activeCount":102},[],{"trials":36472,"activeCount":102},[],{"trials":36474,"activeCount":102},[36475],{"nctId":36414,"briefTitle":36415,"status":108,"phases":36476,"primaryCompletion":36417,"completion":36417,"start":36418,"enrollment":36419,"conditions":36477,"interventions":36478},[91],[4992,7568,2922],[36405,36422,36423,36424,36405,36423,36424],{"trials":36480,"activeCount":102},[],{"trials":36482,"activeCount":102},[],{"trials":36484,"activeCount":102},[],{"intervention":36486,"totalTrials":195,"cells":36487},"SAR421869",{"EARLY_PHASE1":36488,"PHASE1":36490,"PHASE2":36492,"PHASE3":36503,"PHASE4":36505,"NA":36507},{"trials":36489,"activeCount":102},[],{"trials":36491,"activeCount":102},[],{"trials":36493,"activeCount":102},[36494],{"nctId":36495,"briefTitle":36496,"status":884,"phases":36497,"primaryCompletion":28846,"completion":28846,"start":36498,"enrollment":2371,"conditions":36499,"interventions":36502},"NCT01505062","Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B",[90,91],"2012-03-26",[36500,36501],"Usher Syndrome","Retinitis Pigmentosa",[36486],{"trials":36504,"activeCount":102},[],{"trials":36506,"activeCount":102},[],{"trials":36508,"activeCount":102},[],{"intervention":36510,"totalTrials":195,"cells":36511},"Oxaliplatin, capecitabine, radiotherapy",{"EARLY_PHASE1":36512,"PHASE1":36514,"PHASE2":36516,"PHASE3":36524,"PHASE4":36526,"NA":36528},{"trials":36513,"activeCount":102},[],{"trials":36515,"activeCount":102},[],{"trials":36517,"activeCount":102},[36518],{"nctId":36519,"briefTitle":36520,"status":108,"phases":36521,"primaryCompletion":8607,"completion":8607,"start":3508,"enrollment":6630,"conditions":36522,"interventions":36523},"NCT00174616","CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision",[91],[9177],[36510],{"trials":36525,"activeCount":102},[],{"trials":36527,"activeCount":102},[],{"trials":36529,"activeCount":102},[],{"intervention":36531,"totalTrials":195,"cells":36532},"Docetaxel + CDDP",{"EARLY_PHASE1":36533,"PHASE1":36535,"PHASE2":36537,"PHASE3":36546,"PHASE4":36548,"NA":36550},{"trials":36534,"activeCount":102},[],{"trials":36536,"activeCount":102},[],{"trials":36538,"activeCount":102},[36539],{"nctId":36540,"briefTitle":34635,"status":108,"phases":36541,"primaryCompletion":3354,"completion":3354,"start":10073,"enrollment":20,"conditions":36542,"interventions":36544},"NCT00432315",[91],[36543],"Carcinoma, Squamous Cell",[36531,36545],"docetaxel + CDDP",{"trials":36547,"activeCount":102},[],{"trials":36549,"activeCount":102},[],{"trials":36551,"activeCount":102},[],{"intervention":36553,"totalTrials":195,"cells":36554},"docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy",{"EARLY_PHASE1":36555,"PHASE1":36557,"PHASE2":36559,"PHASE3":36568,"PHASE4":36570,"NA":36572},{"trials":36556,"activeCount":102},[],{"trials":36558,"activeCount":102},[],{"trials":36560,"activeCount":102},[36561],{"nctId":36562,"briefTitle":36563,"status":108,"phases":36564,"primaryCompletion":8315,"completion":8315,"start":9522,"enrollment":8717,"conditions":36565,"interventions":36566},"NCT00174772","Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)",[91],[17899],[36553,36567],"docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin",{"trials":36569,"activeCount":102},[],{"trials":36571,"activeCount":102},[],{"trials":36573,"activeCount":102},[],{"intervention":36567,"totalTrials":195,"cells":36575},{"EARLY_PHASE1":36576,"PHASE1":36578,"PHASE2":36580,"PHASE3":36586,"PHASE4":36588,"NA":36590},{"trials":36577,"activeCount":102},[],{"trials":36579,"activeCount":102},[],{"trials":36581,"activeCount":102},[36582],{"nctId":36562,"briefTitle":36563,"status":108,"phases":36583,"primaryCompletion":8315,"completion":8315,"start":9522,"enrollment":8717,"conditions":36584,"interventions":36585},[91],[17899],[36553,36567],{"trials":36587,"activeCount":102},[],{"trials":36589,"activeCount":102},[],{"trials":36591,"activeCount":102},[],{"intervention":10697,"totalTrials":195,"cells":36593},{"EARLY_PHASE1":36594,"PHASE1":36596,"PHASE2":36598,"PHASE3":36604,"PHASE4":36606,"NA":36608},{"trials":36595,"activeCount":102},[],{"trials":36597,"activeCount":102},[],{"trials":36599,"activeCount":102},[36600],{"nctId":10689,"briefTitle":10690,"status":108,"phases":36601,"primaryCompletion":3417,"completion":8235,"start":3317,"enrollment":10692,"conditions":36602,"interventions":36603},[91],[16,10694,10695],[10697,10698,10673],{"trials":36605,"activeCount":102},[],{"trials":36607,"activeCount":102},[],{"trials":36609,"activeCount":102},[],{"intervention":10698,"totalTrials":195,"cells":36611},{"EARLY_PHASE1":36612,"PHASE1":36614,"PHASE2":36616,"PHASE3":36622,"PHASE4":36624,"NA":36626},{"trials":36613,"activeCount":102},[],{"trials":36615,"activeCount":102},[],{"trials":36617,"activeCount":102},[36618],{"nctId":10689,"briefTitle":10690,"status":108,"phases":36619,"primaryCompletion":3417,"completion":8235,"start":3317,"enrollment":10692,"conditions":36620,"interventions":36621},[91],[16,10694,10695],[10697,10698,10673],{"trials":36623,"activeCount":102},[],{"trials":36625,"activeCount":102},[],{"trials":36627,"activeCount":102},[],{"intervention":36629,"totalTrials":195,"cells":36630},"Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus",{"EARLY_PHASE1":36631,"PHASE1":36633,"PHASE2":36635,"PHASE3":36646,"PHASE4":36648,"NA":36650},{"trials":36632,"activeCount":102},[],{"trials":36634,"activeCount":102},[],{"trials":36636,"activeCount":102},[36637],{"nctId":36638,"briefTitle":36639,"status":108,"phases":36640,"primaryCompletion":10178,"completion":7284,"start":8745,"enrollment":249,"conditions":36641,"interventions":36642},"NCT01064141","A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines",[91],[18210,2317],[36629,36643,36644,36645],"OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines","Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines","Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl",{"trials":36647,"activeCount":102},[],{"trials":36649,"activeCount":102},[],{"trials":36651,"activeCount":102},[],{"intervention":36643,"totalTrials":195,"cells":36653},{"EARLY_PHASE1":36654,"PHASE1":36656,"PHASE2":36658,"PHASE3":36664,"PHASE4":36666,"NA":36668},{"trials":36655,"activeCount":102},[],{"trials":36657,"activeCount":102},[],{"trials":36659,"activeCount":102},[36660],{"nctId":36638,"briefTitle":36639,"status":108,"phases":36661,"primaryCompletion":10178,"completion":7284,"start":8745,"enrollment":249,"conditions":36662,"interventions":36663},[91],[18210,2317],[36629,36643,36644,36645],{"trials":36665,"activeCount":102},[],{"trials":36667,"activeCount":102},[],{"trials":36669,"activeCount":102},[],{"intervention":36644,"totalTrials":195,"cells":36671},{"EARLY_PHASE1":36672,"PHASE1":36674,"PHASE2":36676,"PHASE3":36682,"PHASE4":36684,"NA":36686},{"trials":36673,"activeCount":102},[],{"trials":36675,"activeCount":102},[],{"trials":36677,"activeCount":102},[36678],{"nctId":36638,"briefTitle":36639,"status":108,"phases":36679,"primaryCompletion":10178,"completion":7284,"start":8745,"enrollment":249,"conditions":36680,"interventions":36681},[91],[18210,2317],[36629,36643,36644,36645],{"trials":36683,"activeCount":102},[],{"trials":36685,"activeCount":102},[],{"trials":36687,"activeCount":102},[],{"intervention":36645,"totalTrials":195,"cells":36689},{"EARLY_PHASE1":36690,"PHASE1":36692,"PHASE2":36694,"PHASE3":36700,"PHASE4":36702,"NA":36704},{"trials":36691,"activeCount":102},[],{"trials":36693,"activeCount":102},[],{"trials":36695,"activeCount":102},[36696],{"nctId":36638,"briefTitle":36639,"status":108,"phases":36697,"primaryCompletion":10178,"completion":7284,"start":8745,"enrollment":249,"conditions":36698,"interventions":36699},[91],[18210,2317],[36629,36643,36644,36645],{"trials":36701,"activeCount":102},[],{"trials":36703,"activeCount":102},[],{"trials":36705,"activeCount":102},[],{"intervention":36707,"totalTrials":195,"cells":36708},"SARS-CoV-2 mRNA vaccine formulation 1",{"EARLY_PHASE1":36709,"PHASE1":36711,"PHASE2":36713,"PHASE3":36724,"PHASE4":36726,"NA":36728},{"trials":36710,"activeCount":102},[],{"trials":36712,"activeCount":102},[],{"trials":36714,"activeCount":102},[36715],{"nctId":36716,"briefTitle":36717,"status":884,"phases":36718,"primaryCompletion":36719,"completion":36719,"start":14719,"enrollment":121,"conditions":36720,"interventions":36721},"NCT04798027","Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",[90,91],"2022-06-27",[4266],[36707,36722,36723],"SARS-CoV-2 mRNA vaccine formulation 2","SARS-CoV-2 mRNA vaccine formulation 3",{"trials":36725,"activeCount":102},[],{"trials":36727,"activeCount":102},[],{"trials":36729,"activeCount":102},[],{"intervention":36722,"totalTrials":195,"cells":36731},{"EARLY_PHASE1":36732,"PHASE1":36734,"PHASE2":36736,"PHASE3":36742,"PHASE4":36744,"NA":36746},{"trials":36733,"activeCount":102},[],{"trials":36735,"activeCount":102},[],{"trials":36737,"activeCount":102},[36738],{"nctId":36716,"briefTitle":36717,"status":884,"phases":36739,"primaryCompletion":36719,"completion":36719,"start":14719,"enrollment":121,"conditions":36740,"interventions":36741},[90,91],[4266],[36707,36722,36723],{"trials":36743,"activeCount":102},[],{"trials":36745,"activeCount":102},[],{"trials":36747,"activeCount":102},[],{"intervention":36723,"totalTrials":195,"cells":36749},{"EARLY_PHASE1":36750,"PHASE1":36752,"PHASE2":36754,"PHASE3":36760,"PHASE4":36762,"NA":36764},{"trials":36751,"activeCount":102},[],{"trials":36753,"activeCount":102},[],{"trials":36755,"activeCount":102},[36756],{"nctId":36716,"briefTitle":36717,"status":884,"phases":36757,"primaryCompletion":36719,"completion":36719,"start":14719,"enrollment":121,"conditions":36758,"interventions":36759},[90,91],[4266],[36707,36722,36723],{"trials":36761,"activeCount":102},[],{"trials":36763,"activeCount":102},[],{"trials":36765,"activeCount":102},[],{"intervention":3340,"totalTrials":195,"cells":36767},{"EARLY_PHASE1":36768,"PHASE1":36770,"PHASE2":36772,"PHASE3":36778,"PHASE4":36780,"NA":36782},{"trials":36769,"activeCount":102},[],{"trials":36771,"activeCount":102},[],{"trials":36773,"activeCount":102},[36774],{"nctId":3332,"briefTitle":3333,"status":108,"phases":36775,"primaryCompletion":3335,"completion":3335,"start":986,"enrollment":3336,"conditions":36776,"interventions":36777},[91],[1788],[3339,3340,3341],{"trials":36779,"activeCount":102},[],{"trials":36781,"activeCount":102},[],{"trials":36783,"activeCount":102},[],{"intervention":3341,"totalTrials":195,"cells":36785},{"EARLY_PHASE1":36786,"PHASE1":36788,"PHASE2":36790,"PHASE3":36796,"PHASE4":36798,"NA":36800},{"trials":36787,"activeCount":102},[],{"trials":36789,"activeCount":102},[],{"trials":36791,"activeCount":102},[36792],{"nctId":3332,"briefTitle":3333,"status":108,"phases":36793,"primaryCompletion":3335,"completion":3335,"start":986,"enrollment":3336,"conditions":36794,"interventions":36795},[91],[1788],[3339,3340,3341],{"trials":36797,"activeCount":102},[],{"trials":36799,"activeCount":102},[],{"trials":36801,"activeCount":102},[],{"intervention":32728,"totalTrials":195,"cells":36803},{"EARLY_PHASE1":36804,"PHASE1":36806,"PHASE2":36808,"PHASE3":36814,"PHASE4":36816,"NA":36818},{"trials":36805,"activeCount":102},[],{"trials":36807,"activeCount":102},[],{"trials":36809,"activeCount":102},[36810],{"nctId":32721,"briefTitle":32722,"status":108,"phases":36811,"primaryCompletion":8846,"completion":8846,"start":9785,"enrollment":32724,"conditions":36812,"interventions":36813},[91],[32726],[32712,32728],{"trials":36815,"activeCount":102},[],{"trials":36817,"activeCount":102},[],{"trials":36819,"activeCount":102},[],{"intervention":36821,"totalTrials":195,"cells":36822},"CYD dengue vaccine serotypes (1, 2, 3, 4).",{"EARLY_PHASE1":36823,"PHASE1":36825,"PHASE2":36827,"PHASE3":36837,"PHASE4":36839,"NA":36841},{"trials":36824,"activeCount":102},[],{"trials":36826,"activeCount":102},[],{"trials":36828,"activeCount":102},[36829],{"nctId":36830,"briefTitle":36831,"status":108,"phases":36832,"primaryCompletion":11210,"completion":7430,"start":8349,"enrollment":680,"conditions":36833,"interventions":36835},"NCT00875524","Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects",[91],[18211,18210,2317,36834],"Dengue Disease",[36821,36836],"Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide",{"trials":36838,"activeCount":102},[],{"trials":36840,"activeCount":102},[],{"trials":36842,"activeCount":102},[],{"intervention":36836,"totalTrials":195,"cells":36844},{"EARLY_PHASE1":36845,"PHASE1":36847,"PHASE2":36849,"PHASE3":36855,"PHASE4":36857,"NA":36859},{"trials":36846,"activeCount":102},[],{"trials":36848,"activeCount":102},[],{"trials":36850,"activeCount":102},[36851],{"nctId":36830,"briefTitle":36831,"status":108,"phases":36852,"primaryCompletion":11210,"completion":7430,"start":8349,"enrollment":680,"conditions":36853,"interventions":36854},[91],[18211,18210,2317,36834],[36821,36836],{"trials":36856,"activeCount":102},[],{"trials":36858,"activeCount":102},[],{"trials":36860,"activeCount":102},[],{"intervention":36862,"totalTrials":195,"cells":36863},"Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine",{"EARLY_PHASE1":36864,"PHASE1":36866,"PHASE2":36868,"PHASE3":36880,"PHASE4":36882,"NA":36884},{"trials":36865,"activeCount":102},[],{"trials":36867,"activeCount":102},[],{"trials":36869,"activeCount":102},[36870],{"nctId":36871,"briefTitle":36872,"status":108,"phases":36873,"primaryCompletion":36874,"completion":36874,"start":36875,"enrollment":956,"conditions":36876,"interventions":36878},"NCT01732627","Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older",[91],"2013-01-17","2012-11-12",[4992,7568,2922,36877],"Invasive Meningococcal Disease",[36862,36879],"Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined",{"trials":36881,"activeCount":102},[],{"trials":36883,"activeCount":102},[],{"trials":36885,"activeCount":102},[],{"intervention":36879,"totalTrials":195,"cells":36887},{"EARLY_PHASE1":36888,"PHASE1":36890,"PHASE2":36892,"PHASE3":36898,"PHASE4":36900,"NA":36902},{"trials":36889,"activeCount":102},[],{"trials":36891,"activeCount":102},[],{"trials":36893,"activeCount":102},[36894],{"nctId":36871,"briefTitle":36872,"status":108,"phases":36895,"primaryCompletion":36874,"completion":36874,"start":36875,"enrollment":956,"conditions":36896,"interventions":36897},[91],[4992,7568,2922,36877],[36862,36879],{"trials":36899,"activeCount":102},[],{"trials":36901,"activeCount":102},[],{"trials":36903,"activeCount":102},[],{"intervention":32266,"totalTrials":195,"cells":36905},{"EARLY_PHASE1":36906,"PHASE1":36908,"PHASE2":36910,"PHASE3":36916,"PHASE4":36918,"NA":36920},{"trials":36907,"activeCount":102},[],{"trials":36909,"activeCount":102},[],{"trials":36911,"activeCount":102},[36912],{"nctId":32260,"briefTitle":32261,"status":884,"phases":36913,"primaryCompletion":1220,"completion":1220,"start":32263,"enrollment":10753,"conditions":36914,"interventions":36915},[90,91],[2665],[32266,2667],{"trials":36917,"activeCount":102},[],{"trials":36919,"activeCount":102},[],{"trials":36921,"activeCount":102},[],{"intervention":32757,"totalTrials":195,"cells":36923},{"EARLY_PHASE1":36924,"PHASE1":36926,"PHASE2":36928,"PHASE3":36934,"PHASE4":36936,"NA":36938},{"trials":36925,"activeCount":102},[],{"trials":36927,"activeCount":102},[],{"trials":36929,"activeCount":102},[36930],{"nctId":32751,"briefTitle":32752,"status":108,"phases":36931,"primaryCompletion":8298,"completion":8298,"start":3821,"enrollment":32754,"conditions":36932,"interventions":36933},[91],[32380],[32757,32742],{"trials":36935,"activeCount":102},[],{"trials":36937,"activeCount":102},[],{"trials":36939,"activeCount":102},[],{"intervention":36941,"totalTrials":195,"cells":36942},"RSV vaccine candidate",{"EARLY_PHASE1":36943,"PHASE1":36945,"PHASE2":36947,"PHASE3":36957,"PHASE4":36959,"NA":36961},{"trials":36944,"activeCount":102},[],{"trials":36946,"activeCount":102},[],{"trials":36948,"activeCount":102},[36949],{"nctId":36950,"briefTitle":36951,"status":108,"phases":36952,"primaryCompletion":36953,"completion":36953,"start":5331,"enrollment":36954,"conditions":36955,"interventions":36956},"NCT06251024","Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older",[91],"2025-03-11",4541,[20474,36],[36941],{"trials":36958,"activeCount":102},[],{"trials":36960,"activeCount":102},[],{"trials":36962,"activeCount":102},[],{"intervention":31588,"totalTrials":195,"cells":36964},{"EARLY_PHASE1":36965,"PHASE1":36967,"PHASE2":36969,"PHASE3":36975,"PHASE4":36977,"NA":36979},{"trials":36966,"activeCount":102},[],{"trials":36968,"activeCount":102},[],{"trials":36970,"activeCount":102},[36971],{"nctId":31582,"briefTitle":31583,"status":108,"phases":36972,"primaryCompletion":8406,"completion":2834,"start":8315,"enrollment":10746,"conditions":36973,"interventions":36974},[91],[26251,21801],[31587,31566,31588,31566],{"trials":36976,"activeCount":102},[],{"trials":36978,"activeCount":102},[],{"trials":36980,"activeCount":102},[],{"intervention":32474,"totalTrials":195,"cells":36982},{"EARLY_PHASE1":36983,"PHASE1":36985,"PHASE2":36987,"PHASE3":36993,"PHASE4":36995,"NA":36997},{"trials":36984,"activeCount":102},[],{"trials":36986,"activeCount":102},[],{"trials":36988,"activeCount":102},[36989],{"nctId":32467,"briefTitle":32468,"status":108,"phases":36990,"primaryCompletion":32470,"completion":32470,"start":32471,"enrollment":2101,"conditions":36991,"interventions":36992},[90,91],[32462,5335],[32474,32449,32475,32475,32475,32475],{"trials":36994,"activeCount":102},[],{"trials":36996,"activeCount":102},[],{"trials":36998,"activeCount":102},[],{"intervention":32475,"totalTrials":195,"cells":37000},{"EARLY_PHASE1":37001,"PHASE1":37003,"PHASE2":37005,"PHASE3":37011,"PHASE4":37013,"NA":37015},{"trials":37002,"activeCount":102},[],{"trials":37004,"activeCount":102},[],{"trials":37006,"activeCount":102},[37007],{"nctId":32467,"briefTitle":32468,"status":108,"phases":37008,"primaryCompletion":32470,"completion":32470,"start":32471,"enrollment":2101,"conditions":37009,"interventions":37010},[90,91],[32462,5335],[32474,32449,32475,32475,32475,32475],{"trials":37012,"activeCount":102},[],{"trials":37014,"activeCount":102},[],{"trials":37016,"activeCount":102},[],{"intervention":32585,"totalTrials":195,"cells":37018},{"EARLY_PHASE1":37019,"PHASE1":37021,"PHASE2":37023,"PHASE3":37029,"PHASE4":37031,"NA":37033},{"trials":37020,"activeCount":102},[],{"trials":37022,"activeCount":102},[],{"trials":37024,"activeCount":102},[37025],{"nctId":32579,"briefTitle":32580,"status":884,"phases":37026,"primaryCompletion":3766,"completion":3766,"start":32582,"enrollment":8272,"conditions":37027,"interventions":37028},[91],[12592],[32585,31494],{"trials":37030,"activeCount":102},[],{"trials":37032,"activeCount":102},[],{"trials":37034,"activeCount":102},[],{"intervention":37036,"totalTrials":195,"cells":37037},"XRP9881",{"EARLY_PHASE1":37038,"PHASE1":37040,"PHASE2":37042,"PHASE3":37051,"PHASE4":37053,"NA":37055},{"trials":37039,"activeCount":102},[],{"trials":37041,"activeCount":102},[],{"trials":37043,"activeCount":102},[37044],{"nctId":37045,"briefTitle":37046,"status":108,"phases":37047,"primaryCompletion":9785,"completion":3396,"start":7523,"enrollment":37048,"conditions":37049,"interventions":37050},"NCT00087958","Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment",[91],168,[5264],[37036],{"trials":37052,"activeCount":102},[],{"trials":37054,"activeCount":102},[],{"trials":37056,"activeCount":102},[],{"intervention":37058,"totalTrials":195,"cells":37059},"AVE1625 B",{"EARLY_PHASE1":37060,"PHASE1":37062,"PHASE2":37064,"PHASE3":37072,"PHASE4":37074,"NA":37076},{"trials":37061,"activeCount":102},[],{"trials":37063,"activeCount":102},[],{"trials":37065,"activeCount":102},[37066],{"nctId":37067,"briefTitle":37068,"status":108,"phases":37069,"primaryCompletion":10320,"completion":10320,"start":8395,"enrollment":8592,"conditions":37070,"interventions":37071},"NCT00345410","Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia",[91],[17609,7454],[37058],{"trials":37073,"activeCount":102},[],{"trials":37075,"activeCount":102},[],{"trials":37077,"activeCount":102},[],{"intervention":31867,"totalTrials":195,"cells":37079},{"EARLY_PHASE1":37080,"PHASE1":37082,"PHASE2":37084,"PHASE3":37090,"PHASE4":37092,"NA":37094},{"trials":37081,"activeCount":102},[],{"trials":37083,"activeCount":102},[],{"trials":37085,"activeCount":102},[37086],{"nctId":31862,"briefTitle":31863,"status":108,"phases":37087,"primaryCompletion":7330,"completion":3429,"start":10005,"enrollment":294,"conditions":37088,"interventions":37089},[91],[14171],[31867,21338],{"trials":37091,"activeCount":102},[],{"trials":37093,"activeCount":102},[],{"trials":37095,"activeCount":102},[],{"intervention":37097,"totalTrials":195,"cells":37098},"(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis",{"EARLY_PHASE1":37099,"PHASE1":37101,"PHASE2":37103,"PHASE3":37111,"PHASE4":37113,"NA":37115},{"trials":37100,"activeCount":102},[],{"trials":37102,"activeCount":102},[],{"trials":37104,"activeCount":102},[37105],{"nctId":37106,"briefTitle":37107,"status":108,"phases":37108,"primaryCompletion":7284,"completion":8106,"start":10178,"enrollment":2411,"conditions":37109,"interventions":37110},"NCT01689324","Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents",[90,91],[28,31,25],[37097],{"trials":37112,"activeCount":102},[],{"trials":37114,"activeCount":102},[],{"trials":37116,"activeCount":102},[],{"intervention":37118,"totalTrials":195,"cells":37119},"RSV vaccine formulation 1",{"EARLY_PHASE1":37120,"PHASE1":37122,"PHASE2":37124,"PHASE3":37136,"PHASE4":37138,"NA":37140},{"trials":37121,"activeCount":102},[],{"trials":37123,"activeCount":102},[],{"trials":37125,"activeCount":102},[37126],{"nctId":37127,"briefTitle":37128,"status":108,"phases":37129,"primaryCompletion":37130,"completion":37130,"start":37131,"enrollment":37132,"conditions":37133,"interventions":37134},"NCT04491877","Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers",[90,91],"2023-04-13","2020-09-17",259,[20474],[37118,37135],"RSV vaccine formulation 2",{"trials":37137,"activeCount":102},[],{"trials":37139,"activeCount":102},[],{"trials":37141,"activeCount":102},[],{"intervention":37135,"totalTrials":195,"cells":37143},{"EARLY_PHASE1":37144,"PHASE1":37146,"PHASE2":37148,"PHASE3":37154,"PHASE4":37156,"NA":37158},{"trials":37145,"activeCount":102},[],{"trials":37147,"activeCount":102},[],{"trials":37149,"activeCount":102},[37150],{"nctId":37127,"briefTitle":37128,"status":108,"phases":37151,"primaryCompletion":37130,"completion":37130,"start":37131,"enrollment":37132,"conditions":37152,"interventions":37153},[90,91],[20474],[37118,37135],{"trials":37155,"activeCount":102},[],{"trials":37157,"activeCount":102},[],{"trials":37159,"activeCount":102},[],{"intervention":37161,"totalTrials":195,"cells":37162},"SAR100842",{"EARLY_PHASE1":37163,"PHASE1":37165,"PHASE2":37167,"PHASE3":37175,"PHASE4":37177,"NA":37179},{"trials":37164,"activeCount":102},[],{"trials":37166,"activeCount":102},[],{"trials":37168,"activeCount":102},[37169],{"nctId":37170,"briefTitle":37171,"status":108,"phases":37172,"primaryCompletion":10811,"completion":7330,"start":8298,"enrollment":6313,"conditions":37173,"interventions":37174},"NCT01651143","Proof of Biological Activity of SAR100842 in Systemic Sclerosis",[91],[31637],[37161],{"trials":37176,"activeCount":102},[],{"trials":37178,"activeCount":102},[],{"trials":37180,"activeCount":102},[],{"intervention":37182,"totalTrials":195,"cells":37183},"Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb",{"EARLY_PHASE1":37184,"PHASE1":37186,"PHASE2":37188,"PHASE3":37203,"PHASE4":37205,"NA":37207},{"trials":37185,"activeCount":102},[],{"trials":37187,"activeCount":102},[],{"trials":37189,"activeCount":102},[37190],{"nctId":37191,"briefTitle":37192,"status":108,"phases":37193,"primaryCompletion":37194,"completion":37195,"start":37196,"enrollment":2892,"conditions":37197,"interventions":37198},"NCT04583618","Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.",[91],"2021-08-09","2022-01-20","2020-10-08",[1927],[37182,37199,37200,37201,37202],"Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI","Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII","Pneumococcal 13 - valent conjugate vaccine-Prevnar 13","Pneumococcal Vaccine Polyvalent-Pneumovax 23",{"trials":37204,"activeCount":102},[],{"trials":37206,"activeCount":102},[],{"trials":37208,"activeCount":102},[],{"intervention":37199,"totalTrials":195,"cells":37210},{"EARLY_PHASE1":37211,"PHASE1":37213,"PHASE2":37215,"PHASE3":37221,"PHASE4":37223,"NA":37225},{"trials":37212,"activeCount":102},[],{"trials":37214,"activeCount":102},[],{"trials":37216,"activeCount":102},[37217],{"nctId":37191,"briefTitle":37192,"status":108,"phases":37218,"primaryCompletion":37194,"completion":37195,"start":37196,"enrollment":2892,"conditions":37219,"interventions":37220},[91],[1927],[37182,37199,37200,37201,37202],{"trials":37222,"activeCount":102},[],{"trials":37224,"activeCount":102},[],{"trials":37226,"activeCount":102},[],{"intervention":37200,"totalTrials":195,"cells":37228},{"EARLY_PHASE1":37229,"PHASE1":37231,"PHASE2":37233,"PHASE3":37239,"PHASE4":37241,"NA":37243},{"trials":37230,"activeCount":102},[],{"trials":37232,"activeCount":102},[],{"trials":37234,"activeCount":102},[37235],{"nctId":37191,"briefTitle":37192,"status":108,"phases":37236,"primaryCompletion":37194,"completion":37195,"start":37196,"enrollment":2892,"conditions":37237,"interventions":37238},[91],[1927],[37182,37199,37200,37201,37202],{"trials":37240,"activeCount":102},[],{"trials":37242,"activeCount":102},[],{"trials":37244,"activeCount":102},[],{"intervention":37201,"totalTrials":195,"cells":37246},{"EARLY_PHASE1":37247,"PHASE1":37249,"PHASE2":37251,"PHASE3":37257,"PHASE4":37259,"NA":37261},{"trials":37248,"activeCount":102},[],{"trials":37250,"activeCount":102},[],{"trials":37252,"activeCount":102},[37253],{"nctId":37191,"briefTitle":37192,"status":108,"phases":37254,"primaryCompletion":37194,"completion":37195,"start":37196,"enrollment":2892,"conditions":37255,"interventions":37256},[91],[1927],[37182,37199,37200,37201,37202],{"trials":37258,"activeCount":102},[],{"trials":37260,"activeCount":102},[],{"trials":37262,"activeCount":102},[],{"intervention":37202,"totalTrials":195,"cells":37264},{"EARLY_PHASE1":37265,"PHASE1":37267,"PHASE2":37269,"PHASE3":37275,"PHASE4":37277,"NA":37279},{"trials":37266,"activeCount":102},[],{"trials":37268,"activeCount":102},[],{"trials":37270,"activeCount":102},[37271],{"nctId":37191,"briefTitle":37192,"status":108,"phases":37272,"primaryCompletion":37194,"completion":37195,"start":37196,"enrollment":2892,"conditions":37273,"interventions":37274},[91],[1927],[37182,37199,37200,37201,37202],{"trials":37276,"activeCount":102},[],{"trials":37278,"activeCount":102},[],{"trials":37280,"activeCount":102},[],{"intervention":37282,"totalTrials":195,"cells":37283},"ChimeriVax-WN02 vaccine",{"EARLY_PHASE1":37284,"PHASE1":37286,"PHASE2":37288,"PHASE3":37296,"PHASE4":37298,"NA":37300},{"trials":37285,"activeCount":102},[],{"trials":37287,"activeCount":102},[],{"trials":37289,"activeCount":102},[37290],{"nctId":37291,"briefTitle":37292,"status":108,"phases":37293,"primaryCompletion":3307,"completion":8388,"start":8846,"enrollment":25218,"conditions":37294,"interventions":37295},"NCT00746798","Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults",[91],[35898],[37282,37282,37282],{"trials":37297,"activeCount":102},[],{"trials":37299,"activeCount":102},[],{"trials":37301,"activeCount":102},[],{"intervention":32673,"totalTrials":195,"cells":37303},{"EARLY_PHASE1":37304,"PHASE1":37306,"PHASE2":37308,"PHASE3":37314,"PHASE4":37316,"NA":37318},{"trials":37305,"activeCount":102},[],{"trials":37307,"activeCount":102},[],{"trials":37309,"activeCount":102},[37310],{"nctId":32667,"briefTitle":32668,"status":108,"phases":37311,"primaryCompletion":32670,"completion":32670,"start":2824,"enrollment":2314,"conditions":37312,"interventions":37313},[91],[16],[32673,32674,32675,32675],{"trials":37315,"activeCount":102},[],{"trials":37317,"activeCount":102},[],{"trials":37319,"activeCount":102},[],{"intervention":32674,"totalTrials":195,"cells":37321},{"EARLY_PHASE1":37322,"PHASE1":37324,"PHASE2":37326,"PHASE3":37332,"PHASE4":37334,"NA":37336},{"trials":37323,"activeCount":102},[],{"trials":37325,"activeCount":102},[],{"trials":37327,"activeCount":102},[37328],{"nctId":32667,"briefTitle":32668,"status":108,"phases":37329,"primaryCompletion":32670,"completion":32670,"start":2824,"enrollment":2314,"conditions":37330,"interventions":37331},[91],[16],[32673,32674,32675,32675],{"trials":37333,"activeCount":102},[],{"trials":37335,"activeCount":102},[],{"trials":37337,"activeCount":102},[],{"intervention":37339,"totalTrials":195,"cells":37340},"Polysaccharide Diphtheria Toxoid Conjugate Vaccine",{"EARLY_PHASE1":37341,"PHASE1":37343,"PHASE2":37345,"PHASE3":37354,"PHASE4":37356,"NA":37358},{"trials":37342,"activeCount":102},[],{"trials":37344,"activeCount":102},[],{"trials":37346,"activeCount":102},[37347],{"nctId":37348,"briefTitle":37349,"status":108,"phases":37350,"primaryCompletion":3307,"completion":8731,"start":3430,"enrollment":37351,"conditions":37352,"interventions":37353},"NCT00355121","Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®",[91],882,[7568,31,25,28,12983],[37339,37339,37339],{"trials":37355,"activeCount":102},[],{"trials":37357,"activeCount":102},[],{"trials":37359,"activeCount":102},[],{"intervention":37361,"totalTrials":195,"cells":37362},"SAR422459",{"EARLY_PHASE1":37363,"PHASE1":37365,"PHASE2":37367,"PHASE3":37375,"PHASE4":37377,"NA":37379},{"trials":37364,"activeCount":102},[],{"trials":37366,"activeCount":102},[],{"trials":37368,"activeCount":102},[37369],{"nctId":37370,"briefTitle":37371,"status":884,"phases":37372,"primaryCompletion":28846,"completion":28846,"start":21700,"enrollment":6434,"conditions":37373,"interventions":37374},"NCT01367444","Phase I\u002FIIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration",[90,91],[6436],[37361],{"trials":37376,"activeCount":102},[],{"trials":37378,"activeCount":102},[],{"trials":37380,"activeCount":102},[],{"intervention":37382,"totalTrials":195,"cells":37383},"FOLFOX 4",{"EARLY_PHASE1":37384,"PHASE1":37386,"PHASE2":37388,"PHASE3":37398,"PHASE4":37400,"NA":37402},{"trials":37385,"activeCount":102},[],{"trials":37387,"activeCount":102},[],{"trials":37389,"activeCount":102},[37390],{"nctId":37391,"briefTitle":37392,"status":108,"phases":37393,"primaryCompletion":3317,"start":3367,"enrollment":31635,"conditions":37394,"interventions":37396},"NCT00160030","Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer",[91],[37395],"Esophageal Neoplasms",[37382,37397],"5-FU \u002F Cisplatin",{"trials":37399,"activeCount":102},[],{"trials":37401,"activeCount":102},[],{"trials":37403,"activeCount":102},[],{"intervention":37397,"totalTrials":195,"cells":37405},{"EARLY_PHASE1":37406,"PHASE1":37408,"PHASE2":37410,"PHASE3":37416,"PHASE4":37418,"NA":37420},{"trials":37407,"activeCount":102},[],{"trials":37409,"activeCount":102},[],{"trials":37411,"activeCount":102},[37412],{"nctId":37391,"briefTitle":37392,"status":108,"phases":37413,"primaryCompletion":3317,"start":3367,"enrollment":31635,"conditions":37414,"interventions":37415},[91],[37395],[37382,37397],{"trials":37417,"activeCount":102},[],{"trials":37419,"activeCount":102},[],{"trials":37421,"activeCount":102},[],{"intervention":37423,"totalTrials":195,"cells":37424},"Hexadecasaccharide",{"EARLY_PHASE1":37425,"PHASE1":37427,"PHASE2":37429,"PHASE3":37438,"PHASE4":37440,"NA":37442},{"trials":37426,"activeCount":102},[],{"trials":37428,"activeCount":102},[],{"trials":37430,"activeCount":102},[37431],{"nctId":37432,"briefTitle":37433,"status":108,"phases":37434,"primaryCompletion":3308,"completion":3308,"start":8184,"enrollment":37435,"conditions":37436,"interventions":37437},"NCT00123565","Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction",[91],1257,[17676],[37423],{"trials":37439,"activeCount":102},[],{"trials":37441,"activeCount":102},[],{"trials":37443,"activeCount":102},[],{"intervention":18984,"totalTrials":195,"cells":37445},{"EARLY_PHASE1":37446,"PHASE1":37448,"PHASE2":37450,"PHASE3":37456,"PHASE4":37458,"NA":37460},{"trials":37447,"activeCount":102},[],{"trials":37449,"activeCount":102},[],{"trials":37451,"activeCount":102},[37452],{"nctId":18977,"briefTitle":18978,"status":884,"phases":37453,"primaryCompletion":18980,"completion":18980,"start":246,"enrollment":11211,"conditions":37454,"interventions":37455},[90,91],[5264],[18919,18983,18984,18985,18986],{"trials":37457,"activeCount":102},[],{"trials":37459,"activeCount":102},[],{"trials":37461,"activeCount":102},[],{"intervention":18985,"totalTrials":195,"cells":37463},{"EARLY_PHASE1":37464,"PHASE1":37466,"PHASE2":37468,"PHASE3":37474,"PHASE4":37476,"NA":37478},{"trials":37465,"activeCount":102},[],{"trials":37467,"activeCount":102},[],{"trials":37469,"activeCount":102},[37470],{"nctId":18977,"briefTitle":18978,"status":884,"phases":37471,"primaryCompletion":18980,"completion":18980,"start":246,"enrollment":11211,"conditions":37472,"interventions":37473},[90,91],[5264],[18919,18983,18984,18985,18986],{"trials":37475,"activeCount":102},[],{"trials":37477,"activeCount":102},[],{"trials":37479,"activeCount":102},[],{"intervention":18986,"totalTrials":195,"cells":37481},{"EARLY_PHASE1":37482,"PHASE1":37484,"PHASE2":37486,"PHASE3":37492,"PHASE4":37494,"NA":37496},{"trials":37483,"activeCount":102},[],{"trials":37485,"activeCount":102},[],{"trials":37487,"activeCount":102},[37488],{"nctId":18977,"briefTitle":18978,"status":884,"phases":37489,"primaryCompletion":18980,"completion":18980,"start":246,"enrollment":11211,"conditions":37490,"interventions":37491},[90,91],[5264],[18919,18983,18984,18985,18986],{"trials":37493,"activeCount":102},[],{"trials":37495,"activeCount":102},[],{"trials":37497,"activeCount":102},[],{"intervention":37499,"totalTrials":195,"cells":37500},"Quadrivalent Influenza mRNA Vaccine MRT5410",{"EARLY_PHASE1":37501,"PHASE1":37503,"PHASE2":37505,"PHASE3":37518,"PHASE4":37520,"NA":37522},{"trials":37502,"activeCount":102},[],{"trials":37504,"activeCount":102},[],{"trials":37506,"activeCount":102},[37507],{"nctId":37508,"briefTitle":37509,"status":108,"phases":37510,"primaryCompletion":37511,"completion":37511,"start":37512,"enrollment":5333,"conditions":37513,"interventions":37514},"NCT05624606","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older",[90,91],"2024-03-28","2022-11-28",[5335],[37499,37515,37516,37517],"Quadrivalent Recombinant Influenza vaccine RIV4","Quadrivalent Inactivated Influenza Standard Dose QIV-SD","Quadrivalent Inactivated Influenza High Dose QIV-HD",{"trials":37519,"activeCount":102},[],{"trials":37521,"activeCount":102},[],{"trials":37523,"activeCount":102},[],{"intervention":37515,"totalTrials":195,"cells":37525},{"EARLY_PHASE1":37526,"PHASE1":37528,"PHASE2":37530,"PHASE3":37536,"PHASE4":37538,"NA":37540},{"trials":37527,"activeCount":102},[],{"trials":37529,"activeCount":102},[],{"trials":37531,"activeCount":102},[37532],{"nctId":37508,"briefTitle":37509,"status":108,"phases":37533,"primaryCompletion":37511,"completion":37511,"start":37512,"enrollment":5333,"conditions":37534,"interventions":37535},[90,91],[5335],[37499,37515,37516,37517],{"trials":37537,"activeCount":102},[],{"trials":37539,"activeCount":102},[],{"trials":37541,"activeCount":102},[],{"intervention":37516,"totalTrials":195,"cells":37543},{"EARLY_PHASE1":37544,"PHASE1":37546,"PHASE2":37548,"PHASE3":37554,"PHASE4":37556,"NA":37558},{"trials":37545,"activeCount":102},[],{"trials":37547,"activeCount":102},[],{"trials":37549,"activeCount":102},[37550],{"nctId":37508,"briefTitle":37509,"status":108,"phases":37551,"primaryCompletion":37511,"completion":37511,"start":37512,"enrollment":5333,"conditions":37552,"interventions":37553},[90,91],[5335],[37499,37515,37516,37517],{"trials":37555,"activeCount":102},[],{"trials":37557,"activeCount":102},[],{"trials":37559,"activeCount":102},[],{"intervention":37517,"totalTrials":195,"cells":37561},{"EARLY_PHASE1":37562,"PHASE1":37564,"PHASE2":37566,"PHASE3":37572,"PHASE4":37574,"NA":37576},{"trials":37563,"activeCount":102},[],{"trials":37565,"activeCount":102},[],{"trials":37567,"activeCount":102},[37568],{"nctId":37508,"briefTitle":37509,"status":108,"phases":37569,"primaryCompletion":37511,"completion":37511,"start":37512,"enrollment":5333,"conditions":37570,"interventions":37571},[90,91],[5335],[37499,37515,37516,37517],{"trials":37573,"activeCount":102},[],{"trials":37575,"activeCount":102},[],{"trials":37577,"activeCount":102},[],{"intervention":11288,"totalTrials":195,"cells":37579},{"EARLY_PHASE1":37580,"PHASE1":37582,"PHASE2":37584,"PHASE3":37590,"PHASE4":37592,"NA":37594},{"trials":37581,"activeCount":102},[],{"trials":37583,"activeCount":102},[],{"trials":37585,"activeCount":102},[37586],{"nctId":11283,"briefTitle":11284,"status":108,"phases":37587,"primaryCompletion":2487,"completion":7430,"start":8683,"enrollment":112,"conditions":37588,"interventions":37589},[90,91],[1357],[2752,2754,11288],{"trials":37591,"activeCount":102},[],{"trials":37593,"activeCount":102},[],{"trials":37595,"activeCount":102},[],{"intervention":37597,"totalTrials":195,"cells":37598},"ChimeriVax™-JE vaccine",{"EARLY_PHASE1":37599,"PHASE1":37601,"PHASE2":37603,"PHASE3":37612,"PHASE4":37614,"NA":37616},{"trials":37600,"activeCount":102},[],{"trials":37602,"activeCount":102},[],{"trials":37604,"activeCount":102},[37605],{"nctId":37606,"briefTitle":37607,"status":108,"phases":37608,"primaryCompletion":3622,"completion":3622,"start":9862,"enrollment":178,"conditions":37609,"interventions":37610},"NCT00319592","A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX",[91],[17265],[37597,37611],"JE-VAX® vaccine",{"trials":37613,"activeCount":102},[],{"trials":37615,"activeCount":102},[],{"trials":37617,"activeCount":102},[],{"intervention":37611,"totalTrials":195,"cells":37619},{"EARLY_PHASE1":37620,"PHASE1":37622,"PHASE2":37624,"PHASE3":37630,"PHASE4":37632,"NA":37634},{"trials":37621,"activeCount":102},[],{"trials":37623,"activeCount":102},[],{"trials":37625,"activeCount":102},[37626],{"nctId":37606,"briefTitle":37607,"status":108,"phases":37627,"primaryCompletion":3622,"completion":3622,"start":9862,"enrollment":178,"conditions":37628,"interventions":37629},[91],[17265],[37597,37611],{"trials":37631,"activeCount":102},[],{"trials":37633,"activeCount":102},[],{"trials":37635,"activeCount":102},[],{"intervention":37637,"totalTrials":195,"cells":37638},"Oxaliplatin, capecitabine",{"EARLY_PHASE1":37639,"PHASE1":37641,"PHASE2":37643,"PHASE3":37651,"PHASE4":37653,"NA":37655},{"trials":37640,"activeCount":102},[],{"trials":37642,"activeCount":102},[],{"trials":37644,"activeCount":102},[37645],{"nctId":37646,"briefTitle":37647,"status":108,"phases":37648,"primaryCompletion":987,"completion":987,"start":8753,"enrollment":9275,"conditions":37649,"interventions":37650},"NCT00421824","Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX\u002FRT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer",[91],[9177],[37637,37637],{"trials":37652,"activeCount":102},[],{"trials":37654,"activeCount":102},[],{"trials":37656,"activeCount":102},[],{"intervention":32765,"totalTrials":195,"cells":37658},{"EARLY_PHASE1":37659,"PHASE1":37661,"PHASE2":37663,"PHASE3":37669,"PHASE4":37671,"NA":37673},{"trials":37660,"activeCount":102},[],{"trials":37662,"activeCount":102},[],{"trials":37664,"activeCount":102},[37665],{"nctId":32759,"briefTitle":32760,"status":884,"phases":37666,"primaryCompletion":8196,"completion":8196,"start":8762,"enrollment":195,"conditions":37667,"interventions":37668},[91],[32763],[32765,32766],{"trials":37670,"activeCount":102},[],{"trials":37672,"activeCount":102},[],{"trials":37674,"activeCount":102},[],{"intervention":18832,"totalTrials":195,"cells":37676},{"EARLY_PHASE1":37677,"PHASE1":37679,"PHASE2":37681,"PHASE3":37687,"PHASE4":37689,"NA":37691},{"trials":37678,"activeCount":102},[],{"trials":37680,"activeCount":102},[],{"trials":37682,"activeCount":102},[37683],{"nctId":18826,"briefTitle":18827,"status":3661,"phases":37684,"primaryCompletion":18829,"completion":18829,"start":1055,"enrollment":102,"conditions":37685,"interventions":37686},[91],[9210],[9200,9212,18832],{"trials":37688,"activeCount":102},[],{"trials":37690,"activeCount":102},[],{"trials":37692,"activeCount":102},[],{"intervention":21092,"totalTrials":195,"cells":37694},{"EARLY_PHASE1":37695,"PHASE1":37697,"PHASE2":37699,"PHASE3":37705,"PHASE4":37707,"NA":37709},{"trials":37696,"activeCount":102},[],{"trials":37698,"activeCount":102},[],{"trials":37700,"activeCount":102},[37701],{"nctId":21086,"briefTitle":21087,"status":108,"phases":37702,"primaryCompletion":3623,"completion":5272,"start":3633,"enrollment":21089,"conditions":37703,"interventions":37704},[91],[25,31,28,20655,12983],[21077,21092],{"trials":37706,"activeCount":102},[],{"trials":37708,"activeCount":102},[],{"trials":37710,"activeCount":102},[],{"intervention":37712,"totalTrials":195,"cells":37713},"Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate",{"EARLY_PHASE1":37714,"PHASE1":37716,"PHASE2":37718,"PHASE3":37727,"PHASE4":37729,"NA":37731},{"trials":37715,"activeCount":102},[],{"trials":37717,"activeCount":102},[],{"trials":37719,"activeCount":102},[37720],{"nctId":37721,"briefTitle":37722,"status":108,"phases":37723,"primaryCompletion":8261,"completion":3354,"start":8156,"enrollment":37724,"conditions":37725,"interventions":37726},"NCT00700635","Dose Comparison Study of Menactra® in US Children",[91],333,[4992,2949,2489],[37712,37712,37712],{"trials":37728,"activeCount":102},[],{"trials":37730,"activeCount":102},[],{"trials":37732,"activeCount":102},[],{"intervention":37734,"totalTrials":195,"cells":37735},"SAR440234",{"EARLY_PHASE1":37736,"PHASE1":37738,"PHASE2":37740,"PHASE3":37751,"PHASE4":37753,"NA":37755},{"trials":37737,"activeCount":102},[],{"trials":37739,"activeCount":102},[],{"trials":37741,"activeCount":102},[37742],{"nctId":37743,"briefTitle":37744,"status":884,"phases":37745,"primaryCompletion":37746,"completion":37746,"start":37747,"enrollment":538,"conditions":37748,"interventions":37750},"NCT03594955","First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome",[90,91],"2021-02-06","2018-10-24",[37749],"Leukaemia",[37734],{"trials":37752,"activeCount":102},[],{"trials":37754,"activeCount":102},[],{"trials":37756,"activeCount":102},[],{"intervention":9684,"totalTrials":195,"cells":37758},{"EARLY_PHASE1":37759,"PHASE1":37761,"PHASE2":37763,"PHASE3":37769,"PHASE4":37771,"NA":37773},{"trials":37760,"activeCount":102},[],{"trials":37762,"activeCount":102},[],{"trials":37764,"activeCount":102},[37765],{"nctId":9675,"briefTitle":9676,"status":108,"phases":37766,"primaryCompletion":8745,"completion":8745,"start":8731,"enrollment":9678,"conditions":37767,"interventions":37768},[91],[9680],[9682,9683,9684],{"trials":37770,"activeCount":102},[],{"trials":37772,"activeCount":102},[],{"trials":37774,"activeCount":102},[],{"intervention":5423,"totalTrials":195,"cells":37776},{"EARLY_PHASE1":37777,"PHASE1":37779,"PHASE2":37781,"PHASE3":37787,"PHASE4":37789,"NA":37791},{"trials":37778,"activeCount":102},[],{"trials":37780,"activeCount":102},[],{"trials":37782,"activeCount":102},[37783],{"nctId":5416,"briefTitle":5417,"status":884,"phases":37784,"primaryCompletion":4734,"completion":4734,"start":5419,"enrollment":3767,"conditions":37785,"interventions":37786},[90,91],[5421,2665],[5423,5400,5298,5277,5424],{"trials":37788,"activeCount":102},[],{"trials":37790,"activeCount":102},[],{"trials":37792,"activeCount":102},[],{"intervention":1277,"totalTrials":195,"cells":37794},{"EARLY_PHASE1":37795,"PHASE1":37797,"PHASE2":37799,"PHASE3":37805,"PHASE4":37807,"NA":37809},{"trials":37796,"activeCount":102},[],{"trials":37798,"activeCount":102},[],{"trials":37800,"activeCount":102},[37801],{"nctId":1268,"briefTitle":1269,"status":108,"phases":37802,"primaryCompletion":964,"completion":1271,"start":1272,"enrollment":875,"conditions":37803,"interventions":37804},[91],[1274],[1276,1277,642,642],{"trials":37806,"activeCount":102},[],{"trials":37808,"activeCount":102},[],{"trials":37810,"activeCount":102},[],{"intervention":194,"totalTrials":195,"cells":37812},{"EARLY_PHASE1":37813,"PHASE1":37815,"PHASE2":37817,"PHASE3":37823,"PHASE4":37825,"NA":37827},{"trials":37814,"activeCount":102},[],{"trials":37816,"activeCount":102},[],{"trials":37818,"activeCount":102},[37819],{"nctId":184,"briefTitle":185,"status":108,"phases":37820,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":37821,"interventions":37822},[91],[155],[193,97,194],{"trials":37824,"activeCount":102},[],{"trials":37826,"activeCount":102},[],{"trials":37828,"activeCount":102},[],{"intervention":5370,"totalTrials":195,"cells":37830},{"EARLY_PHASE1":37831,"PHASE1":37833,"PHASE2":37835,"PHASE3":37841,"PHASE4":37843,"NA":37845},{"trials":37832,"activeCount":102},[],{"trials":37834,"activeCount":102},[],{"trials":37836,"activeCount":102},[37837],{"nctId":5362,"briefTitle":5363,"status":108,"phases":37838,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":5367,"conditions":37839,"interventions":37840},[90,91],[5335],[5370,5371,5372,5319,5339,5338],{"trials":37842,"activeCount":102},[],{"trials":37844,"activeCount":102},[],{"trials":37846,"activeCount":102},[],{"intervention":5371,"totalTrials":195,"cells":37848},{"EARLY_PHASE1":37849,"PHASE1":37851,"PHASE2":37853,"PHASE3":37859,"PHASE4":37861,"NA":37863},{"trials":37850,"activeCount":102},[],{"trials":37852,"activeCount":102},[],{"trials":37854,"activeCount":102},[37855],{"nctId":5362,"briefTitle":5363,"status":108,"phases":37856,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":5367,"conditions":37857,"interventions":37858},[90,91],[5335],[5370,5371,5372,5319,5339,5338],{"trials":37860,"activeCount":102},[],{"trials":37862,"activeCount":102},[],{"trials":37864,"activeCount":102},[],{"intervention":5372,"totalTrials":195,"cells":37866},{"EARLY_PHASE1":37867,"PHASE1":37869,"PHASE2":37871,"PHASE3":37877,"PHASE4":37879,"NA":37881},{"trials":37868,"activeCount":102},[],{"trials":37870,"activeCount":102},[],{"trials":37872,"activeCount":102},[37873],{"nctId":5362,"briefTitle":5363,"status":108,"phases":37874,"primaryCompletion":5365,"completion":5365,"start":5366,"enrollment":5367,"conditions":37875,"interventions":37876},[90,91],[5335],[5370,5371,5372,5319,5339,5338],{"trials":37878,"activeCount":102},[],{"trials":37880,"activeCount":102},[],{"trials":37882,"activeCount":102},[],{"intervention":37884,"totalTrials":195,"cells":37885},"SL77.0499-10",{"EARLY_PHASE1":37886,"PHASE1":37888,"PHASE2":37890,"PHASE3":37899,"PHASE4":37901,"NA":37903},{"trials":37887,"activeCount":102},[],{"trials":37889,"activeCount":102},[],{"trials":37891,"activeCount":102},[37892],{"nctId":37893,"briefTitle":37894,"status":108,"phases":37895,"primaryCompletion":8579,"completion":8579,"start":8175,"enrollment":37896,"conditions":37897,"interventions":37898},"NCT00409357","Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia",[91],473,[28076],[37884],{"trials":37900,"activeCount":102},[],{"trials":37902,"activeCount":102},[],{"trials":37904,"activeCount":102},[],{"intervention":37906,"totalTrials":195,"cells":37907},"Live attenuated Japanese encephalitis virus; Yellow fever virus",{"EARLY_PHASE1":37908,"PHASE1":37910,"PHASE2":37912,"PHASE3":37921,"PHASE4":37923,"NA":37925},{"trials":37909,"activeCount":102},[],{"trials":37911,"activeCount":102},[],{"trials":37913,"activeCount":102},[37914],{"nctId":37915,"briefTitle":37916,"status":108,"phases":37917,"primaryCompletion":8667,"completion":5272,"start":7482,"enrollment":9275,"conditions":37918,"interventions":37919},"NCT00982137","Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)",[91],[17265,2296],[37906,37920,37906,37906],"Yellow fever virus; Live attenuated Japanese encephalitis virus",{"trials":37922,"activeCount":102},[],{"trials":37924,"activeCount":102},[],{"trials":37926,"activeCount":102},[],{"intervention":37920,"totalTrials":195,"cells":37928},{"EARLY_PHASE1":37929,"PHASE1":37931,"PHASE2":37933,"PHASE3":37939,"PHASE4":37941,"NA":37943},{"trials":37930,"activeCount":102},[],{"trials":37932,"activeCount":102},[],{"trials":37934,"activeCount":102},[37935],{"nctId":37915,"briefTitle":37916,"status":108,"phases":37936,"primaryCompletion":8667,"completion":5272,"start":7482,"enrollment":9275,"conditions":37937,"interventions":37938},[91],[17265,2296],[37906,37920,37906,37906],{"trials":37940,"activeCount":102},[],{"trials":37942,"activeCount":102},[],{"trials":37944,"activeCount":102},[],{"intervention":2912,"totalTrials":195,"cells":37946},{"EARLY_PHASE1":37947,"PHASE1":37949,"PHASE2":37951,"PHASE3":37957,"PHASE4":37959,"NA":37961},{"trials":37948,"activeCount":102},[],{"trials":37950,"activeCount":102},[],{"trials":37952,"activeCount":102},[37953],{"nctId":2903,"briefTitle":2904,"status":108,"phases":37954,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":2908,"conditions":37955,"interventions":37956},[90,91],[2910,36],[2896,2879,2897,2897,2897,2879,2912],{"trials":37958,"activeCount":102},[],{"trials":37960,"activeCount":102},[],{"trials":37962,"activeCount":102},[],{"intervention":992,"totalTrials":195,"cells":37964},{"EARLY_PHASE1":37965,"PHASE1":37967,"PHASE2":37969,"PHASE3":37975,"PHASE4":37977,"NA":37979},{"trials":37966,"activeCount":102},[],{"trials":37968,"activeCount":102},[],{"trials":37970,"activeCount":102},[37971],{"nctId":983,"briefTitle":984,"status":884,"phases":37972,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":37973,"interventions":37974},[91],[990],[942,992,993,972],{"trials":37976,"activeCount":102},[],{"trials":37978,"activeCount":102},[],{"trials":37980,"activeCount":102},[],{"intervention":37982,"totalTrials":195,"cells":37983},"Chimeric dengue serotype",{"EARLY_PHASE1":37984,"PHASE1":37986,"PHASE2":37988,"PHASE3":37996,"PHASE4":37998,"NA":38000},{"trials":37985,"activeCount":102},[],{"trials":37987,"activeCount":102},[],{"trials":37989,"activeCount":102},[37990],{"nctId":37991,"briefTitle":37992,"status":108,"phases":37993,"primaryCompletion":9190,"completion":8762,"start":5262,"enrollment":875,"conditions":37994,"interventions":37995},"NCT00730288","Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects",[91],[2316,18210,2317,18211],[37982,37982,37982],{"trials":37997,"activeCount":102},[],{"trials":37999,"activeCount":102},[],{"trials":38001,"activeCount":102},[],{"intervention":38003,"totalTrials":195,"cells":38004},"Fluzone: Influenza virus vaccine",{"EARLY_PHASE1":38005,"PHASE1":38007,"PHASE2":38009,"PHASE3":38017,"PHASE4":38019,"NA":38021},{"trials":38006,"activeCount":102},[],{"trials":38008,"activeCount":102},[],{"trials":38010,"activeCount":102},[38011],{"nctId":38012,"briefTitle":38013,"status":108,"phases":38014,"primaryCompletion":8316,"completion":8156,"start":8762,"enrollment":599,"conditions":38015,"interventions":38016},"NCT00623181","Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults",[91],[16],[38003,38003],{"trials":38018,"activeCount":102},[],{"trials":38020,"activeCount":102},[],{"trials":38022,"activeCount":102},[],{"intervention":38024,"totalTrials":195,"cells":38025},"Inactivated influenza vaccine",{"EARLY_PHASE1":38026,"PHASE1":38028,"PHASE2":38030,"PHASE3":38038,"PHASE4":38040,"NA":38042},{"trials":38027,"activeCount":102},[],{"trials":38029,"activeCount":102},[],{"trials":38031,"activeCount":102},[38032],{"nctId":38033,"briefTitle":38034,"status":108,"phases":38035,"primaryCompletion":9190,"completion":9190,"start":3608,"enrollment":4920,"conditions":38036,"interventions":38037},"NCT00343681","A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine",[91],[16,15230],[38024],{"trials":38039,"activeCount":102},[],{"trials":38041,"activeCount":102},[],{"trials":38043,"activeCount":102},[],{"intervention":38045,"totalTrials":195,"cells":38046},"SSR180575",{"EARLY_PHASE1":38047,"PHASE1":38049,"PHASE2":38051,"PHASE3":38061,"PHASE4":38063,"NA":38065},{"trials":38048,"activeCount":102},[],{"trials":38050,"activeCount":102},[],{"trials":38052,"activeCount":102},[38053],{"nctId":38054,"briefTitle":38055,"status":108,"phases":38056,"primaryCompletion":8315,"completion":8315,"start":3563,"enrollment":38057,"conditions":38058,"interventions":38060},"NCT00502515","Dose-effect of SSR180575 in Diabetic Neuropathy",[91],309,[38059],"Diabetic Neuropathies",[38045],{"trials":38062,"activeCount":102},[],{"trials":38064,"activeCount":102},[],{"trials":38066,"activeCount":102},[],{"intervention":38068,"totalTrials":195,"cells":38069},"Oxaliplatin, Paclitaxel",{"EARLY_PHASE1":38070,"PHASE1":38072,"PHASE2":38074,"PHASE3":38083,"PHASE4":38085,"NA":38087},{"trials":38071,"activeCount":102},[],{"trials":38073,"activeCount":102},[],{"trials":38075,"activeCount":102},[38076],{"nctId":38077,"briefTitle":38078,"status":108,"phases":38079,"completion":9522,"start":9282,"enrollment":6434,"conditions":38080,"interventions":38082},"NCT00611962","Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin",[91],[38081],"Neoplasms, Germ Cell and Embryonal",[38068],{"trials":38084,"activeCount":102},[],{"trials":38086,"activeCount":102},[],{"trials":38088,"activeCount":102},[],{"intervention":30759,"totalTrials":195,"cells":38090},{"EARLY_PHASE1":38091,"PHASE1":38093,"PHASE2":38095,"PHASE3":38101,"PHASE4":38103,"NA":38105},{"trials":38092,"activeCount":102},[],{"trials":38094,"activeCount":102},[],{"trials":38096,"activeCount":102},[38097],{"nctId":30751,"briefTitle":30752,"status":884,"phases":38098,"primaryCompletion":30754,"completion":30754,"start":30755,"enrollment":2389,"conditions":38099,"interventions":38100},[90,91],[30757],[30759,5400,30760],{"trials":38102,"activeCount":102},[],{"trials":38104,"activeCount":102},[],{"trials":38106,"activeCount":102},[],{"intervention":30760,"totalTrials":195,"cells":38108},{"EARLY_PHASE1":38109,"PHASE1":38111,"PHASE2":38113,"PHASE3":38119,"PHASE4":38121,"NA":38123},{"trials":38110,"activeCount":102},[],{"trials":38112,"activeCount":102},[],{"trials":38114,"activeCount":102},[38115],{"nctId":30751,"briefTitle":30752,"status":884,"phases":38116,"primaryCompletion":30754,"completion":30754,"start":30755,"enrollment":2389,"conditions":38117,"interventions":38118},[90,91],[30757],[30759,5400,30760],{"trials":38120,"activeCount":102},[],{"trials":38122,"activeCount":102},[],{"trials":38124,"activeCount":102},[],{"intervention":38126,"totalTrials":195,"cells":38127},"ARD6562, Docetaxel",{"EARLY_PHASE1":38128,"PHASE1":38130,"PHASE2":38132,"PHASE3":38140,"PHASE4":38142,"NA":38144},{"trials":38129,"activeCount":102},[],{"trials":38131,"activeCount":102},[],{"trials":38133,"activeCount":102},[38134],{"nctId":38135,"briefTitle":38136,"status":108,"phases":38137,"start":7523,"enrollment":3510,"conditions":38138,"interventions":38139},"NCT00291005","PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone",[91],[2804],[38126],{"trials":38141,"activeCount":102},[],{"trials":38143,"activeCount":102},[],{"trials":38145,"activeCount":102},[],{"intervention":38147,"totalTrials":195,"cells":38148},"Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1",{"EARLY_PHASE1":38149,"PHASE1":38151,"PHASE2":38153,"PHASE3":38169,"PHASE4":38171,"NA":38173},{"trials":38150,"activeCount":102},[],{"trials":38152,"activeCount":102},[],{"trials":38154,"activeCount":102},[38155],{"nctId":38156,"briefTitle":38157,"status":108,"phases":38158,"primaryCompletion":38159,"completion":38159,"start":38160,"enrollment":38161,"conditions":38162,"interventions":38163},"NCT02587520","Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects",[90,91],"2017-02-21","2015-10-22",1363,[31,25,28,13514],[38147,38164,38165,38166,38167,38168],"Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2","Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3","Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4","Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed","Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine",{"trials":38170,"activeCount":102},[],{"trials":38172,"activeCount":102},[],{"trials":38174,"activeCount":102},[],{"intervention":38164,"totalTrials":195,"cells":38176},{"EARLY_PHASE1":38177,"PHASE1":38179,"PHASE2":38181,"PHASE3":38187,"PHASE4":38189,"NA":38191},{"trials":38178,"activeCount":102},[],{"trials":38180,"activeCount":102},[],{"trials":38182,"activeCount":102},[38183],{"nctId":38156,"briefTitle":38157,"status":108,"phases":38184,"primaryCompletion":38159,"completion":38159,"start":38160,"enrollment":38161,"conditions":38185,"interventions":38186},[90,91],[31,25,28,13514],[38147,38164,38165,38166,38167,38168],{"trials":38188,"activeCount":102},[],{"trials":38190,"activeCount":102},[],{"trials":38192,"activeCount":102},[],{"intervention":38165,"totalTrials":195,"cells":38194},{"EARLY_PHASE1":38195,"PHASE1":38197,"PHASE2":38199,"PHASE3":38205,"PHASE4":38207,"NA":38209},{"trials":38196,"activeCount":102},[],{"trials":38198,"activeCount":102},[],{"trials":38200,"activeCount":102},[38201],{"nctId":38156,"briefTitle":38157,"status":108,"phases":38202,"primaryCompletion":38159,"completion":38159,"start":38160,"enrollment":38161,"conditions":38203,"interventions":38204},[90,91],[31,25,28,13514],[38147,38164,38165,38166,38167,38168],{"trials":38206,"activeCount":102},[],{"trials":38208,"activeCount":102},[],{"trials":38210,"activeCount":102},[],{"intervention":38166,"totalTrials":195,"cells":38212},{"EARLY_PHASE1":38213,"PHASE1":38215,"PHASE2":38217,"PHASE3":38223,"PHASE4":38225,"NA":38227},{"trials":38214,"activeCount":102},[],{"trials":38216,"activeCount":102},[],{"trials":38218,"activeCount":102},[38219],{"nctId":38156,"briefTitle":38157,"status":108,"phases":38220,"primaryCompletion":38159,"completion":38159,"start":38160,"enrollment":38161,"conditions":38221,"interventions":38222},[90,91],[31,25,28,13514],[38147,38164,38165,38166,38167,38168],{"trials":38224,"activeCount":102},[],{"trials":38226,"activeCount":102},[],{"trials":38228,"activeCount":102},[],{"intervention":38167,"totalTrials":195,"cells":38230},{"EARLY_PHASE1":38231,"PHASE1":38233,"PHASE2":38235,"PHASE3":38241,"PHASE4":38243,"NA":38245},{"trials":38232,"activeCount":102},[],{"trials":38234,"activeCount":102},[],{"trials":38236,"activeCount":102},[38237],{"nctId":38156,"briefTitle":38157,"status":108,"phases":38238,"primaryCompletion":38159,"completion":38159,"start":38160,"enrollment":38161,"conditions":38239,"interventions":38240},[90,91],[31,25,28,13514],[38147,38164,38165,38166,38167,38168],{"trials":38242,"activeCount":102},[],{"trials":38244,"activeCount":102},[],{"trials":38246,"activeCount":102},[],{"intervention":38168,"totalTrials":195,"cells":38248},{"EARLY_PHASE1":38249,"PHASE1":38251,"PHASE2":38253,"PHASE3":38259,"PHASE4":38261,"NA":38263},{"trials":38250,"activeCount":102},[],{"trials":38252,"activeCount":102},[],{"trials":38254,"activeCount":102},[38255],{"nctId":38156,"briefTitle":38157,"status":108,"phases":38256,"primaryCompletion":38159,"completion":38159,"start":38160,"enrollment":38161,"conditions":38257,"interventions":38258},[90,91],[31,25,28,13514],[38147,38164,38165,38166,38167,38168],{"trials":38260,"activeCount":102},[],{"trials":38262,"activeCount":102},[],{"trials":38264,"activeCount":102},[],{"intervention":38266,"totalTrials":195,"cells":38267},"AVE2268",{"EARLY_PHASE1":38268,"PHASE1":38270,"PHASE2":38272,"PHASE3":38280,"PHASE4":38282,"NA":38284},{"trials":38269,"activeCount":102},[],{"trials":38271,"activeCount":102},[],{"trials":38273,"activeCount":102},[38274],{"nctId":38275,"briefTitle":38276,"status":108,"phases":38277,"primaryCompletion":8762,"completion":8762,"start":3608,"enrollment":17938,"conditions":38278,"interventions":38279},"NCT00361738","Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment",[91],[19],[38266],{"trials":38281,"activeCount":102},[],{"trials":38283,"activeCount":102},[],{"trials":38285,"activeCount":102},[],{"intervention":31923,"totalTrials":195,"cells":38287},{"EARLY_PHASE1":38288,"PHASE1":38290,"PHASE2":38292,"PHASE3":38298,"PHASE4":38300,"NA":38302},{"trials":38289,"activeCount":102},[],{"trials":38291,"activeCount":102},[],{"trials":38293,"activeCount":102},[38294],{"nctId":31918,"briefTitle":31919,"status":884,"phases":38295,"primaryCompletion":3335,"completion":3335,"start":1340,"enrollment":576,"conditions":38296,"interventions":38297},[91],[12262],[31903,31923],{"trials":38299,"activeCount":102},[],{"trials":38301,"activeCount":102},[],{"trials":38303,"activeCount":102},[],{"intervention":38305,"totalTrials":195,"cells":38306},"SL650472, Clopidogrel",{"EARLY_PHASE1":38307,"PHASE1":38309,"PHASE2":38311,"PHASE3":38320,"PHASE4":38322,"NA":38324},{"trials":38308,"activeCount":102},[],{"trials":38310,"activeCount":102},[],{"trials":38312,"activeCount":102},[38313],{"nctId":38314,"briefTitle":38315,"status":108,"phases":38316,"primaryCompletion":7509,"completion":7509,"start":8777,"enrollment":38317,"conditions":38318,"interventions":38319},"NCT00300339","Mixed Antagonist of Serotonin for Claudication Optimal Therapy",[91],599,[32726],[38305],{"trials":38321,"activeCount":102},[],{"trials":38323,"activeCount":102},[],{"trials":38325,"activeCount":102},[],{"intervention":38327,"totalTrials":195,"cells":38328},"VASOPRESSIN V1B RECEPTOR ANTAGONIST",{"EARLY_PHASE1":38329,"PHASE1":38331,"PHASE2":38333,"PHASE3":38341,"PHASE4":38343,"NA":38345},{"trials":38330,"activeCount":102},[],{"trials":38332,"activeCount":102},[],{"trials":38334,"activeCount":102},[38335],{"nctId":38336,"briefTitle":38337,"status":108,"phases":38338,"primaryCompletion":9190,"completion":9190,"start":10339,"enrollment":465,"conditions":38339,"interventions":38340},"NCT01606384","Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder",[91],[18504],[38327],{"trials":38342,"activeCount":102},[],{"trials":38344,"activeCount":102},[],{"trials":38346,"activeCount":102},[],{"intervention":18274,"totalTrials":195,"cells":38348},{"EARLY_PHASE1":38349,"PHASE1":38351,"PHASE2":38353,"PHASE3":38359,"PHASE4":38361,"NA":38363},{"trials":38350,"activeCount":102},[],{"trials":38352,"activeCount":102},[],{"trials":38354,"activeCount":102},[38355],{"nctId":18268,"briefTitle":18269,"status":108,"phases":38356,"primaryCompletion":2311,"completion":8166,"start":8315,"enrollment":18271,"conditions":38357,"interventions":38358},[91],[18211,18210,2317,18212],[18194,18274],{"trials":38360,"activeCount":102},[],{"trials":38362,"activeCount":102},[],{"trials":38364,"activeCount":102},[],{"intervention":1458,"totalTrials":195,"cells":38366},{"EARLY_PHASE1":38367,"PHASE1":38369,"PHASE2":38371,"PHASE3":38377,"PHASE4":38379,"NA":38381},{"trials":38368,"activeCount":102},[],{"trials":38370,"activeCount":102},[],{"trials":38372,"activeCount":102},[38373],{"nctId":1449,"briefTitle":1450,"status":108,"phases":38374,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":38375,"interventions":38376},[91],[351],[77,1458,1459],{"trials":38378,"activeCount":102},[],{"trials":38380,"activeCount":102},[],{"trials":38382,"activeCount":102},[],{"intervention":1459,"totalTrials":195,"cells":38384},{"EARLY_PHASE1":38385,"PHASE1":38387,"PHASE2":38389,"PHASE3":38395,"PHASE4":38397,"NA":38399},{"trials":38386,"activeCount":102},[],{"trials":38388,"activeCount":102},[],{"trials":38390,"activeCount":102},[38391],{"nctId":1449,"briefTitle":1450,"status":108,"phases":38392,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":38393,"interventions":38394},[91],[351],[77,1458,1459],{"trials":38396,"activeCount":102},[],{"trials":38398,"activeCount":102},[],{"trials":38400,"activeCount":102},[],{"intervention":38402,"totalTrials":195,"cells":38403},"Nolpitantium besylate",{"EARLY_PHASE1":38404,"PHASE1":38406,"PHASE2":38408,"PHASE3":38417,"PHASE4":38419,"NA":38421},{"trials":38405,"activeCount":102},[],{"trials":38407,"activeCount":102},[],{"trials":38409,"activeCount":102},[38410],{"nctId":38411,"briefTitle":38412,"status":108,"phases":38413,"primaryCompletion":3622,"completion":3622,"start":8667,"enrollment":1332,"conditions":38414,"interventions":38416},"NCT00232258","Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study",[91],[2103,38415],"Inflammatory Bowel Disease",[38402],{"trials":38418,"activeCount":102},[],{"trials":38420,"activeCount":102},[],{"trials":38422,"activeCount":102},[],{"intervention":38424,"totalTrials":195,"cells":38425},"Oxaliplatin, 5-Fluorouracil",{"EARLY_PHASE1":38426,"PHASE1":38428,"PHASE2":38430,"PHASE3":38438,"PHASE4":38440,"NA":38442},{"trials":38427,"activeCount":102},[],{"trials":38429,"activeCount":102},[],{"trials":38431,"activeCount":102},[38432],{"nctId":38433,"briefTitle":38434,"status":108,"phases":38435,"completion":7538,"start":5251,"enrollment":1134,"conditions":38436,"interventions":38437},"NCT00611507","A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer",[91],[9092],[38424],{"trials":38439,"activeCount":102},[],{"trials":38441,"activeCount":102},[],{"trials":38443,"activeCount":102},[],{"intervention":19199,"totalTrials":195,"cells":38445},{"EARLY_PHASE1":38446,"PHASE1":38448,"PHASE2":38450,"PHASE3":38456,"PHASE4":38458,"NA":38460},{"trials":38447,"activeCount":102},[],{"trials":38449,"activeCount":102},[],{"trials":38451,"activeCount":102},[38452],{"nctId":19194,"briefTitle":19195,"status":108,"phases":38453,"primaryCompletion":165,"completion":165,"start":955,"enrollment":1977,"conditions":38454,"interventions":38455},[91],[18513],[19199,18506],{"trials":38457,"activeCount":102},[],{"trials":38459,"activeCount":102},[],{"trials":38461,"activeCount":102},[],{"intervention":38463,"totalTrials":195,"cells":38464},"Clostridium difficile toxoids A and B",{"EARLY_PHASE1":38465,"PHASE1":38467,"PHASE2":38469,"PHASE3":38478,"PHASE4":38480,"NA":38482},{"trials":38466,"activeCount":102},[],{"trials":38468,"activeCount":102},[],{"trials":38470,"activeCount":102},[38471],{"nctId":38472,"briefTitle":38473,"status":108,"phases":38474,"primaryCompletion":7284,"completion":2760,"start":8453,"enrollment":38475,"conditions":38476,"interventions":38477},"NCT01230957","Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults",[91],650,[21801,26251],[38463,38463,38463,38463,38463,38463],{"trials":38479,"activeCount":102},[],{"trials":38481,"activeCount":102},[],{"trials":38483,"activeCount":102},[],{"intervention":38485,"totalTrials":195,"cells":38486},"Oxaliplatin + cisplatin + 5-Fluorouracil",{"EARLY_PHASE1":38487,"PHASE1":38489,"PHASE2":38491,"PHASE3":38500,"PHASE4":38502,"NA":38504},{"trials":38488,"activeCount":102},[],{"trials":38490,"activeCount":102},[],{"trials":38492,"activeCount":102},[38493],{"nctId":38494,"briefTitle":38495,"status":108,"phases":38496,"primaryCompletion":8846,"completion":8846,"start":38497,"enrollment":7224,"conditions":38498,"interventions":38499},"NCT00259402","Oxaliplatin in Esophagus Cancer (Advanced) 1st Line",[91],"2000-02",[37395],[38485],{"trials":38501,"activeCount":102},[],{"trials":38503,"activeCount":102},[],{"trials":38505,"activeCount":102},[],{"intervention":9480,"totalTrials":339,"cells":38507},{"EARLY_PHASE1":38508,"PHASE1":38510,"PHASE2":38532,"PHASE3":38534,"PHASE4":38536,"NA":38538},{"trials":38509,"activeCount":102},[],{"trials":38511,"activeCount":102},[38512,38516,38520,38524,38528],{"nctId":9468,"briefTitle":9469,"status":108,"phases":38513,"primaryCompletion":8215,"completion":8215,"start":3307,"enrollment":8717,"conditions":38514,"interventions":38515},[90],[8839],[9455,1406],{"nctId":9474,"briefTitle":9475,"status":108,"phases":38517,"primaryCompletion":8261,"completion":8261,"start":8349,"enrollment":8717,"conditions":38518,"interventions":38519},[90],[8839],[9479,9480],{"nctId":1394,"briefTitle":1395,"status":108,"phases":38521,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":38522,"interventions":38523},[90],[351],[77,1403,1404,1405,1406,1407],{"nctId":9502,"briefTitle":9503,"status":108,"phases":38525,"primaryCompletion":8261,"completion":8261,"start":8315,"enrollment":8717,"conditions":38526,"interventions":38527},[90],[8839],[9479,9480],{"nctId":12705,"briefTitle":12706,"status":108,"phases":38529,"primaryCompletion":10178,"completion":10178,"start":8107,"enrollment":402,"conditions":38530,"interventions":38531},[90],[12709],[12711,9480,1266],{"trials":38533,"activeCount":102},[],{"trials":38535,"activeCount":102},[],{"trials":38537,"activeCount":102},[],{"trials":38539,"activeCount":102},[],{"intervention":38541,"totalTrials":619,"cells":38542},"Eliglustat",{"EARLY_PHASE1":38543,"PHASE1":38545,"PHASE2":38571,"PHASE3":38573,"PHASE4":38575,"NA":38577},{"trials":38544,"activeCount":102},[],{"trials":38546,"activeCount":102},[38547,38555,38563],{"nctId":38548,"briefTitle":38549,"status":108,"phases":38550,"primaryCompletion":26791,"completion":26791,"start":2824,"enrollment":6313,"conditions":38551,"interventions":38553},"NCT02536937","A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate",[90],[38552],"Gaucher Disease",[38554],"eliglustat",{"nctId":38556,"briefTitle":38557,"status":108,"phases":38558,"primaryCompletion":38559,"completion":38559,"start":38560,"enrollment":622,"conditions":38561,"interventions":38562},"NCT06193304","A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth",[90],"2014-09-21","2014-08-25",[17332],[38541],{"nctId":38564,"briefTitle":38565,"status":108,"phases":38566,"primaryCompletion":38567,"completion":38567,"start":38568,"enrollment":284,"conditions":38569,"interventions":38570},"NCT06188325","A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers",[90],"2018-03-26","2018-01-01",[17332],[38541],{"trials":38572,"activeCount":102},[],{"trials":38574,"activeCount":102},[],{"trials":38576,"activeCount":102},[],{"trials":38578,"activeCount":102},[],{"intervention":1403,"totalTrials":619,"cells":38580},{"EARLY_PHASE1":38581,"PHASE1":38583,"PHASE2":38597,"PHASE3":38599,"PHASE4":38601,"NA":38603},{"trials":38582,"activeCount":102},[],{"trials":38584,"activeCount":102},[38585,38589,38593],{"nctId":1394,"briefTitle":1395,"status":108,"phases":38586,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":38587,"interventions":38588},[90],[351],[77,1403,1404,1405,1406,1407],{"nctId":19498,"briefTitle":19499,"status":108,"phases":38590,"primaryCompletion":2857,"completion":2857,"start":3416,"enrollment":988,"conditions":38591,"interventions":38592},[90],[36],[1403,12711],{"nctId":18066,"briefTitle":18067,"status":108,"phases":38594,"primaryCompletion":18069,"completion":18069,"start":4968,"enrollment":9319,"conditions":38595,"interventions":38596},[90],[19],[8275,18072,18073],{"trials":38598,"activeCount":102},[],{"trials":38600,"activeCount":102},[],{"trials":38602,"activeCount":102},[],{"trials":38604,"activeCount":102},[],{"intervention":38606,"totalTrials":659,"cells":38607},"SAR405838",{"EARLY_PHASE1":38608,"PHASE1":38610,"PHASE2":38626,"PHASE3":38628,"PHASE4":38630,"NA":38632},{"trials":38609,"activeCount":102},[],{"trials":38611,"activeCount":102},[38612,38619],{"nctId":38613,"briefTitle":38614,"status":108,"phases":38615,"primaryCompletion":1078,"completion":1078,"start":38616,"enrollment":13,"conditions":38617,"interventions":38618},"NCT01636479","Phase 1 Safety Testing of SAR405838",[90],"2012-07-13",[1193],[38606],{"nctId":38620,"briefTitle":38621,"status":108,"phases":38622,"primaryCompletion":1355,"completion":1355,"start":10811,"enrollment":703,"conditions":38623,"interventions":38624},"NCT01985191","A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients",[90],[1193],[38606,38625],"Pimasertib",{"trials":38627,"activeCount":102},[],{"trials":38629,"activeCount":102},[],{"trials":38631,"activeCount":102},[],{"trials":38633,"activeCount":102},[],{"intervention":3744,"totalTrials":659,"cells":38635},{"EARLY_PHASE1":38636,"PHASE1":38638,"PHASE2":38648,"PHASE3":38650,"PHASE4":38652,"NA":38654},{"trials":38637,"activeCount":102},[],{"trials":38639,"activeCount":102},[38640,38644],{"nctId":3735,"briefTitle":3736,"status":108,"phases":38641,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":3740,"conditions":38642,"interventions":38643},[90],[1788],[3381,3743,3744],{"nctId":18034,"briefTitle":18035,"status":108,"phases":38645,"primaryCompletion":18037,"completion":18037,"start":18038,"enrollment":988,"conditions":38646,"interventions":38647},[90],[8187],[11524,18041],{"trials":38649,"activeCount":102},[],{"trials":38651,"activeCount":102},[],{"trials":38653,"activeCount":102},[],{"trials":38655,"activeCount":102},[],{"intervention":10610,"totalTrials":659,"cells":38657},{"EARLY_PHASE1":38658,"PHASE1":38660,"PHASE2":38670,"PHASE3":38672,"PHASE4":38674,"NA":38676},{"trials":38659,"activeCount":102},[],{"trials":38661,"activeCount":102},[38662,38666],{"nctId":10603,"briefTitle":10604,"status":108,"phases":38663,"primaryCompletion":10606,"completion":10606,"start":10607,"enrollment":3740,"conditions":38664,"interventions":38665},[90],[591],[10610,10611,10611],{"nctId":10613,"briefTitle":10614,"status":108,"phases":38667,"primaryCompletion":10616,"completion":10616,"start":10617,"enrollment":34,"conditions":38668,"interventions":38669},[90],[591],[10610,10611,10611,10610],{"trials":38671,"activeCount":102},[],{"trials":38673,"activeCount":102},[],{"trials":38675,"activeCount":102},[],{"trials":38677,"activeCount":102},[],{"intervention":21788,"totalTrials":659,"cells":38679},{"EARLY_PHASE1":38680,"PHASE1":38682,"PHASE2":38692,"PHASE3":38694,"PHASE4":38696,"NA":38698},{"trials":38681,"activeCount":102},[],{"trials":38683,"activeCount":102},[38684,38688],{"nctId":21782,"briefTitle":21783,"status":108,"phases":38685,"primaryCompletion":8777,"completion":8777,"start":3623,"enrollment":391,"conditions":38686,"interventions":38687},[90],[21786],[21788,21775,21775,21775],{"nctId":31573,"briefTitle":31574,"status":884,"phases":38689,"primaryCompletion":8395,"completion":8395,"start":5307,"enrollment":2685,"conditions":38690,"interventions":38691},[90],[21801,31577],[21788,31566,31566],{"trials":38693,"activeCount":102},[],{"trials":38695,"activeCount":102},[],{"trials":38697,"activeCount":102},[],{"trials":38699,"activeCount":102},[],{"intervention":38701,"totalTrials":659,"cells":38702},"Quadrivalent RIV with H3 strain 1",{"EARLY_PHASE1":38703,"PHASE1":38705,"PHASE2":38730,"PHASE3":38732,"PHASE4":38734,"NA":38736},{"trials":38704,"activeCount":102},[],{"trials":38706,"activeCount":102},[38707,38718],{"nctId":38708,"briefTitle":38709,"status":108,"phases":38710,"primaryCompletion":38711,"completion":38711,"start":18237,"enrollment":455,"conditions":38712,"interventions":38713},"NCT04144179","Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age",[90],"2020-02-24",[16],[38701,38714,38715,38716,38717],"Quadrivalent RIV with H3 strain 2","Quadrivalent RIV with H3 strain 3","Quadrivalent RIV with H3 strain 4","Quadrivalent RIV with 2018-2019 NH H3 strain",{"nctId":38719,"briefTitle":38720,"status":108,"phases":38721,"primaryCompletion":38722,"completion":38722,"start":38723,"enrollment":249,"conditions":38724,"interventions":38726},"NCT04451954","Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects",[90],"2021-09-20","2020-07-02",[38725,36],"Influenza Immunisation",[38701,38727,38714,38728,38717,38729],"Quadrivalent RIV with H3 strain 1 and adjuvant","Quadrivalent RIV with H3 strain 2 and adjuvant","Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant",{"trials":38731,"activeCount":102},[],{"trials":38733,"activeCount":102},[],{"trials":38735,"activeCount":102},[],{"trials":38737,"activeCount":102},[],{"intervention":38714,"totalTrials":659,"cells":38739},{"EARLY_PHASE1":38740,"PHASE1":38742,"PHASE2":38752,"PHASE3":38754,"PHASE4":38756,"NA":38758},{"trials":38741,"activeCount":102},[],{"trials":38743,"activeCount":102},[38744,38748],{"nctId":38708,"briefTitle":38709,"status":108,"phases":38745,"primaryCompletion":38711,"completion":38711,"start":18237,"enrollment":455,"conditions":38746,"interventions":38747},[90],[16],[38701,38714,38715,38716,38717],{"nctId":38719,"briefTitle":38720,"status":108,"phases":38749,"primaryCompletion":38722,"completion":38722,"start":38723,"enrollment":249,"conditions":38750,"interventions":38751},[90],[38725,36],[38701,38727,38714,38728,38717,38729],{"trials":38753,"activeCount":102},[],{"trials":38755,"activeCount":102},[],{"trials":38757,"activeCount":102},[],{"trials":38759,"activeCount":102},[],{"intervention":38717,"totalTrials":659,"cells":38761},{"EARLY_PHASE1":38762,"PHASE1":38764,"PHASE2":38774,"PHASE3":38776,"PHASE4":38778,"NA":38780},{"trials":38763,"activeCount":102},[],{"trials":38765,"activeCount":102},[38766,38770],{"nctId":38708,"briefTitle":38709,"status":108,"phases":38767,"primaryCompletion":38711,"completion":38711,"start":18237,"enrollment":455,"conditions":38768,"interventions":38769},[90],[16],[38701,38714,38715,38716,38717],{"nctId":38719,"briefTitle":38720,"status":108,"phases":38771,"primaryCompletion":38722,"completion":38722,"start":38723,"enrollment":249,"conditions":38772,"interventions":38773},[90],[38725,36],[38701,38727,38714,38728,38717,38729],{"trials":38775,"activeCount":102},[],{"trials":38777,"activeCount":102},[],{"trials":38779,"activeCount":102},[],{"trials":38781,"activeCount":102},[],{"intervention":1405,"totalTrials":659,"cells":38783},{"EARLY_PHASE1":38784,"PHASE1":38786,"PHASE2":38796,"PHASE3":38798,"PHASE4":38800,"NA":38802},{"trials":38785,"activeCount":102},[],{"trials":38787,"activeCount":102},[38788,38792],{"nctId":1394,"briefTitle":1395,"status":108,"phases":38789,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":38790,"interventions":38791},[90],[351],[77,1403,1404,1405,1406,1407],{"nctId":18066,"briefTitle":18067,"status":108,"phases":38793,"primaryCompletion":18069,"completion":18069,"start":4968,"enrollment":9319,"conditions":38794,"interventions":38795},[90],[19],[8275,18072,18073],{"trials":38797,"activeCount":102},[],{"trials":38799,"activeCount":102},[],{"trials":38801,"activeCount":102},[],{"trials":38803,"activeCount":102},[],{"intervention":4951,"totalTrials":659,"cells":38805},{"EARLY_PHASE1":38806,"PHASE1":38808,"PHASE2":38820,"PHASE3":38822,"PHASE4":38824,"NA":38826},{"trials":38807,"activeCount":102},[],{"trials":38809,"activeCount":102},[38810,38816],{"nctId":38811,"briefTitle":38812,"status":108,"phases":38813,"primaryCompletion":1355,"completion":1355,"start":3429,"enrollment":576,"conditions":38814,"interventions":38815},"NCT02625636","A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients",[90],[554],[4951,4952],{"nctId":4946,"briefTitle":4947,"status":3661,"phases":38817,"primaryCompletion":1041,"completion":1041,"start":965,"enrollment":102,"conditions":38818,"interventions":38819},[90],[554],[4951,4952,4939],{"trials":38821,"activeCount":102},[],{"trials":38823,"activeCount":102},[],{"trials":38825,"activeCount":102},[],{"trials":38827,"activeCount":102},[],{"intervention":4952,"totalTrials":659,"cells":38829},{"EARLY_PHASE1":38830,"PHASE1":38832,"PHASE2":38842,"PHASE3":38844,"PHASE4":38846,"NA":38848},{"trials":38831,"activeCount":102},[],{"trials":38833,"activeCount":102},[38834,38838],{"nctId":38811,"briefTitle":38812,"status":108,"phases":38835,"primaryCompletion":1355,"completion":1355,"start":3429,"enrollment":576,"conditions":38836,"interventions":38837},[90],[554],[4951,4952],{"nctId":4946,"briefTitle":4947,"status":3661,"phases":38839,"primaryCompletion":1041,"completion":1041,"start":965,"enrollment":102,"conditions":38840,"interventions":38841},[90],[554],[4951,4952,4939],{"trials":38843,"activeCount":102},[],{"trials":38845,"activeCount":102},[],{"trials":38847,"activeCount":102},[],{"trials":38849,"activeCount":102},[],{"intervention":17879,"totalTrials":659,"cells":38851},{"EARLY_PHASE1":38852,"PHASE1":38854,"PHASE2":38867,"PHASE3":38869,"PHASE4":38871,"NA":38873},{"trials":38853,"activeCount":102},[],{"trials":38855,"activeCount":102},[38856,38860],{"nctId":17873,"briefTitle":17874,"status":108,"phases":38857,"primaryCompletion":8570,"completion":8062,"start":10339,"enrollment":391,"conditions":38858,"interventions":38859},[90],[17877],[17879,1276],{"nctId":38861,"briefTitle":38862,"status":884,"phases":38863,"primaryCompletion":5271,"completion":5271,"start":8261,"enrollment":339,"conditions":38864,"interventions":38866},"NCT00807170","Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases",[90],[38865],"Non-small Cell Lung Cancer (NSCLC)",[17879,17879,17879],{"trials":38868,"activeCount":102},[],{"trials":38870,"activeCount":102},[],{"trials":38872,"activeCount":102},[],{"trials":38874,"activeCount":102},[],{"intervention":38876,"totalTrials":659,"cells":38877},"SAR113244",{"EARLY_PHASE1":38878,"PHASE1":38880,"PHASE2":38895,"PHASE3":38897,"PHASE4":38899,"NA":38901},{"trials":38879,"activeCount":102},[],{"trials":38881,"activeCount":102},[38882,38889],{"nctId":38883,"briefTitle":38884,"status":3661,"phases":38885,"primaryCompletion":38886,"completion":38886,"start":965,"enrollment":102,"conditions":38887,"interventions":38888},"NCT02331810","Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients",[90],"2017-05",[4801],[38876],{"nctId":38890,"briefTitle":38891,"status":108,"phases":38892,"primaryCompletion":1054,"completion":1054,"start":150,"enrollment":1134,"conditions":38893,"interventions":38894},"NCT02321709","Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients",[90],[4801],[38876],{"trials":38896,"activeCount":102},[],{"trials":38898,"activeCount":102},[],{"trials":38900,"activeCount":102},[],{"trials":38902,"activeCount":102},[],{"intervention":38904,"totalTrials":659,"cells":38905},"Pneumococcal vaccine Formulation 1",{"EARLY_PHASE1":38906,"PHASE1":38908,"PHASE2":38930,"PHASE3":38932,"PHASE4":38934,"NA":38936},{"trials":38907,"activeCount":102},[],{"trials":38909,"activeCount":102},[38910,38919],{"nctId":38911,"briefTitle":38912,"status":108,"phases":38913,"primaryCompletion":1339,"completion":1339,"start":978,"enrollment":465,"conditions":38914,"interventions":38916},"NCT01444352","Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults",[90],[3149,38915,20790],"Streptococcus Pneumoniae Infections",[38904,38917,38918],"Pneumococcal vaccine Formulation 2","Pneumococcal vaccine Formulation 3",{"nctId":38920,"briefTitle":38921,"status":108,"phases":38922,"primaryCompletion":5217,"completion":5217,"start":955,"enrollment":33554,"conditions":38923,"interventions":38924},"NCT01444339","Study of Two Investigational Pneumococcal Vaccines in Healthy Adults",[90],[3149,38915,20790],[38925,38926,38927,38928,38929],"Pneumococcal Vaccine Formulation 1","Pneumococcal Vaccine Formulation 2","Pneumococcal Vaccine Formulation 3","Pneumococcal Vaccine Formulation 4","Pneumococcal Vaccine Formulation 5",{"trials":38931,"activeCount":102},[],{"trials":38933,"activeCount":102},[],{"trials":38935,"activeCount":102},[],{"trials":38937,"activeCount":102},[],{"intervention":38917,"totalTrials":659,"cells":38939},{"EARLY_PHASE1":38940,"PHASE1":38942,"PHASE2":38952,"PHASE3":38954,"PHASE4":38956,"NA":38958},{"trials":38941,"activeCount":102},[],{"trials":38943,"activeCount":102},[38944,38948],{"nctId":38911,"briefTitle":38912,"status":108,"phases":38945,"primaryCompletion":1339,"completion":1339,"start":978,"enrollment":465,"conditions":38946,"interventions":38947},[90],[3149,38915,20790],[38904,38917,38918],{"nctId":38920,"briefTitle":38921,"status":108,"phases":38949,"primaryCompletion":5217,"completion":5217,"start":955,"enrollment":33554,"conditions":38950,"interventions":38951},[90],[3149,38915,20790],[38925,38926,38927,38928,38929],{"trials":38953,"activeCount":102},[],{"trials":38955,"activeCount":102},[],{"trials":38957,"activeCount":102},[],{"trials":38959,"activeCount":102},[],{"intervention":38918,"totalTrials":659,"cells":38961},{"EARLY_PHASE1":38962,"PHASE1":38964,"PHASE2":38974,"PHASE3":38976,"PHASE4":38978,"NA":38980},{"trials":38963,"activeCount":102},[],{"trials":38965,"activeCount":102},[38966,38970],{"nctId":38911,"briefTitle":38912,"status":108,"phases":38967,"primaryCompletion":1339,"completion":1339,"start":978,"enrollment":465,"conditions":38968,"interventions":38969},[90],[3149,38915,20790],[38904,38917,38918],{"nctId":38920,"briefTitle":38921,"status":108,"phases":38971,"primaryCompletion":5217,"completion":5217,"start":955,"enrollment":33554,"conditions":38972,"interventions":38973},[90],[3149,38915,20790],[38925,38926,38927,38928,38929],{"trials":38975,"activeCount":102},[],{"trials":38977,"activeCount":102},[],{"trials":38979,"activeCount":102},[],{"trials":38981,"activeCount":102},[],{"intervention":38983,"totalTrials":659,"cells":38984},"Z0063",{"EARLY_PHASE1":38985,"PHASE1":38987,"PHASE2":39006,"PHASE3":39008,"PHASE4":39010,"NA":39012},{"trials":38986,"activeCount":102},[],{"trials":38988,"activeCount":102},[38989,38999],{"nctId":38990,"briefTitle":38991,"status":108,"phases":38992,"primaryCompletion":38993,"completion":38993,"start":38994,"enrollment":402,"conditions":38995,"interventions":38997},"NCT03065816","Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects",[90],"2017-05-02","2017-02-09",[38996],"Gastroesophageal Reflux Disease",[38983,38998],"Gaviscon",{"nctId":39000,"briefTitle":39001,"status":108,"phases":39002,"primaryCompletion":39003,"completion":39003,"start":7616,"enrollment":9319,"conditions":39004,"interventions":39005},"NCT03069963","PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects",[90],"2017-04-23",[38996],[38983,38998],{"trials":39007,"activeCount":102},[],{"trials":39009,"activeCount":102},[],{"trials":39011,"activeCount":102},[],{"trials":39013,"activeCount":102},[],{"intervention":38998,"totalTrials":659,"cells":39015},{"EARLY_PHASE1":39016,"PHASE1":39018,"PHASE2":39028,"PHASE3":39030,"PHASE4":39032,"NA":39034},{"trials":39017,"activeCount":102},[],{"trials":39019,"activeCount":102},[39020,39024],{"nctId":38990,"briefTitle":38991,"status":108,"phases":39021,"primaryCompletion":38993,"completion":38993,"start":38994,"enrollment":402,"conditions":39022,"interventions":39023},[90],[38996],[38983,38998],{"nctId":39000,"briefTitle":39001,"status":108,"phases":39025,"primaryCompletion":39003,"completion":39003,"start":7616,"enrollment":9319,"conditions":39026,"interventions":39027},[90],[38996],[38983,38998],{"trials":39029,"activeCount":102},[],{"trials":39031,"activeCount":102},[],{"trials":39033,"activeCount":102},[],{"trials":39035,"activeCount":102},[],{"intervention":39037,"totalTrials":195,"cells":39038},"Glucopyranosyl Lipid A",{"EARLY_PHASE1":39039,"PHASE1":39041,"PHASE2":39054,"PHASE3":39056,"PHASE4":39058,"NA":39060},{"trials":39040,"activeCount":102},[],{"trials":39042,"activeCount":102},[39043],{"nctId":39044,"briefTitle":39045,"status":108,"phases":39046,"primaryCompletion":39047,"completion":39048,"start":39049,"enrollment":6434,"conditions":39050,"interventions":39052},"NCT03463135","A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients",[90],"2019-05-08","2020-03-10","2018-05-07",[39051],"Food Allergy",[39037,39053],"Sublingual Immuno Therapy",{"trials":39055,"activeCount":102},[],{"trials":39057,"activeCount":102},[],{"trials":39059,"activeCount":102},[],{"trials":39061,"activeCount":102},[],{"intervention":39053,"totalTrials":195,"cells":39063},{"EARLY_PHASE1":39064,"PHASE1":39066,"PHASE2":39072,"PHASE3":39074,"PHASE4":39076,"NA":39078},{"trials":39065,"activeCount":102},[],{"trials":39067,"activeCount":102},[39068],{"nctId":39044,"briefTitle":39045,"status":108,"phases":39069,"primaryCompletion":39047,"completion":39048,"start":39049,"enrollment":6434,"conditions":39070,"interventions":39071},[90],[39051],[39037,39053],{"trials":39073,"activeCount":102},[],{"trials":39075,"activeCount":102},[],{"trials":39077,"activeCount":102},[],{"trials":39079,"activeCount":102},[],{"intervention":39081,"totalTrials":195,"cells":39082},"Latanoprost",{"EARLY_PHASE1":39083,"PHASE1":39085,"PHASE2":39095,"PHASE3":39097,"PHASE4":39099,"NA":39101},{"trials":39084,"activeCount":102},[],{"trials":39086,"activeCount":102},[39087],{"nctId":39088,"briefTitle":39089,"status":108,"phases":39090,"primaryCompletion":965,"completion":965,"start":2824,"enrollment":349,"conditions":39091,"interventions":39093},"NCT02531152","28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension",[90],[39092],"Open Angle Glaucoma -Ocular Hypertension",[39081,39094],"SAR366234",{"trials":39096,"activeCount":102},[],{"trials":39098,"activeCount":102},[],{"trials":39100,"activeCount":102},[],{"trials":39102,"activeCount":102},[],{"intervention":39094,"totalTrials":195,"cells":39104},{"EARLY_PHASE1":39105,"PHASE1":39107,"PHASE2":39113,"PHASE3":39115,"PHASE4":39117,"NA":39119},{"trials":39106,"activeCount":102},[],{"trials":39108,"activeCount":102},[39109],{"nctId":39088,"briefTitle":39089,"status":108,"phases":39110,"primaryCompletion":965,"completion":965,"start":2824,"enrollment":349,"conditions":39111,"interventions":39112},[90],[39092],[39081,39094],{"trials":39114,"activeCount":102},[],{"trials":39116,"activeCount":102},[],{"trials":39118,"activeCount":102},[],{"trials":39120,"activeCount":102},[],{"intervention":39122,"totalTrials":195,"cells":39123},"DNL747",{"EARLY_PHASE1":39124,"PHASE1":39126,"PHASE2":39134,"PHASE3":39136,"PHASE4":39138,"NA":39140},{"trials":39125,"activeCount":102},[],{"trials":39127,"activeCount":102},[39128],{"nctId":39129,"briefTitle":39130,"status":884,"phases":39131,"primaryCompletion":2370,"completion":2370,"start":2959,"enrollment":335,"conditions":39132,"interventions":39133},"NCT03757351","Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis",[90],[13266],[39122],{"trials":39135,"activeCount":102},[],{"trials":39137,"activeCount":102},[],{"trials":39139,"activeCount":102},[],{"trials":39141,"activeCount":102},[],{"intervention":39143,"totalTrials":195,"cells":39144},"ORG101 - Experimental 1",{"EARLY_PHASE1":39145,"PHASE1":39147,"PHASE2":39158,"PHASE3":39160,"PHASE4":39162,"NA":39164},{"trials":39146,"activeCount":102},[],{"trials":39148,"activeCount":102},[39149],{"nctId":39150,"briefTitle":39151,"status":108,"phases":39152,"primaryCompletion":39153,"completion":39153,"start":39154,"enrollment":112,"conditions":39155,"interventions":39156},"NCT05131373","Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris",[90],"2023-11-27","2021-09-28",[16885,4922],[39143,39157],"ORG101PL - Placebo 1",{"trials":39159,"activeCount":102},[],{"trials":39161,"activeCount":102},[],{"trials":39163,"activeCount":102},[],{"trials":39165,"activeCount":102},[],{"intervention":39157,"totalTrials":195,"cells":39167},{"EARLY_PHASE1":39168,"PHASE1":39170,"PHASE2":39176,"PHASE3":39178,"PHASE4":39180,"NA":39182},{"trials":39169,"activeCount":102},[],{"trials":39171,"activeCount":102},[39172],{"nctId":39150,"briefTitle":39151,"status":108,"phases":39173,"primaryCompletion":39153,"completion":39153,"start":39154,"enrollment":112,"conditions":39174,"interventions":39175},[90],[16885,4922],[39143,39157],{"trials":39177,"activeCount":102},[],{"trials":39179,"activeCount":102},[],{"trials":39181,"activeCount":102},[],{"trials":39183,"activeCount":102},[],{"intervention":39185,"totalTrials":195,"cells":39186},"Itepekimab AI",{"EARLY_PHASE1":39187,"PHASE1":39189,"PHASE2":39199,"PHASE3":39201,"PHASE4":39203,"NA":39205},{"trials":39188,"activeCount":102},[],{"trials":39190,"activeCount":102},[39191],{"nctId":39192,"briefTitle":39193,"status":108,"phases":39194,"primaryCompletion":39195,"completion":39195,"start":13341,"enrollment":305,"conditions":39196,"interventions":39197},"NCT06114238","Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe",[90],"2022-03-08",[382],[39185,39198],"Itepekimab PFS",{"trials":39200,"activeCount":102},[],{"trials":39202,"activeCount":102},[],{"trials":39204,"activeCount":102},[],{"trials":39206,"activeCount":102},[],{"intervention":39198,"totalTrials":195,"cells":39208},{"EARLY_PHASE1":39209,"PHASE1":39211,"PHASE2":39217,"PHASE3":39219,"PHASE4":39221,"NA":39223},{"trials":39210,"activeCount":102},[],{"trials":39212,"activeCount":102},[39213],{"nctId":39192,"briefTitle":39193,"status":108,"phases":39214,"primaryCompletion":39195,"completion":39195,"start":13341,"enrollment":305,"conditions":39215,"interventions":39216},[90],[382],[39185,39198],{"trials":39218,"activeCount":102},[],{"trials":39220,"activeCount":102},[],{"trials":39222,"activeCount":102},[],{"trials":39224,"activeCount":102},[],{"intervention":39226,"totalTrials":195,"cells":39227},"RSV\u002FhMPV vaccine dose A1",{"EARLY_PHASE1":39228,"PHASE1":39230,"PHASE2":39254,"PHASE3":39256,"PHASE4":39258,"NA":39260},{"trials":39229,"activeCount":102},[],{"trials":39231,"activeCount":102},[39232],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39235,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39238,"interventions":39241},"NCT06583031","Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years",[90],"2024-10-09",385,[39239,39240],"RSV Infection","hMPV",[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],"RSV\u002FhMPV vaccine dose A2","RSV\u002FhMPV vaccine dose A3","RSV\u002FhMPV vaccine dose B1","RSV\u002FhMPV vaccine dose B2","RSV\u002FhMPV vaccine dose B3","RSV\u002FhMPV vaccine dose C1","RSV\u002FhMPV vaccine dose C2","RSV\u002FhMPV vaccine dose C3","RSV\u002FhMPV vaccine dose 1","RSV\u002FhMPV vaccine dose 2","RSV\u002FhMPV vaccine dose 3","Monovalent RSV Vaccine",{"trials":39255,"activeCount":102},[],{"trials":39257,"activeCount":102},[],{"trials":39259,"activeCount":102},[],{"trials":39261,"activeCount":102},[],{"intervention":39242,"totalTrials":195,"cells":39263},{"EARLY_PHASE1":39264,"PHASE1":39266,"PHASE2":39272,"PHASE3":39274,"PHASE4":39276,"NA":39278},{"trials":39265,"activeCount":102},[],{"trials":39267,"activeCount":102},[39268],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39269,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39270,"interventions":39271},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39273,"activeCount":102},[],{"trials":39275,"activeCount":102},[],{"trials":39277,"activeCount":102},[],{"trials":39279,"activeCount":102},[],{"intervention":39243,"totalTrials":195,"cells":39281},{"EARLY_PHASE1":39282,"PHASE1":39284,"PHASE2":39290,"PHASE3":39292,"PHASE4":39294,"NA":39296},{"trials":39283,"activeCount":102},[],{"trials":39285,"activeCount":102},[39286],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39287,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39288,"interventions":39289},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39291,"activeCount":102},[],{"trials":39293,"activeCount":102},[],{"trials":39295,"activeCount":102},[],{"trials":39297,"activeCount":102},[],{"intervention":39244,"totalTrials":195,"cells":39299},{"EARLY_PHASE1":39300,"PHASE1":39302,"PHASE2":39308,"PHASE3":39310,"PHASE4":39312,"NA":39314},{"trials":39301,"activeCount":102},[],{"trials":39303,"activeCount":102},[39304],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39305,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39306,"interventions":39307},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39309,"activeCount":102},[],{"trials":39311,"activeCount":102},[],{"trials":39313,"activeCount":102},[],{"trials":39315,"activeCount":102},[],{"intervention":39245,"totalTrials":195,"cells":39317},{"EARLY_PHASE1":39318,"PHASE1":39320,"PHASE2":39326,"PHASE3":39328,"PHASE4":39330,"NA":39332},{"trials":39319,"activeCount":102},[],{"trials":39321,"activeCount":102},[39322],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39323,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39324,"interventions":39325},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39327,"activeCount":102},[],{"trials":39329,"activeCount":102},[],{"trials":39331,"activeCount":102},[],{"trials":39333,"activeCount":102},[],{"intervention":39246,"totalTrials":195,"cells":39335},{"EARLY_PHASE1":39336,"PHASE1":39338,"PHASE2":39344,"PHASE3":39346,"PHASE4":39348,"NA":39350},{"trials":39337,"activeCount":102},[],{"trials":39339,"activeCount":102},[39340],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39341,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39342,"interventions":39343},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39345,"activeCount":102},[],{"trials":39347,"activeCount":102},[],{"trials":39349,"activeCount":102},[],{"trials":39351,"activeCount":102},[],{"intervention":39247,"totalTrials":195,"cells":39353},{"EARLY_PHASE1":39354,"PHASE1":39356,"PHASE2":39362,"PHASE3":39364,"PHASE4":39366,"NA":39368},{"trials":39355,"activeCount":102},[],{"trials":39357,"activeCount":102},[39358],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39359,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39360,"interventions":39361},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39363,"activeCount":102},[],{"trials":39365,"activeCount":102},[],{"trials":39367,"activeCount":102},[],{"trials":39369,"activeCount":102},[],{"intervention":39248,"totalTrials":195,"cells":39371},{"EARLY_PHASE1":39372,"PHASE1":39374,"PHASE2":39380,"PHASE3":39382,"PHASE4":39384,"NA":39386},{"trials":39373,"activeCount":102},[],{"trials":39375,"activeCount":102},[39376],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39377,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39378,"interventions":39379},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39381,"activeCount":102},[],{"trials":39383,"activeCount":102},[],{"trials":39385,"activeCount":102},[],{"trials":39387,"activeCount":102},[],{"intervention":39249,"totalTrials":195,"cells":39389},{"EARLY_PHASE1":39390,"PHASE1":39392,"PHASE2":39398,"PHASE3":39400,"PHASE4":39402,"NA":39404},{"trials":39391,"activeCount":102},[],{"trials":39393,"activeCount":102},[39394],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39395,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39396,"interventions":39397},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39399,"activeCount":102},[],{"trials":39401,"activeCount":102},[],{"trials":39403,"activeCount":102},[],{"trials":39405,"activeCount":102},[],{"intervention":39250,"totalTrials":195,"cells":39407},{"EARLY_PHASE1":39408,"PHASE1":39410,"PHASE2":39416,"PHASE3":39418,"PHASE4":39420,"NA":39422},{"trials":39409,"activeCount":102},[],{"trials":39411,"activeCount":102},[39412],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39413,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39414,"interventions":39415},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39417,"activeCount":102},[],{"trials":39419,"activeCount":102},[],{"trials":39421,"activeCount":102},[],{"trials":39423,"activeCount":102},[],{"intervention":39251,"totalTrials":195,"cells":39425},{"EARLY_PHASE1":39426,"PHASE1":39428,"PHASE2":39434,"PHASE3":39436,"PHASE4":39438,"NA":39440},{"trials":39427,"activeCount":102},[],{"trials":39429,"activeCount":102},[39430],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39431,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39432,"interventions":39433},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39435,"activeCount":102},[],{"trials":39437,"activeCount":102},[],{"trials":39439,"activeCount":102},[],{"trials":39441,"activeCount":102},[],{"intervention":39252,"totalTrials":195,"cells":39443},{"EARLY_PHASE1":39444,"PHASE1":39446,"PHASE2":39452,"PHASE3":39454,"PHASE4":39456,"NA":39458},{"trials":39445,"activeCount":102},[],{"trials":39447,"activeCount":102},[39448],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39449,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39450,"interventions":39451},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39453,"activeCount":102},[],{"trials":39455,"activeCount":102},[],{"trials":39457,"activeCount":102},[],{"trials":39459,"activeCount":102},[],{"intervention":39253,"totalTrials":195,"cells":39461},{"EARLY_PHASE1":39462,"PHASE1":39464,"PHASE2":39470,"PHASE3":39472,"PHASE4":39474,"NA":39476},{"trials":39463,"activeCount":102},[],{"trials":39465,"activeCount":102},[39466],{"nctId":39233,"briefTitle":39234,"status":108,"phases":39467,"primaryCompletion":4263,"completion":4263,"start":39236,"enrollment":39237,"conditions":39468,"interventions":39469},[90],[39239,39240],[39226,39242,39243,39244,39245,39246,39247,39248,39249,39250,39251,39252,39253],{"trials":39471,"activeCount":102},[],{"trials":39473,"activeCount":102},[],{"trials":39475,"activeCount":102},[],{"trials":39477,"activeCount":102},[],{"intervention":39479,"totalTrials":195,"cells":39480},"Pneumococcal Conjugate Vaccine",{"EARLY_PHASE1":39481,"PHASE1":39483,"PHASE2":39493,"PHASE3":39495,"PHASE4":39497,"NA":39499},{"trials":39482,"activeCount":102},[],{"trials":39484,"activeCount":102},[39485],{"nctId":39486,"briefTitle":39487,"status":108,"phases":39488,"primaryCompletion":16520,"completion":16520,"start":39489,"enrollment":19403,"conditions":39490,"interventions":39491},"NCT06698198","Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)",[90],"2018-12-03",[1927],[39479,39492],"Prevnar 13®",{"trials":39494,"activeCount":102},[],{"trials":39496,"activeCount":102},[],{"trials":39498,"activeCount":102},[],{"trials":39500,"activeCount":102},[],{"intervention":39492,"totalTrials":195,"cells":39502},{"EARLY_PHASE1":39503,"PHASE1":39505,"PHASE2":39511,"PHASE3":39513,"PHASE4":39515,"NA":39517},{"trials":39504,"activeCount":102},[],{"trials":39506,"activeCount":102},[39507],{"nctId":39486,"briefTitle":39487,"status":108,"phases":39508,"primaryCompletion":16520,"completion":16520,"start":39489,"enrollment":19403,"conditions":39509,"interventions":39510},[90],[1927],[39479,39492],{"trials":39512,"activeCount":102},[],{"trials":39514,"activeCount":102},[],{"trials":39516,"activeCount":102},[],{"trials":39518,"activeCount":102},[],{"intervention":3743,"totalTrials":195,"cells":39520},{"EARLY_PHASE1":39521,"PHASE1":39523,"PHASE2":39529,"PHASE3":39531,"PHASE4":39533,"NA":39535},{"trials":39522,"activeCount":102},[],{"trials":39524,"activeCount":102},[39525],{"nctId":3735,"briefTitle":3736,"status":108,"phases":39526,"primaryCompletion":3738,"completion":3738,"start":3739,"enrollment":3740,"conditions":39527,"interventions":39528},[90],[1788],[3381,3743,3744],{"trials":39530,"activeCount":102},[],{"trials":39532,"activeCount":102},[],{"trials":39534,"activeCount":102},[],{"trials":39536,"activeCount":102},[],{"intervention":1149,"totalTrials":195,"cells":39538},{"EARLY_PHASE1":39539,"PHASE1":39541,"PHASE2":39547,"PHASE3":39549,"PHASE4":39551,"NA":39553},{"trials":39540,"activeCount":102},[],{"trials":39542,"activeCount":102},[39543],{"nctId":1141,"briefTitle":1142,"status":108,"phases":39544,"primaryCompletion":913,"completion":913,"start":1144,"enrollment":1145,"conditions":39545,"interventions":39546},[90],[1147],[1149,1150,1151,1152],{"trials":39548,"activeCount":102},[],{"trials":39550,"activeCount":102},[],{"trials":39552,"activeCount":102},[],{"trials":39554,"activeCount":102},[],{"intervention":1152,"totalTrials":195,"cells":39556},{"EARLY_PHASE1":39557,"PHASE1":39559,"PHASE2":39565,"PHASE3":39567,"PHASE4":39569,"NA":39571},{"trials":39558,"activeCount":102},[],{"trials":39560,"activeCount":102},[39561],{"nctId":1141,"briefTitle":1142,"status":108,"phases":39562,"primaryCompletion":913,"completion":913,"start":1144,"enrollment":1145,"conditions":39563,"interventions":39564},[90],[1147],[1149,1150,1151,1152],{"trials":39566,"activeCount":102},[],{"trials":39568,"activeCount":102},[],{"trials":39570,"activeCount":102},[],{"trials":39572,"activeCount":102},[],{"intervention":39574,"totalTrials":195,"cells":39575},"SSR97225",{"EARLY_PHASE1":39576,"PHASE1":39578,"PHASE2":39586,"PHASE3":39588,"PHASE4":39590,"NA":39592},{"trials":39577,"activeCount":102},[],{"trials":39579,"activeCount":102},[39580],{"nctId":39581,"briefTitle":39582,"status":884,"phases":39583,"primaryCompletion":3417,"completion":3417,"start":3317,"enrollment":622,"conditions":39584,"interventions":39585},"NCT00547261","Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer",[90],[2803],[39574],{"trials":39587,"activeCount":102},[],{"trials":39589,"activeCount":102},[],{"trials":39591,"activeCount":102},[],{"trials":39593,"activeCount":102},[],{"intervention":39595,"totalTrials":195,"cells":39596},"rifapentine",{"EARLY_PHASE1":39597,"PHASE1":39599,"PHASE2":39609,"PHASE3":39611,"PHASE4":39613,"NA":39615},{"trials":39598,"activeCount":102},[],{"trials":39600,"activeCount":102},[39601],{"nctId":39602,"briefTitle":39603,"status":108,"phases":39604,"primaryCompletion":1055,"completion":1055,"start":3438,"enrollment":2636,"conditions":39605,"interventions":39607},"NCT01690403","Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients",[90],[39606],"Tuberculosis",[39595,39608],"EFZ EMT TDF",{"trials":39610,"activeCount":102},[],{"trials":39612,"activeCount":102},[],{"trials":39614,"activeCount":102},[],{"trials":39616,"activeCount":102},[],{"intervention":39608,"totalTrials":195,"cells":39618},{"EARLY_PHASE1":39619,"PHASE1":39621,"PHASE2":39627,"PHASE3":39629,"PHASE4":39631,"NA":39633},{"trials":39620,"activeCount":102},[],{"trials":39622,"activeCount":102},[39623],{"nctId":39602,"briefTitle":39603,"status":108,"phases":39624,"primaryCompletion":1055,"completion":1055,"start":3438,"enrollment":2636,"conditions":39625,"interventions":39626},[90],[39606],[39595,39608],{"trials":39628,"activeCount":102},[],{"trials":39630,"activeCount":102},[],{"trials":39632,"activeCount":102},[],{"trials":39634,"activeCount":102},[],{"intervention":38715,"totalTrials":195,"cells":39636},{"EARLY_PHASE1":39637,"PHASE1":39639,"PHASE2":39645,"PHASE3":39647,"PHASE4":39649,"NA":39651},{"trials":39638,"activeCount":102},[],{"trials":39640,"activeCount":102},[39641],{"nctId":38708,"briefTitle":38709,"status":108,"phases":39642,"primaryCompletion":38711,"completion":38711,"start":18237,"enrollment":455,"conditions":39643,"interventions":39644},[90],[16],[38701,38714,38715,38716,38717],{"trials":39646,"activeCount":102},[],{"trials":39648,"activeCount":102},[],{"trials":39650,"activeCount":102},[],{"trials":39652,"activeCount":102},[],{"intervention":38716,"totalTrials":195,"cells":39654},{"EARLY_PHASE1":39655,"PHASE1":39657,"PHASE2":39663,"PHASE3":39665,"PHASE4":39667,"NA":39669},{"trials":39656,"activeCount":102},[],{"trials":39658,"activeCount":102},[39659],{"nctId":38708,"briefTitle":38709,"status":108,"phases":39660,"primaryCompletion":38711,"completion":38711,"start":18237,"enrollment":455,"conditions":39661,"interventions":39662},[90],[16],[38701,38714,38715,38716,38717],{"trials":39664,"activeCount":102},[],{"trials":39666,"activeCount":102},[],{"trials":39668,"activeCount":102},[],{"trials":39670,"activeCount":102},[],{"intervention":30835,"totalTrials":195,"cells":39672},{"EARLY_PHASE1":39673,"PHASE1":39675,"PHASE2":39681,"PHASE3":39683,"PHASE4":39685,"NA":39687},{"trials":39674,"activeCount":102},[],{"trials":39676,"activeCount":102},[39677],{"nctId":30828,"briefTitle":30829,"status":108,"phases":39678,"primaryCompletion":30831,"completion":30831,"start":30832,"enrollment":858,"conditions":39679,"interventions":39680},[90],[19],[8036,30835,30836],{"trials":39682,"activeCount":102},[],{"trials":39684,"activeCount":102},[],{"trials":39686,"activeCount":102},[],{"trials":39688,"activeCount":102},[],{"intervention":30836,"totalTrials":195,"cells":39690},{"EARLY_PHASE1":39691,"PHASE1":39693,"PHASE2":39699,"PHASE3":39701,"PHASE4":39703,"NA":39705},{"trials":39692,"activeCount":102},[],{"trials":39694,"activeCount":102},[39695],{"nctId":30828,"briefTitle":30829,"status":108,"phases":39696,"primaryCompletion":30831,"completion":30831,"start":30832,"enrollment":858,"conditions":39697,"interventions":39698},[90],[19],[8036,30835,30836],{"trials":39700,"activeCount":102},[],{"trials":39702,"activeCount":102},[],{"trials":39704,"activeCount":102},[],{"trials":39706,"activeCount":102},[],{"intervention":39708,"totalTrials":195,"cells":39709},"AVE0005",{"EARLY_PHASE1":39710,"PHASE1":39712,"PHASE2":39720,"PHASE3":39722,"PHASE4":39724,"NA":39726},{"trials":39711,"activeCount":102},[],{"trials":39713,"activeCount":102},[39714],{"nctId":39715,"briefTitle":39716,"status":108,"phases":39717,"primaryCompletion":2834,"completion":2834,"start":3307,"enrollment":988,"conditions":39718,"interventions":39719},"NCT00921661","Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer",[90],[5240,9156],[39708],{"trials":39721,"activeCount":102},[],{"trials":39723,"activeCount":102},[],{"trials":39725,"activeCount":102},[],{"trials":39727,"activeCount":102},[],{"intervention":39729,"totalTrials":195,"cells":39730},"Clostridium difficile vaccine",{"EARLY_PHASE1":39731,"PHASE1":39733,"PHASE2":39741,"PHASE3":39743,"PHASE4":39745,"NA":39747},{"trials":39732,"activeCount":102},[],{"trials":39734,"activeCount":102},[39735],{"nctId":39736,"briefTitle":39737,"status":108,"phases":39738,"primaryCompletion":3609,"completion":5307,"start":9706,"enrollment":7653,"conditions":39739,"interventions":39740},"NCT00127803","Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers",[90],[21786],[39729,39729,39729],{"trials":39742,"activeCount":102},[],{"trials":39744,"activeCount":102},[],{"trials":39746,"activeCount":102},[],{"trials":39748,"activeCount":102},[],{"intervention":9487,"totalTrials":195,"cells":39750},{"EARLY_PHASE1":39751,"PHASE1":39753,"PHASE2":39759,"PHASE3":39761,"PHASE4":39763,"NA":39765},{"trials":39752,"activeCount":102},[],{"trials":39754,"activeCount":102},[39755],{"nctId":9482,"briefTitle":9483,"status":108,"phases":39756,"primaryCompletion":8570,"completion":8570,"start":8215,"enrollment":1676,"conditions":39757,"interventions":39758},[90],[8839],[9455,9487],{"trials":39760,"activeCount":102},[],{"trials":39762,"activeCount":102},[],{"trials":39764,"activeCount":102},[],{"trials":39766,"activeCount":102},[],{"intervention":39768,"totalTrials":195,"cells":39769},"ACAM3000 MVA Vaccine",{"EARLY_PHASE1":39770,"PHASE1":39772,"PHASE2":39780,"PHASE3":39782,"PHASE4":39784,"NA":39786},{"trials":39771,"activeCount":102},[],{"trials":39773,"activeCount":102},[39774],{"nctId":39775,"briefTitle":39776,"status":108,"phases":39777,"primaryCompletion":3430,"completion":3430,"start":7538,"enrollment":599,"conditions":39778,"interventions":39779},"NCT00079820","Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults",[90],[32605],[39768],{"trials":39781,"activeCount":102},[],{"trials":39783,"activeCount":102},[],{"trials":39785,"activeCount":102},[],{"trials":39787,"activeCount":102},[],{"intervention":19496,"totalTrials":195,"cells":39789},{"EARLY_PHASE1":39790,"PHASE1":39792,"PHASE2":39798,"PHASE3":39800,"PHASE4":39802,"NA":39804},{"trials":39791,"activeCount":102},[],{"trials":39793,"activeCount":102},[39794],{"nctId":19491,"briefTitle":19492,"status":108,"phases":39795,"primaryCompletion":2857,"completion":2857,"start":8683,"enrollment":1260,"conditions":39796,"interventions":39797},[90],[36],[19496,19484],{"trials":39799,"activeCount":102},[],{"trials":39801,"activeCount":102},[],{"trials":39803,"activeCount":102},[],{"trials":39805,"activeCount":102},[],{"intervention":39807,"totalTrials":195,"cells":39808},"bsi-201 + topotecan",{"EARLY_PHASE1":39809,"PHASE1":39811,"PHASE2":39822,"PHASE3":39824,"PHASE4":39826,"NA":39828},{"trials":39810,"activeCount":102},[],{"trials":39812,"activeCount":102},[39813],{"nctId":39814,"briefTitle":39815,"status":108,"phases":39816,"primaryCompletion":9532,"completion":164,"start":2800,"enrollment":11211,"conditions":39817,"interventions":39818},"NCT00422682","A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors",[90],[10973],[39807,39819,39820,39821],"bsi-201 + temozolomide","bsi-201 + gemcitabine","bsi-201 + carboplatin\u002Fpaclitaxel",{"trials":39823,"activeCount":102},[],{"trials":39825,"activeCount":102},[],{"trials":39827,"activeCount":102},[],{"trials":39829,"activeCount":102},[],{"intervention":39819,"totalTrials":195,"cells":39831},{"EARLY_PHASE1":39832,"PHASE1":39834,"PHASE2":39840,"PHASE3":39842,"PHASE4":39844,"NA":39846},{"trials":39833,"activeCount":102},[],{"trials":39835,"activeCount":102},[39836],{"nctId":39814,"briefTitle":39815,"status":108,"phases":39837,"primaryCompletion":9532,"completion":164,"start":2800,"enrollment":11211,"conditions":39838,"interventions":39839},[90],[10973],[39807,39819,39820,39821],{"trials":39841,"activeCount":102},[],{"trials":39843,"activeCount":102},[],{"trials":39845,"activeCount":102},[],{"trials":39847,"activeCount":102},[],{"intervention":39820,"totalTrials":195,"cells":39849},{"EARLY_PHASE1":39850,"PHASE1":39852,"PHASE2":39858,"PHASE3":39860,"PHASE4":39862,"NA":39864},{"trials":39851,"activeCount":102},[],{"trials":39853,"activeCount":102},[39854],{"nctId":39814,"briefTitle":39815,"status":108,"phases":39855,"primaryCompletion":9532,"completion":164,"start":2800,"enrollment":11211,"conditions":39856,"interventions":39857},[90],[10973],[39807,39819,39820,39821],{"trials":39859,"activeCount":102},[],{"trials":39861,"activeCount":102},[],{"trials":39863,"activeCount":102},[],{"trials":39865,"activeCount":102},[],{"intervention":39821,"totalTrials":195,"cells":39867},{"EARLY_PHASE1":39868,"PHASE1":39870,"PHASE2":39876,"PHASE3":39878,"PHASE4":39880,"NA":39882},{"trials":39869,"activeCount":102},[],{"trials":39871,"activeCount":102},[39872],{"nctId":39814,"briefTitle":39815,"status":108,"phases":39873,"primaryCompletion":9532,"completion":164,"start":2800,"enrollment":11211,"conditions":39874,"interventions":39875},[90],[10973],[39807,39819,39820,39821],{"trials":39877,"activeCount":102},[],{"trials":39879,"activeCount":102},[],{"trials":39881,"activeCount":102},[],{"trials":39883,"activeCount":102},[],{"intervention":39885,"totalTrials":195,"cells":39886},"SAR103168",{"EARLY_PHASE1":39887,"PHASE1":39889,"PHASE2":39898,"PHASE3":39900,"PHASE4":39902,"NA":39904},{"trials":39888,"activeCount":102},[],{"trials":39890,"activeCount":102},[39891],{"nctId":39892,"briefTitle":39893,"status":108,"phases":39894,"primaryCompletion":3335,"completion":8107,"start":2799,"enrollment":3740,"conditions":39895,"interventions":39897},"NCT00981240","Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory\u002F Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes",[90],[39896],"Acute Myelogenous Leukemia",[39885],{"trials":39899,"activeCount":102},[],{"trials":39901,"activeCount":102},[],{"trials":39903,"activeCount":102},[],{"trials":39905,"activeCount":102},[],{"intervention":31015,"totalTrials":195,"cells":39907},{"EARLY_PHASE1":39908,"PHASE1":39910,"PHASE2":39916,"PHASE3":39918,"PHASE4":39920,"NA":39922},{"trials":39909,"activeCount":102},[],{"trials":39911,"activeCount":102},[39912],{"nctId":31009,"briefTitle":31010,"status":108,"phases":39913,"primaryCompletion":1272,"completion":1272,"start":8062,"enrollment":703,"conditions":39914,"interventions":39915},[90],[31013],[31015,31002],{"trials":39917,"activeCount":102},[],{"trials":39919,"activeCount":102},[],{"trials":39921,"activeCount":102},[],{"trials":39923,"activeCount":102},[],{"intervention":1404,"totalTrials":195,"cells":39925},{"EARLY_PHASE1":39926,"PHASE1":39928,"PHASE2":39934,"PHASE3":39936,"PHASE4":39938,"NA":39940},{"trials":39927,"activeCount":102},[],{"trials":39929,"activeCount":102},[39930],{"nctId":1394,"briefTitle":1395,"status":108,"phases":39931,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":39932,"interventions":39933},[90],[351],[77,1403,1404,1405,1406,1407],{"trials":39935,"activeCount":102},[],{"trials":39937,"activeCount":102},[],{"trials":39939,"activeCount":102},[],{"trials":39941,"activeCount":102},[],{"intervention":7287,"totalTrials":195,"cells":39943},{"EARLY_PHASE1":39944,"PHASE1":39946,"PHASE2":39952,"PHASE3":39954,"PHASE4":39956,"NA":39958},{"trials":39945,"activeCount":102},[],{"trials":39947,"activeCount":102},[39948],{"nctId":7280,"briefTitle":7281,"status":108,"phases":39949,"primaryCompletion":7283,"completion":7283,"start":7284,"enrollment":1874,"conditions":39950,"interventions":39951},[90],[3892],[7273,3869,7287,3871],{"trials":39953,"activeCount":102},[],{"trials":39955,"activeCount":102},[],{"trials":39957,"activeCount":102},[],{"trials":39959,"activeCount":102},[],{"intervention":32175,"totalTrials":195,"cells":39961},{"EARLY_PHASE1":39962,"PHASE1":39964,"PHASE2":39970,"PHASE3":39972,"PHASE4":39974,"NA":39976},{"trials":39963,"activeCount":102},[],{"trials":39965,"activeCount":102},[39966],{"nctId":32168,"briefTitle":32169,"status":108,"phases":39967,"primaryCompletion":32171,"completion":32171,"start":32172,"enrollment":349,"conditions":39968,"interventions":39969},[90],[32115],[32175,32127,32176],{"trials":39971,"activeCount":102},[],{"trials":39973,"activeCount":102},[],{"trials":39975,"activeCount":102},[],{"trials":39977,"activeCount":102},[],{"intervention":32176,"totalTrials":195,"cells":39979},{"EARLY_PHASE1":39980,"PHASE1":39982,"PHASE2":39988,"PHASE3":39990,"PHASE4":39992,"NA":39994},{"trials":39981,"activeCount":102},[],{"trials":39983,"activeCount":102},[39984],{"nctId":32168,"briefTitle":32169,"status":108,"phases":39985,"primaryCompletion":32171,"completion":32171,"start":32172,"enrollment":349,"conditions":39986,"interventions":39987},[90],[32115],[32175,32127,32176],{"trials":39989,"activeCount":102},[],{"trials":39991,"activeCount":102},[],{"trials":39993,"activeCount":102},[],{"trials":39995,"activeCount":102},[],{"intervention":2285,"totalTrials":195,"cells":39997},{"EARLY_PHASE1":39998,"PHASE1":40000,"PHASE2":40006,"PHASE3":40008,"PHASE4":40010,"NA":40012},{"trials":39999,"activeCount":102},[],{"trials":40001,"activeCount":102},[40002],{"nctId":2276,"briefTitle":2277,"status":108,"phases":40003,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":2281,"conditions":40004,"interventions":40005},[90],[2283],[2285,2286,2287,43],{"trials":40007,"activeCount":102},[],{"trials":40009,"activeCount":102},[],{"trials":40011,"activeCount":102},[],{"trials":40013,"activeCount":102},[],{"intervention":2286,"totalTrials":195,"cells":40015},{"EARLY_PHASE1":40016,"PHASE1":40018,"PHASE2":40024,"PHASE3":40026,"PHASE4":40028,"NA":40030},{"trials":40017,"activeCount":102},[],{"trials":40019,"activeCount":102},[40020],{"nctId":2276,"briefTitle":2277,"status":108,"phases":40021,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":2281,"conditions":40022,"interventions":40023},[90],[2283],[2285,2286,2287,43],{"trials":40025,"activeCount":102},[],{"trials":40027,"activeCount":102},[],{"trials":40029,"activeCount":102},[],{"trials":40031,"activeCount":102},[],{"intervention":2287,"totalTrials":195,"cells":40033},{"EARLY_PHASE1":40034,"PHASE1":40036,"PHASE2":40042,"PHASE3":40044,"PHASE4":40046,"NA":40048},{"trials":40035,"activeCount":102},[],{"trials":40037,"activeCount":102},[40038],{"nctId":2276,"briefTitle":2277,"status":108,"phases":40039,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":2281,"conditions":40040,"interventions":40041},[90],[2283],[2285,2286,2287,43],{"trials":40043,"activeCount":102},[],{"trials":40045,"activeCount":102},[],{"trials":40047,"activeCount":102},[],{"trials":40049,"activeCount":102},[],{"intervention":40051,"totalTrials":195,"cells":40052},"TIV-HA Vaccine formulation 1 at low dose",{"EARLY_PHASE1":40053,"PHASE1":40055,"PHASE2":40077,"PHASE3":40079,"PHASE4":40081,"NA":40083},{"trials":40054,"activeCount":102},[],{"trials":40056,"activeCount":102},[40057],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40060,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40063,"interventions":40068},"NCT06850051","A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.",[90],"2025-12-11","2025-03-19",[36,40064,40065,40066,40067],"Influenza Vaccination","Respiratory Syncytial Virus Vaccination","Parainfluenza Vaccination","Human Metapneumovirus Vaccination",[40051,40069,40070,40071,40072,40073,40074,40075,40076],"TIV-HA formulation 1 at high dose","TIV-HA formulation 2 at low dose","TIV-HA formulation 2 at high dose","RSV\u002FhMPV\u002FPIV3 formulation 2 at low dose","RSV\u002FhMPV\u002FPIV3 formulation 1 at high dose","RSV\u002FhMPV\u002FPIV3 formulation 2 at high dose","RSV\u002FhMPV\u002FPIV3 formulation 1 at low dose","RIV4",{"trials":40078,"activeCount":102},[],{"trials":40080,"activeCount":102},[],{"trials":40082,"activeCount":102},[],{"trials":40084,"activeCount":102},[],{"intervention":40069,"totalTrials":195,"cells":40086},{"EARLY_PHASE1":40087,"PHASE1":40089,"PHASE2":40095,"PHASE3":40097,"PHASE4":40099,"NA":40101},{"trials":40088,"activeCount":102},[],{"trials":40090,"activeCount":102},[40091],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40092,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40093,"interventions":40094},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40096,"activeCount":102},[],{"trials":40098,"activeCount":102},[],{"trials":40100,"activeCount":102},[],{"trials":40102,"activeCount":102},[],{"intervention":40070,"totalTrials":195,"cells":40104},{"EARLY_PHASE1":40105,"PHASE1":40107,"PHASE2":40113,"PHASE3":40115,"PHASE4":40117,"NA":40119},{"trials":40106,"activeCount":102},[],{"trials":40108,"activeCount":102},[40109],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40110,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40111,"interventions":40112},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40114,"activeCount":102},[],{"trials":40116,"activeCount":102},[],{"trials":40118,"activeCount":102},[],{"trials":40120,"activeCount":102},[],{"intervention":40071,"totalTrials":195,"cells":40122},{"EARLY_PHASE1":40123,"PHASE1":40125,"PHASE2":40131,"PHASE3":40133,"PHASE4":40135,"NA":40137},{"trials":40124,"activeCount":102},[],{"trials":40126,"activeCount":102},[40127],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40128,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40129,"interventions":40130},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40132,"activeCount":102},[],{"trials":40134,"activeCount":102},[],{"trials":40136,"activeCount":102},[],{"trials":40138,"activeCount":102},[],{"intervention":40072,"totalTrials":195,"cells":40140},{"EARLY_PHASE1":40141,"PHASE1":40143,"PHASE2":40149,"PHASE3":40151,"PHASE4":40153,"NA":40155},{"trials":40142,"activeCount":102},[],{"trials":40144,"activeCount":102},[40145],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40146,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40147,"interventions":40148},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40150,"activeCount":102},[],{"trials":40152,"activeCount":102},[],{"trials":40154,"activeCount":102},[],{"trials":40156,"activeCount":102},[],{"intervention":40073,"totalTrials":195,"cells":40158},{"EARLY_PHASE1":40159,"PHASE1":40161,"PHASE2":40167,"PHASE3":40169,"PHASE4":40171,"NA":40173},{"trials":40160,"activeCount":102},[],{"trials":40162,"activeCount":102},[40163],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40164,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40165,"interventions":40166},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40168,"activeCount":102},[],{"trials":40170,"activeCount":102},[],{"trials":40172,"activeCount":102},[],{"trials":40174,"activeCount":102},[],{"intervention":40074,"totalTrials":195,"cells":40176},{"EARLY_PHASE1":40177,"PHASE1":40179,"PHASE2":40185,"PHASE3":40187,"PHASE4":40189,"NA":40191},{"trials":40178,"activeCount":102},[],{"trials":40180,"activeCount":102},[40181],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40182,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40183,"interventions":40184},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40186,"activeCount":102},[],{"trials":40188,"activeCount":102},[],{"trials":40190,"activeCount":102},[],{"trials":40192,"activeCount":102},[],{"intervention":40075,"totalTrials":195,"cells":40194},{"EARLY_PHASE1":40195,"PHASE1":40197,"PHASE2":40203,"PHASE3":40205,"PHASE4":40207,"NA":40209},{"trials":40196,"activeCount":102},[],{"trials":40198,"activeCount":102},[40199],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40200,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40201,"interventions":40202},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40204,"activeCount":102},[],{"trials":40206,"activeCount":102},[],{"trials":40208,"activeCount":102},[],{"trials":40210,"activeCount":102},[],{"intervention":40076,"totalTrials":195,"cells":40212},{"EARLY_PHASE1":40213,"PHASE1":40215,"PHASE2":40221,"PHASE3":40223,"PHASE4":40225,"NA":40227},{"trials":40214,"activeCount":102},[],{"trials":40216,"activeCount":102},[40217],{"nctId":40058,"briefTitle":40059,"status":108,"phases":40218,"primaryCompletion":40061,"completion":40061,"start":40062,"enrollment":9678,"conditions":40219,"interventions":40220},[90],[36,40064,40065,40066,40067],[40051,40069,40070,40071,40072,40073,40074,40075,40076],{"trials":40222,"activeCount":102},[],{"trials":40224,"activeCount":102},[],{"trials":40226,"activeCount":102},[],{"trials":40228,"activeCount":102},[],{"intervention":40230,"totalTrials":195,"cells":40231},"Investigational Tdap vaccine Formulation B",{"EARLY_PHASE1":40232,"PHASE1":40234,"PHASE2":40251,"PHASE3":40253,"PHASE4":40255,"NA":40257},{"trials":40233,"activeCount":102},[],{"trials":40235,"activeCount":102},[40236],{"nctId":40237,"briefTitle":40238,"status":108,"phases":40239,"primaryCompletion":40240,"completion":40240,"start":40241,"enrollment":2998,"conditions":40242,"interventions":40246},"NCT03958799","A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada",[90],"2021-04-06","2019-06-26",[40243,40244,40245],"Tetanus Immunisation (Healthy Volunteers)","Diphtheria Immunisation (Healthy Volunteers)","Pertussis Immunisation (Healthy Volunteers)",[40230,40247,40248,40249,40250],"Investigational Tdap vaccine Formulation C","Investigational Tdap vaccine Formulation A","Investigational Tdap vaccine Formulation D","Licensed Tdap vaccine",{"trials":40252,"activeCount":102},[],{"trials":40254,"activeCount":102},[],{"trials":40256,"activeCount":102},[],{"trials":40258,"activeCount":102},[],{"intervention":40247,"totalTrials":195,"cells":40260},{"EARLY_PHASE1":40261,"PHASE1":40263,"PHASE2":40269,"PHASE3":40271,"PHASE4":40273,"NA":40275},{"trials":40262,"activeCount":102},[],{"trials":40264,"activeCount":102},[40265],{"nctId":40237,"briefTitle":40238,"status":108,"phases":40266,"primaryCompletion":40240,"completion":40240,"start":40241,"enrollment":2998,"conditions":40267,"interventions":40268},[90],[40243,40244,40245],[40230,40247,40248,40249,40250],{"trials":40270,"activeCount":102},[],{"trials":40272,"activeCount":102},[],{"trials":40274,"activeCount":102},[],{"trials":40276,"activeCount":102},[],{"intervention":40248,"totalTrials":195,"cells":40278},{"EARLY_PHASE1":40279,"PHASE1":40281,"PHASE2":40287,"PHASE3":40289,"PHASE4":40291,"NA":40293},{"trials":40280,"activeCount":102},[],{"trials":40282,"activeCount":102},[40283],{"nctId":40237,"briefTitle":40238,"status":108,"phases":40284,"primaryCompletion":40240,"completion":40240,"start":40241,"enrollment":2998,"conditions":40285,"interventions":40286},[90],[40243,40244,40245],[40230,40247,40248,40249,40250],{"trials":40288,"activeCount":102},[],{"trials":40290,"activeCount":102},[],{"trials":40292,"activeCount":102},[],{"trials":40294,"activeCount":102},[],{"intervention":40249,"totalTrials":195,"cells":40296},{"EARLY_PHASE1":40297,"PHASE1":40299,"PHASE2":40305,"PHASE3":40307,"PHASE4":40309,"NA":40311},{"trials":40298,"activeCount":102},[],{"trials":40300,"activeCount":102},[40301],{"nctId":40237,"briefTitle":40238,"status":108,"phases":40302,"primaryCompletion":40240,"completion":40240,"start":40241,"enrollment":2998,"conditions":40303,"interventions":40304},[90],[40243,40244,40245],[40230,40247,40248,40249,40250],{"trials":40306,"activeCount":102},[],{"trials":40308,"activeCount":102},[],{"trials":40310,"activeCount":102},[],{"trials":40312,"activeCount":102},[],{"intervention":40250,"totalTrials":195,"cells":40314},{"EARLY_PHASE1":40315,"PHASE1":40317,"PHASE2":40323,"PHASE3":40325,"PHASE4":40327,"NA":40329},{"trials":40316,"activeCount":102},[],{"trials":40318,"activeCount":102},[40319],{"nctId":40237,"briefTitle":40238,"status":108,"phases":40320,"primaryCompletion":40240,"completion":40240,"start":40241,"enrollment":2998,"conditions":40321,"interventions":40322},[90],[40243,40244,40245],[40230,40247,40248,40249,40250],{"trials":40324,"activeCount":102},[],{"trials":40326,"activeCount":102},[],{"trials":40328,"activeCount":102},[],{"trials":40330,"activeCount":102},[],{"intervention":40332,"totalTrials":195,"cells":40333},"SAR428926",{"EARLY_PHASE1":40334,"PHASE1":40336,"PHASE2":40346,"PHASE3":40348,"PHASE4":40350,"NA":40352},{"trials":40335,"activeCount":102},[],{"trials":40337,"activeCount":102},[40338],{"nctId":40339,"briefTitle":40340,"status":108,"phases":40341,"primaryCompletion":40342,"completion":40342,"start":40343,"enrollment":402,"conditions":40344,"interventions":40345},"NCT02575781","A Study of SAR428926 in Patients With Advanced Solid Tumors",[90],"2018-06","2015-10-05",[1193],[40332],{"trials":40347,"activeCount":102},[],{"trials":40349,"activeCount":102},[],{"trials":40351,"activeCount":102},[],{"trials":40353,"activeCount":102},[],{"intervention":40355,"totalTrials":195,"cells":40356},"otamixaban XRP0673",{"EARLY_PHASE1":40357,"PHASE1":40359,"PHASE2":40368,"PHASE3":40370,"PHASE4":40372,"NA":40374},{"trials":40358,"activeCount":102},[],{"trials":40360,"activeCount":102},[40361],{"nctId":40362,"briefTitle":40363,"status":108,"phases":40364,"primaryCompletion":2790,"completion":2790,"start":9984,"enrollment":2636,"conditions":40365,"interventions":40367},"NCT01126086","Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment",[90],[40366],"Hepatic Impairment",[40355],{"trials":40369,"activeCount":102},[],{"trials":40371,"activeCount":102},[],{"trials":40373,"activeCount":102},[],{"trials":40375,"activeCount":102},[],{"intervention":40377,"totalTrials":195,"cells":40378},"AVE9633",{"EARLY_PHASE1":40379,"PHASE1":40381,"PHASE2":40390,"PHASE3":40392,"PHASE4":40394,"NA":40396},{"trials":40380,"activeCount":102},[],{"trials":40382,"activeCount":102},[40383],{"nctId":40384,"briefTitle":40385,"status":884,"phases":40386,"primaryCompletion":3417,"completion":3417,"start":1341,"enrollment":3828,"conditions":40387,"interventions":40389},"NCT00543972","Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed\u002FRefractory CD33-Positive Acute Myeloid Leukemia",[90],[40388],"Myeloid Leukemia",[40377],{"trials":40391,"activeCount":102},[],{"trials":40393,"activeCount":102},[],{"trials":40395,"activeCount":102},[],{"trials":40397,"activeCount":102},[],{"intervention":31022,"totalTrials":195,"cells":40399},{"EARLY_PHASE1":40400,"PHASE1":40402,"PHASE2":40408,"PHASE3":40410,"PHASE4":40412,"NA":40414},{"trials":40401,"activeCount":102},[],{"trials":40403,"activeCount":102},[40404],{"nctId":31017,"briefTitle":31018,"status":108,"phases":40405,"primaryCompletion":2834,"completion":2834,"start":7292,"enrollment":284,"conditions":40406,"interventions":40407},[90],[18378],[31002,31022],{"trials":40409,"activeCount":102},[],{"trials":40411,"activeCount":102},[],{"trials":40413,"activeCount":102},[],{"trials":40415,"activeCount":102},[],{"intervention":40417,"totalTrials":195,"cells":40418},"Humanized anti-Factor Bb monoclonal antibody",{"EARLY_PHASE1":40419,"PHASE1":40421,"PHASE2":40432,"PHASE3":40434,"PHASE4":40436,"NA":40438},{"trials":40420,"activeCount":102},[],{"trials":40422,"activeCount":102},[40423],{"nctId":40424,"briefTitle":40425,"status":108,"phases":40426,"primaryCompletion":40427,"completion":40427,"start":40428,"enrollment":349,"conditions":40429,"interventions":40431},"NCT06326814","A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults",[90],"2023-05-05","2021-10-11",[40430],"Paroxysmal Nocturnal Hemoglobinuria",[40417],{"trials":40433,"activeCount":102},[],{"trials":40435,"activeCount":102},[],{"trials":40437,"activeCount":102},[],{"trials":40439,"activeCount":102},[],{"intervention":40441,"totalTrials":195,"cells":40442},"SAR153191-P3 drug product",{"EARLY_PHASE1":40443,"PHASE1":40445,"PHASE2":40457,"PHASE3":40459,"PHASE4":40461,"NA":40463},{"trials":40444,"activeCount":102},[],{"trials":40446,"activeCount":102},[40447],{"nctId":40448,"briefTitle":40449,"status":108,"phases":40450,"primaryCompletion":40451,"completion":40451,"start":40452,"enrollment":5282,"conditions":40453,"interventions":40454},"NCT06159452","Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects",[90],"2010-12-21","2010-07-09",[990],[40441,40455,40456],"SAR153191-P2 drug product","SAR153191-C1F3 drug product",{"trials":40458,"activeCount":102},[],{"trials":40460,"activeCount":102},[],{"trials":40462,"activeCount":102},[],{"trials":40464,"activeCount":102},[],{"intervention":40455,"totalTrials":195,"cells":40466},{"EARLY_PHASE1":40467,"PHASE1":40469,"PHASE2":40475,"PHASE3":40477,"PHASE4":40479,"NA":40481},{"trials":40468,"activeCount":102},[],{"trials":40470,"activeCount":102},[40471],{"nctId":40448,"briefTitle":40449,"status":108,"phases":40472,"primaryCompletion":40451,"completion":40451,"start":40452,"enrollment":5282,"conditions":40473,"interventions":40474},[90],[990],[40441,40455,40456],{"trials":40476,"activeCount":102},[],{"trials":40478,"activeCount":102},[],{"trials":40480,"activeCount":102},[],{"trials":40482,"activeCount":102},[],{"intervention":40456,"totalTrials":195,"cells":40484},{"EARLY_PHASE1":40485,"PHASE1":40487,"PHASE2":40493,"PHASE3":40495,"PHASE4":40497,"NA":40499},{"trials":40486,"activeCount":102},[],{"trials":40488,"activeCount":102},[40489],{"nctId":40448,"briefTitle":40449,"status":108,"phases":40490,"primaryCompletion":40451,"completion":40451,"start":40452,"enrollment":5282,"conditions":40491,"interventions":40492},[90],[990],[40441,40455,40456],{"trials":40494,"activeCount":102},[],{"trials":40496,"activeCount":102},[],{"trials":40498,"activeCount":102},[],{"trials":40500,"activeCount":102},[],{"intervention":19085,"totalTrials":195,"cells":40502},{"EARLY_PHASE1":40503,"PHASE1":40505,"PHASE2":40511,"PHASE3":40513,"PHASE4":40515,"NA":40517},{"trials":40504,"activeCount":102},[],{"trials":40506,"activeCount":102},[40507],{"nctId":19078,"briefTitle":19079,"status":108,"phases":40508,"primaryCompletion":5238,"completion":164,"start":3564,"enrollment":34,"conditions":40509,"interventions":40510},[90],[5421,5284,19082,19083],[19085,19071,19086],{"trials":40512,"activeCount":102},[],{"trials":40514,"activeCount":102},[],{"trials":40516,"activeCount":102},[],{"trials":40518,"activeCount":102},[],{"intervention":18022,"totalTrials":195,"cells":40520},{"EARLY_PHASE1":40521,"PHASE1":40523,"PHASE2":40529,"PHASE3":40531,"PHASE4":40533,"NA":40535},{"trials":40522,"activeCount":102},[],{"trials":40524,"activeCount":102},[40525],{"nctId":18015,"briefTitle":18016,"status":108,"phases":40526,"primaryCompletion":18018,"completion":18018,"start":18019,"enrollment":988,"conditions":40527,"interventions":40528},[90],[8187],[11524,18022],{"trials":40530,"activeCount":102},[],{"trials":40532,"activeCount":102},[],{"trials":40534,"activeCount":102},[],{"trials":40536,"activeCount":102},[],{"intervention":40538,"totalTrials":195,"cells":40539},"Insulin Lispro SAR342434",{"EARLY_PHASE1":40540,"PHASE1":40542,"PHASE2":40551,"PHASE3":40553,"PHASE4":40555,"NA":40557},{"trials":40541,"activeCount":102},[],{"trials":40543,"activeCount":102},[40544],{"nctId":40545,"briefTitle":40546,"status":108,"phases":40547,"primaryCompletion":18046,"completion":18046,"start":40548,"enrollment":305,"conditions":40549,"interventions":40550},"NCT03903016","A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes",[90],"2019-03-26",[591],[40538,40538],{"trials":40552,"activeCount":102},[],{"trials":40554,"activeCount":102},[],{"trials":40556,"activeCount":102},[],{"trials":40558,"activeCount":102},[],{"intervention":40560,"totalTrials":195,"cells":40561},"GZ402668",{"EARLY_PHASE1":40562,"PHASE1":40564,"PHASE2":40575,"PHASE3":40577,"PHASE4":40579,"NA":40581},{"trials":40563,"activeCount":102},[],{"trials":40565,"activeCount":102},[40566],{"nctId":40567,"briefTitle":40568,"status":108,"phases":40569,"primaryCompletion":40570,"completion":40570,"start":18282,"enrollment":576,"conditions":40571,"interventions":40573},"NCT02977533","A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis",[90],"2018-05-16",[40572],"Progressive Multiple Sclerosis",[40560,40574],"Acyclovir",{"trials":40576,"activeCount":102},[],{"trials":40578,"activeCount":102},[],{"trials":40580,"activeCount":102},[],{"trials":40582,"activeCount":102},[],{"intervention":40574,"totalTrials":195,"cells":40584},{"EARLY_PHASE1":40585,"PHASE1":40587,"PHASE2":40593,"PHASE3":40595,"PHASE4":40597,"NA":40599},{"trials":40586,"activeCount":102},[],{"trials":40588,"activeCount":102},[40589],{"nctId":40567,"briefTitle":40568,"status":108,"phases":40590,"primaryCompletion":40570,"completion":40570,"start":18282,"enrollment":576,"conditions":40591,"interventions":40592},[90],[40572],[40560,40574],{"trials":40594,"activeCount":102},[],{"trials":40596,"activeCount":102},[],{"trials":40598,"activeCount":102},[],{"trials":40600,"activeCount":102},[],{"intervention":40602,"totalTrials":195,"cells":40603},"sodium valproate",{"EARLY_PHASE1":40604,"PHASE1":40606,"PHASE2":40615,"PHASE3":40617,"PHASE4":40619,"NA":40621},{"trials":40605,"activeCount":102},[],{"trials":40607,"activeCount":102},[40608],{"nctId":40609,"briefTitle":40610,"status":108,"phases":40611,"primaryCompletion":40612,"completion":40612,"start":30815,"enrollment":339,"conditions":40613,"interventions":40614},"NCT03681158","Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects",[90],"2019-04-11",[15598],[40602],{"trials":40616,"activeCount":102},[],{"trials":40618,"activeCount":102},[],{"trials":40620,"activeCount":102},[],{"trials":40622,"activeCount":102},[],{"intervention":861,"totalTrials":195,"cells":40624},{"EARLY_PHASE1":40625,"PHASE1":40627,"PHASE2":40633,"PHASE3":40635,"PHASE4":40637,"NA":40639},{"trials":40626,"activeCount":102},[],{"trials":40628,"activeCount":102},[40629],{"nctId":853,"briefTitle":854,"status":108,"phases":40630,"primaryCompletion":856,"completion":856,"start":857,"enrollment":858,"conditions":40631,"interventions":40632},[90],[752],[846,861,862],{"trials":40634,"activeCount":102},[],{"trials":40636,"activeCount":102},[],{"trials":40638,"activeCount":102},[],{"trials":40640,"activeCount":102},[],{"intervention":862,"totalTrials":195,"cells":40642},{"EARLY_PHASE1":40643,"PHASE1":40645,"PHASE2":40651,"PHASE3":40653,"PHASE4":40655,"NA":40657},{"trials":40644,"activeCount":102},[],{"trials":40646,"activeCount":102},[40647],{"nctId":853,"briefTitle":854,"status":108,"phases":40648,"primaryCompletion":856,"completion":856,"start":857,"enrollment":858,"conditions":40649,"interventions":40650},[90],[752],[846,861,862],{"trials":40652,"activeCount":102},[],{"trials":40654,"activeCount":102},[],{"trials":40656,"activeCount":102},[],{"trials":40658,"activeCount":102},[],{"intervention":40660,"totalTrials":195,"cells":40661},"SAR442257",{"EARLY_PHASE1":40662,"PHASE1":40664,"PHASE2":40676,"PHASE3":40678,"PHASE4":40680,"NA":40682},{"trials":40663,"activeCount":102},[],{"trials":40665,"activeCount":102},[40666],{"nctId":40667,"briefTitle":40668,"status":108,"phases":40669,"primaryCompletion":40670,"completion":40671,"start":40672,"enrollment":40673,"conditions":40674,"interventions":40675},"NCT04401020","First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL",[90],"2024-03-02","2026-05-11","2020-07-24",47,[1193],[40660],{"trials":40677,"activeCount":102},[],{"trials":40679,"activeCount":102},[],{"trials":40681,"activeCount":102},[],{"trials":40683,"activeCount":102},[],{"intervention":40685,"totalTrials":195,"cells":40686},"MVA",{"EARLY_PHASE1":40687,"PHASE1":40689,"PHASE2":40697,"PHASE3":40699,"PHASE4":40701,"NA":40703},{"trials":40688,"activeCount":102},[],{"trials":40690,"activeCount":102},[40691],{"nctId":40692,"briefTitle":40693,"status":3661,"phases":40694,"primaryCompletion":2800,"completion":2800,"start":3430,"enrollment":102,"conditions":40695,"interventions":40696},"NCT00389103","Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)",[90],[32605,206],[40685],{"trials":40698,"activeCount":102},[],{"trials":40700,"activeCount":102},[],{"trials":40702,"activeCount":102},[],{"trials":40704,"activeCount":102},[],{"intervention":31657,"totalTrials":195,"cells":40706},{"EARLY_PHASE1":40707,"PHASE1":40709,"PHASE2":40715,"PHASE3":40717,"PHASE4":40719,"NA":40721},{"trials":40708,"activeCount":102},[],{"trials":40710,"activeCount":102},[40711],{"nctId":31652,"briefTitle":31653,"status":108,"phases":40712,"primaryCompletion":3564,"completion":3564,"start":3622,"enrollment":703,"conditions":40713,"interventions":40714},[90],[1147],[22132,31657],{"trials":40716,"activeCount":102},[],{"trials":40718,"activeCount":102},[],{"trials":40720,"activeCount":102},[],{"trials":40722,"activeCount":102},[],{"intervention":18942,"totalTrials":195,"cells":40724},{"EARLY_PHASE1":40725,"PHASE1":40727,"PHASE2":40733,"PHASE3":40735,"PHASE4":40737,"NA":40739},{"trials":40726,"activeCount":102},[],{"trials":40728,"activeCount":102},[40729],{"nctId":18935,"briefTitle":18936,"status":108,"phases":40730,"primaryCompletion":18938,"completion":18938,"start":18939,"enrollment":622,"conditions":40731,"interventions":40732},[90],[5264,36],[18933,18942,18943],{"trials":40734,"activeCount":102},[],{"trials":40736,"activeCount":102},[],{"trials":40738,"activeCount":102},[],{"trials":40740,"activeCount":102},[],{"intervention":18943,"totalTrials":195,"cells":40742},{"EARLY_PHASE1":40743,"PHASE1":40745,"PHASE2":40751,"PHASE3":40753,"PHASE4":40755,"NA":40757},{"trials":40744,"activeCount":102},[],{"trials":40746,"activeCount":102},[40747],{"nctId":18935,"briefTitle":18936,"status":108,"phases":40748,"primaryCompletion":18938,"completion":18938,"start":18939,"enrollment":622,"conditions":40749,"interventions":40750},[90],[5264,36],[18933,18942,18943],{"trials":40752,"activeCount":102},[],{"trials":40754,"activeCount":102},[],{"trials":40756,"activeCount":102},[],{"trials":40758,"activeCount":102},[],{"intervention":40760,"totalTrials":195,"cells":40761},"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).",{"EARLY_PHASE1":40762,"PHASE1":40764,"PHASE2":40776,"PHASE3":40778,"PHASE4":40780,"NA":40782},{"trials":40763,"activeCount":102},[],{"trials":40765,"activeCount":102},[40766],{"nctId":40767,"briefTitle":40768,"status":108,"phases":40769,"primaryCompletion":40770,"completion":40770,"start":40771,"enrollment":40772,"conditions":40773,"interventions":40774},"NCT06165276","A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study",[90],"2008-08-27","2006-07-25",285,[2894],[40760,40775],"Meningococcal Group C-CRM197 Conjugate Vaccine",{"trials":40777,"activeCount":102},[],{"trials":40779,"activeCount":102},[],{"trials":40781,"activeCount":102},[],{"trials":40783,"activeCount":102},[],{"intervention":40775,"totalTrials":195,"cells":40785},{"EARLY_PHASE1":40786,"PHASE1":40788,"PHASE2":40794,"PHASE3":40796,"PHASE4":40798,"NA":40800},{"trials":40787,"activeCount":102},[],{"trials":40789,"activeCount":102},[40790],{"nctId":40767,"briefTitle":40768,"status":108,"phases":40791,"primaryCompletion":40770,"completion":40770,"start":40771,"enrollment":40772,"conditions":40792,"interventions":40793},[90],[2894],[40760,40775],{"trials":40795,"activeCount":102},[],{"trials":40797,"activeCount":102},[],{"trials":40799,"activeCount":102},[],{"trials":40801,"activeCount":102},[],{"intervention":40803,"totalTrials":195,"cells":40804},"insulin glargine- new formulation",{"EARLY_PHASE1":40805,"PHASE1":40807,"PHASE2":40815,"PHASE3":40817,"PHASE4":40819,"NA":40821},{"trials":40806,"activeCount":102},[],{"trials":40808,"activeCount":102},[40809],{"nctId":40810,"briefTitle":40811,"status":108,"phases":40812,"primaryCompletion":177,"completion":177,"start":10178,"enrollment":576,"conditions":40813,"interventions":40814},"NCT01676233","Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus",[90],[554],[8424,40803],{"trials":40816,"activeCount":102},[],{"trials":40818,"activeCount":102},[],{"trials":40820,"activeCount":102},[],{"trials":40822,"activeCount":102},[],{"intervention":19296,"totalTrials":195,"cells":40824},{"EARLY_PHASE1":40825,"PHASE1":40827,"PHASE2":40833,"PHASE3":40835,"PHASE4":40837,"NA":40839},{"trials":40826,"activeCount":102},[],{"trials":40828,"activeCount":102},[40829],{"nctId":19288,"briefTitle":19289,"status":108,"phases":40830,"primaryCompletion":19291,"completion":19291,"start":19292,"enrollment":19293,"conditions":40831,"interventions":40832},[90],[5335],[19296,19297],{"trials":40834,"activeCount":102},[],{"trials":40836,"activeCount":102},[],{"trials":40838,"activeCount":102},[],{"trials":40840,"activeCount":102},[],{"intervention":18031,"totalTrials":195,"cells":40842},{"EARLY_PHASE1":40843,"PHASE1":40845,"PHASE2":40851,"PHASE3":40853,"PHASE4":40855,"NA":40857},{"trials":40844,"activeCount":102},[],{"trials":40846,"activeCount":102},[40847],{"nctId":18024,"briefTitle":18025,"status":108,"phases":40848,"primaryCompletion":18027,"completion":18027,"start":18028,"enrollment":622,"conditions":40849,"interventions":40850},[90],[19,11522],[11524,18031,18032],{"trials":40852,"activeCount":102},[],{"trials":40854,"activeCount":102},[],{"trials":40856,"activeCount":102},[],{"trials":40858,"activeCount":102},[],{"intervention":32525,"totalTrials":195,"cells":40860},{"EARLY_PHASE1":40861,"PHASE1":40863,"PHASE2":40869,"PHASE3":40871,"PHASE4":40873,"NA":40875},{"trials":40862,"activeCount":102},[],{"trials":40864,"activeCount":102},[40865],{"nctId":32518,"briefTitle":32519,"status":108,"phases":40866,"primaryCompletion":32521,"completion":32521,"start":32522,"enrollment":1145,"conditions":40867,"interventions":40868},[90],[36],[32511,32525],{"trials":40870,"activeCount":102},[],{"trials":40872,"activeCount":102},[],{"trials":40874,"activeCount":102},[],{"trials":40876,"activeCount":102},[],{"intervention":40878,"totalTrials":195,"cells":40879},"Genz-112638",{"EARLY_PHASE1":40880,"PHASE1":40882,"PHASE2":40893,"PHASE3":40895,"PHASE4":40897,"NA":40899},{"trials":40881,"activeCount":102},[],{"trials":40883,"activeCount":102},[40884],{"nctId":40885,"briefTitle":40886,"status":108,"phases":40887,"primaryCompletion":40888,"completion":40888,"start":40889,"enrollment":552,"conditions":40890,"interventions":40891},"NCT06143904","A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants",[90],"2009-07-05","2009-06-03",[30197],[40878,40878,40892],"[14C]-Genz-112638",{"trials":40894,"activeCount":102},[],{"trials":40896,"activeCount":102},[],{"trials":40898,"activeCount":102},[],{"trials":40900,"activeCount":102},[],{"intervention":40892,"totalTrials":195,"cells":40902},{"EARLY_PHASE1":40903,"PHASE1":40905,"PHASE2":40911,"PHASE3":40913,"PHASE4":40915,"NA":40917},{"trials":40904,"activeCount":102},[],{"trials":40906,"activeCount":102},[40907],{"nctId":40885,"briefTitle":40886,"status":108,"phases":40908,"primaryCompletion":40888,"completion":40888,"start":40889,"enrollment":552,"conditions":40909,"interventions":40910},[90],[30197],[40878,40878,40892],{"trials":40912,"activeCount":102},[],{"trials":40914,"activeCount":102},[],{"trials":40916,"activeCount":102},[],{"trials":40918,"activeCount":102},[],{"intervention":40920,"totalTrials":195,"cells":40921},"Influenza A Vaccine: ACAM FLU-A",{"EARLY_PHASE1":40922,"PHASE1":40924,"PHASE2":40933,"PHASE3":40935,"PHASE4":40937,"NA":40939},{"trials":40923,"activeCount":102},[],{"trials":40925,"activeCount":102},[40926],{"nctId":40927,"briefTitle":40928,"status":108,"phases":40929,"primaryCompletion":9532,"completion":8315,"start":3563,"enrollment":6630,"conditions":40930,"interventions":40931},"NCT00819013","Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults",[90],[16],[40920,40920,40920,40932],"Saline placebo",{"trials":40934,"activeCount":102},[],{"trials":40936,"activeCount":102},[],{"trials":40938,"activeCount":102},[],{"trials":40940,"activeCount":102},[],{"intervention":40932,"totalTrials":195,"cells":40942},{"EARLY_PHASE1":40943,"PHASE1":40945,"PHASE2":40951,"PHASE3":40953,"PHASE4":40955,"NA":40957},{"trials":40944,"activeCount":102},[],{"trials":40946,"activeCount":102},[40947],{"nctId":40927,"briefTitle":40928,"status":108,"phases":40948,"primaryCompletion":9532,"completion":8315,"start":3563,"enrollment":6630,"conditions":40949,"interventions":40950},[90],[16],[40920,40920,40920,40932],{"trials":40952,"activeCount":102},[],{"trials":40954,"activeCount":102},[],{"trials":40956,"activeCount":102},[],{"trials":40958,"activeCount":102},[],{"intervention":40960,"totalTrials":195,"cells":40961},"Pneumococcal Vaccine High Dose",{"EARLY_PHASE1":40962,"PHASE1":40964,"PHASE2":40975,"PHASE3":40977,"PHASE4":40979,"NA":40981},{"trials":40963,"activeCount":102},[],{"trials":40965,"activeCount":102},[40966],{"nctId":40967,"briefTitle":40968,"status":108,"phases":40969,"primaryCompletion":2760,"completion":152,"start":986,"enrollment":10820,"conditions":40970,"interventions":40971},"NCT01446926","Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants",[90],[3625,3149,38915],[40960,40972,40960,40972,40973,40972,40974,40974,40972,40960,40972],"Tris buffered saline","Pneumococcal Vaccine Low Dose","Pneumococcal Vaccine Middle Dose",{"trials":40976,"activeCount":102},[],{"trials":40978,"activeCount":102},[],{"trials":40980,"activeCount":102},[],{"trials":40982,"activeCount":102},[],{"intervention":40972,"totalTrials":195,"cells":40984},{"EARLY_PHASE1":40985,"PHASE1":40987,"PHASE2":40993,"PHASE3":40995,"PHASE4":40997,"NA":40999},{"trials":40986,"activeCount":102},[],{"trials":40988,"activeCount":102},[40989],{"nctId":40967,"briefTitle":40968,"status":108,"phases":40990,"primaryCompletion":2760,"completion":152,"start":986,"enrollment":10820,"conditions":40991,"interventions":40992},[90],[3625,3149,38915],[40960,40972,40960,40972,40973,40972,40974,40974,40972,40960,40972],{"trials":40994,"activeCount":102},[],{"trials":40996,"activeCount":102},[],{"trials":40998,"activeCount":102},[],{"trials":41000,"activeCount":102},[],{"intervention":40973,"totalTrials":195,"cells":41002},{"EARLY_PHASE1":41003,"PHASE1":41005,"PHASE2":41011,"PHASE3":41013,"PHASE4":41015,"NA":41017},{"trials":41004,"activeCount":102},[],{"trials":41006,"activeCount":102},[41007],{"nctId":40967,"briefTitle":40968,"status":108,"phases":41008,"primaryCompletion":2760,"completion":152,"start":986,"enrollment":10820,"conditions":41009,"interventions":41010},[90],[3625,3149,38915],[40960,40972,40960,40972,40973,40972,40974,40974,40972,40960,40972],{"trials":41012,"activeCount":102},[],{"trials":41014,"activeCount":102},[],{"trials":41016,"activeCount":102},[],{"trials":41018,"activeCount":102},[],{"intervention":40974,"totalTrials":195,"cells":41020},{"EARLY_PHASE1":41021,"PHASE1":41023,"PHASE2":41029,"PHASE3":41031,"PHASE4":41033,"NA":41035},{"trials":41022,"activeCount":102},[],{"trials":41024,"activeCount":102},[41025],{"nctId":40967,"briefTitle":40968,"status":108,"phases":41026,"primaryCompletion":2760,"completion":152,"start":986,"enrollment":10820,"conditions":41027,"interventions":41028},[90],[3625,3149,38915],[40960,40972,40960,40972,40973,40972,40974,40974,40972,40960,40972],{"trials":41030,"activeCount":102},[],{"trials":41032,"activeCount":102},[],{"trials":41034,"activeCount":102},[],{"trials":41036,"activeCount":102},[],{"intervention":41038,"totalTrials":195,"cells":41039},"Amlitelimab DP1",{"EARLY_PHASE1":41040,"PHASE1":41042,"PHASE2":41052,"PHASE3":41054,"PHASE4":41056,"NA":41058},{"trials":41041,"activeCount":102},[],{"trials":41043,"activeCount":102},[41044],{"nctId":41045,"briefTitle":41046,"status":108,"phases":41047,"primaryCompletion":4696,"completion":4696,"start":41048,"enrollment":6313,"conditions":41049,"interventions":41050},"NCT05796479","A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants",[90],"2022-04-28",[36],[41038,41051],"Amlitelimab DP2",{"trials":41053,"activeCount":102},[],{"trials":41055,"activeCount":102},[],{"trials":41057,"activeCount":102},[],{"trials":41059,"activeCount":102},[],{"intervention":41051,"totalTrials":195,"cells":41061},{"EARLY_PHASE1":41062,"PHASE1":41064,"PHASE2":41070,"PHASE3":41072,"PHASE4":41074,"NA":41076},{"trials":41063,"activeCount":102},[],{"trials":41065,"activeCount":102},[41066],{"nctId":41045,"briefTitle":41046,"status":108,"phases":41067,"primaryCompletion":4696,"completion":4696,"start":41048,"enrollment":6313,"conditions":41068,"interventions":41069},[90],[36],[41038,41051],{"trials":41071,"activeCount":102},[],{"trials":41073,"activeCount":102},[],{"trials":41075,"activeCount":102},[],{"trials":41077,"activeCount":102},[],{"intervention":38727,"totalTrials":195,"cells":41079},{"EARLY_PHASE1":41080,"PHASE1":41082,"PHASE2":41088,"PHASE3":41090,"PHASE4":41092,"NA":41094},{"trials":41081,"activeCount":102},[],{"trials":41083,"activeCount":102},[41084],{"nctId":38719,"briefTitle":38720,"status":108,"phases":41085,"primaryCompletion":38722,"completion":38722,"start":38723,"enrollment":249,"conditions":41086,"interventions":41087},[90],[38725,36],[38701,38727,38714,38728,38717,38729],{"trials":41089,"activeCount":102},[],{"trials":41091,"activeCount":102},[],{"trials":41093,"activeCount":102},[],{"trials":41095,"activeCount":102},[],{"intervention":38728,"totalTrials":195,"cells":41097},{"EARLY_PHASE1":41098,"PHASE1":41100,"PHASE2":41106,"PHASE3":41108,"PHASE4":41110,"NA":41112},{"trials":41099,"activeCount":102},[],{"trials":41101,"activeCount":102},[41102],{"nctId":38719,"briefTitle":38720,"status":108,"phases":41103,"primaryCompletion":38722,"completion":38722,"start":38723,"enrollment":249,"conditions":41104,"interventions":41105},[90],[38725,36],[38701,38727,38714,38728,38717,38729],{"trials":41107,"activeCount":102},[],{"trials":41109,"activeCount":102},[],{"trials":41111,"activeCount":102},[],{"trials":41113,"activeCount":102},[],{"intervention":38729,"totalTrials":195,"cells":41115},{"EARLY_PHASE1":41116,"PHASE1":41118,"PHASE2":41124,"PHASE3":41126,"PHASE4":41128,"NA":41130},{"trials":41117,"activeCount":102},[],{"trials":41119,"activeCount":102},[41120],{"nctId":38719,"briefTitle":38720,"status":108,"phases":41121,"primaryCompletion":38722,"completion":38722,"start":38723,"enrollment":249,"conditions":41122,"interventions":41123},[90],[38725,36],[38701,38727,38714,38728,38717,38729],{"trials":41125,"activeCount":102},[],{"trials":41127,"activeCount":102},[],{"trials":41129,"activeCount":102},[],{"trials":41131,"activeCount":102},[],{"intervention":38625,"totalTrials":195,"cells":41133},{"EARLY_PHASE1":41134,"PHASE1":41136,"PHASE2":41142,"PHASE3":41144,"PHASE4":41146,"NA":41148},{"trials":41135,"activeCount":102},[],{"trials":41137,"activeCount":102},[41138],{"nctId":38620,"briefTitle":38621,"status":108,"phases":41139,"primaryCompletion":1355,"completion":1355,"start":10811,"enrollment":703,"conditions":41140,"interventions":41141},[90],[1193],[38606,38625],{"trials":41143,"activeCount":102},[],{"trials":41145,"activeCount":102},[],{"trials":41147,"activeCount":102},[],{"trials":41149,"activeCount":102},[],{"intervention":41151,"totalTrials":195,"cells":41152},"Monovalent subvirion H5N1 influenza vaccine",{"EARLY_PHASE1":41153,"PHASE1":41155,"PHASE2":41164,"PHASE3":41166,"PHASE4":41168,"NA":41170},{"trials":41154,"activeCount":102},[],{"trials":41156,"activeCount":102},[41157],{"nctId":41158,"briefTitle":41159,"status":108,"phases":41160,"primaryCompletion":2799,"completion":5271,"start":8505,"enrollment":8366,"conditions":41161,"interventions":41162},"NCT00664417","Study of Different Formulations of an Intramuscular A\u002FH5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine",[90],[16,15230],[41151,41151,41151,41151,41151,41151,41151,41151,41163],"Physiological saline",{"trials":41165,"activeCount":102},[],{"trials":41167,"activeCount":102},[],{"trials":41169,"activeCount":102},[],{"trials":41171,"activeCount":102},[],{"intervention":41163,"totalTrials":195,"cells":41173},{"EARLY_PHASE1":41174,"PHASE1":41176,"PHASE2":41182,"PHASE3":41184,"PHASE4":41186,"NA":41188},{"trials":41175,"activeCount":102},[],{"trials":41177,"activeCount":102},[41178],{"nctId":41158,"briefTitle":41159,"status":108,"phases":41179,"primaryCompletion":2799,"completion":5271,"start":8505,"enrollment":8366,"conditions":41180,"interventions":41181},[90],[16,15230],[41151,41151,41151,41151,41151,41151,41151,41151,41163],{"trials":41183,"activeCount":102},[],{"trials":41185,"activeCount":102},[],{"trials":41187,"activeCount":102},[],{"trials":41189,"activeCount":102},[],{"intervention":41191,"totalTrials":195,"cells":41192},"Metformin 1000 mg",{"EARLY_PHASE1":41193,"PHASE1":41195,"PHASE2":41204,"PHASE3":41206,"PHASE4":41208,"NA":41210},{"trials":41194,"activeCount":102},[],{"trials":41196,"activeCount":102},[41197],{"nctId":41198,"briefTitle":41199,"status":108,"phases":41200,"primaryCompletion":2834,"completion":2834,"start":8683,"enrollment":1260,"conditions":41201,"interventions":41202},"NCT01551615","A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib",[90],[8839],[41191,41203],"Vandetanib 800 mg",{"trials":41205,"activeCount":102},[],{"trials":41207,"activeCount":102},[],{"trials":41209,"activeCount":102},[],{"trials":41211,"activeCount":102},[],{"intervention":41203,"totalTrials":195,"cells":41213},{"EARLY_PHASE1":41214,"PHASE1":41216,"PHASE2":41222,"PHASE3":41224,"PHASE4":41226,"NA":41228},{"trials":41215,"activeCount":102},[],{"trials":41217,"activeCount":102},[41218],{"nctId":41198,"briefTitle":41199,"status":108,"phases":41219,"primaryCompletion":2834,"completion":2834,"start":8683,"enrollment":1260,"conditions":41220,"interventions":41221},[90],[8839],[41191,41203],{"trials":41223,"activeCount":102},[],{"trials":41225,"activeCount":102},[],{"trials":41227,"activeCount":102},[],{"trials":41229,"activeCount":102},[],{"intervention":31079,"totalTrials":195,"cells":41231},{"EARLY_PHASE1":41232,"PHASE1":41234,"PHASE2":41240,"PHASE3":41242,"PHASE4":41244,"NA":41246},{"trials":41233,"activeCount":102},[],{"trials":41235,"activeCount":102},[41236],{"nctId":31071,"briefTitle":31072,"status":108,"phases":41237,"primaryCompletion":8107,"completion":10005,"start":3417,"enrollment":349,"conditions":41238,"interventions":41239},[90],[31075,31076,31077],[19816,31079],{"trials":41241,"activeCount":102},[],{"trials":41243,"activeCount":102},[],{"trials":41245,"activeCount":102},[],{"trials":41247,"activeCount":102},[],{"intervention":41249,"totalTrials":195,"cells":41250},"AVE8062",{"EARLY_PHASE1":41251,"PHASE1":41253,"PHASE2":41262,"PHASE3":41264,"PHASE4":41266,"NA":41268},{"trials":41252,"activeCount":102},[],{"trials":41254,"activeCount":102},[41255],{"nctId":41256,"briefTitle":41257,"status":108,"phases":41258,"primaryCompletion":3821,"completion":3821,"start":8395,"enrollment":967,"conditions":41259,"interventions":41261},"NCT01907685","Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors",[90],[41260],"Advanced Neoplastic Disease",[41249,1348],{"trials":41263,"activeCount":102},[],{"trials":41265,"activeCount":102},[],{"trials":41267,"activeCount":102},[],{"trials":41269,"activeCount":102},[],{"intervention":41271,"totalTrials":195,"cells":41272},"RIPK1 inhibitor",{"EARLY_PHASE1":41273,"PHASE1":41275,"PHASE2":41285,"PHASE3":41287,"PHASE4":41289,"NA":41291},{"trials":41274,"activeCount":102},[],{"trials":41276,"activeCount":102},[41277],{"nctId":41278,"briefTitle":41279,"status":108,"phases":41280,"primaryCompletion":40428,"completion":40428,"start":41281,"enrollment":1260,"conditions":41282,"interventions":41284},"NCT04982991","Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants",[90],"2021-08-05",[41283],"Multiple Sclerosis Healthy Subjects",[41271],{"trials":41286,"activeCount":102},[],{"trials":41288,"activeCount":102},[],{"trials":41290,"activeCount":102},[],{"trials":41292,"activeCount":102},[],{"intervention":41294,"totalTrials":195,"cells":41295},"Rilzabrutinib crystalline form",{"EARLY_PHASE1":41296,"PHASE1":41298,"PHASE2":41309,"PHASE3":41311,"PHASE4":41313,"NA":41315},{"trials":41297,"activeCount":102},[],{"trials":41299,"activeCount":102},[41300],{"nctId":41301,"briefTitle":41302,"status":108,"phases":41303,"primaryCompletion":1573,"completion":1573,"start":41304,"enrollment":9041,"conditions":41305,"interventions":41307},"NCT06342700","A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants",[90],"2024-03-25",[41306,36],"Autoimmune Disorder",[41294,41308],"Rilzabrutinib amorphous form",{"trials":41310,"activeCount":102},[],{"trials":41312,"activeCount":102},[],{"trials":41314,"activeCount":102},[],{"trials":41316,"activeCount":102},[],{"intervention":41308,"totalTrials":195,"cells":41318},{"EARLY_PHASE1":41319,"PHASE1":41321,"PHASE2":41327,"PHASE3":41329,"PHASE4":41331,"NA":41333},{"trials":41320,"activeCount":102},[],{"trials":41322,"activeCount":102},[41323],{"nctId":41301,"briefTitle":41302,"status":108,"phases":41324,"primaryCompletion":1573,"completion":1573,"start":41304,"enrollment":9041,"conditions":41325,"interventions":41326},[90],[41306,36],[41294,41308],{"trials":41328,"activeCount":102},[],{"trials":41330,"activeCount":102},[],{"trials":41332,"activeCount":102},[],{"trials":41334,"activeCount":102},[],{"intervention":30980,"totalTrials":195,"cells":41336},{"EARLY_PHASE1":41337,"PHASE1":41339,"PHASE2":41345,"PHASE3":41347,"PHASE4":41349,"NA":41351},{"trials":41338,"activeCount":102},[],{"trials":41340,"activeCount":102},[41341],{"nctId":30973,"briefTitle":30974,"status":884,"phases":41342,"primaryCompletion":30976,"completion":30977,"start":25194,"enrollment":13,"conditions":41343,"interventions":41344},[90],[30757],[30980,2705],{"trials":41346,"activeCount":102},[],{"trials":41348,"activeCount":102},[],{"trials":41350,"activeCount":102},[],{"trials":41352,"activeCount":102},[],{"intervention":19307,"totalTrials":195,"cells":41354},{"EARLY_PHASE1":41355,"PHASE1":41357,"PHASE2":41363,"PHASE3":41365,"PHASE4":41367,"NA":41369},{"trials":41356,"activeCount":102},[],{"trials":41358,"activeCount":102},[41359],{"nctId":19299,"briefTitle":19300,"status":108,"phases":41360,"primaryCompletion":19302,"completion":19302,"start":19303,"enrollment":19304,"conditions":41361,"interventions":41362},[90],[16,5335],[19307,5338],{"trials":41364,"activeCount":102},[],{"trials":41366,"activeCount":102},[],{"trials":41368,"activeCount":102},[],{"trials":41370,"activeCount":102},[],{"intervention":41372,"totalTrials":195,"cells":41373},"Insulin glargine new formulation HOE901",{"EARLY_PHASE1":41374,"PHASE1":41376,"PHASE2":41385,"PHASE3":41387,"PHASE4":41389,"NA":41391},{"trials":41375,"activeCount":102},[],{"trials":41377,"activeCount":102},[41378],{"nctId":41379,"briefTitle":41380,"status":108,"phases":41381,"primaryCompletion":177,"completion":177,"start":1032,"enrollment":7653,"conditions":41382,"interventions":41384},"NCT01838083","Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus",[90],[41383],"Type1 Diabetes",[41372],{"trials":41386,"activeCount":102},[],{"trials":41388,"activeCount":102},[],{"trials":41390,"activeCount":102},[],{"trials":41392,"activeCount":102},[],{"intervention":41394,"totalTrials":195,"cells":41395},"SAR231893 (REGN668) DP1",{"EARLY_PHASE1":41396,"PHASE1":41398,"PHASE2":41407,"PHASE3":41409,"PHASE4":41411,"NA":41413},{"trials":41397,"activeCount":102},[],{"trials":41399,"activeCount":102},[41400],{"nctId":41401,"briefTitle":41402,"status":108,"phases":41403,"primaryCompletion":2857,"completion":2857,"start":8107,"enrollment":3740,"conditions":41404,"interventions":41405},"NCT01537640","Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects",[90],[8839],[41394,41406],"SAR231893 (REGN668) DP2",{"trials":41408,"activeCount":102},[],{"trials":41410,"activeCount":102},[],{"trials":41412,"activeCount":102},[],{"trials":41414,"activeCount":102},[],{"intervention":41406,"totalTrials":195,"cells":41416},{"EARLY_PHASE1":41417,"PHASE1":41419,"PHASE2":41425,"PHASE3":41427,"PHASE4":41429,"NA":41431},{"trials":41418,"activeCount":102},[],{"trials":41420,"activeCount":102},[41421],{"nctId":41401,"briefTitle":41402,"status":108,"phases":41422,"primaryCompletion":2857,"completion":2857,"start":8107,"enrollment":3740,"conditions":41423,"interventions":41424},[90],[8839],[41394,41406],{"trials":41426,"activeCount":102},[],{"trials":41428,"activeCount":102},[],{"trials":41430,"activeCount":102},[],{"trials":41432,"activeCount":102},[],{"intervention":41434,"totalTrials":195,"cells":41435},"Fexinidazole",{"EARLY_PHASE1":41436,"PHASE1":41438,"PHASE2":41447,"PHASE3":41449,"PHASE4":41451,"NA":41453},{"trials":41437,"activeCount":102},[],{"trials":41439,"activeCount":102},[41440],{"nctId":41441,"briefTitle":41442,"status":108,"phases":41443,"primaryCompletion":41444,"completion":41444,"start":2379,"enrollment":1134,"conditions":41445,"interventions":41446},"NCT05607173","A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment",[90],"2023-05-03",[2381],[41434],{"trials":41448,"activeCount":102},[],{"trials":41450,"activeCount":102},[],{"trials":41452,"activeCount":102},[],{"trials":41454,"activeCount":102},[],{"intervention":41456,"totalTrials":195,"cells":41457},"SAR260301",{"EARLY_PHASE1":41458,"PHASE1":41460,"PHASE2":41469,"PHASE3":41471,"PHASE4":41473,"NA":41475},{"trials":41459,"activeCount":102},[],{"trials":41461,"activeCount":102},[41462],{"nctId":41463,"briefTitle":41464,"status":108,"phases":41465,"primaryCompletion":1042,"completion":1042,"start":7349,"enrollment":8454,"conditions":41466,"interventions":41467},"NCT01673737","A Phase I\u002FIb Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer",[90],[1193],[41456,41468],"Vemurafenib",{"trials":41470,"activeCount":102},[],{"trials":41472,"activeCount":102},[],{"trials":41474,"activeCount":102},[],{"trials":41476,"activeCount":102},[],{"intervention":41468,"totalTrials":195,"cells":41478},{"EARLY_PHASE1":41479,"PHASE1":41481,"PHASE2":41487,"PHASE3":41489,"PHASE4":41491,"NA":41493},{"trials":41480,"activeCount":102},[],{"trials":41482,"activeCount":102},[41483],{"nctId":41463,"briefTitle":41464,"status":108,"phases":41484,"primaryCompletion":1042,"completion":1042,"start":7349,"enrollment":8454,"conditions":41485,"interventions":41486},[90],[1193],[41456,41468],{"trials":41488,"activeCount":102},[],{"trials":41490,"activeCount":102},[],{"trials":41492,"activeCount":102},[],{"trials":41494,"activeCount":102},[],{"intervention":41496,"totalTrials":195,"cells":41497},"RSV\u002FhMPV mRNA LNP 1",{"EARLY_PHASE1":41498,"PHASE1":41500,"PHASE2":41512,"PHASE3":41514,"PHASE4":41516,"NA":41518},{"trials":41499,"activeCount":102},[],{"trials":41501,"activeCount":102},[41502],{"nctId":41503,"briefTitle":41504,"status":108,"phases":41505,"primaryCompletion":598,"completion":598,"start":667,"enrollment":26713,"conditions":41506,"interventions":41508},"NCT06237296","Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and\u002For Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older",[90],[20474,36,41507],"Metapneumovirus Infection",[41496,41509,41510,41511],"RSV\u002FhMPV mRNA LNP 2","RSV mRNA LNP 1","hMPV mRNA LNP 1",{"trials":41513,"activeCount":102},[],{"trials":41515,"activeCount":102},[],{"trials":41517,"activeCount":102},[],{"trials":41519,"activeCount":102},[],{"intervention":41509,"totalTrials":195,"cells":41521},{"EARLY_PHASE1":41522,"PHASE1":41524,"PHASE2":41530,"PHASE3":41532,"PHASE4":41534,"NA":41536},{"trials":41523,"activeCount":102},[],{"trials":41525,"activeCount":102},[41526],{"nctId":41503,"briefTitle":41504,"status":108,"phases":41527,"primaryCompletion":598,"completion":598,"start":667,"enrollment":26713,"conditions":41528,"interventions":41529},[90],[20474,36,41507],[41496,41509,41510,41511],{"trials":41531,"activeCount":102},[],{"trials":41533,"activeCount":102},[],{"trials":41535,"activeCount":102},[],{"trials":41537,"activeCount":102},[],{"intervention":41510,"totalTrials":195,"cells":41539},{"EARLY_PHASE1":41540,"PHASE1":41542,"PHASE2":41548,"PHASE3":41550,"PHASE4":41552,"NA":41554},{"trials":41541,"activeCount":102},[],{"trials":41543,"activeCount":102},[41544],{"nctId":41503,"briefTitle":41504,"status":108,"phases":41545,"primaryCompletion":598,"completion":598,"start":667,"enrollment":26713,"conditions":41546,"interventions":41547},[90],[20474,36,41507],[41496,41509,41510,41511],{"trials":41549,"activeCount":102},[],{"trials":41551,"activeCount":102},[],{"trials":41553,"activeCount":102},[],{"trials":41555,"activeCount":102},[],{"intervention":41511,"totalTrials":195,"cells":41557},{"EARLY_PHASE1":41558,"PHASE1":41560,"PHASE2":41566,"PHASE3":41568,"PHASE4":41570,"NA":41572},{"trials":41559,"activeCount":102},[],{"trials":41561,"activeCount":102},[41562],{"nctId":41503,"briefTitle":41504,"status":108,"phases":41563,"primaryCompletion":598,"completion":598,"start":667,"enrollment":26713,"conditions":41564,"interventions":41565},[90],[20474,36,41507],[41496,41509,41510,41511],{"trials":41567,"activeCount":102},[],{"trials":41569,"activeCount":102},[],{"trials":41571,"activeCount":102},[],{"trials":41573,"activeCount":102},[],{"intervention":41575,"totalTrials":195,"cells":41576},"SAR446959",{"EARLY_PHASE1":41577,"PHASE1":41579,"PHASE2":41587,"PHASE3":41589,"PHASE4":41591,"NA":41593},{"trials":41578,"activeCount":102},[],{"trials":41580,"activeCount":102},[41581],{"nctId":41582,"briefTitle":41583,"status":108,"phases":41584,"primaryCompletion":738,"completion":738,"start":1399,"enrollment":6313,"conditions":41585,"interventions":41586},"NCT06704932","A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee",[90],[13537],[41575],{"trials":41588,"activeCount":102},[],{"trials":41590,"activeCount":102},[],{"trials":41592,"activeCount":102},[],{"trials":41594,"activeCount":102},[],{"intervention":41596,"totalTrials":195,"cells":41597},"Meningococcal Polysaccharide Tetanus Protein Conjugate",{"EARLY_PHASE1":41598,"PHASE1":41600,"PHASE2":41608,"PHASE3":41610,"PHASE4":41612,"NA":41614},{"trials":41599,"activeCount":102},[],{"trials":41601,"activeCount":102},[41602],{"nctId":41603,"briefTitle":41604,"status":108,"phases":41605,"primaryCompletion":8315,"completion":3396,"start":8505,"enrollment":412,"conditions":41606,"interventions":41607},"NCT00631995","Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers",[90],[4992,2949],[41596,41596,41596,41596,41596],{"trials":41609,"activeCount":102},[],{"trials":41611,"activeCount":102},[],{"trials":41613,"activeCount":102},[],{"trials":41615,"activeCount":102},[],{"intervention":41617,"totalTrials":195,"cells":41618},"SAR442085",{"EARLY_PHASE1":41619,"PHASE1":41621,"PHASE2":41631,"PHASE3":41633,"PHASE4":41635,"NA":41637},{"trials":41620,"activeCount":102},[],{"trials":41622,"activeCount":102},[41623],{"nctId":41624,"briefTitle":41625,"status":108,"phases":41626,"primaryCompletion":41627,"completion":41628,"start":18046,"enrollment":655,"conditions":41629,"interventions":41630},"NCT04000282","First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma",[90],"2022-08-29","2023-09-04",[1160],[41617],{"trials":41632,"activeCount":102},[],{"trials":41634,"activeCount":102},[],{"trials":41636,"activeCount":102},[],{"trials":41638,"activeCount":102},[],{"intervention":41640,"totalTrials":195,"cells":41641},"Hydroxychloroquine SAR321068",{"EARLY_PHASE1":41642,"PHASE1":41644,"PHASE2":41655,"PHASE3":41657,"PHASE4":41659,"NA":41661},{"trials":41643,"activeCount":102},[],{"trials":41645,"activeCount":102},[41646],{"nctId":41647,"briefTitle":41648,"status":884,"phases":41649,"primaryCompletion":41650,"completion":41650,"start":41651,"enrollment":535,"conditions":41652,"interventions":41654},"NCT04333654","Hydroxychloroquine in Outpatient Adults With COVID-19",[90],"2020-05-26","2020-04-12",[41653],"Coronavirus Infection",[41640],{"trials":41656,"activeCount":102},[],{"trials":41658,"activeCount":102},[],{"trials":41660,"activeCount":102},[],{"trials":41662,"activeCount":102},[],{"intervention":41664,"totalTrials":195,"cells":41665},"MELATONIN",{"EARLY_PHASE1":41666,"PHASE1":41668,"PHASE2":41679,"PHASE3":41681,"PHASE4":41683,"NA":41685},{"trials":41667,"activeCount":102},[],{"trials":41669,"activeCount":102},[41670],{"nctId":41671,"briefTitle":41672,"status":108,"phases":41673,"primaryCompletion":41674,"completion":41674,"start":41675,"enrollment":98,"conditions":41676,"interventions":41678},"NCT03514732","Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders",[90],"2017-07-05","2017-03-17",[41677],"Sleep Disorder (Healthy Volunteers)",[41664],{"trials":41680,"activeCount":102},[],{"trials":41682,"activeCount":102},[],{"trials":41684,"activeCount":102},[],{"trials":41686,"activeCount":102},[],{"intervention":41688,"totalTrials":195,"cells":41689},"RSV vaccine formulation 1 dose",{"EARLY_PHASE1":41690,"PHASE1":41692,"PHASE2":41709,"PHASE3":41711,"PHASE4":41713,"NA":41715},{"trials":41691,"activeCount":102},[],{"trials":41693,"activeCount":102},[41694],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41697,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41700,"interventions":41701},"NCT07071558","Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age",[90],"2026-03-17","2025-07-14",[5815],[41688,41702,41703,41704,41705,41706,41707,41708],"RSV vaccine formulation 2 dose","RSV vaccine formulation 3 dose","RSV vaccine formulation 4 dose","RSV vaccine formulation 5 dose","RSV vaccine formulation 6 dose","RSV vaccine formulation 7 dose","RSV vaccine formulation 8 dose",{"trials":41710,"activeCount":102},[],{"trials":41712,"activeCount":102},[],{"trials":41714,"activeCount":102},[],{"trials":41716,"activeCount":102},[],{"intervention":41702,"totalTrials":195,"cells":41718},{"EARLY_PHASE1":41719,"PHASE1":41721,"PHASE2":41727,"PHASE3":41729,"PHASE4":41731,"NA":41733},{"trials":41720,"activeCount":102},[],{"trials":41722,"activeCount":102},[41723],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41724,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41725,"interventions":41726},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41728,"activeCount":102},[],{"trials":41730,"activeCount":102},[],{"trials":41732,"activeCount":102},[],{"trials":41734,"activeCount":102},[],{"intervention":41703,"totalTrials":195,"cells":41736},{"EARLY_PHASE1":41737,"PHASE1":41739,"PHASE2":41745,"PHASE3":41747,"PHASE4":41749,"NA":41751},{"trials":41738,"activeCount":102},[],{"trials":41740,"activeCount":102},[41741],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41742,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41743,"interventions":41744},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41746,"activeCount":102},[],{"trials":41748,"activeCount":102},[],{"trials":41750,"activeCount":102},[],{"trials":41752,"activeCount":102},[],{"intervention":41704,"totalTrials":195,"cells":41754},{"EARLY_PHASE1":41755,"PHASE1":41757,"PHASE2":41763,"PHASE3":41765,"PHASE4":41767,"NA":41769},{"trials":41756,"activeCount":102},[],{"trials":41758,"activeCount":102},[41759],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41760,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41761,"interventions":41762},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41764,"activeCount":102},[],{"trials":41766,"activeCount":102},[],{"trials":41768,"activeCount":102},[],{"trials":41770,"activeCount":102},[],{"intervention":41705,"totalTrials":195,"cells":41772},{"EARLY_PHASE1":41773,"PHASE1":41775,"PHASE2":41781,"PHASE3":41783,"PHASE4":41785,"NA":41787},{"trials":41774,"activeCount":102},[],{"trials":41776,"activeCount":102},[41777],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41778,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41779,"interventions":41780},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41782,"activeCount":102},[],{"trials":41784,"activeCount":102},[],{"trials":41786,"activeCount":102},[],{"trials":41788,"activeCount":102},[],{"intervention":41706,"totalTrials":195,"cells":41790},{"EARLY_PHASE1":41791,"PHASE1":41793,"PHASE2":41799,"PHASE3":41801,"PHASE4":41803,"NA":41805},{"trials":41792,"activeCount":102},[],{"trials":41794,"activeCount":102},[41795],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41796,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41797,"interventions":41798},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41800,"activeCount":102},[],{"trials":41802,"activeCount":102},[],{"trials":41804,"activeCount":102},[],{"trials":41806,"activeCount":102},[],{"intervention":41707,"totalTrials":195,"cells":41808},{"EARLY_PHASE1":41809,"PHASE1":41811,"PHASE2":41817,"PHASE3":41819,"PHASE4":41821,"NA":41823},{"trials":41810,"activeCount":102},[],{"trials":41812,"activeCount":102},[41813],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41814,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41815,"interventions":41816},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41818,"activeCount":102},[],{"trials":41820,"activeCount":102},[],{"trials":41822,"activeCount":102},[],{"trials":41824,"activeCount":102},[],{"intervention":41708,"totalTrials":195,"cells":41826},{"EARLY_PHASE1":41827,"PHASE1":41829,"PHASE2":41835,"PHASE3":41837,"PHASE4":41839,"NA":41841},{"trials":41828,"activeCount":102},[],{"trials":41830,"activeCount":102},[41831],{"nctId":41695,"briefTitle":41696,"status":108,"phases":41832,"primaryCompletion":41698,"completion":41698,"start":41699,"enrollment":6655,"conditions":41833,"interventions":41834},[90],[5815],[41688,41702,41703,41704,41705,41706,41707,41708],{"trials":41836,"activeCount":102},[],{"trials":41838,"activeCount":102},[],{"trials":41840,"activeCount":102},[],{"trials":41842,"activeCount":102},[],{"intervention":5130,"totalTrials":195,"cells":41844},{"EARLY_PHASE1":41845,"PHASE1":41847,"PHASE2":41853,"PHASE3":41855,"PHASE4":41857,"NA":41859},{"trials":41846,"activeCount":102},[],{"trials":41848,"activeCount":102},[41849],{"nctId":5122,"briefTitle":5123,"status":884,"phases":41850,"primaryCompletion":5125,"completion":5125,"start":5126,"enrollment":5127,"conditions":41851,"interventions":41852},[90],[2910,36],[5130,5131,5132,5133],{"trials":41854,"activeCount":102},[],{"trials":41856,"activeCount":102},[],{"trials":41858,"activeCount":102},[],{"trials":41860,"activeCount":102},[],{"intervention":5131,"totalTrials":195,"cells":41862},{"EARLY_PHASE1":41863,"PHASE1":41865,"PHASE2":41871,"PHASE3":41873,"PHASE4":41875,"NA":41877},{"trials":41864,"activeCount":102},[],{"trials":41866,"activeCount":102},[41867],{"nctId":5122,"briefTitle":5123,"status":884,"phases":41868,"primaryCompletion":5125,"completion":5125,"start":5126,"enrollment":5127,"conditions":41869,"interventions":41870},[90],[2910,36],[5130,5131,5132,5133],{"trials":41872,"activeCount":102},[],{"trials":41874,"activeCount":102},[],{"trials":41876,"activeCount":102},[],{"trials":41878,"activeCount":102},[],{"intervention":1196,"totalTrials":195,"cells":41880},{"EARLY_PHASE1":41881,"PHASE1":41883,"PHASE2":41889,"PHASE3":41891,"PHASE4":41893,"NA":41895},{"trials":41882,"activeCount":102},[],{"trials":41884,"activeCount":102},[41885],{"nctId":1186,"briefTitle":1187,"status":108,"phases":41886,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":402,"conditions":41887,"interventions":41888},[90],[1193],[1195,1151,1196,1197],{"trials":41890,"activeCount":102},[],{"trials":41892,"activeCount":102},[],{"trials":41894,"activeCount":102},[],{"trials":41896,"activeCount":102},[],{"intervention":41898,"totalTrials":195,"cells":41899},"SAR445229",{"EARLY_PHASE1":41900,"PHASE1":41902,"PHASE2":41912,"PHASE3":41914,"PHASE4":41916,"NA":41918},{"trials":41901,"activeCount":102},[],{"trials":41903,"activeCount":102},[41904],{"nctId":41905,"briefTitle":41906,"status":108,"phases":41907,"primaryCompletion":41908,"completion":41908,"start":41909,"enrollment":22329,"conditions":41910,"interventions":41911},"NCT07146750","A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants",[90],"2026-04-08","2025-08-25",[36],[41898],{"trials":41913,"activeCount":102},[],{"trials":41915,"activeCount":102},[],{"trials":41917,"activeCount":102},[],{"trials":41919,"activeCount":102},[],{"intervention":41921,"totalTrials":195,"cells":41922},"FUROSEMIDE",{"EARLY_PHASE1":41923,"PHASE1":41925,"PHASE2":41934,"PHASE3":41936,"PHASE4":41938,"NA":41940},{"trials":41924,"activeCount":102},[],{"trials":41926,"activeCount":102},[41927],{"nctId":41928,"briefTitle":41929,"status":108,"phases":41930,"primaryCompletion":8298,"completion":8298,"start":7284,"enrollment":3828,"conditions":41931,"interventions":41933},"NCT01724788","Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis",[90],[41932],"Renal Failure",[41921,41921],{"trials":41935,"activeCount":102},[],{"trials":41937,"activeCount":102},[],{"trials":41939,"activeCount":102},[],{"trials":41941,"activeCount":102},[],{"intervention":41943,"totalTrials":195,"cells":41944},"mRNA NA vaccine",{"EARLY_PHASE1":41945,"PHASE1":41947,"PHASE2":41956,"PHASE3":41958,"PHASE4":41960,"NA":41962},{"trials":41946,"activeCount":102},[],{"trials":41948,"activeCount":102},[41949],{"nctId":41950,"briefTitle":41951,"status":108,"phases":41952,"primaryCompletion":304,"completion":304,"start":3014,"enrollment":7399,"conditions":41953,"interventions":41954},"NCT05426174","Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older",[90],[5335,36],[41943,41955],"High Dose Quadrivalent Influenza Vaccine",{"trials":41957,"activeCount":102},[],{"trials":41959,"activeCount":102},[],{"trials":41961,"activeCount":102},[],{"trials":41963,"activeCount":102},[],{"intervention":41955,"totalTrials":195,"cells":41965},{"EARLY_PHASE1":41966,"PHASE1":41968,"PHASE2":41974,"PHASE3":41976,"PHASE4":41978,"NA":41980},{"trials":41967,"activeCount":102},[],{"trials":41969,"activeCount":102},[41970],{"nctId":41950,"briefTitle":41951,"status":108,"phases":41971,"primaryCompletion":304,"completion":304,"start":3014,"enrollment":7399,"conditions":41972,"interventions":41973},[90],[5335,36],[41943,41955],{"trials":41975,"activeCount":102},[],{"trials":41977,"activeCount":102},[],{"trials":41979,"activeCount":102},[],{"trials":41981,"activeCount":102},[],{"intervention":41983,"totalTrials":195,"cells":41984},"SAR407899A",{"EARLY_PHASE1":41985,"PHASE1":41987,"PHASE2":41996,"PHASE3":41998,"PHASE4":42000,"NA":42002},{"trials":41986,"activeCount":102},[],{"trials":41988,"activeCount":102},[41989],{"nctId":41990,"briefTitle":41991,"status":108,"phases":41992,"primaryCompletion":7349,"completion":7349,"start":8062,"enrollment":576,"conditions":41993,"interventions":41995},"NCT01485900","Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment",[90],[41994],"Chronic Kidney Disease",[41983],{"trials":41997,"activeCount":102},[],{"trials":41999,"activeCount":102},[],{"trials":42001,"activeCount":102},[],{"trials":42003,"activeCount":102},[],{"intervention":42005,"totalTrials":195,"cells":42006},"SAR445514",{"EARLY_PHASE1":42007,"PHASE1":42009,"PHASE2":42019,"PHASE3":42021,"PHASE4":42023,"NA":42025},{"trials":42008,"activeCount":102},[],{"trials":42010,"activeCount":102},[42011],{"nctId":42012,"briefTitle":42013,"status":884,"phases":42014,"primaryCompletion":42015,"completion":42015,"start":4678,"enrollment":6313,"conditions":42016,"interventions":42018},"NCT05839626","A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM) and Relapsed\u002FRefractory Light-chain Amyloidosis (RRLCA)",[90],"2025-05-26",[1225,42017],"Amyloid Light-chain Amyloidosis",[42005],{"trials":42020,"activeCount":102},[],{"trials":42022,"activeCount":102},[],{"trials":42024,"activeCount":102},[],{"trials":42026,"activeCount":102},[],{"intervention":42028,"totalTrials":195,"cells":42029},"Trivalent-Darwin influenza vaccine",{"EARLY_PHASE1":42030,"PHASE1":42032,"PHASE2":42045,"PHASE3":42047,"PHASE4":42049,"NA":42051},{"trials":42031,"activeCount":102},[],{"trials":42033,"activeCount":102},[42034],{"nctId":42035,"briefTitle":42036,"status":108,"phases":42037,"primaryCompletion":42038,"completion":42038,"start":42039,"enrollment":504,"conditions":42040,"interventions":42041},"NCT06507553","Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older",[90],"2025-03-04","2024-08-12",[16,36],[42028,42042,42043,42044],"Augment-Tasmania influenza vaccine","TIV-2X Darwin influenza vaccine","Trivalent-Tasmania influenza vaccine",{"trials":42046,"activeCount":102},[],{"trials":42048,"activeCount":102},[],{"trials":42050,"activeCount":102},[],{"trials":42052,"activeCount":102},[],{"intervention":42042,"totalTrials":195,"cells":42054},{"EARLY_PHASE1":42055,"PHASE1":42057,"PHASE2":42063,"PHASE3":42065,"PHASE4":42067,"NA":42069},{"trials":42056,"activeCount":102},[],{"trials":42058,"activeCount":102},[42059],{"nctId":42035,"briefTitle":42036,"status":108,"phases":42060,"primaryCompletion":42038,"completion":42038,"start":42039,"enrollment":504,"conditions":42061,"interventions":42062},[90],[16,36],[42028,42042,42043,42044],{"trials":42064,"activeCount":102},[],{"trials":42066,"activeCount":102},[],{"trials":42068,"activeCount":102},[],{"trials":42070,"activeCount":102},[],{"intervention":42043,"totalTrials":195,"cells":42072},{"EARLY_PHASE1":42073,"PHASE1":42075,"PHASE2":42081,"PHASE3":42083,"PHASE4":42085,"NA":42087},{"trials":42074,"activeCount":102},[],{"trials":42076,"activeCount":102},[42077],{"nctId":42035,"briefTitle":42036,"status":108,"phases":42078,"primaryCompletion":42038,"completion":42038,"start":42039,"enrollment":504,"conditions":42079,"interventions":42080},[90],[16,36],[42028,42042,42043,42044],{"trials":42082,"activeCount":102},[],{"trials":42084,"activeCount":102},[],{"trials":42086,"activeCount":102},[],{"trials":42088,"activeCount":102},[],{"intervention":42044,"totalTrials":195,"cells":42090},{"EARLY_PHASE1":42091,"PHASE1":42093,"PHASE2":42099,"PHASE3":42101,"PHASE4":42103,"NA":42105},{"trials":42092,"activeCount":102},[],{"trials":42094,"activeCount":102},[42095],{"nctId":42035,"briefTitle":42036,"status":108,"phases":42096,"primaryCompletion":42038,"completion":42038,"start":42039,"enrollment":504,"conditions":42097,"interventions":42098},[90],[16,36],[42028,42042,42043,42044],{"trials":42100,"activeCount":102},[],{"trials":42102,"activeCount":102},[],{"trials":42104,"activeCount":102},[],{"trials":42106,"activeCount":102},[],{"intervention":18329,"totalTrials":195,"cells":42108},{"EARLY_PHASE1":42109,"PHASE1":42111,"PHASE2":42117,"PHASE3":42119,"PHASE4":42121,"NA":42123},{"trials":42110,"activeCount":102},[],{"trials":42112,"activeCount":102},[42113],{"nctId":18324,"briefTitle":18325,"status":108,"phases":42114,"primaryCompletion":8106,"completion":7330,"start":8062,"enrollment":5407,"conditions":42115,"interventions":42116},[90],[1193],[17931,9134,5277,18329,18330],{"trials":42118,"activeCount":102},[],{"trials":42120,"activeCount":102},[],{"trials":42122,"activeCount":102},[],{"trials":42124,"activeCount":102},[],{"intervention":18330,"totalTrials":195,"cells":42126},{"EARLY_PHASE1":42127,"PHASE1":42129,"PHASE2":42135,"PHASE3":42137,"PHASE4":42139,"NA":42141},{"trials":42128,"activeCount":102},[],{"trials":42130,"activeCount":102},[42131],{"nctId":18324,"briefTitle":18325,"status":108,"phases":42132,"primaryCompletion":8106,"completion":7330,"start":8062,"enrollment":5407,"conditions":42133,"interventions":42134},[90],[1193],[17931,9134,5277,18329,18330],{"trials":42136,"activeCount":102},[],{"trials":42138,"activeCount":102},[],{"trials":42140,"activeCount":102},[],{"trials":42142,"activeCount":102},[],{"intervention":42144,"totalTrials":195,"cells":42145},"SAR443765",{"EARLY_PHASE1":42146,"PHASE1":42148,"PHASE2":42158,"PHASE3":42160,"PHASE4":42162,"NA":42164},{"trials":42147,"activeCount":102},[],{"trials":42149,"activeCount":102},[42150],{"nctId":42151,"briefTitle":42152,"status":108,"phases":42153,"primaryCompletion":13481,"completion":13481,"start":42154,"enrollment":2685,"conditions":42155,"interventions":42156},"NCT05366764","First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants",[90],"2022-06-08",[155],[42144,42157],"Salbutamol or levosalbutamol",{"trials":42159,"activeCount":102},[],{"trials":42161,"activeCount":102},[],{"trials":42163,"activeCount":102},[],{"trials":42165,"activeCount":102},[],{"intervention":42157,"totalTrials":195,"cells":42167},{"EARLY_PHASE1":42168,"PHASE1":42170,"PHASE2":42176,"PHASE3":42178,"PHASE4":42180,"NA":42182},{"trials":42169,"activeCount":102},[],{"trials":42171,"activeCount":102},[42172],{"nctId":42151,"briefTitle":42152,"status":108,"phases":42173,"primaryCompletion":13481,"completion":13481,"start":42154,"enrollment":2685,"conditions":42174,"interventions":42175},[90],[155],[42144,42157],{"trials":42177,"activeCount":102},[],{"trials":42179,"activeCount":102},[],{"trials":42181,"activeCount":102},[],{"trials":42183,"activeCount":102},[],{"intervention":42185,"totalTrials":195,"cells":42186},"SAR441255",{"EARLY_PHASE1":42187,"PHASE1":42189,"PHASE2":42200,"PHASE3":42202,"PHASE4":42204,"NA":42206},{"trials":42188,"activeCount":102},[],{"trials":42190,"activeCount":102},[42191],{"nctId":42192,"briefTitle":42193,"status":108,"phases":42194,"primaryCompletion":42195,"completion":42195,"start":42196,"enrollment":391,"conditions":42197,"interventions":42199},"NCT04521738","First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects",[90],"2019-09-26","2019-04-25",[42198,11522],"Overweight",[42185],{"trials":42201,"activeCount":102},[],{"trials":42203,"activeCount":102},[],{"trials":42205,"activeCount":102},[],{"trials":42207,"activeCount":102},[],{"intervention":11161,"totalTrials":195,"cells":42209},{"EARLY_PHASE1":42210,"PHASE1":42212,"PHASE2":42218,"PHASE3":42220,"PHASE4":42222,"NA":42224},{"trials":42211,"activeCount":102},[],{"trials":42213,"activeCount":102},[42214],{"nctId":11156,"briefTitle":11157,"status":108,"phases":42215,"primaryCompletion":2856,"completion":2856,"start":965,"enrollment":576,"conditions":42216,"interventions":42217},[90],[19],[11161,11142],{"trials":42219,"activeCount":102},[],{"trials":42221,"activeCount":102},[],{"trials":42223,"activeCount":102},[],{"trials":42225,"activeCount":102},[],{"intervention":42227,"totalTrials":195,"cells":42228},"insulin glargine U200 HOE901",{"EARLY_PHASE1":42229,"PHASE1":42231,"PHASE2":42241,"PHASE3":42243,"PHASE4":42245,"NA":42247},{"trials":42230,"activeCount":102},[],{"trials":42232,"activeCount":102},[42233],{"nctId":42234,"briefTitle":42235,"status":108,"phases":42236,"primaryCompletion":150,"completion":150,"start":11210,"enrollment":2685,"conditions":42237,"interventions":42238},"NCT02201199","Single Dose Clamp Study To Compare Concentration\u002FTime Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus",[90],[554],[42227,42239,42240],"insulin glargine U500 HOE901","insulin glargine U100 HOE901",{"trials":42242,"activeCount":102},[],{"trials":42244,"activeCount":102},[],{"trials":42246,"activeCount":102},[],{"trials":42248,"activeCount":102},[],{"intervention":42239,"totalTrials":195,"cells":42250},{"EARLY_PHASE1":42251,"PHASE1":42253,"PHASE2":42259,"PHASE3":42261,"PHASE4":42263,"NA":42265},{"trials":42252,"activeCount":102},[],{"trials":42254,"activeCount":102},[42255],{"nctId":42234,"briefTitle":42235,"status":108,"phases":42256,"primaryCompletion":150,"completion":150,"start":11210,"enrollment":2685,"conditions":42257,"interventions":42258},[90],[554],[42227,42239,42240],{"trials":42260,"activeCount":102},[],{"trials":42262,"activeCount":102},[],{"trials":42264,"activeCount":102},[],{"trials":42266,"activeCount":102},[],{"intervention":42240,"totalTrials":195,"cells":42268},{"EARLY_PHASE1":42269,"PHASE1":42271,"PHASE2":42277,"PHASE3":42279,"PHASE4":42281,"NA":42283},{"trials":42270,"activeCount":102},[],{"trials":42272,"activeCount":102},[42273],{"nctId":42234,"briefTitle":42235,"status":108,"phases":42274,"primaryCompletion":150,"completion":150,"start":11210,"enrollment":2685,"conditions":42275,"interventions":42276},[90],[554],[42227,42239,42240],{"trials":42278,"activeCount":102},[],{"trials":42280,"activeCount":102},[],{"trials":42282,"activeCount":102},[],{"trials":42284,"activeCount":102},[],{"intervention":42286,"totalTrials":195,"cells":42287},"parainfluenza virus type 3 vaccine",{"EARLY_PHASE1":42288,"PHASE1":42290,"PHASE2":42304,"PHASE3":42306,"PHASE4":42308,"NA":42310},{"trials":42289,"activeCount":102},[],{"trials":42291,"activeCount":102},[42292],{"nctId":42293,"briefTitle":42294,"status":108,"phases":42295,"primaryCompletion":36092,"completion":36092,"start":42296,"enrollment":8620,"conditions":42297,"interventions":42299},"NCT06604767","Study of a Respiratory Syncytial Virus\u002FHuman Metapneumovirus\u002FParainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older",[90],"2024-09-17",[20474,41507,42298],"Parainfluenzae Virus Infection",[42286,42300,42301,42302,42303],"RSV\u002FhMPV\u002FPIV3 vaccine","RSV\u002FhMPV vaccine","RSV vaccine 1","RSV vaccine 2",{"trials":42305,"activeCount":102},[],{"trials":42307,"activeCount":102},[],{"trials":42309,"activeCount":102},[],{"trials":42311,"activeCount":102},[],{"intervention":42300,"totalTrials":195,"cells":42313},{"EARLY_PHASE1":42314,"PHASE1":42316,"PHASE2":42322,"PHASE3":42324,"PHASE4":42326,"NA":42328},{"trials":42315,"activeCount":102},[],{"trials":42317,"activeCount":102},[42318],{"nctId":42293,"briefTitle":42294,"status":108,"phases":42319,"primaryCompletion":36092,"completion":36092,"start":42296,"enrollment":8620,"conditions":42320,"interventions":42321},[90],[20474,41507,42298],[42286,42300,42301,42302,42303],{"trials":42323,"activeCount":102},[],{"trials":42325,"activeCount":102},[],{"trials":42327,"activeCount":102},[],{"trials":42329,"activeCount":102},[],{"intervention":42301,"totalTrials":195,"cells":42331},{"EARLY_PHASE1":42332,"PHASE1":42334,"PHASE2":42340,"PHASE3":42342,"PHASE4":42344,"NA":42346},{"trials":42333,"activeCount":102},[],{"trials":42335,"activeCount":102},[42336],{"nctId":42293,"briefTitle":42294,"status":108,"phases":42337,"primaryCompletion":36092,"completion":36092,"start":42296,"enrollment":8620,"conditions":42338,"interventions":42339},[90],[20474,41507,42298],[42286,42300,42301,42302,42303],{"trials":42341,"activeCount":102},[],{"trials":42343,"activeCount":102},[],{"trials":42345,"activeCount":102},[],{"trials":42347,"activeCount":102},[],{"intervention":42302,"totalTrials":195,"cells":42349},{"EARLY_PHASE1":42350,"PHASE1":42352,"PHASE2":42358,"PHASE3":42360,"PHASE4":42362,"NA":42364},{"trials":42351,"activeCount":102},[],{"trials":42353,"activeCount":102},[42354],{"nctId":42293,"briefTitle":42294,"status":108,"phases":42355,"primaryCompletion":36092,"completion":36092,"start":42296,"enrollment":8620,"conditions":42356,"interventions":42357},[90],[20474,41507,42298],[42286,42300,42301,42302,42303],{"trials":42359,"activeCount":102},[],{"trials":42361,"activeCount":102},[],{"trials":42363,"activeCount":102},[],{"trials":42365,"activeCount":102},[],{"intervention":42303,"totalTrials":195,"cells":42367},{"EARLY_PHASE1":42368,"PHASE1":42370,"PHASE2":42376,"PHASE3":42378,"PHASE4":42380,"NA":42382},{"trials":42369,"activeCount":102},[],{"trials":42371,"activeCount":102},[42372],{"nctId":42293,"briefTitle":42294,"status":108,"phases":42373,"primaryCompletion":36092,"completion":36092,"start":42296,"enrollment":8620,"conditions":42374,"interventions":42375},[90],[20474,41507,42298],[42286,42300,42301,42302,42303],{"trials":42377,"activeCount":102},[],{"trials":42379,"activeCount":102},[],{"trials":42381,"activeCount":102},[],{"trials":42383,"activeCount":102},[],{"intervention":42385,"totalTrials":195,"cells":42386},"HSV 2 Formulation 1",{"EARLY_PHASE1":42387,"PHASE1":42389,"PHASE2":42405,"PHASE3":42407,"PHASE4":42409,"NA":42411},{"trials":42388,"activeCount":102},[],{"trials":42390,"activeCount":102},[42391],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42394,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42396,"interventions":42398},"NCT04222985","Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2",[90],"2020-02-18",[42397],"Genital Herpes",[42385,42399,42400,42401,42402,42403,42404],"HSV 2 Formulation 2","HSV 2 Formulation 3","HSV 2 Formulation 4","HSV 2 Formulation 5","HSV 2 Formulation 6","Sodium Chloride 0.9%",{"trials":42406,"activeCount":102},[],{"trials":42408,"activeCount":102},[],{"trials":42410,"activeCount":102},[],{"trials":42412,"activeCount":102},[],{"intervention":42399,"totalTrials":195,"cells":42414},{"EARLY_PHASE1":42415,"PHASE1":42417,"PHASE2":42423,"PHASE3":42425,"PHASE4":42427,"NA":42429},{"trials":42416,"activeCount":102},[],{"trials":42418,"activeCount":102},[42419],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42420,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42421,"interventions":42422},[90],[42397],[42385,42399,42400,42401,42402,42403,42404],{"trials":42424,"activeCount":102},[],{"trials":42426,"activeCount":102},[],{"trials":42428,"activeCount":102},[],{"trials":42430,"activeCount":102},[],{"intervention":42400,"totalTrials":195,"cells":42432},{"EARLY_PHASE1":42433,"PHASE1":42435,"PHASE2":42441,"PHASE3":42443,"PHASE4":42445,"NA":42447},{"trials":42434,"activeCount":102},[],{"trials":42436,"activeCount":102},[42437],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42438,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42439,"interventions":42440},[90],[42397],[42385,42399,42400,42401,42402,42403,42404],{"trials":42442,"activeCount":102},[],{"trials":42444,"activeCount":102},[],{"trials":42446,"activeCount":102},[],{"trials":42448,"activeCount":102},[],{"intervention":42401,"totalTrials":195,"cells":42450},{"EARLY_PHASE1":42451,"PHASE1":42453,"PHASE2":42459,"PHASE3":42461,"PHASE4":42463,"NA":42465},{"trials":42452,"activeCount":102},[],{"trials":42454,"activeCount":102},[42455],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42456,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42457,"interventions":42458},[90],[42397],[42385,42399,42400,42401,42402,42403,42404],{"trials":42460,"activeCount":102},[],{"trials":42462,"activeCount":102},[],{"trials":42464,"activeCount":102},[],{"trials":42466,"activeCount":102},[],{"intervention":42402,"totalTrials":195,"cells":42468},{"EARLY_PHASE1":42469,"PHASE1":42471,"PHASE2":42477,"PHASE3":42479,"PHASE4":42481,"NA":42483},{"trials":42470,"activeCount":102},[],{"trials":42472,"activeCount":102},[42473],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42474,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42475,"interventions":42476},[90],[42397],[42385,42399,42400,42401,42402,42403,42404],{"trials":42478,"activeCount":102},[],{"trials":42480,"activeCount":102},[],{"trials":42482,"activeCount":102},[],{"trials":42484,"activeCount":102},[],{"intervention":42403,"totalTrials":195,"cells":42486},{"EARLY_PHASE1":42487,"PHASE1":42489,"PHASE2":42495,"PHASE3":42497,"PHASE4":42499,"NA":42501},{"trials":42488,"activeCount":102},[],{"trials":42490,"activeCount":102},[42491],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42492,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42493,"interventions":42494},[90],[42397],[42385,42399,42400,42401,42402,42403,42404],{"trials":42496,"activeCount":102},[],{"trials":42498,"activeCount":102},[],{"trials":42500,"activeCount":102},[],{"trials":42502,"activeCount":102},[],{"intervention":42404,"totalTrials":195,"cells":42504},{"EARLY_PHASE1":42505,"PHASE1":42507,"PHASE2":42513,"PHASE3":42515,"PHASE4":42517,"NA":42519},{"trials":42506,"activeCount":102},[],{"trials":42508,"activeCount":102},[42509],{"nctId":42392,"briefTitle":42393,"status":884,"phases":42510,"primaryCompletion":2816,"completion":2816,"start":42395,"enrollment":9319,"conditions":42511,"interventions":42512},[90],[42397],[42385,42399,42400,42401,42402,42403,42404],{"trials":42514,"activeCount":102},[],{"trials":42516,"activeCount":102},[],{"trials":42518,"activeCount":102},[],{"trials":42520,"activeCount":102},[],{"intervention":42522,"totalTrials":195,"cells":42523},"ALN-AT3SC",{"EARLY_PHASE1":42524,"PHASE1":42526,"PHASE2":42538,"PHASE3":42540,"PHASE4":42542,"NA":42544},{"trials":42525,"activeCount":102},[],{"trials":42527,"activeCount":102},[42528],{"nctId":42529,"briefTitle":42530,"status":108,"phases":42531,"primaryCompletion":42532,"completion":42532,"start":42533,"enrollment":5195,"conditions":42534,"interventions":42536},"NCT02035605","A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients",[90],"2017-07-20","2014-01-20",[752,42535],"Hemophilia B",[42522,42537],"Sterile Normal Saline",{"trials":42539,"activeCount":102},[],{"trials":42541,"activeCount":102},[],{"trials":42543,"activeCount":102},[],{"trials":42545,"activeCount":102},[],{"intervention":42537,"totalTrials":195,"cells":42547},{"EARLY_PHASE1":42548,"PHASE1":42550,"PHASE2":42556,"PHASE3":42558,"PHASE4":42560,"NA":42562},{"trials":42549,"activeCount":102},[],{"trials":42551,"activeCount":102},[42552],{"nctId":42529,"briefTitle":42530,"status":108,"phases":42553,"primaryCompletion":42532,"completion":42532,"start":42533,"enrollment":5195,"conditions":42554,"interventions":42555},[90],[752,42535],[42522,42537],{"trials":42557,"activeCount":102},[],{"trials":42559,"activeCount":102},[],{"trials":42561,"activeCount":102},[],{"trials":42563,"activeCount":102},[],{"intervention":42565,"totalTrials":195,"cells":42566},"A\u002FH5N1 inactivated, split-virion influenza vaccine+Adjuvant",{"EARLY_PHASE1":42567,"PHASE1":42569,"PHASE2":42578,"PHASE3":42580,"PHASE4":42582,"NA":42584},{"trials":42568,"activeCount":102},[],{"trials":42570,"activeCount":102},[42571],{"nctId":42572,"briefTitle":42573,"status":108,"phases":42574,"primaryCompletion":8570,"completion":5217,"start":2800,"enrollment":11135,"conditions":42575,"interventions":42576},"NCT00457509","Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults",[90],[24249,32089,15230],[42565,42565,42565,42565,42577],"A\u002FH5N1 inactivated, split-virion influenza vaccine",{"trials":42579,"activeCount":102},[],{"trials":42581,"activeCount":102},[],{"trials":42583,"activeCount":102},[],{"trials":42585,"activeCount":102},[],{"intervention":42577,"totalTrials":195,"cells":42587},{"EARLY_PHASE1":42588,"PHASE1":42590,"PHASE2":42596,"PHASE3":42598,"PHASE4":42600,"NA":42602},{"trials":42589,"activeCount":102},[],{"trials":42591,"activeCount":102},[42592],{"nctId":42572,"briefTitle":42573,"status":108,"phases":42593,"primaryCompletion":8570,"completion":5217,"start":2800,"enrollment":11135,"conditions":42594,"interventions":42595},[90],[24249,32089,15230],[42565,42565,42565,42565,42577],{"trials":42597,"activeCount":102},[],{"trials":42599,"activeCount":102},[],{"trials":42601,"activeCount":102},[],{"trials":42603,"activeCount":102},[],{"intervention":11168,"totalTrials":195,"cells":42605},{"EARLY_PHASE1":42606,"PHASE1":42608,"PHASE2":42614,"PHASE3":42616,"PHASE4":42618,"NA":42620},{"trials":42607,"activeCount":102},[],{"trials":42609,"activeCount":102},[42610],{"nctId":11163,"briefTitle":11164,"status":108,"phases":42611,"primaryCompletion":3416,"completion":3416,"start":8062,"enrollment":284,"conditions":42612,"interventions":42613},[90],[554],[11142,11168],{"trials":42615,"activeCount":102},[],{"trials":42617,"activeCount":102},[],{"trials":42619,"activeCount":102},[],{"trials":42621,"activeCount":102},[],{"intervention":42623,"totalTrials":195,"cells":42624},"SAR443216 IV",{"EARLY_PHASE1":42625,"PHASE1":42627,"PHASE2":42639,"PHASE3":42641,"PHASE4":42643,"NA":42645},{"trials":42626,"activeCount":102},[],{"trials":42628,"activeCount":102},[42629],{"nctId":42630,"briefTitle":42631,"status":884,"phases":42632,"primaryCompletion":42633,"completion":42633,"start":42634,"enrollment":359,"conditions":42635,"interventions":42637},"NCT05013554","Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed\u002FRefractory HER2 Expressing Solid Tumors",[90],"2024-01-15","2021-08-16",[1193,5264,42636,5395,2665],"Lung Neoplasm Malignant",[42623,42638],"SAR443216 SC",{"trials":42640,"activeCount":102},[],{"trials":42642,"activeCount":102},[],{"trials":42644,"activeCount":102},[],{"trials":42646,"activeCount":102},[],{"intervention":42638,"totalTrials":195,"cells":42648},{"EARLY_PHASE1":42649,"PHASE1":42651,"PHASE2":42657,"PHASE3":42659,"PHASE4":42661,"NA":42663},{"trials":42650,"activeCount":102},[],{"trials":42652,"activeCount":102},[42653],{"nctId":42630,"briefTitle":42631,"status":884,"phases":42654,"primaryCompletion":42633,"completion":42633,"start":42634,"enrollment":359,"conditions":42655,"interventions":42656},[90],[1193,5264,42636,5395,2665],[42623,42638],{"trials":42658,"activeCount":102},[],{"trials":42660,"activeCount":102},[],{"trials":42662,"activeCount":102},[],{"trials":42664,"activeCount":102},[],{"intervention":42666,"totalTrials":195,"cells":42667},"Shz QIV 0.25 mL, 2 doses",{"EARLY_PHASE1":42668,"PHASE1":42670,"PHASE2":42681,"PHASE3":42683,"PHASE4":42685,"NA":42687},{"trials":42669,"activeCount":102},[],{"trials":42671,"activeCount":102},[42672],{"nctId":42673,"briefTitle":42674,"status":108,"phases":42675,"primaryCompletion":42676,"completion":42676,"start":3839,"enrollment":32226,"conditions":42677,"interventions":42678},"NCT03430089","Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine",[90],"2019-06-06",[16,15047],[42666,42679,42680],"Shz QIV 0.5 mL, 2 doses","Shz QIV 0.5 mL, single dose",{"trials":42682,"activeCount":102},[],{"trials":42684,"activeCount":102},[],{"trials":42686,"activeCount":102},[],{"trials":42688,"activeCount":102},[],{"intervention":42679,"totalTrials":195,"cells":42690},{"EARLY_PHASE1":42691,"PHASE1":42693,"PHASE2":42699,"PHASE3":42701,"PHASE4":42703,"NA":42705},{"trials":42692,"activeCount":102},[],{"trials":42694,"activeCount":102},[42695],{"nctId":42673,"briefTitle":42674,"status":108,"phases":42696,"primaryCompletion":42676,"completion":42676,"start":3839,"enrollment":32226,"conditions":42697,"interventions":42698},[90],[16,15047],[42666,42679,42680],{"trials":42700,"activeCount":102},[],{"trials":42702,"activeCount":102},[],{"trials":42704,"activeCount":102},[],{"trials":42706,"activeCount":102},[],{"intervention":42680,"totalTrials":195,"cells":42708},{"EARLY_PHASE1":42709,"PHASE1":42711,"PHASE2":42717,"PHASE3":42719,"PHASE4":42721,"NA":42723},{"trials":42710,"activeCount":102},[],{"trials":42712,"activeCount":102},[42713],{"nctId":42673,"briefTitle":42674,"status":108,"phases":42714,"primaryCompletion":42676,"completion":42676,"start":3839,"enrollment":32226,"conditions":42715,"interventions":42716},[90],[16,15047],[42666,42679,42680],{"trials":42718,"activeCount":102},[],{"trials":42720,"activeCount":102},[],{"trials":42722,"activeCount":102},[],{"trials":42724,"activeCount":102},[],{"intervention":38928,"totalTrials":195,"cells":42726},{"EARLY_PHASE1":42727,"PHASE1":42729,"PHASE2":42735,"PHASE3":42737,"PHASE4":42739,"NA":42741},{"trials":42728,"activeCount":102},[],{"trials":42730,"activeCount":102},[42731],{"nctId":38920,"briefTitle":38921,"status":108,"phases":42732,"primaryCompletion":5217,"completion":5217,"start":955,"enrollment":33554,"conditions":42733,"interventions":42734},[90],[3149,38915,20790],[38925,38926,38927,38928,38929],{"trials":42736,"activeCount":102},[],{"trials":42738,"activeCount":102},[],{"trials":42740,"activeCount":102},[],{"trials":42742,"activeCount":102},[],{"intervention":38929,"totalTrials":195,"cells":42744},{"EARLY_PHASE1":42745,"PHASE1":42747,"PHASE2":42753,"PHASE3":42755,"PHASE4":42757,"NA":42759},{"trials":42746,"activeCount":102},[],{"trials":42748,"activeCount":102},[42749],{"nctId":38920,"briefTitle":38921,"status":108,"phases":42750,"primaryCompletion":5217,"completion":5217,"start":955,"enrollment":33554,"conditions":42751,"interventions":42752},[90],[3149,38915,20790],[38925,38926,38927,38928,38929],{"trials":42754,"activeCount":102},[],{"trials":42756,"activeCount":102},[],{"trials":42758,"activeCount":102},[],{"trials":42760,"activeCount":102},[],{"intervention":8552,"totalTrials":195,"cells":42762},{"EARLY_PHASE1":42763,"PHASE1":42765,"PHASE2":42771,"PHASE3":42773,"PHASE4":42775,"NA":42777},{"trials":42764,"activeCount":102},[],{"trials":42766,"activeCount":102},[42767],{"nctId":8543,"briefTitle":8544,"status":108,"phases":42768,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":359,"conditions":42769,"interventions":42770},[90],[8549],[8335,8335,8508,8551,8552,8553,8554],{"trials":42772,"activeCount":102},[],{"trials":42774,"activeCount":102},[],{"trials":42776,"activeCount":102},[],{"trials":42778,"activeCount":102},[],{"intervention":8553,"totalTrials":195,"cells":42780},{"EARLY_PHASE1":42781,"PHASE1":42783,"PHASE2":42789,"PHASE3":42791,"PHASE4":42793,"NA":42795},{"trials":42782,"activeCount":102},[],{"trials":42784,"activeCount":102},[42785],{"nctId":8543,"briefTitle":8544,"status":108,"phases":42786,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":359,"conditions":42787,"interventions":42788},[90],[8549],[8335,8335,8508,8551,8552,8553,8554],{"trials":42790,"activeCount":102},[],{"trials":42792,"activeCount":102},[],{"trials":42794,"activeCount":102},[],{"trials":42796,"activeCount":102},[],{"intervention":8554,"totalTrials":195,"cells":42798},{"EARLY_PHASE1":42799,"PHASE1":42801,"PHASE2":42807,"PHASE3":42809,"PHASE4":42811,"NA":42813},{"trials":42800,"activeCount":102},[],{"trials":42802,"activeCount":102},[42803],{"nctId":8543,"briefTitle":8544,"status":108,"phases":42804,"primaryCompletion":8546,"completion":8546,"start":8547,"enrollment":359,"conditions":42805,"interventions":42806},[90],[8549],[8335,8335,8508,8551,8552,8553,8554],{"trials":42808,"activeCount":102},[],{"trials":42810,"activeCount":102},[],{"trials":42812,"activeCount":102},[],{"trials":42814,"activeCount":102},[],{"intervention":42816,"totalTrials":195,"cells":42817},"SAR228810",{"EARLY_PHASE1":42818,"PHASE1":42820,"PHASE2":42828,"PHASE3":42830,"PHASE4":42832,"NA":42834},{"trials":42819,"activeCount":102},[],{"trials":42821,"activeCount":102},[42822],{"nctId":42823,"briefTitle":42824,"status":108,"phases":42825,"primaryCompletion":1042,"completion":1042,"start":3335,"enrollment":391,"conditions":42826,"interventions":42827},"NCT01485302","Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients",[90],[32763],[42816,42816],{"trials":42829,"activeCount":102},[],{"trials":42831,"activeCount":102},[],{"trials":42833,"activeCount":102},[],{"trials":42835,"activeCount":102},[],{"intervention":31175,"totalTrials":195,"cells":42837},{"EARLY_PHASE1":42838,"PHASE1":42840,"PHASE2":42846,"PHASE3":42848,"PHASE4":42850,"NA":42852},{"trials":42839,"activeCount":102},[],{"trials":42841,"activeCount":102},[42842],{"nctId":31169,"briefTitle":31170,"status":108,"phases":42843,"primaryCompletion":31172,"completion":31172,"start":5015,"enrollment":988,"conditions":42844,"interventions":42845},[90],[13266,131],[31145,31145,31175,31176],{"trials":42847,"activeCount":102},[],{"trials":42849,"activeCount":102},[],{"trials":42851,"activeCount":102},[],{"trials":42853,"activeCount":102},[],{"intervention":31176,"totalTrials":195,"cells":42855},{"EARLY_PHASE1":42856,"PHASE1":42858,"PHASE2":42864,"PHASE3":42866,"PHASE4":42868,"NA":42870},{"trials":42857,"activeCount":102},[],{"trials":42859,"activeCount":102},[42860],{"nctId":31169,"briefTitle":31170,"status":108,"phases":42861,"primaryCompletion":31172,"completion":31172,"start":5015,"enrollment":988,"conditions":42862,"interventions":42863},[90],[13266,131],[31145,31145,31175,31176],{"trials":42865,"activeCount":102},[],{"trials":42867,"activeCount":102},[],{"trials":42869,"activeCount":102},[],{"trials":42871,"activeCount":102},[],{"intervention":8067,"totalTrials":166,"cells":42873},{"EARLY_PHASE1":42874,"PHASE1":42876,"PHASE2":42888,"PHASE3":42898,"PHASE4":43057,"NA":43389},{"trials":42875,"activeCount":102},[],{"trials":42877,"activeCount":102},[42878,42884],{"nctId":42879,"briefTitle":42880,"status":108,"phases":42881,"primaryCompletion":987,"completion":8693,"start":5271,"enrollment":9319,"conditions":42882,"interventions":42883},"NCT01195454","Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®",[90],[554],[8067,8067],{"nctId":40810,"briefTitle":40811,"status":108,"phases":42885,"primaryCompletion":177,"completion":177,"start":10178,"enrollment":576,"conditions":42886,"interventions":42887},[90],[554],[8424,40803],{"trials":42889,"activeCount":102},[42890,42894],{"nctId":8051,"briefTitle":8052,"status":108,"phases":42891,"primaryCompletion":7283,"completion":7283,"start":5238,"enrollment":313,"conditions":42892,"interventions":42893},[91],[19],[8046,8056,8057,8024],{"nctId":8059,"briefTitle":8060,"status":108,"phases":42895,"primaryCompletion":3438,"completion":3438,"start":8062,"enrollment":8063,"conditions":42896,"interventions":42897},[91],[19],[8066,8067,8024],{"trials":42899,"activeCount":102},[42900,42907,42911,42915,42919,42923,42927,42931,42935,42939,42943,42947,42951,42955,42962,42966,42970,42974,42981,42985,42989,42993,42997,43001,43005,43009,43013,43017,43021,43027,43031,43037,43041,43045,43049,43053],{"nctId":42901,"briefTitle":42902,"status":108,"phases":42903,"primaryCompletion":3565,"completion":3565,"start":5251,"enrollment":42904,"conditions":42905,"interventions":42906},"NCT00272090","Insulin Glargine in Type 1 Diabetes Mellitus",[92],489,[578],[8067],{"nctId":8121,"briefTitle":8122,"status":108,"phases":42908,"primaryCompletion":7189,"completion":7189,"start":8124,"enrollment":8125,"conditions":42909,"interventions":42910},[92],[19],[8128,8067,8024],{"nctId":10637,"briefTitle":10638,"status":108,"phases":42912,"primaryCompletion":10640,"completion":10641,"start":10642,"enrollment":10643,"conditions":42913,"interventions":42914},[92],[10645],[8508,10647,8067],{"nctId":8136,"briefTitle":8137,"status":108,"phases":42916,"primaryCompletion":986,"completion":986,"start":3307,"enrollment":8139,"conditions":42917,"interventions":42918},[92],[22],[8057,8142,8024],{"nctId":8567,"briefTitle":8568,"status":884,"phases":42920,"primaryCompletion":8570,"completion":8570,"start":8505,"enrollment":402,"conditions":42921,"interventions":42922},[92],[8572],[8057,8209,8574],{"nctId":11988,"briefTitle":11989,"status":108,"phases":42924,"primaryCompletion":165,"completion":165,"start":3354,"enrollment":3767,"conditions":42925,"interventions":42926},[92],[554],[8067,11993,8766],{"nctId":8162,"briefTitle":8163,"status":108,"phases":42928,"primaryCompletion":8165,"completion":8165,"start":8166,"enrollment":8167,"conditions":42929,"interventions":42930},[92],[830],[8170,8067,8046,8024],{"nctId":8576,"briefTitle":8577,"status":108,"phases":42932,"completion":8579,"start":7538,"enrollment":8580,"conditions":42933,"interventions":42934},[92],[22],[8583,8424],{"nctId":8202,"briefTitle":8203,"status":108,"phases":42936,"primaryCompletion":8205,"start":8184,"enrollment":8206,"conditions":42937,"interventions":42938},[92],[22],[8057,8209,8024,8210],{"nctId":8589,"briefTitle":8590,"status":108,"phases":42940,"completion":3563,"start":7523,"enrollment":8592,"conditions":42941,"interventions":42942},[92],[22],[8583,8424],{"nctId":8222,"briefTitle":8223,"status":108,"phases":42944,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":42945,"interventions":42946},[92],[19],[8128,8067,8046,8024,8230],{"nctId":22548,"briefTitle":22549,"status":108,"phases":42948,"primaryCompletion":10811,"completion":4969,"start":10178,"enrollment":6655,"conditions":42949,"interventions":42950},[92],[19],[22537,8067],{"nctId":26109,"briefTitle":26110,"status":108,"phases":42952,"primaryCompletion":977,"completion":977,"start":8364,"enrollment":26112,"conditions":42953,"interventions":42954},[92],[10076],[8424,26098],{"nctId":42956,"briefTitle":42957,"status":108,"phases":42958,"primaryCompletion":1355,"completion":1355,"start":1011,"enrollment":42959,"conditions":42960,"interventions":42961},"NCT02401243","Study of Two Titration Algorithms With Insulin Glargine 300 Units\u002FmL in Type 2 Diabetes Mellitus Patients",[92],253,[19],[8256],{"nctId":8240,"briefTitle":8241,"status":108,"phases":42963,"primaryCompletion":5306,"completion":5306,"start":3354,"enrollment":8243,"conditions":42964,"interventions":42965},[92],[19],[8046,8067,8024,8191],{"nctId":8604,"briefTitle":8605,"status":108,"phases":42967,"primaryCompletion":8607,"start":8175,"enrollment":8608,"conditions":42968,"interventions":42969},[92],[22],[8209,8611,8057],{"nctId":8247,"briefTitle":8248,"status":108,"phases":42971,"primaryCompletion":8250,"completion":8250,"start":8251,"enrollment":8252,"conditions":42972,"interventions":42973},[92],[19],[8255,8256,8024,8209],{"nctId":42975,"briefTitle":42976,"status":108,"phases":42977,"completion":7538,"start":8176,"enrollment":305,"conditions":42978,"interventions":42980},"NCT00563225","20 Week Bridging Study in Type II DM",[92],[42979],"Diabetes Mellitus Type II",[8057],{"nctId":27099,"briefTitle":27100,"status":108,"phases":42982,"primaryCompletion":2662,"completion":2662,"start":27102,"enrollment":19708,"conditions":42983,"interventions":42984},[92],[19],[8067,8067,27088],{"nctId":22554,"briefTitle":22555,"status":108,"phases":42986,"primaryCompletion":966,"completion":7330,"start":10178,"enrollment":6502,"conditions":42987,"interventions":42988},[92],[554],[22537,8067],{"nctId":12055,"briefTitle":12056,"status":108,"phases":42990,"primaryCompletion":3858,"completion":12058,"start":12059,"enrollment":8738,"conditions":42991,"interventions":42992},[92],[554],[12062,8067,10566],{"nctId":12064,"briefTitle":12065,"status":108,"phases":42994,"primaryCompletion":12067,"completion":12067,"start":1031,"enrollment":12068,"conditions":42995,"interventions":42996},[92],[19],[8057,8057,10566],{"nctId":8631,"briefTitle":8632,"status":108,"phases":42998,"primaryCompletion":8156,"start":2800,"enrollment":8634,"conditions":42999,"interventions":43000},[92],[8187],[8209,8637,8057],{"nctId":28180,"briefTitle":28181,"status":108,"phases":43002,"primaryCompletion":3509,"completion":3509,"start":9183,"enrollment":22329,"conditions":43003,"interventions":43004},[92],[22],[8067,28169],{"nctId":8278,"briefTitle":8279,"status":108,"phases":43006,"primaryCompletion":964,"completion":964,"start":2855,"enrollment":8281,"conditions":43007,"interventions":43008},[92],[830],[8284,8067,8024],{"nctId":10559,"briefTitle":10560,"status":884,"phases":43010,"primaryCompletion":10562,"completion":10562,"start":10563,"enrollment":9707,"conditions":43011,"interventions":43012},[92],[19],[8128,8067,10566],{"nctId":10572,"briefTitle":10573,"status":108,"phases":43014,"primaryCompletion":189,"completion":189,"start":10575,"enrollment":10576,"conditions":43015,"interventions":43016},[92],[19],[8284,8067,9369],{"nctId":8295,"briefTitle":8296,"status":108,"phases":43018,"primaryCompletion":7430,"completion":7430,"start":8298,"enrollment":8299,"conditions":43019,"interventions":43020},[92],[830],[8046,8302,8303,8057,8024],{"nctId":43022,"briefTitle":43023,"status":108,"phases":43024,"primaryCompletion":1041,"completion":1041,"start":3429,"enrollment":3915,"conditions":43025,"interventions":43026},"NCT02585674","Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo",[92],[19],[8067],{"nctId":29661,"briefTitle":29662,"status":108,"phases":43028,"primaryCompletion":17767,"completion":17767,"start":29664,"enrollment":29665,"conditions":43029,"interventions":43030},[92],[22],[8424,29650],{"nctId":43032,"briefTitle":43033,"status":108,"phases":43034,"completion":9826,"start":8185,"enrollment":20,"conditions":43035,"interventions":43036},"NCT00537251","32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus",[92],[578],[8067],{"nctId":8646,"briefTitle":8647,"status":108,"phases":43038,"completion":1341,"start":8579,"enrollment":8290,"conditions":43039,"interventions":43040},[92],[8187],[8424,8583],{"nctId":8328,"briefTitle":8329,"status":108,"phases":43042,"primaryCompletion":8316,"completion":8316,"start":8331,"enrollment":8332,"conditions":43043,"interventions":43044},[92],[22],[8335,8067,8024],{"nctId":8361,"briefTitle":8362,"status":108,"phases":43046,"primaryCompletion":8364,"start":8365,"enrollment":8366,"conditions":43047,"interventions":43048},[92],[22],[8057,8265,8024,8369],{"nctId":11622,"briefTitle":11623,"status":108,"phases":43050,"primaryCompletion":1055,"completion":1055,"start":3821,"enrollment":11625,"conditions":43051,"interventions":43052},[92],[554],[8067,8551],{"nctId":8663,"briefTitle":8664,"status":108,"phases":43054,"primaryCompletion":8666,"completion":8666,"start":8667,"enrollment":8668,"conditions":43055,"interventions":43056},[92],[8670],[8335,8672,8424,8551],{"trials":43058,"activeCount":102},[43059,43063,43067,43071,43077,43083,43089,43093,43099,43105,43109,43115,43122,43129,43133,43141,43147,43153,43158,43162,43166,43170,43176,43183,43187,43193,43197,43205,43209,43213,43217,43223,43227,43231,43235,43239,43243,43247,43254,43262,43269,43273,43279,43286,43290,43296,43302,43306,43310,43314,43320,43324,43330,43334,43343,43350,43356,43360,43368,43374,43378,43382],{"nctId":8373,"briefTitle":8374,"status":108,"phases":43060,"primaryCompletion":8376,"completion":8376,"start":8377,"enrollment":8378,"conditions":43061,"interventions":43062},[93],[19],[8256,8209,8381,8382,8383,8024],{"nctId":8385,"briefTitle":8386,"status":108,"phases":43064,"primaryCompletion":8388,"completion":8388,"start":8316,"enrollment":4760,"conditions":43065,"interventions":43066},[93],[19],[8265,8024,8057],{"nctId":8680,"briefTitle":8681,"status":108,"phases":43068,"primaryCompletion":8683,"completion":8683,"start":955,"enrollment":8684,"conditions":43069,"interventions":43070},[93],[22],[8256,8687,8688],{"nctId":43072,"briefTitle":43073,"status":884,"phases":43074,"primaryCompletion":8349,"start":8762,"enrollment":2371,"conditions":43075,"interventions":43076},"NCT00627471","Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)",[93],[830],[8057,8057],{"nctId":43078,"briefTitle":43079,"status":108,"phases":43080,"completion":8666,"start":9513,"enrollment":875,"conditions":43081,"interventions":43082},"NCT00322075","LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous",[93],[8187],[8424],{"nctId":43084,"briefTitle":43085,"status":108,"phases":43086,"primaryCompletion":3355,"completion":3355,"start":18773,"enrollment":14558,"conditions":43087,"interventions":43088},"NCT00174824","Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients",[93],[22],[8067],{"nctId":8392,"briefTitle":8393,"status":108,"phases":43090,"primaryCompletion":8316,"start":8395,"enrollment":8396,"conditions":43091,"interventions":43092},[93],[22],[8057,8190,8399,8400,8401,8024],{"nctId":43094,"briefTitle":43095,"status":108,"phases":43096,"completion":7538,"start":5251,"enrollment":6313,"conditions":43097,"interventions":43098},"NCT00576862","Extension to Study HMR1964A\u002F3011 in Belgium",[93],[8187],[8256],{"nctId":43100,"briefTitle":43101,"status":108,"phases":43102,"primaryCompletion":9872,"completion":9872,"start":5251,"enrollment":967,"conditions":43103,"interventions":43104},"NCT00540709","PUMP STUDY MDI Lantus\u002FLispro vs Continuous Insulin+Lispro",[93],[8187],[8057],{"nctId":8403,"briefTitle":8404,"status":108,"phases":43106,"primaryCompletion":8406,"completion":8406,"start":8235,"enrollment":8407,"conditions":43107,"interventions":43108},[93],[22],[8057,8142,8024],{"nctId":43110,"briefTitle":43111,"status":108,"phases":43112,"primaryCompletion":8453,"completion":8453,"start":8316,"enrollment":9707,"conditions":43113,"interventions":43114},"NCT00701831","Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control",[93],[22],[8067],{"nctId":43116,"briefTitle":43117,"status":108,"phases":43118,"primaryCompletion":2834,"completion":2834,"start":5271,"enrollment":43119,"conditions":43120,"interventions":43121},"NCT01169818","Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus",[93],555,[22],[8057],{"nctId":43123,"briefTitle":43124,"status":108,"phases":43125,"primaryCompletion":8822,"completion":8822,"start":8331,"enrollment":703,"conditions":43126,"interventions":43128},"NCT00518427","Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine",[93],[43127],"Diabetes Type 2",[8057],{"nctId":14065,"briefTitle":14066,"status":108,"phases":43130,"primaryCompletion":3335,"completion":3335,"start":3354,"enrollment":14068,"conditions":43131,"interventions":43132},[93],[22],[8424,14052],{"nctId":43134,"briefTitle":43135,"status":108,"phases":43136,"primaryCompletion":8364,"completion":8364,"start":43137,"enrollment":43138,"conditions":43139,"interventions":43140},"NCT00390728","Insulin Glargine in Type I Diabetes Mellitus> Main Study \"AT.LANTUS\": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: \"HALT\"(Hypoglycaemia Avoidance With Lantus Trial)",[93],"2002-04",2346,[578],[8057],{"nctId":43142,"briefTitle":43143,"status":108,"phases":43144,"primaryCompletion":8777,"completion":8777,"start":9862,"enrollment":19781,"conditions":43145,"interventions":43146},"NCT00258804","Insulin Glargine During and After the Period of Fasting in Ramadan",[93],[22],[8067],{"nctId":43148,"briefTitle":43149,"status":108,"phases":43150,"primaryCompletion":3307,"completion":3307,"start":8822,"enrollment":22774,"conditions":43151,"interventions":43152},"NCT00659477","Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)",[93],[22],[8424],{"nctId":43154,"briefTitle":13090,"status":108,"phases":43155,"primaryCompletion":9862,"start":9592,"conditions":43156,"interventions":43157},"NCT00311818",[93],[19],[8067],{"nctId":8690,"briefTitle":8691,"status":108,"phases":43159,"primaryCompletion":2857,"completion":2857,"start":8693,"enrollment":8694,"conditions":43160,"interventions":43161},[93],[22],[8256,8687],{"nctId":8698,"briefTitle":8699,"status":108,"phases":43163,"primaryCompletion":164,"completion":164,"start":7292,"enrollment":465,"conditions":43164,"interventions":43165},[93],[578],[8687,8256],{"nctId":8411,"briefTitle":8412,"status":108,"phases":43167,"primaryCompletion":3417,"completion":3417,"start":3608,"enrollment":17,"conditions":43168,"interventions":43169},[93],[22],[8057,8265,8209,8024],{"nctId":43171,"briefTitle":43172,"status":108,"phases":43173,"primaryCompletion":8156,"completion":8156,"start":9559,"enrollment":335,"conditions":43174,"interventions":43175},"NCT00335465","Lantus Effect on Myocardial Glucose Metabolism in T2",[93],[22],[8067],{"nctId":43177,"briefTitle":43178,"status":108,"phases":43179,"completion":7538,"start":9592,"enrollment":43180,"conditions":43181,"interventions":43182},"NCT00576368","An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice",[93],4464,[8187],[8256],{"nctId":8708,"briefTitle":8709,"status":884,"phases":43184,"primaryCompletion":3821,"completion":3821,"start":955,"enrollment":335,"conditions":43185,"interventions":43186},[93],[22],[8256,8687],{"nctId":43188,"briefTitle":43189,"status":108,"phases":43190,"primaryCompletion":9909,"start":8185,"enrollment":726,"conditions":43191,"interventions":43192},"NCT00313937","SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1",[93],[578],[8067],{"nctId":8714,"briefTitle":8715,"status":108,"phases":43194,"primaryCompletion":966,"completion":966,"start":3366,"enrollment":8717,"conditions":43195,"interventions":43196},[93],[22],[8256,8551,8687,8720],{"nctId":43198,"briefTitle":43199,"status":108,"phases":43200,"primaryCompletion":43201,"completion":43201,"start":43202,"enrollment":12897,"conditions":43203,"interventions":43204},"NCT03760991","Evaluation of the Efficacy and Safety of Insulin Glargine 300 U\u002FmL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin",[93],"2020-09-23","2018-12-18",[19],[8256],{"nctId":8722,"briefTitle":8723,"status":108,"phases":43206,"primaryCompletion":5238,"completion":5238,"start":5271,"enrollment":1574,"conditions":43207,"interventions":43208},[93],[22],[8256,8687,8508],{"nctId":8728,"briefTitle":8729,"status":108,"phases":43210,"primaryCompletion":3366,"completion":3366,"start":8731,"enrollment":29,"conditions":43211,"interventions":43212},[93],[578],[8687,8256],{"nctId":8417,"briefTitle":8418,"status":108,"phases":43214,"completion":8420,"start":8421,"enrollment":3471,"conditions":43215,"interventions":43216},[93],[19],[8424,8425,8037],{"nctId":43218,"briefTitle":43219,"status":108,"phases":43220,"primaryCompletion":9522,"completion":9522,"start":3488,"enrollment":12934,"conditions":43221,"interventions":43222},"NCT00354939","Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement",[93],[8117],[8067],{"nctId":8427,"briefTitle":8428,"status":108,"phases":43224,"primaryCompletion":8430,"completion":8430,"start":8431,"enrollment":8139,"conditions":43225,"interventions":43226},[93],[19],[8256,8037,8276,8434,8435,8436,8437,8438,8439],{"nctId":8735,"briefTitle":8736,"status":108,"phases":43228,"primaryCompletion":3438,"completion":3438,"start":8731,"enrollment":8738,"conditions":43229,"interventions":43230},[93],[22],[8256,8508,8209],{"nctId":8742,"briefTitle":8743,"status":884,"phases":43232,"primaryCompletion":2857,"completion":2857,"start":8745,"enrollment":34,"conditions":43233,"interventions":43234},[93],[22],[8335,8067,8748],{"nctId":8450,"briefTitle":8451,"status":108,"phases":43236,"primaryCompletion":8453,"completion":8453,"start":1341,"enrollment":8454,"conditions":43237,"interventions":43238},[93],[19],[8067,8265,8024],{"nctId":8750,"briefTitle":8751,"status":108,"phases":43240,"primaryCompletion":1022,"completion":1022,"start":8753,"enrollment":8754,"conditions":43241,"interventions":43242},[93],[22],[8209,8057,8757,8209],{"nctId":8458,"briefTitle":8459,"status":108,"phases":43244,"primaryCompletion":8461,"completion":8461,"start":8462,"enrollment":8463,"conditions":43245,"interventions":43246},[93],[22],[8256,8037,8466],{"nctId":43248,"briefTitle":43249,"status":108,"phases":43250,"primaryCompletion":8364,"completion":8364,"start":3489,"enrollment":43251,"conditions":43252,"interventions":43253},"NCT00399724","A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus",[93],7376,[22],[8067],{"nctId":43255,"briefTitle":43256,"status":108,"phases":43257,"primaryCompletion":43258,"completion":43258,"start":43259,"enrollment":20023,"conditions":43260,"interventions":43261},"NCT02545842","Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III\u002FFPG GOAL)",[93],"2018-04-20","2015-09-07",[19],[8256],{"nctId":43263,"briefTitle":43264,"status":108,"phases":43265,"primaryCompletion":10170,"completion":10170,"start":43266,"enrollment":10711,"conditions":43267,"interventions":43268},"NCT02606357","Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan",[93],"2015-11-22",[22],[8256],{"nctId":11639,"briefTitle":11640,"status":108,"phases":43270,"primaryCompletion":11642,"completion":11642,"start":11643,"enrollment":10321,"conditions":43271,"interventions":43272},[93],[22],[8424,8424,8551,11646,11647],{"nctId":43274,"briefTitle":43275,"status":108,"phases":43276,"completion":5250,"start":12198,"enrollment":1583,"conditions":43277,"interventions":43278},"NCT00565162","Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus",[93],[8187],[8057],{"nctId":43280,"briefTitle":43281,"status":108,"phases":43282,"primaryCompletion":43283,"completion":43283,"start":3078,"enrollment":2835,"conditions":43284,"interventions":43285},"NCT04980027","Evaluation of the Safety and Efficacy of Insulin Glargine 300 U\u002Fml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs",[93],"2022-12-23",[19],[8067],{"nctId":11649,"briefTitle":11650,"status":108,"phases":43287,"primaryCompletion":11652,"completion":11652,"start":11653,"enrollment":11654,"conditions":43288,"interventions":43289},[93],[22],[8424,8424,8551,11646,11647],{"nctId":43291,"briefTitle":43292,"status":108,"phases":43293,"primaryCompletion":5238,"completion":5238,"start":8453,"enrollment":14169,"conditions":43294,"interventions":43295},"NCT01226043","Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus",[93],[22],[8057],{"nctId":43297,"briefTitle":43298,"status":108,"phases":43299,"completion":7523,"start":3527,"enrollment":1601,"conditions":43300,"interventions":43301},"NCT00609895","The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing",[93],[8187],[8256],{"nctId":8479,"briefTitle":8480,"status":108,"phases":43303,"primaryCompletion":164,"completion":2760,"start":3366,"enrollment":8482,"conditions":43304,"interventions":43305},[93],[22],[8067,8056,8024],{"nctId":12431,"briefTitle":12432,"status":108,"phases":43307,"primaryCompletion":8156,"start":8666,"enrollment":12434,"conditions":43308,"interventions":43309},[93],[22],[8067,12437],{"nctId":8774,"briefTitle":8775,"status":884,"phases":43311,"primaryCompletion":8235,"completion":8235,"start":8777,"enrollment":8620,"conditions":43312,"interventions":43313},[93],[22],[8057,8209],{"nctId":43315,"briefTitle":43316,"status":108,"phases":43317,"completion":9706,"start":7538,"enrollment":988,"conditions":43318,"interventions":43319},"NCT00553020","Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes",[93],[22],[8067],{"nctId":8781,"briefTitle":8782,"status":108,"phases":43321,"primaryCompletion":151,"completion":151,"start":3438,"enrollment":8784,"conditions":43322,"interventions":43323},[93],[22],[8256,8687],{"nctId":43325,"briefTitle":43326,"status":108,"phases":43327,"start":9113,"enrollment":8620,"conditions":43328,"interventions":43329},"NCT00174681","Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes",[93],[22],[8057],{"nctId":8788,"briefTitle":8789,"status":108,"phases":43331,"primaryCompletion":8298,"completion":8298,"start":987,"enrollment":8791,"conditions":43332,"interventions":43333},[93],[578],[8256,8687],{"nctId":43335,"briefTitle":43336,"status":108,"phases":43337,"primaryCompletion":43338,"completion":43338,"start":43339,"enrollment":10074,"conditions":43340,"interventions":43342},"NCT03406000","Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U\u002FmL",[93],"2019-02-04","2018-01-22",[43341],"Type I Diabetes Mellitus",[8256],{"nctId":43344,"briefTitle":43345,"status":108,"phases":43346,"primaryCompletion":8731,"completion":8731,"start":8505,"enrollment":43347,"conditions":43348,"interventions":43349},"NCT00693771","Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin",[93],313,[22],[8057],{"nctId":43351,"briefTitle":43352,"status":108,"phases":43353,"primaryCompletion":8205,"completion":8205,"start":3355,"enrollment":19158,"conditions":43354,"interventions":43355},"NCT00488527","DOMME Dose Optimization Multicentric Mexican Evaluation",[93],[22],[8067],{"nctId":17218,"briefTitle":17219,"status":884,"phases":43357,"primaryCompletion":5271,"completion":5271,"start":8731,"enrollment":2636,"conditions":43358,"interventions":43359},[93],[22],[8256,17205],{"nctId":43361,"briefTitle":43362,"status":108,"phases":43363,"primaryCompletion":43364,"completion":43364,"start":43365,"enrollment":11211,"conditions":43366,"interventions":43367},"NCT02967237","Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment",[93],"2017-07-24","2016-01-04",[22],[8424],{"nctId":43369,"briefTitle":43370,"status":108,"phases":43371,"start":3367,"enrollment":3386,"conditions":43372,"interventions":43373},"NCT00268645","Insulin Glargine in Type 2 Diabetes",[93],[22],[8057],{"nctId":8801,"briefTitle":8802,"status":108,"phases":43375,"primaryCompletion":8205,"completion":8205,"start":3355,"enrollment":8804,"conditions":43376,"interventions":43377},[93],[578],[8424,8583],{"nctId":8486,"briefTitle":8487,"status":108,"phases":43379,"primaryCompletion":151,"completion":151,"start":6471,"enrollment":442,"conditions":43380,"interventions":43381},[93],[22],[8256,8024,8491,8492],{"nctId":43383,"briefTitle":43384,"status":108,"phases":43385,"primaryCompletion":152,"completion":152,"start":9984,"enrollment":43386,"conditions":43387,"interventions":43388},"NCT01127269","Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes",[93],178,[22],[8256],{"trials":43390,"activeCount":102},[43391,43398],{"nctId":43392,"briefTitle":43393,"status":108,"phases":43394,"primaryCompletion":8316,"completion":8316,"start":5307,"enrollment":43395,"conditions":43396,"interventions":43397},"NCT00423215","LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus",[],1007,[22],[8067],{"nctId":43399,"briefTitle":43400,"status":108,"phases":43401,"primaryCompletion":43402,"completion":38711,"start":43403,"enrollment":43404,"conditions":43405,"interventions":43407},"NCT03703869","Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.",[],"2019-06-28","2018-03-06",4589,[43406],"Diabetes",[8067],{"intervention":1348,"totalTrials":40673,"cells":43409},{"EARLY_PHASE1":43410,"PHASE1":43412,"PHASE2":43434,"PHASE3":43568,"PHASE4":43628,"NA":43636},{"trials":43411,"activeCount":102},[],{"trials":43413,"activeCount":102},[43414,43420,43424,43428],{"nctId":43415,"briefTitle":43416,"status":108,"phases":43417,"primaryCompletion":2857,"completion":2857,"start":3317,"enrollment":3828,"conditions":43418,"interventions":43419},"NCT00545246","A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients",[90],[2803],[9158,5232],{"nctId":17858,"briefTitle":17859,"status":108,"phases":43421,"primaryCompletion":977,"completion":977,"start":9984,"enrollment":6445,"conditions":43422,"interventions":43423},[90],[5220],[17863,17864,5232],{"nctId":41256,"briefTitle":41257,"status":108,"phases":43425,"primaryCompletion":3821,"completion":3821,"start":8395,"enrollment":967,"conditions":43426,"interventions":43427},[90],[41260],[41249,1348],{"nctId":43429,"briefTitle":43430,"status":108,"phases":43431,"primaryCompletion":986,"completion":977,"start":3366,"enrollment":576,"conditions":43432,"interventions":43433},"NCT01148615","A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors",[90],[1193],[1347,1348],{"trials":43435,"activeCount":102},[43436,43442,43447,43454,43458,43464,43470,43474,43478,43482,43486,43490,43494,43498,43502,43506,43510,43516,43522,43526,43533,43537,43541,43545,43551,43557,43564],{"nctId":43437,"briefTitle":43438,"status":108,"phases":43439,"primaryCompletion":3623,"completion":3623,"start":9800,"enrollment":1676,"conditions":43440,"interventions":43441},"NCT00916097","NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)",[91],[12355],[2763],{"nctId":43443,"briefTitle":34635,"status":884,"phases":43444,"start":9862,"enrollment":7653,"conditions":43445,"interventions":43446},"NCT00263016",[91],[30031],[1348],{"nctId":43448,"briefTitle":43449,"status":108,"phases":43450,"completion":7483,"start":43451,"enrollment":875,"conditions":43452,"interventions":43453},"NCT00819728","Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer",[91],"2000-06",[30031],[1348,18130],{"nctId":5227,"briefTitle":5228,"status":884,"phases":43455,"primaryCompletion":3564,"completion":3564,"start":2800,"enrollment":2611,"conditions":43456,"interventions":43457},[91],[2703],[5232,5233,5223],{"nctId":43459,"briefTitle":43460,"status":108,"phases":43461,"primaryCompletion":5307,"completion":5307,"start":9826,"conditions":43462,"interventions":43463},"NCT00268710","Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]",[91],[2804],[5232],{"nctId":43465,"briefTitle":43466,"status":108,"phases":43467,"primaryCompletion":2800,"completion":2800,"start":8185,"enrollment":2777,"conditions":43468,"interventions":43469},"NCT00069888","A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy",[91],[1357],[1348],{"nctId":18882,"briefTitle":18883,"status":108,"phases":43471,"primaryCompletion":5271,"completion":5271,"start":10320,"enrollment":18885,"conditions":43472,"interventions":43473},[91],[5275],[17970,5232,18880],{"nctId":3560,"briefTitle":3561,"status":108,"phases":43475,"primaryCompletion":3563,"completion":3564,"start":3565,"enrollment":3566,"conditions":43476,"interventions":43477},[91],[1357,3568,3569],[3571,1348,672],{"nctId":2756,"briefTitle":2757,"status":108,"phases":43479,"primaryCompletion":2759,"completion":2759,"start":2760,"enrollment":271,"conditions":43480,"interventions":43481},[91],[2750],[2763,2764,671],{"nctId":5259,"briefTitle":5260,"status":108,"phases":43483,"primaryCompletion":954,"completion":3416,"start":5262,"enrollment":2281,"conditions":43484,"interventions":43485},[91],[5264],[5206,1348,5266],{"nctId":5268,"briefTitle":5269,"status":108,"phases":43487,"primaryCompletion":5271,"completion":5271,"start":5272,"enrollment":5273,"conditions":43488,"interventions":43489},[91],[5275],[1348,4640,5277,4643,5266,5206],{"nctId":17883,"briefTitle":17884,"status":108,"phases":43491,"primaryCompletion":8683,"completion":8683,"start":8395,"enrollment":5407,"conditions":43492,"interventions":43493},[91],[9092],[1348,1276,9148],{"nctId":17889,"briefTitle":17890,"status":108,"phases":43495,"primaryCompletion":1022,"completion":1022,"start":3509,"enrollment":6472,"conditions":43496,"interventions":43497},[91],[9132],[1348,1276],{"nctId":9162,"briefTitle":9163,"status":108,"phases":43499,"primaryCompletion":5238,"completion":5238,"start":8205,"enrollment":7224,"conditions":43500,"interventions":43501},[91],[5395],[2763,9167,5242],{"nctId":5279,"briefTitle":5280,"status":108,"phases":43503,"primaryCompletion":5271,"completion":5271,"start":3608,"enrollment":5282,"conditions":43504,"interventions":43505},[91],[5284],[1348,5286,5206],{"nctId":17895,"briefTitle":17896,"status":108,"phases":43507,"primaryCompletion":1055,"completion":1055,"start":1339,"enrollment":402,"conditions":43508,"interventions":43509},[91],[17899],[2763,17901],{"nctId":43511,"briefTitle":43512,"status":108,"phases":43513,"primaryCompletion":9513,"completion":9513,"start":8364,"enrollment":2858,"conditions":43514,"interventions":43515},"NCT00268671","Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)",[90,91],[12355],[1348],{"nctId":43517,"briefTitle":43518,"status":884,"phases":43519,"primaryCompletion":8667,"completion":8667,"start":3367,"enrollment":659,"conditions":43520,"interventions":43521},"NCT00620100","To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent",[91],[5275],[1348],{"nctId":12351,"briefTitle":12352,"status":108,"phases":43523,"primaryCompletion":8753,"start":9183,"enrollment":3566,"conditions":43524,"interventions":43525},[91],[12355],[12335,5232],{"nctId":43527,"briefTitle":43528,"status":108,"phases":43529,"primaryCompletion":3564,"completion":3564,"start":9862,"enrollment":988,"conditions":43530,"interventions":43532},"NCT00723086","Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer",[91],[43531],"Therapy, Prostatic Neoplasms",[5232],{"nctId":17917,"briefTitle":17918,"status":108,"phases":43534,"primaryCompletion":8349,"completion":3335,"start":8607,"enrollment":8454,"conditions":43535,"interventions":43536},[91],[9132,1344],[5232,17864,17922],{"nctId":10016,"briefTitle":10017,"status":108,"phases":43538,"primaryCompletion":6471,"completion":6471,"start":7349,"enrollment":659,"conditions":43539,"interventions":43540},[91],[2804],[2764,2763],{"nctId":5303,"briefTitle":5304,"status":108,"phases":43542,"primaryCompletion":5306,"completion":5306,"start":5307,"enrollment":5308,"conditions":43543,"interventions":43544},[91],[5310],[5206,1348,5286],{"nctId":43546,"briefTitle":43547,"status":108,"phases":43548,"completion":5250,"start":3488,"enrollment":339,"conditions":43549,"interventions":43550},"NCT00617968","GETNA2 Neoadj. TAX+Femara vs Femara in g I\u002FII Breast Cancer",[91],[5275],[2763],{"nctId":43552,"briefTitle":43553,"status":108,"phases":43554,"start":3326,"enrollment":40673,"conditions":43555,"interventions":43556},"NCT00539669","TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian",[91],[12362],[1348],{"nctId":43558,"briefTitle":43559,"status":884,"phases":43560,"primaryCompletion":8667,"completion":8667,"start":8175,"enrollment":622,"conditions":43561,"interventions":43563},"NCT00494338","Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer",[91],[43562],"Metastatic Prostate Cancer",[1348],{"nctId":19146,"briefTitle":19147,"status":884,"phases":43565,"primaryCompletion":5250,"completion":9190,"start":7482,"enrollment":576,"conditions":43566,"interventions":43567},[91],[19150],[1348,4640],{"trials":43569,"activeCount":102},[43570,43574,43578,43582,43586,43590,43594,43598,43602,43606,43610,43614,43620,43624],{"nctId":17944,"briefTitle":17945,"status":108,"phases":43571,"primaryCompletion":17947,"completion":17947,"start":17948,"enrollment":6655,"conditions":43572,"interventions":43573},[92],[12355],[2763,17901,5243],{"nctId":19614,"briefTitle":19615,"status":884,"phases":43575,"primaryCompletion":2928,"completion":4261,"start":19617,"enrollment":19618,"conditions":43576,"interventions":43577},[92],[19603],[1195,1348],{"nctId":17952,"briefTitle":17953,"status":108,"phases":43579,"primaryCompletion":2834,"completion":2834,"start":8235,"enrollment":6502,"conditions":43580,"interventions":43581},[92],[9092],[17922,1276,1348],{"nctId":17958,"briefTitle":17959,"status":108,"phases":43583,"primaryCompletion":7349,"completion":7349,"start":8570,"enrollment":8366,"conditions":43584,"interventions":43585},[92],[17899],[1348,1276],{"nctId":24348,"briefTitle":24349,"status":884,"phases":43587,"primaryCompletion":10178,"completion":10178,"start":3563,"enrollment":7452,"conditions":43588,"interventions":43589},[92],[2804],[1348,24337,24353],{"nctId":9236,"briefTitle":9237,"status":108,"phases":43591,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":9242,"conditions":43592,"interventions":43593},[92],[5395],[1348,5286,9167],{"nctId":18174,"briefTitle":18175,"status":108,"phases":43595,"primaryCompletion":8745,"completion":8745,"start":18177,"enrollment":18178,"conditions":43596,"interventions":43597},[92],[5264],[1348,17922,4640,4643],{"nctId":17972,"briefTitle":17973,"status":108,"phases":43599,"primaryCompletion":9592,"completion":9592,"start":17975,"enrollment":2294,"conditions":43600,"interventions":43601},[91,92],[12355,17977,9156],[5232,17864,17922],{"nctId":27798,"briefTitle":27799,"status":108,"phases":43603,"primaryCompletion":3416,"completion":3416,"start":9190,"enrollment":27801,"conditions":43604,"interventions":43605},[92],[2804,9156],[1347,1348,27787],{"nctId":19167,"briefTitle":19168,"status":108,"phases":43607,"primaryCompletion":7430,"completion":7430,"start":3327,"enrollment":19170,"conditions":43608,"interventions":43609},[92],[5275],[4640,4643,1348,19173,5277],{"nctId":2821,"briefTitle":2822,"status":108,"phases":43611,"primaryCompletion":2824,"completion":2825,"start":2826,"enrollment":2827,"conditions":43612,"interventions":43613},[92],[1357],[2794,1348,671],{"nctId":43615,"briefTitle":43616,"status":108,"phases":43617,"start":5251,"enrollment":3566,"conditions":43618,"interventions":43619},"NCT00539630","TAX + Cisplatin + 5 F\u002FU vs Cisplatin + 5 F\u002FU in SCCHN",[92],[36543],[1348],{"nctId":1336,"briefTitle":1337,"status":108,"phases":43621,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":43622,"interventions":43623},[92],[1344,1345],[1347,1348,642],{"nctId":2831,"briefTitle":2832,"status":108,"phases":43625,"primaryCompletion":2834,"completion":2834,"start":2800,"enrollment":2835,"conditions":43626,"interventions":43627},[92],[2804],[1348,2838,671],{"trials":43629,"activeCount":102},[43630],{"nctId":43631,"briefTitle":43632,"status":108,"phases":43633,"primaryCompletion":3317,"start":3609,"enrollment":3740,"conditions":43634,"interventions":43635},"NCT00280098","Docetaxel in the Treatment of Hormone Refractory Prostate Cancer",[93],[2804],[5232],{"trials":43637,"activeCount":102},[43638],{"nctId":43639,"briefTitle":43640,"status":108,"phases":43641,"primaryCompletion":987,"completion":987,"start":3495,"enrollment":3740,"conditions":43642,"interventions":43643},"NCT00452985","Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer",[],[12362],[1348,5277],{"intervention":1347,"totalTrials":284,"cells":43645},{"EARLY_PHASE1":43646,"PHASE1":43648,"PHASE2":43675,"PHASE3":43706,"PHASE4":43741,"NA":43743},{"trials":43647,"activeCount":102},[],{"trials":43649,"activeCount":102},[43650,43654,43658,43662,43668],{"nctId":43415,"briefTitle":43416,"status":108,"phases":43651,"primaryCompletion":2857,"completion":2857,"start":3317,"enrollment":3828,"conditions":43652,"interventions":43653},[90],[2803],[9158,5232],{"nctId":19938,"briefTitle":19939,"status":108,"phases":43655,"primaryCompletion":1339,"completion":1339,"start":5272,"enrollment":1601,"conditions":43656,"interventions":43657},[90],[2803],[9158,9167],{"nctId":43429,"briefTitle":43430,"status":108,"phases":43659,"primaryCompletion":986,"completion":977,"start":3366,"enrollment":576,"conditions":43660,"interventions":43661},[90],[1193],[1347,1348],{"nctId":43663,"briefTitle":43664,"status":108,"phases":43665,"primaryCompletion":955,"completion":987,"start":3396,"enrollment":9786,"conditions":43666,"interventions":43667},"NCT00876044","A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients",[90],[5421],[9158],{"nctId":43669,"briefTitle":43670,"status":108,"phases":43671,"primaryCompletion":1340,"completion":1340,"start":8822,"enrollment":2636,"conditions":43672,"interventions":43674},"NCT00644124","Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma",[90],[43673],"Lymphoma, Non-Hodgkin",[9158],{"trials":43676,"activeCount":102},[43677,43683,43690,43694,43698],{"nctId":43678,"briefTitle":43679,"status":108,"phases":43680,"primaryCompletion":8235,"completion":8235,"start":3430,"enrollment":988,"conditions":43681,"interventions":43682},"NCT00396591","AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites",[91],[12362],[1347],{"nctId":43684,"briefTitle":43685,"status":108,"phases":43686,"primaryCompletion":8505,"completion":1022,"start":8753,"enrollment":380,"conditions":43687,"interventions":43689},"NCT00327171","Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer",[91],[2803,43688],"Cancer of the Ovary",[1347,1347],{"nctId":32342,"briefTitle":32343,"status":108,"phases":43691,"primaryCompletion":2759,"completion":2759,"start":7283,"enrollment":6604,"conditions":43692,"interventions":43693},[91],[9210],[1347,32347,18130,9159],{"nctId":9151,"briefTitle":9152,"status":108,"phases":43695,"primaryCompletion":2790,"completion":3335,"start":8315,"enrollment":9154,"conditions":43696,"interventions":43697},[91],[5240,9156],[9158,5256,9159,9160],{"nctId":43699,"briefTitle":43700,"status":108,"phases":43701,"primaryCompletion":8196,"completion":8196,"start":3609,"enrollment":8804,"conditions":43702,"interventions":43705},"NCT00284141","Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma",[91],[43703,43704],"Pulmonary Diseases","Neoplasms, Lung",[1347],{"trials":43707,"activeCount":102},[43708,43715,43719,43723,43727,43733,43737],{"nctId":43709,"briefTitle":43710,"status":108,"phases":43711,"primaryCompletion":5216,"completion":964,"start":2857,"enrollment":43712,"conditions":43713,"interventions":43714},"NCT01661270","A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy",[92],332,[9210],[1347],{"nctId":27798,"briefTitle":27799,"status":108,"phases":43716,"primaryCompletion":3416,"completion":3416,"start":9190,"enrollment":27801,"conditions":43717,"interventions":43718},[92],[2804,9156],[1347,1348,27787],{"nctId":22644,"briefTitle":22645,"status":108,"phases":43720,"primaryCompletion":3821,"completion":2834,"start":8607,"enrollment":22647,"conditions":43721,"interventions":43722},[92],[5240,9156],[1347,20149,20149],{"nctId":18383,"briefTitle":18384,"status":884,"phases":43724,"primaryCompletion":3354,"completion":987,"start":7509,"enrollment":1012,"conditions":43725,"interventions":43726},[92],[18160],[1347,9134],{"nctId":43728,"briefTitle":43729,"status":108,"phases":43730,"primaryCompletion":3354,"completion":3354,"start":3608,"enrollment":967,"conditions":43731,"interventions":43732},"NCT00327444","Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites",[91,92],[12362,18754],[9158,9158],{"nctId":19401,"briefTitle":9210,"status":108,"phases":43734,"primaryCompletion":8165,"completion":8165,"start":7349,"enrollment":19403,"conditions":43735,"interventions":43736},[92],[9210],[19406,18130,9148,9149],{"nctId":1336,"briefTitle":1337,"status":108,"phases":43738,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":43739,"interventions":43740},[92],[1344,1345],[1347,1348,642],{"trials":43742,"activeCount":102},[],{"trials":43744,"activeCount":102},[43745],{"nctId":43746,"briefTitle":43747,"status":108,"phases":43748,"primaryCompletion":43749,"completion":43749,"start":43750,"enrollment":3121,"conditions":43751,"interventions":43753},"NCT05178745","Resection Observatory",[],"2022-05-27","2016-09-07",[43752,5240],"Metastatic Colorectal Cancer",[9148,1347,18130],{"intervention":43755,"totalTrials":2611,"cells":43756},"Alfuzosin",{"EARLY_PHASE1":43757,"PHASE1":43759,"PHASE2":43761,"PHASE3":43770,"PHASE4":43838,"NA":43878},{"trials":43758,"activeCount":102},[],{"trials":43760,"activeCount":102},[],{"trials":43762,"activeCount":102},[43763],{"nctId":43764,"briefTitle":43765,"status":108,"phases":43766,"primaryCompletion":3355,"start":8777,"enrollment":10348,"conditions":43767,"interventions":43769},"NCT00336921","Alfuzosin for Treating Acute Urinary Retention",[91],[43768],"Acute Urinary Retention",[43755],{"trials":43771,"activeCount":102},[43772,43779,43788,43796,43804,43810,43819,43825,43832],{"nctId":43773,"briefTitle":43774,"status":108,"phases":43775,"completion":3633,"start":3528,"enrollment":12897,"conditions":43776,"interventions":43777},"NCT00540891","The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score",[92],[28076],[43778],"ALFUZOSIN",{"nctId":43780,"briefTitle":43781,"status":108,"phases":43782,"primaryCompletion":3317,"completion":3317,"start":8666,"enrollment":43783,"conditions":43784,"interventions":43786},"NCT00399464","Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia",[92],1177,[43785],"Prostatic Hyperplasia",[43787],"alfuzosin",{"nctId":43789,"briefTitle":43790,"status":108,"phases":43791,"primaryCompletion":9785,"completion":9785,"start":3608,"enrollment":43792,"conditions":43793,"interventions":43795},"NCT00629720","Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology",[92],29,[43794],"Urinary Bladder Neurogenic",[43787],{"nctId":43797,"briefTitle":43798,"status":108,"phases":43799,"primaryCompletion":9532,"completion":3354,"start":7509,"enrollment":2636,"conditions":43800,"interventions":43803},"NCT00576823","Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology",[92],[43801,43802],"Hydronephrosis","Neurogenic Bladder",[43755],{"nctId":43805,"briefTitle":43806,"status":108,"phases":43807,"primaryCompletion":3633,"completion":3633,"start":10073,"enrollment":4929,"conditions":43808,"interventions":43809},"NCT00290030","ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH",[92],[43785,43768],[43755],{"nctId":43811,"briefTitle":43812,"status":108,"phases":43813,"completion":9130,"start":10073,"enrollment":43814,"conditions":43815,"interventions":43818},"NCT00029822","Clinical Trial in Males With BPH (Enlarged Prostate)",[92],1522,[43816,43785,43817],"Urinary Retention","Benign Prostatic Hypertrophy",[43755],{"nctId":43820,"briefTitle":43821,"status":884,"phases":43822,"start":8526,"enrollment":1809,"conditions":43823,"interventions":43824},"NCT00453908","Alfuzosin Versus Placebo in Acute Urinary Retention",[92],[43816],[43755],{"nctId":43826,"briefTitle":43827,"status":108,"phases":43828,"primaryCompletion":8349,"completion":8388,"start":3317,"enrollment":13377,"conditions":43829,"interventions":43831},"NCT00549939","Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction",[92],[43830],"Neurogenic Urinary Bladder",[43755],{"nctId":43833,"briefTitle":43834,"status":884,"phases":43835,"completion":3563,"start":5262,"enrollment":3471,"conditions":43836,"interventions":43837},"NCT00454402","ALF-STONE: Alfuzosin in Uretheric Stones",[92],[43785],[43755],{"trials":43839,"activeCount":102},[43840,43846,43852,43859,43865,43872],{"nctId":43841,"briefTitle":43842,"status":108,"phases":43843,"primaryCompletion":7509,"start":8395,"enrollment":599,"conditions":43844,"interventions":43845},"NCT00401661","Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin",[93],[43785],[43755],{"nctId":43847,"briefTitle":43848,"status":108,"phases":43849,"primaryCompletion":3317,"completion":8822,"start":9513,"enrollment":9618,"conditions":43850,"interventions":43851},"NCT00486785","SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin",[93],[43785],[43755],{"nctId":43853,"briefTitle":43854,"status":108,"phases":43855,"completion":8184,"start":9522,"enrollment":1444,"conditions":43856,"interventions":43858},"NCT00542165","Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy",[93],[43857],"BPH\u002FLUTS\u002FSexual Functions",[43755],{"nctId":43860,"briefTitle":43861,"status":108,"phases":43862,"completion":8184,"start":3488,"enrollment":178,"conditions":43863,"interventions":43864},"NCT00637715","Once Daily Given Alfuzosin in the Treatment of BPH",[93],[28076],[43755],{"nctId":43866,"briefTitle":43867,"status":108,"phases":43868,"completion":9130,"start":9872,"enrollment":1223,"conditions":43869,"interventions":43871},"NCT00575913","Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study",[93],[43870],"Prostatic Diseases",[43755],{"nctId":43873,"briefTitle":43874,"status":108,"phases":43875,"primaryCompletion":8777,"completion":8777,"start":8579,"enrollment":12,"conditions":43876,"interventions":43877},"NCT00280605","ALF-ONE : ALFuzosin ONcE Daily",[93],[43785],[43755],{"trials":43879,"activeCount":102},[43880],{"nctId":43881,"briefTitle":43882,"status":108,"phases":43883,"primaryCompletion":3564,"completion":3564,"start":3622,"enrollment":20653,"conditions":43884,"interventions":43885},"NCT00941343","Benign Prostatic Hyperplasia in Taiwan",[94],[43870],[43755],{"intervention":16279,"totalTrials":335,"cells":43887},{"EARLY_PHASE1":43888,"PHASE1":43890,"PHASE2":43892,"PHASE3":43901,"PHASE4":43946,"NA":43984},{"trials":43889,"activeCount":102},[],{"trials":43891,"activeCount":102},[],{"trials":43893,"activeCount":102},[43894],{"nctId":43895,"briefTitle":43896,"status":108,"phases":43897,"primaryCompletion":2790,"completion":2790,"start":5217,"enrollment":10863,"conditions":43898,"interventions":43899},"NCT01213368","Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation",[91],[9562],[43900],"DRONEDARONE",{"trials":43902,"activeCount":102},[43903,43909,43916,43923,43929,43936,43940],{"nctId":43904,"briefTitle":43905,"status":108,"phases":43906,"primaryCompletion":9909,"completion":9909,"start":9965,"enrollment":9900,"conditions":43907,"interventions":43908},"NCT00697086","European Study of Dronedarone in Atrial Fibrillation",[92],[9562],[16279],{"nctId":43910,"briefTitle":43911,"status":884,"phases":43912,"primaryCompletion":986,"completion":986,"start":3366,"enrollment":43913,"conditions":43914,"interventions":43915},"NCT01151137","Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy",[92],3236,[9562],[16279],{"nctId":43917,"briefTitle":43918,"status":884,"phases":43919,"primaryCompletion":7483,"completion":8364,"start":8420,"enrollment":43920,"conditions":43921,"interventions":43922},"NCT00696631","European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure",[92],653,[20614],[16279],{"nctId":43924,"briefTitle":43925,"status":108,"phases":43926,"primaryCompletion":9872,"completion":9872,"start":8185,"enrollment":12465,"conditions":43927,"interventions":43928},"NCT00259376","American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm",[92],[9562,20738],[16279],{"nctId":43930,"briefTitle":43931,"status":108,"phases":43932,"primaryCompletion":8822,"completion":8822,"start":5250,"enrollment":43933,"conditions":43934,"interventions":43935},"NCT00174785","A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation",[92],4628,[9562,20738],[21990],{"nctId":21984,"briefTitle":21985,"status":108,"phases":43937,"primaryCompletion":8846,"completion":8846,"start":10320,"enrollment":21987,"conditions":43938,"interventions":43939},[92],[9562],[21990,21991],{"nctId":43941,"briefTitle":43942,"status":108,"phases":43943,"primaryCompletion":8364,"completion":8364,"start":8185,"enrollment":7438,"conditions":43944,"interventions":43945},"NCT00259428","EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)",[92],[9562,20738],[16279],{"trials":43947,"activeCount":102},[43948,43955,43961,43965,43972,43978],{"nctId":43949,"briefTitle":43950,"status":108,"phases":43951,"primaryCompletion":977,"completion":977,"start":5217,"enrollment":43952,"conditions":43953,"interventions":43954},"NCT01140581","Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation",[93],402,[9562],[43900],{"nctId":43956,"briefTitle":43957,"status":884,"phases":43958,"primaryCompletion":3335,"completion":3335,"start":5217,"enrollment":5521,"conditions":43959,"interventions":43960},"NCT01198873","Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement",[93],[9562],[16279],{"nctId":16274,"briefTitle":16275,"status":108,"phases":43962,"primaryCompletion":986,"completion":986,"start":3316,"enrollment":7321,"conditions":43963,"interventions":43964},[93],[9562],[16279,16261],{"nctId":43966,"briefTitle":43967,"status":884,"phases":43968,"primaryCompletion":977,"completion":977,"start":8570,"enrollment":43969,"conditions":43970,"interventions":43971},"NCT01026090","Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)",[93],292,[9562],[16279],{"nctId":43973,"briefTitle":43974,"status":884,"phases":43975,"primaryCompletion":8107,"completion":8107,"start":3366,"enrollment":8139,"conditions":43976,"interventions":43977},"NCT01135017","Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers",[93],[9562],[16279],{"nctId":43979,"briefTitle":43980,"status":108,"phases":43981,"primaryCompletion":3416,"completion":3416,"start":8453,"enrollment":18448,"conditions":43982,"interventions":43983},"NCT01199081","Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation",[93],[9562],[16279],{"trials":43985,"activeCount":102},[43986],{"nctId":43987,"briefTitle":43988,"status":108,"phases":43989,"primaryCompletion":43990,"completion":43990,"start":119,"enrollment":43991,"conditions":43992,"interventions":43993},"NCT05279833","Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation",[],"2022-03-31",87810,[9562],[21990,43994],"sotalol",{"intervention":5277,"totalTrials":858,"cells":43996},{"EARLY_PHASE1":43997,"PHASE1":43999,"PHASE2":44017,"PHASE3":44043,"PHASE4":44053,"NA":44055},{"trials":43998,"activeCount":102},[],{"trials":44000,"activeCount":102},[44001,44005,44009,44013],{"nctId":18317,"briefTitle":18318,"status":108,"phases":44002,"primaryCompletion":10005,"completion":10005,"start":5217,"enrollment":284,"conditions":44003,"interventions":44004},[90],[18321],[17931,9134,5277],{"nctId":19078,"briefTitle":19079,"status":108,"phases":44006,"primaryCompletion":5238,"completion":164,"start":3564,"enrollment":34,"conditions":44007,"interventions":44008},[90],[5421,5284,19082,19083],[19085,19071,19086],{"nctId":18423,"briefTitle":18424,"status":108,"phases":44010,"primaryCompletion":966,"completion":966,"start":1339,"enrollment":284,"conditions":44011,"interventions":44012},[90],[18427],[5222,18381,5277],{"nctId":18324,"briefTitle":18325,"status":108,"phases":44014,"primaryCompletion":8106,"completion":7330,"start":8062,"enrollment":5407,"conditions":44015,"interventions":44016},[90],[1193],[17931,9134,5277,18329,18330],{"trials":44018,"activeCount":102},[44019,44023,44027,44031,44035,44039],{"nctId":18349,"briefTitle":18350,"status":108,"phases":44020,"primaryCompletion":165,"completion":7284,"start":955,"enrollment":7373,"conditions":44021,"interventions":44022},[91],[18353],[17931,9134,5277],{"nctId":5268,"briefTitle":5269,"status":108,"phases":44024,"primaryCompletion":5271,"completion":5271,"start":5272,"enrollment":5273,"conditions":44025,"interventions":44026},[91],[5275],[1348,4640,5277,4643,5266,5206],{"nctId":19108,"briefTitle":19109,"status":108,"phases":44028,"primaryCompletion":1022,"completion":977,"start":8316,"enrollment":1601,"conditions":44029,"interventions":44030},[91],[19112],[19071,19086,19114],{"nctId":17903,"briefTitle":17904,"status":884,"phases":44032,"primaryCompletion":17906,"completion":17907,"start":17908,"enrollment":1182,"conditions":44033,"interventions":44034},[91],[17910],[1195,5400,1276,5277,5424],{"nctId":5416,"briefTitle":5417,"status":884,"phases":44036,"primaryCompletion":4734,"completion":4734,"start":5419,"enrollment":3767,"conditions":44037,"interventions":44038},[90,91],[5421,2665],[5423,5400,5298,5277,5424],{"nctId":18445,"briefTitle":18446,"status":108,"phases":44040,"primaryCompletion":2487,"completion":2487,"start":7292,"enrollment":18448,"conditions":44041,"interventions":44042},[91],[18450],[5222,18381,5277],{"trials":44044,"activeCount":102},[44045,44049],{"nctId":19167,"briefTitle":19168,"status":108,"phases":44046,"primaryCompletion":7430,"completion":7430,"start":3327,"enrollment":19170,"conditions":44047,"interventions":44048},[92],[5275],[4640,4643,1348,19173,5277],{"nctId":18374,"briefTitle":18375,"status":108,"phases":44050,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":44051,"interventions":44052},[92],[18378],[17931,5277,18380,9134,18130,18381,10000],{"trials":44054,"activeCount":102},[],{"trials":44056,"activeCount":102},[44057],{"nctId":43639,"briefTitle":43640,"status":108,"phases":44058,"primaryCompletion":987,"completion":987,"start":3495,"enrollment":3740,"conditions":44059,"interventions":44060},[],[12362],[1348,5277],{"intervention":17931,"totalTrials":6445,"cells":44062},{"EARLY_PHASE1":44063,"PHASE1":44065,"PHASE2":44081,"PHASE3":44107,"PHASE4":44117,"NA":44119},{"trials":44064,"activeCount":102},[],{"trials":44066,"activeCount":102},[44067,44071,44075],{"nctId":18317,"briefTitle":18318,"status":108,"phases":44068,"primaryCompletion":10005,"completion":10005,"start":5217,"enrollment":284,"conditions":44069,"interventions":44070},[90],[18321],[17931,9134,5277],{"nctId":18324,"briefTitle":18325,"status":108,"phases":44072,"primaryCompletion":8106,"completion":7330,"start":8062,"enrollment":5407,"conditions":44073,"interventions":44074},[90],[1193],[17931,9134,5277,18329,18330],{"nctId":44076,"briefTitle":44077,"status":108,"phases":44078,"primaryCompletion":3821,"completion":954,"start":3366,"enrollment":538,"conditions":44079,"interventions":44080},"NCT01161836","An Open-label Study Investigating the Disposition and QT\u002FQTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)",[90],[18427],[17931],{"trials":44082,"activeCount":102},[44083,44091,44095,44099,44103],{"nctId":44084,"briefTitle":44085,"status":108,"phases":44086,"primaryCompletion":8205,"completion":8205,"start":8156,"enrollment":3828,"conditions":44087,"interventions":44090},"NCT00677079","Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],[44088,44089],"Primary Peritoneal Cancer","Advanced Epithelial Ovarian Cancer",[17931],{"nctId":18349,"briefTitle":18350,"status":108,"phases":44092,"primaryCompletion":165,"completion":7284,"start":955,"enrollment":7373,"conditions":44093,"interventions":44094},[91],[18353],[17931,9134,5277],{"nctId":19101,"briefTitle":19102,"status":108,"phases":44096,"primaryCompletion":164,"completion":15642,"start":5217,"enrollment":11683,"conditions":44097,"interventions":44098},[91],[19105],[19071,17931],{"nctId":17924,"briefTitle":17925,"status":108,"phases":44100,"primaryCompletion":977,"completion":977,"start":9984,"enrollment":17927,"conditions":44101,"interventions":44102},[91],[17929],[17931,5233,17864],{"nctId":21126,"briefTitle":21127,"status":108,"phases":44104,"primaryCompletion":8570,"completion":978,"start":3317,"enrollment":3356,"conditions":44105,"interventions":44106},[91],[5264],[21117,21131],{"trials":44108,"activeCount":102},[44109,44113],{"nctId":18374,"briefTitle":18375,"status":108,"phases":44110,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":44111,"interventions":44112},[92],[18378],[17931,5277,18380,9134,18130,18381,10000],{"nctId":21143,"briefTitle":21144,"status":108,"phases":44114,"primaryCompletion":1339,"completion":8107,"start":8731,"enrollment":21146,"conditions":44115,"interventions":44116},[92],[5264],[21117,17931],{"trials":44118,"activeCount":102},[],{"trials":44120,"activeCount":102},[44121],{"nctId":44122,"briefTitle":44123,"status":44124,"phases":44125,"conditions":44126,"interventions":44127},"NCT01130259","An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer","NO_LONGER_AVAILABLE",[],[5264],[21131],{"intervention":25511,"totalTrials":552,"cells":44129},{"EARLY_PHASE1":44130,"PHASE1":44132,"PHASE2":44134,"PHASE3":44136,"PHASE4":44168,"NA":44170},{"trials":44131,"activeCount":102},[],{"trials":44133,"activeCount":102},[],{"trials":44135,"activeCount":102},[],{"trials":44137,"activeCount":102},[44138,44146,44150,44154,44158,44164],{"nctId":44139,"briefTitle":44140,"status":108,"phases":44141,"primaryCompletion":44142,"completion":44142,"start":44143,"enrollment":8980,"conditions":44144,"interventions":44145},"NCT03765437","Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam",[92],"2019-03-17","2019-01-15",[16],[25511],{"nctId":25505,"briefTitle":25506,"status":108,"phases":44147,"primaryCompletion":164,"completion":3438,"start":8683,"enrollment":25508,"conditions":44148,"interventions":44149},[92],[16],[25511,25511,25511,25494],{"nctId":26043,"briefTitle":26044,"status":884,"phases":44151,"primaryCompletion":26046,"completion":26046,"start":26047,"enrollment":26048,"conditions":44152,"interventions":44153},[92],[7891],[25511,26032],{"nctId":27636,"briefTitle":27637,"status":108,"phases":44155,"primaryCompletion":7189,"completion":7189,"start":24271,"enrollment":27639,"conditions":44156,"interventions":44157},[92],[16],[25511,27625,27642],{"nctId":44159,"briefTitle":44160,"status":108,"phases":44161,"primaryCompletion":7330,"completion":2487,"start":966,"enrollment":465,"conditions":44162,"interventions":44163},"NCT01967784","Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan",[92],[16],[25511],{"nctId":28730,"briefTitle":28731,"status":884,"phases":44165,"primaryCompletion":13320,"completion":13320,"start":28733,"enrollment":14308,"conditions":44166,"interventions":44167},[92],[5335],[28719,28736],{"trials":44169,"activeCount":102},[],{"trials":44171,"activeCount":102},[44172,44182,44189,44197],{"nctId":44173,"briefTitle":44174,"status":108,"phases":44175,"primaryCompletion":44176,"completion":44176,"start":44177,"enrollment":44178,"conditions":44179,"interventions":44181},"NCT06059456","Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023\u002F24",[],"2023-12-15","2023-10-02",2078,[44180],"Influenza Immunization (Healthy Volunteers)",[25511,28381],{"nctId":44183,"briefTitle":44184,"status":108,"phases":44185,"primaryCompletion":5292,"completion":5292,"start":44186,"enrollment":3460,"conditions":44187,"interventions":44188},"NCT05568979","Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022\u002F23",[],"2022-10-06",[7891],[25511,28381],{"nctId":44190,"briefTitle":44191,"status":108,"phases":44192,"primaryCompletion":44193,"completion":44193,"start":44194,"enrollment":10090,"conditions":44195,"interventions":44196},"NCT01945424","Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry",[],"2019-09-15","2013-08-16",[7916,16],[25511],{"nctId":44198,"briefTitle":44199,"status":108,"phases":44200,"primaryCompletion":4615,"completion":4615,"start":44201,"enrollment":44202,"conditions":44203,"interventions":44204},"NCT05078060","Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021\u002F22",[],"2021-10-12",1804,[7891],[25511,28381],{"intervention":18130,"totalTrials":538,"cells":44206},{"EARLY_PHASE1":44207,"PHASE1":44209,"PHASE2":44219,"PHASE3":44229,"PHASE4":44239,"NA":44241},{"trials":44208,"activeCount":102},[],{"trials":44210,"activeCount":102},[44211,44215],{"nctId":31445,"briefTitle":31446,"status":108,"phases":44212,"primaryCompletion":3366,"completion":7292,"start":5307,"enrollment":5407,"conditions":44213,"interventions":44214},[90],[10973],[19114,31450],{"nctId":18125,"briefTitle":18126,"status":108,"phases":44216,"primaryCompletion":7430,"completion":7430,"start":2311,"enrollment":576,"conditions":44217,"interventions":44218},[90],[1193],[9212,9149,18130,9234],{"trials":44220,"activeCount":102},[44221,44225],{"nctId":43448,"briefTitle":43449,"status":108,"phases":44222,"completion":7483,"start":43451,"enrollment":875,"conditions":44223,"interventions":44224},[91],[30031],[1348,18130],{"nctId":32342,"briefTitle":32343,"status":108,"phases":44226,"primaryCompletion":2759,"completion":2759,"start":7283,"enrollment":6604,"conditions":44227,"interventions":44228},[91],[9210],[1347,32347,18130,9159],{"trials":44230,"activeCount":102},[44231,44235],{"nctId":18374,"briefTitle":18375,"status":108,"phases":44232,"primaryCompletion":15982,"completion":15982,"start":5238,"enrollment":655,"conditions":44233,"interventions":44234},[92],[18378],[17931,5277,18380,9134,18130,18381,10000],{"nctId":19401,"briefTitle":9210,"status":108,"phases":44236,"primaryCompletion":8165,"completion":8165,"start":7349,"enrollment":19403,"conditions":44237,"interventions":44238},[92],[9210],[19406,18130,9148,9149],{"trials":44240,"activeCount":102},[],{"trials":44242,"activeCount":102},[44243],{"nctId":43746,"briefTitle":43747,"status":108,"phases":44244,"primaryCompletion":43749,"completion":43749,"start":43750,"enrollment":3121,"conditions":44245,"interventions":44246},[],[43752,5240],[9148,1347,18130],{"intervention":5102,"totalTrials":339,"cells":44248},{"EARLY_PHASE1":44249,"PHASE1":44251,"PHASE2":44253,"PHASE3":44255,"PHASE4":44269,"NA":44280},{"trials":44250,"activeCount":102},[],{"trials":44252,"activeCount":102},[],{"trials":44254,"activeCount":102},[],{"trials":44256,"activeCount":102},[44257,44261,44265],{"nctId":20258,"briefTitle":20259,"status":108,"phases":44258,"primaryCompletion":20261,"completion":20261,"start":12781,"enrollment":412,"conditions":44259,"interventions":44260},[92],[5167],[13222,5102],{"nctId":5094,"briefTitle":5095,"status":108,"phases":44262,"primaryCompletion":5097,"completion":5097,"start":5098,"enrollment":5099,"conditions":44263,"interventions":44264},[92],[2910,36],[5020,5102,5103,5104,5105,5106,5107,2940,2900,5108,5109,5110,5110,5105,2940],{"nctId":7626,"briefTitle":7627,"status":108,"phases":44266,"primaryCompletion":7629,"completion":7629,"start":7630,"enrollment":7631,"conditions":44267,"interventions":44268},[92],[4992,7568,2922],[5020,5102],{"trials":44270,"activeCount":102},[44271],{"nctId":44272,"briefTitle":44273,"status":108,"phases":44274,"primaryCompletion":44275,"completion":44275,"start":44276,"enrollment":44277,"conditions":44278,"interventions":44279},"NCT02864927","Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea",[93],"2019-06-12","2016-07-21",1311,[4992,7568,2922],[5102,5102],{"trials":44281,"activeCount":102},[44282],{"nctId":44283,"briefTitle":44284,"status":108,"phases":44285,"primaryCompletion":44286,"completion":44286,"start":1355,"enrollment":465,"conditions":44287,"interventions":44288},"NCT02699840","Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation",[],"2016-07-25",[4992,7568,2922],[5102,5102,5102],{"intervention":9148,"totalTrials":339,"cells":44290},{"EARLY_PHASE1":44291,"PHASE1":44293,"PHASE2":44295,"PHASE3":44305,"PHASE4":44315,"NA":44317},{"trials":44292,"activeCount":102},[],{"trials":44294,"activeCount":102},[],{"trials":44296,"activeCount":102},[44297,44301],{"nctId":9143,"briefTitle":9144,"status":108,"phases":44298,"primaryCompletion":8745,"completion":8745,"start":1341,"enrollment":112,"conditions":44299,"interventions":44300},[91],[9140],[5286,9148,9149],{"nctId":17883,"briefTitle":17884,"status":108,"phases":44302,"primaryCompletion":8683,"completion":8683,"start":8395,"enrollment":5407,"conditions":44303,"interventions":44304},[91],[9092],[1348,1276,9148],{"trials":44306,"activeCount":102},[44307,44311],{"nctId":19401,"briefTitle":9210,"status":108,"phases":44308,"primaryCompletion":8165,"completion":8165,"start":7349,"enrollment":19403,"conditions":44309,"interventions":44310},[92],[9210],[19406,18130,9148,9149],{"nctId":9262,"briefTitle":9263,"status":529,"phases":44312,"start":9265,"conditions":44313,"interventions":44314},[92],[5254],[9268,9269,9270,5256],{"trials":44316,"activeCount":102},[],{"trials":44318,"activeCount":102},[44319],{"nctId":43746,"briefTitle":43747,"status":108,"phases":44320,"primaryCompletion":43749,"completion":43749,"start":43750,"enrollment":3121,"conditions":44321,"interventions":44322},[],[43752,5240],[9148,1347,18130],{"intervention":28381,"totalTrials":339,"cells":44324},{"EARLY_PHASE1":44325,"PHASE1":44327,"PHASE2":44329,"PHASE3":44335,"PHASE4":44341,"NA":44343},{"trials":44326,"activeCount":102},[],{"trials":44328,"activeCount":102},[],{"trials":44330,"activeCount":102},[44331],{"nctId":34709,"briefTitle":34710,"status":108,"phases":44332,"primaryCompletion":34712,"completion":34712,"start":2817,"enrollment":34713,"conditions":44333,"interventions":44334},[91],[16],[28381,28381,28381,34700,34716],{"trials":44336,"activeCount":102},[44337],{"nctId":28376,"briefTitle":28377,"status":108,"phases":44338,"primaryCompletion":27125,"completion":27125,"start":19588,"enrollment":204,"conditions":44339,"interventions":44340},[92],[7891],[28381,28365],{"trials":44342,"activeCount":102},[],{"trials":44344,"activeCount":102},[44345,44349,44353],{"nctId":44173,"briefTitle":44174,"status":108,"phases":44346,"primaryCompletion":44176,"completion":44176,"start":44177,"enrollment":44178,"conditions":44347,"interventions":44348},[],[44180],[25511,28381],{"nctId":44183,"briefTitle":44184,"status":108,"phases":44350,"primaryCompletion":5292,"completion":5292,"start":44186,"enrollment":3460,"conditions":44351,"interventions":44352},[],[7891],[25511,28381],{"nctId":44198,"briefTitle":44199,"status":108,"phases":44354,"primaryCompletion":4615,"completion":4615,"start":44201,"enrollment":44202,"conditions":44355,"interventions":44356},[],[7891],[25511,28381],{"intervention":24479,"totalTrials":445,"cells":44358},{"EARLY_PHASE1":44359,"PHASE1":44361,"PHASE2":44363,"PHASE3":44365,"PHASE4":44378,"NA":44386},{"trials":44360,"activeCount":102},[],{"trials":44362,"activeCount":102},[],{"trials":44364,"activeCount":102},[],{"trials":44366,"activeCount":102},[44367,44371],{"nctId":24473,"briefTitle":24474,"status":108,"phases":44368,"primaryCompletion":9532,"completion":3396,"start":3308,"enrollment":24476,"conditions":44369,"interventions":44370},[92],[7568,10899,10900,10901,2978],[24479,24462,24480,24481],{"nctId":44372,"briefTitle":44373,"status":108,"phases":44374,"primaryCompletion":3417,"completion":8315,"start":1341,"enrollment":44375,"conditions":44376,"interventions":44377},"NCT00539032","Immunology and Safety of Menactra® in Children in Saudi Arabia",[92],238,[4992,10856],[24479,24479],{"trials":44379,"activeCount":102},[44380],{"nctId":44381,"briefTitle":44382,"status":108,"phases":44383,"primaryCompletion":6471,"completion":2487,"start":8693,"enrollment":8340,"conditions":44384,"interventions":44385},"NCT01270503","Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines",[93],[4992,13504],[24479,24479,24479],{"trials":44387,"activeCount":102},[44388],{"nctId":44389,"briefTitle":44390,"status":108,"phases":44391,"primaryCompletion":8165,"completion":965,"start":954,"enrollment":10746,"conditions":44392,"interventions":44393},"NCT01689155","Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children",[],[4992,2949],[24479],{"intervention":5199,"totalTrials":445,"cells":44395},{"EARLY_PHASE1":44396,"PHASE1":44398,"PHASE2":44400,"PHASE3":44402,"PHASE4":44420,"NA":44422},{"trials":44397,"activeCount":102},[],{"trials":44399,"activeCount":102},[],{"trials":44401,"activeCount":102},[],{"trials":44403,"activeCount":102},[44404,44412,44416],{"nctId":44405,"briefTitle":44406,"status":108,"phases":44407,"primaryCompletion":5478,"completion":5478,"start":44408,"enrollment":166,"conditions":44409,"interventions":44411},"NCT02878603","Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)",[92],"2016-10-06",[44410],"Acquired Thrombotic Thrombocytopenic Purpura",[5199],{"nctId":28398,"briefTitle":28399,"status":108,"phases":44413,"primaryCompletion":2816,"completion":2816,"start":28122,"enrollment":1134,"conditions":44414,"interventions":44415},[91,92],[5197],[5199,28387,28403,28404],{"nctId":5190,"briefTitle":5191,"status":108,"phases":44417,"primaryCompletion":5193,"completion":5193,"start":5194,"enrollment":5195,"conditions":44418,"interventions":44419},[92],[5197],[5199,3022,5200],{"trials":44421,"activeCount":102},[],{"trials":44423,"activeCount":102},[44424],{"nctId":44425,"briefTitle":44426,"status":108,"phases":44427,"primaryCompletion":44428,"completion":44428,"start":42154,"enrollment":445,"conditions":44429,"interventions":44431},"NCT05263193","Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)",[],"2022-10-28",[44430],"Immune-mediated Thrombocytopenic Purpura",[5199],{"intervention":44433,"totalTrials":659,"cells":44434},"DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines",{"EARLY_PHASE1":44435,"PHASE1":44437,"PHASE2":44439,"PHASE3":44441,"PHASE4":44451,"NA":44453},{"trials":44436,"activeCount":102},[],{"trials":44438,"activeCount":102},[],{"trials":44440,"activeCount":102},[],{"trials":44442,"activeCount":102},[44443],{"nctId":44444,"briefTitle":44445,"status":108,"phases":44446,"primaryCompletion":8607,"completion":3417,"start":3430,"enrollment":44447,"conditions":44448,"interventions":44449},"NCT00401531","Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants",[92],412,[18625,13810,25,28,20655],[44433,44450],"DTaP-HB-IPV and Pneumococcal polysaccharide vaccines",{"trials":44452,"activeCount":102},[],{"trials":44454,"activeCount":102},[44455],{"nctId":44456,"briefTitle":44457,"status":108,"phases":44458,"primaryCompletion":3429,"completion":1054,"start":3459,"enrollment":2403,"conditions":44459,"interventions":44460},"NCT02610348","Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age",[94],[18625],[44433,44450],{"intervention":44450,"totalTrials":659,"cells":44462},{"EARLY_PHASE1":44463,"PHASE1":44465,"PHASE2":44467,"PHASE3":44469,"PHASE4":44475,"NA":44477},{"trials":44464,"activeCount":102},[],{"trials":44466,"activeCount":102},[],{"trials":44468,"activeCount":102},[],{"trials":44470,"activeCount":102},[44471],{"nctId":44444,"briefTitle":44445,"status":108,"phases":44472,"primaryCompletion":8607,"completion":3417,"start":3430,"enrollment":44447,"conditions":44473,"interventions":44474},[92],[18625,13810,25,28,20655],[44433,44450],{"trials":44476,"activeCount":102},[],{"trials":44478,"activeCount":102},[44479],{"nctId":44456,"briefTitle":44457,"status":108,"phases":44480,"primaryCompletion":3429,"completion":1054,"start":3459,"enrollment":2403,"conditions":44481,"interventions":44482},[94],[18625],[44433,44450],{"intervention":44484,"totalTrials":659,"cells":44485},"DTaP-IPV\u002FHib",{"EARLY_PHASE1":44486,"PHASE1":44488,"PHASE2":44490,"PHASE3":44492,"PHASE4":44494,"NA":44496},{"trials":44487,"activeCount":102},[],{"trials":44489,"activeCount":102},[],{"trials":44491,"activeCount":102},[],{"trials":44493,"activeCount":102},[],{"trials":44495,"activeCount":102},[],{"trials":44497,"activeCount":102},[44498,44505],{"nctId":44499,"briefTitle":44500,"status":108,"phases":44501,"primaryCompletion":7430,"completion":7430,"start":8315,"enrollment":44502,"conditions":44503,"interventions":44504},"NCT00855855","Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease",[],20830,[17157,25,31,13810,28],[44484],{"nctId":44506,"briefTitle":44507,"status":108,"phases":44508,"primaryCompletion":11210,"completion":1031,"start":3564,"enrollment":44509,"conditions":44510,"interventions":44512},"NCT00804284","Database Surveillance Safety Study of PENTACEL® Vaccine",[],62538,[25,31,28,44511],"Haemophilus Influenzae",[44484,44513],"Other DTap Vaccines",{"intervention":44515,"totalTrials":659,"cells":44516},"None administered in this study",{"EARLY_PHASE1":44517,"PHASE1":44519,"PHASE2":44521,"PHASE3":44523,"PHASE4":44525,"NA":44527},{"trials":44518,"activeCount":102},[],{"trials":44520,"activeCount":102},[],{"trials":44522,"activeCount":102},[],{"trials":44524,"activeCount":102},[],{"trials":44526,"activeCount":102},[],{"trials":44528,"activeCount":102},[44529,44536],{"nctId":44530,"briefTitle":44531,"status":108,"phases":44532,"primaryCompletion":8106,"completion":8106,"start":9706,"enrollment":44533,"conditions":44534,"interventions":44535},"NCT00728260","36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds",[],1421,[4992,13504],[44515],{"nctId":44537,"briefTitle":44538,"status":108,"phases":44539,"primaryCompletion":8106,"completion":8106,"start":9706,"enrollment":44540,"conditions":44541,"interventions":44542},"NCT00254995","Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine",[],62626,[4992,13504],[44515],{"intervention":44544,"totalTrials":195,"cells":44545},"Flublok Quadrivalent influenza vaccine RIV4",{"EARLY_PHASE1":44546,"PHASE1":44548,"PHASE2":44550,"PHASE3":44552,"PHASE4":44554,"NA":44556},{"trials":44547,"activeCount":102},[],{"trials":44549,"activeCount":102},[],{"trials":44551,"activeCount":102},[],{"trials":44553,"activeCount":102},[],{"trials":44555,"activeCount":102},[],{"trials":44557,"activeCount":102},[44558],{"nctId":44559,"briefTitle":44560,"status":108,"phases":44561,"primaryCompletion":44562,"completion":44562,"start":5031,"enrollment":44563,"conditions":44564,"interventions":44565},"NCT04460781","Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring",[],"2022-02-28",96175,[16],[44544,44566],"Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4",{"intervention":44566,"totalTrials":195,"cells":44568},{"EARLY_PHASE1":44569,"PHASE1":44571,"PHASE2":44573,"PHASE3":44575,"PHASE4":44577,"NA":44579},{"trials":44570,"activeCount":102},[],{"trials":44572,"activeCount":102},[],{"trials":44574,"activeCount":102},[],{"trials":44576,"activeCount":102},[],{"trials":44578,"activeCount":102},[],{"trials":44580,"activeCount":102},[44581],{"nctId":44559,"briefTitle":44560,"status":108,"phases":44582,"primaryCompletion":44562,"completion":44562,"start":5031,"enrollment":44563,"conditions":44583,"interventions":44584},[],[16],[44544,44566],{"intervention":44586,"totalTrials":195,"cells":44587},"Tetanus Toxoid, acellular pertussis, diphtheria toxoid",{"EARLY_PHASE1":44588,"PHASE1":44590,"PHASE2":44592,"PHASE3":44594,"PHASE4":44596,"NA":44598},{"trials":44589,"activeCount":102},[],{"trials":44591,"activeCount":102},[],{"trials":44593,"activeCount":102},[],{"trials":44595,"activeCount":102},[],{"trials":44597,"activeCount":102},[],{"trials":44599,"activeCount":102},[44600],{"nctId":44601,"briefTitle":44602,"status":108,"phases":44603,"primaryCompletion":8406,"completion":3438,"start":3609,"enrollment":44604,"conditions":44605,"interventions":44606},"NCT00258882","Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine",[],327293,[28],[44586],{"intervention":44608,"totalTrials":195,"cells":44609},"CYD-TDV Dengue Vaccine",{"EARLY_PHASE1":44610,"PHASE1":44612,"PHASE2":44614,"PHASE3":44616,"PHASE4":44618,"NA":44620},{"trials":44611,"activeCount":102},[],{"trials":44613,"activeCount":102},[],{"trials":44615,"activeCount":102},[],{"trials":44617,"activeCount":102},[],{"trials":44619,"activeCount":102},[],{"trials":44621,"activeCount":102},[44622],{"nctId":44623,"briefTitle":44624,"status":108,"phases":44625,"primaryCompletion":5098,"completion":5098,"start":2402,"enrollment":166,"conditions":44626,"interventions":44627},"NCT04023708","Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy",[],[7731],[44608],{"intervention":43994,"totalTrials":195,"cells":44629},{"EARLY_PHASE1":44630,"PHASE1":44632,"PHASE2":44634,"PHASE3":44636,"PHASE4":44638,"NA":44640},{"trials":44631,"activeCount":102},[],{"trials":44633,"activeCount":102},[],{"trials":44635,"activeCount":102},[],{"trials":44637,"activeCount":102},[],{"trials":44639,"activeCount":102},[],{"trials":44641,"activeCount":102},[44642],{"nctId":43987,"briefTitle":43988,"status":108,"phases":44643,"primaryCompletion":43990,"completion":43990,"start":119,"enrollment":43991,"conditions":44644,"interventions":44645},[],[9562],[21990,43994],{"intervention":44647,"totalTrials":195,"cells":44648},"Stamaril®",{"EARLY_PHASE1":44649,"PHASE1":44651,"PHASE2":44653,"PHASE3":44655,"PHASE4":44657,"NA":44659},{"trials":44650,"activeCount":102},[],{"trials":44652,"activeCount":102},[],{"trials":44654,"activeCount":102},[],{"trials":44656,"activeCount":102},[],{"trials":44658,"activeCount":102},[],{"trials":44660,"activeCount":102},[44661],{"nctId":44662,"briefTitle":44663,"status":108,"phases":44664,"primaryCompletion":44665,"completion":44665,"start":30195,"enrollment":21099,"conditions":44666,"interventions":44667},"NCT03541694","Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea",[],"2018-05-30",[2296],[44647],{"intervention":44669,"totalTrials":195,"cells":44670},"Pentacel®",{"EARLY_PHASE1":44671,"PHASE1":44673,"PHASE2":44675,"PHASE3":44677,"PHASE4":44679,"NA":44681},{"trials":44672,"activeCount":102},[],{"trials":44674,"activeCount":102},[],{"trials":44676,"activeCount":102},[],{"trials":44678,"activeCount":102},[],{"trials":44680,"activeCount":102},[],{"trials":44682,"activeCount":102},[44683],{"nctId":44684,"briefTitle":44685,"status":108,"phases":44686,"primaryCompletion":44687,"completion":44687,"start":44688,"enrollment":44689,"conditions":44690,"interventions":44691},"NCT01129362","Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines",[],"2014-12-30","2010-02-08",1195,[28],[44669,44692],"Other Pertussis Vaccines",{"intervention":44692,"totalTrials":195,"cells":44694},{"EARLY_PHASE1":44695,"PHASE1":44697,"PHASE2":44699,"PHASE3":44701,"PHASE4":44703,"NA":44705},{"trials":44696,"activeCount":102},[],{"trials":44698,"activeCount":102},[],{"trials":44700,"activeCount":102},[],{"trials":44702,"activeCount":102},[],{"trials":44704,"activeCount":102},[],{"trials":44706,"activeCount":102},[44707],{"nctId":44684,"briefTitle":44685,"status":108,"phases":44708,"primaryCompletion":44687,"completion":44687,"start":44688,"enrollment":44689,"conditions":44709,"interventions":44710},[],[28],[44669,44692],{"intervention":44712,"totalTrials":195,"cells":44713},"DTaP-IPV-Hep B-PRP-T combined vaccine",{"EARLY_PHASE1":44714,"PHASE1":44716,"PHASE2":44718,"PHASE3":44720,"PHASE4":44722,"NA":44724},{"trials":44715,"activeCount":102},[],{"trials":44717,"activeCount":102},[],{"trials":44719,"activeCount":102},[],{"trials":44721,"activeCount":102},[],{"trials":44723,"activeCount":102},[],{"trials":44725,"activeCount":102},[44726],{"nctId":44727,"briefTitle":44728,"status":108,"phases":44729,"primaryCompletion":44730,"completion":44730,"start":44731,"enrollment":44732,"conditions":44733,"interventions":44734},"NCT06793826","Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea",[],"2026-01-15","2025-01-17",713,[18625,12789],[44712],{"intervention":44736,"totalTrials":195,"cells":44737},"Quadrivalent Intradermal Influenza Vaccine",{"EARLY_PHASE1":44738,"PHASE1":44740,"PHASE2":44742,"PHASE3":44744,"PHASE4":44746,"NA":44748},{"trials":44739,"activeCount":102},[],{"trials":44741,"activeCount":102},[],{"trials":44743,"activeCount":102},[],{"trials":44745,"activeCount":102},[],{"trials":44747,"activeCount":102},[],{"trials":44749,"activeCount":102},[44750],{"nctId":44751,"briefTitle":44752,"status":108,"phases":44753,"primaryCompletion":44754,"completion":44754,"start":44755,"enrollment":6630,"conditions":44756,"interventions":44757},"NCT02554409","Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry",[],"2019-04-30","2015-10-13",[7916,16],[44736],{"intervention":44759,"totalTrials":195,"cells":44760},"VaxigripTetra inj.",{"EARLY_PHASE1":44761,"PHASE1":44763,"PHASE2":44765,"PHASE3":44767,"PHASE4":44769,"NA":44771},{"trials":44762,"activeCount":102},[],{"trials":44764,"activeCount":102},[],{"trials":44766,"activeCount":102},[],{"trials":44768,"activeCount":102},[],{"trials":44770,"activeCount":102},[],{"trials":44772,"activeCount":102},[44773],{"nctId":44774,"briefTitle":44775,"status":108,"phases":44776,"primaryCompletion":44777,"completion":44777,"start":5151,"enrollment":44778,"conditions":44779,"interventions":44780},"NCT05406180","Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above",[],"2019-12-27",675,[16],[44759],{"intervention":44782,"totalTrials":195,"cells":44783},"Trivalent Recombinant Influenza Vaccine",{"EARLY_PHASE1":44784,"PHASE1":44786,"PHASE2":44788,"PHASE3":44790,"PHASE4":44792,"NA":44794},{"trials":44785,"activeCount":102},[],{"trials":44787,"activeCount":102},[],{"trials":44789,"activeCount":102},[],{"trials":44791,"activeCount":102},[],{"trials":44793,"activeCount":102},[],{"trials":44795,"activeCount":102},[44796],{"nctId":44797,"briefTitle":44798,"status":108,"phases":44799,"primaryCompletion":1220,"completion":1220,"start":32471,"enrollment":43395,"conditions":44800,"interventions":44802},"NCT06765187","A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire",[],[5335,44801],"Health Volunteers",[44782],{"intervention":44804,"totalTrials":195,"cells":44805},"Tetanus and diphtheria toxoids and acellular pertussis",{"EARLY_PHASE1":44806,"PHASE1":44808,"PHASE2":44810,"PHASE3":44812,"PHASE4":44814,"NA":44816},{"trials":44807,"activeCount":102},[],{"trials":44809,"activeCount":102},[],{"trials":44811,"activeCount":102},[],{"trials":44813,"activeCount":102},[],{"trials":44815,"activeCount":102},[],{"trials":44817,"activeCount":102},[44818],{"nctId":44819,"briefTitle":44820,"status":108,"phases":44821,"primaryCompletion":8184,"completion":9559,"start":3367,"enrollment":44822,"conditions":44823,"interventions":44824},"NCT00524732","Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age",[],7156,[28,25],[44804],{"intervention":44826,"totalTrials":195,"cells":44827},"VaxigripTetra®",{"EARLY_PHASE1":44828,"PHASE1":44830,"PHASE2":44832,"PHASE3":44834,"PHASE4":44836,"NA":44838},{"trials":44829,"activeCount":102},[],{"trials":44831,"activeCount":102},[],{"trials":44833,"activeCount":102},[],{"trials":44835,"activeCount":102},[],{"trials":44837,"activeCount":102},[],{"trials":44839,"activeCount":102},[44840],{"nctId":44841,"briefTitle":44842,"status":108,"phases":44843,"primaryCompletion":44844,"completion":44844,"start":44845,"enrollment":5333,"conditions":44846,"interventions":44847},"NCT05832333","Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months",[],"2022-02-07","2019-10-05",[16],[44826],{"intervention":44849,"totalTrials":195,"cells":44850},"Sodium valporate",{"EARLY_PHASE1":44851,"PHASE1":44853,"PHASE2":44855,"PHASE3":44857,"PHASE4":44859,"NA":44861},{"trials":44852,"activeCount":102},[],{"trials":44854,"activeCount":102},[],{"trials":44856,"activeCount":102},[],{"trials":44858,"activeCount":102},[],{"trials":44860,"activeCount":102},[],{"trials":44862,"activeCount":102},[44863],{"nctId":44864,"briefTitle":44865,"status":108,"phases":44866,"primaryCompletion":379,"completion":379,"start":44867,"enrollment":44868,"conditions":44869,"interventions":44871},"NCT06714448","A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia",[],"2025-04-29",455,[15598,44870],"Seizures",[44849],{"intervention":44873,"totalTrials":195,"cells":44874},"Menactra®",{"EARLY_PHASE1":44875,"PHASE1":44877,"PHASE2":44879,"PHASE3":44881,"PHASE4":44883,"NA":44885},{"trials":44876,"activeCount":102},[],{"trials":44878,"activeCount":102},[],{"trials":44880,"activeCount":102},[],{"trials":44882,"activeCount":102},[],{"trials":44884,"activeCount":102},[],{"trials":44886,"activeCount":102},[44887],{"nctId":44888,"briefTitle":44889,"status":108,"phases":44890,"primaryCompletion":8349,"completion":8388,"start":8205,"enrollment":44891,"conditions":44892,"interventions":44893},"NCT00862277","Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine",[],763,[2922,4992],[44873,44894],"Menomune®",{"intervention":44894,"totalTrials":195,"cells":44896},{"EARLY_PHASE1":44897,"PHASE1":44899,"PHASE2":44901,"PHASE3":44903,"PHASE4":44905,"NA":44907},{"trials":44898,"activeCount":102},[],{"trials":44900,"activeCount":102},[],{"trials":44902,"activeCount":102},[],{"trials":44904,"activeCount":102},[],{"trials":44906,"activeCount":102},[],{"trials":44908,"activeCount":102},[44909],{"nctId":44888,"briefTitle":44889,"status":108,"phases":44910,"primaryCompletion":8349,"completion":8388,"start":8205,"enrollment":44891,"conditions":44911,"interventions":44912},[],[2922,4992],[44873,44894],{"intervention":44513,"totalTrials":195,"cells":44914},{"EARLY_PHASE1":44915,"PHASE1":44917,"PHASE2":44919,"PHASE3":44921,"PHASE4":44923,"NA":44925},{"trials":44916,"activeCount":102},[],{"trials":44918,"activeCount":102},[],{"trials":44920,"activeCount":102},[],{"trials":44922,"activeCount":102},[],{"trials":44924,"activeCount":102},[],{"trials":44926,"activeCount":102},[44927],{"nctId":44506,"briefTitle":44507,"status":108,"phases":44928,"primaryCompletion":11210,"completion":1031,"start":3564,"enrollment":44509,"conditions":44929,"interventions":44930},[],[25,31,28,44511],[44484,44513],{"intervention":44932,"totalTrials":195,"cells":44933},"Connected Solution with H2S app which connects with blood glucose meter",{"EARLY_PHASE1":44934,"PHASE1":44936,"PHASE2":44938,"PHASE3":44940,"PHASE4":44942,"NA":44944},{"trials":44935,"activeCount":102},[],{"trials":44937,"activeCount":102},[],{"trials":44939,"activeCount":102},[],{"trials":44941,"activeCount":102},[],{"trials":44943,"activeCount":102},[],{"trials":44945,"activeCount":102},[44946],{"nctId":44947,"briefTitle":44948,"status":108,"phases":44949,"primaryCompletion":44950,"completion":44950,"start":19302,"enrollment":12,"conditions":44951,"interventions":44952},"NCT05684341","A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan",[94],"2024-06-18",[19],[44932]]